<SEC-DOCUMENT>0000906709-21-000005.txt : 20210226
<SEC-HEADER>0000906709-21-000005.hdr.sgml : 20210226
<ACCEPTANCE-DATETIME>20210225191636
ACCESSION NUMBER:		0000906709-21-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210226
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		21682647

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nktr-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:b34aba47-bd43-4f7a-949b-84c5bc7946a0,g:a0d0df82-7542-4b00-8e8b-b5cca2744d03,d:fabf795112b143ffbb3dd9981b4dd620--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:nktr="http://www.nektar.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl8zLTEtMS0xLTA_5bab2f31-c859-4f81-aeb9-2ac2eabac1b5">false</ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl81LTEtMS0xLTA_0b653746-54bb-4c75-989c-7036b2fe290d">2020</ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl82LTEtMS0xLTA_628f093b-34bc-4477-9d4c-bf07cd6eb782">FY</ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl85LTEtMS0xLTA_1ecec2bb-61cf-4fe7-8e55-a15eeecf8925">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="i6aff924a587b4d04b0235e3e8f640342_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="iad64b443cc304ed6be30d2cc5df58e4f_D20200101-20201231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_65dac629-914e-42fe-8970-b4d9eec444dc">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i08812424de7c416cae903c24bf2273ec_D20190101-20191231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_d24a00d0-9f20-48ec-989c-a46dae10d5c7">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231" name="nktr:LeaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231" name="nktr:LeaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:RoyaltyAgreementContingentPaymentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjQvZnJhZzo2MGU0YjBjYmU0M2Y0NDhkODgwZWU4ZTVkOWQ5ZWFkNS90YWJsZToxNDExY2M0NTdjYTQ0YmRhOWM0ZDhkYjUwNmM0NDlhNi90YWJsZXJhbmdlOjE0MTFjYzQ1N2NhNDRiZGE5YzRkOGRiNTA2YzQ0OWE2XzEtMS0xLTEtMA_189d4b70-b35d-4fad-bc59-9ccd2dbe2313"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.</span></ix:nonNumeric><ix:nonNumeric contextRef="i62313148fd754f3b929b315ce6ba6955_D20200101-20201231" name="nktr:RegulatoryMilestonesPaymentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDIvZnJhZzphYzA1ODJiYWU4MWQ0MjFlODk4MDIyYzc4Zjk4ZjJlNC90YWJsZTo2N2U5Njc0OTZhZTI0Mzc2YmZhOTU0MjlmMTYxZDk4OS90YWJsZXJhbmdlOjY3ZTk2NzQ5NmFlMjQzNzZiZmE5NTQyOWYxNjFkOTg5XzEtMS0xLTEtMA_8a7778e9-4566-4532-aa44-97efafe138f1">A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" name="nktr:PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDIvZnJhZzphYzA1ODJiYWU4MWQ0MjFlODk4MDIyYzc4Zjk4ZjJlNC90YWJsZTo2N2U5Njc0OTZhZTI0Mzc2YmZhOTU0MjlmMTYxZDk4OS90YWJsZXJhbmdlOjY3ZTk2NzQ5NmFlMjQzNzZiZmE5NTQyOWYxNjFkOTg5XzItMi0xLTEtNDMyOQ_adad7643-dbae-49dc-b1af-2d5831deb45e">2</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie5e6f011e7504a50be5144345c76cef1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i640af33a74bf419599a75c9360372c8e_I20210217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61c61ebd4ad4075a8831d9455982999_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i37ce07361f9b43129f976c314af40cd8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2104eacf6c1c4d319643e63ddfcaa810_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2127771393fd4344bc56f116378dbc80_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e1d56d6d224026a4762d3a7d7d113c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bbf49b668643278f282f67a79338f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced44c3d5ae947b09f1caf9892e918ed_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic383fe79ff4f463db81e7ac42a6ad50d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0fa75cc5764250b904e9532e10dcfc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75782c14a414b63b988ae2765e32773_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20f13baec094f3ab62602a7600f949a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aaedea71c1a4731b57ba3b49a31cb47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ee016ab66c4bc7b24baff974c4e434_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc09b131139d4563b60db10c398e0c39_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic317cce5e2e84fb1ac5250f54df57bec_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4c76f968fe4a4093752003d5013bc3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9e7353cdeb4fe6b0ec92f7ee97d3df_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782737b6925642ae80e85211d3061393_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c8ff8ae9384f8495fb9cb6ddd60570_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b17c7c97be4099ae192bd62fc5521d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada3a911b4f14caea46af4c30f06e014_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970c509f43724f619b397e04e8673b95_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f25f1ab252404589804ff8b213aacd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide09c0c4709d4b5aa0c73844f694a2db_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63874fca1d514b93a990a5f8aab4aa34_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f23b96cd474a7d9187b5b79c2a289b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33907907e75044d9835ba51785a384b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5542093f845a450e83bcc68e3b46375f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4590dba62bf9491c9a6eb5b8d6bb51c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a1357fd1ed41e0991dc2af7ce5c5c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7b0526e6124631a8651436a2212d83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbb019599e084003800372045527cde5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fdd2b443374491091615a02e9e811a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7087384b4384d5ea1895430f29aa031_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c38660192d4485bb12209404a88e784_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880d3494fb4e4f6abd5b72316ba10da3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf098280e6d44e0936905fbe28dcb34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3387462eae3140f4abc3e28f4e4a5af3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c1044cd8154ba294e48097dcf6ecfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ac0337faf647b189a16641a720d4d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5065cf5b40d5475aa1b717b89709499d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08affc16b104b92823fab10fa4ae3a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717a3b33fb444b809d0adef0ac06725b_D20200413-20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:A775PercentSeniorSecuredNotesDueOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i09546958c5654aba9b0e1a853838b859_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PartnerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f416a959f974cfba77544c098dfe27a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PartnerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f5461407a5437d9bfeb28b339c42e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PartnerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aff924a587b4d04b0235e3e8f640342_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c77957329da4893900ec8abef0354d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699fa2275d694e3ead84ac6a1b9d588a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>nktr:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i34700219468e42b4b7930f9dbb4d6186_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2258862b93e9480c951e464dfe2bbbe0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db7646976b34d70acfa2081ee826ee4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21605fedf17490fa0886eae32da3156_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad64b443cc304ed6be30d2cc5df58e4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08812424de7c416cae903c24bf2273ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c2e96ec4df4105ae39e0cc524fc251_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf6d1cf2ec944050a87027e7a515ee06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e26256948a488cb8e3fcf49df9474a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8e58a6675bb4673ad4c4d985c0ad671_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9809b46a63494218a0bf6b5f8fc63571_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2df0af8bd514d598273623513f12d91_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9c3756efac45638b8661f85a56b87b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3ed71369cd465faecd143e23ac8cf7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0a7100bd064c2c83c71589ae758e3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da7225c246f45e7a9949c2da1d6f10b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23df56833c5f4df59292bc311c03aad8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic26b559e13a246219de39b20472737fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2266b3ff82324cb9b553040cded08f91_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45127b4769de4be5b7b965f5763fbc1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689fee9ace2e4522b887678cba220fa6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a80ca3f7680478d982f63ab514437f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84cbf02176864c678db5f9dfbd89d813_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c28da8080c84fcd807f2604a6cc1e1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ddd0c57faa4c2dbab65ca8fd54a4f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678825b8367a45639e3d62d20e1b8682_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dbdad1aa0874eb8a53d8398977fd31d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39c346907c8444d9f56f268dff89776_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if876fe666ac74deaa248054e2378e704_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6228c808807e4675801149c5c4dc1518_D20151005-20151005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-05</xbrli:startDate><xbrli:endDate>2015-10-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f550fdfeac243e7b6be6c3906cace58_D20200413-20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050aa7da5e164a6e8417d8a966766809_I20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ib51f0c55e3654f49b5399e4a17397835_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc93e99a4dbd4acdadb139babe668fc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae1943d37a234e1f9eaaacf476982b71_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b2a2e647ae4ccf8b8c44c8755aa414_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id176c911867d49139246e27dafec984d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>nktr:term</xbrli:measure></xbrli:unit><xbrli:context id="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-24</xbrli:startDate><xbrli:endDate>2012-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-30</xbrli:startDate><xbrli:endDate>2020-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id831546d70e34870a583f96469cf6e54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff329ef00ee4a19babec2ac7467b6c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f23237f9b92424f88e3de119d082d83_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b99c4859de149f481fb7758fe823053_I20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3d4ded8eb8431ea5eb96372d1f1204_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-25</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-17</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-25</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a82bbe23bd4eae896743496772f42c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b607b1feca94f0183fc01112b406e0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8e5acc2c64493693d38c6ecf8677de_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b40bb677024548b6bead5496558bb3_D20130301-20130331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-01</xbrli:startDate><xbrli:endDate>2013-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcce05db00d34655b9af2ffe52859e3e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84e821beaee4d8fa7e6add65a5ac46d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7bb6c1b8b6481197a849cf13dc94fb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332680e5c95e48e8b3da3635ec5a64c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27d8215eb84441c583e455931394edc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0a827a30fd4d489cff709fb4aa1743_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f92162d4b9462fb32ed8b535a14bac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ab7fd63345456ba7a5755e4c5fc5d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:CommercialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65324047a4db4c8091e27eab6cf2aa8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:CommercialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2caaa2f541394f9f8d1cc79cf9ea3dc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6fe490e41b448e8aff782bf7c54d50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e772010232f40508602a3871880b34c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279eee577f1441378d79802f9bc91494_D20180403-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45baea1b97d54688a1dfe6bcf696082b_D20180403-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5660632f144317b4ee56bdf1d105ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165b47e55f0b4fe19b116d4073ab3d17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0404b34bd7e6426abaa4ad1ff3be9107_D20180626-20180626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-26</xbrli:startDate><xbrli:endDate>2018-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id759869545ce4f8082f87a13f96f56c7_D20200617-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:AmendedAndRestated2017PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3242ee4bdb4141c29d4a338d4cabf96e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fbb3ef5ea4f4882bde7a74c1ef8e365_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5da921eb5c043ae837ab819c1a4f230_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie75ccda9579e4320804a6b82cbbeadca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243a1e61f3224fbbbbd5e7b34dc9d858_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4cbf542cfaa4814959fffc6a9d3eb50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8c53d2886c4e2688588fb7a66cb738_D20200617-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a180f9d74404418b6c1394ddf6e243a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07fee986be7e4e88975b835fff607f89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5b28fa1440433cbc1a30bd468e6bc4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737d623ece374d02a554cd0314567319_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b180b5818184f9e90a1d9ac77c0ad36_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813fad316fa349b09cbd0d54f5119511_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7500307ef7d243f28fbd31084f547085_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27aa90ea43d8491ab680477d8a5ad091_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d89b8ee0d5b4ad28995c6a5cb013afe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia149e6df5d9d423fb6f0a80e7e807499_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c73bdc0467470a82fe6dd56ac35921_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaIncludingADYNOVATEAndADYNOVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddeeba83838249e69191a50f51901ae9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaIncludingADYNOVATEAndADYNOVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a26ba1b2354834aeab39bb01122273_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaIncludingADYNOVATEAndADYNOVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2ed6dd5c174996a8348c2074df2753_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008803fb67f84ea78e2af3795d82cb16_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46c9120dc3e494394b2305aceabd21d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed655596acc4f6f9abb2c38103052ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53dd51cb16d64a37af811757be9bc88d_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e9200632c24e1cb5376206c84bd1ba_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3d41b108484518862f7675ed0d6023_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae6895fea5d4170abf536b7118795ac_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib881bc00509644faa5b6cc9e5670bda9_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:ClinicalTrialAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc54d4429a14507ba0977108771d46f_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33adc58a946240659c54e96e6b40bfbf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681999e295a9436988be9a734fa0d419_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89eb6575dc8d4b6bb3d9b58cb422c933_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8d2460a3d24fe19b5e25e5c18d4d4c_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a165c7d11824e3faaca690b9fe43ccb_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4324d57f84ab4a79b48761bdcdb78475_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5b0431feeb42af96a92b8ebf28fd8b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51d000e6aadc462a8e1d068ac6eb6bda_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a7acaae93b47a18c69f0744596371d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e8ffaec982447283e3be646c848349_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856405b13edf4a6cab22db02d72d1802_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1754f034bd974728bed8387d9d72bd50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f578ac138d243159b20e2c8695c088d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i211b0ecf8dd9414bac8969426d745f43_I20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090200b2df2d4328a10feb73ea2cc913_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa0bac114c54b30ad4a8c72b57d49d2_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f006004c02b411e86bd510eb0e3d194_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822a697b55f34b999f5d046661cdda27_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57ed396a7ce4982a8cf0c38400928a6_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86b4fcdb85a4a40a92ae61ccbb060f2_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a2d0c7f5b14febb5d605a70ac5be5a_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b3538d8838435d98d28e77de6a0b87_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e1d5fa4cee46038d0164972eca0589_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9608ed0e8f234f719db44f2ce29c4216_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73287f5728f4758aff50c38e58bc67c_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53699e8247e24936abad5db41f079668_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee84d18bf2448248442d25abe69bc54_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f692c7b7c64b63aa43f5f9beb82f27_D20101001-20101031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2010-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdff3824bed0496593ee26344105cfaa_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9669dda51f8d469b90ab31add3c0cf0a_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdbf7038932f481ebc0426c961831d78_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052214e857b447dfbc2f68ed467ab528_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255f8243240945a4a13c9479fe28d04f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbbc53198d1c48749ec868cd04228392_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e61ba2f5e447299c9460d38e8e3b38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54b2f1a2f4f47eda9c396ece8af832b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b459d9407c3488188caf6e79fd2c1b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:TerminatedPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62313148fd754f3b929b315ce6ba6955_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74acef52e11470f833bd478aa3ef19b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b295854248b4d328d13f61824dc9c9a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce8950c4b5b4e54b98c6758fc52a69c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf4765dc2e844f291e9697ef1a040c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495ad3c9a56241a4b0d81e8e4e6fb3d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8a180bb15a483f80a891f8010c1d15_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b77ba2c841b4c28b4c4a4cd5a77324f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a89348225b1444f879860b43fe8e9c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d8392820334097a6e73600dbdc66b5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1db549bc0acb4adba3eec24ace8bedd0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c80c0982a6f47049d8b696c71aad77f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca56cd80aa4498ab650c1512e10d771_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a0f1d0bae304ea191fafac40840dd22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270d9a256b0148cf80b4c9020001e2ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01a6511f0d24250b24e5b947e4fc152_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d489e7ce4f48beaabcdd6ed7a7661b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1352258179264aee894c5a3fcf3294cd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5394f004851433191f100501cea9fac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d86a1180eaa4ff892518dd3441f1bb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb46e064c7448bb96b707d5238157cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4ca2a391ba4e4e82c217bd8fd54a9d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:segment</xbrli:measure></xbrli:unit><xbrli:context id="i0724493c13744e74aba58429991051ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8930ee506074b1a80dcb28134fd5773_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide398b6debeb4fb7a095f0df2975ccd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i049d56950da443d782603343643146ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0866d8705ad34c20932d7388fb164e35_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817f31328f764ac8a65d4340427e73dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32b099d78c041bcb200c8d5438e369a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62cad6a1a032445e971b3fd80be0ab88_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib912063d910845aaa45f66edaa7d2535_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ca9a944946417a9bd26c7ff3bd0df2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee76c326075144bc9957970824864572_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd671a84bd84c26a9c4e33c4b75a08c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d365863714c4ed5890fc77835d41d57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c86ae7fa4cc46ac95c142f23e235a82_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb25dc75983449abf52bac9890f50f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccee95850b064fbd8b0c1431a6df105f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85fff8d911974f27b78a9941b7f50432_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eabcb407913449e87ce37aa8d0de239_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d086dadf3f44dba9615056bd07087d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d6b1d26b224dc59df8dcedba587fed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf35774709d841d3b44284705950593c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7199da49f7844202b5dabcf7a621af2e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0342284791141f9aca1142441d62cf0_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0e3cb012e04c40b706573437e7c400_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia127b30b5a3e436e9d93336b81801699_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ecf9e44f3a485789e47ee440d1fb61_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d570eb5ffd48c4939a02adc32bc003_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115533df786243e0b7e302d7e193fa82_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4adfa1d6b5b54a02b009b9b036e26e11_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4187a897c35f46c2a1363434d9f54ce6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ffc21a2ccee43aa8a8e12d940741920_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7710329fc21449a944ba1739f98c260_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifabf795112b143ffbb3dd9981b4dd620_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ4_e717da2e-d1af-40e6-89dc-eb217d3b7b53">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MzNlZmU1MTA0YTlkNGVkMjlkYTU5YTU2ODFiZWUzZGIvdGFibGVyYW5nZTozM2VmZTUxMDRhOWQ0ZWQyOWRhNTlhNTY4MWJlZTNkYl8wLTAtMS0xLTA_1490a31a-7073-4696-abc5-d228920006e1">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8yNjk_a253f7df-ffb9-4681-af0c-d106e55feec0"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8yNjk_700d2aac-2b76-478a-b5d4-67f7b2737a62">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6ZTNiMTc0MDA0NjZlNDZlN2FhNDMxZDA4YTUyOTUzZDYvdGFibGVyYW5nZTplM2IxNzQwMDQ2NmU0NmU3YWE0MzFkMDhhNTI5NTNkNl8wLTAtMS0xLTA_dd5fa498-5839-421f-9748-0174db085c33">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU4_b1715ccb-0e9e-4a0b-8d10-f971d8b8a575">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ0_4c338f7c-48fb-48c9-b386-6390aebfa49d">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6NDdiMmYyODMzYWM1NGU3OGI4ODhmOTY2N2JjYjg3ZjMvdGFibGVyYW5nZTo0N2IyZjI4MzNhYzU0ZTc4Yjg4OGY5NjY3YmNiODdmM18wLTAtMS0xLTA_08ff9243-c9cb-4180-9f09-05f04eb5b721">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6NDdiMmYyODMzYWM1NGU3OGI4ODhmOTY2N2JjYjg3ZjMvdGFibGVyYW5nZTo0N2IyZjI4MzNhYzU0ZTc4Yjg4OGY5NjY3YmNiODdmM18wLTItMS0xLTA_96862025-6293-47ce-b2fe-0f37547ff8cc">94-3134940</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU1_8070beac-33cc-430e-8faa-42ade9084319">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ1_7518b88b-4fc5-4fe9-a1c4-80432a288188">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUy_297851b4-0c65-4752-87e7-92114a5cd743">California</ix:nonNumeric> <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU2_0b89d90e-5114-4db4-9bf7-49b6b7ace9be">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUz_8a6074df-2fd7-47b0-a29d-8d1171e5fb91">415</ix:nonNumeric>-<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ2_69b82ab8-1802-4aed-ab82-8df8cab85eea">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6M2QzODZhYjVlNjgwNDg0ZWIzODdjMDU3MjliNGFlODEvdGFibGVyYW5nZTozZDM4NmFiNWU2ODA0ODRlYjM4N2MwNTcyOWI0YWU4MV8xLTAtMS0xLTA_e8cb2440-d67a-46d1-8135-e8bcdeaed5bc">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6M2QzODZhYjVlNjgwNDg0ZWIzODdjMDU3MjliNGFlODEvdGFibGVyYW5nZTozZDM4NmFiNWU2ODA0ODRlYjM4N2MwNTcyOWI0YWU4MV8xLTEtMS0xLTA_32b8f29e-67c4-4a00-a8e4-9e8919fbc1c2">NKTR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6M2QzODZhYjVlNjgwNDg0ZWIzODdjMDU3MjliNGFlODEvdGFibGVyYW5nZTozZDM4NmFiNWU2ODA0ODRlYjM4N2MwNTcyOWI0YWU4MV8xLTItMS0xLTA_cf967417-24c9-4615-82b4-4a343cf0803a">NASDAQ Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUx_a3112e9f-18b0-4294-82f0-206990fe3833">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ5_a926333a-8769-4600-9fcb-1126863bd15e">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU0_b659c249-e465-40ff-9570-dc51e4518ca9">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU3_035109ee-906f-4ac8-9d25-d40a9778db09">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. :</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:20.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MGUxMGQ2NjQwZGM5NDE0Yzk0MTU4NTExNDNhOWMxNDMvdGFibGVyYW5nZTowZTEwZDY2NDBkYzk0MTRjOTQxNTg1MTE0M2E5YzE0M18wLTAtMS0xLTA_65ad5d3e-58ab-48bf-a891-8fca8ebe0230">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MGUxMGQ2NjQwZGM5NDE0Yzk0MTU4NTExNDNhOWMxNDMvdGFibGVyYW5nZTowZTEwZDY2NDBkYzk0MTRjOTQxNTg1MTE0M2E5YzE0M18xLTQtMS0xLTA_f0b3db36-b9d7-4d5f-9c6a-34d8f3e3e118">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MGUxMGQ2NjQwZGM5NDE0Yzk0MTU4NTExNDNhOWMxNDMvdGFibGVyYW5nZTowZTEwZDY2NDBkYzk0MTRjOTQxNTg1MTE0M2E5YzE0M18yLTEtMS0xLTA_ddb95d12-3a65-485d-96e9-4d4c2904968a">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF84MjQ2MzM3MjEyOTc2_32d21edd-92d1-4837-b3bd-6194ff4f1fea">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUw_f17d3bec-1091-40e2-a26b-5185594abf04">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the registrant&#8217;s common stock on the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June&#160;30, 2020, as reported on The NASDAQ Global Select Market, was approximately $<ix:nonFraction unitRef="usd" contextRef="ie5e6f011e7504a50be5144345c76cef1_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zMDUx_5fe30d76-0024-4917-a33e-625a0e56602c">4.1</ix:nonFraction> billion. This calculation excludes approximately 1,117,000 shares held by directors and executive officers of the registrant. Exclusion of these shares does not constitute a determination that each such person is an affiliate of the registrant.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;17, 2021, the number of outstanding shares of the registrant&#8217;s common stock was <ix:nonFraction unitRef="shares" contextRef="i640af33a74bf419599a75c9360372c8e_I20210217" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zMzcx_44eb93c4-c578-4d55-ad9e-7f682dbc616c">182,182,063</ix:nonFraction>. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ3_a4c010a8-2fb3-4d01-bef5-2cc1608bb082" escape="true">Portions of registrant&#8217;s definitive Proxy Statement to be filed for its 2020 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_1975">Summary of Risks</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_1975">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_22">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_25">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_28">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_31">50</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_37">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_40">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_43">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_58">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_58">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_58">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_61">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_61">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_61">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_166">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_166">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_166">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_169">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_169">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_169">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_172">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_172">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_172">107</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_175">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_178">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_178">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_178">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_181">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_181">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_181">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_184">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_184">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_184">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_187">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_187">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_187">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_190">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_190">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_190">108</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_193">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_196">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_196">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_196">109</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_199">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_199">114</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this annual report on Form&#160;10-K, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation or success of our collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this annual report on Form 10-K. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this annual report on Form 10-K, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:63pt"><span><br/></span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_1975"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item IA in this Form 10-K, which risks include, among others:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of bempegaldesleukin, our lead immuno-oncology (I-O) candidate, and our business will be significantly harmed if we are not successful in developing this drug candidate;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies could have a material and adverse impact on the value of our I-O pipeline;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on our collaboration partners to initiate, properly conduct and prioritize clinical trials for bempegaldesleukin and NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the operations of our collaboration partners may be more affected by the COVID-19 pandemic than we are, or they may adopt more restrictive procedures for addressing the COVID-19 pandemic, either of which would delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if the market size for a new drug that received approval is significantly smaller than we anticipate, it could negatively impact our revenue, results of operations and financial condition;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if third-party payers (including government programs) do not provide payment or reimbursement for our products, those products will not be widely accepted, which would negatively impact our business, results of operations and financial condition; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our revenue is exclusively derived from our collaboration agreements. If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be negatively harmed; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Business Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our drug candidates successfully.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to drug candidates granted Breakthrough Therapy designation by the United States Food and Drug Administration (FDA); </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available on commercially reasonable terms.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of general risks that are also faced by business generally. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_16"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Nektar Therapeutics is a research-based biopharmaceutical company focused on discovering and developing innovative medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value. We refer to our drug candidates where we retain at least U.S. commercial rights as &#8220;proprietary programs,&#8221; and refer to our other drug candidate programs where we have licensed U.S. and potentially other commercial rights to collaboration partners as &#8220;collaboration partner programs.&#8221;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Proprietary Programs</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the area of oncology, we have a particular focus on developing medicines in the area of I-O, which is a therapeutic approach based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. We are developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T&#160;cells and natural killer (NK) cells, to increase their numbers and to improve their function to recognize and attack cancer cells.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Bempegaldesleukin (previously referred to as NKTR-214), our lead I-O candidate, is a biologic with biased signaling through one of the Interleukin-2 (IL-2) receptor subunits (CD122) that can stimulate proliferation and growth of tumor-killing immune cells in the tumor micro-environment and increase expression of PD-1 on these immune cells.  Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to improve the standard of care in multiple oncology settings. To this end, we are executing a comprehensive clinical development program for bempegaldesleukin, including a broad clinical collaboration with the Bristol-Myers Squibb Company (BMS), several clinical collaborations with other third parties with pharmacological agents that have potential complementary mechanisms to bempegaldesleukin, as well as pursuing our own independent clinical studies.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 12, 2018, we entered into a Strategic Collaboration Agreement (BMS Collaboration Agreement) with BMS pursuant to which we and BMS are jointly developing bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab, a PD-1 inhibitor) and certain other agents. The key economic components of the collaboration transaction included BMS making a non-refundable up-front payment of $1.0 billion to Nektar and an $850.0 million premium equity investment in our common stock, BMS being responsible for a majority of the clinical costs of the collaboration development plan, wherein our annual funding obligation for collaboration development is limited to $125.0 million, Nektar retaining a 65% profit interest in bempegaldesleukin, and Nektar having the right to record global revenue for bempegaldesleukin commercial sales. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin under a broad joint development plan (Collaboration Development Plan) that was updated pursuant to an Amendment No. 1 entered into on January 9, 2020. The Collaboration Development Plan includes the ongoing registrational trials in first-line metastatic melanoma (for which the FDA granted Breakthrough Therapy designation), first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), muscle-invasive bladder cancer and adjuvant melanoma, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with a tyrosine kinase inhibitor in first line RCC to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently underway. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as specifically allowed under the BMS Collaboration Agreement, we are independently studying bempegaldesleukin in combination with agents outside of the Collaboration Development Plan. On February 12, 2021, we entered into a financing and co-development collaboration with SFJ Pharmaceuticals to support a Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in patients with squamous cell carcinoma of the head and neck whose tumors express PD-L1 (Combined Positive Score [CPS] &#8805;1) (the &#8220;SCCHN Study&#8221;). On February 17, 2021, we announced that we entered into a clinical trial and collaboration agreement with Merck (known as &#8220;MSD&#8221; outside the United States and Canada) under which Merck will supply Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> free of charge to us to support the SCCHN Study. In addition, we are independently studying bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a non-small cell lung cancer (NSCLC) Phase 1/2 trial.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are also conducting development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action.  For example, we are working in collaboration with Vaccibody AS to evaluate bempegaldesleukin in combination with Vaccibody&#8217;s personalized cancer neoantigen vaccine in a Phase 1 proof-of-concept study in patients with locally advanced or metastatic tumors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are also developing bempegaldesleukin in combination with NKTR-262. NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic bempegaldesleukin to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. The Phase 1/2 dose-escalation and expansion trial in patients with solid tumors is currently ongoing. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our next most advanced I-O program is NKTR-255.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of NK cells and induces survival of both effector and CD8 memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and the formation of long-term immunological memory, which may lead to sustained anti-tumor immune response.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular toxicity molecules as well as enhance CAR-T therapies. We have initiated a Phase 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. At the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, we reported early findings from the Phase 1 dose escalation study that demonstrated expansion of lymphocytes, increases in NK and CD8+ T cells in patients with multiple myeloma and non-Hodgkin lymphoma.  We have entered into a preclinical research collaboration with Janssen Research and Development, LLC (Janssen) to test the combination of NKTR-255 with therapies in Janssen&#8217;s oncology portfolio. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Virology</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary drug candidates, bempegaldesleukin and NKTR-255, also have potential applications in the area of virology. With regard to bempegaldesleukin, we believe this drug candidate&#8217;s ability to directly increase the numbers of anti-viral CD4+, CD8+ and NK lymphocytes, which are known to be critical for the resolution of many viral infections in people, and specifically infections with respiratory coronaviruses in a variety of animal models, could be useful as a therapeutic in treating individuals affected with COVID-19. We are studying in the clinic bempegaldesleukin as a treatment for mild COVID-19.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With regard to NKTR-255, we believe this drug candidate&#8217;s ability to activate and proliferate NK cells and memory CD8+ T cells to target activated CD4+ T cells can result in killing virus-infected cells.  We have entered into a preclinical research collaboration with Gilead to test the combination of NKTR-255 with therapies in Gilead&#8217;s antiviral portfolio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Collaboration Partner Programs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Immunology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease. The breakdown of mechanisms assuring recognition of self and non-self is what underlies all autoimmune diseases. A failure of the body&#8217;s self-tolerance mechanisms is known to result from pathogenic auto reactive T&#160;lymphocytes. By increasing the number of regulatory T&#160;cells (which are specific immune cells in the body that modulate the immune system and prevent autoimmune disease by maintaining self-tolerance), these pathogenic auto reactive T&#160;lymphocytes can be reduced, and the proper balance of effector and regulatory T&#160;cells can be achieved to restore the body&#8217;s self-tolerance mechanisms. There is consistent evidence that suboptimal regulatory T cell numbers and their lack of activity play a significant role in a myriad of autoimmune diseases. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T&#160;cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358 (&#8220;Lilly Agreement&#8221;). We received an initial payment of&#160;$150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones. We were responsible for completing Phase&#160;1 clinical development and certain drug product development and supply activities. We also share Phase&#160;1b and Phase 2 development </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will have the option to contribute funding to Phase&#160;3 development on an indication-by-indication basis, ranging from&#160;zero to 25%&#160;of the global Phase&#160;3 development costs. Based upon our level of contribution to the Phase 3 development costs and the level of annual global product sales, we are eligible to receive a royalty rate up to the low twenties for sales of NKTR-358 upon approval. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have completed the first Phase&#160;1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy subjects, and we also completed a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE).  Lilly has completed a single-ascending dose study of NKTR-358 in Japanese and Caucasian healthy subjects, and is conducting two Phase 2 studies of NKTR-358 in patients with SLE and ulcerative colitis as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Other Collaboration Partner Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxegol), under a global license agreement with AstraZeneca AB (AstraZeneca). MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral peripherally-acting opioid antagonist, for the treatment of opioid-induced constipation, a side effect caused by chronic administration of prescription opioid pain medicines. AstraZeneca markets and sells MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in collaboration with Daiichi Sankyo, Inc. (Daiichi). Kyowa Hakko Kirin Co. Ltd. (Kirin) has exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the naloxegol brand name in the EU) in the EU, Iceland, Liechtenstein, Norway and Switzerland.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a collaboration with Baxalta, Inc. (Baxalta, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Takeda) to develop and commercialize PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients. Under this collaboration, we worked with Baxalta to develop ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia A based on ADVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Antihemophilic Factor (Recombinant)). ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was first approved by the FDA in late 2015 for Hemophilia A. ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has also been approved in the European Union, Japan, Korea, Canada, and certain other countries using the same or similar brand names such as ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also have a number of license, manufacturing and supply agreements with other leading biotechnology and pharmaceutical companies, including Amgen, Inc., Pfizer and UCB Pharma (UCB). More than 10 products using our PEGylation technology have received regulatory approval in the U.S. or the EU. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We were incorporated in California in 1990 and reincorporated in Delaware in 1998. We maintain our executive offices at 455 Mission Bay Boulevard South, San Francisco, California 94158, and our main telephone number is (415)&#160;482-5300. Our website is located at www.nektar.com. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Technology Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a leader in the polymer conjugation field, we have advanced our technology platform to include new advanced polymer technologies that can be tailored in specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules, including many classes of drugs targeting numerous disease areas. Polymer conjugation or PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen&#8217;s Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegfilgrastim) and UCB&#8217;s CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol). Nearly all of the PEGylated drugs approved over the last fifteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of well-known biotechnology and pharmaceutical companies. PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body. Its primary use to date has been in currently approved biologic drugs to favorably alter their pharmacokinetic or pharmacodynamic properties. However, in spite of its widespread success in commercial drugs, there are some limitations with the first-generation PEGylation approaches that have been used with biologics. For example, these first generation techniques cannot be used successfully to create small molecule drugs which could potentially benefit from the application of the technology. Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With our expertise and proprietary technology in polymer conjugation, we have created the next generation of PEGylation technology. Our advanced polymer conjugation technology platform is designed to overcome the limitations of  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first generation techniques to allow for the application of technology to a broader range of molecules across many therapeutic areas. We have also developed robust manufacturing processes for generating second generation PEGylation reagents that allow us to utilize the full potential of these newer approaches.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve efficacy or safety of a drug as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve targeting or binding affinity of a drug to its target receptors with the potential to improve efficacy and reduce toxicity or drug resistance;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve solubility of a drug;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">enable oral administration of parenterally-administered drugs, or drugs that must be administered intravenously or subcutaneously, and increase oral bioavailability of small molecules;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">prevent drugs from crossing the blood-brain barrier, or reduce their rate of passage into the brain, thereby limiting undesirable central nervous system effects;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce first-pass metabolism effects of certain drug classes with the potential to improve efficacy, which could reduce the need for other medicines and reduce toxicity;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce the rates of drug absorption and of elimination or metabolism by improving stability of the drug in the body and providing it with more time to act on its target;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differentially alter binding affinity of a drug for multiple receptors, improving its selectivity for one receptor over another; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce immune response to certain macromolecules with the potential to prolong their effectiveness with repeated doses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a broad range of approaches that we may use when designing our own drug candidates, some of which are further described below.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large Molecule Pro-Drug Releasable Polymer Conjugates (Cytokines)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customized approaches with large molecule polymer conjugates can be applied to biologics, in particular cytokines, which utilize the polymer as a means to bias action to a certain receptor or receptor sub-type.   In addition, a cytokine&#8217;s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended. An example of this is bempegaldesleukin, which is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient&#8217;s own immune system to fight cancer, without over-activating the immune system, with an every two or every three-week dosing schedule.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large Molecule Polymer Conjugates (Proteins and Peptides)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customized approaches with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today. Through rational drug design, a protein&#8217;s or peptide&#8217;s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended. An example of this is Baxalta&#8217;s ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. In December 2016, the FDA expanded the approval of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for use in surgical settings for both adults and pediatric patients, and also for the treatment of Hemophilia A in pediatric patients under 12 years of age.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our scientists have shown that we can also optimize relative receptor binding characteristics of large molecule conjugates. For instance, the cytokine IL-2 has two different receptor complexes in the body that cause opposing effects on the immune system. We have engineered different novel conjugates of IL-2 with optimized differential receptor binding to the IL-2 receptor categories in the immune system. By biasing the receptor binding of these molecules in complementary ways, we have made two different drug candidates: bempegaldesleukin, which selectively activates effector T&#160;cells, which kill tumors; and NKTR-358, which selectively activates regulatory T&#160;cells, which can reduce the pathological immune activation that underlies many autoimmune diseases.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Stable Polymer Conjugates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customized approach for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit. In addition, this approach can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that have low bioavailability when delivered orally. The benefits of this approach can also include: improved potency, modified biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane barriers in the body, such as the blood-brain barrier. An example of reducing transport across the blood-brain barrier is MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an orally-available peripherally-acting opioid antagonist that is approved in the United States, the EU and other countries. </span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Pro-Drug Releasable Polymer Conjugates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase its efficacy and improve its side effect profile. We are currently using this platform for NKTR-262.  For NKTR-262 and other oncolytics, this platform can improve sub-optimal half-lives that can limit therapeutic efficacy. With our releasable polymer conjugate technology platform, we believe that oncolytic drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Fragment Polymer Conjugates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody. The specially designed PEG replaces the function of the fragment crystallizable (Fc) domain of full length antibodies with a branched architecture PEG with either stable or degradable linkage. This approach can be used to reduce antigenicity, reduce glomerular filtration rate, enhance uptake by inflamed tissues, and retain antigen-binding affinity and recognition. One approved product on the market that utilizes our technology with an antibody fragment is CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certoluzimab pegol), which was developed by our partner UCB and is approved for the treatment of Crohn&#8217;s Disease and ankylosing spondylitis in the U.S., axial spondyloarthritis in the EU and psoriatic arthritis and rheumatoid arthritis in the U.S. and EU.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The key elements of our business strategy are described below:</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advance Our Proprietary Clinical Pipeline of Drug Candidates that Leverage Our Advanced Polymer Conjugate Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our objective is to create value by advancing our lead drug candidates through various stages of clinical development. To support this strategy, we leverage the expertise and experience within our internal research, preclinical, clinical development and regulatory departments. A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of existing drugs and drug candidates as well as established pharmacologic targets and drugs directed to those targets. For some of our novel drug candidates, we may seek to study the drug candidates in indications for which the parent drugs have not been studied or approved. We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies. In addition, in certain instances we have the opportunity to develop new treatments for patients for which the parent drugs are not currently approved.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensure Future Growth of our Proprietary Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business. Our discovery research organization is continuing to identify new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and proteins, peptides and antibodies, across multiple therapeutic areas. We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early-stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transition to a Fully-Integrated Specialty Biotechnology Company with a Commercial Capability in the I-O Therapeutic Area</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are successful with the development of bempegaldesleukin or one of our I-O drug candidates and one or more of them is approved, we plan to establish a commercial capability in the U.S. and other select major markets to market, sell and distribute these proprietary I-O therapies.&#160;&#160;Under our BMS Collaboration Agreement, we retained significant global commercial rights to bempegaldesleukin including global co-promotion rights for all combinations of bempegaldesleukin with any BMS proprietary therapy, and we lead global commercialization for all other bempegaldesleukin combination regimens. We also have the contractual right under our BMS Collaboration Agreement to record all worldwide sales and revenue&#160;for bempegaldesleukin and we have final decision-making authority regarding the pricing of bempegaldesleukin.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selectively Enter into Strategic Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We decide on a drug-candidate-by-drug-candidate basis, how far to advance clinical development (e.g., Phase&#160;1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches. When we determine to seek a partner, our strategy is to selectively access a partner&#8217;s development, regulatory, or commercial capabilities with the structure of the collaboration depending on factors such as economic risk sharing, the cost and complexity of development, marketing and commercialization needs, therapeutic areas, potential for combination of drug programs, and geographic capabilities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continue to Build a Leading Intellectual Property Estate in the Field of Polymer Conjugate Chemistry across Therapeutic Modalities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are committed to continuing to build on our intellectual property position in the field of polymer conjugate chemistry. To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions, including among others, polymer materials, conjugates, formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nektar Proprietary Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table summarizes our proprietary drugs that are being developed by us or in collaboration with other pharmaceutical companies or independent investigators. The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug Candidate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (CD122-preferential IL-2 pathway agonist)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immuno-oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2, and Phase 3 studies ongoing in multiple indications</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358 (cytokine Treg stimulant)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune Disease</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-262 (toll-like receptor agonist)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 (IL-15 receptor agonist)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immuno-oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 1/2</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research/Preclinical</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Status definitions are:</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 or Pivotal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; drug candidate in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).</span></div><div style="padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate in clinical trials to establish dosing and efficacy in patients.</span></div><div style="padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate in clinical trials, typically in healthy subjects, to test safety.</span></div><div style="padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research/Preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate is being studied in research by way of in vitro studies and/or animal studies</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Nektar Proprietary Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-oncology (I-O)</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bempegaldesleukin (previously known as NKTR-214, cytokine immunostimulatory therapy)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient&#8217;s own immune system to fight cancer without over-activating the immune system.&#160;&#160;Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural (NK) cell populations in the body, which are known as endogenous tumor-infiltrating lymphocytes (TILs). Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122-specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and NK cells. CD122, which is also known as the IL-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these CD8+ effector T cells. This receptor selectivity is intended to increase efficacy and improve safety over existing immunostimulatory cytokine drugs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The development program for bempegaldesleukin includes combinations with a number of therapeutic approaches where we believe there is a strong biologic rationale for complementary mechanisms of action. On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement with BMS, pursuant to which we and BMS collaborated to conduct Phase&#160;1/2 clinical trials evaluating bempegaldesleukin and BMS&#8217; human monoclonal antibody that binds to PD-1, known as Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as a potential combination treatment regimen in five tumor types and eight potential indications (each, a Combined Therapy Trial). In the first phase of the PIVOT-02 study, we evaluated the clinical benefit, safety, and tolerability of combining bempegaldesleukin with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in thirty-eight patients. Interim data from the dose-escalation phase of the trial was presented at the 2017 SITC meeting in November 2017. We identified the recommended Phase 2 dose for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The second phase of the expansion cohorts, which now falls under the BMS Collaboration Agreement entered into on February 13, 2018, and described below, is evaluating the safety and efficacy of combining bempegaldesleukin with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 13, 2018, we entered into the second agreement with BMS (the BMS Collaboration Agreement), pursuant to which we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and in combination with other compounds (whether from BMS, a third party, or from our own portfolio). Under the BMS Collaboration Agreement, we and BMS will collaborate to develop and conduct clinical studies of bempegaldesleukin pursuant to the Collaboration Development Plan, and we will jointly commercialize bempegaldesleukin on a worldwide basis. </span><span style="color:#2e2e2e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2018, the closing date of the transaction,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased $850.0 million of our common stock at a purchase price of $102.60 per share pursuant to a Share Purchase Agreement (Purchase Agreement). We are eligible to receive additional cash payments up to a total of approximately $1.455&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon achievement of certain development and regulatory milestones, and up to a total of $350.0&#160;million upon achievement of certain sales milestones. Under the BMS Collaboration Agreement, we have the contractual right to record all worldwide sales and revenue for bempegaldesleukin. BMS will lead commercialization for combinations of bempegaldesleukin with BMS proprietary medicines, and we will lead all other commercialization efforts for bempegaldesleukin. We will have the final decision-making authority regarding the pricing for bempegaldesleukin. Bempegaldesleukin will be sold on a stand-alone basis and there will be no fixed-dose combinations or co-packaging without the consent of both parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On August 1, 2019, we and BMS announced that the FDA granted Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with previously untreated unresectable or metastatic melanoma.  Breakthrough Therapy designation is intended to expedite the development and review of medicines aimed at treating serious or life-threatening disease where there is preliminary evidence that the investigational therapy may offer substantial improvement over existing therapies on at least one clinically significant endpoint. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into an Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. Specifically, pursuant to the updated Collaboration Development Plan, bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently being evaluated in ongoing registrational trials in first-line metastatic melanoma, first-line cisplatin ineligible, PDL1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), muscle-invasive bladder cancer, and adjuvant melanoma, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with either axitinib or cabozantinib in first line RCC in order to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently underway. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amendment did not alter the cost-sharing methodology under the BMS Collaboration Agreement. The parties share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, we share clinical development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BMS 67.5% and Nektar 32.5%. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. BMS supplies Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> free of charge. We also share commercialization related costs, 35% BMS and 65% Nektar. Our share of development costs is limited to an annual cap of $125.0 million. Neither party will develop a therapy using an IL-2 agonist in combination with a small or large molecule that binds to the PD(L)-1 target, in indications included in the Collaboration Development Plan (each, a Competing Combination), whether alone or in collaboration with any third party, during a limited exclusivity period from the closing date under the BMS Collaboration Agreement until the later of (i) the first commercial sale of bempegaldesleukin or (ii) the third anniversary of the closing date, but each party may develop a Competing Combination on its own (but not in collaboration with any third party) during the three years after the end of the foregoing limited exclusivity period. Other than as described above, Nektar may independently develop and commercialize bempegaldesleukin either alone or in combination with other Nektar proprietary compounds or third party compounds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Outside of the Collaboration Development Plan with BMS, we are also conducting a broad array of development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. Our strategic objective is to establish bempegaldesleukin as a key component with many immuno-oncology combination regimens with the potential to raise the standard of care in multiple oncology settings.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, as specifically allowed under the BMS Collaboration Agreement, we are independently studying bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a PD-1 inhibitor.  On February 12, 2021, we entered into a financing and co-development collaboration with SFJ Pharmaceuticals to support a Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with head and neck cancer whose tumors express PD-L1 (Combined Positive Score [CPS] &#8805;1).  Also, we are working in collaboration with Vaccibody AS to evaluate bempegaldesleukin with Vaccibody&#8217;s personalized cancer neoantigen vaccine in a Phase 1 proof-of-concept study.  In addition, we are independently studying bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a non-small cell lung cancer (NSCLC) Phase 1/2 trial. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With our non-BMS clinical collaborations for bempegaldesleukin, generally each party supports the collaboration based on its expertise and resources. For example, our co-development collaboration agreement with SFJ includes both financial support in the form of up to $150 million to fund the Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in head and neck cancer, as well as operational support in managing the clinical trial.  In addition, we announced on February 17, 2021, that we had entered into a clinical trial collaboration and supply agreement with Merck wherein we will receive supplies of Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost to us. We expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging scientific findings in cancer biology and preclinical development work.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to these non-BMS clinical collaborations for bempegaldesleukin, we intend to initiate further clinical development programs, on our own or in collaboration with other potential partners, to explore the potential of combining bempegaldesleukin with other therapies such as cancer vaccines (other than Vaccibody&#8217;s personalized cancer neoantigen vaccine), adoptive cell therapy, and other small molecules and biological agents in order to generate novel immuno-oncology approaches.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-262</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to overcome the body&#8217;s dysfunction of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T&#160;cells. NKTR-262 is being developed as a single intra-tumoral injection to be administered at the start of therapy with bempegaldesleukin in order to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. We initiated enrollment of patients in the initial Phase 1/2 clinical study in April 2018, which we call the REVEAL study, and the dose-escalation portion of this clinical study is ongoing.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-255</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of NK cells and induces survival of both effector and CD8 memory T cells. Recombindant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and the formation of long-term immunological memory, which may lead to sustained anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular toxicity molecules as well as enhance CAR-T therapies. We have initiated a Phase 1 clinical study </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. Additionally, we have entered into separate preclinical research collaborations with Gilead and Janssen to test the combination of NKTR-255 with therapies in Gilead&#8217;s antiviral portfolio and Janssen&#8217;s oncology portfolio, respectively. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Partner Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table outlines our collaborations with a number of pharmaceutical companies that currently license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products. More than ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe. There are also a number of other candidates that have been filed for approval or are in various stages of clinical development. These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary or Target<br/>Indications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug<br/>Marketer/Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Status(1)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2015*</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxegol tablets) and&#160;&#160;MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid-induced constipation in adult patients with chronic non-cancer pain (US); Opioid-induced constipation in adult patients who have and inadequate response to laxatives (EU).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2014*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn&#8217;s disease, Rheumatoid arthritis, and Psoriasis/ Ankylosing Spondylitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2008**</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (C.E.R.A.) (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche&#160;Ltd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2007**</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegaptanib sodium injection)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Age-related macular degeneration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2004</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegvisomant)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2003</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegfilgrastim)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2002</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dapirolizumab Pegol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma (Biogen)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Status definitions are:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; regulatory approval to market and sell product obtained in one or more of the U.S., EU or other countries. Year indicates first regulatory approval.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; an application for approval and marketing has been filed with the applicable government health authority.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 or Pivotal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; drug candidate in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate in clinical trials to establish dosing and efficacy in patients.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a drug candidate in clinical trials, typically in healthy subjects, to test safety.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research/Preclinical &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a drug candidate is being studied in research by way of in vitro studies and/or animal studies.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  *&#160;&#160;&#160;&#160;In December 2020, pursuant to a purchase and sale agreement (the &#8220;2020 Purchase and Sale Agreement&#8221;) we sold our rights to receive royalties on future worldwide new sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and specified licensed products under a Right to Sublicense Agreement, dated October 27, 2017) from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With respect to all of our collaboration and license agreements with third parties, please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition&#8221; and &#8220;We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.&#8221; </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Collaboration Partner Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a number of drug candidates in clinical development and approved products in collaboration with our partners where we invented the drug candidate or where our collaboration partners have licensed our proprietary intellectual property to enable one of their drug candidates. Our agreements with collaboration partners may involve several elements including an intellectual property license as well as the development, commercialization, and manufacturing and supply obligations. We typically receive consideration from our collaboration partners in the form of upfront payments, milestone payments and royalties on sales. In certain cases, we also manufacture and supply our proprietary polymer materials to our partners.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-358, Agreement with Eli Lilly and Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NKTR-358 is designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease. Current systemic treatments for autoimmune disease, including corticosteroids and anti-TNF agents, suppress the immune system broadly and come with severe side effects. NKTR-358 targets the CD25 sub-receptor in the IL-2 pathway in order to stimulate proliferation and growth of regulatory T cells, which are specific immune cells in the body that modulate the immune system and prevent autoimmune disease by maintaining self-tolerance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into the Lilly Agreement, pursuant to which we and Lilly will co&#8209;develop NKTR-358. Under the terms of the Lilly Agreement, we received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. We have completed our Phase&#160;1 clinical development and certain drug product development and drug supply responsibilities assigned to us under the Lilly Agreement. We will share Phase&#160;2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will also have the option to contribute funding to Phase&#160;3 development on an indication-by-indication basis, ranging from zero to 25% of the global Phase&#160;3 development costs. We are eligible to receive up to double-digit sales royalty rates that escalate based upon our contribution to Phase&#160;3 development costs and the level of global product annual sales. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have completed the first Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy subjects. Results from this study demonstrated a multiple-fold increase in regulatory T cells with no change in CD8 positive or natural killer cell levels and no dose-limiting toxicities were observed. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with SLE. Lilly has completed a single-ascending dose study of NKTR-358 in Japanese and Caucasian healthy subjects, and is conducting two Phase 2 studies of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358 in patients with SLE and ulcerative colitis as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (previously referred to as BAX 855), ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in Europe) and Longer-Acting Blood Clotting Proteins for Hemophilia A, Agreement with Subsidiaries of Baxalta Incorporated</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement (Baxalta License Agreement) with certain subsidiaries of Baxalta (which has been acquired by Takeda), to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology. The first product in this collaboration, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (previously referred to as BAX 855), is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein that was developed to increase the half-life of ADVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method). ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was first approved by the FDA on November 30, 2015.&#160;&#160;Since then it has been approved in one or more indications for Hemophilia A in the EU, Japan, and other countries around the world.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are entitled to $35.0 million of sales milestone payments, as well as royalties on net sales varying by product and country of sale. With regard to the sales milestone payments, we received a $10.0 million dollar milestone payment in 2019 for annual net sales in 2018 achieving the sales milestone specified in the Baxalta License Agreement for this payment.  With regard to royalties, our royalties start in the mid-single digits for net sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion. Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents to a third party that were previously exclusively licensed to Baxalta under the Baxalta License Agreement. Under the right to sublicense agreement, Baxalta paid us $12.0 million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the third party products covered under the sublicense throughout the term of the right to sublicense agreement.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, pursuant to the 2020 Purchase and Sale Agreement we sold our rights to receive royalties on future worldwide new sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and from the third party products under the right to sublicense agreement from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires. This 2020 Purchase and Sale Agreement is further discussed in Note 7 of our Consolidated Financial Statements.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately one in 5,000 live births and there are about 20,000 people with hemophilia in the US. All races and ethnic groups are affected. Hemophilia A is four times as common as Hemophilia B while more than half of patients with Hemophilia A have the severe form of hemophilia.  According to 360 Research Reports, the worldwide market for human coagulation Factor VIII products was $7.4 billion in 2019.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> and MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in Europe), Agreement with AstraZeneca AB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was developed using our oral small molecule polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an orally-available peripherally-acting mu-opioid antagonist which is a medication for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications. Opioids attach to specific proteins called opioid receptors. When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On September 16, 2014, the FDA approved MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain. On </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the naloxegol brand name in the EU) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). The EC&#8217;s approval applies to all EU member countries plus Iceland and Norway. AstraZeneca launched the commercial sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. in March 2015 and MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany, the first EU member country, in August 2015. Under the terms of our license agreement with AstraZeneca, AstraZeneca made an initial license payment of $125.0&#160;million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received milestone payments of $70.0&#160;million and $25.0&#160;million upon the acceptance of regulatory approval applications of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by the FDA and the EMA, respectively, in 2013. We received an additional developmental milestone payment of $35.0 million upon the FDA&#8217;s approval of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and $40.0 million for MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany. We are also entitled to up to $375.0 million in sales milestones for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the program achieves certain annual commercial sales levels and significant double-digit royalty payments starting at 20% of net sales in the U.S. and, for countries AstraZeneca has not entered into sublicensing agreements, 18% of net sales in rest of world. On March 1, 2016, AstraZeneca announced that it had entered into an agreement with Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Nektar&#8217;s receipt of a 40% share of royalty payments made by Kirin to AstraZeneca will be financially equivalent to Nektar receiving high single-digit to low double-digit royalties depending on Kirin&#8217;s annual net sales levels. Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a)&#160;a specified period of time after the first commercial sale of the product in that country or (b)&#160;the expiration of patent rights in that particular country. In December 2020, pursuant to the 2020 Purchase and Sale Agreement, we sold our rights to receive royalties on future worldwide new sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires. This 2020 Purchase and Sale Agreement is further discussed in Note 7 of our Consolidated Financial Statements. AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fixed-dose combination product and has the right to develop multiple products which combine MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with opioids.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of patents relevant to MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, some of which are listed in the FDA&#8217;s &#8220;Orange Book.&#8221;&#160;The &#8220;Orange Book&#8221; currently lists six patents for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Four patents (i.e., U.S. Patent Nos. 7,056,500, 7,662,365, 7,786,133 and 9,012,469) are &#8220;composition of matter patents,&#8221; one of which has a patent expiry extending into 2032.&#160;In addition, two patents (i.e., U.S. Patent Nos. 8,067,431 and 8,617,530) are directed to methods of treatment.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2000, we entered into a license, manufacturing and supply agreement covering our proprietary PEGylation materials for use in CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol) with Celltech Chiroscience Ltd., which was acquired by UCB in 2004. Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses. We also manufacture and supply UCB with our proprietary PEGylation reagent used in the manufacture of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on a fixed price per gram. We were also entitled to receive royalties on net sales of the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product for the longer of ten years from the first commercial sale of the product anywhere in the world or the expiration of patent rights in a particular country. In February 2012, we sold our rights to receive royalties on all future worldwide net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012 until the agreement with UCB is terminated or expires. This sale is further discussed in Note&#160;7 of our Consolidated Financial Statements. Our agreement with UCB Pharma expires upon the expiration of all of UCB&#8217;s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties. In addition, UCB may terminate the agreement should it cease the development and marketing of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and either party may terminate for cause under certain conditions.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (C.E.R.A.) (Continuous Erythropoietin Receptor Activator), Agreement with F.&#160;Hoffmann-La&#160;Roche Ltd and Hoffmann-La Roche Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (Roche), which was amended and restated in its entirety in December 2005. Pursuant to the agreement, we license our intellectual property related to our proprietary PEGylation materials for the manufacture and commercialization of Roche&#8217;s MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis. As of the end of 2006, we were no longer required to manufacture and supply our proprietary PEGylation materials for MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our original agreement. In February 2012, we entered into a toll-manufacturing agreement with Roche under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which we manufactured our proprietary PEGylation material for MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Roche entered into the toll-manufacturing agreement with the objective of establishing us as a secondary back-up source on a non-exclusive basis through December 31, 2016. Under the terms of this agreement, Roche paid us an up-front payment of $5.0 million plus a total of $22.0 million in performance-based milestone payments upon our achievement of certain manufacturing readiness, validation and production milestones, including the delivery of specified quantities of PEGylation materials, all of which were successfully completed by the end of January 2013. In 2013, we delivered additional quantities of PEGylation materials used by Roche to produce PEGASYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for total consideration of approximately $18.6 million. We were also entitled to receive royalties on net sales of the MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. In February 2012, we sold all of our future rights to receive royalties on future worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012. This sale is further discussed in Note&#160;7 of our Consolidated Financial Statements. As of December 31, 2016, we no longer had any continuing manufacturing or supply obligations under this MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with Bausch Health Companies Inc., formerly Valeant Pharmaceuticals International, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2002, we entered into a license, manufacturing and supply agreement with Eyetech, Inc. (subsequently acquired by Valeant Pharmaceuticals International, Inc. or Valeant), pursuant to which we license certain intellectual property related to our proprietary PEGylation technology for the development and commercialization of Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a PEGylated anti-vascular endothelial growth factor aptamer currently approved in the U.S.&#160;and EU for age-related macular degeneration. Under the terms of the agreement, we will receive royalties on net product sales in any particular country for the longer of ten years from the date of the first commercial sale of the product in that country or the duration of patent coverage. Our agreement with Valeant expires upon the expiration of our last relevant patent containing a valid claim. In addition, Valeant may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with Pfizer, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In January 2000, we entered into a license, manufacturing and supply agreement (LMS Agreement) with Sensus Drug Development Corporation (subsequently acquired by Pharmacia Corp. in 2001 and then acquired by Pfizer in 2003), for the PEGylation of Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegvisomant), a human growth hormone receptor antagonist for the treatment of acromegaly. In January 2017, we entered into a master material supply agreement (Supply Agreement) with Pfizer, in which the LMS Agreement was terminated.  We currently manufacture our proprietary PEGylation reagent for Pfizer on a price per gram basis under the Supply Agreement.  Our obligation under the Supply Agreement to supply our proprietary PEGylation reagent to Pfizer continues until December 31, 2023.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with Amgen, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In July 1995, we entered into a non-exclusive supply and license agreement (the 1995 Agreement) with Amgen, Inc., pursuant to which we licensed our proprietary PEGylation technology to be used in the development and manufacture of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> selectively stimulates the production of neutrophils that are depleted by cytotoxic chemotherapy, a condition called neutropenia that makes it more difficult for the body to fight infections. On October&#160;29, 2010, we amended and restated the 1995 Agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and an amended and restated license agreement with Amgen Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $50.0&#160;million upfront payment in return for guaranteeing supply of certain quantities of Polymer Materials to Amgen. According to its terms, the 2010 Agreement expired on October&#160;29, 2020.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dapirolizumab Pegol, Agreement with UCB Pharma S.A.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., (UCB) under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEGylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE). In 2014, UCB and Biogen completed a Phase 1b randomized, double-blind, placebo-controlled clinical study in approximately 24 patients with SLE. Data from the study was published in September 2015 at the Annual American College of Rheumatology Meeting and showed that multiple administrations of dapirolizumab pegol given over 12 weeks were generally well-tolerated and the safety profile supported further development of the compound. Exploratory analyses from the same study showed greater improvement in clinical measures of disease activity in the dapriolizumab pegol group versus placebo. In 2016, UCB initiated a multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging Phase 2 clinical study followed by an observational period to evaluate the efficacy and safety of patients with moderately to severely active SLE receiving stable standard of care </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medications. In October 2018, UCB announced that the primary endpoint of the study to demonstrate a dose response at 24 weeks on the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) was not met and stated that it and Biogen will continue to further evaluate these data while assessing potential next steps.  In July 2019, Biogen announced a plan to initiate with UCB a Phase 3 study of dapriolizumab pegol in patients with active SLE, which clinical study is currently ongoing.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Development and Approval Process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The research and development, clinical testing, manufacture and marketing of products using our technologies are subject to regulation by the FDA and by comparable regulatory agencies in other countries. These national agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing (in&#160;vitro, in animals, and in human clinical trials), manufacture, labeling, storage, recordkeeping, approval, marketing, advertising and promotion of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S.&#160;depends on whether the chemical composition of the product has previously been approved for use in other dosage forms. If the product is a new chemical entity that has not been previously approved, the process includes the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extensive preclinical laboratory and animal testing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission of an Investigational New Drug (IND) prior to commencing clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for the intended indication;&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extensive pharmaceutical development for the characterization of the chemistry, manufacturing process and controls for the active ingredient and drug product; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of a New Drug Application (NDA) for approval of a drug or a Biological License Application (BLA) for approval of a biological product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests, including those relating to systemic toxicity normally required for the IND and NDA or BLA, and clinical trials, may not be necessary if the company has a right of reference to existing preclinical or clinical data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section&#160;505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation. Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations. The results of the preclinical tests for drugs, biological products and combination products subject to the primary jurisdiction of the FDA&#8217;s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) are submitted to the FDA as part of the IND and are reviewed by the FDA before clinical trials can begin. Clinical trials may begin 30&#160;days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period. Clinical trials involve the administration of the drug to healthy volunteers or patients under the supervision of a qualified, identified medical investigator according to a protocol submitted in the IND for FDA review. Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP). Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study. Each protocol is submitted to the FDA in the IND.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Apart from the IND process described above, each clinical study must be reviewed by an independent Institutional Review Board (IRB), and the IRB must be kept current with respect to the status of the clinical study. The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted. The IRB also reviews and approves the informed consent form to be signed by the trial participants and any significant changes in the clinical trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Clinical trials are typically conducted in three sequential phases. Phase 1 involves the initial introduction of the drug into healthy human subjects (in most cases) and the product generally is tested for tolerability, pharmacokinetics, absorption, metabolism and excretion. Phase 2 involves studies in a limited patient population to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">determine the preliminary efficacy of the product for specific targeted indications;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">determine dosage and regimen of administration;&#160;and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identify possible adverse effects and safety risks.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If Phase 2 trials demonstrate that a product appears to be effective and to have an acceptable safety profile, Phase 3 trials are typically undertaken to evaluate the further clinical efficacy and safety of the drug and formulation within an expanded patient population at geographically dispersed clinical study sites and in large enough trials to provide statistical proof of efficacy and tolerability. The FDA, the clinical trial sponsor, the investigators or the IRB may suspend clinical trials at any time if any one of them believes that study participants are being subjected to an unacceptable health risk. In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Following a series of formal meetings and communications between the drug sponsor and the regulatory agencies, the results of product development, preclinical studies and clinical studies are submitted to the FDA as an NDA or BLA for approval of the marketing and commercial shipment of the drug product. The FDA may deny approval if applicable regulatory criteria are not satisfied or may require additional clinical or pharmaceutical testing or requirements. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria for approval. Additionally, the approved labeling may narrowly limit the conditions of use of the product, including the intended uses, or impose warnings, precautions or contraindications which could significantly limit the potential market for the product. Further, as a condition of approval, the FDA may impose post-market surveillance, or Phase 4, studies or risk evaluation and mitigation strategies. Product approvals, once obtained, may be withdrawn if compliance with regulatory standards is not maintained or if safety concerns arise after the product reaches the market. The FDA may require additional post-marketing clinical testing and pharmacovigilance programs to monitor the effect of drug products that have been commercialized and has the power to prevent or limit future marketing of the product based on the results of such programs. After approval, there are ongoing reporting obligations concerning adverse reactions associated with the product, including expedited reports for serious and unexpected adverse events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each manufacturing establishment producing the active pharmaceutical ingredient and finished drug product for the U.S.&#160;market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment. Such inspections are also held periodically after commercialization. Manufacturing establishments of U.S.&#160;marketed products are subject to inspections by the FDA for compliance with cGMP and other U.S.&#160;regulatory requirements. They are also subject to U.S.&#160;federal, state, and local regulations regarding workplace safety, environmental protection and hazardous controls, among others.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In situations where our partners are responsible for clinical and regulatory approval procedures, we may still participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for polymer conjugation materials or drug product. For our proprietary products, we prepare and submit an IND and are responsible for additional clinical and regulatory procedures for drug candidates being developed under an IND. The clinical and manufacturing, development and regulatory review and approval process generally takes a number of years and requires the expenditure of substantial resources. Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and success in obtaining marketing approvals from the FDA and equivalent foreign health authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales of our products outside the U.S.&#160;are subject to local regulatory requirements governing clinical trials and marketing approval for drugs. Such requirements vary widely from country to country.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA may grant Fast Track or Breakthrough Therapy designation to a drug candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Important features of Fast Track or Breakthrough Therapy designation include a potentially reduced clinical program and close, early communication between the FDA and the sponsor company to improve the efficiency of product development.  On August 1, 2019, we and BMS announced that the FDA granted Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with previously untreated unresectable or metastatic melanoma.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;The company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. In addition, the Orphan Drug Act provides for protocol assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be &#8220;clinically superior&#8221; to the original orphan </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug in that it is more effective, safer or otherwise makes a &#8220;major contribution to patient care&#8221; or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Similar incentives also are available for orphan drugs in the EU.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage, Reimbursement, and Pricing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales of any products for which we may obtain regulatory approval depend, in part, on the coverage and reimbursement status of those products. In the U.S., sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payers. Third-party payers include government programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care providers, private health insurers and other organizations. Other countries and jurisdictions will also have their own unique mechanisms for approval and reimbursement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process for determining whether a payer will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payer will pay for the product. Third-party payers may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication. Third-party payers may also refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Further, private payers often follow the coverage and payment policies established by certain government programs, such as Medicare and Medicaid, which require manufacturers to comply with certain rebate, price reporting, and other obligations. For example, the Medicaid Drug Rebate Program, which is part of the Medicaid program (a program for financially needy patients, among others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services under which the manufacturer agrees to report certain prices to the government and pay rebates to state Medicaid programs on outpatient drugs furnished to Medicaid patients, as a condition for receiving federal reimbursement for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Further, in order for a pharmaceutical product to receive federal reimbursement under Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the Public Health Service&#8217;s 340B drug pricing program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Third-party payers are increasingly challenging the prices charged for medical products and services, and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the price of therapeutics have been a focus in this effort. The U.S. government and state legislatures have shown significant interest in implementing cost-containment programs, including price controls and restrictions on reimbursement, among other controls. Adoption of price controls or other cost-containment measures could limit coverage for or the amounts that federal and state governments or private payers will pay for health care products and services, which could also result in reduced demand for our drug candidates or additional pricing pressures and affect our ultimate profitability, if approved. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes, referred to as the &#8220;HIPAA All-payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website.  Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If our drug candidates become commercialized, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act (collectively, the Affordable Care Act), enacted in 2010, expanded the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal fraud statutes contained within 42 U.S.C. &#167;&#160;1320a-7b. Pursuant to the Affordable Care Act, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent. Although we would not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. Penalties for a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,463 and $23,331 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In each country or jurisdiction outside of the U.S. in which we seek and receive regulatory approval to commercialize our products, we will be subject to additional laws and regulations specific to those locations. These regulations and laws will also impact, among other things, our proposed sales and marketing programs in those jurisdictions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legislative and Regulatory Landscape</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of products regulated by the FDA or other government agencies. In addition to new legislation, FDA and healthcare fraud and abuse and coverage and reimbursement regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. Further, the 2020 Presidential and Congressional elections and political developments have caused the future state of many core aspects of the current health care marketplace to be uncertain. While specific changes and their timing are not yet apparent, there may be significant changes to the healthcare environment in the future that could have an adverse effect on anticipated revenues from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval. Furthermore, federal agencies, Congress, state legislatures, and the private sector have shown significant interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for or the amounts that federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures and affect our ultimate profitability.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We own more than 300 U.S. and 1,050 foreign patents and a number of pending patent applications that cover various aspects of our technologies. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our advanced polymer conjugate technologies and our proprietary drug candidates. More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, methods of administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates. Our patent portfolio contains patents and patent applications that encompass our advanced polymer conjugate technology platforms. Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world. Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid). In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets. Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets. Please refer to Item&#160;1A. Risk Factors, including but not limited to &#8220;We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.&#8221; In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs. Even if we believe we are free to work with a proprietary drug, we cannot guarantee that we will not be accused of, or determined to be, infringing a third party&#8217;s rights and be prohibited from working with the drug or found liable for damages. Any such restriction on access or liability for damages would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, opposition, reexamination or other proceedings that can result in the revocation of the patent or maintenance of the patent but in an amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">short period of protection, if any, following the commercialization of products encompassed by our patent.&#160;We may have to participate in post-grant proceedings before the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us. Please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;U.S.&#160;and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions and reagents, and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions. We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. We could incur substantial costs in defending ourselves and our partners against any such claims. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S.&#160;and abroad and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from third parties. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternative technology. The failure to obtain licenses if needed may have a material adverse effect on our business, results of operations and financial condition. Please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived from our collaboration agreements with partners, under which we may receive a combination of revenue elements including up-front payments for licensing agreements, clinical research reimbursement or co-funding, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties and/or product sales revenue. Our revenues are concentrated among a limited number of collaboration partners under long-term arrangements. In particular, our collaboration arrangements with BMS represent 89% of our revenues for the year ended December 31, 2018, and Lilly represented 42% of our revenues for the year ended December 31, 2017, and these arrangements provide for the most significant portion of our potential future development and regulatory milestone payments. The relative portion of such revenues in any particular year, however, is dependent upon the mix of any milestone payments or other license revenues recognized and volume of recurring royalty revenues and product sales. Additionally, for the majority of 2020, we derived substantially all of our cash royalty revenue from our collaboration arrangements with Takeda for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AstraZeneca for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we derive the significant majority of our product sales from UCB and Pfizer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Backlog</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to our collaboration agreements, we manufacture and supply our proprietary polymer conjugation materials. Inventory is produced and sales are made pursuant to customer purchase orders for delivery generally based on rolling four to eight quarter forecasts, of which at least two quarters are generally binding. Our backlog is not significant, and, in light of industry practice and our own experience, we do not believe that backlog as of any particular date is indicative of future results.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world. We frequently compete with pharmaceutical companies and other institutions with greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Science and Technology Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We face intense science and technology competition from a multitude of technologies seeking to enhance the efficacy, safety and ease of use of approved drugs and new drug molecule candidates. A number of the drug candidates in our pipeline have direct and indirect competition from large pharmaceutical and biopharmaceutical companies. With our advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules. We constantly monitor scientific and medical developments in order to improve our current technologies, seek licensing opportunities where appropriate, and determine the best applications for our technology platforms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the fields of advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories, Ltd., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.). Several other chemical, biotechnology and pharmaceutical companies may also be developing advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits. Some of these companies license intellectual property or PEGylation materials to other companies, while others apply the technology to create their own drug candidates.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product and Program Specific Competition</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bempegaldesleukin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILs, chimeric antigen receptor-expressing T&#160;cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead (through its acquisition of Kite Pharma)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapetuics LLC, Anaveon AG, Adaptimmune LLC, and Iovance Biotherapeutics, Inc. In the cytokine-based therapies space, potential competitors include Novartis AG, Alkermes PLC, NantWorks LLC, Eli Lilly &amp; Co. (through its acquisition of Armo Biosciences), Roche, and Sanofi SA (through its acquisition of Synthorx, Inc.), and in the checkpoint inhibitor space potential competitors include Tesaro, Inc., Macrogenics, Inc., Merck, Bristol-Myers Squibb, and Roche.&#160;&#160;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-358</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease.&#160;In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Jassen Pharmaceuticals, AstraZeneca and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2 based therapies (Amgen, Inc., BMS (through its acquisition of Delnia, Inc.), ILTOO Pharma, and Sanofi SA, through its acquisition of Synthorx, Inc.).</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-255</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous companies engaged in developing immunotherapies with different approaches to enhancing NK cell populations which are a key component of the innate immune system. The approaches include engineered biologics targeting the IL-15 pathway as well as autologous and allogenic cell therapy approaches. For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.).</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are no other once-daily oral drugs that act specifically to block or reverse the action of opioids on receptors in the gastrointestinal tract which are approved specifically for the treatment of opioid-induced constipation (OIC) or opioid bowel dysfunction (OBD) in patients with chronic, non-cancer pain. The only approved oral treatment for opioid-induced constipation in adults with chronic, non-cancer pain is a twice daily oral therapy called AMITIZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lubiprostone), which acts by specifically activating CIC-2 chloride channels in the gastrointestinal tract to increase secretions. AMITIZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is marketed by Mallincrodt Pharmaceuticals and Takeda. There is also a subcutaneous treatment and an oral treatment known as RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is marketed by Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc., which previously acquired Salix) under a license from Progenics Pharmaceuticals, Inc.&#160;In 2014, RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Subjectaneous Injection was approved by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA for adult patients with chronic non-cancer pain. On July 22, 2016, Relistor (methylnaltrexone bromide) oral tablets for the treatment of OCI in adult patients with chronic non-cancer pain was approved by FDA. Other therapies used to treat OIC and OBD include over-the-counter laxatives and stool softeners, such as docusate sodium, senna, and milk of magnesia. These therapies do not address the underlying cause of constipation as a result of opioid use and are generally viewed as ineffective or only partially effective to treat the symptoms of OIC and OBD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of companies developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations. Potential competitors include Merck, GlaxoSmithKline plc, Ironwood Pharmaceuticals, Inc. in collaboration with Actavis plc (acquired by Teva Pharmaceutical Industries Ltd.), Purdue Pharma L.P. in collaboration with Shionogi &amp; Co., Ltd., Mundipharma Int. Limited, Theravance, Inc., Develco Pharma, Mallincrodt Pharmaceuticals, and Takeda.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On June 6, 2014, the FDA approved Biogen Idec&#8217;s ELOCTATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [antihemophilic factor (recombinant), Fc fusion protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with Hemophilia A. ELOCTATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is intended to be an extended half-life Factor VIII therapy with prolonged circulation in the body with the potential to extend the interval between prophylactic infusions. Prior to its 2014 approval, the fusion protein in ELOCTATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was not used outside of the clinical trial setting for Hemophilia A patients. On August 31, 2018, Bayer Healthcare received FDA approval for JIVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (antihemophilic factor (recombinant) PEGylated-aucl), an extended half-life Factor VIII for Hemophilia A treatment in patients 12 and older which became commercially available in the third quarter of 2018. In addition, on February 19, 2019, Novo Nordisk received FDA approval for ESPEROCT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [antihemophilic factor (recombinant), glycoPEGylated-exei] a glycoPEGylated Factor VIII product with an extended half-life for use in adults and children with Hemophilia A.&#160;&#160;The Biogen, Bayer, and Novo Nordisk products are competitors in the extended half-life Factor VIII market.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our total research and development expenditures can be disaggregated into the following significant types of expenses (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third party and direct materials costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, overhead and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation and depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a manufacturing facility located in Huntsville, Alabama that is capable of manufacturing our proprietary PEG reagents for subsequent conjugation to active pharmaceutical ingredients (APIs). The facility is also used to produce APIs themselves, as well as PEG conjugates of those APIs, to support the early phases of clinical development of our proprietary drug candidates. The facility and associated equipment are designed and operated to be consistent with all applicable laws and regulations. As we do not maintain the capability to manufacture biologics nor finished drug products for our development programs, we primarily utilize contract manufacturers to manufacture biologics and finished drug product for us. We also utilize the services of contract manufacturers to manufacture APIs and finished drug products required for later phases of clinical development and eventual commercialization.  Our contract manufacturers have contractual obligations to comply with all applicable laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We source drug starting materials for our manufacturing activities from one or more suppliers. For the drug starting materials necessary for our proprietary drug candidate development, we have agreements for the supply of such drug components with drug manufacturers or suppliers that we believe have sufficient capacity to meet our demands. However, from time to time, we source critical raw materials and services from one or a limited number of suppliers and there is a risk that if such supply or services were interrupted, it could materially harm our business. In addition, we typically order raw materials and services on a purchase order basis for early phase clinical development products and enter into long-term supply arrangements only for late stage products nearing regulatory approval for marketing authorization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a manufacturer of PEG reagents for the U.S.&#160;market, we are subject to inspections by the FDA and the U.S. Environmental Protection Agency for compliance with cGMP and other U.S.&#160;regulatory requirements, including U.S.&#160;federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. To our knowledge, we comply with all material governmental regulations applicable to our business.  We would be subject to significant penalties for failure to comply with these laws and regulations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Consultants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we had 718&#160;employees, of which 561&#160;employees were engaged in research and development, manufacturing, commercial operations and quality activities and 157&#160;employees in general administrative function. Of the 718&#160;employees, 639 were located in the U.S. and 79 were located in India. We have a number of employees who hold advanced degrees, such as a Ph.D. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages. As part of our measures to attract and retain personnel, we provide a number of benefits to our full-time employees, including health insurance, life insurance, retirement plans, and paid holiday and vacation time. We believe that we maintain good relations with our employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To complement our own expert professional staff, we utilize specialists in regulatory affairs, pharmacovigilance, process engineering, manufacturing, quality assurance and clinical development. These individuals include scientific advisors as well as independent consultants.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.nektar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information in, or that can be accessed through, our website is not part of this annual report on Form&#160;10-K. Our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K and amendments to those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities Exchange Commission (SEC). The public may read and copy any materials we file with the SEC at the SEC&#8217;s Public Reference Room at 100&#160;F&#160;Street, NE, Washington,&#160;D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS OF THE REGISTRANT</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth the names, ages and positions of our executive officers as of February&#160;25, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Age</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Position</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Howard W. Robin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, President and Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gil M. Labrucherie, J.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Operating Officer and Chief Financial Officer </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Northcott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jillian B. Thomsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Finance and Chief Accounting Officer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark A. Wilson, J.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan Zalevsky, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Research and Development Officer</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Howard W. Robin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our President and Chief Executive Officer since January 2007 and has served as a member of our board of directors since February 2007. Mr.&#160;Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr.&#160;Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr.&#160;Robin was Director</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen&#160;&amp; Co. prior to joining Berlex. Mr.&#160;Robin serves as a director of the Biotechnology Industry Organization, the world&#8217;s largest biotechnology industry trade organization, and also serves as a director of BayBio, a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gil M. Labrucherie </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Senior Vice President, Chief Financial Officer since June 2016, and added the role of Chief Operating Officer in October 2019. Mr.&#160;Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr.&#160;Labrucherie was Vice President of Corporate Development at E2open, a platform enterprise software as a service company. While at E2open, Mr.&#160;Labrucherie was responsible for global corporate alliances and merger and acquisitions. Mr.&#160;Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. Mr.&#160;Labrucherie received his J.D. from the Berkeley Law School and his B.A. from the University of California Davis.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">John Northcott</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President and Chief Commercial Officer since December 2019. From 2015 to 2019, Mr. Northcott served as the Chief Commercial Officer of Pharmacyclics. From 2013 to 2015, Mr. Northcott was Chief Commercial Officer at Lexicon Pharmaceuticals. He has held commercial roles from 2007 to 2013 in both U.S. and Global marketing with Genentech and the Roche Group, including the role of International Business Leader. Prior to Roche/Genentech, Mr. Northcott held management positions in sales and marketing in a variety of therapeutic areas at other pharmaceutical companies including Merck and Pfizer. Mr. Northcott received a bachelor&#8217;s degree in Business Administration from St. Francis Xavier University.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jillian B. Thomsen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Senior Vice President, Finance and Chief Accounting Officer since February 2010. From March 2006 through March 2008, Ms.&#160;Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before joining Nektar, Ms.&#160;Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Ms.&#160;Thomsen began her career as a certified public accountant at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms.&#160;Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mark A. Wilson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President and General Counsel since June 2016. Mr. Wilson joined Nektar in May 2002 and initially served as Patent Counsel and then as Senior Patent Counsel to the company prior to 2008 when he was promoted to Vice President, Intellectual Property. Before joining Nektar in 2002, Mr. Wilson was an associate at Reed &amp; Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in Pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the California Bar.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jonathan Zalevsky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Research &amp; Development Officer since October 2019. Dr. Zalevsky served as our Senior Vice President, Biology and Preclinical Development from April 2017 through November 2017 and served as our Senior Vice President, Research and Chief Science Officer from November 2017 to October 2019. From July 2015 through April 2017, Dr. Zalevsky served as our Vice President, Biology and Preclinical Development. Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, Inc. Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual bachelor degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Research and Development Efforts</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of bempegaldesleukin, our lead I-O candidate.&#160;We are executing a clinical development program for bempegaldesleukin and clinical and regulatory outcomes for bempegaldesleukin, if not successful, will significantly harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize bempegaldesleukin. In general, most investigational drugs, including I-O drug candidates such as bempegaldesleukin, do not become approved drugs. Accordingly, there is a very meaningful risk that bempegaldesleukin will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;To date, reported clinical outcomes from bempegaldesleukin have had a significant impact on our market valuation, and business prospects and we expect this to continue in future periods.&#160;If one or more clinical studies of bempegaldesleukin are delayed (as a result of, for example, our collaboration partner causing a delay of the initiation or completion of one or more clinical trials for reasons outside of our control) or not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under the BMS Collaboration Agreement, we are entitled to up to approximately $1.455 billion in development milestone payments (of which we have received $50.0 million) that are based upon clinical and regulatory successes from the bempegaldesleukin development program. One or more failures in bempegaldesleukin studies could jeopardize such milestone payments, and any product sales or royalty revenue or commercial milestone payments that we would otherwise be entitled to receive could be reduced, delayed or eliminated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in clinical trials of drug candidates. We have ongoing trials evaluating bempegaldesleukin, including trials evaluating bempegaldesleukin as a potential combination treatment with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as other ongoing and planned combination trials. Our partner Lilly is conducting two Phase 2 studies of NKTR-358 in patients with SLE and ulcerative colitis as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis. We also continue to enroll patients in a Phase 1/2 study evaluating bempegaldesleukin in combination with NKTR-262 in patients with solid tumors.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. These and other clinical studies may not begin on time, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as bempegaldesleukin and NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial to the detriment of enrollment rates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay our ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year.&#160; Our clinical trial plans for bempegaldesleukin, NKTR-262, and NKTR-255 face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of component therapies, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Drug development is a long and inherently uncertain process with a high risk of failure at every stage of development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of proprietary drug candidates and partnered drug candidates in research and development ranging from the early discovery research phase through preclinical testing and clinical trials. Preclinical testing and clinical studies are long, expensive, difficult to design and implement and have highly uncertain outcomes that are difficult to predict. It will take us, or our collaborative partners, many years to conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our drug candidates. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes, or our and our partners&#8217; financial constraints.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a highly uncertain scientific and medical endeavor, and failure can unexpectedly occur at any stage of preclinical and clinical development. Typically, there is a high rate of attrition for drug candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care (including commercialization of a competing therapy in the same or similar indication for which our drug candidate is being studied) and other variables (such as commercial supply challenges). The risk of failure increases for our drug candidates that are based on new technologies, such as the application of our advanced polymer conjugate technology to bempegaldesleukin, NKTR-358, NKTR-262, NKTR-255, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other drug candidates currently in discovery research or preclinical development. The failure of one or more of our drug candidates could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our proprietary drug candidates currently in development. For bempegaldesleukin, there are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead Sciences, Inc. (through its acquisition of Kite Pharma, Inc.)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapeutics LLC, Anaveon AG, Adaptimmune LLC, and Novartis AG; potential competitors in the cytokine-based therapies space include Alkermes plc, ImmunityBio, Inc., Neoleukin Therapeutics, Inc., Philogen S.p.A., Roche, Sanofi SA (through its acquisition of Synthorx, Inc.), and Eli Lilly &amp; Co. (through its acquisition of Armo BioSciences); and potential competitors in the checkpoint inhibitor space include GlaxoSmithKline plc (through its acquisition of Tesaro, Inc.), Macrogenics, Inc., Merck, Bristol-Myers Squibb Company, and Roche. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, ILTOO Pharma, Pandion Therapeutics, and Roche). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partners to initiate, properly conduct and prioritize clinical trials for bempegaldesleukin and NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on BMS (through the BMS Collaboration Agreement) and Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for bempegaldesleukin and NKTR-358, respectively.  Furthermore, we will rely on BMS and Lilly to perform specified commercialization activities for bempegaldesleukin and NKTR-358, respectively, pursuant to the applicable agreement. In the event BMS or Lilly fails to initiate, properly conduct and prioritize their obligations under their applicable agreement with us, our business will be significantly harmed.  Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by BMS&#8217;s or Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that efforts would succeed or be sufficient to fully address the harm.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for reasons outside of our control, the operations of our collaboration partners may be more affected by the COVID-19 pandemic than we are, or they may adopt more restrictive procedures for addressing the COVID-19 pandemic, either of which would delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies (other than Nektar-run trials under the BMS Collaboration Agreement), our collaboration partner is generally solely responsible for:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our proprietary drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had cash and investments in marketable securities valued at approximately $1.2 billion. On April 13, 2020, we redeemed our senior notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates &#8212; important examples include bempegaldesleukin and NKTR-358;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our propreitary drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a drug candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our drug candidates even if there is adequate coverage and reimbursement from third-party payers. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the U.S. Secretary of Health and Human Services (HHS) certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the U.S. Secretary of the HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September 25, 2020, the Centers for Medicare and Medicaid (CMS) stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any drug candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we reported a net loss of $444.4 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary drug candidates and the regulatory approval and market success of our drug candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for bempegaldesleukin, NKTR-358, NKTR-262, and NKTR-255;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:18pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. With respect to the ongoing COVID-19 pandemic, national, state and local governments in regions affected by the COVID-19 pandemic have implemented, and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures and other measures.  These measures may disrupt normal business operations both in and outside areas affected by COVID-19, and may have significant negative impacts on our business.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic.  For example, we have implemented work from home policies for most employees and limited business travel. Although we believe these and the other safety measures we have taken in response to the COVID-19 pandemic have not substantially impacted our productivity, it is not certain that this will continue to be the case. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Prolonged remote working arrangements could impact employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and employee work culture. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks. If we, our partners, our suppliers, or our contractors experience a cyberattack, experience data accessibility issues, or encounter communication disruptions, our business may suffer as a result of the loss or theft of our important data, and we may be liable for compromising the protection of personal data.     </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties with whom we seek important goods and services. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties fully due to the COVID-19 pandemic, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. Furthermore, delays and disruptions experienced by our collaborators or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect clinical development or regulatory approvals of our drug candidates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Investigator recruitment, clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. Some patients who are successfully enrolled in clinical trials involving our drug candidates may not be able to comply with clinical trial protocols due to, for example, shelter-in-place orders impeding movement, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The COVID-19 pandemic could affect our ability, and the ability third parties on whom we rely, to successfully manufacture sufficient supplies to complete our clinical trials in a timely manner.  For example, it may be more difficult to obtain materials or manufacturing slots for the products required to conduct our clinical trials due to the demand for recently authorized vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and validity of our clinical trial data. If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency. Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both. As a consequence, a clinical study of our proprietary drug candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, over-enrolling patients into the study or repeating the study), thereby causing substantial harm to our business.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our drug candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a significant negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us. Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change. We do not yet know the full extent of potential impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material negative impact on our operations and our business.</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturering organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CROs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of drugs involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded by the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing drugs for use in clinical trials may be negatively impacted such that there is an insufficient supply of study treatment drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the President of the United States signed into law the CARES Act in response to the COVID-19 pandemic. Throughout the COVID-19 outbreak, there has been public concern over the availability and accessibility of critical medical products, and the CARES Act enhances FDA&#8217;s existing authority with respect to drug shortage measures. Under the CARES Act, we must have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment where the drug or API is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, our results could be materially impacted.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or drug candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop drug candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our drug candidate that such CMO owns independently. This would increase our reliance on such a CMO or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require us to obtain a license from such CMO in order to have another CMO manufacture our products or drug candidates. In addition, in the case of the CMOs that supply our drug candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control. In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our proprietary drug candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary drug candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our drug candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Business Operations</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our drug candidates successfully.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the very early stages of building a commercialization and distribution capabilities for bempegaldesleukin in the United States and Europe. To commercialize any of our drugs that receive regulatory approval for commercialization, we must develop robust internal sales, marketing and distribution capabilities, and manage inventory, supply, labeling, storage, record keeping, and advertising and promotion capabilities, which is both  expensive and time consuming, or enter into arrangements with third parties to perform these services. For example, we have committed to co-commercializing bempegaldesleukin with BMS and establish global distribution and infrastructure for us to be able to book global revenue for bempegaldesleukin if it achieves regulatory approval. Establishing this commercialization capability requires a significant commitment of financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or through partnerships include:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability of sales personnel to obtain access to or successfully educate adequate numbers of physicians about the potential benefits associated with the use of, and to subsequently prescribe, our products;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability to manage and operate our business as we execute our development and growth strategy will require effective planning and execution. Significant rapid growth could strain our management and internal resources, and other problems may arise that could adversely affect our financial performance. We expect that our efforts to grow will place a significant strain on personnel, management systems, infrastructure and other resources. Our ability to effectively manage future growth will also require us to successfully attract, train, motivate, retain and manage new employees and continue to update and improve our operational, financial and management controls and procedures. If we do not manage our growth effectively, our operations and financial performance could be adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered drug candidates. Our strategy also calls for us to undertake increased research and development activities and establish a commercial organization in collaboration with our partners, while simultaneously managing the capital necessary to support this strategy. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of clinical testing, manufacturing, research, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to drug candidates granted Breakthrough Therapy designation by the FDA.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies that could enable us to take advantage of expedited development pathways for certain of our drug candidates, although we cannot be certain that our drug candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant qualifying designations. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is intended to expedite the development and review of drug candidates that are designed to treat serious or life-threatening diseases when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug candidate as a Breakthrough Therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the drug candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received Breakthrough Therapy designation for the treatment of patients with previously untreated unresectable or metastatic melanoma, we may elect not to pursue Breakthrough Therapy designation for our other drug candidates, and the FDA has broad discretion whether or not to grant these designations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accordingly, even if we believe a particular drug candidate is eligible for Breakthrough Therapy, we cannot be assured that the FDA would decide to grant it. Breakthrough Therapy designation does not change the standards for drug approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the Breakthrough Therapy designation. Thus, even though we have received Breakthrough Therapy designation, we may not experience a faster development process or review, and, upon any filing seeking regulatory approval, we may not obtain an approval from the FDA.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. For example, although the FDA granted a Breakthrough Therapy designation to bempegaldesleukin in combination with Opdivo&#174; for the treatment of patients with previously untreated unresectable or metastatic melanoma, there is no guarantee regulatory approval will follow, if at all, for this or any indication of bempegaldesleukin on a timely basis. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a drug candidate. In addition, undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate development programs;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:19pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, it could subject us to substantial liabilities and harm our financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action and shareholder derivative litigation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the year ended December&#160;31, 2020, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $14.47 to $27.96 per share. In response to volatility in the price of our common stock in the past, Plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into potential securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, Plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by Plaintiffs&#8217; securities litigation firms following share price fluctuations. </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements by collaboration partners as to their plans or expectations related to drug candidates and approved drugs in which we have a substantial economic interest;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fluctuations in our results of operations;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our financing needs and activities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general market conditions.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the drug, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 300 U.S. and 1,050 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the drug. Moreover, even if a patent encompassing a drug has not expired prior to the drugs commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In addition, our patents may be subject to post grant proceedings, such as or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary drug candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our drug candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. In response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities while local, national and international conditions warrant. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials which the FDA continues to update. As of June 23, 2020, the FDA noted it was conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. On July 10, 2020, the FDA announced its goal of restarting domestic on-site inspections during the week of July 20, 2020, but such activities will depend on data about the virus&#8217; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally intends to issue a complete response letter.  Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets. In 2020, several companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or drug candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. For example, we are currently involved in German litigation proceedings whereby we and Bayer Healthcare LLC are seeking at least co-ownership rights in certain of each other&#8217;s patent filings related to PEGylated Factor VIII products. We believe that Bayer&#8217;s claims to an ownership interest in these is without merit and we are vigorously defending our exclusive ownership rights to this intellectual property. These German litigation proceedings are currently stayed pending the outcome of ongoing mediation efforts. In the U.S., Bayer filed a complaint against Baxalta and Nektar alleging the ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product infringes a Bayer patent. Although the U.S. court dismissed all of Bayer&#8217;s claims </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against Nektar and Nektar was removed as a defendant, a jury found the Bayer patent was valid and infringed, and awarded Bayer damages, the responsibility of which are borne fully by Baxalta. This damages award does not impact our royalties from sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with Baxalta and Baxalta is currently appealing the decision. In other U.S. proceedings, Nektar and Baxalta filed complaints against Bayer Healthcare alleging Bayer&#8217;s JIVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product infringes several Nektar patents. In addition, in response to notices AstraZeneca and we received from the generic companies, Apotex (Apotex Inc. and Apotex Corp.), MSN Laboratories Pvt. Ltd., and Aurobindo Pharma USA INC. alerting us that they had filed abbreviated new drug applications (ANDAs) with the FDA to market a generic version of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Paragraph IV Certifications), AstraZeneca and we together filed patent infringement suits against each of these generic companies. In these Paragraph IV Certifications, all three generic companies only alleged one patent, U.S. Patent No. 9,012,469, is invalid, unenforceable and/or not infringed by the manufacture, use or sale of their respective generic products. At this time, none of the other five Orange Book listed patents associated with MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are being challenged by these generics companies. In addition, on March 18, 2020, Aether Therapeutics Inc. filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. Also, on June 5, 2020, UCB Pharma S.A. and Celltech R&amp;D Limited (collectively UCB) served notice of a Declaratory Judgment of Patent Invalidity proceeding filed in the United States District Court for the District of Delaware seeking a declaration of invalidity of specified U.S. patents owned by Nektar and licensed to UCB. UCB is also pursuing similar actions in other jurisdictions. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our drugs and platform technologies. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings other than those related to intellectual property. For example, on October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019.&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On December 30, 2020, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, and denied plaintiffs with the ability to file a further amended complaint.  Following the motion to dismiss, on January 29, 2021, the class action plaintiffs filed a Notice to Appeal to appeal the district court&#8217;s decision to the U.S. Court of Appeals for the Ninth Circuit.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California  naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. On January 26, 2021, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, stating (among other things) that &#8220;Defendants&#8217; open disclosure of risks associated with trial delay &#8230; suggests that they acted openly with investors.&#8221; Following the motion, the class action plaintiffs have an opportunity to file in early March a further amended complaint and the case remains pending.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, certain of our current and past directors and executives were named in a shareholder derivative complaint filed in the Court of Chancery of the State of Delaware.  Allegations in this matter are similar to those raised in the putative securities class action complaints filed on October 30, 2018 and August 19, 2019 in the U.S. District Court in California. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the putative securities class action lawsuits and shareholder derivative lawsuits) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at December&#160;31, 2020.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks to our Business</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our drug candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business to subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our drug candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was signed into law and included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had a net operating loss carryforward for federal income tax purposes of approximately $2.0 billion, portions of which will begin to expire in 2021. As of December 31, 2020, we had a total state net operating loss carryforward of approximately $1.3 billion, portions of which will begin to expire in 2026. These net operating loss and tax </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Federal net operating losses, or NOLs, generated in taxable years beginning after December 31, 2017 are not subject to expiration and generally may not be carried back to prior taxable years except that, under the CARES Act, NOLs generated in 2018, 2019 and 2020 may be carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, for any taxable year beginning after December 31, 2020, the deductibility of NOLs is limited to 80% of our taxable income in such taxable year (where taxable income is determined without regard to the net operating loss deduction itself). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Internal Revenue Code of 1986, as amended (the Code), substantial changes in our ownership may limit the amount of our NOLs and tax credits that can be utilized annually to offset our future U.S. federal taxable income, if any. This limitation would generally apply in the event that the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs and tax credits may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs and tax credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs and tax credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs and tax credits.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union (EU) may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the E.U., a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we and others could face new regulatory costs and challenges.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions, our business may be adversely affected following new or increased tariffs that result in the increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_22"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.  Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_25"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.  Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We lease a 153,203 square foot facility in the Mission Bay Area of San&#160;Francisco, California (Mission Bay Facility), under an operating lease which expires in 2030. The Mission Bay Facility is our corporate headquarters and also includes our research and development operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also lease 135,936 square feet of office space in San Francisco (the Third Street Facility), under an operating lease which expires in 2030. The Third Street Facility provides additional space to support our research and development activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alabama</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We currently own a facility consisting of approximately 124,000 square feet in Huntsville, Alabama, which houses laboratories as well as administrative, clinical and commercial manufacturing facilities for our PEGylation and advanced polymer conjugate technology operations as well as manufacturing of APIs for early clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">India</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We own a research and development facility consisting of approximately 88,000&#160;square feet, near Hyderabad, India. In addition, we lease approximately 1,600&#160;square feet of office space in Hyderabad, India, under a three-year operating lease that will expire in 2021.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_28"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.  Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.  With respect to ongoing securities class action and shareholder derivative litigation, please refer to Item 1A. Risk Factors, including without limitation, &#8220;We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.&#8221;</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_31"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.  Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_37"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our common stock trades on The NASDAQ Global Select Market under the symbol &#8220;NKTR.&#8221; The table below sets forth the high and low closing sales prices for our common stock as reported on The NASDAQ Global Select Market during the periods indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of February&#160;17, 2021, there were approximately 159 holders of record of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There were no sales of unregistered securities and there were no common stock repurchases made during the year ended December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding our equity compensation plans as of December&#160;31, 2020 is disclosed in Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this Annual Report on Form&#160;10-K and is incorporated herein by reference from our proxy statement for our 2021 annual meeting of stockholders to be filed with the SEC pursuant to Regulation&#160;14A not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Measurement Comparison</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The material in this section is being furnished and shall not be deemed &#8220;filed&#8221; with the SEC for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following graph compares, for the five year period ended December&#160;31, 2020, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i)&#160;the NASDAQ Composite Index, (ii)&#160;the NASDAQ Pharmaceutical Index, (iii)&#160;the RDG SmallCap Pharmaceutical Index, (iv)&#160;the NASDAQ Biotechnology Index and (v)&#160;the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December&#160;31, 2016, December&#160;31, 2017, December&#160;31, 2018, December&#160;31, 2019 and December&#160;31, 2020. The graph assumes that $100 was invested on December&#160;31, 2015 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq Pharmaceutical Index, the RDG SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><img src="nktr-20201231_g1.jpg" alt="nktr-20201231_g1.jpg" style="height:541px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div id="ifabf795112b143ffbb3dd9981b4dd620_40"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.  Reserved</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_43"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8.8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in &#8220;Part&#160;I, Item&#160;1A&#160;&#8212; Risk Factors.&#8221;</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:8.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and viral infections. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immuno-oncology (I-O), we are executing a clinical development program evaluating bempegaldesleukin (previously referred to as NKTR-214) in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Bristol-Myers Squibb Company (BMS) as well as other independent development work evaluating bempegaldesleukin in combination with other checkpoint inhibitors and agents with potential complementary mechanisms of action. We announced in August of 2019 that the FDA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted a Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with untreated unresectable or metastatic melanoma. We expect our research and development expense to continue to grow over the next few years as we expand and execute our broad clinical development program for bempegaldesleukin. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into Amendment No.&#160;1 (the Amendment) to the February 13, 2018, Strategic Collaboration Agreement (the BMS Collaboration Agreement). Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. Specifically, pursuant to the updated Collaboration Development Plan, bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently being evaluated in ongoing registrational trials in first-line metastatic melanoma, first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), muscle-invasive bladder cancer, and adjuvant melanoma, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with either axitinib or cabozantinib in first line RCC in order to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently underway. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amendment did not alter the cost-sharing methodology under the BMS Collaboration Agreement. The parties share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share clinical development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BMS 67.5% and Nektar 32.5%. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. BMS supplies Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> free of charge. We also share commercialization related costs, 35% BMS and 65% Nektar, which we present in general and administrative expense. Our share of development costs is limited to an annual cap of $125.0 million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, but we recognize our full share of the research and development expense and recognize the reimbursement as a liability. We repay the liability to the extent that our share of development costs is less than the annual cap in a future year, or by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin, if approved. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Collaboration Agreement entitles Nektar to receive up to $1.455 billion of clinical, regulatory and commercial launch milestones. Of these milestones, we received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. Of the remaining milestones, $625.0 million are associated with the approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (which reflects the reduction for the $25.0 million nonrefundable, creditable milestone for the first patient, first visit in the muscle-invasive bladder cancer trial). As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the Collaboration Development Plan with BMS, we are conducting and pursuing additional I-O research and development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. For example, on February 12, 2021, we entered into a financing and co-development collaboration with SFJ Pharmaceuticals to support a Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with head and neck cancer whose tumors express PD-L1. In addition, we are independently studying bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a non-small cell lung cancer (NSCLC) Phase 1/2 trial. Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to enhance the standard of care in multiple oncology settings.  As a result, we expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging scientific findings in cancer biology and preclinical development work.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our non-BMS clinical collaborations for bempegaldesleukin, generally each party supports the collaboration based on its expertise and resources. For example, our co-development collaboration agreement with SFJ includes both financial support in the form of up to $150.0 million to fund the Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in head and neck cancer, as well as operational support in managing the clinical trial.  In addition, we announced on February 17, 2021, that we had entered into a clinical trial collaboration and supply agreement with Merck wherein we will receive supplies of Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost to us. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2020, we received FDA clearance for an Investigational New Drug application for bempegaldesleukin to be evaluated in a Phase 1b clinical study in adult patients who have been diagnosed with mild COVID-19 infection. The study design allows us to evaluate whether bempegaldesleukin&#8217;s adaptive immune-stimulating mechanism to promote priming and proliferation of T cells and NK cells could be useful in the emerging treatment options for COVID-19. Enrollment in the Phase 1b randomized, double-blind, placebo-controlled study is planned to start in early November. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also combining bempegaldesleukin with NKTR-262.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic bempegaldesleukin to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. The Phase 1/2 dose-escalation and expansion trial in patients with solid tumors is currently ongoing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our next most advanced I-O program is NKTR-255. NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of NK cells and induces survival of both effector and CD8 memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular toxicity molecules as well as enhance CAR-T therapies. We have initiated a Phase 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. At the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, we reported early findings from the Phase 1 dose escalation study that demonstrated expansion of lymphocytes, increases in NK and CD8+ T cells in patients with multiple myeloma and non-Hodgkin lymphoma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, we are developing NKTR-358, which is designed to correct the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358. We received an initial payment of $150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones. We were responsible for completing Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the Phase 3 development costs and receive a royalty rate on global NKTR-358 sales up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy subjects. Results from this study demonstrated a multiple-fold increase in regulatory T cells with no change in CD8 positive or natural killer cell levels and no dose-limiting toxicities were observed. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with SLE. Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis and has initiated Phase 2 studies in SLE and ulcerative colitis. Under the terms of the agreement, Lilly is to initiate two additional Phase 2 studies in other auto-immune diseases.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were developing NKTR-181 for the treatment of chronic low back pain in adult patients and had submitted an NDA for NKTR-181. At the FDA advisory committee meeting held on January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of NKTR-181, and, as a result, we withdrew the NDA and decided to make no further investment commitments to this program.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level of our future research and development investment will depend on a number of uncertainties including clinical outcomes, future studies required to advance programs to regulatory approval, and the economics related to potential future collaborations that may include up-front payments, development funding, milestones, and royalties. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements including the BMS Collaboration Agreement, pursuant to which we have recognized $1.11 billion in revenue and recorded $790.2 million in additional paid in capital for shares of our common stock issued in the transaction. While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, including the potential remaining $1.405 billion in development and regulatory milestones under the BMS collaboration, in the medium- to long-term, our plan is to generate significant commercial revenue from our proprietary drugs including bempegaldesleukin. Since we do not have experience commercializing products or an established commercialization organization, there will be substantial risks and uncertainties in future years as we build commercial, organizational, and operational capabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until September 30, 2020, we received royalties and milestones from two approved drugs: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which we have a collaboration with AstraZeneca; and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which we have collaboration agreement with Baxalta Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.). MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral, peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with non-cancer pain which was approved by the FDA and subsequently launched in March 2015 (wherein in the EU, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is sold as MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is indicated for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives, which was approved by health authorities in the European Union and many other countries beginning in 2014). ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a half-life extension product of Factor VIII was approved by the FDA in late 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A (wherein in the EU, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is sold as ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was approved by health authorities in Europe in January 2018, and has also been approved in many other countries).</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on October 1, 2020, our rights to receive royalties arising from the worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and specified licensed products under a Right to Sublicense Agreement, dated October 27, 2017, were sold for $150.0 million pursuant to a capped sale arrangement to entities managed by Healthcare Royalty Management, LLC (collectively, HCR) pursuant to a purchase and sale agreement (the 2020 Purchase and Sale Agreement) entered into on December 16, 2020. With regard to the capped sale arrangement, the 2020 Purchase and Sale Agreement will automatically expire, and HCR&#8217;s right to receive the sold royalties, will cease when HCR has received payments of equalling $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). After the 2020 Purchase and Sale Agreement expires, all rights to receive these royalties return to Nektar. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the clinical development and commercialization efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A. Risk Factors.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the approved drugs and clinical development programs described above are key elements of our future success, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research that we are preparing to advance into the clinic in future years. We are also advancing several other drug candidates in preclinical development in the areas of I-O, immunology, and other therapeutic indications. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market value.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of the COVID-19 Pandemic</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, COVID-19, the disease resulting from a novel strain of coronavirus infection, was declared a global pandemic. Many countries, including the United States and India, initially took steps such as restricting travel, closing schools, and issuing shelter-in-place orders to slow or moderate the spread of the virus. More recently, states and countries have adopted individualized approaches to respond to the COVID-19 pandemic. In particular, local resurgences in number and rates of infections, and the further spread of the virus may result in the return of prior restrictions or the institution of restrictions in the affected areas. Although vaccines intended to reduce the incidence of infection are in development, it remains unclear how long the negative impacts caused by the coronavirus will continue into the future.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, with respect to the operation of our facilities, we are closely adhering to applicable guidelines and orders.  Essential operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with the permissions granted under government ordinances. Across all our locations, we have instituted a temporary work from home policy for all office personnel who do not need to work on site to maintain productivity. At this time, we have not identified a material change to our productivity as a result of these measures, but this could change, particularly if restricted travel, closed schools, and shelter-in-place orders are not removed or significantly eased in the areas in which we operate.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety and well-being of our employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We believe that the safety measures we are taking and instructing our contractors to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials.   </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are currently engaged in the clinical testing of our proprietary drug candidates and the COVID-19 pandemic introduces significant challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, have thus far had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic. The rapid development and fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on our clinical trials, our operations and our business. As a result, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our specific clinical programs as discussed below, is difficult to predict and subject to change.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, for the ongoing registrational clinical trials studying the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cancer indications being led by Nektar (such as adjuvant melanoma, RCC and first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer), although we have not seen evidence to date that the COVID-19 pandemic has had a significant impact on enrollment for these trials, the future impact of the COVID-19 pandemic on these trials is very difficult to predict and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Nektar&#8217;s Phase 1/2 trial studying bempegaldesleukin and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in NSCLC, although the COVID-19 pandemic delayed the initiation of certain investigator sites in Europe earlier in the trial, we currently expect to have initial safety as well as preliminary overall response rate data for the dose-escalation and 0.006 mg/kg NSCLC expansion cohorts of this study in the second half of 2021. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Nektar&#8217;s ongoing clinical study of NKTR-262 (the Phase 1/2 REVEAL study), this study has largely remained on track although we have experienced some challenges with new investigator site initiations. Nektar&#8217;s Phase 1 clinical study of NKTR-255 in patients with relapsed/refractory hematologic malignancies has enrolled slower than anticipated due to challenges caused by the COVID-19 pandemic, and the dose-escalation monotherapy portion of the study is expected to be completed in the first half of 2021. For both of these Nektar-run clinical programs, the ongoing COVID-19 pandemic could still impact investigator site initiations and trial enrollment despite our mitigation efforts.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For clinical studies of our proprietary drug candidates being run by our partners, BMS is enrolling patients in each of the BMS-led registration studies and has re-started initiation of new investigator sites in the third quarter of 2020 following a pause in the initiation of new investigator sites it instituted for all of its studies as a result of the COVID-19 pandemic. In the summer of 2020, BMS extended their timeline estimates by approximately six months for the first data read-outs for the first-line melanoma trial. We will continue to monitor the progress of enrollment of the BMS-led studies and projections for topline clinical outcome data. Our partner Lilly, which is running clinical trials of NKTR-358, has indicated it will likely have delays of at least three to six months following its temporary suspension of recruitment for the ongoing Phase 1b studies in atopic dermatitis and psoriasis as a result of the COVID-19 pandemic. Lilly recently started a Phase 2 study in moderate to severe lupus patients in October and has initiated an additional Phase 2 study in ulcerative colitis. The rapid development and fluidity of the COVID-19 pandemic preclude any firm estimates as to the ultimate effect this disease will have on our collaborators&#8217; clinical trials. As a result, there remains substantial uncertainty as to potential impacts on our collaboration partner studies.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to our IND-enabling research, although the COVID-19 pandemic has caused us to reduce the number of employees working at our sites, a subset of our research-based employees continues to conduct laboratory work in our research facilities (which is permitted under the applicable government ordinances). As a result, we continue to make progress in the identification of new drug candidates.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients. Particularly, in the context of our clinical trials directed to investigational cancer treatments, for example, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for patient visit delays caused by limited access to healthcare facilities, to leverage alternative methods for maintaining clinical trial integrity, and to properly record patient event data that may be influenced by the COVID-19 pandemic.  In addition, to the extent that the integrity of individual patient data is negatively affected by the COVID-19 pandemic, we will consider measures to maintain the integrity of the clinical study overall (such as over-enrolling patients into the study and removing all patients originating from an affected study site when performing statistical analyses of study endpoints). Although these measures may have the benefit of preserving the overall integrity of a clinical study, implementing these measures could result in a delay in completing the study.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this respect, we are also incorporating recent direction and flexibility provided by regulatory authorities, including the FDA in its March 18, 2020 Guidance (most recently updated January 27, 2021) entitled &#8220;FDA Guidance on Conduct of Clinical Trials of Medicinal Products during COVID-19 Public Health Emergency.&#8221; This Guidance is continually being updated by FDA and updates can be found on the FDA&#8217;s website at www.fda.gov. In addition, we may refer to guidance documents from other regulatory agencies, such as, for example, the European Medicines Agency&#8217;s &#8220;Implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials&#8221; found on www.ema.europa.eu, which are also continually being updated.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. At December&#160;31, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million. See Note 5 to our Consolidated Financial Statements for additional information.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_49"></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2020 and 2019</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Additional information required by Item 7 for the year ended December 31, 2018 can be found in Item 7 in our Annual Report on Form 10-K for the year December 31, 2019, filed with the SEC on February 28, 2020 and is incorporated herein by reference.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Decrease)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales decreased for the year ended December&#160;31, 2020 as compared to the year ended December&#160;31, 2019 due to decreased demand from our collaboration partners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect product sales in 2021 to increase compared to 2020 due to increased demand from our collaboration partners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 7 to our Consolidated Financial Statements, on December 16, 2020, we entered into the 2020 Purchase and Sale Agreement with entities managed by Healthcare Royalty Management, LLC (collectively, HCR), under which we agreed to sell to HCR certain of our rights to receive royalty payments arising on worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning October 1, 2020. As a result, we recognized royalty revenue for these products only for the nine months ended September 30, 2020, and recognized these royalties as non-cash royalty revenue for the three months ended December 31, 2020. Accordingly, royalty revenue decreased for the year ended December 31, 2020 as compared to the year ended December 31, 2019. Please see Note 7 to our Consolidated Financial Statements for additional information on the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to recognize any royalty revenue during 2021, because we will recognize all such royalties as non-cash royalty revenue as a result of the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2020, pursuant to the BMS Collaboration Agreement, we recognized $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and $25.0 million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. As a result of these milestones, license, collaboration and other revenue increased during the year ended December&#160;31, 2020 as compared to the year ended December&#160;31, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect that our license, collaboration and other revenue will decrease in 2021 compared to 2020 as a result of the recognition of these milestones in 2020 under our BMS Collaboration Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by geography (in thousands)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,093&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,617&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue attributable to the U.S. for the year ended December&#160;31, 2020 was higher than for the year ended December&#160;31, 2019 primarily due to the recognition of $50.0 million of milestones from the BMS Collaboration Agreement as described above. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,477&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,374&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product gross margin worsened for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 primarily due to a less favorable product mix in 2020 compared to 2019. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. In addition to product sales from reagent materials supplied to the partner where our sales are less than our fully burdened manufacturing cost, we also receive royalty revenue from this collaboration. In the years ended December&#160;31, 2020 and 2019, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We currently expect product gross margin to be negative in 2021 as a result of the anticipated unfavorable product mix described above.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,678&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,566&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,888)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development expense decreased for the year ended December&#160;31, 2020&#160;compared to the year ended December&#160;31, 2019. The clinical trial costs for our bempegaldesleukin, NKTR-255 and NKR-262 programs increased for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. These increased costs were offset by decreases in pre-commercial manufacturing costs for NKTR-181 which we incurred during 2019, manufacturing costs for clinical trials materials, and costs for our clinical development program for NKTR-358. As discussed above, as a result of our decision to withdraw the NKTR-181 NDA in January 2020, we present all costs related to the wind-down of the NKTR-181 program, including pre-commercial manufacturing activities, in the Impairment of assets and other costs related to terminated program line in our Consolidated Statements of Operations for the year ended December&#160;31, 2020. The decrease in NKTR-358 development costs reflects the completion of our Phase 1 clinical development and drug product development deliverables, for which we were responsible for 100% of costs, to the Phase 1b and Phase 2 development, for which we are responsible for 25% of costs and Lilly is responsible for 75% of costs. Additionally, during the&#160;years ended December&#160;31, 2020 and 2019, we recorded net reductions to research and development expense for BMS&#8217; reimbursements of our costs of&#160;$128.2 million and $105.4 million, respectively.&#160;Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin. Please see Note 10 to our Consolidated Financial Statements for additional information regarding our BMS Collaboration Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize our employee and infrastructure resources across multiple development and research programs. The following table shows expenses incurred for clinical and regulatory services, clinical supplies, and preclinical study support provided by third parties as well as contract manufacturing costs for each of our drug candidates. The table also presents other costs and overhead consisting of personnel, facilities and other indirect costs (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Clinical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Study</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (CD122-preferential IL-2 pathway agonist)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2/3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358 (cytokine Treg stimulant)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 (IL-15 receptor agonist)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-262 (toll-like receptor agonist)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONZEALD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (next-generation topoisomerase I inhibitor)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-181 (orally-available mu-opioid analgesic molecule)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other drug candidates</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total clinical development, contract manufacturing and other third party costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel, overhead and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation and depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Clinical Study Status definitions are provided in the chart found in Part&#160;I, Item&#160;1. Business.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Development expenses for bempegaldesleukin include expenses under the BMS Collaboration Agreement, other collaboration agreements and our own independent studies. The amounts for the years ended December&#160;31, 2020 and 2019 include net reductions of $90.4 million and $70.5 million, respectively, of development cost reimbursements from BMS under our collaboration, net of our share of BMS&#8217; costs. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The amounts for the year ended December&#160;31, 2020 and 2019 include reductions of $37.8 million and $34.9 million of employee cost reimbursements from BMS under our collaboration. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect research and development expense to increase for 2021 compared to 2020 primarily as a result of our continued development of bempegaldesleukin, including studies outside of the BMS Collaboration Agreement. In addition, we are collaborating with Lilly to develop NKTR-358, and Lilly will be conducting the recently started Phase 2 studies and other ongoing studies in 2021, for which we are responsible for 25% of costs. We are continuing to enroll patients in the expansion cohorts of the Phase 1/2 study for NKTR-262 in combination with bempegaldesleukin. We will continue our Phase 1/2 dose-escalation and expansion studies for NKTR-255 in multiple myeloma, non-Hodgkin lymphoma, relapsed or refractory head and neck squamous cell carcinoma, and colorectal cancer. The timing and amount of our future clinical investments will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to our drug candidates that we plan to evaluate in clinical development during 2021 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates by applying our polymer conjugate technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for bempegaldesleukin, NKTR-358, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the evolving situation around the COVID-19 pandemic has had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the pandemic. We have experienced delays of approximately three months for some Nektar-run, earlier-stage clinical studies (such as the Phase 1/2 trial studying bempegaldesleukin and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in NSCLC and the Phase 1 dose escalation trial studying NKTR-255 in patients with relapsed/refractory hematologic malignancies) and given the evolving situation around the COVID-19 pandemic it is possible there could be additional delays in the future. In addition, for certain clinical studies involving our proprietary drug candidates that are run by our partners, study timelines have been delayed at least three to six months, and, given the evolving situation around the COVID-19 pandemic, it is possible there could be additional delays in the future. As a result of these delays and potential delays, we may incur additional costs associated with these clinical trials. At this time, we cannot estimate if such increases would have a material effect on our results of operations or financial position. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks and uncertainties associated with our research and development projects are discussed more fully in Item&#160;1A. Risk Factors. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,682&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,712&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,970&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;General and administrative expense includes the cost of administrative staffing, business development, marketing, finance, and legal activities. General and administrative expense increased for the year ended December&#160;31, 2020 compared with the year ended December&#160;31, 2019 primarily due to increased personnel costs as we begin a stage appropriate build of our commercial capability to co-commercialize bempegaldesleukin with BMS. We expect general and administrative expense to increase for 2021 compared to 2020, as we continue to build our commercial capabilities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of the NKTR-181 program.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7 million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5 million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and severance costs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,851&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,310&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,459)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Interest expense decreased for the year ended December&#160;31, 2020 as compared to the year ended December&#160;31, 2019. In October 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes due October 2020. Interest on the 7.75% senior secured notes was calculated based on actual days outstanding over a 360 day year. On April 13, 2020, we redeemed the senior secured notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million. After the repayment, we incurred no interest expense.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue and Non-Cash Interest Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-cash interest expense on liability related to sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 7 to our Consolidated Financial Statements, we continue to recognize non-cash royalty revenue for the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement (as defined in Note 7). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Purchase and Sale Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue for the 2012 Purchase and Sale Agreement increased for the year ended December 31, 2020 as compared to the year ended December 31, 2019 due to increases in net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Non-cash interest expense for the 2012 Purchase and Sales Agreement increased for the&#160;year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019&#160;due to an increase in the estimated implicit interest rate over the life of the transaction, as disclosed above. When forecasted future revenues rise, this results in an increase to the estimated implicit interest rate over the life of the transaction, which, in turn, increases the prospective effective interest rate in the current and future periods. The increase in the estimated implicit rate from the year-ended December 31, 2019 to the year ended December 31, 2020 resulted from an increase in estimate future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the non-cash interest expense. To date, we have amortized $48.1 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $65.9 million of the net proceeds, since RPI (as defined in Note 7) receives all of the benefits of the increases in future royalties. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Purchase and Sale Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7 to the Consolidated Finance Statements and above under Royalty Revenue, we began recognizing non-cash royalty revenue for the 2020 Purchase and Sale Agreement in the three months ended December 31, 2020 and did not recognize any non-cash interest expense due to an immaterial amount of time to impute interest from closing to December 31, 2020. Non-cash royalty revenue and non-cash interest expense will increase for 2021 as we will recognize them for the full year. Our estimate of the imputed interest rate reflects our estimates for sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which result in meeting the 2025 Threshold (as defined in Note 7). Because the 2025 Threshold of $210.0 million and the increase in the threshold to $240.0 million (if the 2025 Threshold is not achieved) limit the amount of royalties payable to HCR, the potential for the implicit interest rate to vary is more limited. Instead, we will receive the benefit of net sales if they exceed the threshold, but do not bear risk of loss or payments to HCR if royalties are less than expected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net decreased for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, primarily due to decreases in market interest rates and lower investment balances which have been utilized to fund our operations and the repayment of our senior notes on April 13, 2020. The effective interest rate earned on investments which we purchased after the COVID-19 pandemic began has been significantly lower than historical interest rates, and we expect this trend to continue. We expect that our interest income and other income (expense), net will decrease for 2021 compared to 2020 due to continued lower interest rates and lower investments balances as we fund our operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2020 vs.<br/>2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to our expected net loss in 2021, we expect income tax expense to be consistent with 2020 and reflect taxable income for our Nektar India operations.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public offering and private placements of debt and equity securities. At December&#160;31, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. As noted above, on April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. We expect the clinical development of our proprietary drug candidates including bempegaldesleukin, NKTR-358, NKTR-262 and NKTR-255 will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions. In April 2018, we received a total of $1.85 billion from BMS including a $1.0 billion upfront payment and an $850.0 million premium investment in our common stock. In July 2017, we entered into a collaboration agreement for NKTR-358 with Lilly, under which we received a $150.0 million upfront payment. In the future, we expect to receive substantial payments from our collaboration agreements with BMS and Lilly. In particular, under the BMS Collaboration Agreement, we are entitled to approximately $1.455 billion of clinical, regulatory and commercial launch milestones (of which, we have received $50.0 million). Of the remaining milestones, $625.0 million are associated with approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (which reflects the reduction for the $25.0 million nonrefundable, creditable milestone for the first patient, first visit in the muscle-invasive bladder cancer trial that BMS paid to us in March 2020).&#160;As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future liquidity and capital resources. We have no credit facility or any other sources of committed capital.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a co-development agreement with SFJ Pharmaceuticals (SFJ), pursuant to which SFJ will pay up to $150.0 million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with pembrolizumab (Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). In exchange for funding the SCCHN Clinical Trial, SFJ is entitled to a series of contingent success-based payments with the first payment due after substantial completion of the SCCHN Clinical Trial which we currently expect to occur in late 2024 or early 2025 as follows: (i) if bempegaldesleukin receives FDA approval for first line metastatic melanoma or the SCCHN Indication, we would pay SFJ $450.0 million over a series of five annual payments with the first annual payment being $30.0 million; (ii) if bempegaldesleukin receives FDA approval in both first line metastatic melanoma and the SCCHN indication, we would pay SFJ an additional $150.0 million paid over a series of seven annual payments; and (iii) if bempegaldesleukin receives FDA approval in an indication other than first line metastatic melanoma or the SCCHN indication, a one-time payment of $37.5 million. See Note 14 to our Consolidated Financial Statements for additional information.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by shelter-in place or similar orders. However, if delays caused by the COVID-19 pandemic in commencing and enrolling patients in our clinical trials or those run by our partners result in a delay in completing these trials, our ability to file for regulatory approval and commercialize these products (if approved) and receive associated milestone payments may also be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for bempegaldesleukin, the sales levels of our products, if and when they are approved, the sales levels for those products for which we are entitled to royalties, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our only significant noncancellable contractual commitments relate to our leases. Please see Note 6 to our Consolidated Financial Statements for additional information.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash flows used in operating activities for the year ended December&#160;31, 2020 totaled $313.3 million, which includes $353.6 million of net operating cash uses and $9.7 million for interest payments on our senior secured notes, partially offset by a $50.0 million in milestones under the BMS Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash flows used in operating activities for the year ended December 31, 2019 totaled $328.7 million, which includes $319.5 million of net operating cash uses and $19.2 million for interest payments on our senior secured notes, partially offset by $10.0 million from our collaboration agreement with Baxalta.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will increase in 2021 compared to 2020 primarily as a result of increased research and development expenses and no offsetting collaboration milestone payments.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We paid $7.3 million and $26.3 million to purchase or construct property, plant and equipment in the years ended December&#160;31, 2020 and 2019, respectively. The significant decrease in capital expenditures from 2019 was primarily due to the construction of leasehold improvements in 2019 at our Third Street facility as more fully described in Note&#160;6 of our Consolidated Financial Statements.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As described in Note 5 to our Consolidated Financial Statements, in the second quarter of 2020, we redeemed the senior secured notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 7 to our Consolidated Financial Statements and as described above, on December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC, pursuant to which we sold our rights to receive royalty payments arising from the worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, beginning on October 1, 2020. We received proceeds of $146.3 million, representing the sale of price $150.0 million, net of transaction costs. See Note 7 for additional details on the 2020 Purchase and Sale Agreement, including the capped nature of the arrangement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $23.4 million and $23.4 million in the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources and evaluate our estimates on an ongoing basis. Actual results may differ materially from those estimates under different assumptions or conditions. We have determined that for the periods in this report, the following accounting policies and estimates are critical in understanding our financial condition and the results of our operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements with pharmaceutical and biotechnology partners, we assess whether the arrangements fall within the scope of Accounting Standards Codification (ASC) 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we record such payments as a reduction of research and development expense or general and administrative expense, based on where we record the underlying expense.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize license, collaboration and other research revenue based on the facts and circumstances of each contractual agreement and includes recognition of upfront fees and milestone payments. At the inception of each agreement, we determine which promises represent distinct performance obligations, for which management must use significant judgment. Additionally, at inception and at each reporting date thereafter, we must determine and update, as appropriate, the transaction price, which includes variable consideration such as development milestones. We must use judgment to determine when to include variable consideration in the transaction price such that inclusion of such variable consideration will not result in a significant reversal of revenue recognized when the contingency surrounding the variable consideration is resolved. We must also allocate the arrangement consideration to performance obligations based on their relative standalone selling prices, which we generally base on our best estimates and which require significant judgment. For example, in estimating the standalone selling prices for granting licenses for our drug candidates, our estimates may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success. For performance obligations satisfied over time, we recognize revenue based on our estimates of expected future costs or other measures of progress.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Contract Manufacturing Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record accruals for the estimated unbilled costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contract. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. In certain circumstances, we may be entitled to reductions of amounts due under these arrangements if delivery is delayed or the yield from the production process is lower than expected. Given the uncertainties with such reductions, we may only recognize </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such decrease when the contract manufacturer agrees with such reduction. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_58"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A hypothetical 50&#160;basis point increase in interest rates would result in an approximate $2.5 million decrease, less than 1%, in the fair value of our available-for-sale securities at December&#160;31, 2020. This potential change is based on sensitivity analyses performed on our investment securities at December&#160;31, 2020. Actual results may differ materially. The same hypothetical 50&#160;basis point increase in interest rates would have resulted in an approximate $4.3 million decrease, less than 1%, in the fair value of our available-for-sale securities at December&#160;31, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we held $1.0 billion of available-for-sale investments, excluding money market funds, with an average time to maturity of five months. To date we have not experienced any liquidity issues with respect to these securities, but should such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even allowing for potential liquidity issues with respect to these securities, our remaining cash, cash equivalents, and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months. Based on our available cash and our expected operating cash requirements, we currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis. Accordingly, we believe there are no other-than-temporary impairments on these securities and have not recorded any provisions for impairment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The majority of our revenue, expense, and capital purchasing activities are transacted in U.S.&#160;dollars. However, we have contracts with contract manufacturing organizations in Europe, transacted in the British pound sterling or Euros, and incur costs from sites in a variety of international locations which are compensated in their respective local currencies. Additionally, a portion of our operations consists of research and development activities outside the United States, with transactions in the Indian Rupee. Accordingly, we are subject to foreign currency exchange risk for these transactions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. We do not utilize derivative financial instruments to manage our exchange rate risks. We do not believe that inflation has had a material adverse impact on our revenues or operations in any of the past three years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.  Financial Statements and Supplementary Data</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_64">Reports of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_64">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_67">Consolidated Balance Sheets at December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_67">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_67"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_67">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_67">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_73">Consolidated Statements of Operations for each of the three years in the period ended December 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_73">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_73">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_73">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_79">Consolidated Statements of Comprehensive Income (Loss) for each of the three years in the period ended December 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_79">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_79">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_79">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_82">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_82">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_82">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_82">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_85">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_85">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_85">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_85">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_88">78</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Nektar Therapeutics</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Nektar Therapeutics (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 25, 2021 expressed unqualified opinion thereon.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:13pt"><span><br/></span></div><div style="margin-bottom:13pt"><span><br/></span></div><div style="margin-bottom:13pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for accrued research and development expenses</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully described in Note 1 to the consolidated financial statements, the Company records expenses and accruals for estimated costs of research and development activities, including third party contract services costs for clinical research and contract manufacturing. Clinical trial and contract manufacturing activities performed by third parties are expensed based upon estimates of work completed in accordance with agreements with the respective Clinical Research Organization (&#8220;CRO&#8221;) or Contract Manufacturing Organization (&#8220;CMO&#8221;). Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. During 2020, the Company incurred $408.7 million of research and development expenses. The Company recorded an accrued liability of $44.2 million and $11.3 million for clinical trial and contract manufacturing expenses, respectively, as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the accounting for accrued clinical trial and contract manufacturing expenses is complex because of the high volume of data used in management&#8217;s estimates, the assumptions used by management to develop their estimates and verifying the cost and extent of unbilled work performed during the reporting period. </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued research and development expenses, including the Company&#8217;s assessment and estimation of accrued costs for clinical trial and contract manufacturing activities performed by third parties. This assessment was done with the Company&#8217;s financial and operational personnel to determine the appropriate project status and estimated accrual of costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the Company&#8217;s accounting for accrued clinical trial and contract manufacturing expenses, our audit procedures included, among others, obtaining supporting evidence from third parties of the research and development activities performed for significant clinical trials and contract manufacturing services. We agreed, on a sample basis, the Company schedules to key milestones and completion terms, activities, timing, and costs to signed CMO and CRO contracts in order to evaluate the status of completion and accuracy of invoices received from the vendors. We met with clinical and manufacturing personnel to understand the status of significant research and development activities. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.</span></div></td></tr><tr style="height:222pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for cost-sharing under the Bristol-Myers Squibb (BMS) Collaboration Agreement</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company and Bristol-Myers Squibb Company (BMS) both conduct research and development activities under a Strategic Collaboration Agreement for bempegaldesleukin (NKTR-214). As more fully explained in note 10 to the consolidated financial statements, the Company and BMS share certain internal and external development costs under the collaboration agreement. The Company&#8217;s research and development costs include external actual and estimated Clinical Research Organizations (&#8220;CRO&#8221;) and Contract Manufacturing Organization (&#8220;CMO&#8221;) costs in addition to internal employee costs. BMS provides reports to support their research and development activities performed and costs incurred in the relevant period under the terms of the agreement. Estimates included in each party&#8217;s research and development costs are trued up to actuals by each party when known. Eligible costs incurred by each party during the reporting period are offset and the net amount is owed to the party with the excess costs. The Company has a net receivable of $38.7 million from BMS under the collaboration as of December 31, 2020. During a reporting period in which there is a net receivable to the Company, the net amount of BMS&#8217; reimbursement of collaboration expense is recorded as a reduction of research and development expense. For the year ended December 31, 2020, the Company recorded $128.2 million as a reduction of research and development expenses for BMS&#8217; share of the Company&#8217;s research and development expenses, net of the Company&#8217;s share of BMS&#8217; research and development expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the cost-sharing under the collaboration agreement was especially challenging because of the complexity of the data used by the Company for determining the actual and estimated research and development activities that are eligible for reimbursement under the collaboration agreement. The research and development expenses include management&#8217;s judgment regarding the estimated third party contract service costs for clinical research and contract manufacturing incurred during the reporting period. Additionally, the Company evaluates the costs incurred and activities performed by BMS to assess their eligibility for reimbursement under the agreement.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We evaluated the design and tested the operating effectiveness of controls over the accounting for the cost-sharing conducted under the collaboration agreement, including the Company&#8217;s assessment and measurement of its and BMS&#8217;s activities performed and costs incurred that are eligible for reimbursement. This includes conducting meetings with program management, clinical operations and manufacturing personnel to determine the progress to date under the collaboration and substantiating the calculation of eligible costs and activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit procedures included, among others, testing the eligibility of the Company&#8217;s research and development costs against the terms of the agreement. We met with Company personnel and reviewed meeting minutes to understand discussions held with BMS during various committee meetings to corroborate our knowledge of the collaboration activities that have occurred to date. We tested the activities reported by the Company and BMS for appropriate classification and disclosure under the collaboration agreement. We obtained an external confirmation from BMS for the net amount owed to the Company.</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1993.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2021</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Nektar Therapeutics</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited Nektar Therapeutics&#8217; internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Nektar Therapeutics (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 25, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except par&#160;value&#160;information)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNC0xLTEtMS0w_a436dc30-57c9-43e7-91f7-9a61108a82e8">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNC0zLTEtMS0w_2afa2ab9-be0e-4aad-b766-07236b157cb6">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNS0xLTEtMS0w_4172ebd6-31ff-424c-9913-90ba86b65bfc">862,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNS0zLTEtMS0w_254babd4-0d04-48f6-8111-848db688784f">1,228,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNi0xLTEtMS0w_6f8bd4d3-ecf0-46ce-9b45-3886d3925a24">38,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNi0zLTEtMS0w_67337ec7-c3d8-4cc2-92c2-591c60a5fea7">36,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNy0xLTEtMS0w_0232c2f5-2ff0-47f6-b964-9fdb0ae42b18">15,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNy0zLTEtMS0w_521e1f9a-ce9e-472f-8df7-3fe3965b5d69">12,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance payments to contract manufacturers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AdvancePaymentsToContractManufacturers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOC0xLTEtMS0w_ea99c0a0-b8bd-46b6-a434-90fd270aadf3">3,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AdvancePaymentsToContractManufacturers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOC0zLTEtMS0w_2fca38ab-67f9-4410-afb2-78a8a8178a7c">31,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOS0xLTEtMS0w_a01475ab-e52b-427f-aa79-9c528f2d804b">18,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOS0zLTEtMS0w_1df49ecc-d8ea-4dbc-899f-1f199fa70bb7">15,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTAtMS0xLTEtMA_2ca2a21c-a7d2-4081-9bfd-6f86dc748d4a">1,138,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTAtMy0xLTEtMA_4eca6efd-4ea5-4f7b-b8b8-cb6758039cf2">1,421,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTEtMS0xLTEtMA_967dc307-1465-405d-818e-343d7b9de7c5">136,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTEtMy0xLTEtMA_a2e7a575-3dc7-4413-b178-5f5c318c2719">279,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTItMS0xLTEtMA_24d2346c-4907-4c19-a2a1-a9a1ebe17c71">59,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTItMy0xLTEtMA_436e5122-d5a4-487c-8e7d-3707fbd67f63">65,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTMtMS0xLTEtMA_cb947cda-0e27-4008-8955-ba5c448b8313">126,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTMtMy0xLTEtMA_73e155fa-7f0c-4efd-9490-21155830e88f">134,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTQtMS0xLTEtMA_a485ee81-894f-4234-8504-debc16e099ef">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTQtMy0xLTEtMA_53405264-c47d-4ec6-836e-9147d121d45f">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTUtMS0xLTEtMA_64ee1596-ed83-4ca4-a09b-e9bddf2cb337">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTUtMy0xLTEtMA_e04dd82f-9179-4c14-af92-a2f4d66593b3">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTYtMS0xLTEtMA_e8c2df47-1766-4843-975e-758a0013644b">1,538,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTYtMy0xLTEtMA_a2515edf-49e9-4175-a88a-d2b273b7d17f">1,977,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured notes, net and interest payable (see Note 5)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SeniorNotesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMS0xLTEtMzQz_689385bd-8e11-4f7e-999f-a20d6ca6153f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeniorNotesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMy0xLTEtMzQz_022c6adb-d8dd-4ebd-9732-ad6fa632a50a">252,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMS0xLTEtMA_fed973af-70f7-4b59-893e-4980d38bd891">22,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMy0xLTEtMA_b06df3bb-47a6-495c-96db-0ec5cee56087">19,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjAtMS0xLTEtMA_5bb3a5f2-ab12-4594-b3c1-803cf7e5fe31">14,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjAtMy0xLTEtMA_4790bad5-80dd-46d1-bc38-af7c9cdb7bcd">11,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjEtMS0xLTEtMA_7cecd7e1-9870-4f53-9fb2-f9014e8bd4a5">44,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjEtMy0xLTEtMA_d6597c4c-fb02-4b4d-8fa5-f45e13a03df8">32,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjItMS0xLTEtMA_f2625f23-998b-4d75-b2ba-fbe6fcec560d">11,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjItMy0xLTEtMA_ed6228aa-330e-4277-b1c7-8cda50e7efe2">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjMtMS0xLTEtMA_ea2e9355-fe01-4466-9646-0f9146a83a60">9,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjMtMy0xLTEtMA_dc5167b1-815a-4cce-9a8b-97dbcce59e62">12,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjYtMS0xLTEtMA_540e61f4-815d-4110-934b-49ed38caa058">13,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjYtMy0xLTEtMA_eb6fce9e-1463-4ad1-bc1e-0599a9cfefb6">12,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjctMS0xLTEtMA_d1b2a5aa-4d46-4373-bb23-105e8242c791">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjctMy0xLTEtMA_6831d8cb-970f-4cac-b292-8af472de8761">5,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjktMS0xLTEtMA_2519a236-abe9-4904-a9be-dacb0d5fb4ef">115,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjktMy0xLTEtMA_f1d1a3c7-e523-4991-baef-132974b101ed">353,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzEtMS0xLTEtMA_96ad7de6-1d8c-4063-ac10-ba19395106a1">136,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzEtMy0xLTEtMA_36f1167e-c9b8-4dca-9a7c-8da64d41524b">142,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzItMS0xLTEtMA_267eccd9-ec14-4e5c-937c-e4b0c304564d">200,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzItMy0xLTEtMA_95cb974d-d228-43be-b81c-a27a02d465a5">72,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzMtMS0xLTEtMA_a260968f-72d5-434b-870b-0986ad85fd37">2,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzMtMy0xLTEtMA_68624558-f0e3-47eb-86aa-16a26f145adb">2,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzQtMS0xLTEtMA_cb5d1ea2-eef4-43cb-825b-0b5c2ed73470">6,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzQtMy0xLTEtMA_b1da1c51-dfc4-45bc-af7e-0ee17f59b4bd">768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzUtMS0xLTEtMA_50c10287-089c-4baa-beb3-bd4230bd25c5">461,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzUtMy0xLTEtMA_2ec53197-7d51-416a-8748-f1a8db31b962">571,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzYtMS0xLTEtMA_2a69ba49-bf44-48f1-8f22-917ecf733f3d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzYtMy0xLTEtMA_58a42a8d-b6a3-4241-b6d4-36b941f8e84e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NjU_8bfac8a7-a6ef-4cfd-8beb-86e33151b048"><ix:nonFraction unitRef="usdPerShare" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NjU_f65f10fd-20ce-41ce-8a90-49cd209ea83b">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NzQ_80d3dcd8-6515-4954-9903-3564996b148a"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NzQ_f87ba13a-4258-4e69-aced-ba426873c374">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_00a204a8-ced4-4310-88df-e8cda1a9b505"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_38fe9548-839d-4645-bcc4-9eb173791173"><ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_5d88679f-bb58-4852-b63b-2cdb533b84f4"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_9c678680-fcea-442f-935e-f33fd7bf2427"><ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_bbbf32bd-d963-4844-8f0e-526acd3d2da0"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_e30b0cd2-4a6c-420d-afff-d8b8f69defd5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated, issued or outstanding at December 31, 2020 or 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMS0xLTEtMA_379f37f0-eb28-41c5-b085-45a0857522e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMy0xLTEtMA_028a595f-cdd6-4c77-b490-57915b8a9854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg0OTE_7460973d-494d-4bb7-ace2-77d1deee7ff4"><ix:nonFraction unitRef="usdPerShare" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg0OTE_f56bd3bb-2d42-4e01-8e8d-9918d6ff1a64">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MDE_defb8c5a-6888-4d10-842d-e0394d017116"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MDE_e5a67801-6223-4ba2-8e40-c2f2886b8c22">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MTE_9f967cf5-133f-40ba-8cb6-57424758e3b6"><ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MTE_dcd9a443-3636-4000-b70e-7abb6c52f3ce">180,091</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MjE_7f1052db-6381-4c0e-bf51-597f3ba002e2"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MjE_8263a138-634e-4d34-81af-6a04977b74e5">176,505</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMS0xLTEtMA_1c1ff9a0-0ba8-4bff-a839-84f2861e83a9">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMy0xLTEtMA_c67b9785-7f4e-4eed-96b5-6b6731d6e10f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDAtMS0xLTEtMA_b68032e1-6524-410b-b196-98636dcde012">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDAtMy0xLTEtMA_b8896c6a-4dc7-48a9-b65d-3a13931fae56">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDEtMS0xLTEtMA_5f6a462e-9f5a-4877-9ce0-86906ccc17fc">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDEtMy0xLTEtMA_170d6043-ee86-49b3-8951-2373b7a2e495">1,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDItMS0xLTEtMA_50079cfd-9200-485f-b049-08bafa2079e4">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDItMy0xLTEtMA_7bc35218-0157-4f9d-b226-de3f34ac3a68">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDMtMS0xLTEtMA_aa533193-38f7-4f44-9b82-f1646a90631d">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDMtMy0xLTEtMA_ba8e7128-7c47-44db-b8b4-cb15c69a80c2">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDQtMS0xLTEtMA_b25cb2bd-b6b0-456e-9b52-f4a0b1fb7d4d">1,538,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDQtMy0xLTEtMA_c743d782-c57b-4d76-87da-081b70e0b2e9">1,977,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;per&#160;share&#160;information)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ce07361f9b43129f976c314af40cd8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMy0xLTEtMS0w_b858849e-c0bd-40f6-97b2-8c47347968ad">17,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2104eacf6c1c4d319643e63ddfcaa810_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMy0zLTEtMS0w_3a5816a8-a658-42fd-9a72-f14dd721d39e">20,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2127771393fd4344bc56f116378dbc80_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMy01LTEtMS0w_7f45990e-38b7-4ddc-8a84-3808ec6d409f">20,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e1d56d6d224026a4762d3a7d7d113c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNC0xLTEtMS0w_855c5932-1c3f-4867-9a1e-918f74daecbc">30,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bbf49b668643278f282f67a79338f6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNC0zLTEtMS0w_5351a873-33d7-4c88-8095-801affb1d3a4">41,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced44c3d5ae947b09f1caf9892e918ed_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNC01LTEtMS0w_9684c436-9282-4fd4-839e-dd094aa2a3de">41,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic383fe79ff4f463db81e7ac42a6ad50d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNS0xLTEtMS0w_05058027-6c79-42ea-a2ca-67551f79a68f">48,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0fa75cc5764250b904e9532e10dcfc_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNS0zLTEtMS0w_c9cfb34e-3343-4200-b6af-3ec1bab1017a">36,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75782c14a414b63b988ae2765e32773_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNS01LTEtMS0w_9c781d73-832b-4865-b792-f98d1b3f6a47">33,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20f13baec094f3ab62602a7600f949a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNi0xLTEtMS0w_07ad1c7d-25ab-4069-9588-b61370761ed3">55,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aaedea71c1a4731b57ba3b49a31cb47_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNi0zLTEtMS0w_550a3d21-0cb0-47f0-a5c3-bae5fb42ce1d">16,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ee016ab66c4bc7b24baff974c4e434_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNi01LTEtMS0w_b9124ba3-6565-491a-af04-367f3009314b">1,097,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNy0xLTEtMS0w_eccaf3e7-f689-4819-9ebc-377eddc6aeb6">152,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNy0zLTEtMS0w_80bacd4b-9079-42ca-9387-f99c836a9abb">114,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNy01LTEtMS0w_5c658d11-5acc-4357-9557-ed334b510d85">1,193,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfOS0xLTEtMS0w_93b20f54-7bfb-492d-835c-047b9e3f05ad">19,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfOS0zLTEtMS0w_293e376c-7c7a-4cdf-9ad0-9dd2818fa445">21,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfOS01LTEtMS0w_227eecca-71a5-46ba-9fe5-fcd1192fe0f6">24,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTAtMS0xLTEtMA_abf74fcf-8f3e-414a-9244-8b11fff8a445">408,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTAtMy0xLTEtMA_e6f35c82-77e6-4018-a1c6-75acb4934734">434,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTAtNS0xLTEtMA_b267a611-0d2c-4037-b74d-bc01b6567844">399,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTEtMS0xLTEtMA_6e214b5d-0312-4038-9c67-0dc20369c7d3">104,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTEtMy0xLTEtMA_5a352a22-dcff-491d-84a8-9ef87d9e5003">98,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTEtNS0xLTEtMA_a79a2a0b-6afa-493f-81aa-521f22ee255c">81,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTItMS0xLTEtMA_9a709370-6a63-4bbc-8ef2-6e1184aa1d4e">45,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTItMy0xLTEtMA_25d53d7c-96cf-4177-8eb7-13e7c11686ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTItNS0xLTEtMA_445e246f-34cf-4b62-a92e-da42b31d1e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTMtMS0xLTEtMA_30c981f8-30ae-48ed-a584-6f95aff1fd7d">578,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTMtMy0xLTEtMA_5091a5d3-da40-44ba-9c0a-b7c4b9cc15d2">554,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTMtNS0xLTEtMA_f4add3ab-2002-4cf6-b0eb-d66bf3d5d020">505,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTQtMS0xLTEtMA_098cf57a-cf7e-489f-bbb6-cd8701c1e5df">425,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTQtMy0xLTEtMA_7e370f6b-a513-476d-a696-b48ac2935c1c">440,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTQtNS0xLTEtMA_ef6ccddd-f0cf-416d-901b-0976402319d1">687,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTYtMS0xLTEtMA_ced85005-8a8c-453e-95fb-ac92cf9e7939">6,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTYtMy0xLTEtMA_b776f5de-a3a2-4b89-a908-21dcb8d747ad">21,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTYtNS0xLTEtMA_cc1ecedd-6d54-4254-b478-8df7fcb93bf7">21,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTctMS0xLTEtMA_729cf39a-904f-4ab2-8fcd-956ce2b6430d">30,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTctMy0xLTEtMA_b8dec2bc-038d-4790-9387-00fd637e8b36">25,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTctNS0xLTEtMA_9df77f5e-cab7-434d-bad5-d973602bc866">21,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTgtMS0xLTEtMA_8323b7cc-1e89-4d90-84f0-6c3fbde5a9c2">18,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTgtMy0xLTEtMA_ec612836-48e6-42b8-93b7-3a9887cc8159">46,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTgtNS0xLTEtMA_8c4657cc-5989-4732-b6e7-010ccfc4e75e">37,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating expense, net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTktMS0xLTEtMA_b0e30a37-c466-4a1e-9c77-1a7463777a24">18,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTktMy0xLTEtMA_089b0afb-48ea-440c-9ae6-56a6efbe1b60">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTktNS0xLTEtMA_53f3c8b3-b961-46b2-b6ac-e1badb69a21f">5,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjAtMS0xLTEtMA_3d271c12-d56f-471b-8777-9759e4199180">443,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjAtMy0xLTEtMA_329461e9-96e5-429c-ab1b-d40abaa1d3a0">440,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjAtNS0xLTEtMA_5a67edb9-aa93-4c71-acf5-c933145d34c5">682,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjEtMS0xLTEtMA_08639f65-2c28-4c32-ae33-9d1ffd055d9c">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjEtMy0xLTEtMA_a87e4bd2-5264-45b8-a50b-741519d0445f">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjEtNS0xLTEtMA_2fe9d79c-404d-4985-844f-ede13be08d9d">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjItMS0xLTEtMA_b6214431-2789-4cf7-8baa-fe21230ba7f7">444,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjItMy0xLTEtMA_3ebcf871-a7f2-45f9-b7ec-1f6aa7e73714">440,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjItNS0xLTEtMA_01a4f3a8-3915-479d-9797-a2f037aa2501">681,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjUtMS0xLTEtMA_61be6456-ab02-4aad-bf5c-970e22f6fe05">2.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjUtMy0xLTEtMA_4d94920c-d7e7-474f-a7a9-e9d98df535cc">2.52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjUtNS0xLTEtMA_836b88b4-5ea6-4804-9eab-11ffd4980aad">4.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjYtMS0xLTEtMA_cd6407f2-d7ca-4350-a6d8-53bc88368d31">2.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjYtMy0xLTEtMA_21806352-ae36-42b0-8933-75291cfaae9b">2.52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjYtNS0xLTEtMA_2e637814-03e0-4a01-80c5-54fbfd33bda0">3.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing net income (loss) per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjgtMS0xLTEtMA_91e4fa0b-8fc7-4a9b-849b-021731ac39a2">178,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjgtMy0xLTEtMA_f12c4a50-193a-48d8-8be9-0eb25fd8e5fd">174,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjgtNS0xLTEtMA_cd40174b-168c-40ae-ac9a-901033839329">169,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjktMS0xLTEtMA_b9e5f5c0-2f4f-4c83-8fb6-b60006719a63">178,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjktMy0xLTEtMA_639bf73b-be49-401d-9d8c-c431243692c3">174,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjktNS0xLTEtMA_df56a672-695b-4b75-a925-8502f90d779e">180,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfMi0xLTEtMS0w_b5b4cea7-8c7f-456f-b9b5-da272cb85b81">444,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfMi0zLTEtMS0w_0f985dd3-dfcd-4605-ae02-fae6596b33b6">440,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfMi01LTEtMS0w_2d8aeb84-451c-40f2-85ab-fe0990043d07">681,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNC0xLTEtMS0w_3dcc970c-02f1-4a06-a2cb-ab729eba6a1f">927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNC0zLTEtMS0w_e7849fb7-ead0-450d-b501-b04ca9f1d808">5,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNC01LTEtMS0w_c6789e60-70ce-49e4-a5a1-924e3ecc1cd0">2,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNS0xLTEtMS0w_b0725e38-a8a8-4a8c-ab59-b48d5e4d8b71">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNS0zLTEtMS0w_9301c0d0-0d9d-4548-906f-3ac2a2685d58">382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNS01LTEtMS0w_ec7b287a-5509-4947-a0dc-e6381d1b3c66">1,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNi0xLTEtMS0w_46061293-b862-4d4a-9d76-dfd19365724b">1,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNi0zLTEtMS0w_9f1499b7-3822-45bd-a76b-c0040cd15339">5,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNi01LTEtMS0w_a7949f95-2853-4171-a973-275f406e3b0f">4,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNy0xLTEtMS0w_dc41ff3d-7617-40f6-acf7-4ab771264f9a">445,730</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNy0zLTEtMS0w_76fa6878-f6e6-476b-ad13-99003f7a136a">435,356</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNy01LTEtMS0w_7b026308-8ff7-4226-a599-6530f8a7588b">677,108</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Excess of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc09b131139d4563b60db10c398e0c39_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS0xLTEtMS0w_b38b09f0-dad5-4b8e-8d88-a08302cd47c3">159,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc09b131139d4563b60db10c398e0c39_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS0zLTEtMS0w_2c02af70-281d-49f3-a7b3-84726ea17f82">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic317cce5e2e84fb1ac5250f54df57bec_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS01LTEtMS0w_5f45c6b1-8739-4385-b31a-6738416ff4f5">2,207,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c4c76f968fe4a4093752003d5013bc3_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS03LTEtMS0w_15d8127c-f9a0-429f-b269-b1ea5147fc11">2,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf9e7353cdeb4fe6b0ec92f7ee97d3df_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS05LTEtMS0w_484be5bd-7330-4abd-b0e8-e5edf7422fb9">2,117,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS0xMS0xLTEtMA_97d9c322-cd94-4ae6-ac21-5be08352e681">87,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi0xLTEtMS0w_a4dbf5d0-0e3e-4f6d-8230-e0d53f6887a7">5,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi0zLTEtMS0w_88968706-372f-4df7-baf6-96ae588c1729">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi01LTEtMS0w_30a00412-4fe7-45f8-a7cb-372e9acf40e4">61,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi0xMS0xLTEtMA_be0a895a-b194-4810-92a3-32ab78b7c0e1">61,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMy01LTEtMS0w_34f3f2e6-7c68-4e61-b800-22a6e9f9c62a">88,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMy0xMS0xLTEtMA_a23b5c40-4f5c-4ca4-b155-1b304716c7c4">88,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of stock to Bristol-Myers Squibb (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0xLTEtMS0zNzI_1a0b84a6-55c2-4c8b-bff6-997adbc9f2b8">8,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0zLTEtMS0zNzI_a4dd4dc3-3ddc-4cb5-a4c3-fd957a321042">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC01LTEtMS0zNzI_421d5b1b-bf80-484b-8f49-6d29b8229ce5">790,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0xMS0xLTEtMzcy_375f7a81-0ac7-48f8-a9ec-81cb88c896e1">790,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of new accounting standards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782737b6925642ae80e85211d3061393_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNS05LTEtMS0zNzI_ef76aec5-1cd9-40ca-9f37-a9d335bc8445">12,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c8ff8ae9384f8495fb9cb6ddd60570_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNS0xMS0xLTEtMzcy_da301383-4196-49ae-9215-0f82fb262f2c">12,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5b17c7c97be4099ae192bd62fc5521d_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC03LTEtMS0w_e3fc0434-4ca9-44b7-b682-1c39f66327d0">4,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada3a911b4f14caea46af4c30f06e014_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC05LTEtMS0w_bdf6edf0-c2b0-4819-b82b-74d63d5083a4">681,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0xMS0xLTEtMA_caaf0e30-5659-43bf-8ca1-93c3d5dc776a">677,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i970c509f43724f619b397e04e8673b95_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi0xLTEtMS0w_ff9afb17-ff35-4be7-ad7d-8e12980233ad">173,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970c509f43724f619b397e04e8673b95_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi0zLTEtMS0w_8674dcfd-84c2-4143-8a56-4251c240885a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f25f1ab252404589804ff8b213aacd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi01LTEtMS0w_ce59b699-6946-47ca-b22b-4539bde89290">3,147,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09c0c4709d4b5aa0c73844f694a2db_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi03LTEtMS0w_88293a49-2271-4184-b4db-e3d450b31d6a">6,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63874fca1d514b93a990a5f8aab4aa34_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi05LTEtMS0w_e36cd5ef-4f8a-4ee5-9c27-5ede0aa75136">1,424,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi0xMS0xLTEtMA_d8aa4b18-4f99-4f33-a7ef-dd4a56af1acc">1,717,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33907907e75044d9835ba51785a384b9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNy0xLTEtMS0w_7729a42c-d65c-40f8-825e-e906685ba4e9">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5542093f845a450e83bcc68e3b46375f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNy01LTEtMS0w_b0a6d5ad-cab4-4684-949f-d74a0b3eb072">23,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNy0xMS0xLTEtMA_33437467-8579-4fce-b5fb-a553f7cbec5b">23,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5542093f845a450e83bcc68e3b46375f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfOC01LTEtMS0w_542a9e6e-b41b-4ab6-8f8e-baa982a3a1b2">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfOC0xMS0xLTEtMA_acb8baa1-d1e5-49ee-86a5-e044d6b51b37">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4590dba62bf9491c9a6eb5b8d6bb51c0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTEtNy0xLTEtMA_ccfa75fc-af6f-48a3-a1c0-7537ce6a01b2">5,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a1357fd1ed41e0991dc2af7ce5c5c3_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTEtOS0xLTEtMA_471d2ed9-f25a-4c54-8810-9f1f65cdd152">440,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTEtMTEtMS0xLTA_174222b6-b604-4e27-a6b2-13fa69b42fb3">435,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd7b0526e6124631a8651436a2212d83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtMS0xLTEtMA_26abec6e-c5e1-4a84-b24e-8247d1584289">176,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7b0526e6124631a8651436a2212d83_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtMy0xLTEtMA_e8c5061b-a6be-4a2e-9afa-cece5ead55d2">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb019599e084003800372045527cde5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtNS0xLTEtMA_4658b21f-2c0f-4e6b-9fc3-e2d1e400c2b5">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fdd2b443374491091615a02e9e811a7_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtNy0xLTEtMA_af65b4e1-c9ef-4ecf-bddf-2fbf740d1dbd">1,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7087384b4384d5ea1895430f29aa031_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtOS0xLTEtMA_e488d9ff-bedf-4cfe-bb72-b6fba9a6efd9">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtMTEtMS0xLTA_15d697c2-f7d2-4969-983b-4e1e62fade09">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c38660192d4485bb12209404a88e784_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtMS0xLTEtMA_2ef9dbb8-75e3-4386-ac4c-89c73266d65e">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c38660192d4485bb12209404a88e784_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtMy0xLTEtMA_a7688587-1aa3-4b56-843a-59ee0e89be93">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880d3494fb4e4f6abd5b72316ba10da3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtNS0xLTEtMA_ab1eebdf-5bac-4d78-a987-ea64c39bca11">23,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtMTEtMS0xLTA_63dec69b-657e-4a3a-999a-ef816fc58c9b">23,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880d3494fb4e4f6abd5b72316ba10da3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTUtNS0xLTEtMA_862e0084-df1b-4b18-a1a8-aa047838d2cf">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTUtMTEtMS0xLTA_f7085520-c202-4023-ac16-9306390db359">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbf098280e6d44e0936905fbe28dcb34_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTYtNy0xLTEtMA_78a7f226-45e8-4fdd-b40c-7c7ac4e2aa3a">1,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3387462eae3140f4abc3e28f4e4a5af3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTYtOS0xLTEtMA_daa6236e-7e82-4fc6-8098-572ef84cacb5">444,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTYtMTEtMS0xLTA_fb744ab7-e909-43f5-a430-3abcf6ef41df">445,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73c1044cd8154ba294e48097dcf6ecfd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtMS0xLTEtMA_1648420a-1110-4221-bc8b-bbb12197c18c">180,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c1044cd8154ba294e48097dcf6ecfd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtMy0xLTEtMA_881278a4-4b4b-49e6-9a52-b1a7882cea22">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ac0337faf647b189a16641a720d4d2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtNS0xLTEtMA_b883b360-f478-49c2-97ca-b16926ae46f9">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5065cf5b40d5475aa1b717b89709499d_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtNy0xLTEtMA_d3a39a47-2330-4d8f-8ab1-bff0dece1c47">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08affc16b104b92823fab10fa4ae3a5_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtOS0xLTEtMA_986f5368-c7d9-426d-9403-e8476bd0d8f4">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtMTEtMS0xLTA_638e9dec-afa3-4cfa-a2f9-c9ea525bdfa7">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMy0xLTEtMS0w_a184b3e5-01d1-43f0-95eb-1339ad433889">444,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMy0zLTEtMS0w_282fdec6-6b07-40eb-baff-df3caf426a67">440,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMy01LTEtMS0w_209bb6c9-9bcb-4fcb-b88b-ba1263658073">681,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNS0xLTEtMS0w_120279fb-bf43-451f-8803-dd81f6e99840">48,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNS0zLTEtMS0w_cb00c22b-5796-465c-9ada-4c587d96d28b">36,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNS01LTEtMS0w_625f99d9-85be-4fa4-9e98-ad1b6722efcb">33,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNi0xLTEtMS0w_3f32c358-0898-47b0-93bd-78f89452379f">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNi0zLTEtMS0w_53c3be9d-7991-4f1d-8410-89f7ee323035">25,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNi01LTEtMS0w_5a100814-5038-424d-a03d-562d4f943500">21,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNy0xLTEtMS0w_4604e32b-504a-42a5-acc6-42c2d45e9eb5">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNy0zLTEtMS0w_ab3b0c56-850d-4d0b-9310-77e7c19bd614">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNy01LTEtMS0w_e9331863-2eed-4b53-b091-f045156671e2">88,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOC0xLTEtMS0w_8d56ba27-5447-4692-823b-5041854bb74a">14,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOC0zLTEtMS0w_a1b16323-ac96-4e45-9278-67ef47f9f4ba">13,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOC01LTEtMS0w_e55816e1-52ea-411e-9f41-c6b3f9138c98">10,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of advance payments to contract manufacturers and equipment for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOS0xLTEtMS0w_e6bc96a9-6f2f-453c-bc2a-4435a23edee5">20,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOS0zLTEtMS0w_a9861ceb-59ea-4fb5-b2a1-fa6063dd2fd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOS01LTEtMS0w_fb905dd2-1b08-4c7d-8594-032f06eefe81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:AccretionOfDiscountNetAndOtherNonCashTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTAtMS0xLTEtMA_560cd2a4-f2c8-4db8-9927-a6b9d4dd563f">3,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccretionOfDiscountNetAndOtherNonCashTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTAtMy0xLTEtMA_c15c2515-2237-431f-a363-b7e4cd98afff">11,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccretionOfDiscountNetAndOtherNonCashTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTAtNS0xLTEtMA_249c8f31-fa83-4a4e-bb38-170b254a10d3">10,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTItMS0xLTEtMA_9983b64f-7f0c-4151-ba10-32db55b3961e">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTItMy0xLTEtMA_8008062e-5f8e-4af5-9a24-5fdad3e5cfd9">6,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTItNS0xLTEtMA_0c576f3e-a618-49bd-802e-88e6e1c3c338">25,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTMtMS0xLTEtMA_219bb885-4a42-46e7-8f7f-b78d4268ab66">2,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTMtMy0xLTEtMA_885d1d5f-00ba-400e-9f00-21cbb7c309b4">1,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTMtNS0xLTEtMA_70fb8b15-80e5-4b6e-a2a9-82dec2c8d523">655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTQtMS0xLTEtMA_d88ed7e6-1e51-4611-8c27-39a49e4ee5d6">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTQtMy0xLTEtMA_fc05be8a-d043-461f-82b1-25c2ac158820">13,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTQtNS0xLTEtMA_fa00380d-6801-4079-b251-f136fd818372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTUtMS0xLTEtMA_251cb2a4-6eb4-4853-9417-bfe30a836c71">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTUtMy0xLTEtMA_e0a4c925-227a-4d8d-8e82-c1aa7e1752b8">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTUtNS0xLTEtMA_a518b2c9-92d6-44ba-8f1e-6c116d8fb521">31,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTYtMS0xLTEtMA_4c83e851-c568-4b73-b956-0e5fccf7ec86">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTYtMy0xLTEtMA_40f3df40-b408-4858-a4c7-fb56e612004e">12,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTYtNS0xLTEtMA_5f6f670f-10ba-4fcc-9625-d3e544f3dce9">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTctMS0xLTEtMA_a8caaf2c-aaa2-4062-ad8f-43e35d748adf">4,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTctMy0xLTEtMA_30fca78f-800f-4854-83f2-0d88b19b026c">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTctNS0xLTEtMA_dde6c9b8-bd6c-40d4-a627-bafcc5f25409">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTgtMS0xLTEtMA_047ae9d6-774c-472a-ab48-414ee56aef92">8,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTgtMy0xLTEtMA_4edeb78a-b430-45fd-8063-0f9debde0d10">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTgtNS0xLTEtMA_c1eb033e-8f9c-41ab-bae2-fd027e07c333">31,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTktMS0xLTEtMA_f3e6dcda-fcb8-4799-a9ad-42fa830a18d2">5,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTktMy0xLTEtMA_8b4dda81-9a57-4dec-b326-4bf6ba41bbfe">16,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTktNS0xLTEtMA_a98dfab1-f704-4257-a1f2-cd0e6596d198">15,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjEtMS0xLTEtMA_8419557f-ec09-4bfb-ae95-99ee91615dcd">313,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjEtMy0xLTEtMA_8b912c81-79d0-4ed0-9b74-aa69887b628d">328,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjEtNS0xLTEtMA_06b2e05d-fc5d-4636-8cf2-9b1bfad28d22">718,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjMtMS0xLTEtMA_65e9af4e-1119-4a42-8b2a-d9a4522929e1">987,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjMtMy0xLTEtMA_683fd3fa-522a-4b26-bcc4-1d89e19fdb11">1,380,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjMtNS0xLTEtMA_b90c73fe-e036-420a-9c7d-c069a78d2cd2">2,271,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjQtMS0xLTEtMA_be66b78c-7baf-477b-9e9b-ff393bcc2805">1,449,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjQtMy0xLTEtMA_018fa348-f763-4937-b078-bb4a6b69d7ab">1,614,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjQtNS0xLTEtMA_b7c9da85-6d51-41e4-94e1-e647ebe8a082">890,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjUtMS0xLTEtMA_e2e64a73-04a2-4e51-a6ec-122c56913c3a">41,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjUtMy0xLTEtMA_69c95558-0331-4e20-9436-5fa6559968f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjUtNS0xLTEtMA_575569d2-332f-4e00-88e6-84a50f30205c">11,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjYtMS0xLTEtMA_e79b8dfe-8f69-45d1-82b0-1bbc345c86fd">7,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjYtMy0xLTEtMA_d5feff35-8f13-45d0-b7d6-4baa01c4e173">26,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjYtNS0xLTEtMA_7deb0c4e-6eb0-43ce-bed4-7821e536f70d">14,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of property and plant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjctMS0xLTEtMA_e14ac6e2-78cb-49d1-aae6-554fea3be3ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjctMy0xLTEtMA_9adba66c-c2d9-498b-a5e8-b72ca51f6594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjctNS0xLTEtMA_9f6bf3fb-31ae-41c0-bd23-cd28aa86af3e">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjgtMS0xLTEtMA_9a63f5a2-79ce-43d4-b4c5-fe5dadfd0841">496,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjgtMy0xLTEtMA_3df35997-103a-4633-aa07-948e8392db92">206,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjgtNS0xLTEtMA_a2216c44-cdd5-4629-ac45-50bb9b04d308">1,379,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock to Bristol-Myers Squibb (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMS0xLTEtMA_eb19a890-a311-4051-bdbe-f16452e861ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMy0xLTEtMA_5a567f6c-ff99-4ea4-89b3-daf3a8ca333d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtNS0xLTEtMA_8e6a3877-070b-465d-ab4f-7a8933f261f3">790,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net of $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:SaleOfFutureRoyaltiesTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMC0xLTEtNDUwMS90ZXh0cmVnaW9uOjgwODk1NTc2OWU4NjQ0YzdhOTcxMGJiMTg3YjQzM2RlXzgyNDYzMzcyMDg0MTY_12cf3769-98b1-4cb1-80f7-e2ff186a78e3">3.8</ix:nonFraction> million of transaction costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMS0xLTEtNDUwMQ_228ec89b-f350-476b-988a-e0a0df9097dd">146,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMy0xLTEtNDUwMQ_badd44e4-92b6-4354-9e0a-fdf0c75ab6df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtNS0xLTEtNDUwMQ_50e86561-b5f9-4adb-90f0-b27f6e057754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMS0xLTEtMzM4_7b38b480-ba9d-429e-8d2b-d168bb8f6ef4">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMy0xLTEtMzM4_966c064c-5aa6-49ad-a006-b02c8132f9ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtNS0xLTEtMzM4_50bd4ac6-8d50-4335-91e0-5bc708581e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMS0xLTEtMA_7daa7058-ebbe-4b04-a758-3b846b102583">23,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMy0xLTEtMA_8b47d72b-e3df-491e-a074-a191b77ac118">23,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtNS0xLTEtMA_63ae6409-86ba-4364-af8c-0b48ee84a525">61,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzMtMS0xLTEtMA_01a94595-ebe8-45c9-b0b5-912521ec5d94">80,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzMtMy0xLTEtMA_2aebb77d-30ad-46b2-8fe0-f66ea45ca307">23,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzMtNS0xLTEtMA_f4e7e79f-bd4c-45d5-b43d-fc497fd7c8c4">851,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzQtMS0xLTEtMA_047adce0-55c1-4be8-9a18-d806126d98d2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzQtMy0xLTEtMA_63c37093-a179-4500-8007-7bba0eb78899">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzQtNS0xLTEtMA_6ffcfd11-7102-46e9-aa71-b6df7552b00f">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzUtMS0xLTEtMA_3af9c2b1-f2d4-4e8f-b4b4-9cad747be8d8">102,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzUtMy0xLTEtMA_23299403-688a-4637-8a92-f78e2634d052">98,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzUtNS0xLTEtMA_655056f0-78fb-4d1c-a983-f9ef0c719fbc">190,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzYtMS0xLTEtMA_f4f5a839-61a5-4f7d-ae57-caaffb7c2d80">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzYtMy0xLTEtMA_b955be56-253d-4580-a4ea-6bfd85d08da5">194,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzYtNS0xLTEtMA_4f0866b5-7c3c-4c5a-a705-b1e77233a48c">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzctMS0xLTEtMA_7a195d1a-1a90-4846-91f5-ffd510e82dfb">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzctMy0xLTEtMA_59870364-b04c-4230-bca4-099c5896b844">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzctNS0xLTEtMA_ca143f2b-0962-4715-9ceb-e9158064fcc6">194,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzktMS0xLTEtMA_52c881c4-f5d3-46af-ad84-39383b3c70ec">9,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzktMy0xLTEtMA_7be33a3b-5561-44fe-b908-3320e6031fde">19,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzktNS0xLTEtMA_11c9dd45-a53b-40f1-99f8-00c4974d12db">19,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDAtMS0xLTEtMA_ace380f0-0999-4a1b-bb44-a362f93ba412">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDAtMy0xLTEtMA_201fb4b1-55e0-4b1a-8a2e-9b53e6eae09c">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDAtNS0xLTEtMA_c0486bb9-0667-431e-b75b-80847d9f9482">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets recognized in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDEtMS0xLTEtMA_53a66b49-3b0e-4048-98c3-811f16e2d0c4">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDEtMy0xLTEtMA_4aef8cc6-d83c-46a9-a809-a022886b62e8">57,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDEtNS0xLTEtMA_5412c323-a9bd-42c2-8ae6-bcd29e88a026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ote&#160;1&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjg_1c7c074e-147e-4905-8210-256fb368798f" continuedAt="i30cc9c34e002438893d11e73fa307299" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i30cc9c34e002438893d11e73fa307299" continuedAt="i388c6a7b7d1e4ee4b539d7ec2e1ffa6b"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNTk_90cc5fcf-f5c7-448e-8761-97245c161dfb" continuedAt="i3467820d5bdc4d34a69749d82e65acdf" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3467820d5bdc4d34a69749d82e65acdf">&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At December&#160;31, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-8" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTE3MA_d072b439-14cf-4dd1-ace7-d102ce8efaa3">1.2</ix:nonFraction> billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $<ix:nonFraction unitRef="usd" contextRef="i717a3b33fb444b809d0adef0ac06725b_D20200413-20200413" decimals="-5" format="ixt:numdotdecimal" name="nktr:RepaymentsOfLongTermDebtIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzI5NTM0NA_3dfeb846-5b7d-4d17-bfdf-a88b3f45aaf8">254.8</ix:nonFraction>&#160;million. See Note 5 for additional information.</span></div><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjk_b09053aa-631b-437d-82c7-d6ffb6651456" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i388c6a7b7d1e4ee4b539d7ec2e1ffa6b" continuedAt="i17dffa45445f42e7928da615bc1c7564"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxNjAyMQ_f766d9f6-de0d-48f2-86c6-6a415bd19309" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMDk4MQ_90f6d51c-b795-49dc-ac60-e1c8f5d91925" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNTM_6c3f9f4e-b6d0-44b0-8020-3550922104eb" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income loss. We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our cash, cash equivalents, short-term investments and long-term investments are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents, short-term investments and long-term investments are held or issued by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjc_de127bf1-35f5-4448-a3c2-ffe479f597f6" continuedAt="i5666e7de61a442e89cc45efa53ea236b" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Significant Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. For the year ended December&#160;31, 2020, our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:NetExpenseReimbursementsFromCollaborationPartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTE1NDQ4NzIxOTEyOTc_5711438d-4d7c-448a-882b-44ed0c5777a3">38.7</ix:nonFraction> million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzA0Mw_9dcb03bf-52a7-4fff-b7a1-440f87594003">0.2</ix:nonFraction> million under customer contracts from our collaboration partners. For the year ended December&#160;31, 2019, our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="nktr:NetExpenseReimbursementsFromCollaborationPartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTE1NDQ4NzIxOTE0NjY_e9368cab-4ac0-43f5-abe9-e17e4b7bae85">24.0</ix:nonFraction> million for unbilled net expense reimbursements from BMS and $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzI3Mw_53082289-38fc-490b-af19-0885c6ad63fe">12.8</ix:nonFraction> million from customer contracts, which included our estimate of $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="nktr:ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMzM4MQ_38594ced-2c37-4c2f-8c12-7f30e1c78bb6">11.6</ix:nonFraction>&#160;million for royalties resulting from net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended December 31, 2019. Since we sold our rights to receive royalties in the 2020 Purchase and Sale Agreement with Healthcare Royalty Management, LLC, as discussed further in Note 7, we did not record accounts receivable for these royalties at </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i17dffa45445f42e7928da615bc1c7564" continuedAt="ifc3ce828a78149a09d540b361b831f2b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5666e7de61a442e89cc45efa53ea236b">December 31, 2020. We generally do not require collateral from our partners. We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable. At December&#160;31, 2019, three different partners represented <ix:nonFraction unitRef="number" contextRef="i09546958c5654aba9b0e1a853838b859_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzg5MA_11d8b589-79ae-4de1-a350-50c77e3e0c0e">65</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i4f416a959f974cfba77544c098dfe27a_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzg5NA_bab52b45-31d8-4a8c-bb0d-37dfbf449e16">17</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i24f5461407a5437d9bfeb28b339c42e0_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzkwMQ_2fb62a82-3d3b-481b-ab78-ec2cc0a6ada5">14</ix:nonFraction>%, respectively, of our accounts receivable.</ix:continuation></span></div><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzk_b02a9e3b-00a2-4682-b50a-b8c0996326a0" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjI_33ee8566-775d-47d6-ac78-c6750c95a3de" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). ASC 842 supersedes the guidance in ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the year ended December 31, 2020 and 2019 under ASC 842. We have not restated the results for the year ended December 31, 2018 continue to report them under ASC 840.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 6 for additional information regarding our leases.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="ifc3ce828a78149a09d540b361b831f2b" continuedAt="i64a4aaac68ab4aaf9be48b79598739cf"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzY_f45538f1-ae11-466c-a223-3cebb26251ff" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57">three</span> to <ix:nonNumeric contextRef="i1c77957329da4893900ec8abef0354d0_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NzA_8bbab59b-4ab2-4932-ac49-226635510bcf">ten years</ix:nonNumeric>, depreciate buildings over the estimated useful life of generally <ix:nonNumeric contextRef="i699fa2275d694e3ead84ac6a1b9d588a_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTMwMzk_2146f125-f565-46b6-9147-19769c31ddf0">twenty years</ix:nonNumeric> and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in <ix:nonFraction unitRef="reporting_unit" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTMzNTI_4f513f5e-0342-4960-9817-6b56f8e44da6">one</ix:nonFraction> reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNDc_f91fd26c-fd7e-4e9b-8b93-177d92c23c00" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzA_abcb1748-6278-4644-aabc-d508f0d103f6" continuedAt="i4ba09c42d26f4af598877e20b2de4205" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i64a4aaac68ab4aaf9be48b79598739cf" continuedAt="iddaafe5a35974e5fa38afc25fc6374a6"><ix:continuation id="i4ba09c42d26f4af598877e20b2de4205"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzE_c83074ef-0980-4293-aadd-24bb49b9222e" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjU_14f097cc-8e45-44a6-9a44-f7eee00ef353" continuedAt="i5af146e0f81049c2bc643eedf65248c3" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="iddaafe5a35974e5fa38afc25fc6374a6" continuedAt="i3a61bdaa772841a89d35b1a85e5de976"><ix:continuation id="i5af146e0f81049c2bc643eedf65248c3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div></ix:continuation><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMDk3OA_4b7bae1b-2fc1-4b40-84f1-113c093500ae" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $<ix:nonFraction unitRef="usd" contextRef="i34700219468e42b4b7930f9dbb4d6186_I20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:WriteOffOfPrepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzI5NTM2MA_5bc6fa83-dcd8-4f22-ac17-2287641af810">19.7</ix:nonFraction>&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $<ix:nonFraction unitRef="usd" contextRef="i34700219468e42b4b7930f9dbb4d6186_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzI5NTM3NQ_f9c236ae-36e2-4570-a610-ff2c8e92b4b3">25.5</ix:nonFraction>&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program after March 31, 2020. As of December&#160;31, 2020, we have substantially completed our wind-down and do not expect to incur additional costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzg_8ff05916-fb94-48f7-9a59-cfd2db0efac7" continuedAt="ied39e427df4e4b71b4fc5e4a89c8e14b" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs) and performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs and PSUs on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i3a61bdaa772841a89d35b1a85e5de976" continuedAt="iae65d8721aae4d66954e2f9c81532001"><ix:continuation id="ied39e427df4e4b71b4fc5e4a89c8e14b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options and RSUs that vest upon the achievement of performance milestones, we estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. We recognize stock-based compensation expense for purchases under the ESPP over the respective six-month purchase period. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under the ESPP. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management will continue to assess the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and which could materially impact our fair value determination.</span></div></ix:continuation><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjY_26c2fae5-8221-46af-9593-9b542f95991d" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net income (loss) available to common stockholders is equal to the reported net income (loss). We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities, which consist of common shares underlying stock options and RSUs. For the years ended December 31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options and RSUs totaling <ix:nonFraction unitRef="shares" contextRef="i2258862b93e9480c951e464dfe2bbbe0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMjk4Njg_c51cb99d-9dde-4277-8723-93c83d72040d">17.4</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i9db7646976b34d70acfa2081ee826ee4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMjk4NzU_9bd29010-ae93-4efb-9599-68e1f8e0f9d8">17.9</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively. For the year ended December 31, 2018, the effect of these dilutive securities under the treasury stock method was approximately <ix:nonFraction unitRef="shares" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzAwMDk_3134a31d-972a-4d07-96c2-20054e0c090b">10.5</ix:nonFraction> million, and we excluded approximately <ix:nonFraction unitRef="shares" contextRef="ic21605fedf17490fa0886eae32da3156_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzAwNDM_0249eea3-c8eb-42f3-9391-fd5db48764f7">3.3</ix:nonFraction> million of weighted-average shares of common stock underlying outstanding stock options from the computation of diluted net income per share because&#160;their effect was antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzI_3bfa0c99-1a95-48f1-a6b5-10643534f070" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="iae65d8721aae4d66954e2f9c81532001"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzM_49f21b6c-200a-445a-ac40-d54d548ac3d3" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive income (loss) is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our other comprehensive income (loss) includes net income (loss), gains and losses from the foreign currency translation of the assets and liabilities of our India and UK subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMDk4MA_5b014f51-79bb-4da2-a43d-6276c0961455" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief, and Economic Security (CARES) Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act has not had a material effect on our results of operations or financial position.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNTg_68b39cdd-4113-45bd-b925-246bdc457323" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Consolidated Financial Statements. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed other recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjMyNw_c8ef8224-0947-4c35-b7bf-8d1dfe832073" continuedAt="id8249d20e8fd4af4a0d95fbdccf01f23" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="id8249d20e8fd4af4a0d95fbdccf01f23" continuedAt="i8eb9622f909e47468cd4dc807e5bb490"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjMyOQ_68d66de9-cb78-425a-8a6f-227136025bad" continuedAt="i81a6c2cc53fe49f68a0cd896926fcb6e" escape="true">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i81a6c2cc53fe49f68a0cd896926fcb6e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMi0xLTEtMS0w_589ca5bc-00ba-4dee-8de8-b259a35bf57e">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMi0zLTEtMS0w_ea13435d-2378-4bb8-b914-45bfa090a760">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMy0xLTEtMS0w_e8cdf546-18eb-46c2-b5b7-164463428908">862,941</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMy0zLTEtMS0w_29d2a6d5-2853-40a1-81c3-15c182c314e0">1,228,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNC0xLTEtMS0w_d0bb43fe-a654-4a30-8c23-3ac93076a260">136,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNC0zLTEtMS0w_5a8c719f-e991-40fd-8a01-72523f527156">279,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNS0xLTEtMS0w_28eabc58-a96f-4f9c-bb3f-ec1a6ceac6a2">1,198,558</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNS0zLTEtMS0w_276683ef-8a31-4317-a8ce-f55975c5c42c">1,603,981</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2020 and 2019 had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_65dac629-914e-42fe-8970-b4d9eec444dc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_d24a00d0-9f20-48ec-989c-a46dae10d5c7">one</span></span> and <ix:nonNumeric contextRef="i83c2e96ec4df4105ae39e0cc524fc251_D20200101-20201231" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTYx_7325fc6d-c1e9-406e-9092-db9dfcf67a8f"><ix:nonNumeric contextRef="idf6d1cf2ec944050a87027e7a515ee06_D20190101-20191231" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTYx_e113bfb5-61f8-467c-84c9-fcd73a6c2ae6">two years</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2020 and 2018, we sold available-for-sale securities totaling $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjIzMA_4fcc1f36-90ae-4531-aa4d-fbd7677b29be">41.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjUwMg_09adebad-4d99-4b1a-82a2-c2f42422290e">12.0</ix:nonFraction>&#160;million, respectively. Gross realized gains and losses on those sales were not significant. During the year ended December&#160;31, 2019, we did <ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjI4Nw_bb6c84d2-1383-4169-bbb0-4b09baff15cd">no</ix:nonFraction>t sell any of our available-for-sale securities. The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i8eb9622f909e47468cd4dc807e5bb490"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjI2MA_c1201c3c-b1d5-49e0-a2cf-f1abeecf12d8">5.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjI3NA_c049e09a-2ec0-441d-9158-0cfca341db7e">6.5</ix:nonFraction>&#160;million at December&#160;31, 2020 and December&#160;31, 2019, respectively, in other current assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjMzMQ_917ec0d6-8100-44a6-97bf-d45614653db8" continuedAt="i9e739588c805431f8eec0bd6e5ecbcb8" escape="true">Our portfolio of cash and investments in marketable securities includes (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i9e739588c805431f8eec0bd6e5ecbcb8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi0zLTEtMS0w_47070174-e62e-42d7-9cc6-77cc3f04515e">686,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi01LTEtMS0w_a5c9e714-6e60-4f4d-9203-00536c647816">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi03LTEtMS01MTU_e8fc9eeb-a2d4-4699-bc8d-470da5707f39">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi05LTEtMS01MTU_eb0015c2-362b-4995-a589-8095ef1f3f9d">687,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e58a6675bb4673ad4c4d985c0ad671_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi0xMS0xLTEtNTE1_1e1ff30a-c34a-423c-b8f1-308c1e4a0144">1,132,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy0zLTEtMS0w_a5aa6601-3cf5-46b8-bc5b-114afb9914d5">313,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy01LTEtMS0w_2e2be465-9a99-48f0-8895-7b99d179554d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy03LTEtMS01MTU_945320aa-114b-4557-97b4-8993b310c18e">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy05LTEtMS01MTU_d9444916-eb4f-4d27-8bd7-16db7902ed0c">313,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2df0af8bd514d598273623513f12d91_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy0xMS0xLTEtNTE1_4bb47f83-8837-4d07-ab96-f2602310c26d">375,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC0zLTEtMS0w_9de2b2bf-d889-4d7c-a62c-d162b5225786">2,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC01LTEtMS0w_c559f50e-8d98-4330-be92-cedec8ffb21c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC03LTEtMS01MTU_7f14b9f7-96da-4d94-97ec-bf5625516c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC05LTEtMS01MTU_fbcfccde-7317-489b-8e9f-cbf968dc4b93">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3ed71369cd465faecd143e23ac8cf7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC0xMS0xLTEtNTE1_d3d27627-9b1f-4857-bcbc-5609c4c64b13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS0zLTEtMS0w_86c4abff-ae56-489d-a16e-246bee341379">1,002,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS01LTEtMS0w_8b700072-9b95-4d58-a9bf-b624979fbee0">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS03LTEtMS01MTU_10694e12-b058-4d1a-94fd-f67d0e5e9b11">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS05LTEtMS01MTU_8352ca60-bddc-4645-ab78-a322cd81ef37">1,003,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0a7100bd064c2c83c71589ae758e3f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS0xMS0xLTEtNTE1_40032a87-5af1-4638-983b-3aa05f246863">1,507,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da7225c246f45e7a9949c2da1d6f10b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNi05LTEtMS01MTU_7c0174c7-8ba3-400c-b9d0-31b6b9fce2d1">179,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23df56833c5f4df59292bc311c03aad8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNi0xMS0xLTEtNTE1_fe54e3f0-0f78-4686-a594-e89db7c2c912">83,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26b559e13a246219de39b20472737fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNy05LTEtMS01MTU_14549654-2dbb-4034-911f-58acac3de3d8">9,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2266b3ff82324cb9b553040cded08f91_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNy0xMS0xLTEtNTE1_eb932a10-9ea4-4663-9565-c99f70b207b0">6,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOC05LTEtMS01MTU_e72838e5-3e4b-42b7-894c-f38843a3f21a">6,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOC0xMS0xLTEtNTE1_f9bef0dc-6cb7-4ab8-b623-30f0a1865ad3">5,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOS05LTEtMS01MTU_b298e2dc-1551-4b36-84de-bde3ae1c9eb7">1,198,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOS0xMS0xLTEtNTE1_24039161-1fcc-49cc-8553-04a81b5ec413">1,603,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. For the years ended December&#160;31, 2020 and 2019, there were <ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_32e53419-02f4-40b8-a95e-3e658c04618c"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_3661c337-f714-417b-9939-f29168fdb71a"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_8311ab9d-9b41-49f3-9838-eff0bea724bf"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_9dd0cb1f-e9ba-49a4-85c5-fd8af7850f31">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December 31, 2019, our gross unrealized gains and losses totaled $<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMzcwMQ_aa6dffc0-7627-4ef7-9134-2bdfcaf5ab24">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMzcxNQ_8b7f6206-407a-4c44-a154-63fe7464f78b">0.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjIzMw_eb65286b-7476-48dc-b3a3-38d59e69c4fb">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjI0MA_70e25b20-5a91-4ee2-947c-1edd7b42a340">6.8</ix:nonFraction> million, respectively. These letters of credit are secured by investments of similar amounts.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90ZXh0cmVnaW9uOjhiOGRjMTYyN2FlNjQ1NmU4ZmZlMGM3YzhhMzNlN2QyXzc5_fc6fb53d-1066-4a6a-8232-bae48da8e136" continuedAt="i64691f6d95d44a42b3ebece1ef98b78c" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i64691f6d95d44a42b3ebece1ef98b78c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90ZXh0cmVnaW9uOjhiOGRjMTYyN2FlNjQ1NmU4ZmZlMGM3YzhhMzNlN2QyXzgx_54e9ad26-2880-4387-b63d-d8ac26406a68" continuedAt="id4f3cb3abbfa4f00a444d3ab150aefe8" escape="true">Inventory consists of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="id4f3cb3abbfa4f00a444d3ab150aefe8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzItMS0xLTEtMA_0fc3764a-ccd5-4cad-9fdf-b435868db890">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzItMy0xLTEtMA_f732a794-3c2f-482e-9b63-27d4b5c853c0">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzMtMS0xLTEtMA_e39d4d38-fcaa-4a0f-8293-9544c2a03757">10,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzMtMy0xLTEtMA_a21b418e-bc1e-43d4-a422-7834cec26f83">8,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzQtMS0xLTEtMA_208c8f43-d22f-4a2d-81ec-7ebf82dbc77a">2,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzQtMy0xLTEtMA_557e2bca-2f17-4985-a404-789830b6eedb">2,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzUtMS0xLTEtMA_3e8fb18c-9703-4e1e-a12f-3f98b6322b91">15,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzUtMy0xLTEtMA_e56c3d39-a2db-4374-9fb8-61290dc6f6ee">12,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;4&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzE3NzY_08696020-30c9-47e1-a536-65b90e329673" continuedAt="i23b5428ad40d4f54980a6d991e6d1505" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="i23b5428ad40d4f54980a6d991e6d1505"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzE3Nzg_f087f6cf-6a41-4b45-8853-b209ccd14cf2" continuedAt="ic632beadea38461abb42a5d9beeed793" escape="true">Property, plant and equipment consists of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="ic632beadea38461abb42a5d9beeed793"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45127b4769de4be5b7b965f5763fbc1e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzItMS0xLTEtMA_76a82c60-e47f-4426-8b18-a4cd4dcf3df6">92,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689fee9ace2e4522b887678cba220fa6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzItMy0xLTEtMA_6a4d05dd-f4b8-4cb6-a469-d700b17a4534">93,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a80ca3f7680478d982f63ab514437f4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzMtMS0xLTEtMA_3020c259-81dd-4378-ae8b-35af69ec5c95">40,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84cbf02176864c678db5f9dfbd89d813_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzMtMy0xLTEtMA_944a5d3f-fb8d-4321-b9e4-c7b3aae58249">36,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c28da8080c84fcd807f2604a6cc1e1a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzQtMS0xLTEtMA_59a02cbb-0982-4555-8bfb-ac37fe2bdf77">28,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ddd0c57faa4c2dbab65ca8fd54a4f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzQtMy0xLTEtMA_fe08d2b9-1b6f-4139-a8fb-4b133835ea50">26,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678825b8367a45639e3d62d20e1b8682_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzUtMS0xLTEtMA_ae600e97-f751-4447-ab1c-0a55268217e1">21,796</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbdad1aa0874eb8a53d8398977fd31d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzUtMy0xLTEtMA_8d97c63a-941c-4e0e-bd32-084a7788d89e">22,030</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39c346907c8444d9f56f268dff89776_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzYtMS0xLTEtMA_1603d8ea-b35c-466d-a302-5e7f42bb5d04">9,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if876fe666ac74deaa248054e2378e704_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzYtMy0xLTEtMA_3236ff7f-e208-4464-a213-76e64b79e62b">9,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzctMS0xLTEtMA_78b8b676-a329-473b-ba71-ae4da8fa41e9">193,450</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzctMy0xLTEtMA_cc8040a2-9815-48c0-9f6a-da02df703bda">188,322</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzgtMS0xLTEtMA_00cd9613-7fa5-469f-be98-04e0a801f4f7">138,488</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzgtMy0xLTEtMA_74f3a6d8-a990-4fca-807d-028f16654bc9">127,875</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzktMS0xLTEtMA_9f01d7fe-dc35-4d68-a0d7-c12e5f97fdb1">54,962</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DepreciablePropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzktMy0xLTEtMA_53f75787-0f21-46d9-9749-53eaaaf4efcc">60,447</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzEwLTEtMS0xLTA_a5a5d820-f136-49b1-9337-f0cfb6457c8a">4,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzEwLTMtMS0xLTA_3c0faa8e-b02f-4884-8914-bf435f1bc632">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzExLTEtMS0xLTA_b3761bec-a381-4896-a4d3-f20ed28dc5e3">59,662</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzExLTMtMS0xLTA_41f4ed09-407f-4b13-b1f9-1bd250b45b18">65,665</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense on property, plant and equipment for the years ended December&#160;31, 2020, 2019, and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzg2MA_fc01f1c2-0901-4b55-91ff-c8d21804f10a">12.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzg2NA_632f5146-e13c-4dc4-aeb1-5ccebaa4d5bb">11.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzg3Mg_0b231b5c-e0a5-4659-bfa7-14733caf3581">8.8</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzI1MzI_6d13482f-1c6e-42b5-960a-a0827c190c92" continuedAt="i7bb2587f163c4efc902416e193cb11c1" escape="true">Senior Secured Notes</ix:nonNumeric></span></div><ix:continuation id="i7bb2587f163c4efc902416e193cb11c1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On October 5, 2015, we completed the sale and issuance of $<ix:nonFraction unitRef="usd" contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxMzY_ff4d7d7e-957c-48d6-aca9-9b0a78cc34bf">250.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxNTI_c35a93b4-e50c-4f00-8ec0-bc5b63a1d08e">7.75</ix:nonFraction>% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxNTk_47b6e487-c17e-45ef-885a-c392adfaa10e">7.75</ix:nonFraction>% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would have been due and payable. In connection with the issuance of the Notes, we paid fees and expenses of $<ix:nonFraction unitRef="usd" contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxNjY_0a1e58df-806d-4590-94fb-36f37a5b2903">8.9</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i6228c808807e4675801149c5c4dc1518_D20151005-20151005" decimals="-5" format="ixt:numdotdecimal" name="nktr:DebtDiscountOnTransactionAndFacilityFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxODA_4a6e072e-5943-4025-8398-25610d954ac5">8.7</ix:nonFraction>&#160;million of transaction and facility fees paid directly to the purchasers of the Notes and other direct issuance costs were recorded as a discount to the senior secured notes, net liability balance in our Consolidated Balance Sheet.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $<ix:nonFraction unitRef="usd" contextRef="i9f550fdfeac243e7b6be6c3906cace58_D20200413-20200413" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxOTQ_219a7cdb-e602-4af9-b9a7-dfa4e963db62">250.0</ix:nonFraction>&#160;million and accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i050aa7da5e164a6e8417d8a966766809_I20200413" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkyMTA_60510b17-bde0-4f83-97f2-3ef8f2917299">4.8</ix:nonFraction>&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;6&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM3NjY_6a98520d-9737-4097-b1c8-691905410841" continuedAt="ia1e3d5b8120d42cdb78b5257bdbceb48" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ia1e3d5b8120d42cdb78b5257bdbceb48" continuedAt="ie84926857cbe413d8bc9d130c202fdb2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our <ix:nonFraction unitRef="sqft" contextRef="ib51f0c55e3654f49b5399e4a17397835_I20201231" decimals="0" format="ixt:numdotdecimal" name="nktr:AreaOfLeasedSpace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzExNTQ0ODcyMTAzMDIz_60b35e80-e61b-454c-817b-f185d2751ca7">153,203</ix:nonFraction> square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional <ix:nonFraction unitRef="sqft" contextRef="ifc93e99a4dbd4acdadb139babe668fc2_I20201231" decimals="0" format="ixt:numdotdecimal" name="nktr:AreaOfLeasedSpace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzExNTQ0ODcyMTAzMDM5_27099eae-5b74-4dea-831f-94d97b523f45">135,936</ix:nonFraction> square foot facility to support our R&amp;D operations at 360 Third Street, San Francisco, California (the Third Street Facility). <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzgyNDYzMzcyMTk3Mjc_ee1cc0bf-d6d1-49e3-9616-d8891379c9ab" continuedAt="i8517a5b70376477485edd1b8f6ce4de8" escape="true">The following table presents key information regarding these leases (dollars in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><ix:continuation id="i8517a5b70376477485edd1b8f6ce4de8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="iae1943d37a234e1f9eaaacf476982b71_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="nktr:AreaOfLeasedSpaceDelivered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzQtMS0xLTEtNjA4OA_6be3a6f4-619d-468b-b765-6726a55c3ffc">13,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i86b2a2e647ae4ccf8b8c44c8755aa414_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="nktr:AreaOfLeasedSpaceDelivered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzQtMy0xLTEtNjA4OA_358aba42-8f97-4dcc-8d4a-ef1322f65906">67,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1943d37a234e1f9eaaacf476982b71_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzUtMS0xLTEtNjA4OA_5d3ab48a-2909-4f61-aa5d-513e80fd30f4">6,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b2a2e647ae4ccf8b8c44c8755aa414_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzUtMy0xLTEtNjA4OA_9e4e49ef-0e3a-4a59-a274-f15ef3fe0ee0">50,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="nktr:AreaOfLeasedSpaceDelivered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzctMS0xLTEtNjA4OA_cf5d5919-e90f-41fd-bcdc-1e1a3316fdce">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231" decimals="0" format="ixt:zerodash" name="nktr:AreaOfLeasedSpaceDelivered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzctMy0xLTEtNjA4OA_dee6594b-eaaf-42d9-ad29-40434f6581e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzgtMS0xLTEtNjA4OA_b9197f5d-73a8-4c63-890a-94f822b06865">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzgtMy0xLTEtNjA4OA_9d6217e5-da07-44a3-83ea-15678f95730b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="term" contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:NumberOfConsecutiveTermsToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNTg_c6c64c70-0e1e-4f8c-8637-23e70910c8d4">Two</ix:nonFraction> consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="term" contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:NumberOfConsecutiveTermsToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNDU_a8fb09ab-cc60-498e-92a9-45a80fe2d690">One</ix:nonFraction> <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a">five</span>-year term</span></div></td></tr></table></ix:continuation></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The monthly base rent for both facilities will escalate over the term of the lease at various intervals. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize rent expense for these operating leases on a straight-line basis over the lease period. <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM3Njg_01166ac6-8001-4caa-9db4-f5b85313b7c5" continuedAt="i5fb18159f0354acb9c38353e7b0a908f" escape="true">The components of lease costs, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i5fb18159f0354acb9c38353e7b0a908f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:64.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzItMS0xLTEtMA_53d51db0-e697-4bad-8906-aa314817a43d">18,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzItMy0xLTEtMA_8371ca11-cbbe-4a19-9b92-b213ec9b5675">14,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzItNS0xLTEtMA_1f011664-7121-470d-97e0-0a85ba0bf9b8">7,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzMtMS0xLTEtMA_e0c2ecd2-d3a6-4db7-920b-e6cb6ec9c576">8,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzMtMy0xLTEtMA_a1a5f501-a5c0-448c-b2ce-7ae7274560c5">6,408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzMtNS0xLTEtMA_7c7489bc-e25a-4962-af32-805fcc5d5997">4,497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzQtMS0xLTEtMA_b0c358e8-8ad5-41b8-9945-4dd9e04416b0">27,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzQtMy0xLTEtMA_57630cb0-a027-461e-a21d-595a41385658">21,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzQtNS0xLTEtMA_3c042bbd-396e-4f9f-8a97-8358e180cd30">12,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2020 and 2019, we recorded operating lease expense of $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzkzNDU4NDg4NDc1NDg_5b8048d3-5fac-411d-bf00-cf76a80607fb">19.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzkzNDU4NDg4NDc1NTY_d3620692-9f0e-4118-a3e0-a1986634baa1">14.7</ix:nonFraction> million, respectively, and paid $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzMxMTU_66700698-03ce-4fdd-989a-c75352e31c9e">16.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzgyNDYzMzcyMTk3Mjk_2825f35d-54cc-4c1c-95ef-44c9bff270a5">8.4</ix:nonFraction>&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash provided by (used in) operating activities in our Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="ie84926857cbe413d8bc9d130c202fdb2"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM3Njk_568e131d-0224-4799-bb47-286792d1b4ca" escape="true"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzEtMS0xLTEtMA_06f23b70-60d4-4591-bd87-4cd32512cba6">17,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzItMS0xLTEtMA_761f8379-eeb3-4845-9393-01332182e01a">20,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzMtMS0xLTEtMA_fea2695e-8a2b-4d65-8729-851386d76139">20,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzQtMS0xLTEtMA_6389f612-247b-4e47-ad03-9783c4cf4ee7">21,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzUtMS0xLTEtMA_fa72436f-f617-458e-a5b4-e23aaff33ea2">22,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzYtMS0xLTEtMA_052a1d0a-5b45-4e73-a583-338eb2707e55">97,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzctMS0xLTEtMA_98da0ee1-d3a9-4af3-baa9-d85863a46a7a">200,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzgtMS0xLTEtMA_363e9795-8743-47de-acb7-bc7132cebfaa">46,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease incentives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzktMS0xLTEtMA_d5c945eb-4f2a-4c42-8047-0b7028ce5f4d">3,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzEwLTEtMS0xLTA_e16b7128-8a52-4538-9e4c-989329aa97d8">150,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzExLTEtMS0xLTA_c2993ae8-1704-46ac-bc6c-353a93565343">13,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzEyLTEtMS0xLTA_40dc2826-783b-435e-8b1e-f4e76782d830">136,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, the weighted-average remaining lease term is <ix:nonNumeric contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM0NDc_3f59869d-5be7-4d2a-8b03-17ff6e6e12f1">9.1</ix:nonNumeric> years and the weighted-average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5Xzk4OTU2MDQ2NjE0MTI_9db95bd6-7f67-42b5-9193-2ef5bdde0bc8">5.9</ix:nonFraction>%.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzU4MDI_c9889025-54f6-4cc6-9e53-aee6abb1f3a3" continuedAt="i491648c24c2645e4b26d55ea5c6fc88d" escape="true">Liabilities Related to the Sales of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="i491648c24c2645e4b26d55ea5c6fc88d" continuedAt="if4feef4eb602424381297ffb7b86c6b2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzcwMw_8461753b-27cf-4a32-bbca-71faa4997436">124.0</ix:nonFraction> million for the 2012 Transaction Royalties.&#160;As part of this sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0Xzc4Mw_068f5bac-9b7c-4a02-ab74-b9f5f256bd24">4.4</ix:nonFraction> million in transaction costs, which we will amortize to interest expense over the estimated life of the 2012 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $<ix:nonFraction unitRef="usd" contextRef="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzExOTc_91b1bb29-f876-4eed-9e93-dd6b20cd2112">124.0</ix:nonFraction> million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxter Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $<ix:nonFraction unitRef="usd" contextRef="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxNDM_065588fa-4656-43eb-a2d2-771227b9437f">210.0</ix:nonFraction>&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $<ix:nonFraction unitRef="usd" contextRef="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxNTk_821007ef-f82e-411d-8237-ea154676de09">240.0</ix:nonFraction>&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $<ix:nonFraction unitRef="usd" contextRef="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216" decimals="-5" format="ixt:numdotdecimal" name="nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxNzU_013e81f7-c7d6-46a7-9d89-fc478c2c0ebe">208.0</ix:nonFraction>&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxOTE_8f03ea65-c759-4e46-b5c2-594941ed9b44">150.0</ix:nonFraction>&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230" decimals="-5" format="ixt:numdotdecimal" name="nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgyMDc_1a7cb101-5a26-40e5-be21-c0c365d48b72">3.8</ix:nonFraction>&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="if4feef4eb602424381297ffb7b86c6b2" continuedAt="i1372fedb7a4c4bc29cc025125b1c45aa"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $<ix:nonFraction unitRef="usd" contextRef="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgyMjE_64f1ca08-adb8-4f55-aee5-900d38593ed5">150.0</ix:nonFraction>&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. We did not recognize any non-cash interest expense from closing on December 30, 2020 to December 31, 2020 as any imputed interest was immaterial.</span></div><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzU4MDQ_4e1d1ee8-c0a1-4503-9038-d20dd6970c0c" continuedAt="id6364b8300cb49bda9ebc197a6f23743" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account during the year ended December&#160;31, 2020 and for the period from the inception of the 2012 Purchase and Sale Agreement on February 24, 2012 (inception) and the 2020 Purchase and Sale Agreement on December 30, 2020 to December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id831546d70e34870a583f96469cf6e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItMS0xLTEtMA_e9f2a519-f16a-4a35-9b1b-a909c98abb37">73,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff329ef00ee4a19babec2ac7467b6c5_I20191231" decimals="-3" format="ixt:zerodash" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItMy0xLTEtMA_93473cf4-0468-4d1e-83e8-82867640c6bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItNS0xLTEtMjQxOQ_436e9dbd-1409-457c-bedb-c14bc233fbaf">73,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f23237f9b92424f88e3de119d082d83_I20120224" decimals="-3" format="ixt:zerodash" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItNy0xLTEtMjQxOQ_630ddbd8-50c6-4458-8285-42c9a040cc9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b99c4859de149f481fb7758fe823053_I20201216" decimals="-3" format="ixt:zerodash" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItOS0xLTEtMjQxOQ_0a8fac87-7880-40b5-acfd-a5534c57ceff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3d4ded8eb8431ea5eb96372d1f1204_I20120224" decimals="-3" format="ixt:zerodash" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItMTEtMS0xLTI0MTk_5e03e562-083d-4d4f-9d7b-63919acf5017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:RoyaltyMonetizationProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtMS0xLTEtMA_c0f2e823-10d7-4500-881e-f39e8afbe094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:RoyaltyMonetizationProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtMy0xLTEtMA_f29f5968-248e-4154-8c31-d37e8f1e52b5">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:RoyaltyMonetizationProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtNS0xLTEtMjQxOQ_df7296bf-2fce-464b-a902-63a777244ba8">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:RoyaltyMonetizationProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtNy0xLTEtMjQxOQ_a3cd0b03-b64d-49af-a55b-4fc421846906">124,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:RoyaltyMonetizationProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtOS0xLTEtMjQxOQ_df066e2a-91f6-4c0d-8452-d1956fda8b56">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:RoyaltyMonetizationProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtMTEtMS0xLTI0MTk_afe8bc1d-2c3d-4fc7-9383-6131f4b38018">274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtMS0xLTEtMA_d56ebdb2-8957-46ff-a3c0-605ae5c0b008">37,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtMy0xLTEtMA_019f6b52-6796-475e-8f07-2863f3cdf6dd">10,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtNS0xLTEtMjQxOQ_50432b2f-7933-47ee-bc2f-258112780f58">48,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtNy0xLTEtMjQxOQ_f7155658-ef2e-4908-b347-e3a8883eb089">245,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtOS0xLTEtMjQxOQ_021a03ef-5c3c-40a3-8afe-3e377ebc9b4c">10,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtMTEtMS0xLTI0MTk_38d227e6-9983-4a65-b8de-1ed0e40cbc10">255,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMS0xLTEtMTY3MQ_34c67c17-3bf3-4ffd-a79d-3c8afbcd9c0b">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMy0xLTEtMTY3MQ_5ba98478-4c0f-4d63-8eff-e41cec128713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtNS0xLTEtMjQxOQ_f6e4a4d6-b800-460b-a8b4-65707b0edd4c">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtNy0xLTEtMjQxOQ_1abac1ee-596c-41ae-89fb-6b1cb58a4023">196,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231" decimals="-3" format="ixt:zerodash" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtOS0xLTEtMjQxOQ_804f299d-8320-4cd6-b292-2304ebcb13d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMTEtMS0xLTI0MTk_91ec613e-1612-4ecc-a01f-6d6a4381735a">196,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMS0xLTEtMA_93dd1817-744a-453d-98c4-a0c7dac580a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMy0xLTEtMA_a2a986b7-aabf-40a1-a8a8-f9dcf1dc7284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtNS0xLTEtMjQxOQ_128aa6fe-8e08-4c32-b9c6-f0b257ebda2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtNy0xLTEtMjQxOQ_a29f35ae-b693-44fb-993d-00298b108dc0">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231" decimals="-3" format="ixt:zerodash" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtOS0xLTEtMjQxOQ_02b14499-5d14-469e-9846-e1005315457c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtMTEtMS0xLTI0MTk_b6a33931-497e-40b5-9c28-eb11b81a48a9">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtMS0xLTEtMA_33f2aede-75ad-4088-a403-c1558a8ca551">65,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtMy0xLTEtMA_c7a61f99-2b32-4d6b-b6e0-02e3bd7116ec">139,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctNS0xLTEtMjQxOQ_7f4612be-754d-48b7-9e2e-0f64d5467af7">205,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctNy0xLTEtMjQxOQ_36fdfb1e-2d8a-4d83-af84-b39be037b4fd">65,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctOS0xLTEtMjQxOQ_2eb40841-d579-45be-aec2-3e15a5ac4705">139,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctMTEtMS0xLTI0MTk_746aeed9-0693-447f-b53a-59dc7bc7883d">205,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctMS0xLTEtMA_fbe1bca1-9576-4ae2-b080-4bfa6bd19653">1,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctMy0xLTEtMA_4a361c7c-76e0-4de2-a99d-b5a568251710">3,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtNS0xLTEtMjQxOQ_d7f97483-9592-4703-adba-6a8c56897756">4,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtNy0xLTEtMjQxOQ_3cb8f8c9-6d37-4f63-8743-a2791f30df6f">1,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtOS0xLTEtMjQxOQ_310d8744-00cf-4a1b-989c-24d25e11d698">3,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtMTEtMS0xLTI0MTk_b5768792-9087-43d0-a0fe-01f4fa49d255">4,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtMS0xLTEtMA_b4d57f37-c77f-49a4-8dea-43223870e0ff">64,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtMy0xLTEtMA_dca561c1-9c6e-44fa-b627-87df3b1a1e24">135,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktNS0xLTEtMjQxOQ_e058c000-6dae-4f2e-8182-abb4c2eecc79">200,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktNy0xLTEtMjQxOQ_c2c6f1fe-34a1-4f76-8fe9-5c448c671966">64,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktOS0xLTEtMjQxOQ_30e0c119-97c4-45c9-beda-b51bd561d7d2">135,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktMTEtMS0xLTI0MTk_b903a9dd-883c-41bc-8453-9feefe4c0615">200,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $<ix:nonFraction unitRef="usd" contextRef="ibe8e5acc2c64493693d38c6ecf8677de_D20140301-20140331" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentMadeForMilestoneNotAchievedYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzE3ODM_ef391e51-59c7-4d6e-a611-05b1d3796f8c">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie9b40bb677024548b6bead5496558bb3_D20130301-20130331" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentMadeForMilestoneNotAchievedYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzE3OTA_f2c39482-e012-4b77-83ac-ba1a5fdf3245">3.0</ix:nonFraction> million, respectively, as a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i1372fedb7a4c4bc29cc025125b1c45aa"><ix:continuation id="id6364b8300cb49bda9ebc197a6f23743"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:42.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzctMS0xLTEtMjQ0Mg_dbe0de27-911a-4d2e-bc4e-cb4788ba2b91">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcce05db00d34655b9af2ffe52859e3e_D20190101-20191231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzQtMy0xLTEtNDM2NQ_fba05246-741b-4177-a079-81180ec7713e">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id84e821beaee4d8fa7e6add65a5ac46d_D20180101-20181231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzctMy0xLTEtMjQ0Mg_c8d040f1-fc33-4646-9ee5-5efdf483f933">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd7bb6c1b8b6481197a849cf13dc94fb_D20180101-20181231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzctNy0xLTEtMjQ0Mg_f735cb9a-cf2a-46a1-b9e8-def8d5a18d45">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzgtMS0xLTEtMjQ0Mg_5e444fc8-daca-4752-8493-34f252f38c17">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcce05db00d34655b9af2ffe52859e3e_D20190101-20191231" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzUtMy0xLTEtNDM2NQ_8cfd0e65-61c8-45fe-b50b-e6838bc2bf9e">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id84e821beaee4d8fa7e6add65a5ac46d_D20180101-20181231" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzgtMy0xLTEtMjQ0Mg_1ef86999-b81f-41d6-9adc-61774f365aae">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd7bb6c1b8b6481197a849cf13dc94fb_D20180101-20181231" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzgtNy0xLTEtMjQ0Mg_ca6df19a-0fb8-4c50-85d3-df36932314e6">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In addition, the 2012 and 2020 Purchase and Sale Agreements grant RPI and HCR, respectively, the right to receive certain reports and other information relating to the 2012 and 2020 Transaction Royalties, respectively, and contains other representations and warranties, covenants and indemnification obligations that are customary for transactions of this nature. To our knowledge, we are currently in compliance with these provisions of the 2012 and 2020 Purchase and Sale Agreements; however, if we were to breach our obligations, we could be required to pay damages to RPI and HCR, respectively, that are not limited to the purchase prices we received in the sale transactions. However, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;8&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzc2Nzk_1f5f6b02-95c5-4055-9163-4a8ebe376b4e" continuedAt="i975f16a1c9ce44afa5d31a412c9c2e50" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i975f16a1c9ce44afa5d31a412c9c2e50" continuedAt="i5786a99e975b41ab82ae1b4b01bee73a"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2020, these commitments were approximately $<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzI3Ng_2904af33-1e08-45f1-8cf5-7f8a438c1c5b">8.0</ix:nonFraction> million, all of which we expect to pay in 2021.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019.&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On December 30, 2020, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, and denied plaintiffs with the ability to file a further amended complaint.  Following the motion to dismiss, on January 29, 2021, the class action plaintiffs filed a Notice to Appeal to appeal the district court&#8217;s decision to the U.S. Court of Appeals for the Ninth Circuit.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California  naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. On January 26, 2021, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, stating (among other things) that &#8220;Defendants&#8217; open disclosure of risks associated with trial delay &#8230; suggests that </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i5786a99e975b41ab82ae1b4b01bee73a" continuedAt="i66fead3a03f44df3a70fbdad0ce59045"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they acted openly with investors.&#8221; Following the motion, the class action plaintiffs have an opportunity to file in early March a further amended complaint and the case remains pending.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, certain of our current and past directors and executives were named in a shareholder derivative complaint filed in the Court of Chancery of the State of Delaware. Allegations in this matter are similar to those raised in the putative securities class action complaints filed on October 30, 2018 and August 19, 2019 in the U.S. District Court in California.  </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded <ix:nonFraction unitRef="usd" contextRef="i332680e5c95e48e8b3da3635ec5a64c9_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NDk_4634987d-23d2-499a-9ae4-9f01e73c6b4b"><ix:nonFraction unitRef="usd" contextRef="i27d8215eb84441c583e455931394edc6_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NDk_b1cf1b1b-2713-4076-b0c4-412ffb4a1740">no</ix:nonFraction></ix:nonFraction> liability for these matters in our Consolidated Balance Sheets at either December&#160;31, 2020 or December 31, 2019. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in a number of foreign countries. As a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="iee0a827a30fd4d489cff709fb4aa1743_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzQ0NjU_19f90acf-a260-4aff-aabf-f6bb879fb32e"><ix:nonFraction unitRef="usd" contextRef="i64f92162d4b9462fb32ed8b535a14bac_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzQ0NjU_5f0483ff-049a-4571-bd5a-3a9a768310a5">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations on our Consolidated Balance Sheets as of December&#160;31, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligations to RPI and HCR described in Note 7. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="ia2ab7fd63345456ba7a5755e4c5fc5d0_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NTc_3ff3e3f9-4c77-4d08-ae28-24c6deb0e04b"><ix:nonFraction unitRef="usd" contextRef="i65324047a4db4c8091e27eab6cf2aa8b_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NTc_c395d973-f1f6-47e1-8ec7-bf1ab3a50940">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Underwriters and Initial Purchasers of our Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with our sale of equity and senior secured debt securities, we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i66fead3a03f44df3a70fbdad0ce59045"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $<ix:nonFraction unitRef="usd" contextRef="i2caaa2f541394f9f8d1cc79cf9ea3dc9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzcxNzg_e360197d-e9a9-4ebb-a760-4f5ada7227f8">10.0</ix:nonFraction> million per incident for merger and acquisition related claims, $<ix:nonFraction unitRef="usd" contextRef="iba6fe490e41b448e8aff782bf7c54d50_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzcyMzc_de06645d-9733-49f1-8e39-d7e3ef7fda2f">10.0</ix:nonFraction> million per incident for securities related claims and $<ix:nonFraction unitRef="usd" contextRef="i9e772010232f40508602a3871880b34c_I20201231" decimals="-4" format="ixt:numdotdecimal" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzcyODc_20f32c77-f946-4520-9350-d98707fe593c">10.0</ix:nonFraction> million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzEwMDE0_2c012a39-1a9e-4ed3-b2ba-e60c71a71d4d" continuedAt="i9d41d960c3b346a8a9f567b8444fd734" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i9d41d960c3b346a8a9f567b8444fd734" continuedAt="icb0fdc098a8145459a363bafac9058ab"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 10, on April 3, 2018, we completed the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="i279eee577f1441378d79802f9bc91494_D20180403-20180403" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzEzMQ_b2f584b2-89ef-490b-ac9a-802c2308c3c9">8,284,600</ix:nonFraction> shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a <ix:nonNumeric contextRef="i45baea1b97d54688a1dfe6bcf696082b_D20180403-20180403" format="ixt-sec:durwordsen" name="nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMTgzMzU_a10ada5a-810d-4c86-ba14-a57aedb8a506">five-year</ix:nonNumeric> period.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2020, we had approximately <ix:nonFraction unitRef="shares" contextRef="i73c1044cd8154ba294e48097dcf6ecfd_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM1NQ_eca2b50a-e4f0-4285-b8c3-ccd30fbbb414">29,784,000</ix:nonFraction> reserved shares of common stock, all of which are reserved for issuance under our equity compensation plans, of which approximately <ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzQ5MA_ca594c06-d71d-4eeb-8e1e-cc9002d9c876">20,894,000</ix:nonFraction> shares may be issued upon the exercise of outstanding options or the vesting of restricted stock units (RSUs) or performance stock units, approximately <ix:nonFraction unitRef="shares" contextRef="ide5660632f144317b4ee56bdf1d105ee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzYwNw_6545d96a-15fe-49b3-bd45-8243a067342b">7,569,000</ix:nonFraction> shares are available for grant under our 2017 Performance Incentive Plan and approximately <ix:nonFraction unitRef="shares" contextRef="i165b47e55f0b4fe19b116d4073ab3d17_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMjM5ODg_f1a3e65d-5667-4f86-813d-c6621cfb44b3">1,321,000</ix:nonFraction> shares are available for grant under our Employee Stock Purchase Plan.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> 2017 Performance Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) was adopted by our board of directors (Board of Directors) on March&#160;28, 2017 and was approved by our stockholders on June&#160;14, 2017. On the date of approval, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (2012 Plan) ceased to be available for future grants. However, options and restricted stock units granted under the 2012 Plan remained outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to the terms of the 2017 Plan, <ix:nonFraction unitRef="shares" contextRef="ide5660632f144317b4ee56bdf1d105ee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzExMTU_37710531-17fc-4b2c-b8bb-286f98f9ef0f">8,300,000</ix:nonFraction> shares of our common stock, reduced by the number of shares of common stock subject to awards granted under the 2012 Plan on or after March 31, 2017 and prior to the adoption of the 2017 Plan, were initially available for awards under the 2017 Plan. On June 26, 2018, our stockholders approved an amendment to the 2017 Plan whereby <ix:nonFraction unitRef="shares" contextRef="i0404b34bd7e6426abaa4ad1ff3be9107_D20180626-20180626" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzE0NTA_8da03e59-c601-4c8d-b272-17af3243f3d1">10,900,000</ix:nonFraction> additional shares were made available for award grants under the 2017 Plan (Amended Plan). On June 17, 2020, the stockholders of Nektar approved an amendment to the Amended Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="id759869545ce4f8082f87a13f96f56c7_D20200617-20200617" decimals="INF" format="ixt:numdotdecimal" name="nktr:CommonStockAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMjI5NDE_01eba9e2-a22e-4b97-ad11-12658dc89be5">10,000,000</ix:nonFraction> shares (Amended and Restated 2017 Plan). Shares issued in respect of any &#8220;full-value award&#8221; granted under the 2017 Plan will be counted against the share limit described above as <ix:nonFraction unitRef="number" contextRef="ide5660632f144317b4ee56bdf1d105ee_I20201231" decimals="INF" name="nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzE2ODg_bc8ec595-c315-45ce-b3f3-c0a4ec86e608">1.5</ix:nonFraction> shares for every one share actually issued in connection with the award. Shares that are subject to or underlie awards which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under the 2017 Plan or the 2012 Plan will again be available for subsequent awards under the 2017 Plan (with any such shares subject to full-value awards increasing the 2017 Plan&#8217;s share limit based on the full-value award ratio described above). Notwithstanding the foregoing, shares that are exchanged by a participant or withheld by us to pay the exercise price of an option granted under the 2017 Plan, as well as any shares exchanged or withheld to satisfy the tax withholding obligations related to any award, will not be available for subsequent awards under the 2017 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The purpose of the current Amended and Restated 2017 Plan and our other incentive plans is to promote our success by providing an additional means for us to attract, motivate, retain and reward directors, officers, employees, and other eligible persons through the grant of awards. Equity-based awards are also intended to further align the interests of award recipients and our stockholders. The Amended and Restated 2017 Plan authorizes stock options, stock appreciation rights, stock bonuses, restricted stock, performance stock, stock units, phantom stock or similar rights to purchase or acquire shares, and other forms of awards granted or denominated in our common stock or units of our common stock, as well as cash bonus awards. Members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries are eligible to receive awards under the Amended and Restated 2017 Plan. Pursuant to the Amended and Restated 2017 Plan, we have granted or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="icb0fdc098a8145459a363bafac9058ab"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. The requisite service period for stock options granted to our employees under the Amended and Restated 2017 Plan as well as our prior plans  is generally <ix:nonNumeric contextRef="i3242ee4bdb4141c29d4a338d4cabf96e_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM4MDE_b48dcc85-2311-4bbc-892a-38452129b6ef">four years</ix:nonNumeric>; the requisite service period for stock options granted to our directors is generally <ix:nonNumeric contextRef="i0fbb3ef5ea4f4882bde7a74c1ef8e365_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM4OTA_4b9a7f91-3944-4950-815d-6444b6409ac1">one year</ix:nonNumeric>. The requisite service period for RSUs and PSUs granted under the Amended and Restated 2017 Plan and our prior plans is generally <ix:nonNumeric contextRef="if5da921eb5c043ae837ab819c1a4f230_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM5OTM_d72eb1bb-c8ce-4444-b62f-01643c14b097">three years</ix:nonNumeric> for employees and <ix:nonNumeric contextRef="ie75ccda9579e4320804a6b82cbbeadca_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzQwMTQ_a1e4f8c3-d991-4861-931e-0edc45d1df96">one year</ix:nonNumeric> for directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Amended and Restated 2017 Plan will terminate on March&#160;27, 2027, unless earlier terminated by the Board of Directors. The maximum term of a stock option or stock appreciation right under the Amended and Restated 2017 Plan and our prior plans is <ix:nonNumeric contextRef="i243a1e61f3224fbbbbd5e7b34dc9d858_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzQyNDA_6442836a-ce6d-4f0e-8ad3-63ba44dd0bfc">eight years</ix:nonNumeric> from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 1994, our Board of Directors adopted the Employee Stock Purchase Plan (ESPP) pursuant to section&#160;423(b) of the Internal Revenue Code of 1986. Under the ESPP, <ix:nonFraction unitRef="shares" contextRef="id4cbf542cfaa4814959fffc6a9d3eb50_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzY1MTU_b8278927-f77a-4ce0-a106-179634e36da0">2,500,000</ix:nonFraction>&#160;shares of our common stock were originally authorized for issuance. On June 17, 2020, the stockholders of Nektar approved an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by <ix:nonFraction unitRef="shares" contextRef="iae8c53d2886c4e2688588fb7a66cb738_D20200617-20200617" decimals="INF" format="ixt:numdotdecimal" name="nktr:CommonStockAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMjI5NTM_6458d5e8-8c8e-4250-9105-8cdb4120fabf">1,000,000</ix:nonFraction> shares. The terms of the ESPP provide eligible employees with the opportunity to acquire an ownership interest in Nektar through participation in a program of periodic payroll deductions for the purchase of our common stock. Employees may elect to enroll or re-enroll in the ESPP on a semi-annual basis. Stock is purchased at <ix:nonFraction unitRef="number" contextRef="i7a180f9d74404418b6c1394ddf6e243a_D20200101-20201231" decimals="2" name="nktr:PercentageOfPurchasePriceOfStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzY4OTg_8954d059-d23e-4e78-8687-b670e37e195b">85</ix:nonFraction>% of the lower of the closing price on the first day of the enrollment period or the last day of the enrollment period.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Retirement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of <ix:nonFraction unitRef="number" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzcxNTA_458efe29-ec44-48dc-baf7-b5678c5199d8">60</ix:nonFraction>% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzczODc_bf7a4dcf-c05f-47c6-8cbb-06822a6fc82e">6,000</ix:nonFraction> per participant. For the years ended December&#160;31, 2020, 2019, and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzc0NTc_465b4159-ddf9-493f-90f0-1ac534ece5a6">3.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzc0NjE_106bce5c-8322-467d-b41b-c6644698bc84">3.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzc0Njk_5f19274e-782b-4ba3-b35f-09f2d92c8591">2.8</ix:nonFraction> million, respectively, of compensation expense in connection with our 401(k) retirement plan.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control Severance Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On December&#160;6, 2006, our Board of Directors approved a Change of Control Severance Benefit Plan (CIC Plan). This CIC Plan has subsequently been amended a number of times by our Board of Directors with the most recent amendment occurring on April&#160;5, 2011. The CIC Plan is designed to make certain benefits available to our eligible employees in the event of a change of control of Nektar and, following such change of control, an employee&#8217;s employment with us or a successor company is terminated in certain specified circumstances. We adopted the CIC Plan to support the continuity of the business in the context of a change of control transaction. The CIC Plan was not adopted in contemplation of any specific change of control transaction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the CIC Plan, in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) or initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) in each case within <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:durwordsen" name="nktr:ChangeInControlSeverancePaymentPeriodForExecutives" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzg3OTYwOTMwMzI5ODE_c11c68eb-422a-4946-9228-6abc4f129c59">twelve months</ix:nonNumeric> following a change of control transaction, (i)&#160;the Chief Executive Officer would be entitled to receive cash severance pay equal to <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:durmonth" name="nktr:ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzg3OTYwOTMwMzMwMDE_d6fb51d0-8627-451b-a035-0f1cca79e793">24</ix:nonNumeric> months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards, and (ii)&#160;our Senior Vice Presidents and Vice Presidents (including Principal Fellows) would each be entitled to receive cash severance pay equal to <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:durwordsen" name="nktr:ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzg3OTYwOTMwMzMwMjU_da2c2b73-75b5-460b-ad79-62d79f9464a9">twelve months</ix:nonNumeric> base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards. In the event of a change of control of Nektar and a subsequent termination of employment initiated by the Company or a successor company other than for Cause within <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:durwordsen" name="nktr:ChangeInControlSeverancePaymentPeriodForExecutives" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMTgzNTY_9bb68547-1595-423a-a154-09958e7a9c34">twelve months</ix:nonNumeric> following a change of control transaction, all other employees would each be entitled to receive cash severance pay equal to <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:durmonth" name="nktr:ChangeInControlSeverancePaymentPeriodForEmployees" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMTgzNjI_4fa74d94-1aef-4126-9871-7fddea99afe7">6</ix:nonNumeric> months base salary plus a pro-rata portion of annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of each such employee&#8217;s unvested outstanding equity awards. Under the CIC Plan, as amended, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI1MDI4_e274d817-5a7c-4769-b4e9-066140e757ab" continuedAt="ica48f1c456bb4c9d9fcd7a583744407d" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica48f1c456bb4c9d9fcd7a583744407d" continuedAt="i2ba676cbeb914cdd86b8140cb77665fa">&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i2ba676cbeb914cdd86b8140cb77665fa" continuedAt="i367ca39b8f1d4df8b7e882853d6c7ce2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI1MDI0_344c7702-bef1-4be1-bdba-824b1792dab9" continuedAt="i24064c5bbd9f4e639b23c1b13d2c3d9c" escape="true">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i24064c5bbd9f4e639b23c1b13d2c3d9c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fee986be7e4e88975b835fff607f89_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzItNC0xLTEtMA_af03f11e-f7c7-46c1-b755-736e5b5920c1">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5b28fa1440433cbc1a30bd468e6bc4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzItNi0xLTEtMA_ef8ba683-1e33-443c-933a-33fe57cfd700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737d623ece374d02a554cd0314567319_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzItOC0xLTEtMA_830a4773-ebc6-4409-b2e0-b2cf811e2432">1,059,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b180b5818184f9e90a1d9ac77c0ad36_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzMtNC0xLTEtMA_8c3e0b05-493c-49dc-9a11-b260f3882f4e">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813fad316fa349b09cbd0d54f5119511_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzMtNi0xLTEtMA_76125c46-5d11-4d70-a84c-0c27c559fc1a">7,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7500307ef7d243f28fbd31084f547085_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzMtOC0xLTEtMA_f69e934f-c801-460d-bf29-2a08ef24ae1c">11,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27aa90ea43d8491ab680477d8a5ad091_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzQtNC0xLTEtMA_024fbd51-f6e9-4c2c-82df-b0327bd1d7ea">4,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d89b8ee0d5b4ad28995c6a5cb013afe_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzQtNi0xLTEtMA_a1617868-a00c-422e-9dc4-eacfcc32ad04">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia149e6df5d9d423fb6f0a80e7e807499_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzQtOC0xLTEtMA_b6004d24-fb0d-4171-ae03-f6604d5da23a">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxalta Incorporated / Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemophilia, including ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c73bdc0467470a82fe6dd56ac35921_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzUtNC0xLTEtMA_ce23b33d-b920-4f7a-ad70-3b762f314713">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeeba83838249e69191a50f51901ae9_D20190101-20191231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzUtNi0xLTEtMA_252db25f-d8cc-45be-b905-4d5bddc143e8">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a26ba1b2354834aeab39bb01122273_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzUtOC0xLTEtMA_05e891ed-cb45-4a07-93d1-b97c7af1f273">20,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2ed6dd5c174996a8348c2074df2753_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzktNC0xLTEtMA_8cf3eff7-387c-4e55-8961-a151a3f111c3">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008803fb67f84ea78e2af3795d82cb16_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzktNi0xLTEtMA_53b5be9d-4d50-4c63-9764-e2bf2742d448">4,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46c9120dc3e494394b2305aceabd21d_D20180101-20181231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzktOC0xLTEtMA_4f51c70c-9a16-4292-b818-98e3c8741dbc">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzEwLTQtMS0xLTA_a63adccb-25da-4085-8ce0-a0dff1353da8">55,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzEwLTYtMS0xLTA_c854e3fa-88dd-48f5-81f8-0d2479063b75">16,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzEwLTgtMS0xLTA_d138e5fb-35db-4035-8c9b-86fbd9f32f3a">1,097,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2020, 2019 and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzE1NzQ_9944e4ba-afe2-4105-aa3c-98582818060d">129.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzE1ODE_6f2118f2-249b-4d2b-9c9b-ec17c088ec02">77.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1Mjc_1c837d4b-6236-4e64-bece-f4254020bc99">95.3</ix:nonFraction>&#160;million of revenue for performance obligations that we had satisfied in prior periods, respectively. For all years, the amount includes all of our royalty revenue and non-cash royalty revenue. For the year ended December 31, 2020, the amount includes $<ix:nonFraction unitRef="usd" contextRef="ifed655596acc4f6f9abb2c38103052ce_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:SalesMilestoneRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1NDI_c3d70add-a2ad-4051-8f1f-976669295e3f">50.0</ix:nonFraction>&#160;million in BMS Collaboration milestones received.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI1MDI2_99def378-8a2f-48f4-9143-730ffe9be295" continuedAt="id2fd865dca5b4c52abec23b3ede8e473" escape="true">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December&#160;31, 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="id2fd865dca5b4c52abec23b3ede8e473"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:82.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTozZGUzN2RjMGE2YWQ0MWM0OTY1MTIzNjRhMzQ3ZWRkOS90YWJsZXJhbmdlOjNkZTM3ZGMwYTZhZDQxYzQ5NjUxMjM2NGEzNDdlZGQ5XzEtMS0xLTEtMA_140b136d-e48c-49a4-a352-6d8f581946c6">8,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of previously unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTozZGUzN2RjMGE2YWQ0MWM0OTY1MTIzNjRhMzQ3ZWRkOS90YWJsZXJhbmdlOjNkZTM3ZGMwYTZhZDQxYzQ5NjUxMjM2NGEzNDdlZGQ5XzItMS0xLTEtMA_eb5554f0-8030-4bf7-96d3-8435e3d5ff9a">5,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTozZGUzN2RjMGE2YWQ0MWM0OTY1MTIzNjRhMzQ3ZWRkOS90YWJsZXJhbmdlOjNkZTM3ZGMwYTZhZDQxYzQ5NjUxMjM2NGEzNDdlZGQ5XzMtMS0xLTEtMA_44b417c6-0be4-45c8-a173-226516326e3a">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, our collaboration agreements with partners included potential future payments for development milestones totaling approximately $<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1Njg_ec7ced40-df1c-467a-855d-b760d89a0231">1.7</ix:nonFraction>&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive other contingent payments, including contingent sales milestones and royalty payments, as described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There have been no material changes to our collaboration agreements for the year ended December&#160;31, 2020, except as described below.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb (BMS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (previously referred to as NKTR-214)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing <ix:nonFraction unitRef="number" contextRef="i53dd51cb16d64a37af811757be9bc88d_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1NzU_09bd0ee1-a5f6-4b77-a694-e6c435a735c8">65</ix:nonFraction>% and BMS sharing <ix:nonFraction unitRef="number" contextRef="i18e9200632c24e1cb5376206c84bd1ba_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1ODA_5b97fc38-2f5e-4730-b65d-0f6b312e313b">35</ix:nonFraction>% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="ibc3d41b108484518862f7675ed0d6023_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1ODU_c4e88563-8e62-426d-b6d9-94f4bcb599a2">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="icae6895fea5d4170abf536b7118795ac_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1OTI_92f7be02-17fe-4d2f-a8ad-24d745bf088c">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="i18e9200632c24e1cb5376206c84bd1ba_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1OTk_67478621-cc2a-4e59-85d0-052d5ed88c5b">35</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="i53dd51cb16d64a37af811757be9bc88d_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2MDQ_40dc3b7f-aad4-4b3e-923b-e60f570f68a2">65</ix:nonFraction>% to Nektar.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i367ca39b8f1d4df8b7e882853d6c7ce2" continuedAt="ibb38d1fd582f4b68b19ed21560e1a28c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The BMS Collaboration Agreement superseded and replaced the Clinical Trial Agreement we entered into with BMS in September 2016 to develop bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the Clinical Trial Agreement, we acted as the sponsor of each Combination Therapy Trial and BMS was responsible for <ix:nonFraction unitRef="number" contextRef="ib881bc00509644faa5b6cc9e5670bda9_D20160901-20160930" decimals="2" name="nktr:PercentageOfOutOfPocketCostsToBeReimbursedByPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2MDk_d869887b-f6aa-4b34-863d-afecc1f83510">50</ix:nonFraction>% of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. We recorded cost reimbursement payments to us from BMS as a reduction to research and development expense. Each party was otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0dc54d4429a14507ba0977108771d46f_D20180401-20180430" decimals="-8" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2MTQ_f0184b0a-9eb1-4ebf-83ac-62d30ce98f04">1.0</ix:nonFraction>&#160;billion. We are eligible to receive additional cash payments up to a total of approximately $<ix:nonFraction unitRef="usd" contextRef="i33adc58a946240659c54e96e6b40bfbf_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2Mjg_3b12b1ba-43ff-42cb-9427-274369bd897f">1.455</ix:nonFraction>&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones and up to a total of $<ix:nonFraction unitRef="usd" contextRef="i681999e295a9436988be9a734fa0d419_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2NDI_6f0e5d93-0579-4647-8af8-8fccfaf58602">350.0</ix:nonFraction>&#160;million upon the achievement of certain sales milestones. In April 2018, BMS also purchased <ix:nonFraction unitRef="shares" contextRef="i89eb6575dc8d4b6bb3d9b58cb422c933_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2NTg_351d2380-8ceb-418d-98aa-6f919e187bda">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i2e8d2460a3d24fe19b5e25e5c18d4d4c_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="nktr:SaleOfStockConsiderationReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2Njk_80056ad5-e05e-46e7-9223-f82c4192b589">850.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i9a165c7d11824e3faaca690b9fe43ccb_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2ODU_c58ec51f-7478-4957-bf12-d34bcc288e68">25.0</ix:nonFraction>&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i9a165c7d11824e3faaca690b9fe43ccb_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3MDA_8b2c469d-270e-4cb0-ac3a-91c173f57da7">25.0</ix:nonFraction>&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;BMS has the right, at its sole discretion, to terminate co-funding its share of the development costs for the adjuvant melanoma collaboration study if the metastatic melanoma collaboration study fails to meet the primary endpoint of progression free survival. If BMS exercises such right, we have the right, in our sole discretion, to continue the adjuvant melanoma study.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="i4324d57f84ab4a79b48761bdcdb78475_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1Xzc5NjM_bfb43cde-4107-49e2-815c-39398d594c24">128.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e5b0431feeb42af96a92b8ebf28fd8b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1Xzc5NzA_fa2163fe-d80e-4b95-badb-850ddf40a1e7">105.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51d000e6aadc462a8e1d068ac6eb6bda_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1Xzc5Nzg_b277e720-f5ba-444f-88eb-1af11b233064">62.5</ix:nonFraction> million, respectively, as a reduction of research and development expenses for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.  As of December&#160;31, 2020 and 2019, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgxODY_5e716f83-cf23-4692-a265-81164011b1a5">38.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09a7acaae93b47a18c69f0744596371d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgxOTQ_fff48bc0-35d3-4cb8-be0c-eab847ce7210">24.0</ix:nonFraction> million, respectively, from BMS in accounts receivable in our Consolidated Balance Sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our share of development costs is limited to an annual cap of $<ix:nonFraction unitRef="usd" contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="nktr:CompanyShareOfDevelopmentCostsAnnualCap" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3MTU_6fca9c98-92de-4004-8536-cf6a084cb717">125.0</ix:nonFraction>&#160;million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, but we recognize our full share of the research and development expense and recognize the reimbursement as a liability. We repay the liability to the extent that our share of development costs are less than the annual cap in a future year, or by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin, if approved. For the year-ended December 31, 2020, our share of the development costs totaled $<ix:nonFraction unitRef="usd" contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:CompanyShareOfDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODY5NzY_0d6025d8-88b5-4c9b-9353-6aabe7b63db1">129.0</ix:nonFraction>&#160;million, thereby exceeding the annual cap by $<ix:nonFraction unitRef="usd" contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:DevelopmentCostsExceeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzEzNzQzODk1NDI3MDY5_3e8e43e4-c08b-47f6-bb15-c8feae85f8a4">4.0</ix:nonFraction>&#160;million. Accordingly, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3MzE_bdde2c4d-18e2-4bb8-b414-3761d2af79be">4.0</ix:nonFraction>&#160;million for BMS&#8217; reimbursement of the excess over the annual cap in our unbilled billed receivable of $<ix:nonFraction unitRef="usd" contextRef="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzExNTQ0ODcyMTY2MTI1_5e716f83-cf23-4692-a265-81164011b1a5">38.7</ix:nonFraction> million, and, due to the repayment provision, we have recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3NDU_d2eb456f-0f39-47d8-a8e1-588c916e0b10">4.0</ix:nonFraction>&#160;million in Other long-term liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize bempegaldesleukin and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2018, we aggregated the total consideration of $<ix:nonFraction unitRef="usd" contextRef="i856405b13edf4a6cab22db02d72d1802_D20180101-20181231" decimals="-7" format="ixt:numdotdecimal" name="nktr:AggregateConsiderationReceivedFromAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3NTk_d4ffa78f-4ac6-440d-a499-13c58ba34122">1.85</ix:nonFraction>&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $<ix:nonFraction unitRef="usd" contextRef="i1754f034bd974728bed8387d9d72bd50_I20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:EstimatedFairValueOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3NzQ_9f40a21f-fb78-4b1c-808e-6e39d7cb8bb9">790.2</ix:nonFraction>&#160;million in stockholders&#8217; equity. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i856405b13edf4a6cab22db02d72d1802_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3OTA_efce7d4a-52ba-4bd4-b2fc-391fe1ab0d7c">1,059.8</ix:nonFraction>&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i1754f034bd974728bed8387d9d72bd50_I20181231" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentRegulatoryAndSalesMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4MDg_57ed75c4-1cca-489a-a711-3c8b6d50e3ba">1.8</ix:nonFraction>&#160;billion to be variable consideration. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="ibb38d1fd582f4b68b19ed21560e1a28c" continuedAt="i5183d05a29ad4d9698bf54e17bb73bbb"><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1f578ac138d243159b20e2c8695c088d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4MjI_8776c347-d7f4-4ae5-b429-cb63bb3958fa">25.0</ix:nonFraction>&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial and $<ix:nonFraction unitRef="usd" contextRef="i1f578ac138d243159b20e2c8695c088d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4Mzc_26b42a65-0d9a-476e-aacf-d3897c914a36">25.0</ix:nonFraction>&#160;million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial. We continue to exclude the other milestones from the transaction price as of December&#160;31, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NKTR-358 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4NTI_12f502d6-6dc7-4df0-8628-6eb22578ef80">150.0</ix:nonFraction>&#160;million in September 2017 and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i211b0ecf8dd9414bac8969426d745f43_I20170823" decimals="INF" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4Njg_466430b6-71bd-4bbc-ace4-bfb132800202">250.0</ix:nonFraction>&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 1B and 2 development costs with <ix:nonFraction unitRef="number" contextRef="i090200b2df2d4328a10feb73ea2cc913_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4ODQ_cbbb409a-9109-4042-b5bc-16f757824218">75</ix:nonFraction>% of those costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="icfa0bac114c54b30ad4a8c72b57d49d2_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4ODk_856b11a1-c664-49a4-9746-5790fa46debf">25</ix:nonFraction>% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from <ix:nonFraction unitRef="number" contextRef="i2f006004c02b411e86bd510eb0e3d194_D20170822-20170823" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4OTM_22ed0427-5eb1-4cd3-85a5-ecb9c4fc5e10">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i822a697b55f34b999f5d046661cdda27_D20170822-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MDM_61a391d9-d275-456f-9154-3f66053d7fed">25</ix:nonFraction>% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="if57ed396a7ce4982a8cf0c38400928a6_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MDg_b1b9c092-cd3b-4767-9b0e-5494225858d6">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="if57ed396a7ce4982a8cf0c38400928a6_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MTM_3e4718b5-764d-40ac-8451-6ff64395f058">75</ix:nonFraction>% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through December&#160;31, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MTg_f9ac283e-bdef-4879-8eae-267104c044ca">150.0</ix:nonFraction>&#160;million received in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $<ix:nonFraction unitRef="usd" contextRef="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MzQ_93bdeef4-c157-4805-935d-499fe4dfaed4">150.0</ix:nonFraction>&#160;million upfront payment as $<ix:nonFraction unitRef="usd" contextRef="ib86b4fcdb85a4a40a92ae61ccbb060f2_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5NTA_e54b058d-c18d-442c-8e75-268da8955c7f">125.9</ix:nonFraction>&#160;million to the license, $<ix:nonFraction unitRef="usd" contextRef="i17a2d0c7f5b14febb5d605a70ac5be5a_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5NjY_fc1491cf-a354-42e3-9477-83dbad0830e7">17.6</ix:nonFraction>&#160;million to our portion of the Phase 1 clinical development and $<ix:nonFraction unitRef="usd" contextRef="i88b3538d8838435d98d28e77de6a0b87_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5ODE_ba47fecb-b23f-4516-b9fe-021a71e4a25b">6.5</ix:nonFraction>&#160;million to the drug product development.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the $<ix:nonFraction unitRef="usd" contextRef="i72e1d5fa4cee46038d0164972eca0589_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5OTU_a53e52e4-9d1d-48d5-80d6-b1ffbabf859e">125.9</ix:nonFraction>&#160;million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of December&#160;31, 2020, we have <ix:nonFraction unitRef="usd" contextRef="i9608ed0e8f234f719db44f2ce29c4216_I20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzExNTQ0ODcyMTU4MTk1_efac7cf1-eca2-47d9-a01e-d2eb48fbf03e">no</ix:nonFraction> deferred revenue related to this agreement.</span></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Incorporated/Takeda: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i5183d05a29ad4d9698bf54e17bb73bbb" continuedAt="ic825a750d0d64fcca5055adf4f072e90"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Hemophilia A program includes ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $<ix:nonFraction unitRef="usd" contextRef="id73287f5728f4758aff50c38e58bc67c_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwMTE_965e306b-aa29-4a95-8dc1-bce906be8ae9">10.0</ix:nonFraction>&#160;million development milestone, which we received in March 2018. During 2018, we earned an additional $<ix:nonFraction unitRef="usd" contextRef="i53699e8247e24936abad5db41f079668_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwMjY_8902afd3-dbba-44b2-be5d-e1b3ed62526e">10.0</ix:nonFraction>&#160;million milestone for annual sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $<ix:nonFraction unitRef="usd" contextRef="i8ee84d18bf2448248442d25abe69bc54_D20171101-20171130" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentsReceivedUnderRightsToSublicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNDE_15589c7c-c679-49c8-a091-b20d1375b2a2">12.0</ix:nonFraction>&#160;million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of December&#160;31, 2020, our deferred revenue related to this agreement is not significant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $<ix:nonFraction unitRef="usd" contextRef="ic5f692c7b7c64b63aa43f5f9beb82f27_D20101001-20101031" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzExNTQ0ODcyMTYxMTMx_39bf2149-dd12-4ba8-b311-4a585dc910e2">50.0</ix:nonFraction> million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We determined that our obligation to manufacture and supply PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen under the 2010 Agreement represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. We recognized revenue through October 2020, the month when the 2010 Agreement expired according to its terms. Accordingly, as of December&#160;31, 2020, we have no deferred revenue related to our agreement with Amgen.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxegol oxalate), previously referred to as naloxegol and NKTR-118,</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2014 and December 2014, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> /MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the US and EU, respectively. As of December&#160;31, 2020, we have received a total of $<ix:nonFraction unitRef="usd" contextRef="icdff3824bed0496593ee26344105cfaa_D20150101-20151231" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzIyOTY5_687da484-cd16-414f-a9f5-9346860f068c">385.0</ix:nonFraction> million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving <ix:nonFraction unitRef="number" contextRef="i9669dda51f8d469b90ab31add3c0cf0a_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNjE_d06a2d38-af3c-4c15-acf3-bbf7891c8632">60</ix:nonFraction>% and Nektar receiving <ix:nonFraction unitRef="number" contextRef="icdbf7038932f481ebc0426c961831d78_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNTY_6024762b-5b22-44fc-a4f1-0455e2a2ae90">40</ix:nonFraction>%. As of December 31, 2020, we have received a total of $<ix:nonFraction unitRef="usd" contextRef="i052214e857b447dfbc2f68ed467ab528_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODgxNzM_ede3a8ef-ab2a-4c5a-8a90-20443f8bc3f4">37.6</ix:nonFraction>&#160;million of milestone payments resulting from these sublicense arrangements, all of which was received in or before 2017.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we do <ix:nonFraction unitRef="usd" contextRef="i255f8243240945a4a13c9479fe28d04f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyMzMzNDk_f924ae5b-1055-4b04-85c4-68373c0edc68">no</ix:nonFraction>t have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of its approval of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the FDA required AstraZeneca to perform a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of OIC in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. by AstraZeneca can be reduced by up to two percentage points to fund <ix:nonFraction unitRef="number" contextRef="idbbc53198d1c48749ec868cd04228392_I20201231" decimals="INF" name="nktr:PercentageOfNetSalesToFundExternalCostsIncurred" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNjY_e61ff928-9ff2-409b-8af1-bd2e841db959">33</ix:nonFraction>% of the external costs incurred by AstraZeneca to fund such post approval study, subject to a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="ic825a750d0d64fcca5055adf4f072e90"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="if3e61ba2f5e447299c9460d38e8e3b38_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfNetSalesToFundExternalCostsIncurredCap" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNzE_2e637378-db98-4b44-aad0-b071db619982">35.0</ix:nonFraction>&#160;million aggregate cap. As a result of the 2020 Purchase and Sale Agreement as described in Note 7, AstraZeneca will deduct these costs from the royalties paid to HCR. Before we entered into the 2020 Purchase and Sale Agreement, our cumulative share of the post-approval study expenses was not significant. Any costs incurred by AstraZeneca can only be recovered by the reduction of the royalty payments. In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, as of December&#160;31, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="ic54b2f1a2f4f47eda9c396ece8af832b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI0MTg4_0c7bd04e-d053-4e9c-a0da-2dae8e999d8b">40.0</ix:nonFraction> million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of December&#160;31, 2020, we have deferred revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i8b459d9407c3488188caf6e79fd2c1b3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI0OTcz_826c8204-9698-4d7a-882b-aeb6bd4a3ca2">2.0</ix:nonFraction> million related to these other collaboration agreements.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;11 &#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDI_68ff2f47-3d86-488a-979f-12c8de279006" continuedAt="if4c6454d5fdd43f48961abfcd666de5a" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if4c6454d5fdd43f48961abfcd666de5a" continuedAt="i3c3bf0cacc8447549f8b61c2037bee46"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDQ_e54b2b47-aeef-433d-81ad-5da83cbde021" continuedAt="i5a8db95ce15546319f432d070a1160f8" escape="true">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i5a8db95ce15546319f432d070a1160f8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74acef52e11470f833bd478aa3ef19b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzItMS0xLTEtMA_26672548-ef66-4b14-bf18-6f120d499737">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b295854248b4d328d13f61824dc9c9a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzItMy0xLTEtMA_6fb39f43-7aa4-49e3-b045-925aa7211d6c">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce8950c4b5b4e54b98c6758fc52a69c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzItNS0xLTEtMA_f495b074-d6d1-4a69-a311-e4678aa29751">4,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf4765dc2e844f291e9697ef1a040c4_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzMtMS0xLTEtMA_b39150a6-4184-4d95-baae-54dd59fa8d1b">57,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495ad3c9a56241a4b0d81e8e4e6fb3d7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzMtMy0xLTEtMA_95c254a3-3e12-4cb5-8887-cc06c46ef65a">63,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8a180bb15a483f80a891f8010c1d15_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzMtNS0xLTEtMA_7195cfc5-d219-465e-8b64-c57682877a56">56,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b77ba2c841b4c28b4c4a4cd5a77324f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzQtMS0xLTEtMA_9e8123f6-e621-4605-8e7a-4e5af53fb692">33,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a89348225b1444f879860b43fe8e9c4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzQtMy0xLTEtMA_d4b70368-6e01-4cb0-ad4f-3bcdf996f224">32,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8392820334097a6e73600dbdc66b5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzQtNS0xLTEtMA_0baa0b59-8a3d-4c50-8e70-a6916e17558c">27,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db549bc0acb4adba3eec24ace8bedd0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMS0xLTEtMzk5Ng_87c1937a-2e29-4b62-8386-4f0ebc0f1c49">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c80c0982a6f47049d8b696c71aad77f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMy0xLTEtMzk5Ng_6e02ff68-7fcc-4f04-871e-5aab23b28d94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca56cd80aa4498ab650c1512e10d771_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtNS0xLTEtMzk5Ng_7e4e04b2-530a-4d1a-978d-8462d452eab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMS0xLTEtMA_e745f081-bbed-4963-9bcf-8bc304662406">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMy0xLTEtMA_ff793fb2-e422-4426-924f-1c0d8f6c7b49">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtNS0xLTEtMA_6dba5108-9fc8-4864-adb4-3e3cc3b9be82">88,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyOQ_859e513c-e32b-431a-959f-c200768356d8">193.7</ix:nonFraction> million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzgyNDYzMzcyMTA1MzM_3b24dbb1-da1b-4fe5-b32c-14b4e4bda041">1.79</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2020, 2019, and 2018.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Black-Scholes Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDg_da277858-143f-4956-b477-e9da2c4f3cdc" continuedAt="ieb5f4bbe098e42e6a92cc61cbc2562c5" escape="true">The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="ieb5f4bbe098e42e6a92cc61cbc2562c5"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzItMS0xLTEtMA_67cccda3-9885-425f-983d-23dcc5e8a223">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzItMy0xLTEtMA_9a9e8611-9799-4f36-b010-a808eb3cd8c2">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzItNS0xLTEtMA_476d05c8-b54f-4888-98d2-a02828d42bf7">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzMtMS0xLTEtMA_c67b6adf-b1ca-47da-9977-54363f0471dd">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzMtMy0xLTEtMA_2edcedbb-4769-49c7-8346-5f9552c62ccd">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzMtNS0xLTEtMA_4701640a-d790-404a-b482-2d64d71ae25a">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzQtMS0xLTEtMA_1ff6086b-9c03-48eb-86b3-5bebb2273297">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzQtMy0xLTEtMA_8ca02f22-aaf4-442b-b8dc-84acece5922e">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzQtNS0xLTEtMA_82d09a5e-e306-445c-9de2-0e1d257d27c6">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzUtMS0xLTEtMA_3202b954-9f39-4c44-ad73-23f3f742b647">5.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzUtMy0xLTEtMA_0b0b8b8b-2eaf-4ed9-8270-f553c3aae433">5.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzUtNS0xLTEtMA_4922b475-2dd7-411c-a649-ec34a4b240d2">5.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzYtMS0xLTEtMA_a18b6e41-4546-4ef9-95c9-b2255fef0d96">10.70</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzYtMy0xLTEtMA_d8ada468-b4ab-4f1d-8750-43f8db451d18">12.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzYtNS0xLTEtMA_394770f5-50c2-4455-be84-38fbd9746ccf">29.86</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of <ix:nonFraction unitRef="number" contextRef="i8a0f1d0bae304ea191fafac40840dd22_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzEwMjk_8280ca06-c87f-49ed-b53f-d7ea40bf6085">zero</ix:nonFraction>. Our estimate of expected volatility is based on </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i3c3bf0cacc8447549f8b61c2037bee46"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMTA_53416f55-ef8a-4ec6-9446-fca2b654dcf9" continuedAt="i4d2a9530aac34b72a79b20bcd8ae804e" escape="true">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):</ix:nonNumeric></span></div><ix:continuation id="i4d2a9530aac34b72a79b20bcd8ae804e" continuedAt="id54805acf69342be8e3b499f1d22a63f"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzEtMS0xLTEtMA_688d9ac8-4065-4d01-a572-e0c923d75973">14,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzEtMy0xLTEtMA_5c00e037-4ab3-4f0b-939e-fd166038dbcd">25.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzItMS0xLTEtMA_8890f9d5-49ac-4bf4-9014-268c24135625">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzItMy0xLTEtMA_49b05f16-39bd-4b50-8182-0b2a3c835ba9">19.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzMtMS0xLTEtMA_c60a86ce-b4a0-4fbc-aefe-116252490163">1,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzMtMy0xLTEtMA_249e2a58-7347-4869-b654-75927cb4506f">11.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzQtMS0xLTEtMA_898f3c00-2cb1-4bde-9d52-7eb6097ffdcd">1,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzQtMy0xLTEtMA_7b04ebdc-204d-4c9b-88a2-3c16b9b7c174">45.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtMS0xLTEtMA_217e8b45-9832-411f-941f-d3b5ce19db5d">13,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtMy0xLTEtMA_b864d620-3755-4a3b-8b3f-96d929d7920b">24.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtNS0xLTEtMA_e158e828-95ea-4a24-a4ca-31b499881c70">3.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtNy0xLTEtMA_621fafcf-e60a-44ff-ad7e-b00e2c30aaa6">23,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctMS0xLTEtMA_653e08b2-52ec-40c6-a8ce-96dd05d28732">9,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctMy0xLTEtMA_73f63d2b-eae2-4a43-8a4b-ea006cc45fe4">22.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctNS0xLTEtMA_f90200d5-ce24-4fd5-bcdf-c057c5c1e5c1">2.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctNy0xLTEtMA_3d237aa1-c20f-4ba0-a25a-405a0915a48e">23,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div></ix:continuation><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id54805acf69342be8e3b499f1d22a63f" continuedAt="i3e12a2e71a9b460396d05939f46fbe5d">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"><ix:continuation id="i3e12a2e71a9b460396d05939f46fbe5d">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2020.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 totaled $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzE5Mzc_6f4bf580-33bb-40d8-8696-cc3b47b15304">15.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzE5NDE_3c866fcf-570c-422d-9880-c3ece1c20ecf">30.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzE5NDg_42dc1308-b88c-480a-8848-ce10318eff80">303.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of RSU Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDc_6931ccc6-9e39-4957-b748-cb2d225cdad1" continuedAt="ia3f7e2bc99934e0eaa499b00935dc805" escape="true">A summary of RSU award activity is as follows (in thousands except for per share amounts):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="ia3f7e2bc99934e0eaa499b00935dc805"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i270d9a256b0148cf80b4c9020001e2ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzEtMS0xLTEtMA_88b6de5e-6ef9-481a-a354-ff465e4f8d3d">4,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i270d9a256b0148cf80b4c9020001e2ce_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzEtMy0xLTEtMA_83eb4577-78b7-4bf7-9631-79dde914251f">30.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzItMS0xLTEtMA_8b26dda1-a588-4d08-98a3-5faa8275a96a">4,686</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzItMy0xLTEtMA_616fc72a-6eb2-4696-8098-2147156ac62d">19.24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzMtMS0xLTEtMA_40c36d64-1678-4a51-af8f-0d7e91ba3a07">1,661</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzMtMy0xLTEtMA_0e1b3810-1c2a-4698-bafc-b8ed3f2c27e2">34.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzQtMS0xLTEtMA_d63bcb38-a1a1-483c-a4b6-51c950cd9631">866</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzQtMy0xLTEtMA_de9823bb-29a4-4709-a729-5f6b9ae44c89">29.66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie01a6511f0d24250b24e5b947e4fc152_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzUtMS0xLTEtMA_90a51466-7330-43ae-9f5e-4ae91d9b5f53">7,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie01a6511f0d24250b24e5b947e4fc152_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzUtMy0xLTEtMA_c3a722ce-762c-43ca-b261-b76ba3b3c8fd">22.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock that vested in the years ended December&#160;31, 2020, 2019 and 2018 totaled $<ix:nonFraction unitRef="usd" contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIxNzQ_825b6b82-e0f2-4f64-9e23-583d507041cb">33.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i52d489e7ce4f48beaabcdd6ed7a7661b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIxNzg_5320d52f-23a4-4953-8126-6a5ecab530b6">32.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1352258179264aee894c5a3fcf3294cd_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIxODU_662fc8eb-d34d-4a7c-b4f3-888b5070c5bc">80.4</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ifabf795112b143ffbb3dd9981b4dd620_151"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Note&#160;12&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODA_6cc45885-7df9-4c3e-99ae-fb4a2113faf9" continuedAt="ia91f6634d9374b99b9ca10b73eb668f6" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ia91f6634d9374b99b9ca10b73eb668f6" continuedAt="if7e0b2297d7f41ef8fd7395639a41f5e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4NzU_64fc84f1-8366-4d7c-897b-c01ab2ae02b6" continuedAt="i5f7a4007db0444659ea8ef6d93b67b2e" escape="true">Income (loss) before provision for income taxes includes the following components (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i5f7a4007db0444659ea8ef6d93b67b2e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzItMS0xLTEtMA_4f786a78-8f4b-4c36-90d6-9cff0145255c">445,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzItMy0xLTEtMA_1d59dd8a-dbda-4c60-994b-41ba090b401b">441,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzItNS0xLTEtMA_9757e12e-76e9-44ca-815d-c43899c9b777">680,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzMtMS0xLTEtMA_16cd4b75-8a09-414e-9dac-ec70405f9ff0">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzMtMy0xLTEtMA_0de9cf50-b7df-4e9a-9334-a7b811407be6">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzMtNS0xLTEtMA_9729efcc-57b9-4050-b056-937127afa730">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzQtMS0xLTEtMA_3ed31392-377c-44a0-ae8c-afcf3a957626">443,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzQtMy0xLTEtMA_a0c8ec24-c728-4343-bc0a-966f9de7715a">440,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzQtNS0xLTEtMA_1b5276bb-3ee1-4b09-afa5-062d39a09a8e">682,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="if7e0b2297d7f41ef8fd7395639a41f5e" continuedAt="i17f3d296de3f4a7bbffe79e8027d0d20"><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODU_d9da37c9-7157-4dc1-99ed-9f8c4919d0fd" continuedAt="icc2463ed2ee24bf3a974c5c32b9d125f" escape="true">The provision for income taxes consists of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="icc2463ed2ee24bf3a974c5c32b9d125f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzMtMS0xLTEtMA_1e4fc98f-407b-490b-b2e0-f796e1b7b012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzMtMy0xLTEtMA_a0263483-34db-4f3f-a1ac-d4d2c037a680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzMtNS0xLTEtMA_5d17f612-a171-4e7f-be30-cb0b2e03afea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzQtMS0xLTEtMA_12d940b5-d057-4492-91a0-f48ebdcb4de4">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzQtMy0xLTEtMA_1f5a94a2-f817-443d-b8f3-b85f6576b363">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzQtNS0xLTEtMA_80c5752f-241c-4b0f-8872-01c4edeb9bb4">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzUtMS0xLTEtMA_f34e9d99-5258-4256-afd0-d08f117d0039">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzUtMy0xLTEtMA_3aaaf757-3116-4c5f-8853-7477c8cae944">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzUtNS0xLTEtMA_89b3be17-f2d6-4f04-942b-ac8175b98613">620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Current</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzYtMS0xLTEtMA_af7ad99a-c0b3-459b-996b-50443386075a">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzYtMy0xLTEtMA_0fff26be-af4e-49e3-90f6-2c14cbf819e9">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzYtNS0xLTEtMA_3e22335f-1f8d-4840-9281-22e309c2bab7">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzgtMS0xLTEtMA_0b37a99f-5237-4889-b16a-16351e10710b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzgtMy0xLTEtMA_ffe0342a-d929-4964-b912-063c3688d888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzgtNS0xLTEtMA_4bf9cfcd-c56a-48c5-b811-1bc5527ed16f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzktMS0xLTEtMA_fa4d2a13-ee29-4c45-a391-6e0860a028fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzktMy0xLTEtMA_2a332273-bc18-4dd0-94d8-498144d3c57a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzktNS0xLTEtMA_e0c59b6d-52c4-43d8-aa91-7ae1efb115e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEwLTEtMS0xLTA_ff933c21-aced-460b-a4c3-1898dad5ecaa">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEwLTMtMS0xLTA_0a8585ea-be28-4e39-b439-b97dc6710712">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEwLTUtMS0xLTA_c835a291-95e2-4125-8fa3-ba7e1af9d09e">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Deferred</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzExLTEtMS0xLTA_c2ad86ce-f7b4-46bb-93b4-8260e3ebe545">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzExLTMtMS0xLTA_c0ef5c2d-af25-4688-b7d3-7570beac429d">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzExLTUtMS0xLTA_133350cd-6aca-4f80-ab72-518852b0cda0">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEyLTEtMS0xLTA_26683af9-21cc-40e6-ba89-7ab1b0e4b38c">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEyLTMtMS0xLTA_e4fb350c-206e-4151-aded-67079ab1f868">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEyLTUtMS0xLTA_5260d02f-9473-4a85-b069-286650920482">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODI_27203e44-dcd5-43dc-89bc-4bef2e42f495" continuedAt="i58abed55495041fa8302dabbba2ebc51" escape="true">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of <ix:nonFraction unitRef="number" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzM2Nw_5e86b5c0-ea92-4ad2-8438-b7cbd3c08a31">21</ix:nonFraction>% for the years ended December&#160;31, 2020, 2019 and 2018 to pretax income (loss) as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i58abed55495041fa8302dabbba2ebc51"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) at federal statutory rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzItMS0xLTEtMA_0ff30b04-96fc-4bf2-ae07-ea2fd225cfd7">93,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzItMy0xLTEtMA_dfe8aafd-ed31-40d3-94ad-d50d6ef4232c">92,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzItNS0xLTEtMA_02d0a079-2a03-4746-b8db-d56687fdf32a">143,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzMtMS0xLTEtMA_c0b052ed-a863-4c75-8596-b47eb932ae55">3,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzMtMy0xLTEtMA_223179e8-84ed-4c9a-ab79-046941dafb86">10,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzMtNS0xLTEtMA_5a811fe3-1c4a-4415-a43a-93756f1545de">17,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on equity issuance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nktr:IncomeTaxReconciliationPremiumOnEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzYtMS0xLTEtMA_0327b3e5-fc7c-48fc-aa5f-73356892a840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nktr:IncomeTaxReconciliationPremiumOnEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzYtMy0xLTEtMA_78e61ece-9aad-48d1-bacc-4d45376c1a39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:IncomeTaxReconciliationPremiumOnEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzYtNS0xLTEtMA_928b5cb5-1da4-49c4-ab62-34043c533759">12,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzctMS0xLTEtMA_924c2524-dce3-4ba2-9a96-85421f02506a">87,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzctMy0xLTEtMA_c18de8f0-9753-4053-ba83-cad5c0be3d73">104,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzctNS0xLTEtMA_27868daa-52ab-4e92-ae27-616cbb565df0">46,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMS0xLTEtNTEzMg_5abc0626-9023-4412-8420-2d325004100f">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" name="nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMy0xLTEtNTEzMg_dd9dc8c7-23da-44ab-b492-499bbc4e556d">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtNS0xLTEtNTEzMg_9922fbc3-32c7-4abd-b3d6-bcb1bb0ed5b6">66,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMS0xLTEtNjM1OQ_c42a7e9c-d817-415b-854c-f76a613332d1">7,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMy0xLTEtNjM1OQ_2492134c-1a36-40cc-9cc0-baf23a044717">7,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtNS0xLTEtNjM1OQ_39d0e648-c8ea-4df6-a996-243593bbe8a5">6,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMS0xLTEtMA_5978d4fe-05e2-4252-8e0a-1d97b8771b4a">6,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMy0xLTEtMA_9607a055-e2a5-4722-9b5a-dca6b4bdb348">5,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtNS0xLTEtMA_51f71bdf-2f4c-4665-9da1-2340ea2a8af3">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzExLTEtMS0xLTA_f1d9d8b1-4223-4184-9378-6e7537498ed8">3,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzExLTMtMS0xLTA_944fbab9-e37a-49e7-862e-35f59aeea72c">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzExLTUtMS0xLTA_83161ec3-f921-457f-aa28-39f23427f6ab">4,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzEyLTEtMS0xLTA_2837e22f-32b6-4b7c-a389-9400728964bb">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzEyLTMtMS0xLTA_60dc521e-c174-44f1-9f00-5262ff45c0f9">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzEyLTUtMS0xLTA_3ec40198-789d-4b07-8d7b-cc7d4d5db51b">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i17f3d296de3f4a7bbffe79e8027d0d20" continuedAt="i7e24dbef6f3b4c7ca3226ada745f4738"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4Nzc_f584e222-9432-440c-81cb-75d61849461e" continuedAt="i816179d625f04c8c845d292d82d0705c" escape="true">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i816179d625f04c8c845d292d82d0705c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzMtMS0xLTEtMA_fff824cf-c6c6-477c-8fd5-e74aed06e499">456,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzMtMy0xLTEtMA_74bd50bd-cbd4-4358-8f9f-5d299ba69582">399,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzQtMS0xLTEtMA_fbc6aac2-e779-4d3a-8e3e-9e2f6dfabe6b">132,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzQtMy0xLTEtMA_b4f3a83f-b090-4204-a7e5-d947407774d8">128,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzUtMS0xLTEtMA_029a985b-0714-43ca-b9a1-47ea9ebe8d8b">35,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzUtMy0xLTEtMA_280bd406-41ec-4d2a-918d-43b4c1848210">36,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMS0xLTEtNTE0Ng_d0940a25-6e2d-43c3-9b51-115b3d8ada8c">32,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:zerodash" name="nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMy0xLTEtNTE1MA_cc607494-6964-4c89-a5bb-b44c4967cdeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMS0xLTEtMA_c3dfbdee-3d77-4fb1-9bf1-3b516ea8965c">32,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMy0xLTEtMA_8f69bb95-5716-494a-bc59-d8885a0f79be">30,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzctMS0xLTEtMA_99e5fb40-8665-4934-bbcc-82d9cda51bac">11,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzctMy0xLTEtMA_d8408a25-888f-4c1f-b110-38189e644a6d">13,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzExLTEtMS0xLTA_27b22cff-6a70-47cb-87c8-ad2538aa6cdb">701,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzExLTMtMS0xLTA_0b6730b4-ebd7-4cd4-b744-57973ea1c753">608,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEyLTEtMS0xLTA_73c0150c-ab8c-419d-bfb4-7c54e4481846">670,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEyLTMtMS0xLTA_a3942f9f-b03d-42da-9448-441b2cbff78f">575,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEzLTEtMS0xLTA_b7702d58-ab79-4a5a-ad48-e6e4a6e97b96">31,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEzLTMtMS0xLTA_7c0f60b6-d8fb-4fed-8288-8139ce6dd189">33,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE0LTEtMS0xLTA_51e1676a-338c-44cf-993f-29e9ec29b309">29,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE0LTMtMS0xLTA_7f9b7e3a-ccc9-4b8d-8af1-3a20ed7fd027">31,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE1LTEtMS0xLTA_070a0ee2-6852-44e4-bf2e-92965236e9e5">1,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE1LTMtMS0xLTA_53652d0d-12c9-413a-8c5d-759615e38f16">1,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE2LTEtMS0xLTA_9ecbccf1-2d14-4728-858c-98a43f90336b">31,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE2LTMtMS0xLTA_45de9b17-5016-457d-a2ff-d1ac09afded5">33,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE3LTEtMS0xLTA_6bf6832a-e89e-4082-ba9b-2cbc5a7b89b1">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE3LTMtMS0xLTA_eddb6eef-efe8-4489-8bd8-78b00a0e8135">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzExNTQ0ODcyMDk4Njgz_1679a805-7f26-4153-813b-02b8c5a13cec">95.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzExNTQ0ODcyMDk4Njk2_6707ebd7-a57d-4e4a-873b-5637884cb62a">114.6</ix:nonFraction> million during the years ended December&#160;31, 2020 and 2019, respectively, primarily due to the additional domestic net operating losses and credits generated in the current year that are not more likely than not of being utilized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Tax Credit Carryforwards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we had a net operating loss carryforward for federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="id5394f004851433191f100501cea9fac_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:NetOperatingLossCarryforwardForIncomeTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzkzNDU4NDg4NDg5MzU_c2ecca05-0175-4394-9f55-22dd1425c95d">2.0</ix:nonFraction> billion, portions of which will begin to expire in 2021. As of December&#160;31, 2020, we had a total state net operating loss carryforward of approximately $<ix:nonFraction unitRef="usd" contextRef="i6d86a1180eaa4ff892518dd3441f1bb0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="nktr:NetOperatingLossCarryforwardForIncomeTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzkzNDU4NDg4NDg5NTE_efcfc404-a9a9-4186-93b4-18b0f2c9086a">1.3</ix:nonFraction> billion, portions of which will begin to expire in 2026. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have federal research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i3fb46e064c7448bb96b707d5238157cc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjExNzk_6d64d044-92ff-4781-9444-f74ae82171e0">98.9</ix:nonFraction>&#160;million, which will begin to expire in 2023 and state research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ida4ca2a391ba4e4e82c217bd8fd54a9d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjExOTU_5a13b32b-782e-4a28-a637-3515e4e2ad4d">44.0</ix:nonFraction>&#160;million which have no expiration date. We have federal orphan drug credits of $<ix:nonFraction unitRef="usd" contextRef="i3fb46e064c7448bb96b707d5238157cc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="nktr:FederalOrphanDrugCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMTA_9180d008-1ba4-44dc-a8e7-19d47726d93d">17.7</ix:nonFraction>&#160;million which will begin to expire in 2026. These tax credits are subject to the same limitations discussed above.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><ix:continuation id="i7e24dbef6f3b4c7ca3226ada745f4738" continuedAt="i700c1f6be4d34d4dacb3b92be189b903"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODM_f48d2621-dd7a-4221-92c2-4785ca8cbaa9" continuedAt="ia024116d04a7495ebb33e33929f80dfa" escape="true">We have the following activity relating to unrecognized tax benefits (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="ia024116d04a7495ebb33e33929f80dfa"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzItMS0xLTEtMA_1f5e967d-f21f-4e28-89e1-1aee8f92acee">77,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzItMy0xLTEtMA_26b629b0-da37-4280-9902-ca6a3d22e4ae">27,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzItNS0xLTEtMA_dad33851-64bd-48df-9c95-91d80d788aa3">20,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzUtMS0xLTEtMA_75b27657-6c2e-4132-9915-7adcfc246a14">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzUtMy0xLTEtMA_33697074-5a49-4472-bd4c-a1979af77b41">49,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzUtNS0xLTEtMA_f231657b-ae33-40a7-8d7d-68b7cd018265">5,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzctMS0xLTEtMA_eadb1fdd-644e-4ab1-a6eb-703518eb4471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzctMy0xLTEtMA_75f24526-3ff7-4fd5-9cd2-4f85d1420c71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzctNS0xLTEtMA_dade79a1-6d35-49d9-ac0e-f75d6f2f469a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEwLTEtMS0xLTA_c0a6c062-45aa-45b9-98e7-3f22a723ad42">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEwLTMtMS0xLTA_57449dc3-f392-4422-9f9e-04b22fcddca9">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEwLTUtMS0xLTA_021b9d8b-03f8-4cc7-a924-9ab687f7e0e6">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEzLTEtMS0xLTA_1cbaf002-01ad-49f5-9826-cba1b46b9750">1,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEzLTMtMS0xLTA_954d1a26-6227-4a74-a360-2aa56839362a">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEzLTUtMS0xLTA_9aaa4839-c3b0-45b0-939d-8a4fa89cda87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE0LTEtMS0xLTA_fb38a184-957c-42b8-8a4d-ea4a750664c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE0LTMtMS0xLTA_a32902a2-658a-4442-a7d2-605c4f7966b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE0LTUtMS0xLTA_a1756357-c0d8-42db-9324-7985b16cc237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE1LTEtMS0xLTA_bc07fc27-b075-4096-9ec3-448477f38a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE1LTMtMS0xLTA_b8120faa-2161-4846-8dc4-9788a95b03ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE1LTUtMS0xLTA_a0f614a2-7fbd-4fc2-8e50-642158e244ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE2LTEtMS0xLTA_1de87728-67d0-4225-94cf-1209f8765dc9">78,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE2LTMtMS0xLTA_3368646b-66d9-42a6-ba41-24f99182a579">77,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE2LTUtMS0xLTA_e23da9a6-38ea-484c-921a-d88657a4dd5e">27,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry forwards rather than resulting in a cash outlay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. Because of net operating losses and research credit carryovers, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any resulting liability resulting from such an examination would have a material effect on our financial position or results of operations.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i700c1f6be4d34d4dacb3b92be189b903">Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2020, 2019 and 2018, <ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_33dd2bd6-2c77-46e4-8c1f-4fb98f1f2741"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_65064956-49e8-4e7d-bb12-5aff91ed4edb"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_76095e73-5a82-41e4-bd35-c3815579b27d"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_93f3a905-6553-4cc9-b090-765b32742332"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_b4b9f16a-b1c9-4bfb-ad3f-8217a74f9570"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_f235e6d7-597c-4c6f-99ef-020649d0dc6c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any changes over the next <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" format="ixt-sec:durwordsen" name="nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMTQyMTg_db42358b-87a1-4121-8ea9-e5e19130c8fa">twelve months</ix:nonNumeric>.</ix:continuation> </span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzOTA_5ae14213-debe-48a1-8efc-ed1482f053dc" continuedAt="ic5388e9367b74bf4b8427abf4aea8f71" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="ic5388e9367b74bf4b8427abf4aea8f71" continuedAt="ifbb88897ce404a138eea12ce233b7fa1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in <ix:nonFraction unitRef="segment" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:NumberOfOperatingBusinessSegment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzQ4_3a133711-c16d-4c8d-8557-1a4a23bfd283">one</ix:nonFraction> business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as <ix:nonFraction unitRef="segment" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:NumberOfOperatingBusinessSegment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzNzQzODk1MzQ4OTMz_3a133711-c16d-4c8d-8557-1a4a23bfd283">one</ix:nonFraction> business segment by our Chief Executive Officer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented <ix:nonFraction unitRef="number" contextRef="i0724493c13744e74aba58429991051ff_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzg3OTYwOTMwMjM3NTE_70617999-dd41-4180-a75b-5ff1c81eef7b">33</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ia8930ee506074b1a80dcb28134fd5773_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzYxMA_398810e4-90d0-4158-a2ac-0e020e50601f">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ide398b6debeb4fb7a095f0df2975ccd3_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwMjg_e340983f-9ded-43e2-ab81-3debf9bf09db">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i049d56950da443d782603343643146ce_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzYxNw_fb66d766-beb1-432e-8c85-228bbeacd9b6">13</ix:nonFraction>% of our revenue, respectively, for the year ended December&#160;31, 2020. Revenue from UCB Pharma, Baxalta / Takeda, and AstraZeneca represented <ix:nonFraction unitRef="number" contextRef="i0866d8705ad34c20932d7388fb164e35_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwMzM_7d525e44-2f3b-4a12-9a2e-4cd25f28d774">28</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i817f31328f764ac8a65d4340427e73dc_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwMzg_bcfb498f-95bd-46d2-ae29-970b6bb93e33">19</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ie32b099d78c041bcb200c8d5438e369a_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwNDM_9e52e1b2-9a2c-42f5-9d5a-38f79bb5622d">17</ix:nonFraction>% of our revenue for the year-ended December 31, 2019. Revenue from BMS represented <ix:nonFraction unitRef="number" contextRef="i62cad6a1a032445e971b3fd80be0ab88_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzcwMg_964b4805-7283-4033-bb64-5153a5575652">89</ix:nonFraction>% of our revenue, for the year ended December&#160;31, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzOTI_2cd84d27-869a-4b42-8b65-5562eef2dbcd" continuedAt="i03533229ccce46eeafdc9a308953042b" escape="true">The following table sets forth revenue by geographic area (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i03533229ccce46eeafdc9a308953042b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib912063d910845aaa45f66edaa7d2535_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzItMS0xLTEtMA_c5b799c2-5b1e-4cc0-a39b-a8e28e48cfc4">64,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ca9a944946417a9bd26c7ff3bd0df2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzItMy0xLTEtMA_a16146ad-a4c3-4816-b58d-908a53e373b2">27,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee76c326075144bc9957970824864572_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzItNS0xLTEtMA_3787f5a2-b14d-4957-861e-9c234b79f9d6">1,090,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd671a84bd84c26a9c4e33c4b75a08c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzMtMS0xLTEtMA_fb6a0b23-81e8-4594-8c87-2b56b0260aa4">87,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d365863714c4ed5890fc77835d41d57_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzMtMy0xLTEtMA_7cc5ca65-0dc1-4cd9-95cd-2b88e551f01f">87,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86ae7fa4cc46ac95c142f23e235a82_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzMtNS0xLTEtMA_248fe770-c80b-4c67-a866-806b21fee7e2">102,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzQtMS0xLTEtMA_256e7508-60d7-49c9-9583-d5c00bb7baea">152,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzQtMy0xLTEtMA_c0cf77d2-495e-4e3b-b1a1-a7773a1f4f77">114,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzQtNS0xLTEtMA_be836463-66c3-49a7-8075-8304cf44fd47">1,193,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i5eb25dc75983449abf52bac9890f50f5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEwNDg_88924f01-c167-4fa8-96db-46cac23a5587">54.5</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="iccee95850b064fbd8b0c1431a6df105f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEwNjk_a6a53565-0bd0-42bf-a376-74291126a090">91</ix:nonFraction>%, of the net book value of our property, plant and equipment was located in the United States and $<ix:nonFraction unitRef="usd" contextRef="i85fff8d911974f27b78a9941b7f50432_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzExNjk_759441e3-24df-4dbb-aa35-ca814c18ff2b">5.1</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i0eabcb407913449e87ce37aa8d0de239_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzExOTA_1fc245a7-3094-431a-82e4-6cf788980922">9</ix:nonFraction>%, was located in India.&#160;At December&#160;31, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifbb88897ce404a138eea12ce233b7fa1">2019, $<ix:nonFraction unitRef="usd" contextRef="ia4d086dadf3f44dba9615056bd07087d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEyMjM_07b78f4b-fd56-4d34-a536-9aab4e76b7af">59.7</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i36d6b1d26b224dc59df8dcedba587fed_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEyNDQ_91317178-bbe8-4f01-8682-56118d80e4dd">92</ix:nonFraction>%, of the net book value of our property, plant and equipment was located in the United States&#160;and $<ix:nonFraction unitRef="usd" contextRef="idf35774709d841d3b44284705950593c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzNDQ_e38f88be-9b8b-4ea6-8935-32dbd8eea972">5.3</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i7199da49f7844202b5dabcf7a621af2e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzNjU_bdd7aef5-0325-42e7-a12b-f18ef7ec7ac4">8</ix:nonFraction>%, was located in India.</ix:continuation></span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;14&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3Xzc2NQ_d07366a6-d213-4601-8b0f-4124832be71d" continuedAt="i5b52e699dc194ed9a4ccdab476b44356" escape="true">Subsequent Event</ix:nonNumeric></span></div><ix:continuation id="i5b52e699dc194ed9a4ccdab476b44356"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 12, 2021, we entered into a co-development agreement (the Agreement) with SFJ Pharmaceuticals XII, L.P., an SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $<ix:nonFraction unitRef="usd" contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementCommittedFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc3MzA_00b2afd1-ab66-4e38-9db8-8c2b0f2734fa">150.0</ix:nonFraction>&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and approval activities for bempegaldesleukin. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and/or the SCCHN Clinical Trial do not meet their primary endpoints. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the completion of certain SCCHN Clinical Trial activities. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc3NzI_e45b728e-dec7-43d5-bf71-6d89903c6705">450.0</ix:nonFraction>&#160;million, paid in annual installments over <ix:nonNumeric contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212" format="ixt-sec:durwordsen" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc5NjQ_6d636513-68a5-428c-88b9-ba0ee810a44a">five years</ix:nonNumeric>. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc3ODY_71065761-309a-4e5d-a0f8-a13493e88b69">150.0</ix:nonFraction>&#160;million, paid in annual installments over <ix:nonNumeric contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212" format="ixt-sec:durwordsen" name="nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc4MDg_41dfc566-9e3d-41e2-a1ce-152842c45bcc">seven years</ix:nonNumeric>. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementAdditionalIndicationPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc4OTE_74cb4451-6bf1-409f-8b5a-d419e1a09dab">37.5</ix:nonFraction>&#160;million to SFJ. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the Agreement. The Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;15&#160;&#8212; <ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90ZXh0cmVnaW9uOmIwMGRlZTU3NDM3ODQyNDVhZDM4ZDUzNzI0NzU0ZDdkXzE0NzE_bf8d0077-5e15-429f-88fb-3f06d746b6d9" continuedAt="i29b5a95e2a954123867ec203a503f69c" escape="true">Selected Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="i29b5a95e2a954123867ec203a503f69c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90ZXh0cmVnaW9uOmIwMGRlZTU3NDM3ODQyNDVhZDM4ZDUzNzI0NzU0ZDdkXzE0NzM_dad1f969-839d-48c5-8b41-bee6bf17f1fd" continuedAt="ie7ffadd942c04244a91a9e76ec1d002c" escape="true">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.</ix:nonNumeric></span></div><ix:continuation id="ie7ffadd942c04244a91a9e76ec1d002c"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0e3cb012e04c40b706573437e7c400_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMS0xLTEtMA_4ae99a70-9be2-493f-af55-b83721d05c55">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia127b30b5a3e436e9d93336b81801699_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMy0xLTEtMA_43590b39-f75e-4f01-9553-40efcb8c6376">5,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ecf9e44f3a485789e47ee440d1fb61_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItNS0xLTEtMA_ad2b4f32-e400-4306-b411-b2d35a64130d">5,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d570eb5ffd48c4939a02adc32bc003_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItNy0xLTEtMA_10afdd28-c3f4-4aa0-adb6-905d44f09ab9">2,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115533df786243e0b7e302d7e193fa82_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItOS0xLTEtMA_83372238-4211-4058-9833-1ca48061948a">4,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adfa1d6b5b54a02b009b9b036e26e11_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMTEtMS0xLTA_b5c5ed42-8e9c-49fb-8f14-318766a11719">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4187a897c35f46c2a1363434d9f54ce6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMTMtMS0xLTA_4e7b2393-7301-4528-884f-12b3f4f731dc">5,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ffc21a2ccee43aa8a8e12d940741920_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMTUtMS0xLTA_fe4bf83a-4805-4ab0-9a86-e7785e7da265">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMS0xLTEtMA_da1bed1a-108b-4a15-a76d-693a95b09121">50,573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMy0xLTEtMA_2e68294c-c522-41dc-b046-048a6d5bb8f9">48,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtNS0xLTEtMA_2527923f-71bb-4960-938c-e9611639fea3">30,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtNy0xLTEtMA_424d7642-bbf2-4519-8b96-5fc600f6997b">23,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtOS0xLTEtMA_9e5b24d0-14ff-4a41-a007-adc03a177271">28,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMTEtMS0xLTA_2d1890e6-18a8-469a-9621-28e83a3c8268">23,315</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMTMtMS0xLTA_d16ce902-b335-4d01-8ef4-355669dc01b2">29,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMTUtMS0xLTA_dc6bd052-f53f-4067-98af-8794af654376">33,862</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMS0xLTEtMA_f81ea005-353b-46ce-9d1e-6e175ffa5082">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMy0xLTEtMA_21baae11-4ea0-483c-9328-c376b5ab4a20">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtNS0xLTEtMA_b8542f9e-fe82-4f4e-b6d1-ad9f01a612d9">5,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtNy0xLTEtMA_20d8ea02-6c53-4ec0-8cb0-f73330920c6d">4,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtOS0xLTEtMA_574939be-592a-486c-be74-27811cf0d6bb">5,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMTEtMS0xLTA_202715a2-1252-4799-acb2-17f832670baf">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMTMtMS0xLTA_a8f2c400-16cf-4491-8e44-f45e7788cdc5">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMTUtMS0xLTA_48c9973b-88c6-458b-bd10-e4292872b511">5,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMS0xLTEtMA_46092d2d-46a6-49b4-9059-f287809ee3c4">108,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMy0xLTEtMA_231d78a1-ba00-45e7-8975-d4fef7039f19">96,436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtNS0xLTEtMA_067838c5-1053-433d-a956-950cca4cba4a">100,531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtNy0xLTEtMA_09fafe19-e0a4-4047-a1ac-b8fba15670ad">102,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtOS0xLTEtMA_4b3dadf1-5570-412c-b4ec-5646bdc83f45">118,463</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMTEtMS0xLTA_6bb1098b-c9d3-4704-88f3-8558aaed3f75">106,686</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMTMtMS0xLTA_065405f1-2da7-41a2-bfd7-3423844768fe">99,048</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMTUtMS0xLTA_8da87de4-8f6e-40aa-bf92-0223db06d9ec">110,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMS0xLTEtMA_3e3dcc6f-a0cc-45ee-9f21-1b76df19ae0e">133,631</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMy0xLTEtMA_8b063fe6-c74e-4a6c-b811-af6781afebb5">77,709</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtNS0xLTEtMA_623a716b-5780-4ef3-86ea-d9d2176bca92">103,050</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtNy0xLTEtMA_f37a19d9-db39-4f47-a0b6-e888a4862f11">110,721</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtOS0xLTEtMA_c310d278-6da3-48e4-8247-0184703341fc">120,687</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMTEtMS0xLTA_037cef0c-e88e-4165-8f95-7cf7be67b83a">110,970</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMTMtMS0xLTA_05a77077-30f7-47bd-9441-1f5955b941fc">98,740</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMTUtMS0xLTA_19fa885a-b756-4e4d-a0b5-43c92a891b2f">109,638</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMS0xLTEtMA_d2f6dabb-df2b-4233-bc36-a2a27c71804c">138,651</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMy0xLTEtMA_4806a6e6-4f2c-4d06-be24-b97effbfe7a5">80,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctNS0xLTEtMA_1bb87492-c37a-4e5b-815b-f6b1bf037bd7">108,586</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctNy0xLTEtMA_91db3ee5-4eec-4fb8-8c25-e6c38bf6035d">117,203</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctOS0xLTEtMA_81e828a5-ecd0-4338-a0c5-eb522aaadafd">119,632</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMTEtMS0xLTA_0dc6b072-58b1-4b09-a8ea-e09c6efef440">110,286</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMTMtMS0xLTA_df3320b5-eb90-40ca-9a72-84d398931579">98,585</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMTUtMS0xLTA_d3ed5c1e-a44e-4209-aaed-714672f08f0f">112,164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share(1)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMS0xLTEtMA_2ba3be3b-fcde-4449-97c4-83fd194b5a2b">0.78</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMy0xLTEtMA_1b9eb6cd-38b9-42ea-a631-cf6a680810db">0.45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktNS0xLTEtMA_575da072-40f5-4286-a068-b04d774a102f">0.61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktNy0xLTEtMA_08b28966-fb59-43f2-9340-c683ec093bce">0.65</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktOS0xLTEtMA_5a3c7834-d984-47f9-8da6-2de129dfb890">0.69</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMTEtMS0xLTA_dc795032-a7e6-46d8-838e-16e7b46620b0">0.63</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMTMtMS0xLTA_59297d3d-9b79-4e1d-b39b-e6d0cc4032d2">0.56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMTUtMS0xLTA_30b47e7d-c025-4e24-a369-ee4e1f200099">0.64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTEtMS0xLTA_3419bf1e-3e14-4803-b4f9-b18a1926c3b9">0.78</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTMtMS0xLTA_03fd1573-030e-4f22-af8a-ffd5b04c9bf8">0.45</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTUtMS0xLTA_8a709d17-8b5b-4438-99d9-2d0ca55e44f5">0.61</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTctMS0xLTA_26136842-356c-45b3-bfad-616836f339eb">0.65</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTktMS0xLTA_5b51e845-0f6c-46f2-a389-25c5361b7a29">0.69</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTExLTEtMS0w_866f3d09-6aa9-4e2e-8079-18cee56f4205">0.63</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTEzLTEtMS0w_c2a4dfa4-92b8-449c-a806-135b326f0db7">0.56</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTE1LTEtMS0w_b3c6b1f5-78a7-407b-90b1-b6676c4a20d0">0.64</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Quarterly income (loss) per share amounts may not total to the year-to-date income (loss) per share due to rounding.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_169"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule&#160;13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management has assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. In making its assessment of internal control over financial reporting, management used the criteria described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based on our evaluation under the framework described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The effectiveness of our internal control over financial reporting as of December&#160;31, 2020 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. There was no change in our internal control over financial reporting during the quarter ended December&#160;31, 2020, which was identified in connection with our management&#8217;s evaluation required by Exchange Act Rules&#160;13a-15(f) and 15d-15(f) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related shelter-in-place requirements, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_172"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_178"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Officers and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information relating to our executive officers required by this item is set forth in Part&#160;I&#160;&#8212; Item&#160;1 of this report under the caption &#8220;Executive Officers of the Registrant&#8221; and is incorporated herein by reference. The other information required by this Item is incorporated by reference from the definitive proxy statement for our 2020 Annual Meeting of Stockholders to be filed with the SEC pursuant to Regulation&#160;14A (Proxy Statement) not later than 120&#160;days after the end of the fiscal year covered by this Form&#160;10-K under the captions &#8220;Corporate Governance and Board of Directors,&#8221; &#8220;Proposal&#160;1&#160;&#8212; Election of Directors&#8221; and &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding our audit committee financial expert will be set forth in the Proxy Statement under the caption &#8220;Audit Committee,&#8221; which information is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a Code of Business Conduct and Ethics applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Business Conduct and Ethics is posted on our website at www.nektar.com. Amendments to, and waivers from, the Code of Business Conduct and Ethics that apply to any of these officers, or persons performing similar functions, and that relate to any element of the code of ethics definition enumerated in Item&#160;406(b) of Regulation&#160;S-K will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a current report on Form&#160;8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted by SEC Rule&#160;10b5-1, certain of our executive officers, directors and other employees have or may set up a predefined, structured stock trading program with their broker to sell our stock. The stock trading program allows a broker acting on behalf of the executive officer, director or other employee to trade our stock during blackout periods or while such executive officer, director or other employee may be aware of material, nonpublic information, if the trade is performed according to a pre-existing contract, instruction or plan that was established with the broker when such executive officer, director or employee was not aware of any material, nonpublic information.  Executive officers and directors can only sell our stock in accordance with our securities trading policy and pursuant to a stock trading program set up under Rule 10b5-1 (wherein &#8220;exercise and hold&#8221; and stock purchases are exempted, and sales outside such a program can proceed upon approval of the Nominating and Corporate Governance Committee of our Board of Directors.  Employees who are not executive officers may trade our stock outside of the stock trading programs set up under Rule&#160;10b5-1 subject to our securities trading policy.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_181"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_184"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_187"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_190"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="ifabf795112b143ffbb3dd9981b4dd620_196"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;15.  Exhibits and Financial Statement Schedules</span></div><div style="padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Consolidated Financial Statements:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following financial statements are filed as part of this Annual Report on Form&#160;10-K under Item&#160;8 &#8220;Financial Statements and Supplementary Data.&#8221;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reports of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_64">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets at December 31, 2020 and 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_67">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations for each of the three years in the period ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_73">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income (Loss) for each of the three years in the period ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_79">75</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_82">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_85">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifabf795112b143ffbb3dd9981b4dd620_88">78</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:51.34pt">Financial Statement Schedules:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All financial statement schedules have been omitted because they are not applicable, or the information required is presented in our consolidated financial statements and notes thereto under Item&#160;8 of this Annual Report on Form&#160;10-K.</span></div><div style="padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:51.34pt">Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Except as so indicated in Exhibit&#160;32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv2w1.htm">Asset Purchase Agreement, dated October&#160;20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to Exhibits&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">3.4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">3.5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-4_1.htm">Specimen Common Stock certificate.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-2.htm">Indenture dated October 5, 2015 by and between Nektar Therapeutics and Wilmington Trust, National Association, and TC Lending, LLC including the form of 7.75% Senior Secured Note due 2020.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex44.htm">Description of Securities. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex103.htm">2000 Equity Incentive Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex102.htm">2000 Non-Officer Equity Incentive Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex104.htm">2008 Equity Incentive Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex107.htm">Discretionary Incentive Compensation Policy++</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex108.htm">Amended and Restated Change of Control Severance Benefit Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415001516/s101346_ex10-1.htm">2012 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415003667/s102370_ex10-1.htm">Forms of Stock Option Agreement, Performance Stock Option Agreement, Restricted Stock Unit Agreement and Performance Restricted Stock Unit Agreement under the 2012 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8(11)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000014/nktr-2020x06x30xexx101.htm">Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9(12)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-ex109_7.htm">Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock Unit Agreement, and Non-Employee Director Restricted Stock Unit Agreement under the Amended and Restated 2017 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10(13)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420414039940/v382555_ex10-1.htm">Employee Stock Purchase Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312513085500/d448841dex107.htm">Amended and Restated Compensation Plan for Non-Employee Directors.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12(15)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000110465904022735/a04-8706_1ex10d4.htm">401(k) Retirement Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312507240872/dex104.htm">Form of Severance Letter for executive officers of the company.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w26.htm">Amended and Restated Letter Agreement, executed effective on December&#160;1, 2008, with Howard W. Robin.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w27.htm">Amended and Restated Letter Agreement, executed effective on December&#160;1, 2008, with John Nicholson.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000095012311020657/f57959exv10w22.htm">Letter Agreement, executed effective on December&#160;10, 2009, with Stephen K. Doberstein,&#160;Ph.D.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex1017.htm">Transition, Separation and General Release Agreement, dated as of January 9, 2020, by and between Stephen K. Doberstein and Nektar Therapeutics.  ++</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18(19)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000090670919000010/nktr2019-09x30xexx101.htm">Separation, Consulting and General Release Agreement effective as of October 15, 2019, by and between Nektar Therapeutics and John Nicholson.++</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19(28)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex1019.htm">Employment Agreement effective as of December 4, 2019, by and between Nektar Therapeutics and John Northcott.++</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312507240872/dex108.htm">Amended and Restated Built-to-Suit&#160;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&#160;17, 2004, as amended on January&#160;11, 2005 and July&#160;19, 2007.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21(18)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459017022445/nktr-ex102_237.htm">Lease Agreement dated August 4, 2017, as amended by the First Amendment to Lease dated as of August 29, 2017, by and between ARE-San Francisco No. 19, LLC and Nektar Therapeutics.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22(20)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312506167850/dex102.htm">Settlement Agreement and General Release, dated June&#160;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL, Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w34.htm">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September&#160;26, 2005, as amended.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w35.htm">Exclusive License Agreement, dated December&#160;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000095012311020657/f57959exv10w31.htm">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&#160;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing, Limited.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26(21)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420409056637/v164533_ex10-1.htm">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&#160;20, 2009.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27(22)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459016022647/nktr-ex101_193.htm">Collaboration and License Agreement dated as of May 30, 2016, by and between Daiichi Sankyo Europe GmbH and Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28(18)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459017022445/nktr-ex101_179.htm">License Agreement effective as of August 23, 2017, by and between Eli Lilly and Company and Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-1.htm">Purchase Agreement dated September 30, 2015 by and among Nektar Therapeutics and TC Lending, LLC and TAO Fund, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-3.htm">Pledge and Security Agreement dated October 5, 2015 by and among Nektar Therapeutics and TC Lending, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31(23)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512209441/d311622dex101.htm">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.32(24)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312513433110/d594595dex101.htm">Amendment No. 1 to License Agreement dated effective as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33(25)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018012975/nktr-ex41_103.htm">Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.34(25)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018012975/nktr-ex101_104.htm">Strategic Collaboration Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr20201231-exx1035.htm">Co-Development Agreement, dated as of February 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr20201231-exx1035.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr20201231-exx1035.htm">, 2021, by and between SFJ Pharmaceuticals XII, L.P. and Nektar Therapeutics.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.36(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191213ex1035.htm">Amendment No. 1 to Strategic Collaboration Agreement dated as of January 9, 2020, by and between Bristol-Myers Squibb and Company an</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191213ex1035.htm">d Nektar Therapeutics.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.37(26)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312518044320/d499642dex101.htm">Share Purchase Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.38(27)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018020709/nktr-ex101_86.htm">Office Lease, effective as of May 31, 2018, by and between Kilroy Realty Finance Partnership, L.P., and Nektar Therapeutics.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr20201231-exx1039.htm">Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex211.htm">Subsidiaries of Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr20201231-exx231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_202">Power of Attorney (reference is made to the signature page).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20201231xexx311.htm">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20201231xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20201231xexx321.htm">Section&#160;1350 Certifications.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Label Linkbase Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document. </span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). </span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit&#160;32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Inline XBRL information is filed herewith.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2008.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 1998.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2000.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on January&#160;23, 2003.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on December 21, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on October&#160;6, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2011.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K, filed on June&#160;17, 2015.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K filed on December&#160;17, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;10-Q, filed on August 7, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form 10-K for the year ended December 31, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on June&#160;27, 2014.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December 31, 2012.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2007.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December 31, 2010.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2006.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2009.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2012.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K filed on February 14, 2018.&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics' Annual Report for the year ended December 31, 2019.  </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Filed herewith.</span></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City and County of San&#160;Francisco, State of California on February&#160;25, 2021.</span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:35.233%"><tr><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABRUCHERIE</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:35.233%"><tr><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLIAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HOMSEN</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Senior Vice President, Finance and Chief Accounting Officer</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="ifabf795112b143ffbb3dd9981b4dd620_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ifabf795112b143ffbb3dd9981b4dd620_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gil M. Labrucherie and Jillian B. Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, President and Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/   G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> M. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABRUCHERIE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gil M. Labrucherie</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ILLIAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HOMSEN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Finance and Chief Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jillian B. Thomsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OBERT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HESS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, Chairman of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Robert B. Chess</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFREY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">JER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeffrey R. Ajer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">YRIAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> J. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">URET</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Myriam J. Curet</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ARIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ASTHAM</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Karin Eastham</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">REER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R. Scott Greer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HITFIELD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Roy A. Whitfield</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>2
<FILENAME>nktr20201231-exx1035.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7c58f41f4c87444fb039996435e95355_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.35</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CO-DEVELOPMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Co-Development Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), made effective as of February ___, 2021 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is by and between Nektar Therapeutics, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and SFJ Pharmaceuticals XII, L.P. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a Delaware limited partnership (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical products and desires to fund and conduct the clinical trial for the development of the Product for the use, in combination with pembrolizumab as a first line treatment of patients with squamous cell carcinoma of the head and neck (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Nektar has rights to the Product, is conducting clinical trials of the Product globally for various indications and would like to enter into an agreement with SFJ to conduct and fund the HNC Clinical Trials of the Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 1</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the following terms which will have the following respective meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;14.10.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accelerated Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i)&#160;an accelerated approval of an indication by the FDA based on a surrogate or an intermediate clinical endpoint under Section&#160;901 of the Food and Drug Administration Safety Innovations Act (FDASIA), and (ii)&#160;that the prescribing label states &#8220;that the drug was approved based upon accelerated approval and that continued approval for the drug (or indication) may be contingent upon verification and description of clinical benefit in a confirmatory trial or trials.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adverse Patent Impact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;13.2.7.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a party, a business entity under common control with, or controlling or controlled by, such party, with &#8220;control&#8221; meaning direct or indirect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ownership of 50% or more of the voting interest in such other entity, and in the case of a partnership, control of the general partner.  Notwithstanding the foregoing, (a)&#160;neither The Blackstone Group Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Blackstone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) nor any of its divisions, including Blackstone Life Sciences Advisors L.L.C. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BXLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), nor any funds managed by Blackstone, BXLS or their respective Affiliates shall be deemed to be an &#8220;Affiliate&#8221; of SFJ, (b)&#160;neither Abingworth LLP nor any of its subsidiaries or divisions, nor any funds managed by the foregoing, shall be deemed to be an &#8220;Affiliate&#8221; of SFJ and (c)&#160;SFJ Pharmaceuticals, Inc. shall not be deemed to be an &#8220;Affiliate&#8221; of SFJ.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.1.5.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the applicable laws, rules and regulations, including any rules, regulations, guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally binding, that may be in effect from time to time.  For clarity, Applicable Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approval Buy-Out Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.7.1. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.4.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Third Party Vendor Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.2.2.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Vendor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.4.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.12&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BEMPEG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means bempegaldesleukin.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (a)&#160;a biologics license application submitted to the FDA pursuant to Section&#160;351(a) of the PHSA and the regulations promulgated thereunder, or its successor application&#59; or (b)&#160;an application for authorization to market and&#47;or sell a biological product in any country or regulatory jurisdiction other than the US submitted to the applicable Regulatory Authority in such country or regulatory jurisdiction, including, with respect to the EU, a marketing authorization application submitted either (i)&#160;to the EMA pursuant to the centralized EU filing procedure or (ii)&#160;to the applicable national Regulatory Authority in an individual EU member state if the centralized EU filing procedure is not used.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Bristol-Myers Squibb Company, a Delaware corporation.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BMS Strategic Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Strategic Collaboration Agreement between BMS and Nektar dated February&#160;13, 2018, as amended by that certain First Amendment to the Strategic Collaboration Agreement dated January&#160;9, 2020.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day that is not a Saturday, Sunday or a US federal holiday.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an Approval Buy-Out Payment or a Change of Control Payment. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each successive period of three&#160;(3) consecutive calendar months ending on March&#160;31, June&#160;30, September&#160;30 and December&#160;31&#59; provided, that, the (a)&#160;the first Calendar Quarter shall begin on the Effective Date and end on the last day of the Calendar Quarter in which the Effective Date falls, and (b)&#160;the final Calendar Quarter shall end on the last day of the Term.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each successive period of twelve&#160;(12) months commencing on January&#160;1 and ending on December&#160;31&#59; provided, that, (a)&#160;the first Calendar Year shall begin on the Effective Date and end on December&#160;31 of the Calendar Year in which the Effective Date falls, and (b)&#160;the final Calendar Year shall end on the last day of the Term.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Case Report Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CRF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the collection of documents designed specifically for recording data pursuant to the Protocol.  A CRF is completed for each Subject and will be in electronic form, validated and in compliance with all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Nektar, at any time prior to the date of the payment by Nektar of the final Success Payment hereunder, (a)&#160;a merger, reorganization or consolidation with a Third Party which results in the voting securities of Nektar outstanding immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at least fifty percent&#160;(50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of the surviving entity immediately after such merger, reorganization or consolidation, (b)&#160;a transaction in which a Third Party becomes the beneficial owner of fifty percent&#160;(50%) or more of the combined voting power of the outstanding securities of Nektar, other than through the issuance of voting securities for the purpose of raising financing to one or more financial or institutional investors that are not then controlled by an entity engaged in the development or commercialization of pharmaceutical or biotechnology products, or (c)&#160;the sale or other transfer of all or substantially all of Nektar&#8217;s business or assets.  For avoidance of doubt, a Licensing Transaction shall not constitute a Change of Control.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.23&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.7.2. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Third Party claim, demand, suit and&#47;or cause of action.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Investigator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the principal investigator at each Site.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.26&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Investigator Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.2.2.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Melanoma Clinical Trial and the HNC Clinical Trials.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.3.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.2.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial Success Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Melanoma Clinical Trial Success Criteria or the HNC Clinical Trial Success Criteria, as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.31&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.5.3.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.32&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.5.4.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.33&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means chemistry, manufacturing and controls.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CMC Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the CMC information intended or required for the submission of an IND or BLA. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.35&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means contract manufacturing organization or contract development and manufacturing organization. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.36&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.37&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial Launch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to the Product, the first sale to a Third Party of such Product in the United States after the applicable Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.38&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the commercial manufacture, marketing, promotion, sale and&#47;or distribution of the Product.  For clarity, Commercialization excludes all activities associated with development and seeking Regulatory Approval for the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.39&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to the performance of activities under this Agreement by Party (and (x)&#160;in the case of SFJ as pertains to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">its role in conducting the HNC Clinical Trials, and (y)&#160;in the case of Nektar as pertains to its role in conducting or monitoring the Melanoma Clinical Trial)&#58; reasonable, diligent, good-faith efforts to accomplish such objective &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.40&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an IL-2 conjugate used for the treatment of HNC. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.41&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Completion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as to a particular Clinical Trial, the earlier of (a)&#160;the date of the final CSR for such Clinical Trial and (b)&#160;the date such Clinical Trial or this Agreement is terminated.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.42&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party means all information and materials provided and&#47;or disclosed (including in written form, electronic form or otherwise) by, or on behalf of, such Party or its Affiliates or their Representatives to the other Party, its Affiliates, or its of their Representatives in connection with this Agreement, including, technical, scientific, regulatory and other information, results, knowledge, techniques, data, analyses, inventions, invention disclosures, plans, processes, methods, know-how, ideas, concepts, test data (including pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing, pricing, distribution, cost, sales, and manufacturing data and descriptions.  In addition, the terms and conditions of this Agreement shall be deemed to be Confidential Information of both SFJ and Nektar.  In addition, the Research Results shall at all times be deemed to be Confidential Information of Nektar, and Nektar and SFJ shall be deemed the disclosing Party and the receiving Party, respectively, with respect thereto.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.43&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for any Person, any direct or indirect liability, contingent or not, of that Person for (a)&#160;any indebtedness, letter of credit or other Indebtedness of another Person, in each case, directly or indirectly guaranteed, endorsed or co-made by that Person, or for which that Person is directly or indirectly liable&#59; (b)&#160;any obligations for undrawn letters of credit for the account of that Person&#59; and (c)&#160;all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices.  The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith&#59; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.44&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;for Intellectual Property, a Party&#8217;s ability to grant applicable licenses, sublicenses and&#47;or other rights thereunder and (b)&#160;for materials and documents, a Party&#8217;s ability to provide, or provide access to, such materials and&#47;or documents, each without violating any contractual obligations to a Third Party.  For clarity, if a Party only can grant a license or sublicense and&#47;or provide rights and&#47;or access of limited scope, for a specific purpose or under certain conditions due to an encumbrance, &#8220;Control&#8221; or &#8220;Controlled&#8221; will be construed to so limit such license, sublicense, provision of rights and&#47;or access.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.45&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, all works of authorship, mask works and any and all other registered and unregistered copyrights and copyrightable works, and all applications, registrations, extensions, and renewals thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.46&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to the applicable Intellectual Property, in the absence of the applicable rights and licenses granted, would be infringed, misappropriated, or otherwise violated by.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.47&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means contract research organization as defined in 21&#160;C.F.R.&#160;312.3(b).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CRO Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.4.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.49&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for with respect to a Clinical Trial, a clinical study report, or other equivalent document or series of materials, constituting a summary report of the clinical and medical data resulting from such Clinical Trial and prepared for incorporation into submissions seeking Regulatory Approval for the Product, and includes all statistical analyses of such data per the Statistical Analysis Plan.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.50&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain electronic data room established by Nektar and to which SFJ and&#47;or its advisors were granted access.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.51&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all clinical and non-clinical research and development activities conducted for the Product, including toxicology, pharmacology test method development and stability testing, process development, formulation development, quality assurance and quality control development, statistical analysis, conducting Clinical Trials, regulatory affairs, and obtaining and maintaining Regulatory Approval, and related digital system and general and administrative support therefor.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.52&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the following internal and external costs, associated with completing the HNC Clinical Trials&#58; (a)&#160;Approved Third Party Vendor Costs, (b)&#160;the SFJ Quarterly Labor Fees as outlined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;G-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (c)&#160;the Nektar Quarterly Labor Fees as outlined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;G-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and (d)&#160;such other costs that are deemed to be Development Costs as provided for in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.53&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Cost Reconciliation Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.5.6.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.54&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a clinical and regulatory development program to be undertaken by the Parties to Develop the Product for the Indication, carry out the Clinical Trials, and seek Regulatory Approval for the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.55&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and ending on the later of (a)&#160;the latest of the Completion Dates of the Clinical Trials, and (b)&#160;the date on which all efforts in pursuit of Regulatory Approval of the Product for any Indication have been concluded or terminated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.56&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;13.2.2.2(b).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.57&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;9.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.58&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Discount Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.7.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.59&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;14.10.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.60&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in the Preamble.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.61&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Union or any successor union of European states thereto having a substantially similar function.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.62&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excess Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;4.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.63&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;in the case of the conduct of human clinical trials with respect to a Competing Product, the period beginning on the Effective Date and ending on December&#160;31, 2025. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.64&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the executive officers of each of Nektar and SFJ identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.65&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Nektar Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;10.1.1.1. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.66&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the US Food and Drug Administration and any successor agency thereto in the US having substantially the same function.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.67&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FFDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the US Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.68&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the first to occur of the HNC Regulatory Approval and the Melanoma Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.69&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means generally accepted accounting principles in the US, as consistently applied by the applicable Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.70&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GMP Manufacturer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Party that is responsible for ensuring that the Product is manufactured in accordance with GMP.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.71&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applicable good clinical practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (a)&#160;the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Use (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) Harmonised Tripartite Guideline for Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95) and any other guidelines for good clinical practice for clinical trials on medicinal products&#59; (b)&#160;the Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto&#59; and (c)&#160;the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of clinical trial Subjects.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.72&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Manufacturing Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applicable good manufacturing practices including, as applicable, (a)&#160;the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003&#47;94&#47;EC laying down the principals and guidelines of good manufacturing practice&#59; (b)&#160;the principles detailed in the US Current Good Manufacturing Practices, 21 C.F.R. Sections&#160;210, 211, 601 and 610&#59; (c)&#160;the Rules Governing Medicinal Product in the European Community, Volume&#160;IV Good Manufacturing Practice for Medicinal Product&#59; (d)&#160;the principles detailed in the ICH Q7A guidelines&#59; and (e)&#160;the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.73&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is broadly defined as and includes&#58; (a)&#160;any elected or appointed government official (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a member of a ministry of health)&#59; (b)&#160;any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function&#59; (c)&#160;any non-US political party officer, employee, or person acting for or on behalf of a non-US political party or candidate for public office&#59; (d)&#160;any employee or person acting for or on behalf of a public international organization&#59; (e)&#160;all government employees and employees of state-owned enterprises&#59; or (f)&#160;any person otherwise categorized as a government official under local law&#59; where &#8220;government&#8221; is meant to include all levels and subdivisions of non-US governments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, local, regional, or national and administrative, legislative, or executive).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.74&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any supranational, federal, national, state or local court, agency, authority, department, regulatory body or other governmental instrumentality.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.75&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.76&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trial Futility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that the HNC Main Clinical Trial meets the end of Phase 2 futility criteria set forth in the HNC Main Clinical Trial Protocol.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.77&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.78&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Main Clinical Trial Protocol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.1.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.79&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trial Success Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means that, following database lock, the results of the HNC Main Clinical Trial meet the overall survival primary endpoint set forth in the HNC Clinical Trial Protocol. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.80&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in the preamble of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.81&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Main Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the clinical trial of the Product for the HNC Indication in accordance with the HNC Main Clinical Trial Protocol, as such protocol may be amended from time to time in accordance with this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.82&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means accelerated or full approval of a BLA for the Product for the HNC Indication by the FDA in the US.  For clarity, &#8220;HNC Regulatory Approval&#8221; excludes any pricing or reimbursement approval that may be necessary or useful for marketing or sale of the Product in the US.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.83&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;1.1.74</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.84&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IDMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the independent data monitoring committee, which will be established pursuant to Section&#160;3.9.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.85&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IDMC Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.9.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.86&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an investigational new drug application, clinical trial application, clinical trial exemption, or similar application or submission filed with or submitted to a Regulatory Authority in a jurisdiction that is necessary to initiate human clinical testing of a pharmaceutical product in such jurisdiction, including any such application filed with the FDA pursuant to 21 C.F.R. Part&#160;312. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.87&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;indebtedness for borrowed money or the deferred price of property or services (excluding accounts payable incurred in the ordinary course of business, earn-out or similar obligations with respect to deferred purchase price and deferred compensation), (b)&#160;obligations evidenced by notes, bonds, debentures or similar instruments, (c)&#160;capital lease obligations (as such term is understood under GAAP as in effect on the date of this Agreement, but excluding obligations treated as operating leases prior to adoption of changes described by ASC Topic&#160;842) and (d)&#160;Contingent Obligations.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.88&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;11.2.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.89&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;11.2.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.90&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;11.2.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.91&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;the HNC Indication and (b)&#160;the Melanoma Indication.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.92&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means technical or scientific know-how, trade secrets, methods, processes, formulae, designs, specifications and data, including biological, chemical, pharmacological, toxicological, pre-clinical, clinical, safety, manufacturing and quality control data and assays&#59; in each case, whether or not confidential, proprietary, patented or patentable. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.93&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Informed Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.3.2.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.94&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.95&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Payment Trigger Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;if the Melanoma Regulatory Approval occurs before the HNC Regulatory Approval, the earliest of (i)&#160;the date on which the database lock for the primary endpoint of median overall survival in the Phase&#160;3 portion of the HNC Main Clinical Trial used for a full approval of a BLA for the Product for the HNC Indication occurs and (ii)&#160;the 18-month anniversary of the last patient-in for the HNC Main Clinical Trial &#91;***&#93;, or (b)&#160;if the HNC Regulatory Approval occurs on or before the Melanoma Regulatory Approval, the day following the HNC Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.96&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Schedule&#160;A Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.97&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Schedule&#160;B Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.98&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all intellectual property and industrial property rights of any kind or nature throughout the world, including all US and foreign, (a)&#160;Patents&#59; (b)&#160;Trademarks&#59; (c)&#160;Copyrights&#59; (d)&#160;rights in computer programs (whether in source code, object code, or other form), algorithms, databases, compilations and data, technology supporting the foregoing, and all documentation, including user manuals and training materials, related to any of the foregoing&#59; (e)&#160;trade secrets and all other Confidential Information, know-how, inventions, proprietary processes, formulae, models, and methodologies&#59; (f)&#160;rights of publicity, privacy, and rights to personal information&#59; (g)&#160;all rights in the foregoing and in other similar intangible assets&#59; and (h)&#160;all applications and registrations for the foregoing. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.99&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investigator&#8217;s Brochure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the written document containing a brief description of the drug substance and formulation of the Product, a summary of the pharmacological and toxicological effects of the Product in animals and human nonclinical models, a summary of the pharmacokinetics and biological disposition of the Product in animals and humans, a summary of information relating to safety and effectiveness of the Product in humans obtained from prior clinical studies, and a description of possible risks and side effects to be anticipated on the basis of prior experience with the Product under investigation or with related drugs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.100&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IRB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means institutional review board, or its equivalent.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.101&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ISC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  has the meaning ascribed to such term Section&#160;3.9.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.102&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JOC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.4.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.103&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JOC Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.4.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.104&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JOC Representative(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.4.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.105&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.5.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.106&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JFC Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.5.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.107&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JFC Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section 5.5.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.108&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JPT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.4.6. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.109&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.1.1</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.110&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.111&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC Representative(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;5.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.112&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge of Nektar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.113&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Leftover Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;4.2.1.3.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.114&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licensing Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; a license or sublicense to a Third Party under any of the Nektar Intellectual Property to Commercialize the Product or an equivalent sale or other transfer of Nektar Intellectual Property that conveys the right to Commercialize the Product (other than, (a) in the case of a Third Party contract testing, development, research and&#47;or manufacturing organization, a license or sublicense to commercially manufacture the Product on behalf of Nektar or its Affiliates, without any license or sublicense to engage in any other Commercialization activities with respect to the Product and (b) in the case of a Third Party wholesaler, distributor or distribution logistics services provider, a license or sublicense to distribute the Product (and&#47;or conduct other typical distribution activities) on behalf of Nektar or its Affiliates, without any license or sublicense to engage in any other Commercialization activities with respect to the Product), in each case, other than in conjunction with a permitted assignment of this Agreement pursuant to Section&#160;14.6 in connection with the sale or other transfer of all or substantially all of its business or assets to which this Agreement relates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.115&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.116&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means liabilities, losses, costs, damages, fees and&#47;or expenses (including reasonable legal expenses and attorneys&#8217; fees) payable to a Third Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.117&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Major European Markets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.118&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Anti-Corruption Law Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a violation by a Party or its Affiliate of an Anti-Corruption Law relating to the subject matter of this Agreement that would, if it were publicly known, have a material adverse effect on the other Party or its Affiliate because of its relationship with such Party. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.119&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;4.1. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.120&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Melanoma Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the clinical trial of the Product for the Melanoma Indication with a protocol title of &#8220;A Study of NKTR-214 Combined with Nivolumab vs. Nivolumab Alone in Participants with Previously Untreated Inoperable or Metastatic Melanoma&#8221; with the ClinicalTrials.gov identifier of NCT03635983, as such protocol may be amended from time to time in accordance with the BMS Strategic Agreement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.121&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Melanoma Clinical Trial Research Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Information arising out of, or resulting from, the Melanoma Clinical Trial and&#47;or the CMC activities contemplated by the Development Program, including the Clinical Trials database for the data collected from each study site for the Melanoma Clinical Trial&#59; but excluding Trial Inventions (including Intellectual Property in or to Trial Inventions).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.122&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Melanoma Clinical Trial Success Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means that the results of the Melanoma Clinical Trial meet the primary endpoint of progression free survival as set forth in the protocol of the Melanoma Clinical Trial. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.123&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Melanoma Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means first-line metastatic or untreated, unresectable melanoma.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.124&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Melanoma Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means accelerated or full approval of a BLA for the Product for the Melanoma Indication by the FDA in the US.  For clarity, &#8220;Melanoma Regulatory Approval&#8221; excludes any pricing or reimbursement approval that may be necessary or useful for marketing or sale of the Product in the US. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.125&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merck</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean MSD International GmbH.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.126&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merck CTCSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Clinical Trial Collaboration and Supply Agreement between Merck and Nektar dated February 11, 2021.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.127&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merck Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Keytruda (pembrolizumab).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.128&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in the Preamble.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.129&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Compliance Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in Section&#160;13.2.6.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.130&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Confidential Information provided and&#47;or disclosed by or on behalf of Nektar or its Affiliates, agents or representatives to SFJ or its Affiliates, agents or representatives hereunder.  For clarity, Nektar Confidential Information will include any and all CMC Information.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.131&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;11.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.132&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Intellectual Property owned or Controlled by Nektar that is necessary or useful for the Development, manufacture, use, sale or import of the Product, including Trial Inventions.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.133&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Indebtedness, liabilities and other obligations of Nektar to SFJ under or in connection with this Agreement and any other documents executed in connection herewith, including, without limitation, all amounts payable to SFJ pursuant to Article&#160;6 hereof, all interest accrued thereon, all fees and all other amounts payable by Nektar to SFJ thereunder or in connection therewith, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and including interest that accrues after the commencement by or against Nektar of any bankruptcy or insolvency proceeding naming such individual or entity as the debtor in such proceeding, and including performing the Nektar Services.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.134&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Quarterly Labor Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the quarterly fees outlined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.135&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means performing or managing all Commercialization, publications, regulatory activities, investigational drug branch (IDB) and study reporting, including those responsibilities set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case with respect to the HNC Clinical Trials and unless the HNC Clinical Trials have terminated.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.136&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar SOPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.1.4. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.137&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any oncology indication, other than the Indications, either alone or in combination with another drug.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.138&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Indication Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means accelerated or full approval of a BLA for the Product for an Other Indication by the FDA in the US.  For clarity, &#8220;Other Indication Regulatory Approval&#8221; excludes any pricing or reimbursement approval that may be necessary or useful for marketing or sale of the Product in the US.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.139&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.140&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in the Preamble.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.141&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; will mean patents, patent applications, patent disclosures, and all related continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.142&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any CRO, Site, Clinical Investigator and&#47;or Vendor to whom Nektar or SFJ has delegated responsibility or whom Nektar or SFJ has engaged in connection with the HNC Clinical Trials or any CMO whom Nektar has engaged to perform CMC related activities (including supply of Product for use in the Clinical Trials).  For clarity, Third Parties that have been delegated responsibility by or engaged by a Permitted Third Party will be considered Permitted Third Parties.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.143&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, corporation, general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, or other entity or Governmental Authority.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.144&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Personally Identifiable Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any information relating to an identified or, in combination with other information, identifiable person or persons captured in an electronic or hardcopy format, including such information as it relates to clinical trials subjects (including key-coded patient data), physicians, clinicians, healthcare professionals, consultants, or other persons participating in the Clinical Trials, and any equivalent definition in the Applicable Laws to the extent that such definition is broader than that provided here. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.145&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PHSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Public Health Service Act as set forth at 42&#160;U.S.C. Chapter&#160;6A, as may be amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.146&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Approval Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;4.3.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.147&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the product containing BEMPEG described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.148&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Product Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means INDs, BLAs and Regulatory Approvals (including all amendments and supplements to any of the foregoing) and other filings with, and formal submissions to, the FDA or other applicable Regulatory Authorities, in each case with respect to the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.149&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly Labor Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Nektar Quarterly Labor Fees and the SFJ Quarterly Labor Fees.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.150&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;9.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.151&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.5.2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.152&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any of the HNC Regulatory Approval and the Melanoma Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.153&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting approval to initiate or conduct clinical testing in humans, for Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.154&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;12.1.3.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.155&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Research Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Information arising out of, or resulting from, the HNC Clinical Trials and&#47;or the CMC activities contemplated by the Development Program, including the Clinical Trials Database&#59; but excluding Trial Inventions (including Intellectual Property in or to Trial Inventions).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.156&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Safety Concern</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;13.2.5.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.157&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;A Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.158&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;B Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.159&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, following or concurrent with the First Regulatory Approval, the occurrence of an HNC Regulatory Approval (if the First Regulatory Approval was a Melanoma Regulatory Approval) or a Melanoma Regulatory Approval (if the First Regulatory Approval was an HNC Regulatory Approval).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.160&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Regulatory Approval Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.161&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Serious Safety Issue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any SUSAR or series of SUSARs directly related to or caused by the administration of the Product in the conduct of the Clinical Trials where such SUSAR or series of SUSARs substantially diminishes the probability of receiving Regulatory Approval for the Product, or results in a Regulatory Authority imposing a clinical hold on further development of the Product which clinical hold is not lifted or removed within &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.162&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in the Preamble.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.163&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;11.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.164&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the provision of clinical development and others services by SFJ in accordance with the RACI as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.165&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ SOPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.1.2. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.166&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Quarterly Labor Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the quarterly fees outlined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.167&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Site</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.2.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.168&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SOPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Nektar SOPs, SFJ SOPs, or CRO SOPs as agreed to by the Parties.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.169&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;The Blackstone Group Inc., its divisions and Affiliates including Blackstone Life Sciences, and any funds or investment vehicles managed by the foregoing, and (b)&#160;Abingworth LLP, its divisions and Affiliates, and any funds or investment vehicles managed by the foregoing.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.170&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.3.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.171&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Statistical Analysis Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.5.6.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.172&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.3.2.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.173&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subject Recruitment Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;3.3.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.174&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section 6.1.3.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.175&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Success Payment Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;13.2.1.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.176&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Success Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.177&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SUSAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a suspected unexpected serious adverse reaction, without regard to causality, that is life-threatening (i.e., causes an immediate risk of death) or that results in any of the following outcomes&#58; death&#59; in-patient hospitalization or prolongation of existing hospitalization&#59; persistent or significant disability or incapacity (i.e., substantial disruption of the ability to conduct normal life functions)&#59; or a congenital anomaly or birth defect.  For clarity, a planned medical or surgical procedure is not, in itself, a SUSAR.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.178&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;13.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.179&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person other than Nektar, SFJ and their Affiliates.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.180&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any actual or threatened infringement, misappropriation, or other violation by a Third Party of any Intellectual Property Controlled by Nektar that relates to this Agreement and&#47;or the Product, including the Trial Inventions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.181&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Intellectual Property owned or Controlled by a Third Party that is necessary or useful for, or could reasonably be expected to be relevant to, the development, manufacture, use, sale or import of the Product, including Trial Inventions.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.182&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timeline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.3.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.183&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timeline Remediation Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.3.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.184&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, all registered and unregistered marks, trade dress rights, logos, taglines, slogans, Internet domain names, web addresses, and other indicia of origin, together with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals thereof, selected for use on the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.185&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trial Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Information, in any form, generated or developed by or on behalf of a Party or any of its Affiliates (including by any of their respective Permitted Third Parties) in the conduct of the HNC Clinical Trials during the Development Term, including the Clinical Trial Database and other data and reports arising out of the HNC Clinical Trials, any Clinical Trial Agreements or any Vendor Agreements or CRO Agreements related to the conduct of the HNC Clinical Trials, including the Research Results&#59; but, in each case, excluding Trial Inventions.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.186&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trial Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (a)&#160;any invention or discovery, whether or not patentable, made, developed, generated, conceived, or reduced to practice by or on behalf of a Party or any of its Affiliates or Permitted Third Parties, or jointly by or on behalf of the Parties or any of their respective Affiliates or Permitted Third Parties, in the course or as a result of the conduct of any Clinical Trial or any other activity conducted pursuant to this Agreement, including, without limitation, any improvement to any Existing Nektar Intellectual Property&#59; and (b)&#160;all Intellectual Property in any of the items described in the preceding clause&#160;(a).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.187&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">US</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">USA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America, its territories and possessions, including Puerto Rico.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.188&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vendor Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;2.4.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.189&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to such term in Section&#160;6.5.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of this Agreement&#58; (a)&#160;words in the singular will be held to include the plural and vice versa as the context requires&#59; (b)&#160;the words &#8220;including&#8221; and &#8220;include&#8221; will mean &#8220;including, without limitation,&#8221; unless otherwise specified&#59; (c)&#160;the terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;herewith,&#8221; and &#8220;hereunder,&#8221; and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provision of this Agreement&#59; and (d)&#160;all references to &#8220;Section&#8221; and &#8220;Exhibit,&#8221; unless otherwise specified, are intended to refer to a Section&#160;or Exhibit&#160;of or to this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any conflict between the terms of this Agreement, the Protocol and&#47;or any other Exhibit, the Protocol will control (as applicable), followed by the terms of this Agreement, and followed by any applicable other Exhibit.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 2</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE clinical trials</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The HNC Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The protocol for the HNC Main Clinical Trial (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Main Clinical Trial Protocol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be finalized by Nektar based on the draft protocol attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and approved by the JOC within &#91;***&#93; days after the Effective Date.  If any additional regional trials are needed in order to supplement the HNC Main Clinical Trial, then the protocol for each such additional clinical trial of the Product (such additional trials,&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional HNC Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the HNC Main Clinical Trial, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and such protocols,&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional HNC Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the HNC Main Clinical Trial Protocol, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HNC Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be prepared by SFJ in consultation with Nektar and approved by the JOC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Changes to the Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.2.1&#160;&#160;&#160;&#160;Any changes to the HNC Main Clinical Trial Protocol, including any country-specific appendices required by Applicable Law and changes made in response to any communications with any Regulatory Authorities, that require a submission to a Regulatory Authority, an IRB or other ethics committee, will be prepared by SFJ, with consultation from Nektar, and will require the JOC&#8217;s approval, which will not be unreasonably withheld or delayed and which will be communicated to the Parties as soon as reasonably practicable following the JOC&#8217;s receipt of the draft amendment from Nektar.  Any changes to any Additional HNC Clinical Trial Protocol, including any country-specific appendices required by Applicable Law and changes made in response to any communications with any Regulatory Authorities, that require a submission to a Regulatory Authority, an IRB or other ethics committee, will be prepared by SFJ, with consultation from Nektar, and will require the JOC&#8217;s approval, which will not be unreasonably withheld or delayed and which will be communicated to the Parties as soon as reasonably practicable following the JOC&#8217;s receipt of the draft amendment from SFJ.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.2.2&#160;&#160;&#160;&#160;If either Party believes that a HNC Clinical Trial Protocol requires an amendment (for example, to comply with any Applicable Laws or based on any communications from any Regulatory Authorities), such Party will inform the JOC.  If the JOC agrees that such an amendment is required, the JOC will provide each Party with written notice thereof as soon as reasonably practicable, and SFJ, with consultation from Nektar, will prepare a draft amendment to such Protocol, which will only be effective and part of such Protocol upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">approval by the JOC pursuant to Section&#160;5.4.5.1, which approval will not be unreasonably withheld and which will be communicated to the Parties as soon as reasonably practicable following the JOC&#8217;s receipt of the draft amendment from such Party.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Protocol Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will be responsible for obtaining all necessary approvals of each HNC Clinical Trial Protocol (including as required by Applicable Laws) on a global basis, in each case prior to the commencement of the applicable HNC Clinical Trial. SFJ will reasonably co-operate with Nektar in such regard. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsorship and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will be the sponsor of the HNC Clinical Trials.  SFJ, together with one or more Permitted Third Parties, will have all responsibilities of a sponsor as specified in Applicable Laws.  The responsibilities of SFJ and Nektar are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of 21 C.F.R. 312.52, SFJ shall be a CRO, and the document set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is the written transfer of Nektar&#8217;s sponsor obligations to SFJ as required by 21 C.F.R.312.52(a) and an assumption of such sponsor obligations by SFJ as required by 21 C.F.R. 312.52(b).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with the Protocol and Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will conduct the HNC Clinical Trials and perform all other responsibilities assigned to it hereunder in compliance with the applicable Protocol, all Applicable Laws and the terms hereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will conduct due diligence with respect to each Permitted Third Party used by SFJ to ensure that such Permitted Third Party can comply with all applicable terms and obligations of this Agreement and Applicable Laws.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with the Timeline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Timeline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The timeline for conducting the HNC Clinical Trials are attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timeline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In conducting the HNC Clinical Trials, the Parties will use Commercially Reasonable Efforts to complete each activity specified on the Timeline (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by the date specified for such Clinical Trial Activity on the Timeline.  The Parties will notify the JOC in writing upon completion or achievement of each of their designated Clinical Trial Activities.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Failure to Complete a Clinical Trial Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Party fails to, or reasonably believes that it will not, complete (a)&#160;any Clinical Trial Activity within &#91;***&#93; days of the date for completion of any Clinical Trial Activity on the Timeline or (b)&#160;the final Clinical Trial Activity within &#91;***&#93; of the date for the final Clinical Trial Activity on the Timeline, the Party will provide the JOC with a written remediation plan detailing the means by which, and the date on which, that Party expects to be able to complete the relevant Clinical Trial Activities (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timeline Remediation Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Following receipt thereof, the JOC Representatives will discuss and consider in good faith such Timeline Remediation Plan.  If the JOC approves such Timeline Remediation Plan (such approval not to be unreasonably withheld or delayed), the JOC will provide the appropriate Party with written notice thereof, specifying the dates on which, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the detail with which, the Party will be required to update the JOC of its progress with respect thereto.  If the JOC is unable to approve such Timeline Remediation Plan, the matter will be decided by the JSC in accordance with Section&#160;5.2.  After approval of a Party&#8217;s Timeline Remediation Plan, if such Party believes in good faith that any modification to such Timeline Remediation Plan is necessary or appropriate, such Party may propose such modification to the JOC and shall disclose to the JOC any additional information or circumstances that have become known to such Party that form the basis for its request for modification.  The JOC will discuss and consider such in good faith such modification, which shall be subject to JOC approval (such approval not to be unreasonably withheld or delayed) as described above.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Failure to Complete a Timeline Remediation Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Nektar fails to complete a Clinical Trial Activity it is responsible for as outlined in an approved Timeline Remediation Plan, then SFJ has the right to withhold any payments due to Nektar pursuant to Section&#160;4.2, suspend the SFJ Services and cease paying Approved Third Party Vendor Costs and incurring other Development Costs until the Clinical Trial Activity is completed, in which event SFJ will not be considered in breach of this Agreement for withholding any such amounts due to Nektar pursuant to this Section&#160;2.3.3, suspending the HNC Clinical Trials, ceasing to pay Approved Third Party Costs and incurring other Development Costs.  If SFJ fails to complete a Clinical Trial Activity it is responsible for as outlined in an approved Timeline Remediation Plan, then Nektar, at its sole discretion, may assume responsibility for completing such Clinical Trial Activity, in which event (a)&#160;SFJ shall reimburse Nektar for the costs incurred by Nektar in completing such Clinical Activity, and (b)&#160;such costs incurred by Nektar shall be included in actual Development Costs for purposes of Section&#160;6.2, and (c)&#160;in no event shall any failure or delay by Nektar in performing any of its obligations hereunder that are dependent upon the completion of such Clinical Trial Activity constitute a breach of this Agreement, or entitle SFJ (i)&#160;to withhold any payments due to Nektar or other amounts SFJ is obligated to pay or incur pursuant to Section&#160;4.2, (ii)&#160;to terminate this Agreement or (iii)&#160;to exercise any other remedy available to it under this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved CROs and Approved Vendors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved CROs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided herein, a Party may delegate any of its responsibilities described in Section&#160;2.2 to (a)&#160;any of its Affiliates (subject to Section&#160;14.1), (b)&#160;any CRO that is listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or to SFJ Pharmaceuticals, Inc., or (c)&#160;any CRO that is identified by a Party from time to time during the Development Term (provided that prior to such delegation, such Party must provide notice to the JOC of the identity of the CRO to which it desires to delegate its responsibilities, the JOC shall discuss the same, and such Party shall take into reasonable consideration any comments from the JOC) (any Person listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or any Person identified in accordance with clause&#160;(c) from time to time, an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that SFJ may not delegate any of its responsibilities to any CRO other than those identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or to SFJ Pharmaceuticals, Inc. without the prior written consent of Nektar. Each Party will be required to enter into a written agreement with each Approved CRO utilized by such Party (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CRO Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on commercially reasonable and customary terms, consistent with industry standards for similar agreements and sufficient to enable such Party to comply with its obligations hereunder with respect to the delegated responsibilities, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">including, but not limited to, Section&#160;2.2.2, and the terms pertaining to ownership of Intellectual Property and publications, and treatment of Confidential Information. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Vendors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except with respect to manufacturing and supply of the Product as provided in Section&#160;3.14.1, a Party will be permitted to contract for services, equipment, tools, materials and&#47;or supplies required for the HNC Clinical Trials or Regulatory Approval with (a)&#160;any Person that is either listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (b)&#160;any Person that is identified by a Party from time to time during the Development Term (provided that prior to such delegation, such Party must provide notice to the JOC of the identity of the Person with which it desires to contract, the JOC shall discuss the same, and such Party shall take into reasonable consideration any comments from the JOC) (any Person listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or any Person identified in accordance with clause&#160;(b) from time to time, an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Vendor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that SFJ may not contract for services, equipment, tools, materials and&#47;or supplies required for the HNC Clinical Trials or Regulatory Approval with any Person other than those identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and SFJ Pharmaceuticals, Inc. without the prior written consent of Nektar.  Each Party will be required to enter into a written agreement with each Approved Vendor utilized by such Party (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vendor Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on commercially reasonable and customary terms, consistent with industry standards for similar agreements and sufficient to enable such Party to comply with its obligations hereunder with respect to the contracted activities, including, but not limited to, the terms pertaining to publications and ownership of Intellectual Property, and treatment of Confidential Information. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For clarity, each Party will remain responsible for all of its obligations under this Agreement, notwithstanding any delegation to an Affiliate or an Approved CRO or any contracting with an Approved Vendor.  Each Party shall use Commercially Reasonable Efforts to oversee the services of its Affiliates and any Approved CRO or Approved Vendor it utilizes to provide services hereunder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.4&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;***&#93; Reasonable Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.1&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Questions Pertaining to the HNC Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Promptly following the Effective Date during the Development Term, Nektar will identify one&#160;(1) individual with knowledge of the HNC Clinical Trials Protocol, the Product and the Merck Product who will be made available at reasonable times during normal business hours in such employee&#8217;s country of residence upon reasonable advance notice to answer SFJ&#8217;s questions directly pertaining to such Protocol.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 3</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CLINICAL TRIALS ACTIVITIES, REGULATORY APPROVAL AND RESPONSIBILITIES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parties&#8217; Roles and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1.1&#160;&#160;&#160;&#160;Nektar will have sole responsibility for the Melanoma Clinical Trial and the clinical trials for all Other Indications. </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1.2&#160;&#160;&#160;&#160;In regards to the HNC Clinical Trials, Nektar will have primary responsibility for all Nektar Services, provided that SFJ will provide operational support for and assist with these activities as specified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1.3&#160;&#160;&#160;&#160;If the HNC Main Clinical Trial meets the HNC Clinical Trial Success Criteria, Nektar shall submit or cause to be submitted a BLA with the FDA and use Commercially Reasonable Efforts to do so &#91;***&#93; of the data read-out indicating that the Clinical Success Criteria were achieved for the HNC Indication, and will use Commercially Reasonable Efforts to perform all activities associated with submitting BLAs and seeking Regulatory Approval for the HNC Indication in the US. </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1.4&#160;&#160;&#160;&#160;If the Melanoma Clinical Trial meets the Melanoma Clinical Trial Success Criteria, Nektar shall (a)&#160;submit, cause of its controlled Affiliates to submit, or use Commercially Reasonable Efforts to cause BMS to submit a BLA with the FDA, (b)&#160;use Commercially Reasonable Efforts to do so (and cause BMS to use Commercially Reasonable Efforts (as that term is defined in the BMS Strategic Collaboration Agreement) to do so) &#91;***&#93; of the data read-out indicating that the Melanoma Clinical Success Criteria were achieved for the Melanoma Indication, and (c)&#160;will use Commercially Reasonable Efforts to perform or cause BMS to use Commercially Reasonable Efforts (as that term is defined in the BMS Strategic Collaboration Agreement) to perform all activities associated with submitting BLAs and seeking Regulatory Approval for the Melanoma Indication in the US.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1.5&#160;&#160;&#160;&#160;If Nektar terminates the BMS Collaboration Agreement as a result of an uncured material breach by BMS under Section 16.2 of the BMS Collaboration Agreement, and the Melanoma Trial is transitioned to Nektar pursuant to Section 16.6(b)(i) of the BMS Collaboration Agreement, then Nektar must use Commercially Reasonable Efforts to (a) complete the Melanoma Trial and (b) if the Melanoma Trial meets the Success Criteria, file a BLA with FDA.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1.6&#160;&#160;&#160;&#160;Following the achievement of Regulatory Approval of the Product in any country, Nektar shall use Commercially Reasonable Efforts to commercialize the Product in such country for the applicable Indication.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will have primary responsibility for conducting the HNC Clinical Trials globally. Subject to the terms hereof, SFJ will use Commercially Reasonable Efforts to conduct, or ensure that the applicable Approved CRO conducts, the HNC Clinical Trials in accordance with SFJ&#8217;s standard operating procedures (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ SOPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that will be provided to Nektar &#91;***&#93; following the selection of the Approved CRO for Nektar&#8217;s review and comment, as well as CRO SOPs, to the extent applicable, and SFJ will reasonably </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consider incorporating such comments.  Following the Effective Date, SFJ may amend any SFJ SOPs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to material amendments to SFJ SOPs that pertain to Clinical Trial Activities and&#47;or other obligations that are, or will be, performed by SFJ or any Permitted Third Party utilized by SFJ during the remainder of the Term or any time thereafter as set forth in this Agreement, SFJ will provide the JOC with a copy of each such amendment to permit the JOC Representatives to review and comment on such amendments and SFJ will reasonably consider incorporating such comments.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will conduct its portion of the Development Program and perform all other of its duties and responsibilities hereunder in accordance with the HNC Main Clinical Trial Protocol and any other approved Additional HNC Clinical Trial Protocols and in material compliance with all Applicable Laws.  Nektar will use Commercially Reasonable Efforts to oversee the Manufacture of the Product, and Nektar will materially comply, and Nektar will require that all Permitted Third Parties of Nektar materially comply, with all Applicable Laws with respect to the analysis, storage, handling, disposal and transfer of the Product.  SFJ will materially comply, and SFJ will require that all Permitted Third Parties of SFJ materially comply, with all Applicable Laws with respect to the storage, handling, disposal and transfer of all quantities of Product and Merck Product supplied by or on behalf of Nektar for use in the conduct of HNC Clinical Trials.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar SOPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms hereof, Nektar will, use Commercially Reasonable Efforts to conduct, or ensure that the applicable Approved CRO conducts, the Melanoma and Other Clinical Trials in accordance with Nektar&#8217;s standard operating procedures (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar SOPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Nektar will use Commercially Reasonable Efforts to conduct its Clinical Trial Activities on the HNC Clinical Trials in accordance with Nektar SOPs that will be provided to SFJ &#91;***&#93; following the Effective Date for SFJ&#8217;s review and comment.  Following the Effective Date, Nektar may amend any Nektar SOPs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to material amendments to Nektar SOPs that pertain to Clinical Trial Activities and&#47;or other obligations that are, or will be, performed by Nektar or any Permitted Third Party utilized by Nektar during the remainder of the Term or any time thereafter as set forth in this Agreement, Nektar will provide the JOC with a copy of each such amendment to permit the JOC Representatives to review and comment on such amendments and Nektar will reasonably consider incorporating such comments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sites and Clinical Investigators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Selection of Sites and Investigators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.1.1&#160;&#160;&#160;&#160;SFJ will select the study sites to conduct the HNC Clinical Trials and will inform the JOC in advance of SFJ&#8217;s choice of each study site&#59; the JOC will have the right to reject any such site(s) which the JOC will determine in its reasonable judgment are not appropriate.  The study sites for the HNC Clinical Trials will be located in one or more of the countries listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.1.2&#160;&#160;&#160;&#160;SFJ will enter, and will ensure that its Affiliates enter, and each Approved CRO will enter, into an agreement with each study site&#59; such an agreement will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;23</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">be substantially in the form agreed upon by the Parties &#91;***&#93; following approval by the JOC of the final Protocol (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (upon execution of such Clinical Trial Agreement, such study site will be deemed a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Site</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  If a study site requires any material changes to such form Clinical Trial Agreement, SFJ will inform the JOC and seek JOC approval of such change, and the JOC will not unreasonably withhold such approval.  For clarity, each Clinical Trial Agreement will be on commercially reasonable and customary terms, consistent with industry standards for similar agreements and sufficient to enable SFJ to comply with its obligations hereunder with respect to such HNC Clinical Trial, including, but not limited to, Section&#160;2.2.2, the terms pertaining to ownership of Intellectual Property and publications, and treatment of Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Obligations During the Clinical Trials Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2.1&#160;&#160;&#160;&#160;During the Development Term, SFJ will conduct meetings with the Clinical Investigators (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Investigator Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), of which the JOC will be provided with reasonable advance notice and in which Nektar will have the right (but not the obligation) to attend and participate.  Minutes of Clinical Investigator Meetings will be made available to the JOC upon request.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2.2&#160;&#160;&#160;&#160;SFJ will provide the JOC with copies of all communications relevant to the HNC Clinical Trials and provided to all Sites, and upon request of the JOC, provide the JOC with copies of any other communications between SFJ and any individual Sites and&#47;or any Affiliate or Approved CRO and any individual Sites.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2.3&#160;&#160;&#160;&#160;If SFJ terminates a Site, SFJ will inform the JOC with the reason for such termination and if reasonably practicable, such notice will be provided reasonably in advance of such termination.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2.4&#160;&#160;&#160;&#160;Nektar will be responsible for preparing and submitting any INDs and amendments thereto to Regulatory Authorities as required by Applicable Laws in the countries for which Sites have been selected, &#91;***&#93;.  Nektar will prepare the CMC Information and any updates to this information and submit it to the applicable Regulatory Authority as required by Applicable Laws.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transparency Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#91;***&#93;, SFJ will provide Nektar access to all records of SFJ related to any direct or indirect payments or other transfers of value made by or on behalf of SFJ (such as by a CRO or other vendor) to health care professionals, IDEC members, consultants or others in connection with the HNC Clinical Trials, which payments or other transfers of value, including all such details as are reasonably required &#91;***&#93; to determine whether any such payment requires the filing of a report with any Governmental Authority &#91;***&#93; pursuant to Applicable Law (such as the Sunshine Act in the United States and similar transparency laws in foreign countries). In the event that Nektar is or becomes aware that any such reports are required to be filed, Nektar shall provide prompt written notice to SFJ providing particulars as to the information to be reported and the time deadlines for the filing of reports.   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subjects and Informed Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subject Recruitment Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will comply with the subject recruitment plan for the HNC Clinical Trials, which will be established by SFJ and communicated to the JOC, for approval by the JOC not to be unreasonably withheld, within a reasonable period of time after the Effective Date not to &#91;***&#93; of the Effective Date (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subject Recruitment Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in recruiting subjects to participate in the HNC Clinical Trials.  For clarity, prior to engaging in any recruiting activities, SFJ will ensure that the applicable IRBs and&#47;or other ethics committees approve any related materials and activities as required by the JOC and all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Informed Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.2.1&#160;&#160;&#160;&#160;SFJ, with consultation from Nektar, will prepare the informed consent document(s) for use in the HNC Clinical Trials. SFJ will ensure that the informed consent of each subject participating in a HNC Clinical Trial be obtained in accordance with all Applicable Laws, including completion of the informed consent document.  Such informed consent document for a HNC Clinical Trial will be substantially in the form to be approved by the JOC &#91;***&#93; following approval by the JOC of the final Protocol for such HNC Clinical Trial (collectively,&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Informed Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (upon obtaining such Informed Consent, a prospective subject will be deemed a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  For clarity, the Informed Consent document that each Subject signs will expressly state that each Subject understands that Nektar is the Sponsor and SFJ is conducting the HNC Clinical Trials and will authorize disclosure of data and results related to the HNC Clinical Trials to Nektar and SFJ, for any purpose, subject to all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.2.2&#160;&#160;&#160;&#160;SFJ will ensure that the Informed Consent has been obtained by a Permitted Third Party from each Subject prior to administration of the Product and&#47;or Merck Product to such Subject in accordance with the HNC Clinical Trials Protocol.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inclusion and Exclusion Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will not waive, and SFJ will require that its Permitted Third Parties do not waive, any exclusion or inclusion criteria specified in the HNC Clinical Trials Protocol.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investigator&#8217;s Brochure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investigator&#8217;s Brochure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will maintain the Investigator&#8217;s Brochure for the Product.  SFJ will, promptly following receipt of written notice from Nektar of the need for an Investigator&#8217;s Brochure update, provide Nektar with all information regarding the HNC Clinical Trials that is necessary to enable Nektar to update the Investigator&#8217;s Brochure.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parties&#8217; Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Promptly following the Effective Date, Nektar will provide SFJ with the most recent version of the Investigator&#8217;s Brochure.  Nektar will also promptly provide SFJ with any updated versions of the Investigator&#8217;s Brochure.  SFJ will ensure that each Site and all applicable IRBs and other ethics committees receive a copy of, and promptly receive any updates to, the Investigator&#8217;s Brochure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;25</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Collection and Data Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CRF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar, with consultation from SFJ, will be responsible for preparing the form of CRF for the HNC Clinical Trials in accordance with the HNC Clinical Trials Protocol and Nektar&#8217;s CRF standards.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Management Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.2.1&#160;&#160;&#160;&#160;SFJ, with consultation from Nektar, will be responsible for preparing the data management plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Management Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the HNC Clinical Trials.  Each Party will use Commercially Reasonable Efforts to comply with the Data Management Plan to be agreed upon by the Parties &#91;***&#93; following approval by the JOC of the final Protocol.  For clarity, the Data Management Plan will be agreed upon by the Parties prior to recruitment of subjects for the HNC Clinical Trials.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.2.2&#160;&#160;&#160;&#160;With respect to any data collected in connection with the HNC Clinical Trials, SFJ will ensure that such data is held in one or more appropriate facilities with information security protections in accordance with all Applicable Laws including (a)&#160;unique accounts for all operators&#59; (b)&#160;cancellation of an account when an employee or other personnel terminates employment&#59; (c)&#160;deactivation of an account when an employee or other personnel ceases working on the Clinical Trials&#59; (d)&#160;required password changes at frequent intervals&#59; and (e)&#160;regular backups of electronic data.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.3.1&#160;&#160;&#160;&#160;Nektar, with consultation from SFJ, will use Commercially Reasonable Efforts to establish a Clinical Trials database for the data collected from each Site for the HNC Clinical Trials (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) &#91;***&#93; following approval by the JOC of the Final HNC Clinical Trial Protocol.  Nektar, with consultation from SFJ, will promptly update the Clinical Trials Database upon any final amendments to the Protocol, as necessary, and in accordance with Section&#160;3.5.3.3. SFJ will promptly update the Clinical Trials Database upon receiving data for the HNC Clinical Trials from any Site and any other applicable Permitted Third Party, and SFJ will ensure that the Sites and such other Permitted Third Parties promptly following collection thereof, provide data in connection with the HNC Clinical Trials to such Party.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.3.2&#160;&#160;&#160;&#160;SFJ will provide the JOC with electronic copies of such data requested by the JOC at JOC meetings and in accordance with Applicable Laws.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.3.3&#160;&#160;&#160;&#160;If, at any time during the Development Term, SFJ decides to change the format of the database for the HNC Clinical Trials, SFJ will so notify the JOC and the Parties will cooperate to ensure that the format that SFJ selects permits SFJ to incorporate the data from the HNC Clinical Trials into its relevant systems and is in compliance with all Applicable Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;26</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.3.4&#160;&#160;&#160;&#160;The Vendor responsible for the database will provide SAS datasets to the Parties in accordance with specifications as defined by Nektar &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.3.5&#160;&#160;&#160;&#160;SFJ will ensure that information included in the Clinical Trials Database is accurate and up-to-date.  Nektar will be responsible for registering, maintaining and updating any registries pertaining to the HNC Clinical Trials to the extent required by any Applicable Laws, including www.clinicaltrials.gov, www.clinicalstudyresults.org, and the PHRMA Website Synopsis.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Promptly following the Effective Date, SFJ will establish and maintain a Clinical Trials master file for each Clinical Trial in the format as agreed upon by the JOC (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding anything to the contrary herein, SFJ will not be permitted to delegate its rights and obligations pursuant to this Section&#160;3.5.4 to any Permitted Third Parties without the prior approval of the JOC, except SFJ may delegate its rights and obligations pursuant to this Section&#160;3.5.4 to any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Source Data Verification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will be responsible for source verification of data records.  At Nektar&#8217;s request, SFJ will provide Nektar with copies of any reports relating to source data verification and other types of HNC Clinical Trials audits.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Statistical Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar statisticians will work with SFJ programmers to perform any statistical analysis required in accordance with the statistical analysis plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Statistical Analysis Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the HNC Clinical Trials.  The Statistical Analysis Plan will initially be developed by Nektar and agreed upon by the Parties &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6.1&#160;&#160;&#160;&#160;SFJ will conduct quality oversight inspections and audits of the facilities and services of the Permitted Third Parties utilized by SFJ in accordance with its standard operating procedures and will provide Nektar with copies of such audit reports upon request.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6.2&#160;&#160;&#160;&#160;During the Development Term, Nektar will conduct quality oversight inspections and audits of the manufacturing facilities for the Product in accordance with its internal policies and Nektar will provide SFJ with copies of such audit reports, subject to SFJ&#8217;s compliance with confidentiality requirements imposed by Nektar&#8217;s contract manufacturers.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audits&#59; Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6.3.1&#160;&#160;&#160;&#160;Upon &#91;***&#93; prior written notice and during normal business hours, no more frequently than once per Calendar Year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Nektar, or an external auditor appointed by Nektar and reasonably acceptable to SFJ, may inspect and&#47;or audit all records created by SFJ and its Affiliates in the conduct of the HNC Clinical Trials for the purpose of confirming SFJ&#8217;s compliance with this Agreement and Applicable Laws in the conduct of the HNC Clinical Trials.&#160; SFJ agrees to make available employees of SFJ and its Affiliates as reasonably requested by Nektar to answer Nektar&#8217;s reasonable questions in connection with such inspection and&#47;or audit.&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;27</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6.3.2&#160;&#160;&#160;&#160;Notwithstanding the foregoing, if Nektar has a reasonable good faith belief that SFJ has materially failed to comply with this Agreement or with Applicable Laws in the conduct of the HNC Clinical Trials, Nektar shall have the right to conduct an audit and&#47;or inspection described in 3.6.3.1 upon &#91;***&#93; prior written notice and without regard to the Annual Limitation.&#160; </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6.3.3&#160;&#160;&#160;&#160;All expenses of any inspection or audit requested by Nektar pursuant to Section 3.6.3 (including the fees and expenses of any external auditor engaged by Nektar for such purpose) shall be borne by Nektar.&#160; All information obtained by Nektar as a result of such inspection or audit shall be Confidential Information subject to Article 9.&#160;Any external auditor appointed by Nektar pursuant to this Section 3.6.3 shall be subject to confidentiality obligations no less restrictive than those set forth in Article 9 with respect to such Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Monitoring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will monitor the HNC Clinical Trials, and share information with the JOC pertaining to monitoring the HNC Clinical Trials, in accordance with the monitoring plan for the Clinical Trials to be agreed upon by the Parties &#91;***&#93; following the Effective Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IRBs and Other Ethics Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8.1&#160;&#160;&#160;&#160;SFJ will be responsible for obtaining the approval of the IRBs and other ethics committees required prior to commencing, and during, the HNC Clinical Trials at every Site.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8.2&#160;&#160;&#160;&#160;SFJ will ensure that IRBs and such other relevant ethics committees have current registrations and accreditations as required by Applicable Law and will provide all ethics committees, including all IRBs, and Regulatory Authorities, with all necessary documentation prior to, and during the course of, the HNC Clinical Trials as required by Applicable Law.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8.3&#160;&#160;&#160;&#160;SFJ will be responsible for responding to all queries from the IRBs and other ethics committees&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (a)&#160;Nektar will make itself reasonably available to assist with any such queries and (b)&#160;if such query relates solely to the CMC Information, the Manufacturing Dossier, and&#47;or preclinical studies, Nektar will prepare the applicable response and provide SFJ with a copy thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IDMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9.1&#160;&#160;&#160;&#160;Nektar, in consultation with SFJ, will establish an IDMC for the Clinical Trials, which will be governed by a charter substantially in the form to be agreed upon by the Parties &#91;***&#93; of the Effective Date (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IDMC Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  For clarity, the IDMC Charter will specify the number of members of the IDMC, which shall be appointed by Nektar, the qualifications of such members, the roles and responsibilities of IDMC members, the role and responsibilities of the IDMC chair, who shall be appointed from among the IDMC members, independent statistical center (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ISC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the study team, the sponsor executive committee, rules of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;28</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conduct of and procedures for IDMC meetings including open sessions and closed sessions, communication of IDMC recommendations, and other subjects mutually agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9.2&#160;&#160;&#160;&#160;Nektar, via the ISC,  will ensure that the IDMC is provided with all required information and data in a timely manner as specified in the IDMC Charter, and SFJ will reasonably cooperate with Nektar in such regard.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Health and Safety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.10.1&#160;&#160;&#160;&#160;In conducting the Clinical Trials, each Party will comply with all Applicable Laws relating to environmental, health and&#47;or safety matters and will be solely responsible for establishing material and specimen handling guidelines and for ensuring use of controls, including appropriate personal protective equipment, that minimize potential worker exposure, obtaining the material safety data sheets and providing the appropriate training for workers who will be potentially exposed to the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.10.2&#160;&#160;&#160;&#160;Each Party will promptly notify the JOC, in writing, of any worker claims of suspected occupational illnesses related to working with the Product, regardless of whether such claims are received during the Development Term or any time thereafter.  After termination of this Agreement for whatever reasons, or expiration of this Agreement, each Party will promptly notify the other Party of any worker claims of suspected occupational illnesses related to working with the Product during the Development Term, of which it has Knowledge.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Completion of the Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11.1&#160;&#160;&#160;&#160;SFJ will use Commercially Reasonable Efforts to keep the Sites participating in the HNC Clinical Trials, operational, including continuing to dose Subjects with the Product and&#47;or Merck Product in accordance with the Protocol, and conducting any follow-up work required, until the Completion Date for such HNC Clinical Trial.  As a HNC Clinical Trial is completed or otherwise terminated at each Site, SFJ will close out such HNC Clinical Trial as specified in the Protocol, including performing all Subject follow-up and providing Nektar with all HNC Clinical Trial data not provided as of such date.  For clarity, copies of documents, including any CRFs and the Clinical Trials Master File will be transferred to Nektar upon the completion of the HNC Clinical Trials and at Nektar&#8217;s request, or at Nektar&#8217;s option, destroyed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such destruction is in compliance with ICH guidelines).  Notwithstanding the foregoing, SFJ will not provide Nektar with any Personally Identifiable Information.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11.2&#160;&#160;&#160;&#160;Upon the Completion Date of a HNC Clinical Trial, SFJ will return to the location specified by Nektar at such time, or, at Nektar option, destroy, any unused Product and&#47;or Merck Product from such HNC Clinical Trial (SFJ&#8217;s expenses in doing so will be included in Development Costs), and will comply with all Applicable Laws in so returning or destroying such Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11.3&#160;&#160;&#160;&#160;The CSR, and any interim CSRs, for each HNC Clinical Trial will be prepared by Nektar, with support from SFJ, in compliance with all Applicable Laws, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;29</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ICH E3 guidelines.  The final, signed CSR for each HNC Clinical Trial (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final HNC Clinical Trial CSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be provided to SFJ promptly following the Completion Date of the HNC Clinical Trials and any interim CSRs will be provided to SFJ promptly after it is completed.  In the event that there are any additional safety or efficacy data pertaining to a HNC Clinical Trial that come into the possession of Nektar after it has provided SFJ with the Final HNC Clinical Trial CSR for such HNC Clinical Trial, Nektar will prepare and promptly provide SFJ with a supplement to such CSR.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.12.1&#160;&#160;&#160;&#160;Timely performance of the Clinical Trials and receipt of Regulatory Approvals are important to the success of this Agreement.  Each Party will use Commercially Reasonable Efforts to complete the Melanoma and HNC Clinical Trials, as appropriate, according to the Timeline and, if the Melanoma and&#47;or HNC Clinical Trials are successful, Nektar shall comply with the provisions of Sections&#160;3.1.1.3, 3.1.1.4 and 3.1.1.5 hereof. In the event that either Party fails to complete its responsibilities according to the Timeline, following discussion by the JSC that such Party failed to use Commercially Reasonable Efforts, the other Party may assume the roles and responsibilities of such Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the event of such failure by SFJ and the assumption by Nektar of any of SFJ&#8217;s roles or responsibilities, SFJ will remain obligated to pay Development Costs under Section&#160;4.2, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in the event of such failure by Nektar and the assumption by SFJ of any of Nektar&#8217;s roles or responsibilities, SFJ&#8217;s costs for the assumption of Nektar&#8217;s roles and responsibilities shall be deemed to be Development Costs. In the event that Nektar fails to use Commercially Reasonable Efforts to so obtain Regulatory Approval for the Product for the Indications, including the obligation to file a BLA for the Product for the Indications with the FDA by the dates set forth in Article&#160;3, and this failure is not cured &#91;***&#93; after receipt of written notice from SFJ requesting such cure, SFJ may terminate this Agreement pursuant to Section&#160;13.2.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge that regulatory matters with respect to the Product will reasonably require coordination with regulatory matters with respect to the Product, and SFJ agrees to cooperate in good faith with Nektar and Merck as reasonably necessary for and in relation to each of Nektar and SFJ, on the one hand, and Merck, on the other hand, to obtain and maintain regulatory approvals (including Regulatory Approvals) with respect to the Product in the case of Nektar and SFJ and with respect to the Merck Product in the case of Merck.  Prior to submitting any written or electronic communication to a Regulatory Authority in a particular country with respect to Merck Product that would reasonably be expected to require a change to the Regulatory Authorityapproved full prescribing information for the Product for such country, SFJ shall cooperate with Nektar in Nektar&#8217;s consultation with Merck.  Nektar shall keep SFJ reasonably informed of its efforts to obtain and maintain Regulatory Approvals and any Other Indication Regulatory Approvals and developments with respect thereto, including Nektar&#8217;s expected timing with respect to submission and receipt of any and all Regulatory Approvals and Other Indication Regulatory Approvals.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacovigilance and Safety Information Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;30</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.13.1&#160;&#160;&#160;&#160;The safety reporting units from each of the Parties shall meet and shall &#91;***&#93; of the Effective Date agree upon a written agreement for exchanging adverse event and other safety information relating to the Product (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  SFJ agrees to provide Nektar with a draft of the Pharmacovigilance Agreement &#91;***&#93; of the Effective Date.  The Pharmacovigilance Agreement will ensure that adverse event and other safety information are exchanged upon terms that will permit (a)&#160;Nektar to comply with Section&#160;10.8 of the BMS Strategic Collaboration Agreement and the terms of the BMS Pharmacovigilance Agreement, and (b)&#160;each Party to comply with Applicable Laws and requirements of Regulatory Authorities. In particular the Pharmacovigilance will include&#58; (i)&#160;Nektar&#8217;s responsibility for establishing and maintaining the Clinical Trials Database pursuant to Section&#160;3.5.3 of this Agreement, and (ii)&#160;Nektar&#8217;s responsibility for establishing and maintaining the Global Drug Safety Database (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARGUS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and reconciling information between ARGUS and the Clinical Trials Database</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.13.2&#160;&#160;&#160;&#160;SFJ agrees not to enter into any clinical activity implicating pharmacovigilance obligations for the Product prior to execution of the Pharmacovigilance Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Supply of the Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14.1.1&#160;&#160;&#160;&#160;Nektar will be the GMP Manufacturer of the Product for the Clinical Trials, either directly or through a CMO.  In particular, with respect to the Clinical Trials, Nektar will maintain in force a clinical supply agreement with a CMO that has sufficient capacity to manufacture and supply GMP-compliant Product for the HNC Clinical Trials in a timely manner in accordance with a clinical supply schedule approved by the JOC (as amended by the JOC from time to time, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Supply Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14.1.2&#160;&#160;&#160;&#160;During the Development Term, Nektar will supply, as determined by the JOC, or cause to be supplied, as determined by the JOC, to SFJ GMP-compliant Product and Merck Product manufactured in compliance with the then-current CMC Information included in the IND submitted to the applicable Regulatory Authority for the HNC Clinical Trials, in accordance with the Clinical Supply Schedule&#160;as set forth in a clinical supply agreement to be entered into between the Parties &#91;***&#93; after the Effective Date.  The costs for the supply of the Product for the HNC Clinical Trials and the costs for the supply of the Merck Product for the HNC Clinical Trials will be borne by Nektar. SFJ will provide the JOC at each JOC meeting with quarterly reports regarding inventory of the Product and Merck Product and the reasonably anticipated needs for the Product and Merck Product to ensure that Nektar can supply the Product and Merck Product in accordance with the Clinical Supply Schedule.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Use of the Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14.2.1&#160;&#160;&#160;&#160;SFJ will (a)&#160;in conducting the HNC Clinical Trials, only use Product and Merck Product supplied by Nektar or such Third Parties designated by Nektar&#59; (b)&#160;only use the Product and Merck Product supplied by Nektar or Third Parties designated by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nektar, and require that its Permitted Third Parties that receive any of the Product and Merck Product supplied by Nektar or Third Parties designated by Nektar only use such Product and Merck Product, for the sole purpose of conducting the HNC Clinical Trials in accordance with the respective HNC Clinical Trials Protocols&#59; and (c)&#160;ensure subject dosing compliance per the respective HNC Clinical Trials Protocols for the HNC Clinical Trials.  Dosage and Administration Instructions will be provided to SFJ by Nektar sufficiently in advance of the HNC Clinical Trials&#8217; commencement.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14.2.2&#160;&#160;&#160;&#160;SFJ, will be responsible for ensuring that the Product and Merck Product is administered solely to the Subjects in HNC Clinical Trials conducted by SFJ in accordance with the respective Protocols.  For each dose administered to a Subject in a HNC Clinical Trial conducted by SFJ, SFJ will implement procedures and ensure that records are maintained specifying the date and time that such dose of the Product and&#47;or Merck Product is administered, the amount of the Product and&#47;or Merck Product administered to such Subject, the lot number of the Product and&#47;or Merck Product from which such dosage came, and the number of the Subject to which such dosage was administered.  SFJ shall provide copies of such records to Nektar upon Nektar&#8217;s reasonable request.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Complaints Related to the Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Development Term, SFJ will promptly forward to Nektar any complaints that it receives related to the Product and&#47;or Merck Product.  SFJ will respond to any complaints of which SFJ becomes aware relating to the Product and&#47;or Merck Product provided that Nektar will provide reasonable cooperation in connection therewith.  Notwithstanding the foregoing, if a complaint pertains to the manufacturing, appearance or general physical characteristics of the Product and&#47;or Merck Product or other processes at the manufacturing facility, Nektar will be solely responsible for responding to such complaint.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recall of the Product in Connection with Study Prior to Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Product and&#47;or Merck Product is recalled for safety reasons or GMP noncompliance prior to Regulatory Approval, SFJ will be responsible for the operational execution of such recall.  Nektar will cooperate with SFJ in connection with any such recall.  The costs for such any such recall will be at Nektar&#8217;s expense and not be a Development Cost, unless such recall and&#47;or costs were based on the material breach of this Agreement, intentional misconduct, or gross negligence of SFJ or any of its Affiliates or Permitted Third Parties, in which case, SFJ will bear the expense of any such recall and such expense will not be a Development Cost.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ and its Affiliates and Nektar and its Affiliates will comply, and each Party will use Commercially Reasonable Efforts to ensure that all Permitted Third Parties utilized by such Party comply, with all Applicable Laws with respect to the storage, handling, disposal and transfer of the Product and Merck Product, and each Party assumes sole responsibility for the violation of such Applicable Laws by such Party or any of its Affiliates or its Permitted Third Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.18.1&#160;&#160;&#160;&#160;&#91;***&#93;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.18.2&#160;&#160;&#160;&#160;Nektar shall (a)&#160;promptly notify SFJ of achieving the Clinical Trial Success Criteria, and (b)&#160;promptly notify SFJ of achieving Regulatory Approval in the Indications and the first Other Indication.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusivity Commitment of SFJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the applicable Exclusive Period, SFJ shall not, and shall cause its Affiliates not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.19.1&#160;&#160;&#160;&#160;any Competing Product (other than Product) alone or in combination (whether fixed dose or co-packaged) with one&#160;(1) or more other active ingredients&#59; or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.19.2&#160;&#160;&#160;&#160;any combination (whether fixed dose or co-packaged) with one&#160;(1) or more other active ingredients of the Product and a Competing Product. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 4</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEVELOPMENT COSTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will be obligated to pay up to One Hundred Fifty Million U.S. Dollars ($150,000,000.00) of Development Costs (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in accordance with Section&#160;4.2.  Any Development Costs in excess of the Maximum Development Costs (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excess Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be borne by Nektar unless otherwise agreed in writing by SFJ and Nektar, and provided that Nektar may request that SFJ pay some or all of the Excess Development Costs and SFJ shall have the sole discretion to decide whether or not to pay any of such Excess Development Costs, and provided further that the failure of SFJ to agree to pay any Excess Development Costs shall not excuse Nektar from its obligation to pay the Excess Development Costs.  Any failure by Nektar to bear any necessary Excess Development Costs that SFJ did not agree to pay shall be deemed to be a material breach of this Agreement by Nektar.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Funding Schedule&#59; Quarterly Reconciliation of Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.1&#160;&#160;&#160;&#160;SFJ will pay up to a total of One Hundred Fifty Million U.S. Dollars ($150,000,000.00) of Development Costs as set forth as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.1.1&#160;&#160;&#160;&#160;SFJ shall promptly pay all Approved Third Party Vendor Costs incurred by SFJ in connection with the HNC Clinical Trials during the Development Term.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.1.2&#160;&#160;&#160;&#160;Development Costs will include the Quarterly Labor Fees.  Payment by SFJ to Nektar of the Quarterly Labor Fees shall be made on a quarterly basis, with each payment made at least fifteen days prior to the end of the Calendar Quarter to which it relates.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.1.3&#160;&#160;&#160;&#160;If (a)&#160;the Development Costs paid by SFJ after paying all required payments under the preceding provisions of this Section&#160;4.2.1 shall be less than the Maximum Development Costs and (b)&#160;the HNC Clinical Trial has not terminated prior to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;33</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">completion due to the occurrence of HNC Clinical Trial Futility or a Safety Concern, then any remaining balance (such amount, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Leftover Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be paid to Nektar by SFJ &#91;***&#93; of the last payment under Section&#160;4.2.1.1 and Section&#160;4.2.1.2, to be used by Nektar for commercialization activities, and such amount paid by SFJ shall be deemed to be included in Development Costs, it being understood that the provisions of this Section 4.2.1.3 shall not apply as a result of or during any period in which SFJ&#8217;s obligations to make payments to Nektar or pay or incur other Development Costs are suspended pursuant to Section&#160;2.3.1. If the HNC Clinical Trial is completed, but the HNC Clinical Trial Success Criteria is not achieved, SFJ shall not have the option of paying the Leftover Funding, if any, to Nektar.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.2&#160;&#160;&#160;&#160;Notwithstanding anything else contained herein to the contrary, in no event shall SFJ be required to pay or incur Development Costs in excess of $150&#160;million.  If the Development Costs exceed $150&#160;million, Nektar shall pay or incur all such excess Development Costs including SFJ&#8217;s ongoing internal costs and continuing to provide the Nektar Services at the expense of Nektar unless otherwise agreed to in writing by SFJ.  Notwithstanding anything else contained herein to the contrary, if the HNC Clinical Trial is terminated prior to completion due to the occurrence of (a)&#160;HNC Clinical Trial Futility or (b)&#160;a Safety Concern, then SFJ shall not pay the Leftover Funding to Nektar nor shall it pay any other Development Costs except for those incurred in the orderly close-out of the HNC Clinical Trials.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.3&#160;&#160;&#160;&#160;Development Costs initially shall be borne by SFJ as provided herein.  Each Party shall comply with the Development Cost Reconciliation Procedures.  With respect to each HNC Clinical Trial, each Party will provide the other Party, &#91;***&#93; of the end of each Calendar Quarter, the estimated Development Costs incurred in accordance with GAAP during such Calendar Quarter by such Party.  A final report of actual Development Costs incurred in accordance with GAAP during such Calendar Quarter by such Party will be provided &#91;***&#93; of the end of each Calendar Quarter.  Such report shall specify in reasonable detail all expenses included in such Development Costs during such Calendar Quarter.  If reasonably requested by the other Party, each Party shall make every reasonable attempt to accommodate the request to provide copies of any applicable invoices within the Development Costs that individually exceed one million dollars ($1,000,000.00).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PreCommercialization Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Nektar will be solely responsible at its own cost (subject to Sections&#160;4.2) for performing those activities reasonably necessary to prepare for Commercial Launch of the Product (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Approval Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Such Pre-Approval Commercialization Activities may include at Nektar&#8217;s sole discretion creating educational or marketing materials, establishing distribution channels and designing packaging and labeling, in each case as reasonably necessary to Commercialize the Product.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 5</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GOVERNANCE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;34</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within sixty&#160;(60) days after the Effective Date, the Parties will establish a joint steering committee to oversee and manage the collaboration (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Party initially will appoint three&#160;(3) individuals to serve as representatives to the JSC (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with each JSC Representative having knowledge and expertise regarding developing products similar to the Product and sufficient decision-making authority within the applicable Party to make decisions on behalf of such Party within the scope of the JSC&#8217;s decisionmaking authority and, if any such individual is not an employee of the appointing Party, such individual shall execute a confidentiality agreement in form and substance acceptable to the other Party (and, for the avoidance of doubt, the appointing Party shall remain responsible to the other Party for any noncompliance by such individual with such confidentiality obligations).  Each Party may replace its JSC Representatives at any time upon written notice to the other Party, which notice may be provided by email from one Party&#8217;s Alliance Manager to the other Party&#8217;s Alliance Manager.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC chairperson (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be designated from the Parties&#8217; JSC Representatives and shall serve for a term of one&#160;(1) year.  SFJ shall appoint the first JSC Chairperson and subsequent appointments will rotate on an annual basis between Nektar and SFJ.  The JSC Chairperson will be responsible for drafting and circulating the draft agenda and ensuring minutes are prepared.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From the Effective Date, through the Development Term the JSC will meet at least once every two months (and for clarity, such meetings are intended to be conducted via teleconference) unless the Parties mutually agree otherwise.  Either Party may call a special meeting of the JSC (by videoconference or teleconference) during the Term by providing at least five&#160;(5) Business Days prior written notice to the other Party, which notice shall include a reasonably detailed description of the matter, in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC may invite individuals who are not JSC Representatives to participate in JSC meetings&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (a)&#160;all JSC Representatives of both Parties consent to such non-member&#8217;s participation&#59; and (b)&#160;such non-member has executed a confidentiality agreement in form and substance acceptable to the non-inviting Party (and, for the avoidance of doubt, the inviting Party shall remain responsible to the non-inviting Party for any noncompliance by such individual with such confidentiality obligations).  For clarity, such non-members will have no voting rights at the JSC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall appoint an individual to act as an alliance manager for such Party (each, an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by providing the name and contact information for the Alliance Manager to the JSC.  Each Party may change its Alliance Manager from time to time in its sole discretion upon written notice to the JSC.  The Alliance Managers shall be the primary point of contact for the Parties regarding the activities contemplated by the Agreement, and the Parties shall use reasonable efforts to ensure that any requests for information and data made outside of the JSC are made through the Alliance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;35</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Managers.  The Alliance Managers shall attend all meetings of the JSC.  For clarity, the Alliance Managers may also be members of the JSC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will bear its own expenses relating to the meetings and activities of the JSC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JSC Responsibilities and Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibilities (Review and Discuss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC&#8217;s responsibilities will include reviewing and discussing (but not approving) the following&#58;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.1&#160;&#160;&#160;&#160;Oversight of the Parties&#8217; collaboration including (a)&#160;overall strategic direction, (b)&#160;developing strategies to maximize the value of the Product for the Indication, and (c)&#160;reviewing and commenting on the Development Program and Regulatory Approval strategies&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.2&#160;&#160;&#160;&#160;material changes in the Development Program, including changes required by, or made to respond to comments from, a Regulatory Authority, that do not require approval pursuant to Section&#160;5.2.2&#59; </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.3&#160;&#160;&#160;&#160;the activities related to, the progress of, and the costs incurred in connection with, the Development Program&#59; </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.4&#160;&#160;&#160;&#160;summaries of the Research Results&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.5&#160;&#160;&#160;&#160;forecast of the estimated timeline (on at least a quarterly basis) for its development activities with respect to the Product for any of the Indications&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.6&#160;&#160;&#160;&#160;the addition to the Development Program of any new HNC Clinical Trials testing the efficacy of the Product for the HNC Indication&#59; and</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.1.7&#160;&#160;&#160;&#160;any other matters the Parties mutually agree in writing will be, or are expressly provided in this Agreement to be, reviewed and discussed by the JSC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibilities (Review and Approve)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC&#8217;s responsibilities will include reviewing and approving (in each case, such approval not to be unreasonably withheld, conditioned or delayed) the following&#58;</font></div><div style="margin-bottom:12pt;text-indent:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.2.1&#160;&#160;&#160;&#160;any change in the Development Program that is not required by, or made to respond to comments from, a Regulatory Authority, that would materially decrease the likelihood of obtaining or materially increase the timeline for obtaining a Regulatory Approval for the HNC Indication or the Melanoma Indication in the US, and that is&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a change to the Indication,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;36</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a change to any primary or secondary endpoint or the ordering of secondary endpoints of the HNC Main Clinical Trial as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or any other HNC Clinical Trial,</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a material change to the Statistical Analysis Plan or material reduction of the statistical powering of a HNC Clinical Trial as set forth in the Protocol for such HNC Clinical Trial,</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the substitution or addition of any arms in any HNC Clinical Trial,</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;any material change to the inclusion criteria or exclusion criteria with respect to a HNC Clinical Trial as set forth in the applicable Protocol, or</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;any change from the CMO that is then engaged, or any material changes to the manufacturing process for either (i)&#160;the drug substance utilized in the Product or (ii)&#160;the final Product that, in either case, will be used in the HNC Clinical Trials&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.2.2&#160;&#160;&#160;&#160;commercially reasonable budgets of CRO and Third Party Vendor costs (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Third Party Vendor Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.2.3&#160;&#160;&#160;&#160;any other matters the Parties mutually agree in writing will be, or are expressly provided in this Agreement to be, reviewed and approved by the JSC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary set forth in this Agreement, the JSC will have no authority to (x)&#160;amend, modify or waive compliance with this Agreement, or (y)&#160;resolve any dispute concerning the validity, interpretation, construction of, or breach of this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall retain sole decision-making authority over all matters within the scope of the JSC&#8217;s oversight other than the matters described in the foregoing Section&#160;5.2.2.  The unanimous approval of the JSC will be required with respect to all matters within its decision-making authority as described in the foregoing Section&#160;5.2.2.  The JSC Representatives of each Party will collectively have one&#160;(1) vote.  The presence of at least one of each Party&#8217;s JSC representatives constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present.  If the JSC cannot reach consensus on an issue for which it has decision-making authority, then Nektar shall have the final decision-making authority, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if SFJ disagrees with any such Nektar decision with regard to any of the matters set forth in Section&#160;5.2.2, then, at SFJ&#8217;s request, the matter shall be escalated to the Executive Officers for attempted resolution by good faith negotiations during a period of &#91;***&#93;.  If, notwithstanding such good faith negotiations, the Executive Officers fail to resolve such matter prior to expiration of such &#91;***&#93; period, and SFJ in good faith continues to disagree with such Nektar decision and such decision materially delays or reduces the probability of achieving Regulatory Approval of any of the Indications, then SFJ shall have the right to terminate this Agreement as provided in Section&#160;13.2.8 upon written notice to Nektar delivered &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;37</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reports to be Provided to the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as may otherwise be agreed by the Parties, at each JSC meeting Nektar with regard to the Melanoma Clinical Trial, the Other Indications and CMC, and SFJ with regard to the HNC Clinical Trials, will provide an update on the progress of their respective responsibilities and Nektar with regard to the U.S. will report on progress toward obtaining Regulatory Approvals in the Indications.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Operations Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within sixty&#160;(60) days of the Effective Date, the Parties will establish a joint operations committee to oversee the conduct of the Clinical Trials (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JOC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Party initially will appoint four&#160;(4) individuals to serve as representatives to the JOC (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JOC Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with each JOC Representative having knowledge and expertise regarding developing products similar to the Product and sufficient seniority within the applicable Party to make decisions within the scope of the JOC&#8217;s decision-making authority.  Each Party may replace its JOC Representatives at any time upon written notice to the other Party, which notice may be provided by email from one Party&#8217;s Alliance Manager to the other Party&#8217;s Alliance Manager.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JOC chairperson (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JOC Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be designated from SFJ&#8217;s JOC Representatives and shall serve throughout the Term.  The JOC Chairperson will be responsible for drafting and circulating the draft agenda and ensuring minutes are prepared.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;From the Effective Date through the Development Term, the JOC will meet at least once every month (and for clarity, such meetings are intended to be conducted via teleconference) unless the Parties mutually agree otherwise.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Either Party may call a special meeting of the JOC (by videoconference or teleconference) during the Development Term by at least five&#160;(5) Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The JOC may invite individuals who are not JOC Representatives to participate in JOC meetings&#59; provided that (a)&#160;the JOC Representatives of both Parties consent to such non-member&#8217;s participation&#59; and (b)&#160;such non-member is subject to confidentiality obligations consistent with those described in Article&#160;10 of this Agreement.  For clarity, such non-members will have no voting rights at the JOC.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For clarity, each Party will bear its own expenses relating to the meetings and activities of the JOC and such costs will not be Development Costs hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;38</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices and Reports to be Provided to the JOC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Unusual or Unforeseen Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will promptly notify the JOC of any unforeseen or unusual events that occur in connection with the HNC Clinical Trials that may affect the quality, integrity, or timeliness of the HNC Clinical Trials.  Nektar will promptly notify the JOC of any unforeseen or unusual events that occur in connection with the Melanoma Clinical Trial that may affect the quality, integrity, or timeliness of the Melanoma Clinical Trial.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Urgent Safety Measures or Serious Breaches</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If SFJ becomes aware of (a)&#160;any urgent safety measures taken by a Clinical Investigator to protect Subjects against immediate hazard or (b)&#160;any serious breaches of the Protocol or any Applicable Laws (including ICH GCP guidelines), SFJ will immediately inform the JOC.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;SFJ will promptly notify the JOC within twenty-four&#160;(24) hours of any inspection by any Governmental Authority, including any Regulatory Authority, in connection with the HNC Clinical Trials.  SFJ will promptly forward to the JOC copies of any inspection findings that a Site receives from any Regulatory Authority.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Nektar will promptly notify the JOC within twenty-four&#160;(24) hours of any inspection by any Governmental Authority, including any Regulatory Authority, (i)&#160;at any CMC facility associated with any of the Clinical Trials or (ii)&#160;in connection with the Melanoma Clinical Trial.  Nektar will promptly forward to the JOC copies of any inspection findings that a CMC facility or a study site for the Melanoma Clinical Trial receives from any Regulatory Authority.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Government Investigations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will promptly notify the JOC upon learning of any investigations by any Governmental Authority in connection with the HNC Clinical Trials.  Nektar will promptly notify the JOC upon learning of any investigations by any Governmental Authority in connection with the Melanoma Clinical Trial.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notification of Error</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party learns of an error or omission in the conduct of the HNC Clinical Trials or Melanoma Clinical Trial that could call into question the validity, or otherwise compromise the quality and&#47;or integrity, of part or all of the HNC Clinical Trials or Melanoma Clinical Trial, or activities conducted in connection therewith, such Party will inform the JOC in writing within twenty-four&#160;(24) hours of either Party learning of such error and&#47;or omission.  In the event that such error and&#47;or omission involves any of the HNC Clinical Trials, the members of the JOC will discuss in good faith a remediation plan to address such error within thirty&#160;(30) days of such written notification.  Such remediation plan will not be effective unless and until approved by the JOC (such approval not to be unreasonably withheld or delayed).  If the JOC approves such remediation plan, the JOC will provide each Party with written notice thereof, specifying the dates on which, and the detail with which the Party responsible for such Clinical Trial Activity will be required to update the JOC of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;39</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">its progress with respect thereto.  If the JOC is not able to approve such remediation plan, the matter will be decided by the JSC pursuant to the procedure described in Section&#160;5.2.4.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to each of the foregoing Sections&#160;5.4.4.1 through 5.4.4.5, the Party responsible for notifying the JOC will notify the Person to whom notice is required to comply with all Applicable Laws.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Progress Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as may otherwise be agreed to by the Parties, at each JOC meeting (a)&#160;SFJ will provide an update on the progress and cost of the HNC Clinical Trials and Regulatory Approval as measured against the Timeline and (b)&#160;Nektar will provide an update on the progress and cost of the Melanoma Clinical Trial and Regulatory Approval as measured against the Timeline.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IP Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to the progress report to be provided by Nektar described in Section&#160;5.4.4.7, at each JOC meeting Nektar shall provide on request an update on (a)&#160;any developments relating to or affecting the Nektar Intellectual Property (including, without limitation, any known Third Party Infringements), (b)&#160;any developments regarding Third Party Intellectual Property and (c)&#160;whether Nektar has licensed or has determined that it will be necessary to license any Intellectual Property in connection with the development, manufacture, use, sale or import of the Product.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Post-Development Term Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following completion of the Development Term and through the end of the Term, any and all notices required pursuant to this Section&#160;5.4 will be provided to the JSC instead of the JOC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibilities and Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JOC&#8217;s responsibilities will include&#58; (a)&#160;approving the initial HNC Clinical Trial Protocol (b)&#160;approving any changes to any HNC Clinical Trial Protocol that requires a submission to a Regulatory Authority, an IRB or other ethics committees&#59; (c)&#160;discussing the activities in connection with, the progress of, and the costs incurred in connection with, the HNC Clinical Trials, including updates from any Clinical Investigator Meetings&#59; (d)&#160;reviewing and discussing any notices that it receives pursuant to the foregoing Section&#160;5.4.4&#59; (e)&#160;discussing and reviewing the Research Results&#59; (f)&#160;reviewing and discussing on at least a quarterly basis the forecast Development Costs and Timeline, and reviewing and approving budgets for Development Costs prepared by the JFC&#59; (g)&#160;reviewing and discussing (as necessary) proof of submission of any safety reports to the Regulatory Authorities, Clinical Investigators, IRBs and any other ethics committees&#59; (h)&#160;reviewing certain data to be provided by each Party at each JOC meeting as requested by the other Party and in accordance with all Applicable Laws&#59; (i)&#160;reviewing performance and progress of the HNC Clinical Trials and Regulatory Approval process&#59; and (j)&#160;any other matters the Parties mutually agree will be, or are expressly provided in this Agreement to be, within the responsibilities of the JOC.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The unanimous approval of the JOC will be required with respect to all matters within its decision-making authority as described in the foregoing Section&#160;5.4.5.1.  The JOC Representatives of each Party will collectively have one&#160;(1) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;40</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vote.  The presence of at least one of each Party&#8217;s JOC representatives constitutes a quorum for the conduct of business at any JOC meeting, and no vote of the JOC may be taken without a quorum present.  If the JOC cannot reach consensus on an issue for which it has decision-making authority, then such matter will be escalated to the JSC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appointment of Joint Project Team</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) days of the establishment of the JOC, the JOC will establish a joint project team (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JPT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be responsible for the day-to-day execution of the HNC Clinical trials.  The responsibilities, leadership, decision-making authority and meeting schedule for the JPT will be specified by the JOC when the JPT is established. Each Party initially will appoint four (4) employees with knowledge and experience in operational matters relating to the conduct of multi-national clinical studies to serve as representatives to the JPT.  Each Party may replace its JPT Representatives at any time upon written notice to the other Party, which notice may be provided by email from one Party&#8217;s Alliance Manager to the other Party&#8217;s Alliance Manager. For clarity, each Party shall bear its own expenses relating to the meetings of the JPT and such costs will not be deemed Development Costs hereunder.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Finance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within five&#160;(5) days of the Effective Date, the Parties will establish a joint finance committee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to manage the financial interactions of the Parties under this Agreement, including preparation and review of budgets, monitoring performance of HNC Clinical Trials vs budgets, reconciliation of costs incurred on a Calendar Quarter basis, and to act as the primary point of contact between the Parties with respect to all financial matters arising under this Agreement.  Each Party initially will appoint one&#160;(1) individual with knowledge and experience in financial matters relating to the conduct of multi-national clinical studies to serve as representatives to the JFC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JFC Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  On reasonable advance notice to the other Party&#8217;s JFC Representative and Alliance Manager (which notice may be provided by email), each JFC Representative may appoint a designee to attend any JFC meeting that the JFC Representative is unable to attend.  Each Party may replace its JFC Representatives at any time upon written notice to the other Party, which notice may be provided by email from one Party&#8217;s Alliance Manager to the other Party&#8217;s Alliance Manager.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JFC chairperson (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">JFC Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be Nektar&#8217;s JFC Representative and shall serve throughout the Term. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JFC shall meet at least once per Calendar Quarter unless otherwise mutually agreed by the Parties, at dates and times to be mutually agreed.   Either Party may request a special meeting of the JFC on prior written notice to the other Party, which special meeting will be held within a reasonable time of the request, at a date and time to be mutually agreed.  The JFC may invite individuals who are not JFC Representatives to participate in JFC meetings&#59; provided that (a)&#160;the JFC Representatives of both Parties consent to such non-member&#8217;s participation&#59; and (b)&#160;such non-member is subject to confidentiality obligations consistent with those set forth in Article&#160;10 of this Agreement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;41</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attendance at Other Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JFC Representatives of both Parties shall have the right to attend any meetings of the JSC, JOC or JPT, on reasonable advance notice to the other Party&#8217;s Alliance Manager, which notice may be provided by email from one Party&#8217;s Alliance Manager to the other Party&#8217;s Alliance Manager.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For clarity, each Party shall bear its own expenses relating to the meetings of the JFC and such costs will not be deemed Development Costs hereunder. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibilities of the JFC (Review and Discuss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The JFC&#8217;s responsibilities will include the following&#58;  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.1&#160;&#160;&#160;&#160;development of procedures for&#58; the maintenance of records by SFJ of Development Costs incurred by it&#59; Calendar Quarterly information sharing&#59; reporting of actual financial results&#59; Calendar Quarterly reconciliation&#59; reasonable cost forecasting&#59; other finance and accounting matters related to Development Costs for HNC Clinical Trials&#59;  and such other procedures as are necessary or desirable to enable each Party to achieve and maintain finance and accounting compliance with Applicable Law (collectively, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Cost Reconciliation Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for approval by the JOC&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.2&#160;&#160;&#160;&#160;preparation of initial Development Costs budgets, of which the JFC Representative designated by SFJ shall prepare the initial draft that the full JFC will then review, discuss and revise (including to include any additional information as the JFC may agree), for all initial HNC Clinical Trials anticipated to commence during Calendar Year 2021, on a Calendar Year basis, promptly following the establishment of the JFC by the JOC, for approval by the JOC&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.3&#160;&#160;&#160;&#160;by October&#160;15, 2021 and by October 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of each Calendar Year thereafter while HNC Clinical Trials are being conducted, preparation and presentation of initial draft versions of Development Costs budgets for all HNC Clinical Trials to be conducted during the following Calendar Year, and presentation of final draft versions of such Development Costs budgets for all HNC Clinical Trials to be conducted during the following Calendar Year to the JOC for approval by November 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of each Calendar Year (unless a different date is mutually agreed by the JFC Representatives)&#59; </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.4&#160;&#160;&#160;&#160;periodic review of the status of Development Cost budgets, the progress of HNC Clinical Trials, and performance of HNC Clinical Trials against Development Cost budgets, including actual Development Costs incurred to date, forecast of remaining Development Costs, and costs contracted with Third Parties,</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.5&#160;&#160;&#160;&#160;periodic review and, if deemed necessary by the JFC, revision of the Quarterly Labor Fees, including any revisions reasonably necessary for Additional HNC Clinical Trial Protocols (if any)&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.6&#160;&#160;&#160;&#160;overseeing Development Cost Reconciliation Procedures&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;42</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.7&#160;&#160;&#160;&#160;providing support to the JSC, JOC and JPT with respect to financial, accounting, budgeting, reporting and other matters that may arise in connection with a Development Costs budget and other activities under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.8&#160;&#160;&#160;&#160;review and discuss any Success Payments that may become due from Nektar to SFJ pursuant to Article&#160;6&#59; and</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.6.9&#160;&#160;&#160;&#160;discussing any other topics or issues relating to any Development Costs budget, other activities of the JFC, or other activities under this Agreement as either Party&#8217;s JFC Representative or the JOC may request.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 6</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PAYMENTS TO SFJ</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will pay to SFJ, in US Dollars, the amounts set forth in this Section&#160;6.1.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.1&#160;&#160;&#160;&#160;Upon the latest to occur of (a)&#160;the First Regulatory Approval and (b)&#160;the Initial Payment Trigger Date (such latest date, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and subject to Section&#160;6.1.3, Nektar will pay SFJ the amounts set forth in Success Payment Schedule&#160;A below (in the column entitled &#8220;Amount of Payment&#8221;) on the dates set forth in the column entitled &#8220;Date of Payment&#8221; (each payment payable pursuant to this Section&#160;6.1.1, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;A Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the first payment payable pursuant to this Section&#160;6.1.1 no later than thirty&#160;(30) days following the Initial Payment Date, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Schedule&#160;A Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Success Payment Schedule&#160;A</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.653%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Payment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amount of<br>Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No later than 30 days following the Initial Payment Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$30,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1-Year Anniversary of Initial Payment Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2-Year Anniversary of Initial Payment Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3-Year Anniversary of Initial Payment Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4-Year Anniversary of Initial Payment Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5-Year Anniversary of Initial Payment Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$450,000,000</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.2&#160;&#160;&#160;&#160;Upon the notification to Nektar of a Second Regulatory Approval (the date such notification, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Regulatory Approval Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and subject to Section&#160;6.1.3, Nektar will pay SFJ the amounts set forth in Success Payment Schedule&#160;B below (in the column entitled &#8220;Amount of Payment&#8221;) on the dates set forth in the column entitled &#8220;Date of Payment&#8221; (each payment payable pursuant to this Section&#160;6.1.2, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;B Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the first </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;43</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payment payable pursuant to this Section&#160;6.1.2 no later than thirty&#160;(30) days following the Second Regulatory Approval Date, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Schedule&#160;B Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Success Payment Schedule&#160;B</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:74.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Payment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amount of<br>Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No later than 30 days following the Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7-Year Anniversary of Second Regulatory Approval Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$150,000,000</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.3&#160;&#160;&#160;&#160;If the Regulatory Approval giving rise to the requirement for Nektar to make payments to SFJ pursuant to Section&#160;6.1.1 or 6.1.2 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is an Accelerated Regulatory Approval, and such Accelerated Regulatory Approval is later withdrawn by the FDA for any reason (other than to issue a full Regulatory Approval), then (a)&#160;Nektar shall have no obligation to make any additional payments pursuant to Section&#160;6.1.1 or 6.1.2, as applicable, during the period after withdrawal of such Accelerated Regulatory Approval and before such time (if ever) as the Specified Regulatory Approval is again obtained (a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (b)&#160;Nektar shall be obligated to use Commercially Reasonable Efforts to (i) resolve any manufacturing issues, if the withdrawal is related to a manufacturing related issue, &#91;***&#93;, and (ii)  obtain Subsequent Regulatory Approval unless such withdrawal is due to safety or efficacy reasons&#59; provided that in no event shall Nektar be required to conduct any additional clinical study to demonstrate the safety and&#47;or efficacy of the Product following withdrawal by the FDA of such Accelerated Regulatory Approval, except as set forth in clause (i) above.  If Subsequent Regulatory Approval is obtained, Nektar&#8217;s obligation to make Success Payments shall resume and the due date for payments pursuant to Section&#160;6.1.1 or 6.1.2, as applicable, following such Subsequent Regulatory Approval shall be extended by the number of days between the withdrawal of the Accelerated Regulatory Approval and the applicable Subsequent Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.4&#160;&#160;&#160;&#160;Within ninety&#160;(90) days following receipt by Nektar of an Other Indication Regulatory Approval, Nektar shall pay SFJ an amount equal to $37,500,000. Nektar shall not be responsible for making more than one payment to SFJ pursuant to this Section&#160;6.1.4.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.5&#160;&#160;&#160;&#160;Each Schedule&#160;A Success Payment, Schedule&#160;B Success Payment and the payment set forth in Section&#160;6.1.4 is referred to as a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Success Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Success Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and shall be subject to adjustment as provided in Section&#160;6.2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;44</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that the actual Development Costs paid or incurred by SFJ hereunder are lower or greater than One Hundred Fifty Million U.S. Dollars ($150,000,000.00) as of the date of payment of any Success Payment, Approval Buyout Payment or Buy-Out Payment, such payment will be multiplied by a fraction, the numerator of which is equal to the actual amount of Development Costs paid or incurred by SFJ hereunder and the denominator of which is One Hundred Fifty Million U.S. Dollars ($150,000,000.00).  In the event that Nektar becomes obligated to make a Success Payment to SFJ while Development Costs are still being paid or incurred, SFJ shall recalculate the applicable adjustment as of the end of each Calendar Year and as of such time as the final amount of actual Development Costs is known and determine any true-up payments required to be made by Nektar with respect to any payment made pursuant to Section&#160;6.1 prior to such time, and Nektar shall pay any such true-up payment to SFJ within thirty (30) days after receipt of invoice from SFJ. For purposes of clarity, in the event that the amount funded by SFJ is less than $150,000,000 as a result of an early termination of the HNC Clinical Trials due to the occurrence of HNC Clinical Trial Futility or Safety Concern, the foregoing pro rata funding provision based on actual SFJ investment shall apply.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Method and Timing of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Success Payments to SFJ will be due as of the applicable dates set forth in Sections&#160;6.1.1, 6.1.2 or 6.1.4, as may be adjusted pursuant to Sections&#160;6.1.3 or 6.2, and shall be paid by wire transfer of immediately available funds to an account specified by SFJ from time to time.  Nektar will provide SFJ with written notice of each wire transfer to SFJ&#8217;s account.  All amounts payable and calculations under this Agreement shall be in US dollars.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Nektar fails to pay any undisputed amount due under this Agreement on the due date therefore, then, without prejudice to any other remedies that SFJ may have, that amount will bear interest from the due date until payment of such amount is made, both before and after any judgment, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.1&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary, on or prior to the Effective Date, SFJ shall deliver to Nektar a duly completed and valid (A)&#160;IRS Form W-9 certifying that SFJ is a United States person, as such term is defined in Section&#160;7701(a)(30) of the IRC, (B)&#160;applicable IRS Form W-8BEN-E claiming treaty benefits under a double taxation treaty with respect to each of &#8220;royalties,&#8221; &#8220;interest&#8221; and &#8220;other income,&#8221; (C) IRS Form W-8IMY to which the forms set forth in the preceding (A) and (B) are attached, or (D) other applicable IRS Form W-8 that indicates no withholding is required in respect of the Product Payments, (in each case ((A) through (D)), the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IRS Withholding Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and SFJ shall provide an updated IRS Withholding Form to Nektar throughout the Term whenever required in order for SFJ to have on file a duly completed and valid IRS Withholding Form.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.2&#160;&#160;&#160;&#160;The Parties hereby acknowledge and agree that payments made under this Agreement will be made without reduction for withholding or similar taxes if Nektar, at the time of any such payment, has on file a duly completed and valid IRS Withholding Form in respect of SFJ, unless such withholding or similar tax is required (x)&#160;by a taxing authority as a result of an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;45</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">audit or examination, (y)&#160;due to the assignment of this Agreement or any payment or other obligation or responsibility hereunder (to the extent permitted) by either Party to an Affiliate or Third Party, the re-domiciling of either Party outside the US or any other circumstance that results in either Party no longer being a United States person for U.S. federal income tax purposes, or that results in SFJ no longer being able to provide an IRS Withholding Form, or (z)&#160;as a result of a change in Applicable Laws at any time during the Term.  In any such case, the Parties shall use commercially reasonable and legal efforts to mitigate the amount of such taxes that would need to be withheld and&#47;or paid. Either Party may request a meeting of the JFC to further discuss any conclusion that a payment should be made with reduction for withholding or similar taxes.  Any amounts withheld pursuant to this Section&#160;6.5 will be timely paid over to the appropriate taxing authority, and will be treated for purposes of this Agreement as having been paid to the Party that otherwise would have received such amounts.  If a Party (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is required to withhold any taxes on the amounts payable to the other Party (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) hereunder as a result of any actions described in clause&#160;(y) above by such Withholding Party (or its Affiliates), the Withholding Party shall pay the Recipient Party such additional amounts as are necessary to ensure receipt by the Recipient Party of the full amount which the Recipient Party would have received but for the deduction on account of such withholding. The paying party shall be liable for and shall pay any sales, use, value-added or other similar taxes imposed on payments required to be made hereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will cooperate and produce on a timely basis any tax forms or reports, including any IRS Forms W-8BEN or W-9, as applicable, reasonably requested by the other Party in connection with any payment made under this Agreement.  Each Party will provide to the other Party any other tax forms that may be reasonably necessary in order for such Party not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.  Each Party will provide, upon request, to the other Party any tax forms at least thirty&#160;(30) days prior to the due date for any such payments&#59; provided that the request for such forms was made in a timely manner.  Each Party will provide the other with commercially reasonable assistance to enable the recovery, as permitted by law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT.  Each Party will provide commercially reasonable cooperation to the other Party, at the other Party&#8217;s expense, in connection with any official or unofficial tax audit or contest relating to tax payments made with respect to amounts paid or payable to such other Party under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approval Buy-Out Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7.1.1&#160;&#160;&#160;&#160;Within one hundred and eighty&#160;(180) days following the Initial Payment Date (in the case of Schedule&#160;A Success Payments) or one hundred and eighty&#160;(180) days following the Second Regulatory Approval Date (in the case of Schedule&#160;B Success Payments), Nektar shall have the right to make a one-time payment (each, an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approval Buy-Out Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in lieu of all (but not less than all) Schedule&#160;A Success Payments or Schedule&#160;B Success Payments, as applicable (in each case as adjusted in accordance with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;46</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;6.2) (other than the Initial Schedule&#160;A Success Payment or Initial Schedule&#160;B Success Payment, as applicable, payable pursuant to Section&#160;6.1, in each case, as adjusted in accordance with Section&#160;6.2, which shall remain due and payable if not previously paid) by written notice delivered to SFJ no later than ninety&#160;(90) days after the date of the Initial Payment Date or Second Regulatory Approval Date, as applicable, which written notice shall set forth the amount of the applicable Approval Buy-Out Payment, the proposed date of closing (which shall occur within one hundred and eighty&#160;(180) days after the Initial Payment Date or Second Regulatory Approval Date, as applicable), and the calculation of the applicable Approval Buy-Out Payment in reasonable detail based upon the proposed closing date.  The Approval Buy-Out Payment will be calculated as follows&#58;</font></div><div style="margin-bottom:12pt"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Where&#58;</font></div><div style="padding-left:130.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#61; Success Payments that the Approval Buy-Out Amount applies to, as adjusted in accordance with Section&#160;6.2</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">r &#61; the Discount Rate</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#61; payment date per schedule</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#61; closing date of buyout </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Approval Buy-Out Payment will be payable in one installment in cash at the closing to an account specified by SFJ.  The discount rate used to calculate each Approval Buy-Out Payment shall be &#91;***&#93; (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Discount Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). If Nektar elects to make an Approval Buy-Out Payment in lieu of the Schedule A Success Payments, then following such payment Nektar shall no longer be subject to the provision of Section 7.1. </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7.1.2&#160;&#160;&#160;&#160;In the event that Nektar becomes obligated to make Schedule&#160;A Success Payments or Schedule&#160;B Payments as a result of an Accelerated Regulatory Approval, then the time period for Nektar to elect to buy out the Schedule&#160;A Success Payments or Schedule&#160;B Payments, as applicable, shall be extended to the date which is ninety&#160;(90) days after such Accelerated Regulatory Approval becomes a full Regulatory Approval, with the applicable Approval Buy-Out Payment to be paid within one hundred eighty&#160;(180) days after the date of such full Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Change of Control is consummated, then within forty-five&#160;(45) days following the closing of such Change of Control, Nektar shall pay SFJ an amount in cash equal to one hundred and fifty percent&#160;(150%) of actual Development Costs paid or incurred by SFJ hereunder prior to such Change of Control (such payment, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that no Change of Control Payment shall be payable to SFJ if either (a)&#160;the HNC Clinical Trial has been completed but the HNC Clinical Trial Success Criteria was not achieved or (b)&#160;HNC Clinical Trial Futility has occurred.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;47</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change of Control Payment, if any, shall be credited toward future Success Payments in chronological order. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 7</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTAIN COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Negative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall not, without SFJ&#8217;s prior written consent, create, incur, allow, or suffer any Lien on any of the Nektar Intellectual Property, or assign or convey any right to receive income with respect to the Nektar Intellectual Property (other than royalty and other license fee obligations to licensors thereof in accordance with the applicable license agreement), including the sale of any Nektar Intellectual Property, or permit any of its subsidiaries to do so&#59; provided, however, that nothing in this provision or this Agreement shall require the consent of SFJ (a)&#160;for Nektar to issue senior secured debt secured by all or substantially all of the assets of Nektar including the Nektar Intellectual Property&#59; or (b)&#160;for any transaction between Nektar and one or more of its Affiliates so long as such Affiliates are bound by the same restrictions as Nektar set forth in this Section&#160;7.1.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without SFJ&#8217;s prior approval, Nektar shall not enter into a Licensing Transaction in the U.S. or Major European Markets to any Third Party&#59; provided that this consent provision will not apply to any transaction between Nektar and one or more Nektar Affiliates so long as Nektar guarantees the obligations and performance of such Nektar Affiliates.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sales of Royalty Streams</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall not, without SFJ&#8217;s consent, sell, transfer or assign, directly or indirectly, in whole or in part, any rights to receive payments of royalties or license fees with respect to the Product or the Nektar Intellectual Property (including any Accounts with respect to such royalties or license fees), other than to a wholly owned direct or indirect subsidiary of Nektar.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restriction on Acquiring or Transacting in Nektar Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ agrees that, unless otherwise agreed in writing by Nektar, until the earliest of (a)&#160;the expiration of the Term and (b)&#160;the date on which the top line results of the last remaining Clinical Trial are published or otherwise become publicly available, neither it nor any of its Affiliates, and its and their respective officers, directors, managers, employees, agents, or representatives will acquire beneficial ownership of or transact in any securities (including any derivative securities or any other instrument that provides the holder thereof with the economic equivalent of ownership of an amount of securities of Nektar) of Nektar.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;48</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affirmative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Government Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall maintain its and all its subsidiaries&#8217; legal existence and good standing in their respective jurisdictions of formation and maintain qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the Development or Commercialization of the Product, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any subsidiary may liquidate or dissolve so long as such liquidation or dissolution would not reasonably be expected to have a material adverse effect on the Development or Commercialization of the Product.  Nektar shall comply, and shall cause each subsidiary to comply, in all material respects, with all laws, ordinances and regulations to which it is subject, noncompliance with which would reasonably be expected to have a material adverse effect on the Development or Commercialization of the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall not become an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.  Nektar shall not become engaged as one of its important activities in extending credit for margin stock (under Regulations&#160;X, T and U of the Federal Reserve Board of Governors).  Neither Nektar&#8217;s nor any of its Subsidiaries&#8217; properties or assets shall be used by Nektar or any Subsidiary in disposing, producing, storing, treating, or transporting any hazardous substance other than legally.  Nektar and each of its subsidiaries shall obtain all consents, approvals and authorizations of, make all declarations or filings with, and give all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted, unless such failure could not reasonably be expected to have a material adverse effect on the Development or Commercialization of the Product.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Protection of Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall use Commercially Reasonable Efforts in the exercise of its business judgment to prosecute, protect, defend and maintain the validity and enforceability of the Nektar Intellectual Property.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that, following an applicable Regulatory Approval, (a) Nektar shall fail to make any Success Payment associated with such Regulatory Approval on or before its due date, (b) Nektar has received written notice from SFJ of such failure, specifying in reasonable detail the particulars of such failure, (c) Nektar has not cured such failure &#91;***&#93; following receipt of such notice and (d) the amount of such Success Payment and&#47;or whether such Success Payment is due and payable has not been disputed, all remaining unpaid Success Payments that are based on such Regulatory Approval shall become immediately due and payable&#59; provided that, in the event of any such acceleration, SFJ&#8217;s rights to receive such Success Payments, if any, shall be adjusted as set forth in Section&#160;6.2 and reduced by any amounts previously paid to SFJ</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon at least &#91;***&#93; and during normal business hours, &#91;***&#93;, Nektar may cause an inspection and&#47;or audit by an independent public accounting firm, to be compensated on the basis of time spent and to be reasonably acceptable to SFJ, to be made of the books and records of SFJ and its Affiliates, and the Approved CROs and Approved Vendors with which it contracts, for the &#91;***&#93; purpose of determining the correctness of Development Costs paid and&#47;or incurred under this Agreement. Upon Nektar&#8217;s reasonable request not more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;49</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">than once in any Calendar Year, SFJ shall use commercially reasonable efforts to exercise any rights it may have under any agreement with a Permitted CRO or a Permitted Vendor to cause an inspection and&#47;or audit by an independent public accounting firm, to be compensated on the basis of time spent, to be made of the books of account of such Permitted CRO or Permitted Vendor for the purpose of determining the correctness of payments made to such Permitted CRO or Permitted Vendor and the correctness of Development Costs paid and&#47;or incurred under this Agreement. All of the expenses of any inspection or audit requested by Nektar hereunder (including the fees and expenses of such independent public accounting firm designated for such purpose) shall be borne by (i)&#160;Nektar, if the independent public accounting firm determines that Development Costs were underpaid by an amount less than or equal to &#91;***&#93; of the Development Costs actually paid or (ii)&#160;Nektar, if the independent public accounting firm determines that the Development Costs previously paid were incorrect by an amount greater than &#91;***&#93; of the Development Costs actually paid. All information obtained by Nektar as a result of any such inspection or audit shall be Confidential Information subject to Article&#160;9. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 8</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECORDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will maintain materially complete and accurate accounting records related to this Agreement in accordance with GAAP.  Each Party will retain such records for two&#160;(2) years after the earlier of expiration or early termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials-Related Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall, and shall cause its Affiliates and its and their Permitted Third Parties conducting Development of the Product to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of the Product hereunder, in sufficient detail to verify compliance with its obligations under this Agreement.  Such books and records shall (a)&#160;be appropriate for patent and regulatory purposes, (b)&#160;be in compliance with Applicable Law, (c)&#160;properly reflect all work done and results achieved in the performance of its Development activities hereunder, and (d)&#160;be retained by such Party for such period as may be required by Applicable Law.   </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 9</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONFIDENTIAL INFORMATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) agrees that, during the Term and for the five&#160;(5)-year period following the expiration or termination of this Agreement (except that the obligations will survive thereafter with respect to any Confidential Information that constitutes a trade secret under Applicable Law) or such longer periods for which such Confidential Information may be maintained pursuant to Article&#160;8, it will keep confidential and will not publish or otherwise disclose and will not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information furnished to it by or on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;50</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">behalf of the other Party (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or its Affiliates in connection with this Agreement.  The foregoing obligations will not apply to any portion of such information or materials that the Receiving Party can demonstrate&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.1&#160;&#160;&#160;&#160;was publicly disclosed by the Disclosing Party before or after such Confidential Information becomes known to the Receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.2&#160;&#160;&#160;&#160;was already known to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality or non-use, prior to when it was received from the Disclosing Party&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.3&#160;&#160;&#160;&#160;is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof without obligation to keep such Confidential Information confidential&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.4&#160;&#160;&#160;&#160;has been published by a Third Party or otherwise enters the public domain through no fault of the Receiving Party or any of its Affiliates in breach of this Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.5&#160;&#160;&#160;&#160;has been independently developed by the Receiving Party or any of its Affiliates, without the aid, application or use of any Confidential Information of the other Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary for complying with Applicable Laws, including regulations promulgated by securities exchanges, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Party required to disclose such information promptly notifies the Disclosing Party prior to making any such disclosure and cooperates with the Disclosing Party&#8217;s efforts to seek confidential treatment or to otherwise limit disclosure.  Each Receiving Party may disclose the other Party&#8217;s Confidential Information to its Affiliates and its and their Representatives, advisors and independent contractors (including Permitted Third Parties) engaged by such Receiving Party, and with respect to SFJ, the Specified Investors, in each case (a)&#160;only to the extent such Persons need to know the Confidential Information solely in connection with the performance of this Agreement or in the case of the Specified Investors, as necessary to monitor and manage its investment in SFJ, and (b)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each Person receiving Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as an equivalent in scope to those set forth in this Article&#160;9 prior to any such disclosure and the Party making such disclosure to such Person shall be liable to the other Party for any breach of such obligations by such disclosee.  &#91;***&#93;.  In any event, each Party agrees to take all reasonable action to avoid unauthorized use or disclosure of Confidential Information of the other Party hereunder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.1&#160;&#160;&#160;&#160;&#91;***&#93;.   </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.2&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided herein, upon expiration or earlier termination of this Agreement, all Confidential Information (including any copies thereof) in written or other tangible form will, at the Disclosing Party&#8217;s direction, be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;51</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">returned to the Disclosing Party or destroyed by the Receiving Party, and any Person(s) to whom the Receiving Party disclosed (with such destruction being certified in writing by an authorized officer of the Receiving Party), except (i)&#160;to the extent such Confidential Information is necessary to exercise any license and&#47;or rights hereunder that survive such expiration or earlier termination&#59; and (ii)&#160;one&#160;(1) copy of each document may be retained by the Receiving Party solely to the extent necessary to permit it to comply with any ongoing rights and responsibilities with respect to such Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Status of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section&#160;9.2 and Section&#160;9.5, the terms of this Agreement are deemed to be Confidential Information and will be subject to the confidentiality requirements of this Article&#160;9, with each Party being deemed a Receiving Party for such purposes.  The Parties each acknowledge that it will be necessary for Nektar to file this Agreement with the U.S. Securities and Exchange Commission and to make other required public disclosures regarding the terms of this Agreement, and accordingly Nektar shall prepare a confidential treatment request in connection with such filing and provide SFJ a reasonable opportunity to review and comment on such filing as well as on such other required public disclosures and thereafter use Commercially Reasonable Efforts to obtain confidential treatment as to the terms of this Agreement&#59; provided that Nektar shall not be required to provide SFJ the opportunity to review and comment on any disclosure previously reviewed and commented upon by SFJ.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties recognize that following the Effective Date the Parties (either individually or jointly) shall issue mutually agreed press release(s) announcing the execution of this Agreement, and thereafter each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding the subject matter of this Agreement, and hereby agree that such additional press releases, public statements and disclosures regarding the terms of this Agreement will be permitted only with the other Party&#8217;s written consent (which shall not be unreasonably withheld, conditioned or delayed).  Any publication, news release or other public announcement relating to the terms of this Agreement will first be reviewed and approved in writing by both Parties&#59; provided, however, that any disclosure of the minimum information which is required by Applicable Law (including the rules of a securities exchange), as reasonably advised by the disclosing Party&#8217;s counsel, may be made without the prior consent of the other Party, although the other Party will be given prompt notice of any such legally required disclosure and to the extent practicable will be provided an opportunity to comment on the proposed disclosure and the disclosing Party will consider in good faith any comments provided by the other Party on such proposed disclosure.  For avoidance of doubt, this Section&#160;9.5 shall not restrict Nektar from releasing public statements or disclosures regarding Nektar&#8217;s development and Commercialization activities with respect to the Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise expressly permitted herein, Nektar will (i)&#160;obtain the written consent of SFJ prior to making any public reference to any of SFJ&#8217;s investors (including without limitation the Specified Investors), including without limitation in any filings with the SEC,  and (ii)&#160;obtain SFJ&#8217;s written consent (which consent will not unreasonably be withheld, conditioned or delayed) prior to referring to SFJ or any of its investors (including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;52</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">without limitation the Specified Investors) in any correspondence with any Regulatory Authority or Governmental Authority (whether or not such references would be expected to become publicly available) or in any press release except as may be required by Applicable Law.  This Section&#160;9.6 shall also apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">vice versa </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to any use by SFJ of Nektar&#8217;s name.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 10</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY AND PERSONALLY </font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IDENTIFIABLE INFORMATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership and Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section&#160;10.1.1.2, it is agreed between the Parties that each Party will retain all right, title and interest in, to and under all Intellectual Property that is Controlled by such Party as of the Effective Date.  </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Without limiting the generality of the foregoing, as between the Parties, Nektar shall be and remain the sole and exclusive owner of all right, title and interest in and to all Nektar Intellectual Property existing as of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Nektar Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including, in the case of Patents within the Existing Nektar Intellectual Property (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Nektar Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), all patent applications filed after the Effective Date that claim priority to, or are foreign counterparts of, patent applications within the Existing Nektar Patents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corresponding Nektar Patent Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and all Patents that may issue or be granted from any patent application within the Existing Nektar Patents or any Corresponding Nektar Patent Application after the Effective Date.  In addition, Nektar shall be and remain the sole and exclusive owner of all right, title and interest in and to all Nektar Intellectual Property arising during the term of this Agreement independent of the conduct of the activities contemplated by this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trial Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Nektar shall be the exclusive and sole owner of, and retain all right, title and interest in and to, all Trial Inventions (which shall constitute Nektar Intellectual Property), regardless of inventorship.  SFJ will promptly disclose, and will cause its Affiliates and all Permitted Third Parties engaged by SFJ or its Affiliates to perform any of SFJ&#8217;s obligations hereunder promptly to disclose, to Nektar in writing in reasonable detail each Trial Invention made, developed, created, generated, conceived or reduced to practice in whole or in part by or on behalf of SFJ, such Affiliate or such Permitted Third Party, which written disclosure shall include all available information and data necessary to support the filing of patent applications Covering such Trial Invention.  SFJ, for itself and on behalf of its Affiliates, hereby assigns, and shall cause such other Permitted Third Parties to assign (subject to Section&#160;10.1.1.2(c)), to Nektar all its right, title and interest in and to Trial Inventions and all information and data necessary to support the filing of patent applications Covering such Trial Inventions.  SFJ will cooperate, and will cause the foregoing Persons to cooperate, with Nektar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;53</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to effectuate and perfect the foregoing ownership, including by promptly executing and recording assignments and other documents consistent with such ownership.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;SFJ shall cause each employee and individual consultant of SFJ or its Affiliates (but excluding Permitted Third Parties of SFJ and its Affiliates, which are separately addressed in Section&#160;10.1.1.2(c)) who conceives, discovers, develops or otherwise makes any Trial Invention to be subject to a present obligation to assign to Nektar all right, title and interest in and to in any such Trial Invention.  In the case of any individual consultant of SFJ or its Affiliates (excluding SFJ&#8217;s and its Affiliates&#8217; Permitted Third Parties), if SFJ is unable to cause such consultant to agree to such assignment obligation despite SFJ&#8217;s using Commercially Reasonable Efforts to negotiate such assignment obligation, then SFJ shall inform Nektar of such inabiltiy to cause such consultant to agree to such assignment obligation and at Nektar&#8217;s sole discretion either&#58; (A)&#160;cause such consultant to grant an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, under their rights in such Trial Invention to develop, make, have made, use, sell, have sold, offer for sale and import the Product for any and all uses, except where prohibited by Applicable Law and except in the case of consultants who are employed by governmental, not-for-profit, or public institutions that have standard policies against such an assignment (in which case, SFJ shall use Commercially Reasonable Efforts to obtain a suitable license, or right to obtain such a license)&#59; or (B)&#160;refrain from using such consultant to conduct activities pursuant to this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;SFJ shall obtain from each Third Party contractor that SFJ or its Affiliate proposes to engage to conduct activities under or in connection with this Agreement on behalf of SFJ or its Affiliates (i)&#160;an assignment, (ii)&#160;an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, or (iii)&#160;a nonexclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers ((i) through (iii) in order of preference), to Nektar of any Trial Invention that such Third Party contractor conceives, discovers, develops or otherwise makes in connection with activities conducted relating to this Agreement.  The Parties acknowledge that it may not be possible to obtain such assignment or license from any such Third Party contractor with respect to technology of broad applicability to the operation of such Third Party contractor&#8217;s business or improvements, or improvements to such Third Party contractor&#8217;s own proprietary technology used in the performance of services on behalf of SFJ or its Affiliate, in each case, on acceptable terms or at all, and accordingly, following notice by SFJ to Nektar, the Parties agree that the inability of SFJ or its Affiliate to obtain such assignment or license from a Third Party contractor on acceptable terms or at all shall not constitute a breach of SFJ&#8217;s obligations under this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trial Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar shall be the sole and exclusive owner of the Trial Data Package including the Research Results included therein.  SFJ, for itself and on behalf of its Affiliates, hereby assigns, and shall cause such other Permitted Third Parties to assign (subject to Section&#160;10.1.1.2(c)), to Nektar all its right, title and interest in and to the Trial Data Package, including the Research Results included therein. SFJ will cooperate, and will cause the foregoing Persons to cooperate, with Nektar to effectuate and perfect the foregoing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;54</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ownership, including by promptly executing and recording assignments and other documents consistent with such ownership.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inventorship&#59; Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inventorship of Trial Inventions will be determined according to the principles of US patent law.  SFJ agrees to cooperate fully, to cause its Affiliates to cooperate fully, and to use Commercially Reasonable Efforts to cause its and their respective Permitted Third Parties to cooperate fully with Nektar in the preparation, filing, prosecution and maintenance of Patents Covering Trial Inventions filed by or on behalf of Nektar claiming any Licensed Know-How.  Such cooperation includes executing all papers and instruments, or requiring its employees, consultants and Permitted Third Parties, to execute such papers and instruments, so as to (a)&#160;effectuate the ownership of Trial Inventions set forth in Section&#160;10.1.1.2(a), including Patents claiming or disclosing Trial Inventions, and (b)&#160;enable Nektar to apply for and to prosecute patent applications claiming Trial Inventions in any country.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The delivery or disclosure by or on behalf of Nektar to SFJ of any information or materials hereunder will not be construed to grant SFJ any rights or license to use any Intellectual Property Controlled by Nektar other than as necessary to comply with its obligations hereunder or as expressly set forth herein.  Except as otherwise expressly permitted in this Agreement, SFJ may not use, publish or otherwise disclose any Intellectual Property Controlled by Nektar without Nektar&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As between SFJ and Nektar, Nektar will have sole and exclusive right to prepare, file, prosecute and maintain all Patents within the Nektar Intellectual Property, including all Patents that cover the Trial Inventions, at its own expense (provided that Nektar shall use Commercially Reasonable Efforts to prosecute and maintain such Patents).  At Nektar&#8217;s request and expense (for reasonable out-of-pocket expenses), SFJ will reasonably cooperate with Nektar in preparing, filing, prosecuting, and maintaining such Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will use Commercially Reasonable Efforts to enforce the Nektar Intellectual Property, including Intellectual Property that covers the Trial Inventions, against Third Party Infringements.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement of Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party learns of Third Party allegations that it or the other Party or any of its or the other Party&#8217;s Affiliates or Permitted Third Parties, have infringed, misappropriated or otherwise violated, or are infringing, misappropriating or otherwise violating, any Intellectual Property of a Third Party in connection with either the Clinical Trials or performing its obligations or duties hereunder, such Party will promptly notify the other Party.  Nektar will have sole control and responsibility of, and discretion with respect to, such allegations and any related actions and&#47;or litigation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;55</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Personally Identifiable Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.1&#160;&#160;&#160;&#160;In conducting the Clinical Trials and its other obligations under this Agreement, each Party will comply, and will use Commercially Reasonable Efforts to require each applicable Permitted Third Party of such Party to comply, with Applicable Laws relating to privacy or data protection applicable to such Party or the Clinical Trials being conducted by or on behalf of such Party, including ensuring that all necessary (a)&#160;consents from Clinical Investigators, Subjects and any others from whom Personally Identifiable Information will be received are obtained&#59; (b)&#160;regulatory notifications are filed in all countries for which Sites have been selected&#59; and (c)&#160;approvals are obtained in all countries for which Sites have been selected, prior to collection or transfer of such Personally Identifiable Information.  Without prejudice to the generality of the foregoing, each Party shall (i)&#160;work together with the other Party in good faith to ensure the information referred to in applicable laws and, if applicable, in particular Articles&#160;13 and 14 of the General Data Protection Regulation (2016&#47;679) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GDPR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made available to data subjects (as defined in the GDPR) in relation to the processing of their Personally Identifiable Information by either Party when acting as a data controller (as defined in the GDPR), and the information is in a concise, transparent, intelligible and easily accessible form, using clear and plain language as required by Article&#160;12 of the GDPR&#59; (ii)&#160;if either Party (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) receives any complaint, notice or communication from a supervisory authority (as defined in the GDPR) which relates directly or indirectly to the other Party&#8217;s (A)&#160;processing of the Personally Identifiable Information&#59; or (B)&#160;potential failure to comply with the provisions of the GDPR, the Data Receiving Party shall, to the extent permitted by law, promptly forward the complaint, notice or communication to the other Party and provide the other Party with reasonable co-operation and assistance in relation to the same&#59; (iii)&#160;if a data subject makes a written request to a Party to exercise their rights in relation to their Personally Identifiable Information that concerns processing in respect of which the other Party is the data controller, that Party shall forward the request to the other Party promptly and in any event within five&#160;(5) Business Days from the date on which it received the request and, upon the other Party&#8217;s reasonable written request, provide that other Party with reasonable co-operation and assistance in relation to that request to enable the other to respond to such request and meet applicable timescales set out under the GDPR&#59; (iv)&#160;if either Party becomes aware of a personal data breach (as defined in the GDPR), it shall notify the other Party without undue delay, and each Party shall co-operate with the other, to the extent reasonably requested, in relation to any notifications to supervisory authorities or to data subjects which either Party is required to make under the GDPR.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.2&#160;&#160;&#160;&#160;Each Party will not process, and will use Commercially Reasonable Efforts to require each applicable Permitted Third Party of such Party to not process, any Personally Identifiable Information in a way that is contrary to Applicable Laws or any Informed Consent.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.3&#160;&#160;&#160;&#160;Each Party will use Commercially Reasonable Efforts to maintain, and will use Commercially Reasonable Efforts to require each applicable Permitted Third Party of such Party to maintain, appropriate and sufficient technical and organizational security measures to maintain the confidentiality of Personally Identifiable Information and to protect such data </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;56</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">against accidental or unlawful destruction or accidental loss, damage, alteration, unauthorized disclosure or access, in particular where such data is transmitted over a network.  These technical and organizational security measures shall ensure a level of security appropriate to the risk, including, as appropriate, (a)&#160;pseudonymisation and encryption&#59; (b)&#160;the ability to ensure the ongoing confidentiality, integrity, availability and resilience of processing systems and services&#59; (c)&#160;the ability to restore the availability and access to the Personally Identifiable Information in a timely manner in the event of a physical or technical incident&#59; and (d)&#160;a process for regularly testing, assessing and evaluating the effectiveness of those measures.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.4&#160;&#160;&#160;&#160;Each Party shall notify the other Party of&#58; (a)&#160;any unauthorized use or disclosure or breach of any Personally Identifiable Information promptly upon discovery of such occurrence&#59; and (b)&#160;the transmittal of any related breach notification to any affected person, Governmental Authority or the media.  Each Party will use Commercially Reasonable Efforts to require each applicable Permitted Third Party of such Party to notify the such Party of&#58; (i)&#160;any unauthorized use or disclosure or breach of any Personally Identifiable Information promptly upon discovery of such occurrence and (ii)&#160;the transmittal of any related breach notification to any affected person, Governmental Authority or the media. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 11</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEMNIFICATION AND INSURANCE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">By SFJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ will indemnify and hold Nektar&#59; its Affiliates and their respective officers, directors, employees and agents (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), harmless from any and all Losses arising or resulting from any Claims by a Third Party against any Nektar Indemnified Parties to the extent arising from (a)&#160;the gross negligence or willful misconduct of SFJ or any of its Affiliates or any of its or their respective Permitted Third Parties in performing SFJ&#8217;s obligations under this Agreement&#59; (b)&#160;SFJ&#8217;s material breach of this Agreement&#59; (c)&#160;any material breach of a Protocol by SFJ, or its Affiliate, or any of its or their respective Permitted Third Parties&#59; except to the extent that any of the foregoing clauses&#160;(a) through (c) was caused by (i)&#160;the gross negligence or willful misconduct of any Nektar Indemnified Party, or (ii)&#160;material breach of this Agreement by Nektar.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">By Nektar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will indemnify and hold SFJ, its Affiliates, SFJ&#8217;s investors (including the Specified Investors) and their respective officers, directors, employees and agents (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), harmless from any and all Losses arising or resulting from any Claims by a Third Party against any SFJ Indemnified Parties to the extent arising from (a)&#160;a Product supplied by Nektar&#59; (b)&#160;a physical injury or death of a Subject that is caused by the Subject&#8217;s participation in the HNC Clinical Trials whether or not directly attributable to the Product&#59; (c)&#160;Nektar&#8217;s gross negligence or willful misconduct in performing its obligations under this Agreement&#59; (d)&#160;Nektar&#8217;s material breach of this Agreement (e)&#160;any material breach of a Protocol by Nektar, or its Affiliate, or of its or their respective Permitted Third Parties, (f)&#160;actual or alleged infringement of any Third Party&#8217;s Intellectual Property by the Product or by either Party in performing its duties or obligations hereunder with respect to the Product&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;57</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;injuries sustained by Subjects in connection with the HNC Clinical Trials or the Melanoma Clinical Trial, including Claims arising prior to the Effective Date based upon physical injury or death of a Subject in connection with the HNC Clinical Trials or the Melanoma Clinical Trial, or from the Commercialization of the Product&#59; except to the extent that any of the foregoing&#160;(a) through (g) were caused by (i)&#160;the gross negligence or willful misconduct of any SFJ Indemnified Party, or (ii)&#160;material breach of this Agreement by, SFJ.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Party believing that it is entitled to indemnification under Section&#160;11.1.1 or 11.1.2 (an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will give prompt written notice (each, an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other Party (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) upon receipt of notice of the commencement of any Claim for which indemnification may be sought, or if earlier, upon the assertion of any such Claim by a Third Party (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Claim of a Third Party as provided in this Section&#160;11.2.1 will not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give notice).  Each Indemnification Claim Notice will contain a description of the Claim and the nature and amount of the Loss (to the extent that the nature and amount of such Loss are known at such time).  The Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Control of Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At its option, the Indemnifying Party may assume the defense of any Claim by giving written notice to the Indemnified Party within thirty&#160;(30) days after the Indemnifying Party&#8217;s receipt of an Indemnification Claim Notice.  The assumption of the defense of a Claim by the Indemnifying Party will not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify the Indemnified Party in respect of the Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified Party&#8217;s claim for indemnification.  Upon assuming the defense of a Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Claim any legal counsel selected by the Indemnifying Party that is reasonably satisfactory to the Indemnified Party.  In the event the Indemnifying Party assumes the defense of a Claim, the Indemnified Party will promptly deliver to the Indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Claim.  Should the Indemnifying Party assume the defense of a Claim, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of such Claim.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Right to Participate in Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting Section&#160;11.2.2, the Indemnified Party will be entitled to (a)&#160;participate in, but not control, the defense of such Claim and to engage counsel of its choice for such purpose&#59; provided, however, that such engagement will be at the Indemnified Party&#8217;s own expense unless the engagement thereof has been specifically authorized by the Indemnifying Party in writing, and (b)&#160;control its defense of such Claim and to engage counsel of its choice for such purpose, at the expense of the Indemnifying </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;58</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party, if the Indemnifying Party has failed to assume the defense and engage counsel in accordance with Section&#160;11.2.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to any Losses related solely to payment of money damages in connection with a Claim and that includes a complete and unconditional release of the Indemnified Party, will not result in the Indemnified Party admitting liability, becoming subject to injunctive or other equitable relief that will otherwise adversely affect the business of the Indemnified Party in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate.  With respect to all other Losses in connection with Claims, where the Indemnifying Party has assumed the defense of the Claim in accordance with Section&#160;11.2.2, the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld, conditioned or delayed).  The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by the Indemnified Party that is reached without the written consent of the Indemnifying Party (which consent will not be unreasonably withheld, conditioned or delayed).  Regardless of whether the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party will not admit any liability with respect to, or settle, compromise or discharge, any Claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld or delayed.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Regardless of whether the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party will reasonably cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.  Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Commencing as of the Effective Date and thereafter during the Development Term, and subject to Section&#160;11.3.2 below, each Party will carry and maintain, at its own expense, insurance coverage of the kind and with liability limits that, at a minimum, satisfy the requirements of Section&#160;11.3.2, to protect itself and the other Party against any claims or liabilities that may arise from the conduct of the HNC Clinical Trials and all other rights and obligations hereunder with insurers with a minimum &#8220;A-VII&#8221; or better A.M. Best rating.  Any deductibles for such insurance policies will be assumed by the insuring Party.  Prior to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;59</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date, and annually, at each anniversary of the Effective Date (unless, during such year, expiration of the applicable policy occurs first, in which case, on such expiration date), at a Party&#8217;s written request the other Party will supply documentation of such insurance coverage via certificates of insurance, if applicable.  Each Party shall endeavor to provide the other Party a minimum of thirty&#160;(30) days&#8217; notice of cancellation or non-renewal, 10 days for non-payment of premium prior written notice if it is unable to obtain appropriate insurance coverage or if its coverage is canceled, unable to be renewed or changed.  For clarity, any insurance coverage or the failure to maintain adequate insurance coverage does not limit or reduce a Party&#8217;s liability under this Agreement.  Each Party will ensure that no subcontractor, including any Permitted Third Party, will continue to perform the work unless such subcontractor is insured as deemed appropriate by the Party engaging the Permitted Third Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Commencing as of the start of the Clinical Trials and thereafter, during the Term (or longer if otherwise stated below), at a minimum, each Party will maintain the following types of insurance coverage at a minimum level that is the greater of (a)&#160;the highest minimum level required by Applicable Law in the countries in which the HNC Clinical Trials and other obligations hereunder are being performed or (b)&#160;the following (to the extent different).</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial General Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  Commercial General Liability, &#91;***&#93; per occurrence&#59; &#91;***&#93; aggregate, including Premises &#38; Operations and Personal Injury. </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Umbrella Excess Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; &#91;***&#93; per occurrence.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; &#91;***&#93; per occurrence.  Nektar will obtain such Clinical Trials Liability insurance on a global basis, and, if required, supplemented Clinical Trials Liability Insurance in the US, at its expense and SFJ will obtain supplemental Clinical Trials Liability insurance on a country specific basis as required by Applicable Law at its expense, which will be considered Development Costs. Coverage must be maintained for as long as required by Applicable Law in each country after release of the last Subject from the Clinical Trials or where there is no legal requirement at least three (3) years after the termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Professional Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; For SFJ, any subcontractor, including any Permitted Third Party, who provides professional services to a Party for the Clinical Trials, will obtain Professional Liability Insurance in lieu of Clinical Trial Insurance, with a minimum limit of &#91;***&#93; per occurrence.  Coverage must be maintained for at least three&#160;(3) years after the later of (a)&#160;expiration or early termination of this Agreement and (b)&#160;release of the last Subject from the HNC Clinical Trials.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Insured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will include the other Party and its Affiliates as additional insured parties on such Party&#8217;s Clinical Trial Liability insurance, as set forth in Section&#160;11.3.2.3 for five&#160;(5) years after the later of termination of this Agreement or release of the last Subject from the Clinical Trials.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;60</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Product Liability Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar will be responsible for maintaining product liability insurance related to the Development and Commercialization of the Product at its expense with SFJ to be named as an additional insured party.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 12</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representations, Warranties and Covenants of Both Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.1&#160;&#160;&#160;&#160;Each Party hereby represents and warrants that it has the requisite corporate power and authority to enter into this Agreement and that this Agreement constitutes a legal and valid obligation binding upon such Party, enforceable in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.2&#160;&#160;&#160;&#160;Each Party hereby represents and warrants that it is not a party to any agreement that would prevent it from fulfilling its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.3&#160;&#160;&#160;&#160;Each Party agrees, on behalf of itself and its Affiliates, that for the performance of its obligations hereunder, it shall (and shall use Commercially Reasonable Efforts to cause its Permitted Third Parties engaged in connection with the subject matter of this Agreement and its and their respective officers, directors, employees, agents, representatives and consultants (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to)&#58;</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.3.1&#160;&#160;&#160;&#160;comply with the Anti-Corruption Laws and shall not take any action that will, or would reasonably be expected to, cause the other Party or its Affiliates to be in violation of any Anti-Corruption Laws&#59; and </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.3.2&#160;&#160;&#160;&#160;promptly provide the other Party with written notice of the following events&#58; (a)&#160;upon becoming aware of any breach or violation by such Party, its Affiliate or any of its or their respective Representatives of any representation, warranty or undertaking set forth in Section&#160;12.1.3.1, or (b)&#160;upon receiving a formal notification that it is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of its Representatives connected with this Agreement that any of them is the target of a formal investigation by a governmental authority for a Material Anti-Corruption Law Violation. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.4&#160;&#160;&#160;&#160;Each Party represents that neither it, nor any of its Affiliates, nor to its Knowledge any Permitted Third Parties engaged by it to perform activities in relation to the Product as of the Effective Date is debarred, and each Party covenants that it shall use reasonable efforts to ensure that neither it, nor any of its Affiliates is debarred, in each case under subsections&#160;306(a) or (b) of the US Federal Food, Drug, and Cosmetic Act (US Generic Drug Enforcement Act of 1992&#59; 21 U.S.C. 335a (a) or (b)), and represents that it has not and covenants that it will not, in each case, to its Knowledge, use in any capacity the services of any Person or Permitted Third Party debarred under this law to conduct the HNC Clinical Trials.  Each Party further represents that as of the Effective Date, neither it, nor any of its Affiliates are excluded from any federal health care program, including but not limited to Medicare and Medicaid.  Each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;61</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party will notify the JSC immediately if any of the representations contained in this Section&#160;12.1.4 becomes untrue to such Party&#8217;s Knowledge in any respect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.5&#160;&#160;&#160;&#160;Each Party hereby represents and warrants that it is licensed, registered, or otherwise qualified in all material respects under all Applicable Laws to do business in each jurisdiction where such licenses, registrations or other qualifications are required.  Each Party further covenants that it and its Permitted Third Parties have, or will have at the required times, such certifications, permits, and authorizations as are required to conduct the HNC Clinical Trials and perform any and all of their obligations in connection with the HNC Clinical Trials supervised by it.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Nektar Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licensure, Registration and Accreditation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar hereby represents and warrants that it is licensed, registered, or otherwise qualified in all material respects under all Applicable Laws to do business in each jurisdiction where such licenses, registrations or other qualifications are required.  Nektar further represents and warrants that there has not been and covenants that there will not be during the Term any breach or default by Nektar under the BMS Strategic Collaboration Agreement or the Merck CTCSA which has not been or will not be, as applicable, timely cured as permitted thereunder, and that the BMS Strategic Collaboration Agreement and Merck CTCSA are and shall continue to be in full force and effect during the Term, except to the extent that such a breach, default or failure as to the BMS Strategic Collaboration Agreement or Merck CTCSA, as applicable, would not have a material adverse effect on Nektar&#8217;s ability to satisfy its obligations under this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.2&#160;&#160;&#160;&#160;&#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CRO Inquiry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar hereby represents and warrants that, up to and as at the Effective Date, after due inquiry to its CRO responsible for conducting the Clinical Trials, Nektar has not received any verbal or written notice of the occurrence of any Serious Safety Issue in the Clinical Trials.    </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar hereby represents and warrants that, prior to the Effective Date, (a)&#160;it has conducted all preclinical and clinical activities related to the development of the Product for the Indications in material compliance with Applicable Laws, and (b)&#160;to the Knowledge of Nektar, all Third Parties utilized by Nektar to perform any portion of the preclinical and clinical activities have conducted such portion of such preclinical activities in material compliance with Applicable Laws.  Nektar will manufacture or contract with a Third Party to manufacture the Product for the Clinical Trials in accordance with GMP.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nektar owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, information, proprietary rights and processes necessary for the Development, manufacture and Commercialization of the Product without, to the Knowledge of Nektar, any known conflict with or known infringement of the rights of others.  To the Knowledge of Nektar, the Development, manufacture and Commercialization of the Product by Nektar does not violate and will not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;62</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">violate any license or infringes or will infringe any intellectual property rights of any Third Party.  There are no pending or, to the Knowledge of Nektar, threatened claims or proceedings by any Person with respect to the ownership, validity or enforceability of the Nektar Intellectual Property. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;12.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, there are no outstanding options, licenses or agreements of any kind granted by Nektar relating to the Development, manufacture and Commercialization of the Product.  Nektar has not received any written communications alleging that Nektar has violated or that the Development, manufacture and Commercialization of the Product would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets or other proprietary rights of any Third Party.  To the Knowledge of Nektar, all issued Patents included in the Nektar Intellectual Property as of the Effective Date are valid and enforceable.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.6&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Representations, Warranty and Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3.1&#160;&#160;&#160;&#160;SFJ hereby represents, warrants and covenants that it will have, as and when needed, sufficient funds to satisfy its obligations hereunder as they become due. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licensure, Registration and Accreditation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ hereby represents and warrants that it is licensed, registered, or otherwise qualified in all material respects under all Applicable Laws to do business in each jurisdiction where such licenses, registrations or other qualifications are required, except as would not reasonably be expected to have a material adverse effect on the Development or Commercialization of the Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DISCLAIMER OF REPRESENTATIONS AND WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4.1&#160;&#160;&#160;&#160;Each Party hereby agrees and understands that because the Clinical Trials and the Product are experimental in nature, the outcome is inherently uncertain and unpredictable.  Each Party hereby agrees and understands that the other Party makes no representation, guarantee or warranty, express or implied, regarding the outcome of the Clinical Trials (including achievement of the applicable Clinical Trial Success Criteria), any Research Results generated after the Effective Date, the ability to obtain Regulatory Approval or the patentability, legal protectability or usefulness of any Intellectual Property arising from the Clinical Trials.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4.2&#160;&#160;&#160;&#160;EXCEPT AS OTHERWISE SET FORTH IN THIS ARTICLE&#160;12, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, EITHER ORAL OR WRITTEN, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING ANY REPRESENTATION OR WARRANTY REGARDING THE USE, RESULTS OR EFFICACY OF THE PRODUCT.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 13</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;63</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of this Agreement (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will commence on the Effective Date and will expire upon the earliest of (i)&#160;termination of this Agreement in accordance with Section&#160;13.2, (ii)&#160;the date of payment of the last Success Payment due based on all applicable Regulatory Approvals which have been received and (iii)&#160;the date of Development Termination, if any.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Either Party may terminate this Agreement immediately in the event of a material breach of this Agreement by the other Party (including, for the avoidance of doubt, a Success Payment Default)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the breaching Party has received written notice from the non-breaching Party of such breach, specifying in the reasonable detail the particulars of the alleged breach and such breach has not been cured &#91;***&#93; after the date of the relevant notice.  For the avoidance of doubt, (i)&#160;it will not be a material breach by Nektar if Nektar elects not to file for Regulatory Approval in the event a Clinical Trial does not achieve its Clinical Trial Success Criteria, (ii)&#160;a material breach by Nektar under the BMS Agreement that materially and adversely impacts the completion of the Melanoma Clinical Trial or the submission of a filing for Regulatory Approval will be deemed to be a material breach of this Agreement by Nektar and (iii) a failure by Nektar to use Commercially Reasonable Efforts to enforce the BMS Agreement in the event of a material breach by BMS under the BMS Agreement that materially and adversely impacts  the completion of the Melanoma Clinical Trial or the submission of a filing for Regulatory Approval will be deemed to be a material breach of this Agreement by Nektar.  The non-breaching Party shall have the right to pursue remedies it may have at law or equity for such breach, including the right to seek damages from the breaching Party.  </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event this Agreement is terminated pursuant to this Section&#160;13.2.1 then Nektar may elect to continue development of the Product.  If any Regulatory Approval or Other Indication Regulatory Approval is obtained following such termination, Nektar shall remain obligated to pay to SFJ any Success Payments that become due and payable pursuant to Article&#160;6 at the time such payments become due and payable pursuant to Article&#160;6 (if ever) (except to the extent of the amount of any Buy-Out Payment pursuant to Section&#160;6.7) as a result of such Regulatory Approval or Other Indication Regulatory Approval, provided that such Success Payments (or Buy-Out Payment paid by Nektar, as applicable) shall be adjusted as set forth in Section&#160;6.2.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Breach for Success Payment Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ may terminate this Agreement immediately in the event that Nektar fails to make any Success Payment on or before its due date (a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Success Payment Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Nektar has received written notice from SFJ of such breach, specifying in the reasonable detail the particulars of the Success Payment Default and such Success Payment Default has not been </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;64</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">cured &#91;***&#93; after the date of the relevant notice.  In the event that SFJ terminates this Agreement pursuant to this Section&#160;13.2.1.2, Nektar shall pay SFJ, &#91;***&#93; following such termination, an amount equal to all remaining unpaid Success Payments arising from Regulatory Approvals or Other Indication Regulatory Approval that occurred prior to such termination, as adjusted pursuant to Section&#160;6.2.  Additionally, if Nektar obtains any Regulatory Approval or Other Indication Regulatory Approval following such termination, Nektar shall remain obligated to pay to SFJ all Success Payments arising from such Regulatory Approval or Other Indication Regulatory Approval in one lump sum payable within thirty&#160;(30) days of such Regulatory Approval or Other Indication Regulatory Approval (except to the extent of the amount of any Buy-Out Payment pursuant to Section&#160;6.7), provided that each lump-sum Success Payment (or Buy-Out Payment paid by Nektar, as applicable) shall be adjusted as set forth in Section&#160;6.2.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Failure to Achieve Clinical Trial Success Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.2.1&#160;&#160;&#160;&#160;SFJ may terminate this Agreement at any time upon written notice to Nektar in the event that any HNC Clinical Trial does not achieve its Clinical Trial Success Criteria.  In the event of such termination by SFJ, or in the event of any termination pursuant to Section&#160;13.2.5 due to a Safety Concern, then SFJ shall have a post-termination obligation to fund the wind down the HNC Clinical Trials (including, for the avoidance of doubt, any non-cancellable obligations, but excluding any costs associated with the continued conduct of the HNC Clinical Trials) and conduct operational wind-down of the HNC Clinical Trials in accordance with good clinical practice guidelines, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that SFJ&#8217;s aggregate post-termination monetary obligation to fund and conduct the operational wind-down of HNC Clinical Trials (which for the avoidance of doubt shall be deemed to be Development Costs paid by SFJ), together with all other Development Costs funded by SFJ prior to such termination, shall in no event exceed the Maximum Development Costs.</font></div><div style="margin-bottom:12pt;text-indent:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.2.2&#160;&#160;&#160;&#160;In the event this Agreement is terminated by SFJ pursuant to Section&#160;13.2.2.1, then&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Nektar may elect to continue development of the Product and obtain Regulatory Approval for the Melanoma Indication or the HNC Indication following such termination.  </font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If, within thirty&#160;(30) days following such termination Nektar notifies SFJ that it has elected not to continue development of the Product and obtain Regulatory Approval for the HNC Indication following such termination as contemplated by clause&#160;(i) of Section&#160;13.2.2.2(a) (a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), SFJ shall have a post-termination obligation to fund the wind down the HNC Clinical Trials (including, for the avoidance of doubt, any non-cancellable obligations but excluding any costs associated with continued conduct of the HNC Clinical Trials) and conduct operational wind-down of the HNC Clinical Trials in accordance with good clinical practice guidelines, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that SFJ&#8217;s aggregate post-termination monetary obligation to fund and conduct the operational wind-down of HNC Clinical Trials (which for the avoidance of doubt shall be deemed to be Development Costs paid by SFJ), together with all other Development Costs funded by SFJ prior to such termination, shall in no event exceed the Maximum Development Costs. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;65</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Failure to Receive Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.3.1&#160;&#160;&#160;&#160;This Agreement will, upon written notice from either Party to the other Party, terminate with no further action from either Party if the Product has not received Regulatory Approval from the FDA for any of the Indications after completion of the Clinical Trials, submission by Nektar or BMS, as applicable, of applications for Regulatory Approvals to the FDA, and after Commercially Reasonable Efforts by Nektar to obtain such Regulatory Approvals based on such submitted applications as may be amended from time to time.  For the avoidance of doubt, if Regulatory Approval for any Indication or any Other Indication is received from the FDA, then his Agreement may not thereafter be terminated pursuant to this Section&#160;13.2.3.1.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.3.2&#160;&#160;&#160;&#160;This Agreement will, upon written notice from either Party to the other Party, terminate with no further action from either Party, if each of the Clinical Trials is completed or terminated and, with respect to each Clinical Trial, (a)&#160;a primary endpoint in such Clinical Trial sufficient for regulatory filing in the U.S. for either full Regulatory Approval or Accelerated Regulatory Approval is not achieved and (b)&#160;SFJ reasonably determines that the Research Results of such Clinical Trial do not support Regulatory Approval.  For avoidance of doubt, if an application for Regulatory Approval is submitted for any of the Indications or any Other Indication, then this Agreement may not thereafter be terminated pursuant to this Section&#160;13.2.3.2.  In the event of any such termination related to the Melanoma Clinical Trial, if (i)&#160;the HNC Clinical Trial has been completed but the HNC Clinical Trial Success Criteria was not achieved or (ii)&#160;HNC Clinical Trial Futility has occurred, then SFJ shall have a post-termination obligation to fund the wind down the HNC Clinical Trials (including, for the avoidance of doubt, any non-cancellable obligations, but excluding any costs associated with the continued conduct of the HNC Clinical Trials) and conduct operational wind-down of the HNC Clinical Trials in accordance with good clinical practice guidelines, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that SFJ&#8217;s aggregate post-termination monetary obligation to fund and conduct the operational wind-down of HNC Clinical Trials (which for the avoidance of doubt shall be deemed to be Development Costs paid by SFJ), together with all other Development Costs funded by SFJ prior to such termination, shall in no event exceed the Maximum Development Costs.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.3.3&#160;&#160;&#160;&#160;In the event that this Agreement is terminated pursuant to this Section&#160;13.2.3, then, if Nektar elects to continue development of the Product for any Indication or Other Indication, obtains any Regulatory Approval or Other Indication Regulatory Approval following such termination, and the Trial Data Package, Research Results or the Melanoma Clinical Trial Research Results are utilized to demonstrate the efficacy of the Product in support of such Regulatory Approval or Other Indication Regulatory Approval, Nektar shall remain obligated to make any Success Payments that become due and payable pursuant to Article&#160;6 at such time that such payments become due and payable (if ever) pursuant to Article&#160;6 as a result of such Regulatory Approval or Other Indication Regulatory Approval (except to the extent of the amount of any Buy-Out Payment paid by Nektar pursuant to Section&#160;6.7), provided that such Success Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section&#160;6.2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;66</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party may terminate this Agreement upon written notice to the other Party if the other Party makes an assignment for the benefit of creditors, or commences a case or proceeding under any bankruptcy, reorganization, insolvency, or similar laws, has a trustee or receiver or similar officer of any court appointed for such Party, or for substantial part of the property of such Party, or bankruptcy, reorganization, insolvency, or liquidation proceedings are instituted by or against such Party without such proceedings being dismissed, in each of the foregoing cases for a period of at least &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.4.1&#160;&#160;&#160;&#160;In the event SFJ terminates this Agreement pursuant to this Section&#160;13.2.4 at any time prior to the First Regulatory Approval, then Nektar will pay SFJ within sixty&#160;(60) days of the date of termination an amount equal to one hundred percent&#160;(100%) of Development Costs paid or incurred by SFJ prior to such termination.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.4.2&#160;&#160;&#160;&#160;In the event SFJ terminates this Agreement pursuant to this Section&#160;13.2.4 at any time on or after the First Regulatory Approval and prior to the Second Regulatory Approval, then (a)&#160;Nektar will pay SFJ within sixty&#160;(60) days of the date of termination an amount equal to all remaining unpaid Schedule&#160;A Success Payments (as adjusted pursuant to Section&#160;6.2) plus (b)&#160;the amount, if any, by which one hundred percent&#160;(100%) of Development Costs paid or incurred by SFJ prior to such termination exceeds the amount set forth in clause&#160;(a). </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.4.3&#160;&#160;&#160;&#160;In the event SFJ terminates this Agreement pursuant to this Section&#160;13.2.4 at any time on or after the Second Regulatory Approval, then Nektar will pay SFJ within sixty&#160;(60) days of the date of termination an amount equal to all remaining unpaid Schedule&#160;A Success Payments and all remaining Schedule&#160;B Success Payments (in each case as adjusted pursuant to Section&#160;6.2).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Safety Concerns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party may terminate this Agreement upon written notice to the other Party if (a)(i)&#160;the IDMC recommends termination of the HNC Clinical Trial for reasons pertaining to the health or safety of the Subjects or as a result of HNC Clinical Trial Futility and (ii)&#160;Nektar in good faith reasonably believes there to be a basis for termination of the HNC Clinical Trial based upon such IDMC recommendation for reasons pertaining to the health or safety of the Subjects or for HNC Clinical Trial Futility, or (b)&#160;the Parties mutually agree a material health or safety concern with respect to the Subjects of the HNC Clinical Trial exists (either (a) or (b) being a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Safety Concern</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In the event that this Agreement terminates pursuant to this Section&#160;13.2.5 due to a Safety Concern, then Nektar will not be obligated to pay SFJ any Success Payments arising from an HNC Regulatory Approval or reimburse SFJ for any Development Costs incurred by SFJ in connection with the HNC Clinical Trials (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that for the avoidance of doubt, Nektar will remain obligated to pay SFJ for any Success Payments arising from a Melanoma Regulatory Approval or an Other Regulatory Approval, regardless of whether such Melanoma Regulatory Approval or Other Regulatory Approval occurs before or after such termination of this Agreement).  Notwithstanding the foregoing, if this Agreement terminates pursuant to this Section&#160;13.2.5&#58; (A)&#160;if (i)&#160;such termination was due to a Safety Concern that was Known by Nektar as being material as of the Effective Date, (ii)&#160;the material data Known to Nektar as of the Effective Date that show, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;67</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">demonstrate, or identify such material Safety Concern were not included in the Data Room, disclosed in writing to SFJ or otherwise publicly known prior to the Effective Date and (iii)&#160;SFJ was not otherwise aware of such Safety Concern as of the Effective Date, then Nektar will pay SFJ within sixty&#160;(60) days of the date of termination an amount equal to three hundred percent&#160;(300%) of Development Costs paid or incurred by SFJ through the date of termination, with all Success Payments previously made to SFJ to be credited against such termination payment, and (B)&#160;if following such termination Nektar elects to continue development of the Product pursuant to the HNC Clinical Trials and obtains HNC Regulatory Approval, Nektar will remain obligated to pay any Success Payments that become due and payable pursuant to Article&#160;6 at such time as such Success Payments become due and payable (if ever) pursuant to Article&#160;6 as a result of such Regulatory Approval or Other Indication Regulatory Approval (except to the extent of the amount of any Buy-Out Payment paid by Nektar pursuant to Section&#160;6.7), provided that such Success Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section&#160;6.2 and shall be reduced by the amount previously paid by Nektar to SFJ pursuant to this Section&#160;13.2.5.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Certain Breaches&#47;Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.6.1&#160;&#160;&#160;&#160;SFJ may terminate this Agreement if (a)&#160;Nektar has breached by its own actions, or by the actions of any of its Representatives, either of Section&#160;12.1.3 or Section&#160;12.1.4 in any material respect, (b)&#160;a Representative of Nektar has breached the policy attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;F1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in any material respect and such breach results in a Material Anti-Corruption Law Violation, or (c)&#160;(i)&#160;Nektar or any of its Representatives on behalf of Nektar makes improper payments to Government Officials or any other person by or (ii)&#160;Nektar or any of its Representatives with respect to services performed on behalf of Nektar accepts any payment, item, or benefit, regardless of value, as an improper inducement to award, obtain or retain business or otherwise gain or grant an improper business advantage from or to any other person or entity, in each case of (i) or (ii) that constitutes a Material Anti-Corruption Law Violation (in any such case ((a), (b) or (c)), a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nektar Compliance Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless such Nektar Compliance Breach can be cured without materially delaying or reducing the probability of completing the Clinical Trials or achieving Regulatory Approval of any of the Indications.  In the event of such termination, Nektar will not be entitled to any further payments under Article&#160;4, regardless of any activities undertaken or agreements with additional Third Parties entered into prior to termination.  In the event that SFJ terminates this Agreement pursuant to this Section&#160;13.2.6.1, then (a)&#160;Nektar will pay SFJ, within sixty&#160;(60) days of the date of termination, an amount equal to one hundred fifty percent&#160;(150%) of Development Costs paid or incurred to Nektar by SFJ prior to such termination and (b)&#160;if Nektar elects to continue development of the Product and obtains any Regulatory Approval or Other Indication Regulatory Approval following such termination, Nektar shall remain obligated to pay to SFJ any Success Payments that become due and payable pursuant to Article&#160;6 at such time that such payments become due and payable (if ever) pursuant to Article&#160;6 as a result of such Regulatory Approval or Other Indication Regulatory Approval (except to the extent of the amount of any Buy-Out Payment paid by Nektar pursuant to Section&#160;6.7), provided that such Success Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section&#160;6.2, and reduced by the amount previously paid by Nektar to SFJ pursuant to this Section&#160;13.2.6.1. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;68</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.6.2&#160;&#160;&#160;&#160;Nektar may terminate this Agreement if (a)&#160;SFJ has breached by its own actions, or by the actions of any of its Representatives, either of Section&#160;12.1.3 or Section&#160;12.1.4 in any material respect, (b)&#160;a Representative of SFJ has breached the policy attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in any material respect and such breach results in a Material Anti-Corruption Law Violation, or (c)&#160;(i)&#160;SFJ or any of its Representatives on behalf of SFJ makes improper payments to Government Officials or any other person or (ii)&#160;SFJ or any of its Representatives with respect to services performed on behalf of SFJ accepts any payment, item, or benefit, regardless of value, as an improper inducement to award, obtain or retain business or otherwise gain or grant an improper business advantage from or to any other person or entity, in each case of (i) or (ii) that constitutes a Material Anti-Corruption Law Violation (in any such case ((a), (b) or (c)), an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFJ Compliance Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless such SFJ Compliance Breach can be cured without materially delaying or reducing the probability of completing the Clinical Trials or achieving Regulatory Approval of any of the Indications.  In the event of such termination, SFJ will not be entitled to any further payments hereunder except as set forth below.  In the event that Nektar terminates this Agreement pursuant to this Section&#160;13.2.6.2, then Nektar shall pay to SFJ an amount equal to the 100% of the Development Costs paid or incurred by SFJ as of the date of such termination, less the amount of all documented out-of-pocket expenses incurred by or on behalf of Nektar as a result or arising out of such violation by SFJ or any of its Representatives (including any and all amounts paid by Nektar as penalties or fines for such violation, in settlement of legal or administrative proceedings relating to such violation, or otherwise).</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.6.3&#160;&#160;&#160;&#160;If a Party learns that any of its Permitted Third Parties has materially breached Section&#160;12.1.3 or Section&#160;12.1.4, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;F1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as applicable, or that improper payments are being or have been made to Government Officials by any of its Permitted Third Parties with respect to services performed on behalf of such Party or in connection with the Clinical Trials, such Party will notify the other Party and, at the other Party&#8217;s option, such Party will terminate its relationship with such Permitted Third Party with respect to the Clinical Trials.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Because of Adverse Patent Impact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ may terminate this Agreement if (a)&#160;Nektar is prevented, by final and non-appealable judgment of a court of competent jurisdiction, from further developing or commercializing the Product for any of the Indications, (b)&#160;the future value of the Product would likely be materially adversely affected due to (i)&#160;a final and non-appealable judgment of a court of competent jurisdiction that Third Party patents that were not publicly disclosed or known to SFJ at the Effective Date are infringed by the manufacture, use, sale, offer for sale or import of the Product for any of the Indications (an&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adverse Patent Impact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (c)&#160;SFJ provides written notice to Nektar of such Adverse Patent Impact and (d)&#160;Nektar does not cure such Adverse Patent Impact within &#91;***&#93; from the date of SFJ&#8217;s notice to Nektar of an Adverse Patent Impact.  In the event that SFJ terminates this Agreement pursuant to this Section&#160;13.2.7, then Nektar shall pay to SFJ, within sixty&#160;(60) days of the date of termination, an amount equal to all Development Costs paid or incurred by SFJ as of the date of termination.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for JSC Decision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  SFJ may, in its sole discretion, terminate this Agreement in its entirety at any time prior to the date of receipt of the first Regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;69</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Approval for any Indication or Other Indication in the event (a)&#160;Nektar exercises its decision-making authority under Section&#160;5.2.4 to approve a matter set forth in Section&#160;5.2.2 and, after escalation to the Executive Officers in accordance with Section&#160;5.2.4, SFJ continues in good faith to disagree with such decision and such decision would materially delay or reduce the probability of achieving Regulatory Approval of any of the Indications. In the event that SFJ terminates this Agreement pursuant to this Section&#160;13.2.8, then Nektar will pay to SFJ, within sixty&#160;(60) days of the date of termination, an amount equal to the 100% of the Development Costs paid or incurred by SFJ as of the date of such termination plus interest at the annual rate of twenty-five percent&#160;(25%) from the date such Development Costs were paid or incurred by SFJ.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Additional Consequences of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any termination of this Agreement pursuant to Section&#160;13.2, then&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.1&#160;&#160;&#160;&#160;effective as of such termination, SFJ shall, and it hereby does, assign to Nektar all of SFJ&#8217;s and its Affiliates&#8217; right, title and interest in and to all Product Filings, if any, then owned or Controlled by SFJ or any of its Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if any such Product Filing is not immediately transferable in a country, SFJ shall provide Nektar with all benefit of such Product Filing and such assistance and cooperation as necessary or reasonably requested by Nektar to timely transfer such Product Filing to Nektar or its designee or, at Nektar&#8217;s option, to enable Nektar to obtain a substitute for such Product Filing without disruption to Nektar&#8217;s development or Commercialization of the Product in such country&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.2&#160;&#160;&#160;&#160;within thirty&#160;(30) days after assignment of the Product Filings, if any, pursuant to Section&#160;13.3.1, SFJ shall deliver to Nektar&#58; (a)&#160;true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates), and disclose to Nektar in writing all previously-undisclosed Research Results within the Trial Data Package&#59; (b)&#160;formally transfer or assign, or cause to be formally transferred or assigned, into the name of Nektar or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates)&#59; and (c)&#160;take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to Nektar or its designee&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.3&#160;&#160;&#160;&#160;at Nektar&#8217;s written request and election in Nektar&#8217;s sole discretion, SFJ shall and hereby does, and shall cause its Affiliates to either&#58; (i)&#160;wind down in accordance with Applicable Law and observing applicable ethical and regulatory guidelines any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination, at SFJ&#8217;s cost and expense (which for the avoidance of doubt shall be deemed to be Development Costs paid by SFJ)&#59; or (ii)&#160;(x)&#160;transfer control to Nektar of any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination and (y)&#160;continue to conduct such Clinical Trials being conducted by or on behalf of SFJ or an Affiliate as of the effective date of termination for up to six&#160;(6) months to enable such transfer to be completed without interruption of any such Clinical Trial, in each case ((x) and (y)), at Nektar&#8217;s cost and expense&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;70</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.4&#160;&#160;&#160;&#160;SFJ shall, and shall cause its Affiliates to, promptly assign to Nektar or its designee any and all Clinical Trial Agreements, CRO Agreements and other Vendor Agreements to which any of them is a party and cooperate in good faith with Nektar to provide appropriate notice and new contact information to the applicable Sites, Clinical Investigators, CROs and other Vendors and Nektar shall accept such assignment of all obligations of SFJ and its Affiliates thereunder without recourse to SFJ other than any indemnification obligations which SFJ may be liable for thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Surviving Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly set forth in Section&#160;13.4.2, expiration or termination of this Agreement for any reason will not release either Party from any obligation or liability which, at the time of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusive Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything herein to the contrary, termination of this Agreement by a Party will be without prejudice to other remedies such Party may have at law or equity&#59; provided that the payment by Nektar to SFJ of the amounts specified as being payable upon a given termination in Section&#160;13.2 shall be in lieu of any claim for damages that SFJ may have arising out of or in connection with the circumstances that formed the basis for such termination..</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Surviving Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following provisions of this Agreement, together with any other provisions that expressly specify that they survive, will survive expiration or earlier termination of this Agreement&#58; </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.3.1&#160;&#160;&#160;&#160;Article&#160;1, Article&#160;8, Article&#160;9, Article&#160;10, Article&#160;11, Section&#160;12.1, Section&#160;12.4, Section&#160;13.4 and Article&#160;14&#59; and</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.3.2&#160;&#160;&#160;&#160;in addition, solely in the case of termination of this Agreement after payment by SFJ to Nektar, or incurrence by SFJ, of any Development Costs, but not in the case of expiration of this Agreement, Sections&#160;6.1&#8211;6.7, 7.1&#8211;7.2 (in the case of such Sections&#160;7.1&#8211;7.2, such provisions shall terminate only after all Nektar Obligations, other than contingent indemnity obligations, have been paid to SFJ or otherwise satisfied in accordance with this Agreement in full), 13.2 and 13.3.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 14</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Relationship with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will be responsible for any breach by its Affiliates of its obligations in connection with this Agreement, and each such Party will remain responsible for any responsibilities that it has delegated to an Affiliate as though such Party had performed (or failed to perform) such responsibilities itself.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;71</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties agree on behalf of themselves and their respective Affiliates that any prior Confidentiality Agreement, by and between Nektar and SFJ (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prior CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is hereby terminated and superseded by this Agreement and that all Information disclosed under or pursuant to the Prior CDAs will constitute Confidential Information disclosed pursuant to this Agreement and will be subject to the terms of Article&#160;9, with the confidentiality and non-use provisions of Article&#160;9 applying retroactively to such Confidential Information from the date of disclosure.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice or other communication required or permitted to be given by either Party under this Agreement will be in writing and will be effective when delivered if delivered by hand, reputable courier service, or five&#160;(5) days after mailing if mailed by registered or certified mail, postage prepaid and return receipt requested, addressed to the other Party at the following addresses or such other address as may be designated by notice pursuant to this Section&#160;14.3&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.1&#160;&#160;&#160;&#160;If to Nektar&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nektar Therapeutics</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">455 Mission Bay Boulevard South, Suite 100</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">South San Francisco, CA 94157</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USA</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  Chief Executive Officer</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nektar Therapeutics</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">455 Mission Bay Boulevard South, Suite 100</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">South San Francisco, CA 94157</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USA</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  General Counsel</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with another copy, which shall not constitute notice, to&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Goodwin Procter LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">601 Marshall Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Redwood City, CA 94063</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Shane Albright</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;72</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3.2&#160;&#160;&#160;&#160;If to SFJ&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SFJ Pharmaceuticals XII, L.P.</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c&#47;o SFJ Pharmaceuticals XII GP LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SIX, 2nd Floor, Cricket Square</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PO Box 2681</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grand Cayman, KY1-1111</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cayman Islands</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  Robert DeBenedetto</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Morrison &#38; Foerster LLP</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">755 Page Mill Road </font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Palo Alto, CA 94304-1018</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  Michael O&#8217;Donnell</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party will be liable for any breach or delay in performance of any obligation under this Agreement to the extent caused by any of the following&#58; war, terrorism, riot, fire, explosion, pandemic, government prescribed shut-downs, accident, flood, sabotage, changes in Applicable Laws, actions of Governmental Authorities, or any other event beyond the reasonable control of such Party.  The Party invoking this Section&#160;14.4 must provide prompt written notice and full particulars of such event to the other Party and will use diligent and commercially reasonable efforts to mitigate the effects of any such force majeure event on such Party&#8217;s compliance with and performance under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party will use the other Party&#8217;s nor any of its Affiliates&#8217; (and, in the case of SFJ and its Affiliates, their respective investors including the Specified Investors) names or trademarks in any promotional materials or advertising without the prior written consent of the other Party except as otherwise expressly permitted in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without the prior written consent of the other Party hereto, neither Party will sell, transfer, assign, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder&#59; provided, however, that either Party may assign, sublicense or transfer this Agreement and all of its rights and obligations hereunder, in their entirety, to any of its Affiliates or to a successor in connection with the sale or other transfer of all or substantially all of its business or assets to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise, and whether this Agreement is actually assigned or is assumed by a Third Party acquirer or the surviving corporation resulting from such transaction by operation of law (e.g., in the context of a reverse triangular merger).  Notwithstanding the foregoing, any assignment of the rights or obligations under this Agreement by a Party (i)&#160;to an Affiliate shall require such Party to guarantee the performance of such Affiliate&#8217;s financial and performance obligations hereunder or (ii)&#160;in connection with the sale or other transfer of all or substantially all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;73</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of such Party&#8217;s business or assets to which this Agreement relates shall require the ultimate Affiliate controlling the other party in such transaction to guarantee such Party&#8217;s financial and performance obligations hereunder and such Party shall remain liable for such financial and performance obligations notwithstanding such sale or other transfer of all or substantially all of such Party&#8217;s business or assets to which this Agreement relates.  Furthermore, notwithstanding any of the foregoing, SFJ may assign its right to receive Success Payments to (a)&#160;the limited partners of SFJ or its parent entities, provided that such limited partners notify Nektar of a single account to which Nektar can make all payments that may become due hereunder and assume sole responsibility for distributing all such payments, or to a liquidating trust or similar entity that is established to receive and distribute Success Payments for the benefit of the limited partners in SFJ, that is required to carry out such responsibilities as a single entity, (and in any case under this clause&#160;(a), Nektar shall have the unconditional right to follow any instruction it receives or rely on any actions, consents and communications received from or taken by such limited partners or liquidating trust or similar entity without any duty to verify or otherwise determine the validity thereof), (b)&#160;an other Third Party to which SFJ assigns this Agreement in its entirety, as permitted by the preceding provisions of this Section&#160;14.6, or (c)&#160;an other Third Party to which SFJ sells, assigns or pledges some or all of the Success Payments as permitted by Section&#160;6.7.3.  This Agreement is binding upon and will inure to the benefit of each of the Parties, its successors and permitted assigns. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will execute such further reasonable documents and perform such further reasonable acts as may be necessary to comply with or more fully effectuate the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party to this Agreement will bear its own costs and expenses, including attorneys&#8217; fees and expenses, in connection with the closing of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The construction and validity of this Agreement and the provisions hereof, and the rights and obligations of the Parties hereunder, will be governed by the internal laws of the State of New York, USA, and, to the extent applicable to Intellectual Property, the applicable federal laws of the US, in each instance without regard to conflict of laws principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties recognize that disputes as to certain matters relating to this Agreement may arise from time to time.  It is the objective of the Parties to establish procedures to facilitate the resolution of disputes in an expedient manner by mutual cooperation and without resort to litigation.  Accordingly, the Parties agree that any dispute, controversy or claim arising under, out of or in connection with this Agreement, including any subsequent amendments, or the validity, enforceability, construction, performance or breach hereof (and including the applicability of this Section&#160;14.10 to any such dispute, controversy or claim) (each a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be resolved as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.1&#160;&#160;&#160;&#160;Either Party shall have the right to refer such Dispute to the Executive Officers for attempted resolution by good faith negotiations for a period of &#91;***&#93;.  Any final decision mutually agreed to by the Executive Officers in writing shall be conclusive and binding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;74</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">on the Parties.  With respect to any Dispute that remains unresolved after the expiration of &#91;***&#93; after a Dispute is notified to the Executive Officers, then such Dispute be submitted to the American Arbitration Association (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for final and binding arbitration pursuant as set forth in Section&#160;14.10.2 in accordance with its Commercial Arbitration Rules then in force.  Notwithstanding the foregoing, no matters relating to breach or alleged breach of the ownership of intellectual property or rights in intellectual property or the validity or enforceability thereof shall be resolved by arbitration, but rather shall be determined by a U.S. federal court of appropriate jurisdiction.  Notwithstanding anything in this Agreement to the contrary, either Party shall be entitled to seek preliminary injunctive relief in any court of competent jurisdiction immediately if necessary to prevent irreparable harm to that Party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Arbitration Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2.1&#160;&#160;&#160;&#160;Either Party shall have the right to initiate arbitration at any time after the expiration of &#91;***&#93; after a Dispute is notified to the Executive Officers.  Questions of jurisdiction and arbitration shall be finally settled by the arbitral tribunal.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2.2&#160;&#160;&#160;&#160;The seat, or legal place, of arbitration shall be New York, New York, and the language of the arbitration shall be English.  References herein to any arbitration rules or procedures mean such rules or procedures as amended from time to time, including any successor rules or procedures, and references herein to the AAA include any successor thereto.  The arbitration shall be before a tribunal comprised of three&#160;(3) arbitrators.  Each Party shall select one arbitrator and within fifteen&#160;(15) days of the second arbitrator&#8217;s appointment, the two&#160;(2) Party-appointed arbitrators shall select the third, who shall serve as the tribunal&#8217;s chair or president.  Any arbitrator(s) not timely selected shall by selected by the AAA.  All three&#160;(3) arbitrators shall be professionals with substantial experience in development and Commercialization of biopharmaceutical products and related legal principles.  An arbitrator shall be deemed to meet these qualifications unless a Party objects within fifteen&#160;(15) days after the arbitrator is appointed.  The Parties acknowledge that this Agreement evidence a transaction involving interstate commerce.  Notwithstanding the provision in Section&#160;14.9 with respect to the applicable substantive law, this arbitration provision, and the arbitration itself, shall be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;&#160;1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">et. seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2.3&#160;&#160;&#160;&#160;Consistent with the expedited nature of arbitration, each Party will, upon the written request of the other Party, promptly provide the other with copies of documents on which the producing Party may rely in support of or in opposition to any claim or defense.  There shall be no right to depositions of witnesses unless the arbitrators find good cause to conclude that such additional discovery is necessary, in which case each Party shall be entitled to take up to a maximum of three&#160;(3) depositions, which shall be held within forty-five&#160;(45) days after such finding of good cause.  Additional depositions may be scheduled only with the permission of the arbitrators, and for good cause shown.  Each deposition shall be limited to a maximum of one&#160;(1) day&#8217;s duration.  The arbitrators shall also have the discretion to allow requests for production of documents, upon a showing of good cause.  All objections are reserved for the arbitration hearing except for objections based on privilege and proprietary or Confidential Information.  The Parties shall not utilize any other discovery mechanisms, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;75</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">including international processes, U.S. federal statutes and third party discovery, to obtain additional evidence for use in the arbitration.  Any Dispute regarding discovery, or the relevance or scope thereof, shall be determined by the arbitrators, which determination shall be conclusive.  All discovery shall be completed within sixty&#160;(60) days following the appointment of the arbitrators.  The arbitrators will conduct any evidentiary hearing or final hearing on the merits within one hundred twenty&#160;(120) days of confirmation of the Panel, and shall issue a reasoned decision within forty-five&#160;(45) days of the conclusion of the evidentiary hearing or final hearing on the merits..</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2.4&#160;&#160;&#160;&#160;The arbitrators shall have no authority to award punitive, enhanced, multiple or other damages not measured by the prevailing Party&#8217;s actual damages, except as may be required by statute.  Each Party expressly waives and foregoes any right to consequential, punitive, special, exemplary or similar damages or lost profits, and the arbitrators will have no authority to award the same.  The arbitrators shall have no power or authority, under the AAA&#8217;s Commercial Arbitration Rules and procedures or otherwise, to relieve the Parties from their agreement hereunder to arbitrate or otherwise to amend or disregard any provision of this Agreement.  The cost of the arbitration, including the fees of the arbitrators and reasonable attorneys&#8217; fees of the prevailing Party, shall be borne by the Party the arbitrator determines has not prevailed in the arbitration.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2.5&#160;&#160;&#160;&#160;If an arbitral award does not impose an injunction on the losing Party or contain a money damages award in excess of five million dollars ($5,000,000), then the arbitral award shall be final and binding and shall only be subject to such challenges as would otherwise be permissible under the Federal Arbitration Act, 9 U.S.C. &#167; 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">et.&#160;seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Judgment on such an award may be entered in any court of competent jurisdiction and the Parties undertake to carry out the award without delay.  In the event that an arbitral award imposes an injunction or contains a monetary award in excess of five million dollars ($5,000,000), the Parties agree that such award may be appealed pursuant to the AAA&#8217;s Optional Appellate Arbitration Rules (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appellate Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and should not be considered to be final and binding until after the time for filing the notice of appeal under the Appellate Rules has expired.  Appeals must be initiated within thirty&#160;(30) days of receipt of the award, as defined by the Appellate Rules, by filing a Notice of Appeal within any AAA office.  Following the appeal process, the decision rendered by the appeal tribunal shall be final and binding and judgment on that award may be entered in any court of competent jurisdiction and the Parties undertake to carry out the award without delay.</font></div><div style="margin-bottom:12pt;text-indent:116.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10.2.6&#160;&#160;&#160;&#160;Except as may be required by law, or to protect or pursue a legal right to enforce or challenge an award in legal proceedings, where needed for the preparation or presentation of a claim or defense in this arbitration, or by order of the arbitral tribunal upon application of a Party, neither a Party nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  TO THE MAXIMUM EXTENT PERMITTED BY LAW AND NOTWITHSTANDING ANY PROVISION IN THIS AGREEMENT TO THE CONTRARY, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;76</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, RELIANCE OR PUNITIVE DAMAGES OR LOST OR IMPUTED PROFITS OR ROYALTIES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCTS LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE.  THE PARTIES AGREE THAT THE LIMITATIONS SPECIFIED IN THIS SECTION&#160;14.11 WILL APPLY EVEN IF ANY LIMITED REMEDY SPECIFIED IN THIS AGREEMENT IS FOUND TO HAVE FAILED OF ITS ESSENTIAL PURPOSE.  WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, &#8220;CONSEQUENTIAL DAMAGES&#8221; WILL BE DEEMED TO INCLUDE, AND NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OF SUCH OTHER PARTY&#8217;S AFFILIATES, REPRESENTATIVES OR STOCKHOLDERS FOR ANY DAMAGES BASED ON OR MEASURED BY LOSS OF PROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY UNACHIEVED EVENT UNDER ARTICLE&#160;6, OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE CONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT.  FOR THE AVOIDANCE OF DOUBT, THIS SECTION&#160;14.11 IS NOT MEANT TO LIMIT NEKTAR&#8217;S OBLIGATION TO PAY SFJ THE AMOUNTS SET FORTH IN ARTICLE&#160;6 OR SECTION&#160;14.2. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant Not to Sue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nektar shall not, and shall cause its Affiliates to not, commence or pursue, or aid any other Person in any action, claim, or other legal proceeding (whether in contract, tort, or otherwise) against the Specified Investors with respect to the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless expressly set forth in this Agreement, all rights and remedies of the Parties, including all rights to payment, rights of termination, rights to injunctive relief, and other rights provided under this Agreement, will be cumulative and in addition to all other remedies provided for in this Agreement, in law, and in equity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing contained herein will be deemed to create a partnership, joint venture, or similar relationship between the Parties, including for tax purposes.  Neither Party is the agent, employee, joint venturer, partner, franchisee, or representative of the other Party.  Each Party specifically acknowledges that it does not have the authority to, and will not, incur any obligations or responsibilities on behalf of the other Party.  Notwithstanding anything to the contrary in this Agreement, each Party (and its officers, directors, agents, employees, and members) will not hold themselves out as employees, agents, representatives, or franchisees of the other Party or enter into any agreements on such Party&#8217;s behalf.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Direction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party will be subject to the supervisory direction of the other Party in regard to the conduct of the Clinical Trials.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;77</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the provisions herein are for the benefit of the Parties only, and are not intended to confer any rights or benefits to any Third Party other than the Specified Investors and their successors and assigns, which are express third party beneficiaries of Sections&#160;9.2, 9.6, 11.1.2, 14.5 and 14.12 hereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No license or any other right is granted to either Party, by implication or otherwise, except as specifically set forth in this Agreement.  All rights not exclusively granted to SFJ are reserved to Nektar and its Affiliates.  Notwithstanding any other provision of this Agreement to the contrary, and for clarity, no Intellectual Property or other proprietary rights Controlled by Nektar or its Affiliates will be assigned or licensed to SFJ in connection with this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nonsolicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term and for a period of twelve&#160;(12) months thereafter, neither Party shall solicit an employee of the other Party who is or has been involved in the performance or oversight of any of the development activities hereunder to terminate his or her employment and accept employment or work as a consultant with the soliciting Party.  Notwithstanding the foregoing, nothing herein shall restrict or preclude the Parties&#8217; right to make generalized searches for employees by way of a general solicitation for employment placed in a trade journal, newspaper or website.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments&#59; No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise specified herein, no amendment, supplement, or modification of this Agreement will be binding on either Party unless it is in writing and signed by both Parties.  No delay or failure on the part of a Party in the exercise of any right under this Agreement or available at law or equity will be construed as a waiver of such right, nor will any single or partial exercise thereof preclude any other exercise thereof.  All waivers must be in writing and signed by the Party against whom the waiver is to be effective.  Any such waiver will constitute a waiver only with respect to the specific matter described in such writing and will in no way impair the rights of the Party granting such waiver in any other respect or at any other time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any provision (or portion thereof) of this Agreement is determined by a court or arbitration to be unenforceable as drafted by virtue of the scope, duration, extent, or character of any obligation contained herein, it is the Parties&#8217; intention that such provision (or portion thereof) will be construed in a manner designed to effectuate the purposes of such provision to the maximum extent enforceable under such Applicable Law.  The Parties will enter into whatever amendment to this Agreement as may be necessary to effectuate such purposes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, including all Exhibits hereto and the Disclosure Letter, contains the entire understanding of the Parties and supersedes, revokes, terminates, and cancels any and all other arrangements, understandings, agreements, term sheets, or representations and warranties, whether oral or written, between the Parties relating to the subject matter of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts&#59; Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement will be executed in two&#160;(2) counterparts, one&#160;(1) for either Party, which, taken together, will constitute one and the same </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;78</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">agreement.  This Agreement will not be binding on the Parties or otherwise effective unless and until executed by both Parties. This Agreement may be executed electronically, such as by DocuSign.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement has been negotiated by the Parties and their respective counsel.  This Agreement will not be construed in favor of or against either Party by reason of the authorship of any provisions hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Follows&#93;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;79</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i7c58f41f4c87444fb039996435e95355_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have caused this Agreement to be executed in duplicate by their duly authorized representatives as of the Effective Date.</font></div><div style="margin-bottom:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nektar Therapeutics</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Howard W. Robin</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; Howard W. Robin</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;February 12, 2021</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Gil M. Labrucherie</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Gil M. Labrucherie</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President, Chief Operating Officer and Chief Financial Officer</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;February 12, 2021</font></div><div style="padding-left:216pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have caused this Agreement to be executed in duplicate by their duly authorized representatives as of the Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature Page to the Co-Development Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SFJ Pharmaceuticals XII, L.P.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;SFJ XII GP LLC,</font></div><div style="padding-left:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Caymans Islands limited liability company</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Its&#58;&#160;&#160;&#160;&#160;General Partner</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Jonathan Roney</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Roney</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Manager</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;February 12, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature Page to the Co-Development Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i7c58f41f4c87444fb039996435e95355_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT LIST</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;A&#160;&#160;&#160;&#160;The Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;B&#160;&#160;&#160;&#160;Current Approved CROs</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;C&#160;&#160;&#160;&#160;Current Approved Vendors</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;D&#160;&#160;&#160;&#160;HNC Main Clinical Draft Trial Protocol </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;E &#160;&#160;&#160;&#160;Executive Officers</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;F1&#160;&#160;&#160;&#160;Nektar Anti-Bribery and Anti-Corruption Practices</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;F2&#160;&#160;&#160;&#160;SFJ Anti-Bribery and Anti-Corruption Practices</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;G-1&#160;&#160;&#160;&#160;SFJ Quarterly Labor Fee</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;G-2&#160;&#160;&#160;&#160;Nektar Quarterly Labor Fee</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;H&#160;&#160;&#160;&#160;RACI</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;I&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Timeline</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;J&#160;&#160;&#160;&#160;Study Site Countries</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit K&#160;&#160;&#160;&#160;TORO</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;105681617.22  </font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>3
<FILENAME>nktr20201231-exx1039.htm
<DESCRIPTION>EX-10.39
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic3276c87826c4ad480ce0c64953b9bde_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.39</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:36pt;margin-top:180pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURCHASE AND SALE AGREEMENT</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">dated as of December 16, 2020</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">between</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEALTHCARE ROYALTY PARTNERS IV, L.P.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HCRP OVERFLOW FUND, L.P.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HCR STAFFORD FUND, L.P.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HCR POTOMAC FUND, L.P., and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HCR CANARY FUND, L.P.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">and</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HCR COLLATERAL MANAGEMENT, LLC,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">solely in its capacity as Purchaser Representative</font></div><div style="margin-bottom:60pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:93.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rules of Construction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II PURCHASE AND SALE OF THE PURCHASED ROYALTIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase and Sale</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Cap, True-Up and Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Assumed Obligations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Assets</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental and Third Party Authorizations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Litigation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Brokers&#8217; Fees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Matters</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approval and Marketing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparty Agreements</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC Matters</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Set-off and Other Sources of Royalty Reduction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Margin Stock</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental and Third Party Authorizations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Litigation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE PURCHASER REPRESENTATIVE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental and Third Party Authorizations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Litigation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VI COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:93.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Books and Records&#59; Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Public Announcement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Further Assurances</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments on Account of the Purchased Royalties</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">License Agreements</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of the License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Audits</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">31</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existence</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Consent&#59; Baxter Consent Amendment&#59; Licensee Confirmations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VII THE CLOSING</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Deliverables of the Seller</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Deliverables of the Purchaser and Purchaser Representative</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VIII INDEMNIFICATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Seller</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Purchaser</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Procedures for Third Party Claims</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Claims</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Time Limitations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusive Remedy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IX CONFIDENTIALITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Confidentiality Agreement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Disclosure</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE X TERMINATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Agreement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Termination</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE XI MISCELLANEOUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Specific Performance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Nature of Relationship</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:93.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments&#59; No Waivers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Third Party Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents and Headings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</font></div><div style="padding-left:13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A-1&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of AZ Confirmation</font></div><div style="padding-left:13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A-2&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Baxter Confirmation</font></div><div style="padding-left:13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit B&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Baxter Consent Amendment</font></div><div style="padding-left:13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit C&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Bill of Sale</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit D&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Schedule</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit E&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Novo Consent</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F-1&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AZ License Agreement</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F-2&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Baxter License Agreement</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F-3&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novo Settlement Agreement</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F-4&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novo Sublicense Agreement</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F-5&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AZ Consent</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F-6&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Baxter Consent </font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit G&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller Account</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit H&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwin Opinion</font></div><div style="padding-left:13.5pt"><font><br></font></div><div style="padding-left:13.7pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule</font></div><div style="padding-left:13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURCHASE AND SALE AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This PURCHASE AND SALE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase and Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), dated as of December 16, 2020, is by and among Nektar Therapeutics, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, HCRP Overflow Fund, L.P., a Delaware limited liability partnership, HCR Stafford Fund, L.P., a Delaware limited liability partnership, HCR Potomac Fund, L.P., a Delaware limited liability partnership, and HCR Canary Fund, L.P., a Delaware limited liability partnership (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and HCR Collateral Management, LLC, solely in its capacity as a representative of the Purchasers (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Seller has the right to receive royalties under the License Agreements&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Seller desires to sell, contribute, assign, transfer, convey and grant to the Purchaser, and the Purchaser desires to purchase, acquire and accept from the Seller, the Purchased Royalties described herein, upon and subject to the terms and conditions set forth in this Purchase and Sale Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties set forth herein and of other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties covenant and agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINED TERMS AND RULES OF CONSTRUCTION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following terms, as used herein, shall have the following respective meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Adynovate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means antihemophilic factor (recombinant) pegylated, rurioctocog alfa pegol.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#91;***&#93;&#8221;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any designated Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such designated Person.  For purposes of this definition, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of Voting Securities, by contract or otherwise, and the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; have meanings correlative to the foregoing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means AstraZeneca AB, a Swedish corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;  means that certain written confirmation substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain letter agreement, effective as of November 20, 2020, by and between the Seller and AZ.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Financing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the financing statement to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the irrevocable direction to AZ to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, AZ Know-How and AZ Patents, to the extent licensed to AZ under the AZ License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, Joint Know-How (as defined in Section 1.91 of the AZ License Agreement) and Licensed Know-How (as defined in Section 1.98 of the AZ License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, (a) that certain License Agreement, dated September 20, 2009, by and between the Seller and AZ and (b) as amended by that certain Amendment No. 1 to the License Agreement, effective as of August 8, 2013, by and between the Seller and AZ.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Stand-Alone Products (as defined in Section 1.150 of the AZ License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Net Sales (as defined in Section 1.114 of the AZ License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, Joint Patents (as defined in Section 1.91 of the AZ License Agreement) and Licensed Patents (as defined in Section 1.99 of the AZ License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Related Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) that certain Master Services Agreement, dated December 15, 2009, by and between AZ and Seller, (b) that certain Manufacturing and Technology Transfer Agreement, dated December 15, 2009, by and between AZ and Seller and (c) that certain Quality Agreement, dated December 15, 2009, by and between AZ and Seller. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the quarterly royalty reports delivered to the Seller by AZ pursuant to Section 7.12 of the AZ License Agreement setting forth AZ Net Sales for each applicable calendar quarter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Royalties Commencement Date and ending on the later of the dates described in Section 7.9(a) and (b) of the AZ License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, any agreement in which the rights granted to AZ under the AZ License Agreement are sublicensed to a sublicensee, or are further sublicensed by such sublicensee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following in respect of any Person&#58; (a) an admission in writing by such Person of its inability to pay its debts as they become due or a general assignment by such Person for the benefit of creditors&#59; (b) the filing of any petition or answer by such Person seeking to adjudicate itself as bankrupt or insolvent, or seeking for itself any liquidation, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of such Person or its debts under any law relating to bankruptcy, insolvency, receivership, winding-up, liquidation, reorganization, examination, relief of debtors or other similar law now or hereafter in effect, or seeking, consenting to or acquiescing in the entry of an order for relief in any case under any such law, or the appointment of or taking possession by a receiver, trustee, custodian, liquidator, examiner, assignee, sequestrator or other similar official for such Person or for any substantial part of its property&#59; (c) corporate or other entity action taken by such Person to authorize any of the actions set forth in clause (a) or (b) of this definition&#59; or (d) without the consent or acquiescence of such Person, the entering of an order for relief or approving a petition for relief or reorganization or any other petition seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or other similar relief under any present or future bankruptcy, insolvency or similar statute, law or regulation, or the filing of any such petition against such Person, or, without the consent or acquiescence of such Person, the entering of an order appointing a trustee, custodian, receiver or liquidator of such Person or of all or any substantial part of the property of such Person, in each case where such petition or order shall remain unstayed or shall not have been stayed or dismissed within thirty (30) days from entry thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Baxalta US Inc., a Delaware corporation and Baxalta GmbH, a Swiss corporation (as assignees from Baxter Healthcare SA, a corporation organized and existing under the laws of Switzerland and Baxter Healthcare Corporation, a Delaware corporation).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain written confirmation substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain letter agreement, dated as of November 8, 2018, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter, as amended, following the date of execution of the Baxter Consent Amendment, by the Baxter Consent Amendment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Consent Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Amendment No. 1 to the Baxter Consent, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Financing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the financing statement to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the irrevocable direction to Baxter to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Baxter Patents and Baxter Know-How, to the extent licensed to Baxter under the Baxter License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means NEKTAR AL KNOW-HOW (as defined in Section 1.46 of the Baxter License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, (a) that Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter, (b)&#160;as amended by that certain Amendment No. 1 to Exclusive Research, Development, License and Manufacturing and Supply </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agreement, effective as of October 19, 2005, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter, (c) as amended by that certain Amendment No. 2 to Exclusive Research, Development, License and Manufacturing and Supply Agreement, effective as of December 14, 2005, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter, (d)&#160;as amended by that certain Amendment No. 3 to Exclusive Research, Development, License and Manufacturing and Supply Agreement, effective as of December 17, 2007, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter, (e)&#160;as amended by that certain Amendment No. 4 to Exclusive Research, Development, License and Manufacturing and Supply Agreement, effective as of December 31, 2008, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter, (f)&#160;as amended by that certain Amendment No. 5 to Exclusive Research, Development, License and Manufacturing and Supply Agreement, effective as of June 7, 2011, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter and (g) as amended by that certain Amendment No. 6 to Exclusive Research, Development, License and Manufacturing and Supply Agreement, effective as of September 17, 2014, by and between the Seller (as successor to Nektar Therapeutics AL, Corporation) and Baxter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means COMMERCIAL PRODUCT (as defined in Section 1.13 of the Baxter License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means NET SALES (as defined in Section 1.52 of the Baxter License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Baxter New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means NEKTAR AL PATENT RIGHTS (as defined in Section 1.49 of the Baxter License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Related Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) that certain Manufacturing and Supply Agreement, dated March 23, 2012, by and between Baxter and Seller and (b) that certain Process and Development Agreement, dated June 16, 2011, by and between Baxter and Seller. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the quarterly royalty reports delivered to the Seller pursuant to Section 9.5 of the Baxter License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Royalties Commencement Date and ending on the date on that the last Royalty payment under the Baxter License is due in accordance with Section 9.2 of the Baxter License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#91;***&#93;&#8221;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain bill of sale, dated as of the Closing Date, executed by the Seller and the Purchaser, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by Applicable Law to remain closed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all shares, interests, participations or other equivalents (however designated, whether voting or non-voting) of such Person&#8217;s capital, whether now </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">outstanding or issued after the Closing Date, including common shares, ordinary shares, preferred shares, membership interests or share capital in a limited liability company or other Person, limited or general partnership interests in a partnership, beneficial interests in trusts or any other equivalent of such ownership interest or any options, warrants and other rights to acquire such shares or interests, including rights to allocations and distributions, dividends, redemption payments and liquidation payments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commercially Reasonable Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Intellectual Property Rights in any country, efforts or actions that would be commercially reasonable for an owner and licensor of such Intellectual Property Rights in such country, which owner and licensor is entitled to the full economic benefit of such Intellectual Property Rights without regard to the transactions contemplated by this Purchase and Sale Agreement or any other business of, or assets owned by, such owner and licensor.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conjugate IX Family</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparty Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the AZ Consent, the Baxter Consent and, following the date of execution thereof, the Novo Consent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as the context requires, Baxter, AZ or Novo Nordisk.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparty Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Baxter Instruction, the AZ Instruction and the Novo Instruction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Disclosure Schedule dated as of the date hereof and attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.11(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the sign &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means United States dollars.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Escrow Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Citizens Bank, N.A., as escrow agent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Escrow Agreement to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date and entered into by the Seller, the Purchaser, the Purchaser Representative and the Escrow Agent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Liabilities and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain letter agreement, dated May 24, 2017, by and between the Seller and HealthCare Royalty Management, LLC, an Affiliate of the Purchaser, as amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration and any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as the context requires, &#8220;FIRST COMMERCIAL SALE&#8221; (as defined in Section 1.27 of the Baxter License Agreement) or &#8220;First Commercial Sale&#8221; (as defined in Section 1.67 of the AZ License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means generally accepted accounting principles in effect in the United States from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the government of the United States, any other nation or any political subdivision thereof, whether state or local, and any agency, authority (including supranational authority), commission, instrumentality, regulatory body, court, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including each Patent Office, the FDA and any other government authority in any country.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means TWO HUNDRED AND TEN MILLION DOLLARS ($210,000,000).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Baxter Intellectual Property Rights, the AZ Intellectual Property Rights and the Novo Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Judgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Baxter Know-How and the AZ Know-How.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the AZ License Agreement, the Baxter License Agreement, the Novo Settlement Agreement and the Novo Sublicense Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the AZ Licensed Products, the Baxter Licensed Products and the Novo Nordisk Factor IX Product (as defined in Section 1(k) of the Novo Settlement Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property or other priority or preferential arrangement of any kind or nature whatsoever, including any conditional sale or any sale with recourse, or any other restriction on transfer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any loss, liability, cost, expense (including reasonable costs of investigation and defense and reasonable attorneys&#8217; fees and expenses), charge, fine, penalty, obligation, judgment, award, assessment, claim or cause of action.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a material adverse effect on (a) the legality, validity or enforceability of any of the Transaction Documents or the License Agreements, (b) the ability of the Seller to perform its obligations under any of the Transaction Documents or the License Agreements, (c) the rights or remedies of the Purchaser under any of the Transaction Documents or the License </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agreements, (d) the right of the Purchaser to receive the Purchased Royalties, the timing, amount or duration of the Purchased Royalties, or the right to receive royalty reports and other information (including audit information) on the terms set forth in the License Agreements and this Purchase and Sale Agreement, or (e) the business of the Seller and its Subsidiaries, taken as a whole.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means TWO HUNDRED AND FORTY MILLION DOLLARS ($240,000,000).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Movantik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any product that contains the compound naloxegol as an active ingredient, in any strengths, forms, formulations, administrations or delivery routes</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Mutually Agreed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means&#58; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;for matters (i) solely related to the Purchased Royalties or (ii) that would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Material Adverse Effect, the Seller shall either take (or refrain from taking) such reasonable actions in respect of each such matter as are reasonably requested by the Purchaser Representative&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;for matters that (i) relate to the matters set forth on Schedule 3.6(a), (ii) relate to the routine maintenance and prosecution of the AZ Patents, the Baxter Patents or the Novo Patents, (iii) do not relate to the Purchased Royalties or (iv) would not reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Material Adverse Effect, the Seller shall have the right (subject to providing written notice to the Purchaser Representative) to take (or refrain from taking) such actions in respect of each such matter as the Seller, acting reasonably, deems appropriate&#59; or</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;for all other matters that (i) involve the AZ Patents, the Baxter Patents or the Novo Patents, other than routine maintenance and prosecution, or (ii) do not meet the criteria set forth in clauses (a) or (b) above), the Seller shall take (or refrain from taking) actions in respect of each such matter as the Seller and the Purchaser Representative, each acting reasonably, mutually agree.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as the context requires, Baxter Net Sales, AZ Net Sales, or Novo Net Sales.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as the context requires, a AZ New Arrangement, a Baxter New Arrangement and a Novo New Arrangement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain letter agreement, in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, by and between the Seller and Novo Nordisk.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Financing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the financing statement to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the irrevocable direction to Novo Nordisk to be agreed upon by the Purchaser Representative and the Seller, dated as of the Closing Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Net Sales (as defined in Section 1(j) of the Novo Settlement Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Nordisk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, Novo Nordisk Inc., a Delaware corporation, Novo Nordisk A&#47;S, a corporation organized and existing under the laws of Denmark and Novo Nordisk Healthcare AG, a corporation organized and existing under the laws of Switzerland.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Nordisk Factor IX Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; is as defined in Section 1(k) of the Novo Settlement Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Conjugate IX Family and the Reagent Family, in each case to the extent licensed to Novo Nordisk under the Novo Settlement Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the quarterly royalty reports delivered to the Seller pursuant to Section 6(c)(i) of the Novo Settlement Agreement, the Novo Report (as defined under Section 1 of the Novo Sublicense Agreement) and the royalty reports delivered to the Seller pursuant to Section 3.6 of the Novo Sublicense Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Royalties Commencement Date and ending on the date on that the last Royalty payment under the Novo Settlement Agreement is due in accordance with the Novo Settlement Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Settlement Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Settlement and License Agreement, dated December 21, 2016, by and among Novo Nordisk and the Seller.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that Right to Sublicense Agreement, dated October 27, 2017, by and between Baxalta Incorporated, Baxter and the Seller.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Settlement Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Sublicense Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;&#91;***&#93;&#8221;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Seller or the Purchaser or the Purchaser Representative, as the context requires, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the Seller, the Purchaser and the Purchaser Representative.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Past Period Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the applicable patent office, including the United States Patent and Trademark Office and any comparable foreign patent office, for any Intellectual Property Rights that are Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the AZ Patents, the Baxter Patents and Novo Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permissible Summary Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) in the case of the AZ License Agreement, any Tax withholding expressly permitted under Section 7.17 of the AZ License Agreement, (b) in the case of the Baxter License Agreement, any Tax withholding expressly permitted under Section 10.5 of the Baxter License Agreement, (c) in the case of the Novo Settlement Agreement, any Tax withholding expressly permitted under Section 6(c)(iii) of the Novo Settlement Agreement and (d) in the case of the Novo </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublicense Agreement, any Tax withholding expressly permitted under Section 3.12 of the Novo Sublicense Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any natural person, firm, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity, including public bodies, whether acting in an individual, fiduciary or other capacity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Adynovate, Movantik and Rebinyn.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase and Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchased Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, on any date prior to the Royalty Termination Date, the AZ Royalties, the Baxter Royalties, the Novo Settlement Royalties and the Novo Sublicense Royalties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Connection Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Tax to the extent that it would not be imposed but for (i) any connection of the Purchaser with the jurisdiction of the applicable taxing authority (other than a connection arising solely from this Purchase and Sale Agreement or any transaction contemplated thereby) or (ii) any failure of the Purchaser to provide any applicable documentation that is reasonably requested by the applicable withholding agent and that the Purchaser is legally eligible to provide.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Excluded Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any non-U.S. withholding Tax withheld by any licensee, Seller, or any other applicable withholding agent in respect of any payment made to the Purchaser pursuant to this Purchase and Sale Agreement other than (i) a Purchaser Indemnified Tax and (ii) a Purchaser Connection Tax.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Indemnified Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any non-U.S. withholding Tax (other than a Purchaser Connection Tax) withheld by any licensee, Seller, or any other applicable withholding agent in respect of any payment made to the Purchaser pursuant to this Purchase and Sale Agreement to the extent that such non-U.S. withholding Tax would have been imposed if the payment in question were payable to Seller.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reagent Family</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed thereto in Section 1(o) in the Novo Settlement Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rebinyn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means coagulation Factor IX (recombinant), glycoPEGylated.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or other regulation of pharmaceuticals in any country.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, all regulatory approvals, registrations, certificates, authorizations, permits and supplements thereto, as well as associated materials (including the product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dossier) pursuant to which the Products may be marketed, sold and distributed by AZ, Baxter or Novo Nordisk, as the case may be, in a jurisdiction, issued by the appropriate Regulatory Agency.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Related Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the AZ Related Agreements and the Baxter Related Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the AZ Royalties, the Baxter Royalties, the Novo Settlement Royalties and the Novo Sublicense Royalties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means October 1, 2020.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means either (a) if the aggregate payments payable to Purchaser on or prior to December 31, 2025 in respect of the Purchased Royalties (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as adjusted for any payment made by Seller pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, are equal or greater than, in the aggregate, the Initial Cap, then the Initial Cap, or (b) if the aggregate payments payable to Purchaser on or prior to December 31, 2025 in respect of the Purchased Royalties (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as adjusted for any payment made by Seller pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, are less than, in the aggregate, the Initial Cap, then the Maximum Cap.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;&#91;***&#93;&#8221;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.13(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that &#8220;Royalty Reduction&#8221; shall not include any Set-off or reduction on account of Taxes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earlier of (a) date on which aggregate payments of the Purchased Royalties actually received by the Purchaser (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal the Royalty Cap or (b) the date of the last Royalty payment under the License Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Reagent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means SELECTED REAGENT (as defined in Section 1.73 of the Baxter License Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Seller Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Seller Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Set-off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any set-off or off-set&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that &#8220;Set-off&#8221; shall not include any Royalty Reduction or set-off on account of Taxes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities of such other Person (irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon the occurrence of any contingency) is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more other Subsidiaries of such Person or by one or more other Subsidiaries of such Person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any U.S. federal, state, local or non-U.S. income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that is not a Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any claim, action, suit or proceeding by a Third Party, including any investigation by any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means this Purchase and Sale Agreement, the Escrow Agreement, the Bill of Sale and the Counterparty Instructions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Uniform Commercial Code as in effect from time to time in the State of Delaware&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, if, with respect to any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the back-up security interest or any portion thereof granted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of Delaware, then &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Purchase and Sale Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States of America, its 50 states, each territory thereof and the District of Columbia.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rules of Construction</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Unless the context otherwise requires, in this Purchase and Sale Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a term has the meaning assigned to it and an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;unless otherwise defined, all terms that are defined in the UCC shall have the meanings stated in the UCC&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the terms &#8220;include,&#8221; &#8220;including&#8221; and similar terms shall be construed as if followed by the phrase &#8220;without limitation&#8221;&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;unless otherwise specified, references to a contract or agreement include references to such contract or agreement as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with its terms (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth herein), and include any annexes, exhibits and schedules hereto or thereto, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, unless otherwise specified, terms defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> by reference to any other contract or agreement shall be deemed to refer to such contract or agreement as in effect on the date of this Purchase and Sale Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any reference to any Person shall be construed to include such Person&#8217;s successors and assigns (subject to any restrictions on assignment, transfer or delegation set forth herein or in any of the other Transaction Document) and any reference to a Person in a particular capacity excludes such Person in other capacities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;references to any Applicable Law shall include such Applicable Law as from time to time in effect, including any amendment, modification, codification, replacement, or reenactment thereof or any substitution therefor&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereunder&#8221; and similar terms shall refer to this Purchase and Sale Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein are references to Articles and Sections of, and Exhibits to, this Purchase and Sale Agreement unless otherwise specified&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;the definitions of terms shall apply equally to the singular and plural forms of the terms defined&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;in the computation of a period of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including&#8221; and each of the words &#8220;to&#8221; and &#8220;until&#8221; means &#8220;to but excluding&#8221;&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;where any payment is to be made, any funds are to be applied or any calculation is to be made under this Purchase and Sale Agreement on a day that is not a Business Day, unless this Purchase and Sale Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;any reference to a term that is defined by reference to its meaning in a License Agreement shall refer to such term&#8217;s meaning in such License Agreement as in existence on the date hereof (and not to any new, substituted or amended version thereof).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The provisions of this Purchase and Sale Agreement shall be construed according to their fair meaning and neither for nor against any Party irrespective of which Party caused such provisions to be drafted.  Each Party acknowledges that it has been represented by an attorney in connection with the preparation and execution of this Purchase and Sale Agreement and the other Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PURCHASE AND SALE OF THE PURCHASED ROYALTIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase and Sale</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Purchase and Sale Agreement, on the Closing Date, the Seller hereby sells, contributes, assigns, transfers, conveys and grants to the Purchaser, and the Purchaser hereby purchases, acquires and accepts from the Seller, all of the Seller&#8217;s rights, title and interest in and to the Purchased Royalties, free and clear of any and all Liens, other than those Liens created under the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Seller and the Purchaser intend and agree that the sale, contribution, assignment, transfer, conveyance and granting of the Purchased Royalties under this Purchase and Sale Agreement shall be, and are, a true, complete, absolute and irrevocable assignment and sale by the Seller to the Purchaser of the Purchased Royalties (including U.S. federal income tax purposes) and that such assignment and sale shall provide the Purchaser with the full benefits of ownership of the Purchased Royalties.  Neither the Seller nor the Purchaser intends the transactions contemplated hereby to be, or for any purpose (including U.S. federal income tax purposes) characterized as, a loan from the Purchaser to the Seller or a pledge or assignment or a security agreement.  The Seller waives any right to contest or otherwise assert that this Purchase and Sale Agreement does not constitute a true, complete, absolute and irrevocable sale and assignment by the Seller to the Purchaser of the Purchased Royalties under Applicable Law, which waiver shall be enforceable against the Seller in any Bankruptcy Event in respect of the Seller.  The sale, contribution, assignment, transfer, conveyance and granting of the Purchased Royalties shall be reflected on the Seller&#8217;s financial statements and other records as a sale of assets to the Purchaser (except to the extent GAAP or the rules of the SEC require otherwise with respect to the Seller&#8217;s consolidated financial statements).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Seller hereby authorizes the Purchaser Representative to execute, record and file, and consents to the Purchaser Representative executing, recording and filing, at the Purchaser&#8217;s sole cost and expense, financing statements in the appropriate filing offices under the UCC (and continuation statements with respect to such financing statements when applicable), and amendments thereto, in such manner and in such jurisdictions as are necessary or appropriate to evidence or perfect the sale, contribution, assignment, transfer, conveyance and grant by the Seller to the Purchaser, and the purchase, acquisition and acceptance by the Purchaser from the Seller, of the Purchased Royalties and to perfect the security interest in the Purchased Royalties granted by the Seller to the Purchaser pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Notwithstanding that the Seller and the Purchaser expressly intend for the sale, contribution, assignment, transfer, conveyance and granting of the Purchased Royalties to be a true, complete, absolute and irrevocable sale and assignment, the Seller hereby assigns, conveys, grants and pledges to the Purchaser, as security for its obligations created hereunder in the event that the transfer contemplated by this Purchase and Sale Agreement is held not to be a sale, a first priority security interest in and to all of the Seller&#8217;s right, title and interest in, to and under the Purchased Royalties and, in such event, this Purchase and Sale Agreement shall constitute a security agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In full consideration for the sale, contribution, assignment, transfer, conveyance and granting of the Purchased Royalties, and subject to the terms and conditions set forth herein, the Purchaser shall pay (or cause to be paid) to the Seller, at the Closing, the sum of ONE HUNDRED AND FIFTY MILLION DOLLARS ($150,000,000), in immediately available funds by wire transfer to the Seller Account (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Cap, True-Up and Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If the aggregate Purchased Royalties received by the Purchaser equal at least the Initial Cap on or prior to December 31, 2025 (such date of receipt, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Cap Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (i) the Purchaser Representative and the Seller shall deliver joint written instructions to the Escrow Agent to instruct the Escrow Agent to pay the sum of the aggregate Purchased Royalties achieved for the calendar quarter during which the Minimum Cap Date occurs, less the Initial Cap (such amount the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Cap Overage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to the Seller pursuant to the payment instructions set forth in such joint written instructions and (ii) the payment of the Purchased Royalties to the Purchaser for the calendar quarter during which the Minimum Cap Date occurs shall be reduced by such Minimum Cap Overage and no further payments of Purchased Royalties are due to the Purchaser hereunder.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If, and only if, the aggregate Purchased Royalties payable to the Purchaser are less than the Initial Cap and the aggregate Purchased Royalties payable to the Purchaser on or prior to December 31, 2025 are determined to be less than the Initial Cap by an amount equal to or less than TWO MILLION DOLLARS ($2,000,000), then the Seller shall have the right, but not the obligation, to pay such amount (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Cap True-Up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Purchaser within thirty (30) days following such determination, by wire transfer of immediately available funds to an account designated in writing by the Purchaser Representative, and upon payment of the Initial Cap True-Up (regardless of whether such payment is made prior to December 31, 2025), no further payments of Purchased Royalties are due to the Purchaser hereunder and the Royalty Cap shall be deemed to have been achieved.  If the aggregate Purchased Royalties payable to the Purchaser do not equal the Initial Cap on or prior to December 31, 2025, and the Seller is not eligible to, or does not exercise the right to, pay the Initial Cap True-Up, the Purchased Royalties shall continue to be paid to the Purchaser until such time that the aggregate Purchased Royalties paid to the Purchaser equals the Maximum Cap.  At such time that the aggregate Purchased Royalties equal the Maximum Cap, no further payments of Purchased Royalties are due to the Purchaser hereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;At any time, the Seller shall have the right, but not the obligation, to pay to the Purchaser the Maximum Cap less the aggregate Purchased Royalties paid to the Purchaser as of such date, by wire transfer of immediately available funds to an account designated in writing by the Purchaser Representative, and upon such payment, no further payments of the Purchased Royalties are due to the Purchaser hereunder and the Royalty Cap shall be deemed to have been achieved.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Assumed Obligations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding any provision in this Purchase and Sale Agreement or any other writing to the contrary, the Purchaser is purchasing, acquiring and accepting only the Purchased Royalties and is not assuming any liability or obligation of the Seller or any of the Seller&#8217;s Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, including any liability or obligation of the Seller under the License Agreements.  All such liabilities and obligations shall be retained by, and remain liabilities and obligations of, the Seller or the Seller&#8217;s Affiliates, as the case may be (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Liabilities and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Assets</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Purchaser does not, by purchase, acquisition or acceptance of the right, title or interest granted hereunder or otherwise pursuant to any of the Transaction Documents, purchase, acquire or accept any assets or contract rights of the Seller under any of the License Agreements, other than the Purchased Royalties, or any other assets of the Seller.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as set forth on the Disclosure Schedule, the Seller hereby makes each of the following representations and warranties to the Purchaser, as of the date hereof, as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Seller is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has all corporate power and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business, as now conducted, and to exercise its rights and to perform its obligations under the License Agreements.  The Seller is duly qualified to transact business and is in good standing in every jurisdiction in which such qualification or standing is required by Applicable Law (except where the failure to be so qualified or in good standing would not have a Material Adverse Effect).  Neither the Purchaser nor, to the Knowledge of the Seller, any of its partners, members or controlling Persons, is an Affiliate of the Seller or any of its Subsidiaries.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The execution and delivery by the Seller of any of the Transaction Documents, the performance by the Seller of its obligations hereunder or thereunder or the consummation by the Seller of the transactions contemplated hereby or thereby will not (i)&#160;contravene, conflict with or violate any term or provision of any of the organizational documents of the Seller or any of its Subsidiaries, (ii)&#160;contravene, conflict with or violate, or give any Governmental Authority or other Person the right to exercise any remedy or obtain any relief under, any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which the Seller or any of its Subsidiaries or any of their respective assets or properties may be subject or bound, (iii)&#160;result in a breach or violation of, constitute a default (with or without notice or lapse of time, or both) under, or give any Person the right to exercise any remedy or obtain any additional rights under, or accelerate the maturity or performance of, or payment under, or cancel or terminate, (A) except as would not have a Material Adverse Effect, any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which the Seller or any of its Subsidiaries is a party or by which the Seller or any of its Subsidiaries or any of their respective assets or properties is bound or committed (other than the License Agreements) or (B) any License Agreement, or (iv) except as provided in any of the Transaction Documents, result in or require the creation or imposition of any Lien on the Intellectual Property Rights, the Products, the License Agreements or the Purchased Royalties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Seller has not granted, nor does there exist, any Lien on or relating to the License Agreements, the Intellectual Property Rights or the Products.  Except for Liens created under the Transaction Documents, the Seller has not granted, nor does there exist, any Lien on or relating to the Purchased Royalties.  Except for the license granted by the Seller to each Counterparty under the License Agreements, there are no licenses, sublicenses or other rights under the Intellectual Property Rights that have been granted to any Third Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Seller has all necessary corporate power and authority to execute and deliver the Transaction Documents, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby.  The execution and delivery of each of the Transaction Documents and the performance by the Seller of its obligations hereunder and thereunder have been duly authorized by all necessary corporate action on the part of the Seller.  Each of the Transaction Documents has been duly executed and delivered by an authorized officer of the Seller.  Each of the Transaction Documents constitutes the legal, valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally and general equitable principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Seller is the exclusive owner of the entire right, title (legal and equitable) and interest in, to and under the Purchased Royalties and the Intellectual Property Rights.  The Seller has duly and legally filed or applied for registration for its ownership interest in the Patents included in the Intellectual Property Rights, including the Patents listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in the appropriate agencies and in the jurisdictions listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Purchased Royalties sold, contributed, assigned, transferred, conveyed and granted to the Purchaser on the Closing Date have not been pledged, sold, contributed, assigned, transferred, conveyed or granted by the Seller to any other Person.  The Seller has full right to sell, contribute, assign, transfer, convey and grant the Purchased Royalties to the Purchaser.  Upon the sale, contribution, assignment, transfer, conveyance and granting by the Seller of the Purchased Royalties to the Purchaser, the Purchaser shall acquire good and marketable title to the Purchased Royalties free and clear of all Liens, other than those Liens created under the Transaction Documents, and shall be the exclusive owner of the Purchased Royalties.  The Purchaser shall have the same rights as the Seller would have with respect to the Purchased Royalties (if the Seller were still the owner of such Purchased Royalties) against any other Person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental and Third Party Authorizations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The execution and delivery by the Seller of the Transaction Documents, the performance by the Seller of its obligations hereunder and thereunder and the consummation by the Seller of the transactions contemplated hereby and thereby do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by, or filing with, any Governmental Authority or any other Person, except for (i) the filing of a Current Report on Form 8-K with the SEC, (ii) the filing of UCC financing statements, (iii) the notice to Baxter contained in the Baxter Instruction, (iv) the notice to AZ contained in the AZ Instruction and (v)&#160;the notice to Novo Nordisk contained in the Novo Instruction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.6  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Litigation</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;There is no action, suit, arbitration proceeding, claim, demand, citation, summons, subpoena or other proceeding (whether civil, criminal, administrative, regulatory or informal) (i)&#160;pending or, to the Knowledge of the Seller, threatened by or against the Seller or any of its Subsidiaries that would have a Material Adverse Effect or (ii) pending against the Seller or, to the Knowledge of the Seller, pending or threatened by or against Baxter, AZ, Novo Nordisk, their Affiliates, or any of their sublicensees, in each case in respect of the License Agreements, the Intellectual Property Rights, the Products or the Purchased Royalties, at law or in equity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;There is no inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative or informal) by or before a Governmental Authority (i)&#160;pending or, to the Knowledge of the Seller, threatened against the Seller or any of its Subsidiaries that would have a Material Adverse Effect or (ii) pending against the Seller or, to the Knowledge of the Seller, pending or threatened by or against Baxter, AZ or Novo Nordisk, in each case in respect of the License Agreements, the Intellectual Property Rights, the Products or the Purchased Royalties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, no event has occurred or circumstance exists that may give rise to or serve as a basis for the commencement of any such action, suit, arbitration proceeding, claim, investigation, proceeding, inquiry or investigation referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Immediately after giving effect to the consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds therefrom, (a) the fair value of the Seller&#8217;s assets will be greater than the sum of its debts, liabilities and other obligations, including contingent liabilities, (b)&#160;the present fair saleable value of the Seller&#8217;s assets will be greater than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other obligations, including contingent liabilities, as they become absolute and matured in the normal course of business, (c) the Seller will be able to realize upon its assets and pay its debts, liabilities and other obligations, including contingent obligations, as they mature, (d)&#160;the Seller will not have unreasonably small capital with which to engage in its business, as now conducted and as proposed to be conducted following the Closing Date, (e) the Seller does not have any present plans or intentions to incur debts or other obligations or liabilities beyond its ability to pay such debts or other obligations or liabilities as they become absolute and matured, (f)&#160;the Seller will not have become subject to any Bankruptcy Event and (g) the Seller will not have been rendered insolvent within the meaning of Section 101(32) of Title 11 of the United States Code.  For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the amount of all contingent obligations at any time shall be computed as the amount that, in light of all facts and circumstances existing at such time, can reasonably be expected to become an actual or matured liability.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.8  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;No deduction or withholding for or on account of any Tax has been made from any payment to the Seller under any License Agreement. No payor under any License Agreement or any taxing authority has ever notified Seller that any such withholding was required or would have been required absent Seller&#8217;s qualification for benefits under an applicable income Tax treaty.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;There are no existing Liens for Taxes on the Purchased Royalties (or any portion thereof).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Seller&#8217;s representations as to tax matters are limited to those representations contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.9  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Brokers&#8217; Fees</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Seller has not taken any action that would entitle any person or entity other than Morgan Stanley &#38; Co, LLC, whose fees will be paid by the Seller, to any commission or broker&#8217;s fee in connection with the transactions contemplated by this Purchase and Sale Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.10  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> None of the Seller or any of its Subsidiaries (a) has violated or is in violation of, has been given notice of any violation of, or, to the Knowledge of the Seller, is under investigation with respect to or has been threatened to be charged with, any violation of, any Applicable Law or any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority or (b) is subject to any judgment, order, writ, decree, injunction, stipulation or consent order issued or entered by any Governmental Authority, in each case, that would have, individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.11  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Matters</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sets forth an accurate and complete list of all issued Patents and pending Patents.  For each Patent listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Seller has indicated (i) the countries in which such Patent is pending, allowed, granted or issued, (ii) the patent number or patent serial number, (iii) the scheduled expiration date of each such issued Patent, (iv)&#160;the expected scheduled expiration date of each Patent issuing from such pending Patent application once issued and (v) the owner thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, in each AZ Patent family listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, there is at least one issued and unexpired or pending valid claim covering the manufacture, use, import, offering for sale, or sale of Movantik.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, in each Baxter Patent family listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, there is at least one issued and unexpired or pending valid claim covering the manufacture, use, import, offering for sale, or sale of Adynovate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;There are no unpaid maintenance or renewal fees payable by the Seller to any Third Party that currently are overdue for any of the Patents.  No Patents have lapsed or been abandoned, cancelled or expired.  To the Knowledge of the Seller, each individual associated with the filing and prosecution of the Patents, including the named inventors of the Patents, has complied in all material respects with all applicable duties of candor and good faith in dealing with any Patent Office, including any duty to disclose to any Patent Office all information known by such inventors to be material to the patentability of the Patents (including any relevant prior art), in each case, in those jurisdictions where such duties exist.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Subsequent to the issuance of each Patent, neither the Seller nor, to the Knowledge of the Seller, any Counterparty, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of such Patent.  To the Knowledge of the Seller, no allowable or allowed subject matter of the Patents is subject to any competing conception claims of allowable or allowed subject matter of any patents of any Third Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;There is no pending or, to the Knowledge of the Seller, threatened opposition, interference, reexamination, injunction, claim, suit, action, citation, summon, subpoena, hearing, inquiry, investigation (by the International Trade Commission or otherwise), complaint, arbitration, mediation, demand, decree or other dispute, disagreement, proceeding or claim (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) challenging the legality, validity, scope, enforceability or ownership of any of the Intellectual Property Rights or that would give rise to any Royalty Reduction against the payments due to the Seller under the License Agreements.  To the Knowledge of the Seller, there are no pending or threatened Disputes by any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Counterparty, or their Affiliates or sublicensees, challenging the legality, validity, scope, enforceability or ownership of any of the Intellectual Property Rights or that would give rise to any Royalty Reduction against the payments due to the Seller under the License Agreements.  There are no Disputes by or with any Third Party against the Seller or, to the Knowledge of the Seller, any Counterparty or any of its sublicensees involving any of the Products.  The Intellectual Property Rights are not subject to any outstanding injunction, judgment, order, decree, ruling, change, settlement or other disposition of a Dispute.  There are no proceedings, other than proceedings in the ordinary course of patent prosecution and except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, with respect to the Patents listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;There is no pending action, suit, proceeding, investigation or claim and, to the Knowledge of the Seller, there is no threatened action, suit, proceeding, investigation or claim, and, to the Knowledge of the Seller, no event has occurred or circumstance exists that (with or without notice or lapse of time, or both) would reasonably be expected to give rise to or serve as a basis for any action, suit, proceeding, investigation or claim by any Person that claims that the manufacture, use, marketing, sale, offer for sale, importation or distribution of any Product does or could infringe on any patent or other intellectual property rights of any Third Party or constitute misappropriation of any other Person&#8217;s trade secrets or other intellectual property rights.  To the Knowledge of the Seller, there are no patents issued, and no pending patent applications, owned by any Third Party that, if issued, would limit or prohibit, in any material respect, the manufacture, use or sale of any Product by the Seller, any Counterparty or any of their respective sublicensees.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Movantik is an AZ Licensed Product, Adynovate is a Baxter Licensed Product and Rebinyn is a Novo Nordisk Factor IX Product (as defined in Section 1(k) of the Novo Settlement Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, there is no Person infringing any of the Intellectual Property Rights, nor has the Seller received any notice under any of the License Agreements of infringement of any of the Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;The Seller and, to the Knowledge of the Seller, each of AZ and Baxter has taken all reasonable precautions to protect the secrecy, confidentiality and&#47;or value of the applicable Know-How.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;The Intellectual Property Rights constitutes all of the intellectual property owned or licensed by the Seller or any of the Seller&#8217;s Affiliates that is, to the Seller&#8217;s Knowledge, necessary for the sale of the Products.  The Seller is the sole and exclusive owner of each of the Patents listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and each of the inventions claimed in such Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Within the last seven years, no legal opinion concerning or with respect to any third party intellectual property rights relating to the Products, including any freedom-to-operate, product clearance, patentability or right-to-use opinion, has been delivered to the Seller. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;There is no Person who is or claims to be an inventor under any Patent who is not a named inventor thereof.  The list of inventors named in each issued and unexpired Patent listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is current and complete.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.12  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approval and Marketing</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, each Counterparty is in compliance with its obligations to maintain Regulatory Approval for the Products pursuant to the applicable License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, each of the Products has received Regulatory Approval for marketing and distribution for the indications and in the countries listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.13  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparty Agreements</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Other than the Transaction Documents, the Related Agreements, the License Agreements, the AZ Consent, the Baxter Consent and the Confidentiality Agreement, there is no contract, agreement or other arrangement (whether written or oral) to which the Seller or any of its Subsidiaries is a party or by which any of their respective assets or properties is bound or committed that affects or otherwise relates to the Purchased Royalties, the License Agreements or the Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit F-1,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">F-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">F-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">F-4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are true, correct and complete copies of the License Agreements. Attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit F-5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">F-6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are true and correct copies of the AZ Consent and the Baxter Consent, redacted solely to the extent necessary to permit the Seller to comply with its obligations of confidentiality to certain third parties. The Seller has provided to the Purchaser Representative true, correct and complete copies of (i) all AZ Royalty Reports, Baxter Royalty Reports, and Novo Royalty Reports and (iii) all material notices and correspondence delivered to the Seller by the Counterparties or by the Seller to the Counterparties since January 1, 2018 pursuant to, or relating to, the License Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each of the License Agreements is in full force and effect and is the legal, valid and binding obligation of the Seller and each Counterparty, enforceable against the Seller and each Counterparty in accordance with its terms, subject, as to enforceability, to bankruptcy, insolvency, reorganization, moratorium or similar laws now or hereafter in effect relating to or affecting creditors&#8217; rights generally, and general equitable principles.  The Seller is not in breach or violation of or in default under any of the License Agreements.  There is no event or circumstance that, upon notice or the passage of time, or both, would constitute or give rise to any breach or default in the performance of any of the License Agreements by the Seller or, to the Knowledge of the Seller, any Counterparty.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Seller has not waived any rights or defaults under the License Agreements or released any Counterparty, in whole or in part, from any of its obligations under any of the License Agreements.  There are no oral waivers or modifications (or pending requests therefor) in respect of any of the License Agreements.  Neither the Seller nor any Counterparty has agreed to amend or waive any provision of the License Agreements, and the Seller has not received or submitted any proposal to do so.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Since the First Commercial Sale of Movantik, the Seller has, to the Knowledge of the Seller, received from AZ the full amount of the AZ Royalties payable in respect of AZ Net Sales of Movantik.  Since the First Commercial Sale of Adynovate, the Seller has, to the Knowledge of the Seller, received from Baxter the full amount of the Baxter Royalties payable in respect of Baxter Net Sales of Adynovate.  Since the Waiver Date (as defined in Section 1(t) of the Novo Settlement Agreement), the Seller has, to the Knowledge of the Seller, received from Novo Nordisk the full amount of Novo Settlement Royalties payable in respect of Novo Net Sales of Rebinyn.  Since the date of the Novo Sublicense Agreement, the Seller has, to the Knowledge of the Seller, received from Baxter the full amount of Novo Sublicense Royalties payable in respect of Net Sales (as defined in the Novo Sublicense Agreement) of the Licensed Product (as defined in the Novo Sublicense Agreement).  No event has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">occurred that would give the Seller or any Counterparty the right to terminate any of the License Agreements or cease paying Royalties under any of the License Agreements.  The Seller has not received any notice of an intention by any Counterparty to terminate or breach any of the License Agreements, in whole or in part, or challenging the validity or enforceability of any of the License Agreements or the obligation to pay the Royalties under any of the License Agreements, or alleging that the Seller or any Counterparty is currently in default of its obligations under any of the License Agreements.  To the Knowledge of the Seller, there is and has been no default, violation or breach of any Counterparty under any of the License Agreements.   The Seller has no intention of terminating any of the License Agreements and has not given any Counterparty any notice of termination of any of the License Agreements, in whole or in part.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Except as provided in the License Agreements, the Seller is not a party to any agreement providing for any sharing of, or providing for or permitting any right of counterclaim, credit, reduction or deduction by contract or otherwise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or permitting any Set-off against, the Royalties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Seller has not consented to an assignment by any Counterparty of any of such Counterparty&#8217;s rights or obligations under any License Agreement, and the Seller does not have Knowledge of any such assignment by any Counterparty.  Except as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Seller has not assigned, in whole or in part, and has not granted, incurred or suffered to exist any Lien on, the License Agreements or any of the Seller&#8217;s rights, title or interest in or to the Intellectual Property Rights or the Products.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Neither the Seller nor any Counterparty has made any claim of indemnification under any of the License Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Seller has not exercised its rights to conduct an audit under any of the License Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, it has received all amounts owed to it under the License Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, Baxter has not granted to any other Person any sublicense pursuant to Section 4.2 of the Baxter License Agreement.  To the Knowledge of the Seller, AZ has not granted to any other Person any sublicense pursuant to Section 4.2 of the AZ License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;To the Knowledge of the Seller, the First Commercial Sale of Adynovate occurred during the month of December, in 2015.  To the Knowledge of the Seller, the First Commercial Sale of Movantik occurred during the month of March, in 2015. To the Knowledge of the Seller, the First Commercial Sale of Rebinyn occurred during the fourth calendar quarter of 2017.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.14  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC Matters</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Seller&#8217;s exact legal name is, and for the preceding 10 years has been, &#8220;Nektar Therapeutics&#8221;.  The Seller&#8217;s principal place of business is, and for the preceding 10 years has been, located in the State of California.  The Seller&#8217;s jurisdiction of organization is, and for the preceding 10 years has been, the State of Delaware.  For the preceding 10 years, the Seller has not been the subject of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any merger or other corporate or other reorganization in which its identity or status was materially changed, except in each case where it was the surviving or resulting Person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.15  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Set-off and Other Sources of Royalty Reduction</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  No Counterparty has exercised, and, to the Knowledge of the Seller, no Counterparty has had the right to exercise, and no event or condition exists that, upon notice or passage of time, or both, would permit any Counterparty to exercise, any Royalty Reduction or Set-off against the Royalties or any other amounts payable to the Seller under any of the License Agreements.  To the Knowledge of the Seller, there are no Third Party patents that would provide a basis for a Royalty Reduction. There are no compulsory licenses granted or, to the Knowledge of the Seller, threatened to be granted with respect to the Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.16  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Margin Stock</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Seller is not engaged in the business of extending credit for the purpose of buying or carrying margin stock, and no portion of the Purchase Price shall be used by the Seller for a purpose that violates Regulation T, U or X promulgated by the Board of Governors of the Federal Reserve System from time to time.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IV</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Purchaser hereby represents and warrants to the Seller, as of the date hereof, as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Such Purchaser is a limited liability partnership duly organized, validly existing and in good standing under the laws of Delaware.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The execution and delivery by such Purchaser of any of the Transaction Documents to which such Purchaser is party, the performance by such Purchaser of its obligations hereunder or thereunder or the consummation by such Purchaser of the transactions contemplated hereby or thereby will not (i)&#160;contravene, conflict with or violate any term or provision of any of the organizational documents of such Purchaser, (ii)&#160;contravene, conflict with or violate, or give any Governmental Authority or other Person the right to exercise any remedy or obtain any relief under, in any material respect, any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which such Purchaser or any of its assets or properties may be subject or bound or (iii)&#160;result in a breach or violation of, constitute a default (with or without notice or lapse of time, or both) under, or give any Person any right to exercise any remedy, or accelerate the maturity or performance of, in any material respect, any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which such Purchaser is a party or by which such Purchaser or any of its assets or properties is bound or committed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Such Purchaser has all necessary trust power and authority to execute and deliver the Transaction Documents to which such Purchaser is a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby.  The execution and delivery of each of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transaction Documents to which such Purchaser is party and the performance by such Purchaser of its obligations hereunder and thereunder have been duly authorized by such Purchaser.  Each of the Transaction Documents to which such Purchaser is party has been duly executed and delivered by such Purchaser.  Each of the Transaction Documents to which such Purchaser is party constitutes the legal, valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally, and general equitable principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental and Third Party Authorizations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The execution and delivery by such Purchaser of the Transaction Documents to which such Purchaser is party, the performance by such Purchaser of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by, or filing with, any Governmental Authority or any other Person, except for the filing of UCC financing statements, the notice to Baxter contained in the Baxter Instruction and the notice to AZ contained in the AZ Instruction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Litigation</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There is no (a) action, suit, arbitration proceeding, claim, demand, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal) pending or, to the knowledge of such Purchaser, threatened by or against such Purchaser, at law or in equity, or (b) inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative or informal) by or before a Governmental Authority pending or, to the knowledge of such Purchaser, threatened against such Purchaser, that, in any case challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE V</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE PURCHASER REPRESENTATIVE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Purchaser Representative hereby represents and warrants to the Seller, as of the date hereof, as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Purchaser Representative is a limited liability company duly organized, validly existing and in good standing under the laws of Delaware.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The execution and delivery by the Purchaser Representative of any of the Transaction Documents to which the Purchaser Representative is party, the performance by the Purchaser Representative of its obligations hereunder or thereunder or the consummation by the Purchaser Representative of the transactions contemplated hereby or thereby will not (i)&#160;contravene, conflict with or violate any term or provision of any of the organizational documents of the Purchaser Representative, (ii)&#160;contravene, conflict with or violate, or give any Governmental Authority or other Person the right to exercise any remedy or obtain any relief under, in any material respect, any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which the Purchaser Representative or any of its assets or properties may be subject or bound or (iii)&#160;result in a breach or violation of, constitute a default (with or without notice or lapse of time, or both) under, or give any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Person any right to exercise any remedy, or accelerate the maturity or performance of, in any material respect, any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which the Purchaser Representative is a party or by which the Purchaser Representative or any of its assets or properties is bound or committed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Purchaser Representative has all necessary trust power and authority to execute and deliver the Transaction Documents to which the Purchaser Representative is a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby.  The execution and delivery of each of the Transaction Documents to which the Purchaser Representative is party and the performance by the Purchaser Representative of its obligations hereunder and thereunder have been duly authorized by the Purchaser Representative.  Each of the Transaction Documents to which the Purchaser Representative is party has been duly executed and delivered by the Purchaser Representative.  Each of the Transaction Documents to which the Purchaser Representative is party constitutes the legal, valid and binding obligation of the Purchaser Representative, enforceable against the Purchaser Representative in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally, and general equitable principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental and Third Party Authorizations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The execution and delivery by the Purchaser Representative of the Transaction Documents to which the Purchaser Representative is party, the performance by the Purchaser Representative of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by, or filing with, any Governmental Authority or any other Person, except for the filing of UCC financing statements, the notice to Baxter contained in the Baxter Instruction and the notice to AZ contained in the AZ Instruction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Litigation</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> There is no (a) action, suit, arbitration proceeding, claim, demand, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal) pending or, to the knowledge of the Purchaser Representative, threatened by or against the Purchaser Representative, at law or in equity, or (b) inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative or informal) by or before a Governmental Authority pending or, to the knowledge of the Purchaser Representative, threatened against the Purchaser Representative, that, in any case challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VI</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties covenant and agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Books and Records&#59; Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Seller shall keep and maintain, or cause to be kept and maintained, at all times, full and accurate books and records adequate to reflect accurately all financial information received and all amounts paid or received under the License Agreements in respect of the Purchased Royalties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#91;***&#93; after receipt by the Seller of (i)&#160;(x) notice of the commencement by any Third Party of, or (y) written notice from any Third Party threatening to commence, in either case any action, suit, arbitration proceeding, claim, demand, investigation or other proceeding relating to this Purchase and Sale Agreement, any of the other Transaction Documents, any License Agreement, any transaction contemplated hereby or thereby or the Purchased Royalties (in any case other than any notice contemplated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), or (ii) any other correspondence relating to the foregoing, the Seller shall (A)&#160;notify the Purchaser Representative in writing of the receipt of such notice or correspondence and provide the Purchaser Representative with a written summary of all material details thereof and (B) to the extent not prohibited by obligations of confidentiality contained in the License Agreements and Counterparty Consents, if such notice is in writing, furnish the Purchaser Representative with a copy thereof and any materials reasonably related thereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 6.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">6.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, following the completion of each calendar quarter during the term of this Purchase and Sale Agreement, as promptly as practicable, but in any event no later than &#91;***&#93; after the Seller receives an AZ Royalty Report, a Baxter Royalty Report and a Novo Royalty Report for such calendar quarter, the Seller shall deliver to the Purchaser Representative a true, correct and complete copy of each report in respect of such completed calendar quarter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 6.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">6.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, promptly &#91;***&#93; after receipt by the Seller of any material written notice, certificate, offer, proposal, correspondence, report or other communication relating to any License Agreement, the Intellectual Property Rights, the Purchased Royalties or, except in relation to the Related Agreements, any Product (in any case, other than any notice contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">6.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), the Seller shall (i)&#160;notify the Purchaser Representative in writing of the receipt thereof and provide the Purchaser Representative with a written summary of all material details thereof and (ii) to the extent not prohibited by obligations of confidentiality contained in the License Agreements and Counterparty Consents, furnish the Purchaser Representative with a copy thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Seller shall provide the Purchaser Representative with written notice &#91;***&#93; after obtaining Knowledge of any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the occurrence of any Bankruptcy Event in respect of the Seller&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any material breach or default by the Seller of or under any material covenant, agreement or other provision of any Transaction Document&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the Seller, any Counterparty or any other Third Party receiving any notice of audit or regulatory action by the FDA (or foreign equivalent thereof) relating to any of the Products or the Purchased Royalties&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any representation or warranty made by the Seller in this Purchase and Sale Agreement or any of the other Transaction Documents (or in any certificate delivered by the Seller to the Purchaser pursuant to this Purchase and Sale Agreement) shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;the occurrence or existence of any change, effect, event, occurrence, state of facts, development or condition that has had, or would have, a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Seller shall notify the Purchaser Representative in &#91;***&#93; prior to any change in, or amendment or alteration of, the Seller&#8217;s (i) legal name, (ii) form or type of organizational structure or (iii)&#160;jurisdiction of organization.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Seller shall notify the Purchaser Representative in writing &#91;***&#93; after becoming aware that any Purchaser Indemnified Tax may be required with respect to any payment under any License.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Public Announcement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No Party shall, and each Party shall cause its Affiliates not to, without the prior written consent of the other Parties (which consent shall not be unreasonably withheld or delayed), issue any press release or make any other public disclosure with respect to this Purchase and Sale Agreement or any of the other Transaction Documents or any of the transactions contemplated hereby or thereby, except if and to the extent that any such release or disclosure is required by Applicable Law, by the rules and regulations of any securities exchange or market on which any security of such Party may be listed or traded or by any Governmental Authority of competent jurisdiction, in which case, the Party proposing to issue such press release or make such public disclosure shall, to the extent reasonably practicable, (a) provide to the other Parties a copy of such proposed release or disclosure and (b) consider in good faith any comments or changes that the other Party may propose or suggest&#59; provided that a Party may freely make any public disclosure identical to a disclosure previously reviewed by the other Party in accordance with the foregoing clauses (a) and (b).  Notwithstanding the foregoing, the Purchaser and the Purchaser Representative understand and agree that the Seller intends to file with the SEC a Current Report on Form 8-K describing the material terms of the transactions contemplated by this Purchase and Sale Agreement and the other Transaction Documents and some or all of the Transaction Documents as exhibits thereto or to another filing with the SEC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Seller shall (a) provide to the Purchaser Representative a draft of such filings with the SEC and (b) consider in good faith any comments or changes that the Purchaser Representative may propose or suggest.  The Seller and the Purchaser Representative shall jointly prepare a press release for dissemination promptly following the Closing, such press release to be agreed upon by the Purchaser Representative and the Seller.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Further Assurances</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Purchase and Sale Agreement, each Party shall execute and deliver such other documents, certificates, instruments, agreements and other writings, take such other actions and perform such additional acts under Applicable Law as may be reasonably requested by the other Party and necessary to implement expeditiously the transactions contemplated by, and to carry out the purposes and intent of the provisions of, this Purchase and Sale Agreement and the other Transaction Documents, including to (i) perfect the sale, contribution, assignment, transfer, conveyance and granting of the Purchased Royalties to the Purchaser pursuant to this Purchase and Sale Agreement, (ii)&#160;perfect, protect, more fully evidence, vest and maintain in the Purchaser good, valid and marketable rights and interests in and to the Purchased Royalties free and clear of all Liens (other than Liens under the Transaction Documents), (iii)&#160;create, evidence and perfect the Purchaser&#8217;s back-up security interest granted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (iv)&#160;enable the Purchaser to exercise or enforce any of the Purchaser&#8217;s rights under any Transaction Document to which the Purchaser is party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Seller, the Purchasers and the Purchaser Representative shall cooperate and provide assistance as reasonably requested by any other Party, at the expense of such other Party (except as otherwise set forth herein), in connection with any litigation, arbitration, investigation or other proceeding (whether threatened, existing, initiated or contemplated prior to, on or after the Closing Date) to which the other Party, any of its Affiliates or controlling persons or any of their respective officers, directors, managers, employees or controlling persons is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such Persons have a direct or indirect interest, in each case relating to any Transaction Document, the transactions contemplated hereby or thereby or the Purchased Royalties, but in all cases excluding any litigation brought by the Seller (for itself or on behalf of any Seller Indemnified Party) against the Purchaser or the Purchaser Representative or brought by the Purchaser or the Purchaser Representative (in each case, for itself or on behalf of any Purchaser Indemnified Party) against the Seller.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Seller shall use its commercially reasonable efforts to comply with all Applicable Laws with respect to the Transaction Documents, the License Agreements and the Purchased Royalties, except where compliance therewith is being contested by the Seller in good faith by appropriate proceedings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Seller shall not enter into any contract, agreement or other legally binding arrangement (whether written or oral), or grant any right to any other Person, in any case that would reasonably be expected to conflict with the Transaction Documents or serve or operate to limit, circumscribe or alter any of the Purchaser&#8217;s rights under the Transaction Documents (or the Purchaser&#8217;s ability to exercise any such rights).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Promptly following the Closing, the Seller shall pay all commissions and broker&#8217;s fees owed to Morgan Stanley &#38; Co. LLC by the Seller in connection with the transactions contemplated by this Purchase and Sale Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments on Account of the Purchased Royalties</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If, notwithstanding the terms of the Counterparty Instructions and the Escrow Agreement, any Counterparty, any of its Affiliates, any of its sublicensees, or any other Person makes any future payment of the Purchased Royalties to the Seller or any of its Subsidiaries, then (i) such amount shall be held by the Seller (or such Subsidiary) in trust for the benefit of the Purchaser, (ii)&#160;the Seller (or such Subsidiary) shall have no right, title or interest whatsoever in such portion of such payment and shall not create or suffer to exist any Lien thereon and (iii)&#160;the Seller (or such Subsidiary) &#91;***&#93;, shall remit such portion of such payment to the Purchaser Account pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the exact form received with all necessary endorsements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All payments required to be made to the Purchaser pursuant to this Purchase and Sale Agreement shall be made by wire transfer of immediately available funds, without Set-off or deduction or withholding for or on account of any Taxes (except as required by Applicable Law), to the account provided by the Purchaser Representative in writing (or to such other account as the Purchaser Representative shall notify the Seller in writing from time to time) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If, notwithstanding the terms of the Counterparty Instructions and the Escrow Agreement, any Counterparty, any of its Affiliates, any of its sublicensees or any other Person makes any payment to the Purchaser that does not consist entirely of Purchased Royalties, then (i) the portion of such payment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that does not constitute Purchased Royalties shall be held by the Purchaser in trust for the benefit of the Seller, (ii) the Purchaser shall have no right, title or interest whatsoever in such payment and shall not create or suffer to exist any Lien thereon and (iii) the Purchaser &#91;***&#93;, shall remit such payment to the Seller Account pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the exact form received with all necessary endorsements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Purchaser shall make all payments required to be made by it to the Seller pursuant to this Purchase and Sale Agreement by wire transfer of immediately available funds, without Set-off or deduction or withholding for or on account of any Taxes (except as required by Applicable Law) to the account set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (or to such other account as the Seller shall notify the Purchaser Representative in writing from time to time) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Seller Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If any Counterparty takes any Set-off against the Purchased Royalties (other than for any prior overpayment of Purchased Royalties actually made to the Purchaser) for any liability, debt or other obligation that the Seller owes or allegedly owes to such Counterparty, then the Seller shall cause the amount of such Set-off to be paid &#91;***&#93; following such Set-off to the Purchaser Account.  If such Counterparty subsequently makes a payment to the Purchaser in respect of a Set-off previously taken against the Purchased Royalties and the Seller previously made a payment to the Purchaser in the amount of such Set-off pursuant to the foregoing sentence, then the Purchaser shall &#91;***&#93;, pay to the Seller the amount of such payment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">License Agreements</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Seller (i) shall perform and comply with in all material respects its obligations under the License Agreements, (ii)&#160;shall not, except as Mutually Agreed, (A)&#160;forgive, release or compromise any Purchased Royalties payable by the applicable Counterparty under any License Agreement, or (B) amend, modify, supplement, restate, waive, cancel or terminate (or consent to any cancellation or termination of), in whole or in part, any provision of or right under any License Agreement, (iii) shall not, except as Mutually Agreed, enter into any new contract, agreement or legally binding arrangement in respect of the Purchased Royalties, the Intellectual Property Rights or, except in relation to the Related Agreements, the Products, and (iv)&#160;shall not agree to do any of the foregoing.  The Seller shall &#91;***&#93; deliver to the Purchaser Representative copies of all fully-executed or definitive writings related to the matters set forth in clauses (ii), (iii) and (iv) of the immediately preceding sentence.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except as otherwise expressly set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and except as Mutually Agreed, the Seller shall not grant or withhold any consent, exercise or waive any right or option, fail to exercise any right or option or deliver to any Counterparty any notice under any License Agreement.  The Seller shall &#91;***&#93; deliver to the Purchaser Representative copies of all fully-executed or definitive writings related to the matters set forth in the immediately preceding sentence.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#91;***&#93; after (i) receiving (x) notice from any Counterparty, including any notice terminating any License Agreement (in whole or in part), alleging any breach of or default under any License Agreement by the Seller related to the Purchased Royalties, or any other material breach or default, or asserting the existence of any facts, circumstances or events that, alone or together with other facts, circumstances or events, would reasonably be expected (with or without the giving of notice or passage of time, or both) to give rise to a breach of or default under any License Agreement by the Seller related to the Purchased Royalties, or any other material breach or default, or the right to terminate any License Agreement (in whole or in part) by such Counterparty, or (y) any other correspondence relating </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to the foregoing, or (ii) the Seller otherwise has Knowledge of any fact, circumstance or event that, alone or together with other facts, circumstances or events, would reasonably be expected (with or without the giving of notice or passage of time, or both) to give rise to a breach of or default under any License Agreement by the Seller related to the Purchased Royalties, or any other material breach or default, or the right to terminate any License Agreement (in whole or in part) by any Counterparty, in each case the Seller shall (A) (x) give written notice thereof to the Purchaser Representative and provide the Purchaser Representative with a written summary of all material details thereof, (y) to the extent not prohibited by obligations of confidentiality contained in the License Agreements and Counterparty Consents, include a copy of any written notice received from such Counterparty, and (z) in the case of any such breach or default or alleged breach or default by the Seller, describe in reasonable detail any corrective action the Seller proposes to take in respect of such breach or default, and (B) in the case of any such breach or default or alleged breach or default by the Seller, use commercially reasonable efforts to cure such breach or default and give written notice to the Purchaser Representative upon curing such breach or default&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, if the Seller fails to promptly cure any such breach or default, without limiting any other rights it may have, the Purchaser Representative shall, on behalf of the Purchasers and upon written notice to the Seller and to the extent permitted by the License Agreements, be entitled to take any and all actions the Purchaser Representative considers reasonably necessary to promptly cure such breach or default, and the Seller shall cooperate with the Purchaser Representative for such purpose and reimburse the Purchaser Representative, &#91;***&#93; following demand, for all out-of-pocket costs and expenses incurred by the Purchaser Representative in connection therewith.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Promptly after the Seller obtains Knowledge of any actual or alleged breach of or default that relates to the Purchased Royalties or any other actual or alleged material breach of or default under any License Agreement by the applicable Counterparty (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or of the existence of any facts, circumstances or events that, alone or together with other facts, circumstances or events, would reasonably be expected (with or without the giving of notice or passage of time, or both) to give rise to any such breach of or default or the right to terminate any License Agreement (in whole or in part) by the Seller, in each case the Seller shall &#91;***&#93; give written notice thereof to the Purchaser Representative and provide the Purchaser Representative with a written summary of all material details thereof and act as Mutually Agreed to take such permissible actions (including commencing legal action against the Defaulting Party and the selection of legal counsel reasonably satisfactory to the Purchaser Representative) to enforce compliance by the Defaulting Party with the relevant provisions of the applicable License Agreement and to exercise any or all of the Seller&#8217;s rights and remedies, whether under such License Agreement or by operation of law, with respect thereto.  If the Seller is required to act as directed by the Purchaser Representative pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then the Purchaser shall reimburse the Seller, promptly on demand, for all out-of-pocket costs and expenses (including the reasonable fees and expenses of the Seller&#8217;s counsel) incurred by the Seller in connection with the Seller&#8217;s actions and exercise of rights and remedies pursuant to clause (ii) of the immediately preceding sentence&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that such out-of-pocket costs and expenses (including the reasonable fees and expenses of the Seller&#8217;s counsel) shall be borne by the Seller if (x) such breach, default or termination event or alleged breach, default or termination event results from a breach of or default under any License Agreement by the Seller or (y) the Seller acts without or contrary to the Purchaser Representative&#8217;s direction.  The Purchaser Representative shall, except to the extent prohibited by the obligations of confidentiality contained in the License Agreements and Counterparty Consents, have the right, at its sole cost and expense, to attend (or, if the Seller is required to act as directed by the Purchaser Representative pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, participate in) any meeting, discussion, action, suit or other proceeding relating to any such breach, default or termination event or alleged breach, default or termination event, including any counterclaim, settlement discussions or meetings&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Purchaser Representative shall have no such right to attend or participate, as applicable, if the exercise thereof </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">would adversely affect the maintenance by the Seller of any applicable attorney-client privilege (and, in such event, the Parties agree to use commercially reasonable efforts to effect such other arrangements to preserve such privilege, including negotiating to enter into a mutually-acceptable joint defense agreement).  Notwithstanding anything to the contrary contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, nothing herein shall prevent, restrict or limit the Purchaser Representative, on behalf of the Purchasers, from directly enforcing, at the Purchaser Representative&#8217;s sole cost and expense, a Defaulting Party&#8217;s payment obligations in respect of the Purchased Royalties with counsel selected by the Purchaser Representative in its sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Seller shall, except to the extent prohibited by obligations of confidentiality contained in the License Agreements and Counterparty Consents, make available its relevant records and personnel to the Purchaser Representative in connection with any such enforcement and provide reasonable assistance and authority to file and bring any legal action in connection therewith, including, if required, being joined as a party plaintiff, and the Purchaser Representative shall reimburse the Seller, promptly on demand, for all out-of-pocket costs and expenses incurred by the Seller in connection therewith, (x)&#160;unless the Defaulting Party&#8217;s breach, default or termination event or alleged breach, default or termination event results from a breach of or default under any License Agreement by the Seller or (y) the Seller acts without or contrary to the Purchaser Representative&#8217;s direction in respect of any such breach or default or alleged breach or default (if the Seller is required to act as directed by the Purchaser Representative pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Prosecution, Enforcement and Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;To the extent required or permitted by the applicable License Agreements and Counterparty Consents, the Seller shall&#160;take any and all actions, and prepare, execute, deliver and file any and all agreements, documents and instruments, that are reasonably necessary or desirable to diligently preserve and maintain the applicable Intellectual Property Rights, including payment of maintenance fees or annuities.  In connection with any actions or decisions by the Seller not to act in respect of matters contemplated by the foregoing sentence, to the extent such action or decision would reasonably be expected to have a Material Adverse Effect, the Seller shall provide advance written notice of all such actions or decisions not to act in order to consult with the Purchaser Representative , and the Seller shall, in good faith, give due consideration to any reasonable suggestions of, the Purchaser Representative .</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;To the extent required or permitted by the applicable License Agreements and Counterparty Consents and as Mutually Agreed, the Seller shall&#160;(A)&#160;diligently defend (and enforce) the applicable Intellectual Property Rights against infringement or interference by any other Person, and against any claims of invalidity or unenforceability, in any jurisdiction (including by bringing any legal action for infringement or defending any counterclaim of invalidity or action of any other Person for declaratory judgment of non-infringement or non-interference) and (B)&#160;when available in respect of any applicable Licensed Product, obtain patents and any corrections, substitutions, reissues and reexaminations thereof and obtain patent term extensions and any other forms of patent term restoration in any country. In connection with the Seller&#8217;s actions or decisions not to act in respect of matters contemplated by the foregoing sentence, the Seller shall provide advance written notice of all such actions or decisions not to act in order to consult with the Purchaser Representative, if applicable, and, if applicable, allow the Purchaser Representative sufficient time to issue instructions.  The Seller shall &#91;***&#93; provide to the Purchaser Representative a copy of any written notice or other documentation received in connection with any such legal action, suit or other proceeding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Seller shall, except to the extent prohibited by obligations of confidentiality contained in the License Agreements and Counterparty Consents, &#91;***&#93; after receipt thereof, provide to the Purchaser Representative a copy of all substantive written notices or other documentation relating to the patentability, enforceability, validity, scope or term of the Patents, and shall provide the Purchaser Representative with a copy of drafts of any written material proposed to be filed in response thereto.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;The Parties shall bear their own costs and expenses in connection with the actions pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; provided that the Purchaser Representative shall reimburse the Seller, promptly on demand, for &#91;***&#93; of all reasonable out of pocket costs and expenses (including the reasonable fees and expenses of the Seller&#8217;s counsel) incurred by the Seller in connection with any actions the Seller is instructed to take by the Purchaser Representative pursuant to Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">6.5(e)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;The Seller shall not disclaim or abandon, or fail to take any Commercially Reasonable Action necessary or desirable to prevent the disclaimer or abandonment of, any Intellectual Property Rights.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Except in connection with any assignment by the Seller of its rights and a delegation by the Seller of its obligations under this Purchase and Sale Agreement pursuant to and in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Seller shall not dispose of, assign or otherwise transfer, in whole or in part, any License Agreement, the Purchased Royalties or any of the Seller&#8217;s right, title or interest in or to the applicable Intellectual Property Rights. The Seller shall not grant any Lien on the Intellectual Property Rights or the License Agreements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.6  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of the License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any other rights or remedies the Purchaser may have under this Purchase and Sale Agreement, if AZ terminates or provides written notice of termination of the AZ License Agreement or the AZ License Agreement otherwise terminates (whether in whole or in part in respect of any AZ Licensed Product in any country), in any case during the AZ Royalty Term, then the Seller shall have the exclusive right, following the effective date of such termination, and shall use Commercially Reasonable Efforts to negotiate a license with a Third Party under the AZ Intellectual Property Rights for such Third Party to make, have made, use, import, offer for sale and sell AZ Licensed Products for any purpose that AZ would have been permitted to make, have made, use, import, offer for sale and sell AZ Licensed Products under the AZ License Agreement (and, if such termination is only in part in respect of a AZ Licensed Product in a particular country (and not in whole), such license (x)&#160;shall apply only to such country and (y) shall not apply to any product that would have constituted a AZ Licensed Product under the AZ License Agreement other than the AZ Licensed Product that was the subject of such termination), which license shall (i) become effective not earlier than the effective date of such termination, (ii)&#160;expire not later than the last day of the AZ Royalty Term (and, if such termination is only in part in respect of a AZ Licensed Product in a particular country (and not in whole), the AZ Royalty Term shall be such term that is applicable under the AZ License Agreement for such AZ Licensed Product in such country) and (iii) include terms, conditions and limitations that are not materially less favorable to the Seller, taking into account the sale of the Purchased Royalties pursuant to the Transaction Documents, than those contained in the AZ License Agreement, including with respect to obligations and costs imposed on the Seller, disclaimers of the Seller&#8217;s liability, intellectual property ownership and control and indemnification of the Seller (any such license, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AZ New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Seller shall consult and reasonably consider any comments from the Purchaser Representative with respect to such negotiation of an AZ New Arrangement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any other rights or remedies the Purchaser may have under this Purchase and Sale Agreement, if Baxter terminates or provides written notice of termination of the Baxter License Agreement or the Novo Sublicense Agreement or the Baxter License Agreement or the Novo Sublicense Agreement otherwise terminates, other than in violation of this Purchase and Sale Agreement, then the Seller shall have the exclusive right, following the effective date of such termination, and shall use Commercially Reasonable Efforts to negotiate a license with a Third Party under the Baxter Intellectual Property Rights for such Third Party to make, have made, use, import, offer for sale and sell the Baxter Licensed Products for any purpose that Baxter would have been permitted to make, have made, use, import, offer for sale and sell Baxter Licensed Products under the Baxter License Agreement or the Novo Sublicense Agreement, which license shall (i) become effective not earlier than the effective date of such termination, (ii)&#160;expire not later than the last day of the Baxter Royalty Term (for purposes of this clause (ii), the Baxter Royalty Term shall be determined assuming that the Baxter License Agreement had not been terminated) and (iii) include terms, conditions and limitations that are not materially less favorable to the Seller, taking into account the sale of the Purchased Royalties pursuant to the Transaction Documents, than those contained in the Baxter License Agreement or the Novo Sublicense Agreement, including with respect to obligations and costs imposed on the Seller, disclaimers of the Seller&#8217;s liability, intellectual property ownership and control and indemnification of the Seller (any such license, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Baxter New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Seller shall consult and reasonably consider any comments from the Purchaser Representative with respect to such negotiation of a Baxter New Arrangement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any other rights or remedies the Purchaser may have under this Purchase and Sale Agreement, if the Novo Settlement Agreement terminates, other than in violation of this Purchase and Sale Agreement, then the Seller shall have the exclusive right, following the effective date of such termination, and shall use Commercially Reasonable Efforts to negotiate a license with a Third Party under the Novo Patents for such Third Party to make, have made, use, import, offer for sale and sell the Novo Nordisk Factor IX Product for any purpose that Novo Nordisk would have been permitted to make, have made, use, import, offer for sale and sell Novo Nordisk Factor IX Product under the Novo Settlement Agreement, which license shall (i) become effective not earlier than the effective date of such termination, (ii)&#160;expire not later than the last day of the Novo Royalty Term (for purposes of this clause (ii), the Novo Royalty Term shall be determined assuming that the Novo Settlement Agreement had not been terminated) and (iii) include terms, conditions and limitations that are not materially less favorable to the Seller, taking into account the sale of the Purchased Royalties pursuant to the Transaction Documents, than those contained in the Novo Settlement Agreement, including with respect to obligations and costs imposed on the Seller, disclaimers of the Seller&#8217;s liability, intellectual property ownership and control and indemnification of the Seller (any such license, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Seller shall consult and reasonably consider any comments from the Purchaser Representative with respect to such negotiation of a Novo New Arrangement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Should the Seller identify any New Arrangement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">6.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5.6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Seller agrees to promptly duly execute and deliver a new license agreement effecting such New Arrangement that satisfies the foregoing requirements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Audits</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Seller shall not, without first consulting the Purchaser Representative, cause an inspection or audit of any Counterparty&#8217;s books and records to be conducted pursuant to and in accordance with Section 10.2 of the Baxter License Agreement, Section 7.14 of the AZ License Agreement, Section 6(c)(iv) of the Novo Settlement Agreement or Section 3.9 of the Novo Sublicense Agreement, as the case may be. From time to time, but not more frequently than once per calendar year, the Purchaser Representative may request the Seller to, and the Seller shall, cause an inspection or audit of any Counterparty&#8217;s books and records in respect of the Purchased Royalties to be conducted pursuant to and in accordance with Section 10.2 of the Baxter License Agreement, Section 7.14 of the AZ License Agreement, Section 6(c)(iv) of the Novo Settlement Agreement or Section 3.9 of the Novo Sublicense Agreement, as the case may be. The Seller shall retain the exclusive right to inspect and audit each Counterparty&#8217;s books and records at any time and from time to time at its sole discretion for payments relating to periods prior to the Royalties Commencement Date (any such audit, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Past Period Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  For the purposes of exercising the Purchaser Representative&#8217;s rights pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in respect of the Baxter License Agreement, the AZ License Agreement or the Novo Sublicense Agreement, the Seller shall appoint such public accounting firm of nationally recognized standing as the Purchaser Representative shall select for such purpose (it being understood and agreed that any such public accounting firm shall, pursuant to Section 10.2 of the Baxter License Agreement, Section 7.14 of the AZ License Agreement or Section 3.9 of the Novo Sublicense Agreement, be reasonably acceptable to Baxter or AZ, respectively). For the purposes of exercising the Purchaser Representative&#8217;s rights pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in respect of the Novo Settlement Agreement, the Seller shall appoint such public accounting firm(s) as the Purchaser Representative shall select from the list set forth in Section 6(c)(iv) of the Novo Settlement Agreement. The Seller and the Purchaser Representative agree that all of the expenses of, and amounts payable to AZ, Baxter or Novo Nordisk, as the case may be, as a result of any inspection or audit carried out at the request of the Purchaser Representative pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that would otherwise be borne by the Seller pursuant to the applicable License Agreement shall instead be borne by the Purchaser Representative and reimbursed to the Seller promptly on demand, including such reasonable fees and expenses of such public accounting firm as are to be borne by the Seller pursuant to Section 10.2 of the Baxter License Agreement, Section 7.14(b) of the AZ License Agreement, Section 6(c)(iv)(H) of the Novo Settlement Agreement or Section 3.9 of the Novo Sublicense Agreement, as the case may be, together with the Seller&#8217;s out-of-pocket costs and expenses incurred in connection with such inspection or audit&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Purchaser Representative shall be reimbursed by the Seller for any such fees and expenses to the extent the Seller is entitled to receive reimbursement from AZ, Baxter or Novo Nordisk, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, for the avoidance of doubt, any audit caused by the Seller pursuant to the first sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any Past Period Audit shall not be deemed to be carried out at the request of the Purchaser Representative and the Purchaser Representative shall have no obligation to reimburse the Seller, pursuant to this sentence, for any fees, costs or expenses incurred by the Seller in connection therewith.  The Seller shall, to the extent not prohibited by obligations of confidentiality contained in the License Agreement pursuant to which an inspection or audit in respect of the Purchased Royalties is conducted, &#91;***&#93; furnish to the Purchaser Representative any inspection or audit report prepared in connection with such inspection or audit.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event that any inspection or audit conducted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> uncovers that the amounts actually paid to the Purchaser for any period in respect of the Purchased Royalties were greater than the amounts that should have been paid to the Purchaser for such period in respect of the Purchased Royalties, the Purchaser Representative shall cause the amount of such overpayment to be paid to the applicable Counterparty &#91;***&#93; after delivery to the Purchaser Representative, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, of the applicable inspection or audit report or certificate, as the case may be, showing such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">overpayment.  In the event that any inspection or audit conducted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> uncovers that the amounts actually paid to the Purchaser for any period in respect of the Purchased Royalties were less than the amounts that should have been paid to the Purchaser for such period in respect of the Purchased Royalties, the Seller shall cooperate and provide assistance as reasonably requested by the Purchaser Representative to cause the amount of such underpayment to be paid to the Purchaser by the applicable Counterparty in accordance with the timeframe set forth in the applicable License Agreement promptly after delivery to the Purchaser Representative, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, of the applicable inspection or audit report or certificate, as the case may be, showing such underpayment.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.8  &#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.9  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All payments to the Purchaser under this Purchase and Sale Agreement shall be made without any deduction or withholding for or on account of any Tax unless required by Applicable Law&#59; provided that, if deduction or withholding for or on account of any Purchaser Indemnified Tax is required by Applicable Law to be made, and is made, from any payment to Purchaser under this Purchase and Sale Agreement, then the Seller shall, &#91;***&#93; after such deduction or withholding is made, make a payment to the Purchaser so that, after all such required deductions and withholdings are made by any applicable withholding agent (including any deductions and withholdings required with respect to any additional payments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), the Purchaser receives an amount equal to the amount that it would have received had no withholding of such Purchaser Indemnified Taxes been made.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Seller shall notify the Purchaser Representative in writing &#91;***&#93; following the receipt of any written notification by any Counterparty or by an Affiliate of such Counterparty that such Counterparty intends to make any Permitted Tax Withholding.  The Seller shall, upon the reasonable request of the Purchaser Representative and at the Purchaser Representative&#8217;s expense, reasonably cooperate with the Purchaser Representative and use its commercially reasonable efforts to make such filings and take such other actions as may be reasonably necessary and specified by the Purchaser Representative in order to allow an exemption from or reduction of any Permitted Tax Withholding.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Parties agree not to take any position that is inconsistent with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on any Tax return or in any Tax audit or other administrative or judicial proceeding unless required by law.  If there is an inquiry by any Governmental Authority of the Seller, the Purchaser or the Purchaser Representative related to the treatment described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties shall cooperate with each other in responding to such inquiry in a commercially reasonable manner that is consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If a Purchaser is entitled to additional amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then such Purchaser shall use commercially reasonable efforts to assign its rights and obligations hereunder to an Affiliate, if, in the reasonable judgment of such Purchaser, such assignment (i)&#160;would eliminate or reduce any additional amounts payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the future and (ii)&#160;would not subject such Purchaser to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Purchaser.&#160; The Seller hereby agrees to pay all reasonable costs and expenses incurred by such Purchaser in connection with any such assignment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.10  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existence</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Seller shall (a) preserve and maintain its existence (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall prohibit the Seller from entering into any merger or consolidation with, or selling or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">otherwise transferring all or substantially all of its assets to, any other Person if the Seller is the continuing or surviving entity or if the surviving or continuing or acquiring entity assumes (either expressly or by operation of law) all of the obligations of the Seller under the Transaction Documents), (b)&#160;preserve and maintain its rights, franchises and privileges unless failure to do any of the foregoing would not have a Material Adverse Effect, (c) qualify and remain qualified in good standing in each jurisdiction where the failure to preserve and maintain such qualifications would have a Material Adverse Effect, including appointing and employing such agents or attorneys in each jurisdiction where it shall be necessary to take action under this Purchase and Sale Agreement, and (d) comply with its organizational documents, except, in the case of this clause (d), for any non-compliance that would not have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.11  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Novo Consent&#59; Baxter Consent Amendment&#59; Licensee Confirmations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Following the Closing, the Seller shall use commercially reasonable efforts to obtain from Novo Nordisk an executed copy of the Novo Consent&#59; provided that the Seller shall not agree to any material changes to the Novo Consent without the prior consent of the Purchaser Representative (not to be unreasonably withheld, conditioned or delayed).  If the Seller shall fail to obtain and deliver to the Purchaser Representative an executed copy of the Novo Consent, then solely to the extent the Novo Settlement Royalties are not received by the Purchaser (other than by reason of breach or negligence by the Escrow Agent, or breach by the Purchaser Representative, under the Escrow Agreement), the Seller shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> make each payment to the Purchaser otherwise due to the Purchaser hereunder such that the Purchaser receives the full amount of such Novo Settlement Royalties that would have been payable to the Purchaser had such Novo Consent been obtained.  Prior to the Seller&#8217;s delivery of, or in the event of the failure of the Seller to obtain, an executed copy of the Novo Consent, such that delivery by the Seller to the Purchaser Representative of (a) the quarterly royalty reports made pursuant to Section 6(c)(i) of the Novo Settlement Agreement or (b) material written notices, certificates, offers, proposals, correspondence, reports or other communications delivered pursuant to the Novo Settlement Agreement relating to the Novo Settlement Agreement, the Novo Patents, the Purchased Royalties or Rebinyn would constitute a breach by the Seller of its confidentiality obligations under the Novo Settlement Agreement, the Seller shall deliver to the Purchaser Representative </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a written summary, certified by an officer of the Seller and to the extent providing such summary is not itself a Confidentiality Breach, of all information contained in such communication that Seller reasonably believes is material (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). If Seller is advised in writing by its counsel that providing the Purchaser Representative such Material Summary will constitute a breach by the Seller of its confidentiality obligations (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the Novo Settlement Agreement, then the Seller shall paraphrase or otherwise describe the substance for the Purchaser Representative of such communication to the maximum extent possible, as the Seller is advised in writing by its counsel, without causing a Confidentiality Breach under the Novo Settlement Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permissible Summary Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Following the Closing, the Seller shall use commercially reasonable efforts to obtain from Baxter an executed copy of the Baxter Consent Amendment&#59; provided that the Seller shall not agree to any material changes to the Baxter Consent Amendment without the prior consent of the Purchaser Representative (not to be unreasonably withheld, conditioned or delayed).  If the Seller shall fail to obtain and deliver to the Purchaser Representative an executed copy of the Baxter Consent Amendment, then solely to the extent the Novo Sublicense Royalties are not received by the Purchaser (other than by reason of breach or negligence by the Escrow Agent, or breach by the Purchaser Representative, under the Escrow Agreement), the Seller shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> make each payment to the Purchaser otherwise due to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchaser hereunder such that the Purchaser receives the full amount of such Novo Sublicense Royalties that would have been payable to the Purchaser had such Baxter Consent Amendment been obtained.  Prior to the Seller&#8217;s delivery of, or in the event of the failure of the Seller to obtain, an executed copy of the Baxter Consent Amendment, such that delivery by the Seller to the Purchaser Representative of (a) the quarterly royalty reports made pursuant to Section 3.6 of the Novo Sublicense Agreement or (b) material written notices, certificates, offers, proposals, correspondence, reports or other communications delivered pursuant to the Novo Sublicense Agreement relating to the Novo Sublicense Agreement, the Licensed Patents (as defined in the Novo Sublicense Agreement), the Purchased Royalties or any Licensed Product (as defined in the Novo Sublicense Agreement) would constitute a breach by the Seller of its confidentiality obligations under the Novo Sublicense Agreement, the Seller shall deliver to the Purchaser </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Material Summary, certified by an officer of the Seller and to the extent providing such summary is not itself a Confidentiality Breach under the Novo Sublicense Agreement, of all information contained in such communication that Seller reasonably believes is material. If Seller is advised in writing by its counsel that providing the Purchaser Representative such Material Summary will constitute a Confidentiality Breach, then the Seller shall provide a Permissible Summary Disclosure to the Purchaser Representative.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Following the Closing, the Seller shall use commercially reasonable efforts to obtain from Baxter an executed copy of the Baxter Confirmation&#59; provided that the Seller shall not agree to any material changes to the Baxter Confirmation without the prior consent of the Purchaser Representative (not to be unreasonably withheld, conditioned or delayed).  If the Seller shall fail to obtain and deliver to the Purchaser Representative an executed copy of the Baxter Confirmation, then solely to the extent the Baxter Royalties are not received by the Purchaser (other than by reason of breach or negligence by the Escrow Agent, or breach by the Purchaser Representative, under the Escrow Agreement), the Seller shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> make each payment to the Purchaser otherwise due to the Purchaser hereunder such that the Purchaser receives the full amount of such Baxter Royalties that would have been payable to the Purchaser had the Baxter Confirmation been obtained.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Following the Closing, the Seller shall use commercially reasonable efforts to obtain from AZ an executed copy of the AZ Confirmation&#59; provided that the Seller shall not agree to any material changes to the AZ Confirmation without the prior consent of the Purchaser Representative (not to be unreasonably withheld, conditioned or delayed).  If the Seller shall fail to obtain and deliver to the Purchaser Representative an executed copy of the AZ Confirmation, then solely to the extent the AZ Royalties are not received by the Purchaser (other than by reason of breach or negligence by the Escrow Agent, or breach by the Purchaser Representative, under the Escrow Agreement), the Seller shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> make each payment to the Purchaser otherwise due to the Purchaser hereunder such that the Purchaser receives the full amount of such AZ Royalties that would have been payable to the Purchaser had the AZ Confirmation been obtained.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VII</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">THE CLOSING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The closing of the transactions contemplated hereby (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall take place at 9&#58;00 a.m., Eastern Standard Time, on the tenth (10th) Business Day following the date hereof, subject to the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  being satisfied (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at the offices of Goodwin Procter LLP located at 100 Northern Avenue, Boston, MA 02210, or on such other date, at such other time or at such other place, in each case as the Parties mutually agree.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Deliverables of the Seller</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160; At the Closing, Seller shall deliver or cause to be delivered to the Purchaser the following&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Bill of Sale duly executed by the Seller&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;each of the Counterparty Instructions duly executed by the Seller&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;an opinion of Goodwin Procter LLP, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;a duly executed counterpart to the Escrow Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;a certificate of an executive officer of the Seller dated as of the Closing Date and&#58;  (ii) attaching copies, certified by such officer as true and complete, of (x) the organizational documents of the Seller and (y) resolutions of the governing body of the Seller authorizing and approving the execution, delivery and performance by the Seller of the Transaction Documents and the transactions contemplated hereby and thereby, (iii)&#160;setting forth the incumbency of the officer or officers of the Seller who have executed and delivered the Transaction Documents, including therein a signature specimen of each such officer or officers and (iv) attaching a copy, certified by such officer as true and complete, of a good standing certificate of the appropriate Governmental Authority of the Seller&#8217;s jurisdiction of organization, stating that the Seller is in good standing under the laws of such jurisdiction&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the AZ Financing Statement, the Baxter Financing Statement and the Novo Financing Statement, to create, evidence and perfect the sale, assignment, transfer, conveyance and grant of the Purchased Royalties pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the back-up security interest granted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.3  &#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Deliverables of the Purchaser and Purchaser Representative</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  At the Closing, the Purchaser Representative shall deliver or cause to be delivered to the Seller the following&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Bill of Sale duly executed by each Purchaser&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a valid, true and properly executed IRS Form W-9 or applicable IRS Form W-8 (or any applicable successor form) for each Purchaser certifying that such Purchaser is exempt from United States federal withholding tax with respect to any and all payments made to such Purchaser in respect of the Purchased Royalties&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;counterparts to the Escrow Agreement, duly executed by each Purchaser and the Purchaser Representative&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Purchase Price in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;a certificate of an executive officer of the Purchaser Representative dated as of the Closing Date and setting forth the incumbency of the officer or officers of each Purchaser and the Purchaser Representative who have executed and delivered the Transaction Documents to which such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchaser or the Purchaser Representative is a party, including therein a signature specimen of each such officer or officers.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VIII</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Seller</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Seller agrees to indemnify and hold harmless the Purchaser and its Affiliates (including the Purchaser Representative) and any or all of their respective partners, directors, trustees, officers, managers, employees, members, agents and controlling persons (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) harmless from and against, and will pay to each Purchaser Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Purchaser Indemnified Party, whether or not involving a Third Party Claim, arising out of (a) any breach of any representation or warranty made by the Seller in any of the Transaction Documents or in any certificate delivered by the Seller to the Purchaser or to the Purchaser Representative in writing pursuant to this Purchase and Sale Agreement, (b) any breach of or default under any covenant or agreement of the Seller in any of the Transaction Documents or License Agreements, (c) any Excluded Liabilities and Obligations or (d)&#160;any brokerage or finder&#8217;s fees or commissions or similar amounts incurred or owed by the Seller to any brokers, financial advisors or comparable other Persons retained or employed by it in connection with the transactions contemplated by this Purchase and Sale Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the foregoing shall exclude any indemnification to any Purchaser Indemnified Party (i) that has the effect of imposing on the Seller any recourse liability for Purchased Royalties because of the insolvency or other creditworthiness problems of any Counterparty or the insufficiency of the Purchased Royalties, whether as a result of the amount of cash flow arising from sales or licensing of the Products or otherwise, in any case unless resulting from the breach or default by the Seller of or under any of the Transaction Documents or License Agreements, (ii)&#160;for any matter in respect of which any Seller Indemnified Party would be entitled to indemnification under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (iii)&#160;to the extent resulting from the bad faith, gross negligence or willful misconduct of any Purchaser Indemnified Party, (iv) to the extent resulting from the failure of any Counterparty to perform any of its obligations under any of the License Agreements, unless resulting from the breach or default by the Seller of or under any of the License Agreements or the Transaction Documents or (v) to the extent resulting from acts or omissions of the Seller based upon the written instructions from any Purchaser Indemnified Party.  Any amounts due to any Purchaser Indemnified Party hereunder shall be payable by the Seller to such Purchaser Indemnified Party upon demand.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Purchaser</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Purchaser and the Purchaser Representative, jointly and severally, agree to indemnify and hold each of the Seller and its Affiliates and any or all of their respective partners, directors, officers, managers, members, employees, agents and controlling Persons (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Seller Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) harmless from and against, and will pay to each Seller Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Seller Indemnified Party, whether or not involving a Third Party Claim, arising out of (a) any breach of any representation or warranty made by the Purchaser or the Purchaser Representative in any of the Transaction Documents or any certificate delivered by the Purchaser or the Purchaser Representative to the Seller in writing pursuant to this Purchase and Sale Agreement, (b) any breach of or default under any covenant or agreement of the Purchaser in any Transaction Document to which the Purchaser or the Purchaser Representative is party or in the Confidentiality Agreement or (c)&#160;any brokerage or finder&#8217;s fees or commissions or similar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">amounts incurred or owed by the Purchaser or the Purchaser Representative to any brokers, financial advisors or comparable other Persons retained or employed by it in connection with the transactions contemplated by this Purchase and Sale Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the foregoing shall exclude any indemnification to any Seller Indemnified Party (i) to the extent resulting from the bad faith, gross negligence or willful misconduct of any Seller Indemnified Party, (ii) for any matter in respect of which any Purchaser Indemnified Party would be entitled to indemnification under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (iii) to the extent resulting from acts or omissions of the Purchaser or the Purchaser Representative based upon the written instructions from any Seller Indemnified Party.  Any amounts due to any Seller Indemnified Party hereunder shall be payable by the Purchaser and the Purchaser Representative to such Seller Indemnified Party upon demand.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Procedures for Third Party Claims</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If any Third Party Claim shall be brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the indemnified party shall, promptly after receipt of notice of the commencement of such Third Party Claim, notify the indemnifying party in writing of the commencement thereof, enclosing a copy of all papers served, if any&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> unless, and only to the extent that, the indemnifying party is actually prejudiced by such omission.  In the event that any Third Party Claim is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the indemnifying party will be entitled, at the indemnifying party&#8217;s sole cost and expense, to participate therein and, to the extent that it may wish, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation.  In any such Third Party Claim, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the sole cost and expense of such indemnified party unless (a) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (b) the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such indemnified party or (c) the named parties to any such Third Party Claim (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of counsel to the indemnified party.  It is agreed that the indemnifying party shall not, in connection with any Third Party Claim or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such indemnified parties.  The indemnifying party shall not be liable for any settlement of any Third Party Claim effected without its written consent, but, if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any Loss by reason of such settlement or judgment.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or discharge of any pending or threatened Third Party Claim in respect of which any indemnified party is or could have been a party and indemnity could be sought hereunder by such indemnified party, unless such settlement, compromise or discharge, as the case may be, (i) includes an unconditional, full written release of such indemnified party, in form and substance reasonably satisfactory to the indemnified party, from all liability on claims that are the subject </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">matter of such claim or proceeding, (ii) does not include any statement as to an admission of fault, culpability or failure to act by or on behalf of any indemnified party and (iii)&#160;does not impose any continuing obligations or restrictions other than customary and reasonable confidentiality obligations relating to such claim, settlement or compromise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Claims</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  A claim by an indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for any matter not involving a Third Party Claim and in respect of which such indemnified party would be entitled to indemnification hereunder may be made by delivering, in good faith, a written notice of demand to the indemnifying party, which notice shall contain (a) a description and the amount of any Losses incurred or suffered or reasonably expected to be incurred or suffered by the indemnified party, (b)&#160;a statement that the indemnified party is entitled to indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for such Losses and a reasonable explanation of the basis therefor, and (c)&#160;a demand for payment in the amount of such Losses.  For all purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Seller shall be entitled to deliver such notice of demand to the Purchaser Representative on behalf of the Seller Indemnified Parties, and the Purchaser Representative shall be entitled to deliver such notice of demand to the Seller on behalf of the Purchaser Indemnified Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Time Limitations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Seller shall have liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to any breach of any representation or warranty made by the Seller in any of the Transaction Documents or certificates delivered by the Seller to the Purchaser or the Purchaser Representative in writing pursuant to this Purchase and Sale Agreement only if the Purchaser Representative notifies the Seller of a claim, specifying the factual basis of such claim in reasonable detail&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Purchaser shall have liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to any breach of any representation or warranty made by the Purchaser or the Purchaser Representative in any of the Transaction Documents or any certificate delivered by the Purchaser or the Purchaser Representative to the Seller in writing pursuant to this Purchase and Sale Agreement (&#91;***&#93;), only if, &#91;***&#93;, the Seller notifies the Purchaser Representative of a claim, specifying the factual basis of such claim in reasonable detail.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.6  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusive Remedy</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Except in the case of actual fraud, intentional misrepresentation, intentional wrongful acts, intentional breach, bad faith or willful misconduct and except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the indemnification afforded by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be the sole and exclusive remedy for any and all Losses awarded against or incurred or suffered by a Party in connection with the transactions contemplated by the Transaction Documents, including with respect to any breach of any representation or warranty made by a Party in any of the Transaction Documents or any certificate delivered by a Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to the other Party in writing pursuant to this Purchase and Sale Agreement or any breach of or default under any covenant or agreement by a Party pursuant to any Transaction Document.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Notwithstanding anything in this Purchase and Sale Agreement to the contrary, (a) in no event shall any Seller Indemnified Party or Purchaser Indemnified Party have any liability for, or Losses be deemed to include, any special, punitive or exemplary damages, or any lost profits, whether in contract or tort, regardless of whether the other Party shall be advised, shall have reason to know, or in fact shall know of the possibility of such damages suffered or incurred by any such Seller Indemnified Party or Purchaser Indemnified Party in connection with this Purchase and Sale Agreement any of the other Transaction Documents or any of the transactions contemplated hereby or thereby, except to the extent any such damages are actually paid to a Third Party in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (b) the Seller shall not have any liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in excess of an amount equal to TWO HUNDRED AND FORTY MILLION DOLLARS ($240,000,000) less the aggregate amount of Purchased Royalties actually received by the Purchaser.  Notwithstanding the foregoing, the limitations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not apply to any claim for indemnification hereunder in the case of actual fraud, intentional misrepresentation, intentional wrongful acts, intentional breach, bad faith or willful misconduct.  The Parties acknowledge and agree that (a)&#160;the Purchaser&#8217;s Losses, if any, for any indemnifiable events under this Purchase and Sale Agreement will typically include Losses for Purchased Royalties that the Purchaser was entitled to receive in respect of its ownership of the Purchased Royalties but did not receive timely or at all due to such indemnifiable event and (b)&#160;subject to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Purchaser shall be entitled to make indemnification claims for all such missing or delayed Purchased Royalties that the Purchaser was entitled to receive in respect of its ownership of the Purchased Royalties as Losses hereunder (which claims shall be reviewed and assessed by the Parties in accordance with the procedures set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), and such missing or delayed Purchased Royalties shall not be deemed special, punitive or exemplary damages, or lost profits for any purpose of this Purchase and Sale Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IX</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Except as provided in this ARTICLE VIII or otherwise agreed in writing by the Parties, the Parties agree that, during the term of this Purchase and Sale Agreement and until the seventh (7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the date of termination of this Purchase and Sale Agreement, each Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall keep confidential, and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Purchase and Sale Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), any information (whether written or oral, or in electronic or other form) furnished to it by or on behalf of the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to the Existing Confidentiality Agreement (as defined below) or this Purchase and Sale Agreement, including the terms of this Purchase and Sale Agreement (such information, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of the Disclosing Party), except for that portion of such information that&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;was already in the Receiving Party&#8217;s possession on a non-confidential basis prior to its disclosure to it by the Disclosing Party, or becomes known to the Receiving Party from a source other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">than the Disclosing Party and its representatives without any breach of this Purchase and Sale Agreement, in each case as evidenced by written records (provided, if such information was disclosed to the Receiving Party on a non-confidential basis by a source that is not the Disclosing Party, such source to the knowledge of the Receiving Party had the right to disclose such information to the Receiving Party without any legal, contractual or fiduciary obligation to, any person with respect to such information)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;is or becomes generally available to the public other than as a result of an act or omission by the Receiving Party or its Affiliates in breach of this Purchase and Sale Agreement&#59; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;was independently developed by the Receiving Party, as evidenced by written records, without use of or reference to the Confidential Information or in violation of the terms of this Purchase and Sale Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Confidentiality Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;  Effective upon the date hereof, the Existing Confidentiality Agreement shall terminate and be of no further force or effect, and shall be superseded by the provisions of this Article VIII.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Disclosure</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  In the event that the Receiving Party or its Affiliates or any of its or its Affiliates&#8217; representatives are requested by a governmental or regulatory authority or required by Applicable Law, regulation or legal process (including the regulations of a stock exchange or governmental or regulatory authority or the order or ruling of a court, administrative agency or other government or regulatory body of competent jurisdiction) to disclose any Confidential Information, the Receiving Party shall promptly, to the extent permitted by Applicable Law, notify the Disclosing Party in writing of such request or requirement so that the Disclosing Party may seek an appropriate protective order or other appropriate remedy (and if the Disclosing Party seeks such an order or other remedy, the Receiving Party will provide such cooperation, at the Receiving Party&#8217;s sole expense, as the Disclosing Party shall reasonably request).  If no such protective order or other remedy is obtained and the Receiving Party or its Affiliates or its or its Affiliates&#8217; representatives are, in the view of their respective counsel (which may include their respective internal counsel), legally required to disclose Confidential Information, the Receiving Party or its Affiliates or its or its Affiliates&#8217; representatives, as the case may be, shall only disclose that portion of the Confidential Information that their respective counsel advises that the Receiving Party or its Affiliates or its or its Affiliates&#8217; representatives, as the case may be, are required to disclose and will exercise commercially reasonable efforts, at the Disclosing Party&#8217;s sole expense, to obtain reliable assurance that confidential treatment will be accorded to that portion of the Confidential Information that is being disclosed.  In any event, the Receiving Party will not oppose action by the Disclosing Party to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information.  Notwithstanding the foregoing, notice to the Disclosing Party shall not be required where disclosure is made (i) in response to a request by a governmental or regulatory authority having competent jurisdiction over the Receiving Party, its Affiliates or its or its Affiliates&#8217; representatives, as the case may be, or (ii) in connection with a routine examination by a regulatory examiner, where in each case such request or examination does not expressly reference the Disclosing Party, its Affiliates, the Purchased Royalties or this Purchase and Sale Agreement. The Receiving Party may disclose Confidential Information to its Affiliates, its and their employees, directors, officers, contractors, agents, and representatives, and to potential or actual acquirers, merger partners, permitted assignees, investment bankers, investors, limited partners, partners, lenders, or other financing sources </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(including, in the case of the Seller, any party evaluating the acquisition of any portion of the Royalties that are not included in the Purchased Royalties), and their respective directors, employees, contractors and agents provided that such person or entity agrees to confidentiality and non-use obligations with respect thereto at least as stringent as those specified for in this Article VIII.  Further, notwithstanding anything contained in this Article VIII to the contrary, the Seller may disclose Confidential Information to the extent such disclosure is reasonably necessary to comply with the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or with any rule, regulation or legal process promulgated by the SEC or a stock exchange, subject to the Seller&#8217;s obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.5 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Relevant Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In addition to, and without limiting, Purchaser&#8217;s and Purchaser Representative&#8217;s obligations under this Article VIII, Purchaser and the Purchaser Representative shall fully comply with any confidentiality obligations of the Seller or any of its Affiliates under the AZ License Agreement, the Baxter License Agreement, the Novo Sublicense Agreement, and the Novo Settlement Agreement that are applicable to the Confidential Information.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE X</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  This Purchase and Sale Agreement shall terminate on the earlier of (a) the Royalty Termination Date and (b) mutual written agreement of the Purchaser and the Seller.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Termination</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Upon the termination of this Purchase and Sale Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, this Purchase and Sale Agreement shall become void and of no further force and effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (a) the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VIII,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive such termination and shall remain in full force and effect, (b) if, upon the termination of this Purchase and Sale Agreement, any Purchased Royalties or other amounts are payable to the Purchaser, this Purchase and Sale Agreement shall remain in full force and effect until any and all such payments have been made in full, and (except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) solely for that purpose, and (c)&#160;nothing contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall relieve any Party from liability for any breach of this Purchase and Sale Agreement that occurs prior to termination.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE XI</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Purchaser hereby appoints and constitutes the Purchaser Representative as agent, proxy and attorney-in-fact, with full power of substitution, to act on behalf of the Purchasers for certain limited purposes, as specified herein, including the full power and authority to act on the Purchasers&#8217; behalf as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Purchasers further agree that such agency, proxy and attorney-in-fact shall be binding upon the successors, heirs, executors, administers and legal representatives of each Purchaser.  All decisions, actions, consents and instructions by the Purchaser Representative shall be binding upon all of the Purchasers, and no Purchaser shall have the right to object to, dissent from, protest or otherwise contest any such decision, action, consent or instruction.  The Seller shall be entitled to rely on any decision, action, consent or instruction of the Purchaser Representative as being the decision, action, consent or instruction of the Purchasers.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Purchaser Representative shall have such powers and authority as are necessary to carry out the functions assigned to it under this Purchase and Sale Agreement.  Without limiting the generality of the foregoing, the Purchaser Representative shall have full power, authority and discretion to (i) consummate the transactions contemplated under the Transaction Documents&#59; (ii) negotiate disputes arising under, or relating to, the Transaction Documents (including pursuant to Article VII hereof)&#59; (iii) receive and disburse to the Purchasers any funds received on behalf of the Purchasers under the Transaction Documents (including pursuant to Article VII hereof)&#59; (iv) withhold any amounts received on behalf of the Purchasers under this Purchase and Sale Agreement or otherwise to satisfy any and all obligations or liabilities incurred by the Purchasers or the Purchaser Representative in the performance of their duties hereunder (including pursuant Article VII hereof)&#59; (v) execute and deliver any amendment or waiver to the Transaction Documents (without the prior approval of the Purchasers)&#59; and (vi) to take all other actions to be taken by or on behalf of the Purchasers in connection with the Transaction Documents.  The Purchaser Representative shall have no duties or obligations hereunder, including any fiduciary duties, except those set forth herein, and such duties and obligations shall be determined solely by the express provisions of this Purchase and Sale Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Purchaser Representative may resign at any time, and may be removed for any reason or no reason by the vote or written consent of the Purchasers.  In the event of the resignation or removal of the Purchaser Representative, a new Purchaser Representative shall be appointed by the vote or written consent of the Purchasers.  Notice of such vote or a copy of the written consent appointing such new Purchaser Representative shall be sent to the Seller&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that until such notice is received, the Seller, as applicable, shall be entitled to rely on the decisions, actions, consents and instructions of the prior Purchaser Representative as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;11.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  All representations, warranties and covenants made in this Purchase and Sale Agreement, in any other Transaction Document or in any certificate delivered pursuant to this Purchase and Sale Agreement shall survive the execution and delivery of this Purchase and Sale Agreement and the Closing.  The rights hereunder to indemnification, payment of Losses or other remedies based on any such representation, warranty or covenant shall not be affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time (whether before or after the execution and delivery of this Purchase and Sale Agreement or the Closing) in respect of the accuracy or inaccuracy of or compliance with, any such representation, warranty or covenant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Specific Performance</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Each Party acknowledges and agrees that, if it fails to perform any of its obligations under any of the Transaction Documents, the other Parties will have no adequate remedy at law.  In such event, each Party agrees that the other Parties shall have the right, in addition to any other rights it may have (whether at law or in equity), to specific performance of this Purchase and Sale Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> All notices, consents, waivers and other communications hereunder shall be in writing and shall be effective (a) upon receipt when sent by registered or certified mail, return receipt requested, postage prepaid, with such receipt to be effective the date of delivery indicated on the return receipt, (b) upon receipt when sent by an overnight courier (costs prepaid and receipt requested), (c) on the date personally </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">delivered to an authorized officer of the Party to which sent or (d)&#160;on the date transmitted by e-mail with a confirmation of receipt, addressed to the recipient as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if to the Seller, to&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nektar Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">455 Mission Bay Boulevard South</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Francisco, California  94158</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; &#160;&#160;&#160;&#160;General Counsel</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Telephone&#58; &#160;&#160;&#160;&#160;&#91;***&#93; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with a copy to (which shall not constitute notice)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwin Procter LLP</font></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100 Northern Avenue</font></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Boston, Massachusetts  02210</font></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Arthur McGivern&#59; Sam Zucker</font></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Telephone&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if to the Purchaser or the Purchaser Representative, to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">300 Atlantic Street, Suite 600</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stamford, CT 06901</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with another copy to (which shall not constitute notice)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">300 Atlantic Street, Suite 600</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stamford, CT 06901</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gibson, Dunn &#38; Crutcher LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">555 Mission Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Francisco, CA 94105</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Ryan Murr</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party may, by notice given in accordance herewith to the other Party, designate any further or different address to which subsequent notices, consents, waivers and other communications shall be sent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Seller shall not be entitled to assign any of its rights or delegate any of its obligations under this Purchase and Sale Agreement without the prior written consent of the Purchaser Representative, except that the Seller may, without the consent of the Purchaser Representative, assign its rights and delegate its obligations under this Purchase and Sale Agreement to any other Person into which it may merge, with which it may consolidate or to which it may sell all or substantially all of its assets or all of the business to which any License Agreement relates if such License Agreement, the Intellectual Property Rights related to such License Agreement and the rights and obligations of the Seller hereunder related thereto are transferred together to such other Person&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the assignee under such assignment agrees to be bound by the terms of the Transaction Documents and furnishes a written agreement to the Purchaser Representative, in form and substance reasonably satisfactory to the Purchaser Representative, to that effect.  Each Purchaser may, without the consent of the Seller, assign any of its rights and delegate any of its obligations under this Purchase and Sale Agreement without restriction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, notwithstanding anything to the contrary set forth in this Purchase and Sale Agreement, such Purchaser shall not, without the prior written consent of the Seller, assign any of the Purchased Royalties or any of its rights or delegate any of its obligations if any such assignment or delegation would otherwise be inconsistent with or violate any of the provisions contained in any of the License Agreements or the Counterparty Consents that are enforceable. The Purchaser Representative may, without the consent of the Seller, assign its rights and obligations under this Purchase and Sale Agreement in full without restriction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, notwithstanding anything to the contrary set forth in this Purchase and Sale Agreement, (a) the Purchaser Representative shall not, without the prior written consent of the Seller, assign any of its rights or delegate any of its obligations if any such assignment or delegation would otherwise be inconsistent with or violate any of the provisions contained in any of the License Agreements or the Counterparty Consents that are enforceable and the Purchaser Representative, (b) the Purchaser Representative shall not, without the prior written consent of the Seller, assign its rights and obligations in part but not in full and (c) the Purchaser Representative shall not, without the prior written consent of the Seller, assign its rights and obligations to more than one (1) assignee, such that at all times under this Purchase and Sale Agreement, the Purchaser Representative is a single Person.  Each Party shall give written notice to the other Parties of any assignment permitted by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> promptly (but in any event within three (3) Business Days) after the occurrence thereof.  The Seller shall be under no obligation to reaffirm any representations, warranties or covenants made in this Purchase and Sale Agreement or any of the other Transaction Documents or take any other action in connection with any such assignment by any Purchaser or by the Purchaser Representative.  Any purported assignment of rights or delegation of obligations in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will be void.  Subject to the foregoing, this Purchase and Sale Agreement will apply to, be binding upon, and inure to the benefit of, the successors and permitted assigns of the Parties.  For the avoidance of doubt, the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will inure to the benefit of the assigns of the Purchaser.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.6  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Nature of Relationship</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The relationship between the Seller and the Purchaser is solely that of seller and purchaser, and neither the Seller nor the Purchaser has any fiduciary or other special relationship with the other Party or any of its Affiliates.  This Purchase and Sale Agreement is not a partnership or similar agreement, and nothing contained herein or in any other Transaction Document shall be deemed to constitute the Seller and the Purchaser as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes.  The Parties agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  This Purchase and Sale Agreement, together with the Exhibits and Schedules hereto and the other Transaction Documents, constitute a complete and exclusive statement of the terms of agreement between the Parties, and supersede all prior agreements, understandings and negotiations, both written and oral, between the Parties, with respect to the subject matter of this Purchase and Sale Agreement.  No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits or Schedules hereto or the other Transaction Documents) has been made or relied upon by any Party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.8  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;THIS PURCHASE AND SALE AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Party irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of (i) the United States District Court for the Southern District of New York and (ii)&#160;the Supreme Court of the State of New York, Borough of Manhattan, for purposes of any claim, action, suit or proceeding arising out of this Purchase and Sale Agreement, any of the other Transaction Documents or any of the transactions contemplated hereby or thereby, and agrees that all claims in respect thereof shall be heard and determined only in such courts.  Each Party agrees to commence any such claim, action, suit or proceeding only in the United States District Court for the Southern District of New York or, if such claim, action, suit or proceeding cannot be brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, Borough of Manhattan, and agrees not to bring any such claim, action, suit or proceeding in any other court.  Each Party hereby waives, and agrees not to assert in any such claim, action, suit or proceeding, to the fullest extent permitted by Applicable Law, any claim that (i)&#160;such Party is not personally subject to the jurisdiction of such courts, (ii) such Party and such Party&#8217;s property is immune from any legal process issued by such courts or (iii) any claim, action, suit or proceeding commenced in such courts is brought in an inconvenient forum.  Each Party agrees that a final judgment in any such claim, action, suit or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Applicable Law.  Each Party acknowledges and agrees that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> constitutes a voluntary and bargained-for agreement between the Parties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Parties agree that service of process in any claim, action, suit or proceeding referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> may be served on any Party anywhere in the world, including by sending or delivering a copy of such process to such Party in any manner provided for the giving of notices in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing in this Purchase and Sale Agreement will affect the right of any Party to serve process in any other manner permitted by Applicable Law.  Each Party waives personal service of any summons, complaint or other process, which may be made by any other means permitted by New York law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.9  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS PURCHASE AND SALE AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A)&#160;CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS PURCHASE AND SALE AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 10.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.10  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If one or more provisions of this Purchase and Sale Agreement are held to be invalid or unenforceable by a court of competent jurisdiction, such provision shall be excluded from this Purchase and Sale Agreement and the balance of this Purchase and Sale Agreement shall be interpreted as if such provision were so excluded and shall remain in full force and effect and be enforceable in accordance with its terms.  Any provision of this Purchase and Sale Agreement held invalid or unenforceable only in part or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid or unenforceable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.11  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  This Purchase and Sale Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  This Purchase and Sale Agreement shall become effective when each Party shall have received a counterpart hereof signed by the other Party.  Any counterpart may be executed by facsimile or other similar means of electronic transmission, including &#8220;PDF&#8221;, and such facsimile or other electronic transmission shall be deemed an original.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.12  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments&#59; No Waivers</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Neither this Purchase and Sale Agreement nor any term or provision hereof may be amended, supplemented, restated, waived, changed or modified except with the written consent of the Parties.  No failure or delay by any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.  No notice to or demand on any Party in any case shall entitle it to any notice or demand in similar or other circumstances.  No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions.  No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder.  The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.13  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Third Party Rights</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Other than the Parties, no Person will have any legal or equitable right, remedy or claim under or with respect to this Purchase and Sale Agreement or any of the other Transaction Documents.  This Purchase and Sale Agreement may be amended or terminated, and any provision of this Purchase and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sale Agreement may be waived, without the consent of any Person who is not a Party.  The Seller shall enforce any legal or equitable right, remedy or claim under or with respect to this Purchase and Sale Agreement for the benefit of the Seller Indemnified Parties and the Purchaser and the Purchaser Representative shall enforce any legal or equitable right, remedy or claim under or with respect to this Purchase and Sale Agreement for the benefit of the Purchaser Indemnified Parties.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.14  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents and Headings</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Table of Contents and headings of the Articles and Sections of this Purchase and Sale Agreement have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof. </font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#123;SIGNATURE PAGE FOLLOWS&#125;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Purchase and Sale Agreement as of the day and year first written above.</font></div><div style="margin-bottom:24pt;margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEKTAR THERAPEUTICS</font></div><div style="margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Howard W. Robin&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;  Howard W. Robin</font></div><div style="margin-top:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;    President and Chief Executive Officer</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font><br></font></div><div style="margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Gil M. Labrucherie&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;  Gil M. Labrucherie</font></div><div style="margin-top:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;    Senior Vice President, Chief Operating</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;             Officer and Chief Financial Officer</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Purchase and Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Purchase and Sale Agreement as of the day and year first written above.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Healthcare Royalty Partners IV, L.P.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HealthCare Royalty GP IV, LLC, its General Partner</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HealthCare Royalty Management, LLC, its</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment Manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Clarke B. Futch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Clarke B. Futch</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;    Authorized Signatory</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HCR Potomac Fund, L.P.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HCR Potomac Fund GP, LLC, its General Partner</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HealthCare Royalty Management, LLC, its</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment Manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Clarke B. Futch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Clarke B. Futch</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;    Authorized Signatory</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HCRP Overflow Fund, L.P.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HCRP Overflow Fund GP, LLC, its General Partner</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HealthCare Royalty Management, LLC, its</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment Manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Clarke B. Futch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Clarke B. Futch</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;  Authorized Signatory</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HCR Canary Fund, L.P.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HCR Canary Fund GP, LLC, its General Partner</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HealthCare Royalty Management, LLC, its</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment Manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Clarke B. Futch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Clarke B. Futch</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;    Authorized Signatory</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HCR Stafford Fund, L.P.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HCR Stafford Fund GP, LLC, its General Partner </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; HealthCare Royalty Management, LLC, its</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment Manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Clarke B. Futch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Purchase and Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Clarke B. Futch</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;    Authorized Signatory</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Purchase and Sale Agreement as of the day and year first written above.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hcr collateral management, llc</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Clarke B. Futch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Clarke B. Futch</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;    Authorized Signatory</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Purchase and Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF AZ CONFIRMATION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A-2</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF BAXTER CONFIRMATION</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF BAXTER CONSENT AMENDMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF BILL OF SALE</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C-1</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DISCLOSURE SCHEDULE</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E-1</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT E</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF NOVO CONSENT</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E-1</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT F-1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AZ LICENSE AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT F-2</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BAXTER LICENSE AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT F-3</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOVO SETTLEMENT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT F-4</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOVO SUBLICENSE AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F-4</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT G</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELLER ACCOUNT</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G-1</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT H</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GOODWIN OPINION</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H-1</font></div></div></div><div id="ic3276c87826c4ad480ce0c64953b9bde_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>nktr20201231-exx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9688541710d84df293b834dae8143768_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.05pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Consent of Independent Registered Public Accounting Firm </font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(1) Registration Statement (Form S-8 No. 333-145259) pertaining to the 401(k) Retirement Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(2) Registration Statement (Form S-8 No. 333-153106) pertaining to the 2008 Equity Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(3) Registration Statement (Form S-8 No. 333-170371) pertaining to the Employee Stock Purchase Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(4) Registration Statement (Form S-8 No. 333-183193) pertaining to the 2012 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(5) Registration Statement (Form S-8 No. 333-197781) pertaining to the Employee Stock Purchase Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(6) Registration Statement (Form S-8 No. 333-206136) pertaining to the 2012 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(7) Registration Statement (Form S-8 No. 333-218777) pertaining to the 2017 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(8) Registration Statement (Form S-8 No. 333-226004) pertaining to the Amended and Restated 2017 Performance Incentive Plan of Nektar Therapeutics, and </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(9) Registration Statement (Form S-8 No. 333-242327) pertaining to the Amended and Restated 2017 Performance Incentive Plan and Amended and Restated Employee Stock Purchase Plan of Nektar Therapeutics&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">of our reports dated February 25, 2021, with respect to the consolidated financial statements of Nektar Therapeutics and the effectiveness of internal control over financial reporting of Nektar Therapeutics included in this Annual Report (Form 10-K) of Nektar Therapeutics for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Redwood City, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">February 25, 2021 </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>nktr-20201231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3561ba36aa8941578602645e96af232c_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&#160;31, 2020&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 25, 2021</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div style="margin-top:6pt;text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>nktr-20201231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i60eeb1083f0b4d3b8d00410ff860fda8_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gil M. Labrucherie, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&#160;31, 2020&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 25, 2021</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABRUCHERIE</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;text-align:right;text-indent:45pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>nktr-20201231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4fc52508a6aa42dfb305d9cf2bac13c0_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:10pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form 10-K, for the year ended December&#160;31, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 25, 2021</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABRUCHERIE</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</font></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nktr-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b34aba47-bd43-4f7a-949b-84c5bc7946a0,g:a0d0df82-7542-4b00-8e8b-b5cca2744d03-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.nektar.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>1007008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetail" roleURI="http://www.nektar.com/role/InventoryDetail">
        <link:definition>2411405 - Disclosure - Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.nektar.com/role/PropertyPlantandEquipment">
        <link:definition>2112104 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2313303 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail">
        <link:definition>2414406 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentAdditionalInformationDetail" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail">
        <link:definition>2415407 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorSecuredNotes" roleURI="http://www.nektar.com/role/SeniorSecuredNotes">
        <link:definition>2116105 - Disclosure - Senior Secured Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorSecuredNotesDetail" roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetail">
        <link:definition>2417408 - Disclosure - Senior Secured Notes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.nektar.com/role/Leases">
        <link:definition>2118106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.nektar.com/role/LeasesTables">
        <link:definition>2319304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2420409 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseInformationDetails" roleURI="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails">
        <link:definition>2421410 - Disclosure - Leases - Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseCostDetails" roleURI="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails">
        <link:definition>2422411 - Disclosure - Leases - Schedule of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails">
        <link:definition>2423412 - Disclosure - Leases - Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1">
        <link:definition>2423412 - Disclosure - Leases - Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties">
        <link:definition>2124107 - Disclosure - Liabilities Related to the Sales of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables">
        <link:definition>2325305 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail">
        <link:definition>2426413 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail">
        <link:definition>2427414 - Disclosure - Liabilities Related to the Sales of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2128108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail">
        <link:definition>2429415 - Disclosure - Commitments and Contingencies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.nektar.com/role/StockholdersEquity">
        <link:definition>2130109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetail" roleURI="http://www.nektar.com/role/StockholdersEquityDetail">
        <link:definition>2431416 - Disclosure - Stockholders' Equity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2132110 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>2333306 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
        <link:definition>2434417 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2435418 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail">
        <link:definition>2436419 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2137111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2338307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2439420 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2440421 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail">
        <link:definition>2441422 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitAwardActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail">
        <link:definition>2443424 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Award Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.nektar.com/role/IncomeTaxes">
        <link:definition>2144112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.nektar.com/role/IncomeTaxesTables">
        <link:definition>2345308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" roleURI="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail">
        <link:definition>2446425 - Disclosure - Income Taxes - Income (Loss) Before Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetail" roleURI="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail">
        <link:definition>2447426 - Disclosure - Income Taxes - Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2448427 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" roleURI="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail">
        <link:definition>2449428 - Disclosure - Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" roleURI="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail">
        <link:definition>2450429 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetail" roleURI="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail">
        <link:definition>2451430 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.nektar.com/role/SegmentReporting">
        <link:definition>2152113 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.nektar.com/role/SegmentReportingTables">
        <link:definition>2353309 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetail" roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail">
        <link:definition>2454431 - Disclosure - Segment Reporting - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuebyGeographicAreaDetail" roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail">
        <link:definition>2455432 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.nektar.com/role/SubsequentEvent">
        <link:definition>2156114 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.nektar.com/role/SubsequentEventDetails">
        <link:definition>2457433 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialData" roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialData">
        <link:definition>2158115 - Disclosure - Selected Quarterly Financial Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataTables" roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables">
        <link:definition>2359310 - Disclosure - Selected Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataDetail" roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail">
        <link:definition>2460434 - Disclosure - Selected Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_SecuritiesRelatedClaimsMember" abstract="true" name="SecuritiesRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ProfitsAndLossesSharingPercentage" abstract="false" name="ProfitsAndLossesSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_DevelopmentCostsExceeded" abstract="false" name="DevelopmentCostsExceeded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PartnerTwoMember" abstract="true" name="PartnerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ManufacturingLaboratoryAndOtherEquipmentMember" abstract="true" name="ManufacturingLaboratoryAndOtherEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" abstract="false" name="UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ClinicalTrialAgreementMember" abstract="true" name="ClinicalTrialAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" abstract="false" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" abstract="false" name="NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" abstract="false" name="MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" abstract="false" name="ShareBasedCompensationPlansShareLimitForEveryOneShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" abstract="false" name="PercentageOfOutOfPocketCostsToBeReimbursedByPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ProspectiveInterestRatePercentage" abstract="false" name="ProspectiveInterestRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" abstract="true" name="A775PercentSeniorSecuredNotesDueOctober2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_TerminatedPartnershipMember" abstract="true" name="TerminatedPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_MissionBayLeaseMember" abstract="true" name="MissionBayLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ReimbursementRecognized" abstract="false" name="ReimbursementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_IncomeTaxesDisclosureTable" abstract="true" name="IncomeTaxesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" abstract="false" name="ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" abstract="false" name="LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_CommonStockAdditionalSharesAuthorized" abstract="false" name="CommonStockAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_AmendedAndRestated2017PlanMember" abstract="true" name="AmendedAndRestated2017PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" abstract="true" name="TwoThousandSeventeenPerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_RepaymentsOfLongTermDebtIncludingInterest" abstract="false" name="RepaymentsOfLongTermDebtIncludingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreementMember" abstract="true" name="PurchaseAndSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NetExpenseReimbursementsFromCollaborationPartner" abstract="false" name="NetExpenseReimbursementsFromCollaborationPartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NumberOfOperatingBusinessSegment" abstract="false" name="NumberOfOperatingBusinessSegment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_CommercialAgreementsMember" abstract="true" name="CommercialAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NonSecuritiesRelatedClaimsMember" abstract="true" name="NonSecuritiesRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_MergerAndAcquisitionRelatedClaimsMember" abstract="true" name="MergerAndAcquisitionRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfPurchasePriceOfStock" abstract="false" name="PercentageOfPurchasePriceOfStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SecuredNotesTable" abstract="true" name="SecuredNotesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" abstract="false" name="DeferredTaxAssetsDepreciationPropertyAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" abstract="false" name="AmountOfNetSalesToFundExternalCostsIncurredCap" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" abstract="false" name="AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_SecuredNotesLineItems" abstract="true" name="SecuredNotesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_BMSCollaborationAgreementMember" abstract="true" name="BMSCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AggregateConsiderationReceivedFromAgreements" abstract="false" name="AggregateConsiderationReceivedFromAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentGross" abstract="false" name="DepreciablePropertyPlantAndEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" abstract="false" name="AmountOfTransactionPriceAllocatedToPerformanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CompanyShareOfDevelopmentCosts" abstract="false" name="CompanyShareOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RSUsAndPSUsMember" abstract="true" name="RSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ScheduleOfLeasesTable" abstract="true" name="ScheduleOfLeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ChangeInControlSeverancePaymentPeriodForExecutives" abstract="false" name="ChangeInControlSeverancePaymentPeriodForExecutives" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_NektarThreeFiveEightMember" abstract="true" name="NektarThreeFiveEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" abstract="false" name="IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AdvancePaymentsToContractManufacturers" abstract="false" name="AdvancePaymentsToContractManufacturers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_AccruedContractManufacturingExpenseCurrent" abstract="false" name="AccruedContractManufacturingExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NKTR181Member" abstract="true" name="NKTR181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_FederalOrphanDrugCredits" abstract="false" name="FederalOrphanDrugCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RemainingAmountAllocatedToTransactionPrice" abstract="false" name="RemainingAmountAllocatedToTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentFromTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentFromTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" abstract="false" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_DrugProductDevelopmentMember" abstract="true" name="DrugProductDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" abstract="false" name="IncomeTaxReconciliationPremiumOnEquityIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AreaOfLeasedSpaceDelivered" abstract="false" name="AreaOfLeasedSpaceDelivered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" abstract="false" name="DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BempegaldesleukinMember" abstract="true" name="BempegaldesleukinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" abstract="false" name="ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_CompanyShareOfDevelopmentCostsAnnualCap" abstract="false" name="CompanyShareOfDevelopmentCostsAnnualCap" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AnnualSalesLevelMilestoneMember" abstract="true" name="AnnualSalesLevelMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationOtherRevenue" abstract="false" name="LicenseCollaborationOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" abstract="false" name="ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" abstract="false" name="EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_NeulastaMember" abstract="true" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SalesMilestoneRevenue" abstract="false" name="SalesMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" abstract="false" name="NumberOfReportingUnitsToEvaluateGoodwillForImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_RoyaltyAgreementContingentPaymentDescription" abstract="false" name="RoyaltyAgreementContingentPaymentDescription" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ChangeInControlSeverancePaymentPeriodForEmployees" abstract="false" name="ChangeInControlSeverancePaymentPeriodForEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PartnerThreeMember" abstract="true" name="PartnerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_HemophiliaMember" abstract="true" name="HemophiliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ComputerFurnitureAndOtherMember" abstract="true" name="ComputerFurnitureAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ThirdStreetLeaseMember" abstract="true" name="ThirdStreetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LegalMattersMember" abstract="true" name="LegalMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" abstract="true" name="SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LeaseExtensionTerm" abstract="false" name="LeaseExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_IncomeTaxesDisclosureLineItems" abstract="true" name="IncomeTaxesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PhaseOneClinicalDevelopmentMember" abstract="true" name="PhaseOneClinicalDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PartnerOneMember" abstract="true" name="PartnerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AstraZenecaAgreementWithKirinMember" abstract="true" name="AstraZenecaAgreementWithKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_NetOperatingLossCarryforwardForIncomeTax" abstract="false" name="NetOperatingLossCarryforwardForIncomeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EstimatedFairValueOfShares" abstract="false" name="EstimatedFairValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NumberOfConsecutiveTermsToExtendLease" abstract="false" name="NumberOfConsecutiveTermsToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" abstract="true" name="HemophiliaIncludingADYNOVATEAndADYNOVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PaymentMadeForMilestoneNotAchievedYearOne" abstract="false" name="PaymentMadeForMilestoneNotAchievedYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentNet" abstract="false" name="DepreciablePropertyPlantAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PartialRepaymentOfRoyaltySaleProceeds" abstract="false" name="PartialRepaymentOfRoyaltySaleProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BaxaltaIncorporatedOrTakedaPLCMember" abstract="true" name="BaxaltaIncorporatedOrTakedaPLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" abstract="false" name="PaymentMadeForMilestoneNotAchievedYearTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstIndication" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementAdditionalIndicationPayment" abstract="false" name="CollaborativeArrangementAdditionalIndicationPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" abstract="false" name="InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" abstract="false" name="PaymentsReceivedUnderRightsToSublicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MOVANTIKAndMOVENTIGMember" abstract="true" name="MOVANTIKAndMOVENTIGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AmgenIncMember" abstract="true" name="AmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" abstract="false" name="ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" abstract="false" name="EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_WriteOffOfPrepayment" abstract="false" name="WriteOffOfPrepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" abstract="false" name="IncomeTaxReconciliationExpenseShareBasedCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" abstract="false" name="ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" abstract="false" name="DebtDiscountOnTransactionAndFacilityFeesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AstraZenecaAbMember" abstract="true" name="AstraZenecaAbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" abstract="false" name="AccretionOfDiscountNetAndOtherNonCashTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RegulatoryMilestonesPaymentDescription" abstract="false" name="RegulatoryMilestonesPaymentDescription" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_UCBPharmaMember" abstract="true" name="UCBPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" abstract="true" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SelectedQuarterlyFinancialDataTable" abstract="true" name="SelectedQuarterlyFinancialDataTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" abstract="true" name="LiabilitiesAndStockholdersEquityDeficitAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" abstract="false" name="IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NektarMember" abstract="true" name="NektarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SelectedQuarterlyFinancialDataLineItems" abstract="true" name="SelectedQuarterlyFinancialDataLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AreaOfLeasedSpace" abstract="false" name="AreaOfLeasedSpace" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" abstract="false" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_RoyaltyMonetizationProceeds" abstract="false" name="RoyaltyMonetizationProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfNetSalesToFundExternalCostsIncurred" abstract="false" name="PercentageOfNetSalesToFundExternalCostsIncurred" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nktr_SaleOfFutureRoyaltiesTransactionCosts" abstract="false" name="SaleOfFutureRoyaltiesTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" abstract="false" name="StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfFutureRoyaltiesNet" abstract="false" name="ProceedsFromSaleOfFutureRoyaltiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsSecondIndication" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" abstract="false" name="PotentialDevelopmentRegulatoryAndSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" abstract="false" name="PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nktr-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b34aba47-bd43-4f7a-949b-84c5bc7946a0,g:a0d0df82-7542-4b00-8e8b-b5cca2744d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/Cover" xlink:type="simple" xlink:href="nktr-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4ca00a33-a7b0-4535-bd3d-486a5f5d62ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2baf603d-ec67-4569-a7a7-92ed04d50b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4ca00a33-a7b0-4535-bd3d-486a5f5d62ca" xlink:to="loc_us-gaap_LiabilitiesCurrent_2baf603d-ec67-4569-a7a7-92ed04d50b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_716c5e6f-797c-4a95-867a-e7692e940ca4" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4ca00a33-a7b0-4535-bd3d-486a5f5d62ca" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_716c5e6f-797c-4a95-867a-e7692e940ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a6baf489-3856-4025-8d52-52b1e72b6d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4ca00a33-a7b0-4535-bd3d-486a5f5d62ca" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a6baf489-3856-4025-8d52-52b1e72b6d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_04c1f634-1637-4d0e-a584-902370e58b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4ca00a33-a7b0-4535-bd3d-486a5f5d62ca" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_04c1f634-1637-4d0e-a584-902370e58b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6aca2c32-baf7-41df-a4b9-d8bccc4a0f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4ca00a33-a7b0-4535-bd3d-486a5f5d62ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6aca2c32-baf7-41df-a4b9-d8bccc4a0f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5b73e2bc-baeb-4831-83cf-bf86f085ba83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7e7d9f8-c195-4fee-89f8-a87e5dc89213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5b73e2bc-baeb-4831-83cf-bf86f085ba83" xlink:to="loc_us-gaap_Liabilities_e7e7d9f8-c195-4fee-89f8-a87e5dc89213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8d31dc6d-0a22-4412-a76b-23c1bedac6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5b73e2bc-baeb-4831-83cf-bf86f085ba83" xlink:to="loc_us-gaap_StockholdersEquity_8d31dc6d-0a22-4412-a76b-23c1bedac6ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2573997d-d350-4bf7-8b80-f7c4bea0f1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5b73e2bc-baeb-4831-83cf-bf86f085ba83" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2573997d-d350-4bf7-8b80-f7c4bea0f1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e9764c83-6a5f-48d8-9114-8cc6abcd631f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_us-gaap_AccountsPayableCurrent_e9764c83-6a5f-48d8-9114-8cc6abcd631f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ee71852-5b0d-49bf-ad47-08366ba8d4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ee71852-5b0d-49bf-ad47-08366ba8d4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_9005f572-431a-4ce4-818f-822ba16adb2e" xlink:href="nktr-20201231.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_9005f572-431a-4ce4-818f-822ba16adb2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_db70e704-16ae-4fcd-b5fe-21ee65e007b2" xlink:href="nktr-20201231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_db70e704-16ae-4fcd-b5fe-21ee65e007b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e5fbf23-f531-4960-aabe-67312bc7b89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e5fbf23-f531-4960-aabe-67312bc7b89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2684a094-44e9-451b-9c67-a4325df4d7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2684a094-44e9-451b-9c67-a4325df4d7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c454e85-9a1b-4c31-b681-223db370c7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c454e85-9a1b-4c31-b681-223db370c7b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent_abef5fc2-a59b-48bd-9e7b-5bc56fcf0b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cf268ad-e122-4745-9328-14da30357ced" xlink:to="loc_us-gaap_SeniorNotesCurrent_abef5fc2-a59b-48bd-9e7b-5bc56fcf0b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c7df80-ac36-45b9-ad21-4f5aab5bacc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c7df80-ac36-45b9-ad21-4f5aab5bacc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a1cac04a-450d-4aad-b1f4-2fe6f08bb240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a1cac04a-450d-4aad-b1f4-2fe6f08bb240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0fde7011-a59a-4bc2-b367-e55e1f74c6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0fde7011-a59a-4bc2-b367-e55e1f74c6f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e8a99bd1-f89d-4cbe-848d-3cb4575b5622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:to="loc_us-gaap_InventoryNet_e8a99bd1-f89d-4cbe-848d-3cb4575b5622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_a180b71d-3c83-4d1d-a7c7-6ebe2d6a1f06" xlink:href="nktr-20201231.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_a180b71d-3c83-4d1d-a7c7-6ebe2d6a1f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c84cb76d-0c84-4afc-8b1e-68b28e29e48b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a1684056-32b1-44c0-8854-434222122612" xlink:to="loc_us-gaap_OtherAssetsCurrent_c84cb76d-0c84-4afc-8b1e-68b28e29e48b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_405e30fe-6c80-4340-90e7-bc92cf0ba1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:to="loc_us-gaap_AssetsCurrent_405e30fe-6c80-4340-90e7-bc92cf0ba1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8c9f29a9-e3b9-472b-bead-d5f11abd5fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8c9f29a9-e3b9-472b-bead-d5f11abd5fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bcb52801-05bc-49cd-8148-a08a8771fceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bcb52801-05bc-49cd-8148-a08a8771fceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d67208ab-d8f1-41cc-8fa1-2c295cbf47f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:to="loc_us-gaap_Goodwill_d67208ab-d8f1-41cc-8fa1-2c295cbf47f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_94793e1a-d236-4e05-9138-d883ba331f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_94793e1a-d236-4e05-9138-d883ba331f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_72cb1409-281d-467b-a0b1-21a9c59d9727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3043a55a-8db6-41ac-941d-fd6b7064bd4b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_72cb1409-281d-467b-a0b1-21a9c59d9727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_60d0be9e-e8b2-4cca-9314-8852b8e4a207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8e790284-0566-43dd-91b4-57bd37943ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_60d0be9e-e8b2-4cca-9314-8852b8e4a207" xlink:to="loc_us-gaap_PreferredStockValue_8e790284-0566-43dd-91b4-57bd37943ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ddcfde23-810d-4ad4-8d3c-c0f8ac5bbe7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_60d0be9e-e8b2-4cca-9314-8852b8e4a207" xlink:to="loc_us-gaap_CommonStockValue_ddcfde23-810d-4ad4-8d3c-c0f8ac5bbe7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_04a41430-f425-4faa-b523-349b85f3950f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_60d0be9e-e8b2-4cca-9314-8852b8e4a207" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_04a41430-f425-4faa-b523-349b85f3950f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be1dc1cc-c0ef-4e27-8686-818fec5bc3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_60d0be9e-e8b2-4cca-9314-8852b8e4a207" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be1dc1cc-c0ef-4e27-8686-818fec5bc3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6cacf8b-98f9-4979-b008-a2655f4dd412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_60d0be9e-e8b2-4cca-9314-8852b8e4a207" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6cacf8b-98f9-4979-b008-a2655f4dd412" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8f271707-c52d-448c-aa59-77d5b7b76b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8eba392f-688c-44fb-bffa-f2d4409ec5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f271707-c52d-448c-aa59-77d5b7b76b51" xlink:to="loc_us-gaap_InterestExpense_8eba392f-688c-44fb-bffa-f2d4409ec5b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_97d15658-3a3b-4e47-84af-c03fd28fc894" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f271707-c52d-448c-aa59-77d5b7b76b51" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_97d15658-3a3b-4e47-84af-c03fd28fc894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1880e2a0-b8e1-45f4-903c-8fd3d910f061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f271707-c52d-448c-aa59-77d5b7b76b51" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1880e2a0-b8e1-45f4-903c-8fd3d910f061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_908dcd0d-6169-4198-b4c2-d8bcc7adb377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7fe6c4e3-5c00-492a-b1f2-8789c7ed9b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_908dcd0d-6169-4198-b4c2-d8bcc7adb377" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7fe6c4e3-5c00-492a-b1f2-8789c7ed9b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_051ce623-d6ee-4ea3-801b-afc58976c875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_908dcd0d-6169-4198-b4c2-d8bcc7adb377" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_051ce623-d6ee-4ea3-801b-afc58976c875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_88ee54bf-ec33-4bb8-be29-c2da95b966f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_908dcd0d-6169-4198-b4c2-d8bcc7adb377" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_88ee54bf-ec33-4bb8-be29-c2da95b966f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_1b09c362-c4c2-47bb-a141-3fd0716a00a8" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_908dcd0d-6169-4198-b4c2-d8bcc7adb377" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_1b09c362-c4c2-47bb-a141-3fd0716a00a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76449081-e4a4-477f-a831-0d0c47fb9a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c3ed7053-816e-4037-b51e-b1122ea69d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_76449081-e4a4-477f-a831-0d0c47fb9a26" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c3ed7053-816e-4037-b51e-b1122ea69d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_74bc8a88-7b5f-4c04-bd7d-7e604534dc9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_76449081-e4a4-477f-a831-0d0c47fb9a26" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_74bc8a88-7b5f-4c04-bd7d-7e604534dc9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de139dc8-36d7-41b3-9b7f-67134d5bda9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0e4c6f28-a02d-4510-95e9-1a0334ad5db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de139dc8-36d7-41b3-9b7f-67134d5bda9d" xlink:to="loc_us-gaap_OperatingIncomeLoss_0e4c6f28-a02d-4510-95e9-1a0334ad5db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ec5fe030-2c9c-4ccf-9569-5b20a54a38bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de139dc8-36d7-41b3-9b7f-67134d5bda9d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ec5fe030-2c9c-4ccf-9569-5b20a54a38bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79821e36-fc98-45d9-9cc8-b0e2bcb1eff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af085e69-959e-4234-962b-349098810e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79821e36-fc98-45d9-9cc8-b0e2bcb1eff2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af085e69-959e-4234-962b-349098810e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019d5a06-cd92-4eb2-a136-c5f15ab02f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79821e36-fc98-45d9-9cc8-b0e2bcb1eff2" xlink:to="loc_us-gaap_CostsAndExpenses_019d5a06-cd92-4eb2-a136-c5f15ab02f09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="nktr-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b7147f29-f10b-4190-aa6d-20e8c3d91d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d7af5c6-9edf-4216-b1de-83531507f8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b7147f29-f10b-4190-aa6d-20e8c3d91d4d" xlink:to="loc_us-gaap_NetIncomeLoss_8d7af5c6-9edf-4216-b1de-83531507f8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_916a4583-f225-4dcc-a78e-261b641e427b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b7147f29-f10b-4190-aa6d-20e8c3d91d4d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_916a4583-f225-4dcc-a78e-261b641e427b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_857be06d-db30-4bde-8246-fe07d7ffe9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b71bb0d5-1e80-42f6-8efb-e7792163a40e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_857be06d-db30-4bde-8246-fe07d7ffe9fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b71bb0d5-1e80-42f6-8efb-e7792163a40e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_889b6946-7e2f-4492-88a4-0813dc947592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_857be06d-db30-4bde-8246-fe07d7ffe9fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_889b6946-7e2f-4492-88a4-0813dc947592" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_009cd3d6-fbdb-4b8c-a8dc-a7e5b6bc38c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_427607ac-7857-409d-9818-328da68394e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_009cd3d6-fbdb-4b8c-a8dc-a7e5b6bc38c2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_427607ac-7857-409d-9818-328da68394e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a7372cb0-0fd0-4948-9109-0de470e01ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_009cd3d6-fbdb-4b8c-a8dc-a7e5b6bc38c2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a7372cb0-0fd0-4948-9109-0de470e01ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1af240c1-2ac8-4feb-b560-e65354c5f06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_009cd3d6-fbdb-4b8c-a8dc-a7e5b6bc38c2" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1af240c1-2ac8-4feb-b560-e65354c5f06e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c9dd44b-488b-4b70-b6db-9483140fa942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_009cd3d6-fbdb-4b8c-a8dc-a7e5b6bc38c2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c9dd44b-488b-4b70-b6db-9483140fa942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0834a115-05b4-4f51-8f19-6f2ad2dc0af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_009cd3d6-fbdb-4b8c-a8dc-a7e5b6bc38c2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0834a115-05b4-4f51-8f19-6f2ad2dc0af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1573dbe-f1aa-4ec4-a598-6d09e8fd5f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_50555018-6c02-4063-a707-9180bb828dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1573dbe-f1aa-4ec4-a598-6d09e8fd5f01" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_50555018-6c02-4063-a707-9180bb828dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ba538d3f-b5d2-4b62-9ad0-fefd4121c835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1573dbe-f1aa-4ec4-a598-6d09e8fd5f01" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ba538d3f-b5d2-4b62-9ad0-fefd4121c835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_60e00304-67c4-446c-9157-e5c8b6bcf417" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1573dbe-f1aa-4ec4-a598-6d09e8fd5f01" xlink:to="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_60e00304-67c4-446c-9157-e5c8b6bcf417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_f5843101-ebff-4869-b52a-d3f05fcafcdd" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1573dbe-f1aa-4ec4-a598-6d09e8fd5f01" xlink:to="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_f5843101-ebff-4869-b52a-d3f05fcafcdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_76fcc214-0e5c-43a7-b27e-4e6ab115a4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_ProfitLoss_76fcc214-0e5c-43a7-b27e-4e6ab115a4d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_4d2adedd-350e-4e8f-83e3-47556f227509" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_4d2adedd-350e-4e8f-83e3-47556f227509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_21ae8ef3-8dd0-4115-b1a7-33623ffea50d" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_21ae8ef3-8dd0-4115-b1a7-33623ffea50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5238e825-1a05-4b42-96d5-800ab642f9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5238e825-1a05-4b42-96d5-800ab642f9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a00cdf4e-4298-490b-8294-2fd50d89ffdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_DepreciationAndAmortization_a00cdf4e-4298-490b-8294-2fd50d89ffdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_75b73611-665b-4e72-a5be-3aed045a1933" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_75b73611-665b-4e72-a5be-3aed045a1933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_51390f4b-015d-4836-b7bf-21b9a3bf03a4" xlink:href="nktr-20201231.xsd#nktr_AccretionOfDiscountNetAndOtherNonCashTransactions"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_51390f4b-015d-4836-b7bf-21b9a3bf03a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eeb4c5cb-dff8-4382-bc41-586ea0910d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eeb4c5cb-dff8-4382-bc41-586ea0910d37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_41fee932-f1d3-4d7f-9022-7f49200ccac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_41fee932-f1d3-4d7f-9022-7f49200ccac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_72004830-57e2-4117-bdc5-15577df93073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_72004830-57e2-4117-bdc5-15577df93073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5f38de01-c864-4acb-9ace-ae487d6bbff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5f38de01-c864-4acb-9ace-ae487d6bbff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5a6a9d47-6212-4169-a8a9-658b03edd87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5a6a9d47-6212-4169-a8a9-658b03edd87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_ca2fd7ac-13a5-4a7a-8ef6-591abdf28b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_ca2fd7ac-13a5-4a7a-8ef6-591abdf28b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f668edd8-eb5b-4d81-ac3f-f57573ad1fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f668edd8-eb5b-4d81-ac3f-f57573ad1fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_5766ac54-51d0-442d-bdf5-1b1778b83aa8" xlink:href="nktr-20201231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07d43efb-f0f0-4bac-a3a7-0a57191953bf" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_5766ac54-51d0-442d-bdf5-1b1778b83aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0602796a-2b6f-4420-b3b7-39b4bb3604a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a623e1-8a58-4ae4-bdd7-cb39ef2d9c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0602796a-2b6f-4420-b3b7-39b4bb3604a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a623e1-8a58-4ae4-bdd7-cb39ef2d9c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af6be9f6-82f1-4f91-bb4a-6fd035fc7359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0602796a-2b6f-4420-b3b7-39b4bb3604a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af6be9f6-82f1-4f91-bb4a-6fd035fc7359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a772a653-7114-4284-a696-1acab4f0c642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0602796a-2b6f-4420-b3b7-39b4bb3604a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a772a653-7114-4284-a696-1acab4f0c642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c06cc19-39b6-4dd5-b560-b6efe9524ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0602796a-2b6f-4420-b3b7-39b4bb3604a1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c06cc19-39b6-4dd5-b560-b6efe9524ca7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_725a4443-08a1-4b49-9d46-c9c1cfa66f36" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ab16cab-04ca-427e-93f1-b3b0d3a76b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_725a4443-08a1-4b49-9d46-c9c1cfa66f36" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ab16cab-04ca-427e-93f1-b3b0d3a76b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_01b77c52-5571-4bce-bb2b-3a8ba3e89243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_725a4443-08a1-4b49-9d46-c9c1cfa66f36" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_01b77c52-5571-4bce-bb2b-3a8ba3e89243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_34216088-d7ce-48b9-9d2a-81b2362d6dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_725a4443-08a1-4b49-9d46-c9c1cfa66f36" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_34216088-d7ce-48b9-9d2a-81b2362d6dd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ceab9b71-7e22-46a6-9896-8266892a0d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ee7b23a2-f7ea-493a-bbee-b36306973235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ceab9b71-7e22-46a6-9896-8266892a0d43" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ee7b23a2-f7ea-493a-bbee-b36306973235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c56af9f-f63b-4ee5-a8d7-4da27c004ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ceab9b71-7e22-46a6-9896-8266892a0d43" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c56af9f-f63b-4ee5-a8d7-4da27c004ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5f65750-8665-4614-931f-28486ed6f817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ceab9b71-7e22-46a6-9896-8266892a0d43" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5f65750-8665-4614-931f-28486ed6f817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_863c3f9f-3f92-4390-9f9f-8a260aceae30" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c9352252-8aaa-4d01-8f55-4bf729df755c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_863c3f9f-3f92-4390-9f9f-8a260aceae30" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c9352252-8aaa-4d01-8f55-4bf729df755c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_eb56f344-9de5-43ef-9d70-2c28faba296c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_863c3f9f-3f92-4390-9f9f-8a260aceae30" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_eb56f344-9de5-43ef-9d70-2c28faba296c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_f9aaa98f-1cd6-497b-8d84-31e7c71b521e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_863c3f9f-3f92-4390-9f9f-8a260aceae30" xlink:to="loc_us-gaap_Cash_f9aaa98f-1cd6-497b-8d84-31e7c71b521e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20201231.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#InventoryDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cecf242a-618b-4a53-b8af-35837a77c932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_92c7c41e-0b7f-49e6-9af8-eb83408800fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cecf242a-618b-4a53-b8af-35837a77c932" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_92c7c41e-0b7f-49e6-9af8-eb83408800fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ee38e8b2-87b9-464a-91ec-c432f3855765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cecf242a-618b-4a53-b8af-35837a77c932" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ee38e8b2-87b9-464a-91ec-c432f3855765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_72699b7b-01d9-4a17-8071-bef997972f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cecf242a-618b-4a53-b8af-35837a77c932" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_72699b7b-01d9-4a17-8071-bef997972f18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipment"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_391dca7c-216f-482e-ba4b-509665f9ef8e" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_af9c9f64-dc85-48ba-ac26-e98775ca207c" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_391dca7c-216f-482e-ba4b-509665f9ef8e" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_af9c9f64-dc85-48ba-ac26-e98775ca207c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a99cf1d8-4d24-4bf1-b4f1-af31daaf229a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_391dca7c-216f-482e-ba4b-509665f9ef8e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a99cf1d8-4d24-4bf1-b4f1-af31daaf229a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dea7ccb0-2b44-4a50-b3fb-8efb73f97b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_2b5ea1c2-6f93-4265-94a1-16b13ea42c50" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_dea7ccb0-2b44-4a50-b3fb-8efb73f97b49" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_2b5ea1c2-6f93-4265-94a1-16b13ea42c50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_89f3898e-330b-4ffe-819d-a6a9a9a1784d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_dea7ccb0-2b44-4a50-b3fb-8efb73f97b49" xlink:to="loc_us-gaap_ConstructionInProgressGross_89f3898e-330b-4ffe-819d-a6a9a9a1784d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="simple" xlink:href="nktr-20201231.xsd#SeniorSecuredNotes"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SeniorSecuredNotesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/Leases" xlink:type="simple" xlink:href="nktr-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesOperatingLeaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesScheduleofLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2091f6ba-4343-4bcf-a90e-a7ac1e90d028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_13f22bb7-676b-4dc3-b895-28d94d44db95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_2091f6ba-4343-4bcf-a90e-a7ac1e90d028" xlink:to="loc_us-gaap_OperatingLeaseCost_13f22bb7-676b-4dc3-b895-28d94d44db95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d0348e68-8e09-40c0-8d52-c58ef0ee6bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_2091f6ba-4343-4bcf-a90e-a7ac1e90d028" xlink:to="loc_us-gaap_VariableLeaseCost_d0348e68-8e09-40c0-8d52-c58ef0ee6bdf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c51616d9-3d94-4c99-a6ee-a39ccdd4f867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c51616d9-3d94-4c99-a6ee-a39ccdd4f867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf235042-732e-43fc-9964-97eeda4f2d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf235042-732e-43fc-9964-97eeda4f2d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_94b2b514-00af-4372-a73c-d1c813080c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_94b2b514-00af-4372-a73c-d1c813080c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac59c6d7-fe42-4532-953b-e270f0d7574c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac59c6d7-fe42-4532-953b-e270f0d7574c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_61b42290-a41c-49a3-9c15-a38adfc6310a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_61b42290-a41c-49a3-9c15-a38adfc6310a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ce04e46d-e08e-4302-abb2-df0580b4ba81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1d99085-94d0-40eb-aa76-6f3bd2148998" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ce04e46d-e08e-4302-abb2-df0580b4ba81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_86f0656b-1630-4eb3-b12b-94bd6426618b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41421c07-091a-4376-b1d6-d8046a65300f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_86f0656b-1630-4eb3-b12b-94bd6426618b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_41421c07-091a-4376-b1d6-d8046a65300f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14e86edb-0055-4f9f-8a8d-edbf6d120cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_86f0656b-1630-4eb3-b12b-94bd6426618b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14e86edb-0055-4f9f-8a8d-edbf6d120cf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73c8f2a0-9bf9-4064-8601-35b4ef43c889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d7259339-8ab2-4574-847c-c3383d368b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73c8f2a0-9bf9-4064-8601-35b4ef43c889" xlink:to="loc_us-gaap_OperatingLeaseLiability_d7259339-8ab2-4574-847c-c3383d368b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1d0d03af-ed38-462e-a0fc-82eea8ab5b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73c8f2a0-9bf9-4064-8601-35b4ef43c889" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1d0d03af-ed38-462e-a0fc-82eea8ab5b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_d3ee93d0-8ef2-45ab-91e4-13a2870b7c8c" xlink:href="nktr-20201231.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73c8f2a0-9bf9-4064-8601-35b4ef43c889" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_d3ee93d0-8ef2-45ab-91e4-13a2870b7c8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyalties"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_7ab3c335-fdb0-4b02-bb8c-df8ddb2dd23d" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_a02c6dc8-f910-422d-bd44-e5a130ee1a5b" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_7ab3c335-fdb0-4b02-bb8c-df8ddb2dd23d" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_a02c6dc8-f910-422d-bd44-e5a130ee1a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_e45de4cb-2e5a-4d44-8ef5-4b415813ef9a" xlink:href="nktr-20201231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_7ab3c335-fdb0-4b02-bb8c-df8ddb2dd23d" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_e45de4cb-2e5a-4d44-8ef5-4b415813ef9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CommitmentsandContingenciesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquity" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockholdersEquityDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockholdersEquityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationRestrictedStockUnitAwardActivityDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4472dff1-c9d8-4c24-99c6-0aa4e0459f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f010f99b-1ce2-4143-a061-03337457c3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4472dff1-c9d8-4c24-99c6-0aa4e0459f63" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f010f99b-1ce2-4143-a061-03337457c3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8ce3d837-1e71-4675-9189-34a44d6b4802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4472dff1-c9d8-4c24-99c6-0aa4e0459f63" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8ce3d837-1e71-4675-9189-34a44d6b4802" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_28ff1b36-2f89-4834-a016-552c5101e4bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f85e7d76-7ba6-4015-aafc-c3360afc24ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_28ff1b36-2f89-4834-a016-552c5101e4bc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f85e7d76-7ba6-4015-aafc-c3360afc24ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_715c7ad0-6add-4a8e-abfd-62e9f2d49f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_28ff1b36-2f89-4834-a016-552c5101e4bc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_715c7ad0-6add-4a8e-abfd-62e9f2d49f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c1ef1d80-dd60-4126-90a2-ef7ec0a7f845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_28ff1b36-2f89-4834-a016-552c5101e4bc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c1ef1d80-dd60-4126-90a2-ef7ec0a7f845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_145ecf96-7a3c-4ee7-a1d5-6adb29e6cbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c58bacae-f54c-4aaa-81c8-5e2d395d3dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_145ecf96-7a3c-4ee7-a1d5-6adb29e6cbcc" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c58bacae-f54c-4aaa-81c8-5e2d395d3dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1a96bdd8-35d5-4b19-85a5-3f814eeafd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_145ecf96-7a3c-4ee7-a1d5-6adb29e6cbcc" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1a96bdd8-35d5-4b19-85a5-3f814eeafd14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3aed3035-b6fa-41a5-8378-983421719d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_145ecf96-7a3c-4ee7-a1d5-6adb29e6cbcc" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3aed3035-b6fa-41a5-8378-983421719d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_24582cd2-9a2c-4c1b-af66-56ba61a6eb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f3fca1b0-6054-4e46-8bec-cfbe0b68a6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_24582cd2-9a2c-4c1b-af66-56ba61a6eb2a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f3fca1b0-6054-4e46-8bec-cfbe0b68a6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_81d61f6a-a2d8-4ab2-a70e-378fa18c985d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_24582cd2-9a2c-4c1b-af66-56ba61a6eb2a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_81d61f6a-a2d8-4ab2-a70e-378fa18c985d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f6e781c9-94c1-47f8-b975-7c6e5d7e6a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f6e781c9-94c1-47f8-b975-7c6e5d7e6a70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_822b4cdc-2213-40cf-9a9c-a490e4d18c04" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_822b4cdc-2213-40cf-9a9c-a490e4d18c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_eac78e78-5a70-4892-a2e2-f321dcc6fb7e" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_eac78e78-5a70-4892-a2e2-f321dcc6fb7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2c106c1e-dd11-47c9-907f-d13f736f37d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2c106c1e-dd11-47c9-907f-d13f736f37d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_31e410e9-0890-4e5d-8b6f-0fd754e9474d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_31e410e9-0890-4e5d-8b6f-0fd754e9474d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_5dc0fb48-6e7b-4a22-9696-80b258749134" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationPremiumOnEquityIssuance"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_5dc0fb48-6e7b-4a22-9696-80b258749134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_c5590499-76bb-4b5c-992b-133fc362c80e" xlink:href="nktr-20201231.xsd#nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_c5590499-76bb-4b5c-992b-133fc362c80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_235e959c-b6e3-469d-a6ce-794b04b6d67f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01eafc3d-a5d6-4d0c-9b26-163ecdd75687" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_235e959c-b6e3-469d-a6ce-794b04b6d67f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_69084b09-da09-4f6b-98bc-618894dd878c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_96f994de-9148-4940-8dd6-da9e00221e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_69084b09-da09-4f6b-98bc-618894dd878c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_96f994de-9148-4940-8dd6-da9e00221e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d0202349-616b-47d6-932d-59d201bf9f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_69084b09-da09-4f6b-98bc-618894dd878c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d0202349-616b-47d6-932d-59d201bf9f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d618e0e5-9b10-4764-8e4d-800b47a00cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2c993f84-530d-449e-9137-439a6119013b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d618e0e5-9b10-4764-8e4d-800b47a00cf6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2c993f84-530d-449e-9137-439a6119013b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2d0a78ba-ec0a-4ab0-9765-f436e7f413d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d618e0e5-9b10-4764-8e4d-800b47a00cf6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2d0a78ba-ec0a-4ab0-9765-f436e7f413d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_14df75cf-b8fd-425b-9c33-7c3872e27149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_14df75cf-b8fd-425b-9c33-7c3872e27149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e3179214-ded0-42db-bdef-ab1420da8718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e3179214-ded0-42db-bdef-ab1420da8718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1f112fc3-960e-4497-8ad1-411d978ea9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1f112fc3-960e-4497-8ad1-411d978ea9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_44374eeb-3af8-413b-8a34-aec9ddf9708a" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:to="loc_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_44374eeb-3af8-413b-8a34-aec9ddf9708a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability_37ca0624-3a43-4277-a84b-859da27437e8" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:to="loc_nktr_DeferredTaxAssetsLeaseLiability_37ca0624-3a43-4277-a84b-859da27437e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_c724f154-e381-4ddb-b6a9-d2c6d444f009" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ba64683d-c5d4-4521-b5f4-ce3f934a1759" xlink:to="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_c724f154-e381-4ddb-b6a9-d2c6d444f009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99b0ead4-a9db-45c4-b0d0-a2880ee125c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_455c5f34-e914-47fc-8d99-21abc9955547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99b0ead4-a9db-45c4-b0d0-a2880ee125c9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_455c5f34-e914-47fc-8d99-21abc9955547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_49579856-e975-43aa-8f08-bb2895e710bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99b0ead4-a9db-45c4-b0d0-a2880ee125c9" xlink:to="loc_us-gaap_DeferredTaxLiabilities_49579856-e975-43aa-8f08-bb2895e710bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReporting" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReporting"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SegmentReporting" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SegmentReportingTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20201231.xsd#SubsequentEvent"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#SubsequentEventDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialData"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialDataTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialDataDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nktr-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b34aba47-bd43-4f7a-949b-84c5bc7946a0,g:a0d0df82-7542-4b00-8e8b-b5cca2744d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/Cover" xlink:type="simple" xlink:href="nktr-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/Cover" xlink:type="extended" id="i77b658d057844d53a1698ec59652d0b1_Cover"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i27b054ff96c041b1b68f2e20a3d525a5_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i65c1c58d99c244deb2d96401ec91a5ad_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="ibcb8683a414c4a3b83657005529f83cb_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1fe3270a-e26d-4f48-a98c-7378ac2e3503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_RevenuesAbstract_1fe3270a-e26d-4f48-a98c-7378ac2e3503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_896b1925-eccc-49a6-b3c1-84012cc28bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1fe3270a-e26d-4f48-a98c-7378ac2e3503" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_896b1925-eccc-49a6-b3c1-84012cc28bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0252d1ea-3001-4d24-8de4-dfe4780e27a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0252d1ea-3001-4d24-8de4-dfe4780e27a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aac4e67d-1a0b-48c1-b70d-800c2370e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aac4e67d-1a0b-48c1-b70d-800c2370e341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d982f28f-13f3-4401-b5cb-c4bff300ae34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d982f28f-13f3-4401-b5cb-c4bff300ae34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_9082cc3c-b375-4095-a7b1-752e5946a1f2" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_9082cc3c-b375-4095-a7b1-752e5946a1f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_826312b5-263e-4bd1-9b9d-3fa60f4a4748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_CostsAndExpenses_826312b5-263e-4bd1-9b9d-3fa60f4a4748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8d6936a0-ae86-482a-bfa2-7f2bae1ad690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_OperatingIncomeLoss_8d6936a0-ae86-482a-bfa2-7f2bae1ad690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_160671c1-5ff7-4a52-aead-9cfcf834e2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_us-gaap_InterestExpense_160671c1-5ff7-4a52-aead-9cfcf834e2dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1c45bb18-3327-4195-9b9c-bf3dd2414347" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1c45bb18-3327-4195-9b9c-bf3dd2414347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5759172e-1a69-4b11-855f-167133de2c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5759172e-1a69-4b11-855f-167133de2c30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e09d5556-a034-4669-b719-ad00a497f568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e09d5556-a034-4669-b719-ad00a497f568" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7212c2ca-df24-484c-b919-0836ef847495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7212c2ca-df24-484c-b919-0836ef847495" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_413a8824-6a51-49a5-b233-05221e725092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_413a8824-6a51-49a5-b233-05221e725092" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33f2f104-95a8-4214-835d-2067dd5cc5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_NetIncomeLoss_33f2f104-95a8-4214-835d-2067dd5cc5e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a12f7b60-3bff-4b20-817a-4fa25be79840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:to="loc_us-gaap_EarningsPerShareBasic_a12f7b60-3bff-4b20-817a-4fa25be79840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0f446626-87de-4c8c-8e34-fed996452d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0f446626-87de-4c8c-8e34-fed996452d8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db3b6ef2-5a55-4920-baab-8177f64fbfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db3b6ef2-5a55-4920-baab-8177f64fbfdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_798b006a-85d4-4968-9367-0222aae6f5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_798b006a-85d4-4968-9367-0222aae6f5aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:to="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_921daef0-4058-4156-bc64-2b50350df6f5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:to="loc_srt_ProductsAndServicesDomain_921daef0-4058-4156-bc64-2b50350df6f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:to="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_da737f05-e76d-47fb-a09d-86f9a4be26dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_us-gaap_ProductMember_da737f05-e76d-47fb-a09d-86f9a4be26dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_402d32d8-58c6-408c-83d8-d3278e057ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_us-gaap_RoyaltyMember_402d32d8-58c6-408c-83d8-d3278e057ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_bc1e835d-33db-4226-b199-bb03459e0c20" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_bc1e835d-33db-4226-b199-bb03459e0c20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_086ae4b8-11b5-48e8-8276-25473877bfd6" xlink:href="nktr-20201231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_086ae4b8-11b5-48e8-8276-25473877bfd6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="nktr-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="i8d3a608791bf46a4868fefdf0cb6f574_CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i6431eb10305d4574b6eebf4a2ab9dda5_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bef133b5-3e1a-4607-a4c8-1bafde9c9b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bef133b5-3e1a-4607-a4c8-1bafde9c9b08" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9303aa0e-bb1d-4fd5-8327-dcbb8f0d96d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_SharesOutstanding_9303aa0e-bb1d-4fd5-8327-dcbb8f0d96d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3ee02c38-1e94-4f1a-87e0-c54c756f7202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockholdersEquity_3ee02c38-1e94-4f1a-87e0-c54c756f7202" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19ec7ad8-6a9d-4ad9-8066-214c731174f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19ec7ad8-6a9d-4ad9-8066-214c731174f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c7508364-76dc-42e2-9f9c-810bc1e4ad17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c7508364-76dc-42e2-9f9c-810bc1e4ad17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f13a224-8518-4db4-ae63-ca489f979efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f13a224-8518-4db4-ae63-ca489f979efa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9c2014f-3041-45a7-9c32-954323e57163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9c2014f-3041-45a7-9c32-954323e57163" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_92a706eb-3378-40ba-9dae-da22d3ae9213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_92a706eb-3378-40ba-9dae-da22d3ae9213" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_db96d9ee-87ed-46f8-82f9-9a8debc6e1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_db96d9ee-87ed-46f8-82f9-9a8debc6e1c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4fa23917-56a9-4d7b-8950-809343adb7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb7093d1-59f1-4bd2-9f97-d0fa8079e6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bef133b5-3e1a-4607-a4c8-1bafde9c9b08" xlink:to="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_752eab6d-8b31-4340-8dea-840d4d20f439_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:to="loc_us-gaap_EquityComponentDomain_752eab6d-8b31-4340-8dea-840d4d20f439_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:to="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be1b6243-f28e-4df6-9109-8f944ef5250b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_CommonStockMember_be1b6243-f28e-4df6-9109-8f944ef5250b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_59a557c8-6599-4f18-960e-fb62ec8e221b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_59a557c8-6599-4f18-960e-fb62ec8e221b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c377d377-31b6-4a9f-968c-ce72372518c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c377d377-31b6-4a9f-968c-ce72372518c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c01869c0-36c6-48fc-94a4-ee3b03eef6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_RetainedEarningsMember_c01869c0-36c6-48fc-94a4-ee3b03eef6f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5c681410-c1a5-46a6-9bdc-9a70f3deb694_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5c681410-c1a5-46a6-9bdc-9a70f3deb694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ab86c7f6-04f3-4395-841c-ea832d533704" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ab86c7f6-04f3-4395-841c-ea832d533704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_caaadfa7-14fc-4bbc-93a9-25bf870a1240" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ab86c7f6-04f3-4395-841c-ea832d533704" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_caaadfa7-14fc-4bbc-93a9-25bf870a1240" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i3302b45f68e44181a94eab151d5ce1e6_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="ied75f559fbcb410e8917178ce90e7b8c_ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="iea0202e71964496daa2487c7cb9aac37_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="id845fa5ee126420aaa09be95c5ddbced_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended" id="ic15ad005330b4490b60b7e6977534d79_OrganizationandSummaryofSignificantAccountingPoliciesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:href="nktr-20201231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6dda55b2-9646-4850-9dbc-e09f605f2d5b" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6dda55b2-9646-4850-9dbc-e09f605f2d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0b7c0029-b0e4-4c1a-b79b-e9eeb02f5ecb" xlink:href="nktr-20201231.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0b7c0029-b0e4-4c1a-b79b-e9eeb02f5ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_cf76053a-5230-4fa6-8252-1459523c4cba" xlink:href="nktr-20201231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_cf76053a-5230-4fa6-8252-1459523c4cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_10a7de36-25c8-4b3d-9645-16b9feb63277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_10a7de36-25c8-4b3d-9645-16b9feb63277" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_9cb3ace2-9aff-40f1-868d-6e8496a17e4d" xlink:href="nktr-20201231.xsd#nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_9cb3ace2-9aff-40f1-868d-6e8496a17e4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ad7fc52c-2ff7-4cf3-a536-498b78c71015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ad7fc52c-2ff7-4cf3-a536-498b78c71015" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ee66db66-e8dd-4671-b25f-ab8f562f9d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ee66db66-e8dd-4671-b25f-ab8f562f9d48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_9e11ebbd-36d0-450d-b7da-5842a47c697d" xlink:href="nktr-20201231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_9e11ebbd-36d0-450d-b7da-5842a47c697d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_e0664c61-c12e-4730-ab14-60997134485f" xlink:href="nktr-20201231.xsd#nktr_WriteOffOfPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_WriteOffOfPrepayment_e0664c61-c12e-4730-ab14-60997134485f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_02f3bf55-ad3e-46da-b6a6-0b4cd806e718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_02f3bf55-ad3e-46da-b6a6-0b4cd806e718" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b3d4d949-d3a9-4c3c-9b35-74ad0e3c1b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b3d4d949-d3a9-4c3c-9b35-74ad0e3c1b12" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7b959616-f751-41fa-a5a1-86172bc6c9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7b959616-f751-41fa-a5a1-86172bc6c9dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:href="nktr-20201231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31231f00-a204-4b80-b852-feeda810c0de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31231f00-a204-4b80-b852-feeda810c0de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_4737237e-c4ee-4fd5-bb14-2c2ceb4046dc" xlink:href="nktr-20201231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_4737237e-c4ee-4fd5-bb14-2c2ceb4046dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a632bd95-6642-4572-b6b3-a43562c57dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:to="loc_us-gaap_BuildingMember_a632bd95-6642-4572-b6b3-a43562c57dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:to="loc_srt_RangeMember_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:to="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e273a17-7c61-43cb-b3e3-b27d0d4bd446" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:to="loc_srt_MinimumMember_2e273a17-7c61-43cb-b3e3-b27d0d4bd446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb1a7873-d252-46c3-9d74-90a7fa9e13ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:to="loc_srt_MaximumMember_cb1a7873-d252-46c3-9d74-90a7fa9e13ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f36c9944-bfe4-47c0-bb69-d65872b2f803_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f36c9944-bfe4-47c0-bb69-d65872b2f803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c950d41-c630-4502-8209-68184d348099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c950d41-c630-4502-8209-68184d348099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_c428c43e-754c-4a41-9343-ecc49c6458bc" xlink:href="nktr-20201231.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:to="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_c428c43e-754c-4a41-9343-ecc49c6458bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2f025e06-d620-4ab0-af07-94e35a877b2d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2f025e06-d620-4ab0-af07-94e35a877b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_585806b7-fe5d-4363-b46b-864055f31972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_585806b7-fe5d-4363-b46b-864055f31972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_7fa202ff-98ed-411f-a636-3dcf3ede5cc9" xlink:href="nktr-20201231.xsd#nktr_A775PercentSeniorSecuredNotesDueOctober2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_585806b7-fe5d-4363-b46b-864055f31972" xlink:to="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_7fa202ff-98ed-411f-a636-3dcf3ede5cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7858a446-f2c0-4c56-8e3e-fa6f42988856_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7858a446-f2c0-4c56-8e3e-fa6f42988856_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4079afc5-6b60-4ced-96b8-c645d0899e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4079afc5-6b60-4ced-96b8-c645d0899e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aa3ee8f9-a9aa-4c4b-be08-8332a30d727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4079afc5-6b60-4ced-96b8-c645d0899e81" xlink:to="loc_us-gaap_SeniorNotesMember_aa3ee8f9-a9aa-4c4b-be08-8332a30d727f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca3811fb-d346-4259-8fe7-eaeea834887f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:to="loc_srt_ProductsAndServicesDomain_ca3811fb-d346-4259-8fe7-eaeea834887f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54145fa8-cd14-4937-a6ed-2312f566af9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:to="loc_srt_ProductsAndServicesDomain_54145fa8-cd14-4937-a6ed-2312f566af9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_f60b4811-2342-4399-88dd-1bbf86986efe" xlink:href="nktr-20201231.xsd#nktr_NKTR181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54145fa8-cd14-4937-a6ed-2312f566af9b" xlink:to="loc_nktr_NKTR181Member_f60b4811-2342-4399-88dd-1bbf86986efe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6f667f76-e4ab-4e45-a049-cd2fa8afab6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6f667f76-e4ab-4e45-a049-cd2fa8afab6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2ef012c-9bd2-41d9-827f-ff59f7274b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2ef012c-9bd2-41d9-827f-ff59f7274b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a14c654c-7429-480d-a181-35b484489cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2ef012c-9bd2-41d9-827f-ff59f7274b3c" xlink:to="loc_us-gaap_AccountsReceivableMember_a14c654c-7429-480d-a181-35b484489cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_18069a62-9984-4df7-ad3a-454e6a90ca49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_18069a62-9984-4df7-ad3a-454e6a90ca49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_64a6a52a-2b77-407e-833a-aae03a37f3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_18069a62-9984-4df7-ad3a-454e6a90ca49" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_64a6a52a-2b77-407e-833a-aae03a37f3fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb3112f9-6123-4f58-a586-caf14b3f37cd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb3112f9-6123-4f58-a586-caf14b3f37cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerOneMember_f6859ee8-b32c-412c-995e-330bd9742e4e" xlink:href="nktr-20201231.xsd#nktr_PartnerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:to="loc_nktr_PartnerOneMember_f6859ee8-b32c-412c-995e-330bd9742e4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerTwoMember_e33f43a3-e20f-4dab-b730-263ef3a5fc3e" xlink:href="nktr-20201231.xsd#nktr_PartnerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:to="loc_nktr_PartnerTwoMember_e33f43a3-e20f-4dab-b730-263ef3a5fc3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerThreeMember_2bfbd777-741c-49a0-bcdb-23b6a28ed4ca" xlink:href="nktr-20201231.xsd#nktr_PartnerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:to="loc_nktr_PartnerThreeMember_2bfbd777-741c-49a0-bcdb-23b6a28ed4ca" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended" id="i651dc886e8cc4d498d071f7043434568_CashandInvestmentsinMarketableSecurities"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended" id="i10db99852f324a32889ed526008cb5ab_CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended" id="i869f988fc6cd40868bffade66359b3b4_CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="i7abfb90dcc0d4339b0a6f93f7d5e0580_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:href="nktr-20201231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_1e22fecc-6d2c-4287-ad36-077b65417f05" xlink:href="nktr-20201231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_1e22fecc-6d2c-4287-ad36-077b65417f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c817bceb-121c-49da-9946-0e9a837cdd53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c817bceb-121c-49da-9946-0e9a837cdd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_ac2763ba-3b5e-486f-a676-1e3811389689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_InterestReceivableCurrent_ac2763ba-3b5e-486f-a676-1e3811389689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_0c19eba7-7367-42a1-b7a7-1d5a02b26ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_0c19eba7-7367-42a1-b7a7-1d5a02b26ba1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_ac1148f1-add2-4f0c-bae6-3ebefcdec910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_ac1148f1-add2-4f0c-bae6-3ebefcdec910" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_77686b4b-71ba-4526-9209-35d419500d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_77686b4b-71ba-4526-9209-35d419500d56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a46409-7cae-4bdd-8f68-ed7221e0bb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a46409-7cae-4bdd-8f68-ed7221e0bb57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_99935710-132b-4be5-9598-46cb01342017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_99935710-132b-4be5-9598-46cb01342017" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:href="nktr-20201231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:to="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:to="loc_srt_RangeMember_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:to="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a7e4d65-3cd8-4fc5-a011-31d39826d582" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:to="loc_srt_MinimumMember_6a7e4d65-3cd8-4fc5-a011-31d39826d582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1c1e7c0-e985-4ac9-bb82-319f7587a50f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:to="loc_srt_MaximumMember_d1c1e7c0-e985-4ac9-bb82-319f7587a50f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="i01bf16bfd75b49eca51f42e4549e84d3_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d1e95a6-8f0d-4eb3-a959-7b77e1a52a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d1e95a6-8f0d-4eb3-a959-7b77e1a52a97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fcf720ec-c32b-426a-8f2a-3e7ce40647a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fcf720ec-c32b-426a-8f2a-3e7ce40647a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_72acb4aa-8cb6-4288-842d-46104b0ee5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_72acb4aa-8cb6-4288-842d-46104b0ee5a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e9c524b-186e-4411-81fb-4ae7b75bc6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e9c524b-186e-4411-81fb-4ae7b75bc6f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_938cbe18-d5bb-4e5f-99ab-f8fc63d553a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_938cbe18-d5bb-4e5f-99ab-f8fc63d553a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_fd1ea022-be7d-495e-a626-d1336bd7bf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_Cash_fd1ea022-be7d-495e-a626-d1336bd7bf94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_65851f03-6d01-4f23-9e13-0d5b25c6e7c4" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_65851f03-6d01-4f23-9e13-0d5b25c6e7c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:to="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d7aef914-de8b-418b-b84d-599981d735b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d7aef914-de8b-418b-b84d-599981d735b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52842a8d-5e9b-4b8e-a9ae-2396d4a15118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52842a8d-5e9b-4b8e-a9ae-2396d4a15118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14253849-bb2b-4ce9-927f-20205038f843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_CommercialPaperMember_14253849-bb2b-4ce9-927f-20205038f843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4154cac0-369c-4bf1-a37b-d72a54fd0f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4154cac0-369c-4bf1-a37b-d72a54fd0f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f0b4872e-54f0-4718-acad-6354042b0e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f0b4872e-54f0-4718-acad-6354042b0e2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_14192073-8dfc-4850-a4b1-5c78d4916c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_CertificatesOfDepositMember_14192073-8dfc-4850-a4b1-5c78d4916c13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4adc71d7-d5f1-4651-9ef3-7834d2c8766b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4adc71d7-d5f1-4651-9ef3-7834d2c8766b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6790142e-a58f-430f-ac0a-1220ad610610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6790142e-a58f-430f-ac0a-1220ad610610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab5dc6d9-b071-47d4-ba8b-f932d04719a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab5dc6d9-b071-47d4-ba8b-f932d04719a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20201231.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended" id="ib9149088a61f4032b02e37a7ea970d11_Inventory"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended" id="ia5df987e1a974db19345072f08aa602d_InventoryTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#InventoryDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryDetail" xlink:type="extended" id="i2cf146057d2b4cfabe427a9a1e185d96_InventoryDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipment"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="extended" id="id34f220591b94afc8bfd2827d4ce65ab_PropertyPlantandEquipment"/>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="extended" id="iee069e212fcc46daacc50419508183e4_PropertyPlantandEquipmentTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" xlink:type="extended" id="i8010d15465124b97ac5adb0ac58583c8_PropertyPlantandEquipmentPropertyPlantandEquipmentDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_ad97b37f-0404-48a2-90c7-9f1f37b1df5b" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_ad97b37f-0404-48a2-90c7-9f1f37b1df5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac7a6ae6-5bef-47e2-832c-c0938b7b3313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac7a6ae6-5bef-47e2-832c-c0938b7b3313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_da526baa-2def-47d0-93e5-33c6eff4416a" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_da526baa-2def-47d0-93e5-33c6eff4416a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ad02e6b4-7ed3-4380-aee3-82b4c3985568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_ConstructionInProgressGross_ad02e6b4-7ed3-4380-aee3-82b4c3985568" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e7d7153b-bf02-4b67-9b68-0de24bcf6052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e7d7153b-bf02-4b67-9b68-0de24bcf6052" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b5778e9-14e8-4d18-a9af-0a07e1aaef91_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b5778e9-14e8-4d18-a9af-0a07e1aaef91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_ef7fd25e-b261-4db3-8ea4-2843d6891e43" xlink:href="nktr-20201231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_ef7fd25e-b261-4db3-8ea4-2843d6891e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_a852a93f-447c-4950-91b9-cb9088f2a12a" xlink:href="nktr-20201231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_LaboratoryEquipmentMember_a852a93f-447c-4950-91b9-cb9088f2a12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_70e25ecd-af99-4423-a08b-8d62b91e81d4" xlink:href="nktr-20201231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_70e25ecd-af99-4423-a08b-8d62b91e81d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_1bd5b32a-4d09-4488-826d-0193f340a8f2" xlink:href="nktr-20201231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_1bd5b32a-4d09-4488-826d-0193f340a8f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_37600278-aff4-4085-9efd-c78e13ff9641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_37600278-aff4-4085-9efd-c78e13ff9641" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail" xlink:type="extended" id="i5e08b681986b4e6295a423e43ad417e8_PropertyPlantandEquipmentAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="simple" xlink:href="nktr-20201231.xsd#SeniorSecuredNotes"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="extended" id="i490dedd4da284f6087201c6be0557860_SeniorSecuredNotes"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SeniorSecuredNotesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotesDetail" xlink:type="extended" id="ie7cc00ab28f243f69cb37b9670929d34_SeniorSecuredNotesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:href="nktr-20201231.xsd#nktr_SecuredNotesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_b20cf7c0-1801-4d9b-a89a-1215ba3a6f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_SeniorNotes_b20cf7c0-1801-4d9b-a89a-1215ba3a6f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e112bc5-072c-4877-ad08-b8ce62c1d68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e112bc5-072c-4877-ad08-b8ce62c1d68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_76336482-94e3-4341-92e2-ac90a794b208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_76336482-94e3-4341-92e2-ac90a794b208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_1724a8f8-b323-4dda-8293-dae3b18769e5" xlink:href="nktr-20201231.xsd#nktr_DebtDiscountOnTransactionAndFacilityFeesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_1724a8f8-b323-4dda-8293-dae3b18769e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_0bf46367-9018-462b-8833-a2b93f6f2977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_0bf46367-9018-462b-8833-a2b93f6f2977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_0e6e7585-69db-4511-af19-792e098f8e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_InterestReceivable_0e6e7585-69db-4511-af19-792e098f8e03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:href="nktr-20201231.xsd#nktr_SecuredNotesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b55add7e-12bf-4b2e-a043-a0c082f9b5c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b55add7e-12bf-4b2e-a043-a0c082f9b5c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb276ec7-2683-42c9-a53f-0b29f7ed11cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb276ec7-2683-42c9-a53f-0b29f7ed11cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e6089886-55cc-4207-9951-1985fbee7929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb276ec7-2683-42c9-a53f-0b29f7ed11cc" xlink:to="loc_us-gaap_SeniorNotesMember_e6089886-55cc-4207-9951-1985fbee7929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:to="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb06c507-2c5a-4c0b-8b62-d1389995665d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb06c507-2c5a-4c0b-8b62-d1389995665d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99461e4f-8b99-4251-86f4-0b48457a3e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99461e4f-8b99-4251-86f4-0b48457a3e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_d1d7a682-4f12-4271-a813-2970a8e6a133" xlink:href="nktr-20201231.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99461e4f-8b99-4251-86f4-0b48457a3e58" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_d1d7a682-4f12-4271-a813-2970a8e6a133" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Leases" xlink:type="simple" xlink:href="nktr-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/Leases" xlink:type="extended" id="i20467695583d492d8c41c34ac081228d_Leases"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesTables" xlink:type="extended" id="i7d2b75c43bbb491bb0fbf5f242831f0c_LeasesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="ia912bac04946422392b63447b966d645_LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:href="nktr-20201231.xsd#nktr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace_2bf46316-c48f-4dd9-be46-5afcf48d4547" xlink:href="nktr-20201231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_nktr_AreaOfLeasedSpace_2bf46316-c48f-4dd9-be46-5afcf48d4547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b812fcc4-2016-4721-b66b-ef47b8cc4137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeaseCost_b812fcc4-2016-4721-b66b-ef47b8cc4137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49f42adb-cd4e-43a1-93f7-b9e33a41ca0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeasePayments_49f42adb-cd4e-43a1-93f7-b9e33a41ca0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20b24df1-ceab-44de-a531-8a492c28dc88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20b24df1-ceab-44de-a531-8a492c28dc88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bbf3d586-30a8-4e86-bea1-f40af22249d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bbf3d586-30a8-4e86-bea1-f40af22249d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:to="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5cc2c2f3-b9d5-466e-ae2c-55c785f61456_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5cc2c2f3-b9d5-466e-ae2c-55c785f61456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:to="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_7e2ad3f1-faaa-4544-a25b-da22e73e98cf" xlink:href="nktr-20201231.xsd#nktr_MissionBayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:to="loc_nktr_MissionBayLeaseMember_7e2ad3f1-faaa-4544-a25b-da22e73e98cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_f94a7efa-6bac-4689-8609-851111defc18" xlink:href="nktr-20201231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:to="loc_nktr_ThirdStreetLeaseMember_f94a7efa-6bac-4689-8609-851111defc18" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesOperatingLeaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails" xlink:type="extended" id="i608df942e50a4377aeb94920c21ce94f_LeasesOperatingLeaseInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:href="nktr-20201231.xsd#nktr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpaceDelivered_166be7fc-4049-4248-bc70-1f1f0eba0396" xlink:href="nktr-20201231.xsd#nktr_AreaOfLeasedSpaceDelivered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_AreaOfLeasedSpaceDelivered_166be7fc-4049-4248-bc70-1f1f0eba0396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_303a1f4b-1dfc-4e91-b1ad-7db89931bf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_303a1f4b-1dfc-4e91-b1ad-7db89931bf94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease_b0da9e3c-3439-4855-8ed7-e53dc38c39ac" xlink:href="nktr-20201231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_NumberOfConsecutiveTermsToExtendLease_b0da9e3c-3439-4855-8ed7-e53dc38c39ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm_8c5f99a0-eef8-442c-9025-582cfc5849e6" xlink:href="nktr-20201231.xsd#nktr_LeaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_LeaseExtensionTerm_8c5f99a0-eef8-442c-9025-582cfc5849e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:to="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_42062bd6-b8c6-4c94-92ff-9d5df7d77844_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:to="loc_us-gaap_LeaseContractualTermDomain_42062bd6-b8c6-4c94-92ff-9d5df7d77844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:to="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_73e51780-28dc-4fff-b398-c55ea0775273" xlink:href="nktr-20201231.xsd#nktr_MissionBayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:to="loc_nktr_MissionBayLeaseMember_73e51780-28dc-4fff-b398-c55ea0775273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_6c9d10b2-7d33-435e-825d-931f28286714" xlink:href="nktr-20201231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:to="loc_nktr_ThirdStreetLeaseMember_6c9d10b2-7d33-435e-825d-931f28286714" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesScheduleofLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="extended" id="i9a5b5bbc753246eebed031732ca19368_LeasesScheduleofLeaseCostDetails"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended" id="i0ac915f6812a46afa3bb728e792d737c_LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyalties"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="extended" id="i0482ccb2e7a4446cb24a6c21c552d730_LiabilitiesRelatedtotheSalesofFutureRoyalties"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="extended" id="i0f8278a635f64de080fe191c6063dbc1_LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended" id="id5c53cfa04794309a967c78fb9543523_LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_8ed44ca0-39f1-4bd5-8f54-5857a381145d" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_8ed44ca0-39f1-4bd5-8f54-5857a381145d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_d1a64bdd-d77a-4197-8e1d-f18ea3cc8574" xlink:href="nktr-20201231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_d1a64bdd-d77a-4197-8e1d-f18ea3cc8574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_1483f22f-7577-452d-95d1-fdd094ce72cd" xlink:href="nktr-20201231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_1483f22f-7577-452d-95d1-fdd094ce72cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_4e137d18-86d2-4ee3-8a03-94f29d0d82ca" xlink:href="nktr-20201231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_4e137d18-86d2-4ee3-8a03-94f29d0d82ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyAgreementContingentPaymentDescription_0bd99c95-e30a-4906-9652-a6c601d13979" xlink:href="nktr-20201231.xsd#nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_RoyaltyAgreementContingentPaymentDescription_0bd99c95-e30a-4906-9652-a6c601d13979" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_5ebf8352-314c-464b-b546-2e178fe3f443" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_5ebf8352-314c-464b-b546-2e178fe3f443" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_ba282ee3-76d1-47dd-b13c-ef18c11ef849" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_ba282ee3-76d1-47dd-b13c-ef18c11ef849" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_f809424d-210b-4a17-b9e0-92673d930190" xlink:href="nktr-20201231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_f809424d-210b-4a17-b9e0-92673d930190" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_7fb048f8-408b-48d1-9a8f-83bbebfad8bb" xlink:href="nktr-20201231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_7fb048f8-408b-48d1-9a8f-83bbebfad8bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_91c3cb42-329f-4533-80b0-74f494eee4d0" xlink:href="nktr-20201231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_91c3cb42-329f-4533-80b0-74f494eee4d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a778091-5514-4681-b451-a11e942d46c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a778091-5514-4681-b451-a11e942d46c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_4548fceb-80fc-4a96-851f-519031bd9f45" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_4548fceb-80fc-4a96-851f-519031bd9f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_c5f9b63d-858d-475d-95cc-4102e62e8784" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_c5f9b63d-858d-475d-95cc-4102e62e8784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_58c88d72-5098-45c6-a006-d58a198ae53b" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_58c88d72-5098-45c6-a006-d58a198ae53b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended" id="id1e429e9526c4125be14821b73dd8b85_LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_556f55f5-d2ce-4047-98b8-a0d672d51286" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_556f55f5-d2ce-4047-98b8-a0d672d51286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_65c871b4-2ad6-4404-a905-2e4ab954f275" xlink:href="nktr-20201231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_65c871b4-2ad6-4404-a905-2e4ab954f275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_684d463a-ec8e-4d57-adce-9fcf1674718d" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_684d463a-ec8e-4d57-adce-9fcf1674718d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_e961456b-da32-4b27-a354-e2b9c9fe8aaa" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_e961456b-da32-4b27-a354-e2b9c9fe8aaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_446c78de-dfb3-418f-a125-c3c6885e2e35" xlink:href="nktr-20201231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_446c78de-dfb3-418f-a125-c3c6885e2e35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_893a7b1f-44cd-4c3e-97ab-077804bd5ee9" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_380fa831-73a8-45b1-a08e-70d8963f34bd" xlink:href="nktr-20201231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_380fa831-73a8-45b1-a08e-70d8963f34bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_59c40467-ac9e-4209-b52d-c21db523c953" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_59c40467-ac9e-4209-b52d-c21db523c953" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_91465fb3-1cc7-4990-91f2-63a1d8782d09" xlink:href="nktr-20201231.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_91465fb3-1cc7-4990-91f2-63a1d8782d09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_41d31a4d-0c62-4c9d-8675-7ef318fcba9a" xlink:href="nktr-20201231.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_41d31a4d-0c62-4c9d-8675-7ef318fcba9a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12db0b91-d6a8-4a56-a2ce-c51739e1c427_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12db0b91-d6a8-4a56-a2ce-c51739e1c427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_67b7c6de-abd2-44e2-b39a-8a935e317338" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_67b7c6de-abd2-44e2-b39a-8a935e317338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_3d98e2c9-435d-4da8-9f94-f10ea815182a" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_3d98e2c9-435d-4da8-9f94-f10ea815182a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended" id="i926171195db2434ebec92ebfa3c0a884_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CommitmentsandContingenciesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended" id="i229f6c2b84f0487bbb6695df96d1ac45_CommitmentsandContingenciesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_230a2205-e57e-4151-855e-643039433c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_230a2205-e57e-4151-855e-643039433c6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_52b9020a-0069-462d-abb8-c7107be7c277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_52b9020a-0069-462d-abb8-c7107be7c277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_6ba4a93a-a682-4965-9819-561304a0b6c9" xlink:href="nktr-20201231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_6ba4a93a-a682-4965-9819-561304a0b6c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4fcfad6c-20db-4933-8c0b-f43849df989b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4fcfad6c-20db-4933-8c0b-f43849df989b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_fc31232e-f67e-428e-8908-5e94a40cfbb4" xlink:href="nktr-20201231.xsd#nktr_LegalMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_LegalMattersMember_fc31232e-f67e-428e-8908-5e94a40cfbb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_d21d7a12-7360-4bb2-b10c-880d4b1483bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_d21d7a12-7360-4bb2-b10c-880d4b1483bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommercialAgreementsMember_5b762e36-8c97-4e04-a08b-cf94b7e68a1b" xlink:href="nktr-20201231.xsd#nktr_CommercialAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_CommercialAgreementsMember_5b762e36-8c97-4e04-a08b-cf94b7e68a1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_c3085bf9-a507-4ca1-9794-e4dc166c09de" xlink:href="nktr-20201231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_c3085bf9-a507-4ca1-9794-e4dc166c09de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember_44d85ca8-dd77-4904-9dd8-e76fba411a7e" xlink:href="nktr-20201231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_SecuritiesRelatedClaimsMember_44d85ca8-dd77-4904-9dd8-e76fba411a7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember_f6bcfbf8-6576-4187-9c78-482323312992" xlink:href="nktr-20201231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_NonSecuritiesRelatedClaimsMember_f6bcfbf8-6576-4187-9c78-482323312992" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:to="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e819c4db-8acb-4aaa-b2af-6a67083517f5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:to="loc_srt_RangeMember_e819c4db-8acb-4aaa-b2af-6a67083517f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21fe1323-6a63-417b-81e0-da562d5ad1f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:to="loc_srt_RangeMember_21fe1323-6a63-417b-81e0-da562d5ad1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9798eaa-f8c4-4302-b0c4-adb9f69d40ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_21fe1323-6a63-417b-81e0-da562d5ad1f4" xlink:to="loc_srt_MaximumMember_d9798eaa-f8c4-4302-b0c4-adb9f69d40ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquity" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockholdersEquity" xlink:type="extended" id="i11c136e397ed4d018e43322b83f9de0b_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockholdersEquityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockholdersEquityDetail" xlink:type="extended" id="i10c9e0c807d54c89ae596b7d246c5070_StockholdersEquityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c3b1aab-cf56-4009-9545-e480d78f95d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c3b1aab-cf56-4009-9545-e480d78f95d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_e9a9e69c-03b0-4f0f-a6e0-385ada712a33" xlink:href="nktr-20201231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_e9a9e69c-03b0-4f0f-a6e0-385ada712a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b623779-9215-4c5f-a2c5-773945bbc775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b623779-9215-4c5f-a2c5-773945bbc775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_47e737cf-fdb7-4632-98d6-2bff621dbb32" xlink:href="nktr-20201231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_47e737cf-fdb7-4632-98d6-2bff621dbb32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_fc9edc01-c128-412e-9244-b66ddc12c093" xlink:href="nktr-20201231.xsd#nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_fc9edc01-c128-412e-9244-b66ddc12c093" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c2ec371-2039-4cd2-83b1-7c63d5d2a360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c2ec371-2039-4cd2-83b1-7c63d5d2a360" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommonStockAdditionalSharesAuthorized_16287c59-b556-4f23-b9db-3c47c7d41a4c" xlink:href="nktr-20201231.xsd#nktr_CommonStockAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_CommonStockAdditionalSharesAuthorized_16287c59-b556-4f23-b9db-3c47c7d41a4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_939c4f96-3f03-4c3b-b5e6-240619a60dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_939c4f96-3f03-4c3b-b5e6-240619a60dc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_a22efc10-64a8-453f-98d9-4d8841d7f0b6" xlink:href="nktr-20201231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_a22efc10-64a8-453f-98d9-4d8841d7f0b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e90a60ae-f193-4e8f-8414-ae746bc683b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e90a60ae-f193-4e8f-8414-ae746bc683b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76b42534-f223-413d-a33f-f83d6d589f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76b42534-f223-413d-a33f-f83d6d589f75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1226e42d-c2e6-47c5-bb23-629bcdc966fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1226e42d-c2e6-47c5-bb23-629bcdc966fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfPurchasePriceOfStock_2fbe7f0f-7019-4e09-8a28-a838d2de6325" xlink:href="nktr-20201231.xsd#nktr_PercentageOfPurchasePriceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_PercentageOfPurchasePriceOfStock_2fbe7f0f-7019-4e09-8a28-a838d2de6325" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_bb147dc1-0ec5-45c1-98e4-630992b64831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_bb147dc1-0ec5-45c1-98e4-630992b64831" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_afcf0905-b8a6-4f9c-8c40-b5ff90edbb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_afcf0905-b8a6-4f9c-8c40-b5ff90edbb8d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0ffac528-cc31-4961-a1fb-770627630faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0ffac528-cc31-4961-a1fb-770627630faa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_32cc3278-cd58-4ec3-86eb-02af6c595c68" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_32cc3278-cd58-4ec3-86eb-02af6c595c68" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_9d5ad794-4b01-48a5-be15-69db784fbb37" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_9d5ad794-4b01-48a5-be15-69db784fbb37" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_d07c1d3c-f5e5-41ba-ad7f-e443b905a34d" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_d07c1d3c-f5e5-41ba-ad7f-e443b905a34d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_7614f06b-0b2d-4a97-9cbd-4c4513c54bea" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_7614f06b-0b2d-4a97-9cbd-4c4513c54bea" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6de77311-af21-41d4-ad50-e6d38a410cc0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6de77311-af21-41d4-ad50-e6d38a410cc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember_8e22afcf-92ba-4b0e-b55d-bfc6a43d688d" xlink:href="nktr-20201231.xsd#nktr_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:to="loc_nktr_EmployeeMember_8e22afcf-92ba-4b0e-b55d-bfc6a43d688d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_56ac7b8d-2dbc-47bf-ad95-838099ba99f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:to="loc_srt_DirectorMember_56ac7b8d-2dbc-47bf-ad95-838099ba99f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97b5325f-b950-4635-bba8-4e57d9776398_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:to="loc_us-gaap_EquityComponentDomain_97b5325f-b950-4635-bba8-4e57d9776398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec628fb3-70b6-4bbe-b7b6-540386151d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:to="loc_us-gaap_EquityComponentDomain_ec628fb3-70b6-4bbe-b7b6-540386151d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6ded1557-ddf7-467b-bdc8-6a3f5a715a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec628fb3-70b6-4bbe-b7b6-540386151d93" xlink:to="loc_us-gaap_CommonStockMember_6ded1557-ddf7-467b-bdc8-6a3f5a715a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:to="loc_us-gaap_PlanNameDomain_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:to="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_5d553ae1-4760-41f8-b955-41831d921e0d" xlink:href="nktr-20201231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_5d553ae1-4760-41f8-b955-41831d921e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_ebe0183b-7d03-46a1-b7a5-0ef06803101c" xlink:href="nktr-20201231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_ebe0183b-7d03-46a1-b7a5-0ef06803101c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmendedAndRestated2017PlanMember_86366505-1812-4335-927d-725712ec1451" xlink:href="nktr-20201231.xsd#nktr_AmendedAndRestated2017PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:to="loc_nktr_AmendedAndRestated2017PlanMember_86366505-1812-4335-927d-725712ec1451" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d88cadd-f405-4af9-ad38-0540fc96ce5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d88cadd-f405-4af9-ad38-0540fc96ce5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f534df30-7d89-49cf-8eee-eafa4a4cfe50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f534df30-7d89-49cf-8eee-eafa4a4cfe50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember_f4e29a41-2af7-4aea-92df-e2aba3fa28ec" xlink:href="nktr-20201231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:to="loc_nktr_RSUsAndPSUsMember_f4e29a41-2af7-4aea-92df-e2aba3fa28ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_baa76052-cf05-425c-9e1b-b3eb7c137594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:to="loc_us-gaap_EmployeeStockMember_baa76052-cf05-425c-9e1b-b3eb7c137594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_691165e0-66e3-470c-9632-68bc330e863c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_691165e0-66e3-470c-9632-68bc330e863c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df9fc972-5864-4f14-86d5-4739589b5d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df9fc972-5864-4f14-86d5-4739589b5d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_af9c3f3e-0af8-4f7d-8005-52246a82b286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df9fc972-5864-4f14-86d5-4739589b5d55" xlink:to="loc_us-gaap_EmployeeStockMember_af9c3f3e-0af8-4f7d-8005-52246a82b286" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="idcb3103c061b42e99c58705106ab758e_LicenseandCollaborationAgreements"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended" id="ib0880510df224bcca1e19df78641af16_LicenseandCollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended" id="i3677f9d91d9842c68c4ab4944ef9c669_LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_8f660edc-789a-4dc9-b75b-ec1b9ed4a736" xlink:href="nktr-20201231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_580eef4e-263a-4f2a-9ee6-142a61567070" xlink:href="nktr-20201231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_8f660edc-789a-4dc9-b75b-ec1b9ed4a736" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_580eef4e-263a-4f2a-9ee6-142a61567070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:href="nktr-20201231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_8f660edc-789a-4dc9-b75b-ec1b9ed4a736" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:to="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:to="loc_dei_EntityDomain_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:to="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9137dc47-7ae5-4b5d-bb83-f950702e5846" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9137dc47-7ae5-4b5d-bb83-f950702e5846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_2b4f54a1-b71d-4873-8ab9-f4f71e9c5ca9" xlink:href="nktr-20201231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_EliLillyAndCompanyMember_2b4f54a1-b71d-4873-8ab9-f4f71e9c5ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_ca192a83-1c6d-4425-b2ce-f8c4d17d5009" xlink:href="nktr-20201231.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_AmgenIncMember_ca192a83-1c6d-4425-b2ce-f8c4d17d5009" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_d7f058c3-1313-443a-bef1-5502c71b95ca" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_d7f058c3-1313-443a-bef1-5502c71b95ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_f02112df-9a54-451a-96d4-50e138066ebf" xlink:href="nktr-20201231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_OtherPartnerMember_f02112df-9a54-451a-96d4-50e138066ebf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember_fa9cb9ac-703f-459d-9449-df62b2473c56" xlink:href="nktr-20201231.xsd#nktr_BempegaldesleukinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_BempegaldesleukinMember_fa9cb9ac-703f-459d-9449-df62b2473c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_a045bae1-4faf-4a03-928c-8074335bec06" xlink:href="nktr-20201231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_NektarThreeFiveEightMember_a045bae1-4faf-4a03-928c-8074335bec06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_3e944674-b878-4fe5-83e4-83a922d413f7" xlink:href="nktr-20201231.xsd#nktr_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_NeulastaMember_3e944674-b878-4fe5-83e4-83a922d413f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_ee64d1a8-1270-49d1-acd2-127b58b01f66" xlink:href="nktr-20201231.xsd#nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_ee64d1a8-1270-49d1-acd2-127b58b01f66" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="id754e8de4ef549e1a1f500cab3fdf6f8_LicenseandCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9660ef45-4da1-4b2d-837c-964eb697941f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9660ef45-4da1-4b2d-837c-964eb697941f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_e8daec82-a92d-497d-83d2-09dd53919b24" xlink:href="nktr-20201231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_SalesMilestoneRevenue_e8daec82-a92d-497d-83d2-09dd53919b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_e624ccd9-61dd-4bf8-9d1e-941aa57fa057" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PotentialDevelopmentMilestones_e624ccd9-61dd-4bf8-9d1e-941aa57fa057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_abb2d25f-03fd-4858-876c-77d4ed547472" xlink:href="nktr-20201231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_abb2d25f-03fd-4858-876c-77d4ed547472" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_15f49cd2-432e-4026-a16d-31e57e2f2256" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_15f49cd2-432e-4026-a16d-31e57e2f2256" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_6d699cc8-c841-40b6-b466-642eafdc2989" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_6d699cc8-c841-40b6-b466-642eafdc2989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_116c8e4a-85c3-497b-a562-36742fc82ccd" xlink:href="nktr-20201231.xsd#nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_116c8e4a-85c3-497b-a562-36742fc82ccd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_90405795-41b4-4ac8-9d07-d5028f23c3e4" xlink:href="nktr-20201231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_90405795-41b4-4ac8-9d07-d5028f23c3e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_8b3e750a-a068-45df-aa3d-ea34237e0fc5" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_8b3e750a-a068-45df-aa3d-ea34237e0fc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_fe48ba94-f14a-4c75-bd61-98e8520d8da1" xlink:href="nktr-20201231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_fe48ba94-f14a-4c75-bd61-98e8520d8da1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_664313c9-4d29-4dfc-ae11-35fbbc9768f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_SharesIssued_664313c9-4d29-4dfc-ae11-35fbbc9768f5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_da1e908b-ebba-4cf8-b7c6-ddf9d1e2e99d" xlink:href="nktr-20201231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_da1e908b-ebba-4cf8-b7c6-ddf9d1e2e99d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_b6e2659d-842b-4e11-9b69-07ad69a8a46b" xlink:href="nktr-20201231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_ReimbursementOfExpenses_b6e2659d-842b-4e11-9b69-07ad69a8a46b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_64ed6821-b114-4f77-8e4e-c425fd23bf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_64ed6821-b114-4f77-8e4e-c425fd23bf68" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_e455456d-76aa-4360-93db-591a839e000f" xlink:href="nktr-20201231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_e455456d-76aa-4360-93db-591a839e000f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCosts_52928103-159a-49fa-a09f-b36a460a5eed" xlink:href="nktr-20201231.xsd#nktr_CompanyShareOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_CompanyShareOfDevelopmentCosts_52928103-159a-49fa-a09f-b36a460a5eed" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentCostsExceeded_429e4ed6-8e04-445f-a5a1-7f74199545ce" xlink:href="nktr-20201231.xsd#nktr_DevelopmentCostsExceeded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_DevelopmentCostsExceeded_429e4ed6-8e04-445f-a5a1-7f74199545ce" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementRecognized_aee51790-f193-4e4d-83a7-df931ff98b3b" xlink:href="nktr-20201231.xsd#nktr_ReimbursementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_ReimbursementRecognized_aee51790-f193-4e4d-83a7-df931ff98b3b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f66dd18b-03b7-4b1b-8ae0-8f205a999cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f66dd18b-03b7-4b1b-8ae0-8f205a999cb0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_101cde46-73c6-41e1-a525-93e0ce9efb9f" xlink:href="nktr-20201231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_101cde46-73c6-41e1-a525-93e0ce9efb9f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_3f694621-4492-47f2-8635-2fc80c59988b" xlink:href="nktr-20201231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_EstimatedFairValueOfShares_3f694621-4492-47f2-8635-2fc80c59988b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_92de7d1b-1ef9-4b1e-9d5e-cf6023b7c4f5" xlink:href="nktr-20201231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_92de7d1b-1ef9-4b1e-9d5e-cf6023b7c4f5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_d55062b5-2eb8-41c2-962d-8e50ad60f0bf" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_d55062b5-2eb8-41c2-962d-8e50ad60f0bf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_13854485-d7b7-497c-b087-179748da4957" xlink:href="nktr-20201231.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_13854485-d7b7-497c-b087-179748da4957" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b1c9a83f-603a-45a2-8e3d-9c42519fd245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b1c9a83f-603a-45a2-8e3d-9c42519fd245" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ede58693-ea81-440a-9818-6889aa24edff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ede58693-ea81-440a-9818-6889aa24edff" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_4133e573-fa9f-4c4c-a152-e235a9b45e02" xlink:href="nktr-20201231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_4133e573-fa9f-4c4c-a152-e235a9b45e02" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d784cbb1-47d2-49ef-bc73-49ceaadf01c6" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d784cbb1-47d2-49ef-bc73-49ceaadf01c6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_28523b9f-cac5-419a-a97d-ddf172853f7b" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_28523b9f-cac5-419a-a97d-ddf172853f7b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_c67541e3-e948-46c5-80d2-2af1304ea4a7" xlink:href="nktr-20201231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_c67541e3-e948-46c5-80d2-2af1304ea4a7" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_fedfed9e-79f9-49e6-9828-f2b4c1f740c4" xlink:href="nktr-20201231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_fedfed9e-79f9-49e6-9828-f2b4c1f740c4" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_ab27cc55-aa11-4e9e-a6f9-447a708b8d30" xlink:href="nktr-20201231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_ab27cc55-aa11-4e9e-a6f9-447a708b8d30" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_4abfa159-0612-4fde-a146-5186e055be99" xlink:href="nktr-20201231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_4abfa159-0612-4fde-a146-5186e055be99" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7a1cb33-62cf-4393-bc0a-7d1d24e9692e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7a1cb33-62cf-4393-bc0a-7d1d24e9692e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_a870e2f5-168d-449d-8e49-d6bcb7d79de4" xlink:href="nktr-20201231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_a870e2f5-168d-449d-8e49-d6bcb7d79de4" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_94182a85-10df-4898-a660-37921726a386" xlink:href="nktr-20201231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_94182a85-10df-4898-a660-37921726a386" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RegulatoryMilestonesPaymentDescription_d626df55-9003-4ec4-ad20-d1124b3d4238" xlink:href="nktr-20201231.xsd#nktr_RegulatoryMilestonesPaymentDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_RegulatoryMilestonesPaymentDescription_d626df55-9003-4ec4-ad20-d1124b3d4238" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_ee3e659c-bb33-481c-bb27-e5ff111fe907" xlink:href="nktr-20201231.xsd#nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_ee3e659c-bb33-481c-bb27-e5ff111fe907" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_9cc0f666-9948-4f35-8a6e-531e0e6e622c" xlink:href="nktr-20201231.xsd#nktr_PercentageOfNetSalesToFundExternalCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_9cc0f666-9948-4f35-8a6e-531e0e6e622c" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_4d8e4a60-30bf-4690-b712-01c36e919072" xlink:href="nktr-20201231.xsd#nktr_AmountOfNetSalesToFundExternalCostsIncurredCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_4d8e4a60-30bf-4690-b712-01c36e919072" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:href="nktr-20201231.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_f80dd81e-a89a-4a49-86d8-aa54cbfeec32_default" xlink:href="nktr-20201231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:to="loc_nktr_MilestoneDomain_f80dd81e-a89a-4a49-86d8-aa54cbfeec32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_889d56ef-360c-4737-b7bb-7bf7f09a563f" xlink:href="nktr-20201231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:to="loc_nktr_MilestoneDomain_889d56ef-360c-4737-b7bb-7bf7f09a563f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_4159cead-18d8-4f53-a842-a2b78b5595d4" xlink:href="nktr-20201231.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_889d56ef-360c-4737-b7bb-7bf7f09a563f" xlink:to="loc_nktr_MilestoneOneMember_4159cead-18d8-4f53-a842-a2b78b5595d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2746eff6-3549-471a-9ef3-7c72a2d438dd_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:to="loc_dei_EntityDomain_2746eff6-3549-471a-9ef3-7c72a2d438dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:to="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_2a716ab1-d6da-4386-80c4-bbff89e5041e" xlink:href="nktr-20201231.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_EliLillyMember_2a716ab1-d6da-4386-80c4-bbff89e5041e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9d1eb7e8-8c09-4f3a-a3bf-234bff051528" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9d1eb7e8-8c09-4f3a-a3bf-234bff051528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_e311226e-37bc-4afd-bfd2-3f527e6d00a3" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_e311226e-37bc-4afd-bfd2-3f527e6d00a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_41f2716b-d419-4a90-a0fa-54d9a3d839e3" xlink:href="nktr-20201231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_EliLillyAndCompanyMember_41f2716b-d419-4a90-a0fa-54d9a3d839e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_42e2b3be-dba4-4262-bd67-1874ac6f97a3" xlink:href="nktr-20201231.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_AmgenIncMember_42e2b3be-dba4-4262-bd67-1874ac6f97a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_78e0b81e-0e79-4594-aa90-2f31e84fcd0c" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_AstraZenecaAbMember_78e0b81e-0e79-4594-aa90-2f31e84fcd0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_008cf2eb-2711-449d-bc38-81c5b5b3995f" xlink:href="nktr-20201231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_OtherPartnerMember_008cf2eb-2711-449d-bc38-81c5b5b3995f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember_e1dc9023-eab4-478f-b230-6e4b26bfbb13" xlink:href="nktr-20201231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_TerminatedPartnershipMember_e1dc9023-eab4-478f-b230-6e4b26bfbb13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f73976d-52c6-423d-8db9-f0bb836f0306_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f73976d-52c6-423d-8db9-f0bb836f0306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_4cd47ef5-4a5a-4130-828b-be17ee110d9e" xlink:href="nktr-20201231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_BMSCollaborationAgreementMember_4cd47ef5-4a5a-4130-828b-be17ee110d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ClinicalTrialAgreementMember_807590bd-a3dc-481f-aacf-f2553393d566" xlink:href="nktr-20201231.xsd#nktr_ClinicalTrialAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_ClinicalTrialAgreementMember_807590bd-a3dc-481f-aacf-f2553393d566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember_04d11aaa-a571-4c34-8abc-bdb8fd9a980e" xlink:href="nktr-20201231.xsd#nktr_HemophiliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_HemophiliaMember_04d11aaa-a571-4c34-8abc-bdb8fd9a980e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_a29a2477-8f4c-4416-86a5-e381fbffd77c" xlink:href="nktr-20201231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_NektarThreeFiveEightMember_a29a2477-8f4c-4416-86a5-e381fbffd77c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_85c56b08-6caf-4e00-b22f-69f41fbe0fe6" xlink:href="nktr-20201231.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_85c56b08-6caf-4e00-b22f-69f41fbe0fe6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_9884c90c-d87c-48be-90f3-30da113217fe" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_9884c90c-d87c-48be-90f3-30da113217fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_65d14550-6d54-48cc-b5d1-1c5ae10b62ae" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_65d14550-6d54-48cc-b5d1-1c5ae10b62ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_f57959a2-2113-4484-b539-cfae849e6bc5" xlink:href="nktr-20201231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_Nektar358Member_f57959a2-2113-4484-b539-cfae849e6bc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_98b63b06-5cff-4527-a588-4e2b52334c00" xlink:href="nktr-20201231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_98b63b06-5cff-4527-a588-4e2b52334c00" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_bcfe0ccb-6e86-49da-a7e8-85a500b25d67" xlink:href="nktr-20201231.xsd#nktr_NektarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_NektarMember_bcfe0ccb-6e86-49da-a7e8-85a500b25d67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_4ea43c59-617b-4cdf-86ef-bb0add0c0279" xlink:href="nktr-20201231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_DrugProductDevelopmentMember_4ea43c59-617b-4cdf-86ef-bb0add0c0279" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_897e75c8-dcdd-4911-840b-f013b86c70a3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:to="loc_srt_ProductsAndServicesDomain_897e75c8-dcdd-4911-840b-f013b86c70a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:to="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_e4ff20c3-4702-4e02-9705-f4f727993337" xlink:href="nktr-20201231.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:to="loc_nktr_Nektar214Member_e4ff20c3-4702-4e02-9705-f4f727993337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_d0743520-eb8b-4242-a01f-fc00af1c9e3c" xlink:href="nktr-20201231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:to="loc_nktr_Nektar358Member_d0743520-eb8b-4242-a01f-fc00af1c9e3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_63ea7304-9f44-4609-bb52-39b89a6c87b6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_63ea7304-9f44-4609-bb52-39b89a6c87b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_11e18ebd-89a7-4372-8a94-04dfb5c05afb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_11e18ebd-89a7-4372-8a94-04dfb5c05afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_3758a04b-d8d8-4448-8948-f3946d67eab4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_11e18ebd-89a7-4372-8a94-04dfb5c05afb" xlink:to="loc_srt_ParentCompanyMember_3758a04b-d8d8-4448-8948-f3946d67eab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_eea6d965-064c-4d31-8ef4-a363e316092d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_eea6d965-064c-4d31-8ef4-a363e316092d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b6fda05-9216-42a4-8318-d48d17ba3e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b6fda05-9216-42a4-8318-d48d17ba3e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_78820410-de20-4734-8a8c-b88901f4adae" xlink:href="nktr-20201231.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b6fda05-9216-42a4-8318-d48d17ba3e71" xlink:to="loc_nktr_OpdivoMember_78820410-de20-4734-8a8c-b88901f4adae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd6ddd78-0068-42b1-b29b-da77a6d3a342_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:to="loc_srt_RangeMember_dd6ddd78-0068-42b1-b29b-da77a6d3a342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:to="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9bace6da-9e26-45b2-ad55-62a42739e557" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:to="loc_srt_MaximumMember_9bace6da-9e26-45b2-ad55-62a42739e557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2dfa0ba3-70fc-4abc-a9b6-ad8592ed2e0e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:to="loc_srt_MinimumMember_2dfa0ba3-70fc-4abc-a9b6-ad8592ed2e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200411da-4707-4691-813d-4af96a87d9f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200411da-4707-4691-813d-4af96a87d9f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49df09a5-29f4-447c-8009-2feba385ba65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49df09a5-29f4-447c-8009-2feba385ba65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_c66b5e03-e2fc-4cba-959b-d81acfe6be3c" xlink:href="nktr-20201231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49df09a5-29f4-447c-8009-2feba385ba65" xlink:to="loc_nktr_SharePurchaseAgreementMember_c66b5e03-e2fc-4cba-959b-d81acfe6be3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dd0d8e55-ce78-4422-ab20-9909d071e566_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dd0d8e55-ce78-4422-ab20-9909d071e566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b8c5bb00-ccfd-453b-b049-4719e2b404a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b8c5bb00-ccfd-453b-b049-4719e2b404a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09186d77-1682-4119-aa0f-5dce79ca4b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b8c5bb00-ccfd-453b-b049-4719e2b404a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09186d77-1682-4119-aa0f-5dce79ca4b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b365bdf-9721-46cf-a0ef-48d47372a233_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:to="loc_srt_SegmentGeographicalDomain_2b365bdf-9721-46cf-a0ef-48d47372a233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f71d88ef-75c8-43ee-a398-8b9030ed96a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:to="loc_srt_SegmentGeographicalDomain_f71d88ef-75c8-43ee-a398-8b9030ed96a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_e61abfa8-3363-44ee-9118-5b6afd98bf88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f71d88ef-75c8-43ee-a398-8b9030ed96a0" xlink:to="loc_us-gaap_EuropeanUnionMember_e61abfa8-3363-44ee-9118-5b6afd98bf88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_d92c178a-a5dd-478d-a049-62274ebd3877_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_d92c178a-a5dd-478d-a049-62274ebd3877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_36b96db2-90f0-46b6-9438-d495ba1ec3c6" xlink:href="nktr-20201231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_36b96db2-90f0-46b6-9438-d495ba1ec3c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_8bbb330f-573e-4b02-8b6b-f9d11ab536ba" xlink:href="nktr-20201231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:to="loc_nktr_DrugProductDevelopmentMember_8bbb330f-573e-4b02-8b6b-f9d11ab536ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember_a7330a2b-b5b9-4114-9704-2815748d48ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:to="loc_us-gaap_UpFrontPaymentArrangementMember_a7330a2b-b5b9-4114-9704-2815748d48ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a8395426-6b7e-43ce-8c33-49e34e9bc0a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_a8395426-6b7e-43ce-8c33-49e34e9bc0a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5d563508-a797-4fe8-91ec-4d17f7d6f00e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5d563508-a797-4fe8-91ec-4d17f7d6f00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_3770a699-1c3e-40f4-b79e-98d4c2c50b63" xlink:href="nktr-20201231.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5d563508-a797-4fe8-91ec-4d17f7d6f00e" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_3770a699-1c3e-40f4-b79e-98d4c2c50b63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended" id="i4d5074a00fbb44f083fc5035f196fa71_LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended" id="i7ab2d29c09d44e4d9348076211a60633_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended" id="i47e026633aef42e3abb901b91c823f8c_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i75aa56ae6898471bbd81b4ad847009c5_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b93d223-7d7b-4a59-a62b-740b003175a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1566bbd4-e3b3-457a-b8bb-ad1381241279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b93d223-7d7b-4a59-a62b-740b003175a3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1566bbd4-e3b3-457a-b8bb-ad1381241279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b93d223-7d7b-4a59-a62b-740b003175a3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7fc164bd-0d30-4ffd-a02b-fc3b930984bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7fc164bd-0d30-4ffd-a02b-fc3b930984bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d4139aa4-e0d8-4b29-ba0a-78cc16eafc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_us-gaap_CostOfSalesMember_d4139aa4-e0d8-4b29-ba0a-78cc16eafc66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a42cdfbd-4926-41e1-aad9-1d0fe2552814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a42cdfbd-4926-41e1-aad9-1d0fe2552814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c352cdcc-6a7d-459f-a499-cec495315d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c352cdcc-6a7d-459f-a499-cec495315d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_3fbd6531-b067-46fb-8d2e-f89dce64e34e" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_3fbd6531-b067-46fb-8d2e-f89dce64e34e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="id182001bc07044d8bbc7106db9293b26_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_37a5342d-c068-4df4-a009-548421d26d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_37a5342d-c068-4df4-a009-548421d26d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39cae494-9c34-4d03-ae1a-67d090d20d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39cae494-9c34-4d03-ae1a-67d090d20d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b086647-0ee9-48ea-9af1-fa8d30f8c533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b086647-0ee9-48ea-9af1-fa8d30f8c533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab326f2c-f121-4b37-8527-3e5d4d4a7cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab326f2c-f121-4b37-8527-3e5d4d4a7cb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_eca38fd6-8d53-4687-b679-4614650f8240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_eca38fd6-8d53-4687-b679-4614650f8240" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:to="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1684703-8a26-4876-8333-d257e5a3a5e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1684703-8a26-4876-8333-d257e5a3a5e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6e51e73b-5f34-429f-bfb9-0e9dbb9c6e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6e51e73b-5f34-429f-bfb9-0e9dbb9c6e4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_64d51979-5e73-43da-ba97-09ea703cfaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_64d51979-5e73-43da-ba97-09ea703cfaf2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" xlink:type="extended" id="i62f228858d45433eacec1d30d0f429d6_StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" xlink:type="extended" id="i4a3e23594b7d40f28a7fcb565436b490_StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationRestrictedStockUnitAwardActivityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail" xlink:type="extended" id="i38ce5b4f6aeb4e24b222b0c3fbce6bb7_StockBasedCompensationRestrictedStockUnitAwardActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_488f205a-592d-4f24-b26f-20d9e2f1061b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_488f205a-592d-4f24-b26f-20d9e2f1061b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2d0d7a9-868e-44e9-9059-7dd645e47079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2d0d7a9-868e-44e9-9059-7dd645e47079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5edfd8-efb7-4895-bb4f-43ff62380368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5edfd8-efb7-4895-bb4f-43ff62380368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2f1e2e6d-4bb8-41f7-b80e-04a471284619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2f1e2e6d-4bb8-41f7-b80e-04a471284619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3834bc40-cce7-457a-8932-04b5c08369a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4c3f4830-5aae-4a7f-8c8b-f818836fe4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4c3f4830-5aae-4a7f-8c8b-f818836fe4d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_322cb103-42a1-4f89-bc9f-c42362d0ca3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_322cb103-42a1-4f89-bc9f-c42362d0ca3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4659fd3-9be8-402f-8b3b-d0c883567391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4659fd3-9be8-402f-8b3b-d0c883567391" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c56975cd-da42-47e5-a02b-a7c469d8c33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c56975cd-da42-47e5-a02b-a7c469d8c33c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5fce0dc7-c1c7-4f4b-8a31-1694965583d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:to="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07e751fd-1865-4beb-9297-1596fdb25e10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07e751fd-1865-4beb-9297-1596fdb25e10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b1112b-72aa-48bc-af76-a4a75b2331d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b1112b-72aa-48bc-af76-a4a75b2331d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e00107bd-31d1-484d-94bf-6ee993b89fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b1112b-72aa-48bc-af76-a4a75b2331d0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e00107bd-31d1-484d-94bf-6ee993b89fa3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxes" xlink:type="extended" id="ie32e306038114338ada3bb72a45a6608_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="extended" id="ieda97fa8f8604563a0e8c1e5f971a377_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" xlink:type="extended" id="i1d5dc1d80dad4edeb3c5dd221c7a762d_IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail" xlink:type="extended" id="i998cf15fc6b7483894036fbd8bf1563e_IncomeTaxesProvisionforIncomeTaxesDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="i7f6dee1b592b4160b148e204aa064a1d_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f75d817f-0fa4-474f-a805-73246a65a382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f75d817f-0fa4-474f-a805-73246a65a382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c8ce82f3-589c-4197-b556-a0a09df42f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c8ce82f3-589c-4197-b556-a0a09df42f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_833c45a4-729c-4f5c-a39c-b1c077f3264c" xlink:href="nktr-20201231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_833c45a4-729c-4f5c-a39c-b1c077f3264c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3d7c68cb-8cca-4e9b-adbd-007419b97929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3d7c68cb-8cca-4e9b-adbd-007419b97929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FederalOrphanDrugCredits_ca8eccbd-9dd0-4a1e-bba0-6d0882ccfc3a" xlink:href="nktr-20201231.xsd#nktr_FederalOrphanDrugCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_FederalOrphanDrugCredits_ca8eccbd-9dd0-4a1e-bba0-6d0882ccfc3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_50f7e643-003c-45d9-9e19-b8bbca55c2f0" xlink:href="nktr-20201231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_50f7e643-003c-45d9-9e19-b8bbca55c2f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_8b5bdca4-a803-4c54-bb94-ad94ed0c6427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_8b5bdca4-a803-4c54-bb94-ad94ed0c6427" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_15fa52ed-25b2-4e34-9f1c-211716738b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_15fa52ed-25b2-4e34-9f1c-211716738b09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_35bea14a-a07a-4ccb-9aad-a6e114b3d31b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_35bea14a-a07a-4ccb-9aad-a6e114b3d31b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c53100c1-edaf-49a6-8a6f-87b2707541f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:to="loc_us-gaap_DomesticCountryMember_c53100c1-edaf-49a6-8a6f-87b2707541f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_557f266e-3fb9-463d-ace9-f4be91730986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_557f266e-3fb9-463d-ace9-f4be91730986" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" xlink:type="extended" id="i6daab0f1e13b41c9a89359d80aa37ceb_IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended" id="i07d5c2371f7545a8a233f267765fa96a_IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="extended" id="i8f00abbdc95c4d4d863a4b88424edc34_IncomeTaxesUnrecognizedTaxBenefitsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReporting" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReporting"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReporting" xlink:type="extended" id="i45e0982c9750448eadb6704b75c49dff_SegmentReporting"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingTables" xlink:type="extended" id="ic737e5fa03444ef59ca7f66058f25737_SegmentReportingTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail" xlink:type="extended" id="i611e930b520c40e1948e463896529b3f_SegmentReportingAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment_2b2ec8a4-93e7-4d87-9154-6619871e284c" xlink:href="nktr-20201231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_nktr_NumberOfOperatingBusinessSegment_2b2ec8a4-93e7-4d87-9154-6619871e284c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ed845fce-79ea-4e4b-9e68-ba74bc83a2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ed845fce-79ea-4e4b-9e68-ba74bc83a2ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a75f4933-38e5-4e8b-9486-74422a1a7a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a75f4933-38e5-4e8b-9486-74422a1a7a68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bec48313-0f2a-4cfd-a784-eed985d18593_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bec48313-0f2a-4cfd-a784-eed985d18593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a4e0d8fb-4a78-4d80-a792-04eb33436479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:to="loc_us-gaap_SalesRevenueNetMember_a4e0d8fb-4a78-4d80-a792-04eb33436479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_aaf4c3fc-3da5-49b6-8a4e-648097f1a961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_aaf4c3fc-3da5-49b6-8a4e-648097f1a961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_492ed1cb-5aee-4bd2-9919-834dd641e63a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:to="loc_srt_NameOfMajorCustomerDomain_492ed1cb-5aee-4bd2-9919-834dd641e63a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:to="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_8e7cf5b7-7b11-45ce-a3d7-ebc4444b242f" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_8e7cf5b7-7b11-45ce-a3d7-ebc4444b242f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember_fb5c0aa5-b6bb-40f8-9dbc-3ad1549f0cd8" xlink:href="nktr-20201231.xsd#nktr_UCBPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_UCBPharmaMember_fb5c0aa5-b6bb-40f8-9dbc-3ad1549f0cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_a4e33ebd-792f-4667-b039-30056208819f" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_a4e33ebd-792f-4667-b039-30056208819f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_9b20863d-d3b5-4c64-a88d-3f4dd3862185" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_AstraZenecaAbMember_9b20863d-d3b5-4c64-a88d-3f4dd3862185" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b753107a-bbd8-4b09-89c5-4e7dd3e430c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b753107a-bbd8-4b09-89c5-4e7dd3e430c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_b21c4f04-ae21-47f2-a7e9-87aa3277e089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_b21c4f04-ae21-47f2-a7e9-87aa3277e089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d4e2f92e-739c-4955-befd-bbb08eaba579_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:to="loc_srt_SegmentGeographicalDomain_d4e2f92e-739c-4955-befd-bbb08eaba579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:to="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_85a8a551-69bf-4cb1-a448-e54d339fa6f9" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:to="loc_country_US_85a8a551-69bf-4cb1-a448-e54d339fa6f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_2a38ddc1-40ae-4dc8-9676-e3f25974d2f1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:to="loc_country_IN_2a38ddc1-40ae-4dc8-9676-e3f25974d2f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended" id="i931d94f86f5d47ec82662a3a3db54c35_SegmentReportingRevenuebyGeographicAreaDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a76e9a16-e1f3-4a3d-aa6b-b1ab90e287b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_bc8d63f7-fc89-4f26-86d0-ff84c02369a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a76e9a16-e1f3-4a3d-aa6b-b1ab90e287b6" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_bc8d63f7-fc89-4f26-86d0-ff84c02369a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bc881c-a38c-4846-9664-0280883029fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_bc8d63f7-fc89-4f26-86d0-ff84c02369a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bc881c-a38c-4846-9664-0280883029fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a76e9a16-e1f3-4a3d-aa6b-b1ab90e287b6" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:to="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_03ff3822-c3a4-4767-98f6-d83485338ee3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:to="loc_srt_SegmentGeographicalDomain_03ff3822-c3a4-4767-98f6-d83485338ee3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:to="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b8d07ccf-bbae-4b87-b182-a8cdfb86976b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:to="loc_country_US_b8d07ccf-bbae-4b87-b182-a8cdfb86976b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5203bfcc-1dd7-48da-a16c-9d8c2abcbbb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:to="loc_us-gaap_NonUsMember_5203bfcc-1dd7-48da-a16c-9d8c2abcbbb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:to="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_50f81234-bb11-488d-bd17-520e40e9e108_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:to="loc_srt_ConsolidationItemsDomain_50f81234-bb11-488d-bd17-520e40e9e108_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_aa664e19-3e81-46e8-95d2-e74a99512f11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:to="loc_srt_ConsolidationItemsDomain_aa664e19-3e81-46e8-95d2-e74a99512f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_7155d7d4-db2b-4400-8913-2339ddb356d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_aa664e19-3e81-46e8-95d2-e74a99512f11" xlink:to="loc_srt_ReportableGeographicalComponentsMember_7155d7d4-db2b-4400-8913-2339ddb356d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20201231.xsd#SubsequentEvent"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended" id="idd325c5505e247c691b3d29d689b6bbf_SubsequentEvent"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended" id="i790e374320b5402ea1bd17f8592cf72d_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_7a12ef08-f9fd-415e-a7e4-22a088beb3b6" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_7a12ef08-f9fd-415e-a7e4-22a088beb3b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_a45b99c4-4b6c-4fcd-ae41-5dbe4923610f" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_a45b99c4-4b6c-4fcd-ae41-5dbe4923610f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_acf89ee1-73c2-4705-9113-9ce47b620a34" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_acf89ee1-73c2-4705-9113-9ce47b620a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_28ac5be3-6f87-45e6-b422-c5b55f29c206" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_28ac5be3-6f87-45e6-b422-c5b55f29c206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_370f2be3-2c23-496f-a920-dd0f039bc4f7" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_370f2be3-2c23-496f-a920-dd0f039bc4f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_b95f40b0-379c-4a73-ab0a-9bdf8510d8bf" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_b95f40b0-379c-4a73-ab0a-9bdf8510d8bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_15e8d010-efdc-4e6d-b464-82def5171e21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_15e8d010-efdc-4e6d-b464-82def5171e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4ae3a0eb-0ece-4af8-ad51-82f28384f1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4ae3a0eb-0ece-4af8-ad51-82f28384f1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2597e3c7-4694-4052-92d5-dc88f0ae8990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4ae3a0eb-0ece-4af8-ad51-82f28384f1d0" xlink:to="loc_us-gaap_SubsequentEventMember_2597e3c7-4694-4052-92d5-dc88f0ae8990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:to="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b09229a-c52d-4284-a94f-39be63730689_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b09229a-c52d-4284-a94f-39be63730689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc697a4-8e35-47fc-abec-f4f77821900a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc697a4-8e35-47fc-abec-f4f77821900a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_8b9fd8df-9171-43db-9bc9-9fbf01a4929a" xlink:href="nktr-20201231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc697a4-8e35-47fc-abec-f4f77821900a" xlink:to="loc_nktr_SFJPharmaceuticalsMember_8b9fd8df-9171-43db-9bc9-9fbf01a4929a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialData"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="extended" id="ic9a354c55259444184e42a9e3971a9a3_SelectedQuarterlyFinancialData"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialDataTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended" id="i65ebeafcc1384e9abe8c6f06685de689_SelectedQuarterlyFinancialDataTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialDataDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail" xlink:type="extended" id="icc8f0f65ac474274a7d7283c8f052599_SelectedQuarterlyFinancialDataDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:href="nktr-20201231.xsd#nktr_SelectedQuarterlyFinancialDataLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6bd2162-7e54-4349-b38c-1a8db59d393a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6bd2162-7e54-4349-b38c-1a8db59d393a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ed7b9254-8c27-4f62-94ab-989be4e76384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ed7b9254-8c27-4f62-94ab-989be4e76384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8afeea91-f777-42be-80f9-fac8ebea9370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8afeea91-f777-42be-80f9-fac8ebea9370" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9301489-7848-4c1d-b1e9-895db6e6282a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9301489-7848-4c1d-b1e9-895db6e6282a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f13c7f5-ddaa-4d7f-bdbb-07e8e3131619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_NetIncomeLoss_5f13c7f5-ddaa-4d7f-bdbb-07e8e3131619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_abe54a6d-b5b8-4e20-88b1-4f6e1e5b56c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:to="loc_us-gaap_EarningsPerShareBasic_abe54a6d-b5b8-4e20-88b1-4f6e1e5b56c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6d34b0df-af89-4e9b-9796-4065f7c5b041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6d34b0df-af89-4e9b-9796-4065f7c5b041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:href="nktr-20201231.xsd#nktr_SelectedQuarterlyFinancialDataTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:to="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00859e46-38f4-45c6-add0-d00a502b1e45_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:to="loc_srt_ProductsAndServicesDomain_00859e46-38f4-45c6-add0-d00a502b1e45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_645305f0-3cc2-4fc5-acff-0d46fa48ba6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:to="loc_srt_ProductsAndServicesDomain_645305f0-3cc2-4fc5-acff-0d46fa48ba6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a2437228-97f9-4b35-a9a2-93943180a050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_645305f0-3cc2-4fc5-acff-0d46fa48ba6b" xlink:to="loc_us-gaap_ProductMember_a2437228-97f9-4b35-a9a2-93943180a050" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nktr-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b34aba47-bd43-4f7a-949b-84c5bc7946a0,g:a0d0df82-7542-4b00-8e8b-b5cca2744d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_cd5aaece-b88f-4705-b81c-ac85d59acf4d_terseLabel_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Related Claims</link:label>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Related Claims [Member]</link:label>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember" xlink:href="nktr-20201231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SecuritiesRelatedClaimsMember" xlink:to="lab_nktr_SecuritiesRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_57f4710e-730d-45f0-9d7a-83c282a13fce_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_30a0b0f6-d847-49de-9430-ead1e8e50afd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_ec8cca8f-db7f-4dc8-82c1-5b25e2018ce0_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8288084e-dbf6-48dd-a393-20a798967d4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bed8e8e8-250a-4724-9f4f-25f1c595883e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bfe56678-ff37-40c3-bb6d-b8ca597c6dd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9428314c-367e-455a-8432-f2cf53561c4b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2edab017-513e-429a-96a1-eeb647319090_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested and released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MissionBayLeaseMember_221c0e6f-5384-4734-9f31-18215544d6e1_terseLabel_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission Bay Lease</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_label_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission Bay Lease [Member]</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_documentation_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission bay lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember" xlink:href="nktr-20201231.xsd#nktr_MissionBayLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MissionBayLeaseMember" xlink:to="lab_nktr_MissionBayLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_58fef3f6-c57c-49af-bf57-e76f16042b1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for award grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarMember_cd659972-17a8-4c4c-bf47-6e733bedb218_terseLabel_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar</link:label>
    <link:label id="lab_nktr_NektarMember_label_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:label id="lab_nktr_NektarMember_documentation_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember" xlink:href="nktr-20201231.xsd#nktr_NektarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarMember" xlink:to="lab_nktr_NektarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_7e404bd9-154e-4e9b-ad9e-60f784c85e41_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_d1c53407-8c3e-4ffa-a69a-95388ec1e836_terseLabel_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_label_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing Expense Current</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:href="nktr-20201231.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:to="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_32f6c60e-9366-4502-8a29-dc768bea5e1c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee08f11-a247-423e-af5d-c96a95943114_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0572c709-c852-43c7-81ab-1c99d32098a7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmgenIncMember_26d6a9f8-a24c-4373-8fcb-664cae48bc12_terseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_5b20bf8d-ca69-4e67-b09a-5a3d21890b1b_verboseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_label_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc [Member]</link:label>
    <link:label id="lab_nktr_AmgenIncMember_documentation_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember" xlink:href="nktr-20201231.xsd#nktr_AmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmgenIncMember" xlink:to="lab_nktr_AmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e225393e-1e0f-4b4d-b345-501e9a5fc1f5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_445f089e-3805-4e3e-b000-b482021d0112_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3b9605c7-ef2c-4d4d-904d-6a59a060fd81_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_74147327-e622-4bf2-bef0-25c9d8ef536f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Deferred Revenue Balance from Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_b8ad69cc-65c4-407f-8b60-42cc6fc6b6df_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional indication payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Indication Payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Indication Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:to="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6bce132b-264c-463a-b118-f085865757a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64567769-04d5-4022-aa79-13537f025b35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_0f23d549-81af-45a7-be79-a03972d3873c_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20201231.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fc194f4c-e20c-41d6-a46e-b8ee2484ec2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ab3ec496-faae-4b0c-8970-3b396bbcc339_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum 401(k) per employee, percentage of annual salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_495e7661-757d-4dd1-b3b9-3dddf59429f6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1b8cec1b-361c-49fe-985a-229315a6d60d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9050de59-b015-4759-abea-b10d859a35a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9c485ee7-6570-4395-87ff-ca61ef9437ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_e3333665-8f2f-4590-b292-7909e5da78a3_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UCBPharmaMember_89d02ba4-ee0d-4488-b4c4-857895af8813_terseLabel_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:label id="lab_nktr_UCBPharmaMember_label_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U C B Pharma [Member]</link:label>
    <link:label id="lab_nktr_UCBPharmaMember_documentation_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember" xlink:href="nktr-20201231.xsd#nktr_UCBPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UCBPharmaMember" xlink:to="lab_nktr_UCBPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_902e0038-30d9-4b87-84e0-3ed867dadce6_terseLabel_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember" xlink:href="nktr-20201231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeStockPurchasePlanMember" xlink:to="lab_nktr_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_cabe9706-9fb1-452a-b550-94ac4481843a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures, and other</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2bdb627b-0bed-45dd-858c-56432e616e83_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b2a20696-78e4-4c3f-a230-83cff123b9f6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_90f4ed38-d376-4f8a-a07f-88acce6e65b9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ad905385-b0a1-4a18-bac6-273565c000c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_cb8e06c7-dd5f-41a3-bccc-082b0758b5c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_42ecd918-510e-46e1-8bb1-31fd7f20ed08_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock_d55a8f80-e5bd-4532-af41-a31094ab098a_terseLabel_en-US" xlink:label="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Shipping And Handling Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer shipping and handling costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:href="nktr-20201231.xsd#nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:to="lab_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_473b3735-e244-4c33-9f2f-6661f0015acb_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20201231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d364a16d-fe96-4cc0-90a7-b35ace14832d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a6cb376f-e8d8-4ce2-93d2-681609036d8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_999fcfb0-83c6-4e1e-9f4b-c6c77b82d56f_terseLabel_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_label_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_documentation_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:href="nktr-20201231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:to="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_a043c386-3c66-47ef-a019-43a617217a50_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20201231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_99dbf29b-8bc3-48e9-b8d7-4114ccc41adb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc74b830-8d0a-4711-93c6-667b43a92e4c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_399bbb82-5898-4333-be95-232aa3bcf818_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_3fb599ee-73f4-4db6-8019-24a15fa2bd6f_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4fb1ebec-cae3-4354-8082-dcdda92ebadc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5a556b72-8f5b-463a-9fdb-2f8a5e2a1160_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8a32282e-7882-435f-8af2-ed5b540a5854_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_63e1004a-d13f-4b9b-af96-4360f64d58de_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e4f86ce3-e4e9-4f8d-a87a-51e7e09749be_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_e8a56358-9841-452d-b568-2d33d73cee58_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_caa07c10-1ac5-4a22-8a03-3692b410174c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2020 or 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_6072c2c9-e587-4558-b552-b2618c942969_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset, reclassified to receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Reclassified to Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:to="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartnerOneMember_74d73259-06f2-4bab-b81b-1eeb3453829a_terseLabel_en-US" xlink:label="lab_nktr_PartnerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner One</link:label>
    <link:label id="lab_nktr_PartnerOneMember_label_en-US" xlink:label="lab_nktr_PartnerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner One [Member]</link:label>
    <link:label id="lab_nktr_PartnerOneMember_documentation_en-US" xlink:label="lab_nktr_PartnerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerOneMember" xlink:href="nktr-20201231.xsd#nktr_PartnerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartnerOneMember" xlink:to="lab_nktr_PartnerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b1d7a8c1-e126-4598-b796-48142559fa89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_5a4d4ffb-b920-4d1f-9b24-c8c445cf62be_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_663569b3-7b90-44c3-b005-28fac91bfccd_terseLabel_en-US" xlink:label="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate for royalties resulting from net sales</link:label>
    <link:label id="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_label_en-US" xlink:label="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Estimate for Royalties Resulting from Net Sales</link:label>
    <link:label id="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_documentation_en-US" xlink:label="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Estimate for Royalties Resulting from Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" xlink:href="nktr-20201231.xsd#nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" xlink:to="lab_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_6cf13030-f843-4070-88dc-6d7257634e35_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f0474cd3-b5bc-4900-8874-4f6c02d94a2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f6b779db-6546-4661-ad6b-5a2802733e95_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_282552c7-a477-4b8f-96b6-53e0727b2cf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_37308e07-f735-420a-9b93-f7cb8911b02c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_c0fe2550-87d4-49c8-a09b-52e39b9cf0c6_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_1ca5fedd-c92f-49f6-b265-03206916a87b_negatedLabel_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized transaction costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_label_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_documentation_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities on sale of future royalties, unamortized transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:href="nktr-20201231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:to="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_d01d054b-fd73-480e-be20-82a2e1ef3bd5_terseLabel_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B M S Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember" xlink:href="nktr-20201231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BMSCollaborationAgreementMember" xlink:to="lab_nktr_BMSCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_d690bd7b-5967-40c4-bcae-0cf8a99503fa_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_label_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_documentation_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxesDisclosureTable" xlink:to="lab_nktr_IncomeTaxesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0c6eca6c-4777-43c0-84c2-e91b52170d37_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_8a61d509-3ccf-4a09-9196-e1c7a400b4e7_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20201231.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bcc49571-ddea-4ee8-9366-ab44d026ce03_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47c2c264-1aef-4c7a-a2c0-99b737714607_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_b3a71a87-26fb-4338-969b-fd093446028b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_bdc8bc76-b7bf-489a-87c1-8a86fdcd031a_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_a496a423-7341-41a5-9c93-c3a70166f303_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_60d9763f-b04f-4552-903f-ecec7de91fb1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_eed43f87-a516-40d9-aa25-9f5355699672_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e277d4cc-ec9c-4085-9380-bd1a1f637a4d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1fcd59c-2d97-4b15-9199-8287c209eec7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from contracts with customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_75632c31-7109-4116-b30e-4b2d16755e32_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage revenue from customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_c11855ef-a628-41c4-bf8d-020da671802b_terseLabel_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75% Senior Secured Notes Due October 2020</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_label_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_documentation_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven point seven five percent senior secured notes due October two thousand and twenty.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:href="nktr-20201231.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:to="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_41f50ea5-0801-4a83-9838-7b54767bf9cd_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc41fa9c-088d-4e01-8d57-3afc3b54346f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options term under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SecuredNotesTable_c543cf01-f8e9-4551-b3ac-32faf5eb5422_terseLabel_en-US" xlink:label="lab_nktr_SecuredNotesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Notes [Table]</link:label>
    <link:label id="lab_nktr_SecuredNotesTable_label_en-US" xlink:label="lab_nktr_SecuredNotesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Notes [Table]</link:label>
    <link:label id="lab_nktr_SecuredNotesTable_documentation_en-US" xlink:label="lab_nktr_SecuredNotesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuredNotesTable" xlink:href="nktr-20201231.xsd#nktr_SecuredNotesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SecuredNotesTable" xlink:to="lab_nktr_SecuredNotesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_37fb1242-fb59-4202-a0f6-23237923ffec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_65d6fa61-fe70-45b7-aa84-69495cffc227_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FederalOrphanDrugCredits_67376e10-86d9-4c58-ba74-19ba5e7ff41e_terseLabel_en-US" xlink:label="lab_nktr_FederalOrphanDrugCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal orphan drug credits</link:label>
    <link:label id="lab_nktr_FederalOrphanDrugCredits_label_en-US" xlink:label="lab_nktr_FederalOrphanDrugCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Orphan Drug Credits</link:label>
    <link:label id="lab_nktr_FederalOrphanDrugCredits_documentation_en-US" xlink:label="lab_nktr_FederalOrphanDrugCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal orphan drug credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FederalOrphanDrugCredits" xlink:href="nktr-20201231.xsd#nktr_FederalOrphanDrugCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FederalOrphanDrugCredits" xlink:to="lab_nktr_FederalOrphanDrugCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f0105fb-f972-401d-9c2b-94d18b04eb94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ed6e8f4f-310e-422a-9568-4b653d8cc7ce_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_c24ebc57-ec9b-4377-a890-6eb8e05beced_terseLabel_en-US" xlink:label="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net sales to fund external costs incurred cap</link:label>
    <link:label id="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_label_en-US" xlink:label="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Net Sales to Fund External Costs Incurred Cap</link:label>
    <link:label id="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_documentation_en-US" xlink:label="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Net Sales to Fund External Costs Incurred Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" xlink:href="nktr-20201231.xsd#nktr_AmountOfNetSalesToFundExternalCostsIncurredCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" xlink:to="lab_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_06fdf024-ab85-401a-b798-933f178d4274_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_64d57264-560c-4f88-a96a-b4181ad2213a_negatedLabel_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on equity issuance</link:label>
    <link:label id="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_label_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Premium On Equity Issuance</link:label>
    <link:label id="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_documentation_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation premium on equity issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationPremiumOnEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" xlink:to="lab_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_ad9b8b80-83da-4170-81d5-5dad73e56c4a_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20201231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AreaOfLeasedSpaceDelivered_03e266b3-1e9d-4c90-9438-fa40f479f6e9_terseLabel_en-US" xlink:label="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased space delivered (in sq ft)</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpaceDelivered_label_en-US" xlink:label="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Leased Space Delivered</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpaceDelivered_documentation_en-US" xlink:label="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased space delivered.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpaceDelivered" xlink:href="nktr-20201231.xsd#nktr_AreaOfLeasedSpaceDelivered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AreaOfLeasedSpaceDelivered" xlink:to="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_76fb278c-a4b6-4da4-a310-824d218a9ec2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UpFrontPaymentArrangementMember_645f681b-d358-4f3b-a0bf-57ba21e8450b_terseLabel_en-US" xlink:label="lab_us-gaap_UpFrontPaymentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_UpFrontPaymentArrangementMember_label_en-US" xlink:label="lab_us-gaap_UpFrontPaymentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UpFrontPaymentArrangementMember" xlink:to="lab_us-gaap_UpFrontPaymentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_f7a38de5-db5b-4d8b-9ec3-6aa2206de2fe_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartnerThreeMember_a2e27623-2a19-43ff-9b12-216ae3333b40_terseLabel_en-US" xlink:label="lab_nktr_PartnerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Three</link:label>
    <link:label id="lab_nktr_PartnerThreeMember_label_en-US" xlink:label="lab_nktr_PartnerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Three [Member]</link:label>
    <link:label id="lab_nktr_PartnerThreeMember_documentation_en-US" xlink:label="lab_nktr_PartnerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerThreeMember" xlink:href="nktr-20201231.xsd#nktr_PartnerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartnerThreeMember" xlink:to="lab_nktr_PartnerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_8a46db63-3369-4822-9e57-7f839692efe7_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_67adc42c-bbdc-4554-b21d-484c525757d5_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1dc0663c-754c-44a5-93cb-21aa5c148af2_verboseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_d97d55f7-6f8c-41e7-b3d0-3c327094c5e8_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fd5ce989-27ae-4e9f-a2a7-212b08e5db9f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b1be075f-34fd-4e8d-a453-387400cd18c8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_8c3afb90-c1da-40f1-ae8a-ebde147f612d_terseLabel_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net expense reimbursements from collaboration partner</link:label>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_label_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Expense Reimbursements From Collaboration Partner</link:label>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_documentation_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net expense reimbursements from collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:href="nktr-20201231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:to="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_4ca7bb54-40a7-4cc9-bd0e-1f301fa94018_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales to fund external costs incurred, due to reduction of 2 percentage points</link:label>
    <link:label id="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_label_en-US" xlink:label="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Net Sales To Fund External Costs Incurred, Due To Reduction Of 2 Percentage Points</link:label>
    <link:label id="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_documentation_en-US" xlink:label="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Net Sales To Fund External Costs Incurred, Due To Reduction Of 2 Percentage Points</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" xlink:href="nktr-20201231.xsd#nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" xlink:to="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4de7fd69-897d-4491-b381-509d156df95d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1df52f46-3dcb-4984-97a2-59570e3da8b0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_b6083f21-fef7-4058-8364-b561253ace6a_terseLabel_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Development</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_label_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase One Clinical Development [Member]</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:href="nktr-20201231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:to="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_e01a97af-3e2d-49de-b660-8c7cd938a78d_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_cc98e146-c85c-49fe-b862-35a81f3b5f84_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Expense Share Based Compensation Cost</link:label>
    <link:label id="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_documentation_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation expense share based compensation cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" xlink:to="lab_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_ff33a39b-5416-4369-93cb-d106e682c3bb_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_35d09ff8-61d4-40c3-bab0-6458ca7aa91a_totalLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_a69e0fbe-f40f-400b-84b6-a1f78b51058b_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20201231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3aa1e6ef-3ba3-43c9-a550-8b4f64d35900_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_c80cc65c-3fae-4551-aa80-c00ca38bfd5a_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" xlink:to="lab_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_5f66f613-3794-432e-8ae9-ec0cdfe5d1ad_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future development, regulatory and sales milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Regulatory And Sales Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development regulatory and sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:to="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_32bf9ffb-7dff-47fa-8878-49289f0ad0da_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Principles of Consolidation and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_b5fb1410-3dea-43e1-bee6-7ad89fe55eac_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_538f39de-9ff4-4d93-aa4f-51735ca1fd0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_74e06f07-ca68-4881-867d-e0f13b865323_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:href="nktr-20201231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_dcf7bdaf-86b6-48f4-b159-bc55f6bcd2c8_terseLabel_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment</link:label>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_label_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Business Segment</link:label>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_documentation_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment" xlink:href="nktr-20201231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfOperatingBusinessSegment" xlink:to="lab_nktr_NumberOfOperatingBusinessSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_773e7c19-d76b-4dbc-a9a0-c9227ddc5651_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5b8cf27a-e766-4f08-b5c1-b839ca3c75de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_7f6d3fa3-6702-47cc-901f-d53451435b73_terseLabel_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received under right to sublicense agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_label_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Received Under Rights To Sublicense Agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_documentation_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received under rights to sublicense agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:href="nktr-20201231.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:to="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_aa620dfd-c03e-476e-9368-5de052d85620_terseLabel_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting unit evaluated for goodwill</link:label>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_label_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units To Evaluate Goodwill For Impairment</link:label>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_documentation_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units to evaluate goodwill for impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:href="nktr-20201231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:to="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2b299009-9f82-4087-9e76-37358d666b61_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_b93421d4-029d-4991-b9a2-d07123b4e4bb_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_9c63ddf4-8a88-49cf-977d-6c8d683299e6_negatedTerseLabel_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to RPI</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_label_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_documentation_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial repayment of royalty sale proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:href="nktr-20201231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:to="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_eaaef49a-bdea-4ffb-83a1-94ea97935e90_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_07876639-d29f-497c-8bf0-9dbd03ed15ae_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_589125f3-e188-44ba-a955-3654f855e24c_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related to the Sales of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_WriteOffOfPrepayment_17f4c824-2bc4-42b2-8f86-1a73b5a32c81_terseLabel_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_label_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_documentation_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment" xlink:href="nktr-20201231.xsd#nktr_WriteOffOfPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_WriteOffOfPrepayment" xlink:to="lab_nktr_WriteOffOfPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_18a09da9-83e5-44d5-a3e1-e8ce01ac966a_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Policy Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20201231.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_70cb93c6-6bd2-4301-b1d8-3a42eaac427b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_58120977-a9ac-4d6a-b892-869d9597290f_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement with RPI</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase And Sale Agreement [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and sale agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreementMember" xlink:to="lab_nktr_PurchaseAndSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_db8bd2a4-e229-4014-bf9f-8fd8ab652d8e_terseLabel_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember" xlink:href="nktr-20201231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LaboratoryEquipmentMember" xlink:to="lab_nktr_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f7ec9add-a638-4093-a06d-97a503960282_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_bd43fc49-2a45-4c03-87a4-d8c811c8453b_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Assets And Other Costs For Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equipment and other costs for terminated program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4a50262d-32bd-4e1f-ac7c-a97c8cfe13b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares available for stock options grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ff81a891-55f9-44c5-8739-979485298ff6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_358cf5e3-0676-40e1-9e67-032962ecdcfa_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments related to contract manufacturing, clinical development and certain other items</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAbMember_20326ced-f99d-45c8-8ab7-ffaa70620707_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAbMember" xlink:to="lab_nktr_AstraZenecaAbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_92ea395d-2aed-4ba4-89a3-7ccbfab73985_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3ddb8098-f199-43d6-90d1-b5395fbc52e6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_de3938cf-617a-4d1f-a98d-12d76ad5a91f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DevelopmentCostsExceeded_79f2dce8-083e-4227-abae-86f6ea882404_terseLabel_en-US" xlink:label="lab_nktr_DevelopmentCostsExceeded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs exceeded</link:label>
    <link:label id="lab_nktr_DevelopmentCostsExceeded_label_en-US" xlink:label="lab_nktr_DevelopmentCostsExceeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Costs Exceeded</link:label>
    <link:label id="lab_nktr_DevelopmentCostsExceeded_documentation_en-US" xlink:label="lab_nktr_DevelopmentCostsExceeded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Costs Exceeded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentCostsExceeded" xlink:href="nktr-20201231.xsd#nktr_DevelopmentCostsExceeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DevelopmentCostsExceeded" xlink:to="lab_nktr_DevelopmentCostsExceeded" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_79a5ebb0-b478-40e5-a67a-2ab24563fdf3_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20201231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_97e4741a-9083-4ea8-8a54-37660289a0ca_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_6cfa4159-a894-4a97-8b95-5d5d12422831_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_356ca350-073b-42ef-b332-046cfe11bb56_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20201231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3101825c-a7da-49e3-87b3-893254518501_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f3fda85e-0de2-4233-b24b-974cebfed66f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ecda4114-9246-4b44-9bcf-19f9b36dfaf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_f2f5b76c-14a8-479c-8294-23e35f3e931a_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d6e8f8cc-24f8-46ca-a8d2-790eef7e6914_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_f41fd626-0e3d-4fec-9556-4005322bc037_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca-Kirin</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Agreement With Kirin [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca agreement with Kirin.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAgreementWithKirinMember" xlink:to="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_5fba12c0-b11c-4fe2-b080-0f1c6807f293_terseLabel_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_label_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Allocated To Transaction Price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_documentation_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:href="nktr-20201231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:to="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b58ad6f3-c01f-4bb4-acf2-135c9ba862b9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5ab9dc47-980d-4953-a809-72d921e4c575_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5f90deae-8c30-4091-bd4e-ab0729cbeb45_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d61e9f3-fcbb-44fd-b620-8cb65d012dc2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_57913995-3267-4411-8574-acd4f5cc1943_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_896deb04-f70e-4483-92f4-08fc0fe62aa0_terseLabel_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_label_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities And Stockholders Equity Deficit [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_documentation_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stock holders equity (deficit) abstract..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:href="nktr-20201231.xsd#nktr_LiabilitiesAndStockholdersEquityDeficitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:to="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e3555112-a026-4fc2-8968-fa3ecff11bc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a84302dd-8686-45b2-b376-c7839fb5f096_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_895d267e-8ab1-40f2-9d96-6d857c167edf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_305ebf9d-b1e8-4eee-bc7e-96d218ead9bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1f820e13-6587-46ac-8eef-2c032f6d734c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_66c970b1-bc06-4817-88c4-6a6259e85d39_terseLabel_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations under Director and Officer Indemnifications per incident</link:label>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_label_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations Under Director And Officer Indemnifications Per Incident</link:label>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_documentation_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations under director and officer indemnifications per incident.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:href="nktr-20201231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:to="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_3970821c-4554-4446-b543-cae5bef574cd_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales to fund external costs incurred</link:label>
    <link:label id="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_label_en-US" xlink:label="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Sales to Fund External Costs Incurred</link:label>
    <link:label id="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_documentation_en-US" xlink:label="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Sales to Fund External Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurred" xlink:href="nktr-20201231.xsd#nktr_PercentageOfNetSalesToFundExternalCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurred" xlink:to="lab_nktr_PercentageOfNetSalesToFundExternalCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9056b70d-58b2-4acc-b749-42ee39713d3d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_b961d6f8-3cc8-49bd-a55c-6d4175e4271d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_adcd9312-ed1c-4c3e-b5be-f4342b85f9db_terseLabel_en-US" xlink:label="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia, Including ADYNOVATE and ADYNOVITM</link:label>
    <link:label id="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_label_en-US" xlink:label="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia Including A D Y N O V A T E And A D Y N O V I [Member]</link:label>
    <link:label id="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_documentation_en-US" xlink:label="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia including ADYNOVATE and ADYNOVI.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" xlink:href="nktr-20201231.xsd#nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" xlink:to="lab_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_61067105-3565-4ceb-8ef9-c32323d09c52_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_32a88103-0ceb-4e0a-a705-51efd93de2aa_terseLabel_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_label_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Furniture And Other [Member]</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture computer and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember" xlink:href="nktr-20201231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ComputerFurnitureAndOtherMember" xlink:to="lab_nktr_ComputerFurnitureAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_bbc461c9-5215-491a-9c00-3ef2542f7c83_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_238aac9f-5340-4b81-bceb-2fa18f404285_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2666c162-84a7-48ba-b764-69a9c0823ec0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_2d4f27cb-654c-4e31-8443-456b04ae5fc2_terseLabel_en-US" xlink:label="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incometax Reconciliation Income Tax Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation income tax sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" xlink:href="nktr-20201231.xsd#nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" xlink:to="lab_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_581b33ea-22f9-49d3-a474-0f8ef8c4bcee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_71c7c963-4742-479b-8a7b-4bf77548d747_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap_f731f442-e846-4bf5-a6e2-45febbf4e9bc_terseLabel_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company share of development costs, annual cap</link:label>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap_label_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Share Of Development Costs, Annual Cap</link:label>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap_documentation_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Share Of Development Costs, Annual Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:href="nktr-20201231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:to="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_591a15f1-8a36-479e-b1a7-c1d2f3b7d149_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c11ba597-b07e-460c-8803-0295e503d884_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_22349f76-1ed3-468b-a78c-ff71cd0c9a42_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_aee47492-dda2-42e7-9430-15cdde213e24_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to Bristol-Myers Squibb (Note 10)</link:label>
    <link:label id="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_448b0419-128b-4e30-b0b7-62debf315523_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock to Bristol-Myers Squibb (Note 10)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d50b9f60-651a-495c-a232-c189eee5dc3a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_21bfedc9-fba0-4ce4-a098-e5a05d62cd13_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_label_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLeasesTable" xlink:to="lab_nktr_ScheduleOfLeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2a702af9-c345-4db8-8524-82bd7c484c70_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units Issued, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d4deacf-485a-4caa-af25-13ca34f06616_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units Issued, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_c30699cd-06c9-4464-9597-81815c55e6cf_terseLabel_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of future royalties transaction costs</link:label>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_label_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Royalties Transaction Costs</link:label>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_documentation_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Royalties Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:href="nktr-20201231.xsd#nktr_SaleOfFutureRoyaltiesTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:to="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_61c3ca2c-d9d3-426e-b43c-745ba0f944e6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_fec0c997-5adb-4713-b9ee-1817f9eaee5f_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LegalMattersMember_9f1b399b-2afa-42c6-b803-99f5020f7d79_terseLabel_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_nktr_LegalMattersMember_label_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Member]</link:label>
    <link:label id="lab_nktr_LegalMattersMember_documentation_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember" xlink:href="nktr-20201231.xsd#nktr_LegalMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LegalMattersMember" xlink:to="lab_nktr_LegalMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NetOperatingLossCarryforwardForIncomeTax_46f8bb79-72c4-48f7-8106-7e6bc4d0896e_terseLabel_en-US" xlink:label="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward for income tax</link:label>
    <link:label id="lab_nktr_NetOperatingLossCarryforwardForIncomeTax_label_en-US" xlink:label="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward For Income Tax</link:label>
    <link:label id="lab_nktr_NetOperatingLossCarryforwardForIncomeTax_documentation_en-US" xlink:label="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward for income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:href="nktr-20201231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:to="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_353a209e-0ffb-43e8-af79-0e7ed5d712f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1762c89e-3119-4267-aaf0-49a3912581fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_HemophiliaMember_a648b758-33c7-4082-99d4-4416d0b70d4f_terseLabel_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia</link:label>
    <link:label id="lab_nktr_HemophiliaMember_label_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia [Member]</link:label>
    <link:label id="lab_nktr_HemophiliaMember_documentation_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember" xlink:href="nktr-20201231.xsd#nktr_HemophiliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_HemophiliaMember" xlink:to="lab_nktr_HemophiliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_43fb7e96-772e-48ab-9d5e-6ec5f440bb6c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_3a79a9f1-beb1-46ee-9ad2-3432ef29476c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f9a8aa58-9b73-4afe-9835-5ad07283237f_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c02c2e03-6555-4061-b4f5-1de6e819e4b5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_a1327eb9-fcac-4cad-9af2-cd8987f4dcbb_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestones, royalties and sales milestones</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:href="nktr-20201231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b225240c-43e0-4313-8720-975bda8025e1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fba680ae-b6e8-4903-b76f-f575caeb942b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_a40556fe-c025-4446-851a-57d11e9a0a66_terseLabel_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_label_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Transaction Price Allocated To Performance Obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_documentation_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:href="nktr-20201231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:to="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ba3abf5b-ddbe-4eb1-afd1-7c4b6e18e846_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_42845899-cd13-4f9d-8a29-274059713672_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ba79defc-21e9-421b-85fc-7e38b298ab8e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfPurchasePriceOfStock_4628aad1-11b3-4b48-bf07-52874d81fe7b_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfPurchasePriceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price of stock</link:label>
    <link:label id="lab_nktr_PercentageOfPurchasePriceOfStock_label_en-US" xlink:label="lab_nktr_PercentageOfPurchasePriceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Purchase Price Of Stock</link:label>
    <link:label id="lab_nktr_PercentageOfPurchasePriceOfStock_documentation_en-US" xlink:label="lab_nktr_PercentageOfPurchasePriceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfPurchasePriceOfStock" xlink:href="nktr-20201231.xsd#nktr_PercentageOfPurchasePriceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfPurchasePriceOfStock" xlink:to="lab_nktr_PercentageOfPurchasePriceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_11f8f88c-b923-4251-abad-d09661af5275_verboseLabel_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units</link:label>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:href="nktr-20201231.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_04417ef2-e21e-47d9-b058-75acec1b5e20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized over a weighted-average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_6ba03ed3-ef8c-4992-a4aa-79f39afcb08e_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_643d4c26-4a58-4830-bfe1-89f36400f96a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: portion representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_5bf81e3d-4a5d-4498-9f5b-a37e621c13f9_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Liability Related to Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b8ac0207-5279-4f31-b075-4b79733fc0b9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones received</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d60cc2b5-dfb0-47e9-b1c4-52d14b216628_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of previously unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b8f22cd-bc91-4d94-ad8b-eabb004b5aa2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_50cf0d5b-da98-4c34-8c1c-8e55d2802352_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a9a75fd2-0961-41e7-8020-e5e1f92361cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_d172130b-fcbd-47f8-b0ba-d8ab7b0036f6_terseLabel_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Significant Supplier Concentrations</link:label>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_label_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory And Significant Supplier Concentrations [Policy Text Block]</link:label>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and significant supplier concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:href="nktr-20201231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:to="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3788bf33-bd02-4ddd-8127-5980ffe32245_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c37ba2fa-0ae8-4d88-9e7d-0ae3dc90e5bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_24cce4de-9244-4e60-8fe5-a0bc1edb8529_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement if threshold is not achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:href="nktr-20201231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0fa7f234-5227-4ab9-a8b8-064f7236b6dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_951cf8ad-8721-4cc3-b25c-d048492ed9ec_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_68328272-af81-4d3c-a65c-6097b9354656_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20201231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cbdd704b-4bd7-4592-9dd1-a5a438a47adf_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, increase (decrease) amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_048c6dd8-c327-4ec5-98ff-30f92b3b4bb8_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_68ceb368-7f15-455c-9290-d0ed8d8b3e01_terseLabel_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:href="nktr-20201231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_90126011-2a1d-4829-8bbc-65bf9d856a54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ad90c8ae-bfc5-4fd2-ab10-912f241a124a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_698c3ae7-7bb8-4a7d-a3ad-ba0cd2339d93_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ec069a7b-f97a-4d02-9a69-39fa00b91a89_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_304c0543-573d-4b5f-a452-53122878bd9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ea1d492e-d29f-46ed-84da-cf60f660ef1a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_e792b4f2-c5df-4222-8072-d3aa340b10bc_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c338861f-a5d5-4d42-9e6f-888ace77ffc6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_5b8df1ce-4ca0-48fc-9c99-75b8e3f78ddb_terseLabel_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_label_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_documentation_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares" xlink:href="nktr-20201231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedFairValueOfShares" xlink:to="lab_nktr_EstimatedFairValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_2f0c0e34-4637-4b65-9b6b-c90f56678341_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_478b56a4-6d2a-4063-8ea2-d47b4814612a_terseLabel_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Performance Incentive Plan</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_label_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen performance incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:href="nktr-20201231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:to="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3a3c89bf-d616-430e-8002-9222423a3554_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_614e3de1-e057-4e9b-8d39-29b4460d5854_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_77d6a02f-ec53-48c7-a96d-3877a6cd74a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_b2b06016-a84b-4b12-993b-63f29b3b9e9f_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:to="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_48ca8644-fd70-4e29-9283-2ddd10c8dfa1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_a1494fca-a565-4ca2-902d-491a843bfa86_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsLeaseLiability" xlink:to="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a48114b-c431-45dc-9158-67e88cd16a2b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea41c821-23f5-483e-a8bc-681d24cb0bc9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_21f0809d-216d-48d2-b2c9-13ace7859096_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program [Policy Text Block]</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1fc13178-5e8d-4a1a-ad85-81ea3ffc2e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4ecc3229-8c3a-4225-af9e-55557fef7c11_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_a7d8b83e-ae58-4650-8af1-aa04103f2081_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Three Five Eight [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar three five eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember" xlink:href="nktr-20201231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightMember" xlink:to="lab_nktr_NektarThreeFiveEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_6e84c505-306e-4a09-a855-f400c984e37a_terseLabel_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal and interest repaid on senior notes</link:label>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_label_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Including Interest</link:label>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_documentation_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:href="nktr-20201231.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:to="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_38976a93-4202-4cf0-9818-bfee36080615_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_2a4aed2b-36d4-4497-9e8b-9a3e3be2d750_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CommercialAgreementsMember_f32786ef-0f08-409e-8b79-59d68ffe6896_terseLabel_en-US" xlink:label="lab_nktr_CommercialAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Agreements</link:label>
    <link:label id="lab_nktr_CommercialAgreementsMember_label_en-US" xlink:label="lab_nktr_CommercialAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Agreements [Member]</link:label>
    <link:label id="lab_nktr_CommercialAgreementsMember_documentation_en-US" xlink:label="lab_nktr_CommercialAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommercialAgreementsMember" xlink:href="nktr-20201231.xsd#nktr_CommercialAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CommercialAgreementsMember" xlink:to="lab_nktr_CommercialAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f390862e-3174-420a-ae61-a7df7b444369_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share, outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca11352b-91c1-4048-a55f-d6db11281638_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share, outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_00ac5cfb-032b-4279-aa1f-5c302f1c46a2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_80eb7218-29fb-413a-86cf-c56ecd1a9c06_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3215f243-83d5-4340-82e0-f11058f16e7e_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_37ee10b5-9d9c-4c1a-a152-77d871378bfc_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_4a2e0322-700b-4143-bbe5-eee06aa15502_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20201231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_05aaf1a7-d02a-46d3-9db2-70de0f33f70b_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fd255f7e-1b00-4860-9439-4c8949a9db90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_66707735-2ff2-4350-817e-b5c69bc9a538_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6a1b9013-7e05-4c30-a407-d3601bba140c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66a5c66d-c581-46c5-bb9b-67b2fb11d51a_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average of potentially dilutive securities (stock options and RSUs) included in calculation of diluted securities under treasury stock method (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_54111980-8037-4ba0-a121-60c2c5100549_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_9409ff6d-10be-4bef-a482-cd69e2efc5a5_terseLabel_en-US" xlink:label="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75 Percent Senior Secured Notes Due October 2020</link:label>
    <link:label id="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_label_en-US" xlink:label="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75 Percent Senior Secured Notes Due October 2020 [Member]</link:label>
    <link:label id="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_documentation_en-US" xlink:label="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75 percent senior secured notes due October 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:href="nktr-20201231.xsd#nktr_A775PercentSeniorSecuredNotesDueOctober2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:to="lab_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18de6b41-f2b1-4f4f-9d2d-a9f2d79e40f4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_63c21439-802a-4033-a9d4-e789a77f750b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_87981166-32ee-42f8-af81-c6fc802b8617_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3073b7f3-b123-4f90-a584-6189561698b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5c758280-99b3-480a-9926-689d4bfea27e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for stock-based compensation award granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_ff6ad15a-4e9d-468f-b3a7-6cc8e4174caf_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_2ab81b2d-17e3-41f6-aba4-ff1312724586_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount repaid</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_9c35704d-2e94-4644-a667-6d5b6a9fd40d_terseLabel_en-US" xlink:label="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance under equity compensation plans</link:label>
    <link:label id="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_label_en-US" xlink:label="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Securities Available For Issuance Under Equity Compensation Plans</link:label>
    <link:label id="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_documentation_en-US" xlink:label="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities remaining available for issuance under equity compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:href="nktr-20201231.xsd#nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:to="lab_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_016e30ab-8817-4379-95a4-1e870230a615_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c28c0d97-092a-4caf-aa04-d6874f7c8e7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_70af3c51-67f6-428a-a85c-2496e2619cf4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fd4ecd71-e7f2-491f-9860-ff9130f2f5cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d9e03e-742a-4548-8a72-2e983d815ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_63b96a20-8f0d-4c4c-bced-09bdb670923a_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20201231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a83bd80c-6013-4f2b-9014-a4681cad1518_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_4a7d648a-24e8-49c2-80ad-fad5262ed240_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_edd5c90a-35c8-426c-bb87-f3afc3c80253_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:href="nktr-20201231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_02e94e74-8f24-4d33-a493-e223df6b5030_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_00fdf23d-79b4-4944-aa89-625559792843_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b13158e9-34e3-4d73-b688-df60e2673f88_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3aa201ed-7d77-4409-9c9b-96fe5692eac6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_d4236d87-3c10-4533-9fe1-70a476e0d8af_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue" xlink:href="nktr-20201231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_850f00e3-b25f-47d3-8f13-29fe14b0ea00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_177ffc2a-9fad-4fe8-9128-7cc3f41f64cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_78a28b62-b8ae-4d08-a5ed-5348535d43a3_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3aee072a-9c07-43ce-99fc-d480df985db9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Provision Related to Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1c2f8599-c56d-417a-8006-8bfb617bf40c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b798e78d-1592-4ea8-a3cb-dc681dd4076b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2683088-fdb8-43c8-869c-f67d5c384a5c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_302c58f4-2caa-4196-a6d1-187ea2983a00_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_c4980881-8597-4b3f-b0a4-85a340926189_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_45de67f7-9f15-4482-bc4e-b3dd8ea2cdcb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8f7b2514-2a36-4dc4-ac1d-10f6d6c87135_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_7803753c-950e-4a52-b208-c03049504f64_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_432f8fcd-3db5-4226-b047-7289a1ff8e8a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_30d25a9d-10ed-4b1a-a6d3-7b5ca2267e17_terseLabel_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Significant Customer Concentrations</link:label>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_label_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Significant Customer Concentrations [Policy Text Block]</link:label>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and significant customer concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:href="nktr-20201231.xsd#nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:to="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_b3a73bd8-48a1-46f7-895a-fc9e6ba9a11c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6338694e-efb2-4cdb-8d39-4924292de971_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for issuance in equity compensation plans</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_b44d8533-a532-4261-a903-53bee2f27db3_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2b7ed0a3-5a3f-4bb7-a7b4-342d09fd5da7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_fae154f3-96c9-4fe2-8e48-041eca9612eb_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, first indication, period to be paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ef593185-bc8a-49ff-bad5-344813812a82_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e7cf38f-6b3f-4c68-96fa-7b01b49e72b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_36bd9f7f-0db1-4200-b304-ff7823c15294_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_320af8ad-ee4c-49f3-961e-dd696db5cbcd_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Liability Related to the Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:to="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_52debd56-81a3-4b41-b727-d004dbc5f301_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_813e48e0-e20e-4aac-a956-da4033fd11a5_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, second indication, period to be paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_e8a8d2d2-8a1a-4eb5-b630-073cd213c2a2_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_9add4ad9-81b4-408d-9aea-33970faf68a1_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2da1b31a-f264-49fa-9f4a-33b711a66491_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2eff3292-ae38-4c76-8aa1-b30a95bd4a80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_d23615db-8ea3-431f-98b5-9b0f1c0aff8f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a98d85ba-d75e-4b06-9eb8-0ed8afe93e95_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c9047c62-fc7b-4a8c-9926-58e87355a694_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmendedAndRestated2017PlanMember_74d4dd0c-e748-4b0b-bfe5-3ec38d1c5b51_terseLabel_en-US" xlink:label="lab_nktr_AmendedAndRestated2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2017 Plan</link:label>
    <link:label id="lab_nktr_AmendedAndRestated2017PlanMember_label_en-US" xlink:label="lab_nktr_AmendedAndRestated2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2017 Plan [Member]</link:label>
    <link:label id="lab_nktr_AmendedAndRestated2017PlanMember_documentation_en-US" xlink:label="lab_nktr_AmendedAndRestated2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2017 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmendedAndRestated2017PlanMember" xlink:href="nktr-20201231.xsd#nktr_AmendedAndRestated2017PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmendedAndRestated2017PlanMember" xlink:to="lab_nktr_AmendedAndRestated2017PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_bba558bb-b3b3-40a1-a3f9-cb50788e9965_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_18fbc4af-a51a-4e19-b7c4-e74a8c4ffe24_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1200dee9-fcf1-4b67-8cc4-d2de09a24779_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7daa7196-b1d7-46f6-ad66-838b5621e426_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e322d0d3-a63a-481d-b0e4-8a8f4152247a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_323ffb85-7bb9-4b5f-b010-4863a4d5dff5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_d2486d50-01a3-4a73-9c6e-58f74f3a5cc4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_73c081c7-2630-4b97-ab13-eccbc4848407_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_70d01031-d9ab-447e-bfc3-b12c30ebf51f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_461a6a2d-7301-47e6-b0c3-cdbe267e9234_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_87a4f69d-61d7-4a17-8c13-175e66308e6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_f1f3cfee-6981-4de5-8535-53f73e86d8b0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4767c0d0-930e-4ad3-ace3-27416d3a16d1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_5055b089-947d-4e52-8fe8-59a939839ff5_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_64bbc8ec-aa6b-4024-83f5-025715dca8e5_terseLabel_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_label_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:href="nktr-20201231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:to="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_43f1eaba-e2dc-4ca8-9597-45b9aeba6b91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5781447c-afd3-4be4-adc0-ee786a5e7d03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_4611ab0b-6e06-468b-9f86-94fe27c55cc4_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_34953ff3-3351-4491-8614-e2192f8598bc_terseLabel_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercialization profits and losses sharing percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_label_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits And Losses Sharing Percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_documentation_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits and losses sharing percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:href="nktr-20201231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:to="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_ffb544ea-bd02-4298-be64-3146115661b9_terseLabel_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration received under agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_label_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Consideration Received From Agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_documentation_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration received from agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:href="nktr-20201231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:to="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_9f0750b0-b99d-4a0c-b0cf-9a362259ca4d_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20201231.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LeaseExtensionTerm_8098873a-a8ca-4f3d-bfc4-4a7eebfccf97_terseLabel_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_nktr_LeaseExtensionTerm_label_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Extension Term</link:label>
    <link:label id="lab_nktr_LeaseExtensionTerm_documentation_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm" xlink:href="nktr-20201231.xsd#nktr_LeaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LeaseExtensionTerm" xlink:to="lab_nktr_LeaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_850c1398-f175-4321-b208-daec88eadd0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited and canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b08e0063-6b76-4365-92e2-44e5a7d8a89c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f1cf4e0a-f402-44f9-b98e-3935f1348154_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0247c0b7-2790-4792-813d-7f0805fed27a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share, options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a62b59ce-223e-4c2f-a0ef-5cf3296fcf3a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0f73d5f1-f5e2-418e-b56e-ea6eb5af75c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50e31a3a-7f2c-42d7-b945-1e1d06c933d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d4eacced-9e53-47cd-8db8-e539ab271556_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_86e55a33-1baa-4bb2-863e-ef609a7d29ca_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_04a61454-6e15-4c72-8339-4e28d266656b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity Under Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_db432cf5-b6b9-45ae-aa5a-15a732cbb6cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_9f93d647-74a6-4eae-a7e1-b337039171a1_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20201231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RSUsAndPSUsMember_1f6e0f4f-928b-4ded-96db-cc4b36c10da4_terseLabel_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_nktr_RSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs [Member]</link:label>
    <link:label id="lab_nktr_RSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember" xlink:href="nktr-20201231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RSUsAndPSUsMember" xlink:to="lab_nktr_RSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_196a3925-4013-4aab-9345-83e07862a97a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_16e8e2b6-1251-469f-882c-a28924ad1b21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_29b38ca7-5515-49d0-a906-ca6d2c369edf_terseLabel_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Securities Related Claims</link:label>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Securities Related Claims [Member]</link:label>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-securities related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember" xlink:href="nktr-20201231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonSecuritiesRelatedClaimsMember" xlink:to="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_991de8fd-9c9d-4b85-a164-7793ed0cbc07_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_872627d2-430c-4ce9-bd0b-1064e2351dd0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_47cba7e2-8ecb-42e4-8272-124ba7e261d9_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_d29ee142-d654-4cb4-a1dd-e7f3693f3f42_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SecuredNotesLineItems_c7f42e5e-d046-4e2d-87d7-a85949112b71_terseLabel_en-US" xlink:label="lab_nktr_SecuredNotesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Notes [Line Items]</link:label>
    <link:label id="lab_nktr_SecuredNotesLineItems_label_en-US" xlink:label="lab_nktr_SecuredNotesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Notes [Line Items]</link:label>
    <link:label id="lab_nktr_SecuredNotesLineItems_documentation_en-US" xlink:label="lab_nktr_SecuredNotesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuredNotesLineItems" xlink:href="nktr-20201231.xsd#nktr_SecuredNotesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SecuredNotesLineItems" xlink:to="lab_nktr_SecuredNotesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f0eb9ad3-3aa9-4420-8f58-56b3427d3bb2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_94ef2740-7adb-4369-bebb-14d01a08cfc8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_650acae4-edec-4329-a018-c68bb1bb9f04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_533bcf85-ddfa-4ea0-a82d-90e4f18fc292_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_bae1dc2e-e4f0-400c-ba57-4f965abf5383_negatedTerseLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: lease incentives</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability tenant improvement reimbursements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:href="nktr-20201231.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:to="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0e7b9ebf-86bd-426b-91dd-01812ed39e8f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of property and plant</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d7faec16-7b58-415a-b038-2e94de734f48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_086415bf-5ff8-4ee7-a5d8-cd435f4d2ce5_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_0b30d4d4-1e2f-4938-b1d9-5c6bbcc31f26_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_1e281603-2856-48ae-9a1a-af4df6d085a8_terseLabel_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for senior vice presidents and vice presidents</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_label_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Senior Vice Presidents and Vice Presidents</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_documentation_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Senior Vice Presidents and Vice Presidents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" xlink:to="lab_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ClinicalTrialAgreementMember_ac3885ea-2be3-4ad4-bcbb-7ad71751da2e_terseLabel_en-US" xlink:label="lab_nktr_ClinicalTrialAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Agreement</link:label>
    <link:label id="lab_nktr_ClinicalTrialAgreementMember_label_en-US" xlink:label="lab_nktr_ClinicalTrialAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Agreement [Member]</link:label>
    <link:label id="lab_nktr_ClinicalTrialAgreementMember_documentation_en-US" xlink:label="lab_nktr_ClinicalTrialAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ClinicalTrialAgreementMember" xlink:href="nktr-20201231.xsd#nktr_ClinicalTrialAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ClinicalTrialAgreementMember" xlink:to="lab_nktr_ClinicalTrialAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_5db2e3bb-53bb-4954-87c5-39ed0473750f_totalLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment, net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_f8db8a96-fa0b-4581-b36d-87105ec98f0e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching 401(k) employer contribution, maximum amount</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f84e6fca-3f07-4fa4-bb4f-c63c6540fa4a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_83b9375d-6817-4a6d-82d1-9a42434e8b12_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_74594810-6aa9-4932-adbd-a8f482c1c5c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3c914710-646b-4c0e-ade9-25cf615745af_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_638d4db0-e9bf-4ec8-ac8d-111cb1fc75e8_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, first indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2efd2763-f06c-4d8b-b53c-30131d0a32d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltyAgreementContingentPaymentDescription_3a2d0338-7ec7-4972-b093-577250150a4b_terseLabel_en-US" xlink:label="lab_nktr_RoyaltyAgreementContingentPaymentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty agreement contingent payment description</link:label>
    <link:label id="lab_nktr_RoyaltyAgreementContingentPaymentDescription_label_en-US" xlink:label="lab_nktr_RoyaltyAgreementContingentPaymentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Contingent Payment Description</link:label>
    <link:label id="lab_nktr_RoyaltyAgreementContingentPaymentDescription_documentation_en-US" xlink:label="lab_nktr_RoyaltyAgreementContingentPaymentDescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty agreement contingent payment description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyAgreementContingentPaymentDescription" xlink:href="nktr-20201231.xsd#nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltyAgreementContingentPaymentDescription" xlink:to="lab_nktr_RoyaltyAgreementContingentPaymentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bce06aab-782f-4659-b2be-1fda52df7850_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_a37cd520-c249-4a1b-b502-5441810ac813_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5714385a-9fa8-4a6f-88ce-0b8bcd250fbe_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_64f5a4c4-cef4-4986-ba9d-495c238e380f_terseLabel_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Sales Level Milestone</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_label_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Sales Level Milestone [Member]</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_documentation_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual sales level milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember" xlink:href="nktr-20201231.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AnnualSalesLevelMilestoneMember" xlink:to="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6eacac49-ff45-48aa-84e0-8ee6ba5c063d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_69d7fa86-dcb4-4a71-bcd0-3d252004e8a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b0ebe5be-53e1-4a0d-9af1-ed932a1a8f5c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_005e8a91-92ef-46ce-b045-b54ffaddba28_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_6de52cca-f1ce-46b5-b13f-cd99ce18c53b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_abcedc05-1559-455e-964c-73e67e2dc597_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d70d0d47-5105-4652-a033-738299bad155_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_f2e11250-44e9-4bee-b597-83c98ccb74e9_terseLabel_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive terms to extend lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_label_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Terms To Extend Lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_documentation_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive five year terms to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:href="nktr-20201231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:to="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_15ce52d4-0f0f-4a2d-b241-36075d31fe00_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_16c1139c-dcc1-4cc9-b8cb-fcb8973a8e1f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0dc939a2-f55c-4398-b8ad-46fa048ea516_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24475947-eb5b-4edb-8d54-103414393766_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e6c8705f-c878-4cdd-a0dc-47fdca7cd400_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7eb80671-c423-4426-bd05-06217c7c7bae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TerminatedPartnershipMember_ca6fd31a-b768-40ec-900c-fb2363b45347_terseLabel_en-US" xlink:label="lab_nktr_TerminatedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Partnership</link:label>
    <link:label id="lab_nktr_TerminatedPartnershipMember_label_en-US" xlink:label="lab_nktr_TerminatedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Partnership [Member]</link:label>
    <link:label id="lab_nktr_TerminatedPartnershipMember_documentation_en-US" xlink:label="lab_nktr_TerminatedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Partnership [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember" xlink:href="nktr-20201231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TerminatedPartnershipMember" xlink:to="lab_nktr_TerminatedPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d808c58e-5866-44e5-bc81-151f5cfeca39_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_782117b0-9fad-4641-a88a-55848ab8761f_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20201231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_aea4f36f-3951-4434-93e3-ef5721990889_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_37357896-3433-43b2-89a6-06cd9477a49d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Information</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f9dd96e6-772d-4df7-9f60-b5f868eb45ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_a95a203b-e0f2-4c23-a718-3d267539d35c_terseLabel_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period subject to lock-up and stand-still provisions period</link:label>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_label_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period</link:label>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_documentation_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period subject to lock-up and stand-still provisions period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:href="nktr-20201231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:to="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5acc013d-b81c-47a7-beb6-0a36745cc198_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5928a7df-65af-4dba-9a1b-a209cd457c72_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options forfeited and canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ce23cff1-9f65-42f9-a039-644e60adcc1f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0152bf33-a92e-42cc-9d66-125b76a86eed_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_e16683ad-3f21-49fd-b697-2ee601de0aee_terseLabel_en-US" xlink:label="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount on transaction and facility fees</link:label>
    <link:label id="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_label_en-US" xlink:label="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discount On Transaction And Facility Fees Paid</link:label>
    <link:label id="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_documentation_en-US" xlink:label="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount on transaction and facility fees paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" xlink:href="nktr-20201231.xsd#nktr_DebtDiscountOnTransactionAndFacilityFeesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" xlink:to="lab_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_8a8d81ad-536b-48f0-b8e6-d2c82e5e837e_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20201231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c5e9b78a-9194-4a8c-a0ce-f5083f4df0f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_359548e3-ad1b-4374-9a3e-f171bcef9c0a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_bc3aa8ae-0476-445d-8b3e-ccb3ebfaa571_terseLabel_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for Chief Executive Officer</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_label_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Chief Executive Officer</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_documentation_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" xlink:to="lab_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62ad906d-010a-4b75-88fd-c126ffdecfe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_005d5c7e-2392-4a7e-ad91-390b98bc6420_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_ccd8e1ca-48f1-4c2a-8a9f-9f79c59841fa_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3239b556-efc6-469b-82e4-9f395be75ce6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c25ff651-1fd4-4f6c-94c5-bbc208af4e03_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic ( in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_e1384d63-3426-40ab-bd1f-bcb3a8033e9e_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_3dc20f39-86f5-4c6c-9b72-1ce89aac0410_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20201231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab66c584-3d54-438d-a921-716695ae8cf5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average weighted average expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f2763b0c-a423-40c6-b1d6-36b4147334ad_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d1843dfd-dbbc-49b1-9908-6f255ebeaee4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ee701657-7ad9-4ff7-8bf1-49fff1d2ed81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4747f404-1df5-42f2-bd8b-8ffbca55eaba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_f55d3be5-adcb-4808-acbc-ad4e10cc3c38_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_5854e4d4-262a-42d0-af4e-f202a339f125_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0ff5cfb-8f75-45e8-bd98-7817fc0675f6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_4e04b87e-7bcb-4368-81fd-8f888317308f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_608d2072-f3c0-4fc1-a805-b8470cfaffee_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e7eea8b1-07bb-4ee3-a552-53d49debf33e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d1f9ef28-0125-40bb-82e0-cdce167287ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_cab8cd5f-bbff-4d51-969e-ce06fafe0ebc_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_a14b3aaa-f14e-4755-b815-00de0dbace54_terseLabel_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Acquisition Related Claims</link:label>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger And Acquisition Related Claims [Member]</link:label>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and acquisition related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:href="nktr-20201231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:to="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_12287a56-dc71-4532-b093-c2ea0e6fe7a7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_f87ce73c-3783-47ea-b45f-3610b906b953_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares to be issued upon exercise of outstanding options or vesting of RSUs</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_label_en-US" xlink:label="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_documentation_en-US" xlink:label="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options and restricted stock units outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:href="nktr-20201231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:to="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6bd822b4-d94d-4fa4-a92e-efec20821bd3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 180,091 shares and 176,505 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_fbb26b4e-8993-4f2e-9ae8-b6a8c2d2afa5_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_177c4c8f-a37f-481b-ad2f-f34a137f89ab_verboseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CommonStockAdditionalSharesAuthorized_3af2a9e1-224c-47f4-90d7-47a33fb316c7_terseLabel_en-US" xlink:label="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in aggregate number of shares authorized (in shares)</link:label>
    <link:label id="lab_nktr_CommonStockAdditionalSharesAuthorized_label_en-US" xlink:label="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Shares Authorized</link:label>
    <link:label id="lab_nktr_CommonStockAdditionalSharesAuthorized_documentation_en-US" xlink:label="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommonStockAdditionalSharesAuthorized" xlink:href="nktr-20201231.xsd#nktr_CommonStockAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CommonStockAdditionalSharesAuthorized" xlink:to="lab_nktr_CommonStockAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d3bc335f-d43d-4db8-ad9f-391b9cae78ca_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_aa6bb39d-1e07-4326-953c-62079d24c170_terseLabel_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MOVANTIK and MOVENTIG</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_label_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M O V A N T I K And M O V E N T I G [Member]</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_documentation_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MOVANTIK and MOVENTIG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember" xlink:href="nktr-20201231.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MOVANTIKAndMOVENTIGMember" xlink:to="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6866b7a3-b4fc-4a83-adc9-3026a3ededa0_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCosts_29844220-f507-43f7-b0f5-77e6d6c0f138_terseLabel_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company share of development costs</link:label>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCosts_label_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Share of Development Costs</link:label>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Share of Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCosts" xlink:href="nktr-20201231.xsd#nktr_CompanyShareOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CompanyShareOfDevelopmentCosts" xlink:to="lab_nktr_CompanyShareOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_bc596feb-b933-4172-90a7-5e494614982a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_cf534be7-4239-4125-b33e-6adfe57542ab_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20201231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_57cd977e-22ae-410c-b47e-9fe447c350f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5bbfa421-3012-4513-bc48-56ba4444d92f_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NeulastaMember_6449ed57-ffe8-4b5b-abcb-c307d164b970_terseLabel_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta</link:label>
    <link:label id="lab_nktr_NeulastaMember_label_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_nktr_NeulastaMember_documentation_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember" xlink:href="nktr-20201231.xsd#nktr_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NeulastaMember" xlink:to="lab_nktr_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_59e9faaa-d2e0-4c6c-a158-790b8f95e6c3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartnerTwoMember_38840709-8354-4ce5-b145-51c3ebb3d78b_terseLabel_en-US" xlink:label="lab_nktr_PartnerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Two</link:label>
    <link:label id="lab_nktr_PartnerTwoMember_label_en-US" xlink:label="lab_nktr_PartnerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Two [Member]</link:label>
    <link:label id="lab_nktr_PartnerTwoMember_documentation_en-US" xlink:label="lab_nktr_PartnerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerTwoMember" xlink:href="nktr-20201231.xsd#nktr_PartnerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartnerTwoMember" xlink:to="lab_nktr_PartnerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_0b2e59a8-e075-4a12-bf6b-8b801b717bee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d921e026-1087-4b33-8985-c2117d0c40f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d5b2cff-b4e3-4207-9a6f-bc700c24bf75_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_eb2f4277-b33d-46db-a39b-d2ee1f3119e0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_93502595-4a8e-4b71-850e-1597e35a3a4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_d5052e7c-2432-4eb9-9bfa-0ddd9d7b7b69_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20201231.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af6f0653-d38c-4702-ad0b-50f29a0932ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_56c2abbc-0b6b-4e70-96f2-4f7e4585367d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_289fe411-7c66-49ac-ac0c-3ae0de031365_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc467bc6-41f2-4f2d-94ef-fb5413a46d47_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5f5cc900-1000-4244-bfdf-baa132f59947_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ba789904-8e9a-4c23-a4c1-ef5b4a572b78_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0455ec9a-fcbb-4f14-b9a6-1cb112094582_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_5f1edfc5-8ec0-466b-acfd-80c95d719588_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_377201d4-0f0a-466f-a244-a0131a316b5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6d4992f3-9112-4ad2-a6a3-e033c244823c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_2c898d1b-3c1f-4014-ad00-f5bfff0c1792_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_a10330cc-fa72-419d-8d57-2d8a92aaf8b9_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20201231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_5713533a-36e4-431c-b146-3f46b88010ce_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e14312d6-41ee-4f07-bd5e-edcc569c0440_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b6af804b-ce2a-4699-b3b2-03a409433d4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e52defbe-5321-4c9e-98df-7ee53ad18dec_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a0685bbb-d554-4b19-ba97-f57c83f3de71_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d1eb1dd3-a5ac-49e8-a1ac-8a49bde1919a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1dd7f232-ab13-4f42-92de-c5a0017bd6ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ca322ac7-50c5-4ff8-8f5d-f2388025c9b2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_75e5b7db-b028-4090-8fb4-c916e860b771_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_71bb85f2-5405-41b8-acd1-b676fb4d08a2_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20201231.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a4e222da-c4eb-4e56-83b7-6966a5f07846_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6aeb6115-f433-4aed-9791-fdda89a5ced8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_beb287b4-21ec-4f3a-ab60-4ba00d357a91_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties, net of $3.8 million of transaction costs</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties, Net</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:to="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ab05ca8b-02bc-4249-87e1-d2e6110e741e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee69209f-3be0-4405-8821-63805d33ddc5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7bb1028-cfc8-4e6e-a1fe-4e8965d3a2e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_fed1baf7-fd34-4be2-8cf9-aa978f34a757_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_9e0da0ad-14ab-47bd-826e-019fff0c45e1_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plan's share limit reduction for every one restricted stock unit granted (in shares)</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_label_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Plans Share Limit For Every One Share</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_documentation_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation plan's share limit for every one share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:href="nktr-20201231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:to="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_54f8e81b-d486-4c0b-91c9-e8c3fb51e631_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapses in statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_47f26299-7537-4603-91f8-330242b4a1fa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4b3b9b76-e7fe-4cdb-bdf7-029f5bb8e999_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_484b718e-3e53-4253-8ed4-4a0e82c96418_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b07900e8-6aa0-4dd6-aaef-c87c8fe56bfa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8cfb7340-be46-4eda-af65-3ec255053854_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_aa6531f6-5303-41d1-8cf6-63a96bc791b8_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:href="nktr-20201231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_4b5291d7-b2ce-4994-82b6-542a1fcef62d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_80fdf2ba-b43a-4f1f-8375-d6a51c2e5ab9_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_eec34dbc-3643-4cb2-a4ca-2809bb10acc6_terseLabel_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components</link:label>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_label_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember" xlink:to="lab_srt_ReportableGeographicalComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0a30ba00-ce8e-4de4-9255-1c85d5479c2d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to prior year, Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_eff35384-56b0-4e8c-9d56-fee07da51917_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to current year, Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ef64c9f9-58c2-4028-bd5a-dd58ef8970eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d879d1c4-cc11-4838-9970-60fa4711d2eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_347b8897-2342-4fe0-bfe5-89c18e794b6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_93480c3f-0341-4afc-84ae-5994e4647f14_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NKTR181Member_00c03f86-3e42-45d7-bc8c-0b0afcef133c_terseLabel_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181</link:label>
    <link:label id="lab_nktr_NKTR181Member_label_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:label id="lab_nktr_NKTR181Member_documentation_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member" xlink:href="nktr-20201231.xsd#nktr_NKTR181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NKTR181Member" xlink:to="lab_nktr_NKTR181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4ac9082e-2cce-4cd4-83c1-07609c580240_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_25289af5-0050-4c42-8b44-2849e0dbe4fa_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e5f0edc7-f50f-485b-b6df-0f4ff529a5cf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f09866e2-d8a9-42f5-88c4-3c5e2324209f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7e3dbb9f-ad98-4f61-b0d7-0aa32779d13c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e9d88b82-ba97-426b-a46a-279b4df4d3f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c34dd78-5723-49df-9d3e-82d4da519e1a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_6b2edb44-53ed-4a63-8ebb-2d55e2c1863d_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20201231.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f88b0696-b4cc-4d05-8d33-8ae8cad6aa2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeMember_ce12e652-67d4-4bef-92ef-bc6c1d6532be_terseLabel_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_nktr_EmployeeMember_label_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_nktr_EmployeeMember_documentation_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember" xlink:href="nktr-20201231.xsd#nktr_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeMember" xlink:to="lab_nktr_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_a8631ae3-acfb-49b9-8f12-4698bc86b942_terseLabel_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_label_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_documentation_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:href="nktr-20201231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:to="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a99eb3f5-3b7c-418a-b3ec-5128698fdac1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_061bcc54-3341-48bf-8366-b577db062436_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3edfbb69-dfb2-40df-9d3f-af0fab5f779d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_64674fd8-bfcd-4ac9-9312-ceaf845e83fd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_53692702-6615-4955-b1ce-89a46c373090_terseLabel_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_label_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development [Member]</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember" xlink:href="nktr-20201231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DrugProductDevelopmentMember" xlink:to="lab_nktr_DrugProductDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b6a86207-6737-4ef4-91d5-fa4da55b5c53_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_65e7c710-e849-412f-b5ed-b1b2b4cea987_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4b3505fd-a41d-4a9f-9417-a834a2ed3ab6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_7df83ee6-277f-4c80-bec1-e26f1f550a2a_negatedTerseLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20201231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_84f0bace-1630-40a3-be97-5ca5298a5622_periodStartLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties&#8212;beginning balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_cd67e84e-a6b6-42ce-a6e6-922e73af46a6_periodEndLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties &#8211; ending balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ca1f65bf-a1fc-4ce3-a531-349571fa0f03_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e2ae7ae5-76eb-4ba1-aec8-a6c0835b87fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_0ca63096-0f94-4de3-b64e-921550b6be94_terseLabel_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implicit interest rate over the life of the agreement</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_label_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Annual Interest Rate Over Life Of Royalty Liability</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_documentation_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual interest rate over life of royalty liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:href="nktr-20201231.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:to="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock_a534fe0f-14a2-4cc0-8861-d32df37eb2a9_terseLabel_en-US" xlink:label="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:label id="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock_label_en-US" xlink:label="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief and Economic Security (CARES) Act [Policy Text Block]</link:label>
    <link:label id="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" xlink:href="nktr-20201231.xsd#nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" xlink:to="lab_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_ea7642ae-ea04-4103-a689-50074580f3ee_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program [Member]</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LeasesLineItems_11c16868-89bd-4515-8528-59b4846ae48e_terseLabel_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_nktr_LeasesLineItems_label_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_nktr_LeasesLineItems_documentation_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems" xlink:href="nktr-20201231.xsd#nktr_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LeasesLineItems" xlink:to="lab_nktr_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b0772253-df4a-413e-b775-a544d5cadee2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_0c1ee1f6-6975-457c-a56c-2ece9f36adcf_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of out-of-pocket costs to be reimbursed by partner</link:label>
    <link:label id="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_label_en-US" xlink:label="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Out Of Pocket Costs To Be Reimbursed By Partner</link:label>
    <link:label id="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_documentation_en-US" xlink:label="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of out of pocket costs to be reimbursed by partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:href="nktr-20201231.xsd#nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:to="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_44670f90-be3a-4fc2-ac2c-33ce4286bb71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 to level 2 transfers</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_3b4a89cc-27d2-424b-84d6-7d8fe049bf36_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_7bba2c61-0383-4df7-a28d-d66f956a2a0b_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_35473a41-8521-4b48-8baa-dd25eee20f78_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_8b7090b8-ecec-4935-bf81-ef573d777c05_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_fbcbe874-93b4-44b5-a6f7-f98b27eb2fc1_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of advance payments to contract manufacturers and equipment for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equipment from terminated program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_d8cc9b48-1bf2-44c7-901f-6ee0786252b6_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_90b07ad9-8020-4c48-b92f-a69bd86ba463_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_056fd5ff-86cf-48aa-ace9-00de519576d2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_73978987-52fd-4092-862d-7dd0c9a6e48b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ec087165-97d7-4338-954e-e6e91a1ff67d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_817717a3-2c0b-473b-943f-381d5ad6e9de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_85d27a13-f235-4fd2-b7ce-d98276cebd9d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0e11d2bb-a60e-4357-9e05-9ea8897ce0ff_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_92df6a66-6918-4ad9-ac9e-d087349cd43d_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, net and interest payable (see Note 5)</link:label>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_label_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesCurrent" xlink:to="lab_us-gaap_SeniorNotesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0bfd3c6f-7bde-4399-af41-9493726e233b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a1c39173-d854-4fdb-abc1-f620a63c9911_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5f962dc0-fee7-4d7c-aaa8-c35cd1fbf95d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DocumentAndEntityInformationAbstract_1e9721ec-39f1-416c-a3f4-5631547da6ba_terseLabel_en-US" xlink:label="lab_nktr_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_nktr_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_nktr_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_nktr_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_nktr_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DocumentAndEntityInformationAbstract" xlink:href="nktr-20201231.xsd#nktr_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract" xlink:to="lab_nktr_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_24f021fc-a7c5-468a-a09e-83d14d05e721_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average volatility factor</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_85fdf878-405e-4317-8703-76046fc9a6d0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense in connection with 401(k) retirement plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_45591880-da79-4dd7-8b88-582027f7a489_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EuropeanUnionMember_0eaf7219-81d0-49fc-9746-904888b84957_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember" xlink:to="lab_us-gaap_EuropeanUnionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b92c1fa1-eef1-48bf-984a-9bea6953876a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_0eb484c8-431b-4feb-8c0f-26e705e0970f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_96c8376b-a949-4419-b9a4-f347992c1629_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock to Bristol-Myers Squibb (Note 10) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e758b5c3-54cf-4131-a3c5-0922c358a08a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_a67c14a4-9c38-4047-ad74-9f1c1f74b9bc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_4b4d8f74-0a64-4830-9007-2afc5961279c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_66ab39c8-a566-4260-95d1-32bd1f1a1957_verboseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, principal amount</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_b9b5464f-44f6-4e5c-9262-5f481b4d733f_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:href="nktr-20201231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_895da313-d579-429c-b226-594f5c6eedff_terseLabel_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty monetization proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_label_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_documentation_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds" xlink:href="nktr-20201231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltyMonetizationProceeds" xlink:to="lab_nktr_RoyaltyMonetizationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3cab4ab4-799e-4928-9c4e-a85556587bf6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5792d3be-bc1d-468c-b566-1ed4c14bcfd8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4b57c6ed-28c0-47b4-9a67-7705db9431f0_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5f1490ae-fd58-4e7a-848f-37cd168530f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37b22a08-1fdf-475e-a9db-da835ecefca7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_323c5dae-7643-409e-9beb-61fd08fb6e32_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataTable_5d3349bb-6dfd-4639-9b96-c16229a050af_terseLabel_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Table]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataTable_label_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Table]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataTable_documentation_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected quarterly financial data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataTable" xlink:href="nktr-20201231.xsd#nktr_SelectedQuarterlyFinancialDataTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable" xlink:to="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_bb659c94-94de-4075-b110-ee6c8dd833f6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_b69a961c-e6a0-4030-9abd-6f60f484f466_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97eedadb-73e2-4586-b7b6-0c29b1d408fe_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1ffe80e0-9a72-4078-b4cd-262201ecceac_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_5a727fb2-bb7c-4e49-8e59-c0381c5b50bb_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20201231.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_0cb1eee2-1853-4bfe-b2dc-06c5f6acb97f_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20201231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_293b6ab9-dad0-4684-8a49-603d74fb7b77_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ea6bf9dd-0888-46a7-87a4-2bf05e0a673d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4da72d64-a012-4cb6-b1d6-f441959da85c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Common Stock Underlying Outstanding Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_70289299-5e32-443d-92e4-ff650f61a9f5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c8e41319-2d90-4ea2-b074-a52d9d431ed4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_be30320b-33b4-472d-a317-4666e90254ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c1782ae8-af08-4e81-ae20-cd290d7c8866_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_51a79d2c-d13d-4fb3-8f39-481f6ec0c24f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aab2bd45-3011-4ee7-96ee-100a970b0408_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_90afe2e1-e8b7-4371-9672-1452ef103f8b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_331524ff-482d-4153-8e65-05ccc3c92c94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share, options forfeited and canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d0251a7d-4271-45a2-936d-83431f15ac9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2134de15-9563-46e4-b8e3-1a0b4572a9d2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8270d731-0ccb-46e8-9eea-b04262e1455f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_8099b064-887c-4a82-a19f-a68f7449ae4a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_dd784643-eedc-4072-9b0f-28a51eb4d9be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ce975ce3-99e5-4af7-bb57-3edf62a7419c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_35842d58-7085-4b96-9385-5ac4af814e61_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_de3c82e7-faf6-42aa-9db4-0d3abc91f61b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_19ae7224-ec8d-4216-973d-5c92a19b22d8_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20201231.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a12194a5-f90c-4657-81e8-61f375763b04_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_2e8828bd-7261-48ad-ac0d-0dbfd29fd54a_terseLabel_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period may increase or decrease due to tax examination</link:label>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_label_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change</link:label>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_documentation_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period increase (decrease) reasonable period of change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:href="nktr-20201231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:to="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0d995368-c97f-463e-b86c-7de0b72a389e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_f9a7363b-4cd5-4486-9d99-05ce86bc36e9_terseLabel_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Lease</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_label_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Lease [Member]</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_documentation_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third street lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember" xlink:href="nktr-20201231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ThirdStreetLeaseMember" xlink:to="lab_nktr_ThirdStreetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e6b6aa0b-f9ab-47b6-9795-aacbb0d25be5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a8533a3a-bce4-4994-a252-5d19324a762a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_3098f6ac-f17f-4e62-b9d2-efec4293f0a9_terseLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment at cost</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Gross</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7ef2c868-1c90-4788-bc96-daac27df79b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29a3c0a2-ef20-48ca-8f34-c2b947d93118_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f92633-dbcd-444a-9bbc-583fcf3de6fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_96c92eb5-4263-4e4d-9a9e-b14132dfa016_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_961743c2-5297-430a-aa44-c4a2bed13617_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5a768f8e-4627-405e-bb69-bde3a2c24676_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9d1e4d9f-ec0a-470a-a07c-b499b8b3f8b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_35961a6e-4cbe-4b11-a359-046514dbebbd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_94c3ce82-7c9a-4830-b3eb-ad2cc4169d4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 to level 1 transfers</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_06d45172-8c1a-452b-ac1e-33a014e0c41d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_514d50a3-286e-4822-98ec-66046cc45937_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_bf950ebd-9cd8-410e-958f-b9ca09b724f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d80b8e43-8350-400c-9df5-73b5b76e3c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_4a180ab9-082f-40fc-a330-9e420ac9fb37_terseLabel_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year two</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_label_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made For Milestone Not Achieved Year Two</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_documentation_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:href="nktr-20201231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:to="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RegulatoryMilestonesPaymentDescription_96cbefa9-e34b-4b38-ac74-2331743f95e1_terseLabel_en-US" xlink:label="lab_nktr_RegulatoryMilestonesPaymentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestones payment, description</link:label>
    <link:label id="lab_nktr_RegulatoryMilestonesPaymentDescription_label_en-US" xlink:label="lab_nktr_RegulatoryMilestonesPaymentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones Payment Description</link:label>
    <link:label id="lab_nktr_RegulatoryMilestonesPaymentDescription_documentation_en-US" xlink:label="lab_nktr_RegulatoryMilestonesPaymentDescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestones payment description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RegulatoryMilestonesPaymentDescription" xlink:href="nktr-20201231.xsd#nktr_RegulatoryMilestonesPaymentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RegulatoryMilestonesPaymentDescription" xlink:to="lab_nktr_RegulatoryMilestonesPaymentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SalesMilestoneRevenue_502edf3f-308a-42b3-93be-55ab20bd235a_terseLabel_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_label_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_documentation_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue" xlink:href="nktr-20201231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SalesMilestoneRevenue" xlink:to="lab_nktr_SalesMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_c04888f8-3fa8-4c97-baa4-823dd7c8585d_terseLabel_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year one</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_label_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made For Milestone Not Achieved Year One</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_documentation_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:href="nktr-20201231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:to="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_45ddbc88-6406-4ad6-a1c1-675be71d30f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2bbeec35-71f0-4d67-97e2-9dbe9f766827_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_2b88822f-acc8-4ebd-a4e0-493b29c0393f_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_19d414b6-6c55-4371-a6f4-c37db75f71f4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_98eb8002-e8c7-4b79-b8a7-1f2c9850d357_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, second indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_aa09aa9e-1790-4b12-9e15-6ddf01f8b8ab_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d1ef2806-3452-4143-82ec-8898c1f84156_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_340fe94e-e948-471d-ac77-fffe97c9ee0b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_34f1f9fc-368a-448d-9375-38f6166fa92e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_fbcc7f1c-d91c-4668-97ea-a3bd5a26796d_negatedLabel_en-US" xlink:label="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_label_en-US" xlink:label="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion Of Discount Net And Other Non Cash Transactions</link:label>
    <link:label id="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_documentation_en-US" xlink:label="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount net and other non-cash transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" xlink:href="nktr-20201231.xsd#nktr_AccretionOfDiscountNetAndOtherNonCashTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" xlink:to="lab_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_28443be9-773e-4fb8-b916-a22543c0e25a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_dd1f0c30-a560-49b9-8a67-5cbe10c214b9_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_label_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_documentation_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems" xlink:to="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_16356df5-0e03-455a-bdc0-3db4f2d025ad_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_58969ca8-5926-47c4-8223-1c5f6a9e3c8f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_2242bc87-2cb0-4a47-b09d-5a45d3f1ee3a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_91313c43-ae52-4920-b34a-ec167e42ada1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_aec797a1-05df-4299-a1fe-c9ac3ee7a7ee_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_7d786633-f5ba-4fda-a1e0-32c16a187534_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_aabca14b-4b4b-479f-a43c-06ed1a794de8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BempegaldesleukinMember_088cb011-4f7b-472d-9057-7b35b84f7257_terseLabel_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:label id="lab_nktr_BempegaldesleukinMember_label_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin [Member]</link:label>
    <link:label id="lab_nktr_BempegaldesleukinMember_documentation_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember" xlink:href="nktr-20201231.xsd#nktr_BempegaldesleukinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BempegaldesleukinMember" xlink:to="lab_nktr_BempegaldesleukinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d41301a9-155b-4b38-ac27-a8cb2d3dc956_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_e3695223-6796-4f47-b04a-1aa71e49e8ad_terseLabel_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective effective interest rate</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_label_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective Interest Rate Percentage</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_documentation_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective interest rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage" xlink:href="nktr-20201231.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProspectiveInterestRatePercentage" xlink:to="lab_nktr_ProspectiveInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_68fe0283-6662-4537-8b71-f8d0aa68ccb0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c0fe23ce-4116-4ec0-a122-748661f24475_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_419c2670-9da7-4b2f-966d-00a301430228_terseLabel_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance payments to contract manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_label_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payments To Contract Manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_documentation_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of advance payments to contract manufacturers, net of amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers" xlink:href="nktr-20201231.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AdvancePaymentsToContractManufacturers" xlink:to="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_289e160c-6602-42c3-b1f8-b616a4ac00c9_terseLabel_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for executives</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_label_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Executives</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_documentation_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for executives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:to="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cbd99f65-4b6a-4016-8bd7-a6ce31c50a21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_82d483f3-0b2c-4086-9396-d429eda3c793_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8645c0e4-7ce3-48ea-8e36-c66e41283bb8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42b4bc68-275d-4235-857b-14b82021191c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_30749314-2643-4515-a1e7-450e5af45500_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20201231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41bf99c9-ac57-449e-97e9-7969b4a0ab00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_5179c3f7-bbee-4d2d-95e4-aac06abb5069_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, penalties recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementRecognized_c8dd4780-60a3-4cb2-aca2-c12a43c8e5d5_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement recognized</link:label>
    <link:label id="lab_nktr_ReimbursementRecognized_label_en-US" xlink:label="lab_nktr_ReimbursementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Recognized</link:label>
    <link:label id="lab_nktr_ReimbursementRecognized_documentation_en-US" xlink:label="lab_nktr_ReimbursementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementRecognized" xlink:href="nktr-20201231.xsd#nktr_ReimbursementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementRecognized" xlink:to="lab_nktr_ReimbursementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_51e3d642-b6f3-431f-b588-b933579757f3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_bf66760c-3ce7-4a2b-b81b-155afa240e35_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes and Bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_51724a38-5f1f-49c9-942e-1351f92f7501_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f9a7fb6b-5d94-45c2-ad18-bb9f918a8444_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fccdfab2-b8f9-4e11-865f-cc4d8a7cf0d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_f0e3e32f-364c-4ab4-9e97-14f79338bcb7_terseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated / Takeda</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_f0cf6111-49d7-4de5-901b-800994ac09bf_verboseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated / Takeda</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_label_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C [Member]</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_documentation_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated or takeda PLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:to="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_bddfc5da-d034-4a59-afc9-c8a011523293_terseLabel_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for employees</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_label_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Employees</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_documentation_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForEmployees" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ChangeInControlSeverancePaymentPeriodForEmployees" xlink:to="lab_nktr_ChangeInControlSeverancePaymentPeriodForEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_a223c4cd-44c5-412b-9b9a-0e0f06dfb13d_terseLabel_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_label_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Laboratory And Other Equipment [Member]</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_documentation_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing laboratory and other equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:href="nktr-20201231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:to="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AreaOfLeasedSpace_9b70368c-3a63-42df-991f-1356a45590bb_terseLabel_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease space (in sq ft)</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_label_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Leased Space</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_documentation_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace" xlink:href="nktr-20201231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AreaOfLeasedSpace" xlink:to="lab_nktr_AreaOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_b1568d55-22f1-4a5c-8de9-75bc8c483f57_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20201231.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06ecd6b8-ddb3-4629-abdf-55574fb65a2b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_50aac0ba-76fd-482c-9e59-8dea6e3bb997_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataLineItems_f91614c3-5243-4735-a0d2-2b3ad335fd9f_terseLabel_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Line Items]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataLineItems_label_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Line Items]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataLineItems_documentation_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected quarterly financial data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:href="nktr-20201231.xsd#nktr_SelectedQuarterlyFinancialDataLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:to="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0ccea62b-6a9f-4a13-85e8-07598d4c1d32_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_853f6d43-2a24-4968-9356-57e9ac40ccfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fa1de036-b36b-4a45-9364-b334fa9b37aa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9446524b-84d0-4351-aecb-7a53fd0ca648_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_e775f498-679b-4839-be44-fbc29f89c87e_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Depreciation Property And Equipment</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets depreciation property and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:to="lab_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5f3f9297-f5f7-40d1-bc0c-204b7270fc75_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_cc7d3f24-fbe1-4cd7-86ce-f1517702f7fb_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_958947ff-84b8-4440-99cd-1d5e7cb9e12f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nktr-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b34aba47-bd43-4f7a-949b-84c5bc7946a0,g:a0d0df82-7542-4b00-8e8b-b5cca2744d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/Cover" xlink:type="simple" xlink:href="nktr-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:href="nktr-20201231.xsd#nktr_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_24ff4bf4-cec8-466c-ad1d-9d19b41571b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentType_24ff4bf4-cec8-466c-ad1d-9d19b41571b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c32161a6-5f0a-48fa-a045-a2901616c0bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentAnnualReport_c32161a6-5f0a-48fa-a045-a2901616c0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_77228e19-1049-4374-b590-b96adc37c705" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentPeriodEndDate_77228e19-1049-4374-b590-b96adc37c705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_43e4ce2b-26a1-452e-ba61-fe5d2a2e00bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_CurrentFiscalYearEndDate_43e4ce2b-26a1-452e-ba61-fe5d2a2e00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d7328fcc-e5f3-401f-a2fb-ba0cb6ab5da6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentTransitionReport_d7328fcc-e5f3-401f-a2fb-ba0cb6ab5da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e7e0f1fd-d9cb-4d00-bdaa-989bdbf35349" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityFileNumber_e7e0f1fd-d9cb-4d00-bdaa-989bdbf35349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2992a141-3270-45f9-8c5d-949fef3ad51a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityRegistrantName_2992a141-3270-45f9-8c5d-949fef3ad51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fd8cab90-0a60-4016-bae9-cc959dae242c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fd8cab90-0a60-4016-bae9-cc959dae242c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd672c25-536b-4faa-8786-50605e0a8b14" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd672c25-536b-4faa-8786-50605e0a8b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f29e8218-c82e-464a-a0a6-c15858576b52" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityAddressAddressLine1_f29e8218-c82e-464a-a0a6-c15858576b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ec8d2e64-3edd-4329-ac3f-a4ae868a8f73" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityAddressCityOrTown_ec8d2e64-3edd-4329-ac3f-a4ae868a8f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0143646d-9b78-4e45-8e7a-e40412d1a91b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityAddressStateOrProvince_0143646d-9b78-4e45-8e7a-e40412d1a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_66e3de69-1dbc-4fb5-b3cf-894abf3ea0ef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityAddressPostalZipCode_66e3de69-1dbc-4fb5-b3cf-894abf3ea0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7d4d5106-c533-46d8-87c9-9157035e2911" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_CityAreaCode_7d4d5106-c533-46d8-87c9-9157035e2911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_903ac39b-72a2-48c0-93d4-1d55dc075cad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_LocalPhoneNumber_903ac39b-72a2-48c0-93d4-1d55dc075cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_53718a4b-e2f2-4216-b3cc-55f74010b674" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_Security12bTitle_53718a4b-e2f2-4216-b3cc-55f74010b674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4db19f31-e0c5-4f9d-ab22-3e7818366665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_TradingSymbol_4db19f31-e0c5-4f9d-ab22-3e7818366665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d5cde374-dc4d-4036-b631-1a5679220416" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_SecurityExchangeName_d5cde374-dc4d-4036-b631-1a5679220416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_88d8e75a-b6f4-43ca-82a0-cc080f0f4670" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_88d8e75a-b6f4-43ca-82a0-cc080f0f4670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3251e96a-45fa-4208-b4bb-5311f7f738f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityVoluntaryFilers_3251e96a-45fa-4208-b4bb-5311f7f738f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9894dbbf-526c-4939-86af-31e0e5e1e4c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityCurrentReportingStatus_9894dbbf-526c-4939-86af-31e0e5e1e4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7b2a00fc-8ebf-4595-b343-65bf1926946f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityInteractiveDataCurrent_7b2a00fc-8ebf-4595-b343-65bf1926946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b0ac08f4-c34c-42e3-8881-54028b705708" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityFilerCategory_b0ac08f4-c34c-42e3-8881-54028b705708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7f392fc7-1532-4fed-a750-df85f67f499a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntitySmallBusiness_7f392fc7-1532-4fed-a750-df85f67f499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c89174c3-2d48-49b8-89af-3f62b2e12f6a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityEmergingGrowthCompany_c89174c3-2d48-49b8-89af-3f62b2e12f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b8166351-6128-4b4c-a1b8-da566e9098a0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b8166351-6128-4b4c-a1b8-da566e9098a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_012b14ab-4d58-40b6-a426-ab2d15edabbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityShellCompany_012b14ab-4d58-40b6-a426-ab2d15edabbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_76bdafba-7e73-4a58-b12c-d9dc33599e29" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityPublicFloat_76bdafba-7e73-4a58-b12c-d9dc33599e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_edbe1eb4-418b-45fe-ab62-1286250c946f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_edbe1eb4-418b-45fe-ab62-1286250c946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3993e582-79d6-4510-9435-bdfeeaca9601" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3993e582-79d6-4510-9435-bdfeeaca9601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_145bb6a1-218c-4d3a-a5f6-4ab4e98bfa3f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_AmendmentFlag_145bb6a1-218c-4d3a-a5f6-4ab4e98bfa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_359ecc35-923d-4ff2-9aee-eb69fa878761" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentFiscalYearFocus_359ecc35-923d-4ff2-9aee-eb69fa878761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1836b0b6-5b89-4379-98cd-3dd6c65eeed4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1836b0b6-5b89-4379-98cd-3dd6c65eeed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4e636235-d47c-4f97-92c1-431a6b28ba08" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_DocumentAndEntityInformationAbstract_447b44f5-7cb5-4fa9-8ef8-3490b9143931" xlink:to="loc_dei_EntityCentralIndexKey_4e636235-d47c-4f97-92c1-431a6b28ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_194d18d9-5966-48ca-a279-8c0c450c6f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_194d18d9-5966-48ca-a279-8c0c450c6f5c" xlink:to="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1abccdb9-de37-4940-8432-8a4153e3900d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1abccdb9-de37-4940-8432-8a4153e3900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8bd0356b-aa0e-4a48-ac53-767ba615af59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8bd0356b-aa0e-4a48-ac53-767ba615af59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_638fd1a9-c240-44fb-9053-d82d83cd8241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_638fd1a9-c240-44fb-9053-d82d83cd8241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0745198c-bcd9-431b-8c93-d89c42b380a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_us-gaap_InventoryNet_0745198c-bcd9-431b-8c93-d89c42b380a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_4bbe9836-312c-4b1b-bf5c-f12c9b41d990" xlink:href="nktr-20201231.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_4bbe9836-312c-4b1b-bf5c-f12c9b41d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_25909e26-dad8-4007-a0cc-3394be58f111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_us-gaap_OtherAssetsCurrent_25909e26-dad8-4007-a0cc-3394be58f111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f76dc04-0de0-42c5-88f0-15aadeaf6dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a84d27a9-5792-431a-877f-903fefa01e4d" xlink:to="loc_us-gaap_AssetsCurrent_3f76dc04-0de0-42c5-88f0-15aadeaf6dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3790e58f-9637-4d24-8c0c-68238c6ec5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3790e58f-9637-4d24-8c0c-68238c6ec5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_119dd232-b547-48b7-a5f5-f06911085e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_119dd232-b547-48b7-a5f5-f06911085e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_13dbe5bd-4581-4f15-a5d5-61ae2983f1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_13dbe5bd-4581-4f15-a5d5-61ae2983f1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c7880006-abe1-43d4-8f69-cc9a6413ff4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_Goodwill_c7880006-abe1-43d4-8f69-cc9a6413ff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c0e85b92-6052-4b5c-b9fe-2cbb7749b0c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c0e85b92-6052-4b5c-b9fe-2cbb7749b0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ce174a3c-ae46-4143-be0c-16fab7b2f455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d7bc6395-40d3-45d1-a966-9c53a7354726" xlink:to="loc_us-gaap_Assets_ce174a3c-ae46-4143-be0c-16fab7b2f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:href="nktr-20201231.xsd#nktr_LiabilitiesAndStockholdersEquityDeficitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_194d18d9-5966-48ca-a279-8c0c450c6f5c" xlink:to="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent_aae52fa5-de9c-444a-907b-9c7773d2edf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_SeniorNotesCurrent_aae52fa5-de9c-444a-907b-9c7773d2edf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_02c17482-01d3-410c-bd27-62133ea78552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_AccountsPayableCurrent_02c17482-01d3-410c-bd27-62133ea78552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ac778d2c-d910-42c8-b24b-2300c39f5a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ac778d2c-d910-42c8-b24b-2300c39f5a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_ab6ac31e-3236-4d60-88d1-81ea1e236858" xlink:href="nktr-20201231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_ab6ac31e-3236-4d60-88d1-81ea1e236858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_60a3635b-5a0f-4c81-83de-237b4b51faee" xlink:href="nktr-20201231.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_60a3635b-5a0f-4c81-83de-237b4b51faee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2f6dac63-0fbc-4591-992d-d2c582b5cdc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2f6dac63-0fbc-4591-992d-d2c582b5cdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_39af7d81-74a4-460c-9561-bb59b4914e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_39af7d81-74a4-460c-9561-bb59b4914e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b0e9285-6c8d-464f-87b0-b5cba64e2156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b0e9285-6c8d-464f-87b0-b5cba64e2156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_efc757d6-068e-4186-a050-0716050d25f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e6558a63-3bd9-4626-a6c5-addd0f3afe1a" xlink:to="loc_us-gaap_LiabilitiesCurrent_efc757d6-068e-4186-a050-0716050d25f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_81b5b129-a19e-4d82-b4b5-b5f3d2142347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_81b5b129-a19e-4d82-b4b5-b5f3d2142347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_425528c5-4c4c-492f-9eec-c592748c73c4" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_425528c5-4c4c-492f-9eec-c592748c73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46848aec-c6ed-4c1b-92b6-6e9c7b6190ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46848aec-c6ed-4c1b-92b6-6e9c7b6190ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_335ee164-6387-493a-9a43-e3b0573ac859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_335ee164-6387-493a-9a43-e3b0573ac859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7ea990d1-b570-4a09-b584-bba7e3aaa220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_Liabilities_7ea990d1-b570-4a09-b584-bba7e3aaa220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_05859c58-6545-425f-ba9d-ff1d90183b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_05859c58-6545-425f-ba9d-ff1d90183b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c1a3ffe1-f004-49ee-b89a-582a6e4d5cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:to="loc_us-gaap_PreferredStockValue_c1a3ffe1-f004-49ee-b89a-582a6e4d5cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b94ec90e-8cde-4ebc-8409-fab4964930b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:to="loc_us-gaap_CommonStockValue_b94ec90e-8cde-4ebc-8409-fab4964930b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8e64f9a8-32ac-4c0f-9c4a-539ed74b7f69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8e64f9a8-32ac-4c0f-9c4a-539ed74b7f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_548ec83b-2db9-4fa1-a0af-4853781611fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_548ec83b-2db9-4fa1-a0af-4853781611fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b168a590-9da3-4488-bb63-6c80c0d2c130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b168a590-9da3-4488-bb63-6c80c0d2c130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6dc56de-8de8-4af7-9e6a-ca979ca7a6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43b82b6a-c3d3-47df-8ebe-24a9c30966b5" xlink:to="loc_us-gaap_StockholdersEquity_d6dc56de-8de8-4af7-9e6a-ca979ca7a6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3a0b849-f56b-452b-92ef-55e184b562f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_161ee5c1-7489-45ef-81e9-b431592e63c8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3a0b849-f56b-452b-92ef-55e184b562f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81deb78e-cd3f-40d4-a47a-f887c7b9f3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81deb78e-cd3f-40d4-a47a-f887c7b9f3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b4a536e3-7b20-47e0-8bda-3ea6517641a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b4a536e3-7b20-47e0-8bda-3ea6517641a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_3e6bf040-1f5c-49df-987b-9b85cf430ec0" xlink:href="nktr-20201231.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_nktr_PreferredStockShareDesignated_3e6bf040-1f5c-49df-987b-9b85cf430ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_72915106-a6ff-431f-8d0e-9a20a6b2ee5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_72915106-a6ff-431f-8d0e-9a20a6b2ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_05aa9d7f-bf66-4a8c-8581-c527c35aae4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_05aa9d7f-bf66-4a8c-8581-c527c35aae4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec5c4295-7d89-42e1-9545-6f2bcaaf8405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec5c4295-7d89-42e1-9545-6f2bcaaf8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1f8646eb-4367-4775-9db9-c3a7d3fb58da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1f8646eb-4367-4775-9db9-c3a7d3fb58da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_29e58867-1f86-4ab0-972b-30b75afeed0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_CommonStockSharesIssued_29e58867-1f86-4ab0-972b-30b75afeed0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eacfa0d7-1cbc-4703-aff6-8933548e824a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_074f4d0f-1510-4324-ace8-9c857155c11c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eacfa0d7-1cbc-4703-aff6-8933548e824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fb78c27b-3879-4a00-808b-f36fd31395c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb78c27b-3879-4a00-808b-f36fd31395c8" xlink:to="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:to="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_921daef0-4058-4156-bc64-2b50350df6f5" xlink:to="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_da737f05-e76d-47fb-a09d-86f9a4be26dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_us-gaap_ProductMember_da737f05-e76d-47fb-a09d-86f9a4be26dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_402d32d8-58c6-408c-83d8-d3278e057ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_us-gaap_RoyaltyMember_402d32d8-58c6-408c-83d8-d3278e057ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_bc1e835d-33db-4226-b199-bb03459e0c20" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_bc1e835d-33db-4226-b199-bb03459e0c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_086ae4b8-11b5-48e8-8276-25473877bfd6" xlink:href="nktr-20201231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a35cb430-d427-4e6b-985c-ac0fc680323e" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_086ae4b8-11b5-48e8-8276-25473877bfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c4aa5b2-7b4f-4416-9dc8-5539fd804cad" xlink:to="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1fe3270a-e26d-4f48-a98c-7378ac2e3503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_RevenuesAbstract_1fe3270a-e26d-4f48-a98c-7378ac2e3503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_896b1925-eccc-49a6-b3c1-84012cc28bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1fe3270a-e26d-4f48-a98c-7378ac2e3503" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_896b1925-eccc-49a6-b3c1-84012cc28bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0252d1ea-3001-4d24-8de4-dfe4780e27a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0252d1ea-3001-4d24-8de4-dfe4780e27a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aac4e67d-1a0b-48c1-b70d-800c2370e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aac4e67d-1a0b-48c1-b70d-800c2370e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d982f28f-13f3-4401-b5cb-c4bff300ae34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d982f28f-13f3-4401-b5cb-c4bff300ae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_9082cc3c-b375-4095-a7b1-752e5946a1f2" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_9082cc3c-b375-4095-a7b1-752e5946a1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_826312b5-263e-4bd1-9b9d-3fa60f4a4748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f30ad3db-908f-41e8-826c-21d06640c158" xlink:to="loc_us-gaap_CostsAndExpenses_826312b5-263e-4bd1-9b9d-3fa60f4a4748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8d6936a0-ae86-482a-bfa2-7f2bae1ad690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_OperatingIncomeLoss_8d6936a0-ae86-482a-bfa2-7f2bae1ad690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_160671c1-5ff7-4a52-aead-9cfcf834e2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_us-gaap_InterestExpense_160671c1-5ff7-4a52-aead-9cfcf834e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1c45bb18-3327-4195-9b9c-bf3dd2414347" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1c45bb18-3327-4195-9b9c-bf3dd2414347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5759172e-1a69-4b11-855f-167133de2c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5759172e-1a69-4b11-855f-167133de2c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e09d5556-a034-4669-b719-ad00a497f568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9800222b-36ff-4352-8774-48307b33fae5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e09d5556-a034-4669-b719-ad00a497f568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7212c2ca-df24-484c-b919-0836ef847495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7212c2ca-df24-484c-b919-0836ef847495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_413a8824-6a51-49a5-b233-05221e725092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_413a8824-6a51-49a5-b233-05221e725092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33f2f104-95a8-4214-835d-2067dd5cc5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_NetIncomeLoss_33f2f104-95a8-4214-835d-2067dd5cc5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a12f7b60-3bff-4b20-817a-4fa25be79840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:to="loc_us-gaap_EarningsPerShareBasic_a12f7b60-3bff-4b20-817a-4fa25be79840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0f446626-87de-4c8c-8e34-fed996452d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a967c68e-ae9e-4f00-8775-e2a8bd3af180" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0f446626-87de-4c8c-8e34-fed996452d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_752d199c-1fff-4bef-81d9-ae0c47a8a13b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db3b6ef2-5a55-4920-baab-8177f64fbfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db3b6ef2-5a55-4920-baab-8177f64fbfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_798b006a-85d4-4968-9367-0222aae6f5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f2e454bc-dbbe-4ab0-95f2-4522595af998" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_798b006a-85d4-4968-9367-0222aae6f5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="nktr-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac9b5a3f-0110-45b7-863d-7a3cef24e843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f60dd308-11a3-4644-af00-b86a75b84bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac9b5a3f-0110-45b7-863d-7a3cef24e843" xlink:to="loc_us-gaap_NetIncomeLoss_f60dd308-11a3-4644-af00-b86a75b84bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edf8b146-2af2-41b1-8bcc-e667a285d79a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac9b5a3f-0110-45b7-863d-7a3cef24e843" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edf8b146-2af2-41b1-8bcc-e667a285d79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e4e48c7a-0301-48b9-8092-5dca9a93c29a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edf8b146-2af2-41b1-8bcc-e667a285d79a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e4e48c7a-0301-48b9-8092-5dca9a93c29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8ff73b93-7230-4cfa-be4d-81fcaaac7202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edf8b146-2af2-41b1-8bcc-e667a285d79a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8ff73b93-7230-4cfa-be4d-81fcaaac7202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_082a9bfc-0456-4aa4-a079-7f0ee8695175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edf8b146-2af2-41b1-8bcc-e667a285d79a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_082a9bfc-0456-4aa4-a079-7f0ee8695175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a87cf2e0-4d22-44e0-a61e-3c4904a4c756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac9b5a3f-0110-45b7-863d-7a3cef24e843" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a87cf2e0-4d22-44e0-a61e-3c4904a4c756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8311e347-6534-457b-b542-f9f11c752ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8311e347-6534-457b-b542-f9f11c752ed8" xlink:to="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_752eab6d-8b31-4340-8dea-840d4d20f439" xlink:to="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be1b6243-f28e-4df6-9109-8f944ef5250b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_CommonStockMember_be1b6243-f28e-4df6-9109-8f944ef5250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_59a557c8-6599-4f18-960e-fb62ec8e221b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_59a557c8-6599-4f18-960e-fb62ec8e221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c377d377-31b6-4a9f-968c-ce72372518c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c377d377-31b6-4a9f-968c-ce72372518c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c01869c0-36c6-48fc-94a4-ee3b03eef6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb9c0638-a075-4808-a127-81b503097481" xlink:to="loc_us-gaap_RetainedEarningsMember_c01869c0-36c6-48fc-94a4-ee3b03eef6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ab86c7f6-04f3-4395-841c-ea832d533704" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5c681410-c1a5-46a6-9bdc-9a70f3deb694" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ab86c7f6-04f3-4395-841c-ea832d533704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_caaadfa7-14fc-4bbc-93a9-25bf870a1240" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ab86c7f6-04f3-4395-841c-ea832d533704" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_caaadfa7-14fc-4bbc-93a9-25bf870a1240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bef133b5-3e1a-4607-a4c8-1bafde9c9b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a39efd-1236-4e37-9d03-d720b8637478" xlink:to="loc_us-gaap_StatementLineItems_bef133b5-3e1a-4607-a4c8-1bafde9c9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bef133b5-3e1a-4607-a4c8-1bafde9c9b08" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9303aa0e-bb1d-4fd5-8327-dcbb8f0d96d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_SharesOutstanding_9303aa0e-bb1d-4fd5-8327-dcbb8f0d96d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3ee02c38-1e94-4f1a-87e0-c54c756f7202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockholdersEquity_3ee02c38-1e94-4f1a-87e0-c54c756f7202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19ec7ad8-6a9d-4ad9-8066-214c731174f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19ec7ad8-6a9d-4ad9-8066-214c731174f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c7508364-76dc-42e2-9f9c-810bc1e4ad17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c7508364-76dc-42e2-9f9c-810bc1e4ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f13a224-8518-4db4-ae63-ca489f979efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f13a224-8518-4db4-ae63-ca489f979efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9c2014f-3041-45a7-9c32-954323e57163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9c2014f-3041-45a7-9c32-954323e57163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_92a706eb-3378-40ba-9dae-da22d3ae9213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_92a706eb-3378-40ba-9dae-da22d3ae9213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_db96d9ee-87ed-46f8-82f9-9a8debc6e1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_db96d9ee-87ed-46f8-82f9-9a8debc6e1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4fa23917-56a9-4d7b-8950-809343adb7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_SharesOutstanding_4fa23917-56a9-4d7b-8950-809343adb7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb7093d1-59f1-4bd2-9f97-d0fa8079e6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8abd006b-006c-416d-86b9-93c5f502da87" xlink:to="loc_us-gaap_StockholdersEquity_fb7093d1-59f1-4bd2-9f97-d0fa8079e6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d9e252ad-0d66-4fad-a665-0fe166f441d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d9e252ad-0d66-4fad-a665-0fe166f441d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3d96525e-9612-407a-af5b-83f37c9ad606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d9e252ad-0d66-4fad-a665-0fe166f441d8" xlink:to="loc_us-gaap_ProfitLoss_3d96525e-9612-407a-af5b-83f37c9ad606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d9e252ad-0d66-4fad-a665-0fe166f441d8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_024cad31-6bb5-4b93-b856-aae424eb74e2" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_024cad31-6bb5-4b93-b856-aae424eb74e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a6626f1f-2c0c-48a5-bc1c-bb3075176151" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a6626f1f-2c0c-48a5-bc1c-bb3075176151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2810241e-a903-40bb-8df4-0e0828a51ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2810241e-a903-40bb-8df4-0e0828a51ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6f5fd759-0d16-47c7-b265-b1b498777b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_us-gaap_DepreciationAndAmortization_6f5fd759-0d16-47c7-b265-b1b498777b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_228deee2-4d8b-4126-b1b0-0f348357eb20" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_228deee2-4d8b-4126-b1b0-0f348357eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_53913c5b-0283-4ba4-85f5-404f901959bb" xlink:href="nktr-20201231.xsd#nktr_AccretionOfDiscountNetAndOtherNonCashTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions_53913c5b-0283-4ba4-85f5-404f901959bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46912c70-cc76-415b-a200-bcfcc41145e1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a120ba49-8236-44ce-a804-8f6d93bb0213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a120ba49-8236-44ce-a804-8f6d93bb0213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9fe8dd56-abd2-4535-b80d-d949136292e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9fe8dd56-abd2-4535-b80d-d949136292e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_2bb258e4-3862-4f02-9fc7-df44e23c5370" xlink:href="nktr-20201231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_2bb258e4-3862-4f02-9fc7-df44e23c5370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b401af86-8634-494e-9c09-a84e30d3aca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b401af86-8634-494e-9c09-a84e30d3aca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_01e1bbd6-0e1c-4e59-ab5d-2c3515cf67ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_01e1bbd6-0e1c-4e59-ab5d-2c3515cf67ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d1b2a6ba-a3ef-4afb-a04c-8995ad3b3baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d1b2a6ba-a3ef-4afb-a04c-8995ad3b3baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e91f370a-82c0-4f47-ac72-65c2dc89a20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e91f370a-82c0-4f47-ac72-65c2dc89a20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3bcb2ec9-d772-4d46-911a-34d8bcbacbfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4e9e2b2f-570b-460a-9112-55b5d2aa4885" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3bcb2ec9-d772-4d46-911a-34d8bcbacbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9922ff95-3803-4ef9-8ea8-694e51dfe2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d9e252ad-0d66-4fad-a665-0fe166f441d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9922ff95-3803-4ef9-8ea8-694e51dfe2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_17c06a32-8330-49bd-ac49-69c51cb94a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_17c06a32-8330-49bd-ac49-69c51cb94a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5328fb81-9199-4565-adda-a81ea0d4b6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5328fb81-9199-4565-adda-a81ea0d4b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6e5d1bfe-e512-4589-be68-ef696be3e70a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6e5d1bfe-e512-4589-be68-ef696be3e70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70c8d160-0ca4-47d3-959d-b455a802e9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70c8d160-0ca4-47d3-959d-b455a802e9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2715e3c-ce10-4e0c-ace4-3b23a589d3a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2715e3c-ce10-4e0c-ace4-3b23a589d3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ba3c135-87e1-4875-adf2-6478dee4b49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceb26850-b4c1-43c6-9cac-3d8c7281e339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ba3c135-87e1-4875-adf2-6478dee4b49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_7c0dc76e-f539-4322-93b8-7425ae127729" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:to="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_7c0dc76e-f539-4322-93b8-7425ae127729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_b1a3154d-8a09-4def-b014-588ab1aece69" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:to="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_b1a3154d-8a09-4def-b014-588ab1aece69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_199dfd92-25bf-4a57-a80e-035044282900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_199dfd92-25bf-4a57-a80e-035044282900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_47add3a6-f092-4d94-be75-f7c8a68bbf1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_47add3a6-f092-4d94-be75-f7c8a68bbf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4210d393-b515-4716-adeb-0f50c435a169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90c61e06-9784-41dc-a540-ed821ef1a91c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4210d393-b515-4716-adeb-0f50c435a169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_444ddeaa-767d-4733-9a8c-fff4d6fd8940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_444ddeaa-767d-4733-9a8c-fff4d6fd8940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2eeabe9-8db2-48b5-99c4-1f8f381a8da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2eeabe9-8db2-48b5-99c4-1f8f381a8da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_148fe19f-e97f-43a9-bff7-9a84f34907e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_148fe19f-e97f-43a9-bff7-9a84f34907e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_133c39e6-4919-4373-806c-9893b4a15c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_133c39e6-4919-4373-806c-9893b4a15c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_07d7aee1-dab0-4f45-a864-7d4c8b1b736e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d1d1562-46dd-4870-8dd5-1492a6239a7b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_07d7aee1-dab0-4f45-a864-7d4c8b1b736e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fe5401bc-8258-4e63-885d-2fd2ef61201a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07d7aee1-dab0-4f45-a864-7d4c8b1b736e" xlink:to="loc_us-gaap_InterestPaidNet_fe5401bc-8258-4e63-885d-2fd2ef61201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_510b0878-12bf-45f7-95ed-4ee50910c035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07d7aee1-dab0-4f45-a864-7d4c8b1b736e" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_510b0878-12bf-45f7-95ed-4ee50910c035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dbf318d9-df8f-4b0f-b93f-70b5ec01628d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07d7aee1-dab0-4f45-a864-7d4c8b1b736e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dbf318d9-df8f-4b0f-b93f-70b5ec01628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nktr-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4bcae350-3e82-4d3b-b387-53eb18e8adf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts_e2b7edf6-6b07-4bb8-bb67-9476233ebd1c" xlink:href="nktr-20201231.xsd#nktr_SaleOfFutureRoyaltiesTransactionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4bcae350-3e82-4d3b-b387-53eb18e8adf3" xlink:to="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts_e2b7edf6-6b07-4bb8-bb67-9476233ebd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d90de5b-a899-4929-8449-5e7eb25e79a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_d2f80c21-2db6-45c1-97cd-9ce88102afba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d90de5b-a899-4929-8449-5e7eb25e79a9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_d2f80c21-2db6-45c1-97cd-9ce88102afba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_39320242-5f5e-4403-9acc-771f45fc6080" xlink:href="nktr-20201231.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_nktr_OrganizationPolicyTextBlock_39320242-5f5e-4403-9acc-771f45fc6080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_280d42f9-60d0-4d52-9b88-e75c79523ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_280d42f9-60d0-4d52-9b88-e75c79523ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_7c148eb8-e571-402f-8571-dc1f2066bd15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_7c148eb8-e571-402f-8571-dc1f2066bd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0264cc24-3b56-46bd-882b-fa50d4b732e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0264cc24-3b56-46bd-882b-fa50d4b732e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9c5c2fcf-75aa-4a0a-82b9-49a7e0fd1ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9c5c2fcf-75aa-4a0a-82b9-49a7e0fd1ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_ac8c6557-e46b-4554-ab12-2f421008a107" xlink:href="nktr-20201231.xsd#nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_ac8c6557-e46b-4554-ab12-2f421008a107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_7ff67b76-04f8-4d6c-bbef-6c3a041a88cb" xlink:href="nktr-20201231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_7ff67b76-04f8-4d6c-bbef-6c3a041a88cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_680010f5-38ff-46a1-9b3e-65149ca8cc2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_680010f5-38ff-46a1-9b3e-65149ca8cc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_73698ce6-2ba6-43d6-b5f9-513b3f2a13f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_73698ce6-2ba6-43d6-b5f9-513b3f2a13f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_a0bd5932-0b66-4097-abcb-204ec9542ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_a0bd5932-0b66-4097-abcb-204ec9542ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_502ca48e-1328-434a-9d0d-bab597d9d878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_502ca48e-1328-434a-9d0d-bab597d9d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock_1596b0ec-4710-48f2-93b1-0a810d8d5bf5" xlink:href="nktr-20201231.xsd#nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock_1596b0ec-4710-48f2-93b1-0a810d8d5bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9ce5003c-65de-4def-8a45-d68bdfa52770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9ce5003c-65de-4def-8a45-d68bdfa52770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_9c7a25dd-074b-40fb-a87d-261dd1a77a8c" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_9c7a25dd-074b-40fb-a87d-261dd1a77a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_538c624a-9257-46f8-a0aa-00e28da436d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_538c624a-9257-46f8-a0aa-00e28da436d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3b2b82bd-ccde-40d6-84e2-9239c41f4850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3b2b82bd-ccde-40d6-84e2-9239c41f4850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f1e4aef9-0ba4-42f8-9d80-c9bdb9d484eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f1e4aef9-0ba4-42f8-9d80-c9bdb9d484eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_194c21e5-6018-41ab-a9dc-8db48ae59f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_194c21e5-6018-41ab-a9dc-8db48ae59f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock_9ab894ea-0464-42fe-80cd-3615e8f9af8c" xlink:href="nktr-20201231.xsd#nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock_9ab894ea-0464-42fe-80cd-3615e8f9af8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6044e3f3-7b9e-4663-b799-816a64417287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd41a31-4312-4cf5-9412-c9bafea4f4a1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6044e3f3-7b9e-4663-b799-816a64417287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb876ae2-b7e8-43e6-ac27-536fb602e26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:href="nktr-20201231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb876ae2-b7e8-43e6-ac27-536fb602e26a" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31231f00-a204-4b80-b852-feeda810c0de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_4737237e-c4ee-4fd5-bb14-2c2ceb4046dc" xlink:href="nktr-20201231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_4737237e-c4ee-4fd5-bb14-2c2ceb4046dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a632bd95-6642-4572-b6b3-a43562c57dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d78d192-2c0c-436f-a257-1bbcec6ef68f" xlink:to="loc_us-gaap_BuildingMember_a632bd95-6642-4572-b6b3-a43562c57dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2e15dbc0-b148-49a6-8ebd-c8beaf8b41ce" xlink:to="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e273a17-7c61-43cb-b3e3-b27d0d4bd446" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:to="loc_srt_MinimumMember_2e273a17-7c61-43cb-b3e3-b27d0d4bd446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb1a7873-d252-46c3-9d74-90a7fa9e13ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dbd0c9d0-2011-47f9-bc94-7c8f9f3467a5" xlink:to="loc_srt_MaximumMember_cb1a7873-d252-46c3-9d74-90a7fa9e13ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f36c9944-bfe4-47c0-bb69-d65872b2f803" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c950d41-c630-4502-8209-68184d348099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c950d41-c630-4502-8209-68184d348099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_c428c43e-754c-4a41-9343-ecc49c6458bc" xlink:href="nktr-20201231.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac684248-ea5c-41d0-adaa-2f9c4def1933" xlink:to="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_c428c43e-754c-4a41-9343-ecc49c6458bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_585806b7-fe5d-4363-b46b-864055f31972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f025e06-d620-4ab0-af07-94e35a877b2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_585806b7-fe5d-4363-b46b-864055f31972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_7fa202ff-98ed-411f-a636-3dcf3ede5cc9" xlink:href="nktr-20201231.xsd#nktr_A775PercentSeniorSecuredNotesDueOctober2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_585806b7-fe5d-4363-b46b-864055f31972" xlink:to="loc_nktr_A775PercentSeniorSecuredNotesDueOctober2020Member_7fa202ff-98ed-411f-a636-3dcf3ede5cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4079afc5-6b60-4ced-96b8-c645d0899e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7858a446-f2c0-4c56-8e3e-fa6f42988856" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4079afc5-6b60-4ced-96b8-c645d0899e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aa3ee8f9-a9aa-4c4b-be08-8332a30d727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4079afc5-6b60-4ced-96b8-c645d0899e81" xlink:to="loc_us-gaap_SeniorNotesMember_aa3ee8f9-a9aa-4c4b-be08-8332a30d727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54145fa8-cd14-4937-a6ed-2312f566af9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ca3811fb-d346-4259-8fe7-eaeea834887f" xlink:to="loc_srt_ProductsAndServicesDomain_54145fa8-cd14-4937-a6ed-2312f566af9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_f60b4811-2342-4399-88dd-1bbf86986efe" xlink:href="nktr-20201231.xsd#nktr_NKTR181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54145fa8-cd14-4937-a6ed-2312f566af9b" xlink:to="loc_nktr_NKTR181Member_f60b4811-2342-4399-88dd-1bbf86986efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2ef012c-9bd2-41d9-827f-ff59f7274b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6f667f76-e4ab-4e45-a049-cd2fa8afab6e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2ef012c-9bd2-41d9-827f-ff59f7274b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a14c654c-7429-480d-a181-35b484489cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2ef012c-9bd2-41d9-827f-ff59f7274b3c" xlink:to="loc_us-gaap_AccountsReceivableMember_a14c654c-7429-480d-a181-35b484489cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_18069a62-9984-4df7-ad3a-454e6a90ca49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c4f0e9d7-15c6-449a-8bb6-6ec545bf7016" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_18069a62-9984-4df7-ad3a-454e6a90ca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_64a6a52a-2b77-407e-833a-aae03a37f3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_18069a62-9984-4df7-ad3a-454e6a90ca49" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_64a6a52a-2b77-407e-833a-aae03a37f3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_eb3112f9-6123-4f58-a586-caf14b3f37cd" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerOneMember_f6859ee8-b32c-412c-995e-330bd9742e4e" xlink:href="nktr-20201231.xsd#nktr_PartnerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:to="loc_nktr_PartnerOneMember_f6859ee8-b32c-412c-995e-330bd9742e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerTwoMember_e33f43a3-e20f-4dab-b730-263ef3a5fc3e" xlink:href="nktr-20201231.xsd#nktr_PartnerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:to="loc_nktr_PartnerTwoMember_e33f43a3-e20f-4dab-b730-263ef3a5fc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartnerThreeMember_2bfbd777-741c-49a0-bcdb-23b6a28ed4ca" xlink:href="nktr-20201231.xsd#nktr_PartnerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae247b7c-1b82-4389-8de7-cd7cd4ca7fd8" xlink:to="loc_nktr_PartnerThreeMember_2bfbd777-741c-49a0-bcdb-23b6a28ed4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:href="nktr-20201231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3237806c-da66-4331-aa9f-cfb177c096ec" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6dda55b2-9646-4850-9dbc-e09f605f2d5b" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6dda55b2-9646-4850-9dbc-e09f605f2d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0b7c0029-b0e4-4c1a-b79b-e9eeb02f5ecb" xlink:href="nktr-20201231.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_0b7c0029-b0e4-4c1a-b79b-e9eeb02f5ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_cf76053a-5230-4fa6-8252-1459523c4cba" xlink:href="nktr-20201231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_cf76053a-5230-4fa6-8252-1459523c4cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_10a7de36-25c8-4b3d-9645-16b9feb63277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_10a7de36-25c8-4b3d-9645-16b9feb63277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_9cb3ace2-9aff-40f1-868d-6e8496a17e4d" xlink:href="nktr-20201231.xsd#nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales_9cb3ace2-9aff-40f1-868d-6e8496a17e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ad7fc52c-2ff7-4cf3-a536-498b78c71015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ad7fc52c-2ff7-4cf3-a536-498b78c71015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ee66db66-e8dd-4671-b25f-ab8f562f9d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ee66db66-e8dd-4671-b25f-ab8f562f9d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_9e11ebbd-36d0-450d-b7da-5842a47c697d" xlink:href="nktr-20201231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_9e11ebbd-36d0-450d-b7da-5842a47c697d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_e0664c61-c12e-4730-ab14-60997134485f" xlink:href="nktr-20201231.xsd#nktr_WriteOffOfPrepayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_nktr_WriteOffOfPrepayment_e0664c61-c12e-4730-ab14-60997134485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_02f3bf55-ad3e-46da-b6a6-0b4cd806e718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_02f3bf55-ad3e-46da-b6a6-0b4cd806e718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b3d4d949-d3a9-4c3c-9b35-74ad0e3c1b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b3d4d949-d3a9-4c3c-9b35-74ad0e3c1b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7b959616-f751-41fa-a5a1-86172bc6c9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_85d2842b-311b-4d4d-895f-e04cfc34ad81" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7b959616-f751-41fa-a5a1-86172bc6c9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7ad710af-ad0b-4adc-97e3-2f93306d9e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8e6d975a-40cc-483e-b994-eeeea4d1ab9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7ad710af-ad0b-4adc-97e3-2f93306d9e82" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8e6d975a-40cc-483e-b994-eeeea4d1ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_225a3790-1b25-4dfe-b677-7075933a0199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ddd8ca07-e1ca-455e-a1d3-74d9e31bb955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_225a3790-1b25-4dfe-b677-7075933a0199" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ddd8ca07-e1ca-455e-a1d3-74d9e31bb955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fc074bff-ddbe-44c4-b4d9-3ea74701149a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_225a3790-1b25-4dfe-b677-7075933a0199" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fc074bff-ddbe-44c4-b4d9-3ea74701149a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_393d7661-54b8-41a3-9b67-0032dccfd40c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4439cb8b-55ec-424c-8403-6b77b9067e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_393d7661-54b8-41a3-9b67-0032dccfd40c" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4439cb8b-55ec-424c-8403-6b77b9067e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e44bc71-3a3a-4eca-a499-3c28d0a95f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4439cb8b-55ec-424c-8403-6b77b9067e93" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e44bc71-3a3a-4eca-a499-3c28d0a95f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_da811bd8-04b9-4cc3-9a21-42cc2412c0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4439cb8b-55ec-424c-8403-6b77b9067e93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_da811bd8-04b9-4cc3-9a21-42cc2412c0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3d1d6e7e-18a9-433b-a60a-6c4a591ce355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4439cb8b-55ec-424c-8403-6b77b9067e93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3d1d6e7e-18a9-433b-a60a-6c4a591ce355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f4bbdb30-6704-49de-b30f-e7e56b804f77" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4439cb8b-55ec-424c-8403-6b77b9067e93" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f4bbdb30-6704-49de-b30f-e7e56b804f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_de19fe86-3347-46e5-a642-49677eb198ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:href="nktr-20201231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_de19fe86-3347-46e5-a642-49677eb198ce" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:to="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e41775bb-36d2-44ff-ae3c-8e75e6b9e67c" xlink:to="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a7e4d65-3cd8-4fc5-a011-31d39826d582" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:to="loc_srt_MinimumMember_6a7e4d65-3cd8-4fc5-a011-31d39826d582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1c1e7c0-e985-4ac9-bb82-319f7587a50f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8e1f0885-8da5-4434-b7e3-4b91ee877ff0" xlink:to="loc_srt_MaximumMember_d1c1e7c0-e985-4ac9-bb82-319f7587a50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:href="nktr-20201231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_63d4c30a-5a6c-41b4-8c49-c55b280b1ba2" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_1e22fecc-6d2c-4287-ad36-077b65417f05" xlink:href="nktr-20201231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_1e22fecc-6d2c-4287-ad36-077b65417f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c817bceb-121c-49da-9946-0e9a837cdd53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c817bceb-121c-49da-9946-0e9a837cdd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_ac2763ba-3b5e-486f-a676-1e3811389689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_InterestReceivableCurrent_ac2763ba-3b5e-486f-a676-1e3811389689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_0c19eba7-7367-42a1-b7a7-1d5a02b26ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_0c19eba7-7367-42a1-b7a7-1d5a02b26ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_ac1148f1-add2-4f0c-bae6-3ebefcdec910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_ac1148f1-add2-4f0c-bae6-3ebefcdec910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_77686b4b-71ba-4526-9209-35d419500d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_77686b4b-71ba-4526-9209-35d419500d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a46409-7cae-4bdd-8f68-ed7221e0bb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50a46409-7cae-4bdd-8f68-ed7221e0bb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_99935710-132b-4be5-9598-46cb01342017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_407eaa80-48cf-4cba-852e-4419ed212fd7" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_99935710-132b-4be5-9598-46cb01342017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7eb09241-710b-4611-9ec9-c97855762d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7eb09241-710b-4611-9ec9-c97855762d31" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:to="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_d7aef914-de8b-418b-b84d-599981d735b3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52842a8d-5e9b-4b8e-a9ae-2396d4a15118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52842a8d-5e9b-4b8e-a9ae-2396d4a15118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14253849-bb2b-4ce9-927f-20205038f843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_CommercialPaperMember_14253849-bb2b-4ce9-927f-20205038f843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4154cac0-369c-4bf1-a37b-d72a54fd0f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4154cac0-369c-4bf1-a37b-d72a54fd0f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f0b4872e-54f0-4718-acad-6354042b0e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f0b4872e-54f0-4718-acad-6354042b0e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_14192073-8dfc-4850-a4b1-5c78d4916c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_726d0d3c-b500-40af-8787-1a70d2872239" xlink:to="loc_us-gaap_CertificatesOfDepositMember_14192073-8dfc-4850-a4b1-5c78d4916c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4adc71d7-d5f1-4651-9ef3-7834d2c8766b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6790142e-a58f-430f-ac0a-1220ad610610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6790142e-a58f-430f-ac0a-1220ad610610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab5dc6d9-b071-47d4-ba8b-f932d04719a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a334a03-5acc-4ca6-9a1c-079b74788dd5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab5dc6d9-b071-47d4-ba8b-f932d04719a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60b61bc6-9004-41bf-a81c-7a68b45a3f33" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d1e95a6-8f0d-4eb3-a959-7b77e1a52a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d1e95a6-8f0d-4eb3-a959-7b77e1a52a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fcf720ec-c32b-426a-8f2a-3e7ce40647a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fcf720ec-c32b-426a-8f2a-3e7ce40647a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_72acb4aa-8cb6-4288-842d-46104b0ee5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_72acb4aa-8cb6-4288-842d-46104b0ee5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e9c524b-186e-4411-81fb-4ae7b75bc6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e9c524b-186e-4411-81fb-4ae7b75bc6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_938cbe18-d5bb-4e5f-99ab-f8fc63d553a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_938cbe18-d5bb-4e5f-99ab-f8fc63d553a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_fd1ea022-be7d-495e-a626-d1336bd7bf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_us-gaap_Cash_fd1ea022-be7d-495e-a626-d1336bd7bf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_65851f03-6d01-4f23-9e13-0d5b25c6e7c4" xlink:href="nktr-20201231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_033d44fd-3bbd-47f1-8ee3-a10bc60a36fc" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_65851f03-6d01-4f23-9e13-0d5b25c6e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20201231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f9fe71f3-db94-4fa2-8759-a92fd037c647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_f588d892-b5ac-4fac-ba45-3d97446828f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f9fe71f3-db94-4fa2-8759-a92fd037c647" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_f588d892-b5ac-4fac-ba45-3d97446828f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_70867722-a293-4de6-b934-ce1d55e7c388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ecbfd8b7-b45e-4afc-90ba-fdf8a86120f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70867722-a293-4de6-b934-ce1d55e7c388" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ecbfd8b7-b45e-4afc-90ba-fdf8a86120f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#InventoryDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0b8bea3a-01a2-44cc-8164-0f1b74a449c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5072e6f4-51a6-48a0-885a-e44c77796b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0b8bea3a-01a2-44cc-8164-0f1b74a449c1" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5072e6f4-51a6-48a0-885a-e44c77796b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3917fe5-be7d-47bf-a351-877ecbfbfbd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0b8bea3a-01a2-44cc-8164-0f1b74a449c1" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3917fe5-be7d-47bf-a351-877ecbfbfbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be485f6d-e45d-40bf-bd44-bd52b5bd4e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0b8bea3a-01a2-44cc-8164-0f1b74a449c1" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be485f6d-e45d-40bf-bd44-bd52b5bd4e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_16d7a8b7-3947-4bb1-965f-a3819aa3955f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0b8bea3a-01a2-44cc-8164-0f1b74a449c1" xlink:to="loc_us-gaap_InventoryNet_16d7a8b7-3947-4bb1-965f-a3819aa3955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_be3878d7-44c3-480e-b75b-f4d2c7341b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bf55517b-f1ed-4ccc-b396-d6a2a267d0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_be3878d7-44c3-480e-b75b-f4d2c7341b01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bf55517b-f1ed-4ccc-b396-d6a2a267d0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ab7298f4-2d9d-43e2-a575-e71297da4c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_74343a8e-83ec-4bb5-a96a-afc0f34cea1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ab7298f4-2d9d-43e2-a575-e71297da4c69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_74343a8e-83ec-4bb5-a96a-afc0f34cea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c299ac43-b269-47a0-a5ef-8da8bf8f7f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c299ac43-b269-47a0-a5ef-8da8bf8f7f70" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b5778e9-14e8-4d18-a9af-0a07e1aaef91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_ef7fd25e-b261-4db3-8ea4-2843d6891e43" xlink:href="nktr-20201231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_ef7fd25e-b261-4db3-8ea4-2843d6891e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_a852a93f-447c-4950-91b9-cb9088f2a12a" xlink:href="nktr-20201231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_LaboratoryEquipmentMember_a852a93f-447c-4950-91b9-cb9088f2a12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_70e25ecd-af99-4423-a08b-8d62b91e81d4" xlink:href="nktr-20201231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_70e25ecd-af99-4423-a08b-8d62b91e81d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_1bd5b32a-4d09-4488-826d-0193f340a8f2" xlink:href="nktr-20201231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_1bd5b32a-4d09-4488-826d-0193f340a8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_37600278-aff4-4085-9efd-c78e13ff9641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb968d26-a87d-43c0-a78d-499dd3b47474" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_37600278-aff4-4085-9efd-c78e13ff9641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ebace06f-79b3-4129-b475-fd997e8e602b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_ad97b37f-0404-48a2-90c7-9f1f37b1df5b" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_ad97b37f-0404-48a2-90c7-9f1f37b1df5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac7a6ae6-5bef-47e2-832c-c0938b7b3313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac7a6ae6-5bef-47e2-832c-c0938b7b3313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_da526baa-2def-47d0-93e5-33c6eff4416a" xlink:href="nktr-20201231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_da526baa-2def-47d0-93e5-33c6eff4416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ad02e6b4-7ed3-4380-aee3-82b4c3985568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_ConstructionInProgressGross_ad02e6b4-7ed3-4380-aee3-82b4c3985568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e7d7153b-bf02-4b67-9b68-0de24bcf6052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdfdc893-8bc1-41e5-b9db-521ffacdbf4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e7d7153b-bf02-4b67-9b68-0de24bcf6052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#PropertyPlantandEquipmentAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8c91490a-ed5b-41ee-b0f6-6c61c7816bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a08d4002-f50e-4a4d-8a90-396ebf48d2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8c91490a-ed5b-41ee-b0f6-6c61c7816bc7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a08d4002-f50e-4a4d-8a90-396ebf48d2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="simple" xlink:href="nktr-20201231.xsd#SeniorSecuredNotes"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ff33ccb1-ad75-4381-a940-974e6d38533a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_961f75dd-9cba-4cd3-9921-2a7b7da99b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ff33ccb1-ad75-4381-a940-974e6d38533a" xlink:to="loc_us-gaap_LongTermDebtTextBlock_961f75dd-9cba-4cd3-9921-2a7b7da99b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SeniorSecuredNotesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fa1f8c7b-ec21-4003-b2b3-2bcd9cce0fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:href="nktr-20201231.xsd#nktr_SecuredNotesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fa1f8c7b-ec21-4003-b2b3-2bcd9cce0fe1" xlink:to="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb276ec7-2683-42c9-a53f-0b29f7ed11cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b55add7e-12bf-4b2e-a043-a0c082f9b5c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb276ec7-2683-42c9-a53f-0b29f7ed11cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e6089886-55cc-4207-9951-1985fbee7929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb276ec7-2683-42c9-a53f-0b29f7ed11cc" xlink:to="loc_us-gaap_SeniorNotesMember_e6089886-55cc-4207-9951-1985fbee7929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:to="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99461e4f-8b99-4251-86f4-0b48457a3e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb06c507-2c5a-4c0b-8b62-d1389995665d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99461e4f-8b99-4251-86f4-0b48457a3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_d1d7a682-4f12-4271-a813-2970a8e6a133" xlink:href="nktr-20201231.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99461e4f-8b99-4251-86f4-0b48457a3e58" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_d1d7a682-4f12-4271-a813-2970a8e6a133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:href="nktr-20201231.xsd#nktr_SecuredNotesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesTable_66c49301-c8f5-4c40-9a60-9a2bfa3edb70" xlink:to="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_b20cf7c0-1801-4d9b-a89a-1215ba3a6f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_SeniorNotes_b20cf7c0-1801-4d9b-a89a-1215ba3a6f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e112bc5-072c-4877-ad08-b8ce62c1d68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e112bc5-072c-4877-ad08-b8ce62c1d68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_76336482-94e3-4341-92e2-ac90a794b208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_76336482-94e3-4341-92e2-ac90a794b208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_1724a8f8-b323-4dda-8293-dae3b18769e5" xlink:href="nktr-20201231.xsd#nktr_DebtDiscountOnTransactionAndFacilityFeesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid_1724a8f8-b323-4dda-8293-dae3b18769e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_0bf46367-9018-462b-8833-a2b93f6f2977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_0bf46367-9018-462b-8833-a2b93f6f2977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_0e6e7585-69db-4511-af19-792e098f8e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SecuredNotesLineItems_f3cab47c-4c06-43d4-8e13-c9644248b1e7" xlink:to="loc_us-gaap_InterestReceivable_0e6e7585-69db-4511-af19-792e098f8e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Leases" xlink:type="simple" xlink:href="nktr-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_195aa986-ad6d-4524-ac20-d01586777b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_593760b7-5c27-48e4-98a7-f53557d96bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_195aa986-ad6d-4524-ac20-d01586777b80" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_593760b7-5c27-48e4-98a7-f53557d96bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a459bdbd-69ac-4d6d-a473-dffb95e4ada6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_d4c11da2-e9ba-47c4-826d-6acb7adffce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a459bdbd-69ac-4d6d-a473-dffb95e4ada6" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_d4c11da2-e9ba-47c4-826d-6acb7adffce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e4fb1946-368b-43ff-86d1-770621dceb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a459bdbd-69ac-4d6d-a473-dffb95e4ada6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e4fb1946-368b-43ff-86d1-770621dceb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe4a73a2-56f2-48c7-8b3a-6362f0b8672f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a459bdbd-69ac-4d6d-a473-dffb95e4ada6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe4a73a2-56f2-48c7-8b3a-6362f0b8672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6011faa1-118f-4ed1-85e1-2760d71bb2b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6011faa1-118f-4ed1-85e1-2760d71bb2b0" xlink:to="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:to="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_5cc2c2f3-b9d5-466e-ae2c-55c785f61456" xlink:to="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_7e2ad3f1-faaa-4544-a25b-da22e73e98cf" xlink:href="nktr-20201231.xsd#nktr_MissionBayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:to="loc_nktr_MissionBayLeaseMember_7e2ad3f1-faaa-4544-a25b-da22e73e98cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_f94a7efa-6bac-4689-8609-851111defc18" xlink:href="nktr-20201231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4f565902-0d8d-47db-a5e0-faa0efba81ec" xlink:to="loc_nktr_ThirdStreetLeaseMember_f94a7efa-6bac-4689-8609-851111defc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:href="nktr-20201231.xsd#nktr_LeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_95d94992-62c1-4758-b6eb-a844dee532df" xlink:to="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace_2bf46316-c48f-4dd9-be46-5afcf48d4547" xlink:href="nktr-20201231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_nktr_AreaOfLeasedSpace_2bf46316-c48f-4dd9-be46-5afcf48d4547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b812fcc4-2016-4721-b66b-ef47b8cc4137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeaseCost_b812fcc4-2016-4721-b66b-ef47b8cc4137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49f42adb-cd4e-43a1-93f7-b9e33a41ca0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeasePayments_49f42adb-cd4e-43a1-93f7-b9e33a41ca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20b24df1-ceab-44de-a531-8a492c28dc88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20b24df1-ceab-44de-a531-8a492c28dc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bbf3d586-30a8-4e86-bea1-f40af22249d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_3e0fa34f-44c8-4c18-a9ff-2e0ce65c50be" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bbf3d586-30a8-4e86-bea1-f40af22249d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2a5178b0-c35b-4773-a3cc-a3d2f89d0585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a5178b0-c35b-4773-a3cc-a3d2f89d0585" xlink:to="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:to="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_42062bd6-b8c6-4c94-92ff-9d5df7d77844" xlink:to="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_73e51780-28dc-4fff-b398-c55ea0775273" xlink:href="nktr-20201231.xsd#nktr_MissionBayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:to="loc_nktr_MissionBayLeaseMember_73e51780-28dc-4fff-b398-c55ea0775273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_6c9d10b2-7d33-435e-825d-931f28286714" xlink:href="nktr-20201231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_d0351b73-3f53-4ac0-b3fb-43ce1658b0ec" xlink:to="loc_nktr_ThirdStreetLeaseMember_6c9d10b2-7d33-435e-825d-931f28286714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:href="nktr-20201231.xsd#nktr_LeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_0195c9ca-1ba7-4036-8ce2-fe63751236a1" xlink:to="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpaceDelivered_166be7fc-4049-4248-bc70-1f1f0eba0396" xlink:href="nktr-20201231.xsd#nktr_AreaOfLeasedSpaceDelivered"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_AreaOfLeasedSpaceDelivered_166be7fc-4049-4248-bc70-1f1f0eba0396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_303a1f4b-1dfc-4e91-b1ad-7db89931bf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_303a1f4b-1dfc-4e91-b1ad-7db89931bf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease_b0da9e3c-3439-4855-8ed7-e53dc38c39ac" xlink:href="nktr-20201231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_NumberOfConsecutiveTermsToExtendLease_b0da9e3c-3439-4855-8ed7-e53dc38c39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm_8c5f99a0-eef8-442c-9025-582cfc5849e6" xlink:href="nktr-20201231.xsd#nktr_LeaseExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_1ff4fd41-e2b5-474a-ac3e-13dd95294e12" xlink:to="loc_nktr_LeaseExtensionTerm_8c5f99a0-eef8-442c-9025-582cfc5849e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesScheduleofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a79ac726-4342-437c-b561-a63a674c4ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f460da05-5958-4e2d-8269-fb5a12c79877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a79ac726-4342-437c-b561-a63a674c4ec1" xlink:to="loc_us-gaap_OperatingLeaseCost_f460da05-5958-4e2d-8269-fb5a12c79877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_2bd77747-3305-4e90-9e75-e44c3a9386a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a79ac726-4342-437c-b561-a63a674c4ec1" xlink:to="loc_us-gaap_VariableLeaseCost_2bd77747-3305-4e90-9e75-e44c3a9386a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5225df59-d22a-4fc1-ad29-68d060c8a2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a79ac726-4342-437c-b561-a63a674c4ec1" xlink:to="loc_us-gaap_LeaseCost_5225df59-d22a-4fc1-ad29-68d060c8a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c8cd016-f291-49e7-8c8c-6610ab92d456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c8cd016-f291-49e7-8c8c-6610ab92d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31607d5e-cec4-4479-a97b-45b8c5d26e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31607d5e-cec4-4479-a97b-45b8c5d26e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38df59c3-c8d4-407d-8d59-343d8369cbc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38df59c3-c8d4-407d-8d59-343d8369cbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e3ec86e5-e127-4ea8-9f1e-02ada8064ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e3ec86e5-e127-4ea8-9f1e-02ada8064ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a6c3317c-3868-44c3-84db-312b56756c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a6c3317c-3868-44c3-84db-312b56756c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9f72ba16-d351-4f5a-bc89-41dd6c7cc042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9f72ba16-d351-4f5a-bc89-41dd6c7cc042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10a02441-c59d-4cee-90ca-ecdc99044f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10a02441-c59d-4cee-90ca-ecdc99044f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_247b1ce7-7e76-49d9-a902-770c4e9d4f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_247b1ce7-7e76-49d9-a902-770c4e9d4f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_b29d309f-ab43-4075-996b-17c730b07530" xlink:href="nktr-20201231.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_b29d309f-ab43-4075-996b-17c730b07530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_35fd45db-e2cb-41c4-a4d9-d9d2b16e3504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_OperatingLeaseLiability_35fd45db-e2cb-41c4-a4d9-d9d2b16e3504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c4df085a-6014-49b8-8811-19a4e0e2132e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c4df085a-6014-49b8-8811-19a4e0e2132e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5a437073-34ba-4793-95af-7899ca040ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d4d8b-94a8-4f70-8cfd-66aa12dd9bd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5a437073-34ba-4793-95af-7899ca040ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="simple" xlink:href="nktr-20201231.xsd#LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_1da43912-496d-4986-a401-163a2cc1e273" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_aa49aaf5-7ba0-4c37-900c-cc3db22620fa" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_1da43912-496d-4986-a401-163a2cc1e273" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_aa49aaf5-7ba0-4c37-900c-cc3db22620fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_477fc7ed-233a-43ba-9575-e40e2e394046" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_50fe7eda-44ea-4931-8d56-779cc497f8da" xlink:href="nktr-20201231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_477fc7ed-233a-43ba-9575-e40e2e394046" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_50fe7eda-44ea-4931-8d56-779cc497f8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2b346b20-9214-4d41-8ce7-3c3f03b5581c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2b346b20-9214-4d41-8ce7-3c3f03b5581c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7a778091-5514-4681-b451-a11e942d46c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_4548fceb-80fc-4a96-851f-519031bd9f45" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_4548fceb-80fc-4a96-851f-519031bd9f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_c5f9b63d-858d-475d-95cc-4102e62e8784" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_c5f9b63d-858d-475d-95cc-4102e62e8784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_58c88d72-5098-45c6-a006-d58a198ae53b" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c49f5240-1487-4a91-b73b-bdbb1346cd7e" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_58c88d72-5098-45c6-a006-d58a198ae53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bd4eeb82-2a9d-4e2b-9fab-a3ae03a69dd8" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_8ed44ca0-39f1-4bd5-8f54-5857a381145d" xlink:href="nktr-20201231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_8ed44ca0-39f1-4bd5-8f54-5857a381145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_d1a64bdd-d77a-4197-8e1d-f18ea3cc8574" xlink:href="nktr-20201231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_d1a64bdd-d77a-4197-8e1d-f18ea3cc8574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_1483f22f-7577-452d-95d1-fdd094ce72cd" xlink:href="nktr-20201231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_1483f22f-7577-452d-95d1-fdd094ce72cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_4e137d18-86d2-4ee3-8a03-94f29d0d82ca" xlink:href="nktr-20201231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_4e137d18-86d2-4ee3-8a03-94f29d0d82ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyAgreementContingentPaymentDescription_0bd99c95-e30a-4906-9652-a6c601d13979" xlink:href="nktr-20201231.xsd#nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_RoyaltyAgreementContingentPaymentDescription_0bd99c95-e30a-4906-9652-a6c601d13979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_5ebf8352-314c-464b-b546-2e178fe3f443" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_5ebf8352-314c-464b-b546-2e178fe3f443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_ba282ee3-76d1-47dd-b13c-ef18c11ef849" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_ba282ee3-76d1-47dd-b13c-ef18c11ef849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_f809424d-210b-4a17-b9e0-92673d930190" xlink:href="nktr-20201231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_f809424d-210b-4a17-b9e0-92673d930190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_7fb048f8-408b-48d1-9a8f-83bbebfad8bb" xlink:href="nktr-20201231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_7fb048f8-408b-48d1-9a8f-83bbebfad8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_91c3cb42-329f-4533-80b0-74f494eee4d0" xlink:href="nktr-20201231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_4484efb1-7ceb-4554-bd85-6be897399c7f" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_91c3cb42-329f-4533-80b0-74f494eee4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5c3848a2-34c9-4dc2-83d6-743d159580b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_0b833083-e157-442f-a44a-b276c88f3fb3" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5c3848a2-34c9-4dc2-83d6-743d159580b8" xlink:to="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_0b833083-e157-442f-a44a-b276c88f3fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5c3848a2-34c9-4dc2-83d6-743d159580b8" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12db0b91-d6a8-4a56-a2ce-c51739e1c427" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_67b7c6de-abd2-44e2-b39a-8a935e317338" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_67b7c6de-abd2-44e2-b39a-8a935e317338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_3d98e2c9-435d-4da8-9f94-f10ea815182a" xlink:href="nktr-20201231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ac0782b-c2de-4eaf-b0e8-bb779fa62c7c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_3d98e2c9-435d-4da8-9f94-f10ea815182a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_2d11c4e6-b013-4f66-889a-a19071671808" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_556f55f5-d2ce-4047-98b8-a0d672d51286" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_556f55f5-d2ce-4047-98b8-a0d672d51286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_65c871b4-2ad6-4404-a905-2e4ab954f275" xlink:href="nktr-20201231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_65c871b4-2ad6-4404-a905-2e4ab954f275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_684d463a-ec8e-4d57-adce-9fcf1674718d" xlink:href="nktr-20201231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_684d463a-ec8e-4d57-adce-9fcf1674718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_e961456b-da32-4b27-a354-e2b9c9fe8aaa" xlink:href="nktr-20201231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_e961456b-da32-4b27-a354-e2b9c9fe8aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_446c78de-dfb3-418f-a125-c3c6885e2e35" xlink:href="nktr-20201231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_446c78de-dfb3-418f-a125-c3c6885e2e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_893a7b1f-44cd-4c3e-97ab-077804bd5ee9" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_893a7b1f-44cd-4c3e-97ab-077804bd5ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_380fa831-73a8-45b1-a08e-70d8963f34bd" xlink:href="nktr-20201231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_380fa831-73a8-45b1-a08e-70d8963f34bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_59c40467-ac9e-4209-b52d-c21db523c953" xlink:href="nktr-20201231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_59c40467-ac9e-4209-b52d-c21db523c953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_91465fb3-1cc7-4990-91f2-63a1d8782d09" xlink:href="nktr-20201231.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_91465fb3-1cc7-4990-91f2-63a1d8782d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_41d31a4d-0c62-4c9d-8675-7ef318fcba9a" xlink:href="nktr-20201231.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_6f23cb85-5b61-4e14-bb01-4dd0a19376a0" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_41d31a4d-0c62-4c9d-8675-7ef318fcba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_38e91c6f-5367-49a5-94d3-6dffcbcced83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7f7fc47b-74e1-405c-a2b7-37959461cfef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_38e91c6f-5367-49a5-94d3-6dffcbcced83" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7f7fc47b-74e1-405c-a2b7-37959461cfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#CommitmentsandContingenciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15e559d6-3f1a-405a-a8ba-29d459bda8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15e559d6-3f1a-405a-a8ba-29d459bda8b6" xlink:to="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4fcfad6c-20db-4933-8c0b-f43849df989b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_fc31232e-f67e-428e-8908-5e94a40cfbb4" xlink:href="nktr-20201231.xsd#nktr_LegalMattersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_LegalMattersMember_fc31232e-f67e-428e-8908-5e94a40cfbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_d21d7a12-7360-4bb2-b10c-880d4b1483bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_d21d7a12-7360-4bb2-b10c-880d4b1483bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommercialAgreementsMember_5b762e36-8c97-4e04-a08b-cf94b7e68a1b" xlink:href="nktr-20201231.xsd#nktr_CommercialAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_CommercialAgreementsMember_5b762e36-8c97-4e04-a08b-cf94b7e68a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_c3085bf9-a507-4ca1-9794-e4dc166c09de" xlink:href="nktr-20201231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_c3085bf9-a507-4ca1-9794-e4dc166c09de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember_44d85ca8-dd77-4904-9dd8-e76fba411a7e" xlink:href="nktr-20201231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_SecuritiesRelatedClaimsMember_44d85ca8-dd77-4904-9dd8-e76fba411a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember_f6bcfbf8-6576-4187-9c78-482323312992" xlink:href="nktr-20201231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8ea5e604-8de1-4de1-b67e-133b3ff1b736" xlink:to="loc_nktr_NonSecuritiesRelatedClaimsMember_f6bcfbf8-6576-4187-9c78-482323312992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:to="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21fe1323-6a63-417b-81e0-da562d5ad1f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e819c4db-8acb-4aaa-b2af-6a67083517f5" xlink:to="loc_srt_RangeMember_21fe1323-6a63-417b-81e0-da562d5ad1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9798eaa-f8c4-4302-b0c4-adb9f69d40ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_21fe1323-6a63-417b-81e0-da562d5ad1f4" xlink:to="loc_srt_MaximumMember_d9798eaa-f8c4-4302-b0c4-adb9f69d40ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b907e13a-b9eb-4932-8cc2-3e4eb45c9bcc" xlink:to="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_230a2205-e57e-4151-855e-643039433c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_230a2205-e57e-4151-855e-643039433c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_52b9020a-0069-462d-abb8-c7107be7c277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_52b9020a-0069-462d-abb8-c7107be7c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_6ba4a93a-a682-4965-9819-561304a0b6c9" xlink:href="nktr-20201231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d5e25626-727e-4744-a326-bf7e087ca26a" xlink:to="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_6ba4a93a-a682-4965-9819-561304a0b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquity" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c6bc8929-0a61-47e8-8f69-94677db20732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ff85cdb-9d79-40ad-aad3-b289e2b2a531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c6bc8929-0a61-47e8-8f69-94677db20732" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ff85cdb-9d79-40ad-aad3-b289e2b2a531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockholdersEquityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f959835d-3706-4612-a711-44c5da84353c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f959835d-3706-4612-a711-44c5da84353c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6de77311-af21-41d4-ad50-e6d38a410cc0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember_8e22afcf-92ba-4b0e-b55d-bfc6a43d688d" xlink:href="nktr-20201231.xsd#nktr_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:to="loc_nktr_EmployeeMember_8e22afcf-92ba-4b0e-b55d-bfc6a43d688d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_56ac7b8d-2dbc-47bf-ad95-838099ba99f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fd194ecb-4cee-4a58-974d-2b40830840d0" xlink:to="loc_srt_DirectorMember_56ac7b8d-2dbc-47bf-ad95-838099ba99f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec628fb3-70b6-4bbe-b7b6-540386151d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97b5325f-b950-4635-bba8-4e57d9776398" xlink:to="loc_us-gaap_EquityComponentDomain_ec628fb3-70b6-4bbe-b7b6-540386151d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6ded1557-ddf7-467b-bdc8-6a3f5a715a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec628fb3-70b6-4bbe-b7b6-540386151d93" xlink:to="loc_us-gaap_CommonStockMember_6ded1557-ddf7-467b-bdc8-6a3f5a715a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d73d1d2d-6e8e-48f5-9ff9-c5c7c4f85464" xlink:to="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_5d553ae1-4760-41f8-b955-41831d921e0d" xlink:href="nktr-20201231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_5d553ae1-4760-41f8-b955-41831d921e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_ebe0183b-7d03-46a1-b7a5-0ef06803101c" xlink:href="nktr-20201231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_ebe0183b-7d03-46a1-b7a5-0ef06803101c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmendedAndRestated2017PlanMember_86366505-1812-4335-927d-725712ec1451" xlink:href="nktr-20201231.xsd#nktr_AmendedAndRestated2017PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cccbc202-2bd9-466c-8979-bd45f3298302" xlink:to="loc_nktr_AmendedAndRestated2017PlanMember_86366505-1812-4335-927d-725712ec1451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4d88cadd-f405-4af9-ad38-0540fc96ce5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f534df30-7d89-49cf-8eee-eafa4a4cfe50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f534df30-7d89-49cf-8eee-eafa4a4cfe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember_f4e29a41-2af7-4aea-92df-e2aba3fa28ec" xlink:href="nktr-20201231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:to="loc_nktr_RSUsAndPSUsMember_f4e29a41-2af7-4aea-92df-e2aba3fa28ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_baa76052-cf05-425c-9e1b-b3eb7c137594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342243fe-7894-4054-9397-b530aa4d2ef2" xlink:to="loc_us-gaap_EmployeeStockMember_baa76052-cf05-425c-9e1b-b3eb7c137594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df9fc972-5864-4f14-86d5-4739589b5d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_691165e0-66e3-470c-9632-68bc330e863c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df9fc972-5864-4f14-86d5-4739589b5d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_af9c3f3e-0af8-4f7d-8005-52246a82b286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df9fc972-5864-4f14-86d5-4739589b5d55" xlink:to="loc_us-gaap_EmployeeStockMember_af9c3f3e-0af8-4f7d-8005-52246a82b286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4bd9e10f-7474-4a61-bd8e-47c323adac99" xlink:to="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c3b1aab-cf56-4009-9545-e480d78f95d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c3b1aab-cf56-4009-9545-e480d78f95d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_e9a9e69c-03b0-4f0f-a6e0-385ada712a33" xlink:href="nktr-20201231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_e9a9e69c-03b0-4f0f-a6e0-385ada712a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b623779-9215-4c5f-a2c5-773945bbc775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b623779-9215-4c5f-a2c5-773945bbc775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_47e737cf-fdb7-4632-98d6-2bff621dbb32" xlink:href="nktr-20201231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding_47e737cf-fdb7-4632-98d6-2bff621dbb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_fc9edc01-c128-412e-9244-b66ddc12c093" xlink:href="nktr-20201231.xsd#nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans_fc9edc01-c128-412e-9244-b66ddc12c093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c2ec371-2039-4cd2-83b1-7c63d5d2a360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c2ec371-2039-4cd2-83b1-7c63d5d2a360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CommonStockAdditionalSharesAuthorized_16287c59-b556-4f23-b9db-3c47c7d41a4c" xlink:href="nktr-20201231.xsd#nktr_CommonStockAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_CommonStockAdditionalSharesAuthorized_16287c59-b556-4f23-b9db-3c47c7d41a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_939c4f96-3f03-4c3b-b5e6-240619a60dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_939c4f96-3f03-4c3b-b5e6-240619a60dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_a22efc10-64a8-453f-98d9-4d8841d7f0b6" xlink:href="nktr-20201231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_a22efc10-64a8-453f-98d9-4d8841d7f0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e90a60ae-f193-4e8f-8414-ae746bc683b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e90a60ae-f193-4e8f-8414-ae746bc683b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76b42534-f223-413d-a33f-f83d6d589f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76b42534-f223-413d-a33f-f83d6d589f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1226e42d-c2e6-47c5-bb23-629bcdc966fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1226e42d-c2e6-47c5-bb23-629bcdc966fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfPurchasePriceOfStock_2fbe7f0f-7019-4e09-8a28-a838d2de6325" xlink:href="nktr-20201231.xsd#nktr_PercentageOfPurchasePriceOfStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_PercentageOfPurchasePriceOfStock_2fbe7f0f-7019-4e09-8a28-a838d2de6325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_bb147dc1-0ec5-45c1-98e4-630992b64831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_bb147dc1-0ec5-45c1-98e4-630992b64831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_afcf0905-b8a6-4f9c-8c40-b5ff90edbb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_afcf0905-b8a6-4f9c-8c40-b5ff90edbb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0ffac528-cc31-4961-a1fb-770627630faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0ffac528-cc31-4961-a1fb-770627630faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_32cc3278-cd58-4ec3-86eb-02af6c595c68" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_32cc3278-cd58-4ec3-86eb-02af6c595c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_9d5ad794-4b01-48a5-be15-69db784fbb37" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer_9d5ad794-4b01-48a5-be15-69db784fbb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_d07c1d3c-f5e5-41ba-ad7f-e443b905a34d" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents_d07c1d3c-f5e5-41ba-ad7f-e443b905a34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_7614f06b-0b2d-4a97-9cbd-4c4513c54bea" xlink:href="nktr-20201231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForEmployees"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dbe3b04c-a0ef-4a0a-bdc6-e0a0d3fa55ef" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForEmployees_7614f06b-0b2d-4a97-9cbd-4c4513c54bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46b95384-7e34-4119-93de-4fa9d8fd4176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6c14d54b-53d5-4851-b5fb-cb25447d5b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46b95384-7e34-4119-93de-4fa9d8fd4176" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6c14d54b-53d5-4851-b5fb-cb25447d5b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f057424f-fe43-4d2a-9738-cb987600793d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_df59b4cc-7895-41d5-8b4d-39720b651ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f057424f-fe43-4d2a-9738-cb987600793d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_df59b4cc-7895-41d5-8b4d-39720b651ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_3d854a0d-1119-4ccb-8393-a76e27b3d986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f057424f-fe43-4d2a-9738-cb987600793d" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_3d854a0d-1119-4ccb-8393-a76e27b3d986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7740086d-45d1-4879-a8ec-71a1afa22d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:href="nktr-20201231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7740086d-45d1-4879-a8ec-71a1afa22d6a" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:to="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d9a0af63-6603-4e0d-bbfb-df6bd2d30e99" xlink:to="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9137dc47-7ae5-4b5d-bb83-f950702e5846" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9137dc47-7ae5-4b5d-bb83-f950702e5846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_2b4f54a1-b71d-4873-8ab9-f4f71e9c5ca9" xlink:href="nktr-20201231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_EliLillyAndCompanyMember_2b4f54a1-b71d-4873-8ab9-f4f71e9c5ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_ca192a83-1c6d-4425-b2ce-f8c4d17d5009" xlink:href="nktr-20201231.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_AmgenIncMember_ca192a83-1c6d-4425-b2ce-f8c4d17d5009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_d7f058c3-1313-443a-bef1-5502c71b95ca" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_d7f058c3-1313-443a-bef1-5502c71b95ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_f02112df-9a54-451a-96d4-50e138066ebf" xlink:href="nktr-20201231.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_53181d66-7426-4dc0-a72a-633e71a6747b" xlink:to="loc_nktr_OtherPartnerMember_f02112df-9a54-451a-96d4-50e138066ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0f73ce15-7e37-4603-bdbc-e8e3ba09b73d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember_fa9cb9ac-703f-459d-9449-df62b2473c56" xlink:href="nktr-20201231.xsd#nktr_BempegaldesleukinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_BempegaldesleukinMember_fa9cb9ac-703f-459d-9449-df62b2473c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_a045bae1-4faf-4a03-928c-8074335bec06" xlink:href="nktr-20201231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_NektarThreeFiveEightMember_a045bae1-4faf-4a03-928c-8074335bec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_3e944674-b878-4fe5-83e4-83a922d413f7" xlink:href="nktr-20201231.xsd#nktr_NeulastaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_NeulastaMember_3e944674-b878-4fe5-83e4-83a922d413f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_ee64d1a8-1270-49d1-acd2-127b58b01f66" xlink:href="nktr-20201231.xsd#nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d65bc8e1-8791-4be1-863e-65e2e012fdaa" xlink:to="loc_nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember_ee64d1a8-1270-49d1-acd2-127b58b01f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_8f660edc-789a-4dc9-b75b-ec1b9ed4a736" xlink:href="nktr-20201231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_b004bcec-bb63-49a9-ae8d-b7c41ce2ebd8" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_8f660edc-789a-4dc9-b75b-ec1b9ed4a736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_580eef4e-263a-4f2a-9ee6-142a61567070" xlink:href="nktr-20201231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_8f660edc-789a-4dc9-b75b-ec1b9ed4a736" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_580eef4e-263a-4f2a-9ee6-142a61567070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba2c71b3-49ac-4522-bbcb-2d4d012be7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba2c71b3-49ac-4522-bbcb-2d4d012be7d3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:href="nktr-20201231.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_889d56ef-360c-4737-b7bb-7bf7f09a563f" xlink:href="nktr-20201231.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_f80dd81e-a89a-4a49-86d8-aa54cbfeec32" xlink:to="loc_nktr_MilestoneDomain_889d56ef-360c-4737-b7bb-7bf7f09a563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_4159cead-18d8-4f53-a842-a2b78b5595d4" xlink:href="nktr-20201231.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_889d56ef-360c-4737-b7bb-7bf7f09a563f" xlink:to="loc_nktr_MilestoneOneMember_4159cead-18d8-4f53-a842-a2b78b5595d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2746eff6-3549-471a-9ef3-7c72a2d438dd" xlink:to="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_2a716ab1-d6da-4386-80c4-bbff89e5041e" xlink:href="nktr-20201231.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_EliLillyMember_2a716ab1-d6da-4386-80c4-bbff89e5041e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9d1eb7e8-8c09-4f3a-a3bf-234bff051528" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9d1eb7e8-8c09-4f3a-a3bf-234bff051528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_e311226e-37bc-4afd-bfd2-3f527e6d00a3" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_e311226e-37bc-4afd-bfd2-3f527e6d00a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_41f2716b-d419-4a90-a0fa-54d9a3d839e3" xlink:href="nktr-20201231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_EliLillyAndCompanyMember_41f2716b-d419-4a90-a0fa-54d9a3d839e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_42e2b3be-dba4-4262-bd67-1874ac6f97a3" xlink:href="nktr-20201231.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_AmgenIncMember_42e2b3be-dba4-4262-bd67-1874ac6f97a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_78e0b81e-0e79-4594-aa90-2f31e84fcd0c" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAbMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_AstraZenecaAbMember_78e0b81e-0e79-4594-aa90-2f31e84fcd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_008cf2eb-2711-449d-bc38-81c5b5b3995f" xlink:href="nktr-20201231.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_OtherPartnerMember_008cf2eb-2711-449d-bc38-81c5b5b3995f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember_e1dc9023-eab4-478f-b230-6e4b26bfbb13" xlink:href="nktr-20201231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c0f40546-c728-4e3f-9034-eab999712147" xlink:to="loc_nktr_TerminatedPartnershipMember_e1dc9023-eab4-478f-b230-6e4b26bfbb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7f73976d-52c6-423d-8db9-f0bb836f0306" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_4cd47ef5-4a5a-4130-828b-be17ee110d9e" xlink:href="nktr-20201231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_BMSCollaborationAgreementMember_4cd47ef5-4a5a-4130-828b-be17ee110d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ClinicalTrialAgreementMember_807590bd-a3dc-481f-aacf-f2553393d566" xlink:href="nktr-20201231.xsd#nktr_ClinicalTrialAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_ClinicalTrialAgreementMember_807590bd-a3dc-481f-aacf-f2553393d566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember_04d11aaa-a571-4c34-8abc-bdb8fd9a980e" xlink:href="nktr-20201231.xsd#nktr_HemophiliaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_HemophiliaMember_04d11aaa-a571-4c34-8abc-bdb8fd9a980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_a29a2477-8f4c-4416-86a5-e381fbffd77c" xlink:href="nktr-20201231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_NektarThreeFiveEightMember_a29a2477-8f4c-4416-86a5-e381fbffd77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_85c56b08-6caf-4e00-b22f-69f41fbe0fe6" xlink:href="nktr-20201231.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_85c56b08-6caf-4e00-b22f-69f41fbe0fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_9884c90c-d87c-48be-90f3-30da113217fe" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_9884c90c-d87c-48be-90f3-30da113217fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_65d14550-6d54-48cc-b5d1-1c5ae10b62ae" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_65d14550-6d54-48cc-b5d1-1c5ae10b62ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_f57959a2-2113-4484-b539-cfae849e6bc5" xlink:href="nktr-20201231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_Nektar358Member_f57959a2-2113-4484-b539-cfae849e6bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_98b63b06-5cff-4527-a588-4e2b52334c00" xlink:href="nktr-20201231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_98b63b06-5cff-4527-a588-4e2b52334c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_bcfe0ccb-6e86-49da-a7e8-85a500b25d67" xlink:href="nktr-20201231.xsd#nktr_NektarMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_NektarMember_bcfe0ccb-6e86-49da-a7e8-85a500b25d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_4ea43c59-617b-4cdf-86ef-bb0add0c0279" xlink:href="nktr-20201231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd591146-6059-42e9-8670-d56f13bbb7f1" xlink:to="loc_nktr_DrugProductDevelopmentMember_4ea43c59-617b-4cdf-86ef-bb0add0c0279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_897e75c8-dcdd-4911-840b-f013b86c70a3" xlink:to="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_e4ff20c3-4702-4e02-9705-f4f727993337" xlink:href="nktr-20201231.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:to="loc_nktr_Nektar214Member_e4ff20c3-4702-4e02-9705-f4f727993337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_d0743520-eb8b-4242-a01f-fc00af1c9e3c" xlink:href="nktr-20201231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7612511d-e418-4550-ae3e-d3c99c4f515e" xlink:to="loc_nktr_Nektar358Member_d0743520-eb8b-4242-a01f-fc00af1c9e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_11e18ebd-89a7-4372-8a94-04dfb5c05afb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_63ea7304-9f44-4609-bb52-39b89a6c87b6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_11e18ebd-89a7-4372-8a94-04dfb5c05afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_3758a04b-d8d8-4448-8948-f3946d67eab4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_11e18ebd-89a7-4372-8a94-04dfb5c05afb" xlink:to="loc_srt_ParentCompanyMember_3758a04b-d8d8-4448-8948-f3946d67eab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b6fda05-9216-42a4-8318-d48d17ba3e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_eea6d965-064c-4d31-8ef4-a363e316092d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b6fda05-9216-42a4-8318-d48d17ba3e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_78820410-de20-4734-8a8c-b88901f4adae" xlink:href="nktr-20201231.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b6fda05-9216-42a4-8318-d48d17ba3e71" xlink:to="loc_nktr_OpdivoMember_78820410-de20-4734-8a8c-b88901f4adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dd6ddd78-0068-42b1-b29b-da77a6d3a342" xlink:to="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9bace6da-9e26-45b2-ad55-62a42739e557" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:to="loc_srt_MaximumMember_9bace6da-9e26-45b2-ad55-62a42739e557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2dfa0ba3-70fc-4abc-a9b6-ad8592ed2e0e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ea3f9c8-e0b7-46d6-9e4d-8cde2552de48" xlink:to="loc_srt_MinimumMember_2dfa0ba3-70fc-4abc-a9b6-ad8592ed2e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49df09a5-29f4-447c-8009-2feba385ba65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_200411da-4707-4691-813d-4af96a87d9f0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49df09a5-29f4-447c-8009-2feba385ba65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_c66b5e03-e2fc-4cba-959b-d81acfe6be3c" xlink:href="nktr-20201231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49df09a5-29f4-447c-8009-2feba385ba65" xlink:to="loc_nktr_SharePurchaseAgreementMember_c66b5e03-e2fc-4cba-959b-d81acfe6be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b8c5bb00-ccfd-453b-b049-4719e2b404a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd0d8e55-ce78-4422-ab20-9909d071e566" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b8c5bb00-ccfd-453b-b049-4719e2b404a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09186d77-1682-4119-aa0f-5dce79ca4b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b8c5bb00-ccfd-453b-b049-4719e2b404a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_09186d77-1682-4119-aa0f-5dce79ca4b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f71d88ef-75c8-43ee-a398-8b9030ed96a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2b365bdf-9721-46cf-a0ef-48d47372a233" xlink:to="loc_srt_SegmentGeographicalDomain_f71d88ef-75c8-43ee-a398-8b9030ed96a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_e61abfa8-3363-44ee-9118-5b6afd98bf88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f71d88ef-75c8-43ee-a398-8b9030ed96a0" xlink:to="loc_us-gaap_EuropeanUnionMember_e61abfa8-3363-44ee-9118-5b6afd98bf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d92c178a-a5dd-478d-a049-62274ebd3877" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_36b96db2-90f0-46b6-9438-d495ba1ec3c6" xlink:href="nktr-20201231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_36b96db2-90f0-46b6-9438-d495ba1ec3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_8bbb330f-573e-4b02-8b6b-f9d11ab536ba" xlink:href="nktr-20201231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:to="loc_nktr_DrugProductDevelopmentMember_8bbb330f-573e-4b02-8b6b-f9d11ab536ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember_a7330a2b-b5b9-4114-9704-2815748d48ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_61aad492-b97c-425d-a5ab-897b81ae1dbf" xlink:to="loc_us-gaap_UpFrontPaymentArrangementMember_a7330a2b-b5b9-4114-9704-2815748d48ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5d563508-a797-4fe8-91ec-4d17f7d6f00e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_a8395426-6b7e-43ce-8c33-49e34e9bc0a3" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5d563508-a797-4fe8-91ec-4d17f7d6f00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_3770a699-1c3e-40f4-b79e-98d4c2c50b63" xlink:href="nktr-20201231.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5d563508-a797-4fe8-91ec-4d17f7d6f00e" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_3770a699-1c3e-40f4-b79e-98d4c2c50b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_790ff085-cb22-4619-bb33-85bb09d37427" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9660ef45-4da1-4b2d-837c-964eb697941f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9660ef45-4da1-4b2d-837c-964eb697941f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_e8daec82-a92d-497d-83d2-09dd53919b24" xlink:href="nktr-20201231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_SalesMilestoneRevenue_e8daec82-a92d-497d-83d2-09dd53919b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_e624ccd9-61dd-4bf8-9d1e-941aa57fa057" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PotentialDevelopmentMilestones_e624ccd9-61dd-4bf8-9d1e-941aa57fa057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_abb2d25f-03fd-4858-876c-77d4ed547472" xlink:href="nktr-20201231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_abb2d25f-03fd-4858-876c-77d4ed547472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_15f49cd2-432e-4026-a16d-31e57e2f2256" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_15f49cd2-432e-4026-a16d-31e57e2f2256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_6d699cc8-c841-40b6-b466-642eafdc2989" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_6d699cc8-c841-40b6-b466-642eafdc2989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_116c8e4a-85c3-497b-a562-36742fc82ccd" xlink:href="nktr-20201231.xsd#nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_116c8e4a-85c3-497b-a562-36742fc82ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_90405795-41b4-4ac8-9d07-d5028f23c3e4" xlink:href="nktr-20201231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_90405795-41b4-4ac8-9d07-d5028f23c3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_8b3e750a-a068-45df-aa3d-ea34237e0fc5" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_8b3e750a-a068-45df-aa3d-ea34237e0fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_fe48ba94-f14a-4c75-bd61-98e8520d8da1" xlink:href="nktr-20201231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_fe48ba94-f14a-4c75-bd61-98e8520d8da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_664313c9-4d29-4dfc-ae11-35fbbc9768f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_SharesIssued_664313c9-4d29-4dfc-ae11-35fbbc9768f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_da1e908b-ebba-4cf8-b7c6-ddf9d1e2e99d" xlink:href="nktr-20201231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_da1e908b-ebba-4cf8-b7c6-ddf9d1e2e99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_b6e2659d-842b-4e11-9b69-07ad69a8a46b" xlink:href="nktr-20201231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_ReimbursementOfExpenses_b6e2659d-842b-4e11-9b69-07ad69a8a46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_64ed6821-b114-4f77-8e4e-c425fd23bf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_64ed6821-b114-4f77-8e4e-c425fd23bf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_e455456d-76aa-4360-93db-591a839e000f" xlink:href="nktr-20201231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_e455456d-76aa-4360-93db-591a839e000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCosts_52928103-159a-49fa-a09f-b36a460a5eed" xlink:href="nktr-20201231.xsd#nktr_CompanyShareOfDevelopmentCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_CompanyShareOfDevelopmentCosts_52928103-159a-49fa-a09f-b36a460a5eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentCostsExceeded_429e4ed6-8e04-445f-a5a1-7f74199545ce" xlink:href="nktr-20201231.xsd#nktr_DevelopmentCostsExceeded"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_DevelopmentCostsExceeded_429e4ed6-8e04-445f-a5a1-7f74199545ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementRecognized_aee51790-f193-4e4d-83a7-df931ff98b3b" xlink:href="nktr-20201231.xsd#nktr_ReimbursementRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_ReimbursementRecognized_aee51790-f193-4e4d-83a7-df931ff98b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f66dd18b-03b7-4b1b-8ae0-8f205a999cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f66dd18b-03b7-4b1b-8ae0-8f205a999cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_101cde46-73c6-41e1-a525-93e0ce9efb9f" xlink:href="nktr-20201231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_101cde46-73c6-41e1-a525-93e0ce9efb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_3f694621-4492-47f2-8635-2fc80c59988b" xlink:href="nktr-20201231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_EstimatedFairValueOfShares_3f694621-4492-47f2-8635-2fc80c59988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_92de7d1b-1ef9-4b1e-9d5e-cf6023b7c4f5" xlink:href="nktr-20201231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_92de7d1b-1ef9-4b1e-9d5e-cf6023b7c4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_d55062b5-2eb8-41c2-962d-8e50ad60f0bf" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_d55062b5-2eb8-41c2-962d-8e50ad60f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_13854485-d7b7-497c-b087-179748da4957" xlink:href="nktr-20201231.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_13854485-d7b7-497c-b087-179748da4957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b1c9a83f-603a-45a2-8e3d-9c42519fd245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b1c9a83f-603a-45a2-8e3d-9c42519fd245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ede58693-ea81-440a-9818-6889aa24edff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ede58693-ea81-440a-9818-6889aa24edff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_4133e573-fa9f-4c4c-a152-e235a9b45e02" xlink:href="nktr-20201231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_4133e573-fa9f-4c4c-a152-e235a9b45e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d784cbb1-47d2-49ef-bc73-49ceaadf01c6" xlink:href="nktr-20201231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d784cbb1-47d2-49ef-bc73-49ceaadf01c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_28523b9f-cac5-419a-a97d-ddf172853f7b" xlink:href="nktr-20201231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_28523b9f-cac5-419a-a97d-ddf172853f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_c67541e3-e948-46c5-80d2-2af1304ea4a7" xlink:href="nktr-20201231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_c67541e3-e948-46c5-80d2-2af1304ea4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_fedfed9e-79f9-49e6-9828-f2b4c1f740c4" xlink:href="nktr-20201231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_fedfed9e-79f9-49e6-9828-f2b4c1f740c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_ab27cc55-aa11-4e9e-a6f9-447a708b8d30" xlink:href="nktr-20201231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_ab27cc55-aa11-4e9e-a6f9-447a708b8d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_4abfa159-0612-4fde-a146-5186e055be99" xlink:href="nktr-20201231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_4abfa159-0612-4fde-a146-5186e055be99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7a1cb33-62cf-4393-bc0a-7d1d24e9692e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7a1cb33-62cf-4393-bc0a-7d1d24e9692e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_a870e2f5-168d-449d-8e49-d6bcb7d79de4" xlink:href="nktr-20201231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_a870e2f5-168d-449d-8e49-d6bcb7d79de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_94182a85-10df-4898-a660-37921726a386" xlink:href="nktr-20201231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_94182a85-10df-4898-a660-37921726a386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RegulatoryMilestonesPaymentDescription_d626df55-9003-4ec4-ad20-d1124b3d4238" xlink:href="nktr-20201231.xsd#nktr_RegulatoryMilestonesPaymentDescription"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_RegulatoryMilestonesPaymentDescription_d626df55-9003-4ec4-ad20-d1124b3d4238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_ee3e659c-bb33-481c-bb27-e5ff111fe907" xlink:href="nktr-20201231.xsd#nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints_ee3e659c-bb33-481c-bb27-e5ff111fe907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_9cc0f666-9948-4f35-8a6e-531e0e6e622c" xlink:href="nktr-20201231.xsd#nktr_PercentageOfNetSalesToFundExternalCostsIncurred"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_PercentageOfNetSalesToFundExternalCostsIncurred_9cc0f666-9948-4f35-8a6e-531e0e6e622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_4d8e4a60-30bf-4690-b712-01c36e919072" xlink:href="nktr-20201231.xsd#nktr_AmountOfNetSalesToFundExternalCostsIncurredCap"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4ef4aa3-2a39-47b0-a558-9250182bb36a" xlink:to="loc_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap_4d8e4a60-30bf-4690-b712-01c36e919072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2aa36733-423d-4c9e-8fbd-e79d55b49b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f6f26e1a-35f8-4b90-ac3d-1c15603c86f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2aa36733-423d-4c9e-8fbd-e79d55b49b85" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f6f26e1a-35f8-4b90-ac3d-1c15603c86f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c93c63a4-9c70-489c-85ba-3ca447ae0a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2aa36733-423d-4c9e-8fbd-e79d55b49b85" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c93c63a4-9c70-489c-85ba-3ca447ae0a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_07df063c-5c1e-4f16-8f70-fde11f9c083d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2aa36733-423d-4c9e-8fbd-e79d55b49b85" xlink:to="loc_us-gaap_ContractWithCustomerLiability_07df063c-5c1e-4f16-8f70-fde11f9c083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a0cb48b-c341-4b06-be91-7f312236a47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_28e1ef38-3717-4af7-a263-bbdcc44fe3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a0cb48b-c341-4b06-be91-7f312236a47c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_28e1ef38-3717-4af7-a263-bbdcc44fe3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce34ffe-d27b-4705-bfcc-9fe659f644f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9505b6b3-b9b9-4144-a896-b64ee9fa44ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce34ffe-d27b-4705-bfcc-9fe659f644f2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9505b6b3-b9b9-4144-a896-b64ee9fa44ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_89650455-f1a4-418c-8fdc-469e1d8262b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce34ffe-d27b-4705-bfcc-9fe659f644f2" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_89650455-f1a4-418c-8fdc-469e1d8262b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_902d6c7b-7846-420f-b84b-49b971f3a326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce34ffe-d27b-4705-bfcc-9fe659f644f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_902d6c7b-7846-420f-b84b-49b971f3a326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f93fd911-1fcc-4ec3-9502-038230d7c7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce34ffe-d27b-4705-bfcc-9fe659f644f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f93fd911-1fcc-4ec3-9502-038230d7c7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1374748d-1476-4912-8605-9b2ed32f8c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1374748d-1476-4912-8605-9b2ed32f8c78" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fc164bd-0d30-4ffd-a02b-fc3b930984bf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d4139aa4-e0d8-4b29-ba0a-78cc16eafc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_us-gaap_CostOfSalesMember_d4139aa4-e0d8-4b29-ba0a-78cc16eafc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a42cdfbd-4926-41e1-aad9-1d0fe2552814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a42cdfbd-4926-41e1-aad9-1d0fe2552814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c352cdcc-6a7d-459f-a499-cec495315d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c352cdcc-6a7d-459f-a499-cec495315d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_3fbd6531-b067-46fb-8d2e-f89dce64e34e" xlink:href="nktr-20201231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345282f4-b7dc-4587-a785-d67d1f9ad5ca" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_3fbd6531-b067-46fb-8d2e-f89dce64e34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b93d223-7d7b-4a59-a62b-740b003175a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_39fd8df0-ceea-4ab7-8ccb-334b63131cb2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b93d223-7d7b-4a59-a62b-740b003175a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1566bbd4-e3b3-457a-b8bb-ad1381241279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b93d223-7d7b-4a59-a62b-740b003175a3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1566bbd4-e3b3-457a-b8bb-ad1381241279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5baf4cf7-48a1-4982-bf86-121d37e2319b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5baf4cf7-48a1-4982-bf86-121d37e2319b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:to="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e1684703-8a26-4876-8333-d257e5a3a5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6e51e73b-5f34-429f-bfb9-0e9dbb9c6e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6e51e73b-5f34-429f-bfb9-0e9dbb9c6e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_64d51979-5e73-43da-ba97-09ea703cfaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_689e9c62-6390-45f2-896b-8fdf9cdeb6d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_64d51979-5e73-43da-ba97-09ea703cfaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82e6e37e-1a9c-46de-bed5-074c9f299db4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_37a5342d-c068-4df4-a009-548421d26d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_37a5342d-c068-4df4-a009-548421d26d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39cae494-9c34-4d03-ae1a-67d090d20d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39cae494-9c34-4d03-ae1a-67d090d20d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b086647-0ee9-48ea-9af1-fa8d30f8c533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b086647-0ee9-48ea-9af1-fa8d30f8c533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab326f2c-f121-4b37-8527-3e5d4d4a7cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab326f2c-f121-4b37-8527-3e5d4d4a7cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_eca38fd6-8d53-4687-b679-4614650f8240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16fd1e82-a039-42d4-85a5-935649c10449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_eca38fd6-8d53-4687-b679-4614650f8240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09ee625d-6470-4004-b3a7-daac8d0a0e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_18822982-c2a1-44c0-9ee4-a38efcc7356b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09ee625d-6470-4004-b3a7-daac8d0a0e19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_18822982-c2a1-44c0-9ee4-a38efcc7356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cd78dcce-6c0b-4bfa-bc15-affec5df7479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09ee625d-6470-4004-b3a7-daac8d0a0e19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cd78dcce-6c0b-4bfa-bc15-affec5df7479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_285aa027-d8ec-4dd1-b123-e5258ecc3608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09ee625d-6470-4004-b3a7-daac8d0a0e19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_285aa027-d8ec-4dd1-b123-e5258ecc3608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3a1cf673-11a4-423d-8857-f438965ba9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09ee625d-6470-4004-b3a7-daac8d0a0e19" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3a1cf673-11a4-423d-8857-f438965ba9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adc6e6eb-6cd1-4423-8676-46c7680638da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09ee625d-6470-4004-b3a7-daac8d0a0e19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adc6e6eb-6cd1-4423-8676-46c7680638da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b9c8abb-86f0-4645-8d0d-cd9c824de6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b9c8abb-86f0-4645-8d0d-cd9c824de6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_251f02cf-7f79-4a7a-bc5c-6b2f4cc72c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_251f02cf-7f79-4a7a-bc5c-6b2f4cc72c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2f2ed75-974b-4c6d-bc19-87c7ed0eb20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2f2ed75-974b-4c6d-bc19-87c7ed0eb20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_85c146e8-c03f-496c-8a81-3e2fbf3cd675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_85c146e8-c03f-496c-8a81-3e2fbf3cd675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60a148d9-e6b8-478c-b4e0-7033256c9dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60a148d9-e6b8-478c-b4e0-7033256c9dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eab363c7-c263-494c-847a-2ad9e50f011e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eab363c7-c263-494c-847a-2ad9e50f011e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ee6c071-0869-4df4-bf2f-b6cfe075f050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ee6c071-0869-4df4-bf2f-b6cfe075f050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3d40fb0a-d798-4f4b-9703-44650621eea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3d40fb0a-d798-4f4b-9703-44650621eea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_67abd606-a136-45eb-a16b-9c3c9933d7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_67abd606-a136-45eb-a16b-9c3c9933d7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bdc038fc-b8b0-4e58-8e39-788e1246b769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bdc038fc-b8b0-4e58-8e39-788e1246b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e4b53436-c8de-418a-9feb-59b2a3a41e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e4b53436-c8de-418a-9feb-59b2a3a41e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3b205c52-c336-4281-9f3b-5c444d6c6fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3b205c52-c336-4281-9f3b-5c444d6c6fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ad7cd99b-af33-4241-8034-aec70177e015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ad7cd99b-af33-4241-8034-aec70177e015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f32a1d0a-8840-4e86-b473-6c1caa02577b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f32a1d0a-8840-4e86-b473-6c1caa02577b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5d941926-a38f-4bff-ba20-88122f7aa6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5d941926-a38f-4bff-ba20-88122f7aa6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6b45d67b-2c96-4c9b-93b7-5f1609bdb1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f507188-4c89-4b34-8fa7-7898ed273496" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6b45d67b-2c96-4c9b-93b7-5f1609bdb1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#StockBasedCompensationRestrictedStockUnitAwardActivityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e1226f2-26ae-4b6f-97c6-4fc625f9f55a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e1226f2-26ae-4b6f-97c6-4fc625f9f55a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:to="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b1112b-72aa-48bc-af76-a4a75b2331d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_07e751fd-1865-4beb-9297-1596fdb25e10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b1112b-72aa-48bc-af76-a4a75b2331d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e00107bd-31d1-484d-94bf-6ee993b89fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b1112b-72aa-48bc-af76-a4a75b2331d0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e00107bd-31d1-484d-94bf-6ee993b89fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45854a10-e53c-4a1a-96be-40851b48eacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_488f205a-592d-4f24-b26f-20d9e2f1061b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_488f205a-592d-4f24-b26f-20d9e2f1061b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2d0d7a9-868e-44e9-9059-7dd645e47079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2d0d7a9-868e-44e9-9059-7dd645e47079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5edfd8-efb7-4895-bb4f-43ff62380368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5edfd8-efb7-4895-bb4f-43ff62380368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2f1e2e6d-4bb8-41f7-b80e-04a471284619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2f1e2e6d-4bb8-41f7-b80e-04a471284619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3834bc40-cce7-457a-8932-04b5c08369a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3834bc40-cce7-457a-8932-04b5c08369a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4c3f4830-5aae-4a7f-8c8b-f818836fe4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4c3f4830-5aae-4a7f-8c8b-f818836fe4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_322cb103-42a1-4f89-bc9f-c42362d0ca3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_322cb103-42a1-4f89-bc9f-c42362d0ca3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4659fd3-9be8-402f-8b3b-d0c883567391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4659fd3-9be8-402f-8b3b-d0c883567391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c56975cd-da42-47e5-a02b-a7c469d8c33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c56975cd-da42-47e5-a02b-a7c469d8c33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5fce0dc7-c1c7-4f4b-8a31-1694965583d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384af134-f4e0-4191-adc5-951e0679200d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5fce0dc7-c1c7-4f4b-8a31-1694965583d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34ef36c0-ad9e-4732-8ccb-287906d8f67a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_36cac4c8-621d-4a17-a0c7-88b3ba46108f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34ef36c0-ad9e-4732-8ccb-287906d8f67a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_36cac4c8-621d-4a17-a0c7-88b3ba46108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_679eddd4-7212-44e4-bed3-816e2fcc30e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2879c52e-74af-4c7d-a70e-1268be1d8fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679eddd4-7212-44e4-bed3-816e2fcc30e6" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2879c52e-74af-4c7d-a70e-1268be1d8fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_946f5300-7e3d-4cdb-9905-9bf1fbeef755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679eddd4-7212-44e4-bed3-816e2fcc30e6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_946f5300-7e3d-4cdb-9905-9bf1fbeef755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e5e3e1d4-7a1e-4433-a6d6-a5c6f053e50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679eddd4-7212-44e4-bed3-816e2fcc30e6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e5e3e1d4-7a1e-4433-a6d6-a5c6f053e50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7c5bfa33-bd9a-4fbf-8b53-0a265ace046e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679eddd4-7212-44e4-bed3-816e2fcc30e6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7c5bfa33-bd9a-4fbf-8b53-0a265ace046e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_49b428ad-d31f-4018-98d7-b036d918efd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679eddd4-7212-44e4-bed3-816e2fcc30e6" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_49b428ad-d31f-4018-98d7-b036d918efd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74d93014-5c2b-4d02-924e-5c52841864a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bf8423b7-3823-4b1c-a4c8-5834d998ed32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74d93014-5c2b-4d02-924e-5c52841864a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bf8423b7-3823-4b1c-a4c8-5834d998ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d665b74a-e1c5-44ab-8c78-1d13f34a4ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74d93014-5c2b-4d02-924e-5c52841864a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d665b74a-e1c5-44ab-8c78-1d13f34a4ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c436783-2bcb-4bd3-bc54-b9a5b2f94ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74d93014-5c2b-4d02-924e-5c52841864a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c436783-2bcb-4bd3-bc54-b9a5b2f94ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_728d9ae5-a3b3-40a8-b40b-dc8d1c69029f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7dfc5155-a5b2-459f-992d-01c7df315160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_728d9ae5-a3b3-40a8-b40b-dc8d1c69029f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7dfc5155-a5b2-459f-992d-01c7df315160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_caace1a1-a7c1-4045-b06f-edc2bf5ff0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7dfc5155-a5b2-459f-992d-01c7df315160" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_caace1a1-a7c1-4045-b06f-edc2bf5ff0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_bf6f2a2e-e5d7-4e33-8521-1e91424d1b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7dfc5155-a5b2-459f-992d-01c7df315160" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_bf6f2a2e-e5d7-4e33-8521-1e91424d1b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4c0a2a15-7c79-4a9f-a6b0-5cd5bcb922a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7dfc5155-a5b2-459f-992d-01c7df315160" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4c0a2a15-7c79-4a9f-a6b0-5cd5bcb922a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e8fb3ea4-fea1-4a52-878f-cdbee65207a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7dfc5155-a5b2-459f-992d-01c7df315160" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e8fb3ea4-fea1-4a52-878f-cdbee65207a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_614a027c-5f46-4fcf-988c-751f9c3344ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_728d9ae5-a3b3-40a8-b40b-dc8d1c69029f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_614a027c-5f46-4fcf-988c-751f9c3344ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d2f167ba-2640-4201-aa9b-1c585618c99a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_614a027c-5f46-4fcf-988c-751f9c3344ef" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d2f167ba-2640-4201-aa9b-1c585618c99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_542f6c6b-dacd-4b2c-a8f6-b8a8e2cca9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_614a027c-5f46-4fcf-988c-751f9c3344ef" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_542f6c6b-dacd-4b2c-a8f6-b8a8e2cca9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c5c2085d-4bd7-436d-a1ee-c8a593c75943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_614a027c-5f46-4fcf-988c-751f9c3344ef" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c5c2085d-4bd7-436d-a1ee-c8a593c75943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fe42db74-443f-416f-a1cc-401812b74558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_614a027c-5f46-4fcf-988c-751f9c3344ef" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fe42db74-443f-416f-a1cc-401812b74558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_898e6b28-8dc2-40cb-8922-01167a4fb45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_728d9ae5-a3b3-40a8-b40b-dc8d1c69029f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_898e6b28-8dc2-40cb-8922-01167a4fb45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_62e49558-e873-4e24-a0e8-c5064f9dfff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62e49558-e873-4e24-a0e8-c5064f9dfff3" xlink:to="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35bea14a-a07a-4ccb-9aad-a6e114b3d31b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c53100c1-edaf-49a6-8a6f-87b2707541f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:to="loc_us-gaap_DomesticCountryMember_c53100c1-edaf-49a6-8a6f-87b2707541f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_557f266e-3fb9-463d-ace9-f4be91730986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0471dd68-f507-4fbe-8a86-da4370c5538d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_557f266e-3fb9-463d-ace9-f4be91730986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_84a01aca-cc29-46be-97f0-88ac8a03ab11" xlink:to="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f75d817f-0fa4-474f-a805-73246a65a382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f75d817f-0fa4-474f-a805-73246a65a382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c8ce82f3-589c-4197-b556-a0a09df42f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c8ce82f3-589c-4197-b556-a0a09df42f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_833c45a4-729c-4f5c-a39c-b1c077f3264c" xlink:href="nktr-20201231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_833c45a4-729c-4f5c-a39c-b1c077f3264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3d7c68cb-8cca-4e9b-adbd-007419b97929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3d7c68cb-8cca-4e9b-adbd-007419b97929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FederalOrphanDrugCredits_ca8eccbd-9dd0-4a1e-bba0-6d0882ccfc3a" xlink:href="nktr-20201231.xsd#nktr_FederalOrphanDrugCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_FederalOrphanDrugCredits_ca8eccbd-9dd0-4a1e-bba0-6d0882ccfc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_50f7e643-003c-45d9-9e19-b8bbca55c2f0" xlink:href="nktr-20201231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_50f7e643-003c-45d9-9e19-b8bbca55c2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_8b5bdca4-a803-4c54-bb94-ad94ed0c6427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_8b5bdca4-a803-4c54-bb94-ad94ed0c6427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_15fa52ed-25b2-4e34-9f1c-211716738b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_41ece609-2406-4645-94ef-3136e2231bb6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_15fa52ed-25b2-4e34-9f1c-211716738b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7db4f138-724b-48f2-a503-fefb036b1af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7db4f138-724b-48f2-a503-fefb036b1af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_becf35a5-c37c-4869-be3b-4fbcb270562e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_becf35a5-c37c-4869-be3b-4fbcb270562e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_428ba2f6-70e0-4f19-88ba-803dbdc408d9" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationPremiumOnEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance_428ba2f6-70e0-4f19-88ba-803dbdc408d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_68daeea1-c423-40f6-a478-95729ef89202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_68daeea1-c423-40f6-a478-95729ef89202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_60fd4904-8dc5-44c6-a16d-60c5834ac426" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost_60fd4904-8dc5-44c6-a16d-60c5834ac426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_b3235b5a-e392-4f83-a1a0-f20a9b5279ab" xlink:href="nktr-20201231.xsd#nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties_b3235b5a-e392-4f83-a1a0-f20a9b5279ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_11eaf180-989b-4204-823a-b9f9e4d1991c" xlink:href="nktr-20201231.xsd#nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties_11eaf180-989b-4204-823a-b9f9e4d1991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_615cd34d-07ca-48a9-b14d-9fa1cd1f7f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_615cd34d-07ca-48a9-b14d-9fa1cd1f7f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1734da5c-7e5c-452a-87c9-8476ae460f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be2b1df2-b207-4708-aa5f-7cdc8ff9553a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1734da5c-7e5c-452a-87c9-8476ae460f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b22369b1-6e75-41e7-99bd-9ec1ebbab26d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b22369b1-6e75-41e7-99bd-9ec1ebbab26d" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de010e92-e008-4c73-b8b0-ba8a166e07d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de010e92-e008-4c73-b8b0-ba8a166e07d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bdc01913-d186-4159-a0f0-acf55e4eb3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bdc01913-d186-4159-a0f0-acf55e4eb3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability_baa4552f-68a8-4f15-accf-4f0b2e71d42c" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_nktr_DeferredTaxAssetsLeaseLiability_baa4552f-68a8-4f15-accf-4f0b2e71d42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_dae0cfa7-59e4-4edb-9d18-0b01c6013b73" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_dae0cfa7-59e4-4edb-9d18-0b01c6013b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87fe3a86-72cf-40d7-820b-c6f7358acd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87fe3a86-72cf-40d7-820b-c6f7358acd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_57589165-2137-419f-aa27-5c13f84bc793" xlink:href="nktr-20201231.xsd#nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment_57589165-2137-419f-aa27-5c13f84bc793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_26f2cece-cfd8-482e-8675-90b5ec0a0ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_26f2cece-cfd8-482e-8675-90b5ec0a0ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_79061304-606c-4ce7-b8ed-386a8709c629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_79061304-606c-4ce7-b8ed-386a8709c629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c8e4677a-d74c-405e-9ffd-53a5a8cc3e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c8e4677a-d74c-405e-9ffd-53a5a8cc3e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_89c22ff8-da13-4e72-af5c-4889b06cebba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_89c22ff8-da13-4e72-af5c-4889b06cebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_11ca5c46-6e0d-470c-a339-635ac0538b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_89c22ff8-da13-4e72-af5c-4889b06cebba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_11ca5c46-6e0d-470c-a339-635ac0538b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_f6b82e71-9f28-476b-9ddc-ccc60c92c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_89c22ff8-da13-4e72-af5c-4889b06cebba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_f6b82e71-9f28-476b-9ddc-ccc60c92c1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d6eb70e1-724c-440c-b19f-1eec82f1e5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_89c22ff8-da13-4e72-af5c-4889b06cebba" xlink:to="loc_us-gaap_DeferredTaxLiabilities_d6eb70e1-724c-440c-b19f-1eec82f1e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_83fee83e-eb08-4e4b-b363-14a184cac7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c47dbdcd-ec06-4af6-bfa5-5124b35a6195" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_83fee83e-eb08-4e4b-b363-14a184cac7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_059150c5-c864-4b88-a934-2ee24be3d2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_059150c5-c864-4b88-a934-2ee24be3d2d2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f38ca788-fe48-44b0-ac9a-e72981e90514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f38ca788-fe48-44b0-ac9a-e72981e90514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_45b15606-c6cf-495e-b939-29e438084732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_45b15606-c6cf-495e-b939-29e438084732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_9f1831f4-4c89-467c-9cc2-6450a000d3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_9f1831f4-4c89-467c-9cc2-6450a000d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a9d9c069-4e88-45dd-bec2-809bdd38da5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a9d9c069-4e88-45dd-bec2-809bdd38da5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_adce5669-4d7b-4150-ae72-826064570d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_adce5669-4d7b-4150-ae72-826064570d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_062426c2-fd0e-436b-a42c-d1a1e2fdae7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_062426c2-fd0e-436b-a42c-d1a1e2fdae7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_674cb8f8-3388-45c6-8c3b-b0e170d27481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_674cb8f8-3388-45c6-8c3b-b0e170d27481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cd74f8a2-4725-4979-8f01-644239daccae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e68e864-5f5f-413b-8c79-066163c81d7a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cd74f8a2-4725-4979-8f01-644239daccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReporting" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d25a20c3-4294-4b74-8363-c5d4741de37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_22816173-866c-4ee2-8084-99ab90c15dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d25a20c3-4294-4b74-8363-c5d4741de37c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_22816173-866c-4ee2-8084-99ab90c15dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_44a4b5af-7baf-425f-b6ce-1bf0e32b89ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_74d46000-2b6b-47f6-8f03-1061e59689f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_44a4b5af-7baf-425f-b6ce-1bf0e32b89ee" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_74d46000-2b6b-47f6-8f03-1061e59689f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2639247b-9409-4416-b403-d18a92cc964a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2639247b-9409-4416-b403-d18a92cc964a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bec48313-0f2a-4cfd-a784-eed985d18593" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a4e0d8fb-4a78-4d80-a792-04eb33436479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:to="loc_us-gaap_SalesRevenueNetMember_a4e0d8fb-4a78-4d80-a792-04eb33436479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_aaf4c3fc-3da5-49b6-8a4e-648097f1a961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcc0d59d-c7b2-461a-8138-bf3063ef8137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_aaf4c3fc-3da5-49b6-8a4e-648097f1a961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_492ed1cb-5aee-4bd2-9919-834dd641e63a" xlink:to="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_8e7cf5b7-7b11-45ce-a3d7-ebc4444b242f" xlink:href="nktr-20201231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_8e7cf5b7-7b11-45ce-a3d7-ebc4444b242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember_fb5c0aa5-b6bb-40f8-9dbc-3ad1549f0cd8" xlink:href="nktr-20201231.xsd#nktr_UCBPharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_UCBPharmaMember_fb5c0aa5-b6bb-40f8-9dbc-3ad1549f0cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_a4e33ebd-792f-4667-b039-30056208819f" xlink:href="nktr-20201231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_a4e33ebd-792f-4667-b039-30056208819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_9b20863d-d3b5-4c64-a88d-3f4dd3862185" xlink:href="nktr-20201231.xsd#nktr_AstraZenecaAbMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_78d2eb0e-7eea-435a-aed9-55c3d2751659" xlink:to="loc_nktr_AstraZenecaAbMember_9b20863d-d3b5-4c64-a88d-3f4dd3862185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3a4ed8fc-88e3-4f73-8f7e-88c1affb4025" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b753107a-bbd8-4b09-89c5-4e7dd3e430c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b753107a-bbd8-4b09-89c5-4e7dd3e430c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_b21c4f04-ae21-47f2-a7e9-87aa3277e089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f8700408-a285-41bc-8511-3022b3a84274" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_b21c4f04-ae21-47f2-a7e9-87aa3277e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d4e2f92e-739c-4955-befd-bbb08eaba579" xlink:to="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_85a8a551-69bf-4cb1-a448-e54d339fa6f9" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:to="loc_country_US_85a8a551-69bf-4cb1-a448-e54d339fa6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_2a38ddc1-40ae-4dc8-9676-e3f25974d2f1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a9705adb-d4b9-49a6-b72b-7e4928c3119e" xlink:to="loc_country_IN_2a38ddc1-40ae-4dc8-9676-e3f25974d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8410fc5a-edff-4fc6-8cb6-e815eb774f63" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment_2b2ec8a4-93e7-4d87-9154-6619871e284c" xlink:href="nktr-20201231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_nktr_NumberOfOperatingBusinessSegment_2b2ec8a4-93e7-4d87-9154-6619871e284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ed845fce-79ea-4e4b-9e68-ba74bc83a2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ed845fce-79ea-4e4b-9e68-ba74bc83a2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a75f4933-38e5-4e8b-9486-74422a1a7a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_936d2721-c6c7-4d6f-ab9a-3d3ef70a6325" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a75f4933-38e5-4e8b-9486-74422a1a7a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fcfd5506-543e-4df1-b65f-a3593dc2c581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fcfd5506-543e-4df1-b65f-a3593dc2c581" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:to="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_03ff3822-c3a4-4767-98f6-d83485338ee3" xlink:to="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b8d07ccf-bbae-4b87-b182-a8cdfb86976b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:to="loc_country_US_b8d07ccf-bbae-4b87-b182-a8cdfb86976b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5203bfcc-1dd7-48da-a16c-9d8c2abcbbb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8d4429a1-3887-48a3-9bf0-2d633fa2dff1" xlink:to="loc_us-gaap_NonUsMember_5203bfcc-1dd7-48da-a16c-9d8c2abcbbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:to="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_aa664e19-3e81-46e8-95d2-e74a99512f11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_50f81234-bb11-488d-bd17-520e40e9e108" xlink:to="loc_srt_ConsolidationItemsDomain_aa664e19-3e81-46e8-95d2-e74a99512f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_7155d7d4-db2b-4400-8913-2339ddb356d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_aa664e19-3e81-46e8-95d2-e74a99512f11" xlink:to="loc_srt_ReportableGeographicalComponentsMember_7155d7d4-db2b-4400-8913-2339ddb356d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a76e9a16-e1f3-4a3d-aa6b-b1ab90e287b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f4992d36-8b77-4859-92bb-abca147117c6" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a76e9a16-e1f3-4a3d-aa6b-b1ab90e287b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_bc8d63f7-fc89-4f26-86d0-ff84c02369a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a76e9a16-e1f3-4a3d-aa6b-b1ab90e287b6" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_bc8d63f7-fc89-4f26-86d0-ff84c02369a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bc881c-a38c-4846-9664-0280883029fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_bc8d63f7-fc89-4f26-86d0-ff84c02369a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bc881c-a38c-4846-9664-0280883029fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20201231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_18b9e408-23ad-4b08-a469-31a7ab91ac44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_e5a6d805-47b8-4bfd-957a-a99b8b0695a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_18b9e408-23ad-4b08-a469-31a7ab91ac44" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_e5a6d805-47b8-4bfd-957a-a99b8b0695a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20201231.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aeffef64-d338-4a5a-9074-6eb91a5ca9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aeffef64-d338-4a5a-9074-6eb91a5ca9c4" xlink:to="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4ae3a0eb-0ece-4af8-ad51-82f28384f1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_15e8d010-efdc-4e6d-b464-82def5171e21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4ae3a0eb-0ece-4af8-ad51-82f28384f1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2597e3c7-4694-4052-92d5-dc88f0ae8990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4ae3a0eb-0ece-4af8-ad51-82f28384f1d0" xlink:to="loc_us-gaap_SubsequentEventMember_2597e3c7-4694-4052-92d5-dc88f0ae8990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:to="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc697a4-8e35-47fc-abec-f4f77821900a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1b09229a-c52d-4284-a94f-39be63730689" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc697a4-8e35-47fc-abec-f4f77821900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_8b9fd8df-9171-43db-9bc9-9fbf01a4929a" xlink:href="nktr-20201231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fc697a4-8e35-47fc-abec-f4f77821900a" xlink:to="loc_nktr_SFJPharmaceuticalsMember_8b9fd8df-9171-43db-9bc9-9fbf01a4929a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91f0d2d5-0ced-4b8f-8d56-f4a9c03df6f9" xlink:to="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_7a12ef08-f9fd-415e-a7e4-22a088beb3b6" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_7a12ef08-f9fd-415e-a7e4-22a088beb3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_a45b99c4-4b6c-4fcd-ae41-5dbe4923610f" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_a45b99c4-4b6c-4fcd-ae41-5dbe4923610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_acf89ee1-73c2-4705-9113-9ce47b620a34" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_acf89ee1-73c2-4705-9113-9ce47b620a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_28ac5be3-6f87-45e6-b422-c5b55f29c206" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_28ac5be3-6f87-45e6-b422-c5b55f29c206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_370f2be3-2c23-496f-a920-dd0f039bc4f7" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_370f2be3-2c23-496f-a920-dd0f039bc4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_b95f40b0-379c-4a73-ab0a-9bdf8510d8bf" xlink:href="nktr-20201231.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6ee3ea68-5915-49a4-885d-0d11ca1d0112" xlink:to="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_b95f40b0-379c-4a73-ab0a-9bdf8510d8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialData"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_54de9e86-3050-4db8-879b-5f888815aae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_ce024935-b0ee-4a11-ab17-96e50308436d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_54de9e86-3050-4db8-879b-5f888815aae9" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_ce024935-b0ee-4a11-ab17-96e50308436d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialDataTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_79b2a54b-a7ef-480a-a82b-9e8ad3299065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_11a55d48-241e-4ac9-ba55-6aca01e76d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_79b2a54b-a7ef-480a-a82b-9e8ad3299065" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_11a55d48-241e-4ac9-ba55-6aca01e76d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="nktr-20201231.xsd#SelectedQuarterlyFinancialDataDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_80a96668-515a-472b-bcb6-42a2db5cfc8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:href="nktr-20201231.xsd#nktr_SelectedQuarterlyFinancialDataTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_80a96668-515a-472b-bcb6-42a2db5cfc8e" xlink:to="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:to="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_645305f0-3cc2-4fc5-acff-0d46fa48ba6b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00859e46-38f4-45c6-add0-d00a502b1e45" xlink:to="loc_srt_ProductsAndServicesDomain_645305f0-3cc2-4fc5-acff-0d46fa48ba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a2437228-97f9-4b35-a9a2-93943180a050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_645305f0-3cc2-4fc5-acff-0d46fa48ba6b" xlink:to="loc_us-gaap_ProductMember_a2437228-97f9-4b35-a9a2-93943180a050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:href="nktr-20201231.xsd#nktr_SelectedQuarterlyFinancialDataLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable_c9e58f38-c05b-48a8-9316-3228962e7ade" xlink:to="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6bd2162-7e54-4349-b38c-1a8db59d393a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6bd2162-7e54-4349-b38c-1a8db59d393a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ed7b9254-8c27-4f62-94ab-989be4e76384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ed7b9254-8c27-4f62-94ab-989be4e76384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8afeea91-f777-42be-80f9-fac8ebea9370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8afeea91-f777-42be-80f9-fac8ebea9370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9301489-7848-4c1d-b1e9-895db6e6282a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9301489-7848-4c1d-b1e9-895db6e6282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f13c7f5-ddaa-4d7f-bdbb-07e8e3131619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_NetIncomeLoss_5f13c7f5-ddaa-4d7f-bdbb-07e8e3131619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_755cfe46-bb95-420f-ba66-8c2544057fcd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_abe54a6d-b5b8-4e20-88b1-4f6e1e5b56c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:to="loc_us-gaap_EarningsPerShareBasic_abe54a6d-b5b8-4e20-88b1-4f6e1e5b56c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6d34b0df-af89-4e9b-9796-4065f7c5b041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_640bf668-df25-4673-9bac-0ddc0ad87fd7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6d34b0df-af89-4e9b-9796-4065f7c5b041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@   @P   ":" 8   #%)A!X     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  'L(  ![" 6[0=3X  ""K241!
M5'A>[=U?J!3W_?_Q\7>5"R56$/*'PNF%L:+0F'P56S35B#1"\4\OB@&M!B4T
M1*()Q]0J8M.BD2I)+(JE58Q54'IAHK38$JIMCT1);$U 41O22*4V$#"U!MH[
M?_OZG,][_9QQ_NTYL[.SZ_,!X\S.SL[.SASG\Y[/WU&W&R(  ( ,_\_/ 0
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MA)M/GCS9S=%]5)%URI0I_E44'3QX,%(IN4U7KER)^OO[_;M1M'#A0G(:.HB
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M[OUY\^:E)C:H+UU#JYN@8J>C1X^ZY9"VF3]_?K-%S)8M6Z(-&S:X952/@ $
M4#F- 3)GSARWO&O7+C=VB%$1T]FS9UW7WT8M8M3W!JUB.H>  0!0N:U;MT8;
M-V[TK[*I!46\IT]4CSH, (#*Y?6GH!P%%4&HMT<-+D:PT'GD,   *J>!I0S)
M4'<@AP$ 4"G543!)_6P,EUK,J))LV"$4RD/   "HU*5+E_Q2><TDK?FENIK6
MR)8H'P$# *!2:B%ARNK>6TTT52]"=1ZH[] >U&$  %1*_6;8."$D0=V#' 8
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MO2];MLPM_^0G/W'S;D?   ! BY1[(#-GSDS,/3APX(";JRY")^H;M ,! P
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ME%XBT5X$#  P0AIFFCX#6L,YZSX$#   (!=U&   0(XH^O^@;J28]6T50
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nktr-20201231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nktr-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" /X!0,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\%*?VLK;]AK]@_XI?%2>2!+CPEH%Q/IR32"-;B_<>39Q9Y^_<21+T/WNAH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^1]B^U>5Y/V>V@VY^UR;MV[.U,8P<_1_[0OP4TO]I3X!>./AUKL^H6FB>/\
MP_?^&]0GL'1+J&WO+:2WE>)G5T$@21BI9& (&5(XH _ER_X(J?\ !,;]B_\
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M?@%I'PZ^(NK^,-%T31?$$/B2"?PW=6UM=/<16US;JC-/!,ACV74A(" Y"_,
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M _\ !67X!:1\.OB+J_C#1=$T7Q!#XD@G\-W5M;73W$5M<VZHS3P3(8]EU(2
M@.0OS  @]#XE_8,\+>(_^">D?[-@USQ;8>"8_!5MX"_M*UN;==8;3H;6.TR9
M&A:'S9(4VN?)VG>V%7C !_/!_P $SOB!^VC^TC_P4&^,_P"V+^SA\'?"_P 4
M+OQ)JFHZ).WBS4+2WM]'2YD@N(X8T:_M',L5M';Q!E9U",P.201U_@_XL_M(
M?L#_ /!PU\+/CA^TQ\-=!^$E_P#'F^&@:O9^'+^VN=,U*VEB@T]YCMO;LQB.
M9K.>0&4$F+(7D@_O-_P3B_X)U?#_ /X)=_LU6_PN^'#:S=:+'J-SJMQ?:Q)!
M+J&HW,Y&Z2=X8HD=E1(HE.P$)%&#G&:X_P#X*G?\$?\ X5?\%=_ GA30_B9=
M>*=);P9?S7VF:EX=GM;>_C$T82: R3V\X\E]L3,H4$M!&<_+B@#\JO\ @^<_
MYM=_[FO_ -PM?K]_P]B_99_Z.6^ '_AP](_^2*\S_P""G'_!#SX6_P#!6+P]
M\-+#XF^*OB59GX6V]Y;Z==:%?V-O/?FZ6T662Y,MI*K/_H<9'EK&,L_!R OR
M9_Q!4_LL_P#0_?'_ /\ !YI'_P K* /U?^%OQ9\+?''P)8^*?!7B7P_XP\,Z
MIYGV/5]$U&'4+"[\N1HI/+GB9HWVR(Z':3AD8'D$5\0?\'1W_*"CXY_]P#_U
M(-,KZ?\ V"OV*O"W_!.W]D[PI\'?!5_X@U3PSX/^V?8[K6YX9[^7[3>3WDGF
M/%%%&<27#@;8U^4*#DY)/V]?V*O"W_!1+]D[Q7\'?&M_X@TOPSXP^Q_;+K1)
MX8+^+[->07D?EO+%+&,R6Z [HV^4L!@X( /P5_X)M?\ !KS\._\ @HQ_P2!\
M)_&+3/'/C?0/B[XMMM6>U@GGM)?#PGM=3O+2%&A%N+A5=+>/<WGG#,S $82O
MHC_@TP^,'PV^#OC7XD_L[^(?A;I_PS_:3\+R3#6[]FFFN?$]O:RB*6-I)9)!
M%)!(5+0PLL,@;S47AR/UB_8*_8J\+?\ !.W]D[PI\'?!5_X@U3PSX/\ MGV.
MZUN>&>_E^TWD]Y)YCQ111G$EPX&V-?E"@Y.2?%?CY_P0Z^$GQR_X*#^&OVF[
M;7/'W@/XJ>');:=KGPQ>6=O:ZM) OEAKJ.>UF,A:#]P^UEW184],T ?D9_P=
M2^ ?"WQ7_P""^G[.WA;QUK7_  C7@GQ+X5\-:5XAU?[9#9_V5IT_B+4XKFY\
M^8-%%Y<+.^^0%%VY8$ BN_\ ^'!?_!++_H]3_P R]X1_^1*_0_\ X*@?\&]/
MP7_X*R_'W2/B+\1?$_Q/T76]%\/P^&X(/#>HV-M:O;Q7-S<*[+/9S.9-]U("
M0X& OR@@D_-__$%3^RS_ -#]\?\ _P 'FD?_ "LH ^[_ /@D_P#"[X+_  !_
M8E\.?#KX"?$?3_BE\/O EW?6$.M6_B"QUN07$]S)?S0S3V2K#YBF\!"A%(1H
M\@YW'\D?^"^G_*TU^Q7_ -R-_P"I=?5^MW_!+_\ X)?^ ?\ @DU\ M7^'7PZ
MU?QAK6B:UX@F\23S^)+JVN;I+B6VMK=D5H((4$>RUC(!0G);YB" .0_:\_X(
MJ?"S]M']OKX8?M%^*=?^(%AXV^$W]E?V18Z5?6D6E7/]G:C+J,'VB.2VDE;=
M-,ROLE3*  ;3EB ?7]?SD?\ !JU^U'\,?^":?[4_[3_PH^,7CWPYX$U>ZO[#
M3K*_UZ[33+"YETFYU*WN4,TQ$<;YN8RJNP) ;&=IK^C>OAG_ (*$_P#!NW^S
M/_P4A^(&H>,O%_A_7?#/CG54BCO?$/A;418W=WY9&UI(I$EMGDVC89&A+E<#
M=\J%0#\KO^#KC]ISX<?\%(OVDOV8?A=\%?'OA+XA>((+O4;">YT34%U#3[>?
M5KC3;>TC:X@WQLQ>VD+*A9E&TE?F7/UQ_P 'JW_*++P#_P!E5T[_ --&L5]*
M?\$^?^#=']F;_@G'\1=/\:>$]!U[Q3XWTE9%L=>\5ZBM]<V9<G+Q11QQ6Z2!
M3M$BQ!PN<-\S$^M_\%0/^"7_ (!_X*R_ +2/AU\1=7\8:+HFB^((?$D$_ANZ
MMK:Z>XBMKFW5&:>"9#'LNI"0$!R%^8 $$ _&"_\ ^#3+PM\9?^"3?@3XP?"'
MQ3X\OOB_XE\ Z3XQ?P_JUS93:9JMQ<Z?#=36=L$@B>%F9V6(R2N/NACR7'VE
M_P &GO[4WP<^*G['VN_#_P $_#W2OA=\2O UTC>-=,M_M$CZR\A=8M0$MP[S
M,"4=&B=V\AEV@*CQY_2W]GKX*:7^S7\ O _PZT*?4+O1/ 'A^P\-Z?/?NCW4
MUO9VT=O$\K(J(9"D:EBJ*"2<*!Q7S+\._P#@AU\)/@U_P4BU/]I_P5KGC[P?
MXUUZ2XDU;1=+O+-?#^JFX7_21+;O:M+B60"9MLR_O0'&TT ?F4ZB3_@^L((!
M!&"".O\ Q;ZO"O\ @NK\.M?_ ."0GC+]HWX-Z1:W$OP,_:\M;#Q5X8MT8^1H
M.L6.LV5W=QHI?:BJBR(VU,LDUB,XB./VU_X<J?"S_A[#_P -B_V_\0/^%F_]
M S[=:?V%_P @?^R/]5]F\_\ X]_F_P!?_K.?N_)7:?\ !3+_ ()?_#/_ (*N
M_ >R\ ?$P^(+.QTO5(]8T_4M"NH[;4+"X1'C.QY(Y8RKQR.K*\; @@C#*K*
M>%_\&N/_ "@H^!G_ ''_ /U(-3K[_KQ_]@K]BKPM_P $[?V3O"GP=\%7_B#5
M/#/@_P"V?8[K6YX9[^7[3>3WDGF/%%%&<27#@;8U^4*#DY)]@H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)W:]1H(@JYE9HPH.X5[I^T3\2_BC^W+_ ,$-_P!HWXR1>/[#PEX?^)'PWO\
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M&QN+WQ#I=KY*VVFFY C^S16X=7\X))/*9&#2 *,_HS0!\ ?\11O["G_1<O\
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M2T.;6XK6<M:P:KIL_)>!K@K!>QQ)<*I_=ETVKC_\$\/^4Z__  45_P"Z:_\
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MSZ7$)]0NK"210R"Y2UCE-L"I5MTVP!64D@$$^#_\$O/^"AEW\5/^""NJ^/\
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MCXR\/:=-K&O^$O".K:UIEA"I:2]NK:SEFBA4!6)9W15 "DY/0]* /*?VG?\
M@LK^R_\ L;_$9?"/Q&^,WA+0?$_VJ*SGTN-IK^ZL)9%W(+E+9)#;+M(8M-L4
M!E)(# GWKX5_%GPQ\<O &F^*O!OB#1_%/AK68O.L=3TN[2ZM;I,XRDB$J<$$
M$9R""#R*^:_^"(GP'\+?"7_@F%\'M2T:PMVUCXB^%-/\8^*-6E_?W^OZMJ5K
M%=W=S=SL3)/(9)2N78D*BJ,*H K?M->)OAM_P17_ &.?V@?C/X4T;9;-=?\
M"37?AZ*Y9=/;6KHP6D*Q1(I^RK<7$D!D*KC+M(1R30!]?45^:WQ[^,'[6O\
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M_15?2-7M?$&E6U_87-O>V-[$EQ;W%O()(KB-P&5T8$AE((((.""*L4 %%%%
M!7AW[7O[-.O_ +3/Q"^#5LEYHT/@'P9XPC\7>*;2Z+FYU5[*"1]-@B0(4*K?
M-#.Y9UQ]E3 ?<0.Q_P"&H_ G_#4__"E?[<_XN;_PBO\ PFW]C?8KC_D#_:_L
M7VGS_+\C_CX^3R_,\SOLV\U'^S/^U?\ #_\ ;!_9^T?XI_#OQ#'KW@+7DN9+
M+5I+2>Q25;>>6WF8QW*1R(%EAE7+J/NY&002 8G[>O[--S^UW^R-XV\!:;?6
MND^(=5LA<>']3N4+1Z3J]M(ES879P"<1744+G )PIX/0^6?';]BKX@?'+]O;
M]CSXQ7-[X1M+;X%V?BC_ (3"T6[N#+=7.K:/#9QBP_<;98UG1RQE,)V;2%))
M41Z9_P %W_V/]9^,L/@.U_: ^'\_B"X ,3I=/_9DA+^6%&H;/L9<MT3SMQ!S
MC'-?6D<@EC#*0RL,@@Y!% 'S#^RM^Q5XI^!W_!2;]JWXQ:M?^'[CPS\=/^$1
M_L&UM)YGO[3^R=+EL[G[4C1+&FZ1P8_+DDRN2VP\5YA^QQ_P1ZE\)_\ !#'3
M_P!D/XQW^B:E<3Z;JMAJ>H>'Y'N;:"2XU:ZO[6XMVN(8V,D+2P.-\8Q)%QD
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M_P"#'[*VJ_&[7/'>D-\*=%F^SW?B/2UEU:U5_MXTXA!:)*\F+L^4=BMA@<X
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M+'[=/PP\>ZC>:,? /PNT75;BPTXEVOI_$%[Y=LET5*;%CALOM2*WF%BUV_R
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M?^'[CPS\=/\ A$?[!M;2>9[^T_LG2Y;.Y^U(T2QIND<&/RY),KDML/%?4%%
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M+[-JEG>2>8\44L@S';N!MC;YBH.!DCZ@HH ^7_\ ABKQ3_P^@_X:+^W^'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY'D+-T H ^=/^"*^NZ=<_P#!/WQU^UCXA\!ZUK/Q@^)6K>*/%/BJRT[3A?\
MB>7^S[^]M;;0[5&".S16]G%!#;_NP7?HI<FL[]GS_@HY\'?C3_P52^'7VO\
M9P_:?^"WQC^)>B:OX>TO5_&O@R+PUIWB"SM(/[1N$N/]*+71A\A=C"-S&TZC
MY1(37J/B[]A;X^?LO?$'QSXB_99^(WP]L]$\?:K/XBO? /Q)T:ZN]"T[59\&
MXN+&ZLI([BV2=P9)(2LJ"1G=0-Q%)\#O^">GQC^)W[87PZ^/?[2WQ)\'Z[XM
M^%&GZA;^$?"G@'1)-/T#1+C4K<VU_-)<73R75V7BV(H;RU7RE8+DL" ?5OQW
M^%W_  O#X'^,O!7]L:KX=_X2_0KW1/[5TR7RK[3/M-N\/VB!_P"&6/?O0]F4
M5\-_ ;Q1\9/^"<O[+>A?"#XA?LNO\2/AOX#\/0:*WB;X8ZG9ZL=:M;:+RGN+
MK1;K[/<B>2-%E=(#<EW=P,D*&^Q/VQOV5?"_[;_[,'C7X4>,XY7\.>-]->PN
M9(50S6C9#Q7$6]642PRI'*A*D!XU..*^6-+^"_\ P44\+1:=X,M_B_\ LPZW
MX5AL193^.=2\(ZM#XK!",HG%A%<_87E.$)S(JY=OE.T!@#A?VJOVH(OV3?V#
M?V+&_8_UFWTWX??$3XM^%/"&DPWGF7\6HZ%?I>NUC))?K-<PJSI&K-E9X0A5
M2FW;5?1OBW^U]I?[?/B_]DR\^-_@+5?$?B7X=CXGZ/\ $H?#Z.WE\'6C:I+8
M2V,.E"Y,5VPD,/E23S'8BDR"<G [[XK_ /!&Z7PY^R=^R'\(OA5J>CV^A_LX
M?%KPYX\U.XUR:2&75;2QDO)KYXA#%(#=3S732*C;(\LP+K@9]6_X8J\4_P##
MZ#_AHO[?X?\ ^$)_X4K_ ,*X^P^?-_:O]H_V[_:/F^7Y7E?9_)^7=YN_?QLQ
M\U '(?\ !*G]K;XK_M+?LI?&#2_$UWX;\6_%[X(>/?$GPQ_MF>W.CZ9XJO\
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M4=9;P1\++CPA%,?'=C97<]G$M]JMQ/'+9SSO;2,GEK&B&1=YV@X]D_X)L_\
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M?#$EQ+:VTT<B7>FW<9@\^WN#9RAD'DRK<A=G[MQ7V1^U?^P%\0#\5_ WQB^
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MGQA^*_AGXR^&?VC++Q'+IC:=X(B\.2^$KS2;.&\:)"EQ*9K=XV<9E+2;F'(
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MQ$\"Z?\  ?Q!X*\;Z9HOPZD\+,USJ.BV\=[8-J<NJ-(L\-[BWFF2'RC$00C
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M?\9:#^S%#XA\&Z_L9F\/:W;>+6-M= *0Q3YGBE0$>9!--&>'-1_\%%OVI?\
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M ,)E/XBEU6V_M&9-D3_98HXEVPPPY4;\.7P[#&/J#]EC]BSQU\#]1^)WQ/\
M&/C'1?B%\?\ XDZ?#:/J"64FD^']+@LXY?L&G6T&9I(K9)99'DD.^21I&8@D
M!: /R[_X*0?\%"OV:_C?^U[^U]HWQ1^*UIX4\2^%O"EK\-/A@8M)U;43INIV
M<IU.ZU%);2!TMY1JR6L)8,),:<"3@*!]C_M;?\%,M=^)_P#P;9>(/VBO "R2
M^*O$/@6U$O\ 9<I9]'O;BXAT_4)$94)'V.22Y<G:,"W))4<CZ]_8*_9IN?V1
M/V1O!/@+4KZUU;Q#I5D;CQ!J=LA6/5M7N9'N;^[&0#B6ZEF<9 .&' Z#BOA#
M^PA_PCVF_M#> O%L>@ZY\'/B[K]UK.DZ1$76>RBU*U0:K;3)L"JKWGGSHR.Q
MS<OD)M (!Z5^S5^RA\//V6/V>=#^&O@;PUHVE^#-(L$LX[.&W5H[U=OSRS$Y
M\Z20DN[N69V8DDDU\J?\$C=#M_@#^VG^V9\"_"NCS:3\+/AQXNT/6_"\$;R&
MPTZ76M(CO+^PM%.4ABBG7S/*C.U#=\(F1NXWX@_\$^/VX=(^%.D_"#P;\?OA
MEK/P\TB51I7C7Q%::UI_C_088&S9 R6%PEKJ$D2[4<W"K',$S+&^YEKZ%_X)
M;?LL?$+]D3X=^-/#OQ+GT'Q3XIUCQ)/X@O?'EA=2FX\<S7.,W%U:R+FTEBCC
MB@$,;O"(XX_+V*-B@'U%1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'Q!\6/^#CS]C'X'?%/Q+X*\4_&3^R_$W@_5;K1-7L_P#A
M$M<G^R7EM,\,\7F1V31OMD1EW(S*<9!(P:^@_!?[>/P@^)/[,6O_ !E\.>/=
M#\0_#3PMI]YJFK:WI;/>1V,%I"T]SOCC5I=Z1J6,>SS.F%)(S^7G_!.#_@IS
M_P ,7?%/]L3PM_PSW^T_\6/M_P"TKXUU7^U_AQX$_M[2K;?-;Q?9I)_/CVW"
M^3O9,<)+$<_-@>I7_P &O&UE^P[_ ,%(_C)XI\%ZU\+-(^-_@_5=0T'P3JLE
MK]KTR*R\*RVDM[/';LZ13W<H9W7S&.(D) )RP!^EOPG^*6A?''X6>&O&OA:^
M_M3PSXPTJUUO2+SR9(/M=G<PI-!+Y<BK(FZ-U;:ZJPS@@'(KH*_&O2_CW^T]
M_P $_O\ @CU\#OVE#\3O!,OPI\#> _!5M>?"ZW\&+/+J&DW"Z;9"X.K/<K-]
MM,<PD"*B1(7*D/LWM]C?\%4_C1\3_A#>Z2^F?M$? _\ 9@^&5WILJ3^+O$]@
M-:\1WFK!R5M;*PN'BM&B6 %RYDED+''DA5W, ?9U%?D[^R-_P5M\?_%?]CO]
MN6PMOBSX9^+?B/\ 9H\&R:QX5^*>A^'8=,@U]I]#O;J&9[%C)!YMO=6<BL O
ME-@#:R]<C]H']K']K+X%_P#!"#7OVI]1^.6FR^)?$7@#P1J7A[2;'P5IJ+H%
MQ=WFF1W=])/(CK<RW<5S(6C,*10F0B-1M#4 ?KS7/^ /A/X6^%']M?\ "+>&
MO#_AK_A)=5GUW5_[*TZ&S_M749]OGWEQY:KYMQ)M7?*^7;:,DX%?GW\7OV@O
MVL_V<_\ @H9\+OA;J'Q&^&_B6V_:FM?$(\.VTOA$VUO\*;C2[.WNV*M'/YNK
M((6D&)7A,DIW9B0".O2O^"5'[1_Q9U?]HK]HW]G[XR>-;#XH^*_@#J.@O#XT
MMM @T)M<M-9L&O8DEM(&,2/#L9,H "-N2QR2 ?;5%?C?^W5_P44^./[+-OXM
M\1^*OVW_ -FGP3\1O!=MJ%]'\$_#GA-/$%MJ+Q!GM=/N-1GE2^2XEC\H;O(M
MQO?.W9S7UY^TS_P4WUSPC_P3?^!WQ)\&Z9H]K\1/VE+OPEX>\'6>KI++I]AJ
MFOQ1RH;CRSN,<$1G?&Y0QB"[OFY /M2BODG]E7P/^UK\"/VD8-$^*WC[P[\>
MOAKXKL+V^E\1V7AJR\+77@:^C:$P67V>.=VN[69&E".%>56CS(P!&?S;\2?\
M''EK\;_&NH>--'_;-\ _ _2=,U._AT7X=7OP6UCQ*FLV<4KQ6LVI:DB!XVG1
M%G"VNWREG"-N9&H _=JBOS0^$_\ P5S\6?M:_'__ ()U:OX0OQX<\#?M':;X
MYF\:: MI#.MQ>:1IB[85GEB\Y%@OHY]K1%/, &[<I KU#XL?M!?%CQ?_ ,%H
M/$O[/WA;Q_\ \(?X9U3]FJZ\5Z1+_8=GJ']B>(Y-=>P@U7$B"2?RHRI^SO*(
M7V<KDEJ /H#XJ_M\?!_X,?LK:K\;M<\=Z0WPIT6;[/=^(]+675K57^WC3B$%
MHDKR8NSY1V*V&!S@ D>OU^ /[#'Q@^.W[!7_  :>>*/C5X3^,7_/I_P@>C?\
M(GI__%"?\5C/9:C^_E63[?\ ;//=_P!_'^XZ)V(_2_\ ;=_:3^*WQ&_;?\+_
M ++_ ,#?&7AWX:^+]4\#7OQ"\1^+M5\/_P!N2Z+I:7<>GVPL[5WC@EFDN7D)
M\QB%6'E3N&0#[/HKY&^%VI?M<^ /V7OBIX>\53_"WQ%\3_!DT<'@OX@>(&&B
M>'?%]FT$+R7]_:69FEM)+<FX$D81$D:- A1&,@^)O#__  5N\9? ?]M#X0:+
M_P -H?"/]J;3OBM\0-+\$ZOX,\-^";33/^$9BOMT2W]I?6]Q*98XYVA#"9W+
M!A@9S@ _5+X=_M1^!/BO\=OB+\-- US[?XV^$_\ 9G_"5Z;]BN(O[*_M&W:Y
ML_WKQK%+YD*LW[IWVXPVT\4?'W]J/P)^R_\ \(5_PG6N?V'_ ,+$\5V/@GP]
M_H5Q<_VAK%[YGV:V_<QOY>_RG_>2;8UV_,XR*^0/^">'_*=?_@HK_P!TU_\
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M9((VN/"FNV\*LQ"@O+)9*D:Y/+.P51DD@#->[?\ !6+_ )19?M+?]DJ\4?\
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M8YKY(\5_\%_/V./!/Q?3P-J/Q\\&)KSLR,\2W-QIT++O#+)?QQ-:1L"C##S
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M>!OAW??LXVWBK2M3O]#A\1_V-<#6S9QZG%YS+-=S&V6*)4FN#%^\,KI(RD.
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MAFSUSQ/!*S_V?J4NB^$8;VPL+M -DT4L[>9Y,A*O]DY1P#M_2G]IK]E?X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"'[CPS\=/^$1_L&UM)YGO[3^R=+EL[G[4C1+&FZ1P8_+DDRN2VP\5]044
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MT^"/Q&T3QSIOA;P-X8U'3;#7VT^[7#W-Y([O!(+5I]L<5N8][A20,2+^H=%
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MD7$QU2WGMM76[A;9Y7E?9UMD5-WF[]XQLQ\U?7]% 'PA\(_^"7_C[P%^Q?\
MMQ?#J\U?P?)K?[2_C7QYXD\,3PW5R;6PM]=L4M[1+UC 'CD1U)E$22A1]UG/
M%6/CK_P2Q\9_&#_@E5\ _@U9^+?#^C^/_@;#X1U%&N(9;_PQXAU#1+6.)K.^
MA*QR7&GRR*6VE5;*1,5^4K7W/10!^<G@G_@FO^TWXU_;F_9W^.GQ0\8_ -&^
M#5SJUM)X+\$:#?Z7I=K:ZGILUI=7-O=3/++/<;OLV(Y(XD*H3O4C:_6>-/\
M@E_X^\1_%;_@H7KL&K^#UM/VLO!6E>&_"*/=7(DTZXM?#EWI<CWX$!$<9GG1
ME,)F)0,2H;"G[OHH ^.]9_X)?:AX]_X)T? +X9WGB[_A$/BQ\ M'\/3>'?%V
MA[[F#2]<TS3TM'D$;^4;JRE'G1R0R!/-BD.0K8QPOCS]C7]LW]LKP_K'PR^.
M'Q/^!.@_!S6 EIK%Q\.]"U2+Q)XIL#GS[25KR9H+)90 CM#YC%'< KW^_J*
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MS)>2P1/<R//.TES(&+OLXB7Y><#ZTHH _._]FK_@BSXA\(?\$8_A9^SWXO\
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M_P"'[CPS\=/^$1_L&UM)YGO[3^R=+EL[G[4C1+&FZ1P8_+DDRN2VP\5]044
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MS?&.EWVN>$=4LM+U.31=3O+.:"TU&.&.9["9D*I,J2*R,48A@KJ5.,$$<5^#
MWQD_X)F_M=?\%)/VID^#WQNNO")\0^"(?!VO>(OBMI>JV]M=7.CV^I>,_LDE
MG9P6L8CN)A?S1!=J"-M)B=]YF!'[YT4 ?D/_ ,%=O^#=W6OB=^SS\>?$?P9^
M)7[0WBOXA?%'Q%%XGE^'MWX[LK7PCK%U-J5J\HEMI8H8V2VMD)@\V?<@M+=0
MS;%4]%XR_P"""'B?XP_\$!M&_9\U'QGXHO?BDMMHWBJT_P"$]UI-:MO!^M0:
M?:P3:/92PJ1;Z=&J7,$2Q&41BXD8-(IP?U6HH _,KX8?\$TOBO\ MR_\%#=4
M^/O[3?@7P3X$L]-^&%Y\+-*\+V&LQ^(I;_[0][#=:DTPACCBBE@O+H)%AG\N
MZ"OM*LK>#^"O^"(G[1'C3]G/X'?LB^/M!^'7_"C?@A\0SXXN_'T.M_:I/%]B
MUUJ4O]G+I30AX9BM[(LADD,0$R;6DV,#^UM% !6#XU^%OAGXE?9O^$C\.:%K
M_P!BW_9_[2T^*Z\C=MW;/,4[<[5SCKM'I6]10!YY\"-+MO#>N_$'1].MX+#2
M-(\11P6%C;1B*VLHWTK3YF2*-<*BF6660A0 7D=NK$GT.N$^$7_)0/BE_P!C
M/!_Z9=+KNZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH X3X1?\E ^*7_8SP?\ IETNN[KA/A%_R4#XI?\ 8SP?
M^F72Z[N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\\\
M-?M9?#7QE\>=8^&&E>-_#M_X_P!!L+?4K_1(;Q6N8()WG1#CHS VTI=%)>-?
M+9U598RX!Z'17&_&;]HGX?\ [.6@QZK\0O'7@[P'IDS^7'>>(M:MM+@D;^Z'
MG=%)Y'&:V=:^(GA_PWX"N_%6HZ[H]AX8T^R?4KK6+F]CBL+:U1#(]P\[,(UB
M5 6+EMH ))Q0!LT5Y?\ !3]MWX+_ +2GBJXT+X=?%WX8>/\ 6[2T:_GT_P -
M^*K'5;J&W5T1IFB@E=Q&'DC4L1@&11G+"NETGX\>!]>^)M[X*L?&7A2\\9:9
M$)[S08-7MY-3M(SN >2V#F5%.UL$J!\I]* .KHHHH X3X1?\E ^*7_8SP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#7CN^\.3V_@[Q/JJNZ-8V6HM\DLNY,#("N70*S%J^%O^"OG_">_\1!.F_\
M"I]_]K_\,J^)?.^Q>1_SY^)/L>?,^7_C^_L['_ ,_)NKY<^,']M?\0I'[$W_
M  A>W_A-_P#A=LG]B^3Y?G_;OM_B7R,;_ESYGD_>X^[GB@#^F"BBL'QK\1=/
M\ ?9OMUOKL_VO?L_LW1+W4MNW;G?]FBDV?>&-V,\XS@X ,+X1?\ )0/BE_V,
M\'_IETNN[KS7]GSQ';^+/$OQ+U"UCOXH+CQ/%M6]L9K*<8T?3%.Z*9$D7D'&
MY1D8(R"#7I5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117'_'[X_>#
M?V6O@UXA^(/Q!\0Z?X5\&^%;0WFIZG>,1';ID*H"J"\DCNRHD:!GD=T1%9V5
M2 ?*'_!7[XI:[\=?["_8W^&E]_9_Q&_:*TJ^CUS7EACOK;P#X2BVIJ6H7EL%
M>0_:XVDL+4,(8Y)YG N89(EW?7_PG^%NA? [X6>&O!7A:Q_LOPSX/TJUT32+
M/SI)_LEG;0I#!%YDC-(^V-%7<[,QQDDG)KY0_P""2/P!\9>(-.\4?M*?'#P]
MJ&D_''XU7=Q-;:9K2A]0^'7A,3EM+\-1,"$CC1%%U+MAMY9)KC_28S/#NK[/
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /C#]KSX ^,OV5/VN)OVLO
MA!X>U#QM)>>'X?#GQ5^'.E*(KWQAI=O(9(-8TY$*+=:Y8H6C2*YWFXM=UO"\
M$FSS/I_X _'[P;^U+\&O#WQ!^'WB'3_%7@WQ5:"\TS4[-B8[A,E6!5@'CD1U
M9'C<*\;HZ.JNK*.PKX _Y1$_\%'/^?;]G/\ :^\5_P#7]>>'_BAJ#_A.FGZG
M;V__ $\K#=0_\N<#?, ??]%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <)\(O^2@?%+_ +&>#_TRZ77=UPGPB_Y*!\4O^QG@_P#3+I==W0 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4.JV>Z6&2:UWK^\MI_*>2-;B&0/#*BNWERQ2(3E37H% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"?"+_D
MH'Q2_P"QG@_],NEUW=<)\(O^2@?%+_L9X/\ TRZ77=T %%%% !1110 4444
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M\M]3M?$OQ+CUB[L;_4E\3Q>=/96;VD#_ /$GTS;MB:65EPN <N<D$\9P/2J
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MM_A_X-UNWL_$_C76/$_V2\N=1\4PW$L,FI7-Q)%YD=G:JRHRJ?(0XSS7U!0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <)\(O\ DH'Q2_[&>#_TRZ77=UPGPB_Y*!\4O^QG
M@_\ 3+I==W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7/_%CXI:%\#OA9XE\:^*;[^R_#/@_2KK6
M]7O/)DG^R6=M"\T\OEQJTC[8T9MJ*S'& "<"N@KX _X*R?\ &>'[4_PB_8JL
MOWOA_P 6[/B;\7?X=GA#3+M/L]ESY;G^T-32&'S;.X%Q;?9][1M$YH Z#_@B
M%\+==\7_  L\<?M0>/;'^S_B-^UIJL'C*6R\Z.7^Q/#D4/D^'M-\R%A#/Y5@
M5E\\0PS/]KVS*9(LU]OT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?AM\0M+;P[XLM=T<T\>VTE.+C=:PFY/V9Y?+ADC:3R]P%?4% !1110 4444
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MOO*EGN)K.*VD,;,\B$BN?_X*7_\ ! /XC_\ !;+_ (4WX_\ B7\8O^%1>)M
M^'^GV&N>"K/PZVMZ5I6N2[I]2FMF&I+&FZ1XX"5,A9+*',L@"X_5^B@#Y_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8W>6^,[37H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_V,\'_IETNN[KA/A%_R4#XI?]C/!_Z9=+KNZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/\6>+-+\!>%=
M2UW7=2T_1=$T6TEO]0U"_N$MK6PMXD+RS2RN0D<:(K,S,0% )) %?$'_  2M
M\)ZK^V7\??&'[<'BO3-0T*/XI^'[;PC\+?#NIV[V^I^&O!UM<R3&6ZVA(I)-
M3NP+Y1MG\F)H1%=2QR$*?\%D/%FJ_M-^*OAI^QKX*U+4+'6_CU=M?^/M0TJX
M>.Z\+^!;)U?4IFEB+O:R7SA+&W:X@DM;@R7,#E2PK[?\)^$]+\!>%=-T+0M,
MT_1=$T6TBL-/T^PMTMK6PMXD"10Q1( D<:(JJJJ %    % &A1110 45Y_\
MM+_M5?#C]C?X67?C7XH^-/#_ ('\,VF]?MFJW2P_:I5ADF^SV\?^LN+AHX96
M2"%7EDV$(C'BOE#Q/_P<A?LKP?LP>/?BQX1\2^,/B7X=^&MWI5GKUOX;\(:B
MMU9OJ4LL5J6-Y%;0I&Q@FS))*B HL>[S9H8Y #[OHK\P/V-_^"\WQD_X*/?\
M)\OPF_9"^(&G>'_^$5\0:K\//'.NWJ_V%K^HV?F1V%M=^8MM GGW"K%(EM>S
MO%)N4GRDEN8?+_V+_P!CO_@J%\?/V\_"'QJ^.WQ<T_X1^#?#WB!QJ7@"PU>.
MZM;[21OF-K%IMD9;":.7[0]JMS=W#7D(02Y=X("P!^K_ ,1_VA? /P<\5>&-
M"\7>./!_A76_&UW]@\.Z?K&LVUC=:_<;XD\FTBE=7N)-\T*[8PQS+&,989^<
M/VZ?^"[W[,'_  3N\=ZSX.^(WQ$V^/=&TH:J_AC2-*NM2OY=\;20VQ>*,VT%
MQ*H4HEQ-%\LL3L4CD5S\W_"?_@T8_9HT+XR^,/%_Q*UOXG_&Z3Q-=RW,,'BK
MQ \,D;S""2:YN;FR\BXN[QKA;I_-9T0I=!6A>2/SV^__ !+^Q%\%_&GQEC^(
MNL?"'X8:M\08;NVOX_$]YX5L9]92XMA&+>87;1&821"*((V_*"--I&T8 /B#
M]I;_ (+C_&C4M.^&C_LU?L@_$_XMZ7\9O!5GK^@>*-5LK[2M/T"_O9[FWAM]
M1C^RF$1Q&*&9Y/ML44D,RR),(72X;0_XV6_M4?L"_P#-(/V:_P!H.S^('_3"
M_P!*OO"ZZ=_W%U%P]]+_ +!V6_\ "#^\_1^B@#\L/@-_P07_ &A4_9@^*?P_
M^,'[</Q/\;VGQ@\%1Z+?6(2ZO5\-ZH)89O-MKV\NWFFLR!<VL\"QVHO;>Y82
M>6RILT/^"9?_  :M? _]@'QWI_C?Q'K_ (@^+_C:WTK4](N%U>U@M?#DT5]'
M+;2D::!(S;K&:6W=+BXGB<32MY8)C\O]/Z* /D_]E_\ X(:?LE_L=>*CKO@/
MX'>#[76UN[6_MM0U@W&OW6FW%J[/!-:2ZA).]I(KMNW0%"2L9))C3;]8444
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ML#<6VF6%Q%$(HIHM,206$<B;5=66 %90)@1*/,KZPHH ^ /^(7']A3_HAO\
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M/\%>%+ZT9&T_Q_K\;ZR;B.>5'D:*:]TR:",A4"QRVV2%,@=DD3'D&C?L;_\
M!9O]K3X-:MIOC/X[^#_A5'=7:V[6-Q?Z?I6LRI&8IEGAO= L)GBC9_D(6Y1V
M$<BNGEN-X!^YU>'_ !^_X*7_ +/7[+6H^(=/^(/QL^&'A76_"MH;S4]$O/$=
MJ-9MT\@7"@6"N;J21XF5DC2-GD#IL5BR@_D#<_\ !I=^TE^U]X5LY?VD?VQ]
M0UK6]!NYTT>T<:IXVM;.WE2$O)'/?W5H\,DCQX>-(B"(8B78G:GK_P  ?^#.
M#X:^ M.\/7OB_P".7Q/O/&7@V[$N@:[X$T_3?!TE@B3FZA=SY-W<37D=Q)*R
MW;W&]4%O$H5+=* /I#_B)4_9L^('^A_!VW^+_P"T3XFC_?77AOX<?#S5+W5;
M*S'#WTB745M&+=)&AC9@Y;?<1 *025\_^.G_  <+?$#X?_V7J6D?LG>(/"_A
MG5?-M;>?XW?$OP_\)-5O;R#8UPEK8:E(\ES;QQSVI^T(VW?*R8!3+>@?\0WW
MP)^(W_):_&'Q_P#VE/L?_(&_X6;\2=0O_P#A'-W^O^Q_9&MMGG[8?,W[\_9X
ML;<'=Z!\"_\ @@/^QM^SO_:G]@?L]^ -0_MCRO/_ .$GMY?%'E^5OV^3_:;W
M'D9\QMWE;-^$W;MBX /@#XZ?\%UOB^O]EVWBW]J?]B#X#>&?'?FW=K>> +?5
M?BMXR\%Q1[)DM+B.U2;2I;C+Q6TLLGEQ2 W$EN&,8 \__P"&T]"_:H_T.X_;
ML_;?_:F\3:1^^L/#?[-?PMD\!ZKI=F_%U?:@@@6.\MQ(+.-&9PT+S856$SE/
MV^^!?[)WPL_9?_M3_A6GPT\ ?#O^W/*_M+_A&/#UII']H>5O\KSOL\:>9L\V
M3;NSM\Q\8W&O0* /Y@O^"H_P6^$^K_L)^.?%>D?LJ?MOS?%W2_L%UK?QH^/T
MUYI]S;V9U"VM5>1FNS;7UQMEM;"*W2V5E@<S9_T9F;\@*_M\_P""H_[#'_#R
MC]A/QS\%/^$H_P"$+_X33[!_Q.?[-_M'[']EU"VO?]1YL6_=]GV?ZQ<;\\XP
M?R!_X@8_^KHO_,;_ /WTH ^ /^#7'_E.O\#/^X__ .H_J=?U^U^0'_!+C_@U
M*_X=K_MV>!OC7_POG_A-/^$+^W_\2;_A"?[.^V?:M/N;+_7_ &^79M^T;_\
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MO#7A_P -?\)+JL^NZO\ V5IT-G_:NHS[?/O+CRU7S;B3:N^5\NVT9)P* /S
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M !9XLTOP%X5U+7==U+3]%T31;26_U#4+^X2VM;"WB0O+-+*Y"1QHBLS,Q 4
MDD 4 :%%?+_Q2_X+6_LC_!_P)?>(M6_:-^$%WI^G>7YL6B>);;7+]]\BQCR[
M.R::YE^9P3Y<;;5#,V%5F'D'_$4;^PI_T7+_ ,LSQ!_\@T ??]%? '_#_3_J
MRO\ ;_\ _#0__=='_#RO]L[Q1_Q,O"W_  3R\07?AG4?]*TB?7?C!H>AZK-9
MO\T#W=A)&TEG<&,J9+=V9HG+(22I- 'W_7YP?\'0'[7G_#%W[ OA'Q3_ ,*P
M^$'Q8^W_ ! L]*_LCXC^'/[>TJVWZ=J4OVF.#S(]MPOD[%?/"2RC'S9'0?\
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M9XL\6:7X"\*ZEKNNZEI^BZ)HMI+?ZAJ%_<);6MA;Q(7EFEE<A(XT169F8@*
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M8)LC6,>79V5S#;1?*@)\N-=S%F;+,S$ \?\ ^(33]G'QC\=O^%@?$OQO\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^!+'P[I/[.7P@N]/T[S/*EUOPU;:Y?OOD:0^9>7JS7,OS.0/,D;:H55PJJH
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M\*VEM93:WXJ\.:2([=,QV\)N;^]0O)([M&OF32,\CN,LSMD@'8?\/8OV6?\
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M^&X_$>J6L:2N[VA:W\/'3(8)"5NLR3)*\P55#*L&" ?TF_\ #V+]EG_HY;X
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MS2/_ )'H _?W_A[%^RS_ -'+? #_ ,.'I'_R11_P]B_99_Z.6^ '_AP](_\
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M ,$;_#]WJ&G>9Y46M_M(V.N6#[XVC/F6=Z\UM+\KDCS(VVL%9<,JL #]7O\
MA[%^RS_T<M\ /_#AZ1_\D4?\/8OV6?\ HY;X ?\ AP](_P#DBOS0^-?['GBO
MX^^%;?1]=_X(P_#"QM+:[6\23PW\9?#GAJZ+JCH UQIT5O,\>)&S&SE"0K%2
MR*1YA_PZ _ZP[_\ FUW_ -T4 ?=__!5/_@XF^"_[$?[(^H^*_A;XZ^&'QG^(
M.H7::/H6AZ%XLL=2CM+B6.5Q>WT=O.9A9Q"([O+&7=H8MT7F^;'_ #I?\/\
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MEG_HY;X ?^'#TC_Y(H_X>Q?LL_\ 1RWP _\ #AZ1_P#)%<?\:_\ @A;^Q_\
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M/'=]XBU;X">'[34-1\OS8M$U;4]#L$V1K&/+L[*YAMHOE0$^7&NYBS-EF9B
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ME_$;4/+^VR^#;2&Y\)ZWLC6"/^T/#TN+&?RH#<B'RA#LFNGG;S) *Y__ (?
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MAE_X0R;5O-U&;]Y<M]LFU".6YS,SGSI(T>3[S(I8J #]?O\ A[%^RS_T<M\
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M?[/?@']I3PK;Z%\1? _@_P ?Z):7:W\&G^)-&MM5M8;A4=%F6*='02!))%#
M9 D89PQKL** /G__ (=._LL_]&T_ #_PWFD?_(]>(>+/^#9?]ASQIXJU+6+S
MX$:?#=ZM=RWL\=AXDUJPM4>1R["*W@O$AAC!)VQQ(J(,*JJH 'W?10!\ ?\
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M3] >$_">E^ O"NFZ%H6F:?HNB:+:16&GZ?86Z6UK86\2!(H8HD 2.-$5555
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M\)'XBT+0/MN_[/\ VE?Q6OG[=N[9YC#=C<N<=-P]: ,+X1?\E ^*7_8SP?\
MIETNN[KS7]GSQ3IGC3Q+\2]3T?4;'5M-N?$\7DW=E<)/!+MT?3%;:Z$J<,"#
M@\$$=J]*H **** "BBB@ HHHH **** "BBB@#/\ %GA/2_'OA74M"UW3-/UK
M1-:M);#4-/O[=+FUO[>5"DL,L3@I)&Z,RLK A@2""#7QA\4O^""?P;M_'=]\
M0O@5/X@_9@^+LGEO;^)?AU=M96$GDQKY5I=Z.3_9]QI[30VTT]JL47VAK<;I
M!OD+?;]% 'P!_P ,K?\ !1#X'?\ $V\+?M6_"#XZ:A<?Z))H/Q'^&2>&-*M(
MF^<W<=SHTC7+W"LBQK$X\HI/*Q.Y$H_X?/?%CX/_ /$M^,7["?[3^B>)I_\
M2K6#X<65G\1-*>S/RH\E_:RPQQ7'F),&MRI946)R<2@#[_HH ^ /^'^G_5E?
M[?\ _P"&A_\ NNC_ (?Z?]65_M__ /AH?_NNOO\ HH ^ /\ A_I_U97^W_\
M^&A_^ZZ/^&R_^"@GQ7_XD&@?L7^ /A/JU_\ ZCQ7XV^+MEKVA:5L_>-]HL],
MC6\E\Q5:)/*/RR2QLWR*U??]% 'P!_PY<\4_M@?\3?\ :_\ CQ\0/BI_:OS:
ME\-O".HS>%?AQ% ?W\5BUI;E;J^^R7;L\5[--'/(L%KYJ_NB&^O_ -FC]E7X
M<?L;_"RT\%?"[P7X?\#^&;38WV/2K58OM4JPQP_:+B3_ %EQ<-'#$KSS,\LF
MP%W8\UZ!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLQ_ WQP/'_AVUMM#GA\6:M<_:;R=;&]E:4VJP(;ILR1)ND\Z4;(\(:_5VB@
MHHHH X3X1?\ )0/BE_V,\'_IETNN[KA/A%_R4#XI?]C/!_Z9=+KNZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M X3X1?\ )0/BE_V,\'_IETNN[KA/A%_R4#XI?]C/!_Z9=+KNZ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\T_:X_:Z\ _L-? C
M6/B1\2]<3P_X4T38L]P8FEDED=@L<4<:@L\C,<!0/4] 30!Z717Q]_P3K_X+
M0?#7_@H1XOU[PE#I7B?X=>/]#DU&Z7PWXIL9+&[OM,M=2N;$7L1=5#8,&)XA
MDV\WFQ$OY1D.9\+?^"^7[/\ \7/CIHW@[39_&]OHWBK6F\-^&O'=]X<GM_!W
MB?55=T:QLM1;Y)9=R8&0%<N@5F+4 ?:E%%% '"?"+_DH'Q2_[&>#_P!,NEUW
M=<)\(O\ DH'Q2_[&>#_TRZ77=T %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5\;_\ !=;]D?X5_MJ?L"ZEX-^+'Q)\,_"/3UU6VO\
M0O%.O7]M:6>G:M&DJPAC/)&C[XWG0H'#%7<@\5]D5YO^UI^R7X#_ &X/@-K?
MPU^)6B)K_A/7U3[3;>:\,B.CAXY8Y$(9'1E!# ]NX)% 'X@_L_?M@^._A7\1
MOBC\ ?B'\._AAXC^/WB#P7\5[OX;?%;0=,B37KB]AU?Q2US:R--&?*BEU*TU
M>6-5>.-4:)61C(QKR7XP?VU_Q"D?L3?\(7M_X3?_ (7;)_8OD^7Y_P!N^W^)
M?(QO^7/F>3][C[N>*_8O_@F=_P $7O!/[!?B;6?&FJW>M^./B7?7FN:?::[K
MNO7&L/8:'=:S>7EM;1><J".62*>.6Y(3Y[J6Z8,P<EK/PS_X(-?L]_"CXV:+
MXNTO3/%\FD>%-7/B+PWX(O/$EU<^$/#.K%Y)&U"STUF,<4Q:0=RB>5&41""2
M ?9E8/C7XBZ?X ^S?;K?79_M>_9_9NB7NI;=NW._[-%)L^\,;L9YQG!QO44
M>,?#GXRZ;H/C#Q[=76D>.XH-:UZ*]LF_X0O6&\Z(:980%L"V)'[R&5<-@_+G
M&"">L_X:+\/_ /0/\=_^$1K7_P BUW=% '"?\-%^'_\ H'^._P#PB-:_^1:/
M^&B_#_\ T#_'?_A$:U_\BUW=% '"?\-%^'_^@?X[_P#"(UK_ .1:/^&B_#__
M $#_ !W_ .$1K7_R+7=T4 <)_P -%^'_ /H'^.__  B-:_\ D6C_ (:+\/\
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MB_#_ /T#_'?_ (1&M?\ R+7=T4 <)_PT7X?_ .@?X[_\(C6O_D6C_AHOP_\
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M /H'^.__  B-:_\ D6C_ (:+\/\ _0/\=_\ A$:U_P#(M=W10!PG_#1?A_\
MZ!_CO_PB-:_^1:/^&B_#_P#T#_'?_A$:U_\ (M=W10!PG_#1?A__ *!_CO\
M\(C6O_D6LG5/&,/Q8^(?@4:/IWB4+H.LS:E?2:AH%]ID44!TV]MP0]S#&KMY
MMQ$-BDOABV-JL1ZC10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH58%<<$<CD_)7[&BB/\ X/(OVKP  !\*;$  =/\ 1?"E %]_^"S?[2'[4O\
MP43^-WPF^ 6K_LB:'X8^%OB*V\+Z;<?%&XU>RU'Q#?-'.D\%K]FGQ<NL]C>G
M"1+^Z1"-XRQ_7&OY^O\ @K%XQ_8F^('[!'[06D_"#X?:#X*_:7TCX@Z=I-G8
M:GIT4/CK4M8_M&P:YGL099;QX&C:Y0F,A6ECD;:=Z22?N7^R]9^+=._9H^'=
MOX^:"3QU!X8TV/Q&T!8Q-J0M8A=%"WS%?.\S&><=: .ZHHHH **** "BBB@
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M?V6.-D<+*^G3C:#%E@#]?Z*^ /\ A_I_U97^W_\ ^&A_^ZZ/^'^G_5E?[?\
M_P"&A_\ NN@#[_KQ']K;_@HW\%_V%/%_@+0_BQXWM_!VH_$Z\EL/#BW&GW<\
M5]+$]ND@>6&)XX%5KJ#+S,BX<G.%8CC?V.O^"HNG?M=^.YO#MS\#/VG_ (2:
M@=OV*7XA?#*^TNPU#]W-))MO(O/MH=BQ '[3)#O:6-8_,8E1^?'_  =5_"'2
M/V@OVY/^">_@+Q"DTF@>-_'6H:!J:12&.1[6[U#P]!*%8<J=DC8(Y% 'ZC_M
MJ_MZ_"?_ ()W?"RP\:_&+Q7_ ,(?X9U358]$M;S^S+S4/-O)(9IDB\NUBED&
M8[>9MQ4+\F"<D ^P5_-[_P %TOVD?$GB_P#X(T6/P0^)VHQWWQE_9Q^-FG>$
M?$%P0D4FNZ?_ &+K$FE:P(Q(Y5;JR,3$L<F1)<@=*_0+_@NG_P %H[O]A[]I
M3X8? W0OB%HGP;N/'6EW&O>)?B)J?A>X\3?\(GI^+B*U-OI\:D7$TUQ;R(-V
MY4VJ67:Q8 'Z0?%CXI:%\#OA9XE\:^*;[^R_#/@_2KK6]7O/)DG^R6=M"\T\
MOEQJTC[8T9MJ*S'& "<"N?\ V7/VH_ G[:/P)T/XE_#37/\ A)?!/B3[1_9N
MI?8KBS^T^1<2VTO[JXCCE7;-#(OS(,[<C(()_'WX&?\ !:&^_;@_9+_;G^!V
MO?$30_C++X'^"NOZ]X9^(>F>%KCPR?%=A_8[179N+"10+>6&XN(DX"ARSE5*
MJ&/E_P#P0Y_X*KZ[\1OV6_V<_P!BKX*^(M.\ ?$2:/6[[Q3XWUBVAG_L:#^U
M[V^%II=I,CQWE]):ONS(/*C!Z.5?RP#^@N_U*WTJ 27,\-O&TD<*O*X12[N$
M1<G^)G95 ZDL .34]?B7_P '+FA?%<?\%#_V#?#?AOXS:UH&E>,?%=IIFEPO
MI%O<1:1KUKJNFA=>N(ALAOI/]-MBMO(BQ1FT?9M%S(!]8?\ !3']I[XD_L;_
M  R^%GA?4OVGOAQ\,]0U+P^--U7Q;=>!9/$?C+QIKJ?9;=9-*\/6Y$"QR222
M22<RK&\T*!-H+$ _02BOQ)_9._X+9?'*_P#^&R/A%XJ\6ZGXK\5_!CX.ZS\0
MO!OCK6/AVG@[67EM[&.8->:3(6B0"2]M6A5H</'"7?<) *^E?^"!_P 6OVG?
MVX?V7OA;\=?BG\:M)U;PMJMGK-C<^%K;P98VMQK<L6HW,$5]/>Q;?+:(Q&-8
M8((T9(U9V=F)H ^P?VU?V]?A/_P3N^%EAXU^,7BO_A#_  SJFJQZ):WG]F7F
MH>;>20S3)%Y=K%+(,QV\S;BH7Y,$Y(!^8/\ B*-_84_Z+E_Y9GB#_P"0:^S_
M (U_L]^ ?VE/"MOH7Q%\#^#_ !_HEI=K?P:?XDT:VU6UAN%1T698IT=!($DD
M4,!D"1AG#&OQA_X(&?L1?!?XQ_\ !23_ (*(Z%XN^$/PP\5:)X)^)26'AW3]
M8\*V-]:Z!;_VIX@3R;2*6)DMX]D,*[8PHQ%&,848 /UN\9?MZ_"?X?\ [9/A
M/]G[5_%?V3XN^.-*DUO1-!_LR\D^VV:+=NTOVE8C;)A;&Z.UY5;]UT^9=WL%
M?BQ_P4PB\87/_!VQ^S%#X!GT*T\77'PINH=/NM9ADGL;(O%XH5YY(HV1I?+C
M+R"(.GF,BIO0-N'L_P $/VX/V@OV2?\ @MYX2_90^-'Q(T#XVZ)\7/"EUXMT
M37K/P?!X<NM!E5;Z1;0QPS.C6ZIIER 7,LI,T1+X#"@#]0**_GO^(G_!SMXE
M^,&H?$SQ]X9_:3\%_!VV\%:EJ$/@7X6WGPMOM?;XB6D,"M;37NJA!]C>XDW*
MBJT7EM_K/D <^T_MB?\ !</XS_%/PM_P3H\6_ O7]-\&+^TQKMWI/B;1[O2H
M+ZQN[R#4])L)+5I)XC.D"7$MY'O@:-V1MP;(1@ ?M/17R+\9_$'QG_8I_8$U
MO4_%_P"T!\*=3\:6NM1R7/Q#\<>'QX?T31=-GNHU9$L+1V\^>.-FC@C:8&61
MH]\G4'\[_@O_ ,%M_C!\&OV^O@%X<U+XS:W^T3\*/VA?$4>AQZAJ_P $W\ 0
M::)YH(+:729V=3>1[[V!I&?S-D2)U:4&@#]RJ*_'7]B+]J[]LG_@H?\ MM?M
ML?"_PS\=O#7@/P]\(?'DVDZ%K%_X%L=7O="MAJ.KP6]I;0KY"2AX[5-\UTT[
M+]F3"DR.U=A^S7_P7V\2>"OV%/VK]9^,FG:%J_Q9_9"UZ7PSK!TB*6VT_P 2
MW$M[+8:=* %;R1+=Q21/MR%5!(0@;  /U:HK^>WP#_P<Z^)_A%J/PR\?>(_V
ME/!7Q>M_&NJ:=%X[^%EG\++[03\.[*:%FNI;+5"I^V/;OM5E9I?,;'EY0EA]
MY_LT_MZ_%CX@?\'+?[0G[/VK^*_M?PB\#_#^TUO1-!_LRSC^Q7CP>'W:7[2L
M0N7RU]=':\K+^]Z?*NT _1^N9^)7QC\-?"+X2^)_'6OZK#:>%/!NG7VJZS?Q
M(]RME;V22/=-LB#.S1B*3*(I?*%0I;BOQT_;Q_;Y_:'\:?\ !0__ (*!? [P
MW\7;WP9X)^%GP)N/&?AN.RT.Q:YTR>WL=!O+H17(C2Y#W$-Q?P+*9B8#=B5!
MNAC U_\ @B)K?Q>_9\_X-L/B1\71\69=8@3P%XL\0> M&D\.6B/X&OK"XUR2
M>=KIM[:@;FZ6.<BY0K'LV ,K&@#]6OV7/VH_ G[:/P)T/XE_#37/^$E\$^)/
MM']FZE]BN+/[3Y%Q+;2_NKB..5=LT,B_,@SMR,@@GT"OQ_\ #W_!=?XA?LZ_
M\&T_P^_:3\:WEAXZ^,?CG4[_ ,.:9<7]A':VEY?_ -K:G%$\L-I''&$AL[)V
MVJ(Q(80I8,^3]*_ [P[^W3^SM^U!X"M/'GBGPM^T3\+_ !T;M_%M[8Z!IWA:
MX^&<NV,P+;_Z2'O[?<S+_JWEVQL20=NX ^ZZ*_%S]H__ (*Z?&'6O^"GOQ7^
M#OB7]H;PC^Q7H?@"^@;P=_PDGP^AUN/Q]:?.&FN+VXF$5O#)L21&0HQ2;;Q)
M$^?U#_81\1_%#Q9^S'X>U#XOZM\+?$/C2Y$CRZM\/+RXN= U2W+DP30M,BL&
M,>T,!E2RDJ0&VJ >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M>/\ [=/[<7@3_@G=^SCK/Q1^(S>(%\,Z-B-_[(T:XU*:6=U;R83Y2F.#S9 L
M*2W#Q0>;+$C2H9%S\P?\$^_^#DC]GW_@HWX[\0>&/!^C?%_2?$'A_2I=;-A?
M^#9M0FO;.&.22>6(:6UYCR]D:!9?+:66YMXH1++($H ^_P"BOS _95_X.TOV
M9?VL?VCO!?PSTWP_\7_#>K>.]5AT33;_ %O1+(6"WD[>7;Q2&VO)Y5\V8QQ!
MA&55I%+E$#.I^U5_P=I?LR_LG?M'>-/AGJ7A_P"+_B35O FJS:)J5_HFB61L
M&O(&\NXBC-S>02MY4PDB+&,*S1L4+H5=@#]/Z*_&#_@J?_P<Q?#CX(?M'>%K
M#P5XF^(&HV7ASPKI'C;3HO#^E+'8>*+S4FM+^&SU$WCV\EO;OHF^(,L5XJ-X
MA%P8$N]*@5OJ#XP?\')'[/OPA_8>\!?']M&^+^O>"?B%JK:)8I8>#9H9K:\C
M@,L\4LUTT%FWE,'A+0W$JRRPW A,PMKAH@#[_HK\\/@-_P '.G[-'Q^_9@^*
M?Q3LX/B?HFE_""TCO-=T[4O"SM=%)Y8;>S$<UN\UD)+JYF$,,<MS&Y,4SLJ0
MQ/,,_P#8=_X.C?V<?V\?CLOP\\.Z%\7] \07&E7^JV*ZKX92Z_M/[';O=36U
MO%IT]W/)<?9XIY$01?O/)**3*\<;@'Z/UXC\4_\ @HW\%_@E^UUX/^!/BKQO
M;Z-\5/'UG'?Z#HLVGW974(I)+B.,BY6(VR,\EM,BH\JL64  ETW?-W[#O_!R
M=^SC_P % OVR5^"?@5?B!#X@U#[?_8FJZKHB6^E>(?LBO*WV=EF>>/?;Q2SI
M]IAA^2(JVR4K&WQ#_P %O/V7F_;+_P"#FWX!?#J#6+CP[JFM?"&XN=&U> MO
MTG5+0>)KRPNL*06$5W;P2%<C<$([T ?K[^T?^WK\)_V2/BG\,?!7Q"\5_P#"
M/^)OC)JIT3P?9_V9>7?]KW@FMH3%YD$3QP_O+RW7=,R+^\SG"L1ZEXH\36'@
MOPUJ.L:I<QV6F:3;27EY<R?<MX8U+N[>P4$GZ5^ /[=?[:EW^W#^TO\ \$M=
M=\1VL.D?$OPI\8;OPE\0-&0QAM'\06&M>&X+V(JCN$5G7S4&X_NY4YK[O_X.
M@?VJ)?@A_P $WW^'NDZQI^A^)OC[K=KX$M+Z_N8K:TL+29P]]/<2R_+';^0I
MADD_@%R&XQN !]7_ +$7_!1OX,?\%'/".M:[\&/&L?C+3/#MXEAJ,@TR]T][
M69DWJ#'=0Q.05Z,%*G!&<@@=S\?_ -HSP)^RM\,[OQE\1O%>B>#/#%BZ1S:C
MJMTL$(=SA$7/+.QZ*H+'!P*_'']@WQ3\#_\ @FG_ ,%R? G@;X%_$?X?^,_A
M)^T%\/;7PQJ$?A?Q%8ZLMCXETN("&ZNO(=VB:X2-L?-^]FOYR5.W</JS_@X=
M_P""=7Q(_;B\!_!OQ-\.-#TGX@W'P:\6CQ'JGP]U>[CMK#QG:_NF>!F<;6?$
M)B"LRJ8[J?DMM! /HC]C#_@KK^SC_P %"/$%WH_PB^*FB>*M;LD>632Y+:ZT
MW4&C39OE2WNXHI9(UWKET4J"<9R#7'_M1_\ !>K]D_\ 8N^.VN?#3XE_%;_A
M&O&WAO[/_:6F_P#",ZQ>?9O/MXKF+][;VDD3;H9HV^5SC=@X(('YY?LX:Y^S
MU\5/^"H?P&LO'O[-?Q'_ &$OV@/"]_=3>';3PWI6FZ?X5\:RCR]UI-.MDIN!
M)#O0-%'&,7$L?GES$:W?A#^SWX!_:4_X.^_VJ="^(O@?P?X_T2T^&NGW\&G^
M)-&MM5M8;A;/PNBS+%.CH) DDBA@,@2,,X8T ?JQ^R5^W)\)/V[? 3^)?A'X
M\T'QQI,!1;DV,C+<63.NY5G@D"S0,1_#(BG@\<&K/[77[9/PU_80^#-S\0?B
MOXFC\)^$;2ZALY+YK.XO#YTS;8T6*WCDE8DY^ZAP 2< $U^87A+X6^&/^"?'
M_!UWX(\"?![PE:^%/!?QG^%$U[XFT?1%:UTJRN(CJ3I<_9D'E1\Z;;H H10U
MRY'S2-OL?\%J/C%\,_VHO^"PO[._[/'Q3\8>"O"_PA^&EM/\2?'G_"5:Q::9
MIFK7!5H]/L3).R[Y/E.Z+< \-[(?FV?* ?JK\!?COX3_ &G?@YX>\?\ @76(
M]?\ "/BNS6_TO4(X9(1<PMD [)561#D$%74,""" 17#_ +7O_!0OX*?L$Z';
M7_Q>^(_AOP.E]%)/9VUY,TE[?)'C>T%K$KSS;=R@^6C<L!U(KX(_X-EOC?H'
M@+5?V@_V7-$\7Z)XU\/_  =\83ZQX(U?2-3M]2L;[P]J#F2)(KB$E9&CD!:4
MDG;)=E-QVX7SG_@GU\ ? G_!2O\ X+D?MS>,_C[X,TKQ=-\(-8L/"OAG1?%4
M(O\ 3K#3TEOX!<+;3CR]KI813+E"H^UR,"3(68 _3W]D+_@H;\$_V]=$N;[X
M0_$CPWXW%C#'/=VUG,T=]8I)G8T]K*$GA!(('F(O((ZBO9J_%;]OKX+?#S_@
MGA_P6Z_83\=?L\>$]"\,?\+DU>]\,>(]+\'(EGI>IZ:\MA!]H-O;CR2B)?2S
M,0@5OLB,2"@=?VIH ^?OVN/^"J7[//[".O6^D_%CXK^%_".M7212QZ7+))=:
MAY<K[$E:V@6258RP/[QE"@*Q) 4D>D?L_?M,_#[]JWP#'XH^&WC/PYXWT"1S
M%]MT>^CNHXW'5'VDE''=6 (]*_(W_@W%_93^&?\ P4B\*?M"?M ?';X9>&O'
MGQ,\4?%74=.N;;QGIT>L_P!A6\=M:7"6L<-TC+'Y;73Q9\M2%@1!@(%'Z0_L
M<?\ !*WX*_L"_%OQ]XQ^%/AF7PI??$=H3JEC:WDBZ7"L62B06H(BB4,TC#"Y
M'FN 0IV@ ^BJ*_);]E_]K+]K?_@LU<_%7XF_ GXU>!_@W\,_ASXQO?#'A70G
M\&6^O-XU-M%;SJ]]=SN'MXY4EB(:W *B=QR45SX/^UM_P<5?&#XE_P#!!#X>
M_'WX9ZS8_#GXICXIQ> ?%SV.E6]]:.Z:7>W;B&.^AE54E7[%-QN9"2GF'#9
M/WAHK\B_V\_VY_VQ/^"<W[=?[/WA_4_B%\,OB'I7[3>L2^'+'PN?!YTNQ\&W
M?GV5O&R72W#W-TJR:E"6:1P'%NP"1[\CK_@Q^VW^T/\ LF?\%S?!W[*_QD^)
MN@?&G0/B_P"$[KQ9I.JV?@Z#PY-X<E5=0E6U5(I7WP*NF3KF1I9&\V,EAAL@
M'ZBT5^)O_!&;]J']O/\ X*R?L(>+O&>F_M!^"_#6L^%/%]SI]E>ZAX L+V[U
MUX[*QG&GR>5Y%O:VH,O,RPRS,;F3YE$:5VEC_P '+>HW'_! JX_:1_L'P_\
M\+:M?$(^'ITR03+I<FO;%F\X*<.T?V-OM7E*YY!C\S@L #]?J*_(_P#:R_:_
M_:W_ ."*=M\,OBM\=_C/X+^-/PR\?>+;3PYXK\/P>"8=$E\&?:(;BX9M/N;9
MFDNDB2&7F=69Q BX!D+CLO\ @NQ_P4_^*?[%G[2WP=^'VA^*K/X&?"_XB6MU
M_;?Q?OO"'_"3QZ->+YGDVL-KY@3>-B%_,0C;<JZG$4@H _1[XL?%+0O@=\+/
M$OC7Q3??V7X9\'Z5=:WJ]YY,D_V2SMH7FGE\N-6D?;&C-M168XP 3@5S/[-O
M[6OP\_:Y_9YTKXK_  _\20ZU\/M:CNIK36)K6?3XW2VGEMYV9+E(Y(U22"4$
MNJC"9&5()^(/A3^U3\>]$_X)[_M+^/IOV@?@9\=] \#_  \U;5O ?C_P79);
M:TFIVFF7,S-J>G!9;%")41E168?NSN0B3:GYL_\ !5W]K7XX?M6_\&S7[,WQ
M;\7?%74KBY\9^--7T/QGI]IIEM8+XK;[7JRV,DSVRQ*D5M#ISIY"Q^7,UPDC
M_/ A(!_2717Y?_\ !4__ (*8?$;_ ((S_LC_  3\$>+?BMHGCGXO_$WQ#<:9
M?_$O6/!WV2RTO3([M'NM2;2;$LKM:P7=K$L*-NDVE\,V4/GO_!)+_@NC??%_
M_@HSI?[.VK_'70_VFO#_ (P\.SZEH/CZU\ 7'@R_@U2 7%Q/IUQ9LBQLHM8'
MD6555>$7<SLP !^P5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_ +;OP4U7]I3]B_XN
M_#K0I]/M-;\?^"M9\-Z?/?NZ6L-Q>6,UO$\K(KN(P\BEBJ,0 <*3Q7J%% 'S
M_P#\+'_:F_Z(W\ /_#R:O_\ ,Q1^S1\+_BG_ ,-3_$;XE_$O0? 'A?\ X2CP
MKX<\,:;IOACQ3=^(/^0;=Z[<RSS2W&G6.S?_ &M&JHJ/_JG)89 KZ HH ***
M* "OA#_@K+_P2_\ 'W[=_P"VA^QY\1?".K^#].T3]GWQJWB3Q%!K%U<PW5[;
MF^TBXV6BQ02(\FRPF&)'C&6C^;!)7[OHH _+/_@X<_X($>)_^"K^M>"_%GPL
MUSPCX8\:Z0IT_71X@NKFULM8LD#M;.3;P3,T\#RSJNY?N7,@W# !]W_X*1?\
M$Q?%7[0?[3OPK_:*^#'B7PKX2^._P=M[RRTUO$NGRW.B^(+*>&=/L=XT!6XC
M13<3[70MM%Q+\A)!'VK10!\$^%_^"<?[0'Q!_9R_:=E^+_Q?L/%'Q2_: \&:
MAX9TOP[I>H:E!\/O!+3:9):1BSMIVDD4-*RM+/Y6\@$A"S/O\C\"_P#!!/QW
MX,_X(\_!WX6Z?XC\#^'_ -I/X%>(KGQ;X7\7:=+=-I:7[ZK<7(BEE\F.=X9;
M66.*3,1PT:_*ZH,_JE10!^?/_!5__@E[\7/V^[?]F?XF>$]9^'7ASXX_L]:[
M#XECTS6+F\N?"NH7;2V%Q/$T\4"W31+-81[&$<;.A<$(6#(__@H;_P $P_C-
M\;_VO/@A^TU\(/%?PWTSXU?"/19M'GT/Q?%?S>%-2%Q',DKH8"9HBHN[K!";
MI/W&63RAG] Z* /R7;_@AI\?]5_:U_:-^+'B3X@?"WQ3KO[1OP-UOX?:G+#%
M>Z1#I>LW<$-O:^3;^7<'[#%!96B-(TS3$F5O+. I^R/^",_[%7BG_@G;_P $
MV?AQ\'?&M_X?U3Q-X/\ [3^V76B3S3V$OVG5+R\C\MY8HI#B.X0'=&OS!@,C
M!/U!10 5\(?\$FO^"7_C[]A#]M#]L/XB^+M7\'ZCHG[07C5?$GAV#1[JYFNK
M*W%]J]QLNUE@C1)-E_",1O(,K)\V "WW?10!\(?'W_@E_P"/OBI_P7W^"/[5
M&GZOX/A^'WPU\%7/AO4]/N+JY769[B2'6T5X8E@:%H\ZE!DM,IPDGR\+N/C[
M_P $O_'WQ4_X+[_!']JC3]7\'P_#[X:^"KGPWJ>GW%U<KK,]Q)#K:*\,2P-"
MT>=2@R6F4X23Y>%W?=]% 'Y;>'_^".'[27[&NG_%7X:?LP?%?X7^#?@I\9M;
MO];NIM9TS4(?%'@"2[@BA?\ L>2SD2%RJQJL;/Y1B$<9!+#=74?MP?\ !&+X
MA?'3XP_L*:GX6\>VWB'3/V6O$B:OXHU?QUK5Y<Z_XDC%[I%P\J2"&833N+"<
MD2/&H+QJ"%^[^D-% 'RA_P %GO\ @F<?^"K_ .Q)?_"VW\4/X0U:'5;77-+U
M!HWEM?M$&]?+N(D93)$T<L@ZG:^Q]K% #\H?M!?\$D_VO?VT/C-^S9\5/BOX
M\^ $GBSX >.-/UJW\.>&+34]/T=M.CNH+B[D^U2I--+=RFRLU5/)AB0>9\W2
MOU>HH _!?_@DEX4^/.K?\%*O^"D^I? #Q1\.=(\4:?\ %&6"?2_'6F7=UHNJ
MK+J_B H[26DB3P2Q&,[6 D4B:0,A^4C[B_9K_P""#'A_PM^Q5\?/A_\ %7Q'
M;^,_'/[3VJ76O^._$FGZ;';)%>R2M<6_V1'#'9:W#M-'YA/[QW8! VT?:WPX
M_9[\ _!SQ5XGUWPCX'\'^%=;\;7?V_Q%J&CZ-;6-UK]QOE?SKN6)%>XDWS3-
MND+',LASECGL* /S3^!__!,/]KNQTCX1_"GQO\??".A? OX(W&G'3K[X<_VO
MH?C#QE9V5L88=/U*3SO)BML;598F?>J@G#!2NS^T7_P2O^-O@'_@J_JG[5O[
M-OBWX4V/B'Q]X>M_"WC#1OB#9:C/9F!!;(UU;FT<.TGEV5F%A)B7,3$R?.0/
MT3HH _*[X7?\$+OB]K'_  45_:;^*?Q6^(?@K7_#?[1'PCO?AY<7FA0W%EJE
MK<WEII=O)(EG)&\,4$0M)UBS<S/M6$MDL^WO?V(O^"7?QN_9[_X(R_%?]E/Q
M=KOPKU*6[\.>)?#7@+5]'DOXUDAU6.]=9=4\V(^6XN+PY$".%C '[QEW-^BE
M% 'YF^!O^"!%S\0?^"!OA/\ 9&^*7B'0;;QAX5N+W5;'Q%H*/J%GIFH/JE]=
MV\T0GCAD=?(NS#(-L;%9)55N0Q]'^!7[&?[7/Q$_:7\ >,OC_P#&_P )V'AC
MX5&Z2Q\-_"V35M-M_'1D2-8KG7//F"2,I3?Y"H\8)8!L.V?NNB@#X4_;;_8\
M_:N^)GQ.\2_\(3XP_9T^)WPQ\6B.%?"'QC\%FXC\*1%66?['-81JUUOR#LN]
MW  W#!+>A?\ !&[_ ()L/_P2G_8ETWX57'B^Y\:Z@NIW>L7NH,DD-LDLY7]U
M;0N[^5$JHO (#2&63"F0BOJFB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH S_%GA/2_'OA74M"UW3-/UK1-:M);#4-/O[=+FUO[>5"DL,L3@I)&
MZ,RLK A@2""#7'_ O]D[X6?LO_VI_P *T^&G@#X=_P!N>5_:7_",>'K32/[0
M\K?Y7G?9XT\S9YLFW=G;YCXQN->@44 >/_"W_@GM\ O@=X[L?%/@KX'_  @\
M'^)M+\S['J^B>#=.T^_M/,C:*3RYXH5D3=&[H=I&5=@>"16?\?O^"?\ \%_C
M+J/B'Q=K'P"^"'Q!^(-]:%X[SQ5X9L7DU6XB@$=O'<WS6EQ,D>(XH_,\N4QH
MHVHVT(?<** /@#P?^Q#\4]1^!/@[PG\4?V9/V0/C'JWAK[;J%WK/B?QS=WGV
M[6-2N#>ZOJ$,$_A:5;3[;?/+.T,+"--R1H D: >@?LF_\$_O+^%GB_X<_&GX
M+?  _"F#Q6WB?P!X-TVX_P"$KTKPO]IA9KR!8[W2K18_].EO[F)U5MB:I);H
ML,-O&K?7]% 'G_@#]D[X6?"CX6:UX%\+?#3P!X:\$^)?/_M?P]I7AZTL]*U7
MSX5@G^T6T<:Q2^9"JQOO4[D4*<@ 5G_!3]B+X+_LU^*KC7?AU\(?AAX UN[M
M&L)]0\-^%;'2KJ:W9T=H6E@B1S&7CC8J3@F-3C*BO4** //_  !^R=\+/A1\
M4]:\=>%OAIX \->-O$OG_P!K^(=*\/6EGJNJ^?,L\_VBYCC667S)E61]['<Z
MACD@&OE#X^_\$O\ Q]\5/^"^_P $?VJ-/U?P?#\/OAKX*N?#>IZ?<75RNLSW
M$D.MHKPQ+ T+1YU*#):93A)/EX7=]WT4 ?EG_P %"?\ @@1XG_:)_P""P/P5
M_:3^'&N>$=%T3PQXGT;Q'XVTC5;JY@DO)["]M9'N;..*"2-IYK6WCC;S&C!:
MWBRQR2OH_P"W7_P1@E_X*:?\%,/"WC/XU?\ ".^(OV=/ G@V?3=(\*6^KW]I
MJESK4\P:6YF,"1%(BFP?)<DDVL/R89Z_06B@#\IOVT/^#6CX.Q_!ZWU7]E/P
MQI'PF^.?AK6].UOPYX@U7Q/K-U9026]RDC+*LSW:CY074B%COC0$A2U>P_\
M!3S_ ()#>-/VU_BM\*/CA\,_B59?!G]HGX7:?)8P:U!IXU*PNX98Y-]L2ZA]
MB//<!&9&!2XE#19;*_?%% 'Y6?LZ?\$5?VE?C?\ M>?"GXP?MH?'SPQ\4+KX
M*WTVJ^%O#WAO1HK>TAO&>)TF>9;6T'$D$$A'D%BT*#> #GD_VP_^".G[:O\
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MTR(22Z\&5OM;09YCV*MOM+[_ "%"^9D;J^[O@I^SWX!_9K\*W&A?#KP/X/\
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M!($D4,%=@"#AB.: .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3Y!_P6*_X(KZ_P#\%7=3^".LV'QKNOA-XH^#$M]>V^KZ7X=DNIKB\N#8.MS
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M\ ^)-)T^&[_L&>,1%$:VDPLD >WMG,89"3;1_-C((!^>?_!/']JWXW?LJ?\
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M1XB\81^(O#_QY\!-X!U/P3)HGE);6KVNF6TS&\^T-YH=-.;Y/(3'VC[WR?,
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M\)_$_P#:&\;_ !5^!WP8U6RUCP+X O?#^G:>+"6TC>.!;V_A7SKV-%<A5VQ
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M^&GPT_M3^W/^%=^%=+\,?VE]F^S?VA]BM(K;S_*WOY>_RMVS>VW=C<<9H ]
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#C_C]X[\3?#/X->(==\&>!M0^)7BO3[0OI7AFSU*TTR35[@D*D9N;ITAA
MC!.YY&)*HKE$E<+&_P 8?\/#_P!NO_I'5_YGOP__ /&:^_Z* /@#_AX?^W7_
M -(ZO_,]^'__ (S1_P /#_VZ_P#I'5_YGOP__P#&:^_ZS_%FC7'B/PKJ6GV>
MK:AH-W?VDMO!J=@D#W6G.Z%5GB6>.6$R(2&42QR(2HW(RY4@'X8_%G]NC]KW
MX/\ Q/\ "_ASPQ^QQ_8UM\*O%<VK>$/"J_$&Q\3P^']6F\&>)R=$@-DJ-);I
M8R_VA%I:'[1;Q1QV\31V]_ID5O\ 3_[-'[:'[87@OX66E]X4_8%_X2^V\7[/
M$5WXLD_:'\,WUSXQGN(8\:E+<0P+%+YD*PK'Y*K!%!'!# D5O%#$GW_X?_9<
M\">%]'\"V-EH?EP_#?59]=T%FO;B2:'4;BUO;6YO)Y6D,EW<3QZC?-++<M(\
MLMS),Y:4^96A\./@II7PG\5>)[[0I]0L]-\57?\ :<^AAT.F6=^[RO=7EM'M
MWPR7;R+).BOY3RHTXC6>XNI9P#XP_P"'A_[=?_2.K_S/?A__ .,T?\/#_P!N
MO_I'5_YGOP__ /&:^_Z* /E_]CK]KG]H?XP>.YM(^,/[)'B#X,Z?+M^QZW:?
M$30?$]@F(YGD^U+%+#<Q?,D*1^3#/N:8[_*5"Q_-;_@L7^S!H/[9_P#P=$_
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M9(FM8KG=)&[M;1%;AW&^8+Y CFDQM?L;_P#*Y)^UC_V2JQ_])O"E>N?L6_\
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M3SJ6LZ!%;MJPM!9>&,Q6LEQ'+%#(TGE9D,3D('"A6977VC_@E%\>_B3\!_\
M@MI^T)^QUXA^)OCSXN> / /A2T\4>'=9\;Z@FHZ[9/(FF32Q270C5YPQU8C+
MG"BV0*JAB*^F/@W_ ,$I?^%2?\%DOBQ^UM_PGO\ :'_"T/"L'AC_ (13^Q/*
M_LSRHM*C\_[9]H;S<_V9G9Y"8\_[WR?,?!O_ ()2_P#"I/\ @LE\6/VMO^$]
M_M#_ (6AX5@\,?\ "*?V)Y7]F>5%I4?G_;/M#>;G^S,[/(3'G_>^3Y@#\Y?^
M#>_X1?&K_@K!_P $XO'&H>.OVM/VC= BTSQS>:9I\V@^*-NJF9=/TV;,VH7*
M371MU,B;;>&2)06G)+>;QSGPC_X+\_'#0?\ @VM\3_%34=<EU7XNV'Q%;X9:
M3XHN+&.XDC22UM[X7DR!!'YD<$LT2.X(+I$7WLQ#?I[_ ,$5/^"4O_#GS]EC
M7_AI_P )[_PL3^W/%=QXG_M+^Q/[(\CS;2SMO(\K[1/NQ]DW;]XSYF-HVY/C
MO[(__!N+X*^"'_!+7XA_LM^/O'-_\0] \?>*)?%(UJPTK^P[O2;@V]E%"8D,
M]P"\;V0?<Q*L)"C(1G< > ?\%'1\7_\ @WY\&?"KX[VO[2?QL^,=CXA\<66@
M?$'PQXVU.+5M+U**:VN[F9]-A9$^PX%O,$1' !:$$E4*GH?V-_\ E<D_:Q_[
M)58_^DWA2O<?#W_!#+Q=\3?B5X#N_P!H3]IKQK\=O WPFUF#6_!OA2X\-V.B
M16\\ 98&U"X@+2Z@Z+Y?SMY98K)G*R,M>G_!O_@E+_PJ3_@LE\6/VMO^$]_M
M#_A:'A6#PQ_PBG]B>5_9GE1:5'Y_VS[0WFY_LS.SR$QY_P![Y/F /BK]@+2O
MC!_P7JTKXQ?&F[_:4^-WP=L_"7C_ %'PS\/_  SX+U!-&TS38K:"UN(7U.W,
M3->Y$\.^.4@Y68<*^P:?['__  7I\>>*/^#</XD?M%^)((=9^*'PGO)?!\EZ
M]E&EOJFHR26,5G>/"CJI4#4[9I0NS<T4NU0"HKW/Q'_P0T\7_#;XF>/;S]GW
M]IOQM\"O!'Q;UF?6_&?A6#PY8ZY%<SW 43OI]S.5EL'=?,^=?,(+)C"QJM>B
M:_\ L)?";_@GW_P1]\5?!S3_ (?_ !"^)GPWTS0;F#6-$T!8KWQ-XA6Y?_2[
MF(-)"C7 WM,%1E*B(")251" ?GK^UQX ^/WP-_X-]+S]IJW_ &M/CMJ7CKXA
M>&O"_B;6[.;5XX-/L4U*\TUECTOR(XY["1//C1C%,(Y$\]3'^]X]0_9>_:-^
M(?[+O[8/[#_C+QK\1?'OB#X8?M6_!?0_#FI6^N:]=WVF6'BU-+L98KO_ $B5
MHH[B\_=I\@5YI))W.]F<U\0?M$>/O"GQE_X)L:W^S;\,_P!HG]H;XS^+HH]'
MM_ _P4U'X92:7J7A5([ZR9[?5;J*U)NC;P^<JXN/LZLT6U6V(]?7?_!;73O#
MG@#_ ().?!#]D6 >(O$7[4_A;PWX.O/ ^FZ%H=])<"YL3%I\]['=QQF"$!(K
ML$>=O4M&Q&"K4 ?2O_!&[XO>,/VZ?VP/VFOV@[GQCXNO_A+-XC_X03X<:%+J
MMPVA?9+%8Q<ZE;6XD^RO]HD2(K.J%P?/7?\ ,ZU^B=>(?\$W/V/[']@K]AKX
M:?">S2W\[PEHL,.I30)L6\U!QYMY/C)^_</*W4X! SQ7M] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%<?\ '[PKXR\<_!KQ#H_P^\7Z?X \8ZE:&WTSQ'>:&-;CT9V(#3BS::%)
M9%3=L#OL#[&=)45HW^,/^'>'[=?_ $D5_P#,">'_ /X]0!]_UQ_[0OQKTO\
M9K^ 7CCXBZ[;ZA=Z)X!\/W_B34(+"-'NIK>SMI+B5(E=D0R%(V"AG4$D98#F
MOC#_ (=X?MU_])%?_,">'_\ X]7C_P#P4)_82_;.\(?L"_'#5O%/[>7_  F'
MAG2_A_KUWJ^@_P#"D]#T_P#MNSCTZX>>T^TQRF2#S8PT?FH"R;]P&0* .?\
M^(U;]EG_ *$'X_\ _@CTC_Y9U]@?\$I/^"U?PL_X+!_\)[_PK30/B!H?_"N_
M[/\ [2_X2>QM+;S_ +;]J\KR?L]S/NQ]DDW;MN-R8SDX_C"K]?\ _@U*_9X^
M.WQ[_P"%\_\ "E?VBO\ A07]E?\ "/?VS_Q0.G^*O[=\S^U/(_X^W7R/)V3?
M<SO\_G[@H _I]HKX _X=X?MU_P#217_S GA__P"/4?\ #O#]NO\ Z2*_^8$\
M/_\ QZ@#[_K\V_\ @OQ_P67^(_\ P28^(O[/=EX$\'^&O&=A\3]2U.#6["^L
M[J?49XK273%6*P,,T86>1;R50724;O+^7@AOH3]CK]F;]I_X'>.YKCXJ?M1^
M'_CAX9O-OFV%W\*+7P_?VFV.8#[+=65ZL:;I'B:3SX)\K"%3RBS/7P__ ,''
MT8E_X*E?\$R58!E;XJ2 @C((_M?PW0![9_P6R_X+.:]^PM_P37^&OQ\^!\'@
MGQ?;?$7Q)IUA:2:_;7%U9R6%WIM]=B15M[B%A*&MHQRY RX*YP1]??MR?M5:
M/^Q!^R'\0OBQKK0_8/ ^C3:@L4LBH+NXQLM[<%F4;IIWBB49!+2*!R17\]7_
M  <9^%]4_8(^ 6I_LMR63K\-]2^*$/Q3^%$T2J+?3M*N+35$U32-J1HL8M=0
MNT:-<L3%=J2>,5]Q_P#!UQ^T?J_BK3/A!^S3X,\(>*OB=KGC;5X_&7BGPAX8
MBEFU+5M"L)"1;X@CEFB6:59&$JQMM-DS<[2I /9_^"$__!8OXF_\%!?&GCSX
M??'CP?X8^'_Q.\.Z3I?BS2--TBUGLTU/0K^".2.Y$4]S/(Q7SH"S @*+J)2
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M!\/Z3XHF6VT:]U/Q#:6EOJ\K9VQV\DD@69C@X"$DX-?CO_P1'_8^^%W[6/\
MP5-_X*2)\3? 7A7Q];:-\498[&UU_38M0M[4SZMX@$DB1RJRK+B)0)  Z@L
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MC#"OR%_X)\_L[?$[]F3_ (+\Z'8:YJ?[)/P]U36?AY,?%/PY^#6C^(;*RO\
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MO_@X5_8R^&'Q2TK3-7^ 6IZ-J^IQ:;JP$NF:SKJVVH QSPNQCE,933 @>/\
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MT)\L'=B5./F&>A\8_M._#7X>>+] \/\ B#XA>!]#U[Q6I?1--U#7K6VO-84
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MF[?+8 \AL$'(/-?*WQX_X+\?LB_ 'X96OBF[^./@7Q-;7DT,,=AX7U6#6=3
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MD\)> ?%'Q5C^)VMVOBR\\1I%?77AG3X[:#;]GFF!>VBCE-VB21["! H&!&H
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M>#Z5^2/_  4+^"G@O]B;_@N-^PBG[,_A#P=X)\4^,M4O]-\9:/X5M8=-@O\
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MLG]L_P#$ZU#4?MGV7S_(_P"/N>79M^T3?<VYW\YP,?0%% !1110 5X_^T?\
ML%?"?]K?XI_#'QK\0O"G_"0>)O@WJIUOP?>?VG>6G]D7AFMIC+Y<$J1S?O+.
MW;;,KK^[QC#,#[!10!XA^V]_P3A^"W_!1WPIHFB?&?P1!XST_P -W;WVFJ=1
MO-/DM)738Y66UEBD*LN,J6*DJI(RH(W;;]B[X:6O[74_QW'ALM\5;C0!X8;7
M)-1NY-FG>8LGD);M*;>/YU!W)&'Y;YOF;/J5% 'G/[5O[)?P]_;?^"&J?#CX
MH^'4\4^#=9D@FN]/:\N+0R/#*DT3"6WDCE0AT4_*XR,@Y!(-/X[_ +$_PH_:
MB^%.F>"?B-X#\/\ CCPUHRHMA:ZW ;U[,I'Y0DCFD)E639P9 ^\Y.6.37J5%
M 'SE^QY_P2._9P_8%UXZO\)OA/X=\+:WY<D*ZL[SZCJ4<;_?1;JZDEF56Z$*
MX!''2N-_:C_X(*_LG_MI?';7/B7\2_A3_P ))XV\2_9_[2U+_A)M8L_M/D6\
M5M%^ZM[N.)=L,,:_*@SMR<DDGZ_HH \H_9*_8;^$G["7@)_#7PC\!Z#X'TF<
MHUR+&-FN+UD7:K3SR%IIV _BD=CR>>34O[+W[%WPT_8RL?%EO\-_#9\/KXYU
M^X\3ZZ\FHW=_+J.HSA1+.TES+(XW;1\JD(#DA06.?4J* /+?BY^Q=\-/CI\>
M?AY\3O%'ALZAX[^%,ES)X6U:/4;NU?33<*JS I#*D<RLJ@;9E=0"V -S9R_V
MO?\ @GI\%/V]M#MK#XO?#CPWXX2QBD@L[F\A:.]L4DQO6"ZB9)X=VU2?+=>5
M!Z@5[-10!\8Z=_P;^_LJ>#]2\$:CX.^&Y^'VN?#_ %*'4M+UGPSJUW8ZI)Y9
M&Z&XNO,:6>*5,HXD9F*NP#*6)K[.HHH \?\ V</V"OA/^R1\4_B=XU^'OA3_
M (1_Q-\9-5&M^,+S^T[R[_M>\$US,)?+GE>.']Y>7#;851?WF,850/0/BQ\+
M="^./PL\2^"O%-C_ &IX9\8:5=:)J]GYTD'VNSN87AGB\R-ED3=&[+N1E89R
M"#@UT%% 'C_PT_8*^$_P?_8VN?V?O#OA3^SOA%=Z5J6B2Z#_ &G>3;[/4&G>
M\B^TR2M<CS&N9SN$NY=_RE<+CDKS_@DE^SIJ?[&VC?L_WOPOTC4?A+X=EGN-
M*T2^N[NZ?3)IY9YI)H+N25KJ.4O<SXD64,HD*@A>*^C:* /F+X0?\$9_V9?V
M?_&/P\\0^"?A/H_A;7/A9+=3^';_ $V^O;>X@DNH4@G>X=9LWK/$BH3=>:<9
M QN.>]_8J_8*^$__  3M^%E_X*^#OA3_ (0_PSJFJR:W=6?]IWFH>;>20PPO
M+YEU++(,QV\*[0P7Y,@9))]@HH \?_9P_8*^$_[)'Q3^)WC7X>^%/^$?\3?&
M351K?C"\_M.\N_[7O!-<S"7RYY7CA_>7EPVV%47]YC&%4#G_ (!?\$N/@3^R
M_P#LL>-?@IX%\#?V'\,OB)]N_P"$AT;^VM0N?[0^VVD=E<_OYIWGCWV\2)^[
MD7;MRN&)-?0%% 'SE>?\$DOV=-3_ &-M&_9_O?A?I&H_"7P[+/<:5HE]=W=T
M^F33RSS2307<DK74<I>YGQ(LH91(5!"\5G_"#_@C/^S+^S_XQ^'GB'P3\)]'
M\+:Y\+);J?P[?Z;?7MO<0274*03O<.LV;UGB14)NO-.,@8W'/T[10!\Q_'K_
M ((S?LO?M/\ QVA^)?COX+^$?$/C2-S+-?RK+$FHN4";KN"-UANR%50#.DA&
M!C%>R?%[]FGX??'WX/R?#_QGX,\.>)/!,L44/]B7UA')91K%CR@D>,)LVKM*
MX*X&,5W%% 'AG[%G_!-3X&?\$[]'U*S^#?PZT?P6-8VB_N8II[R]O%5F94DN
M;B229D4LQ"E]HSP!7(ZI_P $6/V5];_:6F^+UW\$?!ESX^N;@WLU[)%*UM+<
MF7SC<M9[_LIN#)\QF,7F$DY;FOJ&B@#Y@\"?\$9OV:/AO^R1XD^!6E?"ZR3X
M5>+=5;6]4T.YU;4+P37K10Q?:$GFG>>)PEO"%,<B[2F5P22=+XN_\$EOV??C
MQ^R5X.^!?BOP =5^%G@"Y@N]!T0Z[J4/V"6&&>&)OM$=PMQ)MCN)EQ)(P._)
M!(4CZ-HH \N_:R_8L^%?[='PT_X1#XM>"-%\;Z"LAFAAOD99;.0J4,D$T966
M"3:Q&^)U;!ZU%^RC^PY\)/V'?AM+X1^%'@+0?!>@W15KN&SB+RW[*FP-<32%
MI9VV\;I78\GGDUZM10!\?Z;_ ,$"?V.]&\0>*]4M/@+X-M[OQI8SZ=J/EM<K
M'##-"\,HM(_-V6+-'(XWVBQ-SD$'FNY\#_\ !*;X"?#CXV_##XC:/X&EM_&?
MP9\-+X/\':E)K^ISG1M*6*ZB6U\N2X:.8".]N5#3*[@2##?(FWZ'HH ****
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MHKP!XT_X33]H#PIX5_XJK1_[1_L+[5]K_P")E8?.OD:A#L_=3_-LWO\ *<T
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M(_V:?$?B6[\3>(+O6[#Q9X]U2&VC0:Y9^&+*.XGEF5@PCCN=4:PRJ_,=Q .
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MHOB"'2=0N-(OI--OHKM;*]@?9/;2F-B$FC?Y7C;#*>" :^9?V+OC=I?[-/\
MP0N^$/Q#UI]FD^!_@;HFNW9VEB8[;08)2 !R2=F !R20!7(?L(_L/>-+G_@D
M_P#"GP3J7C[Q%X*\0^,F/B_XD:A8P1)K.L-JSW&H:A8PW,9064C3W21FXA4R
M)%"RQ[)&6:, ^OX/C-X/N?AQJ/C&/Q7X;D\(Z.EY)?ZXNIP'3;%+-Y([QI;C
M=Y:"!X9EE+,/+:)PV"IQPGPM_P""A/P"^./CNQ\+>"OCA\(/&'B;5/,^QZ1H
MGC+3M0O[ORXVED\N"*9I'VQH[G:#A48G@$U^8W[!5KKNJ_\ !FM+IGAC0/$'
MBGQ!KWA'Q5HMAI6B:9/J5_>2WFOZE:A8X((Y)&QYV20N%4,S%54L/9/V2M;\
M!_LH_M-_#C3?&?[!GA;]G1/$EY#X6\ ?$E8/#-SJ>I:I)I\Q>WNET\O/833Q
M1W"*3-+YN75F4D@@'Z*_%+XL^%O@=X$OO%/C7Q+X?\'^&=+\O[9J^MZC#I]A
M:>9(L4?F3RLL:;I'1!N(RSJ!R0*Z"OD#_@O5\??^&7_^"3WQ6\<_\(5X ^(G
M]A_V1_Q3WC;1_P"U]"U#S=8L8/\ 2+;>GF;/-\Q/F&V2.-N=N*Y#]K3]O']H
M;1_^"I?_  SA\$O"GPFUF:_^#P\?6VI>,+B^M(M,O?[8EL3)<26Q=I;4(B 0
M1PK(TDH/G*H(H ^[J*^:O^"7/[<&N?MP_!?QC<>,- TCPWX^^%WCK5_AUXKL
M](N9+G3?[3TYT$DEK)(JN8726-AN&1DC/%>-_P#!57_@J5\0?V3_ -ICP+\'
M_AZGP8\'ZUXWT&;7;;QG\7M4O+#PO-)'=QVYTR#[(#+)>8D$A#-&BH\9RQ)4
M 'WO)*L*Y=E49"Y)QR3@#\20*=7X\_\ !9'XO_M3>/O@9^QW=W'A/X9?#SQ5
M>_M"Z-ITUA<>(+C5=*UK5HYV?0;M)K0@MHTWEW$T\<JK<H5M=J@JQKZ7\:?M
MM?M,_$;XQ7'P6^#?AOX#ZO\ %KX5^&-!U3XLZOXBU34X/#=CJ6HP-*+#38H$
M:Z;>L,TB/.1MCDAW!CF@#[OK/\6>+-+\!>%=2UW7=2T_1=$T6TEO]0U"_N$M
MK6PMXD+RS2RN0D<:(K,S,0% )) %?$-S_P %GR/V'U\90^#;!OC&?B6OP2/@
MI]9"V@\9?;1:-:_:]F[[/MS<AO+W^5CY0>:Q/VC/B#^TWJG_  3A_:Z\/_M"
M_#WX;:3'9_"+Q'?:-XJ\!:Y+=:1J/F:9>AK*2VN]MW'/"@C)EV>5)N;:5(VD
M ^^?"?BS2_'OA73==T+4M/UK1-:M(K_3]0L+A+FUO[>5 \4T4J$I)&Z,K*RD
MA@002#6A7YM?\$6?^"@5Q^U)\(_@;\*OA'+X3U+PQ\&?ACX7M_BCKE_*TUQ!
M>R:/$D.E6$$<B-YRRQ.9KF4&)/)>)5>3=Y?UA_P4)_;/7]B/X(:9K-EH\/B3
MQAXT\2:;X)\'Z+-=BTBU?6M1F\JVB>7!*1C#R.0K$)$^ 30![K17QA^SE^VU
M\</AS^UMX2^"W[3WAOX3Z1XC^*FG:IJG@?5_A_JE[/87QTX12W5A/%>(LJW"
M03)('0E&$<G"\55_X(B_MS?&[_@H_P#LJ^&OB[\1M!^&>@>&/$FGW<5HF@"]
M2]NK^WU2[MI)/*F>1(K80PQ*!YLDCRB5OD3:I /KGQ%\6?"WA#QWX=\+:MXE
M\/Z7XF\8?:?[!TB[U&&"_P!;^S1B6Y^RP,PDG\J,AY/+#;%(+8'-=!7R!^V7
M\??^%>_\%8?V+_ W_"%> -<_X6)_PG'_ !4.KZ/]IUWPS]BT>&?_ (E=SO'V
M7[1N\N?Y6\R-0O&,U\=_"/\ X+H_M17?_!-OP7^UOXR^&OP03X+P7AL_&*Z?
MJ.IP:]=(^N_V6MUIUNPEBCCBW*K)--(\CJ[+Y:X! /V#KG_#OQ9\+>+_ !WX
MB\+:3XE\/ZIXF\'_ &;^WM(M-1AGO]$^TQF6V^U0*QD@\V,%X_,"[U!*Y'-?
M-O[;W[:?Q.\-_M'^&O@)^S]H'P^U[XQ>(?#-WXSN[GQKJ5S;:+X>TB"XBM%G
MFCM5:XE:6XEV(J[1^ZD^;CCXT_9D_;4N/V.?VUO^"G'QG^,'A^ST/4_!6D_#
MFYUC1]+U(7-O<7BZ)<6\4-K<2)&62XF,0B+HK8G3*[LB@#]?:*_,S]FG_@N%
MXBOOVF? 7A7XH^)_V2=;T#XO:S'H.@1?"OXF#7]:\+WLL#26\&IPN LRRRH8
M!-!M5998DP=X)]8^(W_!1OXD_#/QWXC^"<WA+2=2_:'U761;_#Y8=-N8O#NO
MZ-<%WCUN?]\[QV]A&DBWL?GJYEA41[?M4 (!]MUS_C_XL^%OA1_8O_"4^)?#
M_AK_ (2758-"TC^U=1AL_P"U=1GW>19V_F,OFW$FUMD29=MIP#@ULZ:EQ%I\
M"W<L,]VL:B:2&(Q1R/CYF5"S%5)S@%F('&3UKY'_ ."N_P ??^%"?\,P?\45
MX \:?\)I^T!X4\*_\55H_P#:/]A?:OM?_$RL/G7R-0AV?NI_FV;W^4YH ^OZ
M*_*V3_@K7^UGXO\  ?[3_CKP=\._@5?^!/V8/B/XLT35I]6U'4[&_P!9T;1H
MQ+Y-M%'YJ?;A'^\>>1TB;>BI"#DCZ,^/_P#P4[U=OA+^SHGP<\-Z#X@^)G[4
M]HE_X+TSQ+J,ECI]C9KI7]IW-W=O$C2LD$+1 I&FYFE49'< ^IOBE\6?"WP.
M\"7WBGQKXE\/^#_#.E^7]LU?6]1AT^PM/,D6*/S)Y66--TCH@W$99U Y(%=!
M7Y)?\%L/'OQW\6?\&_/[1^G_ +0'@+PAX2\6:#?>'K:VU7PEK!OM!\4P-K>E
M.;JUCE/VJV"N7C,5PH;Y0P+!N/LW]E;]M;Q3\<?^"DW[5OP=U:P\/V_AGX%_
M\(C_ &#=6D$R7]W_ &MI<MY<_:G:5HWVR(!'Y<<>%R&WGF@#Z@KG_$7Q9\+>
M$/'?AWPMJWB7P_I?B;QA]I_L'2+O488+_6_LT8EN?LL#,))_*C(>3RPVQ2"V
M!S7P5^SC_P %HO%/C?\ X(S_  F^/OB;POX7U'XK_&+Q)_PA7ASPWI<TNF:9
MJ6LW&MW>FV<0:9YY$01V_G2'<[8CE*@# 'E_Q%\2_'?5?^"V/_!/^R^/OASX
M;:3XFM)OB1-97W@74KRZTF^MI= CVQE;N-)HYX0BK)RR/O5E*Y** ?J+\+?B
MSX6^./@2Q\4^"O$OA_QAX9U3S/L>KZ)J,.H6%WY<C12>7/$S1OMD1T.TG#(P
M/((KH*_'+]C7_@K=\7+W]FW]A+0/A/\ !_X#Z->?M'CX@Q77AK2]/N?#N@Z/
M)H]S,;>2T$,DHMHBQ>>YS%.TA\S8$9\U]>?L2?\ !2;Q?KUW^T5X._:'TOP+
MX7\??LOQ6.H^+M0\(W=S+H%WIUYICZC%=0&Z"RQXBBFW*[';M&2* /M&BOR3
M_:R_X+"?MD_ _P#X)]ZC^U'I7PF^ T'PF\0:?I.J^&+6^UG4[S7]'LK^YA6"
MYU&%%B@G$L4\*B.":,Q/*&+2*"I_1S]MWXUZK^S7^Q?\7?B+H5OI]WK?@'P5
MK/B33X+^-WM9KBSL9KB))51D<QEXU#!74D$X8'F@#U"BOSTM?^"N7Q!^"7_!
M,KPK^T!\8=#^%NG7GQ4@\,6W@32++6I=+MKB\U6SA=Y-1NKLM':VXD-Q<?(9
M/*M827=VW;9OV _^"P.L_%[]K+2_@S\3?%/[,GBOQ#XUT[4-7\,:M\&_'1UZ
MQ'V,H\FGWD,N)8KG[.YE60?)*MO.0J["  ?<OPM^+/A;XX^!+'Q3X*\2^'_&
M'AG5/,^QZOHFHPZA87?ER-%)Y<\3-&^V1'0[2<,C \@BN@K\<OV-?^"MWQ<O
M?V;?V$M ^$_P?^ ^C7G[1X^(,5UX:TO3[GP[H.CR:/<S&WDM!#)*+:(L7GN<
MQ3M(?,V!&?-?0GPQ_P""D/[0OB3X2_M1^#-6\%?#&;]I3]F&'2]0N['0&O[W
MPWXHMKRR&H1);"5HKB.66WBN(U#.VR0QL5< HP!^A-%?,OQ"_;IO?&?B']FW
M2_A&/#^M2?':X7Q#/=:@CSQZ?X5@M%NKR\1(Y8SYS&:SMXR2562[5F1PI0_,
MG[2G_!<?Q%;?M(^/O"OPL\2_LEZ#HGPAUU] UZ/XK_$L:!K/BB[AA5[F#3($
M!$2QR.(?/G+(98Y5VC82 #]-:;)*L*Y=E49"Y)QR3@#\20*_+;X^_P#!?OQ!
MXWTCX%0_!2/X->"_^%W^#G\66?BSXPZU<VOAJ"YBO$LY]#C:Q!>74(I2XD!:
M-% 4Y8DJ.$_X+(_%_P#:F\?? S]CN[N/"?PR^'GBJ]_:%T;3IK"X\07&JZ5K
M6K1SL^@W:36A!;1IO+N)IXY56Y0K:[5!5C0!^PU%?GY\2OV\/VHM'_;RT7]G
M'POX6^".L?$"^^ 5KX^OK^]FU*UT33_$9U3[#=/YJL\[Z6NU_+A$'VAV>(-*
MBEV7SIO^"O'[4?Q&_9)^)GQ!\%_"KX.6.H?LR:_KVB_%Q-=UZ^>VU6710TMY
M!H*PIOR;?8XFNV4*S[!'+C=0!^I%%?G=^U5_P7"CT'PM\&=)^&U[\&_!_C;X
MU_#Z#XDVU]\8?%R:!H'AK3+B.$VZW#1$R7%Q+)*R+%$5W"VG;=A"1POQ._X+
M\^(='_X);?M!?$OPW%\'-<^,?[/FJZ+I6IQZ#KK>)O!^K)J-Y9117UK-!)#*
MT$D5Q<*JLZM'-;2(Q;8P(!^I=-259&8*RDH=K '[IP#@_@0?QKX>^''[?GQY
M^&__  4*^&_PD^.O@7X7Z#H7Q[L]:O/ DGA36+V^U+27TNUANI[75#-$D3R&
M)V.^ ! <*-V-Q\,_X-Q]8_:(UWXN_M63?$>Z^%%YX/3XR>*K?7Y-(EU.35U\
M6Q-ID4J6AG)C_L5+9"D(D_TA2J X44 ?JM2.XC4DD  9)/:OD[]MW]M7XE^'
M/VC_  Y\ OV?M!\ :]\9?$'AFZ\:75QXUO[FVT/P]H\-Q':+/,EJK7$K2W,F
MQ$3:/W<A+<5X1^TE^W;\5_C;_P $POVSO!=QI?@GP1^T5\!_#%Q:>*[>SU2Z
MN-(73[K3?MIU#3YE5+A))=.-T;;S -MU"F\E QH ^_?A9\>? WQS75SX)\9^
M%/&(\/WKZ9JAT/5[?4/[-NE^];S^2[>5*.Z-AAZ5UE?"_P#P;M_!#7_@_P#\
M$P_A_>>)?"7P:\,WGBW1M*UC3;CP!IDMG+K.ER:59M;7.L-(H,VK,6F,[J3&
M<KM/6KL?[>7QW_:&_:8\=V7P(\"?"[Q%\*/@KXJD\(>,;WQ!K]U;ZWK^H06T
M4UY:Z4D$+P120&XC3-R2'='0^7G<H!]-_"W]K'X6?''6+'3O!7Q+\ >,-0U3
M2I-=L[71/$-IJ$UWIT=TUG)>1I%(Q>W6Z1X#*H*"5&0G<"*] K\)O^#;SX^>
M(3X6^%?PM\)>#OA5%XJ_X9O\3>*M&\8ZGH#SZXMY_P )_JEK!IT]TD\;OI7F
M;9FME*$R982*>GZ#WW_!2SQ7XW_X)[?"?QKX/T3P]#\9_BUK>G>"[70-366:
MQTC7OM#PZO'-&LL<KQV*VNHRLHD5B+4#<-V: /K+P!\6?"WQ7_MK_A%O$OA_
MQ+_PC6JSZ%J_]E:C#>?V5J,&WS[.X\MF\JXCW+OB?#KN&0,BCQ_\6?"WPH_L
M7_A*?$OA_P -?\)+JL&A:1_:NHPV?]JZC/N\BSM_,9?-N)-K;(DR[;3@'!KX
M)_9F_P""F>@_ O\ 9(_;9^+?BCP/X!\*Z3\$_C9XMT-[;PCIBZ0_BR:V:RC@
MN;QF=Q+J5W-/'')<'&\F/Y.,'Q#_ (*2>//VE_$>N?L?I\>_!'PK\/:?J7[4
M7@;4-"E\&:U>WLNFJ/M2FQU!;F% T_SLZRP-L(1E**5#. ?L+17Y)>-?^#C;
M6+MO$/Q*\(:O^RG-\&O"=WJ,3^%]:^)R6OQ*\46UG,T37=C9@&",RB*5X+>3
M<\ZM$59=ZY]E^-?_  4S^-_Q#_X*#Z#\&_V<M!^$/BK1_&WP-MOBIHFN^*[J
M]M[:VDN-3:VCN)I;5I#-:&#RL0Q1"1I)E/G*@- 'Z$5S_C_XL^%OA1_8O_"4
M^)?#_AK_ (2758-"TC^U=1AL_P"U=1GW>19V_F,OFW$FUMD29=MIP#@U\:?!
MO_@LLEG_ ,$X_C;\9?BMX<TO0_$W[.WB;6O!'B[2M%OV>POM8T^6*%(K.:95
M;9<27%LB%@2&EQR1BOF7_@I)X\_:7\1ZY^Q^GQ[\$?"OP]I^I?M1>!M0T*7P
M9K5[>RZ:H^U*;'4%N84#3_.SK+ VPA&4HI4,X!^PM%?F'XU_X*__ !^^(W[<
M/Q*^&GPC\+?L^QS_  JUR[T9_ 7COQ5=:3X[\>B&"*5+K2]J_8X8)_-!B:9F
MW+@OY>>/TN\,ZC=:QX<T^[OM/ETF]NK:.:XL994E>RD906B9T)1BA)4E25.,
M@D4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O(OVU_@'XN_:'^"R:5X"^(.K?#3QEI&K66N:1
MK%G)-]G>>UF$GV:]ACDC-S9S -'+"6VNK<YP*YS_ (*C_MS_ /#M?]A/QS\:
MO^$7_P"$T_X0O[!_Q)O[2_L[[9]JU"VLO]?Y4NS;]HW_ .K;.S'&<CR#X3_M
MV_MG>+_BGX:TGQ3^P;_PA_AG5-5M;35]>_X79H>H?V)9R3(D]W]FCB$D_E1E
MI/*0AGV;0<D4 >7_ /!,7_@G9\9O$_QZ\/?&']HG4?"5M>?"#Q7\0_\ A!?#
M_AW2KZP_TK6]=OCJ6JW#73;GAGW3&TC 93:2VTI=G)-?1_[5/[%7BGXX_P#!
M2;]E+XQ:3?\ A^W\,_ O_A+O[>M;N>9+^[_M;2XK.V^RHL31OMD0F3S)(\+@
MKO/%>P? +XB>._B%_P )K_PG/PZ_X5W_ &'XKOM(\/?\3^WU?_A)M'B\O[-J
M_P"Y ^R_:-S_ .C29DC\OYB=PKT"@#XV_:@_9!_:!\*?M<Z[\8_V;/%7PDTW
M5O'N@Z7X>\5Z-\0=+OI[.86$UTT%[;RV<BR"98[N1=C@JVQ<D9XRV_X)+ZRG
M_!/+_A6T?CNQ_P"%K_\ "<#XJ'Q<^EEK'_A)_P"V!JQE^R[]WV;S/W.W?N\O
MG.:^W:* /C?]E_\ 8_\ C[XL_:VT/XR?M*>*OA1J6M> M"U/P_X3T?X?:=?6
M]C M_+;FXO+B2\=I&F>.TB4(@"+N?EL UU'_  4Y_8J\4_MH_P##/?\ PBU_
MX?L/^%3?&KPY\1]7_M6>:+[3IVG?:?/BM_+BDW7#><NQ7V(<'+KQGH/VA_VY
M_P#A0G[=G[.OP5_X1?\ M7_A?O\ PDO_ !.?[2\C^PO['T^.]_U'E-Y_G;]G
M^LCV8S\^<5] 4 ?+_P"RM^Q5XI^!W_!2;]JWXQ:M?^'[CPS\=/\ A$?[!M;2
M>9[^T_LG2Y;.Y^U(T2QIND<&/RY),KDML/%> _!#_@CS\3/A1_P0]\ ? :W\
M7>%=$^/7PHU*Y\3>$?%>F32S:;I.LC5[R]MI!)-;>88GM[IK>8&W.Y)IDVNI
MPWZ/44 ?+VM_\$M?!_C7_@EA-^R]K=[=7.C:EX=&FZCK)59;NZU,R"ZDU9]P
MQ)</?YNF+<M(22<G-?/'[)?_  1Y^(/@?]HWPOK7Q \&_L1Z#X6^'U_!JFG:
ME\./A#;6?B;Q)<1(?+-U+=Q21V&R;RY@]D?-+QKMDC&0?THHH _.K_@HW_P3
M7_:2_;,\5^)O#$'BK]G3Q5\+?%$\\^E:EXY\&W$GB[X9%[41)_8\UFT<4LD<
MAEDCFG*RH7&6DV@5U]O_ ,$U_BG\&/\ @H'\$_C#X!\;^&_%%AX3^%MA\'?&
M_P#PF[7<FK:MI-O>"[?4K::$$/J,DBJ6\[Y#EB3D\?<U% 'Y-7W_  ;\^+OA
M?XGO_!OPW\,?L97?PHUG4[^\B\2^-OA3%K/CWPK!<RO.(+9W5K.]\EY&2(W2
M@)&L8*N%V5],?M/_ /!._P ?>&OB?\.OBQ^S1K7PX\)_%#X<^#'^'8T_Q5HC
M+X<U_02T4L5G*E@(Y+403PJ\8@4(F]U"!>*^S:* /CC_ ()W_L&?%+]FG]MC
M]I;XK_$SQ7X0\5R_'&+PE):S:+#/:O#/IFG3V]VKVTBD0PB255@ GF8Q(#(P
M?.=7]MW]BKXE^(_VC_#GQ]_9^U[P!H/QE\/^&;KP7=6_C6PN;G0_$.CS7$=V
ML$SVK+<1-%<Q[T=-P_>2 KS79?M]?MS_ /##G_"E?^*7_P"$H_X7!\5=#^&7
M_(2^Q?V3_:7G_P"F_P"JD\[R_)_U7R;MW^L7'/H'[+GQ$\=_%?X$Z'K_ ,2_
MAU_PJ?QM?_:/[2\*?V_;Z]_96RXECB_TRW"Q2^9"L<ORCY?-VGE30!\&?M*?
M\$4_B9^T%_P3V_:4T'4_%_@'5?VB_P!IK4] U/Q!K0M[G3/#EFFDW5B;:SAP
MD]SY,5M;2A6<,S23'(4$D?2?[5/[%7BGXX_\%)OV4OC%I-_X?M_#/P+_ .$N
M_MZUNYYDO[O^UM+BL[;[*BQ-&^V1"9/,DCPN"N\\5]044 %?+_[*W[%7BGX'
M?\%)OVK?C%JU_P"'[CPS\=/^$1_L&UM)YGO[3^R=+EL[G[4C1+&FZ1P8_+DD
MRN2VP\5]05^<O@S_ (+(?M%?'+XP_%32?A3^Q=<?$7P;\*/B'J_P]U'Q%!\6
M=*TR6XN-.G"2NEG=P1ON,3Q2! Y7,FWS"02 #F_!/[,G_!23X??&3Q7XXM[C
M]B3Q%X@\17UR]KJ7B:]\3WU_HVG22[XM,MWA@@BCMXE"+^[A1I"N^0NYW5],
M_ +]DGXD7'[=;_'3XM7O@VXUNV^%6C^"-/LO#=]>R6-CJ#S/>:[-%!<(HCBE
MN5M4A<L\K0VZARN-I]%_8N_;+T']M/X;ZGJ^F:5KGA?7O#&K3^'O$WAK6X5A
MU/PYJ4(5I+:95+*WRNCI(C,CHZLIYX]@H ^-?BI^S3^UM\/_ (T^+Y_@K\7?
MAQ<^ ?B-JS:M=V_Q)L=6U?5/ \CVR121Z0T5TL36Y>,2I;2"-(VD?!(R&Z6/
M_@FY9?"/_@CYXD_9=^'%W:H9_AQK'@_2[_5,P0SWU]9W"-=W'E(Q027-P\K[
M$8C>V QZ_4M% 'Q9\7/^"<OC?XG?\$@OA7^S/_;'A^"YTS1O!_A?QQ=PZG=V
MT%WI6G&R&JQVDL</FN9X[:2- ZQ!UE(<H"17VA!"EM"D<:+''&H5548"@<
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M@'XE^ VO?$NTU+4OA_-?^)=.UN'Q-;6"12SI(+5M]K=K#*)&@96"JK?O"1R
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M]K-<6=C#;RO$SJCF,O&Q4LBD@C*@\5\YP?L%?';]G;]J/QWJ/P(\>_#/P_\
M";XU^)V\6^,M.\0Z#<W&L>']1F@2*]N])>"1(9)+@PQ,1= JCEG^?&QOMRB@
M#\P/^",__!%3XI_\$[?CU\./%/C77_ &J:?X/^"NI_#B\CT2^NYYI=1N?&-Y
MKD<L8EMH@;<6MPB%F*OYH8!"N'/NOP:_X)>ZI\,_^"G'BOXMW/BB&\^%>;KQ
M#X/\&#[GA_Q-JD<<&L:B$\H!?-B@RA$C'?J%^=J&5VE^RJ* /@OX2?\ !'2X
MUO\ 9._:^^$GQ2U/1+C1OVD/BQXE\<Z9<Z,SW,FDVFH-:263RK/$BB[@FMED
M*KO0%%Q(>HXSXO?\$ZOVP?VIM0^!8^*OQ*^!^L67P2^,/AKQM"-$TS4=-GU[
M3-.\TW-U=-)YR_V@Q<+'!$L<&&D9I<E57])Z* /R:OO^#?GQ=\+_ !/?^#?A
MOX8_8RN_A1K.IW]Y%XE\;?"F+6?'OA6"YE><06SNK6=[Y+R,D1NE 2-8P5<+
MLKZM^'?_  3QUKX8_P#!6#0OC-I5QX5M?AKX>^ EO\);/2[:/[)?0W<.L+>(
MZ6L,"6L5J+=0H$;+M8!5B" &OKBB@#X+^$G_  1TN-;_ &3OVOOA)\4M3T2X
MT;]I#XL>)?'.F7.C,]S)I-IJ#6DED\JSQ(HNX)K99"J[T!1<2'J.,^+W_!.K
M]L']J;4/@6/BK\2O@?K%E\$OC#X:\;0C1-,U'39]>TS3O--S=732><O]H,7"
MQP1+'!AI&:7)55_2>B@#\ZO^"C?_  37_:2_;,\5^)O#$'BK]G3Q5\+?%$\\
M^E:EXY\&W$GB[X9%[41)_8\UFT<4LD<AEDCFG*RH7&6DV@5]6? WX:_%CX,>
M._!_@^;7/"WB?X,>%/AS9:,^L:K+>2^.-6\1V\B0FYN'/^C-:R6B;W;_ %QN
M&)^[7M-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN:_XE_X2O3OBYHVL7AU*:VOK^QMH)+5(&N86289MK>.%G5Q(5R2VXEJ_7_\
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M?6'A3PS;V%C\4?$NH^+_ !3;W%Q/?1:OJ>H!%O)G6=W"K*(U!B0+$ #A!DY
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M^SI^Q7\3=3\9?"_X2^%O"7BC5MXEU&W22::!7 #QV_FNXMHV"C*0A%//')H
M^<?^"[/@;1/#.O?LBZIINCZ7I^I^)/VL? 5UJ]Y;6D<4^J31PW<$<D[J TKK
M#%%&K.20D:*.% 'Z*5Y_\??V7/ G[4'_  A7_"=:'_;G_"N_%=CXV\/?Z;<6
MW]GZQ9>9]FN?W,B>9L\U_P!W)NC;=\R' H^/O[+G@3]J#_A"O^$ZT/\ MS_A
M7?BNQ\;>'O\ 3;BV_L_6++S/LUS^YD3S-GFO^[DW1MN^9#@4 >@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>nktr-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20201231.xsd" xlink:type="simple"/>
    <context id="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5e6f011e7504a50be5144345c76cef1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i640af33a74bf419599a75c9360372c8e_I20210217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="icda9c88f4be148df8868cedf7bc4b3eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib61c61ebd4ad4075a8831d9455982999_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37ce07361f9b43129f976c314af40cd8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2104eacf6c1c4d319643e63ddfcaa810_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2127771393fd4344bc56f116378dbc80_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if2e1d56d6d224026a4762d3a7d7d113c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36bbf49b668643278f282f67a79338f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iced44c3d5ae947b09f1caf9892e918ed_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic383fe79ff4f463db81e7ac42a6ad50d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c0fa75cc5764250b904e9532e10dcfc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia75782c14a414b63b988ae2765e32773_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if20f13baec094f3ab62602a7600f949a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0aaedea71c1a4731b57ba3b49a31cb47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97ee016ab66c4bc7b24baff974c4e434_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idc09b131139d4563b60db10c398e0c39_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic317cce5e2e84fb1ac5250f54df57bec_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7c4c76f968fe4a4093752003d5013bc3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icf9e7353cdeb4fe6b0ec92f7ee97d3df_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i782737b6925642ae80e85211d3061393_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i35c8ff8ae9384f8495fb9cb6ddd60570_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib5b17c7c97be4099ae192bd62fc5521d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iada3a911b4f14caea46af4c30f06e014_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i970c509f43724f619b397e04e8673b95_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i45f25f1ab252404589804ff8b213aacd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ide09c0c4709d4b5aa0c73844f694a2db_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i63874fca1d514b93a990a5f8aab4aa34_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i61f23b96cd474a7d9187b5b79c2a289b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i33907907e75044d9835ba51785a384b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5542093f845a450e83bcc68e3b46375f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4590dba62bf9491c9a6eb5b8d6bb51c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79a1357fd1ed41e0991dc2af7ce5c5c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd7b0526e6124631a8651436a2212d83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icbb019599e084003800372045527cde5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1fdd2b443374491091615a02e9e811a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7087384b4384d5ea1895430f29aa031_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c38660192d4485bb12209404a88e784_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i880d3494fb4e4f6abd5b72316ba10da3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbf098280e6d44e0936905fbe28dcb34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3387462eae3140f4abc3e28f4e4a5af3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73c1044cd8154ba294e48097dcf6ecfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35ac0337faf647b189a16641a720d4d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5065cf5b40d5475aa1b717b89709499d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id08affc16b104b92823fab10fa4ae3a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i717a3b33fb444b809d0adef0ac06725b_D20200413-20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:A775PercentSeniorSecuredNotesDueOctober2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="i09546958c5654aba9b0e1a853838b859_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PartnerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f416a959f974cfba77544c098dfe27a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PartnerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24f5461407a5437d9bfeb28b339c42e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PartnerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6aff924a587b4d04b0235e3e8f640342_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c77957329da4893900ec8abef0354d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i699fa2275d694e3ead84ac6a1b9d588a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34700219468e42b4b7930f9dbb4d6186_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2258862b93e9480c951e464dfe2bbbe0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9db7646976b34d70acfa2081ee826ee4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic21605fedf17490fa0886eae32da3156_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad64b443cc304ed6be30d2cc5df58e4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08812424de7c416cae903c24bf2273ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83c2e96ec4df4105ae39e0cc524fc251_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf6d1cf2ec944050a87027e7a515ee06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if1e26256948a488cb8e3fcf49df9474a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8e58a6675bb4673ad4c4d985c0ad671_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9809b46a63494218a0bf6b5f8fc63571_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2df0af8bd514d598273623513f12d91_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f9c3756efac45638b8661f85a56b87b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb3ed71369cd465faecd143e23ac8cf7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e0a7100bd064c2c83c71589ae758e3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9da7225c246f45e7a9949c2da1d6f10b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23df56833c5f4df59292bc311c03aad8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic26b559e13a246219de39b20472737fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2266b3ff82324cb9b553040cded08f91_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45127b4769de4be5b7b965f5763fbc1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i689fee9ace2e4522b887678cba220fa6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a80ca3f7680478d982f63ab514437f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84cbf02176864c678db5f9dfbd89d813_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c28da8080c84fcd807f2604a6cc1e1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9ddd0c57faa4c2dbab65ca8fd54a4f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i678825b8367a45639e3d62d20e1b8682_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dbdad1aa0874eb8a53d8398977fd31d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie39c346907c8444d9f56f268dff89776_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if876fe666ac74deaa248054e2378e704_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-05</instant>
        </period>
    </context>
    <context id="i6228c808807e4675801149c5c4dc1518_D20151005-20151005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-05</startDate>
            <endDate>2015-10-05</endDate>
        </period>
    </context>
    <context id="i9f550fdfeac243e7b6be6c3906cace58_D20200413-20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="i050aa7da5e164a6e8417d8a966766809_I20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-13</instant>
        </period>
    </context>
    <context id="ib51f0c55e3654f49b5399e4a17397835_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc93e99a4dbd4acdadb139babe668fc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae1943d37a234e1f9eaaacf476982b71_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i86b2a2e647ae4ccf8b8c44c8755aa414_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id176c911867d49139246e27dafec984d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-24</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="id831546d70e34870a583f96469cf6e54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ff329ef00ee4a19babec2ac7467b6c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f23237f9b92424f88e3de119d082d83_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="i8b99c4859de149f481fb7758fe823053_I20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-16</instant>
        </period>
    </context>
    <context id="i3d3d4ded8eb8431ea5eb96372d1f1204_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-25</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-02-25</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2a82bbe23bd4eae896743496772f42c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b607b1feca94f0183fc01112b406e0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe8e5acc2c64493693d38c6ecf8677de_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="ie9b40bb677024548b6bead5496558bb3_D20130301-20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="ibcce05db00d34655b9af2ffe52859e3e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id84e821beaee4d8fa7e6add65a5ac46d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd7bb6c1b8b6481197a849cf13dc94fb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i332680e5c95e48e8b3da3635ec5a64c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i27d8215eb84441c583e455931394edc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee0a827a30fd4d489cff709fb4aa1743_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64f92162d4b9462fb32ed8b535a14bac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2ab7fd63345456ba7a5755e4c5fc5d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:CommercialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65324047a4db4c8091e27eab6cf2aa8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:CommercialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2caaa2f541394f9f8d1cc79cf9ea3dc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba6fe490e41b448e8aff782bf7c54d50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e772010232f40508602a3871880b34c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i279eee577f1441378d79802f9bc91494_D20180403-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="i45baea1b97d54688a1dfe6bcf696082b_D20180403-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="ide5660632f144317b4ee56bdf1d105ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i165b47e55f0b4fe19b116d4073ab3d17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0404b34bd7e6426abaa4ad1ff3be9107_D20180626-20180626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-26</startDate>
            <endDate>2018-06-26</endDate>
        </period>
    </context>
    <context id="id759869545ce4f8082f87a13f96f56c7_D20200617-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:AmendedAndRestated2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i3242ee4bdb4141c29d4a338d4cabf96e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fbb3ef5ea4f4882bde7a74c1ef8e365_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5da921eb5c043ae837ab819c1a4f230_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie75ccda9579e4320804a6b82cbbeadca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i243a1e61f3224fbbbbd5e7b34dc9d858_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4cbf542cfaa4814959fffc6a9d3eb50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae8c53d2886c4e2688588fb7a66cb738_D20200617-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i7a180f9d74404418b6c1394ddf6e243a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07fee986be7e4e88975b835fff607f89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c5b28fa1440433cbc1a30bd468e6bc4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i737d623ece374d02a554cd0314567319_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0b180b5818184f9e90a1d9ac77c0ad36_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i813fad316fa349b09cbd0d54f5119511_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7500307ef7d243f28fbd31084f547085_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i27aa90ea43d8491ab680477d8a5ad091_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d89b8ee0d5b4ad28995c6a5cb013afe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia149e6df5d9d423fb6f0a80e7e807499_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i40c73bdc0467470a82fe6dd56ac35921_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaIncludingADYNOVATEAndADYNOVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iddeeba83838249e69191a50f51901ae9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaIncludingADYNOVATEAndADYNOVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74a26ba1b2354834aeab39bb01122273_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaIncludingADYNOVATEAndADYNOVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaa2ed6dd5c174996a8348c2074df2753_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i008803fb67f84ea78e2af3795d82cb16_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if46c9120dc3e494394b2305aceabd21d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifed655596acc4f6f9abb2c38103052ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53dd51cb16d64a37af811757be9bc88d_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i18e9200632c24e1cb5376206c84bd1ba_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ibc3d41b108484518862f7675ed0d6023_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="icae6895fea5d4170abf536b7118795ac_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ib881bc00509644faa5b6cc9e5670bda9_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:ClinicalTrialAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i0dc54d4429a14507ba0977108771d46f_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i33adc58a946240659c54e96e6b40bfbf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i681999e295a9436988be9a734fa0d419_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i89eb6575dc8d4b6bb3d9b58cb422c933_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i2e8d2460a3d24fe19b5e25e5c18d4d4c_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i9a165c7d11824e3faaca690b9fe43ccb_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="i4324d57f84ab4a79b48761bdcdb78475_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e5b0431feeb42af96a92b8ebf28fd8b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i51d000e6aadc462a8e1d068ac6eb6bda_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09a7acaae93b47a18c69f0744596371d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47e8ffaec982447283e3be646c848349_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i856405b13edf4a6cab22db02d72d1802_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1754f034bd974728bed8387d9d72bd50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1f578ac138d243159b20e2c8695c088d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i211b0ecf8dd9414bac8969426d745f43_I20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="i090200b2df2d4328a10feb73ea2cc913_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="icfa0bac114c54b30ad4a8c72b57d49d2_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i2f006004c02b411e86bd510eb0e3d194_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i822a697b55f34b999f5d046661cdda27_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="if57ed396a7ce4982a8cf0c38400928a6_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ib86b4fcdb85a4a40a92ae61ccbb060f2_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i17a2d0c7f5b14febb5d605a70ac5be5a_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i88b3538d8838435d98d28e77de6a0b87_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i72e1d5fa4cee46038d0164972eca0589_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i9608ed0e8f234f719db44f2ce29c4216_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id73287f5728f4758aff50c38e58bc67c_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i53699e8247e24936abad5db41f079668_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8ee84d18bf2448248442d25abe69bc54_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="ic5f692c7b7c64b63aa43f5f9beb82f27_D20101001-20101031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2010-10-31</endDate>
        </period>
    </context>
    <context id="icdff3824bed0496593ee26344105cfaa_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i9669dda51f8d469b90ab31add3c0cf0a_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="icdbf7038932f481ebc0426c961831d78_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i052214e857b447dfbc2f68ed467ab528_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i255f8243240945a4a13c9479fe28d04f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbbc53198d1c48749ec868cd04228392_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3e61ba2f5e447299c9460d38e8e3b38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic54b2f1a2f4f47eda9c396ece8af832b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b459d9407c3488188caf6e79fd2c1b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:TerminatedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62313148fd754f3b929b315ce6ba6955_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if74acef52e11470f833bd478aa3ef19b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b295854248b4d328d13f61824dc9c9a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ce8950c4b5b4e54b98c6758fc52a69c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4cf4765dc2e844f291e9697ef1a040c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i495ad3c9a56241a4b0d81e8e4e6fb3d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e8a180bb15a483f80a891f8010c1d15_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0b77ba2c841b4c28b4c4a4cd5a77324f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a89348225b1444f879860b43fe8e9c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i38d8392820334097a6e73600dbdc66b5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1db549bc0acb4adba3eec24ace8bedd0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c80c0982a6f47049d8b696c71aad77f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ca56cd80aa4498ab650c1512e10d771_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8a0f1d0bae304ea191fafac40840dd22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i270d9a256b0148cf80b4c9020001e2ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie01a6511f0d24250b24e5b947e4fc152_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52d489e7ce4f48beaabcdd6ed7a7661b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1352258179264aee894c5a3fcf3294cd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id5394f004851433191f100501cea9fac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d86a1180eaa4ff892518dd3441f1bb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fb46e064c7448bb96b707d5238157cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida4ca2a391ba4e4e82c217bd8fd54a9d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0724493c13744e74aba58429991051ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8930ee506074b1a80dcb28134fd5773_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide398b6debeb4fb7a095f0df2975ccd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i049d56950da443d782603343643146ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0866d8705ad34c20932d7388fb164e35_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i817f31328f764ac8a65d4340427e73dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie32b099d78c041bcb200c8d5438e369a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i62cad6a1a032445e971b3fd80be0ab88_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib912063d910845aaa45f66edaa7d2535_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88ca9a944946417a9bd26c7ff3bd0df2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee76c326075144bc9957970824864572_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iacd671a84bd84c26a9c4e33c4b75a08c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d365863714c4ed5890fc77835d41d57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c86ae7fa4cc46ac95c142f23e235a82_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5eb25dc75983449abf52bac9890f50f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccee95850b064fbd8b0c1431a6df105f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85fff8d911974f27b78a9941b7f50432_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0eabcb407913449e87ce37aa8d0de239_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4d086dadf3f44dba9615056bd07087d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36d6b1d26b224dc59df8dcedba587fed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf35774709d841d3b44284705950593c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7199da49f7844202b5dabcf7a621af2e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0342284791141f9aca1142441d62cf0_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="idb0e3cb012e04c40b706573437e7c400_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia127b30b5a3e436e9d93336b81801699_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2ecf9e44f3a485789e47ee440d1fb61_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00d570eb5ffd48c4939a02adc32bc003_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i115533df786243e0b7e302d7e193fa82_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4adfa1d6b5b54a02b009b9b036e26e11_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4187a897c35f46c2a1363434d9f54ce6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4ffc21a2ccee43aa8a8e12d940741920_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id7710329fc21449a944ba1739f98c260_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>nktr:reporting_unit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>nktr:term</measure>
    </unit>
    <unit id="segment">
        <measure>nktr:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl8zLTEtMS0xLTA_5bab2f31-c859-4f81-aeb9-2ac2eabac1b5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl81LTEtMS0xLTA_0b653746-54bb-4c75-989c-7036b2fe290d">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl82LTEtMS0xLTA_628f093b-34bc-4477-9d4c-bf07cd6eb782">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF80L2ZyYWc6NDE3MzQwZTdmM2M3NDA0MmEwYWZkMTI1MWJlMDI3ODUvdGFibGU6NzIzNmU5NmVkOGYzNDhjYTllNTg0MmY2Yzc4NjMzYWYvdGFibGVyYW5nZTo3MjM2ZTk2ZWQ4ZjM0OGNhOWU1ODQyZjZjNzg2MzNhZl85LTEtMS0xLTA_1ecec2bb-61cf-4fe7-8e55-a15eeecf8925">0000906709</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6aff924a587b4d04b0235e3e8f640342_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="iad64b443cc304ed6be30d2cc5df58e4f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_65dac629-914e-42fe-8970-b4d9eec444dc">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i08812424de7c416cae903c24bf2273ec_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_d24a00d0-9f20-48ec-989c-a46dae10d5c7">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LeaseExtensionTerm
      contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a">P5Y</nktr:LeaseExtensionTerm>
    <nktr:LeaseExtensionTerm
      contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a">P5Y</nktr:LeaseExtensionTerm>
    <nktr:RoyaltyAgreementContingentPaymentDescription
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjQvZnJhZzo2MGU0YjBjYmU0M2Y0NDhkODgwZWU4ZTVkOWQ5ZWFkNS90YWJsZToxNDExY2M0NTdjYTQ0YmRhOWM0ZDhkYjUwNmM0NDlhNi90YWJsZXJhbmdlOjE0MTFjYzQ1N2NhNDRiZGE5YzRkOGRiNTA2YzQ0OWE2XzEtMS0xLTEtMA_189d4b70-b35d-4fad-bc59-9ccd2dbe2313">As a result of worldwide net sales of MIRCERA&#xae; for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.</nktr:RoyaltyAgreementContingentPaymentDescription>
    <nktr:RegulatoryMilestonesPaymentDescription
      contextRef="i62313148fd754f3b929b315ce6ba6955_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDIvZnJhZzphYzA1ODJiYWU4MWQ0MjFlODk4MDIyYzc4Zjk4ZjJlNC90YWJsZTo2N2U5Njc0OTZhZTI0Mzc2YmZhOTU0MjlmMTYxZDk4OS90YWJsZXJhbmdlOjY3ZTk2NzQ5NmFlMjQzNzZiZmE5NTQyOWYxNjFkOTg5XzEtMS0xLTEtMA_8a7778e9-4566-4532-aa44-97efafe138f1">A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</nktr:RegulatoryMilestonesPaymentDescription>
    <nktr:PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDIvZnJhZzphYzA1ODJiYWU4MWQ0MjFlODk4MDIyYzc4Zjk4ZjJlNC90YWJsZTo2N2U5Njc0OTZhZTI0Mzc2YmZhOTU0MjlmMTYxZDk4OS90YWJsZXJhbmdlOjY3ZTk2NzQ5NmFlMjQzNzZiZmE5NTQyOWYxNjFkOTg5XzItMi0xLTEtNDMyOQ_adad7643-dbae-49dc-b1af-2d5831deb45e"
      unitRef="number">0.02</nktr:PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints>
    <dei:DocumentType
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ4_e717da2e-d1af-40e6-89dc-eb217d3b7b53">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MzNlZmU1MTA0YTlkNGVkMjlkYTU5YTU2ODFiZWUzZGIvdGFibGVyYW5nZTozM2VmZTUxMDRhOWQ0ZWQyOWRhNTlhNTY4MWJlZTNkYl8wLTAtMS0xLTA_1490a31a-7073-4696-abc5-d228920006e1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8yNjk_a253f7df-ffb9-4681-af0c-d106e55feec0">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8yNjk_700d2aac-2b76-478a-b5d4-67f7b2737a62">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6ZTNiMTc0MDA0NjZlNDZlN2FhNDMxZDA4YTUyOTUzZDYvdGFibGVyYW5nZTplM2IxNzQwMDQ2NmU0NmU3YWE0MzFkMDhhNTI5NTNkNl8wLTAtMS0xLTA_dd5fa498-5839-421f-9748-0174db085c33">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU4_b1715ccb-0e9e-4a0b-8d10-f971d8b8a575">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ0_4c338f7c-48fb-48c9-b386-6390aebfa49d">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6NDdiMmYyODMzYWM1NGU3OGI4ODhmOTY2N2JjYjg3ZjMvdGFibGVyYW5nZTo0N2IyZjI4MzNhYzU0ZTc4Yjg4OGY5NjY3YmNiODdmM18wLTAtMS0xLTA_08ff9243-c9cb-4180-9f09-05f04eb5b721">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6NDdiMmYyODMzYWM1NGU3OGI4ODhmOTY2N2JjYjg3ZjMvdGFibGVyYW5nZTo0N2IyZjI4MzNhYzU0ZTc4Yjg4OGY5NjY3YmNiODdmM18wLTItMS0xLTA_96862025-6293-47ce-b2fe-0f37547ff8cc">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU1_8070beac-33cc-430e-8faa-42ade9084319">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ1_7518b88b-4fc5-4fe9-a1c4-80432a288188">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUy_297851b4-0c65-4752-87e7-92114a5cd743">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU2_0b89d90e-5114-4db4-9bf7-49b6b7ace9be">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUz_8a6074df-2fd7-47b0-a29d-8d1171e5fb91">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ2_69b82ab8-1802-4aed-ab82-8df8cab85eea">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6M2QzODZhYjVlNjgwNDg0ZWIzODdjMDU3MjliNGFlODEvdGFibGVyYW5nZTozZDM4NmFiNWU2ODA0ODRlYjM4N2MwNTcyOWI0YWU4MV8xLTAtMS0xLTA_e8cb2440-d67a-46d1-8135-e8bcdeaed5bc">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6M2QzODZhYjVlNjgwNDg0ZWIzODdjMDU3MjliNGFlODEvdGFibGVyYW5nZTozZDM4NmFiNWU2ODA0ODRlYjM4N2MwNTcyOWI0YWU4MV8xLTEtMS0xLTA_32b8f29e-67c4-4a00-a8e4-9e8919fbc1c2">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6M2QzODZhYjVlNjgwNDg0ZWIzODdjMDU3MjliNGFlODEvdGFibGVyYW5nZTozZDM4NmFiNWU2ODA0ODRlYjM4N2MwNTcyOWI0YWU4MV8xLTItMS0xLTA_cf967417-24c9-4615-82b4-4a343cf0803a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUx_a3112e9f-18b0-4294-82f0-206990fe3833">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ5_a926333a-8769-4600-9fcb-1126863bd15e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU0_b659c249-e465-40ff-9570-dc51e4518ca9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzU3_035109ee-906f-4ac8-9d25-d40a9778db09">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MGUxMGQ2NjQwZGM5NDE0Yzk0MTU4NTExNDNhOWMxNDMvdGFibGVyYW5nZTowZTEwZDY2NDBkYzk0MTRjOTQxNTg1MTE0M2E5YzE0M18wLTAtMS0xLTA_65ad5d3e-58ab-48bf-a891-8fca8ebe0230">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MGUxMGQ2NjQwZGM5NDE0Yzk0MTU4NTExNDNhOWMxNDMvdGFibGVyYW5nZTowZTEwZDY2NDBkYzk0MTRjOTQxNTg1MTE0M2E5YzE0M18xLTQtMS0xLTA_f0b3db36-b9d7-4d5f-9c6a-34d8f3e3e118">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGFibGU6MGUxMGQ2NjQwZGM5NDE0Yzk0MTU4NTExNDNhOWMxNDMvdGFibGVyYW5nZTowZTEwZDY2NDBkYzk0MTRjOTQxNTg1MTE0M2E5YzE0M18yLTEtMS0xLTA_ddb95d12-3a65-485d-96e9-4d4c2904968a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF84MjQ2MzM3MjEyOTc2_32d21edd-92d1-4837-b3bd-6194ff4f1fea">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzUw_f17d3bec-1091-40e2-a26b-5185594abf04">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ie5e6f011e7504a50be5144345c76cef1_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zMDUx_5fe30d76-0024-4917-a33e-625a0e56602c"
      unitRef="usd">4100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i640af33a74bf419599a75c9360372c8e_I20210217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zMzcx_44eb93c4-c578-4d55-ad9e-7f682dbc616c"
      unitRef="shares">182182063</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xL2ZyYWc6MmM3NmQ3YzU1M2E3NGMzY2FlMmE3ZWFiYjhhOGYxOTQvdGV4dHJlZ2lvbjoyYzc2ZDdjNTUzYTc0YzNjYWUyYTdlYWJiOGE4ZjE5NF8zNzQ3_a4c010a8-2fb3-4d01-bef5-2cc1608bb082">Portions of registrant&#x2019;s definitive Proxy Statement to be filed for its 2020 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNC0xLTEtMS0w_a436dc30-57c9-43e7-91f7-9a61108a82e8"
      unitRef="usd">198955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNC0zLTEtMS0w_2afa2ab9-be0e-4aad-b766-07236b157cb6"
      unitRef="usd">96363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNS0xLTEtMS0w_4172ebd6-31ff-424c-9913-90ba86b65bfc"
      unitRef="usd">862941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNS0zLTEtMS0w_254babd4-0d04-48f6-8111-848db688784f"
      unitRef="usd">1228499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNi0xLTEtMS0w_6f8bd4d3-ecf0-46ce-9b45-3886d3925a24"
      unitRef="usd">38889000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNi0zLTEtMS0w_67337ec7-c3d8-4cc2-92c2-591c60a5fea7"
      unitRef="usd">36802000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNy0xLTEtMS0w_0232c2f5-2ff0-47f6-b964-9fdb0ae42b18"
      unitRef="usd">15292000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNy0zLTEtMS0w_521e1f9a-ce9e-472f-8df7-3fe3965b5d69"
      unitRef="usd">12665000</us-gaap:InventoryNet>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOC0xLTEtMS0w_ea99c0a0-b8bd-46b6-a434-90fd270aadf3"
      unitRef="usd">3908000</nktr:AdvancePaymentsToContractManufacturers>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOC0zLTEtMS0w_2fca38ab-67f9-4410-afb2-78a8a8178a7c"
      unitRef="usd">31834000</nktr:AdvancePaymentsToContractManufacturers>
    <us-gaap:OtherAssetsCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOS0xLTEtMS0w_a01475ab-e52b-427f-aa79-9c528f2d804b"
      unitRef="usd">18020000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfOS0zLTEtMS0w_1df49ecc-d8ea-4dbc-899f-1f199fa70bb7"
      unitRef="usd">15387000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTAtMS0xLTEtMA_2ca2a21c-a7d2-4081-9bfd-6f86dc748d4a"
      unitRef="usd">1138005000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTAtMy0xLTEtMA_4eca6efd-4ea5-4f7b-b8b8-cb6758039cf2"
      unitRef="usd">1421550000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTEtMS0xLTEtMA_967dc307-1465-405d-818e-343d7b9de7c5"
      unitRef="usd">136662000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTEtMy0xLTEtMA_a2e7a575-3dc7-4413-b178-5f5c318c2719"
      unitRef="usd">279119000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTItMS0xLTEtMA_24d2346c-4907-4c19-a2a1-a9a1ebe17c71"
      unitRef="usd">59662000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTItMy0xLTEtMA_436e5122-d5a4-487c-8e7d-3707fbd67f63"
      unitRef="usd">65665000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTMtMS0xLTEtMA_cb947cda-0e27-4008-8955-ba5c448b8313"
      unitRef="usd">126476000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTMtMy0xLTEtMA_73e155fa-7f0c-4efd-9490-21155830e88f"
      unitRef="usd">134177000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTQtMS0xLTEtMA_a485ee81-894f-4234-8504-debc16e099ef"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTQtMy0xLTEtMA_53405264-c47d-4ec6-836e-9147d121d45f"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTUtMS0xLTEtMA_64ee1596-ed83-4ca4-a09b-e9bddf2cb337"
      unitRef="usd">1461000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTUtMy0xLTEtMA_e04dd82f-9179-4c14-af92-a2f4d66593b3"
      unitRef="usd">344000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTYtMS0xLTEtMA_e8c2df47-1766-4843-975e-758a0013644b"
      unitRef="usd">1538767000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTYtMy0xLTEtMA_a2515edf-49e9-4175-a88a-d2b273b7d17f"
      unitRef="usd">1977356000</us-gaap:Assets>
    <us-gaap:SeniorNotesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMS0xLTEtMzQz_689385bd-8e11-4f7e-999f-a20d6ca6153f"
      unitRef="usd">0</us-gaap:SeniorNotesCurrent>
    <us-gaap:SeniorNotesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMy0xLTEtMzQz_022c6adb-d8dd-4ebd-9732-ad6fa632a50a"
      unitRef="usd">252891000</us-gaap:SeniorNotesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMS0xLTEtMA_fed973af-70f7-4b59-893e-4980d38bd891"
      unitRef="usd">22139000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMTktMy0xLTEtMA_b06df3bb-47a6-495c-96db-0ec5cee56087"
      unitRef="usd">19234000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjAtMS0xLTEtMA_5bb3a5f2-ab12-4594-b3c1-803cf7e5fe31"
      unitRef="usd">14532000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjAtMy0xLTEtMA_4790bad5-80dd-46d1-bc38-af7c9cdb7bcd"
      unitRef="usd">11467000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjEtMS0xLTEtMA_7cecd7e1-9870-4f53-9fb2-f9014e8bd4a5"
      unitRef="usd">44207000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjEtMy0xLTEtMA_d6597c4c-fb02-4b4d-8fa5-f45e13a03df8"
      unitRef="usd">32626000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjItMS0xLTEtMA_f2625f23-998b-4d75-b2ba-fbe6fcec560d"
      unitRef="usd">11310000</nktr:AccruedContractManufacturingExpenseCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjItMy0xLTEtMA_ed6228aa-330e-4277-b1c7-8cda50e7efe2"
      unitRef="usd">7304000</nktr:AccruedContractManufacturingExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjMtMS0xLTEtMA_ea2e9355-fe01-4466-9646-0f9146a83a60"
      unitRef="usd">9585000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjMtMy0xLTEtMA_dc5167b1-815a-4cce-9a8b-97dbcce59e62"
      unitRef="usd">12338000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjYtMS0xLTEtMA_540e61f4-815d-4110-934b-49ed38caa058"
      unitRef="usd">13915000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjYtMy0xLTEtMA_eb6fce9e-1463-4ad1-bc1e-0599a9cfefb6"
      unitRef="usd">12516000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjctMS0xLTEtMA_d1b2a5aa-4d46-4373-bb23-105e8242c791"
      unitRef="usd">91000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjctMy0xLTEtMA_6831d8cb-970f-4cac-b292-8af472de8761"
      unitRef="usd">5517000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjktMS0xLTEtMA_2519a236-abe9-4904-a9be-dacb0d5fb4ef"
      unitRef="usd">115779000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMjktMy0xLTEtMA_f1d1a3c7-e523-4991-baef-132974b101ed"
      unitRef="usd">353893000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzEtMS0xLTEtMA_96ad7de6-1d8c-4063-ac10-ba19395106a1"
      unitRef="usd">136373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzEtMy0xLTEtMA_36f1167e-c9b8-4dca-9a7c-8da64d41524b"
      unitRef="usd">142730000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzItMS0xLTEtMA_267eccd9-ec14-4e5c-937c-e4b0c304564d"
      unitRef="usd">200340000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzItMy0xLTEtMA_95cb974d-d228-43be-b81c-a27a02d465a5"
      unitRef="usd">72020000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzMtMS0xLTEtMA_a260968f-72d5-434b-870b-0986ad85fd37"
      unitRef="usd">2464000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzMtMy0xLTEtMA_68624558-f0e3-47eb-86aa-16a26f145adb"
      unitRef="usd">2554000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzQtMS0xLTEtMA_cb5d1ea2-eef4-43cb-825b-0b5c2ed73470"
      unitRef="usd">6516000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzQtMy0xLTEtMA_b1da1c51-dfc4-45bc-af7e-0ee17f59b4bd"
      unitRef="usd">768000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzUtMS0xLTEtMA_50c10287-089c-4baa-beb3-bd4230bd25c5"
      unitRef="usd">461472000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzUtMy0xLTEtMA_2ec53197-7d51-416a-8748-f1a8db31b962"
      unitRef="usd">571965000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzYtMS0xLTEtMA_2a69ba49-bf44-48f1-8f22-917ecf733f3d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzYtMy0xLTEtMA_58a42a8d-b6a3-4241-b6d4-36b941f8e84e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NjU_8bfac8a7-a6ef-4cfd-8beb-86e33151b048"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NjU_f65f10fd-20ce-41ce-8a90-49cd209ea83b"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NzQ_80d3dcd8-6515-4954-9903-3564996b148a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0NzQ_f87ba13a-4258-4e69-aced-ba426873c374"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_00a204a8-ced4-4310-88df-e8cda1a9b505"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_38fe9548-839d-4645-bcc4-9eb173791173"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_5d88679f-bb58-4852-b63b-2cdb533b84f4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_9c678680-fcea-442f-935e-f33fd7bf2427"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_bbbf32bd-d963-4844-8f0e-526acd3d2da0"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmU5N2NiNDNhYWFmYTQyOGY4MTY0ZWEyMmFiYjNlOTZmXzgyNDYzMzcyMDg0Nzk_e30b0cd2-4a6c-420d-afff-d8b8f69defd5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMS0xLTEtMA_379f37f0-eb28-41c5-b085-45a0857522e1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzgtMy0xLTEtMA_028a595f-cdd6-4c77-b490-57915b8a9854"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg0OTE_7460973d-494d-4bb7-ace2-77d1deee7ff4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg0OTE_f56bd3bb-2d42-4e01-8e8d-9918d6ff1a64"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MDE_defb8c5a-6888-4d10-842d-e0394d017116"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MDE_e5a67801-6223-4ba2-8e40-c2f2886b8c22"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MTE_9f967cf5-133f-40ba-8cb6-57424758e3b6"
      unitRef="shares">180091000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MTE_dcd9a443-3636-4000-b70e-7abb6c52f3ce"
      unitRef="shares">180091000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MjE_7f1052db-6381-4c0e-bf51-597f3ba002e2"
      unitRef="shares">176505000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM5YjZhY2QwOTYwMzQ3MmRiOWYyNTQwYTU3NzhkN2JiXzgyNDYzMzcyMDg1MjE_8263a138-634e-4d34-81af-6a04977b74e5"
      unitRef="shares">176505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMS0xLTEtMA_1c1ff9a0-0ba8-4bff-a839-84f2861e83a9"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfMzktMy0xLTEtMA_c67b9785-7f4e-4eed-96b5-6b6731d6e10f"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDAtMS0xLTEtMA_b68032e1-6524-410b-b196-98636dcde012"
      unitRef="usd">3388730000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDAtMy0xLTEtMA_b8896c6a-4dc7-48a9-b65d-3a13931fae56"
      unitRef="usd">3271097000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDEtMS0xLTEtMA_5f6a462e-9f5a-4877-9ce0-86906ccc17fc"
      unitRef="usd">-2295000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDEtMy0xLTEtMA_170d6043-ee86-49b3-8951-2373b7a2e495"
      unitRef="usd">-1005000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDItMS0xLTEtMA_50079cfd-9200-485f-b049-08bafa2079e4"
      unitRef="usd">-2309158000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDItMy0xLTEtMA_7bc35218-0157-4f9d-b226-de3f34ac3a68"
      unitRef="usd">-1864718000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDMtMS0xLTEtMA_aa533193-38f7-4f44-9b82-f1646a90631d"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDMtMy0xLTEtMA_ba8e7128-7c47-44db-b8b4-cb15c69a80c2"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDQtMS0xLTEtMA_b25cb2bd-b6b0-456e-9b52-f4a0b1fb7d4d"
      unitRef="usd">1538767000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF82Ny9mcmFnOjE3ZWU2NTRkODgyZTQ5NjBhNDcxNWRlOWU4OTg4ZDkyL3RhYmxlOmUxMmJhMjMxNThkYTRhZGJhODMyZDIzMDViNWM5ZDQ1L3RhYmxlcmFuZ2U6ZTEyYmEyMzE1OGRhNGFkYmE4MzJkMjMwNWI1YzlkNDVfNDQtMy0xLTEtMA_c743d782-c57b-4d76-87da-081b70e0b2e9"
      unitRef="usd">1977356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37ce07361f9b43129f976c314af40cd8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMy0xLTEtMS0w_b858849e-c0bd-40f6-97b2-8c47347968ad"
      unitRef="usd">17504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2104eacf6c1c4d319643e63ddfcaa810_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMy0zLTEtMS0w_3a5816a8-a658-42fd-9a72-f14dd721d39e"
      unitRef="usd">20117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2127771393fd4344bc56f116378dbc80_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMy01LTEtMS0w_7f45990e-38b7-4ddc-8a84-3808ec6d409f"
      unitRef="usd">20774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2e1d56d6d224026a4762d3a7d7d113c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNC0xLTEtMS0w_855c5932-1c3f-4867-9a1e-918f74daecbc"
      unitRef="usd">30999000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36bbf49b668643278f282f67a79338f6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNC0zLTEtMS0w_5351a873-33d7-4c88-8095-801affb1d3a4"
      unitRef="usd">41222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iced44c3d5ae947b09f1caf9892e918ed_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNC01LTEtMS0w_9684c436-9282-4fd4-839e-dd094aa2a3de"
      unitRef="usd">41976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic383fe79ff4f463db81e7ac42a6ad50d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNS0xLTEtMS0w_05058027-6c79-42ea-a2ca-67551f79a68f"
      unitRef="usd">48563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c0fa75cc5764250b904e9532e10dcfc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNS0zLTEtMS0w_c9cfb34e-3343-4200-b6af-3ec1bab1017a"
      unitRef="usd">36303000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia75782c14a414b63b988ae2765e32773_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNS01LTEtMS0w_9c781d73-832b-4865-b792-f98d1b3f6a47"
      unitRef="usd">33308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if20f13baec094f3ab62602a7600f949a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNi0xLTEtMS0w_07ad1c7d-25ab-4069-9588-b61370761ed3"
      unitRef="usd">55849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0aaedea71c1a4731b57ba3b49a31cb47_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNi0zLTEtMS0w_550a3d21-0cb0-47f0-a5c3-bae5fb42ce1d"
      unitRef="usd">16975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97ee016ab66c4bc7b24baff974c4e434_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNi01LTEtMS0w_b9124ba3-6565-491a-af04-367f3009314b"
      unitRef="usd">1097265000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNy0xLTEtMS0w_eccaf3e7-f689-4819-9ebc-377eddc6aeb6"
      unitRef="usd">152915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNy0zLTEtMS0w_80bacd4b-9079-42ca-9387-f99c836a9abb"
      unitRef="usd">114617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfNy01LTEtMS0w_5c658d11-5acc-4357-9557-ed334b510d85"
      unitRef="usd">1193323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfOS0xLTEtMS0w_93b20f54-7bfb-492d-835c-047b9e3f05ad"
      unitRef="usd">19477000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfOS0zLTEtMS0w_293e376c-7c7a-4cdf-9ad0-9dd2818fa445"
      unitRef="usd">21374000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfOS01LTEtMS0w_227eecca-71a5-46ba-9fe5-fcd1192fe0f6"
      unitRef="usd">24412000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTAtMS0xLTEtMA_abf74fcf-8f3e-414a-9244-8b11fff8a445"
      unitRef="usd">408678000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTAtMy0xLTEtMA_e6f35c82-77e6-4018-a1c6-75acb4934734"
      unitRef="usd">434566000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTAtNS0xLTEtMA_b267a611-0d2c-4037-b74d-bc01b6567844"
      unitRef="usd">399536000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTEtMS0xLTEtMA_6e214b5d-0312-4038-9c67-0dc20369c7d3"
      unitRef="usd">104682000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTEtMy0xLTEtMA_5a352a22-dcff-491d-84a8-9ef87d9e5003"
      unitRef="usd">98712000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTEtNS0xLTEtMA_a79a2a0b-6afa-493f-81aa-521f22ee255c"
      unitRef="usd">81443000</us-gaap:GeneralAndAdministrativeExpense>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTItMS0xLTEtMA_9a709370-6a63-4bbc-8ef2-6e1184aa1d4e"
      unitRef="usd">45189000</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTItMy0xLTEtMA_25d53d7c-96cf-4177-8eb7-13e7c11686ec"
      unitRef="usd">0</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTItNS0xLTEtMA_445e246f-34cf-4b62-a92e-da42b31d1e4c"
      unitRef="usd">0</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <us-gaap:CostsAndExpenses
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTMtMS0xLTEtMA_30c981f8-30ae-48ed-a584-6f95aff1fd7d"
      unitRef="usd">578026000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTMtMy0xLTEtMA_5091a5d3-da40-44ba-9c0a-b7c4b9cc15d2"
      unitRef="usd">554652000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTMtNS0xLTEtMA_f4add3ab-2002-4cf6-b0eb-d66bf3d5d020"
      unitRef="usd">505391000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTQtMS0xLTEtMA_098cf57a-cf7e-489f-bbb6-cd8701c1e5df"
      unitRef="usd">-425111000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTQtMy0xLTEtMA_7e370f6b-a513-476d-a696-b48ac2935c1c"
      unitRef="usd">-440035000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTQtNS0xLTEtMA_ef6ccddd-f0cf-416d-901b-0976402319d1"
      unitRef="usd">687932000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTYtMS0xLTEtMA_ced85005-8a8c-453e-95fb-ac92cf9e7939"
      unitRef="usd">6851000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTYtMy0xLTEtMA_b776f5de-a3a2-4b89-a908-21dcb8d747ad"
      unitRef="usd">21310000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTYtNS0xLTEtMA_cc1ecedd-6d54-4254-b478-8df7fcb93bf7"
      unitRef="usd">21582000</us-gaap:InterestExpense>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTctMS0xLTEtMA_729cf39a-904f-4ab2-8fcd-956ce2b6430d"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTctMy0xLTEtMA_b8dec2bc-038d-4790-9387-00fd637e8b36"
      unitRef="usd">25044000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTctNS0xLTEtMA_9df77f5e-cab7-434d-bad5-d973602bc866"
      unitRef="usd">21196000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTgtMS0xLTEtMA_8323b7cc-1e89-4d90-84f0-6c3fbde5a9c2"
      unitRef="usd">18282000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTgtMy0xLTEtMA_ec612836-48e6-42b8-93b7-3a9887cc8159"
      unitRef="usd">46335000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTgtNS0xLTEtMA_8c4657cc-5989-4732-b6e7-010ccfc4e75e"
      unitRef="usd">37571000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTktMS0xLTEtMA_b0e30a37-c466-4a1e-9c77-1a7463777a24"
      unitRef="usd">-18836000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTktMy0xLTEtMA_089b0afb-48ea-440c-9ae6-56a6efbe1b60"
      unitRef="usd">-19000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMTktNS0xLTEtMA_53f3c8b3-b961-46b2-b6ac-e1badb69a21f"
      unitRef="usd">-5207000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjAtMS0xLTEtMA_3d271c12-d56f-471b-8777-9759e4199180"
      unitRef="usd">-443947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjAtMy0xLTEtMA_329461e9-96e5-429c-ab1b-d40abaa1d3a0"
      unitRef="usd">-440054000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjAtNS0xLTEtMA_5a67edb9-aa93-4c71-acf5-c933145d34c5"
      unitRef="usd">682725000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjEtMS0xLTEtMA_08639f65-2c28-4c32-ae33-9d1ffd055d9c"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjEtMy0xLTEtMA_a87e4bd2-5264-45b8-a50b-741519d0445f"
      unitRef="usd">613000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjEtNS0xLTEtMA_2fe9d79c-404d-4985-844f-ede13be08d9d"
      unitRef="usd">1412000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjItMS0xLTEtMA_b6214431-2789-4cf7-8baa-fe21230ba7f7"
      unitRef="usd">-444440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjItMy0xLTEtMA_3ebcf871-a7f2-45f9-b7ec-1f6aa7e73714"
      unitRef="usd">-440667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjItNS0xLTEtMA_01a4f3a8-3915-479d-9797-a2f037aa2501"
      unitRef="usd">681313000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjUtMS0xLTEtMA_61be6456-ab02-4aad-bf5c-970e22f6fe05"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjUtMy0xLTEtMA_4d94920c-d7e7-474f-a7a9-e9d98df535cc"
      unitRef="usdPerShare">-2.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjUtNS0xLTEtMA_836b88b4-5ea6-4804-9eab-11ffd4980aad"
      unitRef="usdPerShare">4.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjYtMS0xLTEtMA_cd6407f2-d7ca-4350-a6d8-53bc88368d31"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjYtMy0xLTEtMA_21806352-ae36-42b0-8933-75291cfaae9b"
      unitRef="usdPerShare">-2.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjYtNS0xLTEtMA_2e637814-03e0-4a01-80c5-54fbfd33bda0"
      unitRef="usdPerShare">3.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjgtMS0xLTEtMA_91e4fa0b-8fc7-4a9b-849b-021731ac39a2"
      unitRef="shares">178581000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjgtMy0xLTEtMA_f12c4a50-193a-48d8-8be9-0eb25fd8e5fd"
      unitRef="shares">174993000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjgtNS0xLTEtMA_cd40174b-168c-40ae-ac9a-901033839329"
      unitRef="shares">169600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjktMS0xLTEtMA_b9e5f5c0-2f4f-4c83-8fb6-b60006719a63"
      unitRef="shares">178581000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjktMy0xLTEtMA_639bf73b-be49-401d-9d8c-c431243692c3"
      unitRef="shares">174993000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83My9mcmFnOjk5NTEwMTkzODU1NzQ2OTc4ZDhmMmQ1MGVkYmVjNTk3L3RhYmxlOjBhZjFlMzFmMTQwMTRmYmE4YmIyZTMyNzdlM2E1MWU5L3RhYmxlcmFuZ2U6MGFmMWUzMWYxNDAxNGZiYThiYjJlMzI3N2UzYTUxZTlfMjktNS0xLTEtMA_df56a672-695b-4b75-a925-8502f90d779e"
      unitRef="shares">180119000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfMi0xLTEtMS0w_b5b4cea7-8c7f-456f-b9b5-da272cb85b81"
      unitRef="usd">-444440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfMi0zLTEtMS0w_0f985dd3-dfcd-4605-ae02-fae6596b33b6"
      unitRef="usd">-440667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfMi01LTEtMS0w_2d8aeb84-451c-40f2-85ab-fe0990043d07"
      unitRef="usd">681313000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNC0xLTEtMS0w_3dcc970c-02f1-4a06-a2cb-ab729eba6a1f"
      unitRef="usd">-927000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNC0zLTEtMS0w_e7849fb7-ead0-450d-b501-b04ca9f1d808"
      unitRef="usd">5693000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNC01LTEtMS0w_c6789e60-70ce-49e4-a5a1-924e3ecc1cd0"
      unitRef="usd">-2975000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNS0xLTEtMS0w_b0725e38-a8a8-4a8c-ab59-b48d5e4d8b71"
      unitRef="usd">-363000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNS0zLTEtMS0w_9301c0d0-0d9d-4548-906f-3ac2a2685d58"
      unitRef="usd">-382000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNS01LTEtMS0w_ec7b287a-5509-4947-a0dc-e6381d1b3c66"
      unitRef="usd">-1230000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNi0xLTEtMS0w_46061293-b862-4d4a-9d76-dfd19365724b"
      unitRef="usd">-1290000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNi0zLTEtMS0w_9f1499b7-3822-45bd-a76b-c0040cd15339"
      unitRef="usd">5311000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNi01LTEtMS0w_a7949f95-2853-4171-a973-275f406e3b0f"
      unitRef="usd">-4205000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNy0xLTEtMS0w_dc41ff3d-7617-40f6-acf7-4ab771264f9a"
      unitRef="usd">-445730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNy0zLTEtMS0w_76fa6878-f6e6-476b-ad13-99003f7a136a"
      unitRef="usd">-435356000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF83OS9mcmFnOjQ3MzA3YmMyZjRiYzQxODdhNGRhZTMxZGY4YzMzMTU4L3RhYmxlOjU1NzQwZTczZjU2ZTQyOTM5MTIxZjQ1NTZjMTNhOTY4L3RhYmxlcmFuZ2U6NTU3NDBlNzNmNTZlNDI5MzkxMjFmNDU1NmMxM2E5NjhfNy01LTEtMS0w_7b026308-8ff7-4226-a599-6530f8a7588b"
      unitRef="usd">677108000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idc09b131139d4563b60db10c398e0c39_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS0xLTEtMS0w_b38b09f0-dad5-4b8e-8d88-a08302cd47c3"
      unitRef="shares">159524000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idc09b131139d4563b60db10c398e0c39_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS0zLTEtMS0w_2c02af70-281d-49f3-a7b3-84726ea17f82"
      unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic317cce5e2e84fb1ac5250f54df57bec_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS01LTEtMS0w_5f45c6b1-8739-4385-b31a-6738416ff4f5"
      unitRef="usd">2207865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c4c76f968fe4a4093752003d5013bc3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS03LTEtMS0w_15d8127c-f9a0-429f-b269-b1ea5147fc11"
      unitRef="usd">-2111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf9e7353cdeb4fe6b0ec92f7ee97d3df_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS05LTEtMS0w_484be5bd-7330-4abd-b0e8-e5edf7422fb9"
      unitRef="usd">-2117941000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMS0xMS0xLTEtMA_97d9c322-cd94-4ae6-ac21-5be08352e681"
      unitRef="usd">87828000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi0xLTEtMS0w_a4dbf5d0-0e3e-4f6d-8230-e0d53f6887a7"
      unitRef="shares">5721000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi0zLTEtMS0w_88968706-372f-4df7-baf6-96ae588c1729"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi01LTEtMS0w_30a00412-4fe7-45f8-a7cb-372e9acf40e4"
      unitRef="usd">61728000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMi0xMS0xLTEtMA_be0a895a-b194-4810-92a3-32ab78b7c0e1"
      unitRef="usd">61729000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMy01LTEtMS0w_34f3f2e6-7c68-4e61-b800-22a6e9f9c62a"
      unitRef="usd">88101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMy0xMS0xLTEtMA_a23b5c40-4f5c-4ca4-b155-1b304716c7c4"
      unitRef="usd">88101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0xLTEtMS0zNzI_1a0b84a6-55c2-4c8b-bff6-997adbc9f2b8"
      unitRef="shares">8285000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib0b60492e3d94e5380a6fbf746a34d75_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0zLTEtMS0zNzI_a4dd4dc3-3ddc-4cb5-a4c3-fd957a321042"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib5d42a0666b44cda8df439c20c0e47e0_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC01LTEtMS0zNzI_421d5b1b-bf80-484b-8f49-6d29b8229ce5"
      unitRef="usd">790231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0xMS0xLTEtMzcy_375f7a81-0ac7-48f8-a9ec-81cb88c896e1"
      unitRef="usd">790232000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquity
      contextRef="i782737b6925642ae80e85211d3061393_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNS05LTEtMS0zNzI_ef76aec5-1cd9-40ca-9f37-a9d335bc8445"
      unitRef="usd">12577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35c8ff8ae9384f8495fb9cb6ddd60570_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNS0xMS0xLTEtMzcy_da301383-4196-49ae-9215-0f82fb262f2c"
      unitRef="usd">12577000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib5b17c7c97be4099ae192bd62fc5521d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC03LTEtMS0w_e3fc0434-4ca9-44b7-b682-1c39f66327d0"
      unitRef="usd">-4205000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iada3a911b4f14caea46af4c30f06e014_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC05LTEtMS0w_bdf6edf0-c2b0-4819-b82b-74d63d5083a4"
      unitRef="usd">681313000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNC0xMS0xLTEtMA_caaf0e30-5659-43bf-8ca1-93c3d5dc776a"
      unitRef="usd">677108000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i970c509f43724f619b397e04e8673b95_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi0xLTEtMS0w_ff9afb17-ff35-4be7-ad7d-8e12980233ad"
      unitRef="shares">173530000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i970c509f43724f619b397e04e8673b95_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi0zLTEtMS0w_8674dcfd-84c2-4143-8a56-4251c240885a"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45f25f1ab252404589804ff8b213aacd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi01LTEtMS0w_ce59b699-6946-47ca-b22b-4539bde89290"
      unitRef="usd">3147925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide09c0c4709d4b5aa0c73844f694a2db_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi03LTEtMS0w_88293a49-2271-4184-b4db-e3d450b31d6a"
      unitRef="usd">-6316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63874fca1d514b93a990a5f8aab4aa34_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi05LTEtMS0w_e36cd5ef-4f8a-4ee5-9c27-5ede0aa75136"
      unitRef="usd">-1424051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNi0xMS0xLTEtMA_d8aa4b18-4f99-4f33-a7ef-dd4a56af1acc"
      unitRef="usd">1717575000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i33907907e75044d9835ba51785a384b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNy0xLTEtMS0w_7729a42c-d65c-40f8-825e-e906685ba4e9"
      unitRef="shares">2975000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5542093f845a450e83bcc68e3b46375f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNy01LTEtMS0w_b0a6d5ad-cab4-4684-949f-d74a0b3eb072"
      unitRef="usd">23377000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfNy0xMS0xLTEtMA_33437467-8579-4fce-b5fb-a553f7cbec5b"
      unitRef="usd">23377000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5542093f845a450e83bcc68e3b46375f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfOC01LTEtMS0w_542a9e6e-b41b-4ab6-8f8e-baa982a3a1b2"
      unitRef="usd">99795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfOC0xMS0xLTEtMA_acb8baa1-d1e5-49ee-86a5-e044d6b51b37"
      unitRef="usd">99795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4590dba62bf9491c9a6eb5b8d6bb51c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTEtNy0xLTEtMA_ccfa75fc-af6f-48a3-a1c0-7537ce6a01b2"
      unitRef="usd">5311000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i79a1357fd1ed41e0991dc2af7ce5c5c3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTEtOS0xLTEtMA_471d2ed9-f25a-4c54-8810-9f1f65cdd152"
      unitRef="usd">-440667000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTEtMTEtMS0xLTA_174222b6-b604-4e27-a6b2-13fa69b42fb3"
      unitRef="usd">-435356000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ifd7b0526e6124631a8651436a2212d83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtMS0xLTEtMA_26abec6e-c5e1-4a84-b24e-8247d1584289"
      unitRef="shares">176505000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd7b0526e6124631a8651436a2212d83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtMy0xLTEtMA_e8c5061b-a6be-4a2e-9afa-cece5ead55d2"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbb019599e084003800372045527cde5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtNS0xLTEtMA_4658b21f-2c0f-4e6b-9fc3-e2d1e400c2b5"
      unitRef="usd">3271097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fdd2b443374491091615a02e9e811a7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtNy0xLTEtMA_af65b4e1-c9ef-4ecf-bddf-2fbf740d1dbd"
      unitRef="usd">-1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7087384b4384d5ea1895430f29aa031_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtOS0xLTEtMA_e488d9ff-bedf-4cfe-bb72-b6fba9a6efd9"
      unitRef="usd">-1864718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTMtMTEtMS0xLTA_15d697c2-f7d2-4969-983b-4e1e62fade09"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0c38660192d4485bb12209404a88e784_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtMS0xLTEtMA_2ef9dbb8-75e3-4386-ac4c-89c73266d65e"
      unitRef="shares">3586000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0c38660192d4485bb12209404a88e784_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtMy0xLTEtMA_a7688587-1aa3-4b56-843a-59ee0e89be93"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i880d3494fb4e4f6abd5b72316ba10da3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtNS0xLTEtMA_ab1eebdf-5bac-4d78-a987-ea64c39bca11"
      unitRef="usd">23372000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTQtMTEtMS0xLTA_63dec69b-657e-4a3a-999a-ef816fc58c9b"
      unitRef="usd">23373000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i880d3494fb4e4f6abd5b72316ba10da3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTUtNS0xLTEtMA_862e0084-df1b-4b18-a1a8-aa047838d2cf"
      unitRef="usd">94261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTUtMTEtMS0xLTA_f7085520-c202-4023-ac16-9306390db359"
      unitRef="usd">94261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idbf098280e6d44e0936905fbe28dcb34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTYtNy0xLTEtMA_78a7f226-45e8-4fdd-b40c-7c7ac4e2aa3a"
      unitRef="usd">-1290000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3387462eae3140f4abc3e28f4e4a5af3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTYtOS0xLTEtMA_daa6236e-7e82-4fc6-8098-572ef84cacb5"
      unitRef="usd">-444440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTYtMTEtMS0xLTA_fb744ab7-e909-43f5-a430-3abcf6ef41df"
      unitRef="usd">-445730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i73c1044cd8154ba294e48097dcf6ecfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtMS0xLTEtMA_1648420a-1110-4221-bc8b-bbb12197c18c"
      unitRef="shares">180091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i73c1044cd8154ba294e48097dcf6ecfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtMy0xLTEtMA_881278a4-4b4b-49e6-9a52-b1a7882cea22"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35ac0337faf647b189a16641a720d4d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtNS0xLTEtMA_b883b360-f478-49c2-97ca-b16926ae46f9"
      unitRef="usd">3388730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5065cf5b40d5475aa1b717b89709499d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtNy0xLTEtMA_d3a39a47-2330-4d8f-8ab1-bff0dece1c47"
      unitRef="usd">-2295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id08affc16b104b92823fab10fa4ae3a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtOS0xLTEtMA_986f5368-c7d9-426d-9403-e8476bd0d8f4"
      unitRef="usd">-2309158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84Mi9mcmFnOjZmM2VmOWM3ZTE2NzQzNzliODQyN2QyNGMzY2Y1ZDkzL3RhYmxlOmJmNTQwZWU0NzU0NzRkMmY5YTU2NmE3MWMxZjQ4N2M3L3RhYmxlcmFuZ2U6YmY1NDBlZTQ3NTQ3NGQyZjlhNTY2YTcxYzFmNDg3YzdfMTgtMTEtMS0xLTA_638e9dec-afa3-4cfa-a2f9-c9ea525bdfa7"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMy0xLTEtMS0w_a184b3e5-01d1-43f0-95eb-1339ad433889"
      unitRef="usd">-444440000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMy0zLTEtMS0w_282fdec6-6b07-40eb-baff-df3caf426a67"
      unitRef="usd">-440667000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMy01LTEtMS0w_209bb6c9-9bcb-4fcb-b88b-ba1263658073"
      unitRef="usd">681313000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNS0xLTEtMS0w_120279fb-bf43-451f-8803-dd81f6e99840"
      unitRef="usd">48563000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNS0zLTEtMS0w_cb00c22b-5796-465c-9ada-4c587d96d28b"
      unitRef="usd">36303000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNS01LTEtMS0w_625f99d9-85be-4fa4-9e98-ad1b6722efcb"
      unitRef="usd">33308000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNi0xLTEtMS0w_3f32c358-0898-47b0-93bd-78f89452379f"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNi0zLTEtMS0w_53c3be9d-7991-4f1d-8410-89f7ee323035"
      unitRef="usd">25044000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNi01LTEtMS0w_5a100814-5038-424d-a03d-562d4f943500"
      unitRef="usd">21196000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNy0xLTEtMS0w_4604e32b-504a-42a5-acc6-42c2d45e9eb5"
      unitRef="usd">94261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNy0zLTEtMS0w_ab3b0c56-850d-4d0b-9310-77e7c19bd614"
      unitRef="usd">99795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNy01LTEtMS0w_e9331863-2eed-4b53-b091-f045156671e2"
      unitRef="usd">88101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOC0xLTEtMS0w_8d56ba27-5447-4692-823b-5041854bb74a"
      unitRef="usd">14182000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOC0zLTEtMS0w_a1b16323-ac96-4e45-9278-67ef47f9f4ba"
      unitRef="usd">13156000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOC01LTEtMS0w_e55816e1-52ea-411e-9f41-c6b3f9138c98"
      unitRef="usd">10870000</us-gaap:DepreciationAndAmortization>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOS0xLTEtMS0w_e6bc96a9-6f2f-453c-bc2a-4435a23edee5"
      unitRef="usd">20351000</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOS0zLTEtMS0w_a9861ceb-59ea-4fb5-b2a1-fa6063dd2fd3"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfOS01LTEtMS0w_fb905dd2-1b08-4c7d-8594-032f06eefe81"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:AccretionOfDiscountNetAndOtherNonCashTransactions
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTAtMS0xLTEtMA_560cd2a4-f2c8-4db8-9927-a6b9d4dd563f"
      unitRef="usd">-3943000</nktr:AccretionOfDiscountNetAndOtherNonCashTransactions>
    <nktr:AccretionOfDiscountNetAndOtherNonCashTransactions
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTAtMy0xLTEtMA_c15c2515-2237-431f-a363-b7e4cd98afff"
      unitRef="usd">11394000</nktr:AccretionOfDiscountNetAndOtherNonCashTransactions>
    <nktr:AccretionOfDiscountNetAndOtherNonCashTransactions
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTAtNS0xLTEtMA_249c8f31-fa83-4a4e-bb38-170b254a10d3"
      unitRef="usd">10952000</nktr:AccretionOfDiscountNetAndOtherNonCashTransactions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTItMS0xLTEtMA_9983b64f-7f0c-4151-ba10-32db55b3961e"
      unitRef="usd">-1913000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTItMy0xLTEtMA_8008062e-5f8e-4af5-9a24-5fdad3e5cfd9"
      unitRef="usd">-6411000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTItNS0xLTEtMA_0c576f3e-a618-49bd-802e-88e6e1c3c338"
      unitRef="usd">25505000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTMtMS0xLTEtMA_219bb885-4a42-46e7-8f7f-b78d4268ab66"
      unitRef="usd">2627000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTMtMy0xLTEtMA_885d1d5f-00ba-400e-9f00-21cbb7c309b4"
      unitRef="usd">1284000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTMtNS0xLTEtMA_70fb8b15-80e5-4b6e-a2a9-82dec2c8d523"
      unitRef="usd">655000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTQtMS0xLTEtMA_d88ed7e6-1e51-4611-8c27-39a49e4ee5d6"
      unitRef="usd">-2743000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTQtMy0xLTEtMA_fc05be8a-d043-461f-82b1-25c2ac158820"
      unitRef="usd">-13090000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTQtNS0xLTEtMA_fa00380d-6801-4079-b251-f136fd818372"
      unitRef="usd">0</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTUtMS0xLTEtMA_251cb2a4-6eb4-4853-9417-bfe30a836c71"
      unitRef="usd">-4476000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTUtMy0xLTEtMA_e0a4c925-227a-4d8d-8e82-c1aa7e1752b8"
      unitRef="usd">-1190000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTUtNS0xLTEtMA_a518b2c9-92d6-44ba-8f1e-6c116d8fb521"
      unitRef="usd">31652000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTYtMS0xLTEtMA_4c83e851-c568-4b73-b956-0e5fccf7ec86"
      unitRef="usd">2382000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTYtMy0xLTEtMA_40f3df40-b408-4858-a4c7-fb56e612004e"
      unitRef="usd">12967000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTYtNS0xLTEtMA_5f6f670f-10ba-4fcc-9625-d3e544f3dce9"
      unitRef="usd">971000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTctMS0xLTEtMA_a8caaf2c-aaa2-4062-ad8f-43e35d748adf"
      unitRef="usd">4697000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTctMy0xLTEtMA_30fca78f-800f-4854-83f2-0d88b19b026c"
      unitRef="usd">1530000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTctNS0xLTEtMA_dde6c9b8-bd6c-40d4-a627-bafcc5f25409"
      unitRef="usd">1674000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTgtMS0xLTEtMA_047ae9d6-774c-472a-ab48-414ee56aef92"
      unitRef="usd">8644000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTgtMy0xLTEtMA_4edeb78a-b430-45fd-8063-0f9debde0d10"
      unitRef="usd">4349000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTgtNS0xLTEtMA_c1eb033e-8f9c-41ab-bae2-fd027e07c333"
      unitRef="usd">31492000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTktMS0xLTEtMA_f3e6dcda-fcb8-4799-a9ad-42fa830a18d2"
      unitRef="usd">-5516000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTktMy0xLTEtMA_8b4dda81-9a57-4dec-b326-4bf6ba41bbfe"
      unitRef="usd">-16565000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMTktNS0xLTEtMA_a98dfab1-f704-4257-a1f2-cd0e6596d198"
      unitRef="usd">-15331000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjEtMS0xLTEtMA_8419557f-ec09-4bfb-ae95-99ee91615dcd"
      unitRef="usd">-313287000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjEtMy0xLTEtMA_8b912c81-79d0-4ed0-9b74-aa69887b628d"
      unitRef="usd">-328681000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjEtNS0xLTEtMA_06b2e05d-fc5d-4636-8cf2-9b1bfad28d22"
      unitRef="usd">718214000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjMtMS0xLTEtMA_65e9af4e-1119-4a42-8b2a-d9a4522929e1"
      unitRef="usd">987533000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjMtMy0xLTEtMA_683fd3fa-522a-4b26-bcc4-1d89e19fdb11"
      unitRef="usd">1380865000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjMtNS0xLTEtMA_b90c73fe-e036-420a-9c7d-c069a78d2cd2"
      unitRef="usd">2271250000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjQtMS0xLTEtMA_be66b78c-7baf-477b-9e9b-ff393bcc2805"
      unitRef="usd">1449304000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjQtMy0xLTEtMA_018fa348-f763-4937-b078-bb4a6b69d7ab"
      unitRef="usd">1614036000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjQtNS0xLTEtMA_b7c9da85-6d51-41e4-94e1-e647ebe8a082"
      unitRef="usd">890957000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjUtMS0xLTEtMA_e2e64a73-04a2-4e51-a6ec-122c56913c3a"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjUtMy0xLTEtMA_69c95558-0331-4e20-9436-5fa6559968f8"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjUtNS0xLTEtMA_575569d2-332f-4e00-88e6-84a50f30205c"
      unitRef="usd">11963000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjYtMS0xLTEtMA_e79b8dfe-8f69-45d1-82b0-1bbc345c86fd"
      unitRef="usd">7258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjYtMy0xLTEtMA_d5feff35-8f13-45d0-b7d6-4baa01c4e173"
      unitRef="usd">26285000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjYtNS0xLTEtMA_7deb0c4e-6eb0-43ce-bed4-7821e536f70d"
      unitRef="usd">14239000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjctMS0xLTEtMA_e14ac6e2-78cb-49d1-aae6-554fea3be3ab"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjctMy0xLTEtMA_9adba66c-c2d9-498b-a5e8-b72ca51f6594"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjctNS0xLTEtMA_9f6bf3fb-31ae-41c0-bd23-cd28aa86af3e"
      unitRef="usd">2633000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjgtMS0xLTEtMA_9a63f5a2-79ce-43d4-b4c5-fe5dadfd0841"
      unitRef="usd">496213000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjgtMy0xLTEtMA_3df35997-103a-4633-aa07-948e8392db92"
      unitRef="usd">206886000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMjgtNS0xLTEtMA_a2216c44-cdd5-4629-ac45-50bb9b04d308"
      unitRef="usd">-1379936000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMS0xLTEtMA_eb19a890-a311-4051-bdbe-f16452e861ce"
      unitRef="usd">0</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMy0xLTEtMA_5a567f6c-ff99-4ea4-89b3-daf3a8ca333d"
      unitRef="usd">0</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtNS0xLTEtMA_8e6a3877-070b-465d-ab4f-7a8933f261f3"
      unitRef="usd">790231000</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <nktr:SaleOfFutureRoyaltiesTransactionCosts
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMC0xLTEtNDUwMS90ZXh0cmVnaW9uOjgwODk1NTc2OWU4NjQ0YzdhOTcxMGJiMTg3YjQzM2RlXzgyNDYzMzcyMDg0MTY_12cf3769-98b1-4cb1-80f7-e2ff186a78e3"
      unitRef="usd">3800000</nktr:SaleOfFutureRoyaltiesTransactionCosts>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMS0xLTEtNDUwMQ_228ec89b-f350-476b-988a-e0a0df9097dd"
      unitRef="usd">146250000</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtMy0xLTEtNDUwMQ_badd44e4-92b6-4354-9e0a-fdf0c75ab6df"
      unitRef="usd">0</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzAtNS0xLTEtNDUwMQ_50e86561-b5f9-4adb-90f0-b27f6e057754"
      unitRef="usd">0</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMS0xLTEtMzM4_7b38b480-ba9d-429e-8d2b-d168bb8f6ef4"
      unitRef="usd">250000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMy0xLTEtMzM4_966c064c-5aa6-49ad-a006-b02c8132f9ac"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtNS0xLTEtMzM4_50bd4ac6-8d50-4335-91e0-5bc708581e34"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMS0xLTEtMA_7daa7058-ebbe-4b04-a758-3b846b102583"
      unitRef="usd">23396000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtMy0xLTEtMA_8b47d72b-e3df-491e-a074-a191b77ac118"
      unitRef="usd">23355000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzEtNS0xLTEtMA_63ae6409-86ba-4364-af8c-0b48ee84a525"
      unitRef="usd">61735000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzMtMS0xLTEtMA_01a94595-ebe8-45c9-b0b5-912521ec5d94"
      unitRef="usd">-80354000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzMtMy0xLTEtMA_2aebb77d-30ad-46b2-8fe0-f66ea45ca307"
      unitRef="usd">23355000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzMtNS0xLTEtMA_f4e7e79f-bd4c-45d5-b43d-fc497fd7c8c4"
      unitRef="usd">851966000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzQtMS0xLTEtMA_047adce0-55c1-4be8-9a18-d806126d98d2"
      unitRef="usd">20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzQtMy0xLTEtMA_63c37093-a179-4500-8007-7bba0eb78899"
      unitRef="usd">-102000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzQtNS0xLTEtMA_6ffcfd11-7102-46e9-aa71-b6df7552b00f"
      unitRef="usd">-101000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzUtMS0xLTEtMA_3af9c2b1-f2d4-4e8f-b4b4-9cad747be8d8"
      unitRef="usd">102592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzUtMy0xLTEtMA_23299403-688a-4637-8a92-f78e2634d052"
      unitRef="usd">-98542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzUtNS0xLTEtMA_655056f0-78fb-4d1c-a983-f9ef0c719fbc"
      unitRef="usd">190143000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzYtMS0xLTEtMA_f4f5a839-61a5-4f7d-ae57-caaffb7c2d80"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzYtMy0xLTEtMA_b955be56-253d-4580-a4ea-6bfd85d08da5"
      unitRef="usd">194905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzYtNS0xLTEtMA_4f0866b5-7c3c-4c5a-a705-b1e77233a48c"
      unitRef="usd">4762000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzctMS0xLTEtMA_7a195d1a-1a90-4846-91f5-ffd510e82dfb"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzctMy0xLTEtMA_59870364-b04c-4230-bca4-099c5896b844"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzctNS0xLTEtMA_ca143f2b-0962-4715-9ceb-e9158064fcc6"
      unitRef="usd">194905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzktMS0xLTEtMA_52c881c4-f5d3-46af-ad84-39383b3c70ec"
      unitRef="usd">9742000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzktMy0xLTEtMA_7be33a3b-5561-44fe-b908-3320e6031fde"
      unitRef="usd">19199000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfMzktNS0xLTEtMA_11c9dd45-a53b-40f1-99f8-00c4974d12db"
      unitRef="usd">19471000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDAtMS0xLTEtMA_ace380f0-0999-4a1b-bb44-a362f93ba412"
      unitRef="usd">539000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDAtMy0xLTEtMA_201fb4b1-55e0-4b1a-8a2e-9b53e6eae09c"
      unitRef="usd">555000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDAtNS0xLTEtMA_c0486bb9-0667-431e-b75b-80847d9f9482"
      unitRef="usd">618000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDEtMS0xLTEtMA_53a66b49-3b0e-4048-98c3-811f16e2d0c4"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDEtMy0xLTEtMA_4aef8cc6-d83c-46a9-a809-a022886b62e8"
      unitRef="usd">57691000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF84NS9mcmFnOjFhZDYxNzUwYzkxOTRjMDVhMzY4Mjk4NzY0ZGJkODRjL3RhYmxlOjRkZmE2ZmJkYmVmMDRhMzU4ZmJmMTBlODhkZmE4OThhL3RhYmxlcmFuZ2U6NGRmYTZmYmRiZWYwNGEzNThmYmYxMGU4OGRmYTg5OGFfNDEtNS0xLTEtMA_5412c323-a9bd-42c2-8ae6-bcd29e88a026"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjg_1c7c074e-147e-4905-8210-256fb368798f">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&#160;31, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8&#160;million. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation, Principles of Consolidation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#x2019; equity as accumulated other comprehensive income loss. We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our cash, cash equivalents, short-term investments and long-term investments are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents, short-term investments and long-term investments are held or issued by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Significant Customer Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. For the year ended December&#160;31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $0.2 million under customer contracts from our collaboration partners. For the year ended December&#160;31, 2019, our accounts receivable included $24.0 million for unbilled net expense reimbursements from BMS and $12.8 million from customer contracts, which included our estimate of $11.6&#160;million for royalties resulting from net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the three months ended December 31, 2019. Since we sold our rights to receive royalties in the 2020 Purchase and Sale Agreement with Healthcare Royalty Management, LLC, as discussed further in Note 7, we did not record accounts receivable for these royalties at &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020. We generally do not require collateral from our partners. We perform a regular review of our partners&#x2019; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable. At December&#160;31, 2019, three different partners represented 65%, 17% and 14%, respectively, of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Significant Supplier Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 842). ASC 842 supersedes the guidance in ASC 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the year ended December 31, 2020 and 2019 under ASC 842. We have not restated the results for the year ended December 31, 2018 continue to report them under ASC 840.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 6 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57"&gt;three&lt;/span&gt; to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program after March 31, 2020. As of December&#160;31, 2020, we have substantially completed our wind-down and do not expect to incur additional costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs) and performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs and PSUs on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options and RSUs that vest upon the achievement of performance milestones, we estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. We recognize stock-based compensation expense for purchases under the ESPP over the respective six-month purchase period. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under the ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#x2019; stock to the index. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The fair value of an RSU is equal to the closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management will continue to assess the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and which could materially impact our fair value determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net income (loss) available to common stockholders is equal to the reported net income (loss). We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities, which consist of common shares underlying stock options and RSUs. For the years ended December 31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options and RSUs totaling 17.4 million and 17.9 million for the years ended December 31, 2020 and 2019, respectively. For the year ended December 31, 2018, the effect of these dilutive securities under the treasury stock method was approximately 10.5 million, and we excluded approximately 3.3 million of weighted-average shares of common stock underlying outstanding stock options from the computation of diluted net income per share because&#160;their effect was antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive income (loss) is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our other comprehensive income (loss) includes net income (loss), gains and losses from the foreign currency translation of the assets and liabilities of our India and UK subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Aid, Relief, and Economic Security (CARES) Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act has not had a material effect on our results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed other recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNTk_90cc5fcf-f5c7-448e-8761-97245c161dfb">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTE3MA_d072b439-14cf-4dd1-ace7-d102ce8efaa3"
      unitRef="usd">1200000000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:RepaymentsOfLongTermDebtIncludingInterest
      contextRef="i717a3b33fb444b809d0adef0ac06725b_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzI5NTM0NA_3dfeb846-5b7d-4d17-bfdf-a88b3f45aaf8"
      unitRef="usd">254800000</nktr:RepaymentsOfLongTermDebtIncludingInterest>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjk_b09053aa-631b-437d-82c7-d6ffb6651456">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation, Principles of Consolidation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxNjAyMQ_f766d9f6-de0d-48f2-86c6-6a415bd19309">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMDk4MQ_90f6d51c-b795-49dc-ac60-e1c8f5d91925">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNTM_6c3f9f4e-b6d0-44b0-8020-3550922104eb">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#x2019; equity as accumulated other comprehensive income loss. We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our cash, cash equivalents, short-term investments and long-term investments are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents, short-term investments and long-term investments are held or issued by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjc_de127bf1-35f5-4448-a3c2-ffe479f597f6">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Significant Customer Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. For the year ended December&#160;31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $0.2 million under customer contracts from our collaboration partners. For the year ended December&#160;31, 2019, our accounts receivable included $24.0 million for unbilled net expense reimbursements from BMS and $12.8 million from customer contracts, which included our estimate of $11.6&#160;million for royalties resulting from net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the three months ended December 31, 2019. Since we sold our rights to receive royalties in the 2020 Purchase and Sale Agreement with Healthcare Royalty Management, LLC, as discussed further in Note 7, we did not record accounts receivable for these royalties at &lt;/span&gt;&lt;/div&gt;December 31, 2020. We generally do not require collateral from our partners. We perform a regular review of our partners&#x2019; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable. At December&#160;31, 2019, three different partners represented 65%, 17% and 14%, respectively, of our accounts receivable.</nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock>
    <nktr:NetExpenseReimbursementsFromCollaborationPartner
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTE1NDQ4NzIxOTEyOTc_5711438d-4d7c-448a-882b-44ed0c5777a3"
      unitRef="usd">38700000</nktr:NetExpenseReimbursementsFromCollaborationPartner>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzA0Mw_9dcb03bf-52a7-4fff-b7a1-440f87594003"
      unitRef="usd">200000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <nktr:NetExpenseReimbursementsFromCollaborationPartner
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTE1NDQ4NzIxOTE0NjY_e9368cab-4ac0-43f5-abe9-e17e4b7bae85"
      unitRef="usd">24000000.0</nktr:NetExpenseReimbursementsFromCollaborationPartner>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzI3Mw_53082289-38fc-490b-af19-0885c6ad63fe"
      unitRef="usd">12800000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <nktr:ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMzM4MQ_38594ced-2c37-4c2f-8c12-7f30e1c78bb6"
      unitRef="usd">11600000</nktr:ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i09546958c5654aba9b0e1a853838b859_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzg5MA_11d8b589-79ae-4de1-a350-50c77e3e0c0e"
      unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4f416a959f974cfba77544c098dfe27a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzg5NA_bab52b45-31d8-4a8c-bb0d-37dfbf449e16"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i24f5461407a5437d9bfeb28b339c42e0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfNzkwMQ_2fb62a82-3d3b-481b-ab78-ec2cc0a6ada5"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzk_b02a9e3b-00a2-4682-b50a-b8c0996326a0">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Significant Supplier Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjI_33ee8566-775d-47d6-ac78-c6750c95a3de">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 842). ASC 842 supersedes the guidance in ASC 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the year ended December 31, 2020 and 2019 under ASC 842. We have not restated the results for the year ended December 31, 2018 continue to report them under ASC 840.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 6 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzY_f45538f1-ae11-466c-a223-3cebb26251ff">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57"&gt;three&lt;/span&gt; to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1c77957329da4893900ec8abef0354d0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NzA_8bbab59b-4ab2-4932-ac49-226635510bcf">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i699fa2275d694e3ead84ac6a1b9d588a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTMwMzk_2146f125-f565-46b6-9147-19769c31ddf0">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTMzNTI_4f513f5e-0342-4960-9817-6b56f8e44da6"
      unitRef="reporting_unit">1</nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNDc_f91fd26c-fd7e-4e9b-8b93-177d92c23c00">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzA_abcb1748-6278-4644-aabc-d508f0d103f6">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <nktr:ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzE_c83074ef-0980-4293-aadd-24bb49b9222e">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;</nktr:ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjU_14f097cc-8e45-44a6-9a44-f7eee00ef353">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMDk3OA_4b7bae1b-2fc1-4b40-84f1-113c093500ae">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program after March 31, 2020. As of December&#160;31, 2020, we have substantially completed our wind-down and do not expect to incur additional costs.&lt;/span&gt;&lt;/div&gt;</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock>
    <nktr:WriteOffOfPrepayment
      contextRef="i34700219468e42b4b7930f9dbb4d6186_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzI5NTM2MA_5bc6fa83-dcd8-4f22-ac17-2287641af810"
      unitRef="usd">19700000</nktr:WriteOffOfPrepayment>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i34700219468e42b4b7930f9dbb4d6186_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzI5NTM3NQ_f9c236ae-36e2-4570-a610-ff2c8e92b4b3"
      unitRef="usd">25500000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzg_8ff05916-fb94-48f7-9a59-cfd2db0efac7">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs) and performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs and PSUs on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options and RSUs that vest upon the achievement of performance milestones, we estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. We recognize stock-based compensation expense for purchases under the ESPP over the respective six-month purchase period. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under the ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#x2019; stock to the index. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The fair value of an RSU is equal to the closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management will continue to assess the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and which could materially impact our fair value determination.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNjY_26c2fae5-8221-46af-9593-9b542f95991d">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net income (loss) available to common stockholders is equal to the reported net income (loss). We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities, which consist of common shares underlying stock options and RSUs. For the years ended December 31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options and RSUs totaling 17.4 million and 17.9 million for the years ended December 31, 2020 and 2019, respectively. For the year ended December 31, 2018, the effect of these dilutive securities under the treasury stock method was approximately 10.5 million, and we excluded approximately 3.3 million of weighted-average shares of common stock underlying outstanding stock options from the computation of diluted net income per share because&#160;their effect was antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2258862b93e9480c951e464dfe2bbbe0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMjk4Njg_c51cb99d-9dde-4277-8723-93c83d72040d"
      unitRef="shares">17400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9db7646976b34d70acfa2081ee826ee4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMjk4NzU_9bd29010-ae93-4efb-9599-68e1f8e0f9d8"
      unitRef="shares">17900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzAwMDk_3134a31d-972a-4d07-96c2-20054e0c090b"
      unitRef="shares">10500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic21605fedf17490fa0886eae32da3156_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzAwNDM_0249eea3-c8eb-42f3-9391-fd5db48764f7"
      unitRef="shares">3300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzI_3bfa0c99-1a95-48f1-a6b5-10643534f070">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNzM_49f21b6c-200a-445a-ac40-d54d548ac3d3">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive income (loss) is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our other comprehensive income (loss) includes net income (loss), gains and losses from the foreign currency translation of the assets and liabilities of our India and UK subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <nktr:CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfODI0NjMzNzMxMDk4MA_5b014f51-79bb-4da2-a43d-6276c0961455">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Aid, Relief, and Economic Security (CARES) Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act has not had a material effect on our results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</nktr:CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMzYxNTg_68b39cdd-4113-45bd-b925-246bdc457323">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed other recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjMyNw_c8ef8224-0947-4c35-b7bf-8d1dfe832073">Cash and Investments in Marketable Securities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2020 and 2019 had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_65dac629-914e-42fe-8970-b4d9eec444dc"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_d24a00d0-9f20-48ec-989c-a46dae10d5c7"&gt;one&lt;/span&gt;&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2020 and 2018, we sold available-for-sale securities totaling $41.7&#160;million and $12.0&#160;million, respectively. Gross realized gains and losses on those sales were not significant. During the year ended December&#160;31, 2019, we did not sell any of our available-for-sale securities. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report our accrued interest receivable, which totaled $5.1&#160;million and $6.5&#160;million at December&#160;31, 2020 and December&#160;31, 2019, respectively, in other current assets on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. For the years ended December&#160;31, 2020 and 2019, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;At December 31, 2019, our gross unrealized gains and losses totaled $2.1&#160;million and $0.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $8.1 million and $6.8 million, respectively. These letters of credit are secured by investments of similar amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjMyOQ_68d66de9-cb78-425a-8a6f-227136025bad">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMi0xLTEtMS0w_589ca5bc-00ba-4dee-8de8-b259a35bf57e"
      unitRef="usd">198955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMi0zLTEtMS0w_ea13435d-2378-4bb8-b914-45bfa090a760"
      unitRef="usd">96363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMy0xLTEtMS0w_e8cdf546-18eb-46c2-b5b7-164463428908"
      unitRef="usd">862941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfMy0zLTEtMS0w_29d2a6d5-2853-40a1-81c3-15c182c314e0"
      unitRef="usd">1228499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNC0xLTEtMS0w_d0bb43fe-a654-4a30-8c23-3ac93076a260"
      unitRef="usd">136662000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNC0zLTEtMS0w_5a8c719f-e991-40fd-8a01-72523f527156"
      unitRef="usd">279119000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNS0xLTEtMS0w_28eabc58-a96f-4f9c-bb3f-ec1a6ceac6a2"
      unitRef="usd">1198558000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmMxOWYzMWY5MGJlMDQ2OGRiNTk3YWUwZjlhYmQzYzE1L3RhYmxlcmFuZ2U6YzE5ZjMxZjkwYmUwNDY4ZGI1OTdhZTBmOWFiZDNjMTVfNS0zLTEtMS0w_276683ef-8a31-4317-a8ce-f55975c5c42c"
      unitRef="usd">1603981000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i83c2e96ec4df4105ae39e0cc524fc251_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTYx_7325fc6d-c1e9-406e-9092-db9dfcf67a8f">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="idf6d1cf2ec944050a87027e7a515ee06_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTYx_e113bfb5-61f8-467c-84c9-fcd73a6c2ae6">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjIzMA_4fcc1f36-90ae-4531-aa4d-fbd7677b29be"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjUwMg_09adebad-4d99-4b1a-82a2-c2f42422290e"
      unitRef="usd">12000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjI4Nw_bb6c84d2-1383-4169-bbb0-4b09baff15cd"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:InterestReceivableCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjI2MA_c1201c3c-b1d5-49e0-a2cf-f1abeecf12d8"
      unitRef="usd">5100000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMjI3NA_c049e09a-2ec0-441d-9158-0cfca341db7e"
      unitRef="usd">6500000</us-gaap:InterestReceivableCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjMzMQ_917ec0d6-8100-44a6-97bf-d45614653db8">Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi0zLTEtMS0w_47070174-e62e-42d7-9cc6-77cc3f04515e"
      unitRef="usd">686543000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi01LTEtMS0w_a5c9e714-6e60-4f4d-9203-00536c647816"
      unitRef="usd">1035000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi03LTEtMS01MTU_e8fc9eeb-a2d4-4699-bc8d-470da5707f39"
      unitRef="usd">109000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1e26256948a488cb8e3fcf49df9474a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi05LTEtMS01MTU_eb0015c2-362b-4995-a589-8095ef1f3f9d"
      unitRef="usd">687469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8e58a6675bb4673ad4c4d985c0ad671_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMi0xMS0xLTEtNTE1_1e1ff30a-c34a-423c-b8f1-308c1e4a0144"
      unitRef="usd">1132182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy0zLTEtMS0w_a5aa6601-3cf5-46b8-bc5b-114afb9914d5"
      unitRef="usd">313520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy01LTEtMS0w_2e2be465-9a99-48f0-8895-7b99d179554d"
      unitRef="usd">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy03LTEtMS01MTU_945320aa-114b-4557-97b4-8993b310c18e"
      unitRef="usd">67000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9809b46a63494218a0bf6b5f8fc63571_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy05LTEtMS01MTU_d9444916-eb4f-4d27-8bd7-16db7902ed0c"
      unitRef="usd">313497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2df0af8bd514d598273623513f12d91_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfMy0xMS0xLTEtNTE1_4bb47f83-8837-4d07-ab96-f2602310c26d"
      unitRef="usd">375473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC0zLTEtMS0w_9de2b2bf-d889-4d7c-a62c-d162b5225786"
      unitRef="usd">2380000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC01LTEtMS0w_c559f50e-8d98-4330-be92-cedec8ffb21c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC03LTEtMS01MTU_7f14b9f7-96da-4d94-97ec-bf5625516c3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f9c3756efac45638b8661f85a56b87b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC05LTEtMS01MTU_fbcfccde-7317-489b-8e9f-cbf968dc4b93"
      unitRef="usd">2382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb3ed71369cd465faecd143e23ac8cf7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNC0xMS0xLTEtNTE1_d3d27627-9b1f-4857-bcbc-5609c4c64b13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS0zLTEtMS0w_86c4abff-ae56-489d-a16e-246bee341379"
      unitRef="usd">1002443000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS01LTEtMS0w_8b700072-9b95-4d58-a9bf-b624979fbee0"
      unitRef="usd">1081000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS03LTEtMS01MTU_10694e12-b058-4d1a-94fd-f67d0e5e9b11"
      unitRef="usd">176000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib24ec10a1be04ea2bbbcb174f9d49a01_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS05LTEtMS01MTU_8352ca60-bddc-4645-ab78-a322cd81ef37"
      unitRef="usd">1003348000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e0a7100bd064c2c83c71589ae758e3f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNS0xMS0xLTEtNTE1_40032a87-5af1-4638-983b-3aa05f246863"
      unitRef="usd">1507655000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9da7225c246f45e7a9949c2da1d6f10b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNi05LTEtMS01MTU_7c0174c7-8ba3-400c-b9d0-31b6b9fce2d1"
      unitRef="usd">179302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i23df56833c5f4df59292bc311c03aad8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNi0xMS0xLTEtNTE1_fe54e3f0-0f78-4686-a594-e89db7c2c912"
      unitRef="usd">83546000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic26b559e13a246219de39b20472737fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNy05LTEtMS01MTU_14549654-2dbb-4034-911f-58acac3de3d8"
      unitRef="usd">9623000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2266b3ff82324cb9b553040cded08f91_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfNy0xMS0xLTEtNTE1_eb932a10-9ea4-4663-9565-c99f70b207b0"
      unitRef="usd">6951000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOC05LTEtMS01MTU_e72838e5-3e4b-42b7-894c-f38843a3f21a"
      unitRef="usd">6285000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOC0xMS0xLTEtNTE1_f9bef0dc-6cb7-4ab8-b623-30f0a1865ad3"
      unitRef="usd">5829000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOS05LTEtMS01MTU_b298e2dc-1551-4b36-84de-bde3ae1c9eb7"
      unitRef="usd">1198558000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RhYmxlOmNlNzdhMzIwZGRiYjQyNDliNzM1ZTg4NTA4NDdiYmE5L3RhYmxlcmFuZ2U6Y2U3N2EzMjBkZGJiNDI0OWI3MzVlODg1MDg0N2JiYTlfOS0xMS0xLTEtNTE1_24039161-1fcc-49cc-8553-04a81b5ec413"
      unitRef="usd">1603981000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_32e53419-02f4-40b8-a95e-3e658c04618c"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_3661c337-f714-417b-9939-f29168fdb71a"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_8311ab9d-9b41-49f3-9838-eff0bea724bf"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMDY1Mw_9dd0cb1f-e9ba-49a4-85c5-fd8af7850f31"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMzcwMQ_aa6dffc0-7627-4ef7-9134-2bdfcaf5ab24"
      unitRef="usd">2100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfODI0NjMzNzIxMzcxNQ_8b7f6206-407a-4c44-a154-63fe7464f78b"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjIzMw_eb65286b-7476-48dc-b3a3-38d59e69c4fb"
      unitRef="usd">8100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfMjI0MA_70e25b20-5a91-4ee2-947c-1edd7b42a340"
      unitRef="usd">6800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90ZXh0cmVnaW9uOjhiOGRjMTYyN2FlNjQ1NmU4ZmZlMGM3YzhhMzNlN2QyXzc5_fc6fb53d-1066-4a6a-8232-bae48da8e136">Inventory&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90ZXh0cmVnaW9uOjhiOGRjMTYyN2FlNjQ1NmU4ZmZlMGM3YzhhMzNlN2QyXzgx_54e9ad26-2880-4387-b63d-d8ac26406a68">Inventory consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzItMS0xLTEtMA_0fc3764a-ccd5-4cad-9fdf-b435868db890"
      unitRef="usd">2422000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzItMy0xLTEtMA_f732a794-3c2f-482e-9b63-27d4b5c853c0"
      unitRef="usd">1673000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzMtMS0xLTEtMA_e39d4d38-fcaa-4a0f-8293-9544c2a03757"
      unitRef="usd">10703000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzMtMy0xLTEtMA_a21b418e-bc1e-43d4-a422-7834cec26f83"
      unitRef="usd">8267000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzQtMS0xLTEtMA_208c8f43-d22f-4a2d-81ec-7ebf82dbc77a"
      unitRef="usd">2167000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzQtMy0xLTEtMA_557e2bca-2f17-4985-a404-789830b6eedb"
      unitRef="usd">2725000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzUtMS0xLTEtMA_3e8fb18c-9703-4e1e-a12f-3f98b6322b91"
      unitRef="usd">15292000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDMvZnJhZzo4YjhkYzE2MjdhZTY0NTZlOGZmZTBjN2M4YTMzZTdkMi90YWJsZTplMGNhNDU4YjkzM2E0ODIzODkwNWE5YjgzMTkxZmEzNy90YWJsZXJhbmdlOmUwY2E0NThiOTMzYTQ4MjM4OTA1YTliODMxOTFmYTM3XzUtMy0xLTEtMA_e56c3d39-a2db-4374-9fb8-61290dc6f6ee"
      unitRef="usd">12665000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzE3NzY_08696020-30c9-47e1-a536-65b90e329673">Property, Plant and Equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Property, plant and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Depreciation and amortization expense on property, plant and equipment for the years ended December&#160;31, 2020, 2019, and 2018 was $12.5 million, $11.0 million, and $8.8 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzE3Nzg_f087f6cf-6a41-4b45-8853-b209ccd14cf2">Property, plant and equipment consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i45127b4769de4be5b7b965f5763fbc1e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzItMS0xLTEtMA_76a82c60-e47f-4426-8b18-a4cd4dcf3df6"
      unitRef="usd">92977000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i689fee9ace2e4522b887678cba220fa6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzItMy0xLTEtMA_6a4d05dd-f4b8-4cb6-a469-d700b17a4534"
      unitRef="usd">93097000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i3a80ca3f7680478d982f63ab514437f4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzMtMS0xLTEtMA_3020c259-81dd-4378-ae8b-35af69ec5c95"
      unitRef="usd">40121000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i84cbf02176864c678db5f9dfbd89d813_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzMtMy0xLTEtMA_944a5d3f-fb8d-4321-b9e4-c7b3aae58249"
      unitRef="usd">36623000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i3c28da8080c84fcd807f2604a6cc1e1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzQtMS0xLTEtMA_59a02cbb-0982-4555-8bfb-ac37fe2bdf77"
      unitRef="usd">28684000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="if9ddd0c57faa4c2dbab65ca8fd54a4f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzQtMy0xLTEtMA_fe08d2b9-1b6f-4139-a8fb-4b133835ea50"
      unitRef="usd">26910000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i678825b8367a45639e3d62d20e1b8682_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzUtMS0xLTEtMA_ae600e97-f751-4447-ab1c-0a55268217e1"
      unitRef="usd">21796000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i7dbdad1aa0874eb8a53d8398977fd31d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzUtMy0xLTEtMA_8d97c63a-941c-4e0e-bd32-084a7788d89e"
      unitRef="usd">22030000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ie39c346907c8444d9f56f268dff89776_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzYtMS0xLTEtMA_1603d8ea-b35c-466d-a302-5e7f42bb5d04"
      unitRef="usd">9872000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="if876fe666ac74deaa248054e2378e704_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzYtMy0xLTEtMA_3236ff7f-e208-4464-a213-76e64b79e62b"
      unitRef="usd">9662000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzctMS0xLTEtMA_78b8b676-a329-473b-ba71-ae4da8fa41e9"
      unitRef="usd">193450000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzctMy0xLTEtMA_cc8040a2-9815-48c0-9f6a-da02df703bda"
      unitRef="usd">188322000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzgtMS0xLTEtMA_00cd9613-7fa5-469f-be98-04e0a801f4f7"
      unitRef="usd">138488000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzgtMy0xLTEtMA_74f3a6d8-a990-4fca-807d-028f16654bc9"
      unitRef="usd">127875000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzktMS0xLTEtMA_9f01d7fe-dc35-4d68-a0d7-c12e5f97fdb1"
      unitRef="usd">54962000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzktMy0xLTEtMA_53f75787-0f21-46d9-9749-53eaaaf4efcc"
      unitRef="usd">60447000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <us-gaap:ConstructionInProgressGross
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzEwLTEtMS0xLTA_a5a5d820-f136-49b1-9337-f0cfb6457c8a"
      unitRef="usd">4700000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzEwLTMtMS0xLTA_3c0faa8e-b02f-4884-8914-bf435f1bc632"
      unitRef="usd">5218000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzExLTEtMS0xLTA_b3761bec-a381-4896-a4d3-f20ed28dc5e3"
      unitRef="usd">59662000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90YWJsZTo4MDMyODcxNjk4NzU0NGM0YjRjMzUyNTgyYTVlNDhmZS90YWJsZXJhbmdlOjgwMzI4NzE2OTg3NTQ0YzRiNGMzNTI1ODJhNWU0OGZlXzExLTMtMS0xLTA_41f4ed09-407f-4b13-b1f9-1bd250b45b18"
      unitRef="usd">65665000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzg2MA_fc01f1c2-0901-4b55-91ff-c8d21804f10a"
      unitRef="usd">12500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzg2NA_632f5146-e13c-4dc4-aeb1-5ccebaa4d5bb"
      unitRef="usd">11000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDYvZnJhZzoyYjdjNTM2NjlmNzU0MjhmOWViMTBjMTliZTZkYjFmZC90ZXh0cmVnaW9uOjJiN2M1MzY2OWY3NTQyOGY5ZWIxMGMxOWJlNmRiMWZkXzg3Mg_0b231b5c-e0a5-4659-bfa7-14733caf3581"
      unitRef="usd">8800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzI1MzI_6d13482f-1c6e-42b5-960a-a0827c190c92">Senior Secured Notes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would have been due and payable. In connection with the issuance of the Notes, we paid fees and expenses of $8.9&#160;million, of which $8.7&#160;million of transaction and facility fees paid directly to the purchasers of the Notes and other direct issuance costs were recorded as a discount to the senior secured notes, net liability balance in our Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:SeniorNotes
      contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxMzY_ff4d7d7e-957c-48d6-aca9-9b0a78cc34bf"
      unitRef="usd">250000000.0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxNTI_c35a93b4-e50c-4f00-8ec0-bc5b63a1d08e"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxNTk_47b6e487-c17e-45ef-885a-c392adfaa10e"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxNjY_0a1e58df-806d-4590-94fb-36f37a5b2903"
      unitRef="usd">8900000</us-gaap:DeferredFinanceCostsNet>
    <nktr:DebtDiscountOnTransactionAndFacilityFeesPaid
      contextRef="i6228c808807e4675801149c5c4dc1518_D20151005-20151005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxODA_4a6e072e-5943-4025-8398-25610d954ac5"
      unitRef="usd">8700000</nktr:DebtDiscountOnTransactionAndFacilityFeesPaid>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i9f550fdfeac243e7b6be6c3906cace58_D20200413-20200413"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkxOTQ_219a7cdb-e602-4af9-b9a7-dfa4e963db62"
      unitRef="usd">250000000.0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:InterestReceivable
      contextRef="i050aa7da5e164a6e8417d8a966766809_I20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMDkvZnJhZzo4ZDc3ZTIwOGU2YWM0ZWQxYjNjMGVkYTY4ZmYyNDk3MS90ZXh0cmVnaW9uOjhkNzdlMjA4ZTZhYzRlZDFiM2MwZWRhNjhmZjI0OTcxXzgyNDYzMzcyMTkyMTA_60510b17-bde0-4f83-97f2-3ef8f2917299"
      unitRef="usd">4800000</us-gaap:InterestReceivable>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM3NjY_6a98520d-9737-4097-b1c8-691905410841">Leases&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our 153,203 square foot corporate office and R&amp;amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional 135,936 square foot facility to support our R&amp;amp;D operations at 360 Third Street, San Francisco, California (the Third Street Facility). The following table presents key information regarding these leases (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mission Bay Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Street Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease commencement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renewal terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Two consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a"&gt;five&lt;/span&gt;-year terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a"&gt;five&lt;/span&gt;-year term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The monthly base rent for both facilities will escalate over the term of the lease at various intervals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize rent expense for these operating leases on a straight-line basis over the lease period. The components of lease costs, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2020 and 2019, we recorded operating lease expense of $19.0 million and $14.7 million, respectively, and paid $16.2 million and $8.4&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash provided by (used in) operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2020, the weighted-average remaining lease term is 9.1 years and the weighted-average discount rate used to determine the operating lease liability was 5.9%.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nktr:AreaOfLeasedSpace
      contextRef="ib51f0c55e3654f49b5399e4a17397835_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzExNTQ0ODcyMTAzMDIz_60b35e80-e61b-454c-817b-f185d2751ca7"
      unitRef="sqft">153203</nktr:AreaOfLeasedSpace>
    <nktr:AreaOfLeasedSpace
      contextRef="ifc93e99a4dbd4acdadb139babe668fc2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzExNTQ0ODcyMTAzMDM5_27099eae-5b74-4dea-831f-94d97b523f45"
      unitRef="sqft">135936</nktr:AreaOfLeasedSpace>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzgyNDYzMzcyMTk3Mjc_ee1cc0bf-d6d1-49e3-9616-d8891379c9ab">The following table presents key information regarding these leases (dollars in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mission Bay Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Street Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease commencement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renewal terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Two consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a"&gt;five&lt;/span&gt;-year terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a"&gt;five&lt;/span&gt;-year term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="iae1943d37a234e1f9eaaacf476982b71_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzQtMS0xLTEtNjA4OA_6be3a6f4-619d-468b-b765-6726a55c3ffc"
      unitRef="sqft">13907</nktr:AreaOfLeasedSpaceDelivered>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="i86b2a2e647ae4ccf8b8c44c8755aa414_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzQtMy0xLTEtNjA4OA_358aba42-8f97-4dcc-8d4a-ef1322f65906"
      unitRef="sqft">67105</nktr:AreaOfLeasedSpaceDelivered>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iae1943d37a234e1f9eaaacf476982b71_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzUtMS0xLTEtNjA4OA_5d3ab48a-2909-4f61-aa5d-513e80fd30f4"
      unitRef="usd">6698000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i86b2a2e647ae4ccf8b8c44c8755aa414_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzUtMy0xLTEtNjA4OA_9e4e49ef-0e3a-4a59-a274-f15ef3fe0ee0"
      unitRef="usd">50993000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzctMS0xLTEtNjA4OA_cf5d5919-e90f-41fd-bcdc-1e1a3316fdce"
      unitRef="sqft">4940</nktr:AreaOfLeasedSpaceDelivered>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzctMy0xLTEtNjA4OA_dee6594b-eaaf-42d9-ad29-40434f6581e6"
      unitRef="sqft">0</nktr:AreaOfLeasedSpaceDelivered>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzgtMS0xLTEtNjA4OA_b9197f5d-73a8-4c63-890a-94f822b06865"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzgtMy0xLTEtNjA4OA_9d6217e5-da07-44a3-83ea-15678f95730b"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:NumberOfConsecutiveTermsToExtendLease
      contextRef="id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNTg_c6c64c70-0e1e-4f8c-8637-23e70910c8d4"
      unitRef="term">2</nktr:NumberOfConsecutiveTermsToExtendLease>
    <nktr:NumberOfConsecutiveTermsToExtendLease
      contextRef="id176c911867d49139246e27dafec984d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNDU_a8fb09ab-cc60-498e-92a9-45a80fe2d690"
      unitRef="term">1</nktr:NumberOfConsecutiveTermsToExtendLease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM3Njg_01166ac6-8001-4caa-9db4-f5b85313b7c5">The components of lease costs, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzItMS0xLTEtMA_53d51db0-e697-4bad-8906-aa314817a43d"
      unitRef="usd">18985000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzItMy0xLTEtMA_8371ca11-cbbe-4a19-9b92-b213ec9b5675"
      unitRef="usd">14697000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzItNS0xLTEtMA_1f011664-7121-470d-97e0-0a85ba0bf9b8"
      unitRef="usd">7972000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzMtMS0xLTEtMA_e0c2ecd2-d3a6-4db7-920b-e6cb6ec9c576"
      unitRef="usd">8179000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzMtMy0xLTEtMA_a1a5f501-a5c0-448c-b2ce-7ae7274560c5"
      unitRef="usd">6408000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzMtNS0xLTEtMA_7c7489bc-e25a-4962-af32-805fcc5d5997"
      unitRef="usd">4497000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzQtMS0xLTEtMA_b0c358e8-8ad5-41b8-9945-4dd9e04416b0"
      unitRef="usd">27164000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzQtMy0xLTEtMA_57630cb0-a027-461e-a21d-595a41385658"
      unitRef="usd">21105000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpmYWY2ZjZlMjNlMGY0NTI1OTM3N2I5YzlkMWNiNGQ4MC90YWJsZXJhbmdlOmZhZjZmNmUyM2UwZjQ1MjU5Mzc3YjljOWQxY2I0ZDgwXzQtNS0xLTEtMA_3c042bbd-396e-4f9f-8a97-8358e180cd30"
      unitRef="usd">12469000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzkzNDU4NDg4NDc1NDg_5b8048d3-5fac-411d-bf00-cf76a80607fb"
      unitRef="usd">19000000.0</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzkzNDU4NDg4NDc1NTY_d3620692-9f0e-4118-a3e0-a1986634baa1"
      unitRef="usd">14700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzMxMTU_66700698-03ce-4fdd-989a-c75352e31c9e"
      unitRef="usd">16200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzgyNDYzMzcyMTk3Mjk_2825f35d-54cc-4c1c-95ef-44c9bff270a5"
      unitRef="usd">8400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM3Njk_568e131d-0224-4799-bb47-286792d1b4ca">&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzEtMS0xLTEtMA_06f23b70-60d4-4591-bd87-4cd32512cba6"
      unitRef="usd">17938000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzItMS0xLTEtMA_761f8379-eeb3-4845-9393-01332182e01a"
      unitRef="usd">20141000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzMtMS0xLTEtMA_fea2695e-8a2b-4d65-8729-851386d76139"
      unitRef="usd">20780000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzQtMS0xLTEtMA_6389f612-247b-4e47-ad03-9783c4cf4ee7"
      unitRef="usd">21439000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzUtMS0xLTEtMA_fa72436f-f617-458e-a5b4-e23aaff33ea2"
      unitRef="usd">22117000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzYtMS0xLTEtMA_052a1d0a-5b45-4e73-a583-338eb2707e55"
      unitRef="usd">97764000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzctMS0xLTEtMA_98da0ee1-d3a9-4af3-baa9-d85863a46a7a"
      unitRef="usd">200179000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzgtMS0xLTEtMA_363e9795-8743-47de-acb7-bc7132cebfaa"
      unitRef="usd">46380000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzktMS0xLTEtMA_d5c945eb-4f2a-4c42-8047-0b7028ce5f4d"
      unitRef="usd">3511000</nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzEwLTEtMS0xLTA_e16b7128-8a52-4538-9e4c-989329aa97d8"
      unitRef="usd">150288000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzExLTEtMS0xLTA_c2993ae8-1704-46ac-bc6c-353a93565343"
      unitRef="usd">13915000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTpiNzM1ZmNiM2ZjNTA0Y2E4YmU5Nzk0MmE5NDA1NGMzMC90YWJsZXJhbmdlOmI3MzVmY2IzZmM1MDRjYThiZTk3OTQyYTk0MDU0YzMwXzEyLTEtMS0xLTA_40dc2826-783b-435e-8b1e-f4e76782d830"
      unitRef="usd">136373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5XzM0NDc_3f59869d-5be7-4d2a-8b03-17ff6e6e12f1">P9Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90ZXh0cmVnaW9uOmRkY2JkNDg4NDY5NzQ1MDdiNzVkZTVmMGVjZTY2MWQ5Xzk4OTU2MDQ2NjE0MTI_9db95bd6-7f67-42b5-9193-2ef5bdde0bc8"
      unitRef="number">0.059</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzU4MDI_c9889025-54f6-4cc6-9e53-aee6abb1f3a3">Liabilities Related to the Sales of Future Royalties&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the 2012 Transaction Royalties.&#160;As part of this sale, we incurred approximately $4.4 million in transaction costs, which we will amortize to interest expense over the estimated life of the 2012 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products are remitted directly to RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time certain return thresholds are met as described below, of (a) MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, as amended, (c) REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxter Incorporated, Baxalta US Inc. and Baxalta GmbH.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. We did not recognize any non-cash interest expense from closing on December 30, 2020 to December 31, 2020 as any imputed interest was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account during the year ended December&#160;31, 2020 and for the period from the inception of the 2012 Purchase and Sale Agreement on February 24, 2012 (inception) and the 2020 Purchase and Sale Agreement on December 30, 2020 to December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&#x2014;beginning&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the 12 month periods ended December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rates - end of period presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Implicit interest rate over the life of the agreement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prospective effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;In addition, the 2012 and 2020 Purchase and Sale Agreements grant RPI and HCR, respectively, the right to receive certain reports and other information relating to the 2012 and 2020 Transaction Royalties, respectively, and contains other representations and warranties, covenants and indemnification obligations that are customary for transactions of this nature. To our knowledge, we are currently in compliance with these provisions of the 2012 and 2020 Purchase and Sale Agreements; however, if we were to breach our obligations, we could be required to pay damages to RPI and HCR, respectively, that are not limited to the purchase prices we received in the sale transactions. However, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed.&lt;/span&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzcwMw_8461753b-27cf-4a32-bbca-71faa4997436"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties
      contextRef="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0Xzc4Mw_068f5bac-9b7c-4a02-ab74-b9f5f256bd24"
      unitRef="usd">4400000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzExOTc_91b1bb29-f876-4eed-9e93-dd6b20cd2112"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved
      contextRef="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxNDM_065588fa-4656-43eb-a2d2-771227b9437f"
      unitRef="usd">210000000.0</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved
      contextRef="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxNTk_821007ef-f82e-411d-8237-ea154676de09"
      unitRef="usd">240000000.0</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved>
    <nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds
      contextRef="ia47dc2b77cef4acbbcc117014dfbd9ac_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxNzU_013e81f7-c7d6-46a7-9d89-fc478c2c0ebe"
      unitRef="usd">208000000.0</nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgxOTE_8f03ea65-c759-4e46-b5c2-594941ed9b44"
      unitRef="usd">150000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties
      contextRef="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgyMDc_1a7cb101-5a26-40e5-be21-c0c365d48b72"
      unitRef="usd">3800000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i7c148f64087243f1bc0498557b6cce48_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzgyNDYzMzcyMzgyMjE_64f1ca08-adb8-4f55-aee5-900d38593ed5"
      unitRef="usd">150000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzU4MDQ_4e1d1ee8-c0a1-4503-9038-d20dd6970c0c">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account during the year ended December&#160;31, 2020 and for the period from the inception of the 2012 Purchase and Sale Agreement on February 24, 2012 (inception) and the 2020 Purchase and Sale Agreement on December 30, 2020 to December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&#x2014;beginning&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rates - end of period presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Implicit interest rate over the life of the agreement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prospective effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="id831546d70e34870a583f96469cf6e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItMS0xLTEtMA_e9f2a519-f16a-4a35-9b1b-a909c98abb37"
      unitRef="usd">73551000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i0ff329ef00ee4a19babec2ac7467b6c5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItMy0xLTEtMA_93473cf4-0468-4d1e-83e8-82867640c6bc"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItNS0xLTEtMjQxOQ_436e9dbd-1409-457c-bedb-c14bc233fbaf"
      unitRef="usd">73551000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i6f23237f9b92424f88e3de119d082d83_I20120224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItNy0xLTEtMjQxOQ_630ddbd8-50c6-4458-8285-42c9a040cc9c"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i8b99c4859de149f481fb7758fe823053_I20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItOS0xLTEtMjQxOQ_0a8fac87-7880-40b5-acfd-a5534c57ceff"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i3d3d4ded8eb8431ea5eb96372d1f1204_I20120224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzItMTEtMS0xLTI0MTk_5e03e562-083d-4d4f-9d7b-63919acf5017"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtMS0xLTEtMA_c0f2e823-10d7-4500-881e-f39e8afbe094"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtMy0xLTEtMA_f29f5968-248e-4154-8c31-d37e8f1e52b5"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtNS0xLTEtMjQxOQ_df7296bf-2fce-464b-a902-63a777244ba8"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtNy0xLTEtMjQxOQ_a3cd0b03-b64d-49af-a55b-4fc421846906"
      unitRef="usd">124000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtOS0xLTEtMjQxOQ_df066e2a-91f6-4c0d-8452-d1956fda8b56"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzMtMTEtMS0xLTI0MTk_afe8bc1d-2c3d-4fc7-9383-6131f4b38018"
      unitRef="usd">274000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtMS0xLTEtMA_d56ebdb2-8957-46ff-a3c0-605ae5c0b008"
      unitRef="usd">37938000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtMy0xLTEtMA_019f6b52-6796-475e-8f07-2863f3cdf6dd"
      unitRef="usd">10625000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtNS0xLTEtMjQxOQ_50432b2f-7933-47ee-bc2f-258112780f58"
      unitRef="usd">48563000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtNy0xLTEtMjQxOQ_f7155658-ef2e-4908-b347-e3a8883eb089"
      unitRef="usd">245080000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtOS0xLTEtMjQxOQ_021a03ef-5c3c-40a3-8afe-3e377ebc9b4c"
      unitRef="usd">10625000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzQtMTEtMS0xLTI0MTk_38d227e6-9983-4a65-b8de-1ed0e40cbc10"
      unitRef="usd">255705000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMS0xLTEtMTY3MQ_34c67c17-3bf3-4ffd-a79d-3c8afbcd9c0b"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMy0xLTEtMTY3MQ_5ba98478-4c0f-4d63-8eff-e41cec128713"
      unitRef="usd">0</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtNS0xLTEtMjQxOQ_f6e4a4d6-b800-460b-a8b4-65707b0edd4c"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtNy0xLTEtMjQxOQ_1abac1ee-596c-41ae-89fb-6b1cb58a4023"
      unitRef="usd">196960000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtOS0xLTEtMjQxOQ_804f299d-8320-4cd6-b292-2304ebcb13d9"
      unitRef="usd">0</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMTEtMS0xLTI0MTk_91ec613e-1612-4ecc-a01f-6d6a4381735a"
      unitRef="usd">196960000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMS0xLTEtMA_93dd1817-744a-453d-98c4-a0c7dac580a9"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="ice2c4c29a96e4b6cb4298d998e37cde1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzUtMy0xLTEtMA_a2a986b7-aabf-40a1-a8a8-f9dcf1dc7284"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtNS0xLTEtMjQxOQ_128aa6fe-8e08-4c32-b9c6-f0b257ebda2b"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="ic27497c45de74c6b95bcbcf4dcd2cc49_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtNy0xLTEtMjQxOQ_a29f35ae-b693-44fb-993d-00298b108dc0"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="ib03b68ccaab7477380cd4c6dffda731b_D20201217-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtOS0xLTEtMjQxOQ_02b14499-5d14-469e-9846-e1005315457c"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i1ace1cba9c1646318d935f44a7f74b7d_D20120225-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtMTEtMS0xLTI0MTk_b6a33931-497e-40b5-9c28-eb11b81a48a9"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtMS0xLTEtMA_33f2aede-75ad-4088-a403-c1558a8ca551"
      unitRef="usd">65880000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzYtMy0xLTEtMA_c7a61f99-2b32-4d6b-b6e0-02e3bd7116ec"
      unitRef="usd">139375000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctNS0xLTEtMjQxOQ_7f4612be-754d-48b7-9e2e-0f64d5467af7"
      unitRef="usd">205255000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctNy0xLTEtMjQxOQ_36fdfb1e-2d8a-4d83-af84-b39be037b4fd"
      unitRef="usd">65880000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctOS0xLTEtMjQxOQ_2eb40841-d579-45be-aec2-3e15a5ac4705"
      unitRef="usd">139375000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctMTEtMS0xLTI0MTk_746aeed9-0693-447f-b53a-59dc7bc7883d"
      unitRef="usd">205255000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctMS0xLTEtMA_fbe1bca1-9576-4ae2-b080-4bfa6bd19653"
      unitRef="usd">1165000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzctMy0xLTEtMA_4a361c7c-76e0-4de2-a99d-b5a568251710"
      unitRef="usd">3750000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtNS0xLTEtMjQxOQ_d7f97483-9592-4703-adba-6a8c56897756"
      unitRef="usd">4915000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtNy0xLTEtMjQxOQ_3cb8f8c9-6d37-4f63-8743-a2791f30df6f"
      unitRef="usd">1165000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtOS0xLTEtMjQxOQ_310d8744-00cf-4a1b-989c-24d25e11d698"
      unitRef="usd">3750000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtMTEtMS0xLTI0MTk_b5768792-9087-43d0-a0fe-01f4fa49d255"
      unitRef="usd">4915000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtMS0xLTEtMA_b4d57f37-c77f-49a4-8dea-43223870e0ff"
      unitRef="usd">64715000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzgtMy0xLTEtMA_dca561c1-9c6e-44fa-b627-87df3b1a1e24"
      unitRef="usd">135625000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktNS0xLTEtMjQxOQ_e058c000-6dae-4f2e-8182-abb4c2eecc79"
      unitRef="usd">200340000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ia2a82bbe23bd4eae896743496772f42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktNy0xLTEtMjQxOQ_c2c6f1fe-34a1-4f76-8fe9-5c448c671966"
      unitRef="usd">64715000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i3b607b1feca94f0183fc01112b406e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktOS0xLTEtMjQxOQ_30e0c119-97c4-45c9-beda-b51bd561d7d2"
      unitRef="usd">135625000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZTo0YmE3YzMzYzE1ODg0MjQzYTJjMzBhNmY3ZTI1NTViOC90YWJsZXJhbmdlOjRiYTdjMzNjMTU4ODQyNDNhMmMzMGE2ZjdlMjU1NWI4XzktMTEtMS0xLTI0MTk_b903a9dd-883c-41bc-8453-9feefe4c0615"
      unitRef="usd">200340000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:PaymentMadeForMilestoneNotAchievedYearTwo
      contextRef="ibe8e5acc2c64493693d38c6ecf8677de_D20140301-20140331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzE3ODM_ef391e51-59c7-4d6e-a611-05b1d3796f8c"
      unitRef="usd">7000000.0</nktr:PaymentMadeForMilestoneNotAchievedYearTwo>
    <nktr:PaymentMadeForMilestoneNotAchievedYearOne
      contextRef="ie9b40bb677024548b6bead5496558bb3_D20130301-20130331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90ZXh0cmVnaW9uOjY1ZWM0MmJkYzQxODQyNDNiYTQxNzM5YmNjNTZmMWI0XzE3OTA_f2c39482-e012-4b77-83ac-ba1a5fdf3245"
      unitRef="usd">3000000.0</nktr:PaymentMadeForMilestoneNotAchievedYearOne>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzctMS0xLTEtMjQ0Mg_dbe0de27-911a-4d2e-bc4e-cb4788ba2b91"
      unitRef="number">0.202</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="ibcce05db00d34655b9af2ffe52859e3e_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzQtMy0xLTEtNDM2NQ_fba05246-741b-4177-a079-81180ec7713e"
      unitRef="number">0.195</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="id84e821beaee4d8fa7e6add65a5ac46d_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzctMy0xLTEtMjQ0Mg_c8d040f1-fc33-4646-9ee5-5efdf483f933"
      unitRef="number">0.187</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="ifd7bb6c1b8b6481197a849cf13dc94fb_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzctNy0xLTEtMjQ0Mg_f735cb9a-cf2a-46a1-b9e8-def8d5a18d45"
      unitRef="number">0.160</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="i8ad61da5407146c8a98a2b501954e5dc_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzgtMS0xLTEtMjQ0Mg_5e444fc8-daca-4752-8493-34f252f38c17"
      unitRef="number">0.480</nktr:ProspectiveInterestRatePercentage>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="ibcce05db00d34655b9af2ffe52859e3e_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzUtMy0xLTEtNDM2NQ_8cfd0e65-61c8-45fe-b50b-e6838bc2bf9e"
      unitRef="number">0.380</nktr:ProspectiveInterestRatePercentage>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="id84e821beaee4d8fa7e6add65a5ac46d_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzgtMy0xLTEtMjQ0Mg_1ef86999-b81f-41d6-9adc-61774f365aae"
      unitRef="number">0.290</nktr:ProspectiveInterestRatePercentage>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="ifd7bb6c1b8b6481197a849cf13dc94fb_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjEvZnJhZzo2NWVjNDJiZGM0MTg0MjQzYmE0MTczOWJjYzU2ZjFiNC90YWJsZToyY2I0OTUwNjZkMWU0NjE2YjE5ZjNjZDc1NjE4ZGI3OS90YWJsZXJhbmdlOjJjYjQ5NTA2NmQxZTQ2MTZiMTlmM2NkNzU2MThkYjc5XzgtNy0xLTEtMjQ0Mg_ca6df19a-0fb8-4c50-85d3-df36932314e6"
      unitRef="number">0.160</nktr:ProspectiveInterestRatePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzc2Nzk_1f5f6b02-95c5-4055-9163-4a8ebe376b4e">Commitments and Contingencies&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2020, these commitments were approximately $8.0 million, all of which we expect to pay in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019.&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On December 30, 2020, the U.S. District Court in California granted Nektar&#x2019;s motion to dismiss all claims in this securities class action filing, and denied plaintiffs with the ability to file a further amended complaint.  Following the motion to dismiss, on January 29, 2021, the class action plaintiffs filed a Notice to Appeal to appeal the district court&#x2019;s decision to the U.S. Court of Appeals for the Ninth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California  naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. On January 26, 2021, the U.S. District Court in California granted Nektar&#x2019;s motion to dismiss all claims in this securities class action filing, stating (among other things) that &#x201c;Defendants&#x2019; open disclosure of risks associated with trial delay &#x2026; suggests that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;they acted openly with investors.&#x201d; Following the motion, the class action plaintiffs have an opportunity to file in early March a further amended complaint and the case remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2021, certain of our current and past directors and executives were named in a shareholder derivative complaint filed in the Court of Chancery of the State of Delaware. Allegations in this matter are similar to those raised in the putative securities class action complaints filed on October 30, 2018 and August 19, 2019 in the U.S. District Court in California.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either December&#160;31, 2020 or December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We operate in a number of foreign countries. As a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations on our Consolidated Balance Sheets as of December&#160;31, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligations to RPI and HCR described in Note 7. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnification of Underwriters and Initial Purchasers of our Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In connection with our sale of equity and senior secured debt securities, we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Director and Officer Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $10.0 million per incident for merger and acquisition related claims, $10.0 million per incident for securities related claims and $10.0 million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzI3Ng_2904af33-1e08-45f1-8cf5-7f8a438c1c5b"
      unitRef="usd">8000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i332680e5c95e48e8b3da3635ec5a64c9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NDk_4634987d-23d2-499a-9ae4-9f01e73c6b4b"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i27d8215eb84441c583e455931394edc6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NDk_b1cf1b1b-2713-4076-b0c4-412ffb4a1740"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="iee0a827a30fd4d489cff709fb4aa1743_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzQ0NjU_19f90acf-a260-4aff-aabf-f6bb879fb32e"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i64f92162d4b9462fb32ed8b535a14bac_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzQ0NjU_5f0483ff-049a-4571-bd5a-3a9a768310a5"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia2ab7fd63345456ba7a5755e4c5fc5d0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NTc_3ff3e3f9-4c77-4d08-ae28-24c6deb0e04b"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i65324047a4db4c8091e27eab6cf2aa8b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1Xzg3OTYwOTMwNDQ2NTc_c395d973-f1f6-47e1-8ec7-bf1ab3a50940"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="i2caaa2f541394f9f8d1cc79cf9ea3dc9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzcxNzg_e360197d-e9a9-4ebb-a760-4f5ada7227f8"
      unitRef="usd">10000000.0</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="iba6fe490e41b448e8aff782bf7c54d50_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzcyMzc_de06645d-9733-49f1-8e39-d7e3ef7fda2f"
      unitRef="usd">10000000.0</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="i9e772010232f40508602a3871880b34c_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMjcvZnJhZzpkODczMGZiZDM5YmI0YzgwOGIxOTJjYWFjNTUwMGJkNS90ZXh0cmVnaW9uOmQ4NzMwZmJkMzliYjRjODA4YjE5MmNhYWM1NTAwYmQ1XzcyODc_20f32c77-f946-4520-9350-d98707fe593c"
      unitRef="usd">10000000.0</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzEwMDE0_2c012a39-1a9e-4ed3-b2ba-e60c71a71d4d">Stockholders&#x2019; Equity &lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As discussed in Note 10, on April 3, 2018, we completed the issuance and sale of 8,284,600 shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a five-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;At December&#160;31, 2020, we had approximately 29,784,000 reserved shares of common stock, all of which are reserved for issuance under our equity compensation plans, of which approximately 20,894,000 shares may be issued upon the exercise of outstanding options or the vesting of restricted stock units (RSUs) or performance stock units, approximately 7,569,000 shares are available for grant under our 2017 Performance Incentive Plan and approximately 1,321,000 shares are available for grant under our Employee Stock Purchase Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; 2017 Performance Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) was adopted by our board of directors (Board of Directors) on March&#160;28, 2017 and was approved by our stockholders on June&#160;14, 2017. On the date of approval, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (2012 Plan) ceased to be available for future grants. However, options and restricted stock units granted under the 2012 Plan remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Subject to the terms of the 2017 Plan, 8,300,000 shares of our common stock, reduced by the number of shares of common stock subject to awards granted under the 2012 Plan on or after March 31, 2017 and prior to the adoption of the 2017 Plan, were initially available for awards under the 2017 Plan. On June 26, 2018, our stockholders approved an amendment to the 2017 Plan whereby 10,900,000 additional shares were made available for award grants under the 2017 Plan (Amended Plan). On June 17, 2020, the stockholders of Nektar approved an amendment to the Amended Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 10,000,000 shares (Amended and Restated 2017 Plan). Shares issued in respect of any &#x201c;full-value award&#x201d; granted under the 2017 Plan will be counted against the share limit described above as 1.5 shares for every one share actually issued in connection with the award. Shares that are subject to or underlie awards which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under the 2017 Plan or the 2012 Plan will again be available for subsequent awards under the 2017 Plan (with any such shares subject to full-value awards increasing the 2017 Plan&#x2019;s share limit based on the full-value award ratio described above). Notwithstanding the foregoing, shares that are exchanged by a participant or withheld by us to pay the exercise price of an option granted under the 2017 Plan, as well as any shares exchanged or withheld to satisfy the tax withholding obligations related to any award, will not be available for subsequent awards under the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The purpose of the current Amended and Restated 2017 Plan and our other incentive plans is to promote our success by providing an additional means for us to attract, motivate, retain and reward directors, officers, employees, and other eligible persons through the grant of awards. Equity-based awards are also intended to further align the interests of award recipients and our stockholders. The Amended and Restated 2017 Plan authorizes stock options, stock appreciation rights, stock bonuses, restricted stock, performance stock, stock units, phantom stock or similar rights to purchase or acquire shares, and other forms of awards granted or denominated in our common stock or units of our common stock, as well as cash bonus awards. Members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries are eligible to receive awards under the Amended and Restated 2017 Plan. Pursuant to the Amended and Restated 2017 Plan, we have granted or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. The requisite service period for stock options granted to our employees under the Amended and Restated 2017 Plan as well as our prior plans  is generally four years; the requisite service period for stock options granted to our directors is generally one year. The requisite service period for RSUs and PSUs granted under the Amended and Restated 2017 Plan and our prior plans is generally three years for employees and one year for directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Amended and Restated 2017 Plan will terminate on March&#160;27, 2027, unless earlier terminated by the Board of Directors. The maximum term of a stock option or stock appreciation right under the Amended and Restated 2017 Plan and our prior plans is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In February 1994, our Board of Directors adopted the Employee Stock Purchase Plan (ESPP) pursuant to section&#160;423(b) of the Internal Revenue Code of 1986. Under the ESPP, 2,500,000&#160;shares of our common stock were originally authorized for issuance. On June 17, 2020, the stockholders of Nektar approved an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by 1,000,000 shares. The terms of the ESPP provide eligible employees with the opportunity to acquire an ownership interest in Nektar through participation in a program of periodic payroll deductions for the purchase of our common stock. Employees may elect to enroll or re-enroll in the ESPP on a semi-annual basis. Stock is purchased at 85% of the lower of the closing price on the first day of the enrollment period or the last day of the enrollment period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Retirement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $6,000 per participant. For the years ended December&#160;31, 2020, 2019, and 2018, we recognized $3.5 million, $3.5 million, and $2.8 million, respectively, of compensation expense in connection with our 401(k) retirement plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Change in Control Severance Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On December&#160;6, 2006, our Board of Directors approved a Change of Control Severance Benefit Plan (CIC Plan). This CIC Plan has subsequently been amended a number of times by our Board of Directors with the most recent amendment occurring on April&#160;5, 2011. The CIC Plan is designed to make certain benefits available to our eligible employees in the event of a change of control of Nektar and, following such change of control, an employee&#x2019;s employment with us or a successor company is terminated in certain specified circumstances. We adopted the CIC Plan to support the continuity of the business in the context of a change of control transaction. The CIC Plan was not adopted in contemplation of any specific change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Under the CIC Plan, in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) or initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) in each case within twelve months following a change of control transaction, (i)&#160;the Chief Executive Officer would be entitled to receive cash severance pay equal to 24 months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards, and (ii)&#160;our Senior Vice Presidents and Vice Presidents (including Principal Fellows) would each be entitled to receive cash severance pay equal to twelve months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards. In the event of a change of control of Nektar and a subsequent termination of employment initiated by the Company or a successor company other than for Cause within twelve months following a change of control transaction, all other employees would each be entitled to receive cash severance pay equal to 6 months base salary plus a pro-rata portion of annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of each such employee&#x2019;s unvested outstanding equity awards. Under the CIC Plan, as amended, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i279eee577f1441378d79802f9bc91494_D20180403-20180403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzEzMQ_b2f584b2-89ef-490b-ac9a-802c2308c3c9"
      unitRef="shares">8284600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod
      contextRef="i45baea1b97d54688a1dfe6bcf696082b_D20180403-20180403"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMTgzMzU_a10ada5a-810d-4c86-ba14-a57aedb8a506">P5Y</nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i73c1044cd8154ba294e48097dcf6ecfd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM1NQ_eca2b50a-e4f0-4285-b8c3-ccd30fbbb414"
      unitRef="shares">29784000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzQ5MA_ca594c06-d71d-4eeb-8e1e-cc9002d9c876"
      unitRef="shares">20894000</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding>
    <nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans
      contextRef="ide5660632f144317b4ee56bdf1d105ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzYwNw_6545d96a-15fe-49b3-bd45-8243a067342b"
      unitRef="shares">7569000</nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans>
    <nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans
      contextRef="i165b47e55f0b4fe19b116d4073ab3d17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMjM5ODg_f1a3e65d-5667-4f86-813d-c6621cfb44b3"
      unitRef="shares">1321000</nktr:NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ide5660632f144317b4ee56bdf1d105ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzExMTU_37710531-17fc-4b2c-b8bb-286f98f9ef0f"
      unitRef="shares">8300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i0404b34bd7e6426abaa4ad1ff3be9107_D20180626-20180626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzE0NTA_8da03e59-c601-4c8d-b272-17af3243f3d1"
      unitRef="shares">10900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <nktr:CommonStockAdditionalSharesAuthorized
      contextRef="id759869545ce4f8082f87a13f96f56c7_D20200617-20200617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMjI5NDE_01eba9e2-a22e-4b97-ad11-12658dc89be5"
      unitRef="shares">10000000</nktr:CommonStockAdditionalSharesAuthorized>
    <nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare
      contextRef="ide5660632f144317b4ee56bdf1d105ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzE2ODg_bc8ec595-c315-45ce-b3f3-c0a4ec86e608"
      unitRef="number">1.5</nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i3242ee4bdb4141c29d4a338d4cabf96e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM4MDE_b48dcc85-2311-4bbc-892a-38452129b6ef">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i0fbb3ef5ea4f4882bde7a74c1ef8e365_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM4OTA_4b9a7f91-3944-4950-815d-6444b6409ac1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="if5da921eb5c043ae837ab819c1a4f230_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzM5OTM_d72eb1bb-c8ce-4444-b62f-01643c14b097">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ie75ccda9579e4320804a6b82cbbeadca_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzQwMTQ_a1e4f8c3-d991-4861-931e-0edc45d1df96">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i243a1e61f3224fbbbbd5e7b34dc9d858_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzQyNDA_6442836a-ce6d-4f0e-8ad3-63ba44dd0bfc">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id4cbf542cfaa4814959fffc6a9d3eb50_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzY1MTU_b8278927-f77a-4ce0-a106-179634e36da0"
      unitRef="shares">2500000</us-gaap:CommonStockSharesAuthorized>
    <nktr:CommonStockAdditionalSharesAuthorized
      contextRef="iae8c53d2886c4e2688588fb7a66cb738_D20200617-20200617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMjI5NTM_6458d5e8-8c8e-4250-9105-8cdb4120fabf"
      unitRef="shares">1000000</nktr:CommonStockAdditionalSharesAuthorized>
    <nktr:PercentageOfPurchasePriceOfStock
      contextRef="i7a180f9d74404418b6c1394ddf6e243a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzY4OTg_8954d059-d23e-4e78-8687-b670e37e195b"
      unitRef="number">0.85</nktr:PercentageOfPurchasePriceOfStock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzcxNTA_458efe29-ec44-48dc-baf7-b5678c5199d8"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzczODc_bf7a4dcf-c05f-47c6-8cbb-06822a6fc82e"
      unitRef="usd">6000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzc0NTc_465b4159-ddf9-493f-90f0-1ac534ece5a6"
      unitRef="usd">3500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzc0NjE_106bce5c-8322-467d-b41b-c6644698bc84"
      unitRef="usd">3500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzc0Njk_5f19274e-782b-4ba3-b35f-09f2d92c8591"
      unitRef="usd">2800000</us-gaap:DefinedContributionPlanCostRecognized>
    <nktr:ChangeInControlSeverancePaymentPeriodForExecutives
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzg3OTYwOTMwMzI5ODE_c11c68eb-422a-4946-9228-6abc4f129c59">P12M</nktr:ChangeInControlSeverancePaymentPeriodForExecutives>
    <nktr:ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzg3OTYwOTMwMzMwMDE_d6fb51d0-8627-451b-a035-0f1cca79e793">P24M</nktr:ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer>
    <nktr:ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5Xzg3OTYwOTMwMzMwMjU_da2c2b73-75b5-460b-ad79-62d79f9464a9">P12M</nktr:ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents>
    <nktr:ChangeInControlSeverancePaymentPeriodForExecutives
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMTgzNTY_9bb68547-1595-423a-a154-09958e7a9c34">P12M</nktr:ChangeInControlSeverancePaymentPeriodForExecutives>
    <nktr:ChangeInControlSeverancePaymentPeriodForEmployees
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzMvZnJhZzpmMDNmZGYyODc3OTM0ZDRhOTc2YWY0NjlmZjM5YzViOS90ZXh0cmVnaW9uOmYwM2ZkZjI4Nzc5MzRkNGE5NzZhZjQ2OWZmMzljNWI5XzgyNDYzMzcyMTgzNjI_4fa74d94-1aef-4126-9871-7fddea99afe7">P6M</nktr:ChangeInControlSeverancePaymentPeriodForEmployees>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI1MDI4_e274d817-5a7c-4769-b4e9-066140e757ab">License and Collaboration Agreements&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bristol-Myers Squibb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NKTR-358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amgen, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Baxalta Incorporated / Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hemophilia, including ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2020, 2019 and 2018, we recognized $129.6 million, $77.5 million and $95.3&#160;million of revenue for performance obligations that we had satisfied in prior periods, respectively. For all years, the amount includes all of our royalty revenue and non-cash royalty revenue. For the year ended December 31, 2020, the amount includes $50.0&#160;million in BMS Collaboration milestones received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2020, our collaboration agreements with partners included potential future payments for development milestones totaling approximately $1.7&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive other contingent payments, including contingent sales milestones and royalty payments, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;There have been no material changes to our collaboration agreements for the year ended December&#160;31, 2020, except as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb (BMS): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin (previously referred to as NKTR-214)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The BMS Collaboration Agreement superseded and replaced the Clinical Trial Agreement we entered into with BMS in September 2016 to develop bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the Clinical Trial Agreement, we acted as the sponsor of each Combination Therapy Trial and BMS was responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. We recorded cost reimbursement payments to us from BMS as a reduction to research and development expense. Each party was otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion. We are eligible to receive additional cash payments up to a total of approximately $1.455&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones and up to a total of $350.0&#160;million upon the achievement of certain sales milestones. In April 2018, BMS also purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;BMS has the right, at its sole discretion, to terminate co-funding its share of the development costs for the adjuvant melanoma collaboration study if the metastatic melanoma collaboration study fails to meet the primary endpoint of progression free survival. If BMS exercises such right, we have the right, in our sole discretion, to continue the adjuvant melanoma study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#x2019; expenses as research and development expense. For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $128.2 million and $105.4 million and $62.5 million, respectively, as a reduction of research and development expenses for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses.  As of December&#160;31, 2020 and 2019, we have recorded an unbilled receivable of $38.7 million and $24.0 million, respectively, from BMS in accounts receivable in our Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our share of development costs is limited to an annual cap of $125.0&#160;million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, but we recognize our full share of the research and development expense and recognize the reimbursement as a liability. We repay the liability to the extent that our share of development costs are less than the annual cap in a future year, or by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin, if approved. For the year-ended December 31, 2020, our share of the development costs totaled $129.0&#160;million, thereby exceeding the annual cap by $4.0&#160;million. Accordingly, we have recognized $4.0&#160;million for BMS&#x2019; reimbursement of the excess over the annual cap in our unbilled billed receivable of $38.7 million, and, due to the repayment provision, we have recognized a liability of $4.0&#160;million in Other long-term liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize bempegaldesleukin and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During 2018, we aggregated the total consideration of $1.85&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2&#160;million in stockholders&#x2019; equity. We allocated the remaining $1,059.8&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $1.8&#160;billion to be variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we recognized $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial and $25.0&#160;million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial. We continue to exclude the other milestones from the transaction price as of December&#160;31, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0&#160;million in September 2017 and are eligible for up to $250.0&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 1B and 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#x2019;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we are entitled to significant development milestones under this arrangement, through December&#160;31, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $150.0&#160;million received in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0&#160;million upfront payment as $125.9&#160;million to the license, $17.6&#160;million to our portion of the Phase 1 clinical development and $6.5&#160;million to the drug product development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the $125.9&#160;million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of December&#160;31, 2020, we have no deferred revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Baxalta Incorporated/Takeda: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hemophilia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;This Hemophilia A program includes ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $10.0&#160;million development milestone, which we received in March 2018. During 2018, we earned an additional $10.0&#160;million milestone for annual sales of ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/ ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $12.0&#160;million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of December&#160;31, 2020, our deferred revenue related to this agreement is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We determined that our obligation to manufacture and supply PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen under the 2010 Agreement represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#x2019;s right to require production of PEGylation materials at any time. We recognized revenue through October 2020, the month when the 2010 Agreement expired according to its terms. Accordingly, as of December&#160;31, 2020, we have no deferred revenue related to our agreement with Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (naloxegol oxalate), previously referred to as naloxegol and NKTR-118,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In September 2014 and December 2014, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; /MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was approved in the US and EU, respectively. As of December&#160;31, 2020, we have received a total of $385.0 million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving 60% and Nektar receiving 40%. As of December 31, 2020, we have received a total of $37.6&#160;million of milestone payments resulting from these sublicense arrangements, all of which was received in or before 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of its approval of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the FDA required AstraZeneca to perform a post-marketing, observational epidemiological study comparing MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to other treatments of OIC in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. by AstraZeneca can be reduced by up to two percentage points to fund 33% of the external costs incurred by AstraZeneca to fund such post approval study, subject to a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$35.0&#160;million aggregate cap. As a result of the 2020 Purchase and Sale Agreement as described in Note 7, AstraZeneca will deduct these costs from the royalties paid to HCR. Before we entered into the 2020 Purchase and Sale Agreement, our cumulative share of the post-approval study expenses was not significant. Any costs incurred by AstraZeneca can only be recovered by the reduction of the royalty payments. In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In addition, as of December&#160;31, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of December&#160;31, 2020, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI1MDI0_344c7702-bef1-4be1-bdba-824b1792dab9">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bristol-Myers Squibb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NKTR-358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amgen, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Baxalta Incorporated / Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hemophilia, including ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i07fee986be7e4e88975b835fff607f89_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzItNC0xLTEtMA_af03f11e-f7c7-46c1-b755-736e5b5920c1"
      unitRef="usd">50000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4c5b28fa1440433cbc1a30bd468e6bc4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzItNi0xLTEtMA_ef8ba683-1e33-443c-933a-33fe57cfd700"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i737d623ece374d02a554cd0314567319_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzItOC0xLTEtMA_830a4773-ebc6-4409-b2e0-b2cf811e2432"
      unitRef="usd">1059768000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i0b180b5818184f9e90a1d9ac77c0ad36_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzMtNC0xLTEtMA_8c3e0b05-493c-49dc-9a11-b260f3882f4e"
      unitRef="usd">1259000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i813fad316fa349b09cbd0d54f5119511_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzMtNi0xLTEtMA_76125c46-5d11-4d70-a84c-0c27c559fc1a"
      unitRef="usd">7019000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i7500307ef7d243f28fbd31084f547085_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzMtOC0xLTEtMA_f69e934f-c801-460d-bf29-2a08ef24ae1c"
      unitRef="usd">11634000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i27aa90ea43d8491ab680477d8a5ad091_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzQtNC0xLTEtMA_024fbd51-f6e9-4c2c-82df-b0327bd1d7ea"
      unitRef="usd">4167000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i7d89b8ee0d5b4ad28995c6a5cb013afe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzQtNi0xLTEtMA_a1617868-a00c-422e-9dc4-eacfcc32ad04"
      unitRef="usd">5000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ia149e6df5d9d423fb6f0a80e7e807499_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzQtOC0xLTEtMA_b6004d24-fb0d-4171-ae03-f6604d5da23a"
      unitRef="usd">5000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i40c73bdc0467470a82fe6dd56ac35921_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzUtNC0xLTEtMA_ce23b33d-b920-4f7a-ad70-3b762f314713"
      unitRef="usd">346000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iddeeba83838249e69191a50f51901ae9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzUtNi0xLTEtMA_252db25f-d8cc-45be-b905-4d5bddc143e8"
      unitRef="usd">378000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i74a26ba1b2354834aeab39bb01122273_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzUtOC0xLTEtMA_05e891ed-cb45-4a07-93d1-b97c7af1f273"
      unitRef="usd">20328000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iaa2ed6dd5c174996a8348c2074df2753_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzktNC0xLTEtMA_8cf3eff7-387c-4e55-8961-a151a3f111c3"
      unitRef="usd">77000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i008803fb67f84ea78e2af3795d82cb16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzktNi0xLTEtMA_53b5be9d-4d50-4c63-9764-e2bf2742d448"
      unitRef="usd">4578000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="if46c9120dc3e494394b2305aceabd21d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzktOC0xLTEtMA_4f51c70c-9a16-4292-b818-98e3c8741dbc"
      unitRef="usd">535000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzEwLTQtMS0xLTA_a63adccb-25da-4085-8ce0-a0dff1353da8"
      unitRef="usd">55849000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzEwLTYtMS0xLTA_c854e3fa-88dd-48f5-81f8-0d2479063b75"
      unitRef="usd">16975000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTo1M2NiODliMTg2ZWE0MmU2YmNlNWY5ODhhNGYzYWE0NC90YWJsZXJhbmdlOjUzY2I4OWIxODZlYTQyZTZiY2U1Zjk4OGE0ZjNhYTQ0XzEwLTgtMS0xLTA_d138e5fb-35db-4035-8c9b-86fbd9f32f3a"
      unitRef="usd">1097265000</nktr:LicenseCollaborationOtherRevenue>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzE1NzQ_9944e4ba-afe2-4105-aa3c-98582818060d"
      unitRef="usd">129600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzE1ODE_6f2118f2-249b-4d2b-9c9b-ec17c088ec02"
      unitRef="usd">77500000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1Mjc_1c837d4b-6236-4e64-bece-f4254020bc99"
      unitRef="usd">95300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <nktr:SalesMilestoneRevenue
      contextRef="ifed655596acc4f6f9abb2c38103052ce_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1NDI_c3d70add-a2ad-4051-8f1f-976669295e3f"
      unitRef="usd">50000000.0</nktr:SalesMilestoneRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI1MDI2_99def378-8a2f-48f4-9143-730ffe9be295">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December&#160;31, 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&#x2014;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTozZGUzN2RjMGE2YWQ0MWM0OTY1MTIzNjRhMzQ3ZWRkOS90YWJsZXJhbmdlOjNkZTM3ZGMwYTZhZDQxYzQ5NjUxMjM2NGEzNDdlZGQ5XzEtMS0xLTEtMA_140b136d-e48c-49a4-a352-6d8f581946c6"
      unitRef="usd">8071000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTozZGUzN2RjMGE2YWQ0MWM0OTY1MTIzNjRhMzQ3ZWRkOS90YWJsZXJhbmdlOjNkZTM3ZGMwYTZhZDQxYzQ5NjUxMjM2NGEzNDdlZGQ5XzItMS0xLTEtMA_eb5554f0-8030-4bf7-96d3-8435e3d5ff9a"
      unitRef="usd">5516000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90YWJsZTozZGUzN2RjMGE2YWQ0MWM0OTY1MTIzNjRhMzQ3ZWRkOS90YWJsZXJhbmdlOjNkZTM3ZGMwYTZhZDQxYzQ5NjUxMjM2NGEzNDdlZGQ5XzMtMS0xLTEtMA_44b417c6-0be4-45c8-a173-226516326e3a"
      unitRef="usd">2555000</us-gaap:ContractWithCustomerLiability>
    <nktr:PotentialDevelopmentMilestones
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1Njg_ec7ced40-df1c-467a-855d-b760d89a0231"
      unitRef="usd">1700000000</nktr:PotentialDevelopmentMilestones>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="i53dd51cb16d64a37af811757be9bc88d_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1NzU_09bd0ee1-a5f6-4b77-a694-e6c435a735c8"
      unitRef="number">0.65</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="i18e9200632c24e1cb5376206c84bd1ba_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1ODA_5b97fc38-2f5e-4730-b65d-0f6b312e313b"
      unitRef="number">0.35</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="ibc3d41b108484518862f7675ed0d6023_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1ODU_c4e88563-8e62-426d-b6d9-94f4bcb599a2"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="icae6895fea5d4170abf536b7118795ac_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1OTI_92f7be02-17fe-4d2f-a8ad-24d745bf088c"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i18e9200632c24e1cb5376206c84bd1ba_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU1OTk_67478621-cc2a-4e59-85d0-052d5ed88c5b"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i53dd51cb16d64a37af811757be9bc88d_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2MDQ_40dc3b7f-aad4-4b3e-923b-e60f570f68a2"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfOutOfPocketCostsToBeReimbursedByPartner
      contextRef="ib881bc00509644faa5b6cc9e5670bda9_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2MDk_d869887b-f6aa-4b34-863d-afecc1f83510"
      unitRef="number">0.50</nktr:PercentageOfOutOfPocketCostsToBeReimbursedByPartner>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i0dc54d4429a14507ba0977108771d46f_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2MTQ_f0184b0a-9eb1-4ebf-83ac-62d30ce98f04"
      unitRef="usd">1000000000.0</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
      contextRef="i33adc58a946240659c54e96e6b40bfbf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2Mjg_3b12b1ba-43ff-42cb-9427-274369bd897f"
      unitRef="usd">1455000000</nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones>
    <nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
      contextRef="i681999e295a9436988be9a734fa0d419_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2NDI_6f0e5d93-0579-4647-8af8-8fccfaf58602"
      unitRef="usd">350000000.0</nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones>
    <us-gaap:SharesIssued
      contextRef="i89eb6575dc8d4b6bb3d9b58cb422c933_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2NTg_351d2380-8ceb-418d-98aa-6f919e187bda"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="i2e8d2460a3d24fe19b5e25e5c18d4d4c_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2Njk_80056ad5-e05e-46e7-9223-f82c4192b589"
      unitRef="usd">850000000.0</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i9a165c7d11824e3faaca690b9fe43ccb_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU2ODU_c58ec51f-7478-4957-bf12-d34bcc288e68"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i9a165c7d11824e3faaca690b9fe43ccb_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3MDA_8b2c469d-270e-4cb0-ac3a-91c173f57da7"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:ReimbursementOfExpenses
      contextRef="i4324d57f84ab4a79b48761bdcdb78475_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1Xzc5NjM_bfb43cde-4107-49e2-815c-39398d594c24"
      unitRef="usd">128200000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i0e5b0431feeb42af96a92b8ebf28fd8b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1Xzc5NzA_fa2163fe-d80e-4b95-badb-850ddf40a1e7"
      unitRef="usd">105400000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i51d000e6aadc462a8e1d068ac6eb6bda_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1Xzc5Nzg_b277e720-f5ba-444f-88eb-1af11b233064"
      unitRef="usd">62500000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgxODY_5e716f83-cf23-4692-a265-81164011b1a5"
      unitRef="usd">38700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i09a7acaae93b47a18c69f0744596371d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgxOTQ_fff48bc0-35d3-4cb8-be0c-eab847ce7210"
      unitRef="usd">24000000.0</us-gaap:AccountsReceivableNetCurrent>
    <nktr:CompanyShareOfDevelopmentCostsAnnualCap
      contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3MTU_6fca9c98-92de-4004-8536-cf6a084cb717"
      unitRef="usd">125000000.0</nktr:CompanyShareOfDevelopmentCostsAnnualCap>
    <nktr:CompanyShareOfDevelopmentCosts
      contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODY5NzY_0d6025d8-88b5-4c9b-9353-6aabe7b63db1"
      unitRef="usd">129000000.0</nktr:CompanyShareOfDevelopmentCosts>
    <nktr:DevelopmentCostsExceeded
      contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzEzNzQzODk1NDI3MDY5_3e8e43e4-c08b-47f6-bb15-c8feae85f8a4"
      unitRef="usd">4000000.0</nktr:DevelopmentCostsExceeded>
    <nktr:ReimbursementRecognized
      contextRef="i47e8ffaec982447283e3be646c848349_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3MzE_bdde2c4d-18e2-4bb8-b414-3761d2af79be"
      unitRef="usd">4000000.0</nktr:ReimbursementRecognized>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzExNTQ0ODcyMTY2MTI1_5e716f83-cf23-4692-a265-81164011b1a5"
      unitRef="usd">38700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic8d5dc9e1c7249ae982304341da2dc3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3NDU_d2eb456f-0f39-47d8-a8e1-588c916e0b10"
      unitRef="usd">4000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <nktr:AggregateConsiderationReceivedFromAgreements
      contextRef="i856405b13edf4a6cab22db02d72d1802_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3NTk_d4ffa78f-4ac6-440d-a499-13c58ba34122"
      unitRef="usd">1850000000</nktr:AggregateConsiderationReceivedFromAgreements>
    <nktr:EstimatedFairValueOfShares
      contextRef="i1754f034bd974728bed8387d9d72bd50_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3NzQ_9f40a21f-fb78-4b1c-808e-6e39d7cb8bb9"
      unitRef="usd">790200000</nktr:EstimatedFairValueOfShares>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i856405b13edf4a6cab22db02d72d1802_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU3OTA_efce7d4a-52ba-4bd4-b2fc-391fe1ab0d7c"
      unitRef="usd">1059800000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:PotentialDevelopmentRegulatoryAndSalesMilestones
      contextRef="i1754f034bd974728bed8387d9d72bd50_I20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4MDg_57ed75c4-1cca-489a-a711-3c8b6d50e3ba"
      unitRef="usd">1800000000</nktr:PotentialDevelopmentRegulatoryAndSalesMilestones>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i1f578ac138d243159b20e2c8695c088d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4MjI_8776c347-d7f4-4ae5-b429-cb63bb3958fa"
      unitRef="usd">25000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i1f578ac138d243159b20e2c8695c088d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4Mzc_26b42a65-0d9a-476e-aacf-d3897c914a36"
      unitRef="usd">25000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4NTI_12f502d6-6dc7-4df0-8628-6eb22578ef80"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i211b0ecf8dd9414bac8969426d745f43_I20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4Njg_466430b6-71bd-4bbc-ace4-bfb132800202"
      unitRef="usd">250000000.0</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i090200b2df2d4328a10feb73ea2cc913_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4ODQ_cbbb409a-9109-4042-b5bc-16f757824218"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="icfa0bac114c54b30ad4a8c72b57d49d2_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4ODk_856b11a1-c664-49a4-9746-5790fa46debf"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i2f006004c02b411e86bd510eb0e3d194_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU4OTM_22ed0427-5eb1-4cd3-85a5-ecb9c4fc5e10"
      unitRef="number">0</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i822a697b55f34b999f5d046661cdda27_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MDM_61a391d9-d275-456f-9154-3f66053d7fed"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="if57ed396a7ce4982a8cf0c38400928a6_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MDg_b1b9c092-cd3b-4767-9b0e-5494225858d6"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="if57ed396a7ce4982a8cf0c38400928a6_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MTM_3e4718b5-764d-40ac-8451-6ff64395f058"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MTg_f9ac283e-bdef-4879-8eae-267104c044ca"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i1ab673decee74aa694b5e3a084ae1ba7_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5MzQ_93bdeef4-c157-4805-935d-499fe4dfaed4"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="ib86b4fcdb85a4a40a92ae61ccbb060f2_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5NTA_e54b058d-c18d-442c-8e75-268da8955c7f"
      unitRef="usd">125900000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i17a2d0c7f5b14febb5d605a70ac5be5a_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5NjY_fc1491cf-a354-42e3-9477-83dbad0830e7"
      unitRef="usd">17600000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i88b3538d8838435d98d28e77de6a0b87_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5ODE_ba47fecb-b23f-4516-b9fe-021a71e4a25b"
      unitRef="usd">6500000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72e1d5fa4cee46038d0164972eca0589_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODU5OTU_a53e52e4-9d1d-48d5-80d6-b1ffbabf859e"
      unitRef="usd">125900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9608ed0e8f234f719db44f2ce29c4216_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzExNTQ0ODcyMTU4MTk1_efac7cf1-eca2-47d9-a01e-d2eb48fbf03e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id73287f5728f4758aff50c38e58bc67c_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwMTE_965e306b-aa29-4a95-8dc1-bce906be8ae9"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53699e8247e24936abad5db41f079668_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwMjY_8902afd3-dbba-44b2-be5d-e1b3ed62526e"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:PaymentsReceivedUnderRightsToSublicenseAgreement
      contextRef="i8ee84d18bf2448248442d25abe69bc54_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNDE_15589c7c-c679-49c8-a091-b20d1375b2a2"
      unitRef="usd">12000000.0</nktr:PaymentsReceivedUnderRightsToSublicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="ic5f692c7b7c64b63aa43f5f9beb82f27_D20101001-20101031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzExNTQ0ODcyMTYxMTMx_39bf2149-dd12-4ba8-b311-4a585dc910e2"
      unitRef="usd">50000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="icdff3824bed0496593ee26344105cfaa_D20150101-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzIyOTY5_687da484-cd16-414f-a9f5-9346860f068c"
      unitRef="usd">385000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
      contextRef="i9669dda51f8d469b90ab31add3c0cf0a_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNjE_d06a2d38-af3c-4c15-acf3-bbf7891c8632"
      unitRef="number">0.60</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
      contextRef="icdbf7038932f481ebc0426c961831d78_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNTY_6024762b-5b22-44fc-a4f1-0455e2a2ae90"
      unitRef="number">0.40</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i052214e857b447dfbc2f68ed467ab528_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODgxNzM_ede3a8ef-ab2a-4c5a-8a90-20443f8bc3f4"
      unitRef="usd">37600000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i255f8243240945a4a13c9479fe28d04f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyMzMzNDk_f924ae5b-1055-4b04-85c4-68373c0edc68"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <nktr:PercentageOfNetSalesToFundExternalCostsIncurred
      contextRef="idbbc53198d1c48749ec868cd04228392_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNjY_e61ff928-9ff2-409b-8af1-bd2e841db959"
      unitRef="number">0.33</nktr:PercentageOfNetSalesToFundExternalCostsIncurred>
    <nktr:AmountOfNetSalesToFundExternalCostsIncurredCap
      contextRef="if3e61ba2f5e447299c9460d38e8e3b38_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzgyNDYzMzcyODYwNzE_2e637378-db98-4b44-aad0-b071db619982"
      unitRef="usd">35000000.0</nktr:AmountOfNetSalesToFundExternalCostsIncurredCap>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ic54b2f1a2f4f47eda9c396ece8af832b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI0MTg4_0c7bd04e-d053-4e9c-a0da-2dae8e999d8b"
      unitRef="usd">40000000.0</nktr:PotentialDevelopmentMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8b459d9407c3488188caf6e79fd2c1b3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMzkvZnJhZzo5YmQ5ZDg2NjgwMzY0NmUwOTQ3NWVhNGYzMjc4ZTY2NS90ZXh0cmVnaW9uOjliZDlkODY2ODAzNjQ2ZTA5NDc1ZWE0ZjMyNzhlNjY1XzI0OTcz_826c8204-9698-4d7a-882b-aeb6bd4a3ca2"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDI_68ff2f47-3d86-488a-979f-12c8de279006">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, total unrecognized compensation costs of $193.7 million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of 1.79 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2020, 2019, and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Black-Scholes Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of zero. Our estimate of expected volatility is based on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited &amp;amp; canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 totaled $15.9 million, $30.6 million and $303.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of RSU Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;A summary of RSU award activity is as follows (in thousands except for per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock that vested in the years ended December&#160;31, 2020, 2019 and 2018 totaled $33.3 million, $32.4 million and $80.4 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDQ_e54b2b47-aeef-433d-81ad-5da83cbde021">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if74acef52e11470f833bd478aa3ef19b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzItMS0xLTEtMA_26672548-ef66-4b14-bf18-6f120d499737"
      unitRef="usd">2825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b295854248b4d328d13f61824dc9c9a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzItMy0xLTEtMA_6fb39f43-7aa4-49e3-b045-925aa7211d6c"
      unitRef="usd">4294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ce8950c4b5b4e54b98c6758fc52a69c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzItNS0xLTEtMA_f495b074-d6d1-4a69-a311-e4678aa29751"
      unitRef="usd">4629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4cf4765dc2e844f291e9697ef1a040c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzMtMS0xLTEtMA_b39150a6-4184-4d95-baae-54dd59fa8d1b"
      unitRef="usd">57116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i495ad3c9a56241a4b0d81e8e4e6fb3d7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzMtMy0xLTEtMA_95c254a3-3e12-4cb5-8887-cc06c46ef65a"
      unitRef="usd">63224000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e8a180bb15a483f80a891f8010c1d15_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzMtNS0xLTEtMA_7195cfc5-d219-465e-8b64-c57682877a56"
      unitRef="usd">56193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b77ba2c841b4c28b4c4a4cd5a77324f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzQtMS0xLTEtMA_9e8123f6-e621-4605-8e7a-4e5af53fb692"
      unitRef="usd">33295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a89348225b1444f879860b43fe8e9c4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzQtMy0xLTEtMA_d4b70368-6e01-4cb0-ad4f-3bcdf996f224"
      unitRef="usd">32277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38d8392820334097a6e73600dbdc66b5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzQtNS0xLTEtMA_0baa0b59-8a3d-4c50-8e70-a6916e17558c"
      unitRef="usd">27279000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1db549bc0acb4adba3eec24ace8bedd0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMS0xLTEtMzk5Ng_87c1937a-2e29-4b62-8386-4f0ebc0f1c49"
      unitRef="usd">1025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c80c0982a6f47049d8b696c71aad77f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMy0xLTEtMzk5Ng_6e02ff68-7fcc-4f04-871e-5aab23b28d94"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ca56cd80aa4498ab650c1512e10d771_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtNS0xLTEtMzk5Ng_7e4e04b2-530a-4d1a-978d-8462d452eab9"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMS0xLTEtMA_e745f081-bbed-4963-9bcf-8bc304662406"
      unitRef="usd">94261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtMy0xLTEtMA_ff793fb2-e422-4426-924f-1c0d8f6c7b49"
      unitRef="usd">99795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTowNTdhYjEyZTZiZWM0YThmODU0NjExZDY5MmE3MWJhMS90YWJsZXJhbmdlOjA1N2FiMTJlNmJlYzRhOGY4NTQ2MTFkNjkyYTcxYmExXzUtNS0xLTEtMA_6dba5108-9fc8-4864-adb4-3e3cc3b9be82"
      unitRef="usd">88101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyOQ_859e513c-e32b-431a-959f-c200768356d8"
      unitRef="usd">193700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzgyNDYzMzcyMTA1MzM_3b24dbb1-da1b-4fe5-b32c-14b4e4bda041">P1Y9M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDg_da277858-143f-4956-b477-e9da2c4f3cdc">The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzItMS0xLTEtMA_67cccda3-9885-425f-983d-23dcc5e8a223"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzItMy0xLTEtMA_9a9e8611-9799-4f36-b010-a808eb3cd8c2"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzItNS0xLTEtMA_476d05c8-b54f-4888-98d2-a02828d42bf7"
      unitRef="number">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzMtMS0xLTEtMA_c67b6adf-b1ca-47da-9977-54363f0471dd"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzMtMy0xLTEtMA_2edcedbb-4769-49c7-8346-5f9552c62ccd"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzMtNS0xLTEtMA_4701640a-d790-404a-b482-2d64d71ae25a"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzQtMS0xLTEtMA_1ff6086b-9c03-48eb-86b3-5bebb2273297"
      unitRef="number">0.641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzQtMy0xLTEtMA_8ca02f22-aaf4-442b-b8dc-84acece5922e"
      unitRef="number">0.622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzQtNS0xLTEtMA_82d09a5e-e306-445c-9de2-0e1d257d27c6"
      unitRef="number">0.610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzUtMS0xLTEtMA_3202b954-9f39-4c44-ad73-23f3f742b647">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzUtMy0xLTEtMA_0b0b8b8b-2eaf-4ed9-8270-f553c3aae433">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzUtNS0xLTEtMA_4922b475-2dd7-411c-a649-ec34a4b240d2">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzYtMS0xLTEtMA_a18b6e41-4546-4ef9-95c9-b2255fef0d96"
      unitRef="usdPerShare">10.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzYtMy0xLTEtMA_d8ada468-b4ab-4f1d-8750-43f8db451d18"
      unitRef="usdPerShare">12.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo3MzY2MjM1OWVmYTQ0MTgwYmIwYzU0MDc0MDY1NDg2Yy90YWJsZXJhbmdlOjczNjYyMzU5ZWZhNDQxODBiYjBjNTQwNzQwNjU0ODZjXzYtNS0xLTEtMA_394770f5-50c2-4455-be84-38fbd9746ccf"
      unitRef="usdPerShare">29.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8a0f1d0bae304ea191fafac40840dd22_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzEwMjk_8280ca06-c87f-49ed-b53f-d7ea40bf6085"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMTA_53416f55-ef8a-4ec6-9446-fca2b654dcf9">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited &amp;amp; canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2020.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzEtMS0xLTEtMA_688d9ac8-4065-4d01-a572-e0c923d75973"
      unitRef="shares">14885000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzEtMy0xLTEtMA_5c00e037-4ab3-4f0b-939e-fd166038dbcd"
      unitRef="usdPerShare">25.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzItMS0xLTEtMA_8890f9d5-49ac-4bf4-9014-268c24135625"
      unitRef="shares">1654000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzItMy0xLTEtMA_49b05f16-39bd-4b50-8182-0b2a3c835ba9"
      unitRef="usdPerShare">19.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzMtMS0xLTEtMA_c60a86ce-b4a0-4fbc-aefe-116252490163"
      unitRef="shares">1669000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzMtMy0xLTEtMA_249e2a58-7347-4869-b654-75927cb4506f"
      unitRef="usdPerShare">11.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzQtMS0xLTEtMA_898f3c00-2cb1-4bde-9d52-7eb6097ffdcd"
      unitRef="shares">1233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzQtMy0xLTEtMA_7b04ebdc-204d-4c9b-88a2-3c16b9b7c174"
      unitRef="usdPerShare">45.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtMS0xLTEtMA_217e8b45-9832-411f-941f-d3b5ce19db5d"
      unitRef="shares">13637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtMy0xLTEtMA_b864d620-3755-4a3b-8b3f-96d929d7920b"
      unitRef="usdPerShare">24.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtNS0xLTEtMA_e158e828-95ea-4a24-a4ca-31b499881c70">P3Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzUtNy0xLTEtMA_621fafcf-e60a-44ff-ad7e-b00e2c30aaa6"
      unitRef="usd">23478000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctMS0xLTEtMA_653e08b2-52ec-40c6-a8ce-96dd05d28732"
      unitRef="shares">9523000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctMy0xLTEtMA_73f63d2b-eae2-4a43-8a4b-ea006cc45fe4"
      unitRef="usdPerShare">22.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctNS0xLTEtMA_f90200d5-ce24-4fd5-bcdf-c057c5c1e5c1">P2Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZToxZjljNTYxOTc4OWI0Zjg2ODU2OWJjZDljYjQxNGFkYi90YWJsZXJhbmdlOjFmOWM1NjE5Nzg5YjRmODY4NTY5YmNkOWNiNDE0YWRiXzctNy0xLTEtMA_3d237aa1-c20f-4ba0-a25a-405a0915a48e"
      unitRef="usd">23468000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzE5Mzc_6f4bf580-33bb-40d8-8696-cc3b47b15304"
      unitRef="usd">15900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzE5NDE_3c866fcf-570c-422d-9880-c3ece1c20ecf"
      unitRef="usd">30600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzE5NDg_42dc1308-b88c-480a-8848-ce10318eff80"
      unitRef="usd">303400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIyMDc_6931ccc6-9e39-4957-b748-cb2d225cdad1">A summary of RSU award activity is as follows (in thousands except for per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i270d9a256b0148cf80b4c9020001e2ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzEtMS0xLTEtMA_88b6de5e-6ef9-481a-a354-ff465e4f8d3d"
      unitRef="shares">4935000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i270d9a256b0148cf80b4c9020001e2ce_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzEtMy0xLTEtMA_83eb4577-78b7-4bf7-9631-79dde914251f"
      unitRef="usdPerShare">30.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzItMS0xLTEtMA_8b26dda1-a588-4d08-98a3-5faa8275a96a"
      unitRef="shares">4686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzItMy0xLTEtMA_616fc72a-6eb2-4696-8098-2147156ac62d"
      unitRef="usdPerShare">19.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzMtMS0xLTEtMA_40c36d64-1678-4a51-af8f-0d7e91ba3a07"
      unitRef="shares">1661000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzMtMy0xLTEtMA_0e1b3810-1c2a-4698-bafc-b8ed3f2c27e2"
      unitRef="usdPerShare">34.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzQtMS0xLTEtMA_d63bcb38-a1a1-483c-a4b6-51c950cd9631"
      unitRef="shares">866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzQtMy0xLTEtMA_de9823bb-29a4-4709-a729-5f6b9ae44c89"
      unitRef="usdPerShare">29.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie01a6511f0d24250b24e5b947e4fc152_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzUtMS0xLTEtMA_90a51466-7330-43ae-9f5e-4ae91d9b5f53"
      unitRef="shares">7094000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie01a6511f0d24250b24e5b947e4fc152_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90YWJsZTo4NGRhMTYyOTk2ZDg0MWUxYjZhMjEyYjliZTVmYTBjZC90YWJsZXJhbmdlOjg0ZGExNjI5OTZkODQxZTFiNmEyMTJiOWJlNWZhMGNkXzUtMy0xLTEtMA_c3a722ce-762c-43ca-b261-b76ba3b3c8fd"
      unitRef="usdPerShare">22.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i795e20cda3034983a35ef3ba6359583c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIxNzQ_825b6b82-e0f2-4f64-9e23-583d507041cb"
      unitRef="usd">33300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i52d489e7ce4f48beaabcdd6ed7a7661b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIxNzg_5320d52f-23a4-4953-8126-6a5ecab530b6"
      unitRef="usd">32400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1352258179264aee894c5a3fcf3294cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNDUvZnJhZzowZjk5MWFhNGZhNGM0YjNmODFjNDhjNDYwNWU4N2ZlZi90ZXh0cmVnaW9uOjBmOTkxYWE0ZmE0YzRiM2Y4MWM0OGM0NjA1ZTg3ZmVmXzIxODU_662fc8eb-d34d-4a7c-b4f3-888b5070c5bc"
      unitRef="usd">80400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODA_6cc45885-7df9-4c3e-99ae-fb4a2113faf9">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Income (loss) before provision for income taxes includes the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(441,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Deferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% for the years ended December&#160;31, 2020, 2019 and 2018 to pretax income (loss) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit) at federal statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium on equity issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash royalty revenue related to sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense on liability related to sale of future royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $95.0 million and $114.6 million during the years ended December&#160;31, 2020 and 2019, respectively, primarily due to the additional domestic net operating losses and credits generated in the current year that are not more likely than not of being utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Operating Loss and Tax Credit Carryforwards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we had a net operating loss carryforward for federal income tax purposes of approximately $2.0 billion, portions of which will begin to expire in 2021. As of December&#160;31, 2020, we had a total state net operating loss carryforward of approximately $1.3 billion, portions of which will begin to expire in 2026. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have federal research credits of approximately $98.9&#160;million, which will begin to expire in 2023 and state research credits of approximately $44.0&#160;million which have no expiration date. We have federal orphan drug credits of $17.7&#160;million which will begin to expire in 2026. These tax credits are subject to the same limitations discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have the following activity relating to unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry forwards rather than resulting in a cash outlay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. Because of net operating losses and research credit carryovers, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any resulting liability resulting from such an examination would have a material effect on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2020, 2019 and 2018, no significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any changes over the next twelve months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4NzU_64fc84f1-8366-4d7c-897b-c01ab2ae02b6">Income (loss) before provision for income taxes includes the following components (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(441,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzItMS0xLTEtMA_4f786a78-8f4b-4c36-90d6-9cff0145255c"
      unitRef="usd">-445370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzItMy0xLTEtMA_1d59dd8a-dbda-4c60-994b-41ba090b401b"
      unitRef="usd">-441494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzItNS0xLTEtMA_9757e12e-76e9-44ca-815d-c43899c9b777"
      unitRef="usd">680423000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzMtMS0xLTEtMA_16cd4b75-8a09-414e-9dac-ec70405f9ff0"
      unitRef="usd">1423000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzMtMy0xLTEtMA_0de9cf50-b7df-4e9a-9334-a7b811407be6"
      unitRef="usd">1440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzMtNS0xLTEtMA_9729efcc-57b9-4050-b056-937127afa730"
      unitRef="usd">2302000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzQtMS0xLTEtMA_3ed31392-377c-44a0-ae8c-afcf3a957626"
      unitRef="usd">-443947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzQtMy0xLTEtMA_a0c8ec24-c728-4343-bc0a-966f9de7715a"
      unitRef="usd">-440054000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZToyZWY4YTU3MzIwZmQ0NzY1YjhjZjViODg0MzcxZjE4MS90YWJsZXJhbmdlOjJlZjhhNTczMjBmZDQ3NjViOGNmNWI4ODQzNzFmMTgxXzQtNS0xLTEtMA_1b5276bb-3ee1-4b09-afa5-062d39a09a8e"
      unitRef="usd">682725000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODU_d9da37c9-7157-4dc1-99ed-9f8c4919d0fd">The provision for income taxes consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Deferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzMtMS0xLTEtMA_1e4fc98f-407b-490b-b2e0-f796e1b7b012"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzMtMy0xLTEtMA_a0263483-34db-4f3f-a1ac-d4d2c037a680"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzMtNS0xLTEtMA_5d17f612-a171-4e7f-be30-cb0b2e03afea"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzQtMS0xLTEtMA_12d940b5-d057-4492-91a0-f48ebdcb4de4"
      unitRef="usd">165000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzQtMy0xLTEtMA_1f5a94a2-f817-443d-b8f3-b85f6576b363"
      unitRef="usd">139000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzQtNS0xLTEtMA_80c5752f-241c-4b0f-8872-01c4edeb9bb4"
      unitRef="usd">699000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzUtMS0xLTEtMA_f34e9d99-5258-4256-afd0-d08f117d0039"
      unitRef="usd">364000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzUtMy0xLTEtMA_3aaaf757-3116-4c5f-8853-7477c8cae944"
      unitRef="usd">495000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzUtNS0xLTEtMA_89b3be17-f2d6-4f04-942b-ac8175b98613"
      unitRef="usd">620000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzYtMS0xLTEtMA_af7ad99a-c0b3-459b-996b-50443386075a"
      unitRef="usd">529000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzYtMy0xLTEtMA_0fff26be-af4e-49e3-90f6-2c14cbf819e9"
      unitRef="usd">634000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzYtNS0xLTEtMA_3e22335f-1f8d-4840-9281-22e309c2bab7"
      unitRef="usd">1319000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzgtMS0xLTEtMA_0b37a99f-5237-4889-b16a-16351e10710b"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzgtMy0xLTEtMA_ffe0342a-d929-4964-b912-063c3688d888"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzgtNS0xLTEtMA_4bf9cfcd-c56a-48c5-b811-1bc5527ed16f"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzktMS0xLTEtMA_fa4d2a13-ee29-4c45-a391-6e0860a028fa"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzktMy0xLTEtMA_2a332273-bc18-4dd0-94d8-498144d3c57a"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzktNS0xLTEtMA_e0c59b6d-52c4-43d8-aa91-7ae1efb115e4"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEwLTEtMS0xLTA_ff933c21-aced-460b-a4c3-1898dad5ecaa"
      unitRef="usd">-36000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEwLTMtMS0xLTA_0a8585ea-be28-4e39-b439-b97dc6710712"
      unitRef="usd">-21000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEwLTUtMS0xLTA_c835a291-95e2-4125-8fa3-ba7e1af9d09e"
      unitRef="usd">93000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzExLTEtMS0xLTA_c2ad86ce-f7b4-46bb-93b4-8260e3ebe545"
      unitRef="usd">-36000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzExLTMtMS0xLTA_c0ef5c2d-af25-4688-b7d3-7570beac429d"
      unitRef="usd">-21000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzExLTUtMS0xLTA_133350cd-6aca-4f80-ab72-518852b0cda0"
      unitRef="usd">93000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEyLTEtMS0xLTA_26683af9-21cc-40e6-ba89-7ab1b0e4b38c"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEyLTMtMS0xLTA_e4fb350c-206e-4151-aded-67079ab1f868"
      unitRef="usd">613000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpkMDQ0NDkzOWM4NTg0ZWM5ODQ4NDVlZTMyMWNlZjgzYi90YWJsZXJhbmdlOmQwNDQ0OTM5Yzg1ODRlYzk4NDg0NWVlMzIxY2VmODNiXzEyLTUtMS0xLTA_5260d02f-9473-4a85-b069-286650920482"
      unitRef="usd">1412000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODI_27203e44-dcd5-43dc-89bc-4bef2e42f495">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% for the years ended December&#160;31, 2020, 2019 and 2018 to pretax income (loss) as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit) at federal statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium on equity issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash royalty revenue related to sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense on liability related to sale of future royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzM2Nw_5e86b5c0-ea92-4ad2-8438-b7cbd3c08a31"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzItMS0xLTEtMA_0ff30b04-96fc-4bf2-ae07-ea2fd225cfd7"
      unitRef="usd">-93229000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzItMy0xLTEtMA_dfe8aafd-ed31-40d3-94ad-d50d6ef4232c"
      unitRef="usd">-92411000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzItNS0xLTEtMA_02d0a079-2a03-4746-b8db-d56687fdf32a"
      unitRef="usd">143372000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzMtMS0xLTEtMA_c0b052ed-a863-4c75-8596-b47eb932ae55"
      unitRef="usd">3081000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzMtMy0xLTEtMA_223179e8-84ed-4c9a-ab79-046941dafb86"
      unitRef="usd">10511000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzMtNS0xLTEtMA_5a811fe3-1c4a-4415-a43a-93756f1545de"
      unitRef="usd">17295000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <nktr:IncomeTaxReconciliationPremiumOnEquityIssuance
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzYtMS0xLTEtMA_0327b3e5-fc7c-48fc-aa5f-73356892a840"
      unitRef="usd">0</nktr:IncomeTaxReconciliationPremiumOnEquityIssuance>
    <nktr:IncomeTaxReconciliationPremiumOnEquityIssuance
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzYtMy0xLTEtMA_78e61ece-9aad-48d1-bacc-4d45376c1a39"
      unitRef="usd">0</nktr:IncomeTaxReconciliationPremiumOnEquityIssuance>
    <nktr:IncomeTaxReconciliationPremiumOnEquityIssuance
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzYtNS0xLTEtMA_928b5cb5-1da4-49c4-ab62-34043c533759"
      unitRef="usd">12551000</nktr:IncomeTaxReconciliationPremiumOnEquityIssuance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzctMS0xLTEtMA_924c2524-dce3-4ba2-9a96-85421f02506a"
      unitRef="usd">87060000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzctMy0xLTEtMA_c18de8f0-9753-4053-ba83-cad5c0be3d73"
      unitRef="usd">104440000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzctNS0xLTEtMA_27868daa-52ab-4e92-ae27-616cbb565df0"
      unitRef="usd">-46885000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMS0xLTEtNTEzMg_5abc0626-9023-4412-8420-2d325004100f"
      unitRef="usd">7929000</nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost>
    <nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMy0xLTEtNTEzMg_dd9dc8c7-23da-44ab-b492-499bbc4e556d"
      unitRef="usd">-672000</nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost>
    <nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtNS0xLTEtNTEzMg_9922fbc3-32c7-4abd-b3d6-bcb1bb0ed5b6"
      unitRef="usd">-66716000</nktr:IncomeTaxReconciliationExpenseShareBasedCompensationCost>
    <nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMS0xLTEtNjM1OQ_c42a7e9c-d817-415b-854c-f76a613332d1"
      unitRef="usd">-7967000</nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties>
    <nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMy0xLTEtNjM1OQ_2492134c-1a36-40cc-9cc0-baf23a044717"
      unitRef="usd">-7624000</nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties>
    <nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtNS0xLTEtNjM1OQ_39d0e648-c8ea-4df6-a996-243593bbe8a5"
      unitRef="usd">-6995000</nktr:IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties>
    <nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMS0xLTEtMA_5978d4fe-05e2-4252-8e0a-1d97b8771b4a"
      unitRef="usd">6356000</nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties>
    <nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtMy0xLTEtMA_9607a055-e2a5-4722-9b5a-dca6b4bdb348"
      unitRef="usd">5259000</nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties>
    <nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzgtNS0xLTEtMA_51f71bdf-2f4c-4665-9da1-2340ea2a8af3"
      unitRef="usd">4451000</nktr:IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzExLTEtMS0xLTA_f1d9d8b1-4223-4184-9378-6e7537498ed8"
      unitRef="usd">3425000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzExLTMtMS0xLTA_944fbab9-e37a-49e7-862e-35f59aeea72c"
      unitRef="usd">2132000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzExLTUtMS0xLTA_83161ec3-f921-457f-aa28-39f23427f6ab"
      unitRef="usd">4031000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzEyLTEtMS0xLTA_2837e22f-32b6-4b7c-a389-9400728964bb"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzEyLTMtMS0xLTA_60dc521e-c174-44f1-9f00-5262ff45c0f9"
      unitRef="usd">613000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTpmMTgwMGE3OTYwMzM0NmVjYjVlNjVjZTg2YzI5OTU1OS90YWJsZXJhbmdlOmYxODAwYTc5NjAzMzQ2ZWNiNWU2NWNlODZjMjk5NTU5XzEyLTUtMS0xLTA_3ec40198-789d-4b07-8d7b-cc7d4d5db51b"
      unitRef="usd">1412000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4Nzc_f584e222-9432-440c-81cb-75d61849461e">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzMtMS0xLTEtMA_fff824cf-c6c6-477c-8fd5-e74aed06e499"
      unitRef="usd">456284000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzMtMy0xLTEtMA_74bd50bd-cbd4-4358-8f9f-5d299ba69582"
      unitRef="usd">399361000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzQtMS0xLTEtMA_fbc6aac2-e779-4d3a-8e3e-9e2f6dfabe6b"
      unitRef="usd">132994000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzQtMy0xLTEtMA_b4f3a83f-b090-4204-a7e5-d947407774d8"
      unitRef="usd">128015000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nktr:DeferredTaxAssetsLeaseLiability
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzUtMS0xLTEtMA_029a985b-0714-43ca-b9a1-47ea9ebe8d8b"
      unitRef="usd">35672000</nktr:DeferredTaxAssetsLeaseLiability>
    <nktr:DeferredTaxAssetsLeaseLiability
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzUtMy0xLTEtMA_280bd406-41ec-4d2a-918d-43b4c1848210"
      unitRef="usd">36907000</nktr:DeferredTaxAssetsLeaseLiability>
    <nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMS0xLTEtNTE0Ng_d0940a25-6e2d-43c3-9b51-115b3d8ada8c"
      unitRef="usd">32737000</nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties>
    <nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMy0xLTEtNTE1MA_cc607494-6964-4c89-a5bb-b44c4967cdeb"
      unitRef="usd">0</nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMS0xLTEtMA_c3dfbdee-3d77-4fb1-9bf1-3b516ea8965c"
      unitRef="usd">32517000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzYtMy0xLTEtMA_8f69bb95-5716-494a-bc59-d8885a0f79be"
      unitRef="usd">30875000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzctMS0xLTEtMA_99e5fb40-8665-4934-bbcc-82d9cda51bac"
      unitRef="usd">11688000</nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment>
    <nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzctMy0xLTEtMA_d8408a25-888f-4c1f-b110-38189e644a6d"
      unitRef="usd">13568000</nktr:DeferredTaxAssetsDepreciationPropertyAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzExLTEtMS0xLTA_27b22cff-6a70-47cb-87c8-ad2538aa6cdb"
      unitRef="usd">701892000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzExLTMtMS0xLTA_0b6730b4-ebd7-4cd4-b744-57973ea1c753"
      unitRef="usd">608726000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEyLTEtMS0xLTA_73c0150c-ab8c-419d-bfb4-7c54e4481846"
      unitRef="usd">670103000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEyLTMtMS0xLTA_a3942f9f-b03d-42da-9448-441b2cbff78f"
      unitRef="usd">575087000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEzLTEtMS0xLTA_b7702d58-ab79-4a5a-ad48-e6e4a6e97b96"
      unitRef="usd">31789000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzEzLTMtMS0xLTA_7c0f60b6-d8fb-4fed-8288-8139ce6dd189"
      unitRef="usd">33639000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE0LTEtMS0xLTA_51e1676a-338c-44cf-993f-29e9ec29b309"
      unitRef="usd">29707000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE0LTMtMS0xLTA_7f9b7e3a-ccc9-4b8d-8af1-3a20ed7fd027"
      unitRef="usd">31718000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE1LTEtMS0xLTA_070a0ee2-6852-44e4-bf2e-92965236e9e5"
      unitRef="usd">1856000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE1LTMtMS0xLTA_53652d0d-12c9-413a-8c5d-759615e38f16"
      unitRef="usd">1725000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE2LTEtMS0xLTA_9ecbccf1-2d14-4728-858c-98a43f90336b"
      unitRef="usd">31563000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE2LTMtMS0xLTA_45de9b17-5016-457d-a2ff-d1ac09afded5"
      unitRef="usd">33443000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE3LTEtMS0xLTA_6bf6832a-e89e-4082-ba9b-2cbc5a7b89b1"
      unitRef="usd">226000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTo2Y2E5NTk3YTE3NDM0NGM0YjBkNjhjYTY0NmI4OGYzNC90YWJsZXJhbmdlOjZjYTk1OTdhMTc0MzQ0YzRiMGQ2OGNhNjQ2Yjg4ZjM0XzE3LTMtMS0xLTA_eddb6eef-efe8-4489-8bd8-78b00a0e8135"
      unitRef="usd">196000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzExNTQ0ODcyMDk4Njgz_1679a805-7f26-4153-813b-02b8c5a13cec"
      unitRef="usd">-95000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzExNTQ0ODcyMDk4Njk2_6707ebd7-a57d-4e4a-873b-5637884cb62a"
      unitRef="usd">-114600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <nktr:NetOperatingLossCarryforwardForIncomeTax
      contextRef="id5394f004851433191f100501cea9fac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzkzNDU4NDg4NDg5MzU_c2ecca05-0175-4394-9f55-22dd1425c95d"
      unitRef="usd">2000000000.0</nktr:NetOperatingLossCarryforwardForIncomeTax>
    <nktr:NetOperatingLossCarryforwardForIncomeTax
      contextRef="i6d86a1180eaa4ff892518dd3441f1bb0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzkzNDU4NDg4NDg5NTE_efcfc404-a9a9-4186-93b4-18b0f2c9086a"
      unitRef="usd">1300000000</nktr:NetOperatingLossCarryforwardForIncomeTax>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i3fb46e064c7448bb96b707d5238157cc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjExNzk_6d64d044-92ff-4781-9444-f74ae82171e0"
      unitRef="usd">98900000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ida4ca2a391ba4e4e82c217bd8fd54a9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjExOTU_5a13b32b-782e-4a28-a637-3515e4e2ad4d"
      unitRef="usd">44000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <nktr:FederalOrphanDrugCredits
      contextRef="i3fb46e064c7448bb96b707d5238157cc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMTA_9180d008-1ba4-44dc-a8e7-19d47726d93d"
      unitRef="usd">17700000</nktr:FederalOrphanDrugCredits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzU4ODM_f48d2621-dd7a-4221-92c2-4785ca8cbaa9">We have the following activity relating to unrecognized tax benefits (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzItMS0xLTEtMA_1f5e967d-f21f-4e28-89e1-1aee8f92acee"
      unitRef="usd">77410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzItMy0xLTEtMA_26b629b0-da37-4280-9902-ca6a3d22e4ae"
      unitRef="usd">27419000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzItNS0xLTEtMA_dad33851-64bd-48df-9c95-91d80d788aa3"
      unitRef="usd">20483000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzUtMS0xLTEtMA_75b27657-6c2e-4132-9915-7adcfc246a14"
      unitRef="usd">2512000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzUtMy0xLTEtMA_33697074-5a49-4472-bd4c-a1979af77b41"
      unitRef="usd">49858000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzUtNS0xLTEtMA_f231657b-ae33-40a7-8d7d-68b7cd018265"
      unitRef="usd">5664000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzctMS0xLTEtMA_eadb1fdd-644e-4ab1-a6eb-703518eb4471"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzctMy0xLTEtMA_75f24526-3ff7-4fd5-9cd2-4f85d1420c71"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzctNS0xLTEtMA_dade79a1-6d35-49d9-ac0e-f75d6f2f469a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEwLTEtMS0xLTA_c0a6c062-45aa-45b9-98e7-3f22a723ad42"
      unitRef="usd">193000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEwLTMtMS0xLTA_57449dc3-f392-4422-9f9e-04b22fcddca9"
      unitRef="usd">277000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEwLTUtMS0xLTA_021b9d8b-03f8-4cc7-a924-9ab687f7e0e6"
      unitRef="usd">1272000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEzLTEtMS0xLTA_1cbaf002-01ad-49f5-9826-cba1b46b9750"
      unitRef="usd">1450000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEzLTMtMS0xLTA_954d1a26-6227-4a74-a360-2aa56839362a"
      unitRef="usd">144000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzEzLTUtMS0xLTA_9aaa4839-c3b0-45b0-939d-8a4fa89cda87"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE0LTEtMS0xLTA_fb38a184-957c-42b8-8a4d-ea4a750664c3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE0LTMtMS0xLTA_a32902a2-658a-4442-a7d2-605c4f7966b8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE0LTUtMS0xLTA_a1756357-c0d8-42db-9324-7985b16cc237"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE1LTEtMS0xLTA_bc07fc27-b075-4096-9ec3-448477f38a6f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE1LTMtMS0xLTA_b8120faa-2161-4846-8dc4-9788a95b03ae"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE1LTUtMS0xLTA_a0f614a2-7fbd-4fc2-8e50-642158e244ff"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icda9c88f4be148df8868cedf7bc4b3eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE2LTEtMS0xLTA_1de87728-67d0-4225-94cf-1209f8765dc9"
      unitRef="usd">78665000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib61c61ebd4ad4075a8831d9455982999_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE2LTMtMS0xLTA_3368646b-66d9-42a6-ba41-24f99182a579"
      unitRef="usd">77410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i61f23b96cd474a7d9187b5b79c2a289b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90YWJsZTphYzk3ZmFiYTc0MDQ0YmU5ODAyYmZhYjJkZGQ0YzQyOC90YWJsZXJhbmdlOmFjOTdmYWJhNzQwNDRiZTk4MDJiZmFiMmRkZDRjNDI4XzE2LTUtMS0xLTA_e23da9a6-38ea-484c-921a-d88657a4dd5e"
      unitRef="usd">27419000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_33dd2bd6-2c77-46e4-8c1f-4fb98f1f2741"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_65064956-49e8-4e7d-bb12-5aff91ed4edb"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_76095e73-5a82-41e4-bd35-c3815579b27d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_93f3a905-6553-4cc9-b090-765b32742332"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_b4b9f16a-b1c9-4bfb-ad3f-8217a74f9570"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMjEyMjQ_f235e6d7-597c-4c6f-99ef-020649d0dc6c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTEvZnJhZzowNGQ3ODM1YzdkMmQ0MWFmOWZlOWM2NTI1ZGJhMDNlYy90ZXh0cmVnaW9uOjA0ZDc4MzVjN2QyZDQxYWY5ZmU5YzY1MjVkYmEwM2VjXzgyNDYzMzcyMTQyMTg_db42358b-87a1-4121-8ea9-e5e19130c8fa">P12M</nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzOTA_5ae14213-debe-48a1-8efc-ed1482f053dc">Segment Reporting&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 33%, 23%, 14% and 13% of our revenue, respectively, for the year ended December&#160;31, 2020. Revenue from UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 28%, 19%, and 17% of our revenue for the year-ended December 31, 2019. Revenue from BMS represented 89% of our revenue, for the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;At December&#160;31, 2020, $54.5 million, or approximately 91%, of the net book value of our property, plant and equipment was located in the United States and $5.1 million, or approximately 9%, was located in India.&#160;At December&#160;31, &lt;/span&gt;&lt;/div&gt;2019, $59.7 million, or approximately 92%, of the net book value of our property, plant and equipment was located in the United States&#160;and $5.3 million, or approximately 8%, was located in India.</us-gaap:SegmentReportingDisclosureTextBlock>
    <nktr:NumberOfOperatingBusinessSegment
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzQ4_3a133711-c16d-4c8d-8557-1a4a23bfd283"
      unitRef="segment">1</nktr:NumberOfOperatingBusinessSegment>
    <nktr:NumberOfOperatingBusinessSegment
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzNzQzODk1MzQ4OTMz_3a133711-c16d-4c8d-8557-1a4a23bfd283"
      unitRef="segment">1</nktr:NumberOfOperatingBusinessSegment>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0724493c13744e74aba58429991051ff_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzg3OTYwOTMwMjM3NTE_70617999-dd41-4180-a75b-5ff1c81eef7b"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8930ee506074b1a80dcb28134fd5773_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzYxMA_398810e4-90d0-4158-a2ac-0e020e50601f"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ide398b6debeb4fb7a095f0df2975ccd3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwMjg_e340983f-9ded-43e2-ab81-3debf9bf09db"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i049d56950da443d782603343643146ce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzYxNw_fb66d766-beb1-432e-8c85-228bbeacd9b6"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0866d8705ad34c20932d7388fb164e35_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwMzM_7d525e44-2f3b-4a12-9a2e-4cd25f28d774"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i817f31328f764ac8a65d4340427e73dc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwMzg_bcfb498f-95bd-46d2-ae29-970b6bb93e33"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie32b099d78c041bcb200c8d5438e369a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzgyNDYzMzcyMTAwNDM_9e52e1b2-9a2c-42f5-9d5a-38f79bb5622d"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i62cad6a1a032445e971b3fd80be0ab88_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzcwMg_964b4805-7283-4033-bb64-5153a5575652"
      unitRef="number">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzOTI_2cd84d27-869a-4b42-8b65-5562eef2dbcd">The following table sets forth revenue by geographic area (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib912063d910845aaa45f66edaa7d2535_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzItMS0xLTEtMA_c5b799c2-5b1e-4cc0-a39b-a8e28e48cfc4"
      unitRef="usd">64966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88ca9a944946417a9bd26c7ff3bd0df2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzItMy0xLTEtMA_a16146ad-a4c3-4816-b58d-908a53e373b2"
      unitRef="usd">27093000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee76c326075144bc9957970824864572_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzItNS0xLTEtMA_3787f5a2-b14d-4957-861e-9c234b79f9d6"
      unitRef="usd">1090794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacd671a84bd84c26a9c4e33c4b75a08c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzMtMS0xLTEtMA_fb6a0b23-81e8-4594-8c87-2b56b0260aa4"
      unitRef="usd">87949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d365863714c4ed5890fc77835d41d57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzMtMy0xLTEtMA_7cc5ca65-0dc1-4cd9-95cd-2b88e551f01f"
      unitRef="usd">87524000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c86ae7fa4cc46ac95c142f23e235a82_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzMtNS0xLTEtMA_248fe770-c80b-4c67-a866-806b21fee7e2"
      unitRef="usd">102529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzQtMS0xLTEtMA_256e7508-60d7-49c9-9583-d5c00bb7baea"
      unitRef="usd">152915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e42382010684589ae133dbe68f6abdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzQtMy0xLTEtMA_c0cf77d2-495e-4e3b-b1a1-a7773a1f4f77"
      unitRef="usd">114617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90YWJsZTo3MDBlYmExY2IxOGY0YzhlYTUzNzUzNzc0NzM3OGI3ZC90YWJsZXJhbmdlOjcwMGViYTFjYjE4ZjRjOGVhNTM3NTM3NzQ3Mzc4YjdkXzQtNS0xLTEtMA_be836463-66c3-49a7-8075-8304cf44fd47"
      unitRef="usd">1193323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5eb25dc75983449abf52bac9890f50f5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEwNDg_88924f01-c167-4fa8-96db-46cac23a5587"
      unitRef="usd">54500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iccee95850b064fbd8b0c1431a6df105f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEwNjk_a6a53565-0bd0-42bf-a376-74291126a090"
      unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i85fff8d911974f27b78a9941b7f50432_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzExNjk_759441e3-24df-4dbb-aa35-ca814c18ff2b"
      unitRef="usd">5100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0eabcb407913449e87ce37aa8d0de239_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzExOTA_1fc245a7-3094-431a-82e4-6cf788980922"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia4d086dadf3f44dba9615056bd07087d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEyMjM_07b78f4b-fd56-4d34-a536-9aab4e76b7af"
      unitRef="usd">59700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i36d6b1d26b224dc59df8dcedba587fed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEyNDQ_91317178-bbe8-4f01-8682-56118d80e4dd"
      unitRef="number">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idf35774709d841d3b44284705950593c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzNDQ_e38f88be-9b8b-4ea6-8935-32dbd8eea972"
      unitRef="usd">5300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7199da49f7844202b5dabcf7a621af2e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNTcvZnJhZzphYTAyYzUwMmIzMGQ0OTc1OTI1Mzc0YzUyMDcwZjJhMy90ZXh0cmVnaW9uOmFhMDJjNTAyYjMwZDQ5NzU5MjUzNzRjNTIwNzBmMmEzXzEzNjU_bdd7aef5-0325-42e7-a12b-f18ef7ec7ac4"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3Xzc2NQ_d07366a6-d213-4601-8b0f-4124832be71d">Subsequent Event&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February 12, 2021, we entered into a co-development agreement (the Agreement) with SFJ Pharmaceuticals XII, L.P., an SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and approval activities for bempegaldesleukin. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including the treatment of previously untreated unresectable or metastatic melanoma (the &#x201c;Melanoma Indication&#x201d; and the &#x201c;Melanoma Clinical Trial&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and/or the SCCHN Clinical Trial do not meet their primary endpoints. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the completion of certain SCCHN Clinical Trial activities. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0&#160;million, paid in annual installments over five years. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0&#160;million, paid in annual installments over seven years. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5&#160;million to SFJ. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the Agreement. The Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The Agreement may also be terminated by either party for material breach or insolvency of the counterparty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc3MzA_00b2afd1-ab66-4e38-9db8-8c2b0f2734fa"
      unitRef="usd">150000000.0</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication
      contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc3NzI_e45b728e-dec7-43d5-bf71-6d89903c6705"
      unitRef="usd">450000000.0</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid
      contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc5NjQ_6d636513-68a5-428c-88b9-ba0ee810a44a">P5Y</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication
      contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc3ODY_71065761-309a-4e5d-a0f8-a13493e88b69"
      unitRef="usd">150000000.0</nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid
      contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc4MDg_41dfc566-9e3d-41e2-a1ce-152842c45bcc">P7Y</nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid>
    <nktr:CollaborativeArrangementAdditionalIndicationPayment
      contextRef="if0342284791141f9aca1142441d62cf0_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjAvZnJhZzpiMjk0MDdlYjA2NDk0YmE4OWQ5M2E5YmMxMDY5MmM4Ny90ZXh0cmVnaW9uOmIyOTQwN2ViMDY0OTRiYTg5ZDkzYTliYzEwNjkyYzg3XzgyNDYzMzcyMjc4OTE_74cb4451-6bf1-409f-8b5a-d419e1a09dab"
      unitRef="usd">37500000</nktr:CollaborativeArrangementAdditionalIndicationPayment>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90ZXh0cmVnaW9uOmIwMGRlZTU3NDM3ODQyNDVhZDM4ZDUzNzI0NzU0ZDdkXzE0NzE_bf8d0077-5e15-429f-88fb-3f06d746b6d9">Selected Quarterly Financial Data (Unaudited)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Quarterly income (loss) per share amounts may not total to the year-to-date income (loss) per share due to rounding.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90ZXh0cmVnaW9uOmIwMGRlZTU3NDM3ODQyNDVhZDM4ZDUzNzI0NzU0ZDdkXzE0NzM_dad1f969-839d-48c5-8b41-bee6bf17f1fd">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Quarterly income (loss) per share amounts may not total to the year-to-date income (loss) per share due to rounding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb0e3cb012e04c40b706573437e7c400_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMS0xLTEtMA_4ae99a70-9be2-493f-af55-b83721d05c55"
      unitRef="usd">3444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia127b30b5a3e436e9d93336b81801699_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMy0xLTEtMA_43590b39-f75e-4f01-9553-40efcb8c6376"
      unitRef="usd">5485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2ecf9e44f3a485789e47ee440d1fb61_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItNS0xLTEtMA_ad2b4f32-e400-4306-b411-b2d35a64130d"
      unitRef="usd">5691000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d570eb5ffd48c4939a02adc32bc003_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItNy0xLTEtMA_10afdd28-c3f4-4aa0-adb6-905d44f09ab9"
      unitRef="usd">2884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i115533df786243e0b7e302d7e193fa82_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItOS0xLTEtMA_83372238-4211-4058-9833-1ca48061948a"
      unitRef="usd">4398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4adfa1d6b5b54a02b009b9b036e26e11_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMTEtMS0xLTA_b5c5ed42-8e9c-49fb-8f14-318766a11719"
      unitRef="usd">4346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4187a897c35f46c2a1363434d9f54ce6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMTMtMS0xLTA_4e7b2393-7301-4528-884f-12b3f4f731dc"
      unitRef="usd">5558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ffc21a2ccee43aa8a8e12d940741920_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzItMTUtMS0xLTA_fe4bf83a-4805-4ab0-9a86-e7785e7da265"
      unitRef="usd">5815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMS0xLTEtMA_da1bed1a-108b-4a15-a76d-693a95b09121"
      unitRef="usd">50573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMy0xLTEtMA_2e68294c-c522-41dc-b046-048a6d5bb8f9"
      unitRef="usd">48847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtNS0xLTEtMA_2527923f-71bb-4960-938c-e9611639fea3"
      unitRef="usd">30033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtNy0xLTEtMA_424d7642-bbf2-4519-8b96-5fc600f6997b"
      unitRef="usd">23462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtOS0xLTEtMA_9e5b24d0-14ff-4a41-a007-adc03a177271"
      unitRef="usd">28222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMTEtMS0xLTA_2d1890e6-18a8-469a-9621-28e83a3c8268"
      unitRef="usd">23315000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMTMtMS0xLTA_d16ce902-b335-4d01-8ef4-355669dc01b2"
      unitRef="usd">29218000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzMtMTUtMS0xLTA_dc6bd052-f53f-4067-98af-8794af654376"
      unitRef="usd">33862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMS0xLTEtMA_f81ea005-353b-46ce-9d1e-6e175ffa5082"
      unitRef="usd">3811000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMy0xLTEtMA_21baae11-4ea0-483c-9328-c376b5ab4a20"
      unitRef="usd">5773000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtNS0xLTEtMA_b8542f9e-fe82-4f4e-b6d1-ad9f01a612d9"
      unitRef="usd">5570000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtNy0xLTEtMA_20d8ea02-6c53-4ec0-8cb0-f73330920c6d"
      unitRef="usd">4323000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtOS0xLTEtMA_574939be-592a-486c-be74-27811cf0d6bb"
      unitRef="usd">5440000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMTEtMS0xLTA_202715a2-1252-4799-acb2-17f832670baf"
      unitRef="usd">5018000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMTMtMS0xLTA_a8f2c400-16cf-4491-8e44-f45e7788cdc5"
      unitRef="usd">4927000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzQtMTUtMS0xLTA_48c9973b-88c6-458b-bd10-e4292872b511"
      unitRef="usd">5989000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMS0xLTEtMA_46092d2d-46a6-49b4-9059-f287809ee3c4"
      unitRef="usd">108987000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMy0xLTEtMA_231d78a1-ba00-45e7-8975-d4fef7039f19"
      unitRef="usd">96436000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtNS0xLTEtMA_067838c5-1053-433d-a956-950cca4cba4a"
      unitRef="usd">100531000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtNy0xLTEtMA_09fafe19-e0a4-4047-a1ac-b8fba15670ad"
      unitRef="usd">102724000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtOS0xLTEtMA_4b3dadf1-5570-412c-b4ec-5646bdc83f45"
      unitRef="usd">118463000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMTEtMS0xLTA_6bb1098b-c9d3-4704-88f3-8558aaed3f75"
      unitRef="usd">106686000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMTMtMS0xLTA_065405f1-2da7-41a2-bfd7-3423844768fe"
      unitRef="usd">99048000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzUtMTUtMS0xLTA_8da87de4-8f6e-40aa-bf92-0223db06d9ec"
      unitRef="usd">110369000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMS0xLTEtMA_3e3dcc6f-a0cc-45ee-9f21-1b76df19ae0e"
      unitRef="usd">-133631000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMy0xLTEtMA_8b063fe6-c74e-4a6c-b811-af6781afebb5"
      unitRef="usd">-77709000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtNS0xLTEtMA_623a716b-5780-4ef3-86ea-d9d2176bca92"
      unitRef="usd">-103050000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtNy0xLTEtMA_f37a19d9-db39-4f47-a0b6-e888a4862f11"
      unitRef="usd">-110721000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtOS0xLTEtMA_c310d278-6da3-48e4-8247-0184703341fc"
      unitRef="usd">-120687000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMTEtMS0xLTA_037cef0c-e88e-4165-8f95-7cf7be67b83a"
      unitRef="usd">-110970000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMTMtMS0xLTA_05a77077-30f7-47bd-9441-1f5955b941fc"
      unitRef="usd">-98740000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzYtMTUtMS0xLTA_19fa885a-b756-4e4d-a0b5-43c92a891b2f"
      unitRef="usd">-109638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMS0xLTEtMA_d2f6dabb-df2b-4233-bc36-a2a27c71804c"
      unitRef="usd">-138651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMy0xLTEtMA_4806a6e6-4f2c-4d06-be24-b97effbfe7a5"
      unitRef="usd">-80000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctNS0xLTEtMA_1bb87492-c37a-4e5b-815b-f6b1bf037bd7"
      unitRef="usd">-108586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctNy0xLTEtMA_91db3ee5-4eec-4fb8-8c25-e6c38bf6035d"
      unitRef="usd">-117203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctOS0xLTEtMA_81e828a5-ecd0-4338-a0c5-eb522aaadafd"
      unitRef="usd">-119632000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMTEtMS0xLTA_0dc6b072-58b1-4b09-a8ea-e09c6efef440"
      unitRef="usd">-110286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMTMtMS0xLTA_df3320b5-eb90-40ca-9a72-84d398931579"
      unitRef="usd">-98585000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzctMTUtMS0xLTA_d3ed5c1e-a44e-4209-aaed-714672f08f0f"
      unitRef="usd">-112164000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMS0xLTEtMA_2ba3be3b-fcde-4449-97c4-83fd194b5a2b"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMy0xLTEtMA_1b9eb6cd-38b9-42ea-a631-cf6a680810db"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktNS0xLTEtMA_575da072-40f5-4286-a068-b04d774a102f"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktNy0xLTEtMA_08b28966-fb59-43f2-9340-c683ec093bce"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktOS0xLTEtMA_5a3c7834-d984-47f9-8da6-2de129dfb890"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMTEtMS0xLTA_dc795032-a7e6-46d8-838e-16e7b46620b0"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMTMtMS0xLTA_59297d3d-9b79-4e1d-b39b-e6d0cc4032d2"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzktMTUtMS0xLTA_30b47e7d-c025-4e24-a369-ee4e1f200099"
      unitRef="usdPerShare">-0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id7710329fc21449a944ba1739f98c260_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTEtMS0xLTA_3419bf1e-3e14-4803-b4f9-b18a1926c3b9"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id0c533d0b95a45e6a14de514d56e133d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTMtMS0xLTA_03fd1573-030e-4f22-af8a-ffd5b04c9bf8"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifcc719ea1a234d898be11b92fd735b8e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTUtMS0xLTA_8a709d17-8b5b-4438-99d9-2d0ca55e44f5"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTctMS0xLTA_26136842-356c-45b3-bfad-616836f339eb"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i59c8a8bf96524bd9b32d2b96b110dab3_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTktMS0xLTA_5b51e845-0f6c-46f2-a389-25c5361b7a29"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i24ba981bd08f46db893ccb0c8a82e5fb_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTExLTEtMS0w_866f3d09-6aa9-4e2e-8079-18cee56f4205"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4d517fa7fab44ea58250189810d9ec29_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTEzLTEtMS0w_c2a4dfa4-92b8-449c-a806-135b326f0db7"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia4d480e6c3354e75b6ac0706644e5196_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xNjMvZnJhZzpiMDBkZWU1NzQzNzg0MjQ1YWQzOGQ1MzcyNDc1NGQ3ZC90YWJsZTozNmI2OGU5ZWJkNTc0MjcyOGY4ZGQwNjAwZTU2MmI3Mi90YWJsZXJhbmdlOjM2YjY4ZTllYmQ1NzQyNzI4ZjhkZDA2MDBlNTYyYjcyXzEwLTE1LTEtMS0w_b3c6b1f5-78a7-407b-90b1-b6676c4a20d0"
      unitRef="usdPerShare">-0.64</us-gaap:EarningsPerShareDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159361528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 17, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,182,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of registrant&#8217;s definitive Proxy Statement to be filed for its 2020 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159428776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 198,955<span></span>
</td>
<td class="nump">$ 96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">862,941<span></span>
</td>
<td class="nump">1,228,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">38,889<span></span>
</td>
<td class="nump">36,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">15,292<span></span>
</td>
<td class="nump">12,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AdvancePaymentsToContractManufacturers', window );">Advance payments to contract manufacturers</a></td>
<td class="nump">3,908<span></span>
</td>
<td class="nump">31,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">18,020<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,138,005<span></span>
</td>
<td class="nump">1,421,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">136,662<span></span>
</td>
<td class="nump">279,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">59,662<span></span>
</td>
<td class="nump">65,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">126,476<span></span>
</td>
<td class="nump">134,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Other assets</a></td>
<td class="nump">1,538,767<span></span>
</td>
<td class="nump">1,977,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Senior secured notes, net and interest payable (see Note 5)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">252,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">22,139<span></span>
</td>
<td class="nump">19,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">14,532<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">44,207<span></span>
</td>
<td class="nump">32,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedContractManufacturingExpenseCurrent', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">11,310<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">9,585<span></span>
</td>
<td class="nump">12,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">13,915<span></span>
</td>
<td class="nump">12,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">5,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">115,779<span></span>
</td>
<td class="nump">353,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="nump">136,373<span></span>
</td>
<td class="nump">142,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">200,340<span></span>
</td>
<td class="nump">72,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">6,516<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">461,472<span></span>
</td>
<td class="nump">571,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2020 or 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 180,091 shares and 176,505 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,388,730<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,295)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,309,158)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,077,295<span></span>
</td>
<td class="nump">1,405,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,538,767<span></span>
</td>
<td class="nump">$ 1,977,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedContractManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedContractManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AdvancePaymentsToContractManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance payments to contract manufacturers, net of amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AdvancePaymentsToContractManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724243492712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">180,091,000<span></span>
</td>
<td class="nump">176,505,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">180,091,000<span></span>
</td>
<td class="nump">176,505,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724163317208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 152,915<span></span>
</td>
<td class="nump">$ 114,617<span></span>
</td>
<td class="nump">$ 1,193,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">19,477<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
<td class="nump">24,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">408,678<span></span>
</td>
<td class="nump">434,566<span></span>
</td>
<td class="nump">399,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">104,682<span></span>
</td>
<td class="nump">98,712<span></span>
</td>
<td class="nump">81,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="nump">45,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">578,026<span></span>
</td>
<td class="nump">554,652<span></span>
</td>
<td class="nump">505,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(425,111)<span></span>
</td>
<td class="num">(440,035)<span></span>
</td>
<td class="nump">687,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,851)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
<td class="num">(21,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="num">(30,267)<span></span>
</td>
<td class="num">(25,044)<span></span>
</td>
<td class="num">(21,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">18,282<span></span>
</td>
<td class="nump">46,335<span></span>
</td>
<td class="nump">37,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expense, net</a></td>
<td class="num">(18,836)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(5,207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="num">(443,947)<span></span>
</td>
<td class="num">(440,054)<span></span>
</td>
<td class="nump">682,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="num">$ (440,667)<span></span>
</td>
<td class="nump">$ 681,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic ( in dollars per share)</a></td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
<td class="nump">$ 3.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding used in computing net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">178,581<span></span>
</td>
<td class="nump">174,993<span></span>
</td>
<td class="nump">169,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">178,581<span></span>
</td>
<td class="nump">174,993<span></span>
</td>
<td class="nump">180,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 17,504<span></span>
</td>
<td class="nump">$ 20,117<span></span>
</td>
<td class="nump">$ 20,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">30,999<span></span>
</td>
<td class="nump">41,222<span></span>
</td>
<td class="nump">41,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">48,563<span></span>
</td>
<td class="nump">36,303<span></span>
</td>
<td class="nump">33,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 55,849<span></span>
</td>
<td class="nump">$ 16,975<span></span>
</td>
<td class="nump">$ 1,097,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of equipment and other costs for terminated program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159871928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="num">$ (440,667)<span></span>
</td>
<td class="nump">$ 681,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(927)<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
<td class="num">(2,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,290)<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
<td class="num">(4,205)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (445,730)<span></span>
</td>
<td class="num">$ (435,356)<span></span>
</td>
<td class="nump">$ 677,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159525256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 87,828<span></span>
</td>
<td class="nump">$ 12,577<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2,207,865<span></span>
</td>
<td class="num">$ (2,111)<span></span>
</td>
<td class="num">$ (2,117,941)<span></span>
</td>
<td class="nump">$ 12,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">61,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">61,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">88,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock to Bristol-Myers Squibb (Note 10) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock to Bristol-Myers Squibb (Note 10)</a></td>
<td class="nump">790,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">790,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">677,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,205)<span></span>
</td>
<td class="nump">681,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">1,717,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,147,925<span></span>
</td>
<td class="num">(6,316)<span></span>
</td>
<td class="num">(1,424,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">23,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">99,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(435,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
<td class="num">(440,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">1,405,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">23,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">23,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(445,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(444,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,077,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 3,388,730<span></span>
</td>
<td class="num">$ (2,295)<span></span>
</td>
<td class="num">$ (2,309,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159477960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">106 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (444,440,000)<span></span>
</td>
<td class="num">$ (440,667,000)<span></span>
</td>
<td class="nump">$ 681,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(48,563,000)<span></span>
</td>
<td class="num">(36,303,000)<span></span>
</td>
<td class="num">(33,308,000)<span></span>
</td>
<td class="num">$ (255,705,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">30,267,000<span></span>
</td>
<td class="nump">25,044,000<span></span>
</td>
<td class="nump">21,196,000<span></span>
</td>
<td class="nump">196,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">94,261,000<span></span>
</td>
<td class="nump">99,795,000<span></span>
</td>
<td class="nump">88,101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,182,000<span></span>
</td>
<td class="nump">13,156,000<span></span>
</td>
<td class="nump">10,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram', window );">Impairment of advance payments to contract manufacturers and equipment for terminated program</a></td>
<td class="nump">20,351,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions', window );">Accretion of premiums (discounts), net and other non-cash transactions</a></td>
<td class="nump">3,943,000<span></span>
</td>
<td class="num">(11,394,000)<span></span>
</td>
<td class="num">(10,952,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,913,000<span></span>
</td>
<td class="nump">6,411,000<span></span>
</td>
<td class="num">(25,505,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,627,000)<span></span>
</td>
<td class="num">(1,284,000)<span></span>
</td>
<td class="num">(655,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="nump">2,743,000<span></span>
</td>
<td class="nump">13,090,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">4,476,000<span></span>
</td>
<td class="nump">1,190,000<span></span>
</td>
<td class="num">(31,652,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,382,000<span></span>
</td>
<td class="nump">12,967,000<span></span>
</td>
<td class="nump">971,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">4,697,000<span></span>
</td>
<td class="nump">1,530,000<span></span>
</td>
<td class="nump">1,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">8,644,000<span></span>
</td>
<td class="nump">4,349,000<span></span>
</td>
<td class="nump">31,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(5,516,000)<span></span>
</td>
<td class="num">(16,565,000)<span></span>
</td>
<td class="num">(15,331,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(313,287,000)<span></span>
</td>
<td class="num">(328,681,000)<span></span>
</td>
<td class="nump">718,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(987,533,000)<span></span>
</td>
<td class="num">(1,380,865,000)<span></span>
</td>
<td class="num">(2,271,250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">1,449,304,000<span></span>
</td>
<td class="nump">1,614,036,000<span></span>
</td>
<td class="nump">890,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">41,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(7,258,000)<span></span>
</td>
<td class="num">(26,285,000)<span></span>
</td>
<td class="num">(14,239,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales of property and plant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">496,213,000<span></span>
</td>
<td class="nump">206,886,000<span></span>
</td>
<td class="num">(1,379,936,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock to Bristol-Myers Squibb (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">790,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfFutureRoyaltiesNet', window );">Proceeds from sale of future royalties, net of $3.8 million of transaction costs</a></td>
<td class="nump">146,250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">23,396,000<span></span>
</td>
<td class="nump">23,355,000<span></span>
</td>
<td class="nump">61,735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(80,354,000)<span></span>
</td>
<td class="nump">23,355,000<span></span>
</td>
<td class="nump">851,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="num">(102,000)<span></span>
</td>
<td class="num">(101,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">102,592,000<span></span>
</td>
<td class="num">(98,542,000)<span></span>
</td>
<td class="nump">190,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">96,363,000<span></span>
</td>
<td class="nump">194,905,000<span></span>
</td>
<td class="nump">4,762,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">198,955,000<span></span>
</td>
<td class="nump">96,363,000<span></span>
</td>
<td class="nump">194,905,000<span></span>
</td>
<td class="nump">$ 198,955,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">9,742,000<span></span>
</td>
<td class="nump">19,199,000<span></span>
</td>
<td class="nump">19,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
<td class="nump">618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 2,133,000<span></span>
</td>
<td class="nump">$ 57,691,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccretionOfDiscountNetAndOtherNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of discount net and other non-cash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccretionOfDiscountNetAndOtherNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of equipment from terminated program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentFromTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfFutureRoyaltiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Future Royalties, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfFutureRoyaltiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157767144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfFutureRoyaltiesTransactionCosts', window );">Sale of future royalties transaction costs</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfFutureRoyaltiesTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Royalties Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfFutureRoyaltiesTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155713304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&#160;31, 2020, we had approximately $1.2 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8&#160;million. See Note 5 for additional information.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income loss. We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our cash, cash equivalents, short-term investments and long-term investments are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents, short-term investments and long-term investments are held or issued by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Significant Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. For the year ended December&#160;31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $0.2 million under customer contracts from our collaboration partners. For the year ended December&#160;31, 2019, our accounts receivable included $24.0 million for unbilled net expense reimbursements from BMS and $12.8 million from customer contracts, which included our estimate of $11.6&#160;million for royalties resulting from net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended December 31, 2019. Since we sold our rights to receive royalties in the 2020 Purchase and Sale Agreement with Healthcare Royalty Management, LLC, as discussed further in Note 7, we did not record accounts receivable for these royalties at </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020. We generally do not require collateral from our partners. We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable. At December&#160;31, 2019, three different partners represented 65%, 17% and 14%, respectively, of our accounts receivable.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). ASC 842 supersedes the guidance in ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the year ended December 31, 2020 and 2019 under ASC 842. We have not restated the results for the year ended December 31, 2018 continue to report them under ASC 840.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 6 for additional information regarding our leases.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57">three</span> to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program after March 31, 2020. As of December&#160;31, 2020, we have substantially completed our wind-down and do not expect to incur additional costs.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs) and performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs and PSUs on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options and RSUs that vest upon the achievement of performance milestones, we estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. We recognize stock-based compensation expense for purchases under the ESPP over the respective six-month purchase period. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under the ESPP. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management will continue to assess the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and which could materially impact our fair value determination.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net income (loss) available to common stockholders is equal to the reported net income (loss). We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities, which consist of common shares underlying stock options and RSUs. For the years ended December 31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options and RSUs totaling 17.4 million and 17.9 million for the years ended December 31, 2020 and 2019, respectively. For the year ended December 31, 2018, the effect of these dilutive securities under the treasury stock method was approximately 10.5 million, and we excluded approximately 3.3 million of weighted-average shares of common stock underlying outstanding stock options from the computation of diluted net income per share because&#160;their effect was antidilutive.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive income (loss) is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our other comprehensive income (loss) includes net income (loss), gains and losses from the foreign currency translation of the assets and liabilities of our India and UK subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief, and Economic Security (CARES) Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act has not had a material effect on our results of operations or financial position.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Consolidated Financial Statements. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed other recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155436680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,955&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,363&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2020 and 2019 had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_65dac629-914e-42fe-8970-b4d9eec444dc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85Ny9mcmFnOjQ4YzUzZWI0ZjFmNzQzZTlhNDRjMjgyOGI3OGJmYjhjL3RleHRyZWdpb246NDhjNTNlYjRmMWY3NDNlOWE0NGMyODI4Yjc4YmZiOGNfNTU0_d24a00d0-9f20-48ec-989c-a46dae10d5c7">one</span></span> and two years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2020 and 2018, we sold available-for-sale securities totaling $41.7&#160;million and $12.0&#160;million, respectively. Gross realized gains and losses on those sales were not significant. During the year ended December&#160;31, 2019, we did not sell any of our available-for-sale securities. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $5.1&#160;million and $6.5&#160;million at December&#160;31, 2020 and December&#160;31, 2019, respectively, in other current assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507,655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. For the years ended December&#160;31, 2020 and 2019, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December 31, 2019, our gross unrealized gains and losses totaled $2.1&#160;million and $0.3&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $8.1 million and $6.8 million, respectively. These letters of credit are secured by investments of similar amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724158995896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155730696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Property, plant and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,977&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,097&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,684&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,910&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,322&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,488)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,875)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,962&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,662&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense on property, plant and equipment for the years ended December&#160;31, 2020, 2019, and 2018 was $12.5 million, $11.0 million, and $8.8 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157212824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior Secured Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Senior Secured Notes</a></td>
<td class="text">Senior Secured Notes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would have been due and payable. In connection with the issuance of the Notes, we paid fees and expenses of $8.9&#160;million, of which $8.7&#160;million of transaction and facility fees paid directly to the purchasers of the Notes and other direct issuance costs were recorded as a discount to the senior secured notes, net liability balance in our Consolidated Balance Sheet.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162597880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our 153,203 square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional 135,936 square foot facility to support our R&amp;D operations at 360 Third Street, San Francisco, California (the Third Street Facility). The following table presents key information regarding these leases (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a">five</span>-year term</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The monthly base rent for both facilities will escalate over the term of the lease at various intervals. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize rent expense for these operating leases on a straight-line basis over the lease period. The components of lease costs, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"/><td style="width:64.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2020 and 2019, we recorded operating lease expense of $19.0 million and $14.7 million, respectively, and paid $16.2 million and $8.4&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash provided by (used in) operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease incentives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, the weighted-average remaining lease term is 9.1 years and the weighted-average discount rate used to determine the operating lease liability was 5.9%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155706632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract', window );"><strong>Liability Related To Sale Of Potential Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liabilities Related to the Sales of Future Royalties</a></td>
<td class="text">Liabilities Related to the Sales of Future Royalties<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the 2012 Transaction Royalties.&#160;As part of this sale, we incurred approximately $4.4 million in transaction costs, which we will amortize to interest expense over the estimated life of the 2012 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxter Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. We did not recognize any non-cash interest expense from closing on December 30, 2020 to December 31, 2020 as any imputed interest was immaterial.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account during the year ended December&#160;31, 2020 and for the period from the inception of the 2012 Purchase and Sale Agreement on February 24, 2012 (inception) and the 2020 Purchase and Sale Agreement on December 30, 2020 to December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"/><td style="width:42.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In addition, the 2012 and 2020 Purchase and Sale Agreements grant RPI and HCR, respectively, the right to receive certain reports and other information relating to the 2012 and 2020 Transaction Royalties, respectively, and contains other representations and warranties, covenants and indemnification obligations that are customary for transactions of this nature. To our knowledge, we are currently in compliance with these provisions of the 2012 and 2020 Purchase and Sale Agreements; however, if we were to breach our obligations, we could be required to pay damages to RPI and HCR, respectively, that are not limited to the purchase prices we received in the sale transactions. However, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155496296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2020, these commitments were approximately $8.0 million, all of which we expect to pay in 2021.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (U.S. District Court in California), which complaint was subsequently amended on May 15, 2019.&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of our board of directors. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. On December 30, 2020, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, and denied plaintiffs with the ability to file a further amended complaint.  Following the motion to dismiss, on January 29, 2021, the class action plaintiffs filed a Notice to Appeal to appeal the district court&#8217;s decision to the U.S. Court of Appeals for the Ninth Circuit.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in U.S. District Court in California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in U.S. District Court in California  naming the CEO, CFO and certain members of our board of directors, which derivative complaints were consolidated and subsequently amended on July 1, 2020. The class action and shareholder derivative complaints assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. On January 26, 2021, the U.S. District Court in California granted Nektar&#8217;s motion to dismiss all claims in this securities class action filing, stating (among other things) that &#8220;Defendants&#8217; open disclosure of risks associated with trial delay &#8230; suggests that </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they acted openly with investors.&#8221; Following the motion, the class action plaintiffs have an opportunity to file in early March a further amended complaint and the case remains pending.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, certain of our current and past directors and executives were named in a shareholder derivative complaint filed in the Court of Chancery of the State of Delaware. Allegations in this matter are similar to those raised in the putative securities class action complaints filed on October 30, 2018 and August 19, 2019 in the U.S. District Court in California.  </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the securities class action lawsuits and derivative complaints are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either December&#160;31, 2020 or December 31, 2019. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in a number of foreign countries. As a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations on our Consolidated Balance Sheets as of December&#160;31, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligations to RPI and HCR described in Note 7. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Underwriters and Initial Purchasers of our Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with our sale of equity and senior secured debt securities, we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $10.0 million per incident for merger and acquisition related claims, $10.0 million per incident for securities related claims and $10.0 million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157214600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 10, on April 3, 2018, we completed the issuance and sale of 8,284,600 shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a five-year period.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2020, we had approximately 29,784,000 reserved shares of common stock, all of which are reserved for issuance under our equity compensation plans, of which approximately 20,894,000 shares may be issued upon the exercise of outstanding options or the vesting of restricted stock units (RSUs) or performance stock units, approximately 7,569,000 shares are available for grant under our 2017 Performance Incentive Plan and approximately 1,321,000 shares are available for grant under our Employee Stock Purchase Plan.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> 2017 Performance Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) was adopted by our board of directors (Board of Directors) on March&#160;28, 2017 and was approved by our stockholders on June&#160;14, 2017. On the date of approval, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (2012 Plan) ceased to be available for future grants. However, options and restricted stock units granted under the 2012 Plan remained outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to the terms of the 2017 Plan, 8,300,000 shares of our common stock, reduced by the number of shares of common stock subject to awards granted under the 2012 Plan on or after March 31, 2017 and prior to the adoption of the 2017 Plan, were initially available for awards under the 2017 Plan. On June 26, 2018, our stockholders approved an amendment to the 2017 Plan whereby 10,900,000 additional shares were made available for award grants under the 2017 Plan (Amended Plan). On June 17, 2020, the stockholders of Nektar approved an amendment to the Amended Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 10,000,000 shares (Amended and Restated 2017 Plan). Shares issued in respect of any &#8220;full-value award&#8221; granted under the 2017 Plan will be counted against the share limit described above as 1.5 shares for every one share actually issued in connection with the award. Shares that are subject to or underlie awards which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under the 2017 Plan or the 2012 Plan will again be available for subsequent awards under the 2017 Plan (with any such shares subject to full-value awards increasing the 2017 Plan&#8217;s share limit based on the full-value award ratio described above). Notwithstanding the foregoing, shares that are exchanged by a participant or withheld by us to pay the exercise price of an option granted under the 2017 Plan, as well as any shares exchanged or withheld to satisfy the tax withholding obligations related to any award, will not be available for subsequent awards under the 2017 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The purpose of the current Amended and Restated 2017 Plan and our other incentive plans is to promote our success by providing an additional means for us to attract, motivate, retain and reward directors, officers, employees, and other eligible persons through the grant of awards. Equity-based awards are also intended to further align the interests of award recipients and our stockholders. The Amended and Restated 2017 Plan authorizes stock options, stock appreciation rights, stock bonuses, restricted stock, performance stock, stock units, phantom stock or similar rights to purchase or acquire shares, and other forms of awards granted or denominated in our common stock or units of our common stock, as well as cash bonus awards. Members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries are eligible to receive awards under the Amended and Restated 2017 Plan. Pursuant to the Amended and Restated 2017 Plan, we have granted or </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. The requisite service period for stock options granted to our employees under the Amended and Restated 2017 Plan as well as our prior plans  is generally four years; the requisite service period for stock options granted to our directors is generally one year. The requisite service period for RSUs and PSUs granted under the Amended and Restated 2017 Plan and our prior plans is generally three years for employees and one year for directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Amended and Restated 2017 Plan will terminate on March&#160;27, 2027, unless earlier terminated by the Board of Directors. The maximum term of a stock option or stock appreciation right under the Amended and Restated 2017 Plan and our prior plans is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 1994, our Board of Directors adopted the Employee Stock Purchase Plan (ESPP) pursuant to section&#160;423(b) of the Internal Revenue Code of 1986. Under the ESPP, 2,500,000&#160;shares of our common stock were originally authorized for issuance. On June 17, 2020, the stockholders of Nektar approved an amendment and restatement of the Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the plan by 1,000,000 shares. The terms of the ESPP provide eligible employees with the opportunity to acquire an ownership interest in Nektar through participation in a program of periodic payroll deductions for the purchase of our common stock. Employees may elect to enroll or re-enroll in the ESPP on a semi-annual basis. Stock is purchased at 85% of the lower of the closing price on the first day of the enrollment period or the last day of the enrollment period.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Retirement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $6,000 per participant. For the years ended December&#160;31, 2020, 2019, and 2018, we recognized $3.5 million, $3.5 million, and $2.8 million, respectively, of compensation expense in connection with our 401(k) retirement plan.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control Severance Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On December&#160;6, 2006, our Board of Directors approved a Change of Control Severance Benefit Plan (CIC Plan). This CIC Plan has subsequently been amended a number of times by our Board of Directors with the most recent amendment occurring on April&#160;5, 2011. The CIC Plan is designed to make certain benefits available to our eligible employees in the event of a change of control of Nektar and, following such change of control, an employee&#8217;s employment with us or a successor company is terminated in certain specified circumstances. We adopted the CIC Plan to support the continuity of the business in the context of a change of control transaction. The CIC Plan was not adopted in contemplation of any specific change of control transaction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the CIC Plan, in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) or initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) in each case within twelve months following a change of control transaction, (i)&#160;the Chief Executive Officer would be entitled to receive cash severance pay equal to 24 months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards, and (ii)&#160;our Senior Vice Presidents and Vice Presidents (including Principal Fellows) would each be entitled to receive cash severance pay equal to twelve months base salary plus annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of unvested outstanding equity awards. In the event of a change of control of Nektar and a subsequent termination of employment initiated by the Company or a successor company other than for Cause within twelve months following a change of control transaction, all other employees would each be entitled to receive cash severance pay equal to 6 months base salary plus a pro-rata portion of annual target incentive pay, the extension of employee benefits over this severance period and the full acceleration of each such employee&#8217;s unvested outstanding equity awards. Under the CIC Plan, as amended, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157636280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxalta Incorporated / Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemophilia, including ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2020, 2019 and 2018, we recognized $129.6 million, $77.5 million and $95.3&#160;million of revenue for performance obligations that we had satisfied in prior periods, respectively. For all years, the amount includes all of our royalty revenue and non-cash royalty revenue. For the year ended December 31, 2020, the amount includes $50.0&#160;million in BMS Collaboration milestones received.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of previously unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, our collaboration agreements with partners included potential future payments for development milestones totaling approximately $1.7&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive other contingent payments, including contingent sales milestones and royalty payments, as described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There have been no material changes to our collaboration agreements for the year ended December&#160;31, 2020, except as described below.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb (BMS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (previously referred to as NKTR-214)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The BMS Collaboration Agreement superseded and replaced the Clinical Trial Agreement we entered into with BMS in September 2016 to develop bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the Clinical Trial Agreement, we acted as the sponsor of each Combination Therapy Trial and BMS was responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. We recorded cost reimbursement payments to us from BMS as a reduction to research and development expense. Each party was otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion. We are eligible to receive additional cash payments up to a total of approximately $1.455&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones and up to a total of $350.0&#160;million upon the achievement of certain sales milestones. In April 2018, BMS also purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;BMS has the right, at its sole discretion, to terminate co-funding its share of the development costs for the adjuvant melanoma collaboration study if the metastatic melanoma collaboration study fails to meet the primary endpoint of progression free survival. If BMS exercises such right, we have the right, in our sole discretion, to continue the adjuvant melanoma study.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $128.2 million and $105.4 million and $62.5 million, respectively, as a reduction of research and development expenses for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.  As of December&#160;31, 2020 and 2019, we have recorded an unbilled receivable of $38.7 million and $24.0 million, respectively, from BMS in accounts receivable in our Consolidated Balance Sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our share of development costs is limited to an annual cap of $125.0&#160;million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, but we recognize our full share of the research and development expense and recognize the reimbursement as a liability. We repay the liability to the extent that our share of development costs are less than the annual cap in a future year, or by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin, if approved. For the year-ended December 31, 2020, our share of the development costs totaled $129.0&#160;million, thereby exceeding the annual cap by $4.0&#160;million. Accordingly, we have recognized $4.0&#160;million for BMS&#8217; reimbursement of the excess over the annual cap in our unbilled billed receivable of $38.7 million, and, due to the repayment provision, we have recognized a liability of $4.0&#160;million in Other long-term liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize bempegaldesleukin and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2018, we aggregated the total consideration of $1.85&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2&#160;million in stockholders&#8217; equity. We allocated the remaining $1,059.8&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $1.8&#160;billion to be variable consideration. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recognized $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial and $25.0&#160;million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial. We continue to exclude the other milestones from the transaction price as of December&#160;31, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NKTR-358 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0&#160;million in September 2017 and are eligible for up to $250.0&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 1B and 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through December&#160;31, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $150.0&#160;million received in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0&#160;million upfront payment as $125.9&#160;million to the license, $17.6&#160;million to our portion of the Phase 1 clinical development and $6.5&#160;million to the drug product development.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the $125.9&#160;million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of December&#160;31, 2020, we have no deferred revenue related to this agreement.</span></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Incorporated/Takeda: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Hemophilia A program includes ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $10.0&#160;million development milestone, which we received in March 2018. During 2018, we earned an additional $10.0&#160;million milestone for annual sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $12.0&#160;million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of December&#160;31, 2020, our deferred revenue related to this agreement is not significant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We determined that our obligation to manufacture and supply PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen under the 2010 Agreement represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. We recognized revenue through October 2020, the month when the 2010 Agreement expired according to its terms. Accordingly, as of December&#160;31, 2020, we have no deferred revenue related to our agreement with Amgen.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxegol oxalate), previously referred to as naloxegol and NKTR-118,</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2014 and December 2014, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> /MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the US and EU, respectively. As of December&#160;31, 2020, we have received a total of $385.0 million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving 60% and Nektar receiving 40%. As of December 31, 2020, we have received a total of $37.6&#160;million of milestone payments resulting from these sublicense arrangements, all of which was received in or before 2017.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of its approval of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the FDA required AstraZeneca to perform a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of OIC in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. by AstraZeneca can be reduced by up to two percentage points to fund 33% of the external costs incurred by AstraZeneca to fund such post approval study, subject to a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.0&#160;million aggregate cap. As a result of the 2020 Purchase and Sale Agreement as described in Note 7, AstraZeneca will deduct these costs from the royalties paid to HCR. Before we entered into the 2020 Purchase and Sale Agreement, our cumulative share of the post-approval study expenses was not significant. Any costs incurred by AstraZeneca can only be recovered by the reduction of the royalty payments. In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, as of December&#160;31, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of December&#160;31, 2020, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155777224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total unrecognized compensation costs of $193.7 million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of 1.79 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2020, 2019, and 2018.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Black-Scholes Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.86</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of zero. Our estimate of expected volatility is based on </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:51.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 totaled $15.9 million, $30.6 million and $303.4 million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of RSU Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A summary of RSU award activity is as follows (in thousands except for per share amounts):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.83&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(866)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock that vested in the years ended December&#160;31, 2020, 2019 and 2018 totaled $33.3 million, $32.4 million and $80.4 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157660504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Income (loss) before provision for income taxes includes the following components (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(441,494)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,947)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,054)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Current</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Deferred</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% for the years ended December&#160;31, 2020, 2019 and 2018 to pretax income (loss) as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) at federal statutory rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on equity issuance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,716)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,995)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,726&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,563)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $95.0 million and $114.6 million during the years ended December&#160;31, 2020 and 2019, respectively, primarily due to the additional domestic net operating losses and credits generated in the current year that are not more likely than not of being utilized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Tax Credit Carryforwards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2020, we had a net operating loss carryforward for federal income tax purposes of approximately $2.0 billion, portions of which will begin to expire in 2021. As of December&#160;31, 2020, we had a total state net operating loss carryforward of approximately $1.3 billion, portions of which will begin to expire in 2026. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have federal research credits of approximately $98.9&#160;million, which will begin to expire in 2023 and state research credits of approximately $44.0&#160;million which have no expiration date. We have federal orphan drug credits of $17.7&#160;million which will begin to expire in 2026. These tax credits are subject to the same limitations discussed above.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have the following activity relating to unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry forwards rather than resulting in a cash outlay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. Because of net operating losses and research credit carryovers, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any resulting liability resulting from such an examination would have a material effect on our financial position or results of operations.</span></div>Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2020, 2019 and 2018, no significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any changes over the next twelve months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724156960456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 33%, 23%, 14% and 13% of our revenue, respectively, for the year ended December&#160;31, 2020. Revenue from UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 28%, 19%, and 17% of our revenue for the year-ended December 31, 2019. Revenue from BMS represented 89% of our revenue, for the year ended December&#160;31, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2020, $54.5 million, or approximately 91%, of the net book value of our property, plant and equipment was located in the United States and $5.1 million, or approximately 9%, was located in India.&#160;At December&#160;31, </span></div>2019, $59.7 million, or approximately 92%, of the net book value of our property, plant and equipment was located in the United States&#160;and $5.3 million, or approximately 8%, was located in India.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724265875400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Event<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 12, 2021, we entered into a co-development agreement (the Agreement) with SFJ Pharmaceuticals XII, L.P., an SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and approval activities for bempegaldesleukin. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and/or the SCCHN Clinical Trial do not meet their primary endpoints. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the completion of certain SCCHN Clinical Trial activities. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0&#160;million, paid in annual installments over five years. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0&#160;million, paid in annual installments over seven years. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5&#160;million to SFJ. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the Agreement. The Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724156958200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
<td class="text">Selected Quarterly Financial Data (Unaudited)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,485&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,315&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,862&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,440&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,989&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,631)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,709)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,050)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,721)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,687)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,970)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,740)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,638)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,651)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,586)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,203)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share(1)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.64)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Quarterly income (loss) per share amounts may not total to the year-to-date income (loss) per share due to rounding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162747048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div>&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation, Principles of Consolidation and Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income loss. We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our cash, cash equivalents, short-term investments and long-term investments are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents, short-term investments and long-term investments are held or issued by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock', window );">Accounts Receivable and Significant Customer Concentrations</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Significant Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. For the year ended December&#160;31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $0.2 million under customer contracts from our collaboration partners. For the year ended December&#160;31, 2019, our accounts receivable included $24.0 million for unbilled net expense reimbursements from BMS and $12.8 million from customer contracts, which included our estimate of $11.6&#160;million for royalties resulting from net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended December 31, 2019. Since we sold our rights to receive royalties in the 2020 Purchase and Sale Agreement with Healthcare Royalty Management, LLC, as discussed further in Note 7, we did not record accounts receivable for these royalties at </span></div>December 31, 2020. We generally do not require collateral from our partners. We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable. At December&#160;31, 2019, three different partners represented 65%, 17% and 14%, respectively, of our accounts receivable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock', window );">Inventory and Significant Supplier Concentrations</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). ASC 842 supersedes the guidance in ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the year ended December 31, 2020 and 2019 under ASC 842. We have not restated the results for the year ended December 31, 2018 continue to report them under ASC 840.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 6 for additional information regarding our leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF85MS9mcmFnOjI0OGQyMjBkMWEwMzQ4M2JhNWQyMzA5OGFlNzY1NDEzL3RleHRyZWdpb246MjQ4ZDIyMGQxYTAzNDgzYmE1ZDIzMDk4YWU3NjU0MTNfMTI5NjQ_3922bd67-c483-4149-88ce-8dfeea7bee57">three</span> to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock', window );">Impairment of Assets and Other Costs for Terminated Program</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Consolidated Statement of Operations. We did not incur any substantial costs related to the wind-down of Inheris and the NKTR-181 program after March 31, 2020. As of December&#160;31, 2020, we have substantially completed our wind-down and do not expect to incur additional costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs) and performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs and PSUs on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options and RSUs that vest upon the achievement of performance milestones, we estimate the vesting period based on our evaluation of the probability of achievement of each respective milestone and the related estimated date of achievement. We recognize stock-based compensation expense for purchases under the ESPP over the respective six-month purchase period. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models may not provide a reliable single measure of the fair value of our employee stock options or common stock purchased under the ESPP. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management will continue to assess the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and which could materially impact our fair value determination.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net income (loss) available to common stockholders is equal to the reported net income (loss). We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities, which consist of common shares underlying stock options and RSUs. For the years ended December 31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options and RSUs totaling 17.4 million and 17.9 million for the years ended December 31, 2020 and 2019, respectively. For the year ended December 31, 2018, the effect of these dilutive securities under the treasury stock method was approximately 10.5 million, and we excluded approximately 3.3 million of weighted-average shares of common stock underlying outstanding stock options from the computation of diluted net income per share because&#160;their effect was antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive income (loss) is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our other comprehensive income (loss) includes net income (loss), gains and losses from the foreign currency translation of the assets and liabilities of our India and UK subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock', window );">Coronavirus Aid, Relief and Economic Security (CARES) Act</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief, and Economic Security (CARES) Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. government enacted the CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act has not had a material effect on our results of operations or financial position.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Consolidated Financial Statements. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed other recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and significant customer concentrations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer shipping and handling costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of Assets and Other Costs for Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and significant supplier concentrations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157025688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,955&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,363&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text">Our portfolio of cash and investments in marketable securities includes (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507,655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157774152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text">Inventory consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155710440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,977&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,097&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,684&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,910&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,322&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,488)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,875)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,962&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,662&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724156980488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Operating Lease Information</a></td>
<td class="text">The following table presents key information regarding these leases (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMS0xLTEtNjA4OC90ZXh0cmVnaW9uOjRjMTcwNThhNDM2MjQ1Y2ViNGNmODA1MjEyNDFkNDBmXzgyNDYzMzcyMDgzNjY_777156ba-6795-422d-8ae6-884c0b09005a">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZhYmY3OTUxMTJiMTQzZmZiYjNkZDk5ODFiNGRkNjIwL3NlYzpmYWJmNzk1MTEyYjE0M2ZmYmIzZGQ5OTgxYjRkZDYyMF8xMTUvZnJhZzpkZGNiZDQ4ODQ2OTc0NTA3Yjc1ZGU1ZjBlY2U2NjFkOS90YWJsZTo2ZDk1N2E2NjQ0YjI0M2YyYjczNzcyOWM3MDVlYzg5YS90YWJsZXJhbmdlOjZkOTU3YTY2NDRiMjQzZjJiNzM3NzI5YzcwNWVjODlhXzktMy0xLTEtNjA4OC90ZXh0cmVnaW9uOjk5YjZiNWQ2Y2VlODQ3ZGVhMzgyNGUwMzczODNjZDFjXzgyNDYzMzcyMDgzNTM_99d5a5f1-cea4-4505-b749-04db3745ec5a">five</span>-year term</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text">The components of lease costs, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"/><td style="width:64.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments for Operating Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease incentives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12069-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121549808&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155710440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract', window );"><strong>Liability Related To Sale Of Potential Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Summary of Liability Related to Potential Future Royalties</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account during the year ended December&#160;31, 2020 and for the period from the inception of the 2012 Purchase and Sale Agreement on February 24, 2012 (inception) and the 2020 Purchase and Sale Agreement on December 30, 2020 to December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"/><td style="width:42.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157240856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxalta Incorporated / Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemophilia, including ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Deferred Revenue Balance from Collaboration Agreements</a></td>
<td class="text">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December&#160;31, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of previously unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue&#8212;December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162459032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</a></td>
<td class="text">The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.86</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity Under Equity Incentive Plans</a></td>
<td class="text">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:51.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div>(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Restricted Stock Unit Award Activity</a></td>
<td class="text">A summary of RSU award activity is as follows (in thousands except for per share amounts):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.83&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(866)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157205368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text">Income (loss) before provision for income taxes includes the following components (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(441,494)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,947)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,054)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text">The provision for income taxes consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Current</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Deferred</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Tax Provision Related to Continuing Operations</a></td>
<td class="text">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% for the years ended December&#160;31, 2020, 2019 and 2018 to pretax income (loss) as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) at federal statutory rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium on equity issuance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,716)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,995)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,726&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,563)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text">We have the following activity relating to unrecognized tax benefits (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159949096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Revenue by Geographic Area</a></td>
<td class="text">The following table sets forth revenue by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155453256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data</a></td>
<td class="text">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,485&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,315&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,862&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,440&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,989&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,631)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,709)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,050)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,721)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,687)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,970)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,740)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,638)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,651)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,586)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,203)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share(1)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.64)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Quarterly income (loss) per share amounts may not total to the year-to-date income (loss) per share due to rounding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724243714872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Detail)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198,558<span></span>
</td>
<td class="nump">$ 1,603,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetExpenseReimbursementsFromCollaborationPartner', window );">Net expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Contract with customer, asset, reclassified to receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales', window );">Estimate for royalties resulting from net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment', window );">Number of reporting unit evaluated for goodwill | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted-average of potentially dilutive securities (stock options and RSUs) included in calculation of diluted securities under treasury stock method (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Partner One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Partner Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Partner Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_WriteOffOfPrepayment', window );">Write off of prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_A775PercentSeniorSecuredNotesDueOctober2020Member', window );">7.75 Percent Senior Secured Notes Due October 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RepaymentsOfLongTermDebtIncludingInterest', window );">Principal and interest repaid on senior notes</a></td>
<td class="nump">$ 254,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Shares of Common Stock Underlying Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember', window );">Manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember', window );">Manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Estimate for Royalties Resulting from Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetExpenseReimbursementsFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net expense reimbursements from collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NetExpenseReimbursementsFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units to evaluate goodwill for impairment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RepaymentsOfLongTermDebtIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Debt, Including Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RepaymentsOfLongTermDebtIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_WriteOffOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Prepayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_WriteOffOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_PartnerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_PartnerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_PartnerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_PartnerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_PartnerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_PartnerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NKTR181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NKTR181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_A775PercentSeniorSecuredNotesDueOctober2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_A775PercentSeniorSecuredNotesDueOctober2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155537272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 198,955<span></span>
</td>
<td class="nump">$ 96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">862,941<span></span>
</td>
<td class="nump">1,228,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">136,662<span></span>
</td>
<td class="nump">279,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 1,198,558<span></span>
</td>
<td class="nump">$ 1,603,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162871368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">$ 41,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Level 1 to level 2 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Level 2 to level 1 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159843720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 6,285<span></span>
</td>
<td class="nump">5,829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">1,198,558<span></span>
</td>
<td class="nump">1,603,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,002,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,003,348<span></span>
</td>
<td class="nump">1,507,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes and Bonds | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">686,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">687,469<span></span>
</td>
<td class="nump">1,132,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">313,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">313,497<span></span>
</td>
<td class="nump">375,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. government agencies | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,382<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value Hierarchy Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">179,302<span></span>
</td>
<td class="nump">83,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 9,623<span></span>
</td>
<td class="nump">$ 6,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724158797352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,422<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">10,703<span></span>
</td>
<td class="nump">8,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">2,167<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 15,292<span></span>
</td>
<td class="nump">$ 12,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162995848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Property, Plant and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 193,450<span></span>
</td>
<td class="nump">$ 188,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(138,488)<span></span>
</td>
<td class="num">(127,875)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentNet', window );">Depreciable property, plant and equipment, net</a></td>
<td class="nump">54,962<span></span>
</td>
<td class="nump">60,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-progress</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">5,218<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">59,662<span></span>
</td>
<td class="nump">65,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">92,977<span></span>
</td>
<td class="nump">93,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">40,121<span></span>
</td>
<td class="nump">36,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">28,684<span></span>
</td>
<td class="nump">26,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">21,796<span></span>
</td>
<td class="nump">22,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 9,872<span></span>
</td>
<td class="nump">$ 9,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159606008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157382952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior Secured Notes (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SecuredNotesLineItems', window );"><strong>Secured Notes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.75% Senior Secured Notes Due October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SecuredNotesLineItems', window );"><strong>Secured Notes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid', window );">Debt discount on transaction and facility fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal amount repaid</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest Receivable</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtDiscountOnTransactionAndFacilityFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt discount on transaction and facility fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtDiscountOnTransactionAndFacilityFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SecuredNotesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SecuredNotesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159704968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost | $</a></td>
<td class="nump">$ 18,985<span></span>
</td>
<td class="nump">$ 14,697<span></span>
</td>
<td class="nump">$ 7,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments | $</a></td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, percent</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember', window );">Mission Bay Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq ft) | ft&#178;</a></td>
<td class="nump">153,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember', window );">Third Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq ft) | ft&#178;</a></td>
<td class="nump">135,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162125320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating Lease Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 57,691<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember', window );">Mission Bay Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpaceDelivered', window );">Leased space delivered (in sq ft) | ft&#178;</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">13,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 6,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfConsecutiveTermsToExtendLease', window );">Number of consecutive terms to extend lease | term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember', window );">Third Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpaceDelivered', window );">Leased space delivered (in sq ft) | ft&#178;</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfConsecutiveTermsToExtendLease', window );">Number of consecutive terms to extend lease | term</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AreaOfLeasedSpaceDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased space delivered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AreaOfLeasedSpaceDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease extension term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfConsecutiveTermsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive five year terms to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfConsecutiveTermsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155566440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 18,985<span></span>
</td>
<td class="nump">$ 14,697<span></span>
</td>
<td class="nump">$ 7,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">8,179<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">4,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 27,164<span></span>
</td>
<td class="nump">$ 21,105<span></span>
</td>
<td class="nump">$ 12,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724263181544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 17,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">20,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">20,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">21,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">22,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2026 and thereafter</a></td>
<td class="nump">97,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">200,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: portion representing interest</a></td>
<td class="num">(46,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Less: lease incentives</a></td>
<td class="num">(3,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">150,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(13,915)<span></span>
</td>
<td class="num">$ (12,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 136,373<span></span>
</td>
<td class="nump">$ 142,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724243757320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">106 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 16, 2020</div></th>
<th class="th"><div>Feb. 24, 2012</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyAgreementContingentPaymentDescription', window );">Royalty agreement contingent payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result of worldwide net sales of MIRCERA&#174; for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,563<span></span>
</td>
<td class="nump">$ 36,303<span></span>
</td>
<td class="nump">$ 33,308<span></span>
</td>
<td class="nump">$ 255,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="nump">$ 25,044<span></span>
</td>
<td class="nump">$ 21,196<span></span>
</td>
<td class="nump">196,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">Purchase and Sale Agreement 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">Purchase and Sale Agreement 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="nump">$ 10,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved', window );">Payment of transaction related to purchase and sale agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved', window );">Payment of transaction related to purchase and sale agreement if threshold is not achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds', window );">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Purchase and Sale Agreement with RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo', window );">Payment made for milestone not achieved year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne', window );">Payment made for milestone not achieved year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for milestone not achieved year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for milestone not achieved year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyAgreementContingentPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement contingent payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyAgreementContingentPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159137048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">106 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties&#8212;beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,563<span></span>
</td>
<td class="nump">$ 36,303<span></span>
</td>
<td class="nump">$ 33,308<span></span>
</td>
<td class="nump">255,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="nump">25,044<span></span>
</td>
<td class="nump">$ 21,196<span></span>
</td>
<td class="nump">196,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties &#8211; ending balance</a></td>
<td class="nump">$ 205,255<span></span>
</td>
<td class="nump">205,255<span></span>
</td>
<td class="nump">73,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(4,915)<span></span>
</td>
<td class="num">(4,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,915)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">200,340<span></span>
</td>
<td class="nump">200,340<span></span>
</td>
<td class="nump">72,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">Purchase and Sale Agreement 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties&#8212;beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties &#8211; ending balance</a></td>
<td class="nump">65,880<span></span>
</td>
<td class="nump">65,880<span></span>
</td>
<td class="nump">$ 73,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(1,165)<span></span>
</td>
<td class="num">(1,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">64,715<span></span>
</td>
<td class="nump">$ 64,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Implicit interest rate over the life of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">Purchase and Sale Agreement 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties&#8212;beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="nump">10,625<span></span>
</td>
<td class="nump">10,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to the sale of future royalties &#8211; ending balance</a></td>
<td class="nump">139,375<span></span>
</td>
<td class="nump">139,375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(3,750)<span></span>
</td>
<td class="num">(3,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,750)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">$ 135,625<span></span>
</td>
<td class="nump">$ 135,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Implicit interest rate over the life of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annual interest rate over life of royalty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities on sale of future royalties, unamortized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PartialRepaymentOfRoyaltySaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial repayment of royalty sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PartialRepaymentOfRoyaltySaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProspectiveInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prospective interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProspectiveInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyMonetizationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyMonetizationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159789752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember', window );">Legal Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_CommercialAgreementsMember', window );">Commercial Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember', window );">Merger and Acquisition Related Claims | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember', window );">Securities Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember', window );">Non-Securities Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations under director and officer indemnifications per incident.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_CommercialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_CommercialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157884088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 03, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod', window );">Stock issued during period subject to lock-up and stand-still provisions period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding', window );">Number of shares to be issued upon exercise of outstanding options or vesting of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,894,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum 401(k) per employee, percentage of annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Matching 401(k) employer contribution, maximum amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense in connection with 401(k) retirement plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ChangeInControlSeverancePaymentPeriodForExecutives', window );">Change in control severance payment period for executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer', window );">Change in control severance payment period for Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents', window );">Change in control severance payment period for senior vice presidents and vice presidents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ChangeInControlSeverancePaymentPeriodForEmployees', window );">Change in control severance payment period for employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfPurchasePriceOfStock', window );">Percentage of purchase price of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CommonStockAdditionalSharesAuthorized', window );">Increase in aggregate number of shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember', window );">2017 Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans', window );">Number of shares available for issuance under equity compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for stock options grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for award grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare', window );">Share-based compensation plan's share limit reduction for every one restricted stock unit granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options term under equity incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans', window );">Number of shares available for issuance under equity compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_AmendedAndRestated2017PlanMember', window );">Amended and Restated 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CommonStockAdditionalSharesAuthorized', window );">Increase in aggregate number of shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance in equity compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nktr_EmployeeMember', window );">Employee | 2017 Performance Incentive Plan | Shares of Common Stock Underlying Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nktr_EmployeeMember', window );">Employee | 2017 Performance Incentive Plan | RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | 2017 Performance Incentive Plan | Shares of Common Stock Underlying Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | 2017 Performance Incentive Plan | RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Control Severance Payment Period For Chief Executive Officer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ChangeInControlSeverancePaymentPeriodForEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in control severance payment period for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ChangeInControlSeverancePaymentPeriodForEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ChangeInControlSeverancePaymentPeriodForExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in control severance payment period for executives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ChangeInControlSeverancePaymentPeriodForExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Control Severance Payment Period For Senior Vice Presidents and Vice Presidents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CommonStockAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CommonStockAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities remaining available for issuance under equity compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfPurchasePriceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfPurchasePriceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options and restricted stock units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation plan's share limit for every one share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period subject to lock-up and stand-still provisions period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_AmendedAndRestated2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_AmendedAndRestated2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nktr_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nktr_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724158637288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 55,849<span></span>
</td>
<td class="nump">$ 16,975<span></span>
</td>
<td class="nump">$ 1,097,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,059,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">7,019<span></span>
</td>
<td class="nump">11,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | Neulasta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">4,167<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated / Takeda | Hemophilia, Including ADYNOVATE and ADYNOVITM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">20,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 4,578<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BempegaldesleukinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BempegaldesleukinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724139500376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th">
<div>Aug. 23, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligation recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,600,000<span></span>
</td>
<td class="nump">$ 77,500,000<span></span>
</td>
<td class="nump">$ 95,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,889,000<span></span>
</td>
<td class="nump">36,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,516,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,516,000<span></span>
</td>
<td class="nump">768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Development milestones received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,516,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
<td class="nump">8,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,462,000<span></span>
</td>
<td class="nump">$ 30,033,000<span></span>
</td>
<td class="nump">$ 48,847,000<span></span>
</td>
<td class="nump">$ 50,573,000<span></span>
</td>
<td class="nump">33,862,000<span></span>
</td>
<td class="nump">$ 29,218,000<span></span>
</td>
<td class="nump">$ 23,315,000<span></span>
</td>
<td class="nump">$ 28,222,000<span></span>
</td>
<td class="nump">$ 152,915,000<span></span>
</td>
<td class="nump">114,617,000<span></span>
</td>
<td class="nump">1,193,323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints', window );">Percentage of net sales to fund external costs incurred, due to reduction of 2 percentage points</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesMilestoneRevenue', window );">Sales milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember', window );">NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RegulatoryMilestonesPaymentDescription', window );">Regulatory milestones payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones', window );">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,455,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones', window );">Eligible additional cash payments receivable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Nektar's | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember', window );">Nektar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments', window );">Percentage of upfront payment, market access milestones, royalties and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyMember', window );">Eli Lilly | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Nektar 214 | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,200,000<span></span>
</td>
<td class="nump">105,400,000<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700,000<span></span>
</td>
<td class="nump">$ 24,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CompanyShareOfDevelopmentCostsAnnualCap', window );">Company share of development costs, annual cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CompanyShareOfDevelopmentCosts', window );">Company share of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DevelopmentCostsExceeded', window );">Development costs exceeded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementRecognized', window );">Reimbursement recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Clinical Trial Agreement | Nektar 214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner', window );">Percentage of out-of-pocket costs to be reimbursed by partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bristol Myers Squibb Collaboration Agreement | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AggregateConsiderationReceivedFromAgreements', window );">Total consideration received under agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedFairValueOfShares', window );">Estimated fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RemainingAmountAllocatedToTransactionPrice', window );">Remaining amount allocated to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones', window );">Potential future development, regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bristol Myers Squibb Collaboration Agreement | Nektar 214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated / Takeda | Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement', window );">Received under right to sublicense agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated / Takeda | Hemophilia | Annual Sales Level Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated / Takeda | Hemophilia | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Nektar's | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Phase 1 Clinical Development | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Drug Product Development | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">Astra Zeneca Ab | MOVANTIK and MOVENTIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfNetSalesToFundExternalCostsIncurred', window );">Percentage of net sales to fund external costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap', window );">Amount of net sales to fund external costs incurred cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">Astra Zeneca Ab | MOVANTIK and MOVENTIG | Upfront Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,600,000<span></span>
</td>
<td class="nump">$ 385,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">Astra Zeneca Ab | AstraZeneca-Kirin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner', window );">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_TerminatedPartnershipMember', window );">Terminated Partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MilestoneAxis=nktr_MilestoneOneMember', window );">Milestone One | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AggregateConsiderationReceivedFromAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration received from agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AggregateConsiderationReceivedFromAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfNetSalesToFundExternalCostsIncurredCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Sales to Fund External Costs Incurred Cap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfNetSalesToFundExternalCostsIncurredCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CompanyShareOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company Share of Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CompanyShareOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CompanyShareOfDevelopmentCostsAnnualCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company Share Of Development Costs, Annual Cap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CompanyShareOfDevelopmentCostsAnnualCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentCostsExceeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Costs Exceeded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DevelopmentCostsExceeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible additional cash payments receivable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments received under rights to sublicense agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentsReceivedUnderRightsToSublicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfNetSalesToFundExternalCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Sales to Fund External Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfNetSalesToFundExternalCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Net Sales To Fund External Costs Incurred, Due To Reduction Of 2 Percentage Points</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of out of pocket costs to be reimbursed by partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development regulatory and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RegulatoryMilestonesPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestones payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RegulatoryMilestonesPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RemainingAmountAllocatedToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount allocated to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RemainingAmountAllocatedToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SalesMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_ClinicalTrialAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_ClinicalTrialAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_TerminatedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_TerminatedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157192024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Beginning balance</a></td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of previously unearned revenue</a></td>
<td class="num">(5,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Ending balance</a></td>
<td class="nump">$ 2,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159474584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 94,261<span></span>
</td>
<td class="nump">$ 99,795<span></span>
</td>
<td class="nump">$ 88,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,825<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">4,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">57,116<span></span>
</td>
<td class="nump">63,224<span></span>
</td>
<td class="nump">56,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">33,295<span></span>
</td>
<td class="nump">32,277<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162102104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 193.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over a weighted-average period</a></td>
<td class="text">1 year 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="nump">$ 30.6<span></span>
</td>
<td class="nump">$ 303.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 80.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162843848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Average volatility factor</a></td>
<td class="nump">64.10%<span></span>
</td>
<td class="nump">62.20%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average weighted average expected life</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 10.70<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
<td class="nump">$ 29.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724158756120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">14,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, options granted (in shares) | shares</a></td>
<td class="nump">1,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, options exercised (in shares) | shares</a></td>
<td class="num">(1,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, options forfeited and canceled (in shares) | shares</a></td>
<td class="num">(1,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, exercisable (in shares) | shares</a></td>
<td class="nump">9,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">19.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">11.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, options forfeited and canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">45.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">24.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life, outstanding</a></td>
<td class="text">3 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, exercisable</a></td>
<td class="text">2 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, outstanding | $</a></td>
<td class="nump">$ 23,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, exercisable | $</a></td>
<td class="nump">$ 23,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159336728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Award Activity (Detail) - Restricted Stock Units (RSU)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units Issued, Beginning balance (in shares) | shares</a></td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">4,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(1,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and canceled (in shares) | shares</a></td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units Issued, Ending balance (in shares) | shares</a></td>
<td class="nump">7,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">19.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">34.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited and canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">29.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724155599848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income (Loss) Before Provision for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (445,370)<span></span>
</td>
<td class="num">$ (441,494)<span></span>
</td>
<td class="nump">$ 680,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="num">$ (443,947)<span></span>
</td>
<td class="num">$ (440,054)<span></span>
</td>
<td class="nump">$ 682,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159896616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159616824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase (decrease) amount</a></td>
<td class="num">$ (95,000,000.0)<span></span>
</td>
<td class="num">$ (114,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">$ 3,081,000<span></span>
</td>
<td class="nump">10,511,000<span></span>
</td>
<td class="nump">$ 17,295,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange', window );">Unrecognized tax benefits, period may increase or decrease due to tax examination</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardForIncomeTax', window );">Net operating loss carryforward for income tax</a></td>
<td class="nump">2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">98,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FederalOrphanDrugCredits', window );">Federal orphan drug credits</a></td>
<td class="nump">17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardForIncomeTax', window );">Net operating loss carryforward for income tax</a></td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">$ 44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FederalOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FederalOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetOperatingLossCarryforwardForIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NetOperatingLossCarryforwardForIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits, period increase (decrease) reasonable period of change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724255269800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Provision Related to Continuing Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) at federal statutory rate</a></td>
<td class="num">$ (93,229)<span></span>
</td>
<td class="num">$ (92,411)<span></span>
</td>
<td class="nump">$ 143,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(3,081)<span></span>
</td>
<td class="num">(10,511)<span></span>
</td>
<td class="num">(17,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance', window );">Premium on equity issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">87,060<span></span>
</td>
<td class="nump">104,440<span></span>
</td>
<td class="num">(46,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,929<span></span>
</td>
<td class="num">(672)<span></span>
</td>
<td class="num">(66,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(7,967)<span></span>
</td>
<td class="num">(7,624)<span></span>
</td>
<td class="num">(6,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">6,356<span></span>
</td>
<td class="nump">5,259<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">4,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation expense share based compensation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeTaxReconciliationPremiumOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation premium on equity issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncomeTaxReconciliationPremiumOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724162102104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 456,284<span></span>
</td>
<td class="nump">$ 399,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credits</a></td>
<td class="nump">132,994<span></span>
</td>
<td class="nump">128,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">35,672<span></span>
</td>
<td class="nump">36,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">32,737<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">32,517<span></span>
</td>
<td class="nump">30,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment', window );">Other</a></td>
<td class="nump">11,688<span></span>
</td>
<td class="nump">13,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">701,892<span></span>
</td>
<td class="nump">608,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(670,103)<span></span>
</td>
<td class="num">(575,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">31,789<span></span>
</td>
<td class="nump">33,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(29,707)<span></span>
</td>
<td class="num">(31,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(1,856)<span></span>
</td>
<td class="num">(1,725)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(31,563)<span></span>
</td>
<td class="num">(33,443)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Liability Related to the Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724267560056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 77,410<span></span>
</td>
<td class="nump">$ 27,419<span></span>
</td>
<td class="nump">$ 20,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Tax positions related to current year, Additions</a></td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">49,858<span></span>
</td>
<td class="nump">5,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions related to prior year, Additions</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions</a></td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses in statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 78,665<span></span>
</td>
<td class="nump">$ 77,410<span></span>
</td>
<td class="nump">$ 27,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724157991768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfOperatingBusinessSegment', window );">Number of operating business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 59,662<span></span>
</td>
<td class="nump">$ 65,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">54,500<span></span>
</td>
<td class="nump">59,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | BMS | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | UCB | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Baxalta Incorporated / Takeda | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Astra Zeneca Ab | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Geographic Concentration Risk | India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfOperatingBusinessSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfOperatingBusinessSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_UCBPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_UCBPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724244337176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 23,462<span></span>
</td>
<td class="nump">$ 30,033<span></span>
</td>
<td class="nump">$ 48,847<span></span>
</td>
<td class="nump">$ 50,573<span></span>
</td>
<td class="nump">$ 33,862<span></span>
</td>
<td class="nump">$ 29,218<span></span>
</td>
<td class="nump">$ 23,315<span></span>
</td>
<td class="nump">$ 28,222<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
<td class="nump">$ 114,617<span></span>
</td>
<td class="nump">$ 1,193,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,966<span></span>
</td>
<td class="nump">27,093<span></span>
</td>
<td class="nump">1,090,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,949<span></span>
</td>
<td class="nump">$ 87,524<span></span>
</td>
<td class="nump">$ 102,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724159467416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - Subsequent Event - SFJ Pharmaceuticals<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication', window );">Success-based payments, first indication</a></td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid', window );">Success-based payments, first indication, period to be paid</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication', window );">Success-based payments, second indication</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid', window );">Success-based payments, second indication, period to be paid</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementAdditionalIndicationPayment', window );">Additional indication payment</a></td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementAdditionalIndicationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Indication Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementAdditionalIndicationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, First Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, Second Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139724250143816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SelectedQuarterlyFinancialDataLineItems', window );"><strong>Selected Quarterly Financial Data [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 23,462<span></span>
</td>
<td class="nump">$ 30,033<span></span>
</td>
<td class="nump">$ 48,847<span></span>
</td>
<td class="nump">$ 50,573<span></span>
</td>
<td class="nump">$ 33,862<span></span>
</td>
<td class="nump">$ 29,218<span></span>
</td>
<td class="nump">$ 23,315<span></span>
</td>
<td class="nump">$ 28,222<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
<td class="nump">$ 114,617<span></span>
</td>
<td class="nump">$ 1,193,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,323<span></span>
</td>
<td class="nump">5,570<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">5,989<span></span>
</td>
<td class="nump">4,927<span></span>
</td>
<td class="nump">5,018<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
<td class="nump">24,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">102,724<span></span>
</td>
<td class="nump">100,531<span></span>
</td>
<td class="nump">96,436<span></span>
</td>
<td class="nump">108,987<span></span>
</td>
<td class="nump">110,369<span></span>
</td>
<td class="nump">99,048<span></span>
</td>
<td class="nump">106,686<span></span>
</td>
<td class="nump">118,463<span></span>
</td>
<td class="nump">408,678<span></span>
</td>
<td class="nump">434,566<span></span>
</td>
<td class="nump">399,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(110,721)<span></span>
</td>
<td class="num">(103,050)<span></span>
</td>
<td class="num">(77,709)<span></span>
</td>
<td class="num">(133,631)<span></span>
</td>
<td class="num">(109,638)<span></span>
</td>
<td class="num">(98,740)<span></span>
</td>
<td class="num">(110,970)<span></span>
</td>
<td class="num">(120,687)<span></span>
</td>
<td class="num">(425,111)<span></span>
</td>
<td class="num">(440,035)<span></span>
</td>
<td class="nump">687,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (117,203)<span></span>
</td>
<td class="num">$ (108,586)<span></span>
</td>
<td class="num">$ (80,000)<span></span>
</td>
<td class="num">$ (138,651)<span></span>
</td>
<td class="num">$ (112,164)<span></span>
</td>
<td class="num">$ (98,585)<span></span>
</td>
<td class="num">$ (110,286)<span></span>
</td>
<td class="num">$ (119,632)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="num">$ (440,667)<span></span>
</td>
<td class="nump">$ 681,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic ( in dollars per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
<td class="nump">$ 3.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SelectedQuarterlyFinancialDataLineItems', window );"><strong>Selected Quarterly Financial Data [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 2,884<span></span>
</td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="nump">$ 5,558<span></span>
</td>
<td class="nump">$ 4,346<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
<td class="nump">$ 17,504<span></span>
</td>
<td class="nump">$ 20,117<span></span>
</td>
<td class="nump">$ 20,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SelectedQuarterlyFinancialDataLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected quarterly financial data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SelectedQuarterlyFinancialDataLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[ \&Z(%*4SS=XAVZY5E"GK&(4 "U66RC7:4"UR[FKVF/]!E,^X)O62UE.UR
M&9K *@]!J;B-8)4E7+N\OR98+LR9X,^4A?6.M6..AC9J5<9P[4+_FMJ,2P7R
M_"?='(\6.^)EWQU<V+A5&<-M2!F&&=3XQZG8 8")C4B5(ER[KG_B.F7-8LYL
M>MP TK_PN@/?L49JE2!<N[HOJ(+<P%?(]=XMWZ. A)D ;]72LB.->)I"; :*
MAT\GZ*USZCB.BS:0G9]Q8JU*O"I_>';9A]0:4;9&P2Y=\J2.9 / X_UB;F-2
M)0K/+N5[1Z&[ES#&;$V.9K(&H,=A,![^8>-4Y06O55[X!CO"[A,#S8+IQ!+6
M6H2F4F;UBZT!\SN1-FY51O!:982O/($,"KME4Y,(6<O(CO1HDU*OTGJOE=;O
MJ\F\4C-K"S0UJR=F1VQP527R7BN1GS)%1+['U[4MWE.M969';&!6:;S72N/-
MU*$1I)XU%[52T8#S"0L(F&$8$@ "F"B'M'&LM-ZS2W7!,4AQDJ#;3,)M63^;
M=IRF$MRK1-^SZW7!Z"XE8JT7V&^ H&)(1>D&LWKW_;_=@5>IOV?7[.EH,D?#
M+*(*:HBA4@1RMBDD)PE>US*SXS5L/_U*Z/U6&X4@!BVS>:H!ILE3?J7W?JN-
MP2Q;)C0$]W!<%XCC F5@4'0#\1EJ!Z?X=]5[KN-0Z;O?2M]_3+1!C*'@0I\S
M!7/'3'9\1QF2YG)=<VI4O.7L@*-[X<&?<^8?H7C0N;&+\WX3+ ^V4!#>2[WG
M6Q&0K_H2M0%UIJ69,ZGK%%'N'7_Y&5B?_RIUSY(R:H02ZN"775X6F[VXXFA)
MT K4)4(K6.,4F.D^Q+[/\D"($7T -OZ,>1)!6D+@/$1?C4#L1P!W '>&A4+3
MZ13%<)6O3E&0A?%_"&PI+."2PI9"X*N8[.LL"C.'=9-K7T3HN2TV.?I9F$@7
MR$9X9\:N+0D\7ARN\@[(3G= 0MV4S'F"F?RQCX1T1'.1(MVM.K7%0Y4^?7NR
M&\+H(C/"8U+1 - 8FE6^]%OVS@X[0A.X6"O[#6!-+<PJ5_HM6V@%JZ*3=IR7
M'6[RW<:JRHY^J^PX F("2$U91%[0/:G75CN45K1+Y^S<N:QCUCOHK^O$9[Y3
M2%BF4/[EK?;R:ODM9&B^ /2JQ_,/*0]8YTV)$K("4^?T'&90Y-\F\A/%-Z9;
MO^1*\=0<Q@1#'.L'X/Z*<[4_T2\HOQ#=_ M02P,$%     @ $9I94D9DT4=<
M!P  I1T  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RMF6UOV[H5Q[\*
MX17#O4!2BZ0>VR1 FW2[P;+;K$XW["4CT[%02?0E*:?9I]^A;$NV^) ,V)O$
MD@[)/X]XSN^0NG@6\H=:<Z[1SZ9NU>5LK?7FPWRNRC5OF'HO-KR%)RLA&Z;A
M4C[-U49RMNP;-?6<1%$Z;UC5SJXN^GOW\NI"=+JN6GXOD>J:ALF7S[P6SY<S
M/#O<^%8]K;6Y,;^ZV+ GON#Z^^9>PM5\Z&59-;Q5E6B1Y*O+V2?\X9H6ID%O
M\<^*/ZNCW\A,Y5&('^;B=GDYBXPB7O-2FRX8_-OR:U[7IB?0\<>^T]DPIFEX
M_/O0^U_ZR<-D'IGBUZ+^5[74Z\M9/D-+OF)=K;^)Y]_X?D*)Z:\4M>K_HN>]
M;31#9:>T:/:-04%3M;O_[.?>$4<-<.QI0/8-R%L;T'T#VD]TIZR?U@W3[.I"
MBF<DC37T9G[TONE;PVRJUKS&A9;PM()V^NI:M$K4U9)IOD2?6<W:DJ.%Z4ZA
M<_1]<8-^>?<K>H>J%CVL1:=8NU07<PTCF_;S<C_*Y]THQ#/*#2_?(XK/$(E(
MY&A^_>;FN#AM/H?Y#I,FPZ1)WQ_U3;J3DK<:,:5@GA\"/=*A1]KW&/MZ9&J-
MP#>H-#_X'UVU934,X?35KJND[\J$V?8*%WF1)!?S[;%/;+,BI2D=K$Z$QH/0
M."ATL192GVLN&WBE6ZYTXU.YZR<]&CY/21'CB4K;#!.2QT7AUID,.I.@SD]E
M*3I0!JFBY.#,QYJ[1";6Z#3/\V*BT6&5YA%Q*TP'A6E0X2VXK]5"OKATI;97
M$E*0B2Z'%4G3Q*TK&W1E8<\MMWT0;]A+_VZ1%J@4K9:0,2%SM-T*?G222^=;
MSVQ7%5$^T>TPPCF-W;KS07<>U/U5K[F$E'<<FBZ%N>VTO,\J)Q(=5@G-,[?$
M8I!8!"4^",WJ-T@L[,$QS:-H&N$.NYC@)(G<,G$T)O4H*/1.M$]O"O)]/R<2
M:)JFTY7JL"-9@;$GRO$1?G!0Z;V$BD3JES.T ?;H/H>:]+DQDL]0R[53-K;D
M)(5#M6V6)MX PR,^, DO59#,=-4^H9I#"8&DJ17.Q>J\@PO_LMCW.HGW.$NG
MLAUV-,:99_7B$5(X3*F_"K%\KNK:*8Y:@V9I$DW3_:MFI])&+.$PEW;1'_"=
M@S-Q:JFSK6CLR4MX1!$.L^A5;39?^F239E-Y#L,BRVB2>B2.+,)IL**YN_WT
M^?;N]N'VRP)]^OT&+1Z^7O_MMZ]W-U^^+?[\IYS@["/Z\H_OMP__#A0[>$0,
M#C-FP=M*P&: 0RZ$NK$5FJL^6/OXK5I(/9!U#((,N-$OBG/T.QBAY%>G VV@
M3/.YPX0D)"]\"V^D#@YC9R@T]F*=^FR:$(+IM,QPF.&"^+B(1^K@,'9 HNS
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M-;N^;#^[JZ\O^4X6><7N:B!V94GKEQM6\*>K&9J]?G"?KS>R^6!^?;FE:_;
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M4OD&SS^!U]3D9$E^WLRE$K"5?IT)UV_"]4VX_HEP7Z#G%'6IJ2YU5T4KB,!
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M<EXH@/Q\Q>337G.COI1N?WF9_P]02P,$%     @ $9I94K\YB!_I"   *"<
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MI6XR/23$PR.(S8PX8U=&,,Z1!NP<1T9(XD>0,4WX^&F>#[J$GW_^XDF46/)
M62/MAC3@$2)8$.@8;42N1%#>Q[,D'^0*]\N5V]5*%-:%Q4MA.UP$A+PI@4UG
M#U/^[(79_2>(]1$]PY$N!^;<+FQ* _?,O<"!GO0U*!I^YHE/]_2I-5T;<K$4
MW94IAN]DC/0Y A9E2 ,!@8)8CT*,-S)K%M!P7 WP0=QPO[B9C]$CN28/XK%L
M&N/BX P[D;<H9Z2_$7/LZ1:"I!F<Q#'_=J%A$H\?Q?D@?[A?_G@)"].S]E!%
M^AY9FB$!.D>@N%46Z*2H56Y[:.1=_]@N@S;B?FUTO]UL*OLN0UX1T\NOI#+%
MVPB85]D$\="]:0-IWON$>]!)H5\GV=W8Y.72/B!Y?8Z(/NAVU4N6(-$R1X T
MHQG2\$&1H:<W%PYZ*/3KH5->]L&VSE_P$A&Z6B3B[@W/,1Q6'1!<3--Q6H/
M"?T"YZ3!35KS5M%4KJ90%5\??)AG^H]-^:\MDT,),7;H!HT^%>F-P1PGAU,%
MDDX08)3$&=(*0I"GII@=O!%4B_;1OHJEB.T8=^_)[+_=O^[UQ;[D=/+]#?V\
MZ%[:&J;IWB'[EK>03A588053!I\2N)^V>RVK^Z#EQKYW]""UEK6]7(L<9)8!
MP.\K"5JR_V 6V+\<=_T?4$L#!!0    ( !&:65(<4SW[* (  (H$   8
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MC\TZK_P?.:.H*K(;IDY6K[(;OZ[\RB_SJLLNE\NZKSI?K;/KNO1+[]KGCSL
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M!-4-&6'DBZ5%TV@Y(DU@0P/;&AQW)H6H.8^N\K+?@G'"E6HX3$-6NG$;5$%
M77Q2U1QXJ,L/P)*%:UHY389ZN#N@#M#CUT,ZOLQ+U(;9#7JN -U/K.-G@!M
ME&Q/BE:1;H'.B]]ZU3O$;Z 4@'I .JO[ 7\G$*/2QTR6'A"]BZW+'N)!']$"
MONV"!%:N&SRQ*_N6OAJQRDE4XS_["DPN^AY%AEA$:HZ>PQ/?YKY$;CR#+<[:
M?*!B42 =:-4&49$@H7'+,F];^I.E#$(S=B?N061 (1,YR%JJH@HV.?C,P2&/
M.G3LIPS+Q9/S+^E,\(]G!#"H?3 !31"1(W1*U"@^A%H<V6OONPT+"-M*T(IX
M*+<CK1,]U%W4Z0^_N[R\?J2.0HN&$R)/=3*V^0?07$&UDRUJ(5K=\5G)/S,2
MSN*'>VU9GR%2@5ZBV4J?@\ED=X<\(?!C :?@$\AA$3ARBXZ\P[N0YP,OX+_O
MQI!JIBG8&G#%T,?!9]#UJ9"U# &C.@'Z^KJ86S?_.%I0^7JT+P  4*!'C[$#
M#L;7N]XH-%BK1#0 !IL,UVH\T8S\FVX#6NWX+BRD\>MH4/&UQC$;*[="C"^$
M7[*FA .1[4>-4R]*\7=EEXBA6["CI/%)X@OA<F:[Q.<*'A:8[OJ0E\"-@MT9
MK<GR9+$4?%U4XDH)D,T:))77;#%Z6#9^@0_U#:VPP*3)UW0H5#JL*0C"V[SL
MB2_0!0-+T1SX,0\VUC<::1C_;):MZ[I@*T6:I5J?E2#GA?#?UY$E,9R;!3=L
M";BD2*U#>LWH,0QNAUYG.+;RUM>@BJHS<F &2&)76K\,?IZ\* XUT-N*@Z$Q
M.8.Y^&CL9LL.'G>U:.];=@?(2DD,BFH.]B%2?LUP2\R!6ZW%$P2V0,/*)U*^
M(RN*JQ ,D1V!?ANP$'5#B,)S@$.&S,:K3_ #*1.C?H#2'I##X@1T;FL.'WO0
MIPT+OV] 86-0LA2-GP@,\C<]MR#/%MD,]!F>ZK>^6(MV6*#NI\7RICG@E\1'
MIU37?L,.4>OTV;QA>XLY0 Q;P%/*4?B%;G34%O!#8&+,A;$$R"*9=W#\<2,P
M+1%T\HU8Y\RR?D<:#U;9<DRWP@2>&-3..O$L:L31T0#H\^AH6D?/: X..6@[
M4*(-,!Z(.K#^RJ,'^WYD+Z]8GV7@X6XQ7'.WONY;VDN4+#(8A)+XSI1:!FP+
MU<E7(3\EFN40QS(%687I<07,G0E2(,1!%VELUXN:R&(T*RH#P,44R$%=B3%'
M[@>#/R,]P_^B$$O88I;P!/#6<;=OGGT+&BC[1154]-C?5&W7],R*/VU8_35%
M:J3$>!@T^OC63/0^0AMB4/H';@WLR0^%  ,V</ QR)'Y<)<?2+)LJ)G8W1CZ
M9BL\":O:@K,#0!S?L#("Y0D8;3> 4$1Z\,7>F*"8?080&$-MT/03WAS+O2*D
M"QQ;&"#8;1)'(OEFJ!Z'2!E'ZVW&VK#6L%W-)4EQ3K;0=0>V(@5XV\T!.;HJ
M\J9 IR2'Y^M;-)*\N!5!8=?L][Y&F'1A9!L("S%:$F7C-2TO,!!K12&!Q<E"
ML6)9M*XA8BK ",4\NX*CSNB_V>N$"P"H-VE^XFW,3]P$YQE5NMI["5;O3FJP
M\YF#9F_\VF-V03C@P+X:^ ?9EE/=<*(2]1TI4@C?0"NU3*B%&]&)#(SPRF$(
MR7#[QF'5!84ALA]N3]L!YP%T%?OE,X1B3S$"<@=:7-2EY-^#B63/P;)M#785
M94O4D/'X82%UE4E'!U;FA.'HA1GR.PG)&>BEK=WF7W+8^A;(IN?$O<BS&6]E
M62&F:CE#,2V0DFU$4^E9)HV\$4PF=AO%;(EQ.!XCX]YW!&(2:N*ZA#'4YFY/
MA,0M5A 1U&3 QV<HW*(SF 3KBBG$; ';@'!B>K/C*!L!AP]*_1O]NKHA(P"+
M(#8QI^Q7\ ?Z@VQ'#3K(444]#@'$'^1C@5F5)"]Z_RK$>;8$)]AW9ZJO*,H$
MQN&#R[9 K94DSFFWP6:^56T\6"Q O0^^]1]8A-!\Q2@+$7)(B+\?#<^2K !M
M_!UPH,'],[#@8@&:X[3FM$*2LP'KM:-81).BB8C<95Y("O<.G?]6R10";]A_
MZ\&U#";1Z3=H:MAJDLRSAD,K'.%@B-DR$=7A-0,8X+I(C T%:.HLJ>/%+DRV
M=1#/%9*0(;4^-N[3JB3&-.-ON&)0B])E,F6-;S^H+XBN$,$MU=QL<> 4WL:#
MK0/G-I9G4(B173VX\HYS56S*_@U ;YS9JT"@4J?(=_T]8@DXUL9C48'/S4)^
M8'!-C66'9;Q#AFG;KAW9 O_1%<J;AK@VYXIG4==JD']5/&6A9 <:J"K:F?D
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M#:2:+M%A4TU3_\8=A7T+ZI=@5P,8UQ^DV._3YDCJ"[5,Y-^4[;MY]I(#&:[
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M('#TY&O2Q\S8(VABVC8^KVE[ZY]LG7W ,]H#2L?$0IL8HY>^9=!U^^&FKN[
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M!5V!:Q J+6F4A*KAHU#DT1O+56D_S8#N#]LUFN$.Z9.=PSW?4LLX-()+"Q^
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M $1N?-MCC@;*8'@J'] _QM@IEK5P>&?4'[+R]?6H&$&%&]$I_]GL?L%]/-.
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M*]D+!:(S07N6/TO/3G\&-Y)P$PD=2=0!8Q[@!5N+Q%ZF\'%>$R&*Z*Q2[D%
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MXUM\X_+X+N0;Z1H:I+=JA:TG\T</CX2+[Q?&#\'V_$[?TH9@._YSK5 &.EJ
MWU<6_)0^T 'E)<\7_P102P,$%     @ $9I94H)C-J ]#0  V2<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&ULU5II<^.X$?TK*&>3V%6T+,EWYJBR
M/;/92=7L..,]/J3R :(@"3%)< '0LO/K\[H!@M1A>78G1^6++9) H_'Z>@WR
M]=+8>[=0RHO'LJC<F[V%]_6?CHY<OE"E= -3JPI/9L:6TN/2SH]<;96<\J2R
M.!H/AV='I=35WMO7?._6OGUM&E_H2MU:X9JRE/;I6A5F^69OM-?>^*SG"T\W
MCMZ^KN5<W2G_8WUK<764I$QUJ2JG326LFKW9NQK]Z?J$QO. G[1:NMYO03N9
M&'-/%Q^F;_:&I) J5.Y)@L2_!W6CBH($08U?HLR]M"1-[/]NI7_+>\=>)M*I
M&U/\K*=^\6;O8D],U4PVA?]LEM^IN)]3DI>;PO%?L0QCQU@Q;YPW99R,ZU)7
MX;]\C#CT)EP,GYDPCA/&K'=8B+5\)[U\^]J:I; T&M+H!V^59T,Y79%1[KS%
M4XUY_NV=-_G]PA139=T?Q?M?&NV?7A]Y2*;G1WF4<AVDC)^1,AJ+CZ;R"R?>
M5U,U715P!)627N-6K^OQ3HGO5#X0QZ-,C(?CX0YYQVF?QRSO^!EY86?B;U<3
MYRU<X>\[9)XDF2<L\^0KL?MR*7_XW<5X=/XJRA(WIBSAN3Q"7#DQU0XNX=14
MZ$I\;[P2HV$F,.*JMKH0QX36Z"(32R5R4]:%\ACJ%TIHYQI9Y4K(:BJ<+)0P
M,W&1C2].LK/A4+B%M,K1/=-8FDJK.EZU@3VMD.*.AHC;QN8+Q("XFENE$)L>
M[NH7XOKCW4#\L%!X$F71Z*:R:JZ=5Q9J\,K-Y!^(1N&-R)7U2!FBP"*'31T>
M>_P]=%X7A:BM>= 4^4X@\T"!&8+W\$E)*VIEM9D.>B A0SG)07Y;2,RX\@+^
MH\H)5&]]B%%92"A20_:C1D"KXDF,+[-SH# $"E!;V0>HVL'1AR(3$GKAYG*A
M\P5O,,T@%1/& 3)"4@4-\[Z&-6F8]>2LJC/,+BZ#.E&+4CZ)2; @%FIJB""+
MJD=E<^U4,)IGZ'0U%Z;V#!H4HF$/"G#2[1DIZZW.R25:TVKOQ/[GNQ_= 8T'
MKISD:0^]$=F:BN?9Z=EE7T-"0CY(7<@)'(N@F%L)S^AP@%>>B]N>^ _X4U$Z
M9H.Q\5<7&67'X]&O6^0]'-X\*17#);DJK3!X485/7Z#F?AB GP=B*:'3%&@#
MSLD3*S QTDX)Z:FV\')C >YU>^]=>^^ XO6CA')B?)&%-6G_+) P>.@DNEYJ
MH&E_:2J$_$F8-1"?@BM, 1DM$6;+ @:KGG;%M%](Q*W:0'2+!V.A\4N0C",D
MN9*4FA#<DW7)L\8W6(Y-Y@;B.[-4#\IFR5L)@&?\D^>0Y[-.M-^T)*80[<##
M7@0,Q%V796@XTD_).,2YP8(9TM_Q<-AWL2U095ABVN3!(C2_:CBI8.CV)-%/
M<7()V^_> *91<IM!Q^@3(5U%GT!6IS@.^V!OHPRRN16VI09<&BGJ:0W[J,;*
M\N<Q*CY%GQJ?M:5CP^V23U*<(N-/.>M'G9(H)#/H )!0D"XCK'(ZU:2P+%JP
M6,]23M?=@U6,WK%-4;%_12M#"?:T3N_1>9O<:?QJN,S$]^K>HU[LW$%?,-W3
M56[)CP/D<Y2Y.877-KNO5&?9^(6Q^I_KQ< 3+F%+ 9WAJM.EG9&]/R,$)/E*
MEV@&H?*ZM@!H\GI7DXM1R"/0B3.,AZ]F35$<(OH;%>#DVZ-7V]VO-1I5V@F1
MA8;'R#G"R?D )A?\0I?:@^6ZW.H)C9@ 28%4-1J<MEN@_5(X(V=5[3PPK(9]
ML5,[-U45J3AS!@:8-$U;Y+Q$LWM!!-FL>:%5Z\FA;JK'&BF5GK,' 0BR&_%\
MW,T)^Z*@S& Y >B*<,WX(<;/E.;+&;R05J$RF?5E&;);7V)EO*BE9H%352 !
MVF= ->M!SB@SM)N)$3MU8 GDD,_'J=AGP#BK-]AZQ+V'TKKQ7>O'5/M79$6&
MZ5;L.^'$'9G%NBQAB;BL^P <$P24]$K4@R<;!(S!5=9JF8RJ'E&/JWG(I1)@
M6J]S75,1!Q D::$*?M@XVE,MGU:9#K)A'@I=%0O'+N?.R$N7BJ!W_8+8J=%?
M%>L1/W.SL*:7C^$9D@G3ITFAYS+4*JL*CE'*\!#+&&7!R.0DO\W$S)Y%W=C:
M!$Y'3_/&6IJV.T7P;4K;P6=U*M#,-!& #*8U)?4+G-Z;/%?.$=+,LGF')*?+
MUZ62D7@'6TC/35,F($0_8'TJC,S?0^5F/TFTA]CM#+:B7RJR,J*1I"?KB/B9
M:\('E-,1IGYA33,/.2'P.C(SH]7R_,/@I!%"SC&%HWSM S@<!9;%2X@/ODQ/
MB5>X) _*PNFTHDK3 M>O&\$0+R'>)GL7JW[D,5F\I(J#90+AMW0ND!Y-3-4X
M0F.=[F2;_#M;I>$U_-:;LET2>B-X"Q2XL *;N26]E,9RX&;;AJP//ZW2(=(Q
M%$YME8G)DG+V!G7D=*S],V2I%W&Y=(NPV63'C]R0)2JV28T[OZ%U>I[3-HLH
M(:XIO&R-)Z?H$8EG)TLBUN#/TNK8,B1/ SA815%<;$3A;FL/J)6@:K[!&;:/
MCXWF@^KC&LM@9:K#7U 8]4PGFIM\AQHQEGE+/[!6#X$NH&@ B6D?=F$77-=2
MT^E0W@3UII0Q0[\<<E%_Q:0?E=FF!_@70],W.$D(?#7EG;FJE&46,*.GU+R[
M5RSVMRO9]58K"Q#S(/E?@,$JS)L5Y NS[;-[12Y309E(C1*L/#4JRH_63/?"
MREQB$IGIM9&!!.-O4Q64V"$>=*E/?-KV93/FPLJE1.?=E#R#$\.*$40RRF9B
M^VK@^-BTA0M5:J6E9>O$VHA5 F?920B2&>C<)-9C!@4\)/(;J2V>VGOE1: Y
M8<,L>UN[''G1]U=W[Z[^&NG^QS#?5-O4W742@09:?*LFMI'@RZ/+RY/0<FT:
M)ITNT ([)>Z_O[N]/:#<G[*4BT3[9'R\/SEH,^X'JH94WC^#KE?8^(V9LMZC
MRXNS@?@Q69($PJ>RTQ<;Y-#2H1;.X6C<>V[O@_XM+5M[2@"T^3IN:ZO?[43L
M/]#G=6% GLV]WEJK%]QXY32"<(X<K%>JNH21^B13U\9ZJKQ/3,=B:2>_7\+A
MW4+7B>OPV7" L:55B6NS4Q!KHU7AK1SL(3?JG!BW-<@Q4SKS\.GLU0=F&HG%
MI@]T#A].*_F-"]>OBL49:J0.XX6NNIU3:P57+?6AK"I41>I#-' *2",WM*O"
MMEY<G/Z^Q:TPRV D9LF%X38G9H,8Y-H"B2FTB:/"\NPVL1;$G17RA8$#<3(<
M[=\?P+<\0.<G[$4_PWUK@,3'TW&,[<;4_6.1+<9=@0K,!FQPTL %F[KE&92W
MPC[/ANW>-?6G#-;*J7+<##E_@^RA"^+V7<<69H1F#V%JEMR=!)_=R IWL68B
M))HB-#W!=^,>>6,UU18ZK6&F4LI[*B(^7Y ETF;"232UO0M9S#C/TM%^U_F!
MSX3MRE2",.B;,PX;ROB]L0/Q;=QE*!8AZ+><\Z/D7 :>E-Z&(*>:><51^\WQ
MX%2 -Q=0+EN[HCG?C <7W9UXU@+:6#QE\;"O0UT]TF^U[72#@F2[3PS$#3>@
M-.N&D#(%('] V:(\$@ZCJVY??#(W/'N^3*14V<KEE+4N]QJ%<::CY^[??+AI
MCY=^6"#0VFOP5M=K6 MZ]:!B"N8ENOSH=:E<>U"]1:^4NTJ# "/N31D\Y7*3
M4W?+O77[^NJ433<*OI8T@G93Y=#0!0[(GM;V Y.P*=?KN%LNNQEO,?.0DX?V
M4N0)KSSBU:M %1T/&8H54I+/73;&D\>D%=+)2KC1O1QKN)V1;=]M.'O6='9
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MP?GI7CA7:2^\J?GCK8GQWI3\<Z$D$*4!>#XSQK<7M$#ZFN_MOP!02P,$%
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MD_S4Y/ TCX&'H^1+Q^9-%V&RW\4/N41+SEQ36PI/R"J#VS9.*V#/K<W56;!
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MB+6 315JA["-711(^$Q\U/ U4EY_=%@7W0X/M!IM95.+_X8(/ .@> <F[6?
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M:W-H965T<R]S:&5E=#$Y+GAM;*U8;6_;1A+^*P,U5\0 38FD1$F);<!.TEZ
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M :N^71'2N98=B6H! XAXOJR%[]Q[+[M"._8,.[,$[H$?A.3]Y)5 PQ\0%"
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MV3P[\5/6<&'5QGT362IK5>.6:\%1'VD#GJ^4LL,%,1@_DKW^/U!+ P04
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M&E#O_TZLZ!N_HF]H1=^<L*(QB)_^=?)WEZ0U_'^"FTCKY>8,43M+%GFUVZ2
M[4O7M7#R1;*LMKNT/"0;(/D_NK1N70WOY65REY;)SS5NN5E6 *"TR(%)E'E*
MT,G+957OJAH@06^_<46ZARGG.G7F[H$E[!"ATF27[QRN%^&8U=TZ 9S+$-B
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M^; UIXPG399@U.3MF?)8\AH XO#&95HXK96XQFFVWF1YHQ*D-YA?]=[;2O_
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MC" PYWM6*QMS51<!ZT1.PSF2Q58E6\S6-]EN?EY^WY^)-1F0B#T[ ;+W1P(
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M4#<<UA9M7*VA8;O!=X3WH7TEE7I5U!81^R)^;UI5(K7VV;E5XN/&5:LXEK_
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M^#1@GD E/MV0!ZP],$$CU_T=XI*0UIL_Q4RX+5M^F6CD9E4T-BU&;3^V[*A
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;+56;6_;-A#^*P=M&!*
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MU H,+J>]B^C\<LCVWN";Q*T]& /?9*'U'4\^%M->R YAB;EC!$&O>WR+9<E
MY,;W%K/7'<D;#\=[]"M_=[K+0EA\J\L_9>'6TU[6@P*7HB[=5[W]@.U]!HR7
MZ]+Z)VP;VP&=F-?6Z:K=3/-*JN8M'MHX'&S(PE<VQ.V&V/O='.2]?"><F$V,
MWH)A:T+C@;^JWTW.2<6DS)VAKY+VN=EGI"M9.+D5BQ+MZ:3O")0_]?,6X+(!
MB%\!B&*XULJM+;Q7!18_ O3)F\ZE>._297P4\1WF9Y!$ <1A'![!2[HK)AXO
M.7[%OR\6UAG*@G^.8*8=9NHQTU<PYR2.HBX1]!*^;- ()]4*_$GP435:H:1[
M*9S'@6_7"$M=DE88T#$K0&JSJ)R%.]R!?$0G4:R$*;SAFDR@;,DL"$ 82[;T
M0==6J,*>GL.UM%Y+EV('5R*7I70[N%U+4P"YP!6@6VUNDNN*])<C/1S,<>.P
M6J A7J(1?*H5\BAK;1V:"CX)59.T:3T)?YS,-R)'DDM)&C180%&;UF_8H3"
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ML&DPC!X,NZ6S$N]Y\8Z$@4>H3_T9>>'@:.CDA7_J*+D7NJBD;A4G_[K9:*,
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M?(,&K4P_;\S<U&:B V9&D%^0.#PC41 %>^###\/#[#W<Q[2VN8W:W$:.+S[
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M-T 8:QW-7)2]*;UU-:PPPWBGA'[+M)\:CHE< %),P66QIE+I 5(2L )<$_%
M%9ED%-S1="688E2"3^"&"S7C&>. S\!ASN_/]3.6?=!1[N_.P?MW'\ [8_UM
MP5=21Y&#OM(5&5S]M$(_VJ)''>C/:7H",/P(D(>\%O?QJ]UA\MR]K_M8-Q/5
MS41E/-P1[X(P ;Z3;$4_@C,IJ>Z&Z<X5(Q.6;9MP38E<"3H%>@K?FMX(5LQ+
MJS]X(>H'(R*9!#^N= )PJ6@N?SK@X1H>+N'Y'?"^""XEN-=I2,;^T1B^:)JW
M=7V\C1.4<8P0K(<(>KK!ZY;L?IW=/RS[E;ZGK>FW@<*=])]P5_J@3A\XTYNY
MVC;!@D:I(8J#.M<64-  %,0H:0<4UH!")Z!O7)$,I$\48L\IE%L*R9I";?C#
M!C0(DS@(XKT26NQ"#R<Q;*\BJJN(G%78*0^^,BJ(2!>/X(JN:0:08\K&=?CX
M&!F5U/ 29_5GN9;#<C*/N51MPY,TV^YYR/=Q>]NA9W7;^SUD'E6!GF/H&G>X
M\^& OXG/HRK2,T+#*.Q 8-46HE?.O=:DJ*WU&/O[S&@S#+PH#((.@%9OH5MP
MQUPLN2"*ZJFHZ';JCKC^TH%_P1N) ZW<0O\8J0.M($.W(K],'MC4W3 .@T[R
M6.F%;NT]@#PMNNGAKIEA51.Z9?,0\D0MY/$Z/C[0"BN,_P]YXI;.1WZ8['.G
M:0<A1C!&'?BLLD*WM(YYGE.1,OV-O"%+*MY.&60U%7G'2!ED-1>Y-?=ERJ"F
MU&*( ]2Q>D([2UNWV+Z>,JBII[[?D=Y**3IP[=I-F"K2,\*$40< *Z?(O7QU
M\P4UEZRZ[7X2[?&ES2X*_*A#T9 54^06TS\G&9L3LS.69F=V?W)W N9\345A
MEI1 [\B+U,S?M[/(BBL*CY)%5GR16WQ?P:*FYB(<=W'(:BYR:^X!'&KJ:H>B
M(JNHR*VHAU"HN6SM*!Y;<<7N!:N;0+BY2-4=1WOT:;'JPF4U%;LU]9H7]+$Z
ML@ 7JQ=79]"U$[=RBH_SJ&#GK, MN)=OW(_BIOK"*,%>8RB;=C$._(Y- ;8Z
MC=TZ/:::VS.6$K/@UDIX3I=<,N7JB159'!SEH%GIQ>YU[9L'+6R<@B0APOM#
MUK0*DV!_(]G?.8PT)\&:67.M<B"C,^WFG43:7VP/5[<WBB_+\\D)5XKGY>6"
MDBD5QD"_GW&]>:INS)%G?<0]_ ]02P,$%     @ $9I94CC[? == @  *@8
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M    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*V66V_:,!B&_XH5;5(K;>0
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M<0L#+BBTM]&7[G#-SAP8-FB_:?=\M55>&BBO5(CRQUM.:78C9Q8"6208UB8
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M]&&:NWDS<7H;KK<K[?"R'(8;?)\!XS?@\[76[GGB;\S=&]+\7U!+ P04
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M^[("&IV<EJT">]37D-2IQI?6#<2&JVB+7S+%)8/N1*$LIFD74O\ *9FTI<K
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ME)<1H[!2] !XOQ1";6_T5^#=_URX^A=02P,$%     @ $9I94BT]Y%#' P
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MS2(4!MXB")E/Y=ZR!FI8)K:& S!L9S-U!^8KBKN9%->SW6YMMT';3Z5!6L>
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M"TN5?)H57A!SGJI2W_PY:\A49@T9M'"IJX!C#U\(<%,ZC_/2-$M89H'8'XY
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M 0LRMK)]&R^-U?1VOQ]A=-TQNO:,K@\FVI9.-Z4[APD67$HN"WK:OHK[ZM&
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MC7VU'29X5P)I#/#Y5@C]/#$;-+>OQ?]02P,$%     @ $9I94OL>@[=Z P
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MNJ>RPY7NDU$8 _U]P;EZGI@-ZLY[_#]02P,$%     @ $9I94OBT[&YE P
M>@H  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULK59=K]HX$/TKHVA7
M:J6%?/!Q:05(0%IU'ZI%O6K[L-H'DTS NDZ<V@8N_W['3LA"&W+9JB\0VW/.
M>,[8GID>I7K2.T0#S[DH],S;&5.^]7V=[#!GNB]++&@EDRIGAH9JZ^M2(4L=
M*!=^% 1C/V>\\.93-[=6\ZG<&\$+7"O0^SQGZK1$(8\S+_3.$Y_X=F?LA#^?
MEFR+CV@^EVM%([]A27F.A>:R (79S%N$;^.)M7<&7S@>]<4WV$@V4C[9P9_I
MS OLAE!@8BP#H[\#KE (2T3;^%9S>HU+"[S\/K._=[%3+!NF<27%5YZ:W<R;
M>)!BQO;"?)+'#UC',[)\B13:_<*QM@T\2/;:R+P&TPYR7E3_[+G6X0(0#6\
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M;<MLGLPV6FSM#+<2&B="N]S@#,ZDN8#/UT+HUXTQ4$SULU]02P,$%     @
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M+$\1Y8,66[NO?A0:=^GV=H,G+Y#& +^OA-"'!Y.@/LO-_P-02P,$%     @
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MN4?*H:TW]U(O9FUMY3/A\OYHE/W*K)V9?1&9+ ']H,^@T1B]#M%2R1VKT_L
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M\)MAQG]G=I3J2>\ #'FI1*WGWLZ8_:WOZV('%=,W<@\U/BFEJIC!I=KZ>J^
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M[XNJF<CW&.&5@?R^84SL.]4$[0MO]@]02P,$%     @ $9I94F7V*S)^ @
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MR@J _?U1:_/R4#@X?%#J_0M02P,$%     @ $9I94DDYJ?52 @  7@P   T
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MG)*:77>]'LR#:'OU]@\S/7]A"_;_*.*_4$L#!!0    ( !&:65*7BKL<P
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M)X-SO1+&/P_<X*KJG\T!5! I<R3AA+FJ.CQ*%&5U+2NX>\7.>,U5*5@70AL
M)@A@\F: [."6!Y I IF^(N3$0_@?6*9G[&89O>H,@<S((2NA+!#NQ0T@<P0R
M?[-(3IPN \@"@2S>#/*<VT4 ^1Z!?/^&D/\F >0'!/(#+>2-F7,EG[H3C"L
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M'N6:.>:@G-A!".:=B!*/''-03C[U"19?#MGF\.!:6_N.G85K1#GFH/P5MVH
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M#8JL!D56@R*K09'5H,AJ_E/6>^?6?QP_/LO.-OU;/AO_FK=X 5!+ 0(4 Q0
M   ( !&:65('04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ $9I94O]:L.?N    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ $9I94IE<
MG",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    "  1FEE2>NYN]9L&   M&@  &               @($-
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ $9I94D9D
MT4=<!P  I1T  !@              ("!W@X  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( !&:65(QS:VMY (  '8*   8
M  " @7 6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  1
MFEE2O;)G=(4&  "^&P  &               @(&*&0  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ $9I94E?#WVLQ P  L@D  !@
M         ("!12   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( !&:65+/+D1JK@4  (49   8              " @:PC  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  1FEE2OSF('^D(   H)P
M&               @(&0*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ $9I94AQ3/?LH @  B@0  !@              ("!KS(  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !&:65)* @PKO"@
M #R%   8              " @0TU  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  1FEE2Y0SN_$('  !N$@  &0              @('_
M70  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !&:65+V
MU9*B9@(  !4%   9              " @7AE  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ $9I94HW1!5;4 P  (PD  !D
M     ("!%6@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M"  1FEE2S=;V&QL$  #Q"   &0              @($@;   >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !&:65*4_B"[- <  !81   9
M              " @7)P  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ $9I94KALX)[P#0  ""P  !D              ("!W7<  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  1FEE2=6G3OUP.
M  #P*0  &0              @($$A@  >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( !&:65*"8S:@/0T  -DG   9              "
M@9>4  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ $9I9
M4B_CK<FM'   Q5P  !D              ("!"Z(  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  1FEE2DZ72L9L'  #;$@  &0
M        @('OO@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( !&:65+=N0.K6PH  # ;   9              " @<'&  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ $9I94L'I/DF7!   (PH
M !D              ("!4]$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  1FEE2:*B4   '  #C$0  &0              @($AU@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !&:65)[>Q_'
MXP0  #X+   9              " @5C=  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ $9I94N"DF]"D+P  !:0  !D
M ("!<N(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  1
MFEE2J*;&Y/$#  "#"0  &0              @(%-$@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !&:65*8]_VN:P(  !0%   9
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M970S,"YX;6Q02P$"% ,4    "  1FEE2G:9!Y>0%   5#@  &0
M    @($,*@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M !&:65)UZ*GTZ 8  )\2   9              " @2<P 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ $9I94H%JBT". @  5@4  !D
M             ("!1C<! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  1FEE2?#FZ_>@$   0"P  &0              @($+.@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !&:65(_(Q0MA@8
M (\<   9              " @2H_ 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ $9I94F]CK/NW @  $P<  !D              ("!
MYT4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  1FEE2
M[AYS;7P#  #/#   &0              @('52 $ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( !&:65(@4(S(U00  .X6   9
M      " @8A, 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ $9I94CC[? == @  *@8  !D              ("!E%$! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  1FEE2R3XN6KL#  !=#P
M&0              @($H5 $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( !&:65*[A&'\90(  .<%   9              " @1I8 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ $9I94@C7>F3W
M @  [@D  !D              ("!MEH! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  1FEE2N*J"OCP#   J"@  &0
M@('D70$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !&:
M65)LC^OPC@,  . ,   9              " @5=A 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ $9I94J< +;2? @  *P<  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( !&:65)<KUJHPP8  ,4@   9
M  " @6UZ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M$9I94BT]Y%#' P  J@X  !D              ("!9X$! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  1FEE2CEP)BHL.  #*70  &0
M            @(%EA0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( !&:65+B%V/TG0(   D&   9              " @2>4 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ $9I94EG!T\B% P
MB0T  !D              ("!^Y8! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  1FEE2^QZ#MWH#  "%"P  &0              @(&W
MF@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !&:65+X
MM.QN90,  'H*   9              " @6B> 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ $9I94FS+:H,B!   X0\  !D
M     ("!!*(! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !&:65*<$3.R^ ,  *8,   9              "
M@4"T 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ $9I9
M4M-KJ\C: P  ) T  !D              ("!;[@! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    "  1FEE2N2'2N'X#  !^"P  &0
M        @(& O $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( !&:65)S0(,)- 0  ,T3   9              " @37  0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ $9I94DBY0!R4 P  [0T
M !D              ("!H,0! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    "  1FEE29?8K,GX"    !P  &0              @(%KR $
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( !&:65*>.[<R
MV 4  %P:   9              " @2#+ 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ $9I94DDYJ?52 @  7@P   T
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;72YX;6Q02P4&     $P 3 #+%   G]X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>264</ContextCount>
  <ElementCount>468</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>106</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Senior Secured Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nektar.com/role/SeniorSecuredNotes</Role>
      <ShortName>Senior Secured Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Liabilities Related to the Sales of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2156114 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2158115 - Disclosure - Selected Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2359310 - Disclosure - Selected Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>Selected Quarterly Financial Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryDetail</Role>
      <ShortName>Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/InventoryTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail</Role>
      <ShortName>Property, Plant and Equipment - Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Senior Secured Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nektar.com/role/SeniorSecuredNotesDetail</Role>
      <ShortName>Senior Secured Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SeniorSecuredNotes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Leases - Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails</Role>
      <ShortName>Leases - Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Leases - Schedule of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Leases - Future Minimum Lease Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Liabilities Related to the Sales of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesDetail</Role>
      <ShortName>Commitments and Contingencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CommitmentsandContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stockholders' Equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityDetail</Role>
      <ShortName>Stockholders' Equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockholdersEquity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail</Role>
      <ShortName>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Award Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Award Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Income Taxes - Income (Loss) Before Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Income (Loss) Before Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Income Taxes - Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail</Role>
      <ShortName>Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Segment Reporting - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail</Role>
      <ShortName>Segment Reporting - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail</Role>
      <ShortName>Segment Reporting - Revenue by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SubsequentEvent</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="nktr-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Selected Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail</Role>
      <ShortName>Selected Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="nktr-20201231.htm">nktr-20201231.htm</File>
    <File>nktr-20201231.xsd</File>
    <File>nktr-20201231_cal.xml</File>
    <File>nktr-20201231_def.xml</File>
    <File>nktr-20201231_lab.xml</File>
    <File>nktr-20201231_pre.xml</File>
    <File>nktr-20201231xexx311.htm</File>
    <File>nktr-20201231xexx312.htm</File>
    <File>nktr-20201231xexx321.htm</File>
    <File>nktr20201231-exx1035.htm</File>
    <File>nktr20201231-exx1039.htm</File>
    <File>nktr20201231-exx231.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nktr-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 31,
   "contextCount": 264,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 655,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://www.nektar.com/20201231": 7,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 12
   },
   "keyCustom": 113,
   "keyStandard": 355,
   "memberCustom": 58,
   "memberStandard": 42,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.nektar.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Senior Secured Notes",
     "role": "http://www.nektar.com/role/SeniorSecuredNotes",
     "shortName": "Senior Secured Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Leases",
     "role": "http://www.nektar.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Liabilities Related to the Sales of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties",
     "shortName": "Liabilities Related to the Sales of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Stockholders' Equity",
     "role": "http://www.nektar.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:AdvancePaymentsToContractManufacturers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Income Taxes",
     "role": "http://www.nektar.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Segment Reporting",
     "role": "http://www.nektar.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156114 - Disclosure - Subsequent Event",
     "role": "http://www.nektar.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158115 - Disclosure - Selected Quarterly Financial Data",
     "role": "http://www.nektar.com/role/SelectedQuarterlyFinancialData",
     "shortName": "Selected Quarterly Financial Data",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Leases (Tables)",
     "role": "http://www.nektar.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables",
     "shortName": "Liabilities Related to the Sales of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - License and Collaboration Agreements (Tables)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.nektar.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.nektar.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359310 - Disclosure - Selected Quarterly Financial Data (Tables)",
     "role": "http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables",
     "shortName": "Selected Quarterly Financial Data (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nktr:NetExpenseReimbursementsFromCollaborationPartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib61c61ebd4ad4075a8831d9455982999_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory (Detail)",
     "role": "http://www.nektar.com/role/InventoryDetail",
     "shortName": "Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment (Detail)",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail",
     "shortName": "Property, Plant and Equipment - Property, Plant and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail",
     "shortName": "Property, Plant and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfSeniorDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Senior Secured Notes (Detail)",
     "role": "http://www.nektar.com/role/SeniorSecuredNotesDetail",
     "shortName": "Senior Secured Notes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i1d5c0f142a864384aee4ee9f0b27a3a3_I20151005",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Leases - Operating Lease Information (Details)",
     "role": "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails",
     "shortName": "Leases - Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "id5d94bebc40e4fbd9977c917beb7f026_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "nktr:AreaOfLeasedSpaceDelivered",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Leases - Schedule of Lease Cost (Details)",
     "role": "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails",
     "shortName": "Leases - Schedule of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Leases - Future Minimum Lease Payments for Operating Leases (Details)",
     "role": "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails",
     "shortName": "Leases - Future Minimum Lease Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
     "shortName": "Liabilities Related to the Sales of Future Royalties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ia51759f568a443da8a8dd1c008cfd71f_D20120224-20120224",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib61c61ebd4ad4075a8831d9455982999_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Liabilities Related to the Sales of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
     "shortName": "Liabilities Related to the Sales of Future Royalties - Summary of Liability Related to Potential Future Royalties (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i3d3d4ded8eb8431ea5eb96372d1f1204_I20120224",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Commitments and Contingencies (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
     "shortName": "Commitments and Contingencies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i27d8215eb84441c583e455931394edc6_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i45baea1b97d54688a1dfe6bcf696082b_D20180403-20180403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stockholders' Equity (Detail)",
     "role": "http://www.nektar.com/role/StockholdersEquityDetail",
     "shortName": "Stockholders' Equity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i45baea1b97d54688a1dfe6bcf696082b_D20180403-20180403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "License and Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib61c61ebd4ad4075a8831d9455982999_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail",
     "shortName": "License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "if74acef52e11470f833bd478aa3ef19b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib61c61ebd4ad4075a8831d9455982999_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail",
     "shortName": "Stock-Based Compensation - Stock Option Activity Under Equity Incentive Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib61c61ebd4ad4075a8831d9455982999_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i270d9a256b0148cf80b4c9020001e2ce_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Award Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Award Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i270d9a256b0148cf80b4c9020001e2ce_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Income Taxes - Income (Loss) Before Provision for Income Taxes (Detail)",
     "role": "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail",
     "shortName": "Income Taxes - Income (Loss) Before Provision for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "idc09b131139d4563b60db10c398e0c39_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "idc09b131139d4563b60db10c398e0c39_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Income Taxes - Provision for Income Taxes (Detail)",
     "role": "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail",
     "shortName": "Income Taxes - Provision for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i2f624b36390f4cb79d03a75b75a0bfbf_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)",
     "role": "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail",
     "shortName": "Income Taxes - Income Tax Provision Related to Continuing Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "icda9c88f4be148df8868cedf7bc4b3eb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib61c61ebd4ad4075a8831d9455982999_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Detail)",
     "role": "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ifc118f55d5dc4d8bb147ae3b5b48a218_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfOperatingBusinessSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Segment Reporting - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail",
     "shortName": "Segment Reporting - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfOperatingBusinessSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)",
     "role": "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail",
     "shortName": "Segment Reporting - Revenue by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "ib912063d910845aaa45f66edaa7d2535_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "if0342284791141f9aca1142441d62cf0_D20210212-20210212",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CollaborativeArrangementCommittedFunding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.nektar.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "if0342284791141f9aca1142441d62cf0_D20210212-20210212",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CollaborativeArrangementCommittedFunding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Selected Quarterly Financial Data (Detail)",
     "role": "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail",
     "shortName": "Selected Quarterly Financial Data (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i12845f8ce46a4314b3964a87715c43c5_D20201001-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:SaleOfFutureRoyaltiesTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:SaleOfFutureRoyaltiesTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20201231.htm",
      "contextRef": "i4cebf4ceb1c041bb8944bbfeaa5d74a0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 106,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_A775PercentSeniorSecuredNotesDueOctober2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.75 percent senior secured notes due October 2020",
        "label": "7.75 Percent Senior Secured Notes Due October 2020 [Member]",
        "terseLabel": "7.75 Percent Senior Secured Notes Due October 2020"
       }
      }
     },
     "localname": "A775PercentSeniorSecuredNotesDueOctober2020Member",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable and significant customer concentrations.",
        "label": "Accounts Receivable And Significant Customer Concentrations [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Significant Customer Concentrations"
       }
      }
     },
     "localname": "AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_AccretionOfDiscountNetAndOtherNonCashTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of discount net and other non-cash transactions.",
        "label": "Accretion Of Discount Net And Other Non Cash Transactions",
        "negatedLabel": "Accretion of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "AccretionOfDiscountNetAndOtherNonCashTransactions",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedContractManufacturingExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract manufacturing expense current.",
        "label": "Accrued Contract Manufacturing Expense Current",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingExpenseCurrent",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AdvancePaymentsToContractManufacturers": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advance payments to contract manufacturers, net of amortization.",
        "label": "Advance Payments To Contract Manufacturers",
        "terseLabel": "Advance payments to contract manufacturers"
       }
      }
     },
     "localname": "AdvancePaymentsToContractManufacturers",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AggregateConsiderationReceivedFromAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate consideration received from agreements.",
        "label": "Aggregate Consideration Received From Agreements",
        "terseLabel": "Total consideration received under agreements"
       }
      }
     },
     "localname": "AggregateConsiderationReceivedFromAgreements",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmendedAndRestated2017PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated 2017 Plan",
        "label": "Amended and Restated 2017 Plan [Member]",
        "terseLabel": "Amended and Restated 2017 Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2017PlanMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen, Inc.",
        "verboseLabel": "Amgen, Inc."
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AmountOfNetSalesToFundExternalCostsIncurredCap": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Sales to Fund External Costs Incurred Cap",
        "label": "Amount of Net Sales to Fund External Costs Incurred Cap",
        "terseLabel": "Amount of net sales to fund external costs incurred cap"
       }
      }
     },
     "localname": "AmountOfNetSalesToFundExternalCostsIncurredCap",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation.",
        "label": "Amount Of Transaction Price Allocated To Performance Obligation",
        "terseLabel": "Amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "AmountOfTransactionPriceAllocatedToPerformanceObligation",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AnnualSalesLevelMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales level milestone.",
        "label": "Annual Sales Level Milestone [Member]",
        "terseLabel": "Annual Sales Level Milestone"
       }
      }
     },
     "localname": "AnnualSalesLevelMilestoneMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased space.",
        "label": "Area Of Leased Space",
        "terseLabel": "Lease space (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLeasedSpace",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AreaOfLeasedSpaceDelivered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased space delivered.",
        "label": "Area Of Leased Space Delivered",
        "terseLabel": "Leased space delivered (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLeasedSpaceDelivered",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AstraZenecaAbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca Ab [Member]",
        "terseLabel": "Astra Zeneca Ab"
       }
      }
     },
     "localname": "AstraZenecaAbMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AstraZenecaAgreementWithKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca agreement with Kirin.",
        "label": "Astra Zeneca Agreement With Kirin [Member]",
        "terseLabel": "AstraZeneca-Kirin"
       }
      }
     },
     "localname": "AstraZenecaAgreementWithKirinMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BaxaltaIncorporatedOrTakedaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baxalta Incorporated or takeda PLC.",
        "label": "Baxalta Incorporated Or Takeda P L C [Member]",
        "terseLabel": "Baxalta Incorporated / Takeda",
        "verboseLabel": "Baxalta Incorporated / Takeda"
       }
      }
     },
     "localname": "BaxaltaIncorporatedOrTakedaPLCMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BempegaldesleukinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bempegaldesleukin",
        "label": "Bempegaldesleukin [Member]",
        "terseLabel": "Bempegaldesleukin"
       }
      }
     },
     "localname": "BempegaldesleukinMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb",
        "verboseLabel": "BMS"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building and Leasehold Improvements.",
        "label": "Building And Leasehold Improvements [Member]",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Control Severance Payment Period For Chief Executive Officer",
        "label": "Change In Control Severance Payment Period For Chief Executive Officer",
        "terseLabel": "Change in control severance payment period for Chief Executive Officer"
       }
      }
     },
     "localname": "ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ChangeInControlSeverancePaymentPeriodForEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control severance payment period for employees.",
        "label": "Change In Control Severance Payment Period For Employees",
        "terseLabel": "Change in control severance payment period for employees"
       }
      }
     },
     "localname": "ChangeInControlSeverancePaymentPeriodForEmployees",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ChangeInControlSeverancePaymentPeriodForExecutives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control severance payment period for executives.",
        "label": "Change In Control Severance Payment Period For Executives",
        "terseLabel": "Change in control severance payment period for executives"
       }
      }
     },
     "localname": "ChangeInControlSeverancePaymentPeriodForExecutives",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Control Severance Payment Period For Senior Vice Presidents and Vice Presidents",
        "label": "Change In Control Severance Payment Period For Senior Vice Presidents and Vice Presidents",
        "terseLabel": "Change in control severance payment period for senior vice presidents and vice presidents"
       }
      }
     },
     "localname": "ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ClinicalTrialAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial agreement.",
        "label": "Clinical Trial Agreement [Member]",
        "terseLabel": "Clinical Trial Agreement"
       }
      }
     },
     "localname": "ClinicalTrialAgreementMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CollaborativeArrangementAdditionalIndicationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Indication Payment",
        "label": "Collaborative Arrangement, Additional Indication Payment",
        "terseLabel": "Additional indication payment"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalIndicationPayment",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, First Indication",
        "label": "Collaborative Arrangement, Success-based Payments, First Indication",
        "terseLabel": "Success-based payments, first indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstIndication",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid",
        "label": "Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid",
        "terseLabel": "Success-based payments, first indication, period to be paid"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, Second Indication",
        "label": "Collaborative Arrangement, Success-based Payments, Second Indication",
        "terseLabel": "Success-based payments, second indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsSecondIndication",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid",
        "label": "Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid",
        "terseLabel": "Success-based payments, second indication, period to be paid"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.",
        "label": "Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones",
        "terseLabel": "Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CommercialAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Agreements",
        "label": "Commercial Agreements [Member]",
        "terseLabel": "Commercial Agreements"
       }
      }
     },
     "localname": "CommercialAgreementsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CommonStockAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Shares Authorized",
        "label": "Common Stock, Additional Shares Authorized",
        "terseLabel": "Increase in aggregate number of shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalSharesAuthorized",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_CompanyShareOfDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company Share of Development Costs",
        "label": "Company Share of Development Costs",
        "terseLabel": "Company share of development costs"
       }
      }
     },
     "localname": "CompanyShareOfDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CompanyShareOfDevelopmentCostsAnnualCap": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company Share Of Development Costs, Annual Cap",
        "label": "Company Share Of Development Costs, Annual Cap",
        "terseLabel": "Company share of development costs, annual cap"
       }
      }
     },
     "localname": "CompanyShareOfDevelopmentCostsAnnualCap",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ComputerFurnitureAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture computer and other.",
        "label": "Computer Furniture And Other [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerFurnitureAndOtherMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Estimate for Royalties Resulting from Net Sales",
        "label": "Contract with Customer, Estimate for Royalties Resulting from Net Sales",
        "terseLabel": "Estimate for royalties resulting from net sales"
       }
      }
     },
     "localname": "ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer shipping and handling costs.",
        "label": "Contract With Customer Shipping And Handling Costs Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ContractWithCustomerShippingAndHandlingCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Coronavirus Aid, Relief and Economic Security (CARES) Act [Policy Text Block]",
        "terseLabel": "Coronavirus Aid, Relief and Economic Security (CARES) Act"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityCARESActPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_DebtDiscountOnTransactionAndFacilityFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt discount on transaction and facility fees paid.",
        "label": "Debt Discount On Transaction And Facility Fees Paid",
        "terseLabel": "Debt discount on transaction and facility fees"
       }
      }
     },
     "localname": "DebtDiscountOnTransactionAndFacilityFeesPaid",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DeferredTaxAssetsDepreciationPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets depreciation property and equipment.",
        "label": "Deferred Tax Assets Depreciation Property And Equipment",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationPropertyAndEquipment",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Liability Related to the Sale of Future Royalties",
        "label": "Deferred Tax Assets, Liability Related to the Sale of Future Royalties",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Gross.",
        "label": "Depreciable Property Plant And Equipment Gross",
        "terseLabel": "Depreciable property, plant and equipment at cost"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentGross",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Net.",
        "label": "Depreciable Property Plant And Equipment Net",
        "totalLabel": "Depreciable property, plant and equipment, net"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentNet",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DevelopmentCostsExceeded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Costs Exceeded",
        "label": "Development Costs Exceeded",
        "terseLabel": "Development costs exceeded"
       }
      }
     },
     "localname": "DevelopmentCostsExceeded",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document And Entity Information [Abstract]",
        "terseLabel": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.nektar.com/20201231",
     "xbrltype": "stringItemType"
    },
    "nktr_DrugProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product development.",
        "label": "Drug Product Development [Member]",
        "terseLabel": "Drug Product Development"
       }
      }
     },
     "localname": "DrugProductDevelopmentMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible additional cash payments receivable upon achievement of certain sales milestones.",
        "label": "Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Eligible additional cash payments receivable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee.",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated annual interest rate over life of royalty liability.",
        "label": "Estimated Annual Interest Rate Over Life Of Royalty Liability",
        "terseLabel": "Implicit interest rate over the life of the agreement"
       }
      }
     },
     "localname": "EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_EstimatedFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of shares.",
        "label": "Estimated Fair Value Of Shares",
        "terseLabel": "Estimated fair value of shares"
       }
      }
     },
     "localname": "EstimatedFairValueOfShares",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_FederalOrphanDrugCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal orphan drug credits.",
        "label": "Federal Orphan Drug Credits",
        "terseLabel": "Federal orphan drug credits"
       }
      }
     },
     "localname": "FederalOrphanDrugCredits",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_HemophiliaIncludingADYNOVATEAndADYNOVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hemophilia including ADYNOVATE and ADYNOVI.",
        "label": "Hemophilia Including A D Y N O V A T E And A D Y N O V I [Member]",
        "terseLabel": "Hemophilia, Including ADYNOVATE and ADYNOVITM"
       }
      }
     },
     "localname": "HemophiliaIncludingADYNOVATEAndADYNOVIMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_HemophiliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hemophilia.",
        "label": "Hemophilia [Member]",
        "terseLabel": "Hemophilia"
       }
      }
     },
     "localname": "HemophiliaMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equipment and other costs for terminated program.",
        "label": "Impairment Of Assets And Other Costs For Terminated Program",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgram",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Assets and Other Costs for Terminated Program",
        "label": "Impairment of Assets and Other Costs for Terminated Program [Member]",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Assets and Other Costs for Terminated Program",
        "label": "Impairment of Assets and Other Costs for Terminated Program [Policy Text Block]",
        "terseLabel": "Impairment of Assets and Other Costs for Terminated Program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_ImpairmentOfEquipmentFromTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equipment from terminated program.",
        "label": "Impairment Of Equipment From Terminated Program",
        "terseLabel": "Impairment of advance payments to contract manufacturers and equipment for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentFromTerminatedProgram",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncomeTaxReconciliationExpenseShareBasedCompensationCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation expense share based compensation cost.",
        "label": "Income Tax Reconciliation Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationExpenseShareBasedCompensationCost",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Income Tax Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties",
        "terseLabel": "Non-cash interest expense on liability related to sale of future royalties"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncomeTaxReconciliationPremiumOnEquityIssuance": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation premium on equity issuance.",
        "label": "Income Tax Reconciliation Premium On Equity Issuance",
        "negatedLabel": "Premium on equity issuance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPremiumOnEquityIssuance",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncomeTaxesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_IncomeTaxesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation income tax sale of future royalties.",
        "label": "Incometax Reconciliation Income Tax Sale Of Future Royalties",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedTerseLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and significant supplier concentrations.",
        "label": "Inventory And Significant Supplier Concentrations [Policy Text Block]",
        "terseLabel": "Inventory and Significant Supplier Concentrations"
       }
      }
     },
     "localname": "InventoryAndSignificantSupplierConcentrationsPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LeaseExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease extension term.",
        "label": "Lease Extension Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LeaseExtensionTerm",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases [Line Items]",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LegalMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Matters",
        "label": "Legal Matters [Member]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement reimbursements.",
        "label": "Lessee Operating Lease Liability Tenant Improvement Reimbursements",
        "negatedTerseLabel": "Less: lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilitiesAndStockholdersEquityDeficitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities and stock holders equity (deficit) abstract..",
        "label": "Liabilities And Stockholders Equity Deficit [Abstract]",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityDeficitAbstract",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities on sale of future royalties, unamortized transaction costs.",
        "label": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "negatedLabel": "Less: unamortized transaction costs"
       }
      }
     },
     "localname": "LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to the Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Abstract]",
        "terseLabel": "Liability Related To Sale Of Potential Future Royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract",
     "nsuri": "http://www.nektar.com/20201231",
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties noncurrent.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "periodEndLabel": "Liability related to the sale of future royalties \u2013 ending balance",
        "periodStartLabel": "Liability related to the sale of future royalties\u2014beginning balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net",
        "totalLabel": "Liability related to the sale of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liabilities Related to the Sales of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties [Roll Forward]",
        "label": "Liability Related To The Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MOVANTIKAndMOVENTIGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MOVANTIK and MOVENTIG.",
        "label": "M O V A N T I K And M O V E N T I G [Member]",
        "terseLabel": "MOVANTIK and MOVENTIG"
       }
      }
     },
     "localname": "MOVANTIKAndMOVENTIGMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ManufacturingLaboratoryAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing laboratory and other equipment.",
        "label": "Manufacturing Laboratory And Other Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingLaboratoryAndOtherEquipmentMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MergerAndAcquisitionRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger and acquisition related claims.",
        "label": "Merger And Acquisition Related Claims [Member]",
        "terseLabel": "Merger and Acquisition Related Claims"
       }
      }
     },
     "localname": "MergerAndAcquisitionRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions",
        "label": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds",
        "terseLabel": "Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties"
       }
      }
     },
     "localname": "MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_MissionBayLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mission bay lease.",
        "label": "Mission Bay Lease [Member]",
        "terseLabel": "Mission Bay Lease"
       }
      }
     },
     "localname": "MissionBayLeaseMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NKTR181Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NKTR - 181 [Member]",
        "label": "NKTR - 181 [Member]",
        "terseLabel": "NKTR - 181"
       }
      }
     },
     "localname": "NKTR181Member",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar [Member]",
        "label": "Nektar [Member]",
        "terseLabel": "Nektar"
       }
      }
     },
     "localname": "NektarMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar three five eight.",
        "label": "Nektar Three Five Eight [Member]",
        "terseLabel": "NKTR-358"
       }
      }
     },
     "localname": "NektarThreeFiveEightMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NetExpenseReimbursementsFromCollaborationPartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net expense reimbursements from collaboration partner.",
        "label": "Net Expense Reimbursements From Collaboration Partner",
        "terseLabel": "Net expense reimbursements from collaboration partner"
       }
      }
     },
     "localname": "NetExpenseReimbursementsFromCollaborationPartner",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NetOperatingLossCarryforwardForIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward for income tax.",
        "label": "Net Operating Loss Carryforward For Income Tax",
        "terseLabel": "Net operating loss carryforward for income tax"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardForIncomeTax",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "terseLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "verboseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to sale of future royalties",
        "terseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonSecuritiesRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-securities related claims.",
        "label": "Non Securities Related Claims [Member]",
        "terseLabel": "Non-Securities Related Claims"
       }
      }
     },
     "localname": "NonSecuritiesRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NumberOfConsecutiveTermsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive five year terms to extend lease.",
        "label": "Number Of Consecutive Terms To Extend Lease",
        "terseLabel": "Number of consecutive terms to extend lease"
       }
      }
     },
     "localname": "NumberOfConsecutiveTermsToExtendLease",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfOperatingBusinessSegment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating business segment.",
        "label": "Number Of Operating Business Segment",
        "terseLabel": "Number of operating business segment"
       }
      }
     },
     "localname": "NumberOfOperatingBusinessSegment",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units to evaluate goodwill for impairment",
        "label": "Number Of Reporting Units To Evaluate Goodwill For Impairment",
        "terseLabel": "Number of reporting unit evaluated for goodwill"
       }
      }
     },
     "localname": "NumberOfReportingUnitsToEvaluateGoodwillForImpairment",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities remaining available for issuance under equity compensation plans.",
        "label": "Number Of Securities Available For Issuance Under Equity Compensation Plans",
        "terseLabel": "Number of shares available for issuance under equity compensation plans"
       }
      }
     },
     "localname": "NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations under director and officer indemnifications per incident.",
        "label": "Obligations Under Director And Officer Indemnifications Per Incident",
        "terseLabel": "Obligations under Director and Officer Indemnifications per incident"
       }
      }
     },
     "localname": "ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization [Policy Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartialRepaymentOfRoyaltySaleProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partial repayment of royalty sale proceeds.",
        "label": "Partial Repayment Of Royalty Sale Proceeds",
        "negatedTerseLabel": "Payments to RPI"
       }
      }
     },
     "localname": "PartialRepaymentOfRoyaltySaleProceeds",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PartnerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner One",
        "label": "Partner One [Member]",
        "terseLabel": "Partner One"
       }
      }
     },
     "localname": "PartnerOneMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartnerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner Three",
        "label": "Partner Three [Member]",
        "terseLabel": "Partner Three"
       }
      }
     },
     "localname": "PartnerThreeMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartnerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner Two",
        "label": "Partner Two [Member]",
        "terseLabel": "Partner Two"
       }
      }
     },
     "localname": "PartnerTwoMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PaymentMadeForMilestoneNotAchievedYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for milestone not achieved year one.",
        "label": "Payment Made For Milestone Not Achieved Year One",
        "terseLabel": "Payment made for milestone not achieved year one"
       }
      }
     },
     "localname": "PaymentMadeForMilestoneNotAchievedYearOne",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentMadeForMilestoneNotAchievedYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for milestone not achieved year two.",
        "label": "Payment Made For Milestone Not Achieved Year Two",
        "terseLabel": "Payment made for milestone not achieved year two"
       }
      }
     },
     "localname": "PaymentMadeForMilestoneNotAchievedYearTwo",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement if threshold is not achieved"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentsReceivedUnderRightsToSublicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments received under rights to sublicense agreement.",
        "label": "Payments Received Under Rights To Sublicense Agreement",
        "terseLabel": "Received under right to sublicense agreement"
       }
      }
     },
     "localname": "PaymentsReceivedUnderRightsToSublicenseAgreement",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfNetSalesToFundExternalCostsIncurred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Net Sales to Fund External Costs Incurred",
        "label": "Percentage of Net Sales to Fund External Costs Incurred",
        "terseLabel": "Percentage of net sales to fund external costs incurred"
       }
      }
     },
     "localname": "PercentageOfNetSalesToFundExternalCostsIncurred",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "nktr_PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Net Sales To Fund External Costs Incurred, Due To Reduction Of 2 Percentage Points",
        "label": "Percentage Of Net Sales To Fund External Costs Incurred, Due To Reduction Of 2 Percentage Points",
        "terseLabel": "Percentage of net sales to fund external costs incurred, due to reduction of 2 percentage points"
       }
      }
     },
     "localname": "PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of out of pocket costs to be reimbursed by partner.",
        "label": "Percentage Of Out Of Pocket Costs To Be Reimbursed By Partner",
        "terseLabel": "Percentage of out-of-pocket costs to be reimbursed by partner"
       }
      }
     },
     "localname": "PercentageOfOutOfPocketCostsToBeReimbursedByPartner",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfPurchasePriceOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of purchase price of stock.",
        "label": "Percentage Of Purchase Price Of Stock",
        "terseLabel": "Percentage of purchase price of stock"
       }
      }
     },
     "localname": "PercentageOfPurchasePriceOfStock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments",
        "terseLabel": "Percentage of upfront payment, market access milestones, royalties and sales milestones"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner",
        "terseLabel": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PhaseOneClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1 clinical development.",
        "label": "Phase One Clinical Development [Member]",
        "terseLabel": "Phase 1 Clinical Development"
       }
      }
     },
     "localname": "PhaseOneClinicalDevelopmentMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development regulatory and sales milestones.",
        "label": "Potential Development Regulatory And Sales Milestones",
        "terseLabel": "Potential future development, regulatory and sales milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentRegulatoryAndSalesMilestones",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock Net Of Issuance Costs",
        "label": "Proceeds From Issuance Of Common Stock Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock to Bristol-Myers Squibb (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProceedsFromSaleOfFutureRoyaltiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale of Future Royalties, Net",
        "label": "Proceeds From Sale of Future Royalties, Net",
        "terseLabel": "Proceeds from sale of future royalties, net of $3.8 million of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRoyaltiesNet",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Global commercialization profits and losses sharing percentage"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_ProspectiveInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prospective interest rate percentage.",
        "label": "Prospective Interest Rate Percentage",
        "terseLabel": "Prospective effective interest rate"
       }
      }
     },
     "localname": "ProspectiveInterestRatePercentage",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "Purchase and Sale Agreement 2012"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "Purchase and Sale Agreement 2020"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and sale agreement.",
        "label": "Purchase And Sale Agreement [Member]",
        "terseLabel": "Purchase and Sale Agreement with RPI"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreementMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_RSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs and PSUs",
        "label": "RSUs and PSUs [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_RegulatoryMilestonesPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones payment description.",
        "label": "Regulatory Milestones Payment Description",
        "terseLabel": "Regulatory milestones payment, description"
       }
      }
     },
     "localname": "RegulatoryMilestonesPaymentDescription",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ReimbursementRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Recognized",
        "label": "Reimbursement Recognized",
        "terseLabel": "Reimbursement recognized"
       }
      }
     },
     "localname": "ReimbursementRecognized",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RemainingAmountAllocatedToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount allocated to transaction price.",
        "label": "Remaining Amount Allocated To Transaction Price",
        "terseLabel": "Remaining amount allocated to transaction price"
       }
      }
     },
     "localname": "RemainingAmountAllocatedToTransactionPrice",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RepaymentsOfLongTermDebtIncludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Long Term Debt, Including Interest",
        "label": "Repayments Of Long Term Debt, Including Interest",
        "terseLabel": "Principal and interest repaid on senior notes"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtIncludingInterest",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RoyaltyAgreementContingentPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement contingent payment description.",
        "label": "Royalty Agreement Contingent Payment Description",
        "terseLabel": "Royalty agreement contingent payment description"
       }
      }
     },
     "localname": "RoyaltyAgreementContingentPaymentDescription",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_RoyaltyMonetizationProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties.",
        "label": "Royalty Monetization Proceeds",
        "terseLabel": "Royalty monetization proceeds"
       }
      }
     },
     "localname": "RoyaltyMonetizationProceeds",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ Pharmaceuticals"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfFutureRoyaltiesTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Future Royalties Transaction Costs",
        "label": "Sale of Future Royalties Transaction Costs",
        "terseLabel": "Sale of future royalties transaction costs"
       }
      }
     },
     "localname": "SaleOfFutureRoyaltiesTransactionCosts",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SalesMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone revenue.",
        "label": "Sales Milestone Revenue",
        "terseLabel": "Sales milestone revenue"
       }
      }
     },
     "localname": "SalesMilestoneRevenue",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Leases [Table]",
        "label": "Schedule Of Leases [Table]",
        "terseLabel": "Schedule Of Leases [Table]"
       }
      }
     },
     "localname": "ScheduleOfLeasesTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Summary of Liability Related to Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SecuredNotesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured notes.",
        "label": "Secured Notes [Line Items]",
        "terseLabel": "Secured Notes [Line Items]"
       }
      }
     },
     "localname": "SecuredNotesLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_SecuredNotesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured notes.",
        "label": "Secured Notes [Table]",
        "terseLabel": "Secured Notes [Table]"
       }
      }
     },
     "localname": "SecuredNotesTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_SecuritiesRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities related claims.",
        "label": "Securities Related Claims [Member]",
        "terseLabel": "Securities Related Claims"
       }
      }
     },
     "localname": "SecuritiesRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SelectedQuarterlyFinancialDataLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected quarterly financial data.",
        "label": "Selected Quarterly Financial Data [Line Items]",
        "terseLabel": "Selected Quarterly Financial Data [Line Items]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialDataLineItems",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_SelectedQuarterlyFinancialDataTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected quarterly financial data.",
        "label": "Selected Quarterly Financial Data [Table]",
        "terseLabel": "Selected Quarterly Financial Data [Table]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialDataTable",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seven point seven five percent senior secured notes due October two thousand and twenty.",
        "label": "Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]",
        "terseLabel": "7.75% Senior Secured Notes Due October 2020"
       }
      }
     },
     "localname": "SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options and restricted stock units outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding",
        "terseLabel": "Number of shares to be issued upon exercise of outstanding options or vesting of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation plan's share limit for every one share.",
        "label": "Share Based Compensation Plans Share Limit For Every One Share",
        "terseLabel": "Share-based compensation plan's share limit reduction for every one restricted stock unit granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationPlansShareLimitForEveryOneShare",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period subject to lock-up and stand-still provisions period.",
        "label": "Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period",
        "terseLabel": "Stock issued during period subject to lock-up and stand-still provisions period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and restricted stock units.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "verboseLabel": "Stock Options and Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TerminatedPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated Partnership [Member]",
        "label": "Terminated Partnership [Member]",
        "terseLabel": "Terminated Partnership"
       }
      }
     },
     "localname": "TerminatedPartnershipMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ThirdStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third street lease.",
        "label": "Third Street Lease [Member]",
        "terseLabel": "Third Street Lease"
       }
      }
     },
     "localname": "ThirdStreetLeaseMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs related to sale of potential future royalties.",
        "label": "Transaction Costs Related To Sale Of Potential Future Royalties",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "TransactionCostsRelatedToSaleOfPotentialFutureRoyalties",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_TwoThousandSeventeenPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen performance incentive plan.",
        "label": "Two Thousand Seventeen Performance Incentive Plan [Member]",
        "terseLabel": "2017 Performance Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenPerformanceIncentivePlanMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UCBPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma.",
        "label": "U C B Pharma [Member]",
        "terseLabel": "UCB"
       }
      }
     },
     "localname": "UCBPharmaMember",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits, period increase (decrease) reasonable period of change",
        "label": "Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change",
        "terseLabel": "Unrecognized tax benefits, period may increase or decrease due to tax examination"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_WriteOffOfPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off Of Prepayment",
        "label": "Write Off Of Prepayment",
        "terseLabel": "Write off of prepayment"
       }
      }
     },
     "localname": "WriteOffOfPrepayment",
     "nsuri": "http://www.nektar.com/20201231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r364",
      "r365",
      "r370",
      "r371",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r364",
      "r365",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r154",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r168",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r154",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r168",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r53",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r115",
      "r120",
      "r192",
      "r304",
      "r305",
      "r306",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r115",
      "r120",
      "r192",
      "r304",
      "r305",
      "r306",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r115",
      "r120",
      "r192",
      "r304",
      "r305",
      "r306",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r178",
      "r250",
      "r255",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r465",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r465",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r178",
      "r250",
      "r255",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r250",
      "r253",
      "r429",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r250",
      "r253",
      "r429",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r258",
      "r268",
      "r269",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r465",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r258",
      "r268",
      "r269",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r465",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableGeographicalComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]",
        "terseLabel": "Reportable Geographical Components"
       }
      }
     },
     "localname": "ReportableGeographicalComponentsMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r250",
      "r254",
      "r467",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r250",
      "r254",
      "r467",
      "r495",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r180",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r201"
     ],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r58",
      "r59",
      "r60",
      "r452",
      "r474",
      "r475"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r112",
      "r113",
      "r114",
      "r369",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r270",
      "r272",
      "r310",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r272",
      "r300",
      "r309"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r158",
      "r163",
      "r170",
      "r191",
      "r364",
      "r370",
      "r384",
      "r432",
      "r450"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r52",
      "r106",
      "r191",
      "r364",
      "r370",
      "r384"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "verboseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r187",
      "r193"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r184",
      "r188",
      "r193",
      "r437"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r186",
      "r193"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r186",
      "r193"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r35",
      "r478",
      "r479"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r35",
      "r98"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r385"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r358",
      "r359",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r208",
      "r439",
      "r456"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for issuance in equity compensation plans"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 180,091 shares and 176,505 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r74",
      "r443",
      "r460"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r178",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r178",
      "r382",
      "r383",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r178",
      "r382",
      "r383",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r147",
      "r148",
      "r178",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage revenue from customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r178",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation, Principles of Consolidation and Use of Estimates"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Deferred Revenue Balance from Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.",
        "label": "Contract with Customer, Asset, Reclassified to Receivable",
        "terseLabel": "Contract with customer, asset, reclassified to receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetReclassifiedToReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r236",
      "r237",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, Ending balance",
        "periodStartLabel": "Deferred revenue, Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r236",
      "r237",
      "r251"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r236",
      "r237",
      "r251"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Recognition of previously unearned revenue",
        "terseLabel": "Development milestones received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligation recognized"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r259",
      "r266",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Notes and Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r79",
      "r429"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "verboseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r341",
      "r348"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r341"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r341",
      "r348",
      "r350"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r341",
      "r348"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r145",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r433",
      "r434",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior secured notes, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "terseLabel": "Matching 401(k) employer contribution, maximum amount"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r342",
      "r348"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r38",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r342",
      "r348"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r107",
      "r342",
      "r348",
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "terseLabel": "Deferred Revenue Arrangement Type"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r342",
      "r348"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r338",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and other credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Compensation expense in connection with 401(k) retirement plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum 401(k) per employee, percentage of annual salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r96",
      "r199"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r96",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r128",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r444",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic ( in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r444",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r321",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognized over a weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Shares of Common Stock Underlying Outstanding Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r117",
      "r123",
      "r125",
      "r142",
      "r192",
      "r227",
      "r234",
      "r304",
      "r305",
      "r306",
      "r344",
      "r345",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Level 1 to level 2 transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Level 2 to level 1 transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r376",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r259",
      "r260",
      "r265",
      "r266",
      "r376",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r259",
      "r260",
      "r265",
      "r266",
      "r376",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r102",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures, and other"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Areas, Revenues from External Customers [Abstract]",
        "terseLabel": "Revenue by geographic area"
       }
      }
     },
     "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r196",
      "r197",
      "r431"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r109",
      "r351"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r158",
      "r162",
      "r166",
      "r169",
      "r172",
      "r430",
      "r440",
      "r446",
      "r462"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r109",
      "r351"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeLossBeforeProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r322",
      "r331",
      "r337",
      "r346",
      "r353",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r124",
      "r125",
      "r157",
      "r320",
      "r347",
      "r354",
      "r463"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail",
      "http://www.nektar.com/role/IncomeTaxesProvisionforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r102",
      "r317",
      "r318",
      "r331",
      "r332",
      "r336",
      "r343",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax expense (benefit) at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits",
        "terseLabel": "Income tax research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.nektar.com/role/IncomeTaxesIncomeTaxProvisionRelatedtoContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Weighted-average of potentially dilutive securities (stock options and RSUs) included in calculation of diluted securities under treasury stock method (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r155",
      "r394",
      "r395",
      "r445"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest Receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r194"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r50"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r194"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r30",
      "r194"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: portion representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r106",
      "r164",
      "r191",
      "r365",
      "r370",
      "r371",
      "r384"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r106",
      "r191",
      "r384",
      "r436",
      "r454"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r106",
      "r191",
      "r365",
      "r370",
      "r371",
      "r384"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r62",
      "r65",
      "r72",
      "r97",
      "r106",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r132",
      "r158",
      "r162",
      "r166",
      "r169",
      "r172",
      "r191",
      "r384",
      "r441",
      "r458"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r162",
      "r166",
      "r169",
      "r172"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations",
        "verboseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r405",
      "r413"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Operating lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion",
        "verboseLabel": "Operating lease liability, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LeasesFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r402",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r409",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r219",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Information"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r111",
      "r149",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r55",
      "r56",
      "r58"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r69",
      "r73",
      "r227",
      "r386",
      "r391",
      "r392",
      "r442",
      "r459"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r83",
      "r86",
      "r185"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2020 or 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r88",
      "r303"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r83",
      "r84",
      "r185"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r83",
      "r84",
      "r185"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales of property and plant"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Product Sales",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r62",
      "r65",
      "r91",
      "r106",
      "r116",
      "r124",
      "r125",
      "r158",
      "r162",
      "r166",
      "r169",
      "r172",
      "r191",
      "r363",
      "r367",
      "r368",
      "r372",
      "r373",
      "r384",
      "r446"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r204",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r202",
      "r455"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r102",
      "r202",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r19",
      "r435",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitments related to contract manufacturing, clinical development and certain other items"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialData"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Repayment of senior notes",
        "terseLabel": "Principal amount repaid"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r313",
      "r510"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r102",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r234",
      "r307",
      "r453",
      "r473",
      "r475"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r117",
      "r123",
      "r125",
      "r192",
      "r304",
      "r305",
      "r306",
      "r344",
      "r345",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r153",
      "r154",
      "r161",
      "r167",
      "r168",
      "r174",
      "r175",
      "r178",
      "r249",
      "r250",
      "r429"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r408",
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/LeasesOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r147",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Income Tax Provision Related to Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r272",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r272",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r78",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Revenue by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r165",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r279",
      "r289",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity Under Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r104",
      "r143",
      "r144",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r158",
      "r160",
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r438",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "verboseLabel": "Senior secured notes, principal amount"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.",
        "label": "Senior Notes, Current",
        "terseLabel": "Senior secured notes, net and interest payable (see Note 5)"
       }
      }
     },
     "localname": "SeniorNotesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
      "http://www.nektar.com/role/SeniorSecuredNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period for stock-based compensation award granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited and canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited and canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Units Issued, Ending balance (in shares)",
        "periodStartLabel": "Units Issued, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance (in dollars per share)",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Average volatility factor"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for award grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common stock shares available for stock options grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, options forfeited and canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares, options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r281",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, outstanding, ending balance (in shares)",
        "periodStartLabel": "Number of shares, outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price per Share, outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-Average Exercise Price per Share, outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationRestrictedStockUnitAwardActivityDetail",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, options forfeited and canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r102",
      "r274",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options term under equity incentive plans"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r294",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average weighted average expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r112",
      "r113",
      "r114",
      "r117",
      "r123",
      "r125",
      "r142",
      "r192",
      "r227",
      "r234",
      "r304",
      "r305",
      "r306",
      "r344",
      "r345",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r142",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r227",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of stock to Bristol-Myers Squibb (Note 10) (in shares)",
        "verboseLabel": "Sale of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r227",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r227",
      "r234",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockOptionActivityUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of stock to Bristol-Myers Squibb (Note 10)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r234",
      "r273",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r106",
      "r183",
      "r191",
      "r384"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r393",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r393",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r393",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r393",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockholdersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesSummaryofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r259",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r316",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Unrecognized tax benefits, penalties recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Tax positions related to current year, Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Tax positions related to prior year, Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapses in statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UpFrontPaymentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein all amount due is received from customer before delivery of goods or services, and revenue will be recognized upon customer acceptance of delivered goods or services.",
        "label": "Up-front Payment Arrangement [Member]",
        "terseLabel": "Upfront Payment Arrangement"
       }
      }
     },
     "localname": "UpFrontPaymentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, increase (decrease) amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r406",
      "r413"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares outstanding used in computing net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121548805&loc=d3e10037-110241"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e13051-110250"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 1,3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r511": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r512": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r513": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r514": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r515": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r516": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r517": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r518": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r519": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0000906709-21-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-21-000005-xbrl.zip
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M@P]ODOTP3&Y(7UZ!_@F]VM'G>[4<G9_ZR9F7WZP<#G[XX<V&]7WOCS]MR.S
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M9F4/AZPTF3.;*%@F^/0]D;KSX:4+RG&]?5(^527LRA1E9=1:^V@@H?<"+%.
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MDS1>2$">'46A/N8R>VM%,+P"J^6616X6OY+.ZB"\0 W&(\28;; 1(%JCE/?
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M@19NO$@LFJP"!PJ'@TJ:*6^8CRJ@\A6@RG6TRZLRR+K9P_D2X0LI4'>2^_3
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MY\B[B QXH.B/L6B3 FE1ZDHME5M.8O]P3L9B>*Q%]$E[[ID4  J=X4'F9%E
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M.AEXERB+ZQ.X S7#3H%<DK6Z U0:C('M-%?"9\'V!FJE1'[C,8/'Y9]N(],
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MU%OCH+N-ZW$;C[_[^1+VU2^Z'.!-N6V8 SR\M_'E^C:??X1^^[G.@CMQM_5
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MX^]1C,.F16%)YDZ::1'A7U^C:P"UKCODS5%R(T82S!TM8QB\9D/!*Y<84&S
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MA:)"=MV"DH):Q((^<0*V2&\)K,7J+(:T>%#45UCAG?JH:!BEEO7P$ ;-K4K
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MBU-@+JBYP7>V,RZ5P](B# Q@F\'!0']W^!09*_#*&.BX\!"7S$V4H0X.N0/
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M%W!NVETVB2ADC5?V^AJCR>8$0;PU$Y[R1:(R].6*$YPOK1+W-#R&=[+O)-O
M"5,^IKY41A?+W<">)H_3D_?]*U?0_E-R.S40?>AHS?=' )L^9DN;Z"<B+"2:
M-GH/YCEKTV#B9=3Q<$&NBU_3\!KUC'@QFT_)-9K9G*[9 E2:>R*4]\^@J@TL
MF4/5!;O47TLI!BGF>IKX++!W]I!AX-J[3 -JO8&1KW.Z1+JY%)JHXH^Y/+\Z
MW?9..)7AC:(4UQZGKJ._#28'_!>[GFJ2,8QXV8E(%!9%60B7->%T/?>4\'K3
MWH(6*7W7*1&0NY'^IL7%?VI!T=RY^G'P=K6<W< SU%3S'<^=^V#J1UILQ7_
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M_.\Y/8XU=(R.8-9Z S+I8:Z98"<[*/24"-+6-2!2E:;H)[-KE;"RU_,N)K!
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MXZIQ3(H@5.I [Y56NUS'KQZ:G&4S!4OEL?#O0*,Q^(8S6':=V7]C7+-8S-7
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M8.K'J)UA"E@NRR/EK9;.M%)A7%-C6)<VS:P;<#4A58E?.&7II[HOUD4T)ZZ
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M61/&"1!&EP/AG,)PITN"6(^Y?!O]5)>VBYOHKIY.=K;AKS4\U4;^EB=U=B(
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MJ2I&"[M1E3PGSO>GPFO6*3#?BC.-8018@,GM-/;;\BS5-O/3D)4N+T8-(%\
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M9IXX!+Z&Y/DOA<?PS48%!?3B[$O@-GRSFUP/=G=4_<5BW8V ]0DF=/XWB-4
M>/B+S:RVJ4>FC]M\.9*,O,2-4]T&;\OY>[N]3D$[>-Q?^E9P]:PC!@QOE<T5
M%L?UM)K;'X/40S&HY\/J+A=[%;72WZ45?Q(O[#5@#CO<GL=3V:#;O:=&^&P<
MVV8\I)C<G<^P0&"6 C&7H%_J@L<@3?XLKZF>RB1 Z"(!/[S%TJB0HRQ4PR).
M/-(4)>%:W-HZ$=H4RNC<26.D\GVCHCNZS\[U[0[^20=/::ATS/&B[]_Z44SI
MN\"LHOE4R<><.S$K^^D\2B.J*/2OTR3*"^&L9.;-E"F\:6;;4,$]_AA]K&5
M@8HD+Z(Y_V#KW?GI=L\=34P<I^:0+!DPY@.8&I,.S\:^%RNEZ3,8H"A\=%2D
MMCAPKO/!Q**5G^M*1:SPP; 2%R351]%N_?J/M'5W[0-)ILCS85$)86W"MO6J
MJ\3:;#(X5TSR73__P#M7: \/*-B_US.I ":DW]W)IW@_<R=NB+ZN?@CW<L',
M^/Z;:<ING2NZ=7'RYMW[D^V/7E"X@UP$B4@C59^!]*?O8>2K'R!K1Y4'?3%
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M[/]@+IGKT:N3OP>X!'+H8.\>X'([QO)[4O)\0R=+<8V),=70K68249>FGW"
M"ZVU)51UA?#_2MUSO?2K]%=+Q.33SM2?9<I!O&4R0,73LBKFXM9[CD"G:F:P
M'EL(YTX1M>EEFA?FO[.7KQ9JVR/$%/GB92I\_2P3 Y3-]*&)PPIG3+U"E'I^
M=7X<6'Z\<B*G3ZJ48+7#5H=$YP@C!VMDS!J0"0;EE/&K?]Q5#_S;#_LS&7&.
MM-7,)/F0Y:MI5S?*U@J]?E+GR '<338<%PSA)C\6#/%G5\.G8MV-!ELE2C41
MBJ>ZG20N6"5KIC&W8-DBJ#ZG/)VA$]G1S<W&YAH9C0Q.X_]1PR%FT))1VZ!M
MS'U!<<T<-&:6U_,=:;:S3C<(Q*.E9.]OSBL_]^Q0+@O)R162"^\X&@#:&_E7
M3DMZ]N'XZ/##*^=W_Q/X%#H$R6&$Q9N$52UT4FC <Z$K5+.UYJQW?HF@A,;Q
MR%0GZ5B'5$%5?9Z6FIN!S=E&9$/\Q;"FK9&%E)Q/*JY_3D^Y B(G_Y\.S810
M/Y WJR:&6PP6\Z[*L;.E9Y+A6)[BASC!HR'@5 Z!+)9!L]RY4J_$F\0^F=<@
M:,]]FRPZ&[ZJR31/P=&L\&!Z")T43OF7IYLA2F'DM.).2=K:#1,5+X8R]Q%3
M!K9Y) <:FU2UX=\0O.1;NN+J8FAD%YSR@!'R$7?<$Z(KGH8MQ[PGLG7$6AFS
MZ(0F. B$^<=,:\'@2:5\J2?6!JQP"F^E@!Z<9'OK+)%4XND<=XR>=<7M=Q(N
M6IQ5#: B[#'1<@6A='LXC54;!5YRWUFGZ@/0B%U7G6&U:+F@%F'-H70U*O!U
M5>3,_^52J<H-KV7I(_)G,A! _$0O@V03#7T19#X$D1F6Y=IKZFS*H5AI].(@
M"9-0UGAT@B2PLH\I<AOB?=O;Q?_^P(\#=@4C#B(<8?VJ^XF%-A^D[I\X3@MK
MTTN#A26W<69<G$A]./'YH5XF?S!W*<<5<FS.T3*+A@%)4L_+)@O29\?&L$\S
ME.#@LN@\7N+6NVB:%JGCZ3]RN9 K5P\YM.-\8J:]\+3I-!8_X"7@'ZLG'1P'
M/44Z4BEQ8\*X_KKRM:^ZUJZ$6*2+KE98 _W0_\2O< R!6E1UP+6KJ?.^?E5)
M%4[,U4Y_Y@"">X5<&!BW3<;$6^RB);Y=]_CH9/G=E3G!27P1W9Q@P6HKP4.+
M\#D=K5DK',0P<Z)=B%"1T98R$(1)8N;<GQIJV0ZAN"^..X%=IUZ>>POM@5O0
M1X_W7EA:F:U9&_[=5<T#+2&Y';IO*5CPD.Q8@IQ:R*A%*?+M +O.N:9_+$<3
ML0 T>@DMK)>JRN=-<TD=J(I<RY"A$W:<2UQ"3=#M_L3#<Q^4U!M+RFJ$A6$,
M7ZG8 Y,C8O3-I$ ;7 ="?S(#.#H5>)!:O';<'0EM<#X;7YDKHEUD5IVN^?XT
M 4H."-!9USB0!8V5Y) D_@>GWKVJ ,JIT.07/TPBA&%):LX]"1JF0L^A,O ,
MR<;1&H?S]BK.H]ADW(X"R9J U&;2<G>PV,,+JH3M=UCQ:NVY-*)G.BT_&) C
M;!=H:<_&$C=?W)"57F]8<=?N"&.!8U,ALO74VC=G8.R8A6A7-:* /Y2^(I(W
MG&<KK6S@G'D?ZQ$#1KP R1J9+F,U%%U)/S>$@]1GM*YV-5\X8U(Y'P=7>%ZQ
M(6E![,!T%@D;WS-E5-6NR6)YN:B*'%P3MAM'E\/[$1FV]@J4/T@H>T,#D7M6
M(*DI02$QP0+6G2#*! N!3;=.5"M\M0A]8 4OM!YW5^(:P#5PH+=[[I_KM4MM
MR0*A1,TG]$3(R'%9,+V$KXAQ''K;_?K=Q&(]WIKN/WWH;XD+(M7R8:6+!^ O
MTLM*N'T_'1>!2] JH(SO7"EYTBJ\Q#==S(EX)2/OC^:W;4YTCIV4]:08@F>^
M!2?U,^-X$M/XT6O#MZGR*'BV[CM*:TT"\RJ[+D[7 SPY9.0T0CA=IH)W&6J=
M DLE)>9LM==I)_#'=*K<O1R9]VM+3GL':BFCJ>8':*%#.FO'"3@,R%@!$"\!
MP!@\Y='P4=)V=#*NU@X:<K;IT6]/*W7";*X#@2(U=,*"X.Z:$D3P2*<@5*;K
M)8:-K) T5-N$&B^ #E9K[D%B\8E[IN&O54P;;NPANCK]E,\NIL!1G4+*>J@8
M':AE/LW;+8PPJ,-T*?N+DBOCM,LE+*U%Q[$Z%J42Y'".+1UFJ"OY%R#-&ZG0
M0.<G:_:<<ELU,6K)8&+<?EVE<_$/71"KW/!P<(=1YY,%)JTTF7+AD_-\@9DX
M%U') 068\'#BW<]*HFKR7^QLS-)F*7].+KBC#X\ %J#4E5VE]7RB7_ =YR;6
M<EXBD6A]IT4%98 @D6]:\+&K9ZACFH@K/I''"ZGPW&BX)OR -ELE@L*[E%B2
M:"E69 HI=KL<B)ZUQ8HLN.5#1+T EY,G]T09$8Y@_QY'<#O&\CNW]KE7-)^K
M:$S\S$C4%2IMF;8'+&)%@T*'-%\U8AWPQ_Q%](:74HV,OMIN^/.^3AI722$P
M#[+?(H ]%04'7&(C+&%GJ71_$$]9/T3)IXYO(3K*VJB/Y2-=:&/$UW+P:9DT
M0NZP$+N"HRA<U7PA1>7R!;:L5IH6D;8>OI<]VVX;US Q7$B.-EQ6^5P+12R>
M-U'TQ8RT@!1_ABWCY8&\Z*3ZKGQQ^-#VN^<X_UHW9<C%:ZNO4>EC)*6Y4.\$
M4'BUFKGUT(S-&?O3H13J[G___5/>]Q^/3PX/72A+<<: ]KO+:5>R$>./,9I1
MFUX,1^%(_+3DL"AV)'OZFEV=$[V3<#<<))%91O6#K=9A]C&;=:TR*H!Q-Y.^
M8^9";4+399J5V2)WT4OU?OCJ]"Y.$W%(!X^@:P2FS/N#_+5%?@LP!B*,*'40
M^1VS$=@73Y:;AAP$&OV)BK73KFR68!IA6/AU2=:@>[/DNKA=E./_950XW)I4
M,T,%(VKD-2&\@P>[T">R%V&!SXO,):/6-E"PO+KV:W14.1@5N"3S2@DRF;.(
M&<ZK-5F[65O+?ZVK>9[*?XC6(Y51,8<L_4SI#5'RCZ5:5LT:,9PF!+*XH0!2
M0L->YFLEO@'[C'9#E5R @\2%*V?)"M#)2+$R<YA(F0SSMRJO(X.:YYFTJIWA
M]KH@,;,?"I3;H'BKE-%":7+T[I3&.@4CSVZ2O')!Y[_3&*#7N:[EX(#CQ$V0
M!H\J\SE8KVF]8'5']HJ'&/0_+JMRQR^1 _HXC\=_9BAUW8@243YE\\4@[B7%
M[Z;R5$TA&ZY=Z+54W>D_?T3/? =K6&:OR+2IT"* "?2MCDM_=QAPKT<YL:#V
MW.$FF&6D"< :0<UAJ% TS8? V038_:XV9<RG,^@<Y.U1@/V5[#ID8PJNWGTK
MD:_:2L0BM0'LB$\>4S6KT<7LS4XUB=HRJ<']SR\L4L9)OX$/H["NE&/+&J@B
MBZ0) C6-SR<H _1FZ#.$RC+(]A@RT5H61DK62U&E:#)F!XSLAWZTVA?D!H=9
MTY]ZGEUR/-8/I;L?L[R>=2NI\N&N&M(\3Q9AGG-"BATO66)6M7F<LKYBWGN8
MA&[ED"(TT*04VTC6$MJ"21Y6VJY%UL9F*6GT.UMY?;P8S1\K$"%FUIEH-8'C
M0F1-[MTTY"9\+;IKBZOZDRO2@@!]P%[O$[T!<DUYQ>&U"E5/Z"<$,I01.IOD
MO,N%UI[]:LEM*'>R%G@;Z5<_3>)<Z,!>=Y&!J&>%+I8D#!S%R@*]Y-6'IV-V
M27:@:UR@1[/UV18F7]OH&Z.U"UE)?,K"[G.W+3T4D8,CCC%QKI786R%+*,AP
M.+C!6?9YNJ+5HW_ EI00]7E5GRO,PA7'R67R8]U9=*PIA]'=3V,781^>.[6%
M1S8,1O5\"X+T:K@;!,! 9I>A,IP,+'_U)LH31K8EM[[1N9 \ZEJ#^0%+AGFM
MC.-'$OJRMWJN,D=#9BDF.GMH@^!#(;1XG1&#5/U#,$DB :2P#:%;*CZ5=(IN
M!"])5X=T4_XU9-&^)/^X9.&<GJ.R4[+:LN**EI'N'XIXG7#&&X"7IEN9A Z9
MN\*SX^"8@CSD'$N919P;7-C-74<FS".%+/I5IKP_#,0E[QIW8/[I@;H33J.=
M<MEXZ[[<:=;1+8Q/>Z?HO'33IM.W3]PB)WFB*="3F$_H$(IDSA+J""O*7NA6
MNY2_\FK>:3'H!Q1RSNATR7]R%R<0FH@#9!"TD5<\!,M1:N3Z!WO[>Q-/C"KY
MH\!.Z8M.EFC3S7A,E <>D0"VH6G;#SB-9@3=E0SDMX_E\FA,+1C 3OFX:#:/
M#]B#/MI-L/C/= OV'QWLI3O/IKO)"1E#J#4STWI\!_0JN+ N5%52T'1IJE*
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MPNT8Q^$H'4 *V,P8H34 FO5(M)I9C6S(QAV>G ,+O3J@7F6&<(WD60@RIS?
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M:&/'/2:\=UF6D>+J2-9B<8 3"Y9FXJA. Y72CT5*]G'K /MWT)=:,<TTN!S
MC-EHEXP0_2^3T#P3A Z2ARY^':]^$.T?A/4]IXZK?<>##_8.]M"+O9$\O0;@
M;:-%\F2%(_77L8L/%C"XJMY@AWX>E(1I]A7%S8@LS5"REC(SOP^N::XM="UD
MVX4/7_L[EZJG=I-?EJ!<=Y+/>M*J!TH.7)M+OD%[Z6PR;G""C'%K/3(LDS72
MVU9=L6"S R;^N. MO >N[5C4HDU(4:SV'L?B,BN[S%-L6[%TF/_DIQI/O4MM
M,.Z*%SRQXML;4C*Y+5]Q\L25<CEV =MN2[&'===1C3=;(>!J15#Q-]1C)V/U
MV$RD[1KIG-?55;L,\O"^2GU[X?;D^JKM(/J![&&J.<_M.TX&#VD ]+/9-&VV
MVDT.I6Y5-"%\6C&0[0E?L(#[ZY=K>\*>+U&G?3,=__QWT(?/1O7A2=HZX.-)
MT!'A [YS1VL[?\F85HL+@)FB]]'>GEBEF.7^9._)GN/I7P?S#_L?K#4_)I];
MBBM(CTKAN[DJ@=#&66@-C<8*E,;#T@"],.9C3Q0A0O*<%2RWS A/WM@/^/48
MX)81D)Q-F1&\WQTCBP87ZC^W]SW R6[R#BMI&D58,Z3KB%^[L762);(! !6:
M(ZG:0<K*.VQ,S23L ]EPZ^UE)?R1BN;6QS@E&T\J_HFA*F2%QK[,=GKXCJB]
MR/6ODOX6.F$$'!>D\BO?O^13R\+'AW0+0K1@-KGA;FUP0%HL4SP";5@FC<[U
M](R]EOW_DA2>MU64A=Y!.Y3,(5)83#::^\:=0CXZX'J"0>*"N5=57<QWDS?&
M@CQQ:R)F@%1QXH%7]->--AMQQ&W@UL^A(QW3"LYA\@ 4I6*Z%(5TD<E*AA4Q
M*S0K 61^?"-+ !84B*8K@A>[S(RRVXC*TM(8&/A"=LBQ>9G/J&]I]MD6IU@9
MI)M.#3X9P"UP^7ZK2%7MB5K8$BC#.9LZM31R,;"$*5$ZOXO(9 [E2Q#CWTU^
MKH1ZEC=2-^8<K#_.SL,?5UD*MTCL/'V?2-I@(,;"J&7SI>RC8?+%-@PZUJ#4
MQ+/-W73$,><=0#&>YXY3FE94,!D;WTFA=.T+ 1(<D_FDT(?#75*ZS47R.M52
M 6_-33MA!&0+*DH1_I)]<DN\<=>5<@BS>'(UJWI)E+JF&N$70H6A"16R]VB.
MONF>/L-L?=SNP,N:C*.FQ%!WT"9'>+9K.<]CCRL-VEZ%H27T!9.$C11[L 03
MOS"B 1'Q,^DCO4*/81A]BA2E$;FSP2=OX.WP@^)G.\I#2?+VU6K08_0JLRZ^
MAM/BE!3]U$\J'3Q@HC<"Q^&\2[G#1^:N"EO'RJ>#-"_+MH4<2VO6JW!(G*\%
MU)UD=#F9R>'BC6,YTTWE IK,I?O!L@))C5$R<Z>C=6::R%HQEYKQ9IY/B9.+
MFR#'Q;LC[ +*JG'3&-N=X(>::5/=X:H>AZ[DOW/F[JA@/G.J);%<G[!NQPI:
MBZ "8\)EB#TLE)9/T\\NG& E1(SXE'Y:'^'_ZB,7ZNBQGI.0:NVD>!E*=BG]
M4RO ]PA5!6FA7<9*D$#.)7B40>S.,E];1/)%."PY <XW28 BP7,Q_NW/,1ZJ
M\Z /6K^EI^_^)2M#BGU^+N&-1F*$,6I3 )W:Z2,FE]/YV0!U98((]E<NB?C,
M^"Y')U@*9,VW*];XRW]HQRD4R=FIQGT6[L!8#<LN9M"3YIFE9>#E"S[D4L/^
MKI.L7!FNL_9V9/PAM*YTHS>8)XP ,D/9*_#MHG+A[ZM7EO@JYU+A[9Z$4U5U
M;:!BN,M4D5U*2QLA,7&AD8=ZE%PD4BRJU3IK<^XA;[I(Z2NEYN(RBN2P=2+D
M^70C6"('+IO70JF-$<U0Y; .;LPTX\#EH,W@H$7IB.!QT93AT0^;!\ZS(MTT
MWD_ #+./ZUP@X%HB;+QD#+J[ATW$L(E'][")VS&6/PELHEF"*=DWB/(>AU!3
ME@Q!!(NCI;/&Q87)!Q<04>O=":M=YX%"*$A>?T#9R[W-I4-8J ^F7!#AL](G
M&A<A87(&=PEQB^0]>">S.%3L]4?J')U H-,#O@.<-)!@'+_G6J#?ZN69EO!N
MQ<3<O&-7K<3K<DUL4BD_692SW1\@2\F.8Y/(;PN^)N4ZFB7A:GA44*O-U69<
MI]"))*?=;C?!3INC=D=MYZ!OJ<3_@XAPZ/PX.Z/O,F<?0>+OK$X4WFM*TIPI
MSQ?)$%0<W"%0T]GM\DTDGEP3M/_I<J]P+6(I7=4$$20(F'1VD9Z;/>K2,T-U
M'+Z. ]/J2J[!>#93IG5.18K]WVI; G^G7<6<KH&9[D&G-&?9H)8J]*,W#*$/
MRA#5/K,8=J]?!CL387B!UQO ^YK-">G5[,?]>6-FVT_L**ZU@.7C:IP&NRB+
MQ;*!;FPWO/M-7%L%7RHK+L,(N^O1W2^[$M!V+PUIIT?#W\$7^^:?9C;S\E=R
MVQB:X6QC'!]I'%DCU+"(A9QC_B5S:EI4Z)DZ'AZIZEYT1*HL:FM-$:7-!KT/
M!0; %JY8C;& Y00@R/+Z#:5=V$"[W&27CN!(J8T6%L/0JL@KF7JXV+I66MLT
M#]8KC ^1_,S*QN>=HXW_A%.K$4I]:FK/8GA2N0D/OWW=A6+P'RA3DHQLVI#7
MR'N*(+6<WA9+K$R ^BY>OF!GO+EO0PC:9?BW"^<F*'XY,^^6P4T]7_!8LKG7
MLU\MV/+E-:2:!Q;[ZE^-,3WF9B["V:',0S>G&B_!KB08$7ES;ONF:9.'VW?'
MM>0Q^X9\J0#+V4@-L-2HXJ_9:EU4FTPE'4=&BC;5:*L  QNF]18XBNODSGNK
M;3Q9:0AQ3-QDB8Y=SFT^KY:^QT04J@]#\]HG5/I7<ZE#]%VN;/:US&&?>/K+
MS(&E9$968:PS$GX03?XL\[76"70.2!@\V1Q5L0RDTGY\Q+[C/:LC^@U*I:R!
M0<@(&C0.G;%R,9/4?\<';H-QVC U/4B7XR);CZ0[<',L=:%7(31BLH\S_ R1
M>(<L"JD>1+Q<MP8@(BHM,5SR3FI)G3M"28,6$QBCI:1Q4:^1P)-D65W1$C):
M2PHTXIV(VDCY)%*8'V&8AQ*=H_IU;H49@_2-:2NGB+I2C9E_H:9&BK%T#3M&
MK@VHE&X['.1(JUO@CR*>4=]ECN_W7*[/B#(&<-+3+RU[(2$UDT6<)PM/#9IQ
MJPDQB9H']9KHI5&+=-IP>U]6Z+.\]NK6._1J>*C&-K;@C >TD)3CVP FOO6\
M:XW<@W1B],SU(#C0O,AHX\J R6PJB>VRU\5>E;4#P=D?\<0R:PW&/%LB,:6#
MJ:N-5BNHWVME4_)EG;* $AR"3V!I=HA@7#.".G5)3(^UB??!F6ZR[*CFWF&\
M0%K7J9IZ8A3Z5F63L?T,OBX[^N+=*4K$I,@T>?[]_V/JW<,.%9 &0$(B,=^7
MM-,\T$?,4+;_7!RSM[EH?5>RFCP^^$W/>^80A)!<X9A-;+G63H@PA- ,+G:3
M8R?JV16""/RR'Z\-MGUX8$2 6X@T?+9F['1*'!'?A&WB,+E $/--T\2[U[&K
M_*-QKHP<5N>PF/'L7@>J4YKQOS0N?5D5G11XUZ D8I4HQW,3'+UR'A_1?LL?
MWRS+8UN ])V(=2YB(D8*!)X.$W_W7KI5J P.X5EZD<TY7Y <OOROG]__\_#L
MU5=)M3P%Q]4-B+$&T7$(\QUFR/J!-I3C!AKAADR1>"L)V&>/OR&?UU_^XSM9
MO>/[M?L-Z37F- %P[+^S,IO):7Q'1_'GL^.?[A?T-QQ&6KQ7M'AO[A?O\Q=/
M%*"3O%(=LP6!&$2:U/I@P?N/(^DF>+*@]]:WW<A^D<XNBNJ.=L .B7FN,Z(U
MI> (,027WS$A2Q]PW$>]2EVH1)[8U(/#!;,E;W3WU1Q0:[7.C)+6C\WJ]%W[
M#&'OL<[#&B$_-XBJMY?K2E@Q%NS_50DO"AK?UZWTP22!*02^CF6F31#.HM=>
M5?9%&57P^)Q-=3&2IW( ,!TF%O&'76MP.2Z'UPI=*/<%<IQ\+J*,0 $X"F@9
M+8>CZ1\#EK%3;&]+?7-P;[PQLA:Y?VT9?,G&E1J0&M2[[??I2*$1=&SNYIT*
M)N#X,#Z%WW+'@C>O9:M9B*-3G)-,@A*(KYQ+K1K7W:HS*5FBGG>0KO-YL=G)
MC):1HW8X5_ZM$ZO**>=I/8^Z<G(13KMDMCC$: ,<^"\,;33R: &R9.ID;Z,M
M"0E9A)A*<D+XT3DSU@=-BB=;9Q:42'J!T2NCU*)=]('G4/<L74L.Q-(^BW26
M.?R-BS.*Q^9'C'OW:R>57::BPC4&G$A*BN$6D+QPN#N2*'7'[9!\,)56>H88
M*\?\0ARJU#:R<,C*I<"6XJQ-G*KQ)=2NR_664*:G. [6,ITA3<Z<:'X;P$MG
M8M(Q:>5!J*%ER:VE6-E%4 OMW'M^KT2, P6B0RG0-VU09>#6>KM ^E-"?Q[?
M0W]NQUA^5^C/\S[C]]?5P%N1I.,Z^524AT!MO-:Z\ZK:U(&IW":89P]='6F+
M-%DAB=1VRI,1BG03D=R>?*F9Y<PUK)Y$7:Q3R?QT\C^NZZ[O=8'Z?,Y7KJHB
M(R,OBTKY#H.XJP/M!YE-K6-8YVOV#R4/+%QWB@77_QC,D&7V%KMEJR!/?F'
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MZ/B(C,+9D@:)4 F(4\NL^-3)EA;83%NG-2I2UWN_?[]]__)&(2."GGF7 N9
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M0/DZ0V+*EN30:_I FC,R_TA>_E\GB[55C]:N9TJ5PNTA"V$S3+)U3FJ>FQF
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MF]<VW/=7D!*8DG!D8D>*],J:\YY[#/QA$S#NK]!X-C5^)V,0YXKVL F"YY)
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M)HNJ+O-4T.:,+48%*\H0NC)O-RSJ7!<,("I?H R A%,0^H"$,!7&NN]UFI-
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M8TS#4"^,<9USAC"P@CRQK O,!W6"W(TL9W9O#-@*7;0U%JDKS@D8JHZ_8TU
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MU\%=B^O]56V,5CP]6RVOK T?W!CB1K,JF'A"K@= _'Q&)RT/:#6>2Q-^A])
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ME6T+*;/P]'EYP2'"CR].O.Y!X#_TA;8N32*;%]E;!O\>>/_]/1BDU3;28$8
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M7)B9!$]K4EP6S'U0$W"#CI&\Y/S77?,IO.@Y(>48I!#D!_@L#0==$[.3N "
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MW6B1[GHV8?V*5HEFI:-%V+3<'YLB8H-E<9.):!3Y5# 'B'?.2+^)= &0>?-
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MZ-'R$WWX>>\<Z,XV+Z(OO?>?7F<8X23\U?WL%_GU[_2]O?X_JJOH[:]9!01
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M<$$=HI<? T11>9&:F:H4960XGPD-\@H6,P:D_(.F$:>3!($;]>8(7>\:1RH
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MFF/3_6\W\D;OX,@_/MT81GQ#(CPX$$WU=JX/1-,R\U-BYK-3_Z37\G++RT^
MEP?^V<G&6+B[Q<IK04[>"UMOW_%NC'7U\$?[&&3XKV77<PE':S=*?-8(+%=J
M?:@3DH &*I_-BV \)C@"W3%>;0,%(GQ5!7V DT:<C_=B3%-[ ;8*<Z64M]Z"
M*"P0;@ $8P!)3('=+=_!=*#!+ G+"LY)B&%U1I(W"3KN[Y]0;SXG[RGU#\_
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MXUY=L,-MY_[9/(Y&.&;%O09<^X>U='$T-A,J YWS6GD5GJCX/^ANC KY1!1
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M0B Q)/?QX-GL2Q''#K[_+LA&[(3M=PV.N45BNIXJ$@%4YH;0L T4RX6ZC,.
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M2[R 33A'51D4DG.A67%V_OD..YK+)\2^2([B?Z1T8;;NTI 89&A:C&?S.%T
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M44$&&26>J3TIQ3.\PZ(L,9K657'V:Z$7PW)+]QD+/$_[O9-7N7'TX?V4%V]
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MYXKV!]!1"MKG1_M8(TDD$,N\0E& .<&-(<C9F!!AU"CN""8QK*PRP9K:L*5
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MYQ:<.?3':4 1,Z [3!0ALHYI#^5LU?]L16&ETL!PDN8V\\Y2X#J.D:>) M_
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M$S%M3G>2Q\KD)G2&8IS+_A-RF!N$M;/)4G@Q\JQR,&R:1%R.G-R>G(KGH\:
M?DBUHP!Z\8 >:QI P4Q0HA$F0B&>3$".4HE"9(EQZYF5.FL:6O*FNB(4^BB
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M8^(71X+%XU^Q#A9Q/+C^5^JRQXI=J)2;^)J76Q%,LBXI(PBACG"6DG,L!&,
M,SP$2?'GJF_[\)?V>^-^7U\B<KUHOR&;X E?VH,?]J2_\OOTV8.#=V'C+^[9
MM3N3TKWMS! $P-#=GJTD"JB.O?Q3L"9;F[4T]GOY6OK'+40$>,KPSTC)4R8S
M%/[UNUV]2OR/>D[5E>=T>^._K;7WC=:_-]ZOO=WXT-I\M7LMCNNRYE<[V[L[
M;S;7UUH;ZXW=%ORQM;'=VFWLO&[LO(7G:&W"#]3^*7[;[ QOO<%^]QC>*/2;
MP^]SH<W18/CWH]@;_J4JX!W^M=T9JCQP8O]Y[5..KIX1@\I*@:^NJ3&W5E<C
M/.V!/>K'EV=_^2.T^T<']N1ENU.MN?JEBY<@W&@C-C'FA<(J$\K(BS5Z^Q'7
MO*BXYL)]/GQ-TA>4LVM?QB_(M:_=]+8$OY#L^I=O>MN;7Q.L+%:RVRWH%V[-
M7P8OB+CTLU=8@D/X/HS%HW^%Z>I6W8NVU]B 6R1,%=1/Z;7S[LV$V3^#=EOO
M?<N^MMM,QYTK(O8T-VZB:WO9N)DV3L\"R_MHX/LXELG[^#UVCN/+7W3RN/<
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M8F KJT(T-2\QE2<,<&QM#-$JX@G<9XPXH9QE#J#-B'=<%?MDJ0 ^$5,1V+)
M"<(^=\U1"2,K/$/ Y2(Y3GVL^BK*IE&+:JI8 %Y#@!L5(R82;F[IN?/*4>YL
M2D9QSR-GO-@G2P7PL7WB@(Q!E Q) :8)-\0BFS!'3*K$,#8,S-&J<:I132KK
MA/%'"*L\4O.5JAOB_*;&= N<Y]C#E?OH4OY"/.;$.6TX=RY%:T50W.)BARP1
MBTT6 $7O;6)1H22U05P3L$.B\X@I%4/PTD8G@<4$;1HR-X?-BJ,E<K(^8V[
MD5.F ?18:BZTL9$P%ER4.H':$U(Q89:*&\8FC,9PW -WR. JANHM,DP#51CC
M-9/66)<U',*;<F'5-H4;GA0WT"1!26:2&0SJ@U,F8&:5<$I8[))+Q?I9*FX8
M6S_"2Z$#(4A8[Q%G0B$CX$L,C'$G" ZZFJ9'#&LRNJ@(;/UZQ"]K9Y*=HYAC
M,ITO\)C]P;!-?/QYE(,V_?ML5U+_-B#+NL*2+%GU*X33G!,AOW2[H9_W+)04
MR/J8]EDZ.^FO+)O<%CKVOK=][.^"E,I-/,--O#.9Z6B8HS@)CA0H5(@;&I!F
MPB/,E3.1)2RJ%AZFR=43+(DO.'X,,[S@>%$X'EO;U+#(E/1(>641]R$A8P-&
M)@2JB4Z6<]"H*6FR6I6*%QPOL<E<<+PH'(\M8TI5S%YUI(@5B$MGD4E1H.3!
M7#8T19PDX)@W.9F[F++D+2Z\86<_VI[?K^SA$+_'@^Y1GKA0\A3K8T2<R0@8
M:WTLH8VA\Z+PUBRM:EIK4Z-@75(\^81T8A%QPH&Y*.=(.T* 9O10 ^%8-Z6:
M.^6ZY"S5%\T/&]$K:%X@FL=CHJ),3'A-D5)1(@ZJ(K+$2P1ZI'?<L-S@$]#,
M>%/(.A5]%S0OL4%1T+Q(-&]/#N&4RDI"$ [4 YJ90D[Q@)S'Q$D!%S('-#-C
MFH+5"<TE*I'1^E?LQ#SF+5L5-ARV.^W^H%?-8RO1B?H8%B,I 7>M3<FHT-==
MZ&MCTK20D1+N1$"8$9KI2R/CI0(V\Q0S:;S*Y4X$\Z;4=?**%._F$IL6!<\+
MQO/8N!"6"6HI1<&GE(L? M+< JACTBJ8*# &/!O=5+5R<A8X+[%M4>"\6#A/
M6!=6&4M!8DC:9 '.+"%-K$6"DD1IC%0(O[*J29/S.C5365#,8HA*6AD(=>V6
M7YD1FX='MMW+%G5.<;+]?AQE[@U[*@PS^0!/C4'L 4*JYG!'O>Z7GCV\=G#=
MLW>//(2%T?DVZ+T<2V\GK56R RK;R9++8=C^ZVZO=2ZVMT.I%4Z;B=,V)TT.
M8Q4V3&'@-,D0B-0C'1-%,A("NHHE@>>>EZ))=.FP\(3QO6"+XS3VNL'V]PNT
M'QK:8^N#BB!84!X9Z<'Z($H!M)U"A$7E"9%:1E!7_O<?FA+Z1\'VT\7V@LV/
M@NU'PO:$*<*YB)3+A!C/V':2(FMH1,%RZA@))/):8ON9-57HWE _5#HMU-P<
MF4S_S&PV\J#T"V_-Q%M;D^8&P]YHDC1BV$;$=0S("LV13$;8E$@**JRL"J6;
MF,X=H"W%TD\1^@]=P5&@/P_T)X(AV!!@9Y9U%(R KBTR'EODE.?.>$]$H+F7
M(V]*L:AH2('^DX+^0Q=]%.C/ ?T):R5Q.);,.I *I@@L%HD<C@X%*5UB0010
MT0#Z6#29(<L"_5(*4@5;.KY[&!N_'73[_7\V4J][>&;T=#OSF#B_JNY?4K+[
M[6%MG#X\,/QM!MH[[W@Q%.P;$&MAOIF8[]VDO8.-]DDHBWQ2V=XQ"3GG)/)!
M*TP\B2+D 3M4- FYS'S_G-5%4QM]9X&^V>=, 0NP=0H%/ H%C.T>%9G"23ID
M!6&(*QF0E08T(*ZMIX8)3SQ0 ,=-S"[WCBP4\ 0IH*8F3P'^_,"?L'IBDMZ'
M$%#"5?P5@ ]4[1 V2G(,@C*!K*Q*K9J&+6I@</VLGF4-X.1YHN/P37MDYHR"
M-_^<I_G;+ ;JG3JCW=;9]'P766SWH>T^B+W8'YR%))]E^X8'MLAO?1F?":?D
M;=_E(MZ;-,)]#%I@+)"VVB,N6$1&)%#(O:$^F:@,,W 1-[58@ F^I"KV$T?N
M0P8-"W+G1.[8=G9*R21"1)99BC@0+K(&:T1)\$X#YZK<M3%W>R.X0/=I0O<A
M+> "W?F@.V']>D\B7+P!R2 XXA2^.*XTTB&IY)UA+JD*NN**4N9'@6YIPG!F
M]WK;WP>3=]HZ: !,#]K6M0_:@Y-&+QY4A5.#;J,/$,F55NEX<-R+C5[WQ!X,
MVHM(<'SBS/9@-54@TU<@T@OL]GXHPE9W%P2XD]Z?R:VPWDRLYR=-#46-3\Q8
M9#!/B%M'D4X^@+TA?:1.<H9!86&X2>7E-M.W9[U2[%UC6#^$K5%@_0"PGK!#
M-.P_=1YAI@/BRN#AC">,4Y!,10WZ*2@SHHGYY:[3!=9/ M8/88<46-\_K"=L
M% .VB$HB@L+K%.(L=XJS0:!@%),8\*ZEK&P48BX7(SP*K$O@8BIP,0K+C9L[
M7(S3-1N=6-I2U\ ..<\QR&("ANM.YQH4A\M=R.S+I.FA&65.>8](S#-J ^@H
MFB>,I&?)A2BL\71EE>@FG;]W7'&8UA?-#QGJ*&A>+)HG^E)[2:AF,M=(PA?J
M-%@<H*0P:[0&E&LBS,HJETUV1=)@0?.30?.#YO\5-"\2S1.&AO9<BGPW"Y/O
M9L4H<C(J!'+S/GD>E8@KJTPUA9J[_FFY(R*/V:VA,Y7R-S(AYK4@GFC59NT+
MF0J/+8;'ODW:& Y'ABU3"/@,M!)+(C)>*42LXI(II2SEE8VAKVBO/[/#I#:E
M#*5ZNRZ!D7,>*&"_)["/31"LC<,V3\O5T2+.L4<@,HF$M#(F%XF3.(_,+4 O
M0%^XT5(N_,?C@ G#1;#$O'8,.2-)'M.9#1?K$8#?!B>-I22MK(HFQ0M(9ZA?
M\=+\T9,Z=&5P$4 4<X_K[^U^AFYN?CV*E SLS[DRM9YHA6;MS9MQB>;K7O?P
M%:RGW3F&3=XY;[[Q9R7UX<^ULI0W?@YZ%N34[MC>R>8@'O:!,O.3]+H'!Q5I
M#J-JA2]GX<NO4\-!6:"*>$)1$#(AKHA#&LPB9)0PD1-CX-K+Q=ZL:?@\C%F*
MO9\DE3Q*OX=")36BDK'YQ:CADD2#C(P"<6H\L@[X)'!L76[,SRP>]8T0\R2=
M%2I9&BJI:=RH$$A]"&32=K-2Q> ,LM8PQ+TBR/HDD#>,$2X"XU[D_A.TJ>BB
M8LCU,^&6-23U]CZLM>7-U'U8>^PJ?@/>&CF4_HR=F-J%FV;CIJE)IUC#S92D
M0-13#=S$*+*1,60"22E@(8+)3;%,G>:HE93Z^F6J%:#>"U#'5HC5*G(7*!)4
M<L2%T\@*[)#B1!!0*CD7"90(4H#ZA('Z\,9$P?"\&)XP!&B*)BCC$<<\(&ZT
M0)KSA&( PG41ZV#"RBII\EI-(7XVP9KM>%[(,@S87*W@WZ^SHTY37"MZ^I][
M,SUG.(AU]Q<_3F9=')0&H7?DY:G9JTY2PCD#V:B<%>R30MI9BU*D("GLK,HM
M4CCG3<X7T-YH63R\A>@*T=4B,%:(;BZBFPAE1>>3SOYGE2@8D<D@IZ)'!(1G
M551,$3X,9<FYVJ(4HBM$5T.BJZFE7>AM'GJ;L*\QL3PQJQ$S1.3N, $9912R
M-&&FK*4"5XW><YO*N?UD#QQH.UO(V8'F%8,];I-O!H\4NL?N(-:Y%?G36N7S
M]<8TCB*@8-_V?M4??1%)+>4]ZM.'4[Y0C]?BYD_;;_L9'8&WC44LL69XU2/6
M6_F[T<I]&WN[F5D6Z]:CU];);=A>!_:M?_:YU2D[5_UP4?UNH?I]F'3A2>*B
MY$(BZ_)D4VL#<DEXT/]PI*#,IXC%RBI]P1=0)5>CT&BAH*=.07,ZW H%W3,%
MC9UK/!AN*/8HJ*C ^N0)664-BB88'9)@POM,05<,52\45">8/F4*N@,#S>D*
MHX5X[H-X)IL:,>FT=AR):'.?,LR1B=8ADE,XN='8YN$L_ 5^YEDE]3,NU]L'
MQX,8YLXSN<%Y]!1I=_8-J#<IU]HT'9W10M S$?3TW+L@.<X1UZ"\19P)C*P,
M&@GFO ;VU@&$,Z]Q.C,HEB?H6NCMV=';@YF]A=[N2&]CPY>"]B^9J"J'JA:Y
M&&G#&%*"&N*3M=&XN0W?0F^%WNI);S4TJ0NIW8W4)FLUHF1*$XXPBQB!0DV0
MQEX@P4$^@3$7<M<']D+IQ2>2W!.S/9N2[8_5-S$T+"S-?HG#K(%^HWL\Z ]L
M)S],X[@/K[<[L!&'1\=5G^'.O20<//5\E.589?$VW9S*<*L2RR?8YW](#(\X
MAN>,JM:&3+5]?.AB;R=5MWA_9\Q7TT[RDAMZF_M\:BJ/(9$GT*[R&% %][F!
MOW'X@BE1C%C/C,U3>91N"EVGUO]ED,?B ?Z0DWD*P.\5X&,O1"+4<RLP(H99
MQ'702+MH$(Z.BA1TA"\9X+QIYN]F4@!>:X _9/5& ?A] GQ[,HK",<#7(2)U
M;J%@([*^FO!-,&.:&48- %R:IL27JW2?U?">^MD>-T:Z;\5=T\;?\&FOLO_F
M=*PN._75P'@9R?H2 Q;RFXG\I@?^&-!?A,>()IX0]YJ!(>,D<L!U6"IBK&0+
M,U\6#[4EZB!5"*;VQE,AF$41S-A\ EW9)<4<<I$;T*Y(0": GN4Y(Y0S::AG
M"S.?"L$4@JFS\58(9D$$,V&^A93GE2F*I!$.<1 GLH8*I 6FR>"@E(EY9"%N
MDBM&F2TMP536W^\#"^][9O9,&&B'MO>EW3G[_,FW]C%W7G\D:ZVU'QO6Y]"H
M[9Q4L='N -X=T-" Q;1A95]Z]J!Q9'N#1C<U!ONQ'S.(J^X'-D=>4[MC.[X-
M/P38&<1#>)K^BVGK;V(;1A_.:66B_G'4[;>SU%_VXH$=M+_'/WZTPV#_C$TF
M?G$D63S^%>M@$0#>:W^E+GNL^ 5C>.)K7F[%+\G"I6P$(=01SE)RCH5@C":.
MAR I_JS,RMDO[??&9O^7B%POVF_()GC"E_;@ASWIK_P^??;@X%W8^(M[=NW.
MI'1O.S,$ ?!U=SBSX"7 .O;R3\&:;&W6TMCOY=OJ'[<0$> IPS\C)<]DR%#X
MU^]V]2KQ/^HY55?W8=CX;VOM?:/U[XWW:V\W/K0V7^U>B^.ZK/G5SO;NSIO-
M];76QGICMP5_;&ULMW8;.Z\;KW:VWK[?^/?&]N[FWQN-S6WX?J/QVYN=W=U_
MUOZQ?MOL -=VC^$]PL7NI)<OE1$WRF&CF.H$GK-F=>O!L@_L43^^//O+'Z'=
M/SJP)R_;G>K#JU^Z>+W!737B"6->**PR58R\FZ.W'['(BXI%+ES5P]<D?0$V
MQ;4OXQ?DVM=N>EN"7TAV_<LWO>W-KPE6%BO9[1;T"W?W+RTH(B[][!5&SA"'
M#V/EZ%^!L[HO]Z+M-3;@?@B-]>AC-B0:C#2G5-9Y]V;"0IVA[52]]RU[H2_J
M]7=]X&>V<=E.*AMWEXW3L\!RX=F!C^&#N;ZY>6F"^:R:8):VYG?RN.WLGGG<
MWK&MTS6V=[AU\NGK^_;>Z;N?.^MA']Y[_U-KZ^>GO_;XWNG6Z5;K Q][W"K/
MW(]/+7_ZZ>L'^JGU[F2GM26V6IL_/WU]1[9;G[YNM;;W=UI[_*+';;OU@6VO
M_WFP?;I]"#]WL+V^*;9.O_W<^OKZ<#M[_ ZW?F[1#;']=3]MM4?>MEW\X[,3
M#B1G%=)>)<3S&%QGG$#!4D6]T\)I4IJ:%YHK-%>:FB\=S9V>TQQ.1HL0& K)
M!\0E%LA&3.%012F,=(PY65J:%YI[HC176IH_/7(CY^1&@[;1Z3SOC^24UT21
M%M:A%+$Q&',6L%K6AN8/E@_[&+#<&>S'7E5;VHO[L=-O?X_3UO?+VWAN[K.(
M\LF_QW-QZAQW>A&6<AI#XXMM=\YJE^$NL-]M^R"'<!#P-NH#!<,9_![[@\-A
M"/*: _@T"T@>R^TQ?2]6O/!JDA;&U^3:F;A>=WN[(*S=Z(][[4$[]M?"U^.A
MU$#@.ZEE?Y8K=88K=?O5A%N$!>^-PAYAFDCNZR"1I=XAZQ0UT5EI25I9-70!
MMD*-S($G#NZ'M?5OK047M#\.VL?>@:@T-\DI%&W H$7C@)P T3K,O36)!(WU
MRJIHRE(2NG2@G^5&7X#M.[N'K\#_<> _MI^]5-I$B1%<^!%Q$SFRPA)D*(\L
M>D]\P"NKM&F4J,=U_QQLXVRT (;@GSH-./2]V/$GC4$/WO&@2K*<-&/N9*3<
MMO'\<E/:XQ@IKX>">S626RN+;;C6M4YHC8586&P^%MN=C.1B145D&EEM-9@L
MVH.U(@QR7 <1>=!.D955N-R>U%R) O5[B4\6J-</ZF-[Q3 ,= ZF"@XF@+W"
M-3)8)L2LIY9*+8( >P7.0H'ZTX1Z[0R5P@(/Q0)CLR5ZY:A6%@F!#9@M7"&+
M@T=1,DT"<<Q+N;)*FI3-D[BUQ,-<:AG2FR>@,E\ZQG)3WJ,DF=Y$>87 [D)@
MD[FG7&))J&'(:4D1#]PB$Y1$(05BF!0*[KB*P,PSRCQ]SGRPA &:P@)W8X$)
M8R81;HQ3",0)+"!<0%9)ASS&'/M !&,F!U\8653#W4(%]:>"I;:&"BG<C13&
MMHU5AIMD!*):,,2)(L@:Q1!5(G$L(W,XK:SR)L4+",D\=B[C,MDWKVYOV4Q7
MA-ZJN\Z33C)?W#X\'>I^%*ON"M8NC'T7QCZ9,.:"YR0E%I"21.4D=(FL3WF&
M@E.*4,F3L;G"1C35+/ZHA8%FL;K<KPIJ"N<5SJM5'6'AO(5QWMAT53)9J95&
M24:)>+9:;2 ,Y:H;EI0E3&;.8V"\"EDXKW#>D^*\FA85%J9;&-.-[7'E,)4,
M:Z13UNDH!>U.&(.D8#AI$*76;F55*M4D>-91EX].=Z7Y:FF^>G7S5;&(YJN:
MEN:K3[/YZJ-3P[/HQ;K;VGGUWW_OO%G?>+_[O__0E*@_&AOO/FRV]FK_5/5K
MQ2HDN4LK5LI?*,[OI6$H5_?2W;0LMBRV+#8O5CQ,1][YXUD/2>"_[ %*1]&N
MPV[G\:Z9VZUR.(#DUM/GGZ4DW]I>W<7XMSTXCD6*-^+1'K4'8+"V:X_)C9\^
M]OM@3]1]H0",1CEYO]RF->^/#X\/[*7II/5;:I695/=%3GEIZ[[8G--5X/%$
MX+$>4]NW!T6>-VU2JPO7;-TEN3OH^F_[W8,0>_V18ZCN2][X?\?MP<D59^\Y
MU$;]:0]LQ\>&'4S-/FE03%0IB[I%8/7*09C!8^,((X29P(5D3N+@"/;,Z)B_
M?M[,^SM72+6V$R[Y5OLLD/KI<(O^?;CS<8M]:FW0[=-WI]NG!^V=]7<GVQ3^
M^VOK=(_N$?C,T_- ZB%\3NO=CT\?/^#MT_S?^V];AWMBK_6!;A]NL*V/6SF@
MRK?I%KL82(5G(CF0^JGUCFWG__YZ=_+IZ\'^=@L^I>5_[IWF@.H7MG<:TM94
MEP:F'38)HV"#0-SIB'30&EFL&:8^<%4-T!6F*2A_9O4.]XOSVM%AZ4;]Z\21
MNY/;!0:;4!6&=W"AL-DH;)SU1CVF-BF,J"8!<9,8LLHQI+FB,EJB4HYXD\N%
M&86]"GL]*_;RC"AX>A%IU#PY8KV@ B?!0Q+*1;\(U:P0VYS$-DYR$XD++QU!
M6C&#.-,".48LDHII3F1*/(G<!Y!BU=2R\%OAMZ?(;[.4,BC/O9+)2)TBMQP;
MI@3%F 6!"7.>74]PLU<P%*:;E^G8.=,1$32ARJ-D+$:<FH0<E08Y$JT@7"5/
M2&8Z<D7-??W*:PO!%8*[)X+SR43%!/,A.IZB=#AZ0Y.*T:C 0BH$5R>"$^/6
M0IJ[F%N)*,9PKD$-"$2G$>CB(2E.:7)F2'"J:7@AN4)R3XSD9N"X?-GK)$00
MP><VP0X4 !M9G@RK+26Z6*DUH+:?YU&$M<]P]1C/*$4^& [D%G.I/25(N(@U
M$S3*/+-7@Y%*9ZW%JFN+E)GZ4A)6<U8:QM,:[7[_.(9&5;#2B!4LJLZ1L=,?
MMK@_.H />6;-[6<+?CKL).:&1@90B()I;&5R<,-+RWA08I&%I16);58R6S_N
MP;:^A2?LAJ$PJZ]_VGX,KR8D6%AN%I:;[ UI>7!)Y!;7D47$DPQ(4U#E(@Z"
M):FULBIWA5-T[JYPI=-U72!^63=9 +YO!>(J [9@>!$8'@<*M392*RP14S0A
M#H87<C9)9*2-0FM/% 4CK.#W*>-7!$XMEE(ZSGVP.B3.C*?8X\A5Q ]P/Q=H
M+PS:XU 9PQ9C3BC<S%$A+I)&5GF7D1Z-]8F#>%=6)8'[>6X3I.#[@?%=Y=+2
M/XJ8BIB*F)YJFZ1R6]Z[,3OALG,16VV$18YDEYTF&!EJ&6+4.J6= G6(C.Y+
M4Z/[<D%5"4OBE<N(  L%COV4&VZ>TH0EY*N[72MEKG$14Q'3TMC*XSEL_59W
M#78U+\X>O+7ML-D95=E76H"[J 6\SX&*?GL0=V/O>]O'H=KP/OKNET[U+I4&
M472%672%R4Z+C">6:)1(>:D1CY(@IS%&E%H933)>4KNRJG43SD$91K]D;%!(
MNXBIB.F)6];E;JW7W3IIAUO*G/ <(YZ$1]Q;#A:Y$(@XAKDBTBO/:WB[/J_L
M&#MLQ-K/]GACT&W\V6O#WP_0UDGL]1N[@!'G&K]M=P>Q0?#=!JH^07=BO?-C
MX.FKE_J%O69@K^U7YRDQL*;-SP1N*\VM1$)X"O2E'7(I1]2-LL%YDZC30%]-
MJN>N3BMQ@KH ^Y&S8@IR[XC<TTGD6AX"#YXA%D)6/)Q EL.W*1BA+*,$<UIR
M89XV:FN2"U, ?4= DTE <TJ"<"1?P!K,"<T=THD;) ,U3E-J?!0KJ\K@)LBQ
MP'K)8%UR*XJ8BIB>N*.N7)+W8:^>>]M._<EGID125A.$K5=P2^8\41,]TL0[
MK;TV,N>]#&])6J-;\EDEOJR%[E&%RVYJ=. M\UBQX\X@#Q6K&C[:7KA;%=KR
MAA9*!*B(J8BIB*F(J8BI;F*:I3^7IHHI)PT5DE,;-8Y:4$("PY(P<T-_KM+:
MX8$TYG'7FLJM%).2-GJ!B \&<>PM,HDIT)H#8\)YS;E8626T*92J48"Z('?!
MR&7"ZY2TC89IGC0W(CGCG0PA2"P4+LBM 7*G;=U@&29,,\2)D8@;&Y&A1""<
M-$V.2IJHKR%TGU5NR=38H4:[F@[?^.V@V^\_MSR2XCHM8BIB*F)Z5F*:I?6G
M$XXHK[Q1+G)LX#HGAKH U[@78$.%6T0B9N\!.G4_;5;7TW8<[*26_5F4L]D"
M$>-NQY$ECSGC.=\7;"KN%')24S"QF$E2,JH"7EGE38HO9\W=OA%H 7-]K2D+
MNKDUA#B>"!R":+FTB7N&$Y81$[[(J&*!\,(@/.[GZT*2,22,/'4YVX88Y#1U
M2/$@<[=YS6SN-Z-)DQ%6HSAB0?(2YP<4)-]#5L#:9V]MPI%A)*3(8U9<0MI;
M@@SS+/<@5DI:P+)238+KU#SJF8_HU/<RHO-)T=65)3A&82^P29PIRI,DQC&C
M(N912\6<$94G=\Y$IC*?<QYZFNP[FY*Q"0P_E!++\SFC0C:H@'0DU&A,&;-A
M994HUA0,WW=S[64-S3P/M%]63NX.]1*962R@)YK02K 1? ($\UPR1SA#V@J)
M.!7$4XZU%C8#NF"Y8'D2RUPD*A*QC@HX)5QH8'^>DG:4,&M]6,2U76 ^)\S'
M;7-\%,9)8Y T',"MO$6.4H>X8,:%J TU>&65-0E734/O?79C07L-T#Z+MS]$
M;#SV7&$3N!/68I^G?L(M;KBEP5T/]S+HZ^%QSR9ZS%/#+#>(4D7@>M<<.1X<
MBBQP@1TCH7(F-!F1]SCDJ\!]R> NF58\>4N"(-S!"3(&6Y&TM8Y;RWB!>YW@
M+B9">=('$1/B("O$8Q3(>*J0B$#@UBI!F 1MOLDI;V)QGW/]"N1K /E9$$\2
M!1L<C@]7W*I@B%9.. 7'QU)M;KC@"] ?S@\W$28(0,;<$0U0![6>)\:058#\
M$#C8[Q9,,Y_3*9N*J*90RZ'1/ZM<RS+E;E$A!,8,5O"_J 3F/!C-A+."*"TL
MV"C.5$%/<Q;T-&7*79U9[F0BVJ 4-993CX+,[0AQTDA3$5$T6$H-0N:Q&E-L
MYN>WDM104D*+F.92(87@%!N6-!>6"QPU<]Y+'9GC,C<Z>  :+N-9%L;"8]^Q
MPU8&8>$P@_6/N-0<&6Y TP1# 3L6'5846)@UV?R%.P7?A8:+F(J8EE1,,]R6
M.'+*-%R$& A5Z%P_P5AP4>HDK0OEMERJVW+2,\,89XI+A;10V3/C(W(B.62%
M8$EY%[UP-;POGU5/IS+,K+0T*6(J8GH.MG(9N%(C76'GU81E#8? FBA!/^#$
M(6Z=1#II^-9:HZEEECBPK(UI*K.H $YA@T+:14Q%3,LFIII:UN5NK=?=.C7,
MS#L--RE!@42!N(D1:6D%BCE(+)T@CJD:WJ[/*@FB-)PJ'MXBIB*F(J9G*::9
M"LX,#LY*ZI+AAGAC973":;C)X2KW>)%:7>ELL:#ILJ"(G2=TK7WV/EDEDD<V
MR82XM@Q9D!Q2@BD?I<65NT,T&2D3H98-R;-4ERAC"1,J@5X>.(G8&!(\M0D.
M@?#"LUM N;2.>TQ,[XR-+*Y(H#$8E*BPB'O!D=8$(Y-(DL*'0 1@FG/<E/)R
MM+.TCWL2@%Z QZ4 ^C$!O36,2 "HUSX3Q2FE3J(\1!?Q2!6RTE%$6++2.$Z3
M8X!H!O>TF*=HM'ZI"[7VE-S0>LJ4UE-WJAM)03DLJ(R24"X9L5H*PIFT%&S'
MH(?C/^;,O"JMI^:BIJW!A$.7PF42O8S(BT@0M[F8G?*(-.4*] S-J3:Y5XUL
MBBM:U=:QX*T4N#Z8_^#N8"]5K(N&]-@E$+476!*758P(D*81&9LL\G#%B6B#
M$(&6]E,%S1?1[)T#M IC(M;P9DS#?XIB+@15/D2QB*N[ 'U>H&]/^ FDR+W!
M$J(>)[ JI$,F>88B#22"!#UU(C>@HHHTL2EX?PYXG\7%0%((U''.F.+<$&R(
M),)B&DW4A%AU/>!+1YK'0/[XBK=)"L=!8?<F-Z:)/B$7 A!!<DEQ'$APN65L
M$\\U7J( _HD!/BBL<XLYQ^%+ %V0:",XPXD::S$C!?"U OQ$2"!RK8-) /,(
M,.<^1>2<HLC)Y&P.VZ:0S?2FEKRIR.46]@7T3PKTL\R4DL1+$EW@-G"LA-6:
MD6! JS>:&F.*5E\'J$\%"T201GF*D@H4<2,-,IHYN.9)E#39W#>T:CB'19.9
MN</ZI0M5Z4)5 ^:Z,IJ /=-2 C_1P+D6SA%*L>&8 XM%I:LA6A2/@J# 8Z4+
M59UI[MU4X"$F$YS32(G($"BD$EG//=+&*T:E#%+$[+P0^G) M"0N+2G(KTAS
MF!_AI2_#0Z-XPA&AI-9"*T2L!10[(9'FS")A8L11&Q<- UVE(/CI(EAK'!@W
M/#D>>96;), R940Z2W"P[ 'NZ +NQ8%[(KY@'8E@."8DX&@C'I1&U@#6HY7<
M,^.\)634=(46A"\9PDLU1Q%3$=-C%-WXZ%+^0CSF!"P@P[ES*5HKJNZ/Y;Y<
MJOMRTG,G&<A!&H>D4#GS!A1A8XQ%,6DBDQ?:F[,N976:&%VZE)4N9:5%1Q%3
M$=,3,Y=+)Y5:*0L?)HUK+6G$6',44NY3EJ?.6&+AB\5<::8#]6EEU? FE8L*
M\14^*+1=Q%3$M&QBJJEQ76[7FMVNDZ9X4E@+03'R(&?$,67(>B*185BRW/6$
M"5/#Z_59Y<F41F7%RUO$5,14Q/0LQ313Y8)+V&BJ<92!\X@-DP:+Y"+5P3MV
MFS2AT@WE\72SO<GB):6M2I1*Q$7,HW9#0(YCCY17UO-(K64VYS=3@^O1"J7
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M"2B9BL4T)RI+8T*+.",\R'+".64I3PN1,:X+N4,Z!MUF8/LGR_;W:IH,;/\
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M9, "H8J@R(0N'4C7@K8.&7Q/A:GOVV >^/F6+63+SQR(E%+$,HMX2FB<P$_
MRT0)%91@(O%4J"$C]^GS\RU;R0,_W[=%;/DY"62>)FE(>**P'8J ^SE0 >%1
MIE(9)%F6;&6&_3.+SKUSL)UH4#1R6LWJT70V_[&,V\<GH+85+Z0]GN90O=>G
M,^ :W5@V>2V5O^W3CQF/<TYS$$6L$(1&A22YB#@189K#:8)T4B"9P&H8!VM
M"0<H@6WEX>TQ&@;NO5WNO?"XMTC3,DAI21+&P$XHF" L"%+" ^R''$>J8.40
M37OZ+'S'=L+ PK?*P@?^!9P$7&!1/5R[Z+J+XX04H0Q(PLLLR),\E/'MF0;;
M%S![+*;!4FCLA-4P=-4T"RF ,86L-;C@_ *S^L[DM&&:91$;9, YWP;;87T:
MP'M]CA_P_/;@#]-Y]47N3H7^\V^LD>*5=YI8F#SD!GRWM8$ 1XQE09(3R;DD
ME >4P"65DYCG-.5A$"4YHI;%X[CXX=*<P:FYM6S_4&V9!K9_"#-E]V/.:2:R
MB!,9"P5&2BC!2,F ]^%L>9:Q,@QSP_;)*ECAP/9/A>T?"EUD8/N',&UV/Z8Q
MDRD-"I*GG(%ADP+'J[PD :>YE(B<'B4O7J;A.(NWB>T'[)$6>V1=H=V /?)0
M89);JRG^W1WK4%/\G7)NW[=J@I 5-"D2@NWF"$W*@O" HQ<G2J)0EHE ]+0\
M /5FM=GL]A44#U@#3]04&J3!W4F#SMB)F.1@U @2!TP0FO*(Y$H&1*6I9" <
M6!QDMV7L#"+A"8J$^S23!I%P9R+!,X04E9G,"D6XH"4V:T@(I[$@JJ1%ID16
MYB4J" EVCWHTD$1/"G=D/=.^44J6.A5,?BU/V/18CFHV1P3XJ;&:$/U=_X"A
MGR_ 'C_8U/;Y"KU;,(_ZDLV<W:%Z8T_N'1S<X12%'?[_37=>[V0SKZMR+@5^
ML#L5_3]X3PXB\$8B\,^>C40S)DJ,:B=E2"@:2@4+<R+R( VC5!2YT*ALM^0'
MVAJ-Z!9]PT],.-QS_ZK6>3*(B:T3$UX;W;B,LZ"("0LS;%6';3:#(",9YRR0
M/,OSHGCQ,@RB'_"C#"+B*8J(V\1L'$3$MHD(/ZJD5*E$&)(,Q "AJ2P(8UE(
ML"(N2Y*(!X%"$;&*+;%](N*60DW;;$-AA*F:EK5DC1S]! RG?T)8^ULVH:ZR
M>Q^A_-O23+H?$GUO82=F8L]2Q&M+#_#[9(&GXPM9(W@'67DC6?G!M[IBIHHR
MXB%1D:"$REP13CDE1<F *C*PPD2NU:EQ4JRJ5+?L>'IRGNA'*%$>RN@:9,L3
MD2U>G"N.BH(&,4D19X2F<49R5D1$9;F,TIB*((E>O"SR<4)_Q%H;I,KV2Y4M
M#6X-LF2K98EOTR5)D*0J(%FN.*$B+ DK\IBH0B+<25@H7H*>4@3CD-YY'Y\A
M.G8]KG^UR7P;L?F(R^-J.L7,P9D:74A6#S50&R0B3\,R#276  H:@!S,\S@4
M!4V2(H<;MOBX]\.)/X.OZO[DVM^^_:6H@O.,"Y*&+"%498(PF62D9$PIGI61
MR /0D=(Q7(A;E $]%#[<+HNGH8IB7J2EH!EEF2C"/..@\X!MSJ*\X)K%'U#7
M&5C\IBS>F4&\2!(NDY1$22P(V,D!850RDG(E\D0$N6 )JBYT7 3;5.4P\/CM
M\KC"(C:5)"(1)14YYR'-F(R!S6G.HC#7/)X-//YH>-PS3Z@*\C3E"<G*N"2T
M3!C!,F;"0YEE41PSFH-Y0L=9^L-.U.VK8WJT)HB$OV\P/NXV^7C;=ND_[F[Y
M3T5ZEX(599XKRF5(<Z'R/,U+*53&2\ICJ36TAXR:#=+[1M*[[(%.L+!(1,A(
MR(J T)RFI A50I0221C(/!**HX:6CXMG5Y$Q",)!$ [>J"<M"+W.6T6>!5B%
MSP,L0XGB@/"241(419GD1<IS2F_+&S7(P4$./F8Y.+CLGI@<],SYDH4T5A$'
MP9=&A&9A0HI2<B*+,,F#E*JR3&_-93>4X]U:&_#WB[.SB43T4389B:HI)[,&
M^Y)A)V77(7Q430T#PE'=5DOP&(Y$S!9\(K>YW?;3FN5S<5Z=,9 #0+% MW-9
M@[3_$237IZE\/$G]XC[SM?<L:;T%6AM:N=Q4=?CL^Y*2J,SSL*1$)2(F-&6*
M,)%3$A=Q'O.XS )9@@DUSM;D/#YZL/5!%#U)472?$$2#*/I!4=1Y<S(NXYC%
MG"385HI2)0DO@IS$<13(-(A#)21:,>.P* 99-,BB1R&+[C,]?)!%/R:+/(]*
M&):%$#0A+ &!1 ,5DJ)0.0D"1#BB(HR$#K&-:?:<6[YO@9%9SD[E:,Z^KN*X
M_G#VUK8M_?H2==T*GXI$O75@I3U-0T=(0H/DO+GD/'B]ZQN4K)1QCHU @Z+
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MJ.Q*>WMEQ:-S[4N?^PGYK0/Z%%WCB!4#,[:(">@0(7 Y8" ;/=U+E;XVD]R
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M\[-Z="62XE,1#/OM=?#6GN[#"H?=JU$L3<J-]:IVI2/"5MG54E^BZS+NSMM
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M]W#:M2&FKI <^==$37Y_O3O:G8)( "L F/(U*I-O'6K$KOA2-9@_^\HAB9D
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M)/&21!>X#1PK8;5F)!@NA-'4&),![Q)1@@KPGAGPSL: %RUAG(F *,O)!N<
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MFPKT[@AZ; AZ\$S?=Z). 'S1(4L#1UP:@YS7 0%!#%8 2TS, .[ABR(^[RK
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M_E(<=Q#&>BGKS!4B/",B5&G/QX")2=I3.P76IBCP+B,0#T(C:UQ"3E)NE$F
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M]+"T:U:Q&)KL,_<ZZ?9"/W;.A;[-0FET(V4%L>B/L^9,E@+O;W8__AK$3B@
MJXJ"Y\*I@_/\ZH*@_M?]QB9\?G-OK[G6H' OLD7_AGYI'FZLK9+&_L?3YMJG
M@^;:[X?GCE*N[9XU-W=WO/22>X41CB1F]2./M&0*4185-@1['?C2RN9)]^*A
M7#\9Y-HY)\@6@EJ_T%XKA-AY7XWO<XWO_M:.4@KF+V>15$8@3FE VD:)M.8>
M.VPP%G9I)<$8#H$5%<L^YZ&V%-9YYFWE<TU3+QRQ[\<U*\1^=H\^O<ZC#\36
M_G:K^>,+!4]N0_O9]N>_]QK9>S]_/P'O/=M8:^YOKWW:O^#1:]]WK$[@M]8A
M[R5&W.B(#+4&<6$U3I$&:7"6O8P7$;M"Z44<T\W&CC%!6)$(\M%R&$DLD%/<
M(,R#8XJ+Z*]$Z4M ^I[5"<^+0C$YH^:*GD1%[2J9)4VI'$=93]^$&<$L7@K;
M9JV(0[ARKWU::*+7>J/*=46]P:FBAR>M=KL0FF@7:CU9'CUOM<@#.=*,+!/E
M=E#[:7NM[G&_E!;]"<B^7+NU_&XUA',.X>]YH(:R':,"DJ,!\#!.'=L9].NU
MW(&'G6(LZS#C)GO<SB^/Y#H++9#\3?!:H;B<5SI"+%0UI]6<<Z7+5K_0J/''
M?0@R\WG);"_EX$\I2 \%H5M]F+2S1GYE X]G VN3O4_3#GE!EJU0D+:%.G3_
M**NZ9265/'I']K2H>G#<J_7W\@=R@8^QCMVX@D"N1=9*K4(U>.+R]:'=Y8\"
M#VL/C2SK&F3YV%ZTM4.;L: 0RLJ?[A_WIK3 "^%J^RM6,/&()O)I6(WTHJI9
MO1CVU/J5%=8ZG5P.8S(5%/J_9880^A8\OM>"]R'<Z?>'+@^?;4T5DO40U,!@
M3VRF*&4Q+)1:#O.,DKP[+4T)/@C=$Y9K/V)9#</"MT=45,\HH"D;95&A)HO%
M 1858FS# GE94VOTU5,Z:_D9X)]^L5<09J8K=;+F,+US O'/)]SX(TY6HLNQ
M&E6F'1:>S35JQRX\G"#R<-9R3>-BJ3O?=#A^XPF]'%2XKM4-CZX=5MA?KOI1
MR..^7:&P+.ZZNX,)D=)ZB33.56.]M<@$QU$23@M&F%->S(J#B>2()L(DS'*E
M!V<\TTQDK7YL#=;I,G&P7$X./"O+@8%'M8<B-/T\]9<%0D[BF$GDP@H7YX'+
MRBT4-9,.1W?=&&O9U4M=<-L?BI+U:[\]F*C895+>E\J*W=A-CR,K9O@RY_Q.
MJF)\F2GSX$)=9EGHNPF'7?^>UG>3*KN^K=K<3:KL.=HJ-'\2_3,B7J;BUU8.
M^S]>V),_C\S*/#G9N\@V+5ZGW?; PHU/^Y:Z['::-%6737?9/77!7J#<T<9Y
M:EP0H'EWV%XY_K,F\-KV2\W]_*]F,]6=@IX[[@0]OULJATFO9*-4_JXMNKV_
MW6[L-]N-SUMPS3K9V(0PB.;EB_9!XT<3VO>%-S[,+'W <\%UA\W#[Z<-^OUD
M>Q_"JOWOHG'FX3O;^QNY]!)=Q]MKNR?_.5L?+U W5G<$"X($EU7KLUB(LR%O
M[I3(6D:X)LIR%I96B*X;?6^QD'G]8\%/J5<X]^9P#D=.F08 PU)SH8V-A+'@
MHM1)6A?20YYOKW#N_CAW.L8YS13QEA#DG8N(6Y*+RQN*'"4L>N.$5+E@ :\#
M#%8X5^'<V\8YFB3ECDEF,- ZITS S"KAE+#8)5?BG![AG*YP[GEQKCGA<R05
M^7*.%*$$<54418L88:N%RX-GG%Y:476CZ$N!N5OFOUX"]OQM>ZTBH7YU='W)
MV>[7=(3[>6/'4?]74',WJ&E,AXX1>QI]H"@P*Q$/3B%#<:[#[)T$3N6%DDLK
MNDZ4F0]J'H\;S2&H\+J=[BD#F<KI[NUTDSC&$BN2@&&QPF/$N?80POB(E(V*
M*BXD]B+K!G(\IVY@Y72OBE573G=?IYLBU<HKKHWS*%)A$3>2(IL811J+Y'T6
M(C(JBPWQ>7,'"W1<]&6(D6QV\\:UJ<TY=XQ6AKMEX'%KH7N<&?FH[56VX\$Z
MZ-4 ]U.&*!5@WPVPOTR')@Y[)G342-L@$ R91L9P^"T$$S'G1#J\M$)5G4C^
ML&F0!_";EY$.KA"T0M#%C#<K!+TS@D[B3*$DP]YA9#%5B$L2D:4D(&&$Y81I
M(84&!"4/442D0M *02L$7:#D086@=T70J:0!@UB!.A<0,S(KL9@$;-0HI#,S
MA9'R@0$');3.Y9SY\05&T'L>57^VPXFYMR_^7+M6/+_\S$A!OSC1E[E+<9HT
MGT'KY0_/G#4;GT;KIMK_/F$$*AYF05Z^4!BX^QFT@ZS1P<O/>@+_[@BG,=>!
M(9&LA]@22)%+&".?E+0:2ZR2 [\VRQ>%QVM@N^U6<7@TS#7\]Z7/U? _S/!O
M;NT$)BF6AB*3<,S#KY%E$7@R,5I*QIVU)&\D6[Z8"AX-?WUT/+?U,[9/Z^59
MX'SX]V4@PE_VM#C0^(;-HI&_<T=*A<$4-,+,YQD^!&3 -Y%7@@D:&?$F@BG(
MY8M;;5X@$E3#/BWTLWG &OL'.U13D5BNV\8]3 :>>&1$3(AS;UQ*5&$KEE;T
M\E59QBL0X9S.Q/#L^;#[X9/MXF3QH%N<-CZOPUY(3%QV7+D3!S5O^WNE5$EF
M)NZT]MMQOQ"M>#?U;;EY/TMQFYO/,W_(=_R4CR\OS^@67:!^4Z1OR+TX758B
MBU9D-17XS/OBR: 'AL>$AR'2U(5#8HLGEU@'33L>7'W)96>AGX-B:CW305,_
M]WJ3]<#=B%POV@-D$S3VO6V?V-/^TC_.DV9@S#-]./OX5SYD2H^GL%'T=<C,
MMQCS]Q"@Q%[^%+3)+DQ;:GN]C*3_TTK6)64$(=01SE)RCH5@C":.AP"3_(Y:
M6BD4& I+SR#<R>N-=N6RD;ST?'W4W%"IA?(N<L*"=MX$PK"'&3D%1\<)@,=3
MDNCW8[Q"7[J1!8C@WTIE H!<2 C*&7!Y3"E'7!F#G.,*42V5H0%LPMM9U8BK
M ED\*X="2K&99P&>U0*H+X]9ZT5H>UC:04;\/.\ XL_./5.SR\VR%;>5J7@L
M<0FSK 6[B[B$5LM$RP<702!X69('44%X#!WLYS'*K6$V)9O8I;H'#ZM0^Z#U
M>N@R%0N>< ??)E45GC=2R,(':[S6B;M(N Y):ZE]#$DYSQV+;F?] ?:D7$,C
M1G'AVG%L0J,V3V+[9VQ "_?ZKV7Y(&O(DNW#9@N^8Q\^C[?H1[YU^!V8Q0%N
M''X4S;55TOS<.+NX?+#.&F=_'VY1:-=A UC(U_VMS;W6-H2/&YM?3K<VX?JU
M[QB"RI/_G'V<WL*"9:+,*8PD#EE"UA#D@E808P9&!:'>6;FT0E3=L'M7"%^\
MXA4O"6II56CU!6!3IAR;)]T*DN:"I'-:$4J2I)DR*$;'$-=<(,,,0Y@P1HFF
M$1.;/:)..'FMU1I?!B2Q.T'2;9E@!4D/"$E[O1@K4)H+E,Z=0DS14FE$1-I2
MAWB0 FE%#=*","T#8!8S!2@I?>]*T!5/N@\H\8HGO1!0^M0][E68-!<FG3M^
M()DV21***%> 29$K9 -FR"C-//>)QZB*S;.</=36KXHHW0F31$647@HFM7Y6
M/&D^3/I^CB=913F3"0$P*<2%CL@*QU&DS-J4& ,>!2Y!ZX3<6P"KXDEW7AD!
MGY)EZ8^]V(O%)H"*-KT B%K-(U7AU)UP:NM<WEM02P*V",!) '=2#'!*,\28
MCHXJK*(02RM&U=6#'=U<(.ZT^$NWTR?P1WO2;EBVO065NM^)IPK$'@;$*MR:
M"[?\-&X9'2R.D60U+(.X30PY"[\%+;1DEDNKBN0XGE\/Z_Y>L^"EZ"\KS'Z^
M7!<IF-LS<;+L/N]K1]U>60\P'O5B/W:*_5%%+<<XI>(W/P*^7*;VVPM"N>^=
MT.I[Z/=!#!]_>?CHZF'^JX*\N2!O=QKRF&31Y#+D6G&&N H04GJGD/.*,)IW
MKUJ /"[K[)+4^[LWPM(6%L]*"M?JY&WQ$+,\ (FK(.RN$%:4;K\6OS:+BK7K
MA_GX1G'^XFML';KC7C^>/Y13P=AM8.Q@&L:"\(:+Z!!/U"+N>19VXPIAIS"%
M$1:)AZ455A?DXJZ&VZ/8XN7$%C_6G*U&-+4/_?Z$JPHY'Y.,70%C%4[-MR/T
MI,"H JM6=R*13A&:5<T$15PPC4SD/A\Z9=1 L*F"7EHA M>IOO>>T 51=W]3
ME,P?]XJ2Q<-0LV)D"XMC'\J1JN!L/CC[-0UGGAK#;-2(*,P1E]9#Y"@]8H)9
MPX04C#. ,U8WY*+$6$6\GHEXU>&E?O]V4%4)H55":*^(O#:['5_A_EUP_W0:
M]SD.GFHJD=(,@FZ6]^XZ$E'B44FE:="%,!J3=:;8*U5&&XMD3 [_OR!=M)O/
ME)>WC0%9Z!2[FP71#FVK,YE1!K%W6&OU:]<)(,SCZ5.^#4_KWX?C7I9LN]ZS
M?PQ;N5HV\NNHC<6;F]!"\D+=^QYJ"+BYYG=8$D9+$Y!P42$>J 47Q0R86DHR
MRDAH(DLK9IG,VG"AD]<?;6"Z: :C19@:C$*L%?(S@R[ =#8',+_BHJO4!TYK
M)W9L,!=G"D!T,,8'F2S6FY_F,IRUX5-]A8?Z*_;\] R!Z)NSH0,.ST(;\!W-
MW+;-]1T3G!$N .0G"?9$G4"&&(9H3/!RB-AYO;0BEB\NC/^?6PD+%1U\HYX+
MH63I!@U*_018>Z'<?(&US2XXA*K]W__1E-!_7HN+]Q"&*1<:1@[UM922VNQ^
M U/=2']UL\1-R[8_'0^.>_%K]]2V,^5?&&V8_#V%)7=I\\??^\VU/UK;GQM@
M8;NXL?_E;.LP6YL_V_CQQ_[6V7>@-/!]'V8L>7^+;/^ :P[_.-@Z^_(+/.&T
MN=9L;6U^^05D2&P=-H$( :7YL8[_<_:=-];6=[S1VF JD.!)(NZ]1"8*AFR,
MTCI'$K.LQ!VP2@"%/ UQ0R37GG)/)1>1.RJ#$-$*+Q, 4IC5DOES2F+EZT3A
M*^-A'IQBPBV'I38>EPL$XIRG7*I(='.SSC]&X@GX$X].8LHI9YI0 W. 4TY+
M+PL%H\L]22X<:=GHU#Y%USNVO=/R!<HS8R&T$&PMM,$*,33H=5L[.N[YO3SY
MY)FL#P-0L[N]6*RUU7[+@Y(OK/TU_:D\3+75T:?>U4Y:@[W:U[_6:Y]:'=OQ
ML;;9.^[#U?#2NZSY6+,IP8CG>1#&MAS4T]I?>Q:(3#TWH']LX=N@.6,]-V"E
MH92+S/<=M1%>RJ(]!0?-'^\!+VO]!,HUO.58.6[2\,T>=/!P AV;T[N:[;7Z
M>=Y-O>YA.7]W>^UPT@JQT(_+_0#Q?_%N;D2Q.[GVA^U,^I2,NA0>Z3?[KGSQ
MPWIC>WUU9)T/:A,R*RO=K 9V46(NVRABQ=6SM!VZM!0M@]8K_L]':?<M;;E>
M*W3+2J&_EL_*P?4:W/4XP>"5XL2%@1X?';5/ITRTL+WO'WX?FE/M-_C]76DY
MO[GAJ#36OW[X^+4:EJ<>ED_+M7]W4X*/=]"?MAR+KUT/WO8G!++YNBO>7N_X
M9?#A[F[,9P/ S5/L]<II GAQ\9EWR[4?<00 <+-=^.K=C# CZ4>(AD-_7O%I
M*X@2)@FI+><L6&UU", ]L/8I*%)JCM)".&WTR]R:HP4Q^6O8P$^ ,-=3DL^]
M;G^!E$B?G)CXD\;)CN82!H8Y1)5/B%M&D7/>(A@2:[DQBK,L$4/Y=5+4,#*U
MZ^>%Y7'0?V1[@VP\@SV(W/-L4!^JC!X7AFB/P,)^P:@.(IC]0EK8U -F9>O^
M+1GP6[8T#I:&I89 S7IDG/)@:9@BZQ1'#L8L42%=@ %9X9?(W([M+,L$3EE7
M4;QO2JKV!#Y6LX=Y->$L9D@;[:R=*.;#A%!8*KQ8V%@ [$VQM,>;"=ER;;6=
M=0IWQTRJ9N$KAXJ'!7GJ7V1/F8Z/V5#%8^XZ81;C41&.N_<? &LX]MEC8*JW
M62WZN#T8RW5V=KN9<US)0+H.GJB( L_)1V>;WHV=6$KD#AVI/V7Z!;R/ L*"
M9_@R>S><-*8_FQO6BS\C?')$0LH*&/E;%G(NJ-C&;>> C[\V-OV.(8XX1PU*
M6DG$H>N0B8:A$*2CV =*"+V1;L T,*:A0V %+C$],Q0&/LGY3H+648B\,;;F
M=W"U'>1EA-',$6K'_5')EO$,<@B$N1ON.X$4!OZDDX)8UO=#-;+HL/;8T\+K
M[\'1Q%"SO6*1K37(=AU: +\#0'[ [*]_K2_7;I)E'J;LSLM6/U\.;Z,SD04F
M<K2P>*<T'<6W2--EU"_<&EIN=\OB"/^.X.I[WHXSKJ>U1O%NOJY>^_//#[7?
MLD;UI&K#OS]\A0#\KZG,W6V:4#Q7T>QB4@;;:N=_X68U#X9G6YV;2.K%%!]\
MXT.F^#;\H%L,Q;#4%5" 5AO(!5!W0-(X;F<OPK29Y< !=O> 89=6"?";L3/$
MON^U7.[<V.Z>C%*$M<;&WZO-S?7_5_'".[A_F8<J9L'1(/Q9)J2F#6Q8NB,>
M#4J7RLY$,3;U;.=YF%T<G,38@68=#&RO>&FU#Y/R-K!#;VNKOY>\\[ H@%;/
M.<3:ZMI6$T9N\V,U;@\S;A]_^3:0%_#JKT"L+>!%'4 0D*5[-$2<X< 6D^8%
MJO^MI/K7C7H!I%B,1QU($UQ<CGF]]KO]!2!A:]^_E9G&_(G1:Y\/W;]G3,"_
MJWW]^/MZ<ZM9&<##&,"W.!BTAU03^OY*/Q[/C+1<;9%7#&BS^[,+/WJAU3\H
MAG3FI=5_?"NNFGGQ<[E,$-Z-4MMA0C(N:?77T;+3MV/7OJK)HPF$JJ+%ZFH3
MS-,-M+7;.\J56[*EW627RR^,VVS>@A,,TV'' _BZPH3!L^.O(V!U]?'>FN&<
M/PE?KIKT1VRBN*?/VU=RW@W0/K^X5X3MP_6",8VX^9[QO\>VX"ESA?9<!4^=
M4CXF;KUSWA.B,.$AN6"L+S<N$$HD&OURQ]"^?)"---7X<:IWU.^KG9![?=SI
MZVES1%S6^ZM^KP7@&]YPU#]5[>QL]U=SK;&#I1!:)XNX%!)Q%AVR-%"D%*%4
M.<.92EG7$%^2 3A7[VS,4T5MW.?OZK76V.RF7B_"^^%HU'*:J@=XU,H)J.ZY
MVB'%9?7\]BLUR69W4%GEK%5N'NQH,#BL8D))TU@69-64*10M$5PJ&2+."L#\
M1JN\Q@ [W<'MC;#V6[=7W M87+L5>^66V%#L].@,ESSR*VW;'\R&<.,I-D?S
M[?@S!Y*C:74<V_9SDPYMR.N]Z^EA<!RF]+S=<K"8WM-H=5J'QX?3OC-ZA)%^
M41,"Z,*7["E,L6NME&(O=GS\O8QMQL/YEA.Y,\YS]GT'$Q8U20IY%60^A*60
M"=J@Y+G2GGH<7<RR1?I&2+\9FD\BF.G/T2;?PK;@@V"LI7^,1VP<CE[BB^6J
M!CC0U38]H4@SUQ8$R T3$I./W(*)E=QKN5:H_-WNNO*2W!BX_F+FY@:W'&52
MND-N_*(S> Q/9? >>G.*\H3K)#G66=\T$><Q-UH(Y:3WD>L1!#$\V@R+J^6B
MIT29C<V/.SIA%JT4N32RR8+8$CGA*1*&&TYB,([SXN3ZC2@SV:YRE>^ ET[O
M5(D/NE'ER:RMVJAR+ZL[;:SY'6*5=WD7O+ 4YC8<!7*1$N2Q9U($KIVB2RML
M^2JMA%MM71G.*9,%R#OM7;E^,KG_WA6X;56@^?H"S:8JT+P8;7G" LTW'F^8
M.0Y!F*(I!J<L]]QY:KS'N1B?<,1SD=7N%NXXQ)4[AXH(M'78RF%BYQ8I1#?%
MW?+R* 2=&:D>?P-2F;>\=A<28#<J6.1EVY'J</$AP*C/C2J6>Z?P<4@G\I(E
M! ;=7+6R5BQQ7 A@\LG62WNA5?9>:O4 \2&<[N48 9XE5V&]WU:HBMLN.LO8
M_[@C>2+>8HUL<!KQ)$0^&":0P3@P+0R+0=R.V]YU;Q1X[95[HR[RD\D&J0@!
M=[%Y8?ZM4C?QE1\YG@]%VBQ;_VXG[^JUG=.)IU[@2,43^W:W:%[WDO#QLJP"
M+KH$[MLZ/#H>E!M#RMOFL\*MP]SV'ECQ\H6S<8]UN/*;WXOA.+O0W,<L\U3V
MML]:?MGAD002HP:2;@GB(E=-PDRC0#',^49A(.^SLW*03'*G&<;><>."-=%Y
M8I3-)7059[-G+1<_>Y+7"%.WW>Z>%+Y:<)S^7O>D7[A?!H.?Q7EXF,R&L\\$
M%$:S8RAGX?SFZ;#<^M2L=EZTH?#AT5QX!&T&#!CO$,H2L4=3$_3-.R6[DZ.6
MM=$IR]IOX_N\NWWV[28<F'F,WXK>Z!Y#WX?^N_<WY<R&X4HYSL->'@4RA1Q(
MWM]EC_KQ_>B7?X96_ZAM3]^W.L6H%1?-;C0 8YKP_65<<OZA;-3P_L.WEXNW
M9D1,RO>H6-;XZK?Q,KGRO>MN2_"R,.).M[W^/:9YU=BJL55C\;+$MVOL#7)R
M#Z!PN2C)E1G1ILOU+(FXS:.7S_$TXF7Z)N6. J!SU2?T\?*8\<K:71>'&><G
M77I%_?+7%(^8<(C+2/RY7JJ\XBIYR3DDRA;;,FXBD+?PFEMUQI4N]3H[]7HN
M777J'3JUJ';V$"#^&CNG<N/*C5]&IUYTXZ>6<GX.4=UQ G)VS:4X*==-M50*
MBHV70X;B<R[NMCI9!_-?KO>/%6?;6;[JT0H'O&[IYK>DS!PTRSMN@\*1<:UP
MKMN:C.32^"2CX%ELDYA[%$B:,Z'>['863J?_CFGU4J^YB^%]EI>?MLX^DHVU
MX36;?^PWSG[?:T*[MS?727/S[];&K%[S_M?6UF: SS7W&YO?^3 5O]<X;)PU
M/G^$[PGMQOYWTORQSO]SMCY='BF:1*T@!B4B;589$L@XXI UV'BCK7-,+:TH
M5A?B8GVD!2TZ<D?0GYTS*PRL,' & W%*C)J8,(Z16V*<==%3ZQ67>=5>W X#
MSV*O&VQ_KX*_9X*_TTE=7\85\XDCS*5&/)"(-(L:::JEDAQ[Z7Q.Y13,J<*_
M"O_>-OXY2;PDT05N \=*6 VD,!@NA-'4&%-QP!<#@LT1!]S_\FOCRPYG,IK@
M B(<&\2%\LC%X) G>2<D8\G95/' "@<K',PXF+<>4::2<2;O+$Y:1Q8B(2;@
MHL)-@8,7Q>LJ'KA8$'AZ#@(EPP$04",!M ]Q+@H:*!"GWE@,7-";B@M6&%AA
M8(F!VAGCN18&@(^;Q#5)3BFA4]248<%&Q7=F#H57&+A0&+AQG@9BJY/U6B&E
M-48<.X&L3P%9(1CW(BL!I H#*PRL,+# 0!98X"$&'9WFC$0KHC.2*1I( O['
M*Q[X$C"P,2Y?N0[M.=@1$;,H)$58LX!XX F9H!R2S! #<"@P42\.!!^H$GL)
M7;2HIK[0\#4Z,W78[<1!ZZP\@S@Z@'7E-HO7675]'E9G@R3!"HX5X=)K:[2E
M#BS>"!Y%\)<>D)H3VH9#TY@:F=$1Q0J[YL*NQO12KL>)9NZ-" XJ'Z["2.M<
M>9>9J&UR$1O^8+#U@'77[PA(5VYQ>O,^["/UW%-CC8S<2>\X-3H?K8],>8C6
MYO3AJ]/UE2,_H"-/%B43-4D8J1'E.DO>"8ZT9P0%IJ).) H Y.+,<1U,KG+D
MU^O(=SJM7#GR\SKRS,):2(H:Z1*BR8,S2U[LK:(03%BE%(4!M;IRYC?@S)XJ
M;I3G(D3%O<PEL[WSB0<?J/?<C"L?B<J9%\>9SR\16>8#=I@A)WE W-B4,Z,.
M\>0Y)9I+@\N:C)4SOVYG!AMP4GMO<Z%$I9C&/H!3AY2"58RXL32NJIQY89QY
M8W9FQE)&:I$A1>%W')#F@J) C) PCMH)6<W,;\"9B?61>&>-)Y)+1B!69B)Q
M;E52W*E0S<P+Z,RS27N;HG:>!$1]3MHGKY!AFB%)&$G< 4(3X-G P1;,FQ_H
MJ-J+R<LWSXOYG8YT_.Z4DK^D+UX(//WV?#GYJ_$IKR'"T QAZFLY,#/KCU=)
M$E>X=1O<^C*=L ]"1A<<1=H(A;A,$$TPCY'$PD;A(=#  %E,U0'(+B#6NWE7
M&!=H)T7EVT^?JZ]\^PE\>Y+#!W!.TD$T(96!X$*)B'3"$ UJR1+S(<D0(+C
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M6&&X-QM@N"? 8%>#$V40!> [*@W8@%R:DBC//,E"(5PNBE*'\M%CEN5;+-^
MPP8<-M;$3PT.RQ$.7@07#/6$.:E!<Y"<Z" %,5P9G_'2B. V%L4&&S86Q0/
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M68+BI[0@TGD-$H(Q+LL,%'LP[ JQ5:X1#%\53+X%=OO!N2@;X-T [P-*Z]L
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M?G3<T2)K21&77\_ EHU'!UB4=& WC\@ JH<_@G^>5/4Y%X49SQ-6^H"N*YL
MM=;!)UPP('00\YROAW[^H1IM#X 9%HT*LIXBO/:$EF@M>0%A*?O^PTQ/HSN@
M_+T>G(SCUL):757#,NNH+B5!FHX?P/$BK@$BB6H]+AR HH+;)R*J0J@[M]B@
M%57P$"0KV/^V%W!+W1WU;0\&?R[Z3AW[\^N+Y/Z_8%8@63,5-X&F35A:6V\A
MB98U'.L,A0G<:V<R\8"W>$+-W[#U8[M]*+-GW0ZA*E\W:^BV.NTPG%*Z4[U
MA0I;/3_!EHG5-3L8GT-;BKVM?Q#>+CF:X:5WYD?8^)6J%C^^"_9>2<XW0\Z.
M7$3B&3 MSP-G9U@V8K3[AG6<=E/LO)HKOQXIVYVX9#VH[F*A<VK,BR!ST3[-
MX=^TW:/7JRQU"?[V'GE3")Z=HO:Z.(>\UY6MH;Y.>,7>M34\\$K@'778&W0U
MG"=%S247I%_J,MK(.%C^: 27+UKXG@/@A?MBANI:4JWTFNN6N]\":,U]!.^.
M#HL^;/U8[*YG*8#SR_GS^C6=%SZ/9;\_]0$(!:,NS0)0$QVU>XH[C(V+J_I#
M)(&QK>)Y)"$0M=O8_#?>C6>_ PT>'?FZ[>*[Z4!Z>0=2NNE >C?6\AT[D%[I
M0E]QN1=%\-IQG?$@A M<EUDP3KO,^EQE6,MQB0;R@P@;T.8,$0GE#Z )B)\(
M&,F!@W9 !!_Z^UJM\'*M+T8:L=']! /8Z/==:*  CEZC#R--4;I$(>V\*>@T
MP'[>,4P-2T57TCW4[PYZHK93GE>4N2;.G?QF:!1URD9RL%RLZUVE'2R;E9T2
M_>08X^C3L]97]6H6.X\L#$I4V- !E$RG5K0E!UST4[7=Y*..CA)^JJMZ\:3K
MZZ"MM3 ^[W?H:R2M/GR9A;PDP\&PN7_$LI,\YS'4?\'&M:[8Q@9<JQ!..[=H
M8KH:4\(POF-M]),>82H")C. !I:FWJQZ)U%?[,;4-*-$HD,SJI+3V((?^T&M
MN\;WLQ+T:-F1YZ,"D"@ ,RFZ.PS/&@ Y[YU+U5"MIVT1+PO5",BXBE[*46M"
MX;;T'7@]Y]VTZW5<I^OZ#U]TQ)_HV.<?M#,_0ZYM,CNB&SDNL6L%?Y-QO9P5
M,O.Y5;D7TDL07IH7//<VUX6P"F-=Y^L+=O?_7 IV 5U9#'B=PO-K/UJ-=OT3
M=G\1=SZ#XP;<&>[,GNCI%-_I7WHX7Z0&9@\NPG4$[_+V].#UWNG^TQ=L_^F'
M0U%PH63I"...$:&4)DI[053(*(A\6X#XO]%@4%8ZT-5S;Z00@MI<<B_R7''*
ME?#.%NMCFIMS_L;G;*@-U%!#6$DY$5E9$)/A+&7*0),4FI8B>_1X-#X7U3P?
MYEQ$@AH75.W;R-2@F0/SI&___Y'&2PU>'7N/X#P;^"JJ/NOC[ A3*WW3J=J^
MGBR[V]'2/YL9+@<=)-_/D"F(@215?-+!>C.(FC?$H!DH)CZE5+1C_[K(:CTW
M[YN ^ @3@C#+8SA&-P<*]T:"'<V'_91*#"0N1%3C<HCS9<Q9]]S%0)Z!/FH'
MSDP7+H:I2U$YW\O3'(/A.HJSJC!8EZ+T*1H7 WN#:-BVTZ2&7<IG@(>-HZ]G
M=MQ/S019C=FK/T-T?W<ES;4W>NQ^$N[3Y!Z+QE47)4>\:G*2&ET)HS.8L%JE
MW-\VAS2V($S)1HWU8EL1-+LT)5C7G;7G?&VGE<$I.AZLR^3R; ?FC&-,]^+[
M@ $"SX(EHKH&2YUX3""(]T"%M__M:-S/@FW"N@ME]=R4O&Y\TD49OC%](#HE
MNN38"Q>:IOP!/"SVKAD$F=(%ED9<C>LTD<Y%9]]"NP>V38'\EM=3WFVC U_Z
M]"9^?KT=!9@Z.H+]<W&Q)S$_!X/KZ+&>Z;1=O3R)[<$?WFH<WY6Z4@)-'$5S
MH=M1?/1BIR]^.CX<MT5'AV@:8#<?S:ZR2V*NQ\=XS+#:3W%4YO+#XTB^\<J8
MP"_6V[W/M&2EYEEPP@FI; AEIE!G0*6!_P!][N%EIKW(]M^_.:0JJ$S;0#0K
M,B)T@+]I$T@HC)$E' EG_D:Z>B&"8K1@3A@E"A9OX*3)>:ZI,-K^ )OLH9YM
M'C+LI!5()L $$WE)B7&Y)EPK71:2TTSG-]3/4<M9:.A]V!M?0TN_)!-VO89^
MKQ2>BT+12V =S1G8I)%/G!0=Q4^Z)+U>(<W]5(=VZJ@-=TY8G!AEF@!$?V16
M?&^\ J\>H9FW-$'9MZ,6M_I)UOV)G+Z) 8/^',4RCKQ,:O[S9W^=)36_\WJM
M2/HTP#4YHF;>'H]@TXZJ9F)AG)T)PM)%(DZZVD()BJ^PT"VV>B5 ^&/T&H-<
MG)[$6;Y+[Q=S<F*L]0B][[.>[7"VQ%^8@AF3.N==VJ/N36F,@T][<TI[MO,O
MJQ5(N("%VOEK4V@64&--R8P7)8ZNF=2[_KJJ;@^HF^*84O7BZ;EV$>TN+"NG
M5VI]%ZBG426)^;7)D&I\^;T9O=WT[;NGR%Z3K^]*ZN+Z7.9>244RA&/2JS^J
M;)_)H]8(J.^JF,F,FYG(HW$RH]W4KV&<@/TT1PT>;MLENJ\.Z(Z;?46I'/XS
MGL<,+T;KVT]1NXB#8-&N;B)T"Z.K*<7L\]=*I>+JB.N%V04WP$JU00EF0A,A
M^!CMMUEBCV8TN4O^ 7BE5!3HE_*/4H[LI6\5%]_6C+9NBGG=Y>S&W5[L/E[>
MW-]_PAO7Y^AR)4^Z<4:8H>^599XW75;OT@<OYYNH8LM7:1ST5E.7FD($:VR+
M9)#=PU#DY6;I]4W19?%W.89LG:,4N-V"4!Z</:F9-F5P!><B%WEA=*GS,L^]
ML'FPN<LV<:#O'Q]X;0_!].">!T6$+4LB7":)]DP2)FSAO,E\=L,X4)%S)C)1
M:N&,L#)3U+/2:U-@[T\M+ZAMVYSS-SYGRU7N5,E)H*$@HO242&]+8@+5ANL\
M4S>. UUL9WZS:-#/9VLBV+Y!+>AT6L5(&LK>76 O!/VVB'.1E?NJ2XZXGZ;G
M;G2>+QG6,;U6I^PU5"%G37F"'U51 ,,+8[:M-[->:L@Z[_QUK;UY?[O'J"&G
MW9YTN[V%"G%?T=)H5X"@A/\NNI4D7:"-*YTS'=L+>^S2UUS[7-29);WS'>RD
M2A>J.$_K20ECU^HK\9 36-DF@?5NK.4[)K!^>4+JW1863YMTR @L!QBI!IQ8
M]5;>3TFP$PMG4^^!!@"[HC[X3V.$8E5!K..(J;I)J\!&8/'E([WLCH#T)IWW
M$BMJX*(_SM"*BU)B(0[PBUXU2Y=="K>).XL57U$E6?P[E6-[7_?K@#'%8)9T
MG\YX_]B:\[%$=PI::9MK@*'%5+%]>MQD!"=K6D^TQ4+9Z&YK3;!;<W%5YST)
M%4J:IO=2KP54*TE!:LVG44>;C'$^7_\%XJ^:^JM)JL' _<"O_"BR[KQN>GK%
M,7Z813EM]1LT)IMW2"^%_N?*88Y(/>^*DEIYVY4KQSMI[(J%7Y]BDX71T2A*
M\=!X.W$A,157XYU\[R=-\5&;;K*0VG%[,5\R9G7&]^JW'(NO?M9SNL3],7Y8
M^9CD?;:DZ%ZRV:?QA-#Z-K[S<6]U*2FZMQ9\G_D$EWF3)B+,:JU9R 5FV 45
MI*/6ELH&Y36V5KR>H;6^BTCLM=A+^X@::@M&.R/70-$J$CW'CVR%#I\''-BS
MG_8_'QUZ7H#%4CKBE0;KVAM#=(GAVY!KITO&RB ?/:;9)0U%$"!18XP;&N'F
MQ$^/?)(&V@+C)^6LTT7;KA0W(2.C078*E7D!XA@3='4(I60@L6TN7)Y]12^:
M#15]#16=[7VVA\YG12%R1\!TYT0H[$KCN2*N]-R',CA @!M342_#?IER(F'=
MA'B4+TL@CHQQ%D269[+(F.:RI%)FA@M[ ?&(#?%\:^*!YQRR+'"&;KV@1$%$
MSC*B>)X1IV29E0%48VYO3#QP%;F8@/#RE'RUI$N<]0HC1DE:QV^[/C%'%:9<
M1G4C9>G!I;&B-8GX.HK_Y.8&A?%D,FMJ42?SQI7]$31J;#NRM:Q';,6ZC4Z3
M:O6#Z'G V"UV:!IAF>]@N&C2L@C^)A]_6@(:[VTM.%9H72=K+-KM;?KJ=8*I
MM]DU$H>SW?VND>J[=HU\A77<J6RL?A:=3;B2.]@P\O->"QDG>T_W3][]]199
M&IZWE[U[^O+XX+5E;_]^F^V_'YZ\>P]0\OE?U<$YR'A["L_X\.[]+D"'S?<^
MPWK^>I;O?WYW_.[]"W;P][L3@)+W^W_OYO_^_.QT[^FS[)!9V#<-$H9JY4%M
M<9P89C3Q169+JDOJA#O7,=()ZA1<P 'S"RVU"GE1QD*0X$HN5CM&]@^AK?!.
MAS'XDGZ15SY]>;769,'93$DM*8:B%)8C&1VT55DNM;FG_2(Q/PFV).[MO?4(
M8(G_O*Y[\7J:I>8@DVDU'/!>6Z:8(N!C-!9-P1J3$FR3<-1XDR]49&+Q:'VN
M@$EY[_.R#%2 355*5RJ9L:",550HT?2I%QDG[5]N;E@MX= NMFMP*3G]>6Q2
M\2HN#/8Y?E7?G0C6]X>CSWLO#@V8MU(81J3R ;3?#&PHJS2!8[&,9])RJQX]
MEEM,BJTB6Z/%I(->)+I%%DF]/)+IK@=QRQ?=LKO<OA2<^&/O5=L@JKD77CT?
M3?U15>/\ 7>1IP&%" &K/GX-JH$#AD8=9J45G[Y<XN5&>TT-V)&Y**34U 5?
M&!L* #PPTM;2Y&H8U<VG*V'4J%M?1(+I55Z/_PE?OYF IOT*5_\*%_^\6WNZ
M]L%1Y='9_M.WG_?0.'M]!/]]<ZAI!N9\#C1),T>$E04QF@JB\U)[9Z3.L^+1
MXP :)CGS>KHJWYKF-/<KL+E> #42'.00JM1)0#\?ZGOKGYY=V \X.DS=2O_?
MFPF;DEN:"6&=I+DPFBGAA<R S8&UO0WN:YQW_0[IXU%D\R=Z@N>8Q,M+0+/I
M1^_^'$__C%[9W49X/F!Q \;SBT-OX]Q,4'9%R(A@,B<&9 RQUO$,#"PCJ,!Y
M25LER)MLG;R9-EO;$SQ]H;/2(3AE33:_0&'0:3%).$5W>^(JV^<J;""%L8KN
M/E]!B%_8BII?UX,32>X/3.SN \/.-'920#G[Q]GBDN<IPK%SJJ?N8!(-8I _
M0*^QV85WD9;?P/O4!_-9%*H A0^8:E_D>SN'5N=*V*P@#HPSL-B\(=)3#U2K
MLHPY.-T2)!#@%IC+ZZFV(5;T9IBD2F-(;M(DA_I/6/;0UDQVVSX83[JTQNB
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M!'83H*C'.1S$I'@@*@L9H1K,4P$$D>OBT6.^+B>]:=-ZLY;/F1>,2^S;6T@
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M;]]Z]X)Q"7B9%5+D4FE/.7?&%S(4H/.'C?5^=V'U;0>K5N;"\Z")E YL>!D
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M%'[] (@8S[S1^ ?.A,MQ(K8V0I?*"%D6U#CK3"E%F=]:7^J7_5TZ",^:C7G
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MK=XWE+HQC[;(\VI[_6*>Y)W:,5;"$?B,,BSM04;UU18$L2N396[R0!8Y('^
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MU*^<W:&&^)5 _.6DXT:EU,PF@RCQ'G$<)7)6&Z2L(PYL<\>TS]10JXHK/?T
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M#Z.BG!OF"5.<1V!%9P6H!L88@@5)Z1+&I&<UQ1>#OH=Q-$&RM]WZ,Q@\^0/
M#7+">8@^.-;;@[E\. *6.]K^M,W \/JHL"0*UAF%P+/AHS'*[CTD4B)>DQB3
M<H^>L?-])O[S.\'#A7MLM6$X1H$E!MV/6(V#=U03EMNZ*<7:/5[.'G_XFAMZ
M&ZT)CAP9G(\K$*&1I=8C'&%IRQZ0].@97<*VA@CO<C(;'HXGIRPV(N&0J%'"
M^]!NZ[)8=\YGL0GLN_<Q,HZ-9@F9$$%HLDB1=9H@!GN1C$O8Y# ?.5_/]3\+
M<E\3H;D)0AJ!@^6<!:6IQ(QQ)CDC7/K8;O.RN'?GZ&-R4@8E)0*> E!F-"+M
MM4"4:N>B]<&XW#1@ ?=.\YLFJD(G)_@<-DEXO>-.R3699HI\-U'DC#)P:WJ
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M;73.(GHQR*X"/\I5_J=6T<NODSR8S9S94I<TVQ6J7/%CUD]3N6+ MK>>]SZ
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MLWO8]")V/KWY*(-D4A"&I+;9+:P]TMH9 "T<HR;8<@Y6=<J2-/?G.-^Y_D+
M.X=T=>X='%JHNP[YOBMKUF+=.:S;W?KP41$LA9(D)SI9Q*,(R.*DD26,&Q:!
MCJ6YDD?HGF#=66)IP6Y&,'Q[:^\C;$CR0DID(@N(D]SUDOB(B(#=HQY$I_>/
MGM59U[P([7X#P[B7]>/OZJ4+S?WR:7;RS"'@X+0-<RV\FWHX#NQG4(&S(HQ&
M8%]-@7?M\&_S1(N?(^%F+BWL3:AX-[==YMYQ+D"G<XD@CDU"V@F+ B<F$HM-
ML+GMLEIP%."T'QRL7# 1-ZIU,_S?S\>5<O;*EVZ8^-BF9EKC+_H2)P[>O4)K
M0._ K1:0<MXM,XRYA_G$?Y?Y;0Q<.G'UP0H5@[_J=>/LV^SQ*Z9R,>@F6295
M\4R!+@/WG&?]XK$Y__&KU[\T:11UW=TKK XL^24>%YB8<T4TK@P8RN @-BZY
M26_6J;-PT:.KQW/H,AP<V][HN*Q'\W&OZV%.8(!&4)5<K[LWZ2\&3VR^&@QK
M&%W\ZN/AZ$0CZ];92>F+=@6RJIM[E&6/.TP\1#<Z^0,T.L#)TL)L[$"8@EF=
M<;/YL$D[@DG'TUMQT4S6G43CU\,N;%@U/IRT>9N#Z+P@YUP2#6=V *Y[^7,0
M14" L %Q>) =L]F=4$\)/[L,0VQVY^25C5H^&\&!/2Z>\-D#8(-BMQ!"[B37
M>+5M5=L4X0_X?3\"O>QG>@2>FKEQIG&8F:X.#RJ$ 8,XC&7AJV!'MCH8@*P9
M#/.^3J,;@W+UP;@PSBQ0G/U&0)-E("<^E--C+Q[YRR>0\Y"*1R9G4_O]_$)0
MY08]8'M_//7]^]R7+@[+71MM!OLE&>S\X@SVZZ3XL$=MWON]SWM?B30M<:MI
M6F^:9IV]XVP8]'TW*Z^-&@S[L#HY6]LSK77K^>=__OZ3['Q[\VWGVQ[>_O2&
M?/C[S;?=W]_DO$/0-CW9^?U-.4A^1FL]VO[];>^?]W^RG:UM,,#?P+5_[?^S
MM<W_V<IYAZ_PSK<_\3];^2#Y2_C]Y4>7=,!8*20BR<ZEK*GJY!!+6,("2R>#
M.9NT10WHLD9$"C\XK+B6*GJ*F168)6G\N:2MF#4QD <G.U&=;$6UE071XS_[
M%O0+N.:7'\CHNG0\ZY/1=6N-8K_/%!ED'C9G;'\,-H")+0W2S 3$M1=@PW&"
M7(S9JE.)I'/IC%&E9 &S.84M KO<&F)-5#)Z EQ&SW'&)2U@IZ;2>,H=U;]/
M."B=<%!6Y3:J5XWA,SCL]D_B=K/[NK/-S2^8/+_$5DM8%2;5S\%NT+AFG8YK
MH)W<^[@[B<B"]KG@<4T$,-L'.?,EIV:$3^-ZU&C)_9BUYAP !7UYTC6\2K:;
M9]"HI(O&!1ICG.1>E!0/4,YSA!34W%"EWCA;=8TAU&TF/5L5>,.X-VJ2//)=
MOL1ALPDU?QN,9;IO4R=1 HUW&#>JK7&<&&QUG+/$$ECG8&P5CPZL6C=^B4VT
M>/)J@!,T^;51I8?=>JX3=+8_[6ABRI8!%K=0$].L#J+MPW=I/,F+R>.97C=U
M2.48ZO0%6=N>W#KU4WTY.2G23*2"%Y:5A37;J#9[#95D__M\Z^"IY0@75_4^
M;/W\?FS\ !)?2O^7MB/^26V%M6 _TE:8B UJ]-*;W^H-A<U/:=1+V[&V8VW'
MVH[U9XR5B%OIUTW)O>K775VQ'_4#7)<S[:;OOIGY9271;\WW=^G*%BOR#;FD
M']/J-.U>MY6E[<K^I)4]6V^E7=EEK>S9., -9,W#6[P62ELH7;>5;:'T-J'T
M^BUX4L+)KU\+GM?#03Z;5M6V%^OKMN!IYOQPZY!?=_[WILQX<#@R[S"A$7//
ML5,Y]9=QIJ*"/\^&IS![J&7&?S">-2DS_FWGX!7=_?U/\<_?__-YY[V'>_SQ
M[N\?.+SK:.?3YM$_[_^DVP>OV';W;)GQ;?KA$USWOM?[</ FO_-XY]LK_L^G
M?1C;)LWERW?>?X#Q^^/2RWY69IS;:(Q5&!D7<V,'EI!-0B"GF:(D8.&%>/2,
M=3B_>?OF:_+/3V_8<!K#K]ZPH<7!!XJ#EE#E&';"LLB9C"88QIAT.O=8D&9:
M29=/<5 RW.+@*N/@K+<-9\)@QPQ**O>VR>7]C! ,<1R3=]I+IN2C9Z+#]<W;
MB+4XV.+@6N-@H-$G$SE/S )#* V_JPA_XT"2DV2"@VJ*@Z;%P97&P;FV,S90
M!]M*400J09QAB1PG!#D:F+"2$X9#QD&YH/5!BX,M#CXH',0X"(6C$RD%KCU8
M3\9B:H-GU'DP@QL<A,<^],:RZX*#,WV08)M"H!IYECCBUF)D@Y/(8!% [F%C
MG7GTC':T;NWB%@<?. X2 J82"TEI23F+V*G(, TJ$L.2U?1,+>G6/[CB.+@[
MTP<U8XI2IA&G)!]W%AH9^ P1#YH_EL1P;1\]XQUFSA>O;G&PQ<$'A8/<AF1)
MD$XXP4$3=&#Z.N,PDY'*2,@$!_D4!UO_X&KCX';&P(*%FQ^=\"(&3I&.QB-N
MDD,Z$8X8T4I*2X@BI@ AERT0MD#XP($0F,+FEE=,)"X]M81)QAD/)@GNHYP
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M>%P\P#Z[FT YNNY?(>_UMO+4(!_+E.XA']L%UIJ(M8BU":R5OO"XMF=7?&O
M?G"+S(8A90Y[3XB9'1@HXL37Y4K!:)QJZ0TMZQ"QOH$11*@DU(;<9W,F<]_'
M^QPOW;/$_O3-ZBV5,>\?;1S%5\A2)?IBJ9+KS]$&4DLB*+5]\J]VNTAN2P\E
M9+CYKL6<%E>L8O6E[$X!!Z]DH)=9 H>6V.XVLL=7%5_:@CIF ]!3%@3RYVR"
M9ZU@5!$\\PZ>;W)YU#73+!O:>=]L-*KFC$>Y.X0D((LQD0=;6"/CVPMH81&$
MC9BHZU@$(>>(B$40L @"%D' (@CR%5@$(<WE1;U@U'!YD>?)]!T>/$.#0PD/
M7KVJEA?W@P&WF"I:4%P(FI*Y O05*XHOW/;<">E UMC)-#+U@7J!(Y880SY6
MMN0B5C#(&"1,/7:-U#UV6\WNZ+1[I>>GL74P^K1RK%Y=8545%XO%I/@<\2%B
MI24KGR0217?<B53_.WDV2EZ]IFH).I 0D59TFZ&7]-0!"3E*=MP64 G;T*>Y
M/:-Z(US5/4%39=;#\8XF_#(5,"PC&.8>#.>IF1$G*KYT'1_<VP+'VN*F,53/
M$#\[[ ?W ^8)EO40]FQND:9EN:%@8,X/*#4W0H3+U.A'A'O' M0P$=MRC&U;
M>'8$](E%J/LDEI>P 4^L]#V'34A!W"\P#HQ%'):5?0:Q0%#'SA>"H4$HEI7@
MU/N :)<I?4"T>P>?*^/B-O^8)^WG,:%[%H2N'*].+Z&C!U!T(O(J+5F>_N=_
MU V]]CL9>]RQ^)C:A#TS*Y3F=E>:X3WBL;]"[BDK6R>THZJ@>IF>Z6:!?B"N
MESQ<Z:O#")294B($RO<!I8% >7Q :;P'* ?2N<C%7PB4")39 \K4-FB7C9+^
M6RYDC8#Y.L T8K\'!&2X3HQO%8W,0"@Z/;(US!'2WA^KII>ZES>_90'6]AA\
MNF5OM&60,OG71>>6/-)GUW%'$])Z#ICC X'J6D,VHM,8QA(YA=%QV;S-Q.A(
MN2LV#(U+:ENAK7CV+7=^]B 2Z+0&RFWS @?*QH%R2WO,/M4A\M!I96*(9'ZF
M>? 8N*PC/#GE(7/5NL8AL\V0N6(#[O#M)J#I-_SCOWO>>7X7-%N/(Q/'D.R)
M2U<TB3S0'XRT84\05?L/KFA R36W&2D,7&]$@VBO,T\,N2<># D=CVWQ0;#Q
M+XB'()L.0>ZHN^%O2[2%BIO[XBB)=G7Y1&CTA]6XM;!+-Y6%W_?W_;>@:7.#
MY0Q&QL=J.1XN7$8C?3R#(REY ?ZNUKJ+_X+Q0P@1A#G@T$PP"H]=3]I"2$$T
M/:K\WIN0GAA,/UF@$OE2"*SB_D__ QE2,<!Z$-SNCK@<6 //'9%@R'T2&89@
MB%#+<KV^W-0B1QI$*'BAK<)/X4=4.@,"4N$-K6=K2!TQCB_=T8C[,/Z6H%P.
M^GYEY[\$^4ME ET%0[OECL9"WVC@>A,RMD6+Q4'J>= 9$NMSV F_K>J#"#C4
M#S"_0A!+CT&$WB#T'.X/ :C$</"'U+:)XP;B+.G#MHL^Q+F('^#?,$3C!;KU
MY=_Z[T3 %!F'WMCUU?B:-?O5EPRYZ7!K6C*04&^4S2) )(5$.ZQ?!"FXXB;O
MB8N)UP][_Q;/C$-M;$Y[W(:Z+_+)-""^>F-1--F+&N^'UG"J$?-?P1VA'F.P
M:"IM2T3U0!E:. #1C%%*'U\P1S5RXE:1?D0%B.P((FVB\Q_Y\FWEA6];TQ]%
MT6J+C0.YC>VE"P+95M$\^6'BM4)JN1R<*T=GDI$EYSXQ1E4OB[Y@@&9Y_.R"
M/O4*'_[UO\_T2T4OE4WHB/9*+8@4[65&2DPM:YR>3<<)Q93683"I$2&Z:R'$
M" :TLR\2*."Y$R8>()5ANHDKPB2Y7U.KYU+"Q@E(^)\A]007L2>KA/S/J9#_
M4I=&<OX<.I%#&^H?ZHU&/F5<1AEO*V/8%)5+&9LG(./+T//4KHU%"=?/OA2C
M&5<<CS(7JE.J*K16SJ5<*R<@UUW-P(U<2KAZ A+>7G.G^^,-7>V/SZ5,:RC3
MA$RCPJ;J5%55-\VE6.LG(-8=@;&NYU+"C1.0\'+%)7,,:DJ+]=HFC<4$FM,$
MF@8FT,QY8.C^$FAF&/9T+3.X9U8/CWN+]'-;Z,NR3+-CO#VT3%^,/HD9+:I'
M6LOQLD+/CK5V?R)=2D#))NXYS9J83\%FQT2;CJZN(I^&0F SGU+-CE'VP.JZ
MW7HQUEDCG]+-CFEV]])=Z4\A&UPI)/*BY%1CLV.,W9_&OME5UF7C(&GH49*N
MY5/2V3'19AJ;<TJ4LV.I/;P>KX/HJ0I'.*WG5'NS8Z?-N'SSZ1,U3L$>]:Z0
ME9AG5?,IWU.P3;U+?V<H5DZ5^!2L5>]<)^DYU=]3L%>]1;1WU+.&,W[P?!HW
MC%,P7>V$8.4SK- X9N/5NQ4XW\X$XQ2,6-LX<U]J])J1.),[=W(IVE.P6KV7
M4N54:X_99/5?<Z;(+0R/C1+)XU[>9";5S,CQ>LN=B%&)W\ =?]2AM.?,TW2C
M.M_/\M#^.EH^\2,/J,VMF4]?7F:T+8A99#NISB!]\M^78(*NBI/;IC/V^I5;
M9*!;_/>KZS ,R-S8?;I>7AV0"1_!^__SM\T!?WJC\;<]AG%F-U(S];8<JJJY
MA#SC &J^'+JZ[4]?FX]_=%K=K;#9F /B%.>[A]#S0^I,TQQLS)< %W6B1 7B
MMB'U23\47,^BH0^I#B GB*=8@DI[ #5*%)^'[#$]-J3V ,@(/$@.%'6!?++'
M0D?<)1](PV#H>N)3Q"G!2N#R2TB_ *DB+J'&D\S$T*51RH=K#Q)>^Y9;)%U(
M6R#'D8 P054<3I/+B2@RJ2(#"==L<X@D%F'J=/)4L.A!'T)Y73EFI_ K2X(+
MV=ET[+./\1^_][D_MNGDHTK&<R9O6I)@*4*6<J5DJ(KU4?:FZ/&;B]+K6JFB
MU_=1Z]ZH&[NH=9^'K/H2UR\F'U^14#\/R:/D9YW[YX1\V@O!G:\EO[P![=N4
MV+5\.[DKD?TT8+NO;UYT_KB\:77:K;?G:]LBIUF$0W*N&0=$,$#>)_''95 %
M%R95V5F?N"WE105L6V)NX&Q&(W?776_5XM273;*;NLSA8CG^OU"5'G).RB1?
M17(YY&Q [L<,.)GS@ZBZ]9XJ+J].7D^+1$0G%_MW(9U;_+U+ID)U[V(R0IQ2
M<4H]]BGU<ZI3ZFV[^375:?6B1!Y3[(&;^[MNZRM.J1OGBL_<MKEX+<AKZ(Y\
MYN"4NOV4JN9+EIA!$]6&#S6%'M(VF!TSH+D+,Z LKXIFP&,T QY^I"XW!#[<
M?VMUR/TU:3X^WG>^MO[<UAZ8,?_$EZ_WWTCS]I8\M#K=^Z_DXD_R>-/JMLA#
M1_S[];%;5#E0&;6&1*PQ?-<A3T/73Y8DIN,QHQZ8_&SW"?+?^@$/!-Q$Z87'
M8Y<+X9+%99X\OSA5R</RA2JWZT@F. 5[H\!JR(\:>*&ZUZ9/@] F-"J@[)^)
MCAY [EWYXA\PIHHJ1;&X#+(A1Q67_;"GV@@90.%:@?V)0T7I]QSR4?Q"N(0[
MR28X=,2*D-(WFB;\@%%EOX0$K_+UXH46'5-+&EF+8"2%+ILY+Y.V0J977YEE
MQ?,W;06!6\6U$#NA*D/+AJB$W[8=NW=]9605%\+ULUEE(54X2,E1:6W5E?"
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MSI(P^QY^0"S!6^FYDWKB#CHGAK:)<23JCA>$XSM:E&-V!)G3],1FQ'+CF2E
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MUN:57GFL?@AK3"Q9IJHR?%M/]F"((LOV 4<?VUXEE\++P!IG^+PZS.DBS))
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M8'_],4^__.,OSYZMU-'-)O !\K/RW\\?WEP;<@I_+GSWUS@[>5Y^_?S%#,F
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M4120#%5EPTWCI$^%(>A/ SH&C'/PVB7=1$$-91J2:[<_&V]G0X9!@HJWI=9
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M4<5 4LXX"PK+28B2$64U>.H83:))P<EMP&U#+/N3$*N9T1K2Z;SY]C(69!G
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M;T,2/C-;Q;;=!.C9J[T72=]E@.F; :_]=!@'GO%L@J9$A':FJ"O+C$=XGJL
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M:=*D>9R=3!81L*]^#*<#QUGRD"F15*'+SI0F(6I)>%!4*)HR$K0#(?#Y-\B
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M6W8=<:Y(,0F9<7M3C@4G?8XVY,0MQU4M@BZ%T#LA[D6>N[^O#SVRGFP[O,\
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MSG,;W7V!\;"9M-F2D#XVL]V"A=8\96^Y/X1L1:K24?PAR>31)LZ:6H/XH@Y
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M3SY/)8+G0S,^1=J=E^7EZMXW*.53,H ^2<@$30L@GLIR@!^IY=D%%:O8=.O
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MQ&J*7Q3#_T'QQ]6VQQN4N?[YQZ'-'F2W\=7L_9;HMA=RY\A[C[N3!Y_<TWW
M=C-8N130U"94# =%O13&> AHQW$:.8O@9!YT'*/'FP&6L\Q),@(\X,Y@I"<^
M"B!,I.04=Q)8MW(:56\&?H71$%U52 .F=0!3^F%26>YA)9J^T5#",LL4@J?"
MZ4YX-X_QR%[^-AJY_ZY@-ZE5N#3X7$X;3O+OT\MVF"<!:3R&]'[\]D<\\^-3
M>-=,;I-^V2WS8B"H\"S+0%C;!14<(X'Y1'"%M,X)%O"%JF':[8'Y&1+HT)KJ
MVQK\."\".LFE$C3$^0QY7S;7Z=?F;;L$MU '@2;O0$0BI'"EHZXB%I(AZ#&G
M*&P4SL=.BT>GX9XA#2K)LN\4UQ9!"Z88L@7<P$:5G?.4 &1;*EA%@M:4(LKR
MF*.RTD&W?>'NLY^K'O>44H\7 _<<95'F5'31$Q:\P>U):&(C<))!"Z-0-=JS
M3GI[.H>Z.RML?PD]^4-=R:GF(>E2"$$3&9TDCN=,7%(IFV2,E55V\V=PJ+N5
MGKL>ZFXC[P,?V75 ]J]#W6U5N,79W0[R/RQ#$A6*!2.(R$J0$JM)@LBA%*\#
MII4-]&4?ZE8BQC9B/]"AK@#%C*6D1"X0F7&.03A+HE+@J3&*KQ:U>K:'NEL)
MO\.A[A:2.]"AKHXN,1HXNH6BE,910"Q7B:"#F+GE5AO6K8+O,SC4W5F;/<CN
M<(>Z2W.FR5>QBWL?Y][SS)X.<KNB7CG"=5X%%4(T2G"I 0*@DID1/'KFA+:#
M;?!O+^MW\U)]]3><]?G\_%;@8%X]F)GNK81=!NM).WO/<T5MU$?'5-:6<2^U
MSUZ$8+@M2;O)"+/,=-ASQEOI<W%N-H3I9VB;(<Z:V1E\\2.8-OD2R.?FPH_*
M)W;2X58#[*^WW>>SJBMI>8R!@_%22HW?2:_+%8E215ETL//,JNEGC\R?'88Y
MK*XZY!'1;+FQ7@M\PV0":FD&YEC45(L4(MM.8WNF&VTS5-]927V-?5@-[YKC
ME%14(F9/I7%24.>=-M'8')Q"VX2+[=1>*Q5J>3^Q0/"U*<.?K(Y^?7PGI960
M R,F0BGCI20)J53U"F"=$<Y%TRV$9-N1][*V/TV:")"F[] ^O1SF4X/*F@W]
M:&6\R[:8%I*4T5,B7&9$AJ2(S3A594LRJV5,KM:.V##++0<^]&%Z3>W?,MEK
M*J!WU^RZ:&5;LG1%.)N #Q+S&I$FDHSQ1#)G2OFU1#*SX$6,"+VC[[8;@*,E
MSR$4TO=9S<(R_LVG<BG\VQ#7]%DSAH_-[%4\&\)W2/\7?$ED'S!I1>8\$Z.,
M0;%P]%A58B2G1)V,8'CLN-9T'?)HB5)'Z'W?SW9#>3*&@00F3&E59W7B1+:-
MF3T5Q,G,7:()/8%N;;LZ#_G"J;&MT/N^!;Z<\<6KTPFT5X[EX Q=:OQN@?]7
MF,;)\%M1R8"&A/-UBH"@N+PYJHG3BA-T!S5EB0EG7"=V;#/JT1*DFNC[3O_Z
MB+N@GYXM\'XN95/F<+]X!@I"MNAT$,%DB7>5@00E->' T",!D67'UH\[#'ZT
MC*FMB+ZK("_P+FLSO_WQ#<;35<#74(/GEI?5S^A4TJC0C@I,1 )H/D7&(%O9
M;7G9;MQCITL-\=]EBN[#0CG)-RSO*Z"?YI-XYJ>EW5G!?+5@OL]?D0;3MB_J
M=+FI#K)%>XK+1#BC*"[/VEQ]2AS71J12CM!U*[3='Z:C9=@CJ>TN^\PCL^^&
M53<P.5!9>DS(TK)36GR9G+>96!$"+L8^V1 .1, ;L/[%P=Z5=Y>&=L]HB_:>
MZ^8\EG):7GM]!$CMO/S%US/X=9@S+NWC"*]A]B? ^&I2TX%C4<0@<=_G+J,\
M!3H5-%!B9)8.?0R0J=LRV">JHR7AHZGN+@?=?J'<W41V&2(9$J()EA/N74+'
ME0?BL@_$"P]4>.U2ZI80N,VHAXDA/AASJ@G\J<0>EP+@)_G59%+25:ZJP!IO
M#.[XC"C%9,F'9"1(Q8A'0Q/M@"1UG2X9:]$\2M1Q/<4W?2N@0ISI#3A3W)S1
M5?'7O[FQC"ZKO7>!6S,\>4N\CQ.SW(.FF\.KZ0FP*TJ7%9>4,&D-.A\E5<Z(
M@$MX0!<802=3I8C>DV#5 _'.CT^J;;33^ZW:!@>B6# +>%*APU!V?4M+GJ5W
MNF3U9Z+08Q4L))=EMYZ-#X]U^&C:JKIJZ@FZ[ROZS? X74Y=91>T2 BJ+1E1
M H';UB2,<M <K+'=;N,?'NM%\F G01]J/5A 4S9:FPPGBCJ+;D#4Q%.J25+6
M,V<]*-'Q[.?><5Z@_G<0\,9K]#Y#[K<)J?LR/S_WDXLFK]K^LV932,F!@A]W
M1W;8T,B>)+@:.,E <@=.<1TEXRH LI:73!%TJX)5VP5.[H[QD&&5.G,1<6Y$
M!<W0HT0K+@2T4&5*M*1.&.V[G0\>-*QRTV";!%NNP.:322F@JI3.2F5%$H]0
M"J\8XE"YN'PD;7A2C-N.%0EVQO#4CS^WX42G0ZR>U=*W4;>X2/^M&<-L^#]M
M@/,R;'2@5;2&!4FX3YI(!$:\HXIPD+X$5&=NNEGU]PQRM'SH2["]EZ79(8!"
M6XG>K/ $HD6")F6(3TA5EV-FVDC#;+=HR2.,9-F9(+45T7<$Y9:A%.#:$IZE
M6J/@I;\I0A5*E@HD+KH,UOMN893'%<FR+UUJB+_O@,I/?E(VO,_P;7DOO2!Y
M 7FU")8\.F,3D)2#0,?59N+1\"111&VM @ZBXYE1E^&.EA?]"[OOV,D]+"/K
MA#>!M<7H$Y&E9)$S/A!:3EY+@@I MW"XO@S6':>.3SP9KV7 [V-_WJ &_P<Q
MK61<#(2EV5O!B!&EWX$*#$U"7/<-3=9ID05*8*O9[P3C:-^<PRFG[U#!W=G\
M$7"!>#^=SOTXPN5$E(NRM"(D/CHH3:0="24U(W*6\!L1G>H6IMPGJJ,GW<%5
MUW? X-OI;'A>9O!J/)Z7!-E+NZ3T:SGY#I,/PWQECUQ<%^1T3&I5MB 6HR'2
M.4H<RYR@3<N2-98GVFU!WVGXHV55?67T'>B'ELGT&\12R?,FVD6K'W\* \F2
M8%XF0J/FI994(E8;10QD@?9+#-YUS,-Z:*BCI46_0G[4.#N>&(L2-,&)HP&;
MM2;6.H]6K*,&75]FZ4N)L^M][]E;X$\[SH[Q%&APC"1=+#6O-/'EH#4J9H0#
MG"6OT@STF<;9;:7X3G%VVRC@"41"=8'[KSB[_36]9TC4+FIZ NP2/E(TK0(:
MZ0EM=O 97S2PN(0;X[+7/)HJ)42?!*MVBK,[)*FVT<XCQ-EI$TS4I7=J*&GR
M$G@IGNF)]4XH*$7_1#<KZ!CB[+;2U99Q=ML(^A'B[$1R%GATI>!F0L,/WPN7
MG2294?"6*69Y1]_H".+L*O!@)T$?HKSIF^;\?#AK1>/'Z:I<0MRQ(.-]C]L[
MJJDSUM5ZIEPSPYA3*7 I) 2(CI?$0Q&IMU8..J+N2:Z[AY\]_-":,NX0],6Y
MRSKR8&6FTIH0@M8H]NQT8CY*=9^D]XK7NBI4W$RGMYYZ[>4F!5QIKHGA!DK+
M"DF\P!]#-D"MB9YK7\-.V@QI7TMQN=Q<"_6J4?HB=_+5>6EY??EW=-,&7%#/
M.54$5)$!+C?$*@5$2T&%DT)$G6O(8&NDCU#BNA_FK-J+=754H8_9;3E<O(IQ
M,O>C5[,WN&=>X"__X4=S&"@>'*K:$THU[F6:)S1L@B71,&H"F,A-E2.03NB.
MACS]ZZ)O%^,DC(:G;2S:]'?<!R:_#B<0\?-H 9WD/(PP>8^_/A\/\?O+CWTJ
MOXK#5&[C=? 2[5]/O+9H%#NMB+/,$:69H-+3H&.WRYN]8#Q[NAQ8$SW&@6T4
MR")#UU$##%$%5Q+ G>#$QLB) #3BI(HNQ#K=4=;"J7UX?]#%9"<9/Y5C^3M3
M>7WQT9>3Y[:AW]5RV3:0R3'[I".J.K73$S@]&DB6PDJ'EJEUX2 4V@CQT ?X
M??+A(8KUHY<:+9EN[ZR7**_:5#\,K6K7KLW8'JEM5R6UWF_M[*V3 ]/&@E>@
MJ20V0;D[Q2]!F](24021<\E\TD=!EX=Z>3T^6[911=\6\0<X]:/?/+IRD^5Y
M8HX"S54.)!<0DEL@UE%+%#CI)8TYA&Y)S'>?_=BVZQYR;_H36@4W>,58_OO<
M3SS:,LLN58FS9#SC!&=$B0R!D\!H)-;2)$.I2[T:2=O/RWX_K.?/A@KB[_L%
M+R<U:&4-T1%?GN\O.:N"T1S:IJ;.$ DE#:N4O(O9R6! 6\^Z9:IO'N/YJ[A/
M(?:=DO0;3$ZAN,ROXG_/A]/AC;J';T9^>'Z5B2^H52$[XA5%C-$SXHR3!&2*
M3.M(77KP,'^; 8]$ZS7$VWL+;XCSR<VL]%O(I$Q616])2J7C@$,AE#)A!(S.
MP4O&_&I1HPV*OW>8(U%W?Z*L4'W]?G!9![0PLB5:&5W2FPQQT5@B+=HD BT3
MYW@G/3\TTI&HNE>!]E@R?3J9#3Z7J_[6WP#+7)3H:E@?2SUD[TG@/A/MM:%6
M*&:RZF"UX4-O6&SXTZJU=FO4(SC?V5V*/6[05R 6C.H"8XMCFNY*?8PHR3TT
ML*K#/<37HRF]"H>SC*SDHHQ?\DD- F- 2?)*\Z1\8ED^&RUN."'I7XG;2*UG
MY?WF?Y3;ZZ5#AO89;AZ>9!LED8*B0T;Q.Y^"R]HEV:V/?2?UW1KY</OG7K)O
M^A#<QF..'N/!OLR:^$<IF0V3Z5LTTF<7NP0JK7G*WI%)#R%;"45B+#*A03@#
M22;*+$@A. ]69/0>:!C<CW$_F>T>XK7Q617DUR&@B]'H@$9+35(R6N=!.1U,
MXE)'],WH&BGV$L>%MN-T>I+;IW^XOOX,( *5D7@*&9=,BDMFBIH ]32)[)6"
M*N%+:]'L>\+8/JVDWT+Z%0WG\>DGF R;].7,3V#Z$?YL_S0=B"@"\[Z<?R@T
MG"EUQ"FIT!>V-!F;G4I5(FVZP3N\^[(_,U;/&BLHHN\([DT0Y^&_(,Z^-A_P
MS[]_*V'',U^^#$>C3Y/F^W"ZB// SP[ >0?:14)14D1FFHG7N%\)BWN5-XQ[
MT2TMOP<PSYDVCZ*0"G>9Y0@6O?8RD3?^VW#F1Y>,_PQ3F'R']*Z97*;S+4L$
M#%S07!B#O.=,$1E5+GDSBA@CG%0A1+-:OJVGY7=;I,^97H=13]\'YRVVUWX*
M"7&70E+^4MY7:1:O+ZX_LNC>\NI//TDG;2O&DI:!$YM-AG$&J9WT[ZBRZ<E\
M-BTO$+Y@ VG "!,SR2D8(K7@Q-FD"0\YZU*?(HAN1W+UL3YG_CU%=?9]QO]Q
M7J2)XKHZLGSU'6W6<CZ&K]7RA6K#*"]MVIM2^#3RX^D@HUV<(JY5D7&+WA\'
M?.VD)$'KE/!WD;J.O3CWQO+LV79@=?1XF7!E0N[ZOEQ-O5W;;T[[[^7">T C
MAR@,0^((AVMZXJ5K6NF(I$52"4T$3:M8_Y4F])RY^J24W7=;V1OFQJN46ITL
M+8Y7\]E9,RDURP9,<VNB*E6AB@^4N2#!I4!$E"::))F7L=.JUVFXYTR62D+M
ML?!;;W2^9VI.N"BSTT1D*DJYQ=(H&7"3EU0SYS5-L<[A1;TY/6=2/C65]UU"
M;OV\6@NA_=.'X?EPALOMV^\PN3@90_O+@><<<F24:-D67A2Y6**X "=K)4LF
MT]"MB/U.PS]G/AU(Z#V6BMO[#6B_?(;+\"7X@J[X,,+E@0X;@*-(< \D,X?<
MA]+C5C))/!BI0]2XFS^MY>Z^V3QG8CX=-?=8X^[6I,+#DPJKDWK[X]MP<OEV
M7IY &ATD5T*2S'FYPA2)>(%O8K8BZ:2LRW4.]'J;P=%P].#J7'.@O'?,_ US
M]ZZ1R[D&V9:216, #5M%0BB7Y]R%F*+3.E?I!GD/IF,@3U\B7T.'/6M/794$
M/<G+&@B?)KB(+J8_X#F *7<>AC)7PKP=L9Y;XJVPB2?0@G>LUO_ 2,]9S?V+
M<HVB]\[>_K7(%-IJ+I-AF"_-OT6@RV4%X9M_+!=@;\^_C9H+6):.'83 I$F1
M$0K(4ZGP.V=!$BVH<SQH:06KL3[T@/TY$^RQ5+B&ACL?Z=^8 TPF&[?1?PYG
M9^_':?A]F%8G\_IB,9?)P.>8:6F=%*POAS$N$ALE11\V9T<AA;#:F:@W'NX-
M_DB(>%@EKF'BWM<!&]ZF4F/_,\3F=-SNSS1G'Q6NTS$*5FINE$[/.1!CJ.8&
MWYJ\VM"HZI)W&]V1<*EG-:PARY['[F>%V>_'+<9F] 6^PZ1<=BWL_$O#OAR>
M_( X+V77IP/!$2@WB!=->MSMHR!60R"4^ZRC<@H=T&YG\%N/_9Q)<0AQKZ''
M?GU9NN)]<S:$? 5Z4>]GX$H4<LF;DVTU=^MQ002FB'8I&"MS",+TRI2U,%X,
M:?97PAK^['<@WA7Z%Q@/F\D_RAD7^I!M2:@2PW'[%X-$361)1)(5H(''@B<X
MM4Q 2A%PN_5"=FL?U2NL%\.O_I6TAF_[-6'IO+XN7(?IP&@F,]6XG@:>2D_S
MDA<82FLVJ9B(2@;H5GAXZZ%?#&]V$_8:;NQ_<AW/(,U'RX.+UQ>M1"[S$F5(
M#E@YQ) &%TN/9EA(I2>IP>U7^.2C<S6LX7LP':K@6X4SY9X$_=@%WTJ^U-?A
MK$SDVNMKL^=T F,$0UL]<]Q662HI4XH2T$E8+QF-L4M@5*>$L[4('BNMMS?5
M-GV*N.?DPCN BM_?II473_]L^.UK\W8\*\E&EWGK7:#VG0N\)<;#YPOWH-7[
M.%)!)8_,HIR80P<OX'X(4/J"6.*,3(0'2:V@5M)4;TUY#/;<DZ?\N.391A-]
MUW=:FDN+!%T+G)?S1.(XFM+HQ$&)TTLDY*B]%$G;CJWJ;S_WL'G+5>7?]".\
M'G/FRI27]8^75:6TCR98G$(*$3?$D)&Y3A$K+'4N>.=RE^J,G=[MVT,?GZ;W
M%&^%7+8O,S]K+<[K_(!FW/K'9=5R)BC!52;!X5HEM2@7X27J#)1)SA@MG*WB
M6MR'ZECLQ_Y54*&^^ JF!?>[@*I9Z'<MJL<I\=NC]II:HJ^P;JP'!U%S6]H8
M&QITJ2Z)NY;![Y2DPFJF6%K-[7IV?'B@AN^AZ;"-Q.NF0B_;M25(3"E#4LHE
M.]&$<OABB?8B*V^8\K)*WM4=)(<_I>Q!0YN#U'80;X7BON46^*,_OZS#E(Q(
M+/%$-)2MSF9%7,Z.1!5-E-DJJ;M4GMI:U3=!')LQL+. >\ST7<6R('(7-#4W
M_=MP'F>WWUT]&_2\AVPK+.<KJ&*,(:(VT*<I"29:1V*=<<AFJ;+@#MT<_EPU
M_< ^7DO1VXBT[_.9KW\V7\^:>>D?6*Z\2E7P$@"?F\EYN?UZ/R[!B,/OT,8O
M+KS3I)3PI:*I*>7"6;;%="FWHU;@QL49T&YG.-N/??C]>Q]5-8>3<]\EDI8G
M3^U&=A4F?8T- E"$$8A))2]1>]S.C%>$0J;:4L$HZY:Z_,! SU?A?4JP[Y?^
MU7E;E6Y15Z14%T:UF!O@K!9:*ZH(LXP3*= G<=PD8K@RC$-D4K%.ZGUHI.>K
MWUYE6.&0IDUJ*AW;+WO#)&NC3XEDB8BD+]7@D["$HL>1H],15)5 [%LHCLTN
MWUW$CU$T97IO=F8[C7%:>3NZS*FF>5]C4H_C).S!E6VS< ^EZ!HW#S7F)B3G
M4F0@QI; 49P2<<(9$I2@WLO$(5?Q6)X/>1_P>YXX=[?1;XU3[YN&WF7%MF67
M!B5DRH*BB6?1MG Q$PL !'SVTLN8054Y]MR(Z/#6UN,K?/7$O!=M]>UN??[R
M>PD^_H3_6:*1P)V7C'!?SG0]>+0>4R; ?? B>VY72\!OL,#O//H%DZ '6==>
M0!:0@O?H]"M.8BZ++%>1H)D:2! 03&3"*%?E&'T-EA?,E[XT5,&]^S(/TV$:
M^LG%%W_EV5Q&E3G&M )*M :!?@Q%8*4>J+8A"D$!_=(J;;XW(CHVMZ\?T?=8
M<O *V#6<0OR3_!7?F*F/1=C+.-(."*LZ= ]"?*2(C7YTNLJ4.@JIX7@]C#1E
MA^:]X419C:],9I)8G7#I,\(IZT(YKCXFRCP4U/%8C-E&#P>R5M 'C"(+(-1G
MBY!,(I;BKJAPR]7>\L!ME6;=3\-:Z5EE'6R/;>1]B#9''X81WQKP8S381LB9
MYK*0UG4SVMM@NO7N>?BA>S?QV1+W2C>?%(-@5$2J69 <G(O*&JH8U3X896&P
MU0QZE7=KY-21^N+1]66_;@XK&@C4VB+PE)'X(4;/@+F4#;YES&>F']; W=GT
MJH?%!V[]%3]],CN#R>=R#3R'W9M;]3AZ?6WN*(D5A0MM3';)L>2LY%';*'V0
M3DK %5%K][#"N^/8XSAG,<BK>U L\U)MUII"BL4M]42FZ @N'H% 9,%!DOY&
MC]A[SWFZC[G72=4Z^=T4WD!9"I E$*Z%+_6W/?K%H F3'+TLI0TU=)L);1SI
M<#M]39W>.IKJ5;A]GU$^*(!%1UQ*<2F&2$(HC1R==\2#32B!*%D$#NAG]T/H
M@V25'UKW?8KWL?/-$PP''^#4CRYSI"[#YIQ'HQ6AHYA*M5^*T$,.)&4=$D_H
M'JTK3#!=ZFT*\2^GS?=?\-&7;@)^L^H=K!GVT$=0U33:]"/9'OW" N56#EP7
M')N/F+;6].-EA>^MA*9'"=;4J!+,LJ0U,9+KLJ91X@UN/5H(,,QK(TUX%IK<
M<*1339';"*[O&+_7D^%TUHQ^NX#)],M_SX<AE,L4/[Y8G"$X)DR*TA#C2V6C
M4/*(@Q4DN]*)EH.RLIOA^<! AS/3]A-_4TEVO4?FCH8?AJ/11;NMW 3%@\Q*
MMF&D+!%IC2#6!T>RS(:!BRIZUTFAFT9XCIKL15K]A]^>POC]."Z@1,\<]T@?
M%C5"D5R1P".T/<P3,TE1VDUQMY_['-6UAV3Z[L'YVO_PHYE',,WD6S'=()U,
MOOH_(/E/']XL^\V;3)6-"% PW"4D.F4!,B-*41X-6OQ(HVZ+:(?1GJ-">Y=B
MW\TK6_?ZDY_,QK"LOI I9ZS$?SBO))&*H9.MDR2* A.6:@TA=U+JW6<_1Q7N
M*:$*H<XEP.,DWX@':2TVFHV(I1:H 5&R8-%L"Z5\!E@0P5,7C*@2XKX6S;$Y
MG/V)OD:JPXW(()S\QV;LKW]SXS9N&>_5!6[-((@M\3Y.1$0/FEY-ESB FBI<
M>&\+.VD5H@5&K'$,G8/RG19 M,)7"W>(G.H4HG\2K'H@:.+Q2;6-=GIWR>'\
M6SEF2# =P?R/X57DL7<Q.!^)H2+C=NH2<5*Z<M;  Y<H'-71%5\_P.%C(JIJ
MI>E9I'U[Z!_;N]&OJ"EX-_P.;X>G9[-EX :5*K0IO=FW56@%<=Q&8JDI"8(!
M(NVFZ<UC'+&R>Q)LWZ_U1YB/_'3F%U $(-/0G";!FA*< Z5N&TC\XAWG23*1
MN_4)N/W<H];KS@+LV^O_WW#>?#L;CH;%91W-TW!\^NK7__OQY!^OOKY%&5Q^
M_WZ9P@U:)N8M8=Q0-*03([ZT&<<?@[*!LJR[O<W;C'K$/*@F_(V'!H>,@;ON
M\OQ^W)9]: ,$ZT7_W#=>_7B?SK-=#:HS2J(S"A*RD@Z89UE1&GT0&??N;!^.
M\+EOY'T+FUT-^!WNOA5QPY]OOB(?K@O2XPRE]X)P+URI\4F)5Z5>*%>461Z"
MT%7<A#XGL7^EN/%L@@\M557?S*>SYAPF-XJBG(31\+15WQ?\.LU#2._'GR;P
M?=C,IXLNK:Z$6V2IB$R^+#8\X3YA2L2UA*"=<9+E.F+<%_HC=,QX+/[>+6%W
M4+WW;>"7B._I;T/\,FO&L(S-PE7+0[2<H)62<$,J0=D"-R3J4E+",8=^1R=K
M8.WC7R!;>I)UW^;^IV962C7YT:\(9M1\*Y.^ C@=@.8RQN2(9@FAA8R33 S0
M_63>*Y,]5=W,__O'>:E\Z%'Z??L.GR9-'K;B^-!,IS M*:IHPEXW'![X@.M4
M*?5*T9HATN*$K=&1&(/R2$H::7@W;CPTU(NE1Z\ZZ/NR\6;OZ06R]^,;1"Z]
M-*<#IK)TQ961@@.1E&OBF4YH@8 RP#/G'8\#.PWW8IG2NRYZO.G<C! )GN:M
M$"X!ZJ2=B]&2:"7:0:6<<)!:$RTY^)PB=[9;\$B7T?[%E9XTT6/R]QV )_/9
M2?[4Q#_@DL-?F]=H-PW/PWPRA?3Z8G&5/V!,1PO2$ZMBN08V :6A.1':2)[1
MN,)]=&OF=!S\7T2JHZ>[O-JO8^[OWU"2XQG*Z,K&6I3;F'Z&""BK] Y%O0P\
MN#J#&3@JT=)R;<O,4E\A%CN,&I(4Y39S$05T<X9V1?!2&780C=VEV9Z-=3>)
M[C?_8W@^/W]UBCA/_0RNS_;>^.G9[8F5V);?OZ&&X]D0M_'REY-\8T-O*W6>
MSD<%R,4-E\$& 4913SS5EDB5,D'!)P)>2"X,T!Q5)ZH^YBQ>*MV?#7/NOC+[
M]09^.QJ>#A'WUO-Z Y,9ZO?VN<ITD$':X)TDF>%6(Z-1)"3-B+-@%:?))M^M
MXF_/P%XJL1]3OW>YNG^OXE*N:_I^.IU#&F@M!1,1Y9%X^9(C\< 8$2J'$)W1
M-M>I)',#Q ODU=ZZ6'.2NO]!^J)TRAN<WA"?V1[[+RV5 9(2'+6!0"@=#V,I
M@6^B+HUNRK%>*;K1S4=Y:*072(?^-;"&'_L=M5^Y0Y=+V]L?I1@@+F9! ]<E
MILM*'H@L?'5!.T*-1R?<6R]UZ$2+#0.\5#;T(>\U)-@_P#O&9GYKV_N(3O-\
M,D&8 RTA:<L9"8R5XDK&$'27@43)54Y<A*RK]*.\#]0+)%#ONEI#I/U.WQ<)
M@.WV=\N^;X]?7HW'\V)D?1N 5$HJG8C1'I<\H2EQ(@6B'/-6.*"4=LO_Z3C@
M"R1+-7VL(<U^A_#W@QPH[KAE5!"F2KD/EXLSZ#(IDY::>@70S4"Y?YQ_461O
MZ:]AQGYG[JMHWOZ(.!R:3)([*.L<+FT4%SFI,L[6,V*RD<PYY')\,+KOWA%>
M*AMZD?@:'NQW1G[+:,)=KSD=#_\'07D Q8RCZ'&[4D%"EA@5;P@:SH+E[&P0
M.QBIUP.\5!;T(>\U)-CY!'LIG39/]L/0A^$(]0#3(I&%V9.U3HFA$T5%,$0&
M%HCU0(G-G"KOG(NA2B.(S9!>('EZUM,:"NUWHGMU5+W6$2^7-C=N:TIWN 12
M$R/0&9<,& J *S2,@$9PD(/K9J-N,^H+)$U=S:SAT,XGK9>GQM/9\+P467CG
MAY-_^-%\$;" /KS(VDF-KI>4CN/L,R]9&8J4*V0:E7/6=MN.-H_Q4OG1D]37
MQ"/NV54&BA!+%LUY<<E?C=K/0_K:W!# I\DPPL#Q!";A>L<@N[+R 7%)H6.>
M-46WO'2T[78)VGW,E\J62EI9PY[^XYROKT%19*M73$DIJGE <D.PN/)%3IPN
M<?F@J$^:9MJQ;LJV([]4)E75T!H^[1D>O1*&\OL8G_JYY/!.OS9?YF&T$I(R
M8,(J*:TBR11KS)E( K6&H)%OI$U>NJZ1]%N._&+Y5%-#:_BT\W'N?7E$2\O^
M8I$K<L-##"PZ;T4FFI;JR<KC9@PB$5>.GYG+B<LJ]\[;P7R![#N /M?0;^\Z
M5/?"'4 "9;43!+PM]A_UQ%EFB;;6><\EI'RPS,0K5/\B5P_:6L.E_8Z2.P1M
MMFOQ:M3F0#(A0!E!LG>9R"@C\4QQ EPH[X)4<-V]?-\PV[4(7B"?#J>Q-3S;
M[ZAZG<&X*;@Q&2MC"/@NF)+^XB"3$$T)0(_@?<J4Q8Y92-T'?:ELJJ67-03:
M+U![?2+,V?_?WI<UN7$D:;[OKVCK]^B.^QC;7C.2(K6<D5A<DNJVG1=8'!XD
M5B#  5"4:G[]>N"H T=5 AF90%6QK4TBBU3F%_YY1KA[^.%G\.F/R=;U'+<*
MO514\^ACR2MWGOA2JIM29@;_4.3-ON$'U2;M>>VS5:+.N-FA1NU"W;>AOKD<
MET8O2Z"EM=,FU(OQB_%;_#MQ$75]>77KUWXVG+V<3,<PB-HHR0"/;R?1L]6X
M)DOQ^^ ^,T$E>.D;^HJUH?U0QU-PO$-EVT76;R]G9^GY^OA?EG'=,@%6"=EH
M?BXSN4LN=L+_.R#&E;"> XVV)K<D\R CRT;2V*PXJB*H'VK:+Z\[2LO;!?N/
M6LC;? /_(L;+Z< ';F)4BGC/T,8 7(W79372>$-ML$DT&]]5!\\/M>R-S1T:
MV7;,0;G?N#,/=7&M<>O&8V?3GX'T(:-3Y C5#$W<G! UDYHH9C50I<+6C*A]
ME]M'(GBN6M<+8SOTK'6"^"HV6*[B=X5Y7O^Y;B=8>H+,<!W^SX$WGL4@!-$\
MHB<NG$!'BGIB$DL</Q7M^$::7IWXW!%8GZ$^]L7L#FVLU^-E%25:[=6_^NGO
M,'\1(P+=CAI-KORHI"-M7=NM_T81P8Y+F ^EL^&X- RXN)S>:8FX;B#@K:'
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M>[):M2=J>3Y*=0@[U2,MOWZ\4XUQ7;"Q=EMBD@:R0K=2>2(9'L"6VT ", /
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MO5PDF2["!Y^^^/%J]?]<'*%WEGZ]50P@>F%STL3B"4BDMH8$;5PI))):X6;
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MMALY*)IGSJU5-DDEA0 ?(;(D:*(9][:T+P>E-RE7*CE>/O]%G ^_#^=7OZ$
MINN@5L1O?_@=RM=>71F/>'>7!<DMI+!94NX%<*&<#"9)FKGU)L>@-.J0#M+1
M^^J3CY9'>UW8L0\OM_T5F-K\-WQ?1YP?L]H-GH6-H(+,VD.0P&7@G <:10X1
M= AF#\\-WWSR;#5AI<\,[;@L <]TYACQ*2KBT,:CVCA.N\F /GVV6G=W ==Y
M&N\NE\-VK<V<*D^4XXG(S"4)7&<437+ ,Z.:A;.2\:$K/$/[MJ[F]W>/U$9W
MNBB6[VRA/^,CYM<WT /@B2;C';':0AE=X(BCRA&3DI8*RCS0\\J:/7"!/SZ1
M<]"<<\IE._!*>6!!0<K)$LAE9+MUB@2T2]!;SEES8:G0G<Q/Z6N!/[Z0<]"<
M<TIP>W"=;R;3#,/;2\43$3AH/"E#L,A'-B18"H1*+PWCMC0$?EP?R=8:?WPG
M9Z(_CRKK;=.N%%;($&696PEFV83).L%QH4%%:H5V_I&=)O?Z)&=)Q;]@^/E+
M2>?_#E/_&19VS4^W0X0#&4665E"BO$?;QIM,;+2!9,LL<I1+@\A'RM*#B_^Q
MSYV[QFUO@.I\O[J[7L/#@A"<Q\"H())[AHZW=21$ETF47&AT.:(7G;0[/QL)
M_/C^'H7N;7^$^GP_PKN.R<.""%(KEY,@+@":8Y3C;A1$("@"W(V4-L*QQ_41
M'BB!'Q_AH]"][8_0G.]'N/)Z+J<P>U@*46EG5$PD><F)-*"6;<2\B5*[5"99
MQ,?U!1ZR_!^?W_EKW?:W9\_WVSO $E<Y DW1D,ABF1LB [%>,,*TDTXK9<6)
MLG%[]_U.6?$DE572,TI B8C^$//$Z5#&K5C%0BD6CMWL?\^PXJG5QG42QL^S
MXHD:,(KE1)C5BL@ @3CN#&'*Z9P"5\ Z*6)]8A5/!RG"O15/AQ#R6(I%FJSI
M1\73X15/!^E*'U4CQQ#]6)28R\ 8*Q,"N/=$VA")ST83+[U1@0O!TFG*_<]&
M>0^J>#H[W3V$WPYT]OZB!Z"441,2*D=B"$XFXF3(1 ,X)X)UN9O!/\^A5.4@
MX@\J53F$M3ZF+BX[L7[R?QXWL.WV?]XZ"7LOEHV<:A <!-546,:D$-8G+T)
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M2#0EHTDS3RP3:,QE035NXOB;3NX"3Z,S#]P,GU9E#J&BBSXK?@2S#_ =QI>
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MPJ]]D_/QS;\O.\I&N)R7G)!U*H@-+B>;,G%H%1$I4B N1$=<#IDR+QV*I%&
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M0R_]5S\N_PA^!O_K?_Q_4$L#!!0    ( !&:65+$VY)#VT\" $2[ @ 4
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M?M#SNA%;?*N"WJ'>K[*@^>19>/%<GEI#@[RW%W7_4+_-L@0SSE+TWGCZFJ=
MEBL@A5B#YPCCUX[R2W'T)[2&77-F*BWPI0IXJ+M/V]:+7LL&?&)[Q-7C0DY>
MK0W=WD?^@UKM(@#HQ2"4";95-U&Z/L?A6+A4$&,QJ5].'LI4Z7YYF^JG$T/9
MEGRV$1<9L5RU/*LCS')-H$!'BF+Q:TE1 0R"*.D\;#>-40HM#!K[E:;4[7VE
M&(R:Z1[LG6E3[M-EI:W[^.G\TTY(\H4 4 7;7"AGEX2(94<_U=&H&'IB:OGW
MAHMCH9HQ B"]MCFL3/KF_4<OWRM]U-ZA\#DG)W:+G<@:P]5NU,GKD??4O(5
M 2"^E:<+$UZ\/3,2*:W5:"FW/>7;;%N#]<7N%IGG-@O/+[P]<FT$WT$85Z*K
ML4H$@.@O?CG)F&O/<Q4 "2[T HP*W'&BZK, 8.@.U6)KYS<S]5-V$6S_[-@0
M_JGO/%>98.MNU_Y2!SLLWN9*+64DL3:'7[#NJ+R)"+-_6:6?+G25A>.&3GBN
M%=7W;---T#&[K_UAM_UE[>WLD63H?;MFQDT;IQ<A9.RG2*+FO  X.KPX75M3
ME>#@[11X^\9^X;)M@,=R S>$) .CX2V2QV]& &(\!PO//.4%L-V+GUM/G#O'
M<RJ=+U_[\-KQN+Z*%P&.7J8VXR7!XX?77+H_.I_$T];@G@;;;Z(N"9^CR;XP
M%=E)Z]X=L6NSKG.&"7YAPJS!V@28N?/.>(/_&\-MXI]BR=DD67X%HH0,C>Z\
MA9,E&_!LX"2K]*K7/+(&>UWABQ'#]?X:=WS>S@@KGXOHOG(_TG* =Q2N81"N
M3XFTLEW32,X,U.EPD/,R,E[VX^JMG3$)I?<V=&'OV;RH>C*W3CY"UVA>7$\*
M(8+TNZ#P;P$ ZUCSU)(8'AVN:J$O_ACT% G-<=1^]IGO"Y-['"U5E6SVO+KV
M:GG91+>CC&[C2<;=1#X.S?02RHPH=JT 6!02 ,_$[NW1%@ " '.:GPM^GVD%
M0$;'(&YUP^L,QF@71I9T"BJO;V:8*@3[;1HP=0ML&+9(A2O#@QR.O.LU.O3V
MS3,1^6@1320(#>T\+.28,:;&^8=_@R<[79F&KQ4 /$-*<M/LA "H)Z&#((WM
M:#K  7.>GFP3_V,YV=ROS2469\\&-'_XLO6%Z%5QGOPEIP'<F0QXAW W5@H7
M5*0YCU,FB\Y[J_2U%I>G'=Q</EN?ZIHR9_)HVY:.71U/K<<5]]MU+GI(L6YC
M:#0L,H*3ME4F'1L@23.+DLD -)K6XOP5/$.\=H(M^[BP[/GJ3POYF$*JDZH7
MJ3>GQ"4E:F>.ADX*ZW=::']'T\G1IH3)NK2<ZJ5\)O-$RJ:\S_=N C%AD"$B
M/2< #%W(7>"*+CCO&^--@XBXU)83%[C[D8^(/#N]G(F51?J\%]XBZX<M;D1[
M523,ET_8^%QQ,E*]IG==_<&'90;YY"?Q!0'0+@ F#!GB:)*I^'WWDX;+H(FN
M/U,%!CG1I<&%&ZN'3<KQ1E:]*&06O]O>)KS84%SI5/F-B8-U9A<N<(^1S&H;
M^>FXL(!K[/N[*XH?CA&'NJSJ]\WD;UCX9.>OPE-\F/7.W6K#GMCK#SHXN[J+
M:G&=>'@CA:?P_BA[J9OOW(X8P,40I6U9]B"GQRWG%Q]T<[#B' K*5\?'O*^K
M%P"3PM_>S3>W'GV#W4\ZQ2_F"7%W!P<=8Z^DD[#T&(OP/MI-RX)P,Z'&N,I^
M\^?+G4+]>LQ:LA;)$VKHQDNWE<.XSB;QE%\^C[Q0/\3LU?KAE1,;&)BU,5 G
M3D)G619$(P Z2(%URFD\-5=&?3GW"#*$5VF)OB@ Y"\[5Y7X?(_*E*Y9JV;6
M96C3X'8X<T^-468703-\?T:<D-0FL&T/&F1%?B9H!'O9;B/9\/^AH&%WTU9O
M%-'^0>TD8T<C3>5=U/.77;*^&-=U[-.TMSC:H<S%O_-(F/YB'4$7_H.!1[E[
M87%.&%3>VLQ6Z]'&0&+)45?JY4.U]4;":\N\*C36C:CD1NTW4TYWD))S3$O?
M^J3!1FDZ38V)OQ&Y)$^\Y#'XFR_NV>#<+.OLTI0^/_A'3</I=*Z9VT#2^CNW
M8\+8- 0C"J<]YIU",<.,AV5')%U2^9;*++JYTZ2R](N]3J9!PZM/OT-.7P[4
MV[IIWDY<W,:=P--\S TFEC%<GO&SR4;O+30+X#!7.!4:O)88GO=GX^,0E1_4
MO1_*6@[,KI:(ONR[<J]3'<"63P'\%V15D@=<6DY4:Z<I\H28>"UB6#\R"G%R
MF%K.?1X'ES=Z&G#M:R]:5$5?,NOF#H=?D3KOJ/)=!19&\5!: .0\H82[<@O!
MWR95E;1Y(+"K\TKNDE%%IKUB7M2E!/NU6:[^?F'%9"I-C.?&-@%%YRBJK1JA
MMMOJ@+Y_J/##;M_#"LO\'Y?OO+/]<QD_C7?#9Z #?+ZHIS(9!QWIAS?3.@AC
M6 :8PH#J\\KWR2ZEFC!>WY:<R9H*>Q*WN/VFJ;+5MN1.F0N&+AKKKY1XN$[C
M8+, >F!/AW09B"&YPU4AT[CJE_648;SKJT%DH)855.<</+.\$K#%X*/Y3TV
M_Z02"S]&:4<2%H5V]41-J;(K>S WM#%LJ[P9?HWC""^P-&2%4W@FS(A\1O%#
M]<;ODVLCA+?,'Q#1Y-'0(/(%">!-Q(AMT(T9]YC>6)M/2T/63#F%/YGLOQK4
MG#\R->]L^$IZ*\;HRL\7Z\_LV!6A<GAK(XQ*P@Q(FA'$LD.AVA^>?4/1; D3
M %)+C-Q&#H95)"\ SGF'8,<1C_CRTGC^1I:VQ,H7>QEPYX.ILP.)IX*%5U80
M[2ZND0 8>$]"<;<CZ1&X;!\CA(^S54([A8H<^EUD-]N]H#@87R]77!YV]?,7
M=TURD3_;ISW/VF-%\95C<8I>C:E>^L+SY__DZ@&2EMS)/6O!;@I5[0VN!I\0
M_IMVLW4[!,9:.#?7O8P_PMY8$_[8N^_\V\67+VJ:UM]^=''KD8O[SUU(L)Q!
MAXMC.AZ$I/O0Q9&UNW4%0);A\C2".0[?IS;$XH+P-YY9/3C=:L(V7JRS+8F)
M^NH3TDW='KXAA'SL9C_GQHM^W@:EMG[M$UP;5-W(4U &J#/H(L!V-ACN"=*A
M41Z>DU'5<:H)*0BFWFJ+4JDU#SG88+/F0-:@G$2OSB?Q7SO\HNA8Z@K#NHN0
M<K7R>HLI>Q^#EFP37JS1_9C!-^S,C<JO*#QUVWY[/G6'IB>O4>+ EY(P>3F,
MRO<<N!)UORSY[901/XX22A%!T:%5?,+7I([ALG=DE*F=%_K\-HTZW:MFQGNT
MD*_+<4I7CX5V)FSIWX.M;C5C%V9 /]JOYKYFRGJX?*HUUJ0Z3^YS&X[(&AGL
MEABN>6]4L7?#ECCG;0#@9/D6%N;4P2?8 0QRPS0H33H$QS#QHO"90Y?3P(-L
ME0??\A[=/*W4QTF]^S7XX3(S,+/A)?7&MC<[*KO[82,<3T7,%38J? #A.![\
M7,N.,E?VQUTNE[H;KAPU?"#MROW6_A,[_V'7F4*&L.'U<$U2^]'27\*<9/YM
MDCY7#/6J,&+&VP0=E\E7NV$K1\S_')1SW/7IH<B"^OSY\'^$C:K-FT\)Y;X!
M@$W"GW&,!7QU/W]MPQL,;_O5 P) SSWI!AI.3V@U41FD$T^^>ZNQQ*%]WB._
MRUZ]L.#;=O1X^_9]YG=6*&XZG6SP/P<4;QQL4\'1[]*J0%8)UR@,V<Q_* ""
M7>'C4U8OV;[=.0&/P/:HXF!<R%#6X$?/15+J=[V<!A?+=L*QEZN>PELZD21R
M%PZRH\$&&4FXL(RDG4OM-&K1$3:M$RM%C!OJS%>-#V(;=G@_RD_K+M)Y+1%>
MSA(9=! 1O>]@)U$196(&X,ZV7)@N5V+DW;#$RA.S/0=YN'^^0Y:?D<?/)GM"
M@@*D;M5FO5\O<5/<_310<8!.8$5!19S"QF%_.(R-8\QV[JB]G+8T#?7?7/A]
MMLI+6N+#PZD#F]1+ JZ8UTX75_85P3;FG$Y4I2J@2#@QU*KEZ2=QF7+KZI<K
M1QWRM$]2QNL#(R)."KW??,=[?T>L^VE,,5R&2"9!.#R*Z\)@&Y&L0K)@7WG>
M_Y 4#6D7^8,V0Q96+^<];I>I9V\I,SSPG/JZY4QL^ZZ<CQHW3V&^7T-+P")I
MDARDOY)""F/B,3"N8R<^C].']QGV'UHPMNE5W<3KG0E,LW;\'G]!(^C(#AT/
M%$L[QBB!17]V$&*Q\/E?&8AC)?"_BS?\;1SDG 'K'5B0YAXAMY/%V*/=E500
M4:%U3EYBH7+#%E5W"1F,25TN[MVPR:EXON;BY&Q&3,N1WI]5D]\BU-W7Q.*>
M8)+PRC:6[/CV>NK2C1;[8F+)_M?VN;0C@Z;,UW4/-/89ZE69ZZYY)&_W53[L
M"N6^*:SS+?LAN1<+712_9:M,[K>U'"9OXDD/UQH6Q.SST;QSS*<_7+5(9=#7
M\?2)Q*BD(X1JO9OQR5\J5"9P RQ Y1M9CU^+R!&MF;Z4N-]@*D[F5Z7ZE$Q;
ML1_Q8;?LX0NY6./F@_H1;G],(6MTM'#P3C7.(OR _II 'UUX#85YV&JSDWKX
M=N<JZ[:;4*>^;=K8E/B1.NDK1!R,?ARS;-I7KUBR*[\1(X,F4!9-V!_V%:VO
M8@<Q7_>DD=^JACN\G8/FP!"JV8_@D273O.;MQR[<#_BVM =;>_MPWM9'F=6]
M:U,TO [O$WZK\\=#E(ZA]C""NL"4JZ/72<9LTS?:^NR&Q!8!P (Q(7[K:UL^
M1U9N"(P#:WT.Z#JKY9D;$5X[C)XJ%;F.1_&\C4)Y6<K:A4;9#PB?1M;BG65C
M$UM<H,'V']KB6;*'?0JX*D[KU"7&K;K"C4[O4,5MO7M7H>';=C@(D5#[E^JD
M%JV@Z#KO&[ 'VTC31+,0#R!]9)6&4?(&>+H- 09,%D?:9?=UYO?5YX19=N@V
MM5=__)ZX-_-MFUVO0E6W\@ 3CQ*#K31LB>WT#4 ESR 9ZQ(2#F*3ERP+@BV"
M&AJWI48G3&R_T;,Y5R>-(G?&Y=&B!N\E&FF?*3.J?FB459>5@G,EGB6(E)<
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M:MC=</TZ!S%:?Z-\GT6>J.<-B7BBU![QI88V K6#06#IKV5!/Y@>L3:D^HJ
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M<V,3Y55.N[V,F][,U\S)G!/'%3MCA392  J=08"M2^D4GF(8QQ3JZ<0G^1G
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M@*<XC4@J<-<@P]B71==;+K/+.$7HF$>QK4]R04Y_$H41 $<Y(OW+==)W=02
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M4ZQTX]_&I+3JG^29#9N(OJ'D(YT_W/\)O3!//GDQU4YBWP5M<K G*[/[4AR
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M!R6@/0;;725?9;07VKX:I6J)-A3NN[0^[%E?R[/SN1,2F\A7IM-QQ;2)> X
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MIGL>$[;(4"/M8XLE737]-<X+>&X?)7OGN5B[,8L1)VFET$@:^Y*X8[XLHT(
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M1+E'OE<3PWP;[^[:0CMM>%9XK4,KZ>K^6[-;;'J=P[%;N46(I--_]02]D@3
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M''N'0T/N.TM6:3I3C)6O;0U=)CC#$R#N63R,RY<I0; =Z"[RCLC!=(SDGT'
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M"/MN9]U&N-L<+#C2?T9'+''O*6F!#?!*%5LFIH(2S9$N8E4!794( #U/@AV
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MBG$B^$K%AKU[?#BVA#?"UK0O^+)(MQW:S@;;#=.W,VS4>\=$7+QT$O((PEB
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M+B$<@1HZ"2F$\L<P41WEP8!S) 99,8#I-1HQM6 +)+\%\D>D7>+8#>O_B!O
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M3CQ5,$AI,:@8?/.K<.-[CW^HV T[7Y53/LF.-P4TG^UD>FZ!5KK8%V/ K'Y
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M];1PSI9L$RTTM%?QP:H=7@V+HRUR)+= /7.6VX66KY%3G>\0D^;Y?/X&5@$
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M[6IBYR#^E^O,HY)"JVS;@9]]/XZO<^E9WL';W@B27V"QHU;&]&=6Y]Y@5IT
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MR=]\]V@GU;Z;[V;,G5V--CIX_./;^*3(WU!9X=P9$GW#N>JX?@_<;G9@ L^
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M8*H\C9IA@0%2FG$'+9(<K]&K?NVS$/JX*PJ/BBYJ.I- UTR;,7?<D*E<#SW
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M&NWOJ';X0>Z)*LVJ8BT]N?M@+?>"<.LC</L%'3NJ,&L^_#IRX'(*3@_X/?9
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M9%$17R[:[RJI"[J*>+[IUM>KLB[?)7D*1;,374)(,<NHF/;WP*>I!29@X>_
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MP)9#640S*A2#_#2:$]N,:824JA]RM?TE/?HO33YHWRLXOD?> 1&N_QB:1:*
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M!WZ'A>,]AJF?C>J$R6).>(%%)3R;<2L9R22#I?(SA+<UXX>FIF8N5A_5M@_
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MA!FE55]D?/1;SIKKJ5^8:-!)@U*QL'K8TNWR<QQ#;BE/"R4]BA:>]\XOPE2
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MZ^@O=LKXU'*];/ (N*X-H5^Y(W0YNBGG553B>E8:B$'YK$&UR]XH9[ZS7B!
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M8@PCE,4'T26:RH'5F6ZR#VFI+]7?+$U!&IG$*?AQ_CBGJOC^CH81IKJU]-/
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M3S@PY5,XYRCN/ZT3I!=4<4P$J^@5)$4:-U"-T:E[/;'P%WK_<Y2=EI@G'!T
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MR^-0[S^)5@YL?CTQL?U/HG6;_G#OF?L"HN7AX6J]>9NF$NC3W\>'@ 2>J+/
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MG%!V@!?[TG=8+1^TV,F0(8/EB8>_82^&GUQU32PZ/J#>Y&<>7*UD$2.<'1%
M_%%60H<?JGIZH,XRQ;X:PQ,5W$98",@6W$QP?:+9#!^4BE$D_0_BWCRJB:Y+
M'XT#DXC(+*!$ 4%E4D853!P91(PC"(A103!,$143)*049!8C^ HJKT0!1662
M,0I(@# I(@(R#R&)H"*1"F@H25+<BE^O]>O;W[?NZN[;?>\?4711J5.G]G[V
M\YRSS]Z<P^3,G1"0UQ^4M:P,_!YTU?UND6M5U/X@?YVTYLQ<\MCZ [%I[U:W
MK56D]<QO6/)E =5?!BOD@&7"U9 :V%97)7MG :7@)-ZX@.+CH7T.>[B1WJXC
M)!>XZ]4#!#/&U]+>SCI,I-0\<>M\81+:C'M&"9)DB9>(]I/=V;NAY#% #EI
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M:X+Y<'KP$F(VN<RQ9_A*_]3'W]&+U#AV?!-./E-^\NH"*J7<QUS>8<<C3^_
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MS9R974&[5VSZ\W?ZMG&/5Q<%_O*Y,I];>; TO;IY 257:TCNYDQ?H^J(CX-
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M*,=43*M0W+M^>4<&Y3_48Q\1T <,R\JB>[>L:6R ST?S=^D2MMA/6RU&89#
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MK+9$^$C:9#>6P %0E+TPZQ_R%\I_(5T%@$,74"8?1)A<^-0":I-;=4EU&R6
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M<W1H(WR7%V3Q6\$+,NK8*7@:JSF=95$VV2L,:[ITS\M2="CBHK;!MBUI.[$
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MH2>;_+$&VU6%<J0=51; \8]/Y/_3S> _QCK_DTDY^0O_H!HUV(;8[B4ZK6"
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MK5O]G%ER<=AYQ.*:%EDSPYQ47ILFH_<2'E!A4&AV)%!^ZPMH)'$\&DFW@TJ
M&\8:=PT90Y"JM:"B]*QX,>NM:Z_C,SWT-Y5U^1FE^UQS#=IHKN!H.%S*3#EI
M<_6@8+DT\3[;AM?8EMNS#BF1#C>4!O<:I0'$4+8A(#Q!D,$U[=2VK_UBAC?4
M;5P\'!(DWKPK97?")PO1JS+^Y OO$H7]B'37L>S->-"JO03B@@*T YD51(F
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MZ]H'Z^]5C0!:@3"%WB;+MWU 74.8*\)P64IH '.]T_RC4#X'90^*):XAF+M
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M-*F"8BE$RQ;J9[XIOF*BN^22M12>Y5KM$OQ2Z^[!<W%) ;K;_+_/^-SH92_
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MBR\')KV!@R>7[^0UR>4'A)L.3G;W/6O[D_ZZ.E \].AEZ]&_WFQ?"%F/X@Q
M&8XF[ASH63$=@-AQ':2'$DIQ)UB2KWYN*V"X]_;-W"0WBKX-_'HV0,587R?C
MDRV+(#CQ239YA +FV@0OAGTQ2MR+("1 +E:/FHO1Q*CP^4GLVZQ!D]2M+>08
MW,_Q 8\8SRI88>6>+\*],_^%_<M)).TQ6H6OQA6&>CZ)_T*L&HO':X!KC+D(
M<R$ZREX6&^K*(CW/36VZMJJ18UAE>T?5Y:G^2'SOT_WUQU\7Q%<66TA 73]
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M<@.N?\E>E6\QC4O3O$8--N/R\;3G\'FV(*&T,OW?C38KPMIF+(2G:><W8)+
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MC[L9/$9#3/+[V8.@$RO8Z?W RJ_BYMHQ(\SV=C?E;(,%_3ZM*GL#6YC!UM7
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M(RG/3_\$'T<,^,2;8UZ ]A2]<O]<4G;QCP%KC3!.4V'LQ([571_;]PN/':G
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M]EF1PCIQ;.ARQ9G%/])]D9.A#Q=KAB:%:Y*6]'L:-'L#?"69NK,3:SM[?8A
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MZ!G__67+V_ =ZO=M4LAVJU"N*Q@9;@FD57<<.#[G4&$NW[1X21DEO)Y+TVA
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M-6AXO]9EPVBJJM1M99GQ_,M?O;&E+S]0<<K.;L5GWG;(^*<8G;<ZO6YYXH/
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M)$;5X'1]^3=E>)E.WEW=\%XYRNZ&ID^I>H9K<*GZZ:^C&OO+G5!Y*')4+_X
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M]#P%1_^F>K@(=Z;Y-[%SM+"](7"SX$5=%+,Y8IA13'B:,P;3A"&(@DQ"3-,
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MLP//_BVYEV"H77/7G*MOKM(EC\1M^:E<?BN4T#,:D2A(\Q1F6""(6"PAB>(
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MD4!L]FCNYWU9D7)EISZ]XW29_H=HA],$-3:]QZXO;%^!Y1;XE=( =\5"G\@
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MD5V%HX$';)S*1B>';+@1L+ YAF-U8'MD4X.UA;Y)MW*D".L%U5=MN78OO#H
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MD+.P0F[#8V3;X "*(?U=SF#BL'K>ALU$:YK=Z^*VJEQ6O)?KS]PV'0-?EOF
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MNW55G[4J@+2ZZ)#V\UX;L-ZIXQ -&#QO%M&=*69C9*YM)N*+/"@::K0 .S7
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M$T(BM_7'8?2Y+3\=X4TBQ('X8"\_^+/5P+'.I]O<V!+?2(B/SGO^P![ >@-
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M+)7!CV.A6S0SF.*01XC1@#*G@FCV0\_-_->2@XZ,H);;;15P0-Z.U,?!<^Q
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MV^TXC;P^=1IIZD39^KW3,OIL'-^'@=^.\6='FKA5?)^VISWB>Z\>TAQ^JWT
M_;0VC?W^A11+[?/]NBX_5=56-V3X0V>VZ_Y9F]?NFJ [:U6+G,5)%B .(Y$C
M1<((09*FBH1Y0E.22XX";M]$_F9YYL8JM4:&IIM#]JU"QD(O&I6:TP/"*'5H
MJS]KM5RZK]\^I_UT]08S-3*O-9/T18*].F"G#U *@58C8%0"M4Z'1OK7Z2?*
M(:-LV@F;*,6L\W7M)ZX43Z0P+8F&?6N^ZEGY0[PW+\W#,-,EJOG#Y"!SS>-C
MAWDH7YZ%SH18/?ZF]P_;[<)7G2>Q+77@=!&$J8@#0B'&8091G.4P3Y11'0J<
M!9'ZC>XW[71(X^J8+A_L-.<S=B*#I=E*7[9"WZD?5!5H! ?/Z](]5>'Z'+ (
MLX#G&0QRG1JBW$-(2( @3W&&9*:\QLPI-<3K#$QAC5S"7WTPT\R G2/D%=>1
M;8<]I$;8NUW^AWJG]P+[<Y"LL?'I*UT?=%*WR1J#8P_*_L:AV1WJ*Q;5IBZ3
MJ)>?1180&;,DA&DF4X@B3"#!"8,1RE,1I6'.W/*23X>8&\FT$H*]B*ZY'"<H
MVO'&;=B,3!0NL S(W+BDN=^DC9-1)L[7N*3E::K&Q2MOK0#VGE0_]/^T(?E"
MEDU&[/<?:L%\$.73I]6+J#L(5$<UHB1'@O$LA"+31;_R4,)<UQR4,@_C0$8R
M84[6Q^TBS8TYM XF:;TCL<ZQ_)V4_Q1U)L+>PK_3:1[+K>D<:F[L:#^T&-C@
MN;7<OYQTQD;F,RW^W0GR)],W36&O6_$<IY;78*G>J'S7K2A>KMAU\Y-OKMLH
M'O7COPGCV*P>/ZWDNGPR_O^[U^:79N@%27@N@EC #&DG,4$88I)%.KZ-8X[#
MA'"G++L!,LR-EUL5ZET?(R?8:0$Z:MR9[(3FBOK+=\SC'3)CKN0[RCR,S+;C
M3,$MI11=01RI7**U&&]5$M$5IYZRA\Z/&K E^$T43W2K.$4_[8ML:DCH8U4T
M3XF:#2P##A%##%(F. QRRFF:!7D46]4>ZQMD;KQW(*;^\D0CJ,,NSR4\+?;8
M/* T,BL= O1%MA5C? #DL+?E :B)-JPNOE&^-IVN0-&[DW3IWNFVAZY(?[#G
M<^W:@:<QJDILJO=U-'!WBHC@F'(<,)CJJJY(1A3F08@@02D.F4Y""YWJ=9\=
M96[LUX@'B!'V[X[G*,[B:&>IW8S.R*Q7RZ=\WP:@,8YB]6+@]03$V8&F/>W0
MI^O)R8;>BV\YE/E ?N[:3']8ZQR"!2(93Q$F,$("0Y2S".* <"@)3Z(T$CQ"
M3K[@I8'F]NEW:L#M)!UR'O,,I+:1_-N!&CV>?XH1^+,6T_N9S,M(^#^4>6:L
M-SB5>5GC\\<R>ZX?X 7]5C!M3=RO>*<,QGIU_UB*N@C&;[O:,X+SA.4!@7'"
M%$=$J7*,*,Z@C(EDL3Z\G<36CI']N'.CC$9RH$0'![*#O? #R@6YSH:%6S4.
MQB.SS4S@=7#*QH%Y(C^MA5OO9K #N,E.?E\NFSM0O5Z<P^.F<^S<=3SP]0;<
M/M02W&U$_$J*\G^3Y59\*"JV7%?;4BP"G>0N,@2QC!!$7-<60GD,113%7*8T
M"6)'>[!ON+E1_-&N[--^5W:??>MJ)?;";6LK^@)Q=(MQ)^@=T*("(RO8"^O3
M;+0!Q:_QV#OBQ":DC?:GAJ3576[,4I4;W52D6B\+KD\&?EQMZ@1EW<PF""27
MBCI@EE/%)[D^/$-P#M,H29(\RR.,K&S'OD'FQB)=.4$KJ!UM]&+93Q:^$!J9
M(LZ"XZT?D T(/92@;N_0@?K7,17T/G\2 K#1L/WLK:X=W'7VN-S&9['Y(I63
MNJ!A'"98Y#!&^G0MSV)(4XRALA\"$:59+#%>;-8;LK2S(7K&<OKT=R..^79W
MJ_04=0#EEZ5[E9X^?&-"E$DL%*?R+(,(!3G,64YAGDJ1I'DD"',ZO>P+WVFZ
M^HZ/KYU1Y@FUT>GVM&P4J,M&W0$EK]ZA4Q+?7:B&Y+7+[S6X/'?YO3C<U%U^
MK^E]ILOOU5N&1_P._$M3.NF;>!&KK5AP%,4IQQF,61A E"C?+Y<BA%E 4):*
M@&,B7>-\%T>;&[,T\MX=!T-6'*Q- ;:REML]ZG09</M0GA<8)PK@'0;OZNIU
MW_R#YQZH\P+B9&D41C(@2+E2AC+?ECH+3LG<5K\J==U6\[.U>F4557#1(%Z:
M$P'J)DU&Z@6N7]]G4FY>S2EA_9!2-Q'4MV[U*Z]H7Q=7 >N_5NK]%^6&%*8'
MH+Y2:)OQ]7_H>,A&"5CHY:'>+_^/=E;!$]&GC%?U;2NA* D\K4O1/D(JW-=_
M:5G%L@YF_1ULGY5TJPV00N>YZYOU+J>2O5(:LQ]WX*E8*E=5/ZTM":%^1E9;
MJ2ZKP="?9K5]?EZ^WH%R_4J6=<Z\_O&R>17UTST',:^^1#:AR\L/F3Q@>56?
M<V'*ZS=-7&QO%\VXKZKM4]WG4N?+Z%[)'XH7]7&L^#?E BUP$L@@4&X)C1()
M4<9CB&48PTBO=(@&@@1NN<]C2SRW=;*5#;P68CE593WKZ;4SW6<U:2.ORAXJ
M[G4"N1V][T"K.=B]$UKW&53@<YVF653CLQ;ZWZ,RG^L<>*O2YSSPL*7J:]GT
M)/RN2Y J;_E+:>IF<S/V5U$:Z19AEDG)(J(\*<(AD@+#/(PPS!B+I2X\AQAS
M66_LAIW;HK&3NB[8>J>M4?!B&$4WCMY67)NU=0$IQT".Y3S8+0S^T1V9W??
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M<N#)QR&V_LFPW-<8%^*WW<@ ?]82C[1O,1RZ\4]Q]8LQ@Z-85CC9G:>R>]0
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M W_^#9QW"NQ(#"J1P?T2U$+74=?>X73P\'N'=20__^FW59G_O$A:G'YO?04
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M^H=#RZ[KR:-0@(5J[4=O<VF_#=^'I^?Y\D7*;[+:8NZX.=^M"Q/A-I,R)5%
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MKN;#7WR^%E*8O9DYWUO76[ []8$6IJYA^546U8G>[9.I2#QC048"330PI32
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M64P52FG:S*BV%R<VGZU$$YI-4$UG^#<@%V+TR;2PN\:9GJ'/=S>STF@![I?
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MP%3F6%I6Y'^%N;<\H9CDC [M1MJ)]MV+S]X]JV OX&14L%'^!FS+;H,= &Y
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M:&"D;HH?N5")#>X6E.P9S:%-SU<"TH&4/0,Z$BMO@/W'!EBU 59HP7T%]CC
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M :QLUL91T/&TC(8ZOG9./5P!^TVLM#TG$6XT&[9!0HY9 UDZZL@T+-K[X\_
MM?6<[+&%NM7E =LOIA^9(K=5-Y=#8TRDBA-(DQ1#DBH">:XPC%G$29(A1J53
M]A;W*J?&_F5Z#'N P-KL.?LYCZ_C?"4H:D//,+J #7 WU!V,H&'Z^5K'#:R=
M47@5"KN_>5D2T3+MO*&P&].DB_886KT3^TXME9YO9CG*(IGA&$9"<$LP.:1*
M,<@C@E*D8I(D7L<I?"J?'-5LO#<FO;!V(YNA$!R8=MH<H:7=9?!66MX]TEH;
M#WZIS0^H%-<'M2'2@SK5_R:Y07V0.988U*N,$%(9K1!-'E'*HY3 /+<"="Q'
MD,540Y;F.B.$,D58?Y6,J0HW[4D^>,O_G '5C9 NAVI@ZNF!TH6*&(>5=H80
MPQA7=,?-V],2&($D<SKS,V->5?RSJ:$^![E:%N^4715J64@5)GI2Q68N9E)F
M.;'I+I62P@K9(FC(0T.4LR16G$C*>]S$Z67+U!BEL:O/!9U^C>%&,B-!/# 3
M[2QO =NOP-85L/4%\-*93FQDLS:?;9N>=WDN0C7\_9Y^YKS!G9^+<#M\#^BR
M(OLQZ9WY1.U,LU[R$(IFB5 84JH2$TGI#'*>9! KJ5/$,A)3X4..N\5/C>^L
M=<":YT=X>YBY<5A_) :FI1:$ 9:##CL=DC7V:AB5" Y[M]^WCSSEUUVEFL\^
M&E;8O/Q-+1;_M5S]N?RF6+%:*EGF$U_/<)(3)),<9E%N>J[-'DNQ^2EAPG3C
M/"8JC5UZ[MF:IM:)*V.!M1;^8<T%C;V@,MBM<Y]'^'0_#XK;P%V^/V3.#. ,
MQY8,BH8-"B7^]6'UXZ^FC(H(S _[_?]\^:-0@;.;#2NXOW!9NKP[-I=?U,;4
MAT6.5 8UTRDDB#%()2<PDIAQ06.=QEZG"O;*GQH9E&F"GHQMI79?<ZFD7U:\
M!D+7.4IO8 :?=]37**QI5S8C4IT;Z3U[FF_8PN9?;>]:="7YKJWL0'"QDX,P
M#9$>KZGB39+B[?EW+!7>_F,]%/%_G2],089 ;I>JU@&+*5,90@0JD=OS1+&)
M!3(L82(H8C'E"$FG^VE'RI]:IV\M!,9$#^GS \B=[NL!\!BXK^] T2=)QP%,
M/&3>+\-F)/EV3XS\A-F/(W!2</W :^,)J1^W>4<@_<1C_6*5K_:(YJW^K;!W
MJM3FEF_,!,DF$&[2FGU:K8_(A,Y8C&)*6 (UC00D:9+!/%8Y3&.-LR1+,8^\
MKB9<8,O4Z' [@"]*0;.U=0VN-'PV_V#6NZ*3>=V>#5=-DD0;-%4O+1R4SH(W
MJEND-5)3#<S47YM6,7Z TA'0>&*;Y&.W2?94DK<BR>'BL@"@AHSA+C%GU'@O
M &[[L6&((GO$D;\MMZ1PSW[6&_9',E!^+>>L=B>O^O];_;XT;894GJ.<2YBA
M-(8D9Q(R$4DSW^1:(JIEXK85'\ZDJ=%SURFP83\!K]VZLC>Y;$K;1_:R38EL
MNG^3%!G(9P4VJ_(E]9,]SI=EI.01W85I8X<@>?26&YBM=QK-GE9J/#J1AAAL
M_6J>NM6@<FWT-O,(XD=ONY'B_O,=[U >\O6V$>NG5AJ(TXWH-V4(BO?)64:8
MFL:;F 1%9F<N$[;DGBIF5>[G_8S/-K/4RS8;2"0I37":0T$S;28Z6$&>IP)F
M4D4\0PSGU.NXBE.M4QLSCR6-MP=)/R]_J%HGTP;.O[+U'VI3]M=O2MA<$MY3
M&+>&<9NL!(=[X(&NQ-C"^AKLRFCP>_WW(.E8O. *JJ#F5/'HZ>N=L3B4==[]
MY1[3A?OO\[7\MEDKM2GG(/5BH:8LPRGFD B90$+R%%+#8%8R0N4I%SA5U#G^
M/US'U,BIM!)49E83=(_H[@B,#B'VY> ,3"6O<>FS('T$((]X]G*@1@I0*\"*
M"K!R&2Y4NM#3$)R,&8^\.EX0>-KVG:CNS*,7*OSO7=A1*4\9BS@TE&?H+N-V
MDXTFD#'!>211PI57ZJ)_D'M0=^O5CWEAKUQ7.^SE&=6-/9'84]9_#U:6)Q@S
MS" 7BD!"*8$,)0@F,J88$9:EB,TVJPU;C =K6]L_+JQNT>KT;Y*-<V%LQ+MA
MD[@&YGGC*^SEKI*Z/Z@G,R.?EY/L]>I)K3<O]N#DQLH#F_CUR0Z__[%>%<4,
M1S37*1-0QW9"K%($.94(*JT$013KB+E'F,[53HV&.X:#I]KR*_"T*/..6_7O
MQGK -J4HN$?(Y=X6#F'J( @/3#)=<!NC06DUN+:RX2VVI>&#(.L1WPZ"\$@A
M[R&D#W[&5Q76H0)B;\Q.QLCNI8T7-GM[N!-)^[]]87"MBN:X9:8T$GF:PUC8
MS'Y9GIM0D*90FL :95)GE$>]XNJVBJEQ^?ZAU8MCORV8GF%?+XA&B_A441]A
M-08.$.N]<GZ0,&];R]M$>*^\/!K<O7ZR_S['WCKD5U5LUG.Q4;)>I]S]1>?)
M&:(,BXC9^,X 2W+!;$H7 @7BE&22XCC.9]7.W+<-6V_<=T%ZV^33.?8M&V'E
M7M@?U-9<&P%R]3!?+NT)HI4&+XIYYN"[K FC3%.48@PE%Q(20ABDG N8Y%@+
MC:5*M:B;\.-23K(!&[O>J/G44KY%P[EO<8W2%"-L?1W:9-S:#MI&VO]=YX6P
MFV$7 QMZDZR_0:-OGEV,W:%-M<L+[7E1^U@8OK\O35-!D>()),BJ BHB(654
M01Z3&".I611[Y6]TK7AJ4?7-:OD ;^8_K-1U>>C9\Y*W*]YN)#D$B@/SX78^
M?M?.QUNSQSD.X(M:T)OEKG6/>^?<$Y%7M]%]W_=CJV*]F=W/-U;$\/-2SG_,
MY3-;_&V^^?Y553JIQ??YT_VJN@%;ZR?0-,X(%@@FB-K,-A&#C!$3X1.&N)(Q
M-O_O0E@]ZIX:9W4MM2=]ZXO:9X49+FZ#TR0V,+(#\UAIN0V?M[8'E+JX )L3
M;&5*[3"5^=<^2_6I=A2BN@"/AJLN*:)?</61K>WDV)[_+!,-?)@OGDT$-TM8
MEN8Z5Y"DR%!3E)@PBJ<4<JDP0P*1-/.*I8[4,S4:JLT*DF7F&+1N85, P 9F
ME\9">\2_2=Y36QDN#CH#0\BPYUA5HT8Y9_S=#VK./=Y[QB64DJ4D5Z7+?/V#
MS1=V3^33:FU_LSU@_$'QS8S*V,RVJ(9*F!B&9#:0B3(!.:&4Y]QFZ/.ZD^IK
MP-1HQ%I8V(%WOCVB[3T)\VL"Y\G88, ./RDK3:_T QLY=VMDY[C[%6C]@7JU
MAH5Y+.BDK!=Z@2=G?C:,/4GKA="!R5J_<OS%Q4K1YKOOJZ7Z\EP>L,6)F9>Q
MU(0^@IL_>!Q#9GX'(Y(F,9%<<2Y=]<3V"Y\:455:Y*6!H++073/L%7"G*>A2
M. :F%P\DO*3 CKE\@?K7JR)'$_PZYDQ7X^OH,_UBD6[V8;4I;M0/M4#WJ_+O
MN,P1H4T_N7Y</2]-'$($%BI',!/4Q"$YCB#'BD,FD1 D3JDD3EVW3^63Z]K6
M2(#L8LJB_#&NLH-9B_UB$:\F<(M#A@)V8)+89FZ_JI?6KT 'YYL:Y]8!\U3I
M0K@0I ]P(<,/K_I'#3WZ(+,?=O0JPW^=^/WSX[-=S_FA/FJMQ*:Y7'LMJ^2W
M]=)DE$J2Q!F"N8@-FR7($)F(%<2813%1D6$T)S9SKW)J'+:U&E1F7S5Z B;T
M;TSOL4CLV #GUX;#PSHP@P5"U&N1V ^D2]>&'6L;;4G8S_ON2K#GF_WBJWOS
MFBERFW+V^N>\F-F)3A(Q#%%N)T(Y0I#F2L T-;,@$THE%#OM3)VL96IL8XTL
MN\'6S'+K]\MJ"5GG=YW,9)Z1U&&PW4*FBR$<FEGL<CE?K2MRV<>P^^\J ^KF
M.UN"W9=^MRX%W$0_"5G(J.AP1:.&/R=]W8]S3C_<,VVG^*[D<YO$[]W+^P4K
MZHQ*7-,D4EQ"*F0.21PI2)-<0TX%BRC/$-%>-T9/U#4U4FE,W>:>Y"^@-+=?
MSJI3,+L122#P!J:3"W#SS]UY'I&@23M/5#=NML[S?K]*T^GP2D_^://<VX3$
MRHRP97;A+4>]>]D^<L=>2MKZDZWE;1D,%4VB^^+SL@J4[NWEY<_+S7J^+.:B
MG-;-9![Q7!$,<YQ$D$21@%3J!&:8)SQ+%1:IERC\&$9/C=%*$ZW"?&4C^&&-
MM-VTBDH+H&JGCF\#O]T'X$B1$VO6H;G6^@*Y=09T'=Z)V@S]=I^KO0:EVU8[
MOW3<BNS7KEM)JLKY*]!Z7BV>!63N$1LJZ! PAMWCCB4CML2K06G,NGM<\:^K
M_)5)NWO9JHE_66VNQ?>Y^J'D_RJVOO]S-2,LSB/&*8QRI,WXI 5D&$>0*H(B
M)JCF;O-NOVJG-L(TW/)H+"]OACZVPO7+E9E/UM:7MX+ YL^5QSUT]Z8X/5(,
M!_# 7-]@:XT&QFJP30I@[ :-X<!:#NX'PM;CCO\@&(]TQ]_W.PYUQ]\;LY-W
M_-U+&^^.O[>'.W?\_=_N0?I?U8-=O5VM7]H*BKKB#ZH0ZWDY]MA+2UQI1J'"
MA$/"<0Z9R A$&-O+ 9HFRBE[G4>=4Z/[K=7;#E* I\KN*R"WEGN0D2/\#BP?
M'M2!*;Z#Y];B-F#_,"2<'L0>'M:16/WDY]K]6D/1N1]2)[G<L:CQB-S/MQT6
M]WRU!X67QWC;PK^:@6'YK&9)A)346$,<Y0P2Q#&DF"N8)(RCB$N$$_=$#P>K
MF!I!5\>9M\'+NC+3@SX.(^E OA?C,_3220G--H;^&@@:#R*]&**1>//(5Q2*
M)4_"<)(4#[\Y'@>>M'R'\DX_.=C*Q.U2S41$\CS7.<2:Y9 (FD'.&($YPE)F
M(D_RQ.DPDE^U4V-"KQG=RBLGHWM3!%N9\ 1X2BL3?ODNW;$-OC+AB?$45R;,
M;\==F>A@%F!EPI8VM96)CH<]5B:Z;_M?>*EN#U]+:3ZHHO[K9KY4\8PD4G*1
MYS E40H)DREDL8AAFB5<9;'$D79:BSA9R]0HO58:J$V\:GX UEAWFCD-[&G&
M#@;7P 3=&RFO"S-GD;C@YLSQLD>[0G/6O>Y=FO,/]SMK<20)5)/VR6H[/2]L
MDD5[_^YN/5^MZWTQ]O-N5<S+3;,9XEPI@1.8Q3J"1*89I)E"D$JNJ,[2-$?9
M;*D>V$8Y2MN%,,NIO]"JOW2-&W*]2#[W.2P:I)'<SCN,!OP;YRR\ HU+H'6I
MND]<.M4<A;>OM'Z%.ZP0$N60AQ&"V#7J88.02.X?)@A:=H\I^9?5TNKG?5V]
ML,7FI9[CE_HOQIY5=1GZT_/F>:VJ1^:JJ#,#(6YFZ AIR(0P4W1[WI819:B9
M8HZHB##%VGF*WMN,J<5W]O1^J2RZKEQIUIW,WZ4S]N)>4:L)Z-*A^DGG['D7
M-IO#='Z4QAB8E(T/E6)H[46S5 IJ/\#]JE)UN-6@\@6TSO1)G]6_03S6 $9I
MF)'6!"[I**'6!R[&\^1Z0?_2QUL_N!B!G?6$RTL+.L'XO#2,KXK-[;*CM5ZG
MTIG%5)*8\!2F(DD@P5D,6:H)%#B3/$NTF69XB0CUL&%J8]>)Q,WSV@VP?2+(
M].)D$UTTFP@%_-M-'AH/@!G*=I(SU%X,/E5P@7"$F<%),Z8P$7#!R3'N=RJJ
M1YB_<_.Q<U3YV[,0JBBZ1Y6+;\:PI;2*D***26BN>!Y%"*I<9)#PC$*>LPS&
M&@F:)Y'$B?LQX4LLF1IAUC;7=Q3J,SFFYQ:EW88T&\,] LF+6LHAN!\+_X%Y
M\^C]WRNPVRIW;:M4WH#/H[>*1X0_5NN,%.0/VDI^L7X(9$^&^Q=5,%[$'P*'
MG: _2($],QZMEILU$QNK6?S^N=B8 7-],V=\OIAO7F:,1939C QQ9A.<\1A!
MJN($IE+J*-:Y&<.\;E^>K&UJ0],'I=5Z;7J6U^DY-V!EK#3*HQ1BDB!H9E$8
MYD@)F.<T%P98$B=ICU11H> =+Q74/LA7)GIO\C]Q9AX507'')-**$@7-'SDD
M62SMX?T,:FU^G0FJ5,2]\SN%17WX_$VO,3=U#@2XVP0T&(2#ATR5G>!/8RAH
M++T"K:T!,RJY0!(T8]+)"L?-B.3B^ZN,1TXO]<[]6>XE-7M*GY>E),ZMZ;',
M[BQ5ZG.&772LJ180I_:@.<DEI#A+(,YU&J>I9A0IOPUVMXJGMX5>*0:Q'LF,
M'*%VXY6 \(V60;3:[?ZE,?DO]EI^!6=K]KDL47T2BWK@%#C9J$O-8R<@]4#C
M0%)2G[=[K$1="U.RC?UO]8=Y(:RVY1=E,R25%=4["%W-LYGF0F0Z%E!2\P=)
MT]R>_&&082X3AM*,IM*-F/H9,#V":EVPFV-/:_4X?WXLP"^R=J?XRQ58JDH)
M;55VOF6SV;;Q%I/KV6@.*U'#-,0X5+=M@5L-&NMMON0R<7W%>.T6M+^"7T_0
M/1::!@5_I-6EG6[0?/PN7WZH_>/>()Y<2/(O=;S5H]X>[RP9]2^E[_GSCR:>
M-C/SA_]8K_XT$?;J\8DM7V8H)P1S16&6806)YCGD-$XA0R@A6$0*N=VM/%//
MU-:&ZI/5C:V@,A;4UOJ>0#\,[6G^#PC8P$3?$ZL>9]!/(G'Q*?3#I8]\#OVD
MBZ]/HI]^O$?LV=E3M;RS6!7/:W4S7ZK/&_5HAD\9ZTC@"+(DM><8.84Y2S.8
M"*[B2*"8<.J\SWFZKJE1PL[Y@JV]X'=K,2A-]CD-=P9HA^ P''S#3WI'1,XC
MP@N'X$CA7(WDID12MB:'"M;<\#@9F9TI8KPPS,V7G9C+\95^2XS-HGQ;27UD
MI3[6,HM3G*16^312$88D21CD4D002TXTDI&)L^1L8V7PW%86S]3GQ:YMK<-]
MV96&:6.TWY+B.6C=UA(# C8PG[;[.UMB;0Z\@5]J<X^G1O5>/'0$)N2JX;DJ
M1UTN=/1_?YW0];5^=%*J95K5^"H[1$Y3*E@.$XI22#)A92 0AK%(=,JHPB)W
MNFARL/2I!6*E<<!:YT<3NY"YD4)O((9>7&LQ")ZCX:#+(3OW;@6C=N6#ONUW
MW,,/]>NF-W:'H-FY?&:+>[5^K',9(400%WD&D>!F*L5(!GE$)4P82236L5+8
M:67E?%53Z\"EI:!C*K"V>F:-<D#8K8N'P6W@_MX7,N_>?QZ-D%1PHK91>>&\
MU_LDX?#&R%D7/O[]>;YY^;PL-NMR*EJ4*\7WW]FR%M7^'U5L;#C24=1NT^O-
M:(QC+ B&3-D#:Q391)V$027B-%,$,<F<E$;>UHVI,5V9GK)-QV!O+:SGPM[<
M*\H$*C]*5T9*RG#9]^'&I=-O]8%Y.D#BA@H*T,&BFY^K3>M0 =+-Z;#-A3J!
M= Y!&G02"1XN\^0?(^5#D-8*E@0BC#7^66!_93_GC\^/]:5SID1&,Q;#*)$:
M$D0I9+%64% FL%(9RY2:_5!KOG))][I3M@]A=6L8CK=J\]P3MNYBE<DL3U.,
MH4XX@T1+9K!2$<3(A \LSK,$.]T4O@BI,0;T"W$Z/8I>Y/W  UMMUWG=!Z]$
MM >]O33?[&ZAHZ65/>A+-WOLX0?ZS1+NUO7J8IGTK:31XOIY\WVUMK=E9XQQ
MP>(R?8'](Z,:,H(%C%(E8Y91(E7N$\V?KFYJG;2UM@JSKT!1&@Q8:S'XQ<1-
MU6^/+Y3W =XM3 X'Y\"]?HODMPK)RE:P-39<J.D&2LB0\$R-HX9N;M[OAUB.
M;_4X!_).F9#M@2VD*A;J^8_YLA[!HCP7/(IC,\AGEEF0A#1*,IAQG/#<_!)Y
M7'0_4LG4^.25F1Z'%8[A>)HH0J$S,#V\LK"/+-0QA#S.<01 :J0#'.Z?DM_)
MC3,(G#RR<>S=\<YJG+%^YY#&N6<O.YUQSWY6]S?,#\WOZGW;G4GL4C9R)(=G
MN>]7Q68F28RCF%$8)TF;20IED!D*11)+09/4)PH;PLBI<6TYD-4+8Z)C:[\3
M(4&;TRVV>^M&&ICRV[,G]M!)Y>!5^7/['[635[OKG_:ZP5:WZ>@RJ?4V_,F5
M(=IBB.,N0>U\DS,R0R!][&#-('7U2=FR7A5/2EAMCT:;ZBO;J#MENIP)*![4
M3.&4)O8\CKV(9R+G<JN?,!@SEL6*4)4SCU0MYZJ;&J5W# 9*Z_JGK5R>,=XG
M<\A9M!U"ZZ 8#CX'W\+7ZMU9:\'6W*#X^61<"8GC6)E6.GCN?(3@J34[6'85
M5WQ.9U4Y6\J(V51</=K-HN+\5K_P_:O:L/G2T#];6V691C<XS;6*4&YX-TT1
M) G.8,ZS&.I<1HREN1 \\@G #U<S-;Z]%J8?/5<*P69<G(OY\9#*!TVW^/=R
MC ;FT\9 T%@8<$_##820H>.1FD8-_DY[NQ^^G7DZW'[([?.FV+!2^6@F(JT0
M%@J2.#81F!(19#%","-YFL8:$9(EEVZ(=.J;&B4<VQ%9;4T.NR72Q;[_GDA/
M1-]H4Z1C[;"[(@=@&7I;I%OEF^^+'/#?96/DT&M]U%GD#RNBUN@UWJ^:4Z"_
MLN6SMJ=!UZ9'STA,!4JS"%+)K"(PTI"FJ811Q' 4$QPAY+0%ZU'GU%BGMKI5
M_;7Y"D2CL/;8M=Q'\L,-?H=)8'A0!R:>!L_&8IN@HU6L^W58/'UT4X+C.I98
MRF.ICK+2@#E_N96,D'WE<;7>S/^/A<PS[X?D:<44MZ)&E$GQ\FU7&\7OU3Y:
M\-_M&<7/R[+@U>*;^J'6G2JK<X>?5NN//Y5XMK/:8H9RJN(T$F:N&9FY)A(8
M\ECGD*=QR@@3423<E1'\ZY\:]U<>V./)HO(!%(T33:\"E1YJF>U6M8[X*([[
MMY+#L# L]@,/$37LGY>@-A^T]K?GS.N<>C:A\\>18/>1=Q\4_K%$W?M^_:%&
MCOXHGA9P]R]V1-GVWC[OBK7W+Z;?VD5[=+W:S;I>RD;6MDS^Q*P*A;Q=?C75
MK==68'(IOZQL;I3JG^]8,2]ST%;R)X)+2G6:F"E'RB")XA3F7&:0I4+A6"01
M0UX7N8):-[51:GMEYJK>S"XWJCL>@L9%FV*H=;)\JNLF*/WLH6@SS$?@MN3R
M9DT[\"#X)JWJO;(S"/HAUX'"&CCJJM$@V.ZO,0U32;\QY(O:6$'(N_7JQUPJ
M^>[EM\)>D/J\M%=,;=UV[ZTT;)8C27*L,8PX$F: R%-(,4VA)(@JR;#(*/81
M&G*OVHO]1] <LEJTI?#I4VV[O9GYRW-17JNTNMRU!X"U+OB1ND>KN#'V,%@/
M3,<6YE+D]ZX+\V\-S*WQX/H\S-XLZX]82 KUJ'U4?O1'99_\>I1P@1X"/W^+
ME._?(JWOBG96_?^FY@_?-TI>VXC^07U55J[!_'Y/Q@'-\I0D(E($9B9FAB17
M#.8*IU"DJ2(QRC'G7M>GWL"'J47:C=VP-ARTEN^HFMS,M0G:5@X[:9/Y6-R8
M>^*?P,!#0 !9A%;XH(/$%6BP *<_*XM'8%&$MVG+X(H(([LQOAS"V[3302V$
M-S*EY[@KOBOY;-.1G]5Q*(X).=PSOE S@CCA(LTARA()"<()S).,PYCPW'R:
M<4QCX36:AK)L:F-DXYC=3G1AS.(D98+?2R<]UZ'"-;OCN/@6C3GT:#=N._J/
M7Z$Q#SHJ!3-NW+$F-*:O1I#@%?2YZM(>V+[5GY[+X>CNNZGEWGP!ZH/ZH1:K
M)UN;O5)3W"ZOE]L\MN]>.C_;I:]WJ_52S7"4$8IC E%*K.QUG%CEF,S\%*F$
M:9(DD=,1[6',F]H(L770<HNN7 1/UD> @=QZ"(1U$907[SI)UBW1=/]5+F]S
MZZG/#9+@'X'#KOR;-NW XT6G56\UJ+T#I7N@] ]T'"RO2!;@UHP@RTX*</#N
M9>=?9<N^>_.6];E+])8M/-;=HX/]MVKI3=G2E_3A8+>6AFJ)T[><@M<ZXJVH
MH1#;O44U6"T#2=4>#42V$MM+>6=ZR!?39VK19A)S3:F@D(G$A &$*IO*DL*,
MII03%C'N%A ,:>34PH):,K0T.+":;)\F]%@1?<.&&7A0[RKT!U?I'A*[4457
M^]@Y+4G5"Y#V%DR]I*Y^%/^;/:^P>EA:.;%[]K,14FASFMRI)5O87;Y:>&&6
MQ!D56&>0<Z4@D58?+%$$,B:BE'&>1*G3,>B^!DR-FKOVV[Q=@+<B*$^-Z6#[
MB!][>[>.&S,/B?G K+L#MY6EV6K.=)(EM0XT8C7AF+DO=B%9U]N&41FU+T+[
M;-F[G![K7E_5_)$_&[:PC/NUK78F<BE)ED<PC1B&1'!DPE:&H(B1U5O-52*=
MKA6?JF1JC+9CIC=UG83381TH $@#4] N/E]#XN.QFA( IY'61+SQ\EO,. /$
MR26)8^^.M[!PQOJ=Y8%SS_:+ *L37;9(&U^^9QOU8-5ERX^B%@9)8H5E2A#D
MJ38LB&,->9+;1.$8)QG-DDQCGYCO?)53X\2MQ9XG1!W0=8O9PF(V,$5VX!I@
M<NP.1<B@RZ'64<,L=Q3V RN/-_M1ROO5^FEE%;<^*+[Y9L_#UT?FR^^=ZS3-
M[$5:+.P^($,<\CSF5D25:89(I+"75,O)VJ9&)*VQX,MJHZI[*^]62^E)*Z<1
M=F.48+@-3"9;R*RA8&OI +I.3IB$9)73%8Y**$Z^[W.)VTM^-"+5?':_9G;[
MX]O+(U\M[*(3(@SG,-$F]B!V]X 2I&",DUA3I+,D<KKS^*KDJ=%#;1RHK'/C
MA-=PG>[_%X$P<%]W]-^Y7Q_U==N'BZ83%TK\Z\/JQU_-.U7_-3_L=]O7Y8W2
M18^ZT73'XP^,G*2R/L[Z\:=:BWEACR/M'6>M_T?=K>="S31EF>8IAXFD!))$
M(,AD;&86G&H:YRPGQ"FOU,AV3XTV7EV^:*P%I;E6BJ Z?WAEI0@:#TM%.+E:
M+-BZ*!\IU>$\Q>'&^E("[3F.W_X#,V;(FQ<=[P_<O-C]IB:0@K)?FTTBYZ2G
MZ=/:$0W;'L&R2O:LOJ\>Z<HPYN;%;L9NKI=E2LOR;,Z'>2$6*WLU_%[]W+PS
MP/XQTT)(S3@R\UQ-(5%Q#/,TT5 ((G.6"1U)SVQM[I5/;:AJ;+\"I?7E!+BU
MWU>7U*,-W,:/H9 =>! X"2K8V@Y^M]:#TOR L^8^J(45-/6H?V1U4W]D7DN=
M]BBC3T8X]I,M-LSNK]9S>GF[OF=_*,GN;M[72TLZ4EAAI"%.B8"$<0*IHAF,
MB<XHQCD7W",]G$.-4^.OVF;0-1K\%516^V1%<T-;Z#2VR?BHS""1*H$TBCG,
MHXA2JSE(N79+43P(WN.D+AX5<8<=ZM H#CPV'(3O=EWC!^[ #7C?*ZV?"YP^
M.?X"PSI6PK]#\*[68%/#>_,^U*E]'X!.YP-T*6C$Y( >?NUF"O1Y<4B1V,>G
MQ>I%J6+&I=0BD0S*"!,S.B84,BTH%#F+XCA!&%&GC?)^U4]MJ/05R6S\&$*J
MM&TB!X(?%/BA-\L\]6%'P7P(==@^V$]4'+9Q971MV'T,PTC#MJ5.4!EVW^-^
MPK"O2NDQN&RES.?+!T/$=OQ:K5_,_.YV\UVMVTE>'4@QA+ @0D)"1 ))C#BD
MG#(8J4A'J=0\QNX9!OWJGMJPLF,]4'YK1WVP=Q@RAD-TX/%B%\RMY<"8#DK;
M.PM)/68)GE![C!3#03[2,+$+_6(+O5V]6Y70MQ]WJ*&A'V@GQP7/(L<;%/KY
MNC,B]"RB3]*AM6*W^D;938UO]H.949Y%.,T%Q"S%D""I(:6QMF=>4D:2A$:<
MN^<7VB]^:J1>F@;*_ZT2E?T=Z(WC5O01 !UH^R)8!F9F:YN5BZBL Z5Y%^'A
MD^'G$ES&2N9C\5EIL*CP*1\+EI?GF/^G4_"\>FO$;#O'+-Y-K'/TJ1Z4]47]
ML6%KG.3-N=XX27.9)! A'=O%#P%S:2_V)USDPDI2)^Y; WN%3XVN*O.@L<^C
M2^X#YD!0%\ P,#UM$>@3%NY#X<%-%T R$C,Y?!Q^='3$Y9-DM/_.>%1TQ-H=
M(CKV3+_#&+?K![:L+S"8R7NQ6LQE=6ID*>],RS9-?JL_S9=F1C]GBV_F-]65
M^VM>E+*:LRA50J8\AU)R$W"EB$+&3=25)$E&-$\3AIP"KJ!638WXNDY=@1VW
MRGE+US$[.K>N@:UOX/?&.T_MRC#M?)IVWZSU!N;KL1K.^_!(4*!#GBH)8]BH
MQTV"8KE_#B5LX?V8OI. Y?WS>FV/_C7=.HFL! EG,$NUA"1' E*54!N#LE1A
MSBEU"C_/5S4U3K[Y?/WN\\WG^\\?OX'K+Q_ M_O;]__UG[<W'SY^_?8O_YRC
M./LW\/&_?_M\_[]^='L";#<.#0/AP,38,=+P8F7F($1W'HV0['6BME$IZ;S7
M^SSC\$:/V>HWM5!BH^1_/[.UZ92+EY:D/K -NVDSJVD:IS$1&";(ZM5F.($L
MD@@BCIG$.-&2:N=9K&.E4R.4QFS0VMT)!ZSE/?+@>36"P\QX &@')IHW1]5C
MDCT NB--OEN4_]ZBK%N43;S"0JT1>D)T<K+N6M9XDWA/[W8F][[O]@L%/VJM
M; XJU0I"?37!II5%,54MYE5DNOFD3(E5(/ILMVYV'IY%0IC@$'&8,JHA83&&
M>:)R&&4)S241L<3()V8,8-/DQH+&2C"O]-6LQIT]:^<72X9H+;>@<^0V&'C0
M:+WIRMM9&\&N1U> ;4#M%-BVV=Y+5Z"6& X7U0:$.V3X&\*L4>/D@#CN!]0A
MB^ZK,67+NED5Q2?CN#U?-5\^SY</MT^FRO+6WCNE5^NM@:KX9/XY?UC.\@3K
M5)I0'#%$(*%I#BE.4IADBC)!#(-KY:<]U=>4J3%S;9:O'E7OEG"CWW'P'9AU
M:]K\Q;KQ%V [*]AZ K:N %[ZTJ%9NXAPKF%Z"%Y=BFE8(:S>UHPLD'4I:J^%
MLRXNT5\)YZ.I9?/R[;M:+.R%:+9\F6D62Q7A%'*<<A.VDL1P8DK,/S'1C'*<
M,>8JA_.Z^*GQ7&4A*$T$M8WNRC@'X#M-9)>#,G1(Z(.'EU+.<;<OD,LY4.AH
MFCG''>H*YYQXJJ=ZCGJH)#J?5FN;*_GSTK#"8\D0V]482DB:(,)A3F0$"4YB
MR)3@,&,FXI&18"GQRT'L4.G4NG9M,VB-!AVK>RR'>36 6SP3&M;!%QDO1M1?
MP,4#HJ#J*R[UCBN=XH'$*]T3GW=[;(!\4%JMUZ64^G51J$WQ03VME:BF?XW&
M0%=>8*:R+-&$YC#-J DS<DPA5X1 S06B.J<BSYRF7OVJGQI7E2>^/5;E_?%V
MV/48%,6!J:FQO5R-JJP'7?-!8W]Y]\13$Z8GY!Y;(H-"/]+F2-L$=A&754T@
MNTWPU#2!/1(4_/9);PA/;I[XESK>-DIOCW<V5/J7TB]^_:+^O!9B]6SGMP^F
M_*7Y453G>.Y6B[EXJ?[<BBLE&FN*: 9UHC-((AE#+B)A&HOP#&61%IF7I+.O
M 5,;*[XJN\B^,$PF5T^EAE[K#=AUQR^N]6X8MQAW2+@''E2,Z<?!O0*5X>#W
M^N]!U*_ZHA<R%/:V8=2PN"]"^R%R[W+ZKKK=/7-3X*?%BFUF0F02:V3#7Q5#
M(F0&\U0HJ.,DSK((Z4P['0\_6/K4"*Q>8ZHL!*6)ODMN7>Q<5]QZ(C+.@IL3
M&#W6VPXX??%R6[?,D5?;#KCS>K'MT$,]U]J:(\:=8\=WJV)>;FHVQU5IDE.2
M:0USPG-("(D@I4+"6"8J$YRJ&#D=ZO.I=&I=NK5Y]W1_8W;O2QE.#>"XUA88
MUJ'7VBY'U'^MS0.BH&MM+O6.N];F@<2KM3:?=X_Q4K=1;\Q/__Y/S6_,'U9H
M^]__Z?\!4$L#!!0    ( !&:65*#-Y9RR[4  +4C"  5    ;FMT<BTR,#(P
M,3(S,5]P<F4N>&ULW+U;=ULYDB;ZWK\B3\WK027NEUK=/<OI3-=XM3/M9;NZ
MYIP7K@ 0L#E)<;M)RFGUKY\ J2LERA2YP;V5=?%%DHFX? A$! (1__H_OYW-
M?OB*B^6TF__;7\1?^5]^P'GJ\G3^Z=_^\H^/KYC_R__\]W_YEW_]?QC[WS^]
M?_/#SUTZ/\/YZH>7"X05YA_^F*X^__#/C,O??RB+[NR'?W:+WZ=?@;%_7_^C
ME]V7B\7TT^?5#Y)+L?W=Q=^BTA!!.Q:S5DP7!RSH$)G7R<3D@K; _]]/?P.>
M>2Y>,F>T9#IRSCSZR*))":33.G.U_M#9=/[[W^HO$9;X S$W7Z[_^F]_^;Q:
M??G;CS_^\<<??_T6%[._=HM//TK.U8]7/_V7RQ__=N_G_U#KGQ8AA!_7W[W^
MT>7TH1^DCQ4__N]?WWQ(G_$,V'2^7,$\U066T[\MUU]\TR58K67^7;I^V/D3
M]6_LZL=8_1(3DBGQUV_+_)=__Y<??MB(8]'-\#V6'^KO_WC_^LZ2<_Q]!8N_
MIN[LQ_KM'U]V! 8B=/T/5Q=?\-_^LIR>?9GAU=<^+[#\VU_FOZ\6M*#D0FZ6
M^Q^;?_CCS:I?%K@DH*RY?$-?N/SW=96G4H#?5CC/N.'IZO-G7;KS0[,JT>[Z
M7\X@XFS]U4DE=G(%W!?S_,M\-5U=O)Z7;G&V)N]%7*X6D%83K5W4NACF4C2$
M1@@$L^*9TH''(+0*2GQ/$'NOMA'6T]G).+W^_(_TLQ.I2]&Q:)8P>::M30RR
MR"QD$:(6QHDH[U)=Q;\D^:_AM,3TUT_=UQ_I<W^LG-0_K%EB7%R"Z7]LKWF7
M]MNJ?K%(/W2+C NR)E>+PB+=4_M=)%_^Q(]?8$$?Q-+GZ2Q?_>MJ5EHJ<M7U
M(->-THB-O_Q TBBX6&!^L]'93J;7'*_(]N+Z)_O PXOY_!QF[_%+MUA-DI+"
M"K#,% Y,^P(,N#8,9.#T#9MXC#WBXO;:>^%#/E]\'"SGD>#D'2ZF'<DG_TR'
M^,0Y*3V*P 37@6GE-!VL@;,8+.2D7'+<] B4.XOOA13U?)%RN*0'ALK+\T65
MX*OI,L'L_T-87/&@%>J$,C)I03!M)+((5K"")DN0R'G,/:!EU_I[ 48_/\#T
M(N^1F)>/"Y@OIU4LER8R.R5]28FA*>3F<U'(.A;RWX&G:"&:#+9/%V5K_;TP
M8YX?9GJ1]\"8V4CEU72&OYV?15Q,T"$OHF260XJ,(CLRCQDH+O0AYEB4(:GT
M@)7M=??"B'U^&#E*OJ/ QGO\-*U"F*]^@S-RRT.0(#0I4SI.]K"0()+)-6]0
ML"C(1D!O^+B[]EX8<<\5(T?(>10X>3U/W8+,WUHF'T@O^+([GZ\6%R^[C).2
M?8)(OA8'RZM)M&0-,;"4@@D94&J9>H/-HZ3LA2+_7%'4GQ9& :J/\.UU)HE-
MRW23L;NTHB5;)Y,TS"@;JY" >><I!N26&^3@H]"]P6D'$7L!*3Q7(/4A^5%
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MZ8$7JY>P6%Q,YY_^$V;G.!$04\HQL%K(RG30G'FM)/.@A5&H N=- +07=6,
MU%$HZ%JK9 0X>_$5IO3E&;[J%A^(H\M*Z2DN?\:XNOG;50F1CYDK8R,#X,@T
M:,^ ]B1SUM7670:*>>!VH@>3]30ZA^G2V Y[+=4T!A2F5#NI+-]C0MI8Q.=O
MN+KBQ2I?ZH-BEB1M)@I0(HF,>,E>9J\2_:8?R WU +E'B!JFMV-#?/6E@!&
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M5!,7Z_ND#5L1U@AP/6MD!!B[+ZA)MCD92_Z S^B9AN)8P"HO""XD<&#S WW
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MK %LT &Z&"FJ;H^#Y08@9%=8++6'"OC$?.W!EHQT2=$W49\,6D^=T-LP834
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M-?2\7R.]ZQ:KTLVF75?V_2?M"X0.)^J$Y4,]2>Y$?1DP\B"U("^AOKBW0K!
MOB]+P7ECG)59-0FK3]2781,)T$)OIA"GL[6P'WAS2#_P6T>'S)TGB)N;#QZM
MB(E\)UYK_D0L#+Q(S('U41M01;5Y;]07!Z,N8WH*^KX3[9U(QR-P(VZLR?6L
MV.P 2Q":9?0D1T&_1*\S,W1>>9&=,K$)2N^3,O#;HF$P<2]!>Y2"1@>QE^2(
M?^H6EQVJ+FL"G+299Y58I%"2Z=JTQ3OOF #'L_3D@*M&^?_OD38L!(]5_J-8
M.EH3(\#6RV[QI<[QV(KY+IDQM949>!(.ANI@>V00*+@C'FS6((QHT_3S4:K&
MA*CC(7"O-WM?^A@%N,[.<%%?DKR#+[BX9$)H:937M6JI1FT) PO2E346#%>^
M>-WF->Y#U S[K+$YF(Z5_PA ](\/?^^^XF*^;G7X">?IW@.V2[ZT,#I!XDS9
MD&ASU-L$Y2++3H+1)?/BFZ33]R5PV*>(C:'61$LC0-^OW1PO-DF"5^?S?,5%
MX5&30) 1R20J)SR#!)E99337,G*43?J!/$S.L$\(&R.K!PV, $<O<;%:=X]=
MX?)M^1F_=,OIZMH@BR"Y4\SGDC9S(4%'P4QR/NL@;&K4GF(W3</<4I_J6.Q)
M%R. U76(_=/%]1__UQ071-3GB_55^SKFJ;T['<4V+!NRM]J:FMDIBCFO=);)
M.VMC"X3M1][ K25&D:5HH,@QP?-2CIOGY??XNYQ9+D I#5PQ [4K; *2))#\
MN O1:>=]SDVZ2CR)RI&DU'J$R2XD]JZS,0'R]?S+^551TM6K*A<XQ4844AM?
MF*Z]!,A/!2:DY)"MX+9Q]=A]FD8"MOZ1L MS1ZIEI @3EZQ -#G97&<S.]J6
M+FL6P4=6@I*9DP\;H$F$^@A-(SE[!T'8(6H9$\*.<%AN"C2X4EE3W,U4G7&F
M71TQBJ@8"$ZN# =E2Y-(ME<N!N[R-"X/\N2P&,&>^$X%VUF=]_??F%]VR]6:
MT8G. H.I(\H+)_XP$FO!!.:B<RC 2 A#%";>(W0D'L#I,?6T$L7C%-Q;>ZBA
M*\I+*DYR3"RM"^*D!6)? E/H$FINM0,] *I[K"@?=1K@)%!O (7Q&_ ]2Y"=
MA!0U$*LIVOKBV#.O91T?++B.'-%L]Z9Z;N7FHW9BAL7_X5!X.O[#!O]S_%0)
M^7CR7JP3CR$9J2,3WJZKJ4G HM0I34@GG"$AEY-8^ET$#MS5<K1@[D6A([#7
MMXJH'QCU-0F*MAT*SW)M=*71%!8"4$CM2[(J&Z.@22KW<;*&O=4:#RA[5-X(
MH%C+F2>%W'W@4K*(CL01ZJ@D*RW+0BD;LXLE-+&'=?%AGD*.#U9/5L30'8..
M;4%LC3>BU&;'F9"ABU0LH%",T\:1)EERM;= -V +Z=X?*HX'@"=7YCC[25=N
MY@3WBT,>?=W\XQX>9^V@I*='5->??G-F7;]A*:&@$T6Q'(,F+8)DWIG (,B2
MN7*) M]6CL<.FOIPM;8^^M9 -N-]]H',K8%4^:V-$[1A*@>GM?62@OX3\3N2
MD8Y]H>,AIZD7-8SS)>HU>X=/K-W^B#X-2<.9LX\!QG%OG2-O!F103&>T+ :E
M64)!?C ="<HW>0#1T)S<S"6]7N2R8]76]%%,L60?'8NZ]J^"DEC@$5C)Q8.W
M0O+2Y$W1O@2.U\P\!36[Q\;VJ)Z1FYS#GZIO?T2?)J?A,_#'P,.CCU@GG7$!
MM3UX2LP+JQDO(CH-6H?4Y WX*3R8]_#'KT"8FL)L^1NNWA9RV'%!/OC$<"?1
M%LV, ,NT!\Z\-\"0!."<"S9N]V;MF>N=I(W7S#P%*3N]F7Y4,H(TT#5'_^P6
MO[^>KWN!+K=8 A6$*V@NDQ.NUE<H0Q&F<]6<TG]SDRS1'K0-_Q"M*<QZ4LJ8
M</9J.I\NZ;#^>]?E+98B:F^*S;17#+'$B25B0M,O1D9#?T37-BK;3=OPK]":
MXJPGI8P)9\3%1-CLH#I[*M0)0S$*%JRI&\6+ +2#C-EG<,+A@"(BAG]EUA0Y
M3Q7S.'. 9&&_X&)U\6X&\]HLJ^8_O]0$YR'>]>X/Z\'/WI/2GCSN.ZN]N+7:
M-8@B*N]\=A4_%+1YCJS>N[)27TPXI47D3?SN[U+60U_[AQ=X*)$5BS%&.&);
M8*ZS:Q.+*EB6+4B0UF6>6O6TWYO(83WR?I'T0 O[-LH:9PI@IQ$X/ OYO8]L
M:;H:9BF_#SN(3@9/\9K,@="@4#(PSC!T0@:702?;)%\WG &[V0E.*ZW (_.J
M3J&-T3 (%AB4Q(O2"4$T&:+^?=+&;JR>@IJ]C=5ABGEF)FKG-PY/9QZ\5DNC
M]B0^3V;MD@P!DE8L2AN8=L )MUCJ:#4?BR^NN":O-9M;NYL+@-W;:_U8"",D
MY+8P%R*Y&;1=6=2T<TL.P:%'RV631_W[$CAVR_<4!.V^I>E122-(.NSDYJ>+
MZP9Z/!KG/ 8F-'JF<^V\$J P#KR^K%EWUSOISKNA;5C(M0'%OF?N@1H:,^@J
M0Y=O?V,,UF=I&?B:)%:)-BO%6$R'D+,BZ=%_3^O@7=,V4CMW*![V]O$.4\[0
M-9\_G9,X-U6(;Q"6^+F;Y==G7Q;=U\WK\\LWX4CF/TN#]7 0)#+:IQZ!O&2O
M5;8^"-QN4KBCM'._]4:*H4-UW+45^- 8HD^H/3J[Q<6UI*Y:"?CZL%05IK6K
M P4-9T'$P%(,W-?W=T+"7K#9N<2P]X1-D=*/6(<&Q\ON[,LY?=:K\\5\NJK7
M%//\=O7YNOVFXT@P3YE"X$!NIY:* ?>1W$XKZQQH+[;OH'<5C3^^T+ 7?4V!
MTJ>(AX;+KS _+Q2.G-=:^)L=<,71]DX0,9NH))"%Y)6U^JQ1VDR>"VT/I3G<
MJ_?=@9ZGK3OLW5]3,#54P A\Z]M;Y-7T6_W3U8FKG.5<.O(%2]%,<V]JD[#,
M$KF*0I42K&XSPW,G2<.^SVN%LIY5,0)0[934F^MG/"67G'P@)RXF<N=$+>\)
M.3(C1:'=EF/1V )<WR=M6 =JV!S!8?H9^HC\&6G9-*UBV<G9NA? !')P43F*
M;'7MG^1!LL"38Z&(HEP4N9BXU^FX]Y(C#=P.5'377.HCL%ZW.DA<\5CU17^>
MX5IQ\WS93VC]]9W,3R YL'5*K8E(H8E#R;R2B24>E(\D$M6F;W-?#(PTE#P.
MNX-J^=A&(J>QE;72+8.IH[Z!R;SF*E-$K4B^2B6+Y(1H8?=+5.RYX$BCT1/9
MR:=*? 0-R5YV\^5J<9ZJBM:%VY](9\LK@\\EVJB9PTR^B?+D!=<WVEY&G53P
MQMA&8X%VTC32 +4?6]:7+D9P^#ZZ1=!E)XR*+!8NF8Z6?(AH/>,9I8ZI6&Z:
ME,T?;;A.'Y/V ZS>M/',BJ%?Y#RM'PVSU_/2+<XN78/>RW8>6Z=ER<[>_)VL
M7,>G('3@P#";.G4/D45>++/)BN2\L#$UZ<O0O%QG'^=R MQGS6D7%</K6UV=
MF8? F0H6:7_Z+&.35-L^Q(TT@CT(.=OVK7?EC+-$\0/.I]UBW4P.\V_=ZK#"
MZ0<^I0<;]3W:>K) M9O>0PT_"KG7*0H&V9GJ'=&?@B;/VVFT67FC%+39> ^1
M<ZRM>=/-/WW$Q5G]])L2VV!%<29G%E($IA.Y@2%(P22XZ#*$$'T3'A^D9EAK
MT@,*MDW(\3)_+C;C</]GYV<UL1\-_9A=^ %1?'*182(=TUE1:T:C8C*F'%)"
M7K#1\=VG%5EG*VX+\G+F@$TZ*%H\^4*;(]5] ;;^(F,!A3EN%U+OR 3=^^AQ
MVH(GZ/).GN<XR8T@]*Z6;'5ER:Y* Z,QD+-#)HAF"O+JG!VN:[U$XEZ6$$UJ
MDLIYB)AA\-*'<A\X,XZ2] C1<GT!+IW%Y)BT7C$M4V!@5&$\RE <9B%2DW$Q
M#Y,SK(4Y7LW?P<T!,A\!<C8G]GHK7=5V6NZ#]Y894P<W2>[(6S*"B>!-B8@N
MR#:=Q+8I&1=>#E'O]CN4HV0] K!46;Q>9[?707_=025RFPS1+9.IOC6/S$<K
M:P=A'X@7:TV3MYSW21GF@K3!@72DE$>'D]_@[&KWA*"M0%V(^EKK*6OCH-JT
MJHZ'UL:18$P3!V870<,[O<<H^E'<'"CUH<N'/N!7G+_KIO/5^D^OIE_Q'2X2
MUK_?BRW/\6U:=61(/_[1??S<G2]AGE_,\\<_Z,<O+DUL%KD.9)-,%T&_2"?J
ME#8*(8+CX-&"4/N]#>F;LC%A[U"P=&/1W/"PO6'NUFV?2A#7CR 2MTRKK%DM
M$64I6*VE]E&@VQ-[#WS\,%4:/1YX/4EN! ?>+<]N$B5/Q27.A*^MZ7.(!-M0
M1^ *$T&!+:Y)H=DM&D82FQ^HSMU>\Y-D>S LON(B=DT\H==S@APN5^]AA1]6
MM8;LTD+")YPX%!2%)L.XDR0H[QR#S#V+/J&5263K3^!)/T;B2#SL?F#52#,C
M,$8_7R[[:CJ'><(Z9;,V5YPXJY35=)X&C;7X2 L69.T@DP('%S1MKD;.]X/T
MC.3XZ@M-Q\M\:!_F*@??G<]7;^<?%S!?0KJ\@W\%J<Z(N7B%N'P'TSP13FKP
MA3:!DK5K>@;F:__T#*BB\,X&-'NY-D]9=9BZP9XATU;6([ _[_$+7*Q?B[\M
MF\.[<COAL6BK:ET:%YYI*RFT]4HQ<A"#*K:06]^DJ.AA<H:I%&QD?7J0^ AP
M<WT&8\+IUW54P=&B,]XP6XLDM1$4 A81F",CR@-M">1-?.G[I PS-JX17HZ4
M]#AK)-;]*@ZJI;K\ESW4/SQ$0T_5#IN/OKX9%\$ !&_)$[69]"4U^12$Y<R%
MJ?-,7/1-.JK=)>/H>TM<+A'??L$%B7K^:?/A-X4[)M2WMM$QDZ0CQQLU"QX<
M*T89XW*PY)2W8?(QL@:^ESH<!_=N,/N3_IA-PN'=:>_\^][,0\.^LUO@ &U"
MS#&34:^#SBI"0#MR'$N)P:"&#';\1F(+H&_+!K</]5C..@F103(,M=+/);WI
M]V A10?$=L(F(>[^)([*>#P%']O&HY%61N"'KAFJ$?SV#"]=H@C:,F4]N4BJ
M%.9M%LPY;J7(":-O\N!I!SW#/@CN$4E]R'L4L+E_FE[-UKWX%6K+FM7%%HN%
M).,4[0Q#T1@=L<DQ'Q4PBMIDX9$.<-ED4L@!M [[)KA7N+75TYA=H9Z?TGW_
M0WMSFD[]2&X+<)8+40 $$\(7II',D#<HF"0/.3L1HXPC#K<V:83K9C:WW-!)
M,#GH$"2K%QET-AO/HL5ZK:9U1C1*YO(]&.S^^%%Y.T_1X=TKZJ,E-XKC:7W*
MSM>R.(=9?2:S+CDR*<DDBZH/D0W3UB(#E*F6)+HZ@DMHTRY(>("@(2^OCU?T
MP[[-_V7O39?;6G)UP5?I%\ ].0\1_4>>JMW7VW+8WG7B]!]&#DB;71+I0U*N
M[?/T%TE1HS4LDFLQ%U554>$M2S(S 7Q  ID8]N/Z2-&S21A211OMF0"6:V\U
MFV/MS,Z 5(UAB<%Q'";)_-$MC<#J["WR#CC:@?^MGQC_F"Z7)(97X=>:H*L.
MH"A"EH77+5-\J)6"('0$"AD%6HG>I6YGT(,?/SXT["*X>:]<;(V#K]^GB_QE
MM4!<W2:A>'*SL9!?':M;;YRGB(_1'YK3_S*6Q%TG(#S\^2.(F'M&0@]\; V%
MRY/VYEU+(BM!JMH].CE0:=W^GD)_@2RAT4FS^&Q<\M 'MTQ>ZLVMV)MCK:5]
MLL"P84/^\B,DG(CU(S4WD%3URG/V$%$9T*&DVL^!#%FW'-G?/KJA([F7B.:]
M\6L$CN/=>Y9ZRS>)CHN2DB(9$AG*"D[ -Q&P*!L=_8#+01)!?M]*0YO0!T)Z
MXO'H4/)ID\PR4;XH<FHBI*P0E*38W<MBR8%&*8/BB8['X9%RM9V&"8O#H64G
M7H\.,?^)TV_?5YA/?M)WO^%GK&[5U0^KH\4G@D6A,KG'"4.$>L36PDT.+BA/
M89G+R1W@:?#YC3;,<1P.93W+9^SXN\KLK-GDFSSR28Q%9NT,2!:(F4A?120E
M*XJ%(H10/@^2RK;M1ALF1AX,?_O*9\Q//'<)_^VQ9(\\F&<_N;?'GNUH&.;%
M1P3-K8L,DJR=[*R5$&1*]$<6Q?G,M!LH]VS@%Q_&O4X^!> Q6%!,&G )!10T
MTFJ2N0G\.4 <R8O/-C+L\.*S#>=&<$0]>A&M!#,B9E,+F"@X2%Z!%V17?=:Y
MV&RM4X.,9SR:%Y^M!-WUQ6<;KH\4/9OKRLRDYI&4218M087$(,I24W02<J-)
MX?[]XK.]R+N_^&S#_]87?H^\54BLEIE!]>M!%>))E-Y!TAH#LU:+^S72+^+%
M9RO!=7CQV8*+K7'PR$N%23YSBOS 9EGK(S6"$SJ#E[P()YRQO-M\Q2-[\=D9
M"3WPL344[H=YO!15LN* (FKRTE2 D"0"ESE[+;Q"WFU*XMA??'9Q*_;F6&MI
M__:"\0;/IA2&8YYP8R+:0J:+J=IJ1CF(R3+@A1>&,3#I32?!/[[&B-Z MA+:
MDV] NW%P!#[EYWH+<UK^7.+)<HFKTTC1_ SS^]G;O]+W,/N&[^:+1Q)S)Y+)
MP(N*P'.E%SV'R$,F@Q>=)S,7BQ\D:-ECSR-Z7MH%?(>66FM+]?&B'J6GI0[P
MP72Q(AVK)_;RZ_SM^H9I3=HDLAP\R@1225(YIS4XS!90RYRD2]*'U,EH=5IN
M1&]..]NO_OG:&BGK':\W7[WR2LS$)5V\#PP0BZM3K!-X)C1H)U))VBF/W<ZR
MWS][1"]".V-@3XZ-^<+]RM>;E^OG][VOVI_XS-XNV;ON>Z#25$OZ;$7M7* $
M_6$31&TX!".#L2HI3(-TZ1^R-'6=>5&4(4O&",=>UW<DD6NQHX<2=> B6>^&
M:7.R8W;+P4I-MY!WA_R6;;@\ L?W[V&QGCEY0X"(V5JK+$A)5)!CQ,"CU8!*
M)1F\="8,4E#TVTY&<$72#TKVX_$(0'*S<2V$SD5[R$($4"7583C"@W&9&99<
M$,/D"FP'BH,5>^X!BMUX.LX!B9=L>7>QNEC@']/9]/SB_$X*5[D?ABWW]D-V
M6:PW!V5O2@<J!74BJ^PB>%4318IEX%+)8$R@HX?\8+(ZX_=<GJR"ON+SFPO\
M2$S\^D\\^XE_S&>K[\N)3R[EFE1:! 7SY*1;(M\E(I^S$#WQ9JARP=TV/"HO
M:!OL;%6WWI?$1G$,=J/SOS#4[N$3R0VS62,D3(KB2.LA>%M[F$4*,;,PJ ?2
MQZWV.2H_ZQ XW$4^QP8_PA-.I*M^19*07"8"B5APF1P-J61VTO@4!YK*M>U.
M1^75'0R"6\OHR$#X;GZQF*#$Y$B3 'GMU8;$4E\X A,A!\>,0APH8MANHVWN
M,AM#<&L)'1L"IS]Q$DR2DE-L1F%UO<XE77,J1P*,H&C-:I-L;(Y VFB;_/;6
M"-Q60D>$P)-":UX3Z8L5,9"SFZ4F9[?H &3:/2B>,Q&8$E,#-6G;8;=MF@HW
MQ.+NLCHB0$XHK&)"*0Y)^PPJ(8)G*0"FG+QG2A4Y4+.H;AOL!#O[@F"WE41Z
MN_P;"&E_SO*F? GSV[\2_>K)>?W;1"@;>:+HWJ(U%.?G&F@Q4?LE)H4^JV(&
M2NO?8;>=,.B.'8.]R&I[0/I+0,[P6YUD\[6OI(<G"/V*LS!;O3__L9C_Q*IV
MGW%Z'B]HX<OJXBA\ELP7"%')&G]I\-Y$('?$2A;I[_=-XJ/I$;OOHA/F_(@Q
M=U@YM,?=PP_ M[++=,E*DPN+(D5R&Y*"H$B5LL\B<H-2LT$LWC[Y?IR-&&!]
M,GP$Y^@C9+R^6%1^3I+*A3GR.@WCBHQP=. <K].7@T*&@DMQ@/82][?5#47'
M\&+1(_M';XL^SF=I0Y<.2EI6:SO4NMVYE^!U*&"=]RDPQ6(XI%6ZV5DW9!W#
M&T2_0AAS=N$.C^"3>T7( S_X3WC3)__[U%X_^O_'CFS?@&F*R\]X5FT'G4??
M\4LXP^6\7&[P\_Q7.*N_L1.CMUJ@#];N3M&>&127_NJ5=FX6_SJO*Y^63W/Z
M[-4TG-W;P<UHFTPZ[.OH9U]'VZR'W"@R>]S((%+BV+5(=-<=[!<N;;GH3;/Y
M$)0/H6BP,3!02=8!;BQ!2C)'(8Q@)0Q"=^,A)8=#R]UXZB""&ND9LXUIV&..
MT@[+'-KP#3"5:3] *VM+LIA!2$D>C"0WQNMU]BKYQBB]8JIC14D+\W>K G9;
M_;H[>D.S@L0%XH!"^L/7EF!9&[#6IZ2\+2YWLX9][>@8C>,V6'JL$<[AQ/@"
M;&7?@U;Z6OO05O708UM.:2>+6SN\&4=VTQ0J2F4B1=!>U&N'6LWFZDV\3+(P
M&;5V?)#N-<]O;1!_\R&UG,2LL([/ A'J>Q@*BL)+B!!D0":#\3EW:[2^S:IM
M,W%[1D8G%W)OWH_@U?LK_=YI.5DL:J5W#<77G8ULL-8QST'KRBKC.$2E.03.
MT2N1E1DFY_'!W8SP1-Y?\O.^Q3 "+-W:_O)DEC_2N7#SG:_TU9+4D,2VW'2U
M(<>@:*$8<.4LJ%"[!U@9(>88.>EJRG:0"_HM]]G6L/6 C/GAQ-2Z=/_3Q2)]
M#TLDNJJFGGQ;X)JL>K!MR%%:N9(P@F.U9T7PI@[.**"Y9Y+'[(O2G0['Y]=J
MBYQ!Y3P?CNGCQ9!@5ZS2Q4<C,Q&QGNA26W'I1(1Q)M (=-9UZVOV_%IM"TM&
M@*&=F#Y6#&U(T2XYEZT S;P#I9.!P)B!K%W@W@74,NZ%GRVP,UA%2'/L[,#L
MUKCIZ'!^N&[9HI136"('6ZVKTEH1OYP&$]%Y*[U/MMMPM6U7;MG]:FBO?'A1
MM,;9I\4\(>;E.^+LTQ=]?UO,E\N)PZQ4"@RD+QQ4S!I<(0*UTS9(Q[G2N9O!
MVF[A\<=^.\I_?B!AM ;:+3M?^S0L.UXO3S(/ABC+D*T-=,1["PYYAL(=UB;O
M1&K'SK&[;6#\YJT'X!U".*T!N,DP^2/DVLCPC^D9+E?S&7Z<KTY("/@3\U4E
M,[D=L@A1P&I+_H<6U;_,'$K.S*N$5J2.-J[KDBW;_QW.N@TB@.. U>D,)PJY
MM)D[<"8+J'6@X *3X%41/K/L1.KVPMEYR98=!4<&JVT%T!I6EQSZ=1W"U/;B
M4PJ99JL-O6]PF1;3'U68$Q8S\<=K0,GJHRO%--YH <$DPWCFTEO?"5G;K-IR
M@-3!P#68&%KCBX+PUV'Y?4/?9U*3V04^S<Z)QEB<)((D5W7<L**07"L# KEU
M!651JENBW@Z+MRFA/3#:AA;*2$#W?D:?1U;Z[5\_<+:\3^ -:3$()ZJ5MB;7
MR<GD9T8N$R"YEXES+$YU,VO;K=NF;+8-U(8016N4;2SS:;D5U5P3]M@5X?M2
M&\@LO\_/\OOEE>,P*8[\3:$R",Z(O8&OYZ36Q %C9?:2<=^MG+&_/;4IJ&WC
MTQU:A,>/W%M>[\26R)2K/;>9(\H=*:X/KH"3,=*A$;*+'=\6^MQ6F^+<H\/O
MKH)L#>%-3<]MNJ_X>E7B\Q$QK_D0?GW]CF^FA7:)LX2O</5/Q-DU$Y83SY-,
M49%O(WPA_DL*V%AD8%51GN(W5+F;^>US5XVJ?P^,X&9R? %)P5\NSL_#XM?\
MMUSJU?RQF]0#I0SOOK-#)Q3WQ,/#I1OK))UR@3"ND@>5DR#[G UA7&9>N]>S
M.,S<^4.G&W^]%-EO1N?S_.SLW7SQS[#($Z)52N8D(->VSOPH$)0*$(4UR;DB
M2]RUI*_#\J-/0-X&*\\\1?<MC=;^PU9/^B)SGA0:B(Q+4,48<,X'".336VXL
M=ZQ1>OM@>5B'15=/O!]!2O+#V;-<Y,BBYY!-[4T0M($@$D+2G)PC) +%(#VE
MCSJ]?2O)=TIOWT8,(\#2MOEL,B1FG8B01,;:$K80Z]!!C-;Z$HQ(=I!*I!>0
MWKX5,O9,;]]&3*V/R0Z9UL9&FPQ1$F)][50HZM3H "YXJ5$2_V2WP_&EI;=O
M)><MT]NW8?IX,72=:2VS=RBJ%R%U)E=BW<S:*RB<87!<<R<ZIBR\L/3V 3"T
M$]-;8VCK"RE3A$S1:=#1<&(<5\0S.KI4SHP<"&E_FX?V+Y:FO(MW-;PHQHJS
MQ^Z"ZO/F58<P;8K614.NCH-BRH)WT4%@V5B1-1=NF/X:-WL8OV>_(RKVZ:^S
MHXAV1N(/7$SG^<LJ+%:]I6?],9_A:OH_:U%>)6]/C$[.\JA !(JZ%9%3>_YJ
M$*A"]%H58;O5%3ZQR/BM60^(ZHO)K8W7+FD]QJFLC*RMRQVI1-860B;E\"45
M.@44G0/=<I"'RK4:23;RSN :6B@C 5W7!!_TABMM(N0@*7")@DB36M4!X#[Y
M@BZ$;I[^ +E6(\E0WA=J0XAB9Y3]Q$6<]Y.SLJB'^V?\<97SL%&I2M:UN5;*
M).LH5,HEDE?+72&'5FA(,AGG=&U.U;'6OLMRQY2:O#.J^F=\^^;+^SJ2SLM@
M(R]UZE&=_R')-ML0@=4F&;4^#K%;QNC OOY($I5;^/K;B&A/7__M+/>'1J+B
M=/8@/_^<A?,YZ>+_$!_NU=%-I&,E.,G!RGI_K2.GH(9\!\NR\T86211O!<B=
MMG%,&<U[8W)X0>UK)UN:R(](!\7[Y?(BS!)>DJY]JGTAR<M(GKQ:P3S$6G*7
M!,_TA4Q>#]-_^:E='5.:<P,SNJ<8&\[L6!/^=KF:GE>*3V:SB]HS\M(S_DS?
M.OU9\QO*M4?\ZV8JB>?*Z.K&\)0L*.\9>%X$4$3&L[-.9-;M=-]I^6-*7-X9
MD<,+IG5<3)[Q\@>2Y?^)MZG[A(M4Y?D-)XIGR8/*P)*A^"OY#,Y8#1:+)/\Y
MQ> [/GH]M]11I1+O'JCTRO%QY@>_GI^?3U?KY\,PR]=5HFG'V1%/?5P/F;B=
M=]M3^NRM]4[NK?= _IITZ'DR!;0TU9H$#5YE"287@D)*F-T@,ZZWVN6^.42=
M%KMIJVV++4G9")84#Q33"8*(%J3UVBO#4\'2C">-6Z8/C[+[F44#"N_HS-ON
ME0O/?^BPIF[ >H'MH,@U:NVS 5EXJ/@($%P,('Q6VL=,?S%';_ ^S)?+.TML
MNK)Y9I'+4(LR8YT7(,"E)$"BPJAT\J2*0]#^\':.R8!M@YK?AMGN+XP1Y.'^
M1L6K7Q]#]5Y/R\VW?ZWS2%5))623" YY39DDREB$HJ13/A?O?#P(S![=8EOH
M]0&(YS#6CW1&A[L-56_FYV$ZFS@,&@U3X'(]Z^L?T5@$+F64I?!HY2"V_(D]
MC0Q9/<'@2;3M+I/6UQ,?\%LX^R.LZL=M\D%+DN0S"812-ZV$0W">.=#H55 L
ME1B[=4#\_;/'!(T]9#;OCX$C,"_OR0$]GTW+-*TE\;>+L BS%>*&FBQXMH$+
M( XP4#$*B)PE<(YE%6OKO/M/2OU8F*>WU39]NV\D#2"*UH:E.I>X2--P=IUS
M?J4?.EHC4!JRMIY"8:RY=+731"I>18O&!=ZM4<CC:[1M0#Z(H>F)H:UQ\0<N
MON&"XHV3]-\7T^7T5JN2UV=A>G[=E%TRIV/Q$#0CFE+@X*U7@"HG;DQB/C\;
M\6^S8)O,L$$1,P2K6\/G"Z:+Q>V>#G<H42H[G8*#G&LC5T],JVW6 :TI,2C.
MP_W!/H^ YLEEVJ1[#0J5_MC:&B ?Y[.GB2DFD@=6'!AM3<U0L^"3=: <^6R2
M/#?O12>,/+=2F\RL06'2*W,;(F6Y6$T^UW*[=1R(COND* 1T(=66;:&VJ@@%
M3#"6.:FY+;J#ATL?>LN[I;_=]VSOK#HF!W:O^Y?=>3D& &QP*W@ANH6L^ZQI
MJY8(X,@@!VU$UB'SHGJ%0,MX> ^)W9?Y#NQK+/4_PE^UT=A51$6.#EG# ,4E
M!4HRBJ@8?15R],7XK!AV>0[H)/<[*S>6_"YRF_?!Q*8%!(]:OP_762=9HR#:
M#5A1[VZL(C(D_346B\S9%(0)'0"Q_\7]AZT*B0\4R@YS4;\;]T=P<W957'_S
MD/89JX-%E&WZ&9Z<SR]J%_?Z<_*5)D*R( 33@+H2R#4'IS6"(:V17DF9S"!Y
M%5OO=$PWM;M#9'Y(>8T D/><_I.4%A?A[&3U.BP6O^B;?P]G%SC1@M17L ",
M&0^*+#V$&!TDRYF-:).P@W2AZK2[D?G%_0"O?[FT#K-/X]GTVUHLRS]G)),W
MTP4F^OV363XM99IP<>\N>_FI?BM-<RW*,3&HX.GX",8).CZ,!D]N*&C#)5.!
M19.Z95;OM8V1G:S[0>W 4AEGWMB7U3S]H_8 ID7>_O=%S:+?(5'L@4_I(3/L
MN;WUE IV^='763O)Q.2\\,!"S:*VZ,"13PY>&6MS%,Q*,82MO[N-?<^UWWGW
M<;["AW(?32E.)XIF?;9D0UD@&QJRI)#6>104V&K)AZ"W\P[;.E9[H./^F3:,
M3([%KNR>AOKH9PUB8P9,.KV'I>*U=[6#F+3,D/?"!03+>:V[U3DX);4<)+.R
M9TN3OF.^J(4I:UZ^^O7Z+"PW0:^*V2-G!2P=R:"JRL1<&W/8)(4,.23O![$M
MC^]I5-9D&P3\9DUZXGOCV\6OTU6E@;RLZ<]IKCY^O6(U&:V5Q(E0!+&#YWHW
MIAF@R=(%Q5E*K -P.MTR/KB#MC#I3;;S/AD]-J3\YW3U??VD5MWR[],?7^=O
M*3@@"W[Y9E<R]PKK#7U"K)UI'7A;QPQ%Q9QD3K'[LTEZQ-#3>VMWE]T#"I["
M5(\B:1VOOR779/[K.I/,H1"AI )>Q  J,H2HR7+'DDQ0,AO7L=W7W<\=$1+Z
ME-V\'T8VMCA7EP%726,F)!L=D9QC(GL;"VF)U^"D8]['X'WIDCG>R:#<7;K-
M%=^A4+(GJT=PB_R%A+'.+[ST[U[/SW_,9^LJH6I=O8U:"ET@>K*IRD@-,=8>
M)JAM]M8:Z0<9///DKMK>&O?MX/0OB!&@ZAX-&PW#9(2KK1PLBZ:F-)/]M/25
M5DPZPS7/?I#BZP=WT]A-[D_:\[Y9/P+\U$>Y^6RM8%?-[S-FKK6%G(LEEMA(
MJI4<F""+ILA3!]7%)=ZICO7.3L80A>\EW0?JS7=G]0BP\NDLS#Z&\\L$IVQE
MYEED,%CMKBL:?"D>DDXVJ>*T,EURN[9_<[^UB;9/34.=3SNS>400V:A+2BDF
M$B2Y=KF^O9H$SEM/O%"Z2.')VQODG>3N-MH:DMW%^0@N=N!MZSCYZS_G7[_/
M+VKSAB^U1_,*<?8)%V6^.*^MS][/:@^AZ4^L)%YY]UEK&6HBM:U56;RX>D;K
MFOTLR<H*CJQ;++W]VN/ RRYBGA^.YZTA=75CL+:]5RE(MVC!B(RV'<%F)HEO
M@2RP#1H8%F8<DYSQU D_SRS4-D;J"RQ]<K,U,D[.U^]P)[/\&9?5^\\D4GN+
M&&>D,9IIX(X+4)*<?B]L!BNTY0(35YIW@L9S*[7U3_K"1J_\'(&/<E+'J=9!
M=9?M"K)S*>0,11$%*M2"O2P=,'+I2_(FH1ZD$/O.+MJ620[ER.[.Z!&@Y,MW
MXMTKLH*YQH X6V[$<3-A[-6OF]_93%-?4WQ#]BS?TT&IA%"R(%CG5>WVH\!+
M;R%JR4)066 9Q!\>@IC&XP)WQ];]Z\#6@AX!V.\<_Z<_*@.N2@^U5+E(1@>_
MHU/#IP(.$0%#"2JH5% /<AOTZ(X:WR8V!\O]2\A>)-=^ ,GG+W_6=FF?Z#]7
M^U<H?% <1*B78P$#>16Y (H0@RQ!N/M%9(\-X+K_T8V?-<8"H1[X/C;3M2$A
MAD !K!:02CT.A$Y 3DR$*#':Q*75?I"[R0?VTOB*<BQ8ZTM:(P#<EXNXG.9I
M6/RZ;+6])N4R0\9S;C0R, 8I2+:,"#%2@'$Q2<F0XJ1!<C4?W5';EAJ#O=_V
M(H Q(.EF^U6]3LNM>28;7<O%D_]J!6AGB$^%*W FDY98Z;7SL=[8#0*I9[?6
MV _K!P/WD=6O0$8 L8?L+45'21:)P$)Q1(+-X!A97DUFW00GXF^C=-N>CL.!
MJ&=Q=SCKMN']"."SMM@;%GVX*:2+*"-3"0+#0L:;A?IL;0!98)D\1*T':F/_
MT&[:]@,:ZHS;G_$C0,]Z]W6\$>8W%XOI[-NGR^'-U>%<?L1_KG^TG,@D(P^A
M-M;3AOQ)YL%KI0&58]FZXG4>I'"ZV_8:-Q/?'P</%9CU*Y3VMP>/$741_W],
MJZ_S#_3C/W]0*/-E59]#5].SLT^+^<_I<E.L2[\[01\\&I^ $6_)-)/B!D-^
MA'2:=-5R$62W 6H];*;M#45_H&LBG!%8OENI7J_#C^DJG%WJUV<2Y.(GYG?S
MQ>6$IJOA;Q,?C9#6DI8)3NY%TD2@2!HL.1I*QYCL_7'SO6?===MIVPN-_NWA
ML*)J_1;^[ 708_<_EU?)R\VC[V*:5IC73/IS-ETM3R]6RZJLI,P39=%*FPJ4
M'&L2(\5:WF4#(I9BZM3">+\6_C&[.?A>VSZS]FU6QR7:UDC_>%$#+&+O=2?-
MDY]A>E8]<5+A*^5=]^^X2>V]XEJ]X5Q.*-+#G,A&)BXH..,"2<65@FA,SO2]
MQ.YGS3_6PW3OO;2]N>L9J0<6S0C._YUU\YI5ZS/H-IO^5GO63U@2F*3E!#KI
MZ>S) APYZF"3D5EG<H/,(,^Q0Q'4-GH?(+H:@^!;F^);+M5)SNL&Z5=>U<G%
MZOM\46=W3[@1SB9=YQO7"+,("='G"#(IFVQ6/*AN[[N=EFLS/'T@@]H_@U^"
MS7R"%5[ZI(JO4]9J^FJ2D9B"Y,@H9K@/AN4TS!73<#2U&:T^8LO9D_A;&\^'
M^;#V@M8_^C ]GZ[H6'C[$Q>_3F>X_N8D"($E<09&U>I%+4OUU.F@R,XIGFUA
M]X=/;A6$/;-\FZ'J!XVK^A3 ,1O;]1^?\7+R"7[!Q<]IPLM+.CY!STB9 D+A
MGO0,70$B7D% JTQ,ACR6<9G9IZAI--9]A!:V-YF/!?CQ>2;$^TQX^]>/Z>+2
M%%Q>25L3E=!201&B=GF7&8(DM2].9I.U\V68&]O>*.@&\&-ZVFHBVQ& ^E8\
M\'L4((1!)3)0 &GJVW/M<%!G$P@?4T[>F()#P/2)/74#WA$\;_7-_]:^)Z&_
M%H6&;WA:KHL %V3L-]R:B!+1UL<WR[BO(_$\N" <!"==%AF-%+J3F_G<2MT@
M<@3/3/WS=03VY@T68LIZMOEB&B^N_./-_)*3V>PBG-W^87W%O<J&VO!B$B-7
M-B<.#$DEE*:OO$,%1C+O133*#=-2N(>]=P/G$;PCM9+G.""\7O813Z%V,+OI
M9W:']E>_-J37;+Y4F&=DT5VH-VP^@4N*0=2E>(8YQOO]_GK#\-Z;[P;B(WAB
M:B;1<:#X(<5]/5^N/F.:?YNM71!62DB:CI.4)*\3"#@$7B)8RXRPI* E##)]
MJ=/NNN'PB)Z ^I=):[?P]?>J1.]G:Y+F9[6;R**^V&Y"J,N8J=Z(_87IHK84
M64ZD(+J$)?(H6B*')DEP!B,P$8I)VNMD7"='<?NUNP'J:)YZAN7]L4#K]?<I
MEFL:-U-7)KX.TZLSE54DZZ-<(+N-7(/Q.5JG2HS2]HJR![?1#7!'\!1S8(D<
M"_:^X&PZ7_R]WGF2;-=#?6KRU-UO3#*SB6>9H&BL'9-B .)$ 51*1O(H@E3=
M^E7UNJUNV#R6IYEV$CL6K%Y%9<N)-5P59LCL1Y&)R;[.C([T55*:RZ15Q-#O
M"7RU=+?D]2-X.#D Y\<YF.<#*<ILB6%&7NP907%^>3E^\FV!EU7C=[??;4+/
M\Q_:PZB>+7?>T\R>T\6W0&[]>BG"R7)^-LV7Z\[RIUN4G)9WTQF!9QK.KML2
M+Z\'O2@3O99.@45)!RCG'KS,2%%H\-F5K+@=I"ZSE]WO_X1Q+:Z?>"ML?W#R
M5>(JDQJ!EK44TVE>X_,(*0JME,TZZD$F!FVQQ[958X?'X^\O(L.(\TCMY;H@
M=!BKN?GH0]C.AZ@8E04M3%LE5(&"2H+*(H"WD@+AZ)TUC%G"[XNUH#>ER(\I
M7_6!/\YGZ9$?WZI^OQ3UC8KFHGU4*=66+]55)CUU4660W@H6C>:8!YDG,"!-
M+\%";X/WQT?#M87+"&[1UZX]45*?"%Y?+%?S<UR<+)>X(@9\F(8X/9NN?MTC
M46:G*8K(P.NY2+1&<-)+"-:@L%%F/TP3C1WVVK:8N#W2AQ;OD?HDFU^X\U/Z
M[=/5=UQ\K@W#+W#W<:P]KGX(SV9'7HS*^;%6,>9,!J5SO7JU'H)#LL$\\%""
M$-D,\LK7U/E97]%LI'?RM.,ZB8RIF(@C,1JR(3X0@]!EB#8IGE!@S-W>I+JM
M]Q(<C&TP=>?6; "1-'04,DXG'_!;.'N['F-W.<G#!Q8*[=J86E."=%;$2%%K
M+B9FD27#A\86+Z_T;8GI?WV;__P/^NA+5:,O[FO8 \NV =5@(IWWP]_&T'A[
M>[BAEMSQ; R0OV+(4TF,G 9R5XR42&ICK+*Q!UR\;3XI=F^AS7O@8.MWF5>+
M*3F49W_\HH_[\M\7TQAK^E&8_=KT>_-<VIR4!1OJ&U.L,TRCDU"\9I8)U$YU
MJ\MZ9J%V$-A==/.!^-@:$V_/IA^F9V>_UI;R-A$BJD)111V=PG,]326X$#T4
M52Q'GW0*OA,8'ENA3:37'PIZX5QK\9^<?\/9^UG:;#T%[D4@J/)4_2@E-$21
M$(I+*G.;-6/=A'[W<]NT8>I/U'MPJ;6 7X6_PMDJT.;GBQ_5"\)\NO@:_H$Y
M?/KP>D-0K?C4+A%!DM-)J&2 B(6#UDPDRZ,GR'8S_!U6:]/7J$?KWS='6T-D
M?7'P*2Q6,[R:5EV8X+SVT?=!*XJG> !OL@+-D$O'C,%8.@'B]\]NTRRH/_'O
MR:T1W"#71OFGY=;E^-H;9L7*5+/?+,K:/HM<XEA'E:-#&0/ST0[S'/7@;MKX
M!D-'COT)8 0H^OWM)3S\W')E$8V.R2$'9STGI[A^922"T<0LLAHE#Y/7O^4^
MVUZ$]8",^V/-!A13ZX/K%9[_J#%]QN497OQC>CU,*/@4?4A@F2QDCWT&KY2O
M@;V(0A$S=<<X]N$%&@\3&U*B\Y[9VQHB']>/*U])ROAN^A/?3K]]7UUUMV=*
MQ_7\V!+62982O' )'+-U*F3$Q+JAY/$UVCYF'@PH/3&Y/58NSL)R%39;ETBH
M)C\0HK-U^@%J<!(5_1&\$%EQ6;K5:]S]W+8MB0^(B9V9V1H'_P^>SW\0&Z<U
MQCN[J,UE3][\U\?3OY]\?4L\N_SZ_=6L8304\P<'7%A&?F#F$&J_0_IKU"XR
M7DPW*[+-JFU; Q\,0X,)HC7"GHTQ/ER7 CC:-L.\SDX*-4[U%&+H")AX])A5
ML+(;OKJOV<9"#1U\#<GXD>#I#DVWTT$FVC'$HA"$D:%VUPS@26& *Q$,U\8R
MR[9!T:,KC?G)=T?9/H"??AA]I*E8-ZTKW\_*?'&^_O& R5=/K7>(=*O.](XJ
MP2J&]3WSVCHF"M*$(&.9(I"OE8GY$>TP2= O-+M\8CTKA3E="ST$*,/)9$0I
MP>D8F<_2*C%,M\C>27D)J5[;H'OX7/*MP-':5_AC>H;+U7QV.8N^.):SXPAA
M?1(&Y>O(0 <A:)5B04P=YZ'<^=C&DQ(;"WC>"[='@Y/-@YES/FN#!:1AJ8Z4
MM.0SQ0@V%EN8#]K(;D^"]SZXH<>XAW >E/$.G!J-E$]GN FD%=<^8<C 7:Y7
M-5H21Y2 (*)U46NOL]I.T->?/099[R*D!Z6]&\=&EA@LK"(F% -2$]Z5K4_7
M6"389$6@TU2Z_,"K[T$2@P>[%Q_)^;"O.,:41YQ844PK [3/VL6I-I1G4@&&
MZ+VW7'#U@'?\0O*(MQ+:8WG$VW"P]:%QE?EXE>\8+#<A<L@FT\$IG0''DJK)
MU,5YU$SQ9V\!'OC<D60);R68A_)#=^!2:P$_F^"<.4:+#EQBA/@B P09"PBI
MB!JFN1;=BI/Z2!0?/D5X9PCTR<?FF.B2]HB2KUN(@[21O*I0,L22!<BBA463
M&0O=AA+VED@Z?%;Q[NCHFZ/M1UL_FA.O>!%D_R)D54N4@V<06 F@5?9!9B<]
M=@/&7M4$PV<5[WU:[,6YUC;B7IZ\$BBBC @Y!@5*& $Q&TMADE4AF>)M1VNP
M0S7!\!G$.XMZ#RZUU_"3>@/[_^$,4SB)&PJL0Q;KS0E#ZVM"F()0<2J*Y.A4
M29EU&X[XP(>WF;G9H[#WY%=KE7X@W9TQEXK "&27."CEZ4A*DIP8GG3447JO
M!RT.Z+T;<G_2WI-;K87]%1?GTUEU1#8T++]/?UPY(CPGSX2L3" S95V!*"0#
M@RH*$TN,O)LQ?V*1-F,B^Q-_7_P;07K_PYGHMECIK<F@13)T5LD,+M?21E8+
M7$UA\G[.;.LBD<$R*4=RB]B?O$8 NFTS"V/6GG-25,,T':0"ZY.-99"U*5S&
M&&T99"S/"Z@IV0H9>]:4;".FUD?@JS^^/)P'=.6MIZPL%DV1F YUV!X#)URL
MC>,M(N<L^VZ7G<\L=%PU)EM)>#X0NUM#YS5]=YK"V=?%-)S=)\0QJSV+=31C
M3J <+^3SIP)%:"VEE\2I;GF\3ZUR7/4F.X.F-T:W1LQ-@OM5L* RYR$$"-KR
M.OM;U=81J9;[N9)]\(YULR[W/_FXJDYV1L9>#&V-AJ?*J(0/0ED+KB@"M>*&
M&!(TH"1\QU*RM=UN6/:L51M-3<G.".F)R:VQ\L?IWT\^?GW_OXE7].5;^O)O
M5_9/)VTB<V!2K;A#QBC.% 6,+XK(0%:PVT'SZ!)M[E\/CI1^6-P:*+?O'Z].
MRMI;]G]/%]<%O=XYE3Q+D)VM1V9$H$A4@F0Y<"X%M_>G+G>XOWUDL3;WN0<'
M3]]L;PVCAUZRGW#;C<Y<:<W Y-H1Q24Z<6M33IYT0,ZB$:%CE+35NFVNCP\?
M- TGC-8XNSR>I797O0:T]9J.91!\W4?)*=J[])!*0*<\FIBZS?"^]\%M;IH;
M>3N[L;,U%#[5P>.G,[R*]M[@3SR;_[@%;.^BD9$9T*G41A3"DIOOZHV]B%I(
MJ1+K5M7X[%*=X#+88+J#P:5?EK<&T"7XKWB2"K+:&=^@,[4\G$+"=>:5#IJQ
M*'0V7;LYW'QJMTNZP8;''=B,[,#)UA!XL[CX]FDQSQ=I]3N6%08E$W'"<!M!
MI5SJZ-D",;*0,TM,V&[-+I]:I1M$CO\BMS=.-X3,<K&:;&@X77S!Q<]INBP-
M<MZBU<E!3CD3Y#D'IUB$PH@GSB3[6UKC@^],]/FWWICH;_??EQ[;0-N[F9&\
M=/8BG7&@J_)K0\%RDW-@#1>:\PRH.!VGU5T/*!&R3-XG5337V#/$?M]%FT>G
M?@3[.TKVY'+KL^ORT!5<7260J%($2^2V6R;JK9, ;YE>MY4F^^FE[#@__-X'
M-Q?ZOG+ZW5/9C6GC$/A-L)9KCS1-VHO1T:DI:D4AXP4*^=BA\.11;G/IOUWL
MV_LKX: "WXUIC0^#F_8'F-?Y9U-<KNV>D1BL9 I\4:KV^ZRGHQ8@?70^F.1L
M[))EU>DL>&P3;2_Y1^1R]"*E$2)MHWB<(W<8,]">+2AI!;C@%3"52]2)Z5 >
MF #3']9:.Q[]B/<9O.S Z]:.ZIIQ=RM1I-4N,!4AK\O<E:*8W],?17IE*.BO
MB:V]N:B_KS\NC.PBTGE__!U!LN9G$@!MX#L9XEL1_RT;?#7*\NO\$RYJYZQW
M\\4Z07[YZE=-2ERK&6(PV1L-S-1']RS)Q\>B($A20,E)[<0@;>=[V7W;Q\R1
M')+M\'#<2E!)WE@1'TW)@<(2+WA-Q@VU,2[YP5FYS&T,=23%R)3@9O=M,U4;
MH*X_W.\(@=:!ZNF///TYORYF<X(ISB C84S9=8:=2Q"=\Q1XJ9 [/O7?_M2C
MQ=2N$IWWP=[&/N/GRI[+R8K9Y)RM \8,>3(B<HC"DV,3K"5%DT$JT9>G>+UJ
MV^2/D1S&N\MA#."Y>2Z2Q2<'R&*==Y(->%3D8R=2 JU%1N5ZA4_K &-'B=V7
M^0[L:RSU/\)?T_.+\ZOD@A@2UNXX'NM,+AT%A*PU&+*=PDJ/6G?IL=I)[G=6
M;BSY7>0V[X.)K:4_G=W:N,@E,#H6P;)2.YW$!('.4-J]TUY@%GB_]F$/Z=]>
MN=U]>"_2WYF)(PB?OES$Y31/P^+7EU#/SB^K>?K'95,U1EX/KYVR+*OL\.21
M<YEK!QQO@K/9%]8!#=OW6WYL1VTS!D?B7O0KMS$ \&;['\,Y?7F+3QL_7OF\
M;@@*PE-$J)2MTXN8!U&0%(VX%8P>!(G/;JUQF^5^,' ?6?T*I'6H_.4[\?+3
M!06388GW$[.3,5$CDX"B&NL4Z=#6U=ES/*2")G9]X'UJE<8@Z5F<\R%X.P([
M5)O G>-UI_L/]1]4$5W&!"P[<ML@89V=I<A:AT@FPWLRT\QR_*UTN!\#],2>
MVN9#C^PP[$MVXX7A1E.C2Y4=#%(J9,VUC!#99<M;"C:B8BKX P)Q#(=@;[+O
MAJD=!#$"5#U\G_KVKQ]U\,Y5H;;GSF1K@1M'"LA) 4-@!70F[OD45.2#>%D=
M]C9*A.V"A$X/%[N+I?%MPC6+_H;S;XOPXWNM8+GT1Z,T.M;Y[%9P,NZI0&!8
M0+E<&_^+(&1OZ=N/[J)QK<A(SLS^!-4:;?CM/@D;E2R69^=HU^O49241(4CO
MP$7/),-,(5"7FXMN:'ML%^UN-'N2[KQO5H_@''Q[L9C_P##[<T9RN$I0-CS$
M$AQ(64=9*B+!<^Y 1Q-*]BX6U^6M8^MS[X&]-,1,/Q*>]\ON$2#FS6;9S7C)
MV^;X*G4A>Y&X=;7#32V2L"Z35I$'8(2P"F.6S@XRF.[YK34N?1O)B3>0*$</
MSHT"D[Z%K+R Z&N3"Z&))ATB.&^CXP%YCN7P\!Q#Z-@W(+;"VP[2:7V5^GQQ
MNC31FQQ%;:/"2#VC :]DS;CQ.@:.2:9NK8_ZZ0?0"#F[B':[)@#;\+DU:IZL
M2W:QFN\:SEJ)H"(3Y%B8",77KG%1$Z&A$V#VK@ ?K"GCL%CIC;LC.,[^_/%N
M,9^M/H5?][+]KMK#62(FB A11U^O0E0M)50@'->VQC N=<E/V/HD>V9?;3L[
M#@:O(:0R I!=98[67F"O+Y:K^3DNZAO9\O7W,)OA9: <G/1:"0,F6E(<F1!<
MDG78,4J%/J9N[0:V1EJ7S74[^5[Z[,;!Q'D$$-THM<[:2,T<!.LMJ(*.(FFL
MR?/<%IM-89W2M7H'Z1A<^_YAL27N=I!1:T?M9#:["&=K(CY45^)ZSNYU=9QE
MP7@//%5O@A4%T7H$3S8^B:19-!V'23V]T+B1LXM@YP-Q>12V:N]#X,-TAN]7
M>$[1ML*B0I @@JPO:)&1FZ*)LT(S[@0="B8,8]'Z(Z(;>O]5AJ(T@\<H5.-W
M2[*I5@JSA*?Q;/IM#8PO].>R3#&_GWU:X,_I_&))OS>=YXDWAA'-FLQ*X!3
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M=IG ]YH(1J6UTB:#-8$LLS0,O,P1M.<UM1098Z635>NX8#>@O?#7G2&$,V[
M3;3PPG$F@6M/I/A2HW1?H/)(&18T8C>'[.EUNL'KA3_J]"B*UJBZO_FW?R7:
M'7F42GBLYI@L,*O]WG2IU4 <;+&*>T]J<[^.ZK&BNT=6Z(:D%_XRTPO[6V/H
MCD])!_O\VVSZ/T1#0-3<>@:%>TD^96V3*X,%BDDD+\6[*'=PZ&\6Z(:@%_YZ
MT@?S1^#0K^<R?)B&.#U;#VZJ#-QXA<68G#G%MDS6ELN11W !&;@BF [>^Q0'
MZ3'\^):Z >_EOD3T++36]NOZS>3!NY7Z]GCKT9$SGC(J U8F XHC)WX)37XC
MLH0>2_3=_/EM5NV6OOS"+_D'$U-K_+U=KJ;G=6K=NS!=_#V<76QRA7 YD<5X
M96H?KEJ8K6P1X(S44#,P6-+>.]?M"'U\C6[8>KEW]7V*H#62/F.M.YS.OIV<
MUUN6D[/U[V/^.K_%KT^+:<*)%QEM)K/,L?AJH!%\U@BI&";(9M=IOAV=LZYK
M=D/:"[_*'TA$K9'W4$' 30Y!G21][XDU:\V,B*1'&!T9Z"3 FUJVA)J%;%AA
M]SM.;5&L\=3*W5#XPI\!!A57<RS>RQ[[<T8R_3S]]KUF.WZYB&?W,LDF7#JM
ME-.0;756:_N3R)P%BI]J<Y*@?-?"H2U7[H;%E_LJ,+RX1A#:/E3>>14T_=J4
MX=T*W"-//CA9P# 90.E _@;*#+Z^@G!?LE"#Y&]LM\UNR'VYSPP'$.[8H3O!
MC-H9+P&#J^XQ"^ ==V"<\R$(A;D<K/#\>E?=@/ER'RCZ%UWKX[Q#?OCZR+B?
M(#Y17$K45D()OH!**D'@6@ *J8./2B/K5K>YZPZZ8?&%/W$<1'RM,?J0/_U8
M%G6V3J482>ULK2ST6" F6VML$H:0"^-=^Y]V7[0;$E_X4\E00FH.O@=K#&M_
MV*__G/_V.BV<%C*21J60:NF,#Q!JUX><"[?T0UELMRO%K9;M!L"7^V0RL*#&
M!,%W%[-<"_;7=!&"\#YEI[.3V7OZG<L1.:]^W?HZ+*?+5_/%#"?)6*TXDH?B
ME:MC*#0X1JHH0N&2*0PJ=(S)^]Y:M_X?+_PQIJW QP3W!SN@7'DXE]6UM[R<
M3<$)>>>7E2JUUB33_SV"]?66UZ,A5UPX*"*JQ(M5+'6K0>UQ4]T@_L+?A%H)
M^2C!_;[<4'N:TL5B$J*P*6D-(7!RHY"(#Z82KVRPS$67)1L.U[_MIQND7_CC
M4P/1MD;SY3/;G8FVZ]>U6P]O#_;:FZ@Z@8AK#\QPB@!*)B*Y,J"Y,\BTCNB[
MM4K9=0?=$/O"'ZH.(KX1W+1NKHIK%LM#-W=O_TIG%]7).JDML99$=OAK$FS@
MJ399-2(54-)+J.VHP6:>!6FE\6*0WMX[[+4;EE_N0]>AQ-R^S<7M(V9S];<Y
M5/X(BW_@ZB0EHNSWJ\#YKW!6<PA_>WN^^HW*LP=> S]C=;5JYYK3B\4M.9.=
MV'2R"<XR%$77X:BY9O'45VOE(9N8HLW6YXY-7D9'6C>M>KF/<..4RE: :^T>
M#<:]B5<DMN"("RS7Z:'>D9-H&$CK!;?"!.FV[VG8ZQ:[J<_+?2H<$0!:J\%#
M;P ;0M[@,BVF/]9.93;"Y$*!CZ<-4."3%(1,/E+F7*@HLQ+2=<)TM_6Z ?2%
MOQ\.()K6:+NM<Q]QM=:?K_-ZC?KV+UJBMJ^IUZ;O+ZLI\IL+_#K_C)N6D:=%
MW/S[3_-I535$B4;[=#ES03E>OQ(64)?".2_HV?:7Y7WLK!N"7_J[8TMQ'QG6
M)SXE5HPQX-?/ $5J<,$@:,F1H4$C1!H"RMV0^B_T0-FWL%H#\>HFJ0-=M36
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MV6U4$:(T$K@*W*D4DDU-NLP_0U>WC?/O6X]P@I9&7U>XIV]%+X6#3S^[W\K
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M=((V3*4MRZY)-J(/XH<M$'V)ZZ$=-L:\0^SF^@)7J\N;+.,_IZNO]/VJI,V
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M#O3.Y!@J _K P3-VY'"9C\!AWN;A]O(RU^@RXPRPY#HUP62(BL3D1,:B>2U
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MZ\M>EODZ!"$/4_0]BWW@(J&/BWF^2JO?%Q>X^#%--[4NC#GM41'!KJ@Z.=1
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MU4RL KG0&>#9(OU,F!0*ZI(B)Z#E6T(T&4/-*:;%+)ROFF$?_=O_CG^)):*
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M5>@R(,#I9R[I5H 1 N5L^=)">G6A],Y"*19:D/<J7"#A"L,V5C6^C]ICT.#
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M] M+ZSAZ!JNT6;*__P$J"QPT+=$76"Q6J"]N7$C8YY7L 20@#>-("7]=Y[)
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M$+\-0H1Q$#"'4A\<YNF&Y<*3'X[,H@#9#>.6NZR7Q$_EK72PYT:@0*Y\,)Q
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MI?#XM!V,;S3T0&O>CG74!#WK;LXXV=BP)\^FLF"NK"SZ410XHM)V9/AH.H.
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MTOGL)QC2$PR)-LY)F,@ 8F88PLD"&G7P$Q5:_O>K &R=A DAN ;K*!L$HIA
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M+6"TX-VI/+5]:46CIQ%52ZY[Z"G&,-("^4(I(Z9SS=HNL9TSJCF<G&>883:
M8)^%PQ;;-&DUVGP73VQ^^O!X\013?((ILCX-,]W6U*<=6F58BK5;\>6KC"OS
MFAJPJ3J-F]?367O$I>QUBDU)!/9UFJ34YL2ZEXC'0:<RE7?H3!DB<*^\8H2(
MA'J*VA_[?<'-1[I'=T&%B46[WM#7LQLZMF/WAK(7PDP9XF/PKR&(_..<F:.@
M4SVOPLP8&K&);B2'A]!R"SME>$2YYV#E*,R4X<=")!*F]M,@8O.=_0>X#_,,
MHXO8U@\=XCKS/J#18X-+>),H*3#?4."]X;,TG^7XE9CA,[%Y%WQ"C\ SO<AD
M%24P>I#$3"SP^Y6<8*\OO(D!!)H.A EV[,.C-(>[JZS=;PSE?9;G"36 -5TV
M=;U^9Q,0UV2ZV8Z:WZPP_VQU&"O JULA,8+N$@VO1!T.96(;X>:9?]J'NZ'"
MS)VR1844D& "QI_ 71G,QFH3:8Y,R@ _,3UG-=V$-C#9IL4@009VZ%RD4XH&
MF,! 820;<;4>S-<CM423V$J_*DP#&MC;?8V1]WNH0;KX/).Z,.$"GZ@3H\/;
M63HM2:>WQ[%3I]YD:#:7+:+1OD$P[W+K]C;885M@ZX;<S2\0@>]]XK&I/&P"
MVB_9)G&U%*3-7D"C+8RD(;L 86;)6RLP&'W!"4.+^>=FOGJ0I"-4&2/%.)S1
MJSD?A? ITM8L,?I8(0DY>J<)_*_5)YZ>H1:WR,:#?Q+%#4B[;@A?8!8UEH_2
M/O!%CVJAQU"#['3==6NO[L6[_8;B>N"SK!JK,3&,]\,L,J=KS=.\+=ZA1<P8
MN-\7$Q6OS6^PQS#<N>:X0"O&ZBD&EXFFKN'"<<6K!2+#.":K6Y5=F"ROCN1V
MQCY8JS0*+?AHZ>$O]LP?5<E%B]>!220DK#P^-TXQ\\TW!=$+UWP)$W3QR^TN
MU<_(Z)]AS]'![<$0E#1HAV'/T] :4O^2*=2:6.W!_'%G"[AU++@N#!S"0E4Y
M<<NA;EOFZ 26[(8Y,^NZ!K661S<JSL-53F&"/MHF]!"DZ[&QKI.08UUA(D#^
M 680DBM^!:T1[VEO=X_\'+_8H?STIFF&*31C4/]54<>[]LPT9!$L?CB7^/1J
M6OPM;VV5%TEIS&N,8E 7*8I.3F0TEVG"K9[P6)-L@Z=UH5N5(4=;A'A6$6GQ
MI-8HGQ'4\6NM"JD#"];\QTOXB5H#V//2R#G>MO&=--_0F%#\-W[;Z;F8G]59
MBJ%>\HU6"ARLTA0$Z['%WMAP$]FQZ<AIR];$3U76]2FU9NYX#_R.)*7Q)4\#
M+$\)8\8YUTE8?,U1QZ@K=H4G-,<H:KSW"SF511=V!GW(%:@QCERAMZU=-Z]9
MV!-2AI$R+Y^0,KM#RNSHA&GP46ZH2!.W2+RX!6TU(I_ K:0WMSUN-[:]9H-Z
M@"(:10)!XZ Y04LT=[5HGN>@V1M$DI1FVMS]89[XO1GVP9[XTU3%NZU6@N/^
MDL]N>:<IPU''QWIL<%Q4*RGY"C[<-J1]9-* 50ZC]D&7+J9H9+EY*9W(>.(7
M\(\]/'%L4\E]TX?#,:#T/A[WC']QJSUE8P1?+MDB5;/L^UAB(O=?+MHON_7Z
MS<?+\?N+Z.B!@W]^L'7XW6K_4;?Z=\_$QQ\OO!:AE)H*4%4='?3B*8>IJCYV
M9@7M1MZM!@LPNH%%PH&)P&"7/XH^,CLXGRFFLP:.]PH1-ZU![\&7 <20^H9O
MYGP (:5]Z^5/589EFHW2#,0\) 8CE!3@&K@U$E4EL*]<A)XM&JGEL E965[.
M=SGG#.(BA@UG$?WT8=S9IR5*P &+R!NCZRZF4YU1QO91:/*QE2>2A-QLP< W
M^J/2#6S!H<BD3#AUFA<)NQ-E#7:53N3V;S(R\TS"U=N7A NA8*/WY.9QWNY9
ML]>^G,<W"F +G[E!=R!J!K"!4::ZX(7;5C6 >1_N9+/LFRT1OA /PP)XG#3;
ML8<KUH.:?F<-+ NY% 6?4KKW"D:<ZY0#Z[PRVDKH.=5"M>E#RSG-138SE;-R
M&.+TZ*4_/'QQ\.)TM\O?[]2=85"M.=WW*R8'!N&87)U5Q?J9#OO&N'$DE@O(
MTJ3+: ^=N=#7>[&B+6:>C!A)W(^(,80M*4U*)\X7BSHSM0&NEJ"C"R$A#G7=
M-3V3"&LF"T4(%@XY=S4OQ#!=='GSQE6"@YY6<4G/1EBC'/5I$$[/-97(M,@7
MEK^ TF&*(NP\)*U&4#4=OORAU"H&31CN@4@78TH+'H8U'K8D$A]$.4N"IJ=B
MK0M!O)]1 LU,E\-0&S@G^#)E#@,4I5]JJ7&FM"B.,:<]3.H9N;283?::!%C;
M"5G<WCN##=^2*%RNAQW63W+U)%>;<@7S$;;J[3U[P=F5BB2#\=P3F2IYA[L&
MI4ULVRH6AH!"YB9LCYS9SV*Q1. Y44;!GVLGW\VM0NAM&P_IV!>T /W[8G_$
MC@,/GX1%476--9?(HS<1 >JPH-^.O6=_[,IMZI$71$A3;K '^YB\=/,L>*%5
M@=LH0[E&N(8N"+M?('G_/&2?Z<?3YH0%:<NG02@Y!>9MFSS3E>PVQD&82L'E
MZ(W?134HIR?,@L8LO'K"+'QSF 5S7OD!1+^VHX$5.#TX.3@].#2[S?[V_D-N
M6">;TYUAEISA\188M,%JW"%P0L.JZVB#D49MIBJ6+; ;)Q7X860/HVA;#A4C
M\H0ZH&-QFZW@%:.*;99SN4]F0#1+\PEN15&JLEDV"<*O#"R']PZBAOR6[AZ\
M87-(!Q1VT8:KW5!Q_@PKI9#@TX_ P'-I@S![Z.-[N^XTG1Y8W.46I2\O@@RS
M[%01!@><T"M=SM623L4;HWF0;7;'[=DW]2)!N'G$6VK!X7=DU#=#[=A@"WZV
MR(O>@GMMZ,\%&NFDG)J3P46W9@!H%MC62Z"E6DI4Y_V[[F'H+$V,&494R@HU
M/8QSZ,T_69IWW."[70%P=!B-#]X>W!Q$QX='!Z='3!E:S@7+C4!^@9&A$(V2
M/*[IL'*SG@<QZW_;:89?<06$<;>K FZ&*%Z8?Y9D:_7:/3I)U4S'$-!Z1[EO
M6AYVX7C=]L2^;CZ'U#'UPE)@DPG0=5N=P^F[K9:'O4F0!=1'V\)&PY37,4::
ME !ST&4X?>AM6TWN^("QAJCA'^@C6*&@C2PHJH5:A4.Y&]H=I%;-,O8A5179
MRAA.,FY.C6<GN^@1WK\=H3.ZBT'&'.(*5:0#<Q;/87%GZ. ,35:3&LXR,SB6
M*4W.@>+'8=(.2V>-[%@V^XU79F5-R0,3D.W^52RR9B#947:AF+)D$HN0IY\W
MX/!=2B#$<H[@Q+A+,P^!=#-,+78<FJ?W<2C+S7Y197@[I\3\2PK-!% [SU_,
MO!A8;AAXW,N=6NL:NAP(G'P(DFF 8EQR=K],CAI9 CJ9D79RC.'0(H8K4DR8
MZO@F@9R)3,^D8V6E4YF6S\J%$S0LW9+;[N&%8!@&L))M_C_]<D-86)-52C#&
M["9[2CV.8"%ZAMY>#:W!&@N/N>>IRUF!M8]N,@H/Y73U@FN^.%A+3/";>#D)
M@:572R1Z$)2'ZAZ/"K/O";$:AW5DOA4J)<,XC\9FQXH^*=EUD:SC YS"L$MB
MR"<N08].W\>5J,I*[L@II ;)8=]^Z"_I,&E.W&!\L#NY[R3VZ]MC./0&J0:5
M\'S9B-J#N?\VK4$X!;]N(E#\VA9DH= 1L<*C(,<^:K"7*U@+<X0P_Q;H($H]
M>^%('"#BCOEC6AU^*'<_*'7S _:RO-.CFGL=$7J514B'QY#9W/>)><8D^DUB
MW])/&YFXD4MPPI'U$V$Y^GA AM"Z9.\8849*AX20*!OW:Z7+CGK?OX6@8D1Z
M><^/3'&2 49HCI0'8/_V>Z!7.F2E&R?)^U%8(WW.KLTF2)AR+O,WP1/BB1%/
MKY\03]\<XHGV!!T3>AN90Z!Q\! F1*<W8 ?72SHSS!;5S+^P+6?$^M^,!+(C
MV%0@J@058,X3K4WN428\I@7XX-(E9$&+J\2KC+DETU?$H-L3%VEJH;:.$!Q.
MM9]6,SDV8YM#VC(0-?7QIM:L:>I3!L^"Q;'($VK!6FF8]CTZL]VDR%-W#9CK
M0B &+,<4)'_<?HY5UEA71YE(/ 72G-'G[MM&F:MRK/34$DD5<;W MK"QL=LH
M.SV1V,DV^I3E*_=.7J<E"[XE\ Y9/ZKB%)DLZ>O&<+5'8]5]YW%%S^@XL_P;
M&2R>S;R6]>2?.A[M#BZL<G_TR83!'T>;+"8@N:&Z0X$%D+O=H4&:;*SM-+["
M^$/.<.YUXM K(@!Z$W\'(I?7%3XF81IO5Q.X75]FE&(QU);4C04'LM($G)JN
MCGO"4SH'OM2C[H6]GAP<C;@%M_8?\!&WLKBC@AC:LI(P>H*,KC,[4B^5HPED
MQWE9\4]4%M<%M9#@Q*;?1(*OJK,*SJAJLX&$F[O2SG!">$'6!<S;9)-7&IAK
MU K/*![\)@C22!;A[)O9,O5 K#H66!6T;=+H3AN-E8[MW&V-[.$4T@4YSF/W
M)'[![+$\XASL5!AMW5!%QT&)Y(FHZPO)RAO/-,)=M'!+ZX8S#Z^Y+5RVL?0V
MIN P.854BPEU S![5/OG,<TISV>#KD-E_<]W3VY0\=-%O3>T1Y1FX>3)9,[^
M3>F?M@!'+1+:(_UH0[6)C91R_?K\(&HOHQ6H.<V:KZ?1!4;*M5'GYU(=FH"-
MFP(-,!1E? S%&34<UXNY; UL$M&FJFJ2PKX]2&$D;'91I:QK]I2)RSQ,D]G"
M-[-GJ>C:OIIN="'(VJ*%ND?W[2EO )AU5AE;PPW-@0$DY5\I/V-4GAK=K"U\
M [8)B/P=+(RQAF'3F3EN, X^'IJ_TR1U;S>V8=H85M&.;SZ4!BK G_"9%6;M
M]TX-S9/04M4-(=BQ&7GQ.99+8AMVO*8Z&L;T4-@!3W@^(6AVB5K-5^(;,+%&
MWY>6C7*$6J@1A^_H*^;Y58V?'\)B[X^\=C08<K_Y$)G^NRDV"TP"@;N^V6D"
MG0M<\*RZG@OPR6-98[U72DT3XP,Z%NV!WYYGA=N>TXO4"UEG9K#<"Y$/9)_B
M?[?T;8OVK)S176W-#1WI6LS(;/.C$G59V6BM"<7F?J0(_^315;89$8T\UT8;
M'("8@RRX;-^*<Y<<NRBQ"W!@W(!P^F*A*VR]X?%EE?A$;,"YRTXYAX"-5E.$
M3.8$3QL_:1^V!GQW+0OXX9,X?Y$X>Q/GR6='P*[1>RK>WY1;7-@ TDG^03*$
M#!+S;C>W-2H8/#?0+W[0V:&I*W#/LA4+MT'+'P.+WK(^[8G?K.)MUP4F"D3U
M:[)<J*TT?,,0GESXM 2;,7MB)6:MYS+&PKHKM._( ?.%-H+Q6.)*3X\&E-)M
M=/8<PB:,&(_C,%K>(431,SA"X6G%FA'-(SZ9RLJN$MCT< E\CW'Y1&"7"X(0
MZ387PK4QY=,/S+98:9X(R<_QX_5-=HY^G[^-[^;,$2N,I.-H?LJJLD']_"FK
M^LUE5;W..1/0WWBV4N<<4L6C#8_+Q.]<@0VV[-0E][#5\E4FN486]'UW=T^J
M#ZHG7O]RNB%,?65P?MA/@0]HT6@__?B:]AV'%0*#\PTJDF0C"VVU#K>NIQB'
M+C@2G#"GL?75#/&P*)TAV0XB'!]@',#%)2R_F*WKH5,GJY##A \OG3\:16BR
M+'7;C!Q)8#'G+VT1G&F=08-2/@.;3VS>1N_#5SYUE&-J@7=OA#JT>V+<:,V+
M%92;-]ZU2=L(_K0F-*RXA!Z\ \:T@A-&A)_B$$$)Z./B$).O( [!)\\0O*#[
M0A%#.1T\67F*=OSV#@V_4ZSC]P]V:$1*^/&. ?9F_JI"'D8Q(?C/UCAXE,'=
M'E^?9^>[;%R[?J^K]RUX=H$A$QNL5;NNQ$)N(C!<F/M9MO1D(1?"\5 [3%>:
M=@%^NH H(Y1MW!BT%0U:R)G=G!]PR6(VN)I196V#F:V$-]&';5LA-U4]F\T/
M+'+-L6^RU*1=!IZXF<IFNI_UQ@#;)P/B<OAPH+L;7\+>V6J-4$$:O4B=1E5;
MD""DT[#42;.,T)/NLQ)/1;%K*I@@!?RT'X7TNPCXCE\NL%CH?V(=")TQUPU[
MJ,=%V_&1"J;78EFEZQ;1<K-MW+:8U:C!)*G]1JSW-<&%PWVT<<&:3&KC>6)Q
M32J3F=Q"-=ELTN1BLSJ7< 5'Y"?[Z6J>6V>)&E(XW"EUE;!JIJ+ITZ^3H3$)
MOZE+F)D2SKF\+DK+BBO!C,[74MJR*=TL \<,1@:^:2P9&^S;_,D=!5E<( [6
M9P6F!KB']DZ_6A%)P*V+<?J;MG.#N_XQ^-@!].L]TYV+C[_YSL7C]Y<_7X[/
MWD<?;R[/WM]&E*^\_'AY<3N*;B[>_?+^[..'F_^*SJZO;S[\'2X[^_D</K^]
M_O#S[>6;R_=TY5/*F3.*AT\IY]VEG(=B]@;'$*8);?0! ,]*M7LV*%+H .W#
MX_"Z:6MS:5 K__@*G!WW?Z+U[Y< WS2EZFZJR^LHP&.3,A49#*E=TV5,SF:W
MXM)&ESY0\N02VZ9Q<.GQL<E!S&9_-ZU,MXHHM_@S37^ )GU9*(J =\P[SI^^
M_M9FPC939PVF%&YEP47]F W+"TZE4;B+P@B6A1-+TAQ;3X-6/HRTUH[)X,,6
MY-Y0^Z7S.KNZ<"ZDK,H>^8YNZQ@I+*)QH2@[:^6=([C4MY!*)&-,L&OJ!?Z4
M$BO1F_=GCB7V[?D9R>T# [\)N(9Y+Q>70$<T>8:I1J6U$3GMHFH6E[=?(0+_
M5!KJO&8^V6DUKR7B P?K<WHW=F&9QXJ0M2MFNJ"YP:'"U.@TEY2?\(.NW'7W
M\-!MQT]_N0U<^_;&JK70]IU23FC[KKA'<BU8C!=DI 58IQ4HH9&G*:R:EV&@
M4 5?C1GF!U)TTGW?7-VZGW=L"Z_2[HLVQQYE7?U'/.3G>T)SP& F$]%<B9P:
M&@ <$-[JML(.2C,5P]W25$RT[G;YHWT[BOW'[M'-M7O@9K4_;.]86T?WF*UK
MU=A.IO)?K$ ZILS3(D$KD=ZLD*-NL=7]I5V5GK5 NPG%%CMX,M=D5".7 ,R_
M02@9AH/)FF[$R56-FXU@0H[,#MCRF)$7V]4+PWH+FZ-@0Q2*4S$(II_(!9_V
M C3'GMI_T#,]\@Y&4CYPAV [E09;9&O0FBX#";4ZOG7*>E,I@W*5OCX$71BV
M,+[H$\:WC91#B[JW:^>V<-K*@$@I+M\ZSA[.%ZTO@?=JWUW3G'#8WZ@-KR^#
M4QQAMI<\WN;M#=,[0F]P8*$3ZZ#>Y^P^@(N?&T.FZP-0#):&H-V<9N0>^6 I
MIR=KOAG7DJ0ESPV@B/Z-KD3O&FP7'Z&7Y3* -N.PPVO#[6.9U(@Q#X0]GQC
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MXV*: H(1E>VH%P7;,#NB&;%1[:GR(=QC%JHL.-;W/Y*Z/:=YJ4O\B;Y4,R"
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M+6@D)>ZRJ5Z$31VK9!T9'GS;H=^T>.V4]:F[$N7N2:0ZJ9K*TG,L[^(YS"2
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M%<SOV8A@?MV@9Z]P:.'["F!/(3S%",[I;-(.4W<M83"R6,968.J.MHKE&3*
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M]I/X'\^>+_%9_Q<%(^\#IW^?BH!M2W\.=CF9]"?10\.^*<^H),RP?Q%S%L4
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MFF5HJWTZN#A0.-M@SPUD'CQ^3&$#,:-C*4960X!LOP[J>6CMZM?-HFAJ8TC
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M9?+'ZR:"!]9)POC7KF"FDL:DQ&:Z2#"3Z6IV'CM>\V9D+ND%-FWC/IR+=KW
M;LW9IN_8>J:.,6XJ4"JA QFL9DD8Q* *)W6VX)"V_D0ENW<W19;P[ZG//;2F
M2^7:+J:Y#U;)H ;B]QSSH^HU;11=3_HDEULZ?F/R$9< =)_+C9A#PP"+Q2>$
MC&B:./\[A&;D!7 7PQHE"ZN\QZK01@8\?&X-#C2[CR9HN0FDC=$,;/S)V;E
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M/)\+F4+A_'%.K9-S-B7$.QS(75%^#F(L(N#W<2V_0162.&^KG0Q7P%U:I]S
M658)EYNQLH!C^\RAQK,F.&/S$?N;,.P)4>75HC4K6-Y1FUS=:,K/9G(=GWUX
M>_KFY,/EZ=&[X/3#V[/S]T>7IV<?1JB37HW-!G,=G'2S%,2H@[Y@H%J[^:A6
MJ49C!F01>I):&Z-4H)YUY340]?9"*5=BBI(SL>I.69Y&@)IW3NFR[2+N]KK2
M)&?B=8]I^,H!:7R^_PC-5XO!ZD(U^M;K4KL5]DZ.C(8B7&U,MG35E+<I$WZ5
M"5O+';Y(C&<.>?KT9*S6JM.Z(;L'2\5B:M("-28JW]=)^X$J,H$'YGFR$2\<
M*83E./12T7IJ#L%1=@EQO(C#+R'&36FJGY-DCD.US\3E-SWHTFSGWQ3$MLZ*
M*O$_BN:>8D*8J*.M?8LJFP2><D-O>U\DXT.1.FE0<TMHG*BO!C=]NX)J YV]
M-,;$_O+MFC9ESAV%"+1!D2;BH=ME;_A_GS_>96]^NNS-50*>QE3='I?^=D2Z
M[PU+JNU2?BC\?+>XA^VXXP\BTBK62ET7U'S>5ED=P! J2V;])S%K)]1=FC"5
M$Y%O&0K@P>?@S<Y0C:&W?%]^J6TI>'FU#,\,<7!-R[CJ-8,XU#X^6JZ&6LZB
MJ@_J%853_YP7=X8*N[7*5!XUTE4=C*7AJD89R,QXL73RIE.]VXWO6 Z&P]X>
M>B*0\]T0?%9>Y(^:BBII!?[Z#F&_T=9QZPBI<+!O?\>\&8/%W]Q956%ZE*KN
M[2F_YZ90!LX%-<(.+T3EI[X)L&DJ<+G8_+5P @@'X^P;O)(LSN47Q]W:,>_)
M8.&R0>^V8!:=Q?5,;HJU5)+1IQQK7,RX++PLFFNL,0VFD>0I[[6I\ RT;K@'
MQ=<ZBODVTM4?K'(TJ^^DKO%B<$C2BO_UI96>="KM3>-0"ZM5VS;6@QD\]%U+
M:XP9EE=CR[ <V0"1J(.FW'3?H9-70:_>^-M++ T,&DC6HFVO^Z$QDKRQF2F6
MD#MEG[:C:TIHH=CLBX_M20U4+O"FV]8+;OZLR9BVY\I#KTF^3 @OO=KUFZ_J
M-]? X\*F,1",5$]"QZ3'19^C%,-F@VDJX9.. 6L,HUGT69L6VR<"HSJ3 I,]
MI" ,*%#76I("6*=$KTJ2SWXXB1HF-=J*#"A&IV4I0J_:%^O!;XM=[PJT#K<9
MPW LKEB=A#SW@9I";"-,"9B6/NL4.&DM,O[-J2D;R&+NFTY;S5FUYA9*",V/
M+7*U-9)(&6XY;OLEU"F/F]XD HL\Z[WI,+(*+V6>\ E"<YP^-%RF5&0)FW1=
MG[03<NL&U"7E1Z-3XK2^:6";BML^"GYF6DLY(0-K<5.R[7?&C@U<&0]=;"='
MELL1SEG0(1 'B&#5!H/(355S]:( [[J!AAZG"_="O"[;%H%]-C7&]+DA#%TW
M!T<,T^43D"Y\6DF8=<![_?HX*[6&Q)65EB+7VA]RREEQ)4RQ'H@$:7%H:TT-
M95OCF![@KL>5/Y@$)9A7B\@=>/@4ZG3R,DB: H$W:Z^V4_4L2*\XY=LBQ1)9
M)Y%%UF3I3H_Y1]:U*VU@?(P=H:^6H2BUEW^,,%&OEH%WM"8X2@]A9'WJYTG=
ME/FR.[9I=X'SF9&+[&ER;7C7L3BJP<ZE;I$?5O\M39=RZ^B@=&D!4H)@%]L3
M(T#[FDW'KEV-9X"\ U<%A1P^A:+7H5+L#IJ8C+I)3:%7NZXJS<L=[O)R/UU>
MKB1I9*.W'1</+0/$+"X6@Y$LMJ'QOK(]M >>"@7+)2[>]L!LR'C/-O732QI%
MI"=X($3>(3O?+Z+![+^U7@1*=R!0N1\&4IYA^F9ZO)I!<92VO JO9<QPA]@>
M)*DGL(U"9#1K_0>]:Z7,Y# I>26F1Z;(M6SE<!^%(D4-R?J+BPFC\9HJ15O6
MV+?VXH[YB^#-43A,TMKBLTG;&P8K<TX8RD2E2A-T0942<$C: XN^=(G'&90<
M&82(M_@7=50W!B#;*.9-@XO;;B8/1^&5X"BT?OF<(QIX;:J>P %B3L3X;VU%
M'[SAIN:H2Y_>=DXE<F:( 7I<2X$K=/PR%F4REJAS'=L=?Y6DYK5NG9X433#,
MDB7Q=<("1:NMKI)6A-42_$Q3]$/]53%1%^(;L;CRM @G$DPE-**4,V_2RD_H
M+&QLF>BAIHV,TXAQW^NH-#V1 UL3:LD\ 3E>9Z8Y3CB/RV2.FQ<-1?VT);XG
MGL1@*@1(QH@A;+,R@H#K#1=SK&9H\I2CV=@G".>8XY0S#CSE_M.P,Q+!UBOS
ME]7+(8$$K?A;!^@)XYF,SS8P^ZC2PSFPO'W$,#VP?5X4V%TG<NW761Z"B[<1
M Z?9DC\OA-3R#8PRH,/ Q-+CE/DC0SGY2"=R\P75KC3#KI/K'+[/!].ON3TA
MC#VTD]Y@[XE3*AWL*>-"#F<EC;GM%L3='V"+U-E"VZ29U&S62%^N5&!3Z3;V
MQ,%]2] TC?*\:/*)K?5%O+0A9]6_Q(F?2>/*#^RYQUN)_\5F;HX/\F"B."87
M,,K\<502F#:"501(!<I9-4RY1+JJJ@(M5JOQVQTY#OQ*%D)-4=0G0X,*>X9!
M,#3WE?)&/<U-)H,R"D8#]>5<6OR%6L#KR:TF=[*+^+2;)(M#:N^B*3&-1PPN
M.K@KB/UY1.7#5YH]1_:..S-A&T303G,^&HFHFHRP.5>(7)[K-"TKD:R.^(L4
MBL;W8$"^W>CA7LX%V!*S8K0AZL*LF7D9.ZEVKI;T*;5A"\I&B*"BOJSJ/B55
M7 P?S&)9SR(>"JY@/VJ59*$M(8\3KZ2!X^\.46'K1&","#]]W3DKYEPARJAF
M*140S6VI%VA4NQCM"+_G_\PQ!R?K9$ZNZE"L%/,UHJ,&>3K%G+S9GBQ">Y'X
M\3CU-":!QBV&TT@=+'FV4]TNR^VN@AHA/6^&(_\64PT8YM>L6EPT5P@(TN$Q
M!*7F7"_E0E2#@:0;WQ0<_STD5 O1*':;\V!ANH"I3LO>$E*M<=H-+\9E-WSB
M1.N':+;ILI5/;7HIVX9EU8K&H^7,TO4RH1XQIO$(M96+((OU%3#(02^3*3P;
MKY!D"ODKYE2GFGQVQ:J*.2I&T.Z=WI2U1S3;\S4!.7(!EOE1)\=AT X/\3S=
MT0TH4_W1MMGD/AKR2IUJEXP6J!0%2<"97D%;[_KL0NT<:G^R"[7_=*'V>\@&
MO?T$5H3AU3@Q'?7X>Q=!59#4R2'JQ5A?X.5GU%<J:J\5U4/D6R5$&"TL]$$&
MO'VIRR%9Z?H/&FI?LV?^LL<>>2'V2)15A32@?&<M1$_\&VP(#&Z-3;Q%2Q-!
MX:,-UAS^Y?\3E81!)8ZI6'(\RV\ *OPAS%9;T(^OR 2'W5;!GPV:X/3#Y<F[
M=R?'EY^.W@4?S\\^GIQ?_AX<?7@3P+\NSCX<O7OW^[I[O&U3(\2%MZ='KV&K
MQXVZ</AX;+ +9X9\$VW)+4!#'F%I%>[Z:/=]E)M]>/CBX,7S#6_XV+;\!!D*
MT?OJI?'8TL2O+/634.C<))I_E=1WV&OEI@><RN0.@!T5PN(;PZ!.ZRR1$GQ0
M>IQ%#-F[5]18_'@_=0PG7JDS0$BW6LA1D<FI^YF,KR 7/7SV;&-'W;0"=/_W
M-]>1T6#R=9(C%9?#'6/:RRF0W+-QH9^:O%+4KYD&;;!817!U)UE3$7,VBB\*
M]:[86 WSXN>6L=@P?Z=D>7LW,-C;:E "<[N7S7(;D J<@%?8[NOX2"AS'.:2
M/ZTUKY'MC4QS.W:#ZBT$W<_VEU94.A([J)Z=Q"RB$651.N-0("=%B, .*S?P
MUH-G05F@&G&DRYHYY/I>M62[]41L]P8?FP!-9^@:\*"9;L..!\IGK$M+.XF1
M&LY5$W]2<%U&5*]!V1\*\73V;9UMDUCPFNLS>-JDY442UMNA,*(RI828 S2&
MJ>&>S+#;ZB>J18!(]4<G\86]@,ELGFFC:P>RY>$V\\N#IQNWF4?6QTT N121
MS3=^@?]\%F3[&G,N7J\LH?[B3=:[&\H]7\NBEWO,^JV]C7Y1B<746WKC05=R
M;CL3,HJ4GE>0&XTNS-M_LL]ANJ:UPET;<I<!&)-$'H M=OI])<'6>@#7:U/G
M2T^*LA>]SH[2Z0 G-TC6P*E5Z:6[(T^KM;!4Y!%:S(L0R7TCHHICQX#^.4'Z
M%L+,P5IY84:C"D2JOTB8T)YVGH:!QH.%S[,08M2W2ZZ760H#=]BWE(M0&;\E
M*^I4:DCI&*,$TF:81(=77T-U4%$=^<7R54.E(>SO<+$H<9]T39UC3,V87M+6
M\O$A8D(JV.$DF]+[O$FW04*TN*M"^I"JBY7ME*D.'2_4=O3U8*]:X8;O3?;W
MW4-"BU97:VG4SB748__#UK=R;ZD!(^C<3L]K-;WN5/%COD(Y.%F$73:;L]E/
M=]GLGRZ;C=U09*HWD>#@HR(B$>)#"VJ\V:UWN5I8+23UMU*TS\#T'(Y!R62+
M4%F4:;]3Q45T56T:&UC>Z=L>'F'>I,5T-6@Q678S%E6DA-%=*!:)"EXMCJ:E
M:;(ZLG5.7<MA[ZJIV>9:!CFRC(&152KZ_!4V;3!=*[AJ6!+ ):^#F@2UO+$&
MX%&HCU%^5\:$J'S ,JR4KLC$:1L>W-_CJ*\H$/25%E"<:#I?A:VCOJ3484!O
MG_J!+.83N]].V%UPC;?NDLN?!N%AB$,+WY$B#80B43C6@#,:7! N"Y<&/7O=
MW'6+P7E/Z\0;6%,QYL?*7I8<1$!-QMGP&ZB/*W?(^]@FT#VR<*-(3%ZGBZ^>
M$=D>6N-JYD3N!IY"<#+P4]QP0!BEP=Z1W,K!]U+,A'!)U(<)D<HBBT'.PS_+
M8A%E]>+1%$8'-AY"'#Z:$ZX;_@9^X)'2\DE3:6@+_NB(\J2NM.548?IF,(9T
MCON<TN71IE-$(5)&P[SWY)+QSU<MI-L5,NDAV_&$>@EF:":_A>6!T18@[YD*
ML(KTNLR,>:94)HITHD9>0XT%4AITAU8KROZ;]"JM>XO4)7R#GVX%B>VB5R1
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M,5%,WLAV>47.*_ZRRRO^='E%10KKN19\8?&NH\?/(J_':N!V-^].IKE0]Q#
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M8BWU2=/"6]A'4BF-&F0=*JA%S,C(.<XRLR852 9,VV%3?YS$2X*\*'<8B\-
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M]X.#WI(V>2V@^;<6;]_>(O0/: ^Z63W[EH8XRIC[4='$XDZS0<Y)PSZ4P(W
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M!#"N,$6_P)HKX4YIJ(F?4GZG!2=CA;"1^G;4\XOG]AH!A@.6YY9.V J+X'-
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M%NE"#Y8@[F\,O_&0F'?[E4J4X/10Y@>PVH2:4L'EAQA).__U*H3-P/_?E<0
M+W3 X_B1!C^0;:X>,LK\]E5D[,WP6T5H4W#FU]D:C$5+]E-KOU$+>\.E]_5
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MW[Y]??#RE7K[ZN6K5_][\!^/I +HYQRV)+=F.X%VZ-(:GF#5Z,E@/,;BW-$
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M\&7\M;+7MLX4_;_3;'X#_W-9+I/_]_\!4$L#!!0    ( !&:65+*SW=C1\0
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M7I )_I>885UNC(1S'G@L#J$CYVA<Y$EO@CZVP&!?ZE#Z5^UQO%N4J.GY\I]
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MNKS 1K('$3N11W36JE!.I:F%BJE4/FV$XS4VP#17](+X1(*8M$'\^L/ZV<7
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M *;A+CU@^7E3";4W]6;?:@V]V[,"HLB0%/X?.4$V-*E(*3<!MF,-@78[9;U
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M)X(P-QQH:6R-F@EVRX-C P.-#PI#"N>3MD$&/O)!26=(G*#;E>+;PO>(XL1
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M.2<3@@LBUE2D05IP!\:3"?(\:*8L%%'F4+N/P5?:LV[IBL:=3:V_50U,T-J
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MVG.?U0EOY_1\?/6LY[+;VFDY>/9 <UMGYEE[6!/^($MR:J6<)-(KA[3@']-
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M**F=3)U95SK@3>.9J.!L2',D*N#-2)0-:L.@OQ(M0R0UUR4FJA:8F\_%3!
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MF(E$JF9Q]3^N=:54!U%IR%WA;GW2SR3]]OJD7Y_T:U'2CPC[9'+%62"V ^'
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M 7Y0W:8&[\R2?.3>ZWN'X.N6?Z5EHK8=E;<ZE&OH<HTW0[G&4*[1H7(-7I*
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MT(3GQ*+XVU.(6>SM1 @AE9#%+-945'1%B\7]O3DT'7!)U6;-UF K1#I;:>\
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M+A7J"CUM,UAND)1?"J5%]%B!=!#:BT(SR :*@^9EC!C?GA,, D]+%JD"2CR
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M^;]7:7@/_W.S6LS_W_\ 4$L#!!0    ( !&:65+_H'FR$ 0  "D4   7
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M,#(P,3(S,7AE>'@S,3$N:'1M4$L! A0#%     @ $9I94B.=/R_'!P  51\
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=,C,Q+FAT;5!+!08     #0 - &\#  "W.PL    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
